PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hamilton, RG; Peterson, EL; Ownby, DR				Hamilton, RG; Peterson, EL; Ownby, DR			Clinical and laboratory-based methods in the diagnosis of natural rubber latex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on Natural Rubber Latex Sensitivity	FEB 09-10, 2001	SAN FRANCISCO, CA	Malaysian Rubber Res Inst		natural rubber latex; hypersensitivity; skin tests; latex-specific IgE antibody	IN-VITRO TESTS; OCCUPATIONAL ASTHMA; AMMONIATED LATEX; TEST RESPONSES; SKIN; IGE; GLOVES; FOOD; AEROALLERGEN; PERFORMANCE	The accurate diagnosis of hypersensitivity to natural rubber latex is the initial step in the effective management of individuals with latex allergy and in ensuring the quality of epidemiologic studies. The diagnostic algorithm used in the evaluation of an individual with suspected latex allergy begins with a comprehensive clinical history during which risk factors (atopy, food allergies, hand dermatitis) and temporal relationships between symptoms and natural rubber product exposure are identified. If type IV hypersensitivity is suspected because of the delayed nature (hours to days) and confinement of symptoms to the skin-latex product contact areas, patch testing can be conducted to confirm the presence of activated T cells with specificity for rubber chemicals. If type I hypersensitivity is suspected because of ocular, upper and lower airway, and/or systemic symptoms that have rapid onset (minutes) after a definable latex exposure, a confirmatory skin or blood test for IgE antibody may be conducted to verify a state of sensitization within the individual. The definitive diagnosis would then be made only after consideration of the individual's clinical history and confirmatory in vivo and/or in vitro laboratory test results. If discordance remains between highly convincing latex-associated symptoms as identified in the history and repetitively negative confirmatory IgE antibody test results, then one of several types of in vivo provocation tests may be performed for adjudication. This overview examines the current state of the art in both in vivo and in vitro diagnostic methods for latex-specific IgE antibody detection in skin and blood. The performance, advantages, and limitations of each diagnostic method are compared.	Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA; Henry Ford Hosp, Dept Biostat, Detroit, MI 48202 USA; Med Coll Georgia, Sect Allergy, Augusta, GA 30912 USA	Johns Hopkins University; Henry Ford Health System; Henry Ford Hospital; University System of Georgia; Augusta University	Hamilton, RG (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Room 1A20,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.							Biagini R, 2000, J ALLERGY CLIN IMMUN, V105, pS82, DOI 10.1016/S0091-6749(00)90677-8; Biagini RE, 2001, CLIN DIAGN LAB IMMUN, V8, P1145, DOI 10.1128/CDLI.8.6.1145-1149.2001; Brown RH, 1998, ANESTHESIOLOGY, V89, P292, DOI 10.1097/00000542-199808000-00004; Bubak ME, 2000, J ALLERGY CLIN IMMUN, V105, pS83, DOI 10.1016/S0091-6749(00)90680-8; Charous BL, 2000, ANN ALLERG ASTHMA IM, V85, P285, DOI 10.1016/S1081-1206(10)62531-8; Chen Z, 2000, J ALLERGY CLIN IMMUN, V105, pS83, DOI 10.1016/S0091-6749(00)90679-1; Ebo DG, 1997, J ALLERGY CLIN IMMUN, V100, P618, DOI 10.1016/S0091-6749(97)70165-9; Gutman S, 1999, CLIN CHEM, V45, P746; HADJILIADIS D, 1995, J ALLERGY CLIN IMMUN, V96, P431, DOI 10.1016/S0091-6749(95)70067-6; Hadjiliadis D, 1996, J ALLERGY CLIN IMMUN, V97, P1202, DOI 10.1016/S0091-6749(96)70185-9; HALSEY JE, 1992, P INT LAT C SENS LAT, P27; Hamilton RG, 1999, J ALLERGY CLIN IMMUN, V103, P925, DOI 10.1016/S0091-6749(99)70440-9; HAMILTON RG, 1994, J LAB CLIN MED, V123, P594; Hamilton RG, 1998, J ALLERGY CLIN IMMUN, V102, P482, DOI 10.1016/S0091-6749(98)70139-3; Hamilton RG, 2000, CL ALLER IM, V15, P89; Hamilton RG, 1996, J ALLERGY CLIN IMMUN, V98, P872, DOI 10.1016/S0091-6749(96)80003-0; Hamilton RG, 2001, ANN ALLERG ASTHMA IM, V86, P353, DOI 10.1016/S1081-1206(10)62477-5; Hamilton RG, 1997, ANN ALLERG ASTHMA IM, V79, P266, DOI 10.1016/S1081-1206(10)63013-X; HAMILTON RG, 2001, CLIN IMMUNOLOGY PRIN; HAMILTON RG, 1992, P INT LAT C SENS LAT, P28; HEESE A, 1991, J AM ACAD DERMATOL, V25, P831, DOI 10.1016/S0190-9622(08)80977-2; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V93, P813, DOI 10.1016/0091-6749(94)90370-0; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; Kurtz KM, 2001, J ALLERGY CLIN IMMUN, V107, P178, DOI 10.1067/mai.2001.112125; Kurtz KM, 1999, ANN ALLERG ASTHMA IM, V83, P634, DOI 10.1016/S1081-1206(10)62886-4; KURUP VP, 1993, J ALLERGY CLIN IMMUN, V91, P1128, DOI 10.1016/0091-6749(93)90314-6; Laoprasert N, 1998, J ALLERGY CLIN IMMUN, V102, P998, DOI 10.1016/S0091-6749(98)70338-0; Lockey RF, 1995, ALLERGY PROC, V16, P293, DOI 10.2500/108854195778667800; MARCOS C, 1991, ANN ALLERGY, V67, P319; MURRALL PS, 1992, P INT LAT C SENS LAT, P29; Niggemann B, 1998, J ALLERGY CLIN IMMUN, V102, P665, DOI 10.1016/S0091-6749(98)70285-4; NOVEMBRE E, 1995, ALLERGY, V50, P511, DOI 10.1111/j.1398-9995.1995.tb01187.x; Ownby DR, 2000, ANN ALLERG ASTHMA IM, V84, P193, DOI 10.1016/S1081-1206(10)62755-X; PIPKORN U, 1987, ALLERGY, V42, P496, DOI 10.1111/j.1398-9995.1987.tb00371.x; PISATI G, 1994, EUR RESPIR J, V7, P332, DOI 10.1183/09031936.94.07020332; Saxon A, 2000, ANN ALLERG ASTHMA IM, V84, P199, DOI 10.1016/S1081-1206(10)62756-1; TOMAZIC VJ, 1994, J ALLERGY CLIN IMMUN, V93, P751, DOI 10.1016/0091-6749(94)90255-0; TURJANMAA K, 1989, ALLERGY, V44, P181, DOI 10.1111/j.1398-9995.1989.tb02259.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; Turjanmaa K, 1997, ALLERGY, V52, P41, DOI 10.1111/j.1398-9995.1997.tb02544.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURKELTAUB PC, 1989, J ALLERGY CLIN IMMUN, V84, P886, DOI 10.1016/0091-6749(89)90384-9; Vandenplas O, 2001, J ALLERGY CLIN IMMUN, V107, P542, DOI 10.1067/mai.2001.113519; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3	45	55	58	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2		S			S47	S56		10.1067/mai.2002.125334	http://dx.doi.org/10.1067/mai.2002.125334			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	586ET	12170243				2022-12-18	WOS:000177572200008
J	Mullol, J; Fernandez-Morata, JC; Roca-Ferrer, J; Pujols, L; Xaubet, A; Benitez, P; Picado, C				Mullol, J; Fernandez-Morata, JC; Roca-Ferrer, J; Pujols, L; Xaubet, A; Benitez, P; Picado, C			Cyclooxygenase 1 and cyclooxygenase 2 expression is abnormally regulated in human nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cyclooxygenase; nasal polyp; nasal mucosa; IL-1 beta; TNF-alpha; IFN-gamma	NF-KAPPA-B; INHALED PGE(2); MESSENGER-RNA; INDUCED BRONCHOCONSTRICTION; ARACHIDONIC-ACID; EPITHELIAL-CELLS; INDUCTION; SYNTHASE; CYCLO-OXYGENASE-2; INHIBITION	Background: There is evidence that impairment of prostanoid metabolism might be involved in the pathogenesis of nasal polyps (NPs). Prostanoids are synthesized by 2 cyclooxygenase (Cox) enzymes, one constitutive (Cox-1) and another inducible (Cox-2). Objective: The aim of these studies was to investigate Cox-1 and Cox-2 regulation in NPs of aspirin-tolerant human patients compared with that seen in nasal mucosa (NM). Methods: Cultured explants from human NPs and healthy mucosa from patients undergoing polypectomy and corrective nasal surgery, respectively, were examined for Cox-1 and Cox-2 expression by means of semiquantitative competitive PCR and Western blotting. Results: Cox-1 mRNA was spontaneously upregulated in cultured NM but not in NPs. A spontaneous but delayed upregulation of Cox-2 mRNA was found in NPs (24 hours) compared with that seen in NM (6 hours). After cytokine stimulation (IFN-gamma, IL-1beta, and TNF-alpha), the induction of Cox-2 mRNA and protein was also faster in NM (1 hour) than in NPs (4 hours). Conclusion: These data showing an abnormal regulation of Cox-1 and Cox-2 in NPs from aspirin-tolerant patients reinforce the concept that prostanoid metabolism might be important in the pathogenesis of inflammatory nasal diseases and suggest a potential role for this alteration in the formation of NPs.	Univ Barcelona, Hosp Clin,Dept Med, Inst Clin Pneumol & Cirurg Torac, Serv Pneumol, Barcelona, Spain; Univ Barcelona, Serv Otorinolaringol, Barcelona, Spain; Univ Barcelona, IDIBAPS, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Picado, C (corresponding author), Serv Pneumol & Allergia Resp, Villarroel 170, Barcelona 08036, Spain.		/AFX-9519-2022; /AAL-7347-2021; Roca-Ferrer, Jordi/AFQ-4652-2022; Pujols, Laura/G-8920-2015	Roca-Ferrer, Jordi/0000-0002-9527-2273; Pujols, Laura/0000-0003-3708-5098				Auboeuf D, 1997, ANAL BIOCHEM, V245, P141, DOI 10.1006/abio.1996.9986; Baenkler H. W., 1996, Rhinology (Utrecht), V34, P166; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; DJUKANOVIC R, 1995, CLIN EXP ALLERGY, V25, P582, DOI 10.1111/j.1365-2222.1995.tb01104.x; Dworski RT, 1997, AM J RESP CRIT CARE, V155, P351, DOI 10.1164/ajrccm.155.1.9001335; Economopoulos P, 1996, MOL CELL ENDOCRINOL, V117, P141, DOI 10.1016/0303-7207(95)03739-X; Fernandez-Morata JC, 2000, CLIN EXP ALLERGY, V30, P1275; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31, DOI 10.1164/ajrccm.159.1.9804030; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Hao CM, 2000, J CLIN INVEST, V106, P973, DOI 10.1172/JCI9956; HITCHCOCK M, 1978, J PHARMACOL EXP THER, V207, P630; KITA H, 1991, J IMMUNOL, V146, P2712; KITZLER J, 1995, ARCH BIOCHEM BIOPHYS, V316, P856, DOI 10.1006/abbi.1995.1115; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391, DOI 10.1164/ajrccm.161.2.9902034; LARSEN PL, 1997, NASAL POLYPOSIS INFL, P68; Martin C, 2001, AM J PHYSIOL-LUNG C, V280, pL595, DOI 10.1152/ajplung.2001.280.4.L595; MELILLO E, 1994, AM J RESP CRIT CARE, V149, P1138, DOI 10.1164/ajrccm.149.5.8173753; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Morteau O, 2000, J CLIN INVEST, V105, P469, DOI 10.1172/JCI6899; Newton R, 1997, FEBS LETT, V418, P135, DOI 10.1016/S0014-5793(97)01362-8; Okada Y, 2000, J CELL BIOCHEM, V78, P197, DOI 10.1002/(SICI)1097-4644(20000801)78:2<197::AID-JCB3>3.0.CO;2-C; Pang LH, 1998, BRIT J PHARMACOL, V125, P1320, DOI 10.1038/sj.bjp.0702193; PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87; Peebles RS, 2000, AM J RESP CRIT CARE, V162, P676; PETERS SP, 1986, RESPIRATION, V50, P116, DOI 10.1159/000195109; Picado C, 1999, AM J RESP CRIT CARE, V160, P291, DOI 10.1164/ajrccm.160.1.9808048; Pinto S, 1997, PROSTAG LEUKOTR ESS, V57, P533, DOI 10.1016/S0952-3278(97)90556-1; RAUD J, 1988, P NATL ACAD SCI USA, V85, P2315, DOI 10.1073/pnas.85.7.2315; Redington AE, 2001, THORAX, V56, P351, DOI 10.1136/thorax.56.5.351; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Scherle PA, 1998, J IMMUNOL, V161, P5681; Schmid M, 1999, ACTA OTO-LARYNGOL, V119, P277; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Sousa AR, 1997, THORAX, V52, P940, DOI 10.1136/thx.52.11.940; Wallace JL, 2000, GASTROENTEROLOGY, V119, P706, DOI 10.1053/gast.2000.16510; Xu XM, 1996, AM J PHYSIOL-CELL PH, V270, pC259, DOI 10.1152/ajpcell.1996.270.1.C259; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	41	55	55	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					824	830		10.1067/mai.2002.123534	http://dx.doi.org/10.1067/mai.2002.123534			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994707				2022-12-18	WOS:000175687800013
J	Hubeau, C; Puchelle, E; Gaillard, D				Hubeau, C; Puchelle, E; Gaillard, D			Distinct pattern of immune cell population in the lung of human fetuses with cystic fibrosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cystic fibrosis; lung; human fetus; mast cell; macrophage	MAST-CELLS; EPITHELIAL-CELLS; UP-REGULATION; IN-VITRO; INFLAMMATION; EXPRESSION; INFANTS; IL-8; DEGRANULATION; NEUTROPHILS	Background: Airway inflammation and infection are early events in cystic fibrosis (CF) pathogenesis. The existence of an imbalance in the immune cell population of the CF fetal airway before infection remains completely unknown. Objective: The aim of this study was to determine whether early signs of inflammation are observed in CF airways during human fetal development. Methods: Tracheas and lungs were collected from 21 CF and 16 non-CF fetuses. In tissue sections, the numbers of neutrophils, mast cells, macrophages, and B and T lymphocytes were quantitatively analyzed by means of image cytometry. The presence of IL-4, IL-6, IL-8, IL-10, RANTES, IFN-gamma, TNF-alpha and NF kappaB and its inhibitor I kappaB-alpha was qualitatively evaluated by immunofluorescent staining. Results: During fetal airway development, epithelial and glandular differentiation, as well as the distribution of inflammatory markers, was similar in CF and non-CF tissues. Significant differences between CF and non-CF fetal airways were observed only in the numbers of mast cells and macrophages. In the CF trachea, the mast cell number increased slowly but continuously, whereas in the non-CF trachea this number rapidly reached a plateau. In the CF lung, the macrophage number increased with time, whereas in the non-CF lung it decreased. Conclusion: Although no intrinsic inflammation was demonstrated, we observed a distinct appearance of mast cells and macrophages in CF airways in comparison with non-CF airways during fetal development. These 2 cell populations were greater in CF airways at a late stage of fetal development, suggesting their possible involvement in the early onset of inflammation in CF infants.	Univ Reims, IFR 53, INSERM, U514, Reims, France; CHU Maison Blanche, Lab Pol Bouin, Reims, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Reims Champagne-Ardenne; CHU de Reims	Gaillard, D (corresponding author), Fac Med, 51 Rue Cognacq Jay, F-51100 Reims, France.							Armstrong DS, 1997, AM J RESP CRIT CARE, V156, P1197, DOI 10.1164/ajrccm.156.4.96-11058; Bals R, 1999, J CLIN INVEST, V103, P303, DOI 10.1172/JCI6277; BARNES PJ, 1994, AM J RESP CRIT CARE, V150, pS42, DOI 10.1164/ajrccm/150.5_Pt_2.S42; BEDROSSIAN CWM, 1976, HUM PATHOL, V7, P195, DOI 10.1016/S0046-8177(76)80023-8; Boesiger J, 1998, J EXP MED, V188, P1135, DOI 10.1084/jem.188.6.1135; Bonfield TL, 1999, J ALLERGY CLIN IMMUN, V104, P72, DOI 10.1016/S0091-6749(99)70116-8; Cairns JA, 1996, J IMMUNOL, V156, P275; CANTIN A, 1995, AM J RESP CRIT CARE, V151, P939; CHAOUAT G, 1995, J IMMUNOL, V4, P621; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; Geiser M, 2000, EXP LUNG RES, V26, P551; GOULD SJ, 1991, NEUROPATH APPL NEURO, V17, P383, DOI 10.1111/j.1365-2990.1991.tb00738.x; HENDERSON WR, 1992, J PATHOL, V166, P395, DOI 10.1002/path.1711660412; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; MORRIS L, 1991, DEVELOPMENT, V112, P517; Muhlebach MS, 1999, AM J RESP CRIT CARE, V160, P186, DOI 10.1164/ajrccm.160.1.9808096; NADEL JA, 1991, AM REV RESPIR DIS, V144, pS48, DOI 10.1164/ajrccm/144.3_pt_2.S48; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SOBONYA RE, 1986, AM REV RESPIR DIS, V134, P290; SOROKIN SP, 1992, ANAT REC, V232, P527, DOI 10.1002/ar.1092320410; Stockley RA, 1999, AM J RESP CRIT CARE, V160, pS49, DOI 10.1164/ajrccm.160.supplement_1.13; STORDEUR P, 2000, EUR RESPIR REV, V10, P142; STURGESS J, 1982, AM J PATHOL, V106, P303; STURGESS J M, 1984, Journal of Pediatric Gastroenterology and Nutrition, V3, pS55, DOI 10.1097/00005176-198400031-00011; Tabary O, 1998, AM J PATHOL, V153, P921, DOI 10.1016/S0002-9440(10)65633-7; Taub DD, 1996, J CLIN INVEST, V97, P1931, DOI 10.1172/JCI118625; Tirouvanziam R, 2000, AM J RESP CELL MOL, V23, P121, DOI 10.1165/ajrcmb.23.2.4214; VAN SJ, 1990, ANNU REV IMMUNOL, V8, P253; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; Zahm JM, 1997, AM J PHYSIOL-CELL PH, V272, pC853, DOI 10.1152/ajpcell.1997.272.3.C853	32	55	56	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					524	529		10.1067/mai.2001.118516	http://dx.doi.org/10.1067/mai.2001.118516			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590376				2022-12-18	WOS:000171760300009
J	Heinisch, IVWM; Bizer, C; Volgger, W; Simon, HU				Heinisch, IVWM; Bizer, C; Volgger, W; Simon, HU			Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apoptosis; cell surface molecules; cellular activation; eosinophils; inflammation	COLONY-STIMULATING FACTOR; HUMAN 4-1BB; FAS RECEPTOR; T-LYMPHOCYTE; APOPTOSIS; ACTIVATION; MEMBER; FAMILY; CELLS; CYTOKINES	Background: CD137 (ILA/4-1BB), a member of the TNF/nerve growth factor receptor superfamily, has previously been suggested to be involved in T-cell activation and differentiation. Objective: The aim of this study was to investigate expression and potential function of CD137 in eosinophils. Methods: Eosinophils were isolated from normal control subjects as well as from patients with bronchial asthma, patients with atopic dermatitis, and patients with idiopathic eosinophilia. CD137 expression was analyzed by RT-PCR and flow cytometry. The in situ expression of CD137 on eosinophils in nasal polyp and skin tissues was analyzed through use of immunohistochemistry. To examine whether CD137 regulates eosinophil death and apoptosis, cells were stimulated with a plate-bound anti-CD137 antibody in the presence or absence of survival cytokines. Cell death was measured by means of an ethidium bromide exclusion test. Apoptosis was determined by analyzing phosphatidylserine surface exposure. Results: Blood and tissue eosinophils from patients with IgE-mediated allergic responses (atopic dermatitis, extrinsic asthma) express CD137. In contrast, eosinophils from normal control individuals and patients with non-IgE-mediated eosinophilic inflammatory responses (intrinsic asthma, idiopathic eosinophilia) express neither detectable levels of mRNA nor protein for CD137. Expression of CD137 in eosinophils was induced in vitro by stimulating the cells with supernatants derived from in vivo- or in vitro-activated T cells, suggesting that a soluble T cell-derived factor might be responsible for the observed phenomenon. Although CD137 expression was associated with increased IgE levels, IL-4 and IL-13 did not induce CD137 gene expression in eosinophils. Activation of CD137 abrogated both GM-CSF-mediated and IL-5-mediated antiapoptosis in CD137-expressing eosinophils but not in CD137-deficient eosinophils. In contrast, the survival effect of IFN-gamma was not affected by anti-CD137 treatment. Conclusion: Our data indicate that CD137 activation might limit GM-CSF-mediated and IL-5-mediated antiapoptosis of eosinophils. The absence of this potential anti-inflammatory mechanism might further increase eosinophil numbers at inflammatory sites in patients with intrinsic asthma and patients with idiopathic eosinophilia. The T cell-derived factor that induces CD137 expression in eosinophils remains to be identified.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Zurich, Swiss Inst Allergy & Asthma Res, Davos, Switzerland; High Altitude Clin Davos Wolfgang, Davos, Switzerland; Clin Dermatol & Allergy Alexanderhaus, Davos, Switzerland	University of Bern; Swiss Institute of Allergy & Asthma Research; University of Zurich	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.		Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736				ALDERSON MR, 1994, EUR J IMMUNOL, V24, P2219, DOI 10.1002/eji.1830240943; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Hebestreit H, 1998, J EXP MED, V187, P415, DOI 10.1084/jem.187.3.415; Heinisch IVWM, 2000, EUR J IMMUNOL, V30, P3441, DOI 10.1002/1521-4141(2000012)30:12<3441::AID-IMMU3441>3.0.CO;2-L; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Kankaanranta H, 2000, J ALLERGY CLIN IMMUN, V106, P77; Kim YJ, 1998, EUR J IMMUNOL, V28, P881, DOI 10.1002/(SICI)1521-4141(199803)28:03<881::AID-IMMU881>3.0.CO;2-0; Langstein J, 1998, J IMMUNOL, V160, P2488; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; Michel J, 1998, EUR J IMMUNOL, V28, P290, DOI 10.1002/(SICI)1521-4141(199801)28:01<290::AID-IMMU290>3.0.CO;2-S; *NAT HEART LUNG BL, 1992, NIH PUBL; Plotz SG, 1998, J ALLERGY CLIN IMMUN, V102, P1037, DOI 10.1016/S0091-6749(98)70344-6; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Schwarz H, 1996, BLOOD, V87, P2839, DOI 10.1182/blood.V87.7.2839.bloodjournal8772839; SCHWARZ H, 1993, GENE, V134, P295, DOI 10.1016/0378-1119(93)90110-O; SCHWARZ H, 1995, BLOOD, V85, P1043, DOI 10.1182/blood.V85.4.1043.bloodjournal8541043; SIMON HU, 1994, J IMMUNOL, V153, P364; Simon HU, 1998, CLIN EXP ALLERGY, V28, P1321; Simon HU, 2000, ALLERGY, V55, P910, DOI 10.1034/j.1398-9995.2000.055010910.x; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Simon HU, 1996, J EXP MED, V183, P1071, DOI 10.1084/jem.183.3.1071; Simon HU, 1997, J IMMUNOL, V158, P3902; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsuyuki S, 1995, J CLIN INVEST, V96, P2924, DOI 10.1172/JCI118364; VALERIUS T, 1990, J IMMUNOL, V145, P2950; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Wang SA, 1998, AIDS RES HUM RETROV, V14, P223, DOI 10.1089/aid.1998.14.223; Wedi B, 1997, J ALLERGY CLIN IMMUN, V100, P536, DOI 10.1016/S0091-6749(97)70147-7; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868	36	55	59	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					21	28		10.1067/mai.2001.116864	http://dx.doi.org/10.1067/mai.2001.116864			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447378	Bronze			2022-12-18	WOS:000170171200003
J	Smith, AM; Benjamin, DC; Hozic, N; Derewenda, U; Smith, WA; Thomas, WR; Gafvelin, G; van Hage-Hamsten, M; Chapman, MD				Smith, AM; Benjamin, DC; Hozic, N; Derewenda, U; Smith, WA; Thomas, WR; Gafvelin, G; van Hage-Hamsten, M; Chapman, MD			The molecular basis of antigenic cross-reactivity between the group 2 mite allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	FEB 19-26, 1997	SAN FRANCISCO, CA	Amer Acad Allergy Asthma & Immunol		mite; allergen; isoform; epitope	HOUSE-DUST-MITE; GROUP-II DERMATOPHAGOIDES; LEPIDOGLYPHUS-DESTRUCTOR; RECOMBINANT ISOFORMS; EUROGLYPHUS-MAYNEI; MAJOR ALLERGEN; IGE-BINDING; P-I; PTERONYSSINUS; ANTIBODY	Background: Mite group 2 allergens Der p 2, Der f 2, and fur m 2 are 14-kDa proteins of unknown function that share 83% to 85% amino acid sequence identity. Isoforms of the allergens within each genus have been identified which differ by 3 or 4 amino acids, but little is known of the influence of group 2 polymorphisms on human IgE antibody binding. Objective: The purpose of this study was to investigate the importance of interspecies and isoform substitutions on murine mAb and IgE antibody binding and on the molecular structure of the group 2 allergens. Methods: Site-directed mutagenesis was used to incorporate the isoform amino acid substitutions onto the Der p 2.0101 sequence. Recombinant allergens were expressed and purified from Escherichia coli and used to evaluate antibody binding by enzyme-linked immunosorbent assay (ELISA). Molecular modeling of the tertiary structure was used to analyze structural differences between the various group 2 allergens. Results: The substitution of asparagine for aspartic acid at position 114 restored mAb binding of rDer p 2.0101; the other Der p 2 isoforms and the 3 rDer f 2 isoforms also reacted in the 2-site ELISA. The correlation of IgE binding to the Der p 2 isoforms was excellent and tended to be higher in the isoforms with the asparagine 114 substitution (r(2) = 0.87 vs r(2) = 0.95), rEur m 2.0101 bound to all mAb except 7A1: when compared with rDer p 2 for IgE binding, rEur m 2.0101 gave a correlation coefficient of r(2) = 0.68. Molecular modeling revealed that fur m 2 and the storage mite homologs Lep d 2 and Tyr p 2 retain the tertiary fold of Der p 2. fur m 2 has a conserved surface, whereas Lep d 2 and Tyr p 2 present most of the amino acid substitutions on this surface. Lep d 2 and Tyr p 2 did not react with mAb or with sera from patients with IgE to Dermetophagoides species. Conclusion: The isoform substitutions of rDer p 2 can be distinguished by mAb. The allergenic cross-reactivity between Der p 2, Der f 2, and fur m 2 is a direct result of the conserved antigenic surface, whereas the lack of cross-reactivity with Lep d 2 and Sr p 2 is a result of the multiple substitutions across this surface.	Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Western Australia, TVW Inst Child Hlth Res, Perth, WA, Australia; Univ Western Australia, Ctr Child Hlth Res, Perth, WA, Australia; Karolinska Hosp & Inst, Dept Med, Div Clin Immunol & Allergy, Stockholm, Sweden	University of Virginia; University of Virginia; University of Virginia; University of Western Australia; University of Western Australia; Karolinska Institutet; Karolinska University Hospital	Smith, AM (corresponding author), Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.		van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Chapman, Martin/0000-0002-0845-3632; Gafvelin, Guro/0000-0003-1618-4011	NIAID NIH HHS [AI32557, AI34607, AI20565] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034607, U01AI034607, R01AI020565, R01AI032557, R37AI020565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKAGAWA M, 1991, Japanese Journal of Allergology, V40, P1239; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARRUDA LK, 1992, EXP APPL ACAROL, V16, P129, DOI 10.1007/BF01201496; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BRUCCOLERI RE, 1987, BIOPOLYMERS, V26, P137, DOI 10.1002/bip.360260114; BRUCCOLERI RE, 1986, J COMPUT CHEM, V7, P165, DOI 10.1002/jcc.540070210; BRUCCOLERI RE, 1993, MOL SIMULAT, V10, P151, DOI 10.1080/08927029308022163; CHAPMAN MD, 1995, PEDIAT ALLERG IMM-UK, V6, P8, DOI 10.1111/j.1399-3038.1995.tb00378.x; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P124, DOI 10.1159/000235102; Chua KY, 1996, CLIN EXP ALLERGY, V26, P829, DOI 10.1111/j.1365-2222.1996.tb00615.x; COLLOFF MJ, 1991, CLIN EXP ALLERGY, V21, P225, DOI 10.1111/j.1365-2222.1991.tb00834.x; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; Derewenda U, 2001, J ALLERGY CLIN IMMUN, V107, pS126; Eriksson TLJ, 1998, EUR J BIOCHEM, V251, P443, DOI 10.1046/j.1432-1327.1998.2510443.x; Furmonaviciene R, 2000, CLIN EXP ALLERGY, V30, P1307, DOI 10.1046/j.1365-2222.2000.00897.x; Gafvelin G, 2001, J ALLERGY CLIN IMMUN, V107, P511, DOI 10.1067/mai.2001.112264; Gehlhar K, 1997, EUR J BIOCHEM, V247, P217, DOI 10.1111/j.1432-1033.1997.00217.x; Hakkaart GAJ, 1998, CLIN EXP ALLERGY, V28, P169, DOI 10.1046/j.1365-2222.1998.00205.x; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; Kemp SF, 1997, CLIN EXP ALLERGY, V27, P893, DOI 10.1111/j.1365-2222.1997.tb01229.x; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; Morgan MS, 1997, J ALLERGY CLIN IMMUN, V100, P222, DOI 10.1016/S0091-6749(97)70228-8; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; Mueller GA, 2001, J BIOL CHEM, V276, P9359, DOI 10.1074/jbc.M010812200; Mueller GA, 1997, J BIOL CHEM, V272, P26893, DOI 10.1074/jbc.272.43.26893; NISHIYAMA C, 1994, INT ARCH ALLERGY IMM, V105, P62, DOI 10.1159/000236804; Olsson S, 1998, CLIN EXP ALLERGY, V28, P984, DOI 10.1046/j.1365-2222.1998.00375.x; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; Park JW, 1999, ANN ALLERG ASTHMA IM, V83, P533, DOI 10.1016/S1081-1206(10)62865-7; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; SCHMIDT M, 1995, FEBS LETT, V370, P11, DOI 10.1016/0014-5793(95)98164-E; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; Smith AM, 1997, CLIN EXP ALLERGY, V27, P593, DOI 10.1111/j.1365-2222.1997.tb00750.x; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Smith W, 1999, INT ARCH ALLERGY IMM, V118, P15, DOI 10.1159/000024026; SMITH W, 2001, IN PRESS J ALLERGY C; Thomas WR, 1998, ALLERGY, V53, P821, DOI 10.1111/j.1398-9995.1998.tb03987.x; THOMAS WR, 1995, CLIN EXP ALLERGY, V25, P667, DOI 10.1111/j.1365-2222.1995.tb01117.x; TOPHAM CM, 1994, PROTEIN ENG, V7, P869, DOI 10.1093/protein/7.7.869; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P23; VARELA J, 1994, EUR J BIOCHEM, V225, P93, DOI 10.1111/j.1432-1033.1994.00093.x; Yuuki T, 1997, INT ARCH ALLERGY IMM, V112, P44, DOI 10.1159/000237430	44	55	63	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					977	984		10.1067/mai.2001.115629	http://dx.doi.org/10.1067/mai.2001.115629			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	445JR	11398074				2022-12-18	WOS:000169454800007
J	Keramidaris, E; Merson, TD; Steeber, DA; Tedder, TF; Tang, MLK				Keramidaris, E; Merson, TD; Steeber, DA; Tedder, TF; Tang, MLK			L-selectin and intercellular adhesion molecule 1 mediate lymphocyte migration to the inflamed airway/lung during an allergic inflammatory response in an animal model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic airway disease/asthma; adhesion molecules; L-selectin; intercellular adhesion molecule 1; inflammation; migration; lymphocyte	DEFICIENT MICE; PULMONARY MICROCIRCULATION; LEUKOCYTE KINETICS; T-CELLS; LUNGS; SITES; SEQUESTRATION; RECRUITMENT; EXPRESSION; CHALLENGE	T lymphocytes play a critical role in the development of allergic inflammation in asthma, Early in the allergic response, T lymphocytes migrate from the circulation into the lung to initiate and propagate airway inflammation, The adhesion molecules that mediate lymphocyte entry into inflamed lung have not been defined, This study directly examined the roles of L-selectin and intercellular adhesion molecule 1 (ICAM-1) in lymphocyte migration to the lung during an allergic inflammatory response in an animal model of asthma, Short-term (1 hour) in vivo migration assays and various combinations of adhesion molecule-deficient and wild-type mice were used. Migration of in vivo activated lymphocytes into inflamed lung was significantly greater than entry of resting lymphocytes into noninflamed lung (24.5% +/- 2.7% vs 9.5% +/- 1.3%, P = .001). Migration of activated lymphocytes into inflamed lung was inhibited by 30% in the absence of L-selectin (17.3% +/- 1.3%, P = .04), 47% in the absence of cell surface ICAM-1 (13.0% +/- 2.5%, P = .01), and 47% in the absence of endothelial ICAM-1 (13.0% +/- 2.5%, P = .01), Loss of ICAM-1 on both lymphocytes and lung endothelium inhibited lymphocyte migration by 60% (9.8% +/- 1.8%, P = .002), These endings demonstrate dear roles for both L-selectin and ICAM-1 in lymphocyte migration to the lung during an allergic inflammatory response, with ICAM-1 playing a greater role.	Royal Childrens Hosp, Dept Immunol, Parkville, Vic 3052, Australia; Duke Univ, Med Ctr, Dept Immunol, Durham, NC USA	Royal Children's Hospital Melbourne; Duke University	Tang, MLK (corresponding author), Royal Childrens Hosp, Dept Immunol, Flemington Rd, Parkville, Vic 3052, Australia.		Merson, Tobias D/D-5375-2015	Merson, Tobias D/0000-0002-7246-3608; Tang, Mimi/0000-0002-3839-5293				ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BENTLEY AM, 1993, J ALLERGY CLIN IMMUN, V92, P857, DOI 10.1016/0091-6749(93)90064-M; Bullard DC, 1996, J IMMUNOL, V157, P3153; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Doyle NA, 1997, J CLIN INVEST, V99, P526, DOI 10.1172/JCI119189; GARLISI CG, 1995, CLIN IMMUNOL IMMUNOP, V75, P75, DOI 10.1006/clin.1995.1055; GEBB SA, 1995, J APPL PHYSIOL, V79, P493, DOI 10.1152/jappl.1995.79.2.493; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; KING PD, 1995, J IMMUNOL, V154, P6080; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; Molet S, 1999, J ALLERGY CLIN IMMUN, V104, P205, DOI 10.1016/S0091-6749(99)70137-5; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; Nishio K, 1998, AM J RESP CRIT CARE, V157, P599, DOI 10.1164/ajrccm.157.2.9704102; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; Steeber DA, 1998, P NATL ACAD SCI USA, V95, P7562, DOI 10.1073/pnas.95.13.7562; Steeber DA, 1999, J IMMUNOL, V163, P2176; Tang MLK, 1997, J IMMUNOL, V158, P5191; Yamaguchi K, 1997, LAB INVEST, V76, P809	20	55	59	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					734	738		10.1067/mai.2001.114050	http://dx.doi.org/10.1067/mai.2001.114050			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295667				2022-12-18	WOS:000168190100030
J	Ihaku, D; Cameron, L; Suzuki, M; Molet, S; Martin, J; Hamid, Q				Ihaku, D; Cameron, L; Suzuki, M; Molet, S; Martin, J; Hamid, Q			Montelukast, a leukotriene receptor antagonist, inhibits the late airway response to antigen, airway eosinophilia, and IL-5-expressing cells in Brown Norway rats	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Montelukast; IL-5; antigen-induced late response; Brown Norway rat; leukotriene	BRONCHOALVEOLAR LAVAGE; CELLULAR INFILTRATION; ALLERGEN CHALLENGE; MESSENGER-RNA; ATOPIC ASTHMA; GUINEA-PIG; IN-VIVO; EXPRESSION; EOTAXIN; 5-LIPOXYGENASE	Background: Asthma is characterized by airflow obstruction, inflammatory cell infiltration, and the synthesis of mediators, such as T-H2 cytokines and leukotrienes, in the airways. Cysteinyl leukotriene (cysLT) receptor antagonists have recently been associated with clinical improvement of asthma and reduced airway inflammation. Whether the beneficial effects of cysLT antagonists are mediated through the modulation of cytokine expression has not been determined, Objective: The aim of the study was to determine the presence of eosinophils and IL-5 messenger (m)RNA(+) cells within the lungs of antigen-challenged Brown Norway rats after treatment with the cysLT(1) receptor antagonist montelukast (MK). Methods: Ovalbumin-sensitized Brown Norway rats were treated with either MK or saline before ovalbumin challenge, Pulmonary mechanics were monitored for 8 hours. Subsequently, immunocytochemistry and in situ hybridization were used to examine bronchoalveolar lavage (BAL) fluid and lung tissue for cells expressing major basic protein (eosinophils) and IL-5 mRNA, respectively. Simultaneous in situ hybridization and immunocytochemistry was used to phenotype the cells expressing mRNA encoding IL-5. Results: Animals treated with MK had significantly lower lung resistance and fewer eosinophils and IL-5 mRNA(+) cells within BAL fluid and lung tissue compared with that found in saline-treated animals. Colocalizaton studies revealed that the majority of IL-5 mRNA(+) cells were T cells and that the number of IL-5 mRNA(+)/CD3(+) or IL-5 mRNA(+)/major basic proteins cells were significantly less within BAL from animals treated with MK than from those treated with saline. Conclusions: These results indicate that the cysLT(1) receptor antagonist MK can diminish the pulmonary response to antigen, tissue eosinophilia, and the number of cells expressing IL-5 mRNA, suggesting that leukotrienes may also regulate the allergic response through the modulation of inflammation and cytokine synthesis.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; McGill Univ, Montreal Chest Inst, Res Ctr, Montreal, PQ H2X 2P2, Canada	McGill University; McGill University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.			Martin, James/0000-0001-7574-5363				BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; BOCHNER BS, 1995, J IMMUNOL, V154, P799; Busse W, 1998, ANN ALLERG ASTHMA IM, V81, P17, DOI 10.1016/S1081-1206(10)63106-7; DANDURAND RJ, 1994, AM J RESP CRIT CARE, V149, P1499, DOI 10.1164/ajrccm.149.6.8004305; Diamant Z, 1999, CLIN EXP ALLERGY, V29, P42; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; Eidelman DH, 1996, AM J RESP CELL MOL, V15, P582, DOI 10.1165/ajrcmb.15.5.8918365; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933, DOI 10.1164/ajrccm.159.6.9805039; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1992, BLOOD, V80, P1496; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hojo M, 1998, AM J RESP CRIT CARE, V158, P1127, DOI 10.1164/ajrccm.158.4.9804001; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; KAY AB, 1999, J ALLERGY CLIN IMMUN, P103; Koshino T, 1998, BIOCHEM BIOPH RES CO, V247, P510, DOI 10.1006/bbrc.1998.8789; Kotsimbos TC, 1996, P ASSOC AM PHYSICIAN, V108, P368; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; LAVIOLETTE M, 1995, EUR RESPIR J, V8, P1465; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; Mochizuki M, 1998, J IMMUNOL, V160, P60; Munoz NM, 1997, AM J RESP CRIT CARE, V155, P1398, DOI 10.1164/ajrccm.155.4.9105085; Nagase T, 1996, J APPL PHYSIOL, V80, P583, DOI 10.1152/jappl.1996.80.2.583; NAGY L, 1982, CLIN EXP IMMUNOL, V47, P541; Nakamura Y, 1998, THORAX, V53, P835, DOI 10.1136/thx.53.10.835; Noonan MJ, 1998, EUR RESPIR J, V11, P1232, DOI 10.1183/09031936.98.11061232; OSBORN RR, 1992, PULM PHARMACOL, V5, P153, DOI 10.1016/0952-0600(92)90035-F; POWELL WS, 1995, AM J RESP CRIT CARE, V151, P1143; POWELL WS, 1995, J IMMUNOL, V154, P4123; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; SAPIENZA S, 1990, AM REV RESPIR DIS, V142, P353, DOI 10.1164/ajrccm/142.2.353; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SHICHIJO M, 1995, INT ARCH ALLERGY IMM, V107, P587, DOI 10.1159/000237104; Spada CS, 1997, ADV EXP MED BIOL, V400, P699; STANKOVA J, 1992, IMMUNOLOGY, V76, P258; Underwood DC, 1996, AM J RESP CRIT CARE, V154, P850, DOI 10.1164/ajrccm.154.4.8887574; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; WARDLAW AJ, 1989, J ALLERGY CLIN IMMUN, V84, P19, DOI 10.1016/0091-6749(89)90173-5; Wardlaw AJ, 1996, ANN NY ACAD SCI, V796, P124, DOI 10.1111/j.1749-6632.1996.tb32574.x; WATANABE A, 1995, J CLIN INVEST, V96, P1303, DOI 10.1172/JCI118165; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; YU WG, 1995, AM J RESP CELL MOL, V13, P477, DOI 10.1165/ajrcmb.13.4.7546778; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	49	55	60	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1147	1154		10.1016/S0091-6749(99)70006-0	http://dx.doi.org/10.1016/S0091-6749(99)70006-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588994				2022-12-18	WOS:000084289200005
J	Agertoft, L; Pedersen, S				Agertoft, L; Pedersen, S			Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						children; intranasal steroids; knemometry; growth; systemic effect	URINE CORTISOL EXCRETION; ASTHMATIC-CHILDREN; INHALED GLUCOCORTICOSTEROIDS; FLUTICASONE PROPIONATE; SYSTEMIC ACTIVITY; LINEAR GROWTH; DOUBLE-BLIND; KNEMOMETRY; HORMONE	Background: Mometasone furoate (MF) aqueous nasal spray is a potent intranasal glucocorticoid with low systemic bioavailability Knemometry has been shown to be a sensitive method of detecting systemic effects of exogenous steroids in children, Objective: We sought to assess whether MF (100 or 200 mu g) or budesonide intranasal aqueous spray (400 mu g) influences the short-term lower leg growth rate in children with seasonal or perennial allergic rhinitis, Methods: MF, budesonide, and placebo were administered once daily for 2 weeks to 22 children aged 7 to 12 years (mean 10 years) in a randomized, double-blind, crossover study, Lower leg measurements were done before and after each 2-week treatment period. Two-week washout intervals separated each treatment period. Results: There were no significant differences in lower leg growth rates among the MF 200 mu g (0.95 +/- 0.79 mm; mean +/- SD), budesonide 100 mu g (0.73 +/- 0.61 mm), or placebo (0.69 +/- 0.70 mm) groups. The growth rate of the group receiving a 100-mu g dose of MF (1.16 +/- 0.67 mm) was greater than that for the group receiving placebo (P = .024) or budesonide (P = .033), So statistically significant sequence effect (P = .11), carry-over effect (P = .24), overall treatment effect (P = .086), or period effect (P = .065) was detected, Conclusion: No short-term adverse effects on linear lower leg growth rates were detected after once daily MF or budesonide at clinically relevant doses.	Kolding Cty Hosp, Dept Pediat, DK-6000 Kolding, Denmark	Kolding Hospital; University of Southern Denmark	Agertoft, L (corresponding author), Kolding Cty Hosp, Dept Pediat, DK-6000 Kolding, Denmark.			Agertoft, Lone/0000-0001-6840-7921				Agertoft L, 1997, EUR RESPIR J, V10, P1507, DOI 10.1183/09031936.97.10071507; CHANG KC, 1982, CLIN ALLERGY, V12, P369, DOI 10.1111/j.1365-2222.1982.tb02541.x; DEAN HJ, 1990, ACTA PAEDIATR SCAND, V79, P57, DOI 10.1111/j.1651-2227.1990.tb11331.x; Doull IJM, 1998, ARCH DIS CHILD, V78, P172, DOI 10.1136/adc.78.2.172; GELANDER L, 1994, ACTA PAEDIATR, V83, P1249, DOI 10.1111/j.1651-2227.1994.tb13006.x; GHIGO E, 1993, J ENDOCRINOL INVEST, V16, P271, DOI 10.1007/BF03348828; HARTER JG, 1963, NEW ENGL J MED, V269, P591, DOI 10.1056/NEJM196309192691201; HERMANUSSEN M, 1988, ANN HUM BIOL, V15, P1, DOI 10.1080/03014468800009411; HEUCK C, 1995, EUR RESP J S19, V8, pS470; KARLBERG J, 1994, ACTA PAEDIATR, V83, P777, DOI 10.1111/j.1651-2227.1994.tb13138.x; KARLBERG J, 1993, ACTA PAEDIATR, V82, P631, DOI 10.1111/j.1651-2227.1993.tb18029.x; MARSHALL WA, 1975, ANN HUM BIOL, V2, P243, DOI 10.1080/03014467500000821; MORRIS HG, 1975, PEDIATR RES, V9, P579, DOI 10.1203/00006450-197507000-00005; Rachelefsky GS, 1998, J ALLERGY CLIN IMMUN, V101, pS236; Smith CL, 1998, ARZNEIMITTEL-FORSCH, V48, P957; WALES JKH, 1988, ARCH DIS CHILD, V63, P981, DOI 10.1136/adc.63.8.981; WALES JKH, 1989, THESIS U SHEFFIELD; WOLTHERS OD, 1995, RESP MED, V89, P347, DOI 10.1016/0954-6111(95)90006-3; WOLTHERS OD, 1993, ARCH DIS CHILD, V68, P673, DOI 10.1136/adc.68.5.673; WOLTHERS OD, 1992, PEDIATRICS, V89, P839; WOLTHERS OD, 1991, BMJ-BRIT MED J, V303, P163, DOI 10.1136/bmj.303.6795.163; WOLTHERS OD, 1990, BRIT MED J, V301, P145, DOI 10.1136/bmj.301.6744.145; WOLTHERS OD, 1993, PEDIATRICS, V91, P517; WOLTHERS OD, 1992, ACTA PAEDIATR, V81, P902, DOI 10.1111/j.1651-2227.1992.tb12132.x; WOLTHERS OD, 1994, ALLERGY, V49, P96, DOI 10.1111/j.1398-9995.1994.tb00807.x; WOLTHERS OD, 1993, ACTA PAEDIATR, V82, P635, DOI 10.1111/j.1651-2227.1993.tb12780.x; WOLTHERS OD, 1996, KNEMOMETRY ASSESSMEN, P1; ZEITLIN S, 1993, RESP MED, V87, P445, DOI 10.1016/0954-6111(93)90071-7	28	55	58	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					948	952		10.1016/S0091-6749(99)70073-4	http://dx.doi.org/10.1016/S0091-6749(99)70073-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550737	Bronze			2022-12-18	WOS:000083778400015
J	Vaughan, JW; McLaughlin, TE; Perzanowski, MS; Platts-Mills, TAE				Vaughan, JW; McLaughlin, TE; Perzanowski, MS; Platts-Mills, TAE			Evaluation of materials used for bedding encasement: Effect of pore size in blocking cat and dust mite allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mite avoidance; encasements; breathable fabrics; allergen avoidance	ASTHMA	Background: Mattress and pillow encasings are recommended for patients allergic to dust mites. Many encasements block allergen and are vapor permeable but do not allow free passage of air through the material, Recently, breathable fabrics made from tightly woven synthetic fibers or nonwoven synthetics have been recommend as encasements. Objective: The purpose of this study was to develop a method for testing encasement materials made of breathable fabrics. Methods: Dust samples containing a known quantity of allergen (Der f 1, Der p 1, and Fel d 1) were pulled across a variety of fabrics using a modified dust trap. Airflow through the dust trap was controlled with a vacuum pump. Five minutes after dust was introduced, the pump was shut off. A filter located downstream of the fabric collected allergen passing through the fabric during the test and was assayed with ELISA for the relevant allergen, Fabrics to be tested were obtained from manufacturers and specialty catalogs. Results: As the average pore size decreases, the airflow through a fabric becomes restricted, and the pressure differential created by the vacuum pump increases. Dust mite allergens (Der f 1 and Der p 1) were blocked below detectable limits by fabrics of less than 10 mu m in pore size. Fabrics with an average pore size of 6 mu m or less blocked cat allergen (Fel d 1). Conclusion: The method we developed provided a rigorous and reliable test for leakage of common indoor allergens through breathable barrier fabrics. Our results show that tightly woven fabrics and nonwoven synthetic fabrics can block common indoor allergens but still allow airflow.	Univ Virginia, Asthma & Allerg Dis Ctr, Hlth Sci Ctr, Charlottesville, VA 22908 USA	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, Hlth Sci Ctr, Box 225, Charlottesville, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [AI-34607, AI-20565] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034607, U19AI034607, R01AI020565, R37AI020565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; *NAT HEART LUNG BL, 1997, 2 NIH NAT HEART LUNG; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; 1997, J ALLERGY CLIM IMMUN, V100, pS1	9	55	58	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				227	231		10.1016/S0091-6749(99)70495-1	http://dx.doi.org/10.1016/S0091-6749(99)70495-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949312	Bronze			2022-12-18	WOS:000078630100008
J	Dell, SJ; Lowry, GM; Northcutt, JA; Howes, J; Novack, GD; Hart, K				Dell, SJ; Lowry, GM; Northcutt, JA; Howes, J; Novack, GD; Hart, K			A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology	MAY 11-17, 1997	FT LAUDERDALE, FL	Assoc Res Vis & Ophthalmol		loteprednol etabonate; seasonal allergic conjunctivitis; controlled clinical trial; ocular allergy	PRESSURE RESPONSE; EFFICACY; SAFETY	Background: Loteprednol etabonate is a site-active corticosteroid with efficacy and safety in treating ocular inflammation at the 0.5% concentration. Evidence from dose-response studies suggested that the 0.2% concentration might be effective in treating ocular allergy. Objectives: The objective of this study was to evaluate the effects of 0.2% loteprednol etabonate in reducing the signs and symptoms of seasonal allergic conjunctivitis. Methods: This was a randomized, double-masked, placebo-controlled, parallel-group multicenter study. Patients with signs and symptoms of environmental seasonal allergic conjunctivitis received either loteprednol etabonate or placebo bilaterally four times daily for 42 days. Results: Enrolled were 133 patients (66 receiving loteprednol etabonate; 67 receiving placebo). A reduction in severity was seen in both loteprednol etabonate and placebo groups for bulbar conjunctival injection (1.3 vs 0.9 units on a 0 to 3 scale) and itching (3.5 vs 3.1 units on a 0 to 4 scale) over the first 2 weeks. The treatment effect was -0.5 and -0.6 units in favor of loteprednol etabonate (P <.001). Resolution (the proportion of patients with the sign or symptom no longer present) at visit 4 (day 14) strongly favored loteprednol etabonate-treated patients over placebo-treated patients (31% and 9%, and 54% and 38%, for injection and itching, respectively). Both treatments were well tolerated. No patients in either treatment group (0 for loteprednol etabonate and 0 for vehicle) had an elevation of intraocular pressure of 10 mm Hg or greater during the 6 weeks of treatment. Conclusions: Loteprenol etabonate (0.2%) was more effective than placebo in the treatment of seasonal allergic conjunctivitis. Loteprednol etabonate (0.2%) had a safety profile comparable to placebo during this 6-week trial.	PharmaLog Dev Inc, San Rafael, CA 94903 USA; Texas Eye Care, Austin, TX USA; Texas Eye Care, San Antonio, TX USA; Pharmos Corp, Alachua, FL USA; DATA Inc, Murray, KY USA		Novack, GD (corresponding author), PharmaLog Dev Inc, 17 Bridgegate Dr, San Rafael, CA 94903 USA.		Novack, Gary/AAB-3088-2019	Novack, Gary/0000-0002-9699-8543				ABELSON MB, 1990, OPHTHALMOLOGY, V65, P156; [Anonymous], ADV DRUG RES; Asbell Penny, 1997, CLAO Journal, V23, P31; BARTLETT JD, 1993, J OCUL PHARMACOL, V9, P157, DOI 10.1089/jop.1993.9.157; BODOR N, 1984, MED RES REV, V4, P449, DOI 10.1002/med.2610040402; Dell SJ, 1997, AM J OPHTHALMOL, V123, P791, DOI 10.1016/S0002-9394(14)71128-6; DRUZGALA P, 1991, CURR EYE RES, V10, P933, DOI 10.3109/02713689109020329; FRIEDLAENDER MH, 1993, SURV OPHTHALMOL, V38, P105, DOI 10.1016/0039-6257(93)90035-6; Friedlaender MH, 1997, AM J OPHTHALMOL, V123, P455, DOI 10.1016/S0002-9394(14)70171-0; George M., 1997, Investigative Ophthalmology and Visual Science, V38, pS427; *LOT ET POST INFL, IN PRESS OPHTHALMOLO; Meyer FP, 1996, CLIN PHARMACOL THER, V60, P347, DOI 10.1016/S0009-9236(96)90062-4; NEUMANN R, 1994, INT CONGR SER, V1068, P245; RAY WA, 1985, INVEST OPHTH VIS SCI, V26, P1186; REIDENBERG MM, 1968, NEW ENGL J MED, V279, P678, DOI 10.1056/NEJM196809262791304; STEWART RH, 1984, CURR EYE RES, V3, P835, DOI 10.3109/02713688409000796; ZYBSZYNSKI B, 1997, INVEST OPHTH VIS SCI, V38, pS426	17	55	56	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					251	255		10.1016/S0091-6749(98)70094-6	http://dx.doi.org/10.1016/S0091-6749(98)70094-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	113EH	9723669				2022-12-18	WOS:000075537100017
J	Spector, S; Tan, RA				Spector, S; Tan, RA			Antileukotrienes in chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SKIN		Univ Calif Los Angeles, Ctr Med, Div Clin Immunol & Allergy, Los Angeles, CA 90025 USA; Antelope Valley Allergy Med Grp, Palmdale, CA USA	University of California System; University of California Los Angeles	Spector, S (corresponding author), Univ Calif Los Angeles, Ctr Med, Div Clin Immunol & Allergy, Los Angeles, CA 90025 USA.							MAXWELL DL, 1990, J ALLERGY CLIN IMMUN, V86, P759, DOI 10.1016/S0091-6749(05)80180-0; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; Spector SL, 1995, ANN ALLERG ASTHMA IM, V75, P463	3	55	56	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				572	572						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564821				2022-12-18	WOS:000073113500033
J	Nayak, AS; Ellis, MH; Gross, GN; Mendelson, LM; Schenkel, EJ; Lanier, BO; Simpson, B; Mullin, ME; Smith, JA				Nayak, AS; Ellis, MH; Gross, GN; Mendelson, LM; Schenkel, EJ; Lanier, BO; Simpson, B; Mullin, ME; Smith, JA			The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						triamcinolone acetonide; adrenocortical function; corticosteroids; allergic rhinitis; pediatric; hay fever; aqueous nasal spray; clinical trial; pharmacokinetics	DOUBLE-BLIND; PERENNIAL RHINITIS; BECLOMETHASONE DIPROPIONATE; ADRENAL-FUNCTION; AEROSOL; EFFICACY; PLACEBO; CORTICOSTEROIDS; MULTICENTER; FLUNISOLIDE	Background: Suppression of adrenocortical function, a risk associated with oral corticosteroids, is minimized with intranasal corticosteroids. Triamcinolone acetonide (TAA) aqueous nasal spray, at therapeutic doses, has no measurable effect on adrenocortical function in adults with allergic rhinitis. Objective: This double-blind, placebo-controlled study compared the effect of once-daily TAA aqueous nasal spray (220 or 440 mu g) with placebo on adrenocortical function after 6 weeks of treatment in pediatric (children 6 to 12 years of age) patients with allergic rhinitis. The pharmacokinetic profile of TAA was examined after once-daily intranasal administration of TAA aqueous nasal spray 440 mu g for 6 weeks. Methods: Eighty children received TAA aqueous nasal spray 220 mu g or 440 mu g or placebo for 6 weeks. Adrenocortical function was assessed by analyzing plasma cortisol levels before stimulation (0 hour) and at 30 and 60 minutes after a rapid 1-hour intravenous cosyntropin stimulation test performed before treatment and after 6 weeks of treatment. Samples for pharmacokinetic evaluation were collected from 19 patients at baseline (0 hour) and at 0.5, 1, 1.5, and 6 hours after the final dose of study medication. Results: After 6 weeks, no significant effects on adrenocortical function were observed at 30 or 60 minutes after cosyntropin stimulation with either dose of TAA aqueous nasal spray. TAA concentrations in plasma showed rapid elimination of the drug, with little or no accumulation. Conclusions: TAA aqueous nasal spray (220 or 440 mu g/day) has no measurable effect on adrenocortical function in pediatric patients with allergic rhinitis. Pharmacokinetic parameters after 440 mu g/day of TAA aqueous nasal spray indicate a rapid decline of plasma drug levels, with little or no systemic accumulation of study drug.	Univ Texas, SW Med Sch, Dallas, TX 75230 USA; Dept Allergy Immunol, Orange, CA USA; Univ Connecticut, Sch Med, Dept Allergy Immunol, W Hartford, CT USA; Med Coll Penn & Hahnemann Univ, Dept Allergy Immunol, Easton, PA USA; Harris Hosp, Dept Allergy Immunol, Ft Worth, TX USA; Rhone Poulenc Rorer, Collegeville, MN USA; Astra USA, Westborough, MA USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Connecticut; Drexel University	Nayak, AS (corresponding author), 130 Franklin Ave, Normal, IL 61761 USA.							Banov CH, 1996, CLIN THER, V18, P265, DOI 10.1016/S0149-2918(96)80007-5; CLAYTON DE, 1981, J ALLERGY CLIN IMMUN, V67, P2, DOI 10.1016/0091-6749(81)90037-3; FEISS G, 1992, J ALLERGY CLIN IMMUN, V89, P1151, DOI 10.1016/0091-6749(92)90299-H; FINDLAY S, 1992, ANN ALLERGY, V68, P228; GROSSMAN J, 1993, PEDIATRICS, V92, P594; HANES RC, 1990, GOODMAN GILMANS PHAR, P1431; HARDING S M, 1988, European Respiratory Journal, V1, p196S; HOROWITZ M, 1979, MED J AUSTRALIA, V2, P660, DOI 10.5694/j.1326-5377.1979.tb127274.x; Howland WC, 1996, J ALLERGY CLIN IMMUN, V98, P32, DOI 10.1016/S0091-6749(96)70223-3; KOBAYASHI RH, 1995, CLIN THER, V17, P503, DOI 10.1016/0149-2918(95)80115-4; Koepke JW, 1997, ALLERGY ASTHMA PROC, V18, P33, DOI 10.2500/108854197778612844; MABRY RL, 1992, OTOLARYNG HEAD NECK, V107, P855, DOI 10.1177/019459989210700608.2; MAYNARD DE, 1966, ANN INTERN MED, V64, P552, DOI 10.7326/0003-4819-64-3-552; MCEVOY GE, 1995, AHFS DRUG INFORMATIO, P2094; NASACORT AQ, 1997, PHYSICIANS DESK REFE, P2191; ORGEL HA, 1986, J ALLERGY CLIN IMMUN, V77, P858, DOI 10.1016/0091-6749(86)90384-2; ORGEL HA, 1991, J ALLERGY CLIN IMMUN, V88, P257, DOI 10.1016/0091-6749(91)90336-M; PEDERSEN S, 1988, EUR RESPIR J, V1, P433; SCHENKEL EJ, IN PRESS PEDIAT ALLE; SETTIPANE G, 1995, CLIN THER, V17, P252, DOI 10.1016/0149-2918(95)80023-9; SHERMAN B, 1982, J ALLERGY CLIN IMMUN, V69, P208, DOI 10.1016/0091-6749(82)90101-4; SPECKART PF, 1971, ARCH INTERN MED, V128, P761, DOI 10.1001/archinte.128.5.761; SPECTOR S, 1990, ANN ALLERGY, V64, P300; STORMS W, 1991, ANN ALLERGY, V66, P329; Storms WW, 1996, PEDIATR ASTHMA ALLER, V10, P59, DOI 10.1089/pai.1996.10.59; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371; TINKELMAN D, 1990, ANN ALLERGY, V64, P234; TRUHAN AP, 1989, ANN ALLERGY, V62, P375; TURKELTAUB PC, 1982, ALLERGY, V37, P303, DOI 10.1111/j.1398-9995.1982.tb01916.x; TURKELTAUB PC, 1976, J ALLERGY CLIN IMMUN, V58, P597, DOI 10.1016/0091-6749(76)90206-2; VANAS A, 1991, ANN ALLERGY, V67, P156; WELCH MJ, 1991, ANN ALLERGY, V67, P493; WELCH MJ, 1994, CLIN THER, V16, P253; WOOD JB, 1965, LANCET, V1, P243	34	55	55	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				157	162		10.1016/S0091-6749(98)70379-3	http://dx.doi.org/10.1016/S0091-6749(98)70379-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500747				2022-12-18	WOS:000072244800003
J	Ebo, DG; Stevens, WJ; Bridts, CH; Matthieu, L				Ebo, DG; Stevens, WJ; Bridts, CH; Matthieu, L			Contact allergic dermatitis and life-threatening anaphylaxis to chlorhexidine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Univ Antwerp, Dept Immunol Allergol & Rheumatol, B-2610 Antwerp, Belgium; Univ Antwerp, Dept Rheumatol, B-2610 Antwerp, Belgium	University of Antwerp; University of Antwerp	Stevens, WJ (corresponding author), Univ Antwerp, Dept Immunol Allergol & Rheumatol, Univ Pl 1, B-2610 Antwerp, Belgium.		EBO, Didier/H-4894-2016; BRIDTS, Chris HM/M-7933-2016	EBO, Didier/0000-0003-0672-7529; BRIDTS, Chris HM/0000-0002-3324-7320				BERGQVISTKARLSSON A, 1988, CONTACT DERMATITIS, V18, P84, DOI 10.1111/j.1600-0536.1988.tb02745.x; CALNAN CD, 1962, P ROY SOC MED, V55, P39, DOI 10.1177/003591576205500111; NISHIOKA K, 1984, CONTACT DERMATITIS, V11, P191, DOI 10.1111/j.1600-0536.1984.tb00975.x; OHTOSHI T, 1986, CLIN ALLERGY, V16, P155, DOI 10.1111/j.1365-2222.1986.tb00759.x; OKANO M, 1989, ARCH DERMATOL, V125, P50, DOI 10.1001/archderm.125.1.50	5	55	55	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				128	129		10.1016/S0091-6749(98)70205-2	http://dx.doi.org/10.1016/S0091-6749(98)70205-2			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449513				2022-12-18	WOS:000071539800021
J	Sanico, AM; Atsuta, S; Proud, D; Togias, A				Sanico, AM; Atsuta, S; Proud, D; Togias, A			Dose-dependent effects of capsaicin nasal challenge: In vivo evidence of human airway neurogenic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						neurogenic inflammation; capsaicin; nasal lavage; leukocytes; albumin; lysozyme	SUBSTANCE-P; ALLERGIC RHINITIS; INDUCED CONTRACTION; RESPIRATORY-TRACT; MEDIATOR RELEASE; SENSORY NERVES; RAT TRACHEA; GUINEA-PIG; STIMULATION; TACHYKININS	Background: Nerve involvement has been implicated in the pathophysiology of chronic respiratory inflammatory diseases. Peptidergic nerve stimulation has been shown to induce leukocyte activation and plasma extravasation in the airways of various animal species. The occurrence of this phenomenon of neurogenic inflammation in the human airway, however, has not been established. Objective: We conducted this study to determine whether neuronal stimulation can induce reproducible and dose-dependent inflammatory changes in the human upper airway. Methods: Ten volunteers with active allergic rhinitis participated in the study. Capsaicin, the pungent component of hot pepper that specifically stimulates afferent nerve fibers, was administered by means of nasal spray in doses of 1 mu g, 10 mu g, and 100 mu g in a double-blind, randomized, crossover manner with 1 week between doses. Symptom scores before and after capsaicin nasal challenge were recorded by using visual analog scales. Nasal lavage fluids collected before and at 30 minutes, 1 hour, and 4 hours after capsaicin challenge were analyzed for leukocyte counts; albumin and lysozyme levels were measured to evaluate effects on plasma leakage and gland secretion, respectively. Results: Capsaicin nasal challenge produced symptoms of burning, congestion, and rhinorrhea. Leukocyte counts or albumin and lysozyme levels were not significantly increased after administration of 1 mu g of capsaicin at any time point. On the other hand, there were significant increases in leukocyte counts 1 hour (p < 0.05) and 4 hours (p = 0.008) after 10 mu g of capsaicin and 30 minutes (p = 0.009), 1 hour (p = 0.007), and 4 hours (p = 0.007) after 100 mu g of capsaicin. Albumin and lysozyme levels were both significantly in creased 30 minutes after 10 mu g and 100 mu g of capsaicin (p = 0.005 for both). Comparison of changes in symptom scores, leukocyte counts, and albumin and lysozyme levels among the three capsaicin challenges indicated generally increasing effects with higher capsaicin doses. Conclusion: Capsaicin-sensitive nerve stimulation in subjects with active allergic rhinitis produces reproducible and dose-dependent leukocyte influx, albumin leakage, and glandular secretion. These results provide in vivo evidence for the occurrence of neurogenic inflammation in the human upper airway with active allergic disease.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV RESP & CRIT CARE MED,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NHLBI NIH HHS [R29HL48248, R01HL32272] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL048248, R01HL032272] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASAKURA K, 1994, EUR ARCH OTO-RHINO-L, V251, P224, DOI 10.1007/BF00628428; ASAKURA K, 1992, ACTA OTO-LARYNGOL, V112, P545, DOI 10.3109/00016489209137438; BALLATI L, 1992, LIFE SCI, V51, P119; BARANIUK JN, 1991, AM J RESP CELL MOL, V4, P228, DOI 10.1165/ajrcmb/4.3.228; BARNES PJ, 1991, INT ARCH ALLER A IMM, V94, P303, DOI 10.1159/000235392; BARNES PJ, 1991, AM REV RESPIR DIS, V143, pS28, DOI 10.1164/ajrccm/143.3_Pt_2.S28; BARNES PJ, 1986, LANCET, V1, P242; BASCOM R, 1991, J PHARMACOL EXP THER, V259, P1323; BRAUNSTEIN G, 1994, CLIN EXP ALLERGY, V24, P922, DOI 10.1111/j.1365-2222.1994.tb02723.x; BRAUNSTEIN G, 1991, AM REV RESPIR DIS, V144, P630, DOI 10.1164/ajrccm/144.3_Pt_1.630; CAROLAN EJ, 1993, J ALLERGY CLIN IMMUN, V92, P589, DOI 10.1016/0091-6749(93)90083-R; DUJKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434; ELLIS JL, 1992, J PHARMACOL EXP THER, V262, P646; GEPPETTI P, 1988, BRIT J PHARMACOL, V93, P509, DOI 10.1111/j.1476-5381.1988.tb10305.x; GREIFF L, 1995, THORAX, V50, P225, DOI 10.1136/thx.50.3.225; HELME RD, 1987, IMMUNOL CELL BIOL, V65, P267, DOI 10.1038/icb.1987.30; HOLZER P, 1991, PHARMACOL REV, V43, P143; JANCSO N, 1967, BRIT J PHARM CHEMOTH, V31, P138, DOI 10.1111/j.1476-5381.1967.tb01984.x; KNANI J, 1992, J ALLERGY CLIN IMMUN, V90, P880, DOI 10.1016/0091-6749(92)90460-J; KOLASINSKI SL, 1992, ARTHRITIS RHEUM, V35, P369, DOI 10.1002/art.1780350402; LACROIX JS, 1991, CLIN EXP ALLERGY, V21, P595, DOI 10.1111/j.1365-2222.1991.tb00852.x; LUNDBERG JM, 1984, CELL TISSUE RES, V235, P251; LUNDBLAD L, 1983, ACTA OTO-LARYNGOL, V96, P479, DOI 10.3109/00016488309132734; MARTINS MA, 1991, J APPL PHYSIOL, V70, P1950, DOI 10.1152/jappl.1991.70.5.1950; MCDONALD DM, 1988, J NEUROCYTOL, V17, P583, DOI 10.1007/BF01260988; MCDONALD DM, 1988, J NEUROCYTOL, V17, P606; MIZOGUCHI H, 1991, J APPL PHYSIOL, V70, P282, DOI 10.1152/jappl.1991.70.1.282; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; PERNOW B, 1985, J IMMUNOL S, V135, P812; PERSSON CGA, 1992, THORAX, V47, P993, DOI 10.1136/thx.47.12.993; PHILIP G, 1994, J ALLERGY CLIN IMMUN, V94, P1035, DOI 10.1016/0091-6749(94)90122-8; Philip G, 1996, AM J RESP CRIT CARE, V153, P1222, DOI 10.1164/ajrccm.153.4.8616545; PHILIP G, 1994, J ALLERGY CLIN IMMUN, V93, P217; RICCIO MM, 1995, AM J RESP CRIT CARE, V152, P1757, DOI 10.1164/ajrccm.152.6.8520734; ROCHARVEILLER M, 1986, PHARMACOLOGY, V33, P266, DOI 10.1159/000138225; ROCHE N, 1995, AM J RESP CRIT CARE, V151, P1151; SARIA A, 1988, AM REV RESPIR DIS, V137, P1330, DOI 10.1164/ajrccm/137.6.1330; SARIA A, 1985, EUR J PHARMACOL, V106, P207; SEKIZAWA K, 1987, J APPL PHYSIOL, V63, P1401, DOI 10.1152/jappl.1987.63.4.1401; TANAKA DT, 1984, J APPL PHYSIOL, V57, P1551, DOI 10.1152/jappl.1984.57.5.1551; TOGIAS A, 1986, AM J MED S6A, V79, P26; UMENO E, 1990, J APPL PHYSIOL, V69, P2131, DOI 10.1152/jappl.1990.69.6.2131; WIEDERMANN CJ, 1989, N-S ARCH PHARMACOL, V340, P185	43	55	57	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					632	641		10.1016/S0091-6749(97)70167-2	http://dx.doi.org/10.1016/S0091-6749(97)70167-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389293	hybrid			2022-12-18	WOS:A1997YG20200010
J	Ylitalo, L; Turjanmaa, K; Palosuo, T; Reunala, T				Ylitalo, L; Turjanmaa, K; Palosuo, T; Reunala, T			Natural rubber latex allergy in children who had not undergone surgery and children who had undergone multiple operations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; prevalence; atopy; skin prick test; RAST; use test; children; surgery	SPINA-BIFIDA; RISK-FACTORS; CONTACT URTICARIA; IGE; HYPERSENSITIVITY; SENSITIZATION; SENSITIVITY; PREVALENCE; PROTEINS; GLOVES	Background: Children with spina bifida and other children requiring multiple surgical procedures represent a well-known risk group for natural rubber latex allergy. Children not undergoing surgery can also be sensitized, but findings in this group of children with latex allergy have not been thoroughly examined. Objectives: We sought to examine the frequency of latex allergy in a large group of children admitted for inhalant or food allergy testing for the purpose of collecting information on a series of children with latex allergy and comparing the symptoms and findings between those not undergoing surgery and those undergoing multiple operations. Methods: Children admitted to the allergy laboratory of Tampere University Hospital were screened by skin prick tests (SPTs) with latex glove extract, All children with allergy as determined by the screening or admitted because of suspected latex allergy were reexamined from 1995 to 1996. For a definite diagnosis of latex allergy, positive SPT, latex RAST, and latex glove use test results were required. Results: From 1992 to 1995, a total of 3269 children were skin prick tested with latex glove extract, and 55 (1.7%) had a positive response, On reexamination, 37 (1.1%) children had positive responses to SPTs, and 33 (1.0%) were confirmed to have latex allergy by means of RASTs and latex glove use tests. Since 1988, we have identified a total of 30 children with latex allergy who had not undergone surgery and 12 who underwent multiple operations. The clinical histories were similar in both groups; the mean ages at diagnosis were 5.7 and 8.1 years, and the frequency of atopy was 97% and 83%, respectively. Symptoms had occurred in 63% of the children who had not undergone surgery and in 75% of the children who underwent multiple operations. Contact urticaria was the most frequent symptom, and only one child had intraoperative anaphylaxis. Balloons, followed by gloves, were the most common latex products causing symptoms. The children with latex allergy who had not undergone surgery and those who underwent multiple operations showed no significant differences in SPT responses to commercial latex allergen extract or in specific IgE levels. Conclusions: The prevalence of latex allergy among children admitted for inhalent or food allergy testing was 1%. Although multiple operations at an early age are a well-known risk factor for latex allergy, the majority of children with latex allergy identified at screening or admitted because of suspicion of latex allergy belonged to the group of children who had not undergone surgery. One third of all the children studied were free of symptoms, indicating that screening with SPTs can be a valuable tool for detecting occult latex allergy in children.	NATL PUBL HLTH INST,HELSINKI,FINLAND; UNIV HELSINKI HOSP,HELSINKI,FINLAND; TAMPERE UNIV,SCH MED,FIN-33101 TAMPERE,FINLAND	Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital; Tampere University	Ylitalo, L (corresponding author), TAMPERE UNIV HOSP,DEPT DERMATOL,POB 2000,FIN-33521 TAMPERE,FINLAND.							ALENIUS H, 1994, J ALLERGY CLIN IMMUN, V93, P859, DOI 10.1016/0091-6749(94)90378-6; ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; Alenius H, 1996, J IMMUNOL, V156, P1618; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; AXELSSON I, 1988, ACTA PAEDIATR SCAND, V77, P14; BEAUDOUIN E, 1994, EUR J PEDIATR SURG, V4, P90, DOI 10.1055/s-2008-1066075; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; Beezhold DH, 1997, CLIN EXP IMMUNOL, V108, P114, DOI 10.1046/j.1365-2249.1997.d01-983.x; GOLD M, 1991, J ALLERGY CLIN IMMUN, V87, P662, DOI 10.1016/0091-6749(91)90385-2; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KWITTKEN PL, 1995, PEDIATRICS, V95, P693; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Liebke C, 1996, PEDIATR ALLERGY IMMU, V7, P103, DOI 10.1111/j.1399-3038.1996.tb00115.x; LU I, 1995, J IMMUNOL, V155, P2721; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; MAKINENKILJUNEN S, 1993, LANCET, V342, P863, DOI 10.1016/0140-6736(93)92721-5; Michael T, 1996, CLIN EXP ALLERGY, V26, P934; MIKKOLA K, 1997, J ALLERGY CLIN IMMUN, V99, P342; MONERETVAUTRIN DA, 1993, J ALLERGY CLIN IMMUN, V92, P668, DOI 10.1016/0091-6749(93)90009-5; NGUYEN DH, 1991, J UROLOGY, V146, P571, DOI 10.1016/S0022-5347(17)37858-8; Nieto A, 1996, J ALLERGY CLIN IMMUN, V98, P501, DOI 10.1016/S0091-6749(96)70082-9; SHIELD SW, 1992, ALLERGY PROC, V13, P129, DOI 10.2500/108854192778878827; SLATER J, 1989, NEW ENGL J MED, V320, P626; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; SORVA R, 1995, PEDIATR ALLERGY IMMU, V6, P36, DOI 10.1111/j.1399-3038.1995.tb00255.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1995, IMMUNOL ALLERGY CLIN, V15, P71; Turjanmaa K, 1997, ALLERGY, V52, P41, DOI 10.1111/j.1398-9995.1997.tb02544.x; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; Turjanmaa K., 1996, Journal of Allergy and Clinical Immunology, V97, P325, DOI 10.1016/S0091-6749(96)80788-3; WRANGSJO K, 1988, CONTACT DERMATITIS, V19, P264, DOI 10.1111/j.1600-0536.1988.tb02925.x; YASSIN MS, 1992, ANN ALLERGY, V69, P207; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0	34	55	58	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					606	612		10.1016/S0091-6749(97)70163-5	http://dx.doi.org/10.1016/S0091-6749(97)70163-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389289				2022-12-18	WOS:A1997YG20200006
J	LangeveldWildschut, EG; Thepen, T; Bihari, IC; vanReijsen, FC; deVries, IJM; Bruijnzeel, PLB; BruijnzeelKoomen, CAFM				LangeveldWildschut, EG; Thepen, T; Bihari, IC; vanReijsen, FC; deVries, IJM; Bruijnzeel, PLB; BruijnzeelKoomen, CAFM			Evaluation of the atopy patch test and the cutaneous late-phase reaction as relevant models for the study of allergic inflammation in patients with atopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy patch test; late-phase reaction; atopic eczema; Dermatophagoides pteronyssinus; allergic inflammation; eosinophils; neutrophil; T cell; mast cell; E-selectin	ADHESION MOLECULE-1; MAST-CELLS; DERMATITIS; EOSINOPHILS; SKIN; IGE; IL-4; AEROALLERGENS; INFILTRATION; ENDOTHELIUM	Objective: The study was designed to evaluate the atopy patch test (APT) and the late-phase reaction (LPR) after intracutaneous allergen injection as models for the study of allergic inflammation in atopic eczema. Methods: Immunocytochemistry was used to analyze skin biopsy specimens from sites of APTs and LPRs at 2 and 24 hours and To compare these with lesional and nonlesional skin of patients with atopic eczema. Results: A lack of neutrophil infiltration in specimens from both the APT and lesional skin sites was observed, whereas neutrophils were abundantly present in the specimens from LPR sites. With double-staining techniques it was demonstrated that the few neutrophils present in specimens from APT sites and in lesional skin were mostly located in intravascular areas, whereas in the LPR specimens they were located predominantly in extravascular areas. Eosinophils infiltrated at an earlier time point in the LPR as compared with the APT. Furthermore, there was a decrease of intact mast cells in the LPR sites compared with the APT sites and lesional skin. No significant difference in T-cell number was observed between the two tests. Upregulation of E-selectin expression on endothelial cells occurred at an earlier time point in the LPR as compared with the APT. Conclusion: There are important differences in cellular infiltrate between the APT and the LPR. The close macroscopic and microscopic similarities between the specimens from APT sites and lesional skin of patients with atopic eczema support the argument that the APT is a more valid in vivo model with which to study allergic inflammation in atopic eczema than the LPR.	TOEGEPAST NAT WETENSCHAPPELIJH ONDERZOEK,DEPT PHARMACOL,RIJSWIJK,NETHERLANDS		LangeveldWildschut, EG (corresponding author), UNIV UTRECHT HOSP,DEPT DERMATOL ALLERGOL,POSTBUS 85500,NL-3508 GA UTRECHT,NETHERLANDS.		de Vries, Jolanda I.J.M./F-5563-2010	de Vries, Jolanda I.J.M./0000-0002-8653-4040				BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BRUIJNZEEL PLB, 1993, CLIN EXP ALLERGY, V23, P97, DOI 10.1111/j.1365-2222.1993.tb00304.x; BRUIJNZEELKOOME.C, 1986, ARCH DERMATOL RES, V278, P199; BRUIJNZEELKOOME.C, 1988, BRIT J DERMATOL, V118, P229; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; COSTA C, 1989, ACTA DERM-VENEREOL, V69, P41; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; Drebotg S, 1989, ALLERGY S10, V44, P22; DUBOIS GR, 1994, J INVEST DERMATOL, V102, P843, DOI 10.1111/1523-1747.ep12382362; FREW AJ, 1988, J ALLERGY CLIN IMMUN, V81, P1117, DOI 10.1016/0091-6749(88)90878-0; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GROVES RW, 1995, BRIT J DERMATOL, V132, P345, DOI 10.1111/j.1365-2133.1995.tb08666.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HARVIMA IT, 1994, ARCH DERMATOL RES, V287, P61, DOI 10.1007/BF00370720; HOLTHOFER H, 1982, LAB INVEST, V47, P60; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LANGEVELDWILDSCHUT EG, 1995, J ALLERGY CLIN IMMUN, V96, P66, DOI 10.1016/S0091-6749(95)70034-X; LEIFERMAN KM, 1990, LAB INVEST, V62, P579; LEIFERMAN KM, 1989, ALLERGY, V44, P20, DOI 10.1111/j.1398-9995.1989.tb02450.x; LONGLEY J, 1995, J AM ACAD DERMATOL, V32, P545, DOI 10.1016/0190-9622(95)90336-4; MOSER R, 1992, J IMMUNOL, V149, P1432; OTT NL, 1994, J ALLERGY CLIN IMMUN, V94, P120, DOI 10.1016/0091-6749(94)90078-7; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; WAKITA H, 1994, J CUTAN PATHOL, V21, P33, DOI 10.1111/j.1600-0560.1994.tb00688.x; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; ZWEIMAN B, 1993, CURR OPIN IMMUNOL, V5, P950, DOI 10.1016/0952-7915(93)90111-5	30	55	57	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1019	1027		10.1016/S0091-6749(96)80186-2	http://dx.doi.org/10.1016/S0091-6749(96)80186-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977500				2022-12-18	WOS:A1996WB37800004
J	dePaulis, A; Ciccarelli, A; deCrescenzo, G; Cirillo, R; Patella, V; Marone, G				dePaulis, A; Ciccarelli, A; deCrescenzo, G; Cirillo, R; Patella, V; Marone, G			Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by N-formyl-methionyl-leucyl-phenylalanine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; cyclophilin; cyclosporin A; cyclosporin H; histamine leukotriene C-4	INHIBITS MEDIATOR RELEASE; INDUCED HISTAMINE-RELEASE; MAST-CELLS; ARACHIDONIC-ACID; PEPTIDE RECEPTOR; ANTINEOPLASTIC BRYOSTATINS; ATOPIC-DERMATITIS; ANTI-IGE; LEUKOCYTES; MECHANISM	Background: Cyclosporin A (CsA) binds with high affinity to cyclophilin, a critical step in the molecular mechanism of action of cyclosporins, whereas cyclosporin H (CsH) has extremely low affinity for cyclophilin. CsH differs from CsA by the substitution of the L-methyl valine at position 11 with its D-isomer. Methods: We compared the effects of CsA and CsH on the release of preformed (histamine) and de novo synthesized inflammatory mediators (peptide leukotriene C-4) from peripheral blood basophils activated by N-formyl-methionyl-leucyl-phenylalanine (FMLP). Results: CsH (8 to 800 nmol/L) concentration-dependently inhibited histamine and leukotriene C-4 release from purified and unpurified basophils activated by FMLP, whereas CsA (8 to 800 nmol/L) had little inhibitory effect on histamine release from basophils challenged with FMLP. Inhibition of histamine release from basophils challenged with FMLP was extremely rapid and was abolished by washing the cells (three times) before challenge. CsH (8 to 800 nmol/L) had no effect on the release of histamine caused by C5a, platelet activating factor; monocyte chemotactic activating factor, RANTES, IL-8, bryostatin 1, and phorbol myristate. Preincubation of basophils with granulocyte-macrophage colony-stimulating factor (30 and 100 pmol/L), but not IL-1 beta (30 and 100 ng/ml), concentration-dependently reversed the inhibitory effect of CsH on FMLP-induced histamine release. CsH competitively inhibited the effect of FMLP on histamine release from basophils. The dissociation constant (K-d) for the CsH-FMLP receptor complex was approximately 9 x 10(-8) mol/L, more than 10-fold lower than that (congruent to 1.3 x 10(-6) mol/L, of N-t-BOC-methionyl-L-leucyl-phenylalanine (BocMLP), a known formyl peptide, receptor antagonist. CsH inhibited tritiated FMLP binding to human polymorphonuclear leukocytes with a concentration required to inhibit binding by 50% of approximately lately 5.4 x 10(-7) mol/L, whereas BocMLP was less potent with a concentration required to inhibit binding by 50% of approximately 9.1 x 10(-5) mol/L. Scatchard analysis revealed that the decreased tritiated FMLP binding caused by CsH was due to a decrease in the B-max (0.22 +/- 0.04 nmol/L/5 x 10(6) cells vs 0.09 +/- 0.01 nmol/L/5 x 10(6) cells; p < 0.05), without a significant difference in the K-d (5.16 +/- 1.22 nmol/L vs 6.32 +/- 2.42 nmol/L; p = NS). Conclusions: CsH is a potent and selective inhibitor of mediator release from basophils induced by activation of the formyl peptide receptor; if acts by interfering with agonist binding to FMLP receptors.	UNIV NAPLES FEDERICO II, SCH MED, DIV CLIN IMMUNOL, I-80131 NAPLES, ITALY	University of Naples Federico II				Patella, Vincenzo/0000-0001-5640-6446; de Paulis, Amato/0000-0003-0347-2540				ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BENSON A, 1989, TRANSPLANTATION, V47, P696, DOI 10.1097/00007890-198904000-00024; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; Borel JF, 1982, CYCLOSPORINE A, P5; CARP H, 1982, J EXP MED, V155, P264, DOI 10.1084/jem.155.1.264; CASOLARO V, 1993, J IMMUNOL, V151, P5563; CASOLARO V, 1993, J PHARMACOL EXP THER, V267, P1375; CASOLARO V, 1989, AM REV RESPIR DIS, V139, P1375, DOI 10.1164/ajrccm/139.6.1375; CIRILLO R, 1990, J IMMUNOL, V144, P3891; CIRILLO R, 1990, CYTOKINES BASIC PRIN, V68, P351; COLUMBO M, 1990, J IMMUNOL, V145, P3855; COLVIN RB, 1974, LANCET, V1, P212, DOI 10.1016/S0140-6736(74)92512-4; DEBOER M, 1986, J IMMUNOL, V136, P3447; DEPAULIS A, 1991, J IMMUNOL, V146, P2374; DEPAULIS A, 1991, ARTHRITIS RHEUM-US, V34, P1289, DOI 10.1002/art.1780341013; DVORAK AM, 1976, J IMMUNOL, V116, P687; DVORAK AM, 1980, HUM PATHOL, V11, P606, DOI 10.1016/S0046-8177(80)80072-4; FARNAM J, 1985, J IMMUNOL, V134, P541; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GELFAND EW, 1987, J IMMUNOL, V138, P1115; GILBERT HS, 1975, BLOOD, V46, P279; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; KNOL EF, 1991, EUR J IMMUNOL, V21, P881, DOI 10.1002/eji.1830210404; KOSHINO T, 1993, CLIN EXP ALLERGY, V23, P919, DOI 10.1111/j.1365-2222.1993.tb00276.x; KUNA P, 1992, J IMMUNOL, V149, P636; LEGRUE SJ, 1986, SCIENCE, V234, P68, DOI 10.1126/science.3749892; LIU J, 1993, TRENDS PHARMACOL SCI, V14, P182, DOI 10.1016/0165-6147(93)90206-Y; LOPEZ AF, 1990, J ALLERGY CLIN IMMUN, V85, P99, DOI 10.1016/0091-6749(90)90229-W; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MACGLASHAN DW, 1995, CHEM IMMUNOL, V61, P88; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; MARONE G, 1988, ANN NY ACAD SCI, V524, P321, DOI 10.1111/j.1749-6632.1988.tb38555.x; MARONE G, 1984, J PHARMACOL EXP THER, V231, P678; MARONE G, 1988, RES CLIN LAB, V18, P53, DOI 10.1007/BF02918819; MARONE G, 1987, BIOCHEM PHARMACOL, V36, P13, DOI 10.1016/0006-2952(87)90377-7; MARONE G, 1989, J INVEST DERMATOL, V93, P246, DOI 10.1111/1523-1747.ep12277582; MARONE G, 1979, J IMMUNOL, V123, P1669; MARONE G, 1986, J INVEST DERMATOL, V87, P19, DOI 10.1111/1523-1747.ep12523520; MARONE G, 1984, J IMMUNOL, V133, P1542; MARONE G, 1987, INFECT IMMUN, V55, P803, DOI 10.1128/IAI.55.3.803-809.1987; MARONE G, INT ARCH ALLERGY  S1, V76, P70; MOHR H, 1987, IMMUNOBIOLOGY, V175, P420, DOI 10.1016/S0171-2985(87)80070-0; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; NACCACHE PH, 1983, J CELL PHYSIOL, V115, P243, DOI 10.1002/jcp.1041150305; PATELLA V, 1995, J IMMUNOL, V154, P2855; PATELLA V, 1995, BLOOD, V85, P1272, DOI 10.1182/blood.V85.5.1272.bloodjournal8551272; PATELLA V, 1990, J IMMUNOL, V145, P3054; QUESNIAUX VFJ, 1987, EUR J IMMUNOL, V17, P1359, DOI 10.1002/eji.1830170921; ROT A, 1987, P NATL ACAD SCI USA, V84, P7967, DOI 10.1073/pnas.84.22.7967; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHLEIMER RP, 1981, J IMMUNOL, V126, P570; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; SIRAGANIAN RP, 1976, J IMMUNOL, V116, P639; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Snedecor GW, 1980, STAT METHODS, V7th; STELLATO C, 1992, J INVEST DERMATOL, V98, P800, DOI 10.1111/1523-1747.ep12499960; UNDEM BJ, 1988, J PHARMACOL EXP THER, V247, P209; VALENT P, 1992, ADV IMMUNOL, V52, P333, DOI 10.1016/S0065-2776(08)60879-2; VALENT P, 1995, HUMAN BASOPHILS MAST, P38; VONWARTBURG A, 1986, PROG ALLERGY, V38, P28; WARNER JA, 1989, J LEUKOCYTE BIOL, V45, P558, DOI 10.1002/jlb.45.6.558; WEISBART RH, 1986, J IMMUNOL, V137, P3584; WENZELSEIFERT K, 1993, J IMMUNOL, V150, P4591; WENZELSEIFERT K, 1991, J IMMUNOL, V147, P1940	67	55	57	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					152	164		10.1016/S0091-6749(96)70237-3	http://dx.doi.org/10.1016/S0091-6749(96)70237-3			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765829	Bronze			2022-12-18	WOS:A1996VA69200018
J	Fischer, S; Grote, M; Fahlbusch, B; Muller, WD; Kraft, D; Valenta, R				Fischer, S; Grote, M; Fahlbusch, B; Muller, WD; Kraft, D; Valenta, R			Characterization of Phl p 4, a major timothy grass (Phleum pratense) pollen allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						grass pollen allergy; Phl p 4; trypsin resistance; monoclonal antibodies; cross-reactivity; Amb a 1; ragweed allergy; pollen-specific expression	CROSS-REACTIVE ALLERGEN; CDNA CLONING; GROUP-I; IMMUNOLOGICAL CHARACTERIZATION; MOLECULAR CHARACTERIZATION; V-ALLERGENS; IGE-BINDING; PROFILIN; IDENTIFICATION; EXPRESSION	Background: Group 4 grass pollen allergens represent glycoproteins with a molecular weight of 50 to 60 kd, which are present in many grass species. Almost 75% of patients allergic to grass pollen display IgE reactivity to group 4 allergens, which hence can be regarded as major grass pollen allergens. Objective: In this study attempts were made to obtain information regrading the immunologic properties, localization, and occur ence of Phl p 4 and related allergens. Methods: Phl p 4 was detected in timothy grass pollen extracts by immunoblotting with serum IgE and monoclonal antibodies and was localized in pollen by immunelectron microscopy. A peptide sequence from Phl p 4 was obtained by amino acid sequencing. The resistance of Phl p 4 against trypsin was analyzed after treatment of timothy grass pollen extracts with serum IgE and monoclonal antibodies. Cross-reactivities between Phl p 4 and Amb a 1, the major allergen of ragweed, were studied by using monoclonal antibodies and by IgE-inhibition studies. Results: Phl p 4 was characterized as a trypsin-resistant major timothy grass pollen allergen. By immunelectron microscopy Phl p 4 was localized in the exine, cytoplasm, and amyloplast of timothy grass pollen. Significant sequence similarities of a Phl p 4 10 amino acid peptide with Amb a 1, the major ragweed allergen, could be Sound. The immunologic similarity of Phl p 4 and Amb a 1 was confirmed by cross-reactivity of monoclonal antibodies and patients' IgE. Conclusion: Phl p 4 represents a trypsin-resistant major. timothy grass pollen allergen with immunologic similarities to the major ragweed allergen Amb a 1 and therefore must be considered an important cross-reactive component in grass pollen and weed pollen allergy.	UNIV VIENNA,AKH,INST GEN & EXPTL PATHOL,A-1090 VIENNA,AUSTRIA; UNIV MUNSTER,INST MED PHYS,D-4400 MUNSTER,GERMANY; UNIV JENA,INST CLIN IMMUNOL,D-6900 JENA,GERMANY	University of Vienna; University of Munster; Friedrich Schiller University of Jena				Valenta, Rudolf/0000-0001-5944-3365				ANSARI AA, 1987, J IMMUNOL, V139, P4034; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; ENGEL E, 1995, S MOL BIOL ALL AT IM; ESCH RE, 1989, MOL IMMUNOL, V26, P557, DOI 10.1016/0161-5890(89)90007-2; FAHLBUSCH B, 1993, CLIN EXP ALLERGY, V23, P51, DOI 10.1111/j.1365-2222.1993.tb02484.x; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; GROTE M, 1994, J HISTOCHEM CYTOCHEM, V42, P427, DOI 10.1177/42.3.8308259; HEISS S, UNPUB IDENTIFICIATIO; JAGGI KS, 1989, J ALLERGY CLIN IMMUN, V83, P845, DOI 10.1016/0091-6749(89)90024-9; JAGGI KS, 1989, INT ARCH ALLER A IMM, V89, P342, DOI 10.1159/000234973; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P88, DOI 10.1016/0091-6749(94)90075-2; MATTHIESEN F, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P189; MULLER WD, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P185; PEREZ M, 1990, J BIOL CHEM, V265, P16210; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; ROGERS BL, 1991, J IMMUNOL, V147, P2547; ROGERS HJ, 1992, PLANT MOL BIOL, V20, P493, DOI 10.1007/BF00040608; SIDOLI A, 1993, J BIOL CHEM, V268, P21819; SILVANOVICH A, 1991, J BIOL CHEM, V266, P1204; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SONE T, 1994, BIOCHEM BIOPH RES CO, V199, P619, DOI 10.1006/bbrc.1994.1273; SPITZAUER S, 1994, J ALLERGY CLIN IMMUN, V93, P614, DOI 10.1016/S0091-6749(94)70073-7; SU S-N, 1990, Proceedings of the National Science Council Republic of China Part B Life Sciences, V14, P85; SU SN, 1991, CLIN EXP ALLERGY, V21, P449, DOI 10.1111/j.1365-2222.1991.tb01685.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURCICH MP, 1993, PLANT MOL BIOL, V23, P1061, DOI 10.1007/BF00021820; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VALENTA R, 1994, BIOCHEM BIOPH RES CO, V199, P106, DOI 10.1006/bbrc.1994.1201; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANGIJSEGEM F, 1989, MOL MICROBIOL, V3, P1415, DOI 10.1111/j.1365-2958.1989.tb00124.x; VANREE R, 1992, CLIN EXP ALLERGY, V22, P611; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VRTALA S, 1993, J IMMUNOL, V151, P4773; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Wing R. A., 1989, Plant Molecular Biology, V14, P17, DOI 10.1007/BF00015651	42	55	60	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					189	198		10.1016/S0091-6749(96)70242-7	http://dx.doi.org/10.1016/S0091-6749(96)70242-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765834				2022-12-18	WOS:A1996VA69200023
J	Day, JH; Buckeridge, DL; Clark, RH; Briscoe, MP; Phillips, R				Day, JH; Buckeridge, DL; Clark, RH; Briscoe, MP; Phillips, R			A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						triamcinolone acetonide; glucocorticoids; clinical pharmacology; placebo effect; hay fever; rhinitis	CORTICOSTEROIDS; MANAGEMENT; THERAPY	Background: Clinically apparent relief of nasal symptoms of allergic rhinitis is generally recognized to occur. within 3 days to 1 week when intranasal corticosteroids are used. Objective: A study was designed to evaluate the onset of action of triamcinolone acetonide (TA) in patients with ragweed-induced allergic rhinitis with an environmental exposure unit (EEU). Methods: Eighty-five adults with ragweed-induced allergic rhinitis were primed with ragweed allergen in the EEU. Symptoms were recorded during a baseline exposure in the EEU, and subjects were randomized with a 5:1 ratio to receive either TA 400 mu g (n = 71) or its propellant (n = 14). Subjects received study medication for 7 days under supervision in the morning and returned to the EEU in the evening for ragweed allergen challenge and symptom assessment. Clinically apparent onset of action was defined as a 25% decrease in symptom scores from baseline. Results: A mean reduction in nasal congestion from baseline of greater than 25% (onset of action) was observed in the TA group, but not in the placebo group, by 10 hours. This was also observed for itching of the nose or palate and a combined measure of symptoms. In addition, the proportion of subjects with less nasal congestion after 1 day of treatment was greater in the TA group (41%) than in the placebo group (7%) (p < 0.05). Conclusion: The unexpected early relief of symptoms observed in the TA group and, to a lesser extent in the placebo group, has important clinical implications in the treatment of allergic rhinitis.	QUEENS UNIV,KINGSTON,ON K7L 3N6,CANADA; RHONE POULENC RORER CANADA INC,MONTREAL,PQ,CANADA	Queens University - Canada	Day, JH (corresponding author), KINGSTON GEN HOSP,DIV ALLERGY & IMMUNOL,76 STUART ST,KINGSTON,ON K7L 2V7,CANADA.		Clark, Reese/L-5392-2019	Clark, Reese/0000-0002-7363-4640				BRISCOE MP, 1993, J ALLERGY CLIN IMMUN, V91, P198; BROWN SJ, 1993, NASAL STEROIDS BLAST, P5; BUSSE W, 1988, J ALLERGY CLIN IMMUN, V82, P890, DOI 10.1016/0091-6749(88)90031-0; DAY J H, 1991, Clinical and Investigative Medicine, V14, pA5; DRIESSEN MNBM, 1991, EUR RESPIR J, V4, P359; DUSHAY ME, 1989, PHARMACOTHERAPY, V9, P338; FORDYCE WE, 1976, BEHAVIORAL METHODS C; GREENBAUM J, 1977, J ALLERGY CLIN IMMUN, V59, P437, DOI 10.1016/0091-6749(77)90006-9; JONES LM, 1979, ANN ALLERGY, V43, P139; LEWIS WH, 1991, ANN ALLERGY, V67, P37; MABRY RL, 1989, OTOLARYNG HEAD NECK, V100, P636, DOI 10.1177/019459988910000624; MABRY RL, 1992, OTOLARYNG HEAD NECK, V107, P855, DOI 10.1177/019459989210700608.2; McDonald C J, 1983, Stat Med, V2, P417; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; NATHAN RA, 1991, ANN ALLERGY, V67, P332; Pearson ES, 1966, BIOMETRIKA TABLES ST; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; ROSS M, 1981, PSYCHOL REV, V88, P408, DOI 10.1037/0033-295X.88.5.408; SIEGEL SC, 1988, J ALLERGY CLIN IMMUN, V81, P984, DOI 10.1016/0091-6749(88)90166-2; SOLOMON WR, 1976, J ALLERGY CLIN IMMUN, V57, P318, DOI 10.1016/0091-6749(76)90088-9; SOLOMON WR, 1983, ALLERGY PRINCIPLES P, V2, P1143; SPECTOR SL, 1980, J ALLERGY CLIN IMMUN, V66, P129, DOI 10.1016/0091-6749(80)90060-3; TINKELMAN D, 1990, ANN ALLERGY, V64, P234; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WELSH PW, 1979, J ALLERGY CLIN IMMUN, V64, P209, DOI 10.1016/0091-6749(79)90097-6	25	55	56	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1050	1057		10.1016/S0091-6749(96)70257-9	http://dx.doi.org/10.1016/S0091-6749(96)70257-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626981				2022-12-18	WOS:A1996UL26100004
J	Godthelp, T; Holm, AF; Fokkens, WJ; Doornenbal, P; Mulder, PGH; Hoefsmit, ECM; Kleinjan, A; Prens, EP; Rijntjes, E				Godthelp, T; Holm, AF; Fokkens, WJ; Doornenbal, P; Mulder, PGH; Hoefsmit, ECM; Kleinjan, A; Prens, EP; Rijntjes, E			Dynamics of nasal eosinophils in response to a nonnatural allergen challenge in patients with allergic rhinitis and control subjects: A biopsy and brush study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; grass pollen; rhinitis; allergy; nasal biopsy specimens; nasal brush specimens; allergen challenge	PRESUMABLY LANGERHANS CELLS; GRASS-POLLEN ALLERGY; BIOCHEMICAL-ANALYSIS; CATIONIC PROTEIN; MUCOSA; SECRETIONS; INFLUX; REACTIVITY; SPECIMENS; ASTHMA	Background: Eosinophils are thought to play an important role in the symptomatology and pathophysiology of allergic rhinitis. Most quantitative studies on eosinophils in nasal mucosa have focused on the dynamics of eosinophils in the acute and late phases of the allergic reaction by using different cell sampling techniques. Little is known about the dynamics of eosinophils during a more prolonged period of allergen exposure and the activation of eosinophils induced by, allergen challenge. Objective: The aim of this study was to investigate the dynamics and activation of the he eosinophils in the nasal mucosa of patients with an isolated grass pollen allergy during an out-of-season 2-week allergen exposure, mimicking the natural grass pollen season. Methods: Seventeen patients with isolated grass pollen allergy and four control subjects were challenged daily with the allergen during a 2-week period in the winter Nasal brush specimens were obtained before provocation and each day during the provocation period. Biopsy specimens were obtained once before, six times during, and once after the provocation period. Preparations made of nasal brush and nasal biopsy specimens were stained with the monoclonal antibody BMK 13 and Giemsa stain as paneosinophil markers and with the monoclonal antibody EG2 to identify activated eosinophils. Results: We found significant increases in the total number of eosinophils and the number of activated eosinophils in the epithelium and lamina propria. These increases were most explicit in the second week. BMK 13 was found to be a paneosinophil marker superior to Giemsa staining. Conclusion: Eosinophils are not only involved in the acute and late phases of the allergic reaction brit are probably even more involved in the chronic phase.	ERASMUS UNIV ROTTERDAM,DEPT BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM,DEPT CELL BIOL,EM DIV,AMSTERDAM,NETHERLANDS; LEYENBURG HOSP,DEPT OTORHINOLARYNGOL,THE HAGUE,NETHERLANDS	Erasmus University Rotterdam; Vrije Universiteit Amsterdam	Godthelp, T (corresponding author), ERASMUS UNIV ROTTERDAM,DEPT IMMUNOL,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		Fokkens, Wytske WJ/ABF-2185-2020	Prens, Errol/0000-0002-8158-660X				ANDERSSON M, 1989, ALLERGY, V44, P342, DOI 10.1111/j.1398-9995.1989.tb00456.x; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BORRES MP, 1990, ALLERGY, V45, P98, DOI 10.1111/j.1398-9995.1990.tb00465.x; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; DURHAM SR, 1992, J IMMUNOL, V148, P2390; FELTKAMPVROOM TM, 1970, J CLIN PATHOL, V23, P188, DOI 10.1136/jcp.23.2.188; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; FOKKENS WJ, 1992, CLIN EXP ALLERGY, V22, P701, DOI 10.1111/j.1365-2222.1992.tb00194.x; FOKKENS WJ, 1990, INT ARCH ALLER A IMM, V93, P66, DOI 10.1159/000235281; FOKKENS WJ, 1989, J ALLERGY CLIN IMMUN, V84, P39, DOI 10.1016/0091-6749(89)90176-0; FOKKENS WJ, 1989, ALLERGY, V44, P167, DOI 10.1111/j.1398-9995.1989.tb02257.x; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GOLIGHTLY LM, 1992, J LEUKOCYTE BIOL, V51, P386, DOI 10.1002/jlb.51.4.386; GREIFF L, 1990, CLIN EXP ALLERGY, V20, P253, DOI 10.1111/j.1365-2222.1990.tb02680.x; KLEMENTSSON H, 1990, CLIN EXP ALLERGY, V20, P539, DOI 10.1111/j.1365-2222.1990.tb03147.x; KLEMENTSSON H, 1990, J ALLERGY CLIN IMMUN, V86, P466, DOI 10.1016/S0091-6749(05)80201-5; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V94, P1006, DOI 10.1016/0091-6749(94)90119-8; MOQBEL R, 1992, CLIN EXP ALLERGY, V22, P265, DOI 10.1111/j.1365-2222.1992.tb03082.x; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P283, DOI 10.1007/BF00457469; PELIKAN Z, 1989, J ALLERGY CLIN IMMUN, V83, P1068, DOI 10.1016/0091-6749(89)90448-X; PELIKAN Z, 1989, J ALLERGY CLIN IMMUN, V83, P870; PIPKORN U, 1984, J IMMUNOL METHODS, V73, P133, DOI 10.1016/0022-1759(84)90038-3; PIPKORN U, 1989, AM REV RESPIR DIS, V140, P729, DOI 10.1164/ajrccm/140.3.729; PIPKORN U, 1988, J IMMUNOL METHODS, V112, P37, DOI 10.1016/0022-1759(88)90030-0; PIPKORN U, 1988, EUR RESPIR J, V1, P856; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; TOGIAS A, 1988, J ALLERGY CLIN IMMUN, V81, P782, DOI 10.1016/0091-6749(88)90932-3; WACHS M, 1989, J ALLERGY CLIN IMMUN, V84, P492, DOI 10.1016/0091-6749(89)90362-X; WHELAN CFA, 1980, J LARYNGOL OTOL, V94, P399, DOI 10.1017/S0022215100089003; WIHL JA, 1977, ACTA OTO-LARYNGOL, V84, P281, DOI 10.3109/00016487709123968	32	55	60	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					800	811		10.1016/S0091-6749(96)80158-8	http://dx.doi.org/10.1016/S0091-6749(96)80158-8			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613637	Green Published			2022-12-18	WOS:A1996UA97500011
J	Terada, N; Konno, A; Terada, Y; Fukuda, S; Yamashita, T; Abe, T; Shimada, H; Ishida, K; Yoshimura, K; Tanaka, Y; Ra, C; Ishikawa, K; Togawa, K				Terada, N; Konno, A; Terada, Y; Fukuda, S; Yamashita, T; Abe, T; Shimada, H; Ishida, K; Yoshimura, K; Tanaka, Y; Ra, C; Ishikawa, K; Togawa, K			IL-4 upregulates Fc epsilon RI alpha-chain messenger RNA in eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1994 Conference	JUL 23, 1994	TOKYO, JAPAN	Sandoz Pharm Ltd		IL-4; high-affinity IgE receptor; eosinophil; nasal allergy	HIGH-AFFINITY; RECEPTOR; IGE; EXPRESSION; CELLS	By using the reverse transcription polymerase chain reaction and Southern blot hybridization, we demonstrated that Fc epsilon RI alpha-chain (Fc epsilon RI alpha) messenger RNA was expressed in eosinophils purified from the peripheral blood of patients with allergic rhinitis and that this expression was enhanced by IL-4. However studies in which flow cytometry or immunostaining was used did not reveal the expression of Fc epsilon RI alpha protein on eosinophils from peripheral blood Neither IL-4 alone nor the combination of IL-4 and other cytokines could induce detectable Fc epsilon RI alpha protein; nevertheless, they do express Fc epsilon RI alpha mRNA. Double-labeling immunostaining on cryostat sections of nasal mucosa clearly demonstrated that some Fc epsilon RI alpha-positive cells were eosinophil cationic protein-positive, which confirms their eosinophilic nature. Not all the eosinophil cationic protein-positive cells express an Fc epsilon RI alpha signal. Considering that Fc epsilon RI alpha mRNA was detectable in four of five samples of eosinophils from those patients with nasal allergy and that only one of five eosinophil samples from normal subjects expressed Fc epsilon RI alpha mRNA, the level of Fc epsilon RI expression may be correlated with the activation of eosinophils. It seems very likely that some other unidentified factors are required for the process from the expression of Fc epsilon RI alpha mRNA to that of Fc epsilon RI as a protein.	MITSUBISHI KAGAKU BIOCLIN LABS INC, DEPT GENE ANAL, TOKYO, JAPAN; MITSUBISHI KAGAKU BIOCLIN LABS INC, DIV RES & DEV, TOKYO, JAPAN; JUNTENDO UNIV, SCH MED, DEPT IMMUNOL, TOKYO 113, JAPAN; AKITA UNIV, SCH MED, DEPT PARASITOL, AKITA 010, JAPAN; NAGASAKI UNIV, SCH MED, DEPT DERMATOL, NAGASAKI 852, JAPAN; AKITA UNIV, SCH MED, DEPT OTORHINOLARYNGOL, AKITA 010, JAPAN	Mitsubishi Kagaku Bio-Clinical Laboratories; Mitsubishi Kagaku Bio-Clinical Laboratories; Juntendo University; Akita University; Nagasaki University; Akita University	Terada, N (corresponding author), CHIBA UNIV, SCH MED, DEPT OTORHINOLARYNGOL, 1-8-1 INOHANA, CHIBA 260, JAPAN.							CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; ITO E, 1990, JJIAO, V8, P78; KIKUTANI H, 1986, J EXP MED, V164, P1455, DOI 10.1084/jem.164.5.1455; KOCHAN J, 1988, NUCLEIC ACIDS RES, V16, P3584, DOI 10.1093/nar/16.8.3584; LICHTENSTEIN LM, 1973, NATURE, V244, P287, DOI 10.1038/244287a0; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; RA C, 1993, INT IMMUNOL, V5, P47, DOI 10.1093/intimm/5.1.47; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMBOOK J, 1989, MOL CLONING, V9; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; TAKAMURA H, 1994, J OTOLARYNGOL JPN, V97, P61; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WELLER PF, 1993, J IMMUNOL, V150, P2554	19	55	55	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	2	S			1161	1169		10.1016/S0091-6749(95)70201-6	http://dx.doi.org/10.1016/S0091-6749(95)70201-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	TQ509	8543773				2022-12-18	WOS:A1995TQ50900012
J	IGARASHI, Y; GOLDRICH, MS; KALINER, MA; IRANI, AMA; SCHWARTZ, LB; WHITE, MV				IGARASHI, Y; GOLDRICH, MS; KALINER, MA; IRANI, AMA; SCHWARTZ, LB; WHITE, MV			QUANTITATION OF INFLAMMATORY CELLS IN THE NASAL-MUCOSA OF PATIENTS WITH ALLERGIC RHINITIS AND NORMAL SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC RHINITIS; NASAL MUCOSA; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; MAST CELL; IGE	HUMAN EOSINOPHILS; MAST-CELLS; INTERLEUKIN-2 RECEPTOR; MONOCLONAL-ANTIBODIES; ANTIGEN CHALLENGE; INTERFERON-GAMMA; 3T3 FIBROBLASTS; SECRETION; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY	Background: The role of inflammatory cells at the local site of allergic inflammation in the nose is unclear. Methods: nasal biopsy specimens were obtained from 10 patients with symptomatic seasonal allergic rhinitis and 10 normal subjects. Freeze-dried paraffin-embedded sections were stained for mononuclear cells and eosinophils. Tissues in Carnoy's fixative were stained for mast cells. Results: T cells were much more plentiful than B cells or macrophages, and no significant differences were found between the two groups in the number of T cells, T-cells subsets, B cells, and macrophages. However, the number of Cd25+ cells (lymphocyte activation markers) and the number of eosinophils were significantly higher in the allergic group than in the control group. There were no significant differences between the two groups in the total mast cell number. However, mucosal type mast cells were slightly increased, and a higher ratio of mast cells were costained for IgE in the allergic group. IgE+ cells mostly constained for mast cell tryptase and did not costain for J chain. Conclusion: These data suggest that unlike granulocytes, in some mononuclear cells qualitative, not quantitative, changes may be important in allergic rhinitis and that IgE may not be locally produced in the nasal mucosa.	NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20892; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Virginia Commonwealth University								Bachert C, 1990, AM J RHINOL, V4, P215, DOI [10.2500/105065890782009299, DOI 10.2500/105065890782009299]; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DELPRETE GF, 1991, J EXP MED, V174, P809, DOI 10.1084/jem.174.4.809; DURHAM SR, 1992, J IMMUNOL, V148, P2390; FOKKENS WJ, 1992, CLIN EXP ALLERGY, V22, P701, DOI 10.1111/j.1365-2222.1992.tb00194.x; FOKKENS WJ, 1990, INT ARCH ALLER A IMM, V93, P66, DOI 10.1159/000235281; FOX CC, 1985, J IMMUNOL, V135, P483; GANZER U, 1988, ORL J OTO-RHINO-LARY, V50, P257, DOI 10.1159/000276000; GREENE WC, 1986, ANNU REV IMMUNOL, V4, P69, DOI 10.1146/annurev.iy.04.040186.000441; IGARASHI Y, 1993, J ALLERGY CLIN IMMUN, V91, P1082, DOI 10.1016/0091-6749(93)90223-3; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; IRANI AMA, 1987, J IMMUNOL, V138, P4381; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; KIRSHENBAUM AS, 1989, J IMMUNOL, V142, P2424; KLEMENTSSON H, 1990, CLIN EXP ALLERGY, V20, P539, DOI 10.1111/j.1365-2222.1990.tb03147.x; LAILINEN LA, 1993, J ALLERGY CLIN IMMUN, V91, P349; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; LUNDGREN JD, 1991, J ALLERGY CLIN IMMUN, V87, P689, DOI 10.1016/0091-6749(91)90390-A; MEREDITH SD, 1989, J ALLERGY CLIN IMMUN, V84, P920, DOI 10.1016/0091-6749(89)90390-4; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NAGY L, 1982, CLIN EXP IMMUNOL, V47, P541; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; RAMBALDI A, 1987, EUR J IMMUNOL, V17, P153, DOI 10.1002/eji.1830170127; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SCHMUTZLER W, 1985, INT ARCH ALLER A IMM, V77, P177, DOI 10.1159/000233778; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; STEIN H, 1985, LAB INVEST, V52, P676; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; STROBER W, 1988, PEDIATR RES, V24, P549, DOI 10.1203/00006450-198811000-00001; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626	40	55	56	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					716	725		10.1016/S0091-6749(95)70177-X	http://dx.doi.org/10.1016/S0091-6749(95)70177-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897155	Bronze			2022-12-18	WOS:A1995QM01700012
J	OPPENHEIMER, J; ARESON, JG; NELSON, HS				OPPENHEIMER, J; ARESON, JG; NELSON, HS			SAFETY AND EFFICACY OF ORAL IMMUNOTHERAPY WITH STANDARDIZED CAT EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMMUNOTHERAPY; ORAL; CAT	HAY-FEVER PATIENTS; DOUBLE-BLIND TRIAL; GRASS-POLLEN; HYPOSENSITIZATION; ASTHMA; RESPONSES; CHILDREN; ANTIBODY; ALLERGEN; IGE	Fifty-three subjects with positive skin prick test results to cat extract and rhinoconjunctival symptoms on exposure to cat dander were enrolled in a double-blind, placebo-controlled study of oral cat immunotherapy. Responses were assessed by development of symptoms and nasal blockage on exposure to an apartment contaminated with cat dander, by titrated skin prick tests, and by cat-specific IgG and IgE. A total cumulative dose of 2.5 x 10(6) allergy units or 436 U Fel d I were administered over a period of 3 months. Both groups of subjects had significantly fewer symtpoms on exposure to cat dander during the course of the study, but there was no significant difference between active and placebo groups. There were no significant changes in either group in nasal blockage, skin prick test results, or specific IgG levels. Both groups had significant increases in cat-specific IgE, but there were no differences between groups. Subjects receiving active treatment had a slight excess of gastrointestinal complaints. Two subjects receiving active treatment experienced systemic symptoms: one had pulmonary edema, and the other had persistent asthma and urticaria, which may have represented reactions to the treatment. We conclude that oral cat immunotherapy with the preparation and doses used in this study is not effective.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DIV ALLERGY IMMUNOL,DENVER,CO 80206	National Jewish Health								ALPERSTEIN BERNARD B., 1940, JOUR ALLERGY, V11, P498, DOI 10.1016/S0021-8707(40)90461-0; BERNSTEIN C, 1937, J ALLERGY, V8, P221; Bernstein TB, 1938, ARCH INTERN MED, V62, P297, DOI 10.1001/archinte.1938.00180130118008; BJORKSTEN B, 1986, ALLERGY, V41, P290, DOI 10.1111/j.1398-9995.1986.tb02031.x; BLACK JH, 1928, J LAB CLIN MED, V13, P709; COOPER PJ, 1984, CLIN ALLERGY, V14, P541, DOI 10.1111/j.1365-2222.1984.tb02242.x; CRETICOS P S, 1990, Journal of Allergy and Clinical Immunology, V85, P165; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; Curtis H. H, 1900, MEDICAL NEWSLETTER, V77, P16; HARBECK RJ, 1991, DIAGN IMMUNOL, P173; LENG X, 1990, ANN ALLERGY, V64, P27; MCGREW GD, 1937, MIL SURG, V80, P371; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; MOSBECH H, 1987, ALLERGY, V42, P451, DOI 10.1111/j.1398-9995.1987.tb00362.x; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P129, DOI 10.1016/0091-6749(87)90120-5; ROCKWELL GE, 1938, OHIO STATE M J, V34, P784; TAUDORF E, 1989, J ALLERGY CLIN IMMUN, V83, P589, DOI 10.1016/0091-6749(89)90070-5; TAUDORF E, 1985, ALLERGY, V40, P321, DOI 10.1111/j.1398-9995.1985.tb00243.x; TAUDORF E, 1987, J ALLERGY CLIN IMMUN, V80, P153, DOI 10.1016/0091-6749(87)90124-2; TAYLOR G, 1973, J ALLERGY CLIN IMMUN, V52, P193, DOI 10.1016/0091-6749(73)90057-2; THOMMEN AA, 1931, ASTHMA HAY FEVER THE, P764; URBANEK R, 1990, EUR J PEDIATR, V149, P545, DOI 10.1007/BF01957689; VANNIEKERK CH, 1987, CLIN ALLERGY, V17, P507; WENTZ PE, 1990, J ALLERGY CLIN IMMUN, V85, P94, DOI 10.1016/0091-6749(90)90228-V; ZELLER MICHAEL, 1939, JOUR ALLERGY, V10, P579, DOI 10.1016/S0021-8707(39)90252-2	26	55	56	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	1				61	67		10.1016/0091-6749(94)90233-X	http://dx.doi.org/10.1016/0091-6749(94)90233-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MT781	8308183				2022-12-18	WOS:A1994MT78100007
J	KELSO, JM; SAMPSON, HA				KELSO, JM; SAMPSON, HA			FOOD PROTEIN-INDUCED ENTEROCOLITIS TO CASEIN HYDROLYSATE FORMULAS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									USN,MED CTR,DEPT INTERNAL MED,DIV ALLERGY,SAN DIEGO,CA 92134; JOHNS HOPKINS UNIV,BALTIMORE,MD 21218	United States Department of Defense; United States Navy; Johns Hopkins University	KELSO, JM (corresponding author), USN,MED CTR,DEPT CLIN INVEST,SAN DIEGO,CA 92134, USA.				NIAID NIH HHS [AI-24439] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASSADULLAHI TP, 1992, J ALLERGY CLIN IMMUN, V89, P228; PETTEI MJ, 1990, AM J DIS CHILD, V144, P16, DOI 10.1001/archpedi.1990.02150250017011; POWELL GK, 1985, NUTRITION SPECIAL NE, P131; ROSENTHAL E, 1991, ACTA PAEDIATR SCAND, V80, P958, DOI 10.1111/j.1651-2227.1991.tb11760.x; SAMPSON HA, 1992, PEDIATR, V40, P463	5	55	56	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1993	92	6					909	910		10.1016/0091-6749(93)90069-R	http://dx.doi.org/10.1016/0091-6749(93)90069-R			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML893	8258625				2022-12-18	WOS:A1993ML89300017
J	KONDO, N; FUKUTOMI, O; AGATA, H; MOTOYOSHI, F; SHINODA, S; KOBAYASHI, Y; KUWABARA, N; KAMEYAMA, T; ORII, T				KONDO, N; FUKUTOMI, O; AGATA, H; MOTOYOSHI, F; SHINODA, S; KOBAYASHI, Y; KUWABARA, N; KAMEYAMA, T; ORII, T			THE ROLE OF LYMPHOCYTES-T IN PATIENTS WITH FOOD-SENSITIVE ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPIC DERMATITIS; FOOD HYPERSENSITIVITY; CD4 PLUS LYMPHOCYTES-T; INTERLEUKIN-2; INTERFERON-GAMMA	MONOCLONAL-ANTIBODIES; INTERFERON-GAMMA; DOUBLE-BLIND; HUMAN CD4+; HYPERSENSITIVITY; IGE; RESPONSES; ALLERGY; DIFFERENTIATION; RECEPTOR	The role of T lymphocytes was assessed in patients with food-sensitive atopic dermatitis (AD). T lymphocytes plus monocytes responded well to ovalbumin or bovine serum albumin (BSA) in children with AD who were sensitive to hen's egg or cow's milk compared with healthy children and children with immediate allergic symptoms who are sensitive to hen's egg or cow's milk. The responding cells were shown to be predominantly CD4+ T lymphocytes. Interleukin-2 activity and interferon-gamma concentrations in culture supernatants of ovalbumin-stimulated peripheral blood mononuclear cells (PBMCs) from patients with AD who were sensitive to hen's egg were significantly higher than those of healthy children and patients sensitive to hen's egg with immediate symptoms. Expression of Fc is-an-element-of R II on B lymphocytes in cultures of ovalbumin-stimulated PBMCs from patients with AD was significantly higher than that of healthy children, but it tended to be lower than that of patients with immediate symptoms. These results suggest that, in patients with AD who are food sensitive, CD4+ T lymphocytes stimulated by food antigens secrete lymphokines such as interleukin-2 and interferon-gamma that are secreted from TH1 clones in mice, and express Fc is-an-element-of R II on B lymphocyte that is induced by interleukin-4 secreted from TH2 clones in mice. Taken together, cell-mediated immunity may also occur in addition to IgE-mediated hypersensitivity in patients with food-sensitive AD.			KONDO, N (corresponding author), GIFU UNIV,SCH MED,DEPT PEDIAT,TSUKASA MACHI 40,GIFU 500,JAPAN.							BLACK PL, 1980, J ALLERGY CLIN IMMUN, V66, P394, DOI 10.1016/0091-6749(80)90119-0; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BONNEFOY JY, 1987, J IMMUNOL, V138, P2970; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; CHOPRA RK, 1989, CLIN IMMUNOL IMMUNOP, V53, P297, DOI 10.1016/0090-1229(89)90058-5; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P477, DOI 10.1016/0091-6749(76)90191-3; CLEMENT LT, 1988, J IMMUNOL, V141, P1464; Ferguson A, 1988, Nutr Res Rev, V1, P1, DOI 10.1079/NRR19880004; GILLIS S, 1978, J IMMUNOL, V120, P2027; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P256, DOI 10.1016/0091-6749(75)90145-1; KONDO N, 1990, J ALLERGY CLIN IMMUN, V86, P253, DOI 10.1016/S0091-6749(05)80073-9; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PALIARD X, 1988, J IMMUNOL, V141, P849; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROMAGNANI S, 1989, CLIN IMMUNOL IMMUNOP, V50, pS13, DOI 10.1016/0090-1229(89)90110-4; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SCHEINMANN P, 1976, CLIN ALLERGY, V6, P515, DOI 10.1111/j.1365-2222.1976.tb01936.x; THOMAS Y, 1980, J IMMUNOL, V125, P2402; WERNER C, 1977, TISSUE ANTIGENS, V9, P227; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WRAITH DG, 1979, CLIN ALLERGY, V9, P25, DOI 10.1111/j.1365-2222.1979.tb01519.x	31	55	58	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1993	91	2					658	668		10.1016/0091-6749(93)90272-H	http://dx.doi.org/10.1016/0091-6749(93)90272-H			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KN548	8436779				2022-12-18	WOS:A1993KN54800014
J	CHUA, KY; KEHAL, PK; THOMAS, WR; VAUGHAN, PR; MACREADIE, IG				CHUA, KY; KEHAL, PK; THOMAS, WR; VAUGHAN, PR; MACREADIE, IG			HIGH-FREQUENCY BINDING OF IGE TO THE DER-P ALLERGEN EXPRESSED IN YEAST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RECOMBINANT; ALLERGENS; CDNA; YEAST; IGE BINDING; ALLERGENICITY; DER-P-1; HOUSE DUST MITE	COPPER-INDUCIBLE EXPRESSION; ESCHERICHIA-COLI; DERMATOPHAGOIDES-PTERONYSSINUS; MITE ALLERGEN; PROTEINS; CLONING; GENE; VECTORS	The production of allergens from cDNA clones will provide a clonally pure source of material for experimental and perhaps clinical studies. Attempts to produce the major mite allergen, Der p I, in a highly antigenic form in bacteria have, to date, had limited success. In this study, a high level of production of Der p I from a Cup1 gene cassette from pYELC5-13T in Saccharomyces cerevisiae is described. Although the protein was insoluble, it could be readily solubilized in a urea solution and remained in solution when it was returned to more physiologic buffers. An amount equivalent to about 1 mg/L of yeast culture could then be isolated by affinity chromatography with an immobilized monoclonal antibody. This product reacted strongly with IgE in 9/11 sera from mite-allergic patients compared to the 50% reactivity achieved for Der p I previously produced as a fusion by bacteria. Similarly, the intensity of binding and ability to absorb out Der p I specificities were much greater for the yeast, pYELC5-13T, product. Studies with monoclonal antibodies also demonstrated the yeast, Der p I, had a high degree of antigenicity, although clear differences with the native allergen were demonstrated. The high frequency of reactivity with IgE of the pYELC5-13T formally demonstrates that a single gene product of Der p I is a major allergen and demonstrates that even for Der p I, which is synthesized from a proenzyme, considerable antigenicity can be obtained by expressing the mature protein.	CSIRO,DIV BIOMOLEC ENGN,MELBOURNE,VIC 3001,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	CHUA, KY (corresponding author), WESTERN AUSTRALIAN RES INST CHILD HLTH,DIV MOLEC BIOL,GPO BOX D184,PERTH,WA 6001,AUSTRALIA.		Macreadie, Ian/Q-7430-2019; Macreadie, Ian/L-4437-2019; Macreadie, Ian G/F-5997-2010	Macreadie, Ian/0000-0001-5335-7220; Macreadie, Ian G/0000-0001-5335-7220				BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; CHAPMAN MD, 1991, CLIN EXP ALLERGY, V21, P155, DOI 10.1111/j.1365-2222.1991.tb00823.x; CHUA KY, 1991, CLIN EXP ALLERGY, V21, P161, DOI 10.1111/j.1365-2222.1991.tb00825.x; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P124, DOI 10.1159/000235102; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; GREENE WK, J IMMUNOL; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND P, 1988, J IMMUNOL, V140, P4256; MACREADIE IG, 1990, NUCLEIC ACIDS RES, V18, P1078, DOI 10.1093/nar/18.4.1078; MACREADIE IG, 1989, PLASMID, V21, P147, DOI 10.1016/0147-619X(89)90059-0; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MOHAPATRA SS, 1989, EPITOPES ATOPIC ALLE, P61; Sambrook J., 1989, MOL CLONING LAB MANU; SHERMAN F, 1986, LABORATORY COURSE MA; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457	23	55	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				95	102		10.1016/S0091-6749(05)80045-4	http://dx.doi.org/10.1016/S0091-6749(05)80045-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1730842				2022-12-18	WOS:A1992GZ90800011
J	JARJOUR, NN; CALHOUN, WJ; STEVENS, CA; SALISBURY, SM				JARJOUR, NN; CALHOUN, WJ; STEVENS, CA; SALISBURY, SM			EXERCISE-INDUCED ASTHMA IS NOT ASSOCIATED WITH MAST-CELL ACTIVATION OR AIRWAY INFLAMMATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EXERCISE; ASTHMA; HISTAMINE; BRONCHOSCOPY; MAST CELL; BRONCHOPROVOCATION	DEPENDENT CHEMI-LUMINESCENCE; BRONCHOALVEOLAR LAVAGE FLUID; RESPIRATORY HEAT-EXCHANGE; PLASMA HISTAMINE; INDUCED BRONCHOCONSTRICTION; CIRCULATING BASOPHILS; ALLERGEN CHALLENGE; BRONCHIAL-ASTHMA; TRYPTASE; ANTIGEN	Exercise-induced asthma (EIA) may affect up to 90% of patients with asthma. Hyperpnea associated with exercise leads to increased airway water and heat loss, which contributes to the development of EIA. Measurement of circulating mediators has suggested that mast cells may participate in the development of EIA via release of histamine and neutrophil chemotactic factor. To evaluate further the contribution of pulmonary mast cell-mediator release in the pathogenesis of EIA and to determine whether EIA is associated with enhancement of airway inflammation, we studied 11 subjects with mild stable asthma (FEV1, 93% +/- 3% predicted; mean +/- SEM) with significant EIA (after exercise fall in FEV1, 41% +/- 5%). Bronchoalveolar lavage (BAL) was performed immediately (less than 1 hour) after exercise challenge (EC) and repeated 24 hours later (exercise studies). On another occasion, paired BALs were done 24 hours apart (control studies). A minimum of 2 weeks separated the exercise and control pairs. No changes were observed in BAL cell counts, differentials, or reactive oxygen species metabolism after EC. Neither BAL histamine nor BAL tryptase levels increased, either shortly (less than 1 hour) or 24 hours after EC. We conclude that EC in subjects with asthma is not associated with cellular influx to airspace and that mechanisms other than histamine release by pulmonary mast cells may be responsible for EIA.	UNIV WISCONSIN,DEPT MED,PULM & CRIT CARE MED SECT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Calhoun, William/0000-0001-7075-712X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010404] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR 03186] Funding Source: Medline; NIAID NIH HHS [AI 10404] Funding Source: Medline; PHS HHS [K08 01828] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON SD, 1985, J ALLERGY CLIN IMMUN, V76, P673; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BERNSTEIN IL, 1985, CHEST, V88, P136; BIERMAN CW, 1984, J ALLERGY CLIN IMMUN, V73, P654, DOI 10.1016/0091-6749(84)90300-2; BROIDE DH, 1990, AM REV RESPIR DIS, V141, P563, DOI 10.1164/ajrccm/141.3.563; BROWSHER RR, 1983, J BIOL CHEM, V258, P12215; CALHOUN WJ, 1990, J ALLERGY CLIN IMMUN, V86, P306, DOI 10.1016/S0091-6749(05)80092-2; CALHOUN WJ, 1988, J LAB CLIN MED, V112, P147; CALHOUN WJ, 1986, THORAX, V41, P266, DOI 10.1136/thx.41.4.266; CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; DANIEL WW, 1983, BIOSTATISTICS F ANAL; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; HOWARTH PH, 1984, J ALLERGY CLIN IMMUN, V73, P391, DOI 10.1016/0091-6749(84)90414-7; JARJOUR NN, 1990, AM REV RESPIR DIS, V142, P100, DOI 10.1164/ajrccm/142.1.100; JARJOUR NN, 1991, AM REV RESPIR DIS, V144, P83, DOI 10.1164/ajrccm/144.1.83; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1983, LANCET, V1, P520; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCFADDEN ER, 1987, CHEST, V91, pS151, DOI 10.1378/chest.91.6.151S; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; MORGAN DJR, 1983, THORAX, V38, P771, DOI 10.1136/thx.38.10.771; RANKIN JA, 1984, CHEST, V85, P723, DOI 10.1378/chest.85.6.723; RUBINSTEIN I, 1987, NEW ENGL J MED, V317, P482, DOI 10.1056/NEJM198708203170805; SCHWARTZ LB, 1990, J IMMUNOL, V144, P2304; SHULT PA, 1985, J LAB CLIN MED, V106, P638; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002	35	55	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				60	68		10.1016/S0091-6749(05)80041-7	http://dx.doi.org/10.1016/S0091-6749(05)80041-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1730841				2022-12-18	WOS:A1992GZ90800007
J	GRUCHALLA, RS; SULLIVAN, TJ				GRUCHALLA, RS; SULLIVAN, TJ			DETECTION OF HUMAN IGE TO SULFAMETHOXAZOLE BY SKIN TESTING WITH SULFAMETHOXAZOYL-POLY-L-TYROSINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SULFAMETHOXAZOLE; IGE; SULFAMETHOXAZOYL-POLY-L-TYROSINE; SKIN TEST REACTIVITY	PENICILLIN ALLERGY; HYPERSENSITIVITY; DRUGS; EXPERIENCE; DIAGNOSIS	Adverse reactions to sulfamethoxazole (SMX) occur in 4% to 6% of normal individuals. Many of these reactions resemble immunopathologic reactions, but skin test or in vitro evidence of a role for IgE is limited. Earlier RAST studies in our laboratory provided evidence that the N4-SMX hapten was a major determinant in immediate hypersensitivity reactions to SMX. We tested the hypothesis that IgE to this hapten is present on the mast cells of patients who have experienced immediate hypersensitivity reactions temporally related to exposure to SMX. A multivalent skin test reagent, SMX168-poly-L-tyrosine, and a univalent hapten, SMX-tyrosine, were synthesized. Forty-four patients with histories of allergic reactions to SMX and six subjects who had been exposed to the drug, but who had not reacted, were skin tested. Twenty-seven percent of the history-positive patients were skin test positive. None of the control individuals was positive. The immunologic responses to SMX in three patients who had experienced allergic reactions during SMX/trimethoprim therapy were analyzed in serial skin test and RAST assessments. One to three years after the clinical reactions, IgE to SMX could be demonstrated by skin testing in all three patients with a SMX-poly-L-tyrosine skin test reagent. Skin test reactions were inhibited by the monovalent reagent, SMX-tyrosine, in a dose-dependent manner. SMX-specific IgE antibodies could also be detected by RAST in serum obtained within days of the reactions from two of the three individuals. These IgE antibodies could not be detected in samples taken several years after the clinical reaction. RAST-inhibition experiments confirmed the immunologic specificity of the univalent hapten inhibition. The results of these experiments support the concept that the N4-SMX determinant is a major determinant in SMX allergy. These data also demonstrate that IgE to this SMX determinant can be detected by skin testing with a multivalent hapten carrier conjugate.			GRUCHALLA, RS (corresponding author), SOUTHWESTERN MED CTR,DEPT INTERNAL MED,DIV ALLERGY,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							ABERNETHY TJ, 1941, J CLIN INVEST, V20, P433; ARNDT KA, 1976, JAMA-J AM MED ASSOC, V235, P918, DOI 10.1001/jama.235.9.918; CARRINGTON DM, 1987, J ALLERGY CLIN IMMUN, V79, P442, DOI 10.1016/0091-6749(87)90361-7; Cohen MH, 1943, J AMER MED ASSOC, V121, P408, DOI 10.1001/jama.1943.02840060026006; DAVIS BERNARD D., 1942, SCIENCE, V95, P78, DOI 10.1126/science.95.2455.78; de Weck A L, 1972, Int Arch Allergy Appl Immunol, V42, P782; de Weck A L, 1972, Int Arch Allergy Appl Immunol, V42, P798; FARAH FS, 1960, J EXP MED, V112, P1211, DOI 10.1084/jem.112.6.1211; GOODMAN MH, 1937, UJAMA, V109, P1009; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; GRUCHALLA R S, 1990, Journal of Allergy and Clinical Immunology, V85, P157; Hageman PO, 1937, J AMER MED ASSOC, V109, P642, DOI 10.1001/jama.1937.02780350010005; HANSBROUGH JR, 1987, J ALLERGY CLIN IMMUN, V80, P538, DOI 10.1016/0091-6749(87)90004-2; HARLE DG, 1988, MOL IMMUNOL, V25, P1347, DOI 10.1016/0161-5890(88)90050-8; Harvey AM, 1937, J AMER MED ASSOC, V109, P12, DOI 10.1001/jama.1937.02780270014004; HJORTH N, 1968, TXB DERMATOLOGY, V1, P255; Landsteiner K, 1935, J EXP MED, V61, P643, DOI 10.1084/jem.61.5.643; Landsteiner K, 1936, J EXP MED, V64, P625, DOI 10.1084/jem.64.4.625; Leftwich WB, 1944, B JOHNS HOPKINS HOSP, V74, P26; LEVINE BB, 1966, NEW ENGL J MED, V275, P1115, DOI 10.1056/NEJM196611172752009; LEVINE BB, 1966, ANNU REV MED, V17, P23, DOI 10.1146/annurev.me.17.020166.000323; Lyons RH, 1942, J AMER MED ASSOC, V118, P955, DOI 10.1001/jama.1942.02830120019005; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; NISONOFF A, 1967, METHODS IMMUNOLOGY I, V1, P120; PARKER CW, 1981, ARTHRITIS RHEUM, V24, P1024, DOI 10.1002/art.1780240808; PARKER CW, 1964, IMMUNOCHEMICAL BASIS; PARKER CW, 1967, METHODS IMMUNOLOGY I, V1, P133; PARKER CW, 1977, DRUG DESIGN ADVERSE, P153; PARKER CW, 1980, CLIN IMMUNOLOGY, P1219; RATNER B, 1943, ALLERGY ANAPHYLAXIS, P579; RESSLER C, 1987, ANN ALLERGY, V59, P167; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; SHERMAN WB, 1947, AM J MED, V2, P588, DOI 10.1016/0002-9343(47)90049-1; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; Steven R A, 1939, Cal West Med, V50, P419; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; SULLIVAN TJ, 1984, J ALLERGY CLIN IMMUN, V74, P594, DOI 10.1016/0091-6749(84)90112-X; SULZBERGER MB, 1947, J ALLERGY, V18, P92, DOI 10.1016/0021-8707(47)90120-2; WARRINGTON RJ, 1978, CAN MED ASSOC J, V118, P787; WARRINGTON RJ, 1983, CLIN ALLERGY, V13, P235, DOI 10.1111/j.1365-2222.1983.tb02593.x	41	55	57	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					784	792		10.1016/0091-6749(91)90186-R	http://dx.doi.org/10.1016/0091-6749(91)90186-R			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1955637				2022-12-18	WOS:A1991GQ45200014
J	OWNBY, DR				OWNBY, DR			ENVIRONMENTAL-FACTORS VERSUS GENETIC-DETERMINANTS OF CHILDHOOD INHALANT ALLERGIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN, DEPT PEDIAT & COMMUNICABLE DIS, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	OWNBY, DR (corresponding author), HENRY FORD HOSP, PEDIAT ALLERGY IMMUNOL RES LAB, DETROIT, MI 48202 USA.							ALBRECHT P, 1977, J PEDIATR-US, V91, P715, DOI 10.1016/S0022-3476(77)81021-4; ARORA S, 1970, INT ARCH ALLER A IMM, V37, P357, DOI 10.1159/000230798; BAHNA SL, 1983, CLIN EXP IMMUNOL, V51, P624; BAHNA SL, 1983, ALLERGY, V38, P57, DOI 10.1111/j.1398-9995.1983.tb00857.x; BENACERR.B, 1972, SCIENCE, V175, P273, DOI 10.1126/science.175.4019.273; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; BJORKSTEN F, 1981, ACTA MED SCAND, V209, P299; BLUMENTHAL MN, 1986, J ALLERGY CLIN IMMUN, V78, P962, DOI 10.1016/0091-6749(86)90286-1; BLUMENTHAL MN, 1981, AM J MED GENET, V10, P219, DOI 10.1002/ajmg.1320100304; BORECKI I B, 1985, Genetic Epidemiology, V2, P327, DOI 10.1002/gepi.1370020402; BOUSQUET J, 1983, ANN ALLERGY, V51, P291; BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; BUSINCO L, 1988, CLIN ALLERGY, V18, P269, DOI 10.1111/j.1365-2222.1988.tb02869.x; CAROSSO A, 1986, ANN ALLERGY, V56, P300; CARTER CO, 1969, BRIT MED BULL, V25, P52, DOI 10.1093/oxfordjournals.bmb.a070671; Cooke RA, 1916, J IMMUNOL, V1, P201; COOKSON WOCM, 1988, LANCET, V1, P86; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; CRONER S, 1986, ALLERGY, V41, P68, DOI 10.1111/j.1398-9995.1986.tb00277.x; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; DANNAEUS A, 1978, ACTA PAEDIATR SCAND, V67, P497, DOI 10.1111/j.1651-2227.1978.tb16360.x; DELESPESSE G, 1983, MONOGR ALLERGY, V18, P83; DUCHATEAU J, 1983, LANCET, V1, P413; FALTHMAGNUSSON K, 1987, J ALLERGY CLIN IMMUN, V80, P868, DOI 10.1016/S0091-6749(87)80279-8; FRICK OL, 1983, AM J VET RES, V44, P440; FRICK OL, 1986, J ALLERGY CLIN IMMUN, V78, P1013, DOI 10.1016/0091-6749(86)90295-2; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; GERRARD JW, 1978, AM J HUM GENET, V30, P46; GERRARD JW, 1980, ANN ALLERGY, V44, P261; GLOVSKY M M, 1982, Journal of Allergy and Clinical Immunology, V69, P100; Grulee CG, 1936, J PEDIATR-US, V9, P223, DOI 10.1016/S0022-3476(36)80058-4; HAMBURGER RN, 1983, ANN ALLERGY, V51, P281; HAPPLE R, 1982, INT ARCH ALLER A IMM, V68, P90, DOI 10.1159/000233072; HASSTEDT SJ, 1983, AM J MED GENET, V14, P61, DOI 10.1002/ajmg.1320140110; HOLT PG, 1988, INT ARCH ALLER A IMM, V86, P121, DOI 10.1159/000234617; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; JARRETT E, 1979, NATURE, V280, P145, DOI 10.1038/280145a0; JARRETT EEE, 1986, J ALLERGY CLIN IMMUN, V78, P1000, DOI 10.1016/0091-6749(86)90292-7; JARRETT EEE, 1983, IMMUNOLOGY, V48, P49; JARRETT EEE, 1984, IMMUNOLOGY, V53, P365; KEMP AS, 1979, MED J AUSTRALIA, V1, P263, DOI 10.5694/j.1326-5377.1979.tb112072.x; KJELLMAN NIM, 1981, LANCET, V1, P993; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; KJELLMAN NIM, 1979, CLIN ALLERGY, V9, P347, DOI 10.1111/j.1365-2222.1979.tb02493.x; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; LUBS ML, 1972, J PEDIATR-US, V80, P26, DOI 10.1016/S0022-3476(72)80448-7; LUOMA R, 1983, ALLERGY, V38, P339, DOI 10.1111/j.1398-9995.1983.tb04128.x; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; MARSH DG, 1988, ALLERGY, V43, P7, DOI 10.1111/j.1398-9995.1988.tb02434.x; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1982, J EXP MED, V155, P1452, DOI 10.1084/jem.155.5.1452; MEYERS DA, 1987, AM J HUM GENET, V41, P51; MEYERS DA, 1983, AM J MED GENET, V16, P575, DOI 10.1002/ajmg.1320160414; MEYERS DA, 1982, HUM HERED, V32, P15, DOI 10.1159/000153262; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; MILLER DL, 1973, J ALLERGY CLIN IMMUN, V52, P182, DOI 10.1016/0091-6749(73)90035-3; MURRAY AB, 1985, J ALLERGY CLIN IMMUN, V76, P108, DOI 10.1016/0091-6749(85)90812-7; OCONNOR RD, 1984, NEW ENGL REGIONAL AL, V5, P149; OWNBY DR, 1988, J ALLERGY CLIN IMMUN, V82, P634, DOI 10.1016/0091-6749(88)90976-1; PEARSON DJ, 1980, CLIN ALLERGY, V10, P585; QUOIX E, 1988, ALLERGY, V43, P127, DOI 10.1111/j.1398-9995.1988.tb00406.x; RAO DC, 1980, AM J HUM GENET, V32, P620; RATNER B, 1952, ANN ALLERGY, V9, P1; SAKAMOTO M, 1984, J IMMUNOL, V132, P2614; SEN DK, 1974, J ALLERGY CLIN IMMUN, V54, P25, DOI 10.1016/S0091-6749(74)80005-9; SETTIPANE RA, 1988, NEW ENGL REG ALLERGY, V9, P555, DOI 10.2500/108854188778965591; SMITH JM, 1979, CLIN ALLERGY, V9, P153, DOI 10.1111/j.1365-2222.1979.tb01536.x; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573; WELLIVER RC, 1980, NEW ENGL J MED, V303, P1198, DOI 10.1056/NEJM198011203032103; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8; WITTIG HJ, 1978, ANN ALLERGY, V41, P84; WUTHRICH B, 1981, CLIN ALLERGY, V11, P147, DOI 10.1111/j.1365-2222.1981.tb01578.x; ZEIGER RS, 1986, J ALLERGY CLIN IMMUN, V78, P224, DOI 10.1016/0091-6749(86)90016-3; ZETTERSTROM O, 1985, J ALLERGY CLIN IMMUN, V75, P594, DOI 10.1016/0091-6749(85)90035-1; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215	84	55	55	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				279	287		10.1016/S0091-6749(05)80088-0	http://dx.doi.org/10.1016/S0091-6749(05)80088-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	2212404				2022-12-18	WOS:A1990EA85900001
J	SCHWARTZ, HJ; GOLDEN, DBK; LOCKEY, RF				SCHWARTZ, HJ; GOLDEN, DBK; LOCKEY, RF			VENOM IMMUNOTHERAPY IN THE HYMENOPTERA-ALLERGIC PREGNANT PATIENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									AMER ACAD ALLERGY & IMMUNOL, COMM INSECTS, MILWAUKEE, WI USA; UNIV HOSP CLEVELAND, DEPT MED, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT MED, CLEVELAND, OH 44106 USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA; UNIV S FLORIDA, TAMPA, FL 33620 USA	University Hospitals of Cleveland; Case Western Reserve University; Johns Hopkins University; State University System of Florida; University of South Florida								BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; ENTMAN SS, 1984, SOUTHERN MED J, V77, P402, DOI 10.1097/00007611-198403000-00038; ERASMUS C, 1982, ARCH DIS CHILD, V57, P785, DOI 10.1136/adc.57.10.785; FELDT RH, 1971, MAYO CLIN PROC, V46, P794; FITZSIMONS R, 1986, J ALLERGY CLIN IMMUN, V78, P349, DOI 10.1016/S0091-6749(86)80088-4; GLASS RH, 1984, MATERNAL FETAL MED P, P285; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; GREEN JR, 1984, MATERNAL FETAL MED P, P539; GREENBERGER PA, 1985, NEW ENGL J MED, V312, P897, DOI 10.1056/NEJM198504043121406; HARRIS LE, 1975, MAYO CLIN PROC, V50, P85; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; NORMAN PS, 1987, J ALLERGY CLIN IMMUN, V79, P572, DOI 10.1016/S0091-6749(87)80150-1; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P553, DOI 10.1016/0091-6749(85)90028-4; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; Schatz M, 1983, ALLERGY PRINCIPLES P, P935; SCHWARTZ H J, 1984, Journal of Allergy and Clinical Immunology, V73, P189; SCHWARTZ HJ, 1988, CLIN ALLERGY, V18, P461, DOI 10.1111/j.1365-2222.1988.tb02896.x; SETTIPANE GA, 1979, CLIN ALLERGY, V9, P385, DOI 10.1111/j.1365-2222.1979.tb02497.x; SIEGAL DG, 1980, FETAL MANTERNAL MED, P4; Stablein J J, 1984, Compr Ther, V10, P45; STUCKEY M, 1982, LANCET, V2, P41; 1972, DHEW NIH78190 PUBL	25	55	58	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1990	85	4					709	712		10.1016/0091-6749(90)90188-A	http://dx.doi.org/10.1016/0091-6749(90)90188-A			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA437	2324411	Bronze			2022-12-18	WOS:A1990DA43700005
J	RAFFERTY, P; NG, WH; PHILLIPS, G; CLOUGH, J; CHURCH, MK; AURICH, R; OLLIER, S; HOLGATE, ST				RAFFERTY, P; NG, WH; PHILLIPS, G; CLOUGH, J; CHURCH, MK; AURICH, R; OLLIER, S; HOLGATE, ST			THE INHIBITORY ACTIONS OF AZELASTINE HYDROCHLORIDE ON THE EARLY AND LATE BRONCHOCONSTRICTOR RESPONSES TO INHALED ALLERGEN IN ATOPIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SOUTHAMPTON GEN HOSP,IMMUNOPHARMACOL GRP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton								ABRAHAM WM, 1987, AM REV RESPIR DIS, V135, pS49; ABRAHAM WM, 1985, PROSTAGLANDINS, V29, P715, DOI 10.1016/0090-6980(85)90132-7; ACKERMAN SJ, 1983, J IMMUNOL, V131, P2977; ALBAZZAZ MK, 1988, THORAX, V43, P306, DOI 10.1136/thx.43.4.306; ARNOUX B, 1980, EUR J CLIN INVEST, V10, P437, DOI 10.1111/j.1365-2362.1980.tb02082.x; BRITTON JR, 1987, J ALLERGY CLIN IMMUN, V79, P811, DOI 10.1016/0091-6749(87)90214-4; BUSSE W, 1989, J ALLERGY CLIN IMMUN, V83, P400, DOI 10.1016/0091-6749(89)90125-5; CHAND N, 1986, ALLERGY, V41, P473, DOI 10.1111/j.1398-9995.1986.tb00331.x; CHAND N, 1983, EUR J PHARMACOL, V96, P227, DOI 10.1016/0014-2999(83)90311-4; CHAND N, 1985, INT ARCH ALLER A IMM, V77, P451, DOI 10.1159/000233825; CHURCH MK, 1982, CLIN ALLERGY, V12, P223, DOI 10.1111/j.1365-2222.1982.tb02522.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; DEMONCHY JGR, 1985, AGENTS ACTIONS, V16, P252; Diamantis W., 1981, PHARMACOLOGIST, V23, P149; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; FIELDS DAS, 1984, J ALLERGY CLIN IMMUN, V73, P400, DOI 10.1016/0091-6749(84)90415-9; GOSSET P, 1984, J ALLERGY CLIN IMMUN, V74, P827, DOI 10.1016/0091-6749(84)90186-6; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; HONDA M, 1982, ALLERGY, V37, P41, DOI 10.1111/j.1398-9995.1982.tb04115.x; HOWARTH PH, 1987, J ALLERGY CLIN IMMUN, V80, P703, DOI 10.1016/0091-6749(87)90291-0; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEWIS RA, 1984, DRUGS LUNG; LITTLE MM, 1987, J ALLERGY CLIN IMMUN, V79, P204; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; OMALLEY G, 1987, THORAX, V42, P747; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RAFFERTY P, 1987, ALLERGOL IMMUNOL CLI, V2, P188; RAFFERTY P, 1988, THORAX, V43, P220; RAULS DO, 1986, J ALLERGY CLIN IMMUN, V77, P673, DOI 10.1016/0091-6749(86)90407-0; SCHULT PA, 1985, J LAB CLIN MED, V106, P638; SPECTOR SL, 1987, J ALLERGY CLIN IMMUN, V80, P75, DOI 10.1016/S0091-6749(87)80194-X; STORMS W, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90386-0; TWENTYMAN O, IN PRESS FOLIA ALLER; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; ZECHEL HJ, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1184	39	55	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	1				649	657		10.1016/0091-6749(89)90292-3	http://dx.doi.org/10.1016/0091-6749(89)90292-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA314	2572616				2022-12-18	WOS:A1989CA31400001
J	PELIKAN, Z; PELIKANFILIPEK, M				PELIKAN, Z; PELIKANFILIPEK, M			CYTOLOGIC CHANGES IN THE NASAL SECRETIONS DURING THE LATE NASAL RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PELIKAN, Z (corresponding author), INST MED SCI DEKLOKKENBERG, DEPT ALLERGOL & IMMUNOL, GALDERSEWEG 81, 4836 AE BREDA, NETHERLANDS.							AUSTEN KF, 1976, MOL BIOL ASPECTS ACU, P293; BASCOM R, 1986, 12 P INT C ALL CLIN, P113; BHANDARI CM, 1976, ANN ALLERGY, V37, P280; BRYAN W T, 1959, Trans Am Acad Ophthalmol Otolaryngol, V63, P613; BRYAN WTK, 1964, ANN OTO RHINOL LARYN, V73, P474, DOI 10.1177/000348946407300217; BRYAN WTK, 1958, T AM ACAD OTOLARYNGO, V63, P579; CAUNA N, 1969, ANN OTO RHINOL LARYN, V78, P865, DOI 10.1177/000348946907800418; Cohen SG, 1983, ALLERGY PRINCIPLES P, P701; GILLESPIE E, 1977, COMPREHENSIVE IMMU 3, P101; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P73, DOI 10.1016/0091-6749(77)90086-0; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GOETZL EJ, 1977, COMPREHENSIVE IMMU 3, P113; HANSEL FK, 1953, CLIN ALLERGY, P408; HASTIE R, 1979, LAB INVEST, V40, P554; HENSON PM, 1972, J IMMUNOL, V109, P1182; HENSON PM, 1977, IMMUNOLOGY RECEPTORS, P131; HENSON PM, 1982, CLIN ASPECTS IMMUNOL, P687; IGNARRO LJ, 1975, J CYCLIC NUCL PROT, V1, P283; JALOWAYSKI AA, 1983, J ALLERGY CLIN IMMUN, V71, P89, DOI 10.1016/0091-6749(83)90125-2; KAJOSAARI M, 1981, ALLERGY, V36, P329, DOI 10.1111/j.1398-9995.1981.tb01584.x; MURRAY AB, 1969, J ALLERGY, V43, P1, DOI 10.1016/0021-8707(69)90014-8; MYGIND N, 1973, ARCH KLIN EXP OHR, V204, P123, DOI 10.1007/BF00302160; MYGIND N, 1979, ALLERGY, V34, P195, DOI 10.1111/j.1398-9995.1979.tb01699.x; Mygind N, 1979, NASAL ALLERGY, P170; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P283, DOI 10.1007/BF00457469; OKUDA M, 1982, RHINOLOGY S, V19, P115; OLSSON I, 1979, ALLERGY, V34, P353, DOI 10.1111/j.1398-9995.1979.tb02005.x; PARISH WE, 1986, 12 P INT C ALL CLIN, P113; PELIKAN Z, 1986, J ALLERGY CLIN IMMUN, V77, P245; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PELIKAN Z, 1983, J ALLERGY CLIN IMMUN, V72, P657, DOI 10.1016/0091-6749(83)90625-5; PELIKAN Z, 1982, ANN ALLERGY, V49, P200; PELIKAN Z, 1985, J ALLERGY CLIN IMMUN, V75, P112, DOI 10.1016/0091-6749(85)90167-8; PELIKAN Z, 1988, J ALLERGY CLIN IMMUN, V82, P1103, DOI 10.1016/0091-6749(88)90150-9; PELIKAN Z, 1981, 12TH P ANN M EUR AC, P634; PELIKAN Z, 1979, MAST CELL ITS ROLE H, P772; PLATT WR, 1979, COLOR ATLAS TXB HEMA, P526; PLAUT M, 1983, ALLERGY PRINCIPLES P, P119; SASAKI Y, 1977, ANN ALLERGY, V39, P106; SCHLEIMER RP, 1983, CLIN REV ALLERG, V1, P327; SMITH JA, 1980, CELL BIOL INFLAMMATI, P189; SPECTOR SL, 1980, J ALLERGY CLIN IMMUN, V66, P129, DOI 10.1016/0091-6749(80)90060-3; STENSON WF, 1983, CLIN REV ALLERG, V1, P369; STEVENS W J, 1984, Journal of Allergy and Clinical Immunology, V73, P156; VAHERI EINO, 1956, ACTA ALLERGOL, V10, P203, DOI 10.1111/j.1398-9995.1956.tb02997.x; WALDEN SM, 1988, J ALLERGY CLIN IMMUN, V81, P940, DOI 10.1016/0091-6749(88)90157-1; WASSERMAN SI, 1983, 11 P INV S INT C ALL, P29; WASSERMAN SI, 1979, MAST CELL ITS ROLE H, P9; ZWEIMAN B, 1979, MAST CELL ITS ROLE H, P187; 1972, HAMATOLOGISCHE TAFEL, P32	51	55	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1989	83	6					1068	1079		10.1016/0091-6749(89)90448-X	http://dx.doi.org/10.1016/0091-6749(89)90448-X			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC235	2732407	Bronze			2022-12-18	WOS:A1989AC23500009
J	RANKIN, JA				RANKIN, JA			THE CONTRIBUTION OF ALVEOLAR MACROPHAGES TO HYPERREACTIVE AIRWAY DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											RANKIN, JA (corresponding author), YALE UNIV,W HAVEN VET HOSP,SCH MED,PULM DIS SECT,689111A,W HAVEN,CT 06516, USA.							ANDERSON CL, 1981, J IMMUNOL, V126, P2470; ARNOUX B, 1980, EUR J CLIN INVEST, V10, P437, DOI 10.1111/j.1365-2362.1980.tb02082.x; ARNOUX B, 1982, AM REV RESPIR DIS, V125, pA70; AUBAS P, 1984, AM REV RESPIR DIS, V130, P875; BACH MK, 1980, J IMMUNOL, V125, P115; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BRAIN JD, 1984, AM REV RESPIR DIS, V129, P823, DOI 10.1164/arrd.1984.129.5.823; CAPRON A, 1975, NATURE, V253, P474, DOI 10.1038/253474a0; CAPRON A, 1977, EUR J IMMUNOL, V7, P315, DOI 10.1002/eji.1830070515; CARROLL MP, 1985, J ALLERGY CLIN IMMUN, V75, P290, DOI 10.1016/0091-6749(85)90060-0; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; CUNNINGHAM AL, 1984, J IMMUNOL, V132, P197; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DESSAINT JP, 1979, CELL IMMUNOL, V46, P24, DOI 10.1016/0008-8749(79)90242-9; DESSAINT JP, 1979, CELL IMMUNOL, V46, P12, DOI 10.1016/0008-8749(79)90241-7; DESSEIN AJ, 1986, J IMMUNOL, V136, P3829; DRESKIN SC, 1988, JAMA-J AM MED ASSOC, V260, P1265, DOI 10.1001/jama.260.9.1265; DUNNILL MS, 1978, ALLERGY PRINCIPLES P, V2, P678; ELSAS P, 1987, ANN INST PASTEUR IMM, V138, P97, DOI 10.1016/S0769-2625(87)80099-5; ESCHENBACHER WL, 1987, CHEST, V92, P105, DOI 10.1378/chest.92.1.105; FELS AOS, 1986, J APPL PHYSIOL, V60, P353, DOI 10.1152/jappl.1986.60.2.353; FELS AOS, 1982, P NATL ACAD SCI-BIOL, V79, P7866, DOI 10.1073/pnas.79.24.7866; FERRERI NR, 1986, J IMMUNOL, V136, P4188; FICK RB, 1987, J APPL PHYSIOL, V63, P1147, DOI 10.1152/jappl.1987.63.3.1147; FINBLOOM DS, 1983, J IMMUNOL, V30, P1489; FINDBLOOD DS, 1981, J IMMUNOL, V129, P2004; FITZHARRIS P, 1986, J ALLERGY CLIN IMMUN, V77, P235; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; FULLER RW, 1986, CLIN EXP IMMUNOL, V65, P416; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; GODDARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88; GOSSET P, 1984, J ALLERGY CLIN IMMUN, V74, P827, DOI 10.1016/0091-6749(84)90186-6; GRANT JA, 1986, FASEB J, V45, P2653; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; LAVIOLETTE M, 1986, J CLIN INVEST, V77, P54, DOI 10.1172/JCI112301; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; LICHTENSTEIN LM, 1988, J ALLERGY CLIN IMMUN, V81, P814, DOI 10.1016/0091-6749(88)90936-0; LIU MC, 1986, J IMMUNOL, V136, P2588; MACDERMOT J, 1984, PROSTAGLANDINS, V27, P163, DOI 10.1016/0090-6980(84)90071-6; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MAROM Z, 1983, J CLIN INVEST, V72, P122, DOI 10.1172/JCI110949; MAROM Z, 1985, J CLIN INVEST, V75, P191, DOI 10.1172/JCI111674; MAROM Z, 1984, J EXP MED, P844; MARTIN TR, 1987, J CLIN INVEST, V80, P1114, DOI 10.1172/JCI113168; MARTINET Y, 1987, NEW ENGL J MED, V317, P202, DOI 10.1056/NEJM198707233170404; MELEWICZ FM, 1982, CLIN EXP IMMUNOL, V49, P364; MELEWICZ FM, 1981, J IMMUNOL, V126, P1592; MERRILL WW, 1980, J CLIN INVEST, V65, P268, DOI 10.1172/JCI109668; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NAGY L, 1982, CLIN EXP IMMUNOL, V47, P541; NARAYFEJESTOTH A, 1984, J IMMUNOL, V133, P1914; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; RANKIN JA, 1984, J IMMUNOL, V132, P1993; RANKIN JA, 1986, ANN INST PASTEUR IMM, VC137, P364, DOI 10.1016/S0771-050X(86)80056-0; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; RANKIN JA, IN PRESS J CLIN INVE; RANKIN JA, 1988, AM REV RESPIR DIS, V137, pA5; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; REYNOLDS HY, 1987, AM REV RESPIR DIS, V135, P250; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; SIGAL CE, 1987, J CLIN IMMUNOL, V7, P179, DOI 10.1007/BF00916012; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P381, DOI 10.1016/S0025-6196(12)64861-7; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; SPIEGELBERG HL, 1984, ADV IMMUNOL, V35, P61, DOI 10.1016/S0065-2776(08)60574-X; TONNEL AB, 1983, LANCET, V1, P1406; TONNEL AB, 1987, ALLERGY INFLAMMATION; TONNEL M, 1980, CLIN EXP IMMUNOL, V40, P416; VEITH MC, 1983, J EXP MED, V157, P1828, DOI 10.1084/jem.157.6.1828; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765	76	55	55	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					722	729		10.1016/0091-6749(89)90005-5	http://dx.doi.org/10.1016/0091-6749(89)90005-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2651506				2022-12-18	WOS:A1989U342000002
J	BIENENSTOCK, J				BIENENSTOCK, J			AN UPDATE ON MAST-CELL HETEROGENEITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BIENENSTOCK, J (corresponding author), MCMASTER UNIV,DEPT PATHOL,HSC-2N16,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA.							BEAVEN MA, 1983, J PHARMACOL EXP THER, V224, P620; BEFUS AD, 1985, IMMUNOL TODAY, V6, P281, DOI 10.1016/0167-5699(85)90169-0; BEFUS AD, 1987, J IMMUNOL, V138, P2604; BEFUS AD, 1982, J IMMUNOL, V128, P2475; BEFUS AD, 1986, MAST CELL DIFFERENTI, P1; BEFUS D, 1985, INT ARCH ALLER A IMM, V76, P232, DOI 10.1159/000233697; BENFEY PN, 1987, J BIOL CHEM, V262, P5377; BIENENSTOCK J, 1987, INT ARCH ALLER A IMM, V82, P238, DOI 10.1159/000234197; BIENENSTOCK J, 1986, PROG IMMUNOL, V6, P851; ENERBACK L, 1987, INT ARCH ALLER A IMM, V82, P249, DOI 10.1159/000234199; ENERBACK L, 1974, HISTOCHEMISTRY, V42, P301, DOI 10.1007/BF00492678; Enerback L., 1981, MONOGR ALLERGY, V17, P222; FOX CC, 1985, INT ARCH ALLER A IMM, V77, P130, DOI 10.1159/000233767; FOX CC, 1985, J IMMUNOL, V135, P483; HAMAGUCHI Y, 1987, J EXP MED, V165, P268, DOI 10.1084/jem.165.1.268; HEAVEY DJ, 1988, J IMMUNOL, V140; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AMA, 1987, J IMMUNOL, V138, P4381; JARRETT EEE, 1984, IMMUNOL TODAY, V5, P115, DOI 10.1016/0167-5699(84)90046-X; KATZ HR, 1986, J BIOL CHEM, V261, P3393; KIDO H, 1986, J IMMUNOL, V136, P1061; KING SJ, 1985, P NATL ACAD SCI USA, V82, P1214, DOI 10.1073/pnas.82.4.1214; KOBAYASHI T, 1986, J IMMUNOL, V136, P1378; LEE T D G, 1985, Clinical Immunology Reviews, V4, P143; LEUNG KBP, 1986, EUR J RESPIR DIS, V69, P223; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; MATSUDA H, IN PRESS NERVE GROWT; MAYRHOFER G, 1981, INT ARCH ALLER A IMM, V64, P320, DOI 10.1159/000232710; OTSU K, 1987, J EXP MED, V165, P615, DOI 10.1084/jem.165.3.615; OTSUKA H, 1986, AM REV RESPIR DIS, V133, P757; OTSUKA H, 1986, J ALLERGY CLIN IMMUN, V78, P365, DOI 10.1016/S0091-6749(86)80091-4; PEARCE FL, 1982, KLIN WOCHENSCHR, V60, P954, DOI 10.1007/BF01716954; PEARCE FL, 1987, INT ARCH ALLER A IMM, V82, P507, DOI 10.1159/000234266; PEARCE FL, 1986, J PHYSIOL-LONDON, V372, P379, DOI 10.1113/jphysiol.1986.sp016014; PEARCE FL, 1985, INT ARCH ALLER A IMM, V77, P274, DOI 10.1159/000233808; PEARCE FL, 1982, J IMMUNOL, V128, P2481; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; RUITENBER EJ, 1976, NATURE, V264, P258, DOI 10.1038/264258a0; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SELDIN DC, 1985, P NATL ACAD SCI USA, V82, P3871, DOI 10.1073/pnas.82.11.3871; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; SHANAHAN F, 1985, J IMMUNOL, V135, P1331; STADLER BM, IN PRESS LYMPHOKINES; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; STEVENS RL, 1986, J IMMUNOL, V137, P291; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; TOMIOKA M, IN PRESS J ALLERGY C; WELLS E, 1986, J IMMUNOL, V137, P3933; WOODBURY RG, 1978, P NATL ACAD SCI USA, V75, P2785, DOI 10.1073/pnas.75.6.2785; WOODBURY RG, 1978, P NATL ACAD SCI USA, V75, P5311, DOI 10.1073/pnas.75.11.5311; WOODBURY RG, 1984, NATURE, V312, P450, DOI 10.1038/312450a0; YANG YC, 1987, LYMPHOKINE RES, V6, P11	52	55	56	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				763	769		10.1016/0091-6749(88)90929-3	http://dx.doi.org/10.1016/0091-6749(88)90929-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	3286715				2022-12-18	WOS:A1988N703600001
J	SHULT, PA; LEGA, M; JADIDI, S; VRTIS, R; WARNER, T; GRAZIANO, FM; BUSSE, WW				SHULT, PA; LEGA, M; JADIDI, S; VRTIS, R; WARNER, T; GRAZIANO, FM; BUSSE, WW			THE PRESENCE OF HYPODENSE EOSINOPHILS AND DIMINISHED CHEMI-LUMINESCENCE RESPONSE IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,SCH MED,DEPT MED,DIV MINATO KU,600 HIGHLAND AVE,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015685, P50AI010404] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-15685, AI-10404] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RC, 1976, BIOCHEM BIOPH RES CO, V69, P245, DOI 10.1016/S0006-291X(76)80299-9; BASS DA, 1980, J CLIN INVEST, V66, P1265, DOI 10.1172/JCI109978; Beeson PB, 1977, EOSINOPHIL; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CAPRON M, 1984, J IMMUNOL, V132, P462; Cohen SG, 1983, ALLERGY PRINCIPLES P, P701; DAVID JR, 1980, NEW ENGL J MED, V303, P1147, DOI 10.1056/NEJM198011133032004; DESIMONE C, 1982, CLIN EXP IMMUNOL, V48, P249; FILLEY WV, 1982, LANCET, V2, P11; FRIGAS E, 1980, LAB INVEST, V42, P35; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GOETZL EJ, 1975, ARCH PATHOL, V99, P1; HENDERSON WR, 1980, J EXP MED, V152, P265, DOI 10.1084/jem.152.2.265; JORG A, 1982, J EXP MED, V155, P390, DOI 10.1084/jem.155.2.390; KAJITA T, 1985, INT ARCH ALLER A IMM, V78, P406, DOI 10.1159/000233922; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; OLOFSSON T, 1980, SCAND J HAEMATOL, V24, P254; PETERS MS, 1986, CLIN RES, V34, P774; PILOT ML, 1950, AM J CLIN PATHOL, V20, P820; PINCUS SH, 1983, J INVEST DERMATOL, V80, P278, DOI 10.1111/1523-1747.ep12534646; PRIN L, 1984, CLIN EXP IMMUNOL, V57, P735; ROBERTS RL, 1985, BLOOD, V65, P433; SHAW RJ, 1985, FED PROC, V44, P1185; SHULT PA, 1986, J ALLERGY CLIN IMMUN, V77, P702, DOI 10.1016/0091-6749(86)90414-8; SHULT PA, 1985, J LAB CLIN MED, V106, P638; TAI PC, 1976, CLIN EXP IMMUNOL, V24, P415; WINQVIST I, 1982, IMMUNOLOGY, V47, P531; YAMASHITA T, 1985, ARCH BIOCH BIOPHYS, V241, P477; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180; 1975, CHEST, V67, P383	32	55	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					429	437		10.1016/0091-6749(88)90912-8	http://dx.doi.org/10.1016/0091-6749(88)90912-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	2828452				2022-12-18	WOS:A1988M099300010
J	PATTERSON, R; GREENBERGER, PA; LEE, TM; LIOTTA, JL; ONEILL, EA; ROBERTS, M; SOMMERS, H				PATTERSON, R; GREENBERGER, PA; LEE, TM; LIOTTA, JL; ONEILL, EA; ROBERTS, M; SOMMERS, H			PROLONGED EVALUATION OF PATIENTS WITH CORTICOSTEROID-DEPENDENT ASTHMA STAGE OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; GREENBERGER PA, 1986, ANN ALLERGY, V56, P441; OUCHTERLONY O, 1968, HDB IMMUNODIFFUSION, P4; PATTERSON R, 1986, ARCH INTERN MED, V146, P916, DOI 10.1001/archinte.146.5.916; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; PATTERSON R, 1974, INT ARCH ALLER A IMM, V46, P150, DOI 10.1159/000231119; PATTERSON R, 1968, University of Michigan Medical Center Journal, V34, P8; PEPYS J, 1969, MONOGR ALLERGY, V4, P20; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917	11	55	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1987	80	5					663	668		10.1016/0091-6749(87)90285-5	http://dx.doi.org/10.1016/0091-6749(87)90285-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K9930	3316345				2022-12-18	WOS:A1987K993000005
J	NAGATA, S; GLOVSKY, MM				NAGATA, S; GLOVSKY, MM			ACTIVATION OF HUMAN-SERUM COMPLEMENT WITH ALLERGENS .1. GENERATION OF C3A, C4A, AND C5A AND INDUCTION OF HUMAN NEUTROPHIL AGGREGATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SO CALIF, SCH MED, ASTHMA RES LABS, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DIV PULM MED, LOS ANGELES, CA 90033 USA	University of Southern California; University of Southern California								BERRENS L, 1974, ANN NY ACAD SCI, V221, P183, DOI 10.1111/j.1749-6632.1974.tb28216.x; BERRENS L, 1976, IMMUNOCHEMISTRY, V13, P367, DOI 10.1016/0019-2791(76)90369-4; Berrens L, 1979, Bronchopneumologie, V29, P308; BOKISCH VA, 1970, J CLIN INVEST, V49, P2427, DOI 10.1172/JCI106462; CAPORALE LH, 1980, J BIOL CHEM, V255, P758; CARLSEN SD, 1979, ALLERGY, V34, P155, DOI 10.1111/j.1398-9995.1979.tb01563.x; CHENOWETH DE, 1981, NEW ENGL J MED, V304, P497, DOI 10.1056/NEJM198102263040901; CRADDOCK PR, 1977, J CLIN INVEST, V60, P260, DOI 10.1172/JCI108763; DAMERAU B, 1980, INT ARCH ALLER A IMM, V63, P159, DOI 10.1159/000232622; EDWARDS J H, 1974, Clinical Allergy, V4, P379, DOI 10.1111/j.1365-2222.1974.tb01399.x; FERNANDEZ HN, 1978, J IMMUNOL, V120, P109; GLOVSKY MM, 1979, J CLIN INVEST, V64, P804, DOI 10.1172/JCI109527; GOLDSTEIN IM, 1975, J CLIN INVEST, V56, P1155, DOI 10.1172/JCI108191; GORSKI JP, 1981, J IMMUNOL METHODS, V47, P61, DOI 10.1016/0022-1759(81)90257-X; HALPRIN GM, 1973, AM REV RESPIR DIS, V108, P343; HARTMAN CT, 1981, INT ARCH ALLER A IMM, V66, P274; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; HUGLI TE, 1983, MOL IMMUNOL, V20, P637, DOI 10.1016/0161-5890(83)90008-1; JOHNSON AR, 1975, IMMUNOLOGY, V28, P1067; KAUFFMAN JF, 1984, J ALLERGY CLIN IMMUN, V73, P567; LI X, 1982, IMMUNOPHARMACOLOGY, V5, P31, DOI 10.1016/0162-3109(82)90034-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSH DG, 1975, ANTIGENS, V3, P271; MARX JJ, 1976, J ALLERGY CLIN IMMUN, V57, P328, DOI 10.1016/0091-6749(76)90089-0; OLENCHOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P295, DOI 10.1016/0091-6749(78)90161-6; PEREZ HD, 1981, J IMMUNOL, V126, P800; PERKOWSKI SZ, 1983, CIRC RES, V53, P574, DOI 10.1161/01.RES.53.5.574; PRYJMA JR, 1982, J ALLERGY CLIN IMMUN, V70, P306, DOI 10.1016/0091-6749(82)90067-7; SCHEID CR, 1983, J IMMUNOL, V130, P1997; SHOWELL HJ, 1982, INT ARCH ALLER A IMM, V67, P227, DOI 10.1159/000233023; SHOWELL HJ, 1982, INT ARCH ALLER A IMM, V69, P62, DOI 10.1159/000233147; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V64, P526, DOI 10.1016/0091-6749(79)90063-0; STIMLER NP, 1982, J IMMUNOL, V128, P2247; WILLIAMS TJ, 1981, J EXP MED, V153, P136, DOI 10.1084/jem.153.1.136	34	55	56	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1987	80	1					24	32		10.1016/S0091-6749(87)80186-0	http://dx.doi.org/10.1016/S0091-6749(87)80186-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J2194	3496373				2022-12-18	WOS:A1987J219400004
J	RANKIN, JA; KALINER, M; REYNOLDS, HY				RANKIN, JA; KALINER, M; REYNOLDS, HY			HISTAMINE LEVELS IN BRONCHOALVEOLAR LAVAGE FROM PATIENTS WITH ASTHMA, SARCOIDOSIS, AND IDIOPATHIC PULMONARY FIBROSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM HOSP,DEPT PULM MED,W HAVEN,CT; NIAID,ALLERG DIS SECT,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	RANKIN, JA (corresponding author), YALE UNIV,SCH MED,DEPT PULM MED,PULM SECT LC1105,POB 3333,333 CEDAR ST,NEW HAVEN,CT 06510, USA.				PHS HHS [22302] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEAVEN MA, 1976, NEW ENGL J MED, V294, P30, DOI 10.1056/NEJM197601012940108; BEER DJ, 1982, NEW ENGL J MED, V306, P454, DOI 10.1056/NEJM198202253060804; BENDITT EP, 1964, PROG ALLERGY, V8, P195, DOI 10.1159/000320507; BRINKMAN GL, 1968, J ULTRA MOL STRUCT R, V23, P115, DOI 10.1016/S0022-5320(68)80035-8; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P154, DOI 10.1056/NEJM198401193100304; DANIELE RP, 1980, ANN INTERN MED, V92, P406, DOI 10.7326/0003-4819-92-3-406; DAVIS GS, 1982, AM REV RESPIR DIS, V126, P611; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; FOX B, 1981, J CLIN PATHOL, V34, P1333, DOI 10.1136/jcp.34.12.1333; FRIERI M, 1983, J IMMUNOL, V131, P1942; HASLAM PL, 1981, CLIN EXP IMMUNOL, V44, P587; HUNNINGHAKE GW, 1979, AM J PATHOL, V97, P149; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KAWANAMI O, 1979, LAB INVEST, V40, P717; LAMB D, 1982, THORAX, V37, P334, DOI 10.1136/thx.37.5.334; MARTIN WJ, 1983, MAYO CLIN PROC, V58, P751; MERRILL W, 1982, AM REV RESPIR DIS, V126, P617; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; NORRBY K, 1981, VIRCHOWS ARCH B, V38, P57, DOI 10.1007/BF02892802; NORRBY K, 1983, VIRCHOWS ARCH B, V42, P263, DOI 10.1007/BF02890389; NORRBY K, 1984, CELL TISSUE RES, V235, P339; PATTERSON R, 1977, J CLIN INVEST, V59, P217, DOI 10.1172/JCI108631; PATTERSON R, 1974, CLIN EXP IMMUNOL, V16, P223; RANKIN JA, 1984, CHEST, V85, P723, DOI 10.1378/chest.85.6.723; RANKIN JA, 1983, AM REV RESPIR DIS, V127, P442, DOI 10.1164/arrd.1983.127.4.442; REYNOLDS HY, 1977, J CLIN INVEST, V59, P165, DOI 10.1172/JCI108615; ROHRBACH MS, 1978, ANAL BIOCHEM, V84, P272, DOI 10.1016/0003-2697(78)90510-9; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; 1962, AM REV RESPIR DIS, V85, P762	29	55	55	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1987	79	2					371	377		10.1016/0091-6749(87)90158-8	http://dx.doi.org/10.1016/0091-6749(87)90158-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G1791	2434547				2022-12-18	WOS:A1987G179100013
J	HSIEH, KH				HSIEH, KH			ALTERED INTERLEUKIN-2 (IL-2) PRODUCTION AND RESPONSIVENESS AFTER HYPOSENSITIZATION TO HOUSE DUST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HSIEH, KH (corresponding author), NATL TAIWAN UNIV HOSP,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,1 CHANG TE ST,TAIPEI 100,TAIWAN.							ALCOCERVARELA J, 1982, J CLIN INVEST, V69, P1388, DOI 10.1172/JCI110579; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; CANONICA GW, 1979, J IMMUNOL, V123, P2669; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GILLIS S, 1978, J IMMUNOL, V120, P2027; HSIEH KH, 1978, ANN ALLERGY, V41, P182; HSIEH KH, 1984, J ALLERGY CLIN IMMUN, V74, P34, DOI 10.1016/0091-6749(84)90084-8; HSIEH KH, 1982, ANN ALLERGY, V48, P25; HSIEH KH, 1984, ASIAN PAC J ALLERGY, V2, P56; LEVY DA, 1967, J IMMUNOL, V99, P1068; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LINKERISRAELI M, 1983, J IMMUNOL, V130, P2651; MEUER SC, 1982, J IMMUNOL, V129, P1076; MIER JW, 1982, LYMPHOKINES, V6, P137; PHILLIPS GL, 1967, MANUAL CLIN ALLERGY, P519; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; RUSCETTI FW, 1981, BLOOD, V57, P379; SAXON A, 1980, J CLIN INVEST, V65, P1457, DOI 10.1172/JCI109810; SMITH KA, 1980, IMMUNOL REV, V51, P337, DOI 10.1111/j.1600-065X.1980.tb00327.x; STADLER BM, 1982, LYMPHOKINES, V6, P117	27	55	56	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					188	194		10.1016/0091-6749(85)90700-6	http://dx.doi.org/10.1016/0091-6749(85)90700-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE88	3874894				2022-12-18	WOS:A1985APE8800012
J	DESWARTE, RD				DESWARTE, RD			DRUG ALLERGY - PROBLEMS AND STRATEGIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											DESWARTE, RD (corresponding author), ROCKFORD CLIN LTD,2300 N ROCKTON AVE,ROCKFORD,IL 61103, USA.							ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; ADKINSON NF, 1983, CURRENT THERAPY ALLE; BENVENISTE J, 1973, BIOL ROLE IGE SYSTEM; BRETZA J, 1983, AM J MED, V74, P945, DOI 10.1016/0002-9343(83)90787-8; BROWN LA, 1982, J ALLERGY CLIN IMMUN, V69, P51, DOI 10.1016/0091-6749(82)90087-2; CLUFF LE, 1975, CLIN PROBLEMS DRUGS; DAJANI BM, 1981, J ALLERGY CLIN IMMUN, V68, P201, DOI 10.1016/0091-6749(81)90184-6; DAVIES DM, 1981, TXB ADVERSE DRUG REA; DEBARD ML, 1979, ARCH INTERN MED, V139, P196, DOI 10.1001/archinte.139.2.196; DESHAZO RD, 1979, J ALLERGY CLIN IMMUN, V63, P387, DOI 10.1016/0091-6749(79)90211-2; DESWARTE RD, 1980, ALLERGIC DISEASES DI; DESWARTE RD, ALLERGIC DISEASES DI; DUKES MN, 1980, SIDE EFFECTS DRUGS, V9; DUKES MNG, 1973, SIDE EFFECTS DRUGS, V1; DUKES MNG, 1975, SIDE EFFECTS DRUGS, V8; DUNAGIN WG, 1980, MED CLIN N AM, V64, P983, DOI 10.1016/S0025-7125(16)31578-4; ELIAS JA, 1981, AM REV RESPIR DIS, V123, P550; FRITZLER MJ, 1978, J CLIN INVEST, V62, P560, DOI 10.1172/JCI109161; GLOVSKY MM, 1976, J ALLERGY CLIN IMMUN, V57, P134, DOI 10.1016/0091-6749(76)90032-4; GOETZL EJ, 1980, NEW ENGL J MED, V303, P822, DOI 10.1056/NEJM198010023031421; GREENBERGER PA, J ALLERGY CLIN IMMUN; GRIECO MH, 1964, ANN INTERN MED, V60, P204, DOI 10.7326/0003-4819-60-2-204; HUSBY G, 1981, AM J MED, V70, P31, DOI 10.1016/0002-9343(81)90408-3; IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159; INCAUDO G, 1978, J ALLERGY CLIN IMMUN, V61, P329; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; KNAPP AB, 1982, ANN INTERN MED, V97, P374, DOI 10.7326/0003-4819-97-3-374; LIEBERMAN P, 1971, J AMER MED ASSOC, V215, P1106; LINTON AL, 1980, ANN INTERN MED, V93, P735, DOI 10.7326/0003-4819-93-5-735; MATTSON JR, 1975, ARCH INTERN MED, V135, P818, DOI 10.1001/archinte.135.6.818; MENDELSON LM, 1974, J ALLERGY CLIN IMMUN, V54, P125, DOI 10.1016/0091-6749(74)90049-9; MEYLER L, 1955, SIDE EFFECTS DRUGS, V1; MILLER JR, 1983, J ALLERGY CLIN IMMUN, V71, P568; MITCHELL JR, 1976, ANN INTERN MED, V84, P181, DOI 10.7326/0003-4819-84-2-181; NACLERIO R, 1983, J ALLERGY CLIN IMMUN, V71, P294, DOI 10.1016/0091-6749(83)90083-0; NORMAN PS, 1982, DRUGS CHOICE 1982 19; PARKER C, 1980, CLIN IMMUNOLOGY, V2; PEARSALL HR, 1974, J LAB CLIN MED, V83, P728; PETZ LD, 1975, PROGR HEMATOLOGY, V9; PURDY BH, 1984, ANN INTERN MED, V100, P512, DOI 10.7326/0003-4819-100-4-512; ROCKLIN RE, 1974, PROGR CLIN IMMUNOLOG, V2; ROSENOW EC, 1977, IMMUNOLOGIC INFECTIO; ROSENOW EC, 1980, SEMINARS RESP MED, V2, P76; ROSENTHAL A, 1958, JAMA-J AM MED ASSOC, V167, P1118, DOI 10.1001/jama.1958.72990260011014; SETTIPANE GA, 1983, N ENGL REG ALLERGY P, V4, P304; SHEHADI WH, 1982, RADIOLOGY, V143, P11, DOI 10.1148/radiology.143.1.7063711; SOGN DD, 1983, J ALLERGY CLIN IMMUN, V71, P147, DOI 10.1016/0091-6749(83)90358-5; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; SPECTOR SL, 1983, ALLERGY PRINCIPLES P, V2; SPRY CJF, 1980, CLIN HAEMATOL, V9, P521; STEVENSON DD, 1983, J ASTHMA, V20, P31, DOI 10.3109/02770908309078050; STOELTING RK, 1983, ANESTH ANALG, V62, P341; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P500, DOI 10.1016/0091-6749(82)90174-9; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P275, DOI 10.1016/S0091-6749(82)80004-3; SULLIVAN TJ, 1983, CURRENT THERAPY ALLE; THOMPSON JE, 1969, MED J AUST, V36, P1058; VANARSDEL PP, 1983, ALLERGY PRINCIPLES P, V2; WARRINGTON RJ, 1978, CAN MED ASSOC J, V118, P787; WEISS RB, 1982, SEMIN ONCOL, V9, P5; WINGERT WA, 1975, SOUTHERN MED J, V68, P1015, DOI 10.1097/00007611-197508000-00019; 1973, JAMA, V224, P613	61	55	56	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					209	221		10.1016/0091-6749(84)90246-X	http://dx.doi.org/10.1016/0091-6749(84)90246-X			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TJ808	6147370	Bronze			2022-12-18	WOS:A1984TJ80800001
J	HOFFMAN, DR; WOOD, CL				HOFFMAN, DR; WOOD, CL			ALLERGENS IN HYMENOPTERA VENOM .11. ISOLATION OF PROTEIN ALLERGENS FROM VESPULA-MACULIFRONS (YELLOW JACKET) VENOM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HOFFMAN, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL,GREENVILLE,NC 27834, USA.							ALAGON A C, 1982, Journal of Allergy and Clinical Immunology, V69, P114; AUKRUST L, 1982, ALLERGY, V37, P265, DOI 10.1111/j.1398-9995.1982.tb01909.x; Decker LA., 1977, WORTHINGTON ENZYME M, DOI [10.1002/tox.20212, DOI 10.1002/TOX.20212]; FREY MD, 1982, ELECTROPHORESIS, V3, P27, DOI 10.1002/elps.1150030106; GUPTA S, 1983, ANAL BIOCHEM, V128, P196, DOI 10.1016/0003-2697(83)90363-9; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HABERMANN E, 1972, ANAL BIOCHEM, V50, P163, DOI 10.1016/0003-2697(72)90495-2; HOFFMAN D R, 1982, Survey of Immunologic Research, V1, P286; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; HOFFMAN DR, 1978, ANN ALLERGY, V40, P171; HOFFMAN DR, 1980, ANN ALLERGY, V45, P276; HOFFMAN DR, 1982, ANN ALLERGY, V48, P78; HOFFMAN DR, 1983, J ALLERGY CLIN IMMUN, V71, P481, DOI 10.1016/0091-6749(83)90465-7; HOFFMAN DR, 1982, ANN ALLERGY, V48, P82; HOFFMAN DR, 1981, ANN ALLERGY, V47, P23; HOFFMAN DR, 1976, J ALLERGY CLIN IMMUN, V58, P551, DOI 10.1016/0091-6749(76)90201-3; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P364, DOI 10.1016/0091-6749(77)90019-7; HOFFMAN DR, 1981, ANN ALLERGY, V46, P310; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; HOFFMAN DR, 1977, CUTIS, V19, P763; HOFFMAN DR, HDB NATURAL TOXINS I, V3; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V71, P505, DOI 10.1016/0091-6749(83)90469-4; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1983, MOL IMMUNOL, V20, P297, DOI 10.1016/0161-5890(83)90069-X; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLER S, 1983, J ALLERGY CLIN IMMUN, V71, P120, DOI 10.1016/0091-6749(83)90250-6; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWRY OH, 1951, J BIOL CHEM, V193, P265; REGNIER FE, 1982, ANAL BIOCHEM, V126, P1, DOI 10.1016/0003-2697(82)90101-4; REISMAN R E, 1982, Journal of Allergy and Clinical Immunology, V69, P125; SAMMONS DW, 1981, ELECTROPHORESIS, V2, P135, DOI 10.1002/elps.1150020303; WEEKE B, 1973, SCAND J IMMUNOL, V2, P47, DOI 10.1111/j.1365-3083.1973.tb03778.x; WOOD CL, 1983, TOXICON, V21, P291, DOI 10.1016/0041-0101(83)90014-4; WOOD CL, 1983, ANN ALLERGY, V51, P441	36	55	57	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	1					93	103		10.1016/0091-6749(84)90094-0	http://dx.doi.org/10.1016/0091-6749(84)90094-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SZ648	6736487				2022-12-18	WOS:A1984SZ64800015
J	HOLGATE, ST; MANN, JS; CUSHLEY, MJ				HOLGATE, ST; MANN, JS; CUSHLEY, MJ			ADENOSINE AS A BRONCHOCONSTRICTOR MEDIATOR IN ASTHMA AND ITS ANTAGONISM BY METHYLXANTHINES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note											HOLGATE, ST (corresponding author), SOUTHAMPTON GEN HOSP, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND.							ADVENIER C, 1982, BRIT J PHARMACOL, V77, P39, DOI 10.1111/j.1476-5381.1982.tb09266.x; Arch J R, 1978, Essays Biochem, V14, P82; BELARDINELLI L, 1981, J CLIN INVEST, V68, P195, DOI 10.1172/JCI110235; BILLING B, 1982, EUR J RESPIR DIS, V63, P399; BROWN CM, 1982, BRIT J PHARMACOL, V75, P157; BRUNS RF, 1983, P NATL ACAD SCI-BIOL, V80, P2077, DOI 10.1073/pnas.80.7.2077; BUTCHER RW, 1962, J BIOL CHEM, V237, P1244; CHURCH MK, 1983, BRIT J PHARMACOL, V80, P719, DOI 10.1111/j.1476-5381.1983.tb10063.x; CHURCH MK, 1983, FED PROC, V42, P1342; COLEMAN RA, 1976, BRIT J PHARMACOL, V57, P51, DOI 10.1111/j.1476-5381.1976.tb07655.x; CUSHLEY HJ, 1983, THORAX, V38, P705; Cushley M J, 1983, Agents Actions Suppl, V13, P109; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; CUSHLEY MJ, 1982, BRIT J CLIN PHARMACO, V14, pP607; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; DALY JW, 1981, LIFE SCI, V28, P2083, DOI 10.1016/0024-3205(81)90614-7; FARMER JB, 1976, J PHARM PHARMACOL, V28, P748, DOI 10.1111/j.2042-7158.1976.tb04040.x; FINNEY M, BR J PHARM; FREDHOLM BB, 1980, EUR J RESPIR DIS, V61, P29; FREDHOLM BB, 1982, EUR J PHARMACOL, V81, P673, DOI 10.1016/0014-2999(82)90359-4; FREDHOLM BB, 1981, ACTA PHYSIOL SCAND, V111, P507, DOI 10.1111/j.1748-1716.1981.tb06772.x; FREDHOLM BB, 1979, ACTA PHARMACOL TOX, V45, P336; HANDSLIP PDJ, 1981, THORAX, V36, P741, DOI 10.1136/thx.36.10.741; HORROBIN DF, 1977, NEW ENGL J MED, V297, P1181; KALINER MA, 1971, BIOCHIM BIOPHYS ACTA, V252, P160, DOI 10.1016/0304-4165(71)90104-8; KARLSSON JA, 1982, J PHARM PHARMACOL, V34, P788, DOI 10.1111/j.2042-7158.1982.tb06226.x; KUMAKURA K, 1979, PHYSL REGULATORY FUN, P51; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; LUNELL E, 1983, EUR J RESPIR DIS, V64, P333; MANN JS, 1984, THORAX, V39, P230; MANN JS, 1983, CLIN SCI, V65, pP22; MARLIN GE, 1978, BRIT J CLIN PHARMACO, V5, P45, DOI 10.1111/j.1365-2125.1978.tb01596.x; MENTZER RM, 1975, AM J PHYSIOL, V229, P1625; OSSWALD H, 1975, N-S ARCH PHARMACOL, V288, P79, DOI 10.1007/BF00501815; PATON DM, 1979, PHYSL REGULATORY FUN, P69; Persson C G, 1983, Agents Actions Suppl, V13, P115; PERSSON CGA, 1982, LIFE SCI, V30, P2181, DOI 10.1016/0024-3205(82)90292-2; PERSSON CGA, 1981, ACTA PHARMACOL TOX, V49, P313; POLSON JB, 1978, CLIN EXP PHARMACOL P, V5, P535; RICHARDSON JB, 1979, AM REV RESPIR DIS, V119, P785; RUFFIN RE, 1981, EUR J RESPIR DIS, V62, P123; SATTIN A, 1970, MOL PHARMACOL, V6, P13; TRINER L, 1977, EUR J PHARMACOL, V41, P37, DOI 10.1016/0014-2999(77)90368-5; WOLFE JD, 1978, NEW ENGL J MED, V298, P363, DOI 10.1056/NEJM197802162980703	44	55	56	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					302	306		10.1016/0091-6749(84)90262-8	http://dx.doi.org/10.1016/0091-6749(84)90262-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TJ808	6470364				2022-12-18	WOS:A1984TJ80800014
J	KRILIS, S; BALDO, BA; BASTEN, A				KRILIS, S; BALDO, BA; BASTEN, A			ANTIGENS AND ALLERGENS FROM THE COMMON HOUSE DUST MITE DERMATOPHAGOIDES-PTERONYSSINUS .2. IDENTIFICATION OF THE MAJOR IGE-BINDING ANTIGENS BY CROSSED RADIOIMMUNOELECTROPHORESIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SYDNEY,CLIN IMMUNOL RES CTR,SYDNEY,NSW 2006,AUSTRALIA; CSIRO,WHEAT RES UNIT,N RYDE,NSW 2113,AUSTRALIA; ROYAL N SHORE HOSP,KOLLING INST MED RES,ST LEONARDS,NSW 2065,AUSTRALIA	University of Sydney; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research								AUKRUST L, 1978, SCAND J IMMUNOL, V8, P421, DOI 10.1111/j.1365-3083.1978.tb00537.x; Baldo B A, 1981, Contemp Top Mol Immunol, V8, P41; BALDO BA, 1982, INT ARCH ALLER A IMM, V68, P295, DOI 10.1159/000233117; BALDO BA, 1982, PROG ALLERGY, P301; BLANDS J, 1977, ACTA ALLERGOL, V32, P147, DOI 10.1111/j.1398-9995.1977.tb01346.x; BRONSWIJK JE, 1971, J ALLERGY, V47, P31; BUCHANAN DJ, 1972, BR MED J, V3, P364; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; KABASAWA Y, 1976, ACTA ALLERGOL, V31, P442, DOI 10.1111/j.1398-9995.1976.tb01494.x; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P132, DOI 10.1016/0091-6749(84)90275-6; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LOWENSTEIN H, 1976, INT ARCH ALLER A IMM, V51, P38, DOI 10.1159/000231577; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; PRAHL P, 1980, ALLERGY, V33, P241; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P711, DOI 10.1136/adc.49.9.711; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEEKE B, 1973, SCAND J IMMUNOL, V2, P47, DOI 10.1111/j.1365-3083.1973.tb03778.x; WEEKE B, 1974, ACTA ALLERGOL, V29, P402, DOI 10.1111/j.1398-9995.1974.tb01661.x; WEEKE B, 1973, SCAND J IMMUNOL, V2, P149, DOI 10.1111/j.1365-3083.1973.tb03796.x; WRIGHT GLT, 1975, MED J AUSTRALIA, V1, P375, DOI 10.5694/j.1326-5377.1975.tb111453.x	22	55	58	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	2					142	146		10.1016/0091-6749(84)90277-X	http://dx.doi.org/10.1016/0091-6749(84)90277-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE226	6611362				2022-12-18	WOS:A1984TE22600005
J	SHIM, CS; WILLIAMS, MH				SHIM, CS; WILLIAMS, MH			EFFECT OF BRONCHODILATOR THERAPY ADMINISTERED BY CANISTER VERSUS JET NEBULIZER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV PULM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	SHIM, CS (corresponding author), BRONX MUNICIPAL HOSP CTR,VAN ETTEN HOSP,DEPT MED,CHEST SERV,BRONX,NY 10461, USA.							ANDERSON PB, 1982, THORAX, V37, P612, DOI 10.1136/thx.37.8.612; BEREND N, 1978, BRIT J DIS CHEST, V72, P122, DOI 10.1016/0007-0971(78)90021-9; CAYTON RM, 1978, BRIT J DIS CHEST, V72, P222, DOI 10.1016/0007-0971(78)90045-1; CHOOKANG YFJ, 1975, BRIT MED J, V2, P119, DOI 10.1136/bmj.2.5963.119; CHRISTENSSON P, 1981, CHEST, V79, P416, DOI 10.1378/chest.79.4.416; CONNELLAN SJ, 1979, BRIT J CLIN PRACT, V33, P135; DAVIES DS, 1979, SCAND J RESP DIS S, V103, P44; HEIMER D, 1980, J ALLERGY CLIN IMMUN, V66, P75, DOI 10.1016/0091-6749(80)90141-4; NEWMAN SP, 1981, THORAX, V36, P52, DOI 10.1136/thx.36.1.52; TAYLOR WF, 1966, J ALLERGY, V38, P257, DOI 10.1016/0021-8707(66)90018-9; WILSON RSE, 1980, THORAX, V35, P873, DOI 10.1136/thx.35.11.873	11	55	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					387	390		10.1016/0091-6749(84)90413-5	http://dx.doi.org/10.1016/0091-6749(84)90413-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6699319				2022-12-18	WOS:A1984SK15500014
J	ASAI, S; KRZANOWSKI, JJ; ANDERSON, WH; MARTIN, DF; POLSON, JB; LOCKEY, RF; BUKANTZ, SC; SZENTIVANYI, A				ASAI, S; KRZANOWSKI, JJ; ANDERSON, WH; MARTIN, DF; POLSON, JB; LOCKEY, RF; BUKANTZ, SC; SZENTIVANYI, A			EFFECTS OF THE TOXIN OF RED TIDE, PTYCHODISCUS-BREVIS, ON CANINE TRACHEAL SMOOTH-MUSCLE - A POSSIBLE NEW ASTHMA-TRIGGERING MECHANISM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV S FLORIDA, COLL MED, DEPT PHARMACOL & THERAPEUT, TAMPA, FL 33612 USA; UNIV S FLORIDA, COLL MED, DEPT CHEM, TAMPA, FL 33612 USA; JAMES A HALEY VET ADM MED CTR, DEPT INTERNAL MED, DIV ALLERGY & IMMUNOL, TAMPA, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	ASAI, S (corresponding author), UNIV S FLORIDA, COLL MED, DEPT INTERNAL MED, DIV ALLERGY & IMMUNOL, TAMPA, FL 33612 USA.				NHLBI NIH HHS [HL24658] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON WH, 1979, N-S ARCH PHARMACOL, V308, P117, DOI 10.1007/BF00499053; BORISON HL, 1980, BRIT J PHARMACOL, V70, P249, DOI 10.1111/j.1476-5381.1980.tb07930.x; Brydon G A, 1971, Environ Lett, V1, P235; DOIG MT, 1972, ENVIRON LETT, V3, P279, DOI 10.1080/00139307209435474; ELLIS S, 1979, TOXIC DINOFLAGELLATE, P431; FURUKAWA TARO, 1959, JAPANESE JOUR PHYSIOL, V9, P143; HEMMERT WH, 1975, 1ST P INT C TOX DIN, P489; IIZUKA S, 1975, B PLANKTON SOC JPN, V21, P45; IIZUKA S, 1977, STUDIES TOXIC PHYTOP, P14; KATZ B, 1967, P R SOC LOND, V169, P8; LIN YY, 1981, J AM CHEM SOC, V103, P6773, DOI 10.1021/ja00412a053; MARTIN DF, 1976, J CHEM EDUC, V53, P614, DOI 10.1021/ed053p614; MARTIN DF, 1976, J ENV SCI HLTH ALLER, V7, P445; McFARREN E. F., 1965, TOXICON, V3, P111, DOI 10.1016/0041-0101(65)90005-X; Music S I, 1973, JFMA, V60, P27; NACHSHEN DA, 1979, MOL PHARMACOL, V16, P579; NARAHASHI T, 1972, FED PROC, V31, P1124; PADILLA G M, 1973, P265; PADILLA GM, 1979, TOXIC DINOFLAGELLATE, P351; QUCK JA, 1974, P GULF COAST REGIONA, P85; QUICK JA, 1975, 1ST P INT C TOX DIN, P414; RICHARDSON JB, 1979, AM REV RESPIR DIS, V119, P785; Risk M., 1979, P335; SASNER JJ, 1972, TOXICON, V10, P163, DOI 10.1016/0041-0101(72)90242-5; SHIGENOBU K, 1974, J PHARMACOL EXP THER, V190, P280; SNEDECOR GW, 1956, STATISTICAL METHODS; Steidinger K.A., 1979, P435; STEIDINGER KA, 1978, J PHYCOL, V14, P72, DOI 10.1111/j.1529-8817.1978.tb00634.x; STEPHENS NL, 1970, AIRWAY DYNAMICS PHYS, P199; TAYLOR HF, 1917, 848 US COMM FISH DOC, P5; TRIGGLE DJ, 1980, CHEST, V78, P174, DOI 10.1378/chest.78.1_Supplement.174; WESTERFIELD M, 1977, AM J PHYSIOL, V232, pC23, DOI 10.1152/ajpcell.1977.232.1.C23; WOODCOCK AH, 1948, J MAR RES, V7, P56; [No title captured]	34	55	59	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	5					418	428		10.1016/0091-6749(82)90116-6	http://dx.doi.org/10.1016/0091-6749(82)90116-6			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NP934	7200498				2022-12-18	WOS:A1982NP93400003
J	BRATESCU, A; TEODORESCU, M				BRATESCU, A; TEODORESCU, M			CIRCANNUAL VARIATIONS IN THE B-CELL-T-CELL RATIO IN NORMAL HUMAN PERIPHERAL-BLOOD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BRATESCU, A (corresponding author), UNIV ILLINOIS,MED CTR,DEPT MICROBIOL & IMMUNOL,CHICAGO,IL 60680, USA.				NCI NIH HHS [CA21399, CA29552] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABO T, 1978, CLIN EXP IMMUNOL, V33, P441; BRATESCU A, 1981, INFECT IMMUN, V31, P816, DOI 10.1128/IAI.31.2.816-821.1981; BRATESCU A, 1980, CLIN EXP IMMUNOL, V41, P547; BROWN G, 1974, SCAND J IMMUNOL, V3, P161, DOI 10.1111/j.1365-3083.1974.tb01244.x; DEBOER PK, 1981, J IMMUNOL, V126, P277; DWAYER JM, 1976, PROG ALLERGY, V21, P178; Farris EJ, 1938, AM J ANAT, V63, P297, DOI 10.1002/aja.1000630206; FAUCI AS, 1974, J CLIN INVEST, V53, P240, DOI 10.1172/JCI107544; HAEGERT DG, 1978, IMMUNOLOGY, V34, P533; HOFFMAN T, 1977, J IMMUNOL, V119, P1520; KLEINMAN R, 1979, CELL IMMUNOL, V48, P43, DOI 10.1016/0008-8749(79)90097-2; KLEINMAN R, 1978, J IMMUNOL, V120, P2020; KLEINMAN R, 1980, CLIN EXP IMMUNOL, V39, P510; MAYER EP, 1978, CLIN IMMUNOL IMMUNOP, V9, P37, DOI 10.1016/0090-1229(78)90118-6; NELSON HD, 1980, MAJOR PROBL INTERN M, V28, P75; NISHIYA K, 1980, CELL IMMUNOL, V53, P71, DOI 10.1016/0008-8749(80)90427-X; SPRY CJ, 1972, CELL IMMUNOL, V4, P86, DOI 10.1016/0008-8749(72)90007-X; STEEL CM, 1974, NATURE, V247, P387, DOI 10.1038/247387a0; TEODORESCU M, 1979, CLIN IMMUNOL IMMUNOP, V13, P196	19	55	55	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	4					273	280		10.1016/0091-6749(81)90151-2	http://dx.doi.org/10.1016/0091-6749(81)90151-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML525	7026646				2022-12-18	WOS:A1981ML52500005
J	PHANUPHAK, P; KOHLER, PF; STANFORD, RE; SCHOCKET, AL; CARR, RI; CLAMAN, HN				PHANUPHAK, P; KOHLER, PF; STANFORD, RE; SCHOCKET, AL; CARR, RI; CLAMAN, HN			VASCULITIS IN CHRONIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO, MED CTR, DEPT MED, DIV CLIN IMMUNOL, DENVER, CO 80262 USA; UNIV COLORADO, MED CTR, DEPT PATHOL, DENVER, CO 80262 USA; UNIV COLORADO, MED CTR, DEPT DERMATOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; DOMONKOS AN, 1971, ANDREWS DISEASES SKI, P159; FEIG PU, 1976, JAMA-J AM MED ASSOC, V236, P2065, DOI 10.1001/jama.236.18.2065; FINK JN, 1972, ALLERGIC DISEASES DI, P341; GOWER RG, 1977, J INVEST DERMATOL, V69, P477, DOI 10.1111/1523-1747.ep12511631; GREEN GR, 1965, ANN ALLERGY, V23, P30; GREY HM, 1973, SEMIN HEMATOL, V10, P87; KLINE B. S., 1932, JOUR ALLERGY, V3, P531, DOI 10.1016/S0021-8707(32)90148-8; KOHLER PF, 1969, CLIN EXP IMMUNOL, V4, P191; KREIDBERG MB, 1955, NEW ENGL J MED, V253, P1014, DOI 10.1056/NEJM195512082532304; LEVER WF, 1975, HISTOPATHOLOGY SKIN, P133; Lichtenstein L.M., 1978, ALLERGY PRINCIPLES P, P115; MATHISON DA, 1977, ANN INTERN MED, V86, P534, DOI 10.7326/0003-4819-86-5-534; Mayer M.M., 1961, EXPT IMMUNOCHEMISTRY, P133; MCDUFFIE FC, 1973, MAYO CLIN PROC, V48, P340; MOSCHELLA SL, 1975, DERMATOLOGY, P850; PHANUPHAK P, 1978, CLIN ALLERGY, V8, P429, DOI 10.1111/j.1365-2222.1978.tb01493.x; PHANUPHAK P, 1978, ADV ASTHMA ALLERGY, V5, P19; RAMSAY C, 1969, BRIT J DERMATOL, V81, P96, DOI 10.1111/j.1365-2133.1969.tb15987.x; ROTHFIELD NF, 1976, MANUAL CLIN IMMUNOLO, P647; RUITER M, 1964, DERMATOLOGICA, V129, P217, DOI 10.1159/000254629; RYAN TJ, 1972, TXB DERMATOLOGY, P920; SAMS WM, 1975, J INVEST DERMATOL, V64, P441, DOI 10.1111/1523-1747.ep12512411; SISSONS JGP, 1974, LANCET, V2, P1350; SMALL P, 1977, ARTHRITIS RHEUM, V20, P869, DOI 10.1002/art.1780200317; SOTER NA, 1974, J INVEST DERMATOL, V63, P485, DOI 10.1111/1523-1747.ep12680443; SOTER NA, 1976, J INVEST DERMATOL, V66, P344, DOI 10.1111/1523-1747.ep12482901; SOTER NA, 1977, NEW ENGL J MED, V296, P1440, DOI 10.1056/NEJM197706232962505; WARIN RP, 1974, URTICARIA, P15; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; WINCHESTER R, 1976, MANUAL CLIN IMMUNOLO, P665; WINKELMANN RK, 1964, MEDICINE, V43, P59, DOI 10.1097/00005792-196401000-00003; WOLD RT, 1968, SCIENCE, V161, P806, DOI 10.1126/science.161.3843.806; ZUBLER RH, 1976, J IMMUNOL, V116, P232; Zweiman B, 1971, Adv Biol Skin, V11, P123	36	55	55	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	6					436	444		10.1016/0091-6749(80)90237-7	http://dx.doi.org/10.1016/0091-6749(80)90237-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV764	6989879				2022-12-18	WOS:A1980JV76400007
J	GERBER, JG; PAYNE, NA; OELZ, O; NIES, AS; OATES, JA				GERBER, JG; PAYNE, NA; OELZ, O; NIES, AS; OATES, JA			TARTRAZINE AND THE PROSTAGLANDIN SYSTEM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37240; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37240	Vanderbilt University; Vanderbilt University	GERBER, JG (corresponding author), UNIV COLORADO,MED CTR,DIV CLIN PHARMACOL C237,DENVER,CO 80262, USA.							CHAFEE FH, 1967, J ALLERGY, V40, P65, DOI 10.1016/0021-8707(67)90099-8; Cooke RA, 1919, J AMER MED ASSOC, V73, P759, DOI 10.1001/jama.1919.02610360029008; DANON A, 1975, BIOCHIM BIOPHYS ACTA, V388, P71, DOI 10.1016/0005-2760(75)90063-6; HAMBERG M, 1974, BIOCHEM BIOPH RES CO, V61, P942, DOI 10.1016/0006-291X(74)90246-0; HATHWAY DE, 1970, CHEM SOC FOREIGN COM, V1, P247; ISAKSON PC, 1976, PROSTAGLANDINS, V12, P739, DOI 10.1016/0090-6980(76)90049-6; JONES R, 1964, Food Cosmet Toxicol, V2, P447, DOI 10.1016/S0015-6264(64)80287-X; PHILLS JA, 1974, ACTA ALLERGOL, V20, P474; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SMITH AP, 1976, ADV PROSTAG THROMB R, V1, P449; SMITH LJ, 1976, J ALLERGY CLIN IMMUN, V58, P456, DOI 10.1016/0091-6749(76)90189-5; STENIUS BSM, 1976, CLIN ALLERGY, V6, P119, DOI 10.1111/j.1365-2222.1976.tb01889.x; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VEDANTHAN PK, 1977, J ALLERGY CLIN IMMUN, V60, P8, DOI 10.1016/0091-6749(77)90077-X; ZUSMAN RM, 1977, J BIOL CHEM, V252, P2069	17	55	56	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	4					289	294		10.1016/0091-6749(79)90115-5	http://dx.doi.org/10.1016/0091-6749(79)90115-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GR842	429706				2022-12-18	WOS:A1979GR84200011
J	HENDELES, L; BURKEY, S; BIGHLEY, L; RICHARDSON, R				HENDELES, L; BURKEY, S; BIGHLEY, L; RICHARDSON, R			UNPREDICTABILITY OF THEOPHYLLINE SALIVA MEASUREMENTS IN CHRONIC OBSTRUCTIVE PULMONARY-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,COLL PHARM,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,IOWA CITY,IA 52242; VET ADM HOSP,IOWA CITY,IA 52240	University of Iowa; University of Iowa								ENEY RD, 1976, PEDIATRICS, V57, P513; GALANT SP, 1977, AM J DIS CHILD, V131, P970, DOI 10.1001/archpedi.1977.02120220036004; HENDELES L, 1977, DRUG INTEL CLIN PHAR, V11, P12, DOI 10.1177/106002807701100101; JACOBS MH, 1976, JAMA-J AM MED ASSOC, V235, P1983, DOI 10.1001/jama.235.18.1983; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; KOYSOOKO R, 1974, CLIN PHARMACOL THER, V15, P454; LEVY G, 1974, PEDIATRICS, V53, P873; MATHESON LE, 1977, AM J HOSP PHARM, V34, P496, DOI 10.1093/ajhp/34.5.496; SCHACK JA, 1949, J PHARMACOL EXP THER, V97, P283; WEINBERGER MW, 1976, JAMA-J AM MED ASSOC, V235, P2110, DOI 10.1001/jama.235.19.2110	10	55	55	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	6					335	338		10.1016/0091-6749(77)90063-X	http://dx.doi.org/10.1016/0091-6749(77)90063-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ED834	925259				2022-12-18	WOS:A1977ED83400001
J	PAULL, BR; YUNGINGER, JW; GLEICH, GJ				PAULL, BR; YUNGINGER, JW; GLEICH, GJ			MELITTIN - ALLERGEN OF HONEYBEE VENOM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN, DEPT INTERNAL MED, DIV ALLERG DIS, ALLERG DIS RES LAB, ROCHESTER, MN 55901 USA; MAYO CLIN & MAYO FDN, DEPT IMMUNOL, DIV ALLERG DIS, ALLERG DIS RES LAB, ROCHESTER, MN 55901 USA; MAYO CLIN & MAYO FDN, DEPT PEDIAT, DIV ALLERG DIS, ALLERG DIS RES LAB, ROCHESTER, MN 55901 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic								AWDEH ZL, 1968, NATURE, V219, P66, DOI 10.1038/219066a0; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HABERMANN E, 1972, ANAL BIOCHEM, V50, P163, DOI 10.1016/0003-2697(72)90495-2; HABERMANN E, 1967, H-S Z PHYSIOL CHEM, V348, P37, DOI 10.1515/bchm2.1967.348.1.37; HABERMANN E, 1956, NATURE, V178, P1349, DOI 10.1038/1781349a0; HABERMANN E, 1971, VENOMOUS ANIMALS THE, P61; HOFFMAN DR, 1976, FED PROC, V35, P673; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P73; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; Mackler B F, 1972, Clin Allergy, V2, P317, DOI 10.1111/j.1365-2222.1972.tb01296.x; MUNJAL D, 1971, TOXICON, V9, P229, DOI 10.1016/0041-0101(71)90074-2; SHEPHERD GW, 1974, PREP BIOCHEM, V4, P71, DOI 10.1080/00327487408068187; SHIPMAN WH, 1969, ANAL BIOCHEM, V29, P490, DOI 10.1016/0003-2697(69)90333-9; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2; WIDE L, 1967, LANCET, V2, P1105; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4; YUNGINGER JW, 1975, J ALLERGY CLIN IMMUN, V55, P74; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	20	55	55	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	4					334	338		10.1016/0091-6749(77)90056-2	http://dx.doi.org/10.1016/0091-6749(77)90056-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DB886	850023				2022-12-18	WOS:A1977DB88600010
J	GOLBERT, TM				GOLBERT, TM			REVIEW OF CONTROVERSIAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES EMPLOYED IN ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									DENVER GEN HOSP,DEPT MED,DENVER,CO; UNIV COLORADO,MED CTR,DENVER,CO	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								Alexander HL, 1931, ANN INTERN MED, V5, P52, DOI 10.7326/0003-4819-5-1-52; AUSTEN KF, 1963, ADV IMMUNOL, V3, P1, DOI 10.1016/S0065-2776(08)60810-X; BENSON TE, 1975, J ALLERGY CLIN IMMUN, V55, P89; BERG T, 1971, INT ARCH ALLER A IMM, V41, P434, DOI 10.1159/000230537; BERNSTEIN C, 1937, J ALLERGY, V8, P221; Bernstein TB, 1938, ARCH INTERN MED, V62, P297, DOI 10.1001/archinte.1938.00180130118008; BLACK AP, 1956, PEDIATRICS, V17, P716; BLACK J. H., 1939, JOUR ALLERGY, V10, P156, DOI 10.1016/S0021-8707(39)90048-1; BLACK JH, 1928, J LAB CLIN MED, V13, P709; BOHNER CB, 1938, J INDIANA M A, V31, P279; BRENEMAN JC, 1973, ANN ALLERGY, V31, P382; BRENEMAN JC, 1974, ANN ALLERGY, V33, P164; BRONSKY EA, 1971, J ALLERGY, V47, P104; Brown D W Jr, 1971, Otolaryngol Clin North Am, V4, P491; BROWN ETHAN ALLAN, 1938, JOUR ALLERGY, V9, P345, DOI 10.1016/S0021-8707(38)90133-9; Bryan W T, 1971, Otolaryngol Clin North Am, V4, P523; BRYAN W. T. K., 1960, LARYNGOSCOPE, V70, P810; BRYAN WTK, 1972, LARYNGOSCOPE, V82, P1231, DOI 10.1288/00005537-197207000-00013; BRYAN WTK, 1969, LARYNGOSCOPE, V79, P1453, DOI 10.1288/00005537-196908000-00010; BRYAN WTK, 1973, OTOLARYNGOLOGY, V3, P69; BRYAN WTK, 1967, T AM SOC OPHTHALMOL, V8, P14; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; CAPLIN I, 1973, ANN ALLERGY, V31, P375; CHAMBERS VV, 1958, J ALLERGY, V29, P93; CONNELL JT, 1964, J ALLERGY, V35, P169, DOI 10.1016/0021-8707(64)90031-0; COWEN DE, 1974, FEB MIN COL ALL SOC; Curtis H. H, 1900, MEDICAL NEWSLETTER, V77, P16; DICKEY LD, 1971, J AMER MED ASSOC, V217, P214, DOI 10.1001/jama.1971.03190020072026; DICKEY LD, 1974, FEB MIN COL ALL SOC; DIXON FJ, 1958, ARCH PATHOL, V65, P18; Dolowitz D A, 1971, Otolaryngol Clin North Am, V4, P591; DOLOWITZ DA, 1974, ANN ALLERGY, V32, P183; DORFMAN R. I., 1938, JOUR ALLERGY, V9, P464, DOI 10.1016/S0021-8707(38)90552-0; Feinberg SM, 1940, J AMER MED ASSOC, V115, P23; FEINBERG SM, 1946, ALLERGY PRACTICE, P431; FELLNER MJ, 1970, J ALLERGY, V45, P55, DOI 10.1016/0021-8707(70)90017-1; FORSHAM PH, 1948, J CLIN ENDOCRINOL, V8, P15, DOI 10.1210/jcem-8-1-15; FRANKLIN W, 1949, J ALLERGY, V20, P375, DOI 10.1016/0021-8707(49)90027-1; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; Fries J. H., 1959, PEDIATR CLIN N AM, V6, P867, DOI [10.1016/S0031-3955(16)30839-2, DOI 10.1016/S0031-3955(16)30839-2]; GATTERDAM EA, 1934, SW MED, V18, P130; GERMUTH FG, 1953, J EXP MED, V97, P257, DOI 10.1084/jem.97.2.257; GOLBERT TM, 1970, ANN INTERN MED, V72, P395, DOI 10.7326/0003-4819-72-3-395; GOLBERT TM, 1969, J ALLERGY, V44, P96, DOI 10.1016/0021-8707(69)90005-7; GOLBERT TM, 1972, ALLERGIC DISEASES DI, P355; GREEN GR, 1967, ANN INTERN MED, V67, P235, DOI 10.7326/0003-4819-67-2-235; HANSEL FK, 1953, CLIN ALLERGY, P828; HANSEL FK, 1953, CLIN ALLERGY, P286; HANSEL FRENCH K., 1941, JOUR ALLERGY, V12, P457, DOI 10.1016/S0021-8707(41)90222-8; ILIFF ELIZABETH H., 1941, JOUR ALLERGY, V12, P601; INGELFINGER FJ, 1949, NEW ENGL J MED, V241, P337, DOI 10.1056/NEJM194909012410905; INGELFINGER FJ, 1949, NEW ENGL J MED, V241, P303, DOI 10.1056/NEJM194908252410805; ISHIZAKA K, 1970, CLIN EXP IMMUNOL, V6, P25; ISHIZAKA K, 1968, J ALLERGY, V42, P330, DOI 10.1016/0021-8707(68)90095-6; ISHIZAKA K, 1971, 7TH P INT C ALL AMST, P31; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; KAHN IS, 1941, J ALLERGY CLINICAL I, V12, P466; LAKIN JD, 1969, J IMMUNOL, V103, P577; LAKIN JD, 1972, ALLERGIC DISEASES DI, P1; LEE CH, 1969, ARCH OTOLARYNGOL, V90, P87; LEE CH, 1969, ARCH OTOLARYNGOL, V90, P173; Lee CH, 1961, BUCHANAN CO MED B, V25, P9; LEVINE BB, 1968, J CLIN INVEST, V47, P556, DOI 10.1172/JCI105752; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; LEVINE BB, 1965, J ALLERGY, V36, P342, DOI 10.1016/0021-8707(65)90041-9; Levine P, 1926, J IMMUNOL, V11, P449; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN, 1971, ANN INTERN MED, V75, P663; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LIEBERMAN P, 1975, JAMA-J AM MED ASSOC, V231, P728; LIEBERMAN P, 1971, J AMER MED ASSOC, V215, P1106; LIEBERMAN P, 1974, COMMUNICATION   0402; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; LONDON McKINLEY, 1939, JOUR ALLERGY, V10, P453, DOI 10.1016/S0021-8707(39)90515-0; LOVELESS MARY, 1938, JOUR ALLERGY, V9, P321, DOI 10.1016/S0021-8707(38)90132-7; LOVELESS MH, 1950, J ALLERGY, V21, P489, DOI 10.1016/0021-8707(50)90097-9; LOWELL F C, 1945, Bull New Engl Med Cent, V7, P269; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; LOWELL FC, 1956, J ALLERGY, V27, P369, DOI 10.1016/0021-8707(56)90076-4; MCGREW GD, 1937, MIL SURG, V80, P371; MELAM H, 1971, J ALLERGY, V47, P262, DOI 10.1016/S0091-6749(71)80004-0; Miller JB, 1972, FOOD ALLERGY PROVOCA; Missal S C, 1971, Otolaryngol Clin North Am, V4, P479; MISSAL SC, 1974, OTOLARYNG CLIN N AM, V7, P681; MORRIS DL, 1969, ANN ALLERGY, V27, P289; NORMAN PS, 1969, J ALLERGY, V44, P129, DOI 10.1016/0021-8707(69)90137-3; ORANGE RP, 1968, 6TH P C INT ASS ALL, P137; OSLER AG, 1970, CLIN EXP IMMUNOL, V6, P13; PATTERSON R, 1966, J ALLERGY, V37, P295, DOI 10.1016/S0021-8707(96)90013-1; PATTERSON R, 1969, PROG ALLERGY, V13, P332, DOI 10.1159/000287510; PATTERSON R, 1970, AM REV RESPIR DIS, V102, P412; Phillips E, 1933, J ALLERGY, V5, P29; Phillips EW, 1926, J AMER MED ASSOC, V86, P182, DOI 10.1001/jama.1926.02670290022008; PRUZANSKY J, 1972, ALLERGIC DISEASES, P31; PRUZANSKY JJ, 1966, J IMMUNOL, V97, P854; RICHARDSON G, 1961, ANN OTO RHINOL LARYN, V70, P344, DOI 10.1177/000348946107000203; RINKEL H J, 1949, Ann Allergy, V7, P625; RINKEL H J, 1949, Ann Allergy, V7, P631; RINKEL H J, 1949, Ann Allergy, V7, P639; RINKEL HJ, 1962, ARCHIV OTOLARYNGOL, V76, P491; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P205; RINKEL HJ, 1964, ARCHIV OTOLARYNGOL, V79, P71, DOI 10.1001/archotol.79.1.87; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P302; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P42; ROCKWELL GE, 1938, OHIO STATE M J, V34, P784; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SANDERS SH, 1971, OTOLARYNGOL CLIN N A, V3, P565; SPRECACE GA, 1966, J ALLERGY, V38, P9, DOI 10.1016/0021-8707(66)90068-2; SQUIER TL, 1947, J ALLERGY, V18, P156, DOI 10.1016/0021-8707(47)90101-9; STANWORT.DR, 1970, CLIN EXP IMMUNOL, V6, P1; STIER RFE, 1937, NW MED, V36, P166; STULL ARTHUR, 1933, JOUR ALLERGY, V4, P455, DOI 10.1016/S0021-8707(33)90098-2; TADA T, 1970, Journal of Immunology, V104, P377; TERR AI, 1967, MANUAL CLINICAL ALLE, P1; Touart MD, 1922, NY MED J, V116, P199; TUCHINDA M, 1973, J ALLERGY CLIN IMMUN, V51, P131, DOI 10.1016/0091-6749(73)90018-3; TUFT L, 1957, J ALLERGY, V28, P124, DOI 10.1016/0021-8707(57)90018-7; UHR JW, 1967, PROG ALLERGY, V10, P37; URBACH E, 1937, MUNCHEN MED WCHNSCHR, V84, P488; VAUGHAN WT, 1934, J ALLERGY, V6, P78; WALZER M, 1936, J ALLERGY, V7, P597; WEBER J, 1972, JAMA, V222, P712; WIDE L, 1967, LANCET, V2, P1105; WIGHTMAN HB, 1941, J ALLERGY, V12, P605; WILLIAMS RI, 1965, LARYNGOSCOPE, V75, P1428; WILLIAMS RI, 1966, LARYNGOSCOPE, V76, P1389; WILLIAMS RI, 1971, OTOLARYNGOL CLIN N A, V3, P507; WILLOUGHBY JW, 1965, ANN ALLERGY, V23, P543; WILLOUGHBY JW, 1974, OTOLARYNG CLIN N AM, V7, P579; ZELLER MICHAEL, 1939, JOUR ALLERGY, V10, P579, DOI 10.1016/S0021-8707(39)90252-2; ZVAIFLER NJ, 1966, J EXP MED, V123, P935, DOI 10.1084/jem.123.5.935	133	55	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	3					170	190		10.1016/0091-6749(75)90089-5	http://dx.doi.org/10.1016/0091-6749(75)90089-5			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ290	1151012	Bronze			2022-12-18	WOS:A1975AQ29000003
J	KONIG, P; JAFFE, P; GODFREY, S				KONIG, P; JAFFE, P; GODFREY, S			EFFECT OF CORTICOSTEROIDS ON EXERCISE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,CARDIOTHORAC INST,DEPT PAEDIAT,LONDON,ENGLAND; HAMMERSMITH HOSP,DEPT CHILD HLTH,LONDON,ENGLAND	Royal Brompton Hospital; Imperial College London								CONNOLLY N, 1970, Journal of Asthma Research, V8, P31, DOI 10.3109/02770907009105028; GODFREY S, 1973, J ALLERGY CLIN IMMUN, V52, P193; HEIMLICH EM, 1966, J ALLERGY, V37, P103; JONES RS, 1966, BRIT MED J, V2, P972, DOI 10.1136/bmj.2.5520.972; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; MCNEILL RS, 1966, Q J MED, V35, P55; ORIE NGM, 1970, DISODIUM CROMOGLYCAT; Pepys J, 1973, Clin Allergy, V3, P1, DOI 10.1111/j.1365-2222.1973.tb01304.x; SCADDING JG, 1966, LANCET, V1, P701; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; SILVERMAN M, 1973, EXERCISE TUDIES ASTH	11	55	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	1					14	19		10.1016/S0091-6749(74)80003-5	http://dx.doi.org/10.1016/S0091-6749(74)80003-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T5232	4834049				2022-12-18	WOS:A1974T523200002
J	Dadi, H; Jones, TA; Merico, D; Sharfe, N; Ovadia, A; Schejter, Y; Reid, B; Sun, M; Vong, L; Atkinson, A; Lavi, S; Pomerantz, JL; Roifman, CM				Dadi, Harjit; Jones, Tyler A.; Merico, Daniele; Sharfe, Nigel; Ovadia, Adi; Schejter, Yael; Reid, Brenda; Sun, Mark; Vong, Linda; Atkinson, Adelle; Lavi, Sasson; Pomerantz, Joel L.; Roifman, Chaim M.			Combined immunodeficiency and atopy caused by a dominant negative mutation in caspase activation and recruitment domain family member 11 (CARD11)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Caspase activation and recruitment domain family member 11; combined immunodeficiency; hypogammaglobulinemia; nuclear factor kappa B; cytokine secretion; T-cell repertoire; T-cell mitogen and antigen responses; autoimmunity; asthma; eczema and food allergies; atopy	KAPPA-B ACTIVATION; T-CELL-RECEPTOR; OMENN-SYNDROME; LYMPHOCYTE DEVELOPMENT; PHENOTYPE ONTOLOGY; PROTEIN; DEFICIENCY; BCL10; GENE; ELEMENTS	Background: Combined immunodeficiency (CID) is a T-cell defect frequently presenting with recurrent infections, as well as associated immune dysregulation manifesting as autoimmunity or allergic inflammation. Objective: We sought to identify the genetic aberration in 4 related patients with CID, early-onset asthma, eczema, and food allergies, as well as autoimmunity. Methods: We performed whole-exome sequencing, followed by Sanger confirmation, assessment of the genetic variant effect on cell signaling, and evaluation of the resultant immune function. Results: A heterozygous novel c.C88T 1-bp substitution resulting in amino acid change R30W in caspase activation and recruitment domain family member 11 (CARD11) was identified by using whole-exome sequencing and segregated perfectly to family members with severe atopy only but was not found in healthy subjects. We demonstrate that the R30W mutation results in loss of function while also exerting a dominant negative effect on wild-type CARD11. The CARD11 defect altered the classical nuclear factor kappa B pathway, resulting in poor in vitro T-cell responses to mitogens and antigens caused by reduced secretion of IFN-gamma and IL-2. Conclusion: Unlike patients with biallelic mutations in CARD11 causing severe CID, the R30W defect results in a less profound et prominent susceptibility to infections, as well as multiorgan atopy and autoimmunity.	[Dadi, Harjit; Sharfe, Nigel; Ovadia, Adi; Schejter, Yael; Reid, Brenda; Vong, Linda; Atkinson, Adelle; Lavi, Sasson; Roifman, Chaim M.] Hosp Sick Children, Div Immunol & Allergy, Dept Pediat, Toronto, ON, Canada; [Dadi, Harjit; Sharfe, Nigel; Ovadia, Adi; Schejter, Yael; Reid, Brenda; Vong, Linda; Atkinson, Adelle; Lavi, Sasson; Roifman, Chaim M.] Univ Toronto, Toronto, ON, Canada; [Dadi, Harjit; Sharfe, Nigel; Ovadia, Adi; Schejter, Yael; Reid, Brenda; Vong, Linda; Roifman, Chaim M.] Hosp Sick Children, Canadian Ctr Primary Immunodeficiency, Toronto, ON, Canada; [Dadi, Harjit; Sharfe, Nigel; Ovadia, Adi; Schejter, Yael; Reid, Brenda; Vong, Linda; Roifman, Chaim M.] Hosp Sick Children, Jeffrey Modell Res Lab Diag Primary Immunodeficie, Toronto, ON, Canada; [Jones, Tyler A.; Pomerantz, Joel L.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; [Jones, Tyler A.; Pomerantz, Joel L.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD USA; [Merico, Daniele; Sun, Mark] Deep Genom, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Johns Hopkins University; Johns Hopkins University	Roifman, CM (corresponding author), Hosp Sick Children, Div Immunol & Allergy, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca		Jones, Tyler/0000-0002-1818-5985; Merico, Daniele/0000-0002-3728-4401	Immunodeficiency Canada's Distinguished Professorship in Immunology; Program for Immunogenomics; Canadian Centre for Primary Immunodeficiency; Jeffrey Modell Foundation and Immunodeficiency Canada; National Institutes of Health [RO1CA177600]; NATIONAL CANCER INSTITUTE [R01CA177600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007445] Funding Source: NIH RePORTER	Immunodeficiency Canada's Distinguished Professorship in Immunology; Program for Immunogenomics; Canadian Centre for Primary Immunodeficiency; Jeffrey Modell Foundation and Immunodeficiency Canada; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by Immunodeficiency Canada's Distinguished Professorship in Immunology (to C.M.R.), the Program for Immunogenomics and the Canadian Centre for Primary Immunodeficiency (to C.M.R.), the Jeffrey Modell Foundation and Immunodeficiency Canada (to C.M.R.), and RO1CA177600 from the National Institutes of Health (to J.L.P.).	1000 Genomes Project Consortium, 2015, Nature, V526, P68, DOI 10.1038/nature15393; ACHAORBEA H, 1989, ANNU REV IMMUNOL, V7, P371, DOI 10.1146/annurev.iy.07.040189.002103; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Altin JA, 2011, J ALLERGY CLIN IMMUN, V127, P1277, DOI 10.1016/j.jaci.2010.12.1081; [Anonymous], CLIN IMMUNOL; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Bidere N, 2009, NATURE, V458, P92, DOI 10.1038/nature07613; Blake JA, 2013, NUCLEIC ACIDS RES, V41, pD530, DOI 10.1093/nar/gks1050; Brohl AS, 2015, J CLIN IMMUNOL, V35, P32, DOI 10.1007/s10875-014-0106-4; Chan WP, 2013, MOL CELL BIOL, V33, P429, DOI 10.1128/MCB.00850-12; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Eppig JT, 2015, NUCLEIC ACIDS RES, V43, pD726, DOI 10.1093/nar/gku967; Erikson GA, 2016, CELL, V165, P1002, DOI 10.1016/j.cell.2016.03.022; Frucht DM, 2001, GENES IMMUN, V2, P422, DOI 10.1038/sj.gene.6363802; Giliani S, 2006, J PEDIATR-US, V148, P272, DOI 10.1016/j.jpeds.2005.10.004; Greil J, 2013, J ALLERGY CLIN IMMUN, V131, P1376, DOI 10.1016/j.jaci.2013.02.012; Grunebaum E, 2008, J ALLERGY CLIN IMMUN, V122, P1219, DOI 10.1016/j.jaci.2008.08.031; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Jabara HH, 2013, J ALLERGY CLIN IMMUN, V132, P151, DOI 10.1016/j.jaci.2013.04.047; Jattani RP, 2016, J BIOL CHEM, V291, P8338, DOI 10.1074/jbc.M116.717322; Jattani RP, 2016, J BIOL CHEM, V291, P8324, DOI 10.1074/jbc.M115.683714; Johnston JJ, 2013, HUM MOL GENET, V22, pR27, DOI 10.1093/hmg/ddt384; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Kohler Sebastian, 2014, Nucleic Acids Res, V42, pD966, DOI 10.1093/nar/gkt1026; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Lamason RL, 2010, BIOCHEMISTRY-US, V49, P8240, DOI 10.1021/bi101052d; Landrum MJ, 2016, NUCLEIC ACIDS RES, V44, pD862, DOI 10.1093/nar/gkv1222; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Torres JM, 2014, J CLIN INVEST, V124, P5239, DOI 10.1172/JCI77493; McCully RR, 2008, MOL CELL BIOL, V28, P5668, DOI 10.1128/MCB.00418-08; Merico D, 2016, LYMPHOSIGN J, V3, P135, DOI DOI 10.14785/LYMPH0SIGN-2016-0011; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Ng PC, 2001, GENOME RES, V11, P863, DOI 10.1101/gr.176601; Ovadia A, 2016, ENCYCLOPEDIA OF IMMUNOBIOLOGY, VOL 5: PHYSIOLOGY AND IMMUNE SYSTEM DYSFUNCTION, P513, DOI 10.1016/B978-0-12-374279-7.18025-7; Pedersen SM, 2016, MOL CELL BIOL, V36, P794, DOI 10.1128/MCB.00876-15; de Diego RP, 2015, J ALLERGY CLIN IMMUN, V136, P1139, DOI 10.1016/j.jaci.2015.06.031; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Qiao Q, 2013, MOL CELL, V51, P766, DOI 10.1016/j.molcel.2013.08.032; Reva B, 2011, NUCLEIC ACIDS RES, V39, pE118, DOI 10.1093/nar/gkr407; Roifman CM, 2008, J ALLERGY CLIN IMMUN, V121, P1056, DOI 10.1016/j.jaci.2007.12.1148; Roifman CM, 2012, J ALLERGY CLIN IMMUN, V130, P177, DOI 10.1016/j.jaci.2012.04.029; Roifman CM, 2006, J ALLERGY CLIN IMMUN, V117, P897, DOI 10.1016/j.jaci.2006.01.003; Schulze-Luehrmann J, 2006, IMMUNITY, V25, P701, DOI 10.1016/j.immuni.2006.10.010; Sharfe N, 2015, J AUTOIMMUN, V65, P90, DOI 10.1016/j.jaut.2015.09.001; Shibata F, 2007, EUR J HAEMATOL, V79, P81, DOI 10.1111/j.1600-0609.2007.00874.x; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Signorini S, 1999, BLOOD, V94, P3468, DOI 10.1182/blood.V94.10.3468.422k34_3468_3478; Smith CL, 2012, MAMM GENOME, V23, P653, DOI 10.1007/s00335-012-9421-3; Snow AL, 2012, J EXP MED, V209, P2247, DOI 10.1084/jem.20120831; Solomon BD, 2013, P NATL ACAD SCI USA, V110, P9851, DOI 10.1073/pnas.1302575110; Stavropoulos DJ, 2016, NPJ GENOM MED, V1, DOI 10.1038/npjgenmed.2015.12; Stenson PD, 2014, HUM GENET, V133, P1, DOI 10.1007/s00439-013-1358-4; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Tammimies K, 2015, JAMA-J AM MED ASSOC, V314, P895, DOI 10.1001/jama.2015.10078; Turvey SE, 2014, J ALLERGY CLIN IMMUN, V134, P276, DOI 10.1016/j.jaci.2014.06.015; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Xiong HY, 2015, SCIENCE, V347, DOI 10.1126/science.1254806; Yang YK, 2016, J BIOL CHEM, V291, P25921, DOI 10.1074/jbc.M116.754028	66	54	58	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1818	+		10.1016/j.jaci.2017.06.047	http://dx.doi.org/10.1016/j.jaci.2017.06.047			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	28826773	Bronze			2022-12-18	WOS:000432148200027
J	Abolhassani, H; Chou, J; Bainter, W; Platt, CD; Tavassoli, M; Momen, T; Tavakol, M; Eslamian, MH; Gharagozlou, M; Movahedi, M; Ghadami, M; Hamidieh, AA; Azizi, G; Yazdani, R; Afarideh, M; Ghajar, A; Havaei, A; Chavoshzadeh, Z; Mahdaviani, SA; Cheraghi, T; Behniafard, N; Amin, R; Aleyasin, S; Faridhosseini, R; Jabbari-Azad, F; Nabavi, M; Bemanian, MH; Arshi, S; Molatefi, R; Sherkat, R; Mansouri, M; Mesdaghi, M; Babaie, D; Mohammadzadeh, I; Ghaffari, J; Shafiei, A; Kalantari, N; Ahanchian, H; Khoshkhui, M; Soheili, H; Dabbaghzadeh, A; Shirkani, A; Kalmarzi, RN; Mortazavi, SH; Tafaroji, J; Khalili, A; Mohammadi, J; Negahdari, B; Joghataei, MT; al-Ramadi, BK; Picard, C; Parvaneh, N; Rezaei, N; Chatila, TA; Massaad, MJ; Keles, S; Hammarstrom, L; Geha, RS; Aghamohammadi, A				Abolhassani, Hassan; Chou, Janet; Bainter, Wayne; Platt, Craig D.; Tavassoli, Mahmood; Momen, Tooba; Tavakol, Marzieh; Eslamian, Mohammad Hossein; Gharagozlou, Mohammad; Movahedi, Masoud; Ghadami, Mohsen; Hamidieh, Amir Ali; Azizi, Gholamreza; Yazdani, Reza; Afarideh, Mohsen; Ghajar, Alireza; Havaei, Arash; Chavoshzadeh, Zahra; Mahdaviani, Seyed Alireza; Cheraghi, Taher; Behniafard, Nasrin; Amin, Reza; Aleyasin, Soheila; Faridhosseini, Reza; Jabbari-Azad, Farahzad; Nabavi, Mohammamd; Bemanian, Mohammad Hassan; Arshi, Saba; Molatefi, Rasol; Sherkat, Roya; Mansouri, Mahboubeh; Mesdaghi, Mehrnaz; Babaie, Delara; Mohammadzadeh, Iraj; Ghaffari, Javad; Shafiei, Alireza; Kalantari, Najmeddin; Ahanchian, Hamid; Khoshkhui, Maryam; Soheili, Habib; Dabbaghzadeh, Abbas; Shirkani, Afshin; Kalmarzi, Rasoul Nasiri; Mortazavi, Seyed Hamidreza; Tafaroji, Javad; Khalili, Abbas; Mohammadi, Javad; Negahdari, Babak; Joghataei, Mohammad-Taghi; al-Ramadi, Basel K.; Picard, Capucine; Parvaneh, Nima; Rezaei, Nima; Chatila, Talal A.; Massaad, Michel J.; Keles, Sevgi; Hammarstrom, Lennart; Geha, Raif S.; Aghamohammadi, Asghar			Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Combined immunodeficiencies; next-generation DNA sequencing; whole-exome sequencing; targeted gene panel sequencing	MOLECULAR DIAGNOSIS; T-CELLS; DISEASES; UPDATE; IRAN; PREVALENCE; DISORDERS; FEATURES; CRITERIA; REGISTRY	Background: Combined immunodeficiencies (CIDs) are diseases of defective adaptive immunity with diverse clinical phenotypes. Although CIDs are more prevalent in the Middle East than Western countries, the resources for genetic diagnosis are limited. Objectives: This study aims to characterize the categories of patients with CIDs in Iran clinically and genetically. Methods: Clinical and laboratory data were obtained from 696 patients with CIDs. Patients were subdivided into those with syndromic (344 patients) and nonsyndromic (352 patients) CIDs. Targeted DNA sequencing was performed on 243 (34.9%) patients. Results: The overall diagnostic yield of the 243 sequenced patients was 77.8%(189 patients). The clinical diagnosis of hyper-IgE syndrome (P<.001), onset of disease at greater than 5 years (P = .02), and absence of multiple affected family members (P = .04) were significantly more frequent in the patients without a genetic diagnosis. An autosomal recessive disease was found in 62.9% of patients, reflecting the high rate of consanguinity in this cohort. Mutations impairing VDJ recombination and DNA repair were the most common underlying causes of CIDs. However, in patients with syndromic CIDs, autosomal recessive mutations in ataxia-telangiectasia mutated (ATM), autosomal dominant mutations in signal transducer and activator of transcription 3 (STAT3), and microdeletions in 22q11.21 were the most commonly affected genomic loci. Patients with syndromic CIDs had a significantly lower 5-year survival rate rather than those with nonsyndromic CIDs. Conclusions: This study provides proof of principle for the application of targeted next-generation sequencing panels in countries with limited diagnostic resources. The effect of genetic diagnosis on clinical care requires continued improvements in therapeutic resources for these patients.	[Abolhassani, Hassan; Yazdani, Reza; Afarideh, Mohsen; Ghajar, Alireza; Havaei, Arash; Parvaneh, Nima; Rezaei, Nima; Aghamohammadi, Asghar] Childrens Med Ctr, Pediat Ctr Excellence, Res Ctr Immunodeficiencies, Tehran, Iran; [Abolhassani, Hassan; Yazdani, Reza; Afarideh, Mohsen; Ghajar, Alireza; Havaei, Arash; Parvaneh, Nima; Rezaei, Nima; Aghamohammadi, Asghar] Univ Med Sci, Tehran, Iran; [Abolhassani, Hassan; Hammarstrom, Lennart] Karolinska Univ, Huddinge Hosp, Karolinska Inst, Div Clin Immunol,Dept Lab Med, Stockholm, Sweden; [Chou, Janet; Bainter, Wayne; Platt, Craig D.; Chatila, Talal A.; Massaad, Michel J.; Keles, Sevgi; Geha, Raif S.] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Chou, Janet; Bainter, Wayne; Platt, Craig D.; Tafaroji, Javad; Chatila, Talal A.; Massaad, Michel J.; Keles, Sevgi; Geha, Raif S.] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Tavassoli, Mahmood; Momen, Tooba] Isfahan Univ Med Sci, Res Inst Primordial Prevent Noncommunicable Dis, Child Growth & Dev Res Ctr, Dept Allergy & Clin Immunol, Esfahan, Iran; [Tavakol, Marzieh] Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, Iran; [Eslamian, Mohammad Hossein] Hamadan Univ Med Sci, Dept Pediat, Hamadan, Iran; [Gharagozlou, Mohammad; Movahedi, Masoud] Childrens Med Ctr, Asthma & Allergy Pediat Ctr Excellence, Dept Immunol, Tehran, Iran; [Gharagozlou, Mohammad; Movahedi, Masoud] Univ Med Sci, Tehran, Iran; [Ghadami, Mohsen] Univ Tehran Med Sci, Dept Med Genet, Tehran, Iran; [Hamidieh, Amir Ali; Chavoshzadeh, Zahra; Mesdaghi, Mehrnaz; Babaie, Delara] Univ Tehran Med Sci, Oncol & Stem Cell Transplantat Res Ctr, Hematol, Tehran, Iran; [Azizi, Gholamreza] Alborz Univ Med Sci, Imam Hassan Mojtaba Hosp, Dept Lab Med, Karaj, Iran; [Yazdani, Reza] Isfahan Univ Med Sci, Sch Med, Dept Immunol, Esfahan, Iran; [Chavoshzadeh, Zahra; Mesdaghi, Mehrnaz] Shahid Beheshti Univ Med Sci, Mofid Childrens Hosp, Pediat Infect Res Ctr, Tehran, Iran; [Mahdaviani, Seyed Alireza] Shahid Beheshti Univ Med Sci, NRITLD, Pediat Resp Dis Res Ctr, Tehran, Iran; [Cheraghi, Taher] Guilan Univ Med Sci, Shahrivar Childrens Hosp 17, Dept Pediat, Rasht, Iran; [Behniafard, Nasrin] Shahid Sadoughi Univ Med Sci, Dept Allergy & Clin Immunol, Yazd, Iran; [Amin, Reza; Aleyasin, Soheila] Shiraz Univ Med Sci, Namazi Hosp, Dept Pediat Immunol & Allergy, Shiraz, Iran; [Faridhosseini, Reza; Jabbari-Azad, Farahzad; Ahanchian, Hamid; Khoshkhui, Maryam] Mashhad Univ Med Sci, Dept Allergy & Clin Immunol, Mashhad, Iran; [Nabavi, Mohammamd; Bemanian, Mohammad Hassan; Arshi, Saba; Molatefi, Rasol] Iran Univ Med Sci, Rasool & Akram Hosp, Dept Allergy & Clin Immunol, Tehran, Iran; [Molatefi, Rasol] Ardabil Univ Med Sci, Bo Ali Childrens Hosp, Dept Pediat, Ardebil, Iran; [Sherkat, Roya] Isfahan Univ Med Sci, Al Zahra Hosp, Acquired Immunodeficiency Res Ctr, Esfahan, Iran; [Mohammadzadeh, Iraj; Dabbaghzadeh, Abbas] Babol Univ Med Sci, Amirkola Hosp, Noncommunicable Pediat Dis Res Ctr, Babol Sar, Iran; [Ghaffari, Javad] Mazandaran Univ Med Sci, Dept Pediat, Sari, Iran; [Shafiei, Alireza] Univ Tehran Med Sci, Bahrami Hosp, Dept Immunol, Tehran, Iran; [Kalantari, Najmeddin] Golestan Univ Med Sci, Dept Immunol & Allergy, Gorgan, Iran; [Soheili, Habib] Arak Univ Med Sci, Sch Med, Dept Pediat, Arak, Iran; [Shirkani, Afshin] Bushehr Univ Med Sci, Sch Med, Allergy & Clin Immunol Dept, Bushehr, Iran; [Kalmarzi, Rasoul Nasiri] Kurdistan Univ Med Sci, Cellular & Mol Res Ctr, Sanandaj, Iran; [Mortazavi, Seyed Hamidreza] Kermanshah Univ Med Sci, Dept Pediat, Kermanshah, Iran; [Tafaroji, Javad] Qom Univ Med Sci, Dept Pediat, Qom, Iran; [Khalili, Abbas] Shahid Sadoughi Univ Med Sci, Dept Pediat, Yazd, Iran; [Mohammadi, Javad] Univ Tehran, Fac New Sci & Technol, Dept Life Sci Engn, Tehran, Iran; [Negahdari, Babak] Univ Tehran Med Sci, Dept Med Biotechnol, Sch Adv Technol Med, Tehran, Iran; [Joghataei, Mohammad-Taghi] Univ Tehran Med Sci, Sch Med, Cellular & Mol Res Ctr, Tehran, Iran; [Joghataei, Mohammad-Taghi] Univ Tehran Med Sci, Sch Med, Dept Anat & Neurosci, Tehran, Iran; [al-Ramadi, Basel K.] United Arab Univ, Coll Med & Hlth Sci, Dept Med Microbiol & Immunol, Al Ain, U Arab Emirates; [Picard, Capucine] Necker Enfants Malades Hosp, AP HP, Study Ctr Primary Immunodeficiencies, Paris, France; [Rezaei, Nima; Aghamohammadi, Asghar] USERN, Primary Immunodeficiency Dis Network PIDNet, Tehran, Iran; [Yazdani, Reza] Shahid Beheshti Univ Med Sci, Mofid Childrens Hosp, Immunol & Allergy Dept, Tehran, Iran	Tehran University of Medical Sciences; Karolinska Institutet; Karolinska University Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Isfahan University Medical Science; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Isfahan University Medical Science; Shahid Beheshti University Medical Sciences; Shahid Beheshti University Medical Sciences; Shiraz University of Medical Science; Mashhad University Medical Science; Iran University of Medical Sciences; Ardabil University of Medical Sciences; Isfahan University Medical Science; Babol University of Medical Sciences; Mazandaran University Medical Sciences; Tehran University of Medical Sciences; Golestan University of Medical Sciences; Kurdistan University of Medical Sciences; Kermanshah University of Medical Sciences; University of Tehran; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Shahid Beheshti University Medical Sciences	Aghamohammadi, A (corresponding author), Childrens Med Ctr Hosp, 62 Qarib St,Keshavarz Blvd, Tehran 14194, Iran.; Geha, RS (corresponding author), Harvard Med Sch, Dept Pediat, Div Immunol, Boston Childrens Hosp, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu; aghamohammadi@tums.ac.ir	Parvaneh, Nima/A-2523-2010; Azizi, Gholamreza/AAL-4919-2021; Behniafard, Nasrin/AAY-5971-2020; Azizi, Gholamreza/B-9477-2018; mahdaviani, alireza/G-3256-2017; Cheraghi, Taher/P-3381-2019; Hamidieh, Amir Ali/AAG-1735-2020; Mansouri, Mahboubeh/AAY-1292-2021; Babaie, Delara/GLU-0510-2022; Rezaei, Nima/B-4245-2008; molatefi, rasol/M-4655-2018; Afarideh, Mohsen/H-8945-2019; tavakol, marzieh/O-3476-2017; Khoshkhui, Maryam/ABE-9122-2020; shirkani, afshin/A-5503-2018; Mohammadi, Javad/T-7012-2017; ghaffari, javad/E-2358-2017; Eslamian, Mohammad Hossein/F-5958-2017; Negahdari, Babak/W-3602-2019; chavoshzadeh, zahra/AAU-8508-2021; Abolhassani, Hassan/B-3465-2014	Parvaneh, Nima/0000-0002-3397-9716; Azizi, Gholamreza/0000-0001-5658-2511; mahdaviani, alireza/0000-0001-6224-4797; Cheraghi, Taher/0000-0002-9596-0930; Rezaei, Nima/0000-0002-3836-1827; molatefi, rasol/0000-0002-3614-5039; Afarideh, Mohsen/0000-0002-3578-5640; tavakol, marzieh/0000-0003-1312-4486; Mohammadi, Javad/0000-0002-5885-5402; ghaffari, javad/0000-0002-1447-8916; Eslamian, Mohammad Hossein/0000-0003-2842-4836; Abolhassani, Hassan/0000-0002-4838-0407; Hamidieh, Amir Ali/0000-0002-8935-079X; sherkat, Roya/0000-0001-6745-8161; Nabavi, Mohammad/0000-0001-6558-0390; Chatila, Talal/0000-0001-7439-2762; Aghamohammadi, Asghar/0000-0002-9454-1603; momen, tooba/0000-0001-6302-8420; Negahdari, Babak/0000-0002-8742-9138; Mortazavi, Seyyed Hamidreza/0000-0001-8612-3914; Babaie, Delara/0000-0001-6457-1492	Iranian National Science Foundation [91002997]; Alex and Eva Wallstrom Foundation; Division of Immunology at Boston Children's Hospital; Perkin Foundation	Iranian National Science Foundation(Iran National Science Foundation (INSF)); Alex and Eva Wallstrom Foundation; Division of Immunology at Boston Children's Hospital; Perkin Foundation	Supported by grant 91002997 from the Iranian National Science Foundation (to A.A.), the Alex and Eva Wallstrom Foundation (to H.A.), the Division of Immunology at Boston Children's Hospital, and the Perkin Foundation (to R.S.G. and J.C.).	Abdollahpour H, 2012, BLOOD, V119, P3450, DOI 10.1182/blood-2011-09-378158; Aghamohammadi A, 2008, IMMUNOBIOLOGY, V213, P447, DOI 10.1016/j.imbio.2007.10.018; Aghamohammadi A, 2014, J CLIN IMMUNOL, V34, P478, DOI 10.1007/s10875-014-0001-z; Aghamohammadi A, 2009, J CLIN IMMUNOL, V29, P769, DOI 10.1007/s10875-009-9315-7; Al-Herz W, 2015, CLIN IMMUNOL, V161, P170, DOI 10.1016/j.clim.2015.07.013; Al-Mousa H, 2016, J ALLERGY CLIN IMMUN, V137, P1780, DOI 10.1016/j.jaci.2015.12.1310; Arandi N, 2013, SCAND J IMMUNOL, V77, P405, DOI 10.1111/sji.12040; Azarsiz E, 2011, J CLIN IMMUNOL, V31, P106, DOI 10.1007/s10875-010-9472-8; Boyle JM, 2007, J CLIN IMMUNOL, V27, P497, DOI 10.1007/s10875-007-9103-1; Brown L, 2011, BLOOD, V117, P3243, DOI 10.1182/blood-2010-08-300384; Buckley RH, 2000, NEW ENGL J MED, V343, P1313, DOI 10.1056/NEJM200011023431806; Chinnabhandar V, 2014, PEDIATR HEMAT ONCOL, V31, P207, DOI 10.3109/08880018.2013.805346; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Erman B, 2017, SCAND J IMMUNOL, V85, P227, DOI 10.1111/sji.12523; Fang MY, 2016, J CLIN IMMUNOL, V36, pS68, DOI 10.1007/s10875-016-0260-y; Farrokhi AS, 2013, J IMMUNOL METHODS, V394, P94, DOI 10.1016/j.jim.2013.05.008; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Feng YM, 2015, GENET MED, V17, P99, DOI 10.1038/gim.2014.80; Fischer A, 2005, IMMUNOL REV, V203, P98, DOI 10.1111/j.0105-2896.2005.00223.x; Fischer A, 2013, GENE, V525, P170, DOI 10.1016/j.gene.2013.03.092; Gallo V, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00466; Gathmann B, 2012, CLIN EXP IMMUNOL, V167, P479, DOI 10.1111/j.1365-2249.2011.04542.x; Hartberger J, 2016, 17 ESID BARC SPAIN; Kilic SS, 2013, J CLIN IMMUNOL, V33, P74, DOI 10.1007/s10875-012-9763-3; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Lam D. S. T., 2005, Hong Kong Medical Journal, V11, P90; Latif AH, 2014, EXPERT REV CLIN IMMU, V10, P385, DOI 10.1586/1744666X.2014.880654; Lee WI, 2011, IMMUNOBIOLOGY, V216, P1286, DOI 10.1016/j.imbio.2011.06.002; Lipstein EA, 2010, PEDIATRICS, V125, pE1226, DOI 10.1542/peds.2009-1567; Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5; Matthijs G, 2016, EUR J HUM GENET, V24, P1515, DOI 10.1038/ejhg.2016.63; Mellouli F, 2015, J CLIN IMMUNOL, V35, P745, DOI 10.1007/s10875-015-0206-9; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Modell V, 2014, IMMUNOL RES, V60, P132, DOI 10.1007/s12026-014-8498-z; Moens LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114901; Nijman IJ, 2014, J ALLERGY CLIN IMMUN, V133, P529, DOI 10.1016/j.jaci.2013.08.032; Oraei M, 2012, J INVEST ALLERG CLIN, V22, P160; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Saadat M, 2004, ANN HUM BIOL, V31, P263, DOI 10.1080/03014460310001652211; Safaei S, 2012, IRAN J ALLERGY ASTHM, V11, P345, DOI 011.04/ijaai.345348; Sanati Mohammad Hossein, 2004, Iran J Allergy Asthma Immunol, V3, P59; Sedghi M, 2012, J RES MED SCI, V17, P310; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044; Stoddard JL, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00531; Stranneheim H, 2016, J INTERN MED, V279, P3, DOI 10.1111/joim.12399; Stray-Pedersen A, 2017, J ALLERGY CLIN IMMUN, V139, P232, DOI 10.1016/j.jaci.2016.05.042; Suliaman F, 2006, ALLERGY IMMUNOL, V19, P14; Vakilian K, 2015, INT J REPROD BIOMED, V13, P743; van der Spek J, 2015, J CLIN IMMUNOL, V35, P416, DOI 10.1007/s10875-015-0152-6; Vrijenhoek T, 2015, EUR J HUM GENET, V23, P1142, DOI 10.1038/ejhg.2014.279; Yeganeh M, 2008, PEDIAT ALLERG IMM-UK, V19, P303, DOI 10.1111/j.1399-3038.2007.00647.x; Yu H, 2016, J ALLERGY CLIN IMMUN, V138, P1142, DOI 10.1016/j.jaci.2016.05.035; Zhang ZY, 2013, PEDIATR INFECT DIS J, V32, P1127, DOI 10.1097/INF.0b013e31829aa9e9	54	54	56	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1450	1458		10.1016/j.jaci.2017.06.049	http://dx.doi.org/10.1016/j.jaci.2017.06.049			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28916186	Bronze			2022-12-18	WOS:000429197800030
J	Maurer, M; Kaplan, A; Rosen, K; Holden, M; Iqbal, A; Trzaskoma, BL; Yang, M; Casale, TB				Maurer, Marcus; Kaplan, Allen; Rosen, Karin; Holden, Michael; Iqbal, Ahmar; Trzaskoma, Benjamin L.; Yang, Ming; Casale, Thomas B.			The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DAILY DIARY		[Maurer, Marcus] Charite Univ Med Berlin, Allergie Ctr Charite, Dept Dermatol & Allergy, Berlin, Germany; [Kaplan, Allen] Med Univ South Carolina, Charleston, SC 29425 USA; [Rosen, Karin; Holden, Michael; Iqbal, Ahmar; Trzaskoma, Benjamin L.; Yang, Ming] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA; [Casale, Thomas B.] Univ S Florida, Tampa, FL USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Medical University of South Carolina; Roche Holding; Genentech; State University System of Florida; University of South Florida	Maurer, M (corresponding author), Charite Univ Med Berlin, Allergie Ctr Charite, Dept Dermatol & Allergy, Berlin, Germany.	Marcus.Maurer@charite.de	Maurer, Marcus/ABG-2174-2020	Maurer, Marcus/0000-0002-4121-481X; Yang, Ming/0000-0002-6211-9985				FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; Mathias SD, 2012, ALLERGY ASTHMA PROC, V33, P186, DOI 10.2500/aap.2012.33.3508; Mathias SD, 2012, ANN ALLERG ASTHMA IM, V108, P20, DOI 10.1016/j.anai.2011.09.008; Mathias SD, 2010, ANN ALLERG ASTHMA IM, V105, P142, DOI 10.1016/j.anai.2010.06.011; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Saini SS, 2015, J INVEST DERMATOL, V135, P925, DOI [10.1038/jid.2014.512, 10.1038/jid.2014.306]; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Shikiar Richard, 2005, Health Qual Life Outcomes, V3, P36, DOI 10.1186/1477-7525-3-36	9	54	56	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1138	+		10.1016/j.jaci.2017.10.018	http://dx.doi.org/10.1016/j.jaci.2017.10.018			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29132956	Bronze			2022-12-18	WOS:000426974800039
J	O'Sullivan, JA; Bochner, BS				O'Sullivan, Jeremy A.; Bochner, Bruce S.			Eosinophils and eosinophil-associated diseases: An update	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilopoiesis; granule biogenesis; eosinophil subsets; apoptosis; adipose tissue; immunoregulation; asthma; chronic rhinosinusitis with nasal polyposis; biologicals; eosinophilic gastrointestinal disorder	SEVERE ATOPIC-DERMATITIS; CONTROLLED PHASE-3 TRIAL; DOUBLE-BLIND; CHRONIC RHINOSINUSITIS; PERSISTENT ASTHMA; BLOOD EOSINOPHILS; ADIPOSE-TISSUE; HYPEREOSINOPHILIC SYNDROMES; INHALED CORTICOSTEROIDS; GATA3-SPECIFIC DNAZYME	The goal of this series is to offer a survey of the latest literature for clinicians and scientists alike, providing a list of important recent advances relevant to the broad field of allergy and immunology. This particular assignment was to cover the topic of eosinophils. In an attempt to highlight major ideas, themes, trends, and advances relevant to basic and clinical aspects of eosinophil biology, a search of articles published since 2015 in the Journal of Allergy and Clinical Immunology and other high-impact journals was performed. Articles were then reviewed and organized, and then key findings were summarized. Given space limitations, many outstanding articles could not be included, but the hope is that what follows provides a succinct overview of recently published work that has significantly added to our knowledge of eosinophils and eosinophil-associated diseases.	[O'Sullivan, Jeremy A.; Bochner, Bruce S.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Allergy & Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Bochner, BS (corresponding author), 240 E Huron St,Rm M-306, Chicago, IL 60611 USA.	bruce.bochner@northwestern.edu		O'Sullivan, Jeremy/0000-0002-3862-202X; Bochner, Bruce S./0000-0002-9411-6009	National Heart, Lung, and Blood Institute [P01HL107151]; National Institute of Allergy and Infectious Diseases [AI072265, T32AI083216]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL107151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072265, T32AI083216] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Heart, Lung, and Blood Institute (P01HL107151 to B.S.B.) and the National Institute of Allergy and Infectious Diseases (AI072265 to B.S.B. and T32AI083216 to J.A.O.).	Agache I, 2016, ALLERGY, V71, P1192, DOI 10.1111/all.12906; Anderson EL, 2016, ALLERGY, V71, P977, DOI 10.1111/all.12861; Anderson HM, 2017, J ALLERGY CLIN IMMUN, V139, P790, DOI 10.1016/j.jaci.2016.05.033; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Barnig C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141740; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Ben Baruch-Morgenstern N, 2016, J IMMUNOL, V197, P707, DOI 10.4049/jimmunol.1501873; Bettigole SE, 2015, NAT IMMUNOL, V16, P829, DOI 10.1038/ni.3225; Blauvelt A, 2017, LANCET, V389, P2287, DOI 10.1016/S0140-6736(17)31191-1; Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1; Blumenthal KG, 2015, J ALLERGY CLIN IMMUN, V136, P1288, DOI 10.1016/j.jaci.2015.04.005; Bochner BS, 2015, NEW ENGL J MED, V372, P2060, DOI 10.1056/NEJMe1502660; Bolus WR, 2015, J LEUKOCYTE BIOL, V98, P467, DOI 10.1189/jlb.3HI0115-018R; Bouffi C, 2015, J IMMUNOL, V195, P2683, DOI 10.4049/jimmunol.1500510; Brestoff JR, 2015, NATURE, V519, P242, DOI 10.1038/nature14115; Carretero R, 2015, NAT IMMUNOL, V16, P609, DOI 10.1038/ni.3159; Casale TB, 2017, J ALLERGY CLIN IMMUN, V139, P1411, DOI 10.1016/j.jaci.2017.03.006; Chen Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11596; Cheng LE, 2015, J EXP MED, V212, P513, DOI 10.1084/jem.20141671; de Graauw E, 2017, ALLERGY, V72, P1105, DOI 10.1111/all.13131; Dellon ES, 2017, GASTROENTEROLOGY, V152, P776, DOI 10.1053/j.gastro.2016.11.021; Demarche SF, 2017, J ALLERGY CLIN IMMUN, V5; Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC; Doherty TA, 2015, J ALLERGY CLIN IMMUN, V136, P792, DOI 10.1016/j.jaci.2015.05.048; Drissen R, 2016, NAT IMMUNOL, V17, P666, DOI 10.1038/ni.3412; Dworetzky SI, 2017, BLOOD CELL MOL DIS, V63, P62, DOI 10.1016/j.bcmd.2017.01.008; Ferguson GT, 2017, LANCET RESP MED, V5, P568, DOI 10.1016/S2213-2600(17)30190-X; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; Fowler SJ, 2015, J ALLERGY CLIN IMMUN, V135, P822, DOI 10.1016/j.jaci.2014.09.034; Ge XN, 2016, P NATL ACAD SCI USA, V113, pE4837, DOI 10.1073/pnas.1601958113; Goldberg MR, 2017, J ALLERGY CLIN IMMUN, V139, P1388, DOI 10.1016/j.jaci.2016.09.053; Gonem S, 2016, LANCET RESP MED, V4, P699, DOI 10.1016/S2213-2600(16)30179-5; Griseri T, 2015, IMMUNITY, V43, P187, DOI 10.1016/j.immuni.2015.07.008; Gupta SK, 2015, CLIN GASTROENTEROL H, V13, P66, DOI 10.1016/j.cgh.2014.05.021; Han Y, 2017, J ALLERGY CLIN IMMUN, V140, P888, DOI 10.1016/j.jaci.2017.04.015; Hanania NA, 2016, LANCET RESP MED, V4, P781, DOI 10.1016/S2213-2600(16)30265-X; Huang T, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86689; Jacobsen EA, 2017, AM J RESP CRIT CARE, V195, P1321, DOI 10.1164/rccm.201606-1129OC; Jia Y, 2015, J ALLERGY CLIN IMMUN, V135, P799, DOI 10.1016/j.jaci.2015.01.004; Jin JJ, 2015, J ALLER CL IMM-PRACT, V3, P920, DOI 10.1016/j.jaip.2015.06.009; Johnston LK, 2016, J IMMUNOL, V197, P3445, DOI 10.4049/jimmunol.1600611; Kagalwalla AF, 2017, CLIN GASTROENTEROL H, V15, P1698, DOI 10.1016/j.cgh.2017.05.048; Kay AB, 2015, CLIN EXP ALLERGY, V45, P575, DOI 10.1111/cea.12480; Khoury P, 2016, ALLERGY, V71, P803, DOI 10.1111/all.12843; Khoury P, 2015, HAEMATOLOGICA, V100, P300, DOI 10.3324/haematol.2013.091264; Kiwamoto T, 2015, J ALLERGY CLIN IMMUN, V135, P1329, DOI 10.1016/j.jaci.2014.10.027; Klion AD, 2015, HEMATOL-AM SOC HEMAT, P92, DOI 10.1182/asheducation-2015.1.92; Klion AD, 2015, BLOOD, V126, P1069, DOI 10.1182/blood-2014-11-551614; Kotzin JJ, 2016, NATURE, V537, P239, DOI 10.1038/nature19346; Krug N, 2017, J ALLERGY CLIN IMMUN, V140, P625, DOI 10.1016/j.jaci.2017.02.024; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; Lee JJ, 2015, J ALLERGY CLIN IMMUN, V135, P477, DOI 10.1016/j.jaci.2014.07.003; Lingblom C, 2017, ALLERGY, V72, P1406, DOI 10.1111/all.13140; Martin LJ, 2015, J ALLERGY CLIN IMMUN, V135, P1519, DOI 10.1016/j.jaci.2015.03.004; Matthews SP, 2016, IMMUNITY, V44, P795, DOI 10.1016/j.immuni.2016.03.003; Mesnil C, 2016, J CLIN INVEST, V126, P3279, DOI 10.1172/JCI85664; Min JY, 2017, J ALLERGY CLIN IMMUN, V139, P130, DOI 10.1016/j.jaci.2016.07.020; Moshkovits I, 2017, MUCOSAL IMMUNOL, V10, P172, DOI 10.1038/mi.2016.37; Nair P, 2017, NEW ENGL J MED, V376, P2448, DOI 10.1056/NEJMoa1703501; Ortega H, 2015, J ALLERGY CLIN IMMUN, V136, P825, DOI 10.1016/j.jaci.2015.05.039; Ortega HG, 2016, LANCET RESP MED, V4, P549, DOI 10.1016/S2213-2600(16)30031-5; Percopo CM, 2017, J LEUKOCYTE BIOL, V101, P321, DOI 10.1189/jlb.3A0416-166R; Ramirez E, 2017, BRIT J CLIN PHARMACO, V83, P400, DOI 10.1111/bcp.13096; Rank MA, 2016, ALLERGY, V71, P567, DOI 10.1111/all.12817; Roche N, 2017, AM J RESP CRIT CARE, V195, P1189, DOI 10.1164/rccm.201701-0193OC; Rothenberg ME, 2015, J ALLERGY CLIN IMMUN, V135, P500, DOI 10.1016/j.jaci.2014.07.049; Ryan D, 2016, J ALLERGY CLIN IMMUN, V138, P308, DOI 10.1016/j.jaci.2015.11.044; Saffari H, 2016, AM J GASTROENTEROL, V111, P933, DOI 10.1038/ajg.2016.184; Safroneeva E, 2016, GASTROENTEROLOGY, V150, P581, DOI 10.1053/j.gastro.2015.11.004; Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401; Schwartz C, 2015, BLOOD, V125, P3896, DOI 10.1182/blood-2014-10-607788; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Soragni A, 2015, MOL CELL, V57, P1011, DOI 10.1016/j.molcel.2015.01.026; Stacy NI, 2015, VET CLIN PATH, V44, P177, DOI 10.1111/vcp.12246; Suarez-Zamorano N, 2015, NAT MED, V21, P1497, DOI 10.1038/nm.3994; Sugawara R, 2016, J EXP MED, V213, P555, DOI 10.1084/jem.20141388; Sverrild A, 2017, J ALLERGY CLIN IMMUN, V140, P407, DOI 10.1016/j.jaci.2016.10.046; Takahashi T, 2017, J ALLERGY CLIN IMMUN, V140, P720, DOI 10.1016/j.jaci.2017.01.022; Takeda K, 2015, J ALLERGY CLIN IMMUN, V135, P451, DOI 10.1016/j.jaci.2014.08.014; Valencia HA, 2016, ALLERGY, V71, P267, DOI 10.1111/all.12776; Vedel-Krogh S, 2016, AM J RESP CRIT CARE, V193, P965, DOI 10.1164/rccm.201509-1869OC; Wang G, 2016, EUR RESPIR J, V47, P1123, DOI 10.1183/13993003.01098-2015; Wechsler ME, 2017, NEW ENGL J MED, V376, P1921, DOI 10.1056/NEJMoa1702079; Wen T, 2015, J ALLERGY CLIN IMMUN, V135, P187, DOI 10.1016/j.jaci.2014.08.043; Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wilkerson EM, 2016, J PROTEOME RES, V15, P1524, DOI 10.1021/acs.jproteome.6b00006; Withers SB, 2017, SCI REP-UK, V7, DOI 10.1038/srep44571; Zaynagetdinov R, 2015, CANCER RES, V75, P1624, DOI 10.1158/0008-5472.CAN-14-2379; Zeiger RS, 2017, J ALLER CL IMM-PRACT, V5, P144, DOI 10.1016/j.jaip.2016.07.015	90	54	57	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					505	517		10.1016/j.jaci.2017.09.022	http://dx.doi.org/10.1016/j.jaci.2017.09.022			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	29045815	Green Accepted, Bronze			2022-12-18	WOS:000424410800006
J	Acker, WW; Plasek, JM; Blumenthal, KG; Lai, KH; Topaz, M; Seger, DL; Goss, FR; Slight, SP; Bates, DW; Zhou, L				Acker, Warren W.; Plasek, Joseph M.; Blumenthal, Kimberly G.; Lai, Kenneth H.; Topaz, Maxim; Seger, Diane L.; Goss, Foster R.; Slight, Sarah P.; Bates, David W.; Zhou, Li			Prevalence of food allergies and intolerances documented in electronic health records	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food hypersensitivity; allergy and immunology; epidemiology; anaphylaxis; prevalence; electronic health records	DIAGNOSIS; CONSUMPTION; ANAPHYLAXIS; CHILDREN; ADULTS; IMPACT; ENTRY	Background: Food allergy prevalence is reported to be increasing, but epidemiological data using patients' electronic health records (EHRs) remain sparse. Objective: We sought to determine the prevalence of food allergy and intolerance documented in the EHR allergy module. Methods: Using allergy data from a large health care organization's EHR between 2000 and 2013, we determined the prevalence of food allergy and intolerance by sex, racial/ethnic group, and allergen group. We examined the prevalence of reactions that were potentially IgE-mediated and anaphylactic. Data were validated using radioallergosorbent test and ImmunoCAP results, when available, for patients with reported peanut allergy. Results: Among 2.7 million patients, we identified 97,482 patients (3.6%) with 1 or more food allergies or intolerances (mean, 1.4 +/- 0.1). The prevalence of food allergy and intolerance was higher in females (4.2% vs 2.9%; P <.001) and Asians (4.3% vs 3.6%; P <.001). The most common food allergen groups were shellfish (0.9%), fruit or vegetable (0.7%), dairy (0.5%), and peanut (0.5%). Of the 103,659 identified reactions to foods, 48.1% were potentially IgE-mediated (affecting 50.8% of food allergy or intolerance patients) and 15.9% were anaphylactic. About 20% of patients with reported peanut allergy had a radioallergosorbent test/ImmunoCAP performed, of which 57.3% had an IgE level of grade 3 or higher. Conclusions: Our findings are consistent with previously validated methods for studying food allergy, suggesting that the EHR's allergy module has the potential to be used for clinical and epidemiological research. The spectrum of severity observed with food allergy highlights the critical need for more allergy evaluations.	[Acker, Warren W.; Plasek, Joseph M.; Topaz, Maxim; Seger, Diane L.; Slight, Sarah P.; Bates, David W.; Zhou, Li] Brigham & Womens Hosp, Div Gen Med & Primary Care, 75 Francis St, Boston, MA 02115 USA; [Acker, Warren W.] Geisinger Commonwealth Sch Med, Scranton, PA USA; [Plasek, Joseph M.] Univ Utah, Sch Med, Dept Biomed Informat, Salt Lake City, UT USA; [Blumenthal, Kimberly G.; Topaz, Maxim; Bates, David W.; Zhou, Li] Harvard Med Sch, Boston, MA USA; [Blumenthal, Kimberly G.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Blumenthal, Kimberly G.] Massachusetts Gen Hosp, Dept Med, Med Practice Evaluat Ctr, Boston, MA 02114 USA; [Blumenthal, Kimberly G.] Massachusetts Gen Hosp, Edward P Lawrence Ctr Qual & Safety, Boston, MA 02114 USA; [Lai, Kenneth H.; Seger, Diane L.] Partners HealthCare Syst, Clin & Qual Anal, Boston, MA USA; [Goss, Foster R.] Univ Colorado, Dept Emergency Med, Aurora, CO USA; [Slight, Sarah P.] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England; [Slight, Sarah P.] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England; [Zhou, Li] Partners HealthCare Syst, Clin Informat, Partners eCare, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Utah System of Higher Education; University of Utah; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Partners Healthcare System; University of Colorado System; University of Colorado Anschutz Medical Campus; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Partners Healthcare System	Zhou, L (corresponding author), Partners HealthCare, 399 Revolution Dr,Ste 1315, Somerville, MA 02145 USA.	lzhou@bwh.harvard.edu	Blumenthal, Kimberly/AAG-8290-2019; Bates, David/AAE-7283-2019; Plasek, Joseph/AAI-8263-2020; Topaz, Maxim/AAQ-7121-2021	Blumenthal, Kimberly/0000-0003-4773-9817; Plasek, Joseph/0000-0002-9686-3876; Topaz, Maxim/0000-0002-2358-9837; Slight, Sarah P/0000-0002-0339-846X; Acker, Warren/0000-0002-9338-8782	Agency for Healthcare Research and Quality [R01HS022728]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS025375, R01HS022728] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This study was funded by the Agency for Healthcare Research and Quality (grant no. R01HS022728).	AAAAI MEMBERSHIP American Academy of Allergy, 2016, AM AC ALL ASTHM IMM; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Blumenthal KG, 2017, ANN ALLERG ASTHMA IM, V118, P380, DOI 10.1016/j.anai.2016.12.020; Blumenthal KG, 2016, ANN ALLERG ASTHMA IM, V117, P126, DOI 10.1016/j.anai.2016.05.017; Campbell RL, 2014, ANN ALLERG ASTHMA IM, V113, P599, DOI 10.1016/j.anai.2014.10.007; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2016, NEW ENGL J MED, V374, P1435, DOI 10.1056/NEJMoa1514209; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; DunnGalvin A, 2006, ALLERGY, V61, P1336, DOI 10.1111/j.1398-9995.2006.01181.x; Gupta R, 2013, JAMA PEDIATR, V167, P1026, DOI 10.1001/jamapediatrics.2013.2376; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Kotz D, 2011, J ALLERGY CLIN IMMUN, V127, P623, DOI 10.1016/j.jaci.2010.11.021; Kuperman Gilad J, 2003, AMIA Annu Symp Proc, P376; Macy E, 2012, ANN ALLERG ASTHMA IM, V108, P88, DOI 10.1016/j.anai.2011.11.006; Macy E, 2009, AM J MED, V122, DOI 10.1016/j.amjmed.2009.01.034; Panjari M, 2016, CLIN EXP ALLERGY, V46, P602, DOI 10.1111/cea.12699; Plasek JM, 2016, J AM MED INFORM ASSN, V23, pE79, DOI 10.1093/jamia/ocv128; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Rudders SA, 2015, CURR OPIN ALLERGY CL, V15, P350, DOI 10.1097/ACI.0000000000000177; Rudders SA, 2014, J ALLERGY CLIN IMMUN, V134, P960, DOI 10.1016/j.jaci.2014.06.018; Sampson HA, 2014, J ALLERGY CLIN IMMUN, V134, P1016, DOI 10.1016/j.jaci.2014.05.013; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461, DOI 10.1016/S1081-1206(10)62258-2; Topaz M, 2017, INT J MED INFORM, V97, P353, DOI 10.1016/j.ijmedinf.2016.10.006; Topaz M, 2016, J AM MED INFORM ASSN, V23, P601, DOI 10.1093/jamia/ocv143; United States Census Bureau, 2016, OVERVIEW RACE HISPAN; US Census Bureau, 2011 2015 AM COMM SU; Verrill L, 2015, ALLERGY ASTHMA PROC, V36, P458, DOI 10.2500/aap.2015.36.3895; Vierk KA, 2007, J ALLERGY CLIN IMMUN, V119, P1504, DOI 10.1016/j.jaci.2007.03.011; Woods RK, 2002, EUR J CLIN NUTR, V56, P31, DOI 10.1038/sj.ejcn.1601306; Zhou L, 2016, ALLERGY, V71, P1305, DOI 10.1111/all.12881	35	54	56	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1587	+		10.1016/j.jaci.2017.04.006	http://dx.doi.org/10.1016/j.jaci.2017.04.006			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28577971	Green Accepted, Bronze			2022-12-18	WOS:000417206000013
J	Song, WJ; Kim, HJ; Shim, JS; Won, HK; Kang, SY; Sohn, KH; Kim, BK; Jo, EJ; Kim, MH; Kim, SH; Park, HW; Kim, SS; Chang, YS; Morice, AH; Lee, BJ; Cho, SH				Song, Woo-Jung; Kim, Hyun Jung; Shim, Ji-Su; Won, Ha-Kyeong; Kang, Sung-Yoon; Sohn, Kyoung-Hee; Kim, Byung-Keun; Jo, Eun-Jung; Kim, Min-Hye; Kim, Sang-Heon; Park, Heung-Woo; Kim, Sun-Sin; Chang, Yoon-Seok; Morice, Alyn H.; Lee, Byung-Jae; Cho, Sang-Heon			Diagnostic accuracy of fractional exhaled nitric oxide measurement in predicting cough-variant asthma and eosinophilic bronchitis in adults with chronic cough: A systematic review and meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Chronic cough; fractional exhaled nitric oxide; asthma; eosinophilic bronchitis; systematic review	EXACERBATIONS; MEPOLIZUMAB; FENO	Background: Individual studies have suggested the utility of fractional exhaled nitric oxide (FENO) measurement in detecting cough-variant asthma (CVA) and eosinophilic bronchitis (EB) in patients with chronic cough. Objective: We sought to obtain summary estimates of diagnostic test accuracy of FENO measurement in predicting CVA, EB, or both in adults with chronic cough. Methods: Electronic databases were searched for studies published until January 2016, without language restriction. Cross-sectional studies that reported the diagnostic accuracy of FENO measurement for detecting CVA or EB were included. Risk of bias was assessed with Quality Assessment of Diagnostic Accuracy Studies 2. Random effects meta-analyses were performed to obtain summary estimates of the diagnostic accuracy of FENO measurement. Results: A total of 15 studies involving 2187 adults with chronic cough were identified. FENO measurement had a moderate diagnostic accuracy in predicting CVA in patients with chronic cough, showing the summary area under the curve to be 0.87 (95% CI, 0.83-0.89). Specificity was higher and more consistent than sensitivity (0.85 [95% CI, 0.81-0.88] and 0.72 [95% CI, 0.61-0.81], respectively). However, in the nonasthmatic population with chronic cough, the diagnostic accuracy to predict EB was found to be relatively lower (summary area under the curve, 0.81 [95% CI, 0.77-0.84]), and specificity was inconsistent. Conclusions: The present meta-analyses indicated the diagnostic potential of FENO measurement as a rule-in test for detecting CVA in adult patients with chronic cough. However, FENO measurement may not be useful to predict EB in nonasthmatic subjects with chronic cough. These findings warrant further studies to validate the roles of FENO measurement in clinical practice of patients with chronic cough.	[Song, Woo-Jung; Shim, Ji-Su; Won, Ha-Kyeong; Kang, Sung-Yoon; Sohn, Kyoung-Hee; Kim, Byung-Keun; Park, Heung-Woo; Kim, Sun-Sin; Chang, Yoon-Seok; Cho, Sang-Heon] Seoul Natl Univ, Coll Med, Dept Internal Med, Div Allergy & Clin Immunol, Seoul, South Korea; [Kim, Hyun Jung] Korea Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; [Kim, Byung-Keun; Chang, Yoon-Seok] Seoul Natl Univ, Bundang Hosp, Div Allergy & Clin Immunol, Dept Internal Med, Seongnam, South Korea; [Jo, Eun-Jung] Pusan Natl Univ, Coll Med, Dept Internal Med, Busan, South Korea; [Kim, Min-Hye] Ewha Womans Univ, Sch Med, Dept Internal Med, Seoul, South Korea; [Kim, Sang-Heon] Hanyang Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Kim, Sun-Sin] Seoul Natl Univ Hosp, Healthcare Syst Gangnam Ctr, Dept Internal Med, Seoul, South Korea; [Morice, Alyn H.] Univ Hull, Castle Hill Hosp, Hull York Med Sch, Ctr Cardiovasc & Metab Res, Cottingham, England; [Lee, Byung-Jae] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Allergy, Seoul, South Korea; [Cho, Sang-Heon] Seoul Natl Univ, Med Res Ctr, Inst Allergy & Clin Immunol, Seoul, South Korea	Seoul National University (SNU); Korea University; Korea University Medicine (KU Medicine); Seoul National University (SNU); Pusan National University; Ewha Womans University; Hanyang University; Seoul National University (SNU); Seoul National University Hospital; University of Hull; University of York - UK; Sungkyunkwan University (SKKU); Samsung Medical Center; Seoul National University (SNU)	Cho, SH (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, Div Allergy & Clin Immunol, Seoul, South Korea.; Lee, BJ (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Allergy, Seoul, South Korea.	leebj@skku.edu; shcho@snu.ac.kr	Park, Heung-Woo/AAW-7690-2020; Kang, Sung-Yoon/AAG-7523-2020	Park, Heung-Woo/0000-0002-6970-3228; Song, Woo-Jung/0000-0002-4630-9922; Sohn, Kyoung-Hee/0000-0001-8407-8080; Kim, Hyun Jung/0000-0003-2018-2385	SNUH Research Fund [23-2015-0200]	SNUH Research Fund	Supported by grant no. 23-2015-0200 from the SNUH Research Fund.	Alving K, 2010, EUR RESPIR MONOGR, P1, DOI 10.1183/1025448x.00028509; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; BARNES PJ, 1993, THORAX, V48, P1034, DOI 10.1136/thx.48.10.1034; Beghe B, 2015, LANCET RESP MED, V3, P260, DOI 10.1016/S2213-2600(15)00108-3; Campbell JM, 2015, INT J EVID-BASED HEA, V13, P154, DOI 10.1097/XEB.0000000000000061; Chatkin JM, 1999, AM J RESP CRIT CARE, V159, P1810, DOI 10.1164/ajrccm.159.6.9809047; Cockcroft DW, 2010, CHEST, V138, p18S, DOI 10.1378/chest.10-0088; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Deville Walter L, 2002, BMC Med Res Methodol, V2, P9, DOI 10.1186/1471-2288-2-9; Dicpinigaitis PV, 2006, CHEST, V129, p75S, DOI 10.1378/chest.129.1_suppl.75S; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Efthimiadis A, 2002, Eur Respir J Suppl, V37, p19s; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; French CL, 1998, ARCH INTERN MED, V158, P1657, DOI 10.1001/archinte.158.15.1657; GIBSON PG, 1989, LANCET, V1, P1346; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Irwin RS, 2006, CHEST, V129, p1S, DOI 10.1378/chest.129.1_suppl.1S; Korevaar DA, 2015, LANCET RESP MED, V3, P290, DOI 10.1016/S2213-2600(15)00050-8; Kowal K, 2009, J ASTHMA, V46, P692, DOI 10.1080/02770900903056187; Lai KF, 2011, CHINESE MED J-PEKING, V124, P3207, DOI 10.3760/cma.j.issn.0366-6999.2011.20.002; Leeflang MMG, 2014, CLIN MICROBIOL INFEC, V20, P105, DOI 10.1111/1469-0691.12474; Lin G., 2013, CHIN MODERN MED, V20, P42; Macaskill P, 2010, COCHRANE HDB SYSTEMA; Maniscalco M, 2015, RESP MED, V109, P970, DOI 10.1016/j.rmed.2015.05.016; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; Morice AH, 2004, EUR RESPIR J, V24, P481, DOI 10.1183/09031936.04.00027804; Morice AH, 2014, EUR RESPIR J, V44, P1149, DOI 10.1183/09031936.00217813; Ni J, 2014, J DIAGN CONCEPTS PRC, V13, P606; Oh MJ, 2008, CHEST, V134, P990, DOI 10.1378/chest.07-2541; Pacheco A, 2011, RESPIROLOGY, V16, P994, DOI 10.1111/j.1440-1843.2011.02010.x; Paggiaro PL, 2002, EUR RESPIR J, V20, p3S, DOI 10.1183/09031936.02.00000302; Pizzimenti S, 2009, ALLERGY, V64, P395; Qiu JP, 2012, INT J RESP, V32, P1297; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Sato S, 2008, RESP MED, V102, P1452, DOI 10.1016/j.rmed.2008.04.018; Shen X, 2015, INT J RESP, V35, P329; Song WJ, 2017, J ALLER CL IMM-PRACT, V5, P135, DOI 10.1016/j.jaip.2016.07.017; Song WJ, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0069-4; Song WJ, 2015, EUR RESPIR J, V45, P1479, DOI 10.1183/09031936.00218714; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009; Ye L, 2010, J CLIN INTERN MED, V27, P601; Yi F, 2016, CHEST, V149, P1042, DOI 10.1016/j.chest.2016.01.006; Zhang Yong-Ming, 2011, Zhonghua Yi Xue Za Zhi, V91, P1254; Zhu N, 2014, J CLIN PULM MED, V19, P1628	45	54	68	3	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					701	709		10.1016/j.jaci.2016.11.037	http://dx.doi.org/10.1016/j.jaci.2016.11.037			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28088474	Bronze			2022-12-18	WOS:000409241500009
J	Mukai, K; Gaudenzio, N; Gupta, S; Vivanco, N; Bendall, SC; Maecker, HT; Chinthrajah, RS; Tsai, M; Nadeau, KC; Galli, SJ				Mukai, Kaori; Gaudenzio, Nicolas; Gupta, Sheena; Vivanco, Nora; Bendall, Sean C.; Maecker, Holden T.; Chinthrajah, Rebecca S.; Tsai, Mindy; Nadeau, Kari C.; Galli, Stephen J.			Assessing basophil activation by using flow cytometry and mass cytometry in blood stored 24 hours before analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basophils; CD63; CD203c; anti-coagulants; heparin; EDTA; peanut allergy; cytometry by time-of-flight mass spectrometry; platelets	FC-EPSILON-RI; DEPENDENT HISTAMINE-RELEASE; CD63 EXPRESSION; ANTI-IGE; MONOCLONAL-ANTIBODY; UP-REGULATION; DIAGNOSIS; ALLERGY; CELLS; PLATELETS	Background: Basophil activation tests (BATs) have promise for research and for clinical monitoring of patients with allergies. However, BAT protocols vary in blood anticoagulant used and temperature and time of storage before testing, complicating comparisons of results from various studies. Objective: We attempted to establish a BAT protocol that would permit analysis of blood within 24 hours of obtaining the sample. Methods: Blood from 46 healthy donors and 120 patients with peanut allergy was collected into EDTA or heparin tubes, and samples were stored at 4 degrees C or room temperature for 4 or 24 hours before performing BATs. Results: Stimulation with anti-IgE or IL-3 resulted in strong upregulation of basophil CD203c in samples collected in EDTA or heparin, stored at 4 degrees C, and analyzed 24 hours after sample collection. However, a CD63(hi) population of basophils was not observed in any conditions in EDTA-treated samples unless exogenous calcium/magnesium was added at the time of antiIgE stimulation. By contrast, blood samples collected in heparin tubes were adequate for quantification of upregulation of basophil CD203c and identification of a population of CD63 hi basophils, irrespective of whether the specimens were analyzed by means of conventional flow cytometry or cytometry by time-of- flight mass spectrometry, and such tests could be performed after blood was stored for 24 hours at 4 degrees C. Conclusion: BATs to measure upregulation of basophil CD203c and induction of a CD63 hi basophil population can be conducted with blood obtained in heparin tubes and stored at 4 degrees C for 24 hours.	[Mukai, Kaori; Gaudenzio, Nicolas; Vivanco, Nora; Bendall, Sean C.; Tsai, Mindy; Galli, Stephen J.] Stanford Univ, Sch Med, Dept Pathol, Palo Alto, CA 94304 USA; [Mukai, Kaori; Gaudenzio, Nicolas; Chinthrajah, Rebecca S.; Tsai, Mindy; Nadeau, Kari C.; Galli, Stephen J.] Stanford Univ, Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Palo Alto, CA 94304 USA; [Gupta, Sheena; Maecker, Holden T.] Stanford Univ, Sch Med, Human Immune Monitoring Ctr, Inst Immun Transplantat & Infect, Palo Alto, CA 94304 USA; [Maecker, Holden T.; Galli, Stephen J.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Palo Alto, CA 94304 USA; [Chinthrajah, Rebecca S.; Nadeau, Kari C.] Stanford Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Palo Alto, CA 94304 USA; [Vivanco, Nora; Bendall, Sean C.] Stanford Blood Ctr, Palo Alto, CA USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	Galli, SJ (corresponding author), Stanford Univ, Med Ctr, 300 Pasteur Dr,L235,Lane Bldg 235, Stanford, CA 94305 USA.; Galli, SJ (corresponding author), SOM, Dept Pathol, 300 Pasteur Dr,L235,Lane Bldg 235, Stanford, CA 94305 USA.	sgalli@stanford.edu	Bendall, Sean/AGG-0126-2022	Chinthrajah, Sharon/0000-0003-2467-4256; Vivanco Gonzalez, Nora/0000-0002-2805-4006; Tsai, Mindy/0000-0002-8421-4721; Bendall, Sean/0000-0003-1341-2453; Gaudenzio, Nicolas/0000-0002-5648-509X	National Institutes of Health/National Institute of Allergy and Infectious Diseases [5U19AI104209]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI104209] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases grant 5U19AI104209.	AZORSA DO, 1991, BLOOD, V78, P280; Bavbek S, 2009, INT ARCH ALLERGY IMM, V150, P261, DOI 10.1159/000222678; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; Blank U, 2004, TRENDS IMMUNOL, V25, P266, DOI 10.1016/j.it.2004.03.005; Brown SGA, 2004, CLIN EXP ALLERGY, V34, P792, DOI 10.1111/j.1365-2222.2004.01949.x; Buhring HJ, 2001, BLOOD, V97, P3303, DOI 10.1182/blood.V97.10.3303; Buhring HJ, 1999, BLOOD, V94, P2343; Chirumbolo S, 2012, INT ARCH ALLERGY IMM, V158, P99, DOI 10.1159/000331312; Chirumbolo S, 2011, CYTOM PART B-CLIN CY, V80B, P137, DOI 10.1002/cyto.b.20570; Chirumbolo Salvatore, 2008, Clin Mol Allergy, V6, P12, DOI 10.1186/1476-7961-6-12; de Weck AL, 2008, INT ARCH ALLERGY IMM, V146, P177, DOI 10.1159/000115885; DEBRUIJNEADMIRAAL LG, 1992, BLOOD, V80, P134; Ebo DG, 2008, CYTOM PART B-CLIN CY, V74B, P201, DOI 10.1002/cyto.b.20419; Erdmann SM, 2003, CLIN EXP ALLERGY, V33, P607, DOI 10.1046/j.1365-2222.2003.01660.x; Falcone FH, 2000, BLOOD, V96, P4028; Galli SJ, 2000, CURR OPIN HEMATOL, V7, P32, DOI 10.1097/00062752-200001000-00007; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gaudenzio N, 2009, BLOOD, V114, P4979, DOI 10.1182/blood-2009-02-202648; Goding JW, 2003, BBA-MOL BASIS DIS, V1638, P1, DOI 10.1016/S0925-4439(03)00058-9; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; Gounni AS, 2001, FASEB J, V15, P940, DOI 10.1096/fj.00-0378com; GRANT JA, 1986, FASEB J, V45, P2653; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; Karasuyama H, 2011, ANNU REV IMMUNOL, V29, P45, DOI 10.1146/annurev-immunol-031210-101257; Kepley CL, 2000, J IMMUNOL, V165, P5913, DOI 10.4049/jimmunol.165.10.5913; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; Kleine-Tebbe J, 2006, INT ARCH ALLERGY IMM, V141, P79, DOI 10.1159/000094495; KNAUER KA, 1984, INT ARCH ALLER A IMM, V74, P29, DOI 10.1159/000233511; KNOL EF, 1992, J ALLERGY CLIN IMMUN, V90, P92, DOI 10.1016/S0091-6749(06)80015-1; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; MacGlashan DW, 2013, J ALLERGY CLIN IMMUN, V132, P777, DOI 10.1016/j.jaci.2013.06.038; MACGLASHAN DW, 1995, J LEUKOCYTE BIOL, V58, P177, DOI 10.1002/jlb.58.2.177; MacGlashan DW, 1997, INT ARCH ALLERGY IMM, V113, P45; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; McGowan EC, 2013, CURR ALLERGY ASTHM R, V13, P101, DOI 10.1007/s11882-012-0324-x; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; Moneret-Vautrin DA, 1999, ANN ALLERG ASTHMA IM, V82, P33, DOI 10.1016/S1081-1206(10)62657-9; NGUYEN KL, 1990, J ALLERGY CLIN IMMUN, V85, P1020, DOI 10.1016/0091-6749(90)90046-7; NIEUWENHUIS HK, 1987, BLOOD, V70, P838; Ocmant A, 2007, J IMMUNOL METHODS, V320, P40, DOI 10.1016/j.jim.2006.12.002; Oka T, 2013, J ALLERGY CLIN IMMUN, V132, P922, DOI 10.1016/j.jaci.2013.05.004; Ownby DR, 1993, ALLERGY PRINCIPLES P, P1059; Sainte-Laudy J, 2009, HOMEOPATHY, V98, P186, DOI 10.1016/j.homp.2009.09.009; Sainte-Laudy J, 1998, INFLAMM RES, V47, P401, DOI 10.1007/s000110050351; Sanz Maria L., 2007, P391, DOI 10.1159/000104216; Sanz ML, 2002, J INVEST ALLERG CLIN, V12, P143; Sanz ML, 2001, CLIN EXP ALLERGY, V31, P1007, DOI 10.1046/j.1365-2222.2001.01122.x; Schroeder JT, 2001, ADV IMMUNOL, V77, P93, DOI 10.1016/S0065-2776(01)77015-0; Siracusa MC, 2013, J ALLERGY CLIN IMMUN, V132, P789, DOI 10.1016/j.jaci.2013.07.046; Sousa N, 2010, J INVEST ALLERG CLIN, V20, P535; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; Sturm EM, 2010, CYTOM PART B-CLIN CY, V78B, P308, DOI 10.1002/cyto.b.20526; Sturm GJ, 2009, ALLERGY, V64, P1319, DOI 10.1111/j.1398-9995.2009.02004.x; VALENT P, 1990, CRIT REV ONCOL HEMAT, V10, P327, DOI 10.1016/1040-8428(90)90009-H; Voehringer D, 2013, NAT REV IMMUNOL, V13, P362, DOI 10.1038/nri3427; WARNER JA, 1990, J IMMUNOL, V145, P1897; Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690	59	54	55	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					889	+		10.1016/j.jaci.2016.04.060	http://dx.doi.org/10.1016/j.jaci.2016.04.060			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27527263	Green Accepted, Bronze			2022-12-18	WOS:000397295800022
J	Satia, I; Tsamandouras, N; Holt, K; Badri, H; Woodhead, M; Ogungbenro, K; Felton, TW; O'Byrne, PM; Fowler, SJ; Smith, JA				Satia, Imran; Tsamandouras, Nikolaos; Holt, Kimberley; Badri, Huda; Woodhead, Mark; Ogungbenro, Kayode; Felton, Timothy W.; O'Byrne, Paul M.; Fowler, Stephen J.; Smith, Jaclyn A.			Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; transient receptor potential vanilloid type 1 vagus; pharmacodynamic modeling	NEUROTROPHIC FACTORS; INFLAMMATORY PAIN; CHALLENGE; RESPONSIVENESS; METHACHOLINE; SENSITIVITY; PLASTICITY; SYMPTOMS; INSIGHTS; REFLEX	Background: Cough in asthmatic patients is a common and troublesome symptom. It is generally assumed coughing occurs as a consequence of bronchial hyperresponsiveness and inflammation, but the possibility that airway nerves are dysfunctional has not been fully explored. Objectives: We sought to investigate capsaicin- evoked cough responses in a group of patients with well- characterized mild- to-moderate asthma compared with healthy volunteers and assess the influences of sex, atopy, lung physiology, inflammation, and asthma control on these responses. Methods: Capsaicin inhalational challenge was performed, and cough responses were analyzed by using nonlinear mixed- effects modeling to estimate the maximum cough response evoked by any concentration of capsaicin (E-max) and the capsaicin dose inducing half- maximal response (ED50). Results: Ninety- seven patients with stable asthma (median age, 23 years [ interquartile range, 21- 27 years]; 60% female) and 47 healthy volunteers (median age, 38 years [ interquartile range, 29- 47 years]; 64% female) were recruited. Asthmatic patients had higher Emax and lower ED50 values than healthy volunteers. Emax values were 27% higher in female subjects (P 5.006) and 46% higher in patients with nonatopic asthma (P 5.003) compared with healthy volunteers. Also, patients with atopic asthma had a 21% lower Emax value than nonatopic asthmatic patients (P 5.04). The ED50 value was 65% lower in female patients (P 5.0001) and 71% lower in all asthmatic patients (P 5.0008). ED50 values were also influenced by asthma control and serum IgE levels, whereas Emax values were related to 24-hour cough frequency. Age, body mass index, FEV1, PC20, fraction of exhaled nitric oxide, blood eosinophil counts, and inhaled steroid treatment did not influence cough parameters. Conclusion: Patients with stable asthma exhibited exaggerated capsaicin-evoked cough responses consistent with neuronal dysfunction. Nonatopic asthmatic patients had the highest cough responses, suggesting this mechanism might be most important in type 2-low asthma phenotypes.	[Satia, Imran; Holt, Kimberley; Badri, Huda; Woodhead, Mark; Felton, Timothy W.; O'Byrne, Paul M.; Fowler, Stephen J.; Smith, Jaclyn A.] Univ Manchester, Ctr Resp Med & Allergy, Manchester M13 9PL, Lancs, England; [Satia, Imran; Felton, Timothy W.; Smith, Jaclyn A.] Univ Hosp South Manchester, Manchester, NH USA; [Tsamandouras, Nikolaos] Univ Manchester, Manchester Pharm Sch, Ctr Appl Pharmacokinet Res, Manchester M13 9PL, Lancs, England; [Woodhead, Mark; Ogungbenro, Kayode] Cent Manchester NHS Fdn Trust, Manchester, NH USA	University of Manchester; University of Manchester	Smith, JA (corresponding author), Univ Manchester, Univ S Manchester Hosp, Ctr Resp & Allergy Res, Level Educ & Res Ctr 2, Manchester M23 9LT, Lancs, England.	jacky.smith@manchester.ac.uk	Satia, Imran/ABA-2872-2020; Felton, Tim/N-5940-2019; Felton, Tim W/F-1795-2011	Satia, Imran/0000-0003-4206-6000; Felton, Tim/0000-0001-6868-6633; Felton, Tim W/0000-0001-6868-6633; Fowler, Stephen/0000-0002-4524-1663; Badri, Huda/0000-0002-6134-4347; Smith, Jaclyn/0000-0001-8837-4928; Holt, Kimberley/0000-0003-0413-8085; O'Byrne, Paul/0000-0003-0979-281X	National Institute for Health Research, South Manchester Clinical Research Facility [ISRCTN32052878, ISRCTN23684347]; MRC [G1000417, MR/K020293/1] Funding Source: UKRI; Medical Research Council [G1000417, MR/K020293/1] Funding Source: researchfish	National Institute for Health Research, South Manchester Clinical Research Facility; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by the National Institute for Health Research, South Manchester Clinical Research Facility. Clinical Trial Registration: www. controlled- trials. com ISRCTN32052878 and ISRCTN23684347.	Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Beal S. L., 1998, NONMEM USERS GUIDE 7; Boeckman A, 2013, NONMEM USERS GUIDE 5; Bonate PL, 2011, PHARMACOKINETIC-PHARMACODYNAMIC MODELING AND SIMULATION, SECOND EDITION, P1, DOI 10.1007/978-1-4419-9485-1; Canning B J, 2009, Handb Exp Pharmacol, P139, DOI 10.1007/978-3-540-79090-7_5; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Dicpinigaitis PV, 2005, CHEST, V128, P196, DOI 10.1378/chest.128.1.196; Dicpinigaitis PV, 2001, THORAX, V56, P162; Doherty MJ, 2000, THORAX, V55, P643, DOI 10.1136/thorax.55.8.643; Ekstrand Y, 2011, J ASTHMA, V48, P482, DOI 10.3109/02770903.2011.570405; Fujimura M, 1998, Respirology, V3, P267, DOI 10.1111/j.1440-1843.1998.tb00133.x; Gastonguay MR, 2010, J CLIN PHARMACOL, V50, p63S, DOI 10.1177/0091270010378409; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Heaney LG, 2012, THORAX, V67, P268, DOI 10.1136/thoraxjnl-2011-200257; Hilton EC, 2013, J ALLERGY CLIN IMMUN, V132, pe1; Hilton ECY, 2013, J ALLERGY CLIN IMMUN, V132, P847, DOI 10.1016/j.jaci.2013.04.042; Kastelik JA, 2002, AM J RESP CRIT CARE, V166, P961, DOI 10.1164/rccm.2109061; Kidd BL, 2001, BRIT J ANAESTH, V87, P3, DOI 10.1093/bja/87.1.3; Lieu TM, 2012, AM J PHYSIOL-LUNG C, V302, pL941, DOI 10.1152/ajplung.00366.2011; Lindbom L, 2005, COMPUT METH PROG BIO, V79, P241, DOI 10.1016/j.cmpb.2005.04.005; Manfreda J, 2001, CAN MED ASSOC J, V164, P995; Marsden PA, 2008, J ALLERGY CLIN IMMUN, V122, P903, DOI 10.1016/j.jaci.2008.08.029; McGarvey LP, 2014, J ALLERGY CLIN IMMUN, V133, P704, DOI 10.1016/j.jaci.2013.09.016; McGuinness K, 2012, THORAX, V67, pA131, DOI 10.1136/thoraxjnl-2012-202678.220; McMahon SB, 2004, J NEUROBIOL, V61, P72, DOI 10.1002/neu.20093; Mincheva R, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-79; Mould D, 2013, CPT-PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.14; Osman LM, 2001, THORAX, V56, P138, DOI 10.1136/thorax.56.2.138; Plan EL, 2014, CPT-PHARMACOMET SYST, V3, DOI 10.1038/psp.2014.27; Satia I, 2015, AM J RESP CRIT CARE, V191; Satia I, 2014, THORAX, V69, pA80, DOI 10.1136/thoraxjnl-2014-206260.157; Savic RM, 2009, AAPS J, V11, P558, DOI 10.1208/s12248-009-9133-0; Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992; Thomson NC, 2013, RESP MED, V107, P1501, DOI 10.1016/j.rmed.2013.07.017; West PW, 2015, AM J RESP CRIT CARE, V192, P30, DOI 10.1164/rccm.201412-2293OC; Woolf CJ, 1999, P NATL ACAD SCI USA, V96, P7723, DOI 10.1073/pnas.96.14.7723; Yu RJ, 2014, NEUROIMAGE-CLIN, V6, P100, DOI 10.1016/j.nicl.2014.08.019	37	54	56	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					771	+		10.1016/j.jaci.2016.04.045	http://dx.doi.org/10.1016/j.jaci.2016.04.045			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27444176	hybrid			2022-12-18	WOS:000397295800008
J	Rider, CF; Yamamoto, M; Gunther, OP; Hirota, JA; Singh, A; Tebbutt, SJ; Carlsten, C				Rider, Christopher F.; Yamamoto, Masatsugu; Guenther, Oliver P.; Hirota, Jeremy A.; Singh, Amrit; Tebbutt, Scott J.; Carlsten, Chris			Controlled diesel exhaust and allergen coexposure modulates microRNA and gene expression in humans: Effects on inflammatory lung markers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air pollution; allergy; controlled human exposure; inflammatory markers; multi-omics	ANTIOXIDANT N-ACETYLCYSTEINE; AIR-POLLUTION; NASAL CHALLENGE; PARTICULATE MATTER; INNATE IMMUNITY; MESSENGER-RNA; HUMAN AIRWAYS; ASTHMA; EXPOSURE; PARTICLES	Background: Air pollution's association with asthma may be due to its augmentation of allergenic effects, but the role of microRNA (miRNA) and gene expression in this synergy is unknown. Objective: We sought to determine whether exposure to allergen, exposure to diesel exhaust (DE), or coexposures modulate miRNA, gene expression, or inflammatory pathways and whether these measurements are correlated. Methods: Fifteen participants with atopy completed this controlled study of 2 hours of filtered air or DE (300 mu g PM2.5/m(3)) exposure, followed by saline-controlled segmental bronchial allergen challenge. Gene and miRNA expression in bronchial brushings and lung inflammatory markers were measured 48 hours later, in study arms separated by approximately 4 weeks. Expression of miRNAs, messenger RNAs, and inflammatory markers and their interrelationships were determined using regression. Results: Robust linear models indicated that DE plus saline and DE plus allergen significantly modulated the highest number of miRNAs and messenger RNAs, respectively, relative to control (filtered air plus saline). In mixed models, allergen exposure modulated (q <= 0.2) miRNAs including miR-183-5p, miR-3245p, and miR-132-3p and genes including NFKBIZ and CDKN1A, but DE did not significantly modify this allergenic effect. Repression of CDKN1A by allergen-induced miR-132-3p may contribute to shedding of bronchial epithelial cells. Conclusions: Expression of specific miRNAs and genes associated with bronchial immune responses were significantly modulated by DE or allergen. However, DE did not augment the effect of allergen at 48 hours, suggesting that adjuvancy may be transient or require higher or prolonged exposure. In silico analysis suggested a possible mechanism contributing to epithelial wall damage following allergen exposure.	[Rider, Christopher F.; Yamamoto, Masatsugu; Hirota, Jeremy A.; Carlsten, Chris] Univ British Columbia, Chan Yeung Ctr Occupat & Environm Resp Dis COERD, Vancouver, BC, Canada; [Rider, Christopher F.; Yamamoto, Masatsugu; Hirota, Jeremy A.; Tebbutt, Scott J.; Carlsten, Chris] Univ British Columbia, Dept Med, Div Resp Med, Vancouver, BC, Canada; [Guenther, Oliver P.] Gunther Analyt, Vancouver, BC, Canada; [Hirota, Jeremy A.; Singh, Amrit; Tebbutt, Scott J.; Carlsten, Chris] Univ British Columbia, St Pauls Hosp, Ctr Heart Lung Innovat, Vancouver, BC, Canada; [Hirota, Jeremy A.; Singh, Amrit; Tebbutt, Scott J.; Carlsten, Chris] Univ British Columbia, Inst HEART LUNG Hlth, Vancouver, BC, Canada; [Singh, Amrit; Tebbutt, Scott J.] Prevent Organ Failure PROOF Ctr Excellence, Vancouver, BC, Canada; [Carlsten, Chris] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia; University of British Columbia	Carlsten, C (corresponding author), Gordon & Leslie Diamond Hlth Care Ctr, Lung Ctr, 7th Fl,2775 Laurel St, Vancouver, BC V5Z 1M9, Canada.	carlsten@mail.ubc.ca	Rider, Christopher F/H-7073-2019; Yamamoto, Masatsugu/AAH-7093-2020	Rider, Christopher F/0000-0003-0399-5931; Yamamoto, Masatsugu/0000-0003-0596-555X; Gunther, Oliver/0000-0003-1900-715X; Tebbutt, Scott/0000-0002-7908-1581	AllerGen NCE Inc (Allergy, Genes and Environment Network) [GxE2, GxE4]; WorkSafeBC [RG2011-OG07]; BC Lung Association; Canadian Institutes of Health Research (CIHR) [MOP 123319]; Vancouver Coastal Health Research Institute - Centre for Respiratory, Cardiac and Critical Care Medicine Fellowship; CIHR Integrated and Mentored Pulmonary and Cardiovascular Training Program (IMPACT); Sumitomo Life Social Welfare Services Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical Research; CIHR Doctoral Award Frederick Banting and Charles Best Canada Graduate Scholarship	AllerGen NCE Inc (Allergy, Genes and Environment Network); WorkSafeBC; BC Lung Association; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Vancouver Coastal Health Research Institute - Centre for Respiratory, Cardiac and Critical Care Medicine Fellowship; CIHR Integrated and Mentored Pulmonary and Cardiovascular Training Program (IMPACT); Sumitomo Life Social Welfare Services Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical Research; CIHR Doctoral Award Frederick Banting and Charles Best Canada Graduate Scholarship	This research was supported by funding from AllerGen NCE Inc (Allergy, Genes and Environment Network, GxE2; GxE4), WorkSafeBC (RG2011-OG07), the BC Lung Association, and the Canadian Institutes of Health Research (CIHR, MOP 123319). C.F.R. was supported by a Vancouver Coastal Health Research Institute - Centre for Respiratory, Cardiac and Critical Care Medicine Fellowship. M.Y. was supported by fellowships from the CIHR Integrated and Mentored Pulmonary and Cardiovascular Training Program (IMPACT), the Sumitomo Life Social Welfare Services Foundation, and the Mochida Memorial Foundation for Medical and Pharmaceutical Research. A.S. was the recipient of the CIHR Doctoral Award Frederick Banting and Charles Best Canada Graduate Scholarship.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Alrashdan YA, 2012, AM J PHYSIOL-LUNG C, V302, pL1118, DOI 10.1152/ajplung.00232.2011; Anandan C, 2010, ALLERGY, V65, P152, DOI 10.1111/j.1398-9995.2009.02244.x; Baldacci S, 2015, RESP MED, V109, P1089, DOI 10.1016/j.rmed.2015.05.017; Bauer RN, 2012, J ALLERGY CLIN IMMUN, V129, P14, DOI 10.1016/j.jaci.2011.11.004; Birger N, 2011, INHAL TOXICOL, V23, P219, DOI 10.3109/08958378.2011.562256; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Cakmak S, 2012, J ALLERGY CLIN IMMUN, V129, P228, DOI 10.1016/j.jaci.2011.09.025; Carlsten C, 2012, DIESEL EXHAUST MECH; Carlsten C, 2016, THORAX, V71, P35, DOI 10.1136/thoraxjnl-2015-207399; Carlsten C, 2014, EMBO REP, V15, P736, DOI 10.15252/embr.201438480; Carlsten C, 2014, TOXICOL SCI, V139, P479, DOI 10.1093/toxsci/kfu040; Carlsten C, 2012, CURR OPIN ALLERGY CL, V12, P455, DOI 10.1097/ACI.0b013e328357cc55; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483; Diaz-Sanchez D, 2000, CLIN IMMUNOL, V97, P140, DOI 10.1006/clim.2000.4921; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Fry RC, 2014, AM J PHYSIOL-LUNG C, V306, pL1129, DOI 10.1152/ajplung.00348.2013; Fry RC, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-89; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507, DOI 10.1165/ajrcmb.19.3.3143; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Gent JF, 2009, ENVIRON HEALTH PERSP, V117, P1168, DOI 10.1289/ehp.0800335; Ghio AJ, 2012, CURR OPIN PULM MED, V18, P144, DOI 10.1097/MCP.0b013e32834f0e2a; Global Initiative for Asthma, 2014, GINA GLOB STRAT ASTH; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Hirota JA, 2012, CURR OPIN IMMUNOL, V24, P740, DOI 10.1016/j.coi.2012.08.012; Hirota JA, 2012, J ALLERGY CLIN IMMUN, V129, P1116, DOI 10.1016/j.jaci.2011.11.033; Ho SM, 2010, J ALLERGY CLIN IMMUN, V126, P453, DOI 10.1016/j.jaci.2010.07.030; Hou LF, 2011, MUTAT RES-FUND MOL M, V714, P105, DOI 10.1016/j.mrfmmm.2011.05.004; Hsu SD, 2014, NUCLEIC ACIDS RES, V42, pD78, DOI 10.1093/nar/gkt1266; Jardim MJ, 2012, AM J RESP CELL MOL, V47, P536, DOI 10.1165/rcmb.2011-0160OC; Jiang RW, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/s12989-014-0071-3; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; Khan M, 2011, CELL, V147, P907, DOI 10.1016/j.cell.2011.09.049; Knutsen E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075813; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Langley SJ, 2003, J ALLERGY CLIN IMMUN, V112, P362, DOI 10.1067/mai.2003.1654; Le Annie V, 2006, Allergy Asthma Clin Immunol, V2, P109, DOI 10.1186/1710-1492-2-3-109; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Lilly CM, 2005, AM J RESP CRIT CARE, V171, P579, DOI 10.1164/rccm.200404-532OC; Liu AH, 2008, J ALLERGY CLIN IMMUN, V122, P846, DOI 10.1016/j.jaci.2008.10.002; Ma Q, 2010, PHARMACOL THERAPEUT, V125, P376, DOI 10.1016/j.pharmthera.2009.11.004; Martinvalet D, 2005, IMMUNITY, V22, P355, DOI 10.1016/j.immuni.2005.02.004; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Murdoch JR, 2010, MUTAT RES-FUND MOL M, V690, P24, DOI 10.1016/j.mrfmmm.2009.09.005; North ML, 2014, ANN ALLERG ASTHMA IM, V113, P343, DOI 10.1016/j.anai.2014.07.019; O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013; Pawankar R, 2011, WAO WHITE BOOK ALLER; Penttinen P, 2001, ENVIRON HEALTH PERSP, V109, P319, DOI 10.2307/3454889; Perry MM, 2015, CURR OPIN ALLERGY CL, V15, P156, DOI 10.1097/ACI.0000000000000147; Proud D, 2011, IMMUNOL REV, V242, P186, DOI 10.1111/j.1600-065X.2011.01033.x; Pua HH, 2015, CURR OPIN IMMUNOL, V36, P101, DOI 10.1016/j.coi.2015.07.006; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550, DOI 10.1164/ajrccm.161.2.9905052; Sava F, 2012, CLIN CHEST MED, V33, P759, DOI 10.1016/j.ccm.2012.07.003; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Solberg OD, 2012, AM J RESP CRIT CARE, V186, P965, DOI 10.1164/rccm.201201-0027OC; Tashakkor AY, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-532; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Williams AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005889; Woodruff Prescott G, 2013, Ann Am Thorac Soc, V10 Suppl, pS186, DOI 10.1513/AnnalsATS.201303-070AW; Wu S, 2010, ONCOGENE, V29, P2302, DOI 10.1038/onc.2010.34; Yamamoto M, 2013, ENVIRON HEALTH PERSP, V121, P670, DOI 10.1289/ehp.1205963; Yamamoto M, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-655	66	54	55	1	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1690	1700		10.1016/j.jaci.2016.02.038	http://dx.doi.org/10.1016/j.jaci.2016.02.038			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27283384	Bronze			2022-12-18	WOS:000390019300025
J	Guttman-Yassky, E; Ungar, B; Noda, S; Suprun, M; Shroff, A; Dutt, R; Khattri, S; Min, M; Mansouri, Y; Zheng, XZ; Estrada, YD; Singer, GK; Suarez-Farinas, M; Krueger, JG; Lebwohl, MG				Guttman-Yassky, Emma; Ungar, Benjamin; Noda, Shinji; Suprun, Maria; Shroff, Anjali; Dutt, Riana; Khattri, Saakshi; Min, Michelle; Mansouri, Yasaman; Zheng, Xiuzhong; Estrada, Yeriel D.; Singer, Giselle K.; Suarez-Farinas, Mayte; Krueger, James G.; Lebwohl, Mark G.			Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CYCLOSPORINE; IL-23		[Guttman-Yassky, Emma; Ungar, Benjamin; Shroff, Anjali; Dutt, Riana; Khattri, Saakshi; Min, Michelle; Mansouri, Yasaman; Estrada, Yeriel D.; Singer, Giselle K.; Suarez-Farinas, Mayte; Lebwohl, Mark G.] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Immunol, New York, NY 10029 USA; [Suprun, Maria; Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA; [Guttman-Yassky, Emma; Ungar, Benjamin; Noda, Shinji; Zheng, Xiuzhong; Suarez-Farinas, Mayte; Krueger, James G.] Rockefeller Univ, Invest Dermatol Lab, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org	Suprun, Maria/ABE-8323-2020	Suprun, Maria/0000-0001-9161-4021; Sanyal, Riana/0000-0002-6638-9026; Ungar, Benjamin/0000-0003-0882-8163	NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER; NCRR NIH HHS [5UL1RR024143-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Acikgoz G, 2014, CUTAN OCUL TOXICOL, V33, P247, DOI 10.3109/15569527.2013.839997; Lee E, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000217; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Park KY, 2013, ANN DERMATOL, V25, P12, DOI 10.5021/ad.2013.25.1.12; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V136, P1277, DOI 10.1016/j.jaci.2015.06.032; Tosti A, 2006, J AM ACAD DERMATOL, V55, P438, DOI 10.1016/j.jaad.2006.05.008; Vahedi G, 2015, NATURE, V520, P558, DOI 10.1038/nature14154; Volpe E, 2014, J ALLERGY CLIN IMMUN, V134, P373, DOI 10.1016/j.jaci.2014.04.022; Xing LZ, 2014, NAT MED, V20, P1043, DOI 10.1038/nm.3645	9	54	55	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					301	304		10.1016/j.jaci.2015.11.001	http://dx.doi.org/10.1016/j.jaci.2015.11.001			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26607705	Bronze			2022-12-18	WOS:000367724300023
J	Larose, MC; Chakir, J; Archambault, AS; Joubert, P; Provost, V; Laviolette, M; Flamand, N				Larose, Marie-Chantal; Chakir, Jamila; Archambault, Anne-Sophie; Joubert, Philippe; Provost, Veronique; Laviolette, Michel; Flamand, Nicolas			Correlation between CCL26 production by human bronchial epithelial cells and airway eosinophils: Involvement in patients with severe eosinophilic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; bronchial epithelial cells; chemokine; eotaxin; CCL26; IL-13; bronchial mucosa; inflammation; severe asthma	HUMAN CC-CHEMOKINE; EOTAXIN-3/CCL26 GENE-EXPRESSION; MAJOR BASIC-PROTEIN; INDUCED SPUTUM; MOLECULAR-CLONING; EOTAXIN RECEPTOR; MESSENGER-RNA; SIGNAL TRANSDUCER; IL-13 EXPRESSION; DISEASE-ACTIVITY	Background: High pulmonary eosinophil counts are associated with asthma symptoms and severity. Bronchial epithelial cells (BECs) produce CC chemokines, notably CCL26 (eotaxin-3), which recruits and activates eosinophils from asthmatic patients. This suggests that CCL26 production by BECs might be involved in persistent eosinophilia in patients with severe asthma despite treatment with high corticosteroid doses. Objective: We sought to determine whether CCL26 levels correlate with eosinophilia and asthma severity. Methods: Human CC chemokine expression was assessed by means of quantitative PCR or a quantitative PCR array in vehicle-or IL-13-treated BECs. CCL26 was quantitated by means of ELISA. Immunohistochemistry analyses of CCL26 and major basic protein were done on bronchial biopsy specimens. Results: IL-13 selectively induced CCL26 expression by BECs. This increase was time-dependent and more prominent in BECs from patients with severe eosinophilic asthma. CCL26 levels measured in supernatants of IL-13-stimulated BECs also increased with asthma severity as follows: patients with severe eosinophilic asthma > patients with mild asthma approximate to healthy subjects. Immunohistochemistry analyses of bronchial biopsy specimens confirmed increased levels of CCL26 in the epithelium of patients with mild and those with severe eosinophilic asthma. Tissue eosinophil counts did not correlate with CCL26 staining. However, sputum CCL26 levels significantly correlated with sputum eosinophil counts (P <. 0001), suggesting that CCL26 participates in the movement of eosinophils from the tissues to the airway lumen. Conclusions: These results show a relation between CCL26 production by IL-13-stimulated BECs, sputum eosinophil counts, and asthma severity. They also suggest a role for CCL26 in the sustained inflammation observed in patients with severe eosinophilic asthma and reveal CCL26 as a potential target for treating patients with eosinophilic asthma that are refractory to classic therapies.	[Larose, Marie-Chantal; Chakir, Jamila; Archambault, Anne-Sophie; Joubert, Philippe; Provost, Veronique; Laviolette, Michel; Flamand, Nicolas] Univ Laval, Fac Med, Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Quebec City, PQ G1K 7P4, Canada	Laval University	Flamand, N (corresponding author), CRIUCPQ, 2725 Chemin St Foy, Quebec City, PQ G1V 4G5, Canada.	Nicolas.Flamand@criucpq.ulaval.ca	Flamand, Nicolas/H-5823-2019	Flamand, Nicolas/0000-0001-5944-7200; Joubert, Philippe/0000-0001-7784-6387; Archambault, Anne-Sophie/0000-0001-7243-7445				Abonyo BO, 2005, AM J PHYSIOL-LUNG C, V289, pL478, DOI 10.1152/ajplung.00032.2005; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; Berry MA, 2004, J ALLERGY CLIN IMMUN, V114, P1106, DOI 10.1016/j.jaci.2004.08.032; Bhardwaj N, 2012, ANN ALLERG ASTHMA IM, V109, P155, DOI 10.1016/j.anai.2012.06.014; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2005, INT J BIOCHEM CELL B, V37, P2559, DOI 10.1016/j.biocel.2005.06.010; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Brightling CE, 2003, CLIN EXP ALLERGY, V33, P1711, DOI 10.1111/j.1365-2222.2003.01827.x; Catley MC, 2011, PHARMACOL THERAPEUT, V132, P333, DOI 10.1016/j.pharmthera.2011.09.005; Chakir J, 2001, J ALLERGY CLIN IMMUN, V107, P36, DOI 10.1067/mai.2001.111929; Coleman JM, 2012, THORAX, V67, P1061, DOI 10.1136/thoraxjnl-2012-201634; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Duncan CJA, 2003, EUR RESPIR J, V22, P484, DOI 10.1183/09031936.03.00109803a; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; FRIGAS E, 1980, LAB INVEST, V42, P35; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Goulet F, 1996, AM J RESP CELL MOL, V15, P312, DOI 10.1165/ajrcmb.15.3.8810634; GRIFFITHSJOHNSON DA, 1993, BIOCHEM BIOPH RES CO, V197, P1167, DOI 10.1006/bbrc.1993.2599; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hebenstreit D, 2005, MOL IMMUNOL, V42, P295, DOI 10.1016/j.molimm.2004.09.004; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; JOSE PJ, 1994, BIOCHEM BIOPH RES CO, V205, P788, DOI 10.1006/bbrc.1994.2734; JOSE PJ, 1994, THE JOURNAL OF EXPER, V179, P881; Kagami S, 2005, CLIN EXP IMMUNOL, V141, P459, DOI 10.1111/j.1365-2249.2005.02875.x; Kagami S, 2003, CLIN EXP IMMUNOL, V134, P309, DOI 10.1046/j.1365-2249.2003.02273.x; Kitaura M, 1999, J BIOL CHEM, V274, P27975, DOI 10.1074/jbc.274.39.27975; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Komiya A, 2003, CELL IMMUNOL, V225, P91, DOI 10.1016/j.cellimm.2003.10.001; Konikoff MR, 2006, CLIN GASTROENTEROL H, V4, P1328, DOI 10.1016/j.cgh.2006.08.013; Lam M, 2013, INT FORUM ALLERGY RH, V3, P121, DOI 10.1002/alr.21082; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Laprise C, 1999, EUR RESPIR J, V14, P63, DOI 10.1034/j.1399-3003.1999.14a12.x; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Lim E, 2014, J IMMUNOL, V192, P466, DOI 10.4049/jimmunol.1302454; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832, DOI 10.1067/mai.2001.119554; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; Paplinska-Goryca M, 2013, CELL MOL BIOL LETT, V18, P612, DOI 10.2478/s11658-013-0107-y; Park SW, 2005, CHEST, V128, P1921, DOI 10.1378/chest.128.4.1921; Pelaia G, 2012, NAT REV DRUG DISCOV, V11, P958, DOI 10.1038/nrd3792; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Polzer K, 2008, RHEUMATOLOGY, V47, P804, DOI 10.1093/rheumatology/ken033; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Provost V, 2013, J LEUKOCYTE BIOL, V94, P213, DOI 10.1189/jlb.0212074; Provost V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043544; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; Rosenberg HF, 2007, J ALLERGY CLIN IMMUN, V119, P1303, DOI 10.1016/j.jaci.2007.03.048; Saha SK, 2008, J ALLERGY CLIN IMMUN, V121, P685, DOI 10.1016/j.jaci.2008.01.005; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Shinkai A, 1999, J IMMUNOL, V163, P1602; Thomsen Rune, 2010, J Bioinform Comput Biol, V8, P885, DOI 10.1142/S0219720010004963; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; Vaglio A, 2013, ALLERGY, V68, P261, DOI 10.1111/all.12088; van Wetering S, 2007, MOL IMMUNOL, V44, P803, DOI 10.1016/j.molimm.2006.04.008; White JR, 1997, J LEUKOCYTE BIOL, V62, P667, DOI 10.1002/jlb.62.5.667; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Zhou L, 2012, BIOORGAN MED CHEM, V20, P750, DOI 10.1016/j.bmc.2011.12.006	66	54	54	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					904	913		10.1016/j.jaci.2015.02.039	http://dx.doi.org/10.1016/j.jaci.2015.02.039			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25936567	Bronze			2022-12-18	WOS:000362976300009
J	Wang, J; Jones, SM; Pongracic, JA; Song, Y; Yang, N; Sicherer, SH; Makhija, MM; Robison, RG; Moshier, E; Godbold, J; Sampson, HA; Li, XM				Wang, Julie; Jones, Stacie M.; Pongracic, Jacqueline A.; Song, Ying; Yang, Nan; Sicherer, Scott H.; Makhija, Melanie M.; Robison, Rachel G.; Moshier, Erin; Godbold, James; Sampson, Hugh A.; Li, Xiu-Min			Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; Food Allergy Herbal Formula-2; Chinese herbal therapy; peanut allergy	PEANUT ALLERGY; DOUBLE-BLIND; SUBLINGUAL IMMUNOTHERAPY; ORAL IMMUNOTHERAPY; DOSE-ESCALATION; MURINE MODEL; CHILDREN; TOLERABILITY; FAHF-2; ANAPHYLAXIS	Background: Food Allergy Herbal Formula-2 (FAHF-2) is a 9-herb formula based on traditional Chinese medicine that blocks peanut-induced anaphylaxis in a murine model. In phase I studies FAHF-2 was found to be safe and well tolerated. Objective: We sought to evaluate the safety and effectiveness of FAHF-2 as a treatment for food allergy. Methods: In this double-blind, randomized, placebo-controlled study 68 subjects aged 12 to 45 years with allergies to peanut, tree nut, sesame, fish, and/or shellfish, which were confirmed by baseline double-blind, placebo-controlled oral food challenges (DBPCFCs), received FAHF-2 (n = 46) or placebo (n = 22). After 6 months of therapy, subjects underwent DBPCFCs. For those who demonstrated increases in the eliciting dose, a repeat DBPCFC was performed 3 months after stopping therapy. Results: Treatment was well tolerated, with no serious adverse events. By using intent-to-treat analysis, the placebo group had a higher eliciting dose and cumulative dose (P = .05) at the end-of-treatment DBPCFC. There was no difference in the requirement for epinephrine to treat reactions (P = .55). There were no significant differences in allergen-specific IgE and IgG(4) levels, cytokine production by PBMCs, or basophil activation between the active and placebo groups. In vitro immunologic studies performed on subjects' baseline PBMCs incubated with FAHF-2 and food allergen produced significantly less IL-5, greater IL-10 levels, and increased numbers of regulatory T cells than untreated cells. Notably, 44% of subjects had poor drug adherence for at least one third of the study period. Conclusion: FAHF-2 is a safe herbal medication for subjects with food allergy and shows favorable in vitro immunomodulatory effects; however, efficacy for improving tolerance to food allergens is not demonstrated at the dose and duration used.	[Wang, Julie; Song, Ying; Yang, Nan; Sicherer, Scott H.; Sampson, Hugh A.; Li, Xiu-Min] Icahn Sch Med Mt Sinai, Jaffe Food Allergy Inst, New York, NY 10029 USA; [Moshier, Erin; Godbold, James] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA; [Jones, Stacie M.] Univ Arkansas Med Sci, Dept Pediat, Div Allergy & Immunol, Little Rock, AR 72205 USA; [Jones, Stacie M.] Arkansas Childrens Hosp, Little Rock, AR 72202 USA; [Pongracic, Jacqueline A.; Makhija, Melanie M.; Robison, Rachel G.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago	Li, XM (corresponding author), Icahn Sch Med Mt Sinai, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, 1425 Madison Ave,Box 1089, New York, NY 10029 USA.	julie.wang@mssm.edu; xiu-min.li@mssm.edu	li, xiu/GXV-1745-2022	Robison, Rachel/0000-0003-0160-0529	NCATS NIH HHS [TR000039, UL1TR000150, UL1TR000067] Funding Source: Medline; NCCIH NIH HHS [1R01AT001495-01A1, 2R01 AT001495-05A1] Funding Source: Medline; NCRR NIH HHS [UL1RR025741] Funding Source: Medline; NIAID NIH HHS [K23 AI083883] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000150, UL1TR000067] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001495] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI083883] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Bensky D, 1993, MAT MED; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, P1240, DOI 10.1016/j.jaci.2014.12.1917; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Chan CK, 2006, PEDIAT ALLERG IMM-UK, V17, P316, DOI 10.1111/j.1399-3038.2006.00406.x; Chang TT, 2006, PHYTOTHER RES, V20, P342, DOI 10.1002/ptr.1843; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Diggle PJ, 1994, ANALYSIS OF LONGITUD; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Fleiss J., 1986, DESIGN ANAL CLIN EXP, DOI [10.1002/9781118032923.ch1, DOI 10.1002/9781118032923.CH1]; Hsu CH, 2005, PEDIATR ALLERGY IMMU, V16, P76, DOI 10.1111/j.1399-3038.2005.00230.x; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kelly-Pieper K, 2009, J ALTERN COMPLEM MED, V15, P735, DOI 10.1089/acm.2008.0543; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Martorell A, 2011, CLIN EXP ALLERGY, V41, P1297, DOI 10.1111/j.1365-2222.2011.03749.x; Papakostas GI, 2009, EUR NEUROPSYCHOPHARM, V19, P34, DOI 10.1016/j.euroneuro.2008.08.009; Patil SP, 2011, J ALLERGY CLIN IMMUN, V128, P1259, DOI 10.1016/j.jaci.2011.06.015; Qu C, 2007, CLIN EXP ALLERGY, V37, P846, DOI 10.1111/j.1365-2222.2007.02718.x; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, P1309, DOI 10.1016/j.jaci.2011.01.051; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Srivastava K, 2011, CLIN EXP ALLERGY, V41, P582, DOI 10.1111/j.1365-2222.2010.03643.x; Srivastava KD, 2012, ANN ALLERG ASTHMA IM, V108, P351, DOI 10.1016/j.anai.2012.03.008; Srivastava KD, 2009, J ALLERGY CLIN IMMUN, V123, P443, DOI 10.1016/j.jaci.2008.12.1107; Srivastava KD, 2005, J ALLERGY CLIN IMMUN, V115, P171, DOI 10.1016/j.jaci.2004.10.003; Tang MLK, 2015, J ALLERGY CLIN IMMUN, V135, P737, DOI 10.1016/j.jaci.2014.11.034; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Wang JL, 2010, ANN ALLERG ASTHMA IM, V105, P75, DOI 10.1016/j.anai.2010.05.005; Weimer K, 2013, PEDIATR RES, V74, P96, DOI 10.1038/pr.2013.66; Wen MC, 2005, J ALLERGY CLIN IMMUN, V116, P517, DOI 10.1016/j.jaci.2005.05.029	33	54	58	1	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					962	+		10.1016/j.jaci.2015.04.029	http://dx.doi.org/10.1016/j.jaci.2015.04.029			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26044855	Green Accepted			2022-12-18	WOS:000362976300015
J	Gaeta, F; Valluzzi, RL; Alonzi, C; Maggioletti, M; Caruso, C; Romano, A				Gaeta, Francesco; Valluzzi, Rocco Luigi; Alonzi, Cristiana; Maggioletti, Michela; Caruso, Cristiano; Romano, Antonino			Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aztreonam; cross-reactivity; ertapenem; imipenem; meropenem; penicillin allergy; skin tests; tolerability	BETA-LACTAM ANTIBIOTICS; CROSS-REACTIVITY; IMMEDIATE HYPERSENSITIVITY; DRUG HYPERSENSITIVITY; IMIPENEM; CEPHALOSPORINS; DIAGNOSIS; MEROPENEM; CHILDREN; ALLERGY	Background: Studies performed on samples larger than 100 subjects with a documented IgE-mediated hypersensitivity to penicillins have demonstrated a cross-reactivity rate of approximately 1% between penicillins and both imipenem and meropenem, whereas a single study found a cross-reactivity rate of 6.2% with aztreonam in 16 such subjects. Objective: To assess the cross-reactivity and tolerability of aztreonam and 3 carbapenems (imipenem-cilastatin, meropenem, and ertapenem) in patients with documented IgE-mediated hypersensitivity to penicillins. Methods: A total of 212 consecutive subjects with immediate reactions to penicillins and positive results on skin tests to at least 1 penicillin reagent underwent skin tests with aztreonam and carbapenems; subjects with negative results were challenged with escalating doses of aztreonam and carbapenems. Results: All subjects displayed negative skin test results to both aztreonam and carbapenems; 211 accepted challenges and tolerated them. Challenges were not followed by full therapeutic courses. Conclusions: These data indicate the tolerability of both aztreonam and carbapenems in penicillin-allergic subjects. In those who especially require these alternative beta-lactams, however, we recommend pretreatment skin tests, both because rare cases of cross-reactivity have been reported and because negative results indicate tolerability.	[Gaeta, Francesco; Valluzzi, Rocco Luigi; Alonzi, Cristiana; Maggioletti, Michela; Caruso, Cristiano; Romano, Antonino] Complesso Integrato Columbus, Allergy Unit, I-00168 Rome, Italy; [Romano, Antonino] IRCCS Oasi Maria SS, Troina, Italy	IRCCS Oasi Maria SS	Romano, A (corresponding author), Complesso Integrato Columbus, Allergy Unit, Via G Moscati 31, I-00168 Rome, Italy.	antoninoromano@h-columbus.it	Valluzzi, Rocco Luigi/Q-3879-2019; caruso, cristiano/AAR-9502-2020; Gaeta, Francesco/AAC-7107-2020; Romano, Antonino/D-3102-2017	Valluzzi, Rocco Luigi/0000-0003-0029-6254; caruso, cristiano/0000-0001-7631-029X; Gaeta, Francesco/0000-0003-2942-7633; Romano, Antonino/0000-0001-9742-9898	Italian Ministry for University, Scientific and Technological Research (MURST)	Italian Ministry for University, Scientific and Technological Research (MURST)(Ministry of Education, Universities and Research (MIUR))	The authors have received research support from the Italian Ministry for University, Scientific and Technological Research (MURST).	ADKINSON NF, 1984, ANTIMICROB AGENTS CH, V25, P93, DOI 10.1128/AAC.25.1.93; Atanaskovic-Markovic M, 2008, ALLERGY, V63, P237, DOI 10.1111/j.1398-9995.2007.01532.x; Atanaskovic-Markovic M, 2009, J ALLERGY CLIN IMMUN, V124, P167, DOI 10.1016/j.jaci.2009.02.031; Brockow K, 2002, ALLERGY, V57, P45; *JOINT TASK FORC P, 2005, J ALLERGY CLIN IM S2, V0115, pS 483; Macy E, 2013, J ALLER CL IMM-PRACT, V1, P258, DOI 10.1016/j.jaip.2013.02.002; Macy Eric, 2009, Perm J, V13, P12; MOSS RB, 1991, J ALLERGY CLIN IMMUN, V87, P78, DOI 10.1016/0091-6749(91)90215-A; Patriarca G, 2008, INT J IMMUNOPATH PH, V21, P375, DOI 10.1177/039463200802100215; Romano A, 2006, NEW ENGL J MED, V354, P2835, DOI 10.1056/NEJMc053529; Romano A, 1999, J ALLERGY CLIN IMMUN, V103, P1186, DOI 10.1016/S0091-6749(99)70197-1; Romano A, 2013, ALLERGY, V68, P1618, DOI 10.1111/all.12299; Romano A, 2004, ANN INTERN MED, V141, P16, DOI 10.7326/0003-4819-141-1-200407060-00010; Romano A, 2007, ANN INTERN MED, V146, P266, DOI 10.7326/0003-4819-146-4-200702200-00005; Romano A, 2011, J ALLERGY CLIN IMMUN, V127, pS67, DOI 10.1016/j.jaci.2010.11.047; Romano A, 2010, J ALLERGY CLIN IMMUN, V126, P994, DOI 10.1016/j.jaci.2010.06.052; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; SAXON A, 1985, AM J MED, V78, P19, DOI 10.1016/0002-9343(85)90198-6; SAXON A, 1988, J ALLERGY CLIN IMMUN, V82, P213, DOI 10.1016/0091-6749(88)91001-9; Solensky R, 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/j.anai.2010.08.002; Torres MJ, 2002, CLIN EXP ALLERGY, V32, P270, DOI 10.1046/j.1365-2222.2002.01296.x; VEGA JM, 1991, ALLERGY, V46, P196, DOI 10.1111/j.1398-9995.1991.tb00570.x	22	54	53	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					972	976		10.1016/j.jaci.2014.10.011	http://dx.doi.org/10.1016/j.jaci.2014.10.011			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25457154				2022-12-18	WOS:000352238600019
J	Dvorak, CC; Hassan, A; Slatter, MA; Honig, M; Lankester, AC; Buckley, RH; Pulsipher, MA; Davis, JH; Gungor, T; Gabriel, M; Bleesing, JH; Bunin, N; Sedlacek, P; Connell, JA; Crawford, DF; Notarangelo, LD; Pai, SY; Hassid, J; Veys, P; Gennery, AR; Cowan, MJ				Dvorak, Christopher C.; Hassan, Amel; Slatter, Mary A.; Hoenig, Manfred; Lankester, Arjan C.; Buckley, Rebecca H.; Pulsipher, Michael A.; Davis, Jeffrey H.; Guengoer, Tayfun; Gabriel, Melissa; Bleesing, Jacob H.; Bunin, Nancy; Sedlacek, Petr; Connell, James A.; Crawford, David F.; Notarangelo, Luigi D.; Pai, Sung-Yun; Hassid, Jake; Veys, Paul; Gennery, Andrew R.; Cowan, Morton J.			Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe combined immunodeficiency; hematopoietic cell transplantation; sibling donors; unrelated donors; umbilical cord blood; conditioning; serotherapy	VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; COMBINED IMMUNE-DEFICIENCY; CORD BLOOD; B-CELLS; RECONSTITUTION; CHILDREN; ENGRAFTMENT; EXPERIENCE; CLEARANCE	Background: Patients with severe combined immunodeficiency disease who have matched sibling donors (MSDs) can proceed to hematopoietic cell transplantation (HCT) without conditioning chemotherapy. Objective: We sought to determine whether the results of HCT without chemotherapy-based conditioning from matched unrelated donors (URDs), either from volunteer adults or umbilical cord blood, are comparable with those from MSDs. Methods: We performed a multicenter survey of severe combined immunodeficiency transplantation centers in North America, Europe, and Australia to compile retrospective data on patients who have undergone unconditioned HCT from either URDs (n = 37) or MSDs (n = 66). Results: Most patients undergoing URD HCT (92%) achieved donor T-cell engraftment compared with 97% for those with MSDs; however, estimated 5-year overall and event-free survival were worse for URD recipients (71% and 60%, respectively) compared with MSD recipients (92% and 89%, respectively; P < .01 for both). URD recipients who received pre-HCT serotherapy had similar 5-year overall survival (100%) to MSD recipients. The incidences of grade II to IV acute and chronic graft-versus-host disease were higher in URD (50% and 39%, respectively) compared with MSD (22% and 5%, respectively) recipients (P < .01 for both). In the surviving patients there was no difference in T-cell reconstitution at the last follow-up between the URD and MSD recipients; however, MSD recipients were more likely to achieve B-cell reconstitution (72% vs 17%, P < .001). Conclusion: Unconditioned URD HCT achieves excellent rates of donor T-cell engraftment similar to that seen in MSD recipients, and reconstitution rates are adequate. However, only a minority will have myeloid and B-cell reconstitution, and attention must be paid to graft-versus-host disease prophylaxis. This approach might be safer in children ineligible for intense regimens to spare the potential complications of chemotherapy.	[Dvorak, Christopher C.; Hassid, Jake; Cowan, Morton J.] Univ Calif San Francisco, Benioff Childrens Hosp, Div Pediat Allergy Immunol & Blood & Marrow Trans, San Francisco, CA 94143 USA; [Hassan, Amel; Veys, Paul] UCL Inst Child Hlth, Mol Immunol Unit, Ctr Immunodeficiency, London, England; [Slatter, Mary A.; Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Hoenig, Manfred] Univ Med Ctr, Dept Pediat, Ulm, Germany; [Lankester, Arjan C.] Leiden Univ, Med Ctr, Dept Pediat, NL-2300 RA Leiden, Netherlands; [Buckley, Rebecca H.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27706 USA; [Buckley, Rebecca H.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27706 USA; [Pulsipher, Michael A.] Univ Utah, Sch Med, Div Hematol & Hematol Malignancies, Primary Childrens Hosp,Hunstman Canc Inst, Salt Lake City, UT USA; [Davis, Jeffrey H.] British Columbia Childrens Hosp, Hematol Oncol BMT Program, Vancouver, WA USA; [Guengoer, Tayfun] Univ Childrens Hosp, Stem Cell Transplantat Dept, Zurich, Switzerland; [Gabriel, Melissa] Childrens Hosp Westmead, Dept Oncol, Sydney, NSW, Australia; [Bleesing, Jacob H.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; [Bunin, Nancy] Childrens Hosp Philadelphia, Dept Pediat, Div Oncol, Philadelphia, PA 19104 USA; [Sedlacek, Petr] Teaching Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Connell, James A.] Univ Michigan, Div Pediat Hematol Oncol, Ann Arbor, MI 48109 USA; [Crawford, David F.] Univ Oklahoma, Dept Pediat, Oklahoma City, OK USA; [Notarangelo, Luigi D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Immunol, Boston, MA USA; [Notarangelo, Luigi D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Manton Ctr Orphan Dis Res, Boston, MA USA; [Pai, Sung-Yun] Dana Farber Canc Inst, Boston Childrens Hosp, Div Hematol & Oncol, Boston, MA 02115 USA; [Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	University of California System; University of California San Francisco; University of London; University College London; Newcastle University - UK; Ulm University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Duke University; Duke University; Utah System of Higher Education; University of Utah; University Children's Hospital Zurich; University of Sydney; Cincinnati Children's Hospital Medical Center; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Michigan System; University of Michigan; University of Oklahoma System; University of Oklahoma Health Sciences Center; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Dvorak, CC (corresponding author), Univ Calif San Francisco, Benioff Childrens Hosp, Div Pediat Allergy Immunol & Blood & Marrow Trans, 505 Parnassus Ave,M 659, San Francisco, CA 94143 USA.	dvorakc@peds.ucsf.edu	Pai, Sung-Yun/AAH-7762-2019; Buckley, Rebecca/AAB-1578-2019; Güngör, Tayfun/ABF-4256-2020; Dvorak, Christopher C/AAX-1630-2020; Notarangelo, Luigi D/F-9718-2016	Pai, Sung-Yun/0000-0002-0158-8147; Güngör, Tayfun/0000-0002-3261-1186; Dvorak, Christopher C/0000-0002-6146-3952; Notarangelo, Luigi D/0000-0002-8335-0262; Davis, Jeffrey/0000-0002-5959-7345	National Institute of Allergy and Infectious Diseases [1U54AI082973]; NIH Office of Rare Diseases Research, National Center for Advancing Translational Sciences; NATIONAL CANCER INSTITUTE [U24CA076518, P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R13AI094943, U54AI082973, R01AI100887] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH Office of Rare Diseases Research, National Center for Advancing Translational Sciences; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Data collection for this study was facilitated in part through the CIBMTR (U24-CA76518; principal investigator: M. M. Horowitz) and the Primary Immune Deficiency Treatment Consortium (PIDTC) Annual Scientific Workshop (R13 AI094943). The PIDTC is a part of the National Institutes of Health Rare Diseases Clinical Research Network with the DMCC at the University of South Florida. Funding and/or programmatic support for this project has been provided by grant no. 1U54AI082973 from the National Institute of Allergy and Infectious Diseases and the NIH Office of Rare Diseases Research, National Center for Advancing Translational Sciences. The views expressed are those of the authors and do not represent the position of the NIAID, ORDR/NCATS, NIH, or the US Government.	Bacigalupo A, 2005, BONE MARROW TRANSPL, V35, P225, DOI 10.1038/sj.bmt.1704758; Baran-Marszak F, 2004, BLOOD, V104, P2475, DOI 10.1182/blood-2003-10-3508; Bhattacharya A, 2005, BONE MARROW TRANSPL, V36, P295, DOI 10.1038/sj.bmt.1705054; Buckley RH, 2013, J CLIN IMMUNOL, V33, P96, DOI 10.1007/s10875-012-9797-6; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Cavazzana-Calvo M, 2007, BLOOD, V109, P4575, DOI 10.1182/blood-2006-07-029090; Chiesa R, 2012, BRIT J HAEMATOL, V156, P656, DOI 10.1111/j.1365-2141.2011.08994.x; Czechowicz A, 2007, SCIENCE, V318, P1296, DOI 10.1126/science.1149726; Dvorak C, 2008, BONE MARROW TRANSPL, V41, P119, DOI 10.1038/sj.bmt.1705890; Dvorak CC, 2008, BIOL BLOOD MARROW TR, V14, P1125, DOI 10.1016/j.bbmt.2008.07.008; Dvorak CC, 2008, J PEDIAT HEMATOL ONC, V30, P396, DOI 10.1097/MPH.0b013e318168e7a0; Dvorak CC, 2013, J CLIN IMMUNOL, V33, P1156, DOI 10.1007/s10875-013-9917-y; Fernandes JF, 2012, BLOOD, V119, P2949, DOI 10.1182/blood-2011-06-363572; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Griffith LM, 2009, J ALLERGY CLIN IMMUN, V124, P1152, DOI 10.1016/j.jaci.2009.10.022; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Haddad E, 1998, BLOOD, V91, P3646; Haddad E, 2013, J ALLERGY CLIN IMMUN, V131, P994, DOI 10.1016/j.jaci.2013.01.047; Hassan A, 2012, BLOOD, V120, P3615, DOI 10.1182/blood-2011-12-396879; Heimall J, 2012, J CLIN IMMUNOL, V32, P1141, DOI 10.1007/s10875-012-9741-9; Janda A, 2010, BLOOD, V116, P2229, DOI 10.1182/blood-2010-03-275966; Kim VHD, 2013, J ALLERGY CLIN IMMUN, V131, P1233, DOI 10.1016/j.jaci.2012.09.020; Kottaridis PD, 2000, BLOOD, V96, P2419; Kwan A, 2013, J ALLERGY CLIN IMMUN, V132, P140, DOI 10.1016/j.jaci.2013.04.024; Larsson K, 2004, TRANSPLANTATION, V77, P526, DOI 10.1097/01.TP.0000109778.39235.F4; MEUWISSEN HJ, 1969, NEW ENGL J MED, V281, P691, DOI 10.1056/NEJM196909252811302; MURPHY WJ, 1987, J EXP MED, V165, P1212, DOI 10.1084/jem.165.4.1212; O'Marcaigh AS, 2001, BONE MARROW TRANSPL, V27, P703, DOI 10.1038/sj.bmt.1702831; Pichereau C, 2012, BIOL BLOOD MARROW TR, V18, P141, DOI 10.1016/j.bbmt.2011.07.018; Sarzotti-Kelsoe M, 2009, BLOOD, V114, P1445, DOI 10.1182/blood-2009-01-199323; Savic RM, 2013, BIOL BLOOD MARROW TR, V19, P1608, DOI 10.1016/j.bbmt.2013.08.014; SCHULTZ KR, 1995, BONE MARROW TRANSPL, V16, P289; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044; Slatter MA, 2008, J ALLERGY CLIN IMMUN, V121, P361, DOI 10.1016/j.jaci.2007.10.035; Straathof KC, 2009, LANCET, V374, P912, DOI 10.1016/S0140-6736(09)60945-4; Taga T, 2011, PEDIATR TRANSPLANT, V15, pE152, DOI 10.1111/j.1399-3046.2010.01344.x; Xiao Z, 2009, BIOL BLOOD MARROW TR, V15, P1, DOI 10.1016/j.bbmt.2008.10.026	37	54	55	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					935	U263		10.1016/j.jaci.2014.06.021	http://dx.doi.org/10.1016/j.jaci.2014.06.021			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25109802	Green Accepted			2022-12-18	WOS:000343155700023
J	Mulligan, JK; Nagel, W; O'Connell, BP; Wentzel, J; Atkinson, C; Schlosser, RJ				Mulligan, Jennifer K.; Nagel, Whitney; O'Connell, Brendan P.; Wentzel, Jennifer; Atkinson, Carl; Schlosser, Rodney J.			Cigarette smoke exposure is associated with vitamin D3 deficiencies in patients with chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D; secondhand smoke; sinusitis; epithelial cell	PRO-INFLAMMATORY CYTOKINE; DENDRITIC CELLS; EPITHELIAL-CELLS; 2ND-HAND SMOKE; LIQUID-CHROMATOGRAPHY; 25-HYDROXYVITAMIN D; CHILDHOOD ASTHMA; NASAL POLYPS; SINUS MUCOSA; ACTIVE FORM	Background: Cigarette smoke (CS) plays a role in the exacerbation of chronic rhinosinusitis (CRS); however, the mechanism for this is unknown. We hypothesize that CS impairs human sinonasal epithelial cell (HSNEC) conversion of 25(OH) D3 (25VD3) to 1,25-dihydroxyvitamin D3 (1,25VD3) and, furthermore, that supplementation with 1,25VD3 will reverse smoke-induced inflammatory responses by HSNECs. Objective: We sought to determine the effect of CS on vitamin D3 (VD3) levels, conversion, and regulation of CS-induced inflammation in control subjects and patients with CRS. Methods: Blood and sinus tissue explants were collected at the time of surgery from control subjects, patients with chronic rhinosinusitis without nasal polyps, and patients with chronic sinusitis with nasal polyps (CRSwNP). Expression of VD3 metabolizing enzymes were measured by using RT-PCR. Primary HSNECs were cultured from tissue explants. 25VD3 with and without cigarette smoke extract (CSE) was used to examine conversion of 25VD3 to 1,25VD3, as well as HSNEC production of proinflammatory cytokines. Results: CS exposure was associated with reduced circulating and sinonasal 25VD3 levels in all groups compared with those seen in CS-naive, disease-matched counterparts. CS exposure decreased expression of CYP27B1 and was especially pronounced in patients with CRSwNP. CSE impairs control HSNEC conversion of 25VD3. HSNECs from patients with CRSwNP also demonstrate an intrinsic reduction in conversion of 25VD3 to 1,25VD3. Exogenous 1,25VD3 reduces CSE-induced cytokine production by HSNECs. Conclusions: Exposure to CS is associated with reduced 25VD3 levels and an impaired ability of HSNECs to convert 25VD3 to 1,25VD3. Addition of 1,25VD3 reduces the proinflammatory effects of CS on HSNECs. Impaired VD3 conversion by CS exposure represents a novel mechanism through which CS induces its proinflammatory effects.	[Mulligan, Jennifer K.; Nagel, Whitney; O'Connell, Brendan P.; Wentzel, Jennifer; Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC USA; [Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, Charleston, SC USA; [Atkinson, Carl] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC USA; [Mulligan, Jennifer K.; Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Mulligan, JK (corresponding author), 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA.	konopa@musc.edu		Mulligan, Jennifer/0000-0001-6880-6092	Flight Attendant Medical Research Institute [092401, 113039]; National Institutes of Health [R01HL091944]; Department of Veterans Affairs; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091944] Funding Source: NIH RePORTER	Flight Attendant Medical Research Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants from the Flight Attendant Medical Research Institute (092401 to J.K.M. and 113039 to R.J.S.), the National Institutes of Health (R01HL091944 to C. A.), and a grant from the Department of Veterans Affairs.	Adorini L, 2004, SEMIN IMMUNOL, V16, P127, DOI 10.1016/j.smim.2003.12.008; Afzal S, 2013, CLIN CHEM, V59, P771, DOI 10.1373/clinchem.2012.201939; Agrawal T, 2012, EXP MOL PATHOL, V93, P74, DOI 10.1016/j.yexmp.2012.04.004; Ahmed W, 2009, TRANSL RES, V153, P11, DOI 10.1016/j.trsl.2008.11.002; Ayers CM, 2011, INT FORUM ALLERGY RH, V1, P296, DOI 10.1002/alr.20046; Besaratinia A, 2008, LANCET ONCOL, V9, P657, DOI 10.1016/S1470-2045(08)70172-4; Binkley N, 2012, ENDOCRIN METAB CLIN, V39, P287; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Brot C, 1999, EUR J CLIN NUTR, V53, P920, DOI 10.1038/sj.ejcn.1600870; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Carney AS, 2006, AM J RHINOL, V20, P145, DOI 10.1177/194589240602000204; Chetiyanukornkul T, 2004, BIOMED CHROMATOGR, V18, P655, DOI 10.1002/bmc.369; Chirayath MV, 1998, AM J PHYSIOL-GASTR L, V274, pG389, DOI 10.1152/ajpgi.1998.274.2.G389; COX G, 1992, AM J RESP CELL MOL, V7, P507, DOI 10.1165/ajrcmb/7.5.507; Davis KS, 2010, OTOLARYNG HEAD NECK, V143, P152, DOI 10.1016/j.otohns.2010.02.022; Damia AD, 2011, ARCH BRONCONEUMOL, V47, P447, DOI 10.1016/j.arbres.2011.04.007; Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Ginde AA, 2009, ARCH INTERN MED, V169, P384, DOI 10.1001/archinternmed.2008.560; Hackstein H, 2004, NAT REV IMMUNOL, V4, P24, DOI 10.1038/nri1256; Hansdottir S, 2008, J IMMUNOL, V181, P7090, DOI 10.4049/jimmunol.181.10.7090; Hastan D, 2011, ALLERGY, V66, P1216, DOI 10.1111/j.1398-9995.2011.02646.x; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Heaney RP, 2008, CLIN J AM SOC NEPHRO, V3, P1535, DOI 10.2215/CJN.01160308; Hewison M, 2012, P NUTR SOC, V71, P50, DOI 10.1017/S0029665111001650; Higgins TS, 2012, CURR OPIN OTOLARYNGO, V20, P209, DOI 10.1097/MOO.0b013e3283534821; Hudy MH, 2010, EUR RESPIR J, V35, P1256, DOI 10.1183/09031936.00128809; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; Kim YM, 2010, CLIN IMMUNOL, V137, P111, DOI 10.1016/j.clim.2010.05.013; Lange NE, 2012, AM J RESP CRIT CARE, V186, P616, DOI 10.1164/rccm.201110-1868OC; LESMES GR, 1992, AM J MED, V93, pS38, DOI 10.1016/0002-9343(92)90626-M; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; LUND VJ, 1995, ANN OTO RHINOL LARYN, V104, P17, DOI 10.1177/000348949510410s02; Mahoney GN, 2001, J CHROMATOGR B, V753, P179, DOI 10.1016/S0378-4347(00)00540-5; Martin-Pujol A, 2013, ACTA PAEDIATR, V102, pe305, DOI 10.1111/apa.12232; McNally P, 2011, J CYST FIBROS, V10, P428, DOI 10.1016/j.jcf.2011.06.013; Mulligan JK, 2011, CLIN EXP IMMUNOL, V164, P312, DOI 10.1111/j.1365-2249.2011.04325.x; Mulligan JK, 2012, OTOLARYNG HEAD NECK, V147, P773, DOI 10.1177/0194599812448852; Mulligan JK, 2011, INT FORUM ALLERGY RH, V1, P268, DOI 10.1002/alr.20055; Mulligan RM, 2009, AM J RHINOL ALLERGY, V23, pE1, DOI 10.2500/ajra.2009.23.3400; Penna G, 2007, J IMMUNOL, V178, P145, DOI 10.4049/jimmunol.178.1.145; Percival Jennifer, 2005, Nurs Times, V101, P50; Psaltis AJ, 2013, INT FORUM ALLERGY RH, V3, P621, DOI 10.1002/alr.21173; Reh DD, 2009, AM J RHINOL ALLERGY, V23, P562, DOI 10.2500/ajra.2009.23.3377; Schlosser RJ, 2010, AM J RHINOL ALLERGY, V24, P21, DOI 10.2500/ajra.2010.24.3399; Schrumpf JA, 2012, INFECT IMMUN, V80, P4485, DOI 10.1128/IAI.06224-11; Sundar IK, 2011, BIOCHEM BIOPH RES CO, V406, P127, DOI 10.1016/j.bbrc.2011.02.011; Takeda M, 2010, ARTERIOSCL THROM VAS, V30, P2495, DOI 10.1161/ATVBAHA.110.215459; Treyster Zoya, 2011, Reviews on Environmental Health, V26, P187, DOI 10.1515/REVEH.2011.026; Uh ST, 2012, TUBERC RESPIR DIS, V73, P258, DOI 10.4046/trd.2012.73.5.258; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Weiss ST, 2008, CLIN EXP ALLERGY, V38, P385, DOI 10.1111/j.1365-2222.2007.02920.x; Xue ML, 2002, IMMUNOL CELL BIOL, V80, P340, DOI 10.1046/j.1440-1711.80.4august.1.x; Yamin M, 2008, J ALLERGY CLIN IMMUN, V122, P1145, DOI 10.1016/j.jaci.2008.09.033	54	54	56	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					342	+		10.1016/j.jaci.2014.01.039	http://dx.doi.org/10.1016/j.jaci.2014.01.039			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24698317	Bronze			2022-12-18	WOS:000341370800013
J	Sinha, A; Yadav, AK; Chakraborty, S; Kabra, SK; Lodha, R; Kumar, M; Kulshreshtha, A; Sethi, T; Pandey, R; Malik, G; Laddha, S; Mukhopadhyay, A; Dash, D; Ghosh, B; Agrawal, A				Sinha, Anirban; Yadav, Amit Kumar; Chakraborty, Samarpana; Kabra, S. K.; Lodha, R.; Kumar, Manish; Kulshreshtha, Ankur; Sethi, Tavpritesh; Pandey, Rajesh; Malik, Gaurav; Laddha, Saurabh; Mukhopadhyay, Arijit; Dash, Debasis; Ghosh, Balaram; Agrawal, Anurag			Exosome-enclosed microRNAs in exhaled breath hold potential for biomarker discovery in patients with pulmonary diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CONDENSATE; ASTHMA		[Sinha, Anirban; Yadav, Amit Kumar; Chakraborty, Samarpana; Kumar, Manish; Kulshreshtha, Ankur; Sethi, Tavpritesh; Pandey, Rajesh; Malik, Gaurav; Laddha, Saurabh; Mukhopadhyay, Arijit; Dash, Debasis; Ghosh, Balaram; Agrawal, Anurag] CSIR Inst Genom & Integrat Biol, New Delhi 110001, India; [Kabra, S. K.; Lodha, R.] All India Inst Med Sci, New Delhi, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); All India Institute of Medical Sciences (AIIMS) New Delhi	Sinha, A (corresponding author), CSIR Inst Genom & Integrat Biol, New Delhi 110001, India.	a.agrawal@igib.res.in	Kumar, Manish/AAC-2278-2019; Sinha, Anirban/ABA-8612-2021; Laddha, Saurabh V./X-8274-2019; Agrawal, Anurag/GZL-5821-2022; Yadav, Amit Kumar/AAR-3803-2021; KULSHRESHTHA, ANKUR/AFP-2527-2022; Dash, Debasis/F-3137-2012	Kumar, Manish/0000-0002-0855-3406; Sinha, Anirban/0000-0002-4146-9687; Yadav, Amit Kumar/0000-0002-9445-8156; KULSHRESHTHA, ANKUR/0000-0001-5139-6744; Dash, Debasis/0000-0002-5647-3785; Sethi, Tavpritesh/0000-0002-4776-7941; Agrawal, Anurag/0000-0002-0340-5252				Bloemen K, 2011, CLIN EXP ALLERGY, V41, P346, DOI 10.1111/j.1365-2222.2010.03638.x; Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76; Garbacki N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016509; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Izzotti A, 2011, MUTAT RES-FUND MOL M, V717, P9, DOI 10.1016/j.mrfmmm.2010.12.008; Jung M, 2010, CLIN CHEM, V56, P998, DOI 10.1373/clinchem.2009.141580; Keller S, 2006, IMMUNOL LETT, V107, P102, DOI 10.1016/j.imlet.2006.09.005; Sinha A, 2012, EUR RESPIR J, V39, P500, DOI 10.1183/09031936.00047711; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596	9	54	60	2	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					219	222		10.1016/j.jaci.2013.03.035	http://dx.doi.org/10.1016/j.jaci.2013.03.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23683467				2022-12-18	WOS:000321052300029
J	Berin, MC; Mayer, L				Berin, M. Cecilia; Mayer, Lloyd			Can we produce true tolerance in patients with food allergy?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oral tolerance; food allergy; mucosal immunology; immunotherapy; regulatory T	REGULATORY T-CELLS; CD103(+) DENDRITIC CELLS; MYELIN BASIC-PROTEIN; EGG ORAL IMMUNOTHERAPY; GROWTH-FACTOR-BETA; PRU P 3; IMMUNE-RESPONSES; PEANUT ALLERGY; LYMPH-NODES; CLINICAL TOLERANCE	Immune tolerance is defined as nonresponsiveness of the adaptive immune system to antigens. Immune mechanisms preventing inappropriate immune reactivity to innocuous antigens include deletion of reactive lymphocytes and generation of regulatory T (Treg) cells. The normal response to food antigens is the generation of antigen-specific Treg cells. In patients with food allergy, the dominant immune response is a T(H)2-skewed T-cell response and the generation of food-specific IgE antibodies from B cells. It is not known whether a failure of the Treg cell response is behind this inappropriate immune response, but interventions that boost the Treg cell response, such as mucosal immunotherapy, might lead to a restoration of immune tolerance to foods. Tolerance has been notoriously difficult to restore in animal disease models, but limited data from human trials suggest that tolerance (sustained nonresponsiveness) can be re-established in a subset of patients. Furthermore, studies on the natural history of food allergy indicate that spontaneous development of tolerance to foods over time is not uncommon. The current challenge is to understand the mechanisms responsible for restoration of natural or induced tolerance so that interventions can be developed to more successfully induce tolerance in the majority of patients with food allergy. (J Allergy Clin Immunol 2013;131:14-22.)	[Berin, M. Cecilia] Mt Sinai Sch Med, Jaffe Food Allergy Inst, New York, NY 10029 USA; [Berin, M. Cecilia; Mayer, Lloyd] Mt Sinai Sch Med, Inst Immunol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Berin, MC (corresponding author), Mt Sinai Sch Med, Jaffe Food Allergy Inst, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	cecilia.berin@mssm.edu; lloyd.mayer@mssm.edu		berin, cecilia/0000-0002-9051-9249	National Institute of Allergy and Infectious Diseases grant [AI044236]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI093577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK072201] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by National Institute of Allergy and Infectious Diseases grant AI044236.	Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Alpan O, 2004, NAT IMMUNOL, V5, P615, DOI 10.1038/ni1077; Alvarez D, 2006, J IMMUNOL, V176, P2568, DOI 10.4049/jimmunol.176.4.2568; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Arnaboldi PM, 2009, MUCOSAL IMMUNOL, V2, P427, DOI 10.1038/mi.2009.93; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; Blazquez AB, 2008, J IMMUNOL, V180, P4441, DOI 10.4049/jimmunol.180.7.4441; Bogunovic M, 2009, IMMUNITY, V31, P513, DOI 10.1016/j.immuni.2009.08.010; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Carrier Y, 2007, J IMMUNOL, V178, P179, DOI 10.4049/jimmunol.178.1.179; Cassani B, 2011, GASTROENTEROLOGY, V141, P2109, DOI 10.1053/j.gastro.2011.09.015; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHEN YH, 1995, J IMMUNOL, V155, P910; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; de Aguero MG, 2012, J CLIN INVEST, V122, P1700, DOI 10.1172/JCI59725; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; DeLong JH, 2011, J ALLERGY CLIN IMMUN, V127, P1211, DOI 10.1016/j.jaci.2011.02.028; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Dubois B, 2009, GASTROENTEROLOGY, V137, P1019, DOI 10.1053/j.gastro.2009.03.055; Edwards HE, 1940, CAN MED ASSOC J, V43, P234; Eigenmann PA, 1996, PEDIATR ALLERGY IMMU, V7, P12, DOI 10.1111/j.1399-3038.1996.tb00100.x; Fleischer DM, 2005, J ALLERGY CLIN IMMUN, V116, P1087, DOI 10.1016/j.jaci.2005.09.002; Flinterman AE, 2010, CLIN EXP ALLERGY, V40, P590, DOI 10.1111/j.1365-2222.2009.03431.x; Frossard CP, 2004, J ALLERGY CLIN IMMUN, V113, P958, DOI 10.1016/j.jaci.2003.12.017; Fukaura H, 1996, J CLIN INVEST, V98, P70, DOI 10.1172/JCI118779; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Ganeshan K, 2012, J IMMUNOL, V188, P594, DOI 10.4049/jimmunol.1102389; Gilbert RS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027501; Golden DBK, 2010, CURR OPIN ALLERGY CL, V10, P337, DOI 10.1097/ACI.0b013e32833bc0ba; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; Goubier A, 2008, IMMUNITY, V29, P464, DOI 10.1016/j.immuni.2008.06.017; Guilliams M, 2010, BLOOD, V115, P1958, DOI 10.1182/blood-2009-09-245274; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Hammerschmidt SI, 2008, J EXP MED, V205, P2483, DOI 10.1084/jem.20080039; Jaensson E, 2008, J EXP MED, V205, P2139, DOI 10.1084/jem.20080414; Johansson-Lindbom B, 2005, J EXP MED, V202, P1063, DOI 10.1084/jem.20051100; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; KAGNOFF MF, 1978, J IMMUNOL, V120, P1509; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kashyap M, 2008, J IMMUNOL, V180, P2039, DOI 10.4049/jimmunol.180.4.2039; Kawakita A, 2012, ALLERGY, V67, P371, DOI 10.1111/j.1398-9995.2011.02777.x; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Kraus TA, 2006, INFLAMM BOWEL DIS, V12, P82, DOI 10.1097/01.MIB.0000200343.61707.52; Kraus TA, 2005, J CLIN INVEST, V115, P2234, DOI 10.1172/JCI19102; Kraus TA, 2004, GASTROENTEROLOGY, V126, P1771, DOI 10.1053/j.gastro.2004.03.076; Kriegel MA, 2009, P NATL ACAD SCI USA, V106, P16770, DOI 10.1073/pnas.0908957106; Kulis M, 2012, J ALLERGY CLIN IMMUN, V130, P716, DOI 10.1016/j.jaci.2012.05.044; Kulis M, 2011, J ALLERGY CLIN IMMUN, V127, P81, DOI 10.1016/j.jaci.2010.09.014; Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021; Lee SW, 2012, J IMMUNOL, V189, P2697, DOI 10.4049/jimmunol.1201248; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V129, P1579, DOI 10.1016/j.jaci.2012.04.009; Li W, 2012, ALLERGY, V67, P622, DOI 10.1111/j.1398-9995.2012.02798.x; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; LIDER O, 1989, J IMMUNOL, V142, P748; Mascarell L, 2011, MUCOSAL IMMUNOL, V4, P638, DOI 10.1038/mi.2011.28; Mascarell L, 2008, J ALLERGY CLIN IMMUN, V122, P603, DOI 10.1016/j.jaci.2008.06.034; Matteoli G, 2010, GUT, V59, P595, DOI 10.1136/gut.2009.185108; MATTINGLY JA, 1978, J IMMUNOL, V121, P1878; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; McDole JR, 2012, NATURE, V483, P345, DOI 10.1038/nature10863; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; Miller JC, 2012, NAT IMMUNOL, V13, P888, DOI 10.1038/ni.2370; Miller SD, 2007, NAT REV IMMUNOL, V7, P665, DOI 10.1038/nri2153; Mondoulet L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031967; Mondoulet L, 2011, INT ARCH ALLERGY IMM, V154, P299, DOI 10.1159/000321822; Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; NGAN J, 1978, J IMMUNOL, V120, P861; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; Nurmatov U, 2012, COCHRANE DB SYST REV, V9; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Patriarca G, 2003, ALIMENT PHARM THER, V17, P459, DOI 10.1046/j.1365-2036.2003.01468.x; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Round JL, 2011, SCIENCE, V332, P974, DOI 10.1126/science.1206095; Russo M, 2001, AM J RESP CELL MOL, V24, P518, DOI 10.1165/ajrcmb.24.5.4320; Schulke S, 2011, J ALLERGY CLIN IMMUN, V128, P1340, DOI 10.1016/j.jaci.2011.07.036; Schulten V, 2009, J ALLERGY CLIN IMMUN, V124, P100, DOI 10.1016/j.jaci.2009.02.010; Schulz O, 2009, J EXP MED, V206, P3101, DOI 10.1084/jem.20091925; Sheikh A, 2012, PRIM CARE RESP J, V21, P41, DOI 10.4104/pcrj.2011.00071; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Sletten GBG, 2007, INT ARCH ALLERGY IMM, V142, P190, DOI 10.1159/000097021; Smarr CB, 2011, J IMMUNOL, V187, P5090, DOI 10.4049/jimmunol.1100608; Spahn TW, 2002, EUR J IMMUNOL, V32, P1109, DOI 10.1002/1521-4141(200204)32:4<1109::AID-IMMU1109>3.3.CO;2-B; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Staden U, 2008, J ALLERGY CLIN IMMUN, V122, P418, DOI 10.1016/j.jaci.2008.06.002; Tordesillas L, 2009, MOL IMMUNOL, V46, P722, DOI 10.1016/j.molimm.2008.10.018; Tunis MC, 2012, J ALLERGY CLIN IMMUN, V130, P705, DOI 10.1016/j.jaci.2012.04.011; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; van Wijk F, 2005, J IMMUNOL, V174, P174, DOI 10.4049/jimmunol.174.1.174; Varshney P, 2009, J ALLERGY CLIN IMMUN, V123, pS174, DOI 10.1016/j.jaci.2008.12.656; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; Vickery BP, 2010, ANN ALLERG ASTHMA IM, V105, P444, DOI 10.1016/j.anai.2010.09.030; Wells HG, 1911, J INFECT DIS, V8, P66, DOI 10.1093/infdis/8.1.66; Wells HG, 1911, J INFECT DIS, V9, P24; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016; Zhou YF, 2010, NAT MED, V16, P1128, DOI 10.1038/nm.2201	109	54	59	2	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					14	22		10.1016/j.jaci.2012.10.058	http://dx.doi.org/10.1016/j.jaci.2012.10.058			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23265693	Green Accepted			2022-12-18	WOS:000312961200002
J	Vredegoor, DW; Willemse, T; Chapman, MD; Heederik, DJJ; Krop, EJM				Vredegoor, Doris W.; Willemse, Ton; Chapman, Martin D.; Heederik, Dick J. J.; Krop, Esmeralda J. M.			Can f 1 levels in hair and homes of different dog breeds: Lack of evidence to describe any dog breed as hypoallergenic	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Can f 1; dog allergen; dog breeds; environmental exposure; hair; hypoallergenic dogs	CROSSED RADIO-IMMUNOELECTROPHORESIS; ALLERGEN LEVELS; ENDOTOXIN EXPOSURE; SENSITIZATION; CAN-F-1; CAT; IDENTIFICATION; REACTIVITY; COLLECTOR; DANDRUFF	Background: Certain dog breeds are described and marketed as being "hypoallergenic" on the basis of anecdotal reports that these dogs are better tolerated by patients allergic to dogs. Objective: These observations were investigated by comparing Can f 1 (major dog [Canis familiaris] allergen) levels in hair and coat samples and in the home environment of various hypoallergenic (Labradoodle, Poodle, Spanish Waterdog, and Airedale terrier) and non-hypoallergenic dogs (Labrador retriever and a control group). Methods: Hair and coat samples were obtained from dogs, and settled floor and airborne dust samples were taken from the dogs' homes. Can f 1 concentrations were measured by using ELISA, and results were analyzed by using multiple linear regression analyses. Results: Significantly higher Can f 1 concentrations were found in hair and coat samples of hypoallergenic dogs (n = 196, geometric mean [GM], 2.26 mu g/g, geometric standard deviation [GSD], 0.73, and GM, 27.04 mu g/g, GSD, 0.57, respectively) than of non-hypoallergenic dogs (n 5 160, GM, 0.77 mu g/g, GSD, 0.71, and GM, 12.98 mu g/g, GSD, 0.76, respectively). Differences between breeds were small, relative to the variability within a breed. Can f 1 levels in settled floor dust samples were lower for Labradoodles, but no differences were found between the other groups. No differences in airborne levels were found between breeds. Conclusion: So-called hypoallergenic dogs had higher Can f 1 levels in hair and coat samples than did control breeds. These differences did not lead to higher levels of environmental exposure to dog allergens. There is no evidence for the classification of certain dog breeds as being "hypoallergenic." (J Allergy Clin Immunol 2012; 130:904-9.)	[Vredegoor, Doris W.; Heederik, Dick J. J.; Krop, Esmeralda J. M.] Univ Utrecht, Div Environm Epidemiol, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; [Willemse, Ton] Univ Utrecht, Dept Clin Sci Compan Anim, Fac Vet Med, NL-3508 TD Utrecht, Netherlands; [Chapman, Martin D.] Indoor Biotechnol Inc, Charlottesville, VA USA	Utrecht University; Utrecht University; INDOOR Biotechnologies	Krop, EJM (corresponding author), Univ Utrecht, Div Environm Epidemiol, Inst Risk Assessment Sci, POB 80178, NL-3508 TD Utrecht, Netherlands.	e.j.m.krop@uu.nl		Krop, Esmeralda/0000-0002-6009-1181; Heederik, Dick/0000-0002-4550-1437; Chapman, Martin/0000-0002-0845-3632	Faculty of Veterinary Medicine of Utrecht University; National Institute for Environmental Health Sciences; National Institute for Allergy and Infectious Diseases	Faculty of Veterinary Medicine of Utrecht University; National Institute for Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute for Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by a grant from the Honours Program of the Faculty of Veterinary Medicine of Utrecht University, a research program for students. Indoor Biotechnologies, Inc, Charlottesville, Va, provided the Can f 1 kit used in this study.; M.D. Chapman has an ownership position with Indoor Biotechnologies, Inc, and Indoor Biotechnologies, Ltd; has received research support from the National Institute for Environmental Health Sciences and the National Institute for Allergy and Infectious Diseases; and is on the Virginia Biotechnology Association board of directors. E.J.M. Krop acknowledges that Indoor Biotechnologies provided the kit for this study. The rest of the authors declare that they have no relevant conflicts of interest.	BLANDS J, 1977, ACTA ALLERGOL, V32, P147, DOI 10.1111/j.1398-9995.1977.tb01346.x; BOUTIN Y, 1988, CLIN ALLERGY, V18, P287, DOI 10.1111/j.1365-2222.1988.tb02871.x; Custovic A, 2003, J ALLERGY CLIN IMMUN, V111, P402, DOI 10.1067/mai.2003.55; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; Filep S, 2012, ALLERGY, V67, P235, DOI 10.1111/j.1398-9995.2011.02750.x; Filep S, 2012, J ALLERGY CLIN IMMUN, V129, P1408, DOI 10.1016/j.jaci.2011.12.978; FORD AW, 1989, CLIN EXP ALLERGY, V19, P183, DOI 10.1111/j.1365-2222.1989.tb02362.x; Heutelbeck ARR, 2008, J TOXICOL ENV HEAL A, V71, P751, DOI 10.1080/15287390801985513; Hodson T, 1999, J ALLERGY CLIN IMMUN, V103, P581, DOI 10.1016/S0091-6749(99)70227-7; Hooker S. B., 1944, ANN ALLERGY, V2, P281; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Kamata Y, 2007, INT ARCH ALLERGY IMM, V142, P291, DOI 10.1159/000097498; Langley SJ, 2003, J ALLERGY CLIN IMMUN, V112, P362, DOI 10.1067/mai.2003.1654; LINDGREN S, 1988, J ALLERGY CLIN IMMUN, V82, P196, DOI 10.1016/0091-6749(88)90999-2; Mattsson L, 2009, J ALLERGY CLIN IMMUN, V123, P362, DOI 10.1016/j.jaci.2008.11.021; Nicholas C, 2010, ANN ALLERG ASTHMA IM, V105, P228, DOI 10.1016/j.anai.2010.06.019; Nicholas CE, 2011, AM J RHINOL ALLERGY, V25, P252, DOI 10.2500/ajra.2011.25.3606; Noss I, 2008, APPL ENVIRON MICROB, V74, P5621, DOI 10.1128/AEM.00619-08; Noss I, 2010, ANN OCCUP HYG, V54, P651, DOI 10.1093/annhyg/meq026; Ramadour M, 2005, ALLERGY, V60, P1060, DOI 10.1111/j.1398-9995.2005.00824.x; Samadi S, 2010, OCCUP ENVIRON MED, V67, P486, DOI 10.1136/oem.2009.051342; SCHOU C, 1991, CLIN EXP ALLERGY, V21, P321, DOI 10.1111/j.1365-2222.1991.tb01663.x; Schram-Bijkerk D, 2006, INDOOR AIR, V16, P414, DOI 10.1111/j.1600-0668.2006.00435.x; Wilson J, 2010, ENVIRON RES, V110, P189, DOI 10.1016/j.envres.2009.10.007	24	54	55	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					904	+		10.1016/j.jaci.2012.05.013	http://dx.doi.org/10.1016/j.jaci.2012.05.013			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22728082	Green Submitted			2022-12-18	WOS:000309594800010
J	Baroody, FM; Brown, D; Gavanescu, L; DeTineo, M; Naclerio, RM				Baroody, Fuad M.; Brown, David; Gavanescu, Laura; DeTineo, Marcy; Naclerio, Robert M.			Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; perennial; fluticasone furoate; oxymetazoline; clinical trial; rhinitis medicamentosa	NASAL SPRAY; MOMETASONE FUROATE; BENZALKONIUM CHLORIDE; MEDICAMENTOSA; PLACEBO; PROPIONATE; HYDROCHLORIDE; DRUG	Background: In clinical trials, only about 60% of subjects report an excellent response to intranasal steroids, suggesting a need to add therapies to intranasal steroids to provide additional efficacy. Objective: To determine whether the combination of fluticasone furoate and oxymetazoline is more efficacious than either agent alone, and to determine whether rhinitis medicamentosa develops after treatment. Methods: We performed a double-blind, double-dummy, randomized, placebo-controlled parallel study. Sixty patients with perennial allergy were randomized to 4 weeks of once-a-night treatment with fluticasone furoate, oxymetazoline hydrochloride, the combination, or placebo. They were monitored during treatment and for 2 weeks posttreatment. Results: The total nasal symptom score over the 4 weeks of treatment was lower with the combination (median, 143; range, 30-316) compared with treatment with placebo (262; 116-358) and oxymetazoline alone (219; 78-385; ANOVA, P = .04). When acoustic rhinometry was compared between the groups at the end of 4 weeks of treatment, the combination resulted in significantly higher nasal volume (mean + SEM, 15.8 + 1.1 mL; P < .03) compared with both placebo (12.1 + 0.9 mL) and oxymetazoline (12.4 + 0.8 mL) alone. The quality of life data showed no significant differences among the groups. Peak flow showed a nonsignificant improvement with the groups on fluticasone furoate. There was no evidence of rhinitis medicamentosa. Conclusion: The addition of oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. The lack of development of rhinitis medicamentosa suggests the need for a large multicenter study to develop a once-a-day combination of an intranasal steroid and a long-acting topical decongestant. (J Allergy Clin Immunol 2011;127:927-34.)	[Naclerio, Robert M.] Univ Chicago, Med Ctr, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center; University of Chicago	Naclerio, RM (corresponding author), Univ Chicago, Med Ctr, Sect Otolaryngol Head & Neck Surg, 5841 S Maryland Ave,MC 1035, Chicago, IL 60637 USA.	rnacleri@surgery.bsd.uchicago.edu			McHugh Otolaryngology Research Fund; GlaxoSmithKline; Merck; McNeil	McHugh Otolaryngology Research Fund; GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); McNeil	Supported in part by the McHugh Otolaryngology Research Fund and an Investigator Initiated Grant from GlaxoSmithKline.; Disclosure of potential conflict of interest: F. M. Baroody is a speaker for Merck and has received research support from GlaxoSmithKline. R. M. Naclerio is a speaker for GlaxoSmithKline, Merck, and Sepracor; is a consultant for Boehringer Ingelheim; has received research support from GlaxoSmithKline, Merck, and McNeil; and is a member of the American Academy of Otolaryngology-Head and Neck Surgery and the American Academy of Allergy, Asthma & Immunology.	Beck-Speier I, 2006, J PHARMACOL EXP THER, V316, P843, DOI 10.1124/jpet.105.093278; Beck-Speier I, 2009, J PHARMACOL SCI, V110, P276, DOI 10.1254/jphs.09012FP; Bickford L, 1999, BRIT J CLIN PHARMACO, V48, P53, DOI 10.1046/j.1365-2125.1999.00972.x; Bousquet J, 2010, ALLERGY, V65, P1212, DOI [10.1111/j.1398-9995.2010.02439.x, 10.1111/j.1398-9995.2010.02480.x]; Corboz MR, 2008, PULM PHARMACOL THER, V21, P449, DOI 10.1016/j.pupt.2007.06.007; Elwany S, 2001, EUR ARCH OTO-RHINO-L, V258, P116, DOI 10.1007/s004050000309; Ferguson BJ, 2001, OTOLARYNG HEAD NECK, V125, P253, DOI 10.1067/mhn.2001.117717; Graf P, 2000, CLIN THER, V22, P894; GRAF P, 1995, CLIN EXP ALLERGY, V25, P395, DOI 10.1111/j.1365-2222.1995.tb01069.x; Graf P, 1997, ORL J OTO-RHINO-LARY, V59, P39, DOI 10.1159/000276903; Graf P, 1999, ARCH OTOLARYNGOL, V125, P1128, DOI 10.1001/archotol.125.10.1128; Graf Peter, 1996, Rhinology (Utrecht), V34, P9; Graf PM, 1997, AM J RHINOL, V11, P67, DOI 10.2500/105065897781446865; Graf PM, 1998, ORL J OTO-RHINO-LARY, V60, P334, DOI 10.1159/000027620; Gross G, 2010, J ALLERGY CLIN IMMUN, V125, pAB174, DOI 10.1016/j.jaci.2009.12.681; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Koelsch S, 2007, ARZNEIMITTELFORSCH, V57, P475; Lanier BQ, 2010, J ALLERGY CLIN IMMUN, V125, pAB173, DOI 10.1016/j.jaci.2009.12.678; Lin CY, 2004, ANN OTO RHINOL LARYN, V113, P147, DOI 10.1177/000348940411300213; Lockey RF, 2006, J ALLERGY CLIN IMMUN, V118, P1017, DOI 10.1016/j.jaci.2006.06.018; Molderings GJ, 2000, HYPERTENSION, V36, P405, DOI 10.1161/01.HYP.36.3.405; PETRUSON B, 1981, Rhinology (Utrecht), V19, P167; Ratner PH, 2008, ANN ALLERG ASTHMA IM, V100, P74, DOI 10.1016/S1081-1206(10)60408-5; Sudsakorn S, 2006, J PHARMACEUT BIOMED, V40, P1273, DOI 10.1016/j.jpba.2005.09.018; TALAAT M, 1981, J LARYNGOL OTOL, V95, P125, DOI 10.1017/S0022215100090526; Tas A, 2005, OTOLARYNG HEAD NECK, V132, P608, DOI 10.1016/j.otohns.2005.01.010; Vaidyanathan S, 2010, AM J RESP CRIT CARE, V182, P19, DOI 10.1164/rccm.200911-1701OC; Watanabe H, 2003, RHINOLOGY, V41, P167; Westerveld GJ, 2000, EUR RESPIR J, V16, P437, DOI 10.1034/j.1399-3003.2000.016003437.x; YOO JK, 1998, LARYNGOSCOPE, V108, P1255; Zhang L, 2008, ANN OTO RHINOL LARYN, V117, P127, DOI 10.1177/000348940811700211	31	54	61	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					927	934		10.1016/j.jaci.2011.01.037	http://dx.doi.org/10.1016/j.jaci.2011.01.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21377716				2022-12-18	WOS:000289055800014
J	Wang, MQ; Takeda, K; Shiraishi, Y; Okamoto, M; Dakhama, A; Joetham, A; Gelfand, EW				Wang, Meiqin; Takeda, Katsuyuki; Shiraishi, Yoshiki; Okamoto, Masakazu; Dakhama, Azzeddine; Joetham, Anthony; Gelfand, Erwin W.			Peanut-induced intestinal allergy is mediated through a mast cell-IgE-Fc epsilon RI-IL-13 pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut; intestinal allergy; mast cell; IgE; Fc epsilon RI; IL-13	FC-EPSILON-RI; INFLAMMATORY-BOWEL-DISEASE; IMMUNOGLOBULIN-E RECEPTOR; AIRWAY HYPERRESPONSIVENESS; FOOD ALLERGY; INDUCED DIARRHEA; UP-REGULATION; MURINE MODEL; TH2 CELLS; IN-VIVO	Background: Although implicated in the disease, the specific contributions of Fc epsilon RI and IL-13 to the pathogenesis of peanut-induced intestinal allergy are not well defined. Objectives: We sought to determine the contributions of FceRI, IL-13, and mast cells to the development of intestinal mucosal responses in a murine model of peanut-induced intestinal allergy. Methods: Sensitized wild-type (WT), Fc epsilon RI-deficient (Fc epsilon RI(-/-)), and mast cell-deficient (Kit(W-sh/W-sh)) mice received peanut orally every day for 1 week. Bone marrow-derived mast cells (BMMCs) from WT, Fc epsilon RI(-/-), IL-4(-/-), IL-13(-/-), and IL-4/IL-13(-/-) mice were differentiated and transferred into WT, Fc epsilon RI(-/-), and Kit(W-sh/W-sh) recipients. BMMCs from WT and UBI-GFP/BL6 mice were differentiated and transferred into WT and Kit(W-sh/W-sh) mice. Blockade of IL-13 was achieved by using IL-13 receptor alpha 2 (IL-13R alpha 2)-IgG fusion protein. Results: Fc epsilon RI(-/-) mice showed decreased intestinal inflammation (mast cell and eosinophil numbers) and goblet cell metaplasia and reduced levels of IL4, IL6, IL13, and IL17A mRNA expression in the jejunum. Transfer of WT BMMCs to Fc epsilon RI(-/-) recipients restored their ability to develop intestinal allergic responses unlike transfer of Fc epsilon RI(-/-), IL-13(-/-), or IL-4/IL-13(-/-) BMMCs. Fc epsilon RI(-/-) mice exhibited lower IL-13 levels and treatment of WT mice with IL-13 receptor alpha 2 prevented peanut-induced intestinal allergy and inflammation. Conclusions: These data indicate that the development of peanut-induced intestinal allergy is mediated through a mast cell-dependent IgE-Fc epsilon RI-IL-13 pathway. Targeting IL-13 might be a potential treatment for IgE-mediated peanut-induced allergic responses in the intestine. (J Allergy Clin Immunol 2010;126:306-16.)	[Wang, Meiqin; Takeda, Katsuyuki; Shiraishi, Yoshiki; Okamoto, Masakazu; Dakhama, Azzeddine; Joetham, Anthony; Gelfand, Erwin W.] Natl Jewish Hlth, Div Cell Biol, Dept Pediat, Denver, CO 80206 USA	National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Hlth, Div Cell Biol, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njhealth.org	Shiraishi, Yoshiki/Q-3914-2019	Shiraishi, Yoshiki/0000-0001-5275-6318	National Institutes of Health [HL-36577, HL-61005, AI-77609]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, R01HL061005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI077609, R01AI077609] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants HL-36577, HL-61005, and AI-77609.	Blease K, 2001, J IMMUNOL, V166, P5219, DOI 10.4049/jimmunol.166.8.5219; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Brandt EB, 2009, J ALLERGY CLIN IMMUN, V123, P53, DOI 10.1016/j.jaci.2008.10.001; Cardoso CR, 2008, CLIN EXP ALLERGY, V38, P338; Coeffier M, 2005, ALLERGY, V60, P822, DOI 10.1111/j.1398-9995.2005.00782.x; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Dombrowicz D, 2001, J EXP MED, V193, P25, DOI 10.1084/jem.193.1.25; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Eigenmann PA, 2002, PEDIAT ALLERG IMM-UK, V13, P162, DOI 10.1034/j.1399-3038.2002.01015.x; Eigenmann PA, 1996, ADV EXP MED BIOL, V409, P217; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; Fujino S, 2003, GUT, V52, P65, DOI 10.1136/gut.52.1.65; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Hernandes L, 2003, BIOCELL, V27, P347; Hunt J, 2008, J BIOL CHEM, V283, P29882, DOI 10.1074/jbc.M804742200; Ishizuka T, 1999, J IMMUNOL, V162, P2087; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kweon MN, 2000, J CLIN INVEST, V106, P199, DOI 10.1172/JCI8490; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; LYON MF, 1982, GENET RES, V39, P315, DOI 10.1017/S001667230002098X; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Metz M, 2007, IMMUNOL REV, V217, P304, DOI 10.1111/j.1600-065X.2007.00520.x; Miyahara N, 2009, AM J RESP CELL MOL, V40, P672, DOI 10.1165/rcmb.2008-0095OC; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Mullins RJ, 2009, J ALLERGY CLIN IMMUN, V123, P689, DOI 10.1016/j.jaci.2008.12.1116; Nielsen OH, 2003, SCAND J GASTROENTERO, V38, P180, DOI 10.1080/00365520310000672; Okamoto M, 2008, J EXP MED, V205, P1087, DOI 10.1084/jem.20072200; Pons L, 2004, J ALLERGY CLIN IMMUN, V114, P915, DOI 10.1016/j.jaci.2004.06.049; Schaefer BC, 2001, CELL IMMUNOL, V214, P110, DOI 10.1006/cimm.2001.1895; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Taube C, 2004, J IMMUNOL, V172, P6398, DOI 10.4049/jimmunol.172.10.6398; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Taube C, 2006, J IMMUNOL, V176, P3157, DOI 10.4049/jimmunol.176.5.3157; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721, DOI 10.1164/ajrccm.163.3.2005010; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Valeur J, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-33; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	48	54	71	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					306	U43		10.1016/j.jaci.2010.05.017	http://dx.doi.org/10.1016/j.jaci.2010.05.017			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20624645	Green Accepted, Bronze			2022-12-18	WOS:000281203800016
J	Ring, S; Karakhanova, S; Johnson, T; Enk, AH; Mahnke, K				Ring, Sabine; Karakhanova, Svetlana; Johnson, Theron; Enk, Alexander H.; Mahnke, Karsten			Gap junctions between regulatory T cells and dendritic cells prevent sensitization of CD8(+) T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Contact hypersensitivity; regulatory T cells; gap junctions; dendritic cells	CONTACT HYPERSENSITIVITY REACTIONS; INTERCELLULAR COMMUNICATION; CUTTING EDGE; CYCLIC-NUCLEOTIDES; IMMUNE SUPPRESSION; CROSS-PRESENTATION; IN-VIVO; CD4(+)CD25(+); EXPRESSION; CONNEXIN	Background: Regulatory T (Treg) cells suppress the sensitization phase of experimental contact hypersensitivity (CHS) reactions when injected before hapten application. Objective: Our aim was to analyze the mechanisms by which Treg cells suppress the sensitization phase of CHS reactions. Methods: Treg cells were labeled with different fluorescent dyes and injected into naive mice directly before sensitization with the hapten 2,4,6-trinitro-1-chlorobenzene. Two days after sensitization, the lymphoid organs were analyzed for the presence of Treg cells and engagement of gap junctions with other cells. Dendritic cells (DCs) and effector CD8(+)T cells were isolated from the draining lymph nodes (LNs) of the differently treated groups, analyzed by using FACS for activation markers, and assessed for the T-cell stimulatory capacity of the DCs and the priming of effector T cells. Results: Only the LN-homing Treg cells suppressed the sensitization phase in CHS reactions by means of establishing gap junctions with DCs in the dLNs. This gap junctional intercellular communication led to downregulation of T-cell costimulatory molecules on the surface of the DCs, abrogating the priming, activation, and proliferation of hapten-specific CD8(+)T cells. Consequently, the ear-swelling response induced by challenge with the respective hapten was prevented. Conclusion: Treg cells not only modulate ongoing CD4(+)T cell-mediated immune reactions at tissue sites but also abrogate the de novo induction of CD8(+)T cell-driven immune reactions by interfering with T-cell stimulatory activity of DCs through gap junctional intercellular communication. (J Allergy Clin Immunol 2010;125:237-46.)	[Ring, Sabine; Karakhanova, Svetlana; Johnson, Theron; Enk, Alexander H.; Mahnke, Karsten] Univ Heidelberg, Dept Dermatol, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Ring, S (corresponding author), Univ Heidelberg, Dept Dermatol, Vossstr 11, D-69115 Heidelberg, Germany.	Sabine.Ring@med.uni-heidelberg.de			SFB [405 B15, B16]; DFG [KM 1924/2-2]; Wilhelm Sander Foundation; EU [LSHC-CT-2005-518178]; Helmholtz Association	SFB(Austrian Science Fund (FWF)); DFG(German Research Foundation (DFG)); Wilhelm Sander Foundation; EU(European Commission); Helmholtz Association(Helmholtz Association)	Supported by grants to K.M. and A.H.E: SFB 405 B15, B16; DFG KM 1924/2-2; the Wilhelm Sander Foundation; EU-Grant LSHC-CT-2005-518178; and the Helmholtz Association: Alliance on Immunotherapy of Cancer.	Allan RS, 2006, IMMUNITY, V25, P153, DOI 10.1016/j.immuni.2006.04.017; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Belliveau DJ, 2006, J BIOL CHEM, V281, P20920, DOI 10.1074/jbc.M600026200; Bopp T, 2007, J EXP MED, V204, P1303, DOI 10.1084/jem.20062129; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; Bruzzone S, 2001, FASEB J, V15, P10; Bursch LS, 2007, J EXP MED, V204, P3147, DOI 10.1084/jem.20071966; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Denning TL, 2005, J IMMUNOL, V174, P7487, DOI 10.4049/jimmunol.174.12.7487; Doty RT, 1996, J IMMUNOL, V157, P3270; Dubois B, 2003, BLOOD, V102, P3295, DOI 10.1182/blood-2003-03-0727; Eltzschig HK, 2006, CIRC RES, V99, P1100, DOI 10.1161/01.RES.0000250174.31269.70; Evans WH, 2007, CELL COMMUN ADHES, V14, P265, DOI 10.1080/15419060801891034; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Giordano D, 2003, J IMMUNOL, V171, P6421, DOI 10.4049/jimmunol.171.12.6421; Harris AL, 2007, PROG BIOPHYS MOL BIO, V94, P120, DOI 10.1016/j.pbiomolbio.2007.03.011; IA SA, 2009, J EXP MED, V206, P1227; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kanaporis G, 2008, J GEN PHYSIOL, V131, P293, DOI 10.1085/jgp.200709934; Krenacs T, 1997, EUR J IMMUNOL, V27, P1489, DOI 10.1002/eji.1830270627; Kryczek I, 2006, J IMMUNOL, V177, P40, DOI 10.4049/jimmunol.177.1.40; Li K, 2008, BLOOD, V112, P5084, DOI 10.1182/blood-2008-05-156646; Liu HY, 2000, IMMUNITY, V13, P665, DOI 10.1016/S1074-7613(00)00066-2; Mahnke K, 2007, EUR J IMMUNOL, V37, P2117, DOI 10.1002/eji.200636841; Matsue H, 2006, J IMMUNOL, V176, P181, DOI 10.4049/jimmunol.176.1.181; Mendoza-Naranjo A, 2007, J IMMUNOL, V178, P6949, DOI 10.4049/jimmunol.178.11.6949; Misra N, 2004, J IMMUNOL, V172, P4676, DOI 10.4049/jimmunol.172.8.4676; Neijssen J, 2005, NATURE, V434, P83, DOI 10.1038/nature03290; Ochando JC, 2005, J IMMUNOL, V174, P6993, DOI 10.4049/jimmunol.174.11.6993; Onishi Y, 2008, P NATL ACAD SCI USA, V105, P10113, DOI 10.1073/pnas.0711106105; Oviedo-Orta E, 2000, IMMUNOLOGY, V99, P578, DOI 10.1046/j.1365-2567.2000.00991.x; Oviedo-Orta E, 2001, FASEB J, V15, P768, DOI 10.1096/fj.00-0288com; Qu Y, 2002, P NATL ACAD SCI USA, V99, P697, DOI 10.1073/pnas.022324499; Ring S, 2007, J IMMUNOL METHODS, V326, P10, DOI 10.1016/j.jim.2007.06.007; Ring S, 2006, EUR J IMMUNOL, V36, P2981, DOI 10.1002/eji.200636207; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Scemes E, 2007, NEURON GLIA BIOL, V3, P199, DOI 10.1017/S1740925X08000069; Scheuplein F, 2009, J IMMUNOL, V182, P2898, DOI 10.4049/jimmunol.0801711; Schmidt EM, 2009, J IMMUNOL, V182, P274, DOI 10.4049/jimmunol.182.1.274; Schneider MA, 2007, J EXP MED, V204, P735, DOI 10.1084/jem.20061405; Steinbrink K, 1997, J IMMUNOL, V159, P4772; Tang QZ, 2006, NAT IMMUNOL, V7, P83, DOI 10.1038/ni1289; Tseng SY, 2005, J IMMUNOL, V175, P7829, DOI 10.4049/jimmunol.175.12.7829; Veldhoen M, 2006, J IMMUNOL, V176, P6202, DOI 10.4049/jimmunol.176.10.6202; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wong CW, 2006, NAT MED, V12, P950, DOI 10.1038/nm1441; Yoshiki R, 2009, J INVEST DERMATOL, V129, P705, DOI 10.1038/jid.2008.304; Zhang XM, 2004, INT IMMUNOL, V16, P249, DOI 10.1093/intimm/dxh029	48	54	56	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					237	246		10.1016/j.jaci.2009.10.025	http://dx.doi.org/10.1016/j.jaci.2009.10.025			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109751				2022-12-18	WOS:000273660500030
J	Mandhane, PJ; Sears, MR; Poulton, R; Greene, JM; Lou, WYW; Taylor, DR; Hancox, RJ				Mandhane, Piush J.; Sears, Malcolm R.; Poulton, Richie; Greene, Justina M.; Lou, W. Y. Wendy; Taylor, D. Robin; Hancox, Robert J.			Cats and dogs and the risk of atopy in childhood and adulthood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Animals; pets; risk factors; cat; dog; atopy; interaction	PET OWNERSHIP; ALLERGIC SENSITIZATION; BIRTH COHORT; ASTHMA; EXPOSURE; CHILDREN; LIFE; ENVIRONMENT; SYMPTOMS; DISEASES	Background: Exposure to cats and dogs during childhood has been linked to a lower risk of developing allergies. It remains unclear whether this is due to selective avoidance of pets by families with a history of allergies. The effects of pet ownership in adulthood are unknown. Objectives: We sought to assess the association between cat and dog ownership in childhood and early adulthood and the development of atopy in a population-based birth cohort of 1037 subjects. Methods: Ownership of cats or dogs between birth and age 9 years and between the ages of 18 and 32 years was reported. Skin prick tests to common allergens were performed at 13 and 32 years. Results: There was no evidence that families with a history of atopy avoided owning pets. There were significant cat-by-dog interactions for the development of atopy in both childhood and adulthood. Children who had owned both a cat and a dog were less likely to be atopic at age 13 years. Living with only one of these animals was not protective against atopy. Among those who were not atopic by age 13 years, having both a cat and a dog in adulthood was associated with a lower risk of new atopy by age 32 years. This association was only significant among those with a parental history of atopy. These effects were independent of a range of potential confounding factors. Conclusions: There is a synergistic interaction between cat and dog exposure that is associated with a lower risk of developing atopy in childhood and young adulthood. (J Allergy Clin Immunol 2009;424:745-50.)	[Poulton, Richie; Hancox, Robert J.] Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand; [Mandhane, Piush J.] Univ Alberta, Dept Pediat, Edmonton, AB T6G 2M7, Canada; [Sears, Malcolm R.; Greene, Justina M.] McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada; [Sears, Malcolm R.; Greene, Justina M.] St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON, Canada; [Lou, W. Y. Wendy] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON M5S 1A1, Canada; [Taylor, D. Robin] Univ Otago, Dunedin Sch Med, Dept Med & Surg Sci, Dunedin, New Zealand	University of Otago; University of Alberta; McMaster University; McMaster University; University of Toronto; University of Otago	Hancox, RJ (corresponding author), Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand.	bob.hancox@otago.ac.nz	Hancox, Robert/G-4746-2011		Health Research Council of New Zealand; AstraZeneca Canada; Merck Frosst Canada; Health Research Council (New Zealand)	Health Research Council of New Zealand(Health Research Council of New Zealand); AstraZeneca Canada(AstraZeneca); Merck Frosst Canada; Health Research Council (New Zealand)(Health Research Council of New Zealand)	The Dunedin Multidisciplinary Health and Development Research Unit is funded by the Health Research Council of New Zealand. P. J. M. was a CIHR Strategic Training Fellow in the Canadian Child Health Clinician Scientist Program (CCHCSP).W. Y. W. L holds a Canada Research Chair in Statistical Methods for Health Care. M. R. S. holds the AstraZeneca Chair in Respiratory Epidemiology, McMaster University.; P. J. Mandhane has received honoraria from AstraZeneca Canada, Merck Frosst Canada, and the Edmonton Thoracic Society and has received research support from AstraZeneca Canada and Merck Frosst Canada. R. Poulton has received research support from the Health Research Council (New Zealand). R. J. Hancox has received research support front the Health Research Council (New Zealand). The rest of the authors have declared that they have no conflict of interest.	Al-Mousawi MSH, 2004, J ALLERGY CLIN IMMUN, V114, P1389, DOI 10.1016/j.jaci.2004.09.005; Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; Bornehag CG, 2003, ALLERGY, V58, P939, DOI 10.1034/j.1398-9995.2003.00050.x; Bousquet PJ, 2008, ALLERGY, V63, P341, DOI 10.1111/j.1398-9995.2007.01581.x; Braback L, 2002, ACTA PAEDIATR, V91, P1147, DOI 10.1080/080352502320777333; Braun-Fahrlander C, 2000, PEDIATR ALLERGY IMMU, V11, P19, DOI 10.1034/j.1399-3038.2000.00505.x; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Campo P, 2006, J ALLERGY CLIN IMMUN, V118, P1271, DOI 10.1016/j.jaci.2006.08.008; Custovic A, 2003, J ALLERGY CLIN IMMUN, V111, P402, DOI 10.1067/mai.2003.55; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; de Meer G, 2004, J ALLERGY CLIN IMMUN, V113, P433, DOI 10.1016/j.jaci.2003.10.008; Eller E, 2008, ALLERGY, V63, P1491, DOI 10.1111/j.1398-9995.2008.01790.x; Hancox RJ, 2004, THORAX, V59, P376, DOI 10.1136/thx.2003.010363; Hancox RJ, 2008, J ALLERGY CLIN IMMUN, V121, P38, DOI 10.1016/j.jaci.2007.09.052; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Jaakkola JJK, 2002, J ALLERGY CLIN IMMUN, V109, P784, DOI 10.1067/mai.2002.123870; Kaiser L, 2003, J BIOL CHEM, V278, P37730, DOI 10.1074/jbc.M304740200; Kilpelainen M, 2002, ALLERGY, V57, P1130, DOI 10.1034/j.1398-9995.2002.23341.x; Kimbell-Dunn M, 1999, AM J IND MED, V35, P51, DOI 10.1002/(SICI)1097-0274(199901)35:1&lt;51::AID-AJIM7&gt;3.0.CO;2-F; Linneberg A, 2001, CLIN EXP ALLERGY, V31, P1409, DOI 10.1046/j.1365-2222.2001.01178.x; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Oryszczyn MP, 2003, ALLERGY, V58, P1136, DOI 10.1046/j.1398-9995.2003.00314.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Perzanowski MS, 2008, J ALLERGY CLIN IMMUN, V121, P1047, DOI 10.1016/j.jaci.2008.02.005; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Silva P., 1996, CHILD ADULT DUNEDIN; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Svanes C, 2006, J ALLERGY CLIN IMMUN, V118, P691, DOI 10.1016/j.jaci.2006.06.017; Takkouche B, 2008, ALLERGY, V63, P857, DOI 10.1111/j.1398-9995.2008.01732.x; Vargas C, 2008, J ASTHMA, V45, P73, DOI 10.1080/02770900701752540; Virtanen T, 2001, ALLERGY, V56, P48, DOI 10.1034/j.1398-9995.2001.00915.x; von Hertzen L, 2006, J ALLERGY CLIN IMMUN, V117, P151, DOI 10.1016/j.jaci.2005.07.028; Wijga A, 2001, CLIN EXP ALLERGY, V31, P576, DOI 10.1046/j.1365-2222.2001.01072.x	43	54	54	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					745	750		10.1016/j.jaci.2009.06.038	http://dx.doi.org/10.1016/j.jaci.2009.06.038			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19703709	Bronze			2022-12-18	WOS:000270802800019
J	Baroody, FM; Shenaq, D; DeTineo, M; Wang, JH; Naclerio, RM				Baroody, Fuad M.; Shenaq, Deanna; DeTineo, Marcy; Wang, JiangHong; Naclerio, Robert M.			Fluticasone furoate nasal spray reduces the nasal-ocular reflex: A mechanism for the efficacy of topical steroids in controlling allergic eye symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinoconjunctivitis; nasal-ocular reflex; fluticasone furoate nasal spray; nasal challenge; priming; eosinophils	INTRANASAL CORTICOSTEROIDS; MOMETASONE FUROATE; HAY-FEVER; RHINITIS; CHALLENGE; HISTAMINE; MANAGEMENT; RELEASE; DISEASE; HEALTH	Background: Eye symptoms frequently occur in patients with allergic rhinitis and are among the most bothersome symptoms. Intranasal steroids have been shown to reduce ocular symptoms associated with allergic nasal symptoms, even though they do not reach the eye. Objective: To elucidate a mechanism to explain these observations. Methods: We performed a double-blind, placebo-controlled, crossover experiment in 20 subjects with seasonal allergic rhinitis. Nasal antigen challenge was performed consecutively for 3 days after 1 week of treatment with either placebo or fluticasone furoate nasal spray (FFNS). Subjects recorded their nasal and ocular symptoms, and nasal secretions were quantified. Nasal scrapings to quantify eosinophils were obtained before each antigen challenge. Results: Nasal challenge with antigen led to sneezing, a nasonasal, and a nasal-ocular reflex. Priming in the number of sneezes, contralateral nasal secretion weights, and total eye symptoms were observed. Treatment with FFNS reduced sneezing, the nasonasal and nasal-ocular reflexes, and the amount of eosinophils in nasal secretions. Conclusions: We confirmed that a nasal-ocular reflex follows nasal challenge with allergen and that it can contribute to the ocular symptoms associated with allergic rhinitis. FFNS reduced eosinophil infiltration, priming, and ocular symptoms. Furthermore, our results support a mechanism by which control of eye symptoms can be achieved during nasal administration of an intranasal steroid in patients with seasonal allergic rhinitis. (J Allergy Clin Immunol 2009;123:1342-8.)	[Baroody, Fuad M.; Shenaq, Deanna; DeTineo, Marcy; Wang, JiangHong; Naclerio, Robert M.] Univ Chicago, Pritzker Sch Med, Dept Surg, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA	University of Chicago	Baroody, FM (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Surg, Sect Otolaryngol Head & Neck Surg, 5841 S Maryland Ave,MC1035, Chicago, IL 60637 USA.	fbaroody@surgery.bsd.uchicago.edu			GlaxoSmithKline; McHugh Otolaryngology Research Fund	GlaxoSmithKline(GlaxoSmithKline); McHugh Otolaryngology Research Fund	Supported by a research grant from GlaxoSmithKline and by the McHugh Otolaryngology Research Fund.	Allen DB, 2000, J ALLERGY CLIN IMMUN, V106, pS179, DOI 10.1067/mai.2000.110038; Baroody FM, 1999, J APPL PHYSIOL, V86, P659, DOI 10.1152/jappl.1999.86.2.659; BAROODY FM, 1994, AM J RESP CRIT CARE, V149, P1457, DOI 10.1164/ajrccm.149.6.7516250; Baroody FM, 2003, OTOLARYNG HEAD NECK, V128, P616, DOI 10.1016/S0194-5998(03)00257-2; Baroody FM, 2008, ANN ALLERG ASTHMA IM, V100, P194, DOI 10.1016/S1081-1206(10)60442-5; Bielory L, 2008, ANN ALLERG ASTHMA IM, V100, P272, DOI 10.1016/S1081-1206(10)60453-X; Blaiss MS, 1999, ANN ALLERG ASTHMA IM, V83, P449, DOI 10.1016/S1081-1206(10)62850-5; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; Craig TJ, 2004, J ALLERGY CLIN IMMUN, V114, pS139, DOI 10.1016/j.jaci.2004.08.044; DENBURG JA, 1989, CLIN EXP ALLERGY, V19, P249, DOI 10.1111/j.1365-2222.1989.tb02379.x; DeWester J, 2003, ALLERGY ASTHMA PROC, V24, P331; FINEMAN S, 2002, ANN ALLERG ASTHMA IM, V88, pS2; Goetzel RZ, 2004, J OCCUP ENVIRON MED, V46, P398, DOI 10.1097/01.jom.0000121151.40413.bd; KONNO A, 1979, ANN OTO RHINOL LARYN, V88, P258, DOI 10.1177/000348947908800219; MALMBERG H, 1989, ACTA OTO-LARYNGOL, V107, P446, DOI 10.3109/00016488909127538; *MARLB SEPR INC, 2008, ALL AM LANDM SURV NA; Mygind N, 2001, J ALLERGY CLIN IMMUN, V108, pS16, DOI 10.1067/mai.2001.115561; Naclerio R, 2008, OTOLARYNG HEAD NECK, V138, P129, DOI 10.1016/j.otohns.2007.10.027; Noon L, 1911, LANCET, V1, P1572; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V88, P33, DOI 10.1016/0091-6749(91)90298-3; Spangler DL, 2003, CLIN THER, V25, P2245, DOI 10.1016/S0149-2918(03)80217-5; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; WACHS M, 1989, J ALLERGY CLIN IMMUN, V84, P492, DOI 10.1016/0091-6749(89)90362-X; Wagenmann M, 1997, AM J RESP CRIT CARE, V155, P426, DOI 10.1164/ajrccm.155.2.9032173; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; Wuthrich B, 1998, SCHWEIZ MED WSCHR, V128, P139	27	54	66	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1342	1348		10.1016/j.jaci.2009.03.015	http://dx.doi.org/10.1016/j.jaci.2009.03.015			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19428097				2022-12-18	WOS:000266799100027
J	Yerkovich, ST; Roponen, M; Smith, ME; McKenna, K; Bosco, A; Subrata, LS; Mamessier, E; Wikstrom, ME; Le Souef, P; Sly, PD; Holt, PG; Upham, JW				Yerkovich, Stephanie T.; Roponen, Marjut; Smith, Miranda E.; McKenna, Kathy; Bosco, Anthony; Subrata, Lily S.; Mamessier, Emilie; Wikstrom, Matthew E.; Le Souef, Peter; Sly, Peter D.; Holt, Patrick G.; Upham, John W.			Allergen-enhanced thrombomodulin (blood dendritic cell antigen 3, CD141) expression on dendritic cells is associated with a T(H)2-skewed immune response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dendritic cells; thrombomodulin; allergy	HUMAN PERIPHERAL-BLOOD; IFN-GAMMA PRODUCTION; T-CELLS; ASTHMATIC-PATIENTS; MONONUCLEAR-CELLS; INHALED ALLERGEN; BRONCHIAL-MUCOSA; ATOPIC ASTHMA; MITE ALLERGEN; HIGH-RISK	Background: Dendritic cells (DCs) are important in allergic diseases such as asthma, although little is known regarding the mechanisms by which DCs induce T(H)2-polarized responses in atopic individuals. It has been suggested that intrinsic properties of allergens can directly stimulate T(H)2 polarizing functions of DCs, but little is known of the underlying mechanisms. Objective: To identify novel genes expressed by house dust mite (HDM) allergen-exposed DCs. Methods: We screened for allergen-induced gene expression by microarray, and validated differentially expressed genes at the mRNA and protein levels. Results: Thrombomodulin (CD141, blood dendritic cell antigen 3) expression by microarray was higher on HDM-stimulated DCs from atopic (relative to nonatopic) individuals. These findings were confirmed at both the mRNA and protein levels in an independent group. Purified thrombomodulin(+) DCs induced a strongly T(H)2-polarized cytokine response by allergen-specific T cells compared with DCs lacking thrombomodulin. In vivo, thrombomodulin+ circulating DCs were significantly more frequent in subjects with HDM allergy and asthma, compared with control subjects. Furthermore, thrombomodulin expression in blood leukocytes was higher in children with acute asthma than at convalescence 6 weeks later. Conclusion: Thrombomodulin expression on DCs may be involved in the pathogenesis of atopy and asthma. (J Allergy Clin Immunol 2009;123:209-16.)	[Upham, John W.] Univ Queensland, Sch Med, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia; [Yerkovich, Stephanie T.; Roponen, Marjut; Smith, Miranda E.; McKenna, Kathy; Bosco, Anthony; Subrata, Lily S.; Mamessier, Emilie; Wikstrom, Matthew E.; Sly, Peter D.; Holt, Patrick G.; Upham, John W.] Univ Western Australia, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; [Yerkovich, Stephanie T.; Roponen, Marjut; Smith, Miranda E.; McKenna, Kathy; Bosco, Anthony; Subrata, Lily S.; Mamessier, Emilie; Wikstrom, Matthew E.; Sly, Peter D.; Holt, Patrick G.; Upham, John W.] Univ Western Australia, Fac Med & Dent, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Le Souef, Peter] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia	University of Queensland; Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia	Upham, JW (corresponding author), Univ Queensland, Sch Med, Princess Alexandra Hosp, Level 3,R Wing, Brisbane, Qld 4102, Australia.	j.upham@uq.edu.au	Roponen, Marjut/C-2086-2017; Study, Raine/K-4517-2013; Bosco, Anthony/AAC-6900-2022; Le Souef, Peter N/H-5256-2014; Holt, Patrick G/H-1548-2011; Yerkovich, Stephanie/A-9004-2011; Mamessier, Emilie/O-8299-2016; Sly, Peter D/F-1486-2010; Upham, John/F-4420-2010	Roponen, Marjut/0000-0002-4442-9090; Holt, Patrick G/0000-0003-1193-0935; Mamessier, Emilie/0000-0002-3516-0093; Sly, Peter D/0000-0001-6305-2201; Upham, John/0000-0002-0017-3433; Bosco, Anthony/0000-0002-4335-615X; Yerkovich, Stephanie/0000-0003-4163-4782; Le Souef, Peter/0000-0003-0930-1654	National Health and Medical Research Council, Australia	National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia)	Supported by the National Health and Medical Research Council, Australia.	Adams TE, 2006, ARTERIOSCL THROM VAS, V26, P1738, DOI 10.1161/01.ATV.0000228844.65168.d1; Allakhverdi Z, 2005, ALLERGY, V60, P1157, DOI 10.1111/j.1398-9995.2005.00861.x; Bellinghausen I, 2000, J ALLERGY CLIN IMMUN, V105, P988, DOI 10.1067/mai.2000.105526; Bosco A, 2006, J IMMUNOL, V176, P4766, DOI 10.4049/jimmunol.176.8.4766; Charbonnier AS, 2003, J LEUKOCYTE BIOL, V73, P91, DOI 10.1189/jlb.0602289; Chen XQ, 2006, RESPIRATION, V73, P34, DOI 10.1159/000087457; Constant SL, 2002, J CLIN INVEST, V110, P1441, DOI 10.1172/JCI200216109; Demedts IK, 2005, AM J RESP CELL MOL, V32, P177, DOI 10.1165/rcmb.2004-0279OC; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Esmon CT, 2005, BRIT J HAEMATOL, V131, P417, DOI 10.1111/j.1365-2141.2005.05753.x; Gabazza EC, 1999, LUNG, V177, P253, DOI 10.1007/PL00007645; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P1468, DOI 10.1046/j.1365-2745.2002.01504.x; Hamalainen HK, 2001, ANAL BIOCHEM, V299, P63, DOI 10.1006/abio.2001.5369; Hammad H, 2003, EUR CYTOKINE NETW, V14, P219; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; HERBERT JM, 1993, FEBS LETT, V328, P268, DOI 10.1016/0014-5793(93)80941-M; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; Kalinski P, 1997, ADV EXP MED BIOL, V417, P363; Kim HK, 2007, BLOOD COAGUL FIBRIN, V18, P157, DOI 10.1097/MBC.0b013e32801481cb; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Long JA, 2004, AM J RESP CRIT CARE, V170, P485, DOI 10.1164/rccm.200311-1595OC; Martin AC, 2006, AM J RESP CRIT CARE, V173, P617, DOI 10.1164/rccm.200509-1367OC; Matthay MA, 2004, J CLIN INVEST, V114, P20, DOI 10.1172/JCI200422288; MCCACHREN SS, 1991, BLOOD, V78, P3128; McCarthy NE, 2007, CLIN EXP ALLERGY, V37, P72, DOI 10.1111/j.1365-2222.2006.02631.x; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1111/j.1365-2222.1996.tb00571.x; Mullarky IK, 2006, J THROMB HAEMOST, V4, P1580, DOI 10.1111/j.1538-7836.2006.02010.x; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Naldini A, 2003, BRIT J PHARMACOL, V140, P980, DOI 10.1038/sj.bjp.0705514; Naldini A, 2006, J INTERF CYTOK RES, V26, P793, DOI 10.1089/jir.2006.26.793; Navarro A, 2003, J INTERF CYTOK RES, V23, P723, DOI 10.1089/107999003772084833; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; Reider N, 2002, J ALLERGY CLIN IMMUN, V109, P89, DOI 10.1067/mai.2002.120556; Rowe J, 2004, J ALLERGY CLIN IMMUN, V113, P710, DOI 10.1016/j.jaci.2003.12.585; Sohn RH, 2005, BLOOD, V105, P3910, DOI 10.1182/blood-2004-03-0928; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; Taylor RC, 2006, J ALLERGY CLIN IMMUN, V117, P1148, DOI 10.1016/j.jaci.2006.02.014; Terada M, 2004, AM J RESP CRIT CARE, V169, P373, DOI 10.1164/rccm.200308-1156OC; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Tsoumakidou M, 2006, IMMUNOL CELL BIOL, V84, P267, DOI 10.1111/j.1440-1711.2006.01428.x; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; Upham JW, 2002, CLIN EXP ALLERGY, V32, P818, DOI 10.1046/j.1365-2222.2002.01375.x; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Velten FW, 2004, EUR J IMMUNOL, V34, P2800, DOI 10.1002/eji.200324732	47	54	54	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					209	216		10.1016/j.jaci.2008.09.009	http://dx.doi.org/10.1016/j.jaci.2008.09.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	18947863				2022-12-18	WOS:000262793900034
J	de Haar, C; Kool, M; Hassing, I; Bol, M; Lambrecht, BN; Pieters, R				de Haar, Colin; Kool, Mirjam; Hassing, Ine; Bol, Marianne; Lambrecht, Bart N.; Pieters, Raymond			Lung dendritic cells are stimulated by ultrafine particles and play a key role in particle adjuvant activity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; costimulation; allergic inflammation; airways; particulate matter; ultrafine particles	DIESEL EXHAUST PARTICLES; HOUSE-DUST MITE; AIRWAY INFLAMMATION; ALLERGIC SENSITIZATION; ALVEOLAR MACROPHAGES; LYMPH-NODES; MOUSE MODEL; T-CELLS; ANTIGEN; POLLUTION	Background: The adjuvant activity of air pollution particles on allergic airway sensitization is well known, but the cellular mechanisms underlying this adjuvant potential are not clear. Objective: We sough to study the role of dendritic cells and the costimulatory molecules CD80 and CD86 in the adjuvant activity of ultrafine carbon black particles (CBP). Methods: The proliferation of CFSE-labeled DO11.10 CD4 cells was studied after intranasal exposure to particles and ovalbumin (OVA). Next the frequency of myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells and their expression of CD80 and CD86 were studied in the peribronchial lymph nodes (PBLNs). The expression of costimulatory molecules was also studied on bone marrow-derived mDCs after exposure to CBPs in vitro, and the importance of costimulation in CBP adjuvant activity was assessed by using CD80/CD86-deficient mice or cytotoxic T lymphocyte-associated antigen 4 (CTLA4)-Ig in vivo. Results: Our data show that CBPs plus OVA caused proliferation of DO11.10 CD4 cells and high levels of cytokine production in the PBLNs. Furthermore, the combined CBP plus OVA exposure increased the number of mDCs and expression of costimulatory molecules in the PBLNs. In addition, CBPs upregulated the expression of CD80/CD86 molecules on dendritic cells in vitro, which are necessary for the particle adjuvant effects in vivo. Conclusion: Together this study shows the importance of dendritic cells and costimulation in particle adjuvant activity. Furthermore, we show for the first time that CBPs can also directly induce maturation of dendritic cells.	[de Haar, Colin] Erasmus MC, Div Gastroenterol & Nutr, Pediat Lab, NL-3015 GE Rotterdam, Netherlands; [de Haar, Colin; Hassing, Ine; Bol, Marianne; Pieters, Raymond] Univ Utrecht, Inst Risk Assessment Sci, Dept Immunotoxicol, NL-3508 TC Utrecht, Netherlands; [Kool, Mirjam; Lambrecht, Bart N.] Erasmus MC, Dept Pulm Med, NL-3015 GE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Utrecht University; Erasmus University Rotterdam; Erasmus MC	de Haar, C (corresponding author), Erasmus MC, Div Gastroenterol & Nutr, Pediat Lab, Room Ee 1567,Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.	c.dehaar@erasmusmc.nl	Lambrecht, Bart N/K-2484-2014	Lambrecht, Bart N/0000-0003-4376-6834; de Haar, Colin/0000-0003-4358-2410				Becker S, 2003, J TOXICOL ENV HEAL A, V66, P847, DOI 10.1080/15287390306381; Becker S, 2002, TOXICOL IN VITRO, V16, P209, DOI 10.1016/S0887-2333(02)00015-2; Bleck B, 2006, J IMMUNOL, V176, P7431, DOI 10.4049/jimmunol.176.12.7431; Byersdorfer CA, 2001, J IMMUNOL, V167, P6756, DOI 10.4049/jimmunol.167.12.6756; CUMBERBATCH M, 1995, IMMUNOLOGY, V84, P31; D'Amato G, 2002, ALLERGY, V57, P30, DOI 10.1034/j.1398-9995.57.s72.5.x; de Haar C, 2006, CLIN EXP ALLERGY, V36, P1469, DOI 10.1111/j.1365-2222.2006.02586.x; de Haar C, 2005, TOXICOL SCI, V87, P409, DOI 10.1093/toxsci/kfi255; de Heer HJ, 2005, SEMIN IMMUNOL, V17, P295, DOI 10.1016/j.smim.2005.05.002; DEBEER HJ, 2004, J EXP MED, V200, P89; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; Dick CAJ, 2003, INHAL TOXICOL, V15, P39, DOI 10.1080/08958370304454; FUJIMAKI H, 1994, TOXICOLOGY, V92, P261, DOI 10.1016/0300-483X(94)90182-1; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Hochweller K, 2005, EUR J IMMUNOL, V35, P1086, DOI 10.1002/eji.200425891; KeaneMyers A, 1997, J IMMUNOL, V158, P2042; Lambert AL, 2001, EXP LUNG RES, V27, P617, DOI 10.1080/019021401753181863; Lambert AL, 1999, TOXICOL APPL PHARM, V158, P269, DOI 10.1006/taap.1999.8709; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lambrecht BN, 2000, J IMMUNOL, V164, P2937, DOI 10.4049/jimmunol.164.6.2937; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Lohr J, 2004, J IMMUNOL, V173, P5028, DOI 10.4049/jimmunol.173.8.5028; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; Ning YY, 2004, AM J RESP CELL MOL, V30, P744, DOI 10.1165/rcmb.2003-0123OC; Oriss TB, 2005, J IMMUNOL, V174, P854, DOI 10.4049/jimmunol.174.2.854; Peterson B, 1996, ANN ALLERG ASTHMA IM, V77, P263, DOI 10.1016/S1081-1206(10)63318-2; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345; Shi Y, 2002, EUR J IMMUNOL, V32, P155, DOI 10.1002/1521-4141(200201)32:1<155::AID-IMMU155>3.0.CO;2-P; Shortman K, 2001, NAT IMMUNOL, V2, P988, DOI 10.1038/ni1101-988; Srivastava KD, 2002, AM J RESP CRIT CARE, V165, P527, DOI 10.1164/ajrccm.165.4.2106009; Staats HF, 1999, J IMMUNOL, V162, P6141; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; Steerenberg PA, 2003, J TOXICOL ENV HEAL A, V66, P1421, DOI 10.1080/15287390306415; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; van Rift LS, 2004, J ALLERGY CLIN IMMUN, V114, P166, DOI 10.1016/j.jaci.2004.03.044; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51; Wang J, 2000, BLOOD, V95, P2337, DOI 10.1182/blood.V95.7.2337.007k22_2337_2345; Whitekus MJ, 2002, J IMMUNOL, V168, P2560, DOI 10.4049/jimmunol.168.5.2560; Yoshimura S, 2001, INT IMMUNOL, V13, P675, DOI 10.1093/intimm/13.5.675	42	54	54	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1246	1254		10.1016/j.jaci.2008.01.010	http://dx.doi.org/10.1016/j.jaci.2008.01.010			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18313130				2022-12-18	WOS:000255961700026
J	Raby, BA; Klanderman, B; Murphy, A; Mazza, S; Camargo, CA; Silverman, EK; Weiss, ST				Raby, Benjamin A.; Klanderman, Barbara; Murphy, Amy; Mazza, Salvatore; Camargo, Carlos A., Jr.; Silverman, Edwin K.; Weiss, Scott T.			A common mitochondrial haplogroup is associated with elevated total serum IgE levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mitochondria; haplogroup; genetics; asthma; atopy; immunoglobulin E; atopic dermatitis; single nucleotide polymorphism; susceptibility	MATERNAL HISTORY; EUROPEAN MTDNAS; ASTHMA; DNA; CHILDHOOD; ECZEMA; ATOPY; RISK; RESPONSIVENESS; SENSITIZATION	Background: Maternal history of asthma or atopy is among the most consistently reported risk factors for asthma and atopy in children, yet the molecular basis for this observation remains unclear. Mitochondria are inherited exclusively through the maternal line, raising the possibility that sequence variation in the mitochondrial genome contributes to the pathogenesis of asthma and atopy. Objective: We set out to determine whether common European mitochondrial haplogroups are associated with asthma-related atopic phenotypes. Methods: We studied 654 self-reported white children age 5 to 12 years with mild to moderate asthma participating in the Childhood Asthma Management Program. Eight haplogroup-tagging polymorphisms were genotyped with TaqMan probe hybridization assays, and mitochondrial haplogroup tests of association with asthma-related and atopy-related phenotypes were performed with haplo.stats. Results: We found significant evidence of mitochondrial haplogroup association with total serum IgE levels (global significance, P = .04), with carriers of European haplogroup U (frequency 11%) having higher total serum IgE levels (median level, 684 lU/L) compared with noncarriers (389 IU/L; P = .001). Haplogroup U carriers also had trends of greater skin prick test reactivity (P = .03) and higher frequency of atopic dermatitis (P = .07), although global haplogroup tests for these later 2 phenotypes were not significant at an alpha level of 0.05. Conclusion: These data are the first to suggest that common mitochondrial haplogroups influence the atopic diathesis. Clinical implications: These findings may provide a molecular explanation for the prominent influence of maternal history of atopy on the development of atopy in offspring.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02138 USA; Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; Harvard Partners Ctr Genet & Genom, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University	Raby, BA (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA.	benjamin.raby@channing.harvard.edu	Raby, Benjamin/AAK-3866-2021; Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NHLBI NIH HHS [T32 HL07427, P50 HL67664, N01-HR-16049, K08 HL074193] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR016049] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL074193, T32HL007427, P50HL067664] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Bradley M, 2000, ACTA DERM-VENEREOL, V80, P106; Campbell CD, 2005, NAT GENET, V37, P868, DOI 10.1038/ng1607; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Chagnon P, 1999, AM J MED GENET, V85, P20, DOI 10.1002/(SICI)1096-8628(19990702)85:1<20::AID-AJMG6>3.0.CO;2-K; CHAUDHRI G, 1986, J IMMUNOL, V137, P2646; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532; Demenais F, 2001, GENET EPIDEMIOL, V21, pS186, DOI 10.1002/gepi.2001.21.s1.s186; Elson JL, 2001, AM J HUM GENET, V68, P145, DOI 10.1086/316938; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; Harris JM, 2001, BRIT J DERMATOL, V144, P795, DOI 10.1046/j.1365-2133.2001.04135.x; Hashimoto S, 1997, ALLERGY, V52, P909, DOI 10.1111/j.1398-9995.1997.tb01250.x; HUNT NH, 1991, INT J IMMUNOPHARMACO, V13, P1019, DOI 10.1016/0192-0561(91)90056-D; KONDO R, 1993, J MOL EVOL, V36, P517, DOI 10.1007/BF00556356; KUEHR J, 1993, CLIN EXP ALLERGY, V23, P600, DOI 10.1111/j.1365-2222.1993.tb00900.x; Kurukulaaratchy RJ, 2006, ANN ALLERG ASTHMA IM, V97, P84, DOI 10.1016/S1081-1206(10)61375-0; Kurzius-Spencer M, 2004, AM J MED GENET A, V125A, P232, DOI 10.1002/ajmg.a.20481; Li-Weber M, 2002, EUR J IMMUNOL, V32, P2401, DOI 10.1002/1521-4141(200209)32:9&lt;2401::AID-IMMU2401&gt;3.0.CO;2-S; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; PROUVOSTDANON A, 1981, J IMMUNOL, V126, P699; Raby BA, 2005, AM J RESP CRIT CARE, V172, P552, DOI 10.1164/rccm.200501-010OC; Raby BA, 2004, PEDIATRICS, V114, pE327, DOI 10.1542/peds.2003-0838-L; Saxena R, 2006, AM J HUM GENET, V79, P54, DOI 10.1086/504926; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Soto-Quiros ME, 2002, PEDIATR PULM, V33, P237, DOI 10.1002/ppul.10070; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Strafella AP, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-15-j0003.2001; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606; Torroni A, 1996, GENETICS, V144, P1835; van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WALLACE DC, 1997, MOL GENETIC BASIS NE, P237; Wolfreys K, 1997, EUR J IMMUNOL, V27, P297, DOI 10.1002/eji.1830270143; WRIGHT AL, 1994, PEDIATRICS, V94, P895	43	54	54	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					351	358		10.1016/j.jaci.2007.05.029	http://dx.doi.org/10.1016/j.jaci.2007.05.029			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17666217	Bronze			2022-12-18	WOS:000248654900020
J	Wood, RA; Setse, R; Halselv, N				Wood, Robert A.; Setse, Rosawia; Halselv, Neal		Network Hypersensitivity Working G	Irritant skin test reactions to common vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANAPHYLAXIS; IMMEDIATE; RESPONSES; CHILDREN; RUBELLA; MEASLES; MUMPS		Johns Hopkins Univ, Dept Pediat, Sch Med, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Wood, RA (corresponding author), Johns Hopkins Univ, Dept Pediat, Sch Med, 300 N Charles St, Baltimore, MD 21218 USA.							*AM ACAD PED, 2006, RED BOOK, P46; *AM ACAD PED, 2000, RED BOOK; FASANO MB, 1992, J PEDIATR-US, V120, P878, DOI 10.1016/S0022-3476(05)81953-5; Georgitis J W, 2001, Curr Allergy Rep, V1, P11, DOI 10.1007/s11882-001-0091-6; *I VACC SAF, ALL TABL COMP VACC; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Kelso JM, 1999, J ALLERGY CLIN IMMUN, V103, P698, DOI 10.1016/S0091-6749(99)70245-9; KELSO JM, 2003, ALLERGY PRINCIPLES P, P1669; Kumagai T, 1997, J ALLERGY CLIN IMMUN, V100, P130, DOI 10.1016/S0091-6749(97)70204-5; Patrizi A, 1999, CONTACT DERMATITIS, V40, P94, DOI 10.1111/j.1600-0536.1999.tb05998.x; Ponvert C, 2001, VACCINE, V19, P4588, DOI 10.1016/S0264-410X(01)00257-2	11	54	54	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					478	481		10.1016/j.jaci.2007.04.035	http://dx.doi.org/10.1016/j.jaci.2007.04.035			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17544094				2022-12-18	WOS:000248654900042
J	Meller, S; Lauerma, AI; Kopp, FM; Winterberg, F; Anthoni, M; Muller, A; Gombert, M; Haahtela, A; Alenius, H; Rieker, J; Dieu-Nosjean, MC; Kubitza, RC; Gleichmann, E; Ruzicka, T; Zlotnik, A; Homey, B				Meller, Stephan; Lauerma, Antti I.; Kopp, Frank Michael; Winterberg, Franziska; Anthoni, Minna; Mueller, Anja; Gombert, Michael; Haahtela, Anna; Alenius, Harri; Rieker, Juliane; Dieu-Nosjean, Marie-Caroline; Kubitza, Robert Christof; Gleichmann, Ernst; Ruzicka, Thomas; Zlotnik, Albert; Homey, Bernhard			Chemokine responses distinguish chemical-induced allergic from irritant skin inflammation: Memory T cells make the difference	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; chemokines; chemotaxis; inflammation; cell trafficking; irritancy; memory T cells; skin; T(H)1/T(H)2 cells	ACTIVATION-REGULATED CHEMOKINE; MACROPHAGE-DERIVED CHEMOKINE; PLASMACYTOID DENDRITIC CELLS; CONTACT-DERMATITIS; IFN-GAMMA; TNF-ALPHA; EXPRESSION; NICKEL; CXCR3; MICE	Background: As clinical and histological features of allergic and irritant contact dermatitis share common characteristics, the differentiation between them in the preclinical and clinical evaluations of chemicals remains difficult. Objective: To identify the differences in the underlying immunological mechanisms of chemical-induced allergic or irritant skin responses. Methods: We systematically studied the involvement of chemokines in both diseases by quantitative real-time polymerase chain reaction in mice and humans. The cellular origin of relevant chemokines and receptors was determined using immunohistochemistry; functional relevance was demonstrated in vitro by transwell chemotaxis and in vivo by adoptive transfer experiments using a model of hapten-induced murine contact hypersensitivity. Results: Independent of overall skin inflammation, chemical-induced allergic and irritant skin responses showed distinct molecular expression profiles. In particular, chemokine genes predominantly regulated by T-cell effector cytokines demonstrated differential upregulation in hapten-specific skin inflammation. Notably, the expression of CXCR3 ligands, such as CXCL9 (Mig) and CXCL10 (IP-10), was upregulated in chemical-induced allergic skin responses when compared with irritant skin responses. Furthermore, we showed that inflammatory chemokines such as CXCL10 prime leukocytes to respond to CXCL12 (SDF-1), increasing their recruitment both in vitro and in vivo. Conclusion: We provide important insights into the molecular basis of chemical-induced allergic and irritant contact dermatitis, identify novel markers suitable for their differentiation, and demonstrate the cooperation of inflammatory and homeostatic chemokines in the recruitment of pathogenic leukocyte subsets. Clinical implications: Molecular differences between both diseases represent the basis for new approaches to diagnostics and therapy.	Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany; Finnish Inst Occupat Hlth, Control Hypersensitiv Dis, Helsinki, Finland; Univ Dusseldorf, Inst Environm Res, D-4000 Dusseldorf, Germany; Univ Dusseldorf, Dept Radiat Oncol, D-4000 Dusseldorf, Germany; Univ Helsinki, Cent Hosp, Skin & Allergy Hosp, Helsinki, Finland; Finnish Inst Occupat Hlth, Ctr Excellence Immunotoxicol, Helsinki, Finland; Ctr Rech Biomed Cordeliers, INSERM, U255, Lab Immunol Cellulaire & Clin, Paris, France; Neurocrine Biosci, San Diego, CA USA	Heinrich Heine University Dusseldorf; Finnish Institute of Occupational Health; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; University of Helsinki; Helsinki University Central Hospital; Finnish Institute of Occupational Health; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Neurocrine Biosciences	Homey, B (corresponding author), Univ Dusseldorf, Dept Dermatol, Moorenstr 5, D-40225 Dusseldorf, Germany.	Bernhard.Homey@uni-duesseldorf.de	Dieu-Nosjean, Marie-Caroline/AAD-3695-2022; Zlotnik, Albert/C-3791-2011; Dieu-Nosjean, Marie-Caroline/N-3736-2017; Lauerma, Antti/J-8180-2016; Meller, Stephan/GYA-5568-2022	Dieu-Nosjean, Marie-Caroline/0000-0002-1697-8914; Alenius, Harri/0000-0003-0106-8923				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Artik S, 1999, J IMMUNOL, V163, P1143; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bangert C, 2003, J INVEST DERMATOL, V121, P1409, DOI 10.1111/j.1523-1747.2003.12623.x; Bonecchi R, 1998, BLOOD, V92, P2668, DOI 10.1182/blood.V92.8.2668.420k39_2668_2671; Chew A-L, 2006, IRRITANT DERMATITIS; Chew AL, 2003, INT ARCH OCC ENV HEA, V76, P339, DOI 10.1007/s00420-002-0419-0; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Corsini E, 2000, TOXICOLOGY, V142, P203, DOI 10.1016/S0300-483X(99)00145-6; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246, DOI 10.1002/jlb.61.3.246; Flier J, 1999, J INVEST DERMATOL, V113, P574, DOI 10.1046/j.1523-1747.1999.00730.x; Fregert S., 1981, MANUAL CONTACT DERMA, V2nd ed.; Goebeler M, 2001, AM J PATHOL, V158, P431, DOI 10.1016/S0002-9440(10)63986-7; Gombert M, 2005, J IMMUNOL, V174, P5082, DOI 10.4049/jimmunol.174.8.5082; Homey B, 1999, CURR OPIN IMMUNOL, V11, P626, DOI 10.1016/S0952-7915(99)00028-X; Homey B, 2000, J IMMUNOL, V164, P3465, DOI 10.4049/jimmunol.164.7.3465; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Kim CH, 2001, J CLIN INVEST, V108, P1331, DOI 10.1172/JCI200113543; Lehto M, 2003, J INVEST DERMATOL, V120, P633, DOI 10.1046/j.1523-1747.2003.12104.x; Levin CY, 2002, INT IMMUNOPHARMACOL, V2, P183, DOI 10.1016/S1567-5769(01)00171-0; Liao F, 1999, J IMMUNOL, V162, P186; Mantovani A, 2000, J LEUKOCYTE BIOL, V68, P400; Moed H, 2004, BRIT J DERMATOL, V151, P32, DOI 10.1111/j.1365-2133.2004.05975.x; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nakayama T, 2001, INT IMMUNOL, V13, P95, DOI 10.1093/intimm/13.1.95; PIGUET PF, 1991, J EXP MED, V173, P673, DOI 10.1084/jem.173.3.673; Saint-Mezard P, 2004, EUR J DERMATOL, V14, P284; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sebastiani S, 2005, EUR J IMMUNOL, V35, P746, DOI 10.1002/eji.200525800; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Vanbervliet B, 2003, J EXP MED, V198, P823, DOI 10.1084/jem.20020437; VANHOOGSTRATEN IMW, 1993, J INVEST DERMATOL, V101, P26, DOI 10.1111/1523-1747.ep12358502; Wakabayashi T, 2005, IMMUNOL CELL BIOL, V83, P18, DOI 10.1111/j.1440-1711.2005.01310.x; Werfel T, 1997, J IMMUNOL, V158, P2500; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; Xiao T, 2003, CYTOKINE, V23, P126, DOI 10.1016/S1043-4666(03)00221-7; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	41	54	55	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1470	1480		10.1016/j.jaci.2006.12.654	http://dx.doi.org/10.1016/j.jaci.2006.12.654			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17337293				2022-12-18	WOS:000247232800024
J	van Ree, R				van Ree, Ronald			Indoor allergens: Relevance of major allergen measurements and standardization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						major allergen measurements; standardization; biological standardization; immunotherapy; optimal dose; assay differences; sensitization and tolerization thresholds	HOUSE-DUST-MITE; SUBLINGUAL-SWALLOW IMMUNOTHERAPY; 1ST INTERNATIONAL STANDARD; PLACEBO-CONTROLLED EVALUATION; RANDOMIZED CONTROLLED-TRIAL; OBSTRUCTIVE LUNG-DISEASE; DOUBLE-BLIND; DERMATOPHAGOIDES-PTERONYSSINUS; DOSE-RESPONSE; SUBCUTANEOUS IMMUNOTHERAPY	Major allergen measurements have relevance for the standardization of allergen extracts for immunotherapy and for epidemiologic studies into the cause of allergic diseases. Standardization is still centered around overall IgE-binding potencies (biological standardization). Major allergen levels show significant correlation with IgE-binding potencies, but ratios of the two can differ 5- to 10-fold between individual extracts. Major allergen quantities needed for effective and safe subcutaneous immunotherapy are proposed to be between 5 and 20 jig per maintenance shot. Although this figure is not really based on dose-finding studies, it has reached the status of a guiding principle. It is necessary to add major allergen measurements to standardization requirements to design adequate dosage schemes and elucidate the dose-response relation between major allergen dose and therapeutic effect. This will also help clarify to what extent sublingual immunotherapy requires higher doses of major allergen. Fine specificity of different assays toward isoforms and other variants of single allergens often results in diverging allergen measurements. Standardization should be based on certified major allergen references and accompanying assays that are cross-reactive enough to recognize all variants to facilitate comparability. This will also ensure that primary and secondary prevention strategies aiming at regulating allergen exposure will stay on solid ground.	Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	van Ree, R (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	r.vanree@amc.uva.nl						Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; [Anonymous], 1997, J ALLERGY CLIN IMMUN, V99, P583; ARNTZEN FC, 1989, J ALLERGY CLIN IMMUN, V83, P66, DOI 10.1016/0091-6749(89)90479-X; Batard T, 2006, INT ARCH ALLERGY IMM, V140, P295, DOI 10.1159/000093707; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Casanovas M, 2006, INT ARCH ALLERGY IMM, V139, P153, DOI 10.1159/000090392; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; Francis JN, 2005, CURR OPIN ALLERGY CL, V5, P537, DOI 10.1097/01.all.0000191234.97760.88; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; GJESING B, 1985, J ALLERGY CLIN IMMUN, V75, P258, DOI 10.1016/0091-6749(85)90055-7; Gonzalez P, 2002, J INVEST ALLERG CLIN, V12, P263; Grosclaude M, 2002, INT ARCH ALLERGY IMM, V129, P248, DOI 10.1159/000066779; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Hakkaart GAJ, 1998, CLIN EXP ALLERGY, V28, P169, DOI 10.1046/j.1365-2222.1998.00205.x; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HELM RM, 1984, J ALLERGY CLIN IMMUN, V73, P790, DOI 10.1016/0091-6749(84)90449-4; Holloway JA, 2000, LANCET, V356, P1900, DOI 10.1016/S0140-6736(00)03265-7; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; LARSEN JN, 1988, J ALLERGY CLIN IMMUN, V82, P318, DOI 10.1016/0091-6749(88)90002-4; Larsen TH, 2006, ALLERGY, V61, P1173, DOI 10.1111/j.1398-9995.2006.01203.x; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; Lent AM, 2006, J ALLERGY CLIN IMMUN, V118, P1249, DOI 10.1016/j.jaci.2006.07.055; Mirone C, 2004, CLIN EXP ALLERGY, V34, P1408, DOI 10.1111/j.1365-2222.2004.02056.x; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P41, DOI 10.1067/mai.2000.107197; Nettis E, 2002, CLIN EXP ALLERGY, V32, P1745, DOI 10.1046/j.1365-2222.2002.01544.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Olaguibel JM, 1997, ALLERGY, V52, P168, DOI 10.1111/j.1398-9995.1997.tb00971.x; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Ree R, 2004, ALLERGY, V59, P571, DOI 10.1111/j.1398-9995.2004.00499.x; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; Ronmark E, 2003, J ALLERGY CLIN IMMUN, V112, P747, DOI 10.1016/S0091-6749(03)01866-9; Ronmark E, 2003, PEDIAT ALLERG IMM-UK, V14, P91, DOI 10.1034/j.1399-3038.2003.00042.x; Rossi RE, 2004, INT ARCH ALLERGY IMM, V135, P44, DOI 10.1159/000080042; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Smith AM, 2001, INT ARCH ALLERGY IMM, V124, P61, DOI 10.1159/000053669; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; Tabar AI, 2005, J ALLERGY CLIN IMMUN, V116, P109, DOI 10.1016/j.jaci.2005.05.005; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; Vadas P, 2001, JAMA-J AM MED ASSOC, V285, P1746, DOI 10.1001/jama.285.13.1746; van Oort E, 2005, INT ARCH ALLERGY IMM, V136, P113, DOI 10.1159/000083318; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223, DOI 10.1016/S0091-6749(99)70017-5; van Ree R, 1999, ALLERGY CLIN IMMUNOL, V11, P55; van Ree R, 1997, ARB P EHRLICH I BUND, V91, P174; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; vanRee R, 1997, ALLERGY, V52, P795; VANREE R, 1994, ARB PEI GSH, V87, P127; VANREE R, 2005, PHARMEUROPA BIO, P27; Villalmanzo IG, 1999, J INVEST ALLERG CLIN, V9, P321; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; WITTEMAN AM, 1995, INT ARCH ALLERGY IMM, V107, P566, DOI 10.1159/000237100	73	54	57	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					270	277		10.1016/j.jaci.2006.10.033	http://dx.doi.org/10.1016/j.jaci.2006.10.033			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17166574				2022-12-18	WOS:000244327900001
J	Profita, M; La Grutta, S; Carpagnano, E; Riccobono, L; Di Giorgi, R; Bonanno, A; Pace, E; Bonsignore, G; Bousquet, J; Vignola, AM; Gjomarkaj, M				Profita, Mirella; La Grutta, Stefania; Carpagnano, Elisiana; Riccobono, Loredana; Di Giorgi, Rossana; Bonanno, Anna; Pace, Elisabetta; Bonsignore, Giovanni; Bousquet, Jean; Vignola, Antonio Maurizio; Gjomarkaj, Mark			Noninvasive methods for the detection of upper and lower airway inflammation in atopic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exhaled nitric oxide; exhaled breath condensate; atopy; airway inflammation; children	EXHALED NITRIC-OXIDE; BREATH CONDENSATE; ASTHMA; DERMATITIS; MECHANISMS; SYMPTOMS; RHINITIS; REPRODUCIBILITY; POPULATION; REACTIVITY	Background: Exhaled nitric oxide (FEND) and exhaled breath condensate (EBC) are noninvasive methods to assess inflammation. Objective: To investigate the role of the FEND and of the EBC pH and IL-5 levels in atopic children. Methods: We evaluated oral and nasal FEND and the pH and IL-5 of oral and nasal EBC in children with atopic dermatitis (AD; n = 18), allergic rhinitis (AR; n = 18), intermittent asthma (n = 21), moderate persistent asthma (n = 18), and healthy controls (HCs; n = 16). Results: Oral FEND was significantly increased in asthma, whereas the nasal values were increased in AR and asthma in comparison with HCs. The pH of oral EBC was lower in AD and asthma than in AR and HCs, whereas the nasal levels were lower in AD, AR, and asthma than in HCs. The oral IL-5 was higher in AD, AR, and asthma in comparison with HCs, whereas the nasal IL-5 concentrations were higher in asthma and AR than in HCs. In AR, the nasal FEND correlated with the IL-5 values and with the disease duration. In intermittent asthma, oral and nasal pH inversely correlated with the exacerbations, whereas in moderate asthma, the nasal IL-5 positively correlated with exacerbations. In AD, the oral and nasal IL-5 positively correlated with the serum IgE. Conclusion: These markers of nasal and bronchial inflammation, accessible with noninvasive techniques, might be useful to identify patients with uncontrolled diseases and to verify the usefulness of new therapeutic approaches. Clinical implications: These markers are useful tools to monitor the upper and lower airway inflammation in atopic children.	Italian Natl Res Council, Inst Biomed & Mol Immunol, Sect Immunopathol & Clin & Expt Pharmacol Resp Sy, I-90146 Palermo, Italy; Childrens Hosp, ARNAS, Allergy Unit, Palermo, Italy; Univ Bari, Inst Resp Dis, Bari, Italy; Inst Natl Sante & Res Med U454, Montpellier, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR); Universita degli Studi di Bari Aldo Moro	Profita, M (corresponding author), Italian Natl Res Council, Inst Biomed & Mol Immunol, Sect Immunopathol & Clin & Expt Pharmacol Resp Sy, Via Ugo La Malfa 153, I-90146 Palermo, Italy.	profita@ibim.cnr.it	Profita, Mirella/D-8957-2018; Profita, Mirella/AFU-7423-2022; Riccobono, Loredana/F-7950-2015; Bonanno, Anna/AAV-9474-2020; bonanno, anna/F-7613-2015; Profita, Mirella/AAY-3165-2020; Pace, Elisabetta/AAL-2537-2020; Bousquet, Jean/O-4221-2019; La Grutta, Stefania/N-3615-2014	Profita, Mirella/0000-0002-7821-8283; Riccobono, Loredana/0000-0002-0012-3591; bonanno, anna/0000-0003-3448-283X; Pace, Elisabetta/0000-0003-1141-9010; La Grutta, Stefania/0000-0001-8026-0715; CARPAGNANO, GIOVANNA ELISIANA/0000-0001-7931-4704				Borrill Z, 2005, EUR RESPIR J, V25, P269, DOI 10.1183/09031936.05.00085804; Bousquet J, 2004, J ALLERGY CLIN IMMUN, V113, P43, DOI 10.1016/j.jaci.2003.09.047; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Braunstahl GJ, 2005, J ALLERGY CLIN IMMUN, V115, P142, DOI 10.1016/j.jaci.2004.10.041; Brinkman L, 1997, EUR RESPIR J, V10, P1033, DOI 10.1183/09031936.97.10051033; Broide DH, 2001, J ALLERGY CLIN IMMUN, V108, pS65, DOI 10.1067/mai.2001.116436; Carpagnano GE, 2003, AM J RESP CRIT CARE, V167, P1109, DOI 10.1164/rccm.200203-179OC; Covar RA, 2005, J ALLERGY CLIN IMMUN, V115, P700, DOI 10.1016/j.jaci.2005.01.034; Downie SR, 2004, ALLERGY, V59, P320, DOI 10.1111/j.1398-9995.2003.00419.x; DREBORG S, 1993, ALLERGY, V48, P473, DOI 10.1111/j.1398-9995.1993.tb01102.x; Franklin PJ, 2003, THORAX, V58, P1048, DOI 10.1136/thorax.58.12.1048; Galli E, 2003, CURR MOL MED, V3, P127, DOI 10.2174/1566524033361564; Gelfand EW, 2004, J ALLERGY CLIN IMMUN, V114, pS135, DOI 10.1016/j.jaci.2004.08.043; Griese M, 2001, EUR J CLIN INVEST, V31, P915, DOI 10.1046/j.1365-2362.2001.00875.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Holz O, 2005, EUR RESPIR J, V26, P371, DOI 10.1183/09031936.05.00071305; Jouaville LF, 2003, CLIN EXP ALLERGY, V33, P1506, DOI 10.1046/j.1365-2222.2003.01800.x; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903a; Kostikas K, 2002, AM J RESP CRIT CARE, V165, P1364, DOI 10.1164/rccm.200111-068OC; La Grutta S, 2003, AM J RESP CRIT CARE, V167, P1490, DOI 10.1164/rccm.200206-549OC; Lampinen M, 2004, ALLERGY, V59, P793, DOI 10.1111/j.1398-9995.2004.00469.x; Langley SJ, 2003, ANN ALLERG ASTHMA IM, V91, P398, DOI 10.1016/S1081-1206(10)61688-2; Laske N, 2004, PEDIAT ALLERG IMM-UK, V15, P86, DOI 10.1046/j.0905-6157.2003.00106.x; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Mahut B, 2004, J ALLERGY CLIN IMMUN, V113, P252, DOI 10.1016/j.jaci.2003.10.038; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; Mondino C, 2004, J ALLERGY CLIN IMMUN, V114, P761, DOI 10.1016/j.jaci.2004.06.054; Passalacqua G, 2001, CURR OPIN ALLERGY CL, V1, P7; Ricciardolo FLM, 2004, J ALLERGY CLIN IMMUN, V113, P610, DOI 10.1016/j.jaci.2003.12.034; Simons FER, 2003, J ALLERGY CLIN IMMUN, V111, P617, DOI 10.1067/mai.2003.168; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Steerenberg PA, 2003, THORAX, V58, P242, DOI 10.1136/thorax.58.3.242; Valero A, 2005, ALLERGY, V60, P1126, DOI 10.1111/j.1398-9995.2005.00835.x; Von Mutius E, 2000, CLIN EXP ALLERGY, V30, P6	35	54	59	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1068	1074		10.1016/j.jaci.2006.07.028	http://dx.doi.org/10.1016/j.jaci.2006.07.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088131				2022-12-18	WOS:000244282300011
J	Jones, MG; Floyd, A; Nouri-Aria, KT; Jacobson, MR; Durham, SR; Taylor, AN; Cullinan, P				Jones, MG; Floyd, A; Nouri-Aria, KT; Jacobson, MR; Durham, SR; Taylor, AN; Cullinan, P			Is occupational asthma to diisocyanates a non-IgE-mediated disease?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						occupational asthma; isocyanates; IgE	MESSENGER-RNA EXPRESSION; ALLERGEN INHALATION CHALLENGE; COLONY-STIMULATING FACTOR; ACTIVATED T-LYMPHOCYTES; BRONCHIAL BIOPSIES; TOLUENE; MUCOSA; IL-5; GENE; SURVEILLANCE	Background: Exposure to diisocyanates in the workplace is an important cause of occupational asthma. The majority of patients with diisocyanate-induced asthma have no detectable diisocyanate-specific IgE antibodies in serum. There has been much debate as to whether this is due to diisocyanate-induced asthma being mediated by non-IgE mechanisms or whether it is the result of using inappropriate conjugates. Objective: We sought to determine whether RNA message for C epsilon., IL-4, and other associated inflammatory markers could be detected locally within the bronchial mucosa after diisocyanate challenge. Methods: Fiberoptic bronchoscopic bronchial biopsy specimens were obtained at 24 hours after both a control and an active challenge in 5 patients with positive and 7 patients with negative inhalation test responses to diisocyanates. Using both immunohistochemistry and in situ hybridization, we determined mRNA for C epsilon, IL-4, IL-5, and other associated inflammatory markers. Results: There was a striking absence of C epsilon and IL-4 mRNA-positive cells in bronchial biopsy specimens from patients challenged with diisocyanate (C epsilon median of 0 and interquartile range of 0-1.85, IL-4 median of 0 and interquartile range of 0-0.85). In contrast, there were increased numbers of IL-5-, CD25-, and CD4-positive cells and a trend toward an increase in eosinophils after active challenge with diisocyanate. Conclusion: We found a striking absence of both bronchial C epsilon and IL-4 RNA message after inhalation challenge with diisocyanates, irrespective of whether the challenge test response was positive or negative. We propose that diisocyanate-induced asthma is a non-IgE-mediated disease, at least in patients in whom specific IgE antibodies to diisocyanates are undetectable.	Natl Heart & Lung Inst, Imperial Coll, Dept Environm & Occupat Med, Fac Med, London SW3 6LR, England	Imperial College London	Jones, MG (corresponding author), Natl Heart & Lung Inst, Imperial Coll, Dept Environm & Occupat Med, Fac Med, 1B Manresa Rd, London SW3 6LR, England.	meinir.jones@imperial.ac.uk		Jacobson, Mikila/0000-0002-2921-6169	Medical Research Council [G0400503B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; FREW AJ, 1988, J IMMUNOL, V141, P4158; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Hunter DD, 2000, AM J RESP CRIT CARE, V161, P543, DOI 10.1164/ajrccm.161.2.9812083; KALUBI B, 1992, BRAIN RES, V576, P287, DOI 10.1016/0006-8993(92)90692-3; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KESKINEN H, 1988, CLIN ALLERGY, V18, P597, DOI 10.1111/j.1365-2222.1988.tb02911.x; Lange RW, 1999, CHEM RES TOXICOL, V12, P931, DOI 10.1021/tx990045h; Liu Q, 2003, ANN ALLERG ASTHMA IM, V90, P35, DOI 10.1016/S1081-1206(10)61647-X; Maestrelli P, 1997, CLIN EXP ALLERGY, V27, P1292; MAESTRELLI P, 1994, SCAND J WORK ENV HEA, V20, P376, DOI 10.5271/sjweh.1383; Mapp CE, 1998, AM J RESP CRIT CARE, V158, P263, DOI 10.1164/ajrccm.158.1.9704061; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; MASON DY, 1978, J CLIN PATHOL, V31, P454, DOI 10.1136/jcp.31.5.454; McDonald JC, 2000, OCCUP ENVIRON MED, V57, P823, DOI 10.1136/oem.57.12.823; Nouri-Aria KT, 2000, CLIN EXP ALLERGY, V30, P1709, DOI 10.1046/j.1365-2222.2000.00998.x; Ott MG, 2000, OCCUP ENVIRON MED, V57, P43, DOI 10.1136/oem.57.1.43; Park HS, 1999, J ALLERGY CLIN IMMUN, V104, P847, DOI 10.1016/S0091-6749(99)70297-6; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; Piirila PL, 2000, AM J RESP CRIT CARE, V162, P516, DOI 10.1164/ajrccm.162.2.9909026; Provencher S, 1997, OCCUP ENVIRON MED, V54, P272, DOI 10.1136/oem.54.4.272; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Sari-Minodier I, 1999, J OCCUP ENVIRON MED, V41, P582, DOI 10.1097/00043764-199907000-00006; Scheerens H, 1996, BRIT J PHARMACOL, V119, P1665, DOI 10.1111/j.1476-5381.1996.tb16087.x; Tarlo SM, 2002, OCCUP ENVIRON MED, V59, P58, DOI 10.1136/oem.59.1.58; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709, DOI 10.1016/S0091-6749(98)70181-2; Ucgun I, 1998, ALLERGY, V53, P1096, DOI 10.1111/j.1398-9995.1998.tb03822.x; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; VERCELLI D, 1991, J ALLERGY CLIN IMMUN, V88, P285, DOI 10.1016/0091-6749(91)90087-5; Wisnewski AV, 2001, CURR OPIN ALLERGY CL, V1, P169, DOI 10.1097/01.all.0000011003.36723.d8; Wisnewski AV, 2000, AM J RESP CRIT CARE, V162, P2330, DOI 10.1164/ajrccm.162.6.2002086; Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339	36	54	54	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					663	669		10.1016/j.jaci.2005.09.053	http://dx.doi.org/10.1016/j.jaci.2005.09.053			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522468				2022-12-18	WOS:000236263100024
J	Racila, DM; Kline, JN				Racila, DM; Kline, JN			Perspectives in asthma: Molecular use of microbial products in asthma prevention and treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; hygiene hypothesis; regulatory T cell; pathogen-associated molecular patterns	KILLED MYCOBACTERIUM-VACCAE; REGULATORY T-CELLS; MURINE MODEL; CPG OLIGODEOXYNUCLEOTIDES; AIRWAY INFLAMMATION; RESPONSES; LIPOPOLYSACCHARIDE; EOSINOPHILIA; EXPOSURE; ANTIGEN	Asthma and atopy are characterized by T(H)2-type patterns of inflammation. The hygiene hypothesis suggests that early-life environmental exposure to microbes, other pathogens, and their products promotes innate immune responses that suppress atopy; the current epidemic of allergic disease may result from a dearth of such stimuli. Antiatopic responses engendered by these exposures include both T(H)1-type and regulatory-type patterns, the latter including mechanisms of antigen-presenting cells as well as those of lymphoid origin, and are characterized by prominent IL-10 and/or TGF-beta effects. The Toll-like receptors are an important family of innate immune response elements that have many similar structural and functional properties, but have evolved to recognize distinct ligands as well as to be expressed differentially on immune cells. An active and productive area of current research is investigating the utility of microbes and microbial products for modulation of inflammation in asthma and atopic disorders. Clinical trials have been conducted for some of these biologic compounds, such as cytosine-guanine dinucleotide DNA and Mycobacterium vaccae, whereas others remain in preclinical testing.	Univ Iowa, Ctr Hlth, Roy J & Lucille A Carver Coll Med, Div Pulm Crit Care & Occupat Med, Iowa City, IA 52242 USA	University of Iowa	Kline, JN (corresponding author), Univ Iowa, Ctr Hlth, Roy J & Lucille A Carver Coll Med, Div Pulm Crit Care & Occupat Med, C33 GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	joel-kline@uiowa.edu		kline, joel/0000-0002-5523-8855	NHLBI NIH HHS [R01 HL59324, R21HL079448, R21HL079447] Funding Source: Medline; NIEHS NIH HHS [P01 ES0009607] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL079448, R01HL059324, R21HL079447] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Camporota L, 2003, EUR RESPIR J, V21, P287, DOI 10.1183/09031936.03.00042103; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gerhold K, 2002, J ALLERGY CLIN IMMUN, V110, P110, DOI 10.1067/mai.2002.125831; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Jain VV, 2003, AM J PHYSIOL-LUNG C, V285, pL1137, DOI 10.1152/ajplung.00073.2003; Kline JN, 1999, J ALLERGY CLIN IMMUN, V104, P1258, DOI 10.1016/S0091-6749(99)70022-9; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297, DOI 10.1164/ajrccm.160.1.9808144; Kline JN, 1998, J IMMUNOL, V160, P2555; Kreig A. M., 1995, NATURE, V374, P546; Moseman EA, 2004, J IMMUNOL, V173, P4433, DOI 10.4049/jimmunol.173.7.4433; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Wohlleben G, 2004, INT IMMUNOL, V16, P585, DOI 10.1093/intimm/dxh062; Zuany-Amorim C, 2002, J IMMUNOL, V169, P1492, DOI 10.4049/jimmunol.169.3.1492; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	19	54	61	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1202	1205		10.1016/j.jaci.2005.08.050	http://dx.doi.org/10.1016/j.jaci.2005.08.050			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337446	Bronze			2022-12-18	WOS:000235687000004
J	Ryan, KR; Lawson, CA; Lorenzi, AR; Arkwright, PD; Isaacs, JD; Lilic, D				Ryan, KR; Lawson, CA; Lorenzi, AR; Arkwright, PD; Isaacs, JD; Lilic, D			CD4(+)CD25(+) T-regulatory cells are decreased in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AIRE		Newcastle Univ, Fac Med Sci, Dept Rheumatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; St James Univ Hosp, Mol Med Unit, Leeds, W Yorkshire, England; Univ Manchester, Acad Unit Child Hlth, Booth Hall Childrens Hosp, Manchester, Lancs, England	Newcastle University - UK; Saint James's University Hospital; University of Leeds; Royal Manchester Children's Hospital; University of Manchester	Ryan, KR (corresponding author), Newcastle Univ, Fac Med Sci, Dept Rheumatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Arkwright, Peter/C-5149-2012	Isaacs, John/0000-0002-6103-7056; Arkwright, Peter/0000-0002-7411-5375				Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816; FOTENOT JD, 2005, NAT IMMUNOL, V6, P331; Lilic D, 2003, INFECT IMMUN, V71, P5690, DOI 10.1128/IAI.71.10.5690-5699.2003; Lilic D, 2002, CURR OPIN INFECT DIS, V15, P143, DOI 10.1097/00001432-200204000-00007; Liston A, 2003, NAT IMMUNOL, V4, P350, DOI 10.1038/ni906; Montagnoli C, 2002, J IMMUNOL, V169, P6298, DOI 10.4049/jimmunol.169.11.6298; Ramsey C, 2002, HUM MOL GENET, V11, P397, DOI 10.1093/hmg/11.4.397; Su MA, 2004, CURR OPIN IMMUNOL, V16, P746, DOI 10.1016/j.coi.2004.09.009; Villasenor J, 2005, IMMUNOL REV, V204, P156, DOI 10.1111/j.0105-2896.2005.00246.x	10	54	57	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1158	1159		10.1016/j.jaci.2005.08.036	http://dx.doi.org/10.1016/j.jaci.2005.08.036			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275391				2022-12-18	WOS:000235686700032
J	McSharry, CP; McKay, IC; Chaudhuri, R; Livingston, E; Fraser, I; Thomson, NC				McSharry, CP; McKay, IC; Chaudhuri, R; Livingston, E; Fraser, I; Thomson, NC			Short and long-term effects of cigarette smoking independently influence exhaled nitric oxide concentration in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						smoking; nitric oxide; asthma	SYNTHASE ACTIVITY; CARBON-MONOXIDE; NITROGEN-OXIDES; PASSIVE SMOKE; AIR; DISEASE; THERAPY; NASAL; NOS1	Background: The fractional concentration of nitric oxide in exhaled breath (FeNO) is elevated in asthma. FeNO measurement has been proposed as a noninvasive index of disease activity. Cigarette smoking suppresses FeNO, which limits its use in smokers. Objective: To identify and model short-term and long-term influences of cigarette smoking on FeNO. Methods: The smoking history, FeNO, and fractional concentration of carbon monoxide in exhaled breath (FeCO) were measured in 53 subjects with asthma and 51 control subjects. A mathematical model of the short-term and long-term effects of cigarette smoking on FeNO was derived. Results: Subjects with asthma had higher FeNO than controls (P < .001). Smokers had increased FeCO (P < .001). The short-term effect (hours since last cigarette) was associated with increased FeNO (P < .01) and decreased FeCO (P < .05). The long-term effect (years smoked) was associated with decreasing FeNO only in the subjects with asthma (r = -0.62; P = .005). These short-term and long-term effects were independent and were combined in a model predicting FeNO, predicted log(10) FeNO = 1.23 - 0.58e(-0.34t) - 0.00000103 X (lifetime cigarettes), where t = hours since the last cigarette. This gave a convincing prediction of FeNO (r = 0.83; P < .0001). Conclusion: Short-term and long-term effects of smoking influenced the measurement of FeNO. We defined a model that describes these effects. The use of this formula may improve the value of FeNO measurements in smokers with asthma.	Univ Glasgow, Western Infirm, Dept Immunol, Div Immunol Infect & Inflammat, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Resp Med, Div Immunol Infect & Inflammat, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow; University of Glasgow	McSharry, CP (corresponding author), Univ Glasgow, Western Infirm, Dept Immunol, Div Immunol Infect & Inflammat, Glasgow G11 6NT, Lanark, Scotland.	cms4q@clinmed.gla.ac.uk		Thomson, Neil/0000-0003-1632-6630; McSharry, Charles/0000-0003-4758-9038				[Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Ansarin K, 2001, EUR RESPIR J, V17, P934, DOI 10.1183/09031936.01.17509340; ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; Avital A, 2003, PEDIATR PULM, V36, P433, DOI 10.1002/ppul.10377; Barbera JA, 2001, AM J RESP CRIT CARE, V164, P709, DOI 10.1164/ajrccm.164.4.2101023; Bates CA, 2003, J ALLERGY CLIN IMMUN, V111, P256, DOI 10.1067/mai.2003.103; BODIS S, 1994, ANN ONCOL, V5, P371, DOI 10.1093/oxfordjournals.annonc.a058845; Bruce C, 2002, THORAX, V57, P361, DOI 10.1136/thorax.57.4.361; Corradi M, 1999, THORAX, V54, P572, DOI 10.1136/thx.54.7.572; Delen FM, 2000, CHEST, V117, P695, DOI 10.1378/chest.117.3.695; Deveci SE, 2004, RESP MED, V98, P551, DOI 10.1016/j.rmed.2003.11.018; Franklin PJ, 2004, CHEST, V126, P1540, DOI 10.1378/chest.126.5.1540; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323; Gomez FP, 1998, MED CLIN-BARCELONA, V111, P1; Grasemann H, 1999, CLIN EXP ALLERGY, V29, P39; Hoyt JC, 2003, EXP LUNG RES, V29, P17, DOI 10.1080/01902140303759; Hunt JF, 2005, THORAX, V60, P2, DOI 10.1136/thx.2004.024364; Jones SL, 2002, EUR RESPIR J, V20, P601, DOI 10.1183/09031936.02.00285302; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V152, P609, DOI 10.1164/ajrccm.152.2.7543345; Koek GH, 2002, RESP MED, V96, P530, DOI 10.1053/rmed.2002.1312; Lane C, 2004, THORAX, V59, P757, DOI 10.1136/thx.2003.014894; Lehtimaki L, 2000, ANN MED, V32, P417, DOI 10.3109/07853890008995949; Loveless MO, 1997, THORAX, V52, P185, DOI 10.1136/thx.52.2.185; Ludviksdottir D, 1999, EUR RESPIR J, V13, P739, DOI 10.1034/j.1399-3003.1999.13d07.x; Maniscalco M, 2002, ARCH ENVIRON HEALTH, V57, P437, DOI 10.1080/00039890209601434; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800, DOI 10.1164/ajrccm.152.2.7633745; Middleton ET, 2000, CHEST, V117, P758, DOI 10.1378/chest.117.3.758; Node K, 1997, AM J CARDIOL, V79, P1538, DOI 10.1016/S0002-9149(97)00189-6; NORMAN V, 1965, NATURE, V205, P915, DOI 10.1038/205915b0; PERSSON MG, 1994, LANCET, V343, P146, DOI 10.1016/S0140-6736(94)90935-0; Reid DW, 2003, RESPIROLOGY, V8, P479, DOI 10.1046/j.1440-1843.2003.00495.x; Robbins RA, 1996, AM J RESP CRIT CARE, V153, P1631, DOI 10.1164/ajrccm.153.5.8630613; Saito J, 2004, J ALLERGY CLIN IMMUN, V114, P512, DOI 10.1016/j.jaci.2004.05.033; SCHILLING J, 1994, EUR RESPIR J, V7, P467, DOI 10.1183/09031936.94.07030467; Shin HW, 2004, J APPL PHYSIOL, V96, P65, DOI 10.1152/japplphysiol.00575.2003; Silkoff PE, 2004, J ALLERGY CLIN IMMUN, V114, P1241, DOI 10.1016/j.jaci.2004.08.042; SOGNI P, 1995, J HEPATOL, V23, P471, DOI 10.1016/0168-8278(95)80207-X; Thomas PS, 2002, J MOL MED-JMM, V80, P181, DOI 10.1007/s00109-001-0301-7; Thomas SR, 2000, CHEST, V117, P1085, DOI 10.1378/chest.117.4.1085; Thomson NC, 2004, EUR RESPIR J, V24, P822, DOI 10.1183/09031936.04.00039004; Tsang KW, 2004, INT J TUBERC LUNG D, V8, P1301; Tsuchiya M, 2002, CIRCULATION, V105, P1155, DOI 10.1161/hc1002.105935; van's Gravesande Karin Storm, 2003, American Journal of Respiratory and Critical Care Medicine, V168, P228, DOI 10.1164/rccm.200212-1491BC; Verleden GM, 1999, CHEST, V116, P59, DOI 10.1378/chest.116.1.59; Wechsler ME, 2000, AM J RESP CRIT CARE, V162, P2043, DOI 10.1164/ajrccm.162.6.2003089; Yates DH, 1997, EUR RESPIR J, V10, P1483, DOI 10.1183/09031936.97.10071483; Yates DH, 1996, EUR RESPIR J, V9, P1130, DOI 10.1183/09031936.96.09061130; Yates DH, 2001, AM J RESP CRIT CARE, V164, P1043, DOI 10.1164/ajrccm.164.6.2005043	50	54	54	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					88	93		10.1016/j.jaci.2005.03.025	http://dx.doi.org/10.1016/j.jaci.2005.03.025			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990779				2022-12-18	WOS:000235686300014
J	Siebenhaar, F; Staubach, P; Metz, M; Magerl, M; Jung, J; Maurer, M				Siebenhaar, F; Staubach, P; Metz, M; Magerl, M; Jung, J; Maurer, M			Peltier effect-based temperature challenge: An improved method for diagnosing cold urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CLINICAL FINDINGS		Johannes Gutenberg Univ Mainz, Univ Hosp Mainz, Dept Dermatol, Mainz, Germany; Humboldt Univ, Univ Hosp Charite, Dept Dermatol & Allergy, D-10117 Berlin, Germany	Johannes Gutenberg University of Mainz; University Hospital Mainz; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Siebenhaar, F (corresponding author), Johannes Gutenberg Univ Mainz, Univ Hosp Mainz, Dept Dermatol, Mainz, Germany.		Metz, Martin/B-8799-2009; Magerl, Markus/ABI-5335-2020; Metz, Martin/M-5237-2013; Maurer, Marcus/ABG-2174-2020	Metz, Martin/0000-0002-4070-9976; Magerl, Markus/0000-0001-9218-5468; Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X; Siebenhaar, Frank/0000-0003-4532-1644				Koeppel MC, 1996, ANN DERMATOL VENER, V123, P627; Lee CW, 2003, ALLERGY ASTHMA PROC, V24, P9; Mathelier-Fusade P, 1998, ARCH DERMATOL, V134, P106, DOI 10.1001/archderm.134.1.106; NEITTAANMAKI H, 1985, J AM ACAD DERMATOL, V13, P636, DOI 10.1016/S0190-9622(85)70208-3; SIBBALD RG, 1985, DERMATOL CLIN, V3, P57, DOI 10.1016/S0733-8635(18)30918-5; TOTHKASA I, 1981, ARCH DERMATOL RES, V271, P447, DOI 10.1007/BF00406691; Wanderer AA, 2004, IMMUNOL ALLERGY CLIN, V24, P259, DOI 10.1016/j.iac.2004.01.001; WANDERER AA, 1986, J ALLERGY CLIN IMMUN, V78, P417, DOI 10.1016/0091-6749(86)90027-8	8	54	55	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1224	1225		10.1016/j.jaci.2004.07.018	http://dx.doi.org/10.1016/j.jaci.2004.07.018			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536435				2022-12-18	WOS:000225047800034
J	Kedda, MA; Shi, J; Duffy, D; Phelps, S; Yang, I; O'Hara, K; Fong, K; Thompson, PJ				Kedda, MA; Shi, J; Duffy, D; Phelps, S; Yang, I; O'Hara, K; Fong, K; Thompson, PJ			Characterization of two polymorphisms in the leukotriene C-4 synthase gene in an Australian population of subjects with mild, moderate, and severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LTC4 synthase; asthma; disease severity; aspirin intolerant; asthma; promoter polymorphism; Australian population	PROMOTER POLYMORPHISM; MOLECULAR-CLONING; JAPANESE PATIENTS; ASPIRIN; ASSOCIATION; SUSCEPTIBILITY; DISEASE; INTOLERANCE; PREVALENCE	Background: The cysteinyl-leukotrienes (cys-LTs) are proinflammatory mediators that are important in the pathophysiology of asthma. LTC4 synthase is a key enzyme in the cys-LT biosynthetic pathway, and studies in small populations have suggested that a promoter polymorphism (A(-444)C) in the gene might be associated with asthma severity and aspirin intolerance. Objective: We sought to screen the LTC4 synthase gene for polymorphisms and to determine whether there is an association between these polymorphisms and asthma severity or aspirin sensitivity in a large, well-phenotyped population and to determine whether this polymorphism is functionally relevant. Methods: The coding regions of the LTC4 synthase gene were screened for polymorphisms and the A(-444)C polymorphism was analyzed in a large Australian white adult population of mild (n = 282), moderate (n = 236), and severe asthmatic subjects (n = 86) and nonasthmatic subjects (n = 458), as well as in aspirin-intolerant asthmatic subjects (n = 67). The functional activity of the promoter polymorphism was investigated by transient transfection of HL-60 cells with a promoter construct. Results: A new polymorphism was identified in intron 1 of the gene (IVS1-10c>a) but was not associated with asthma. Association studies showed that the A(-444)C polymorphism was weakly associated with asthma per se, but there was no association between the C-444 allele and chronic asthma severity or aspirin intolerance. A meta-analysis of all the genetic studies conducted to date found significant between-study heterogeneity in C-444 allele frequencies within different clinical subgroups. In vitro functional studies showed no significant differences in transcription efficiency between constructs containing the A(-444) allele or the C-444 allele. Conclusions: Our data confirm that, independent of transcriptional activity, the C-444 allele in the LTC4 synthase gene is weakly associated with the asthma phenotype, but it is not related to disease severity or aspirin intolerance.	Univ Western Australia, Cooperat Res Ctr Asthma, Perth, WA 6009, Australia; Univ Western Australia, Asthma & Allergy Res Inst Inc, Perth, WA 6009, Australia; Univ Western Australia, Western Australian Inst Med Res, Perth, WA 6009, Australia; Univ Western Australia, Ctr Epidemiol Lab, Perth, WA 6009, Australia; Prince Charles Hosp, Genet Epidemiol Lab, Queensland Inst Med Res, Brisbane, Qld 4032, Australia; Prince Charles Hosp, Thorac Lab, Brisbane, Qld 4032, Australia	University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; Prince Charles Hospital; QIMR Berghofer Medical Research Institute; Prince Charles Hospital	Thompson, PJ (corresponding author), Sir Charles Gairdner Hosp, Asthma & Allergy Res Inst, Ground Floor,E Block, Perth, WA 6009, Australia.		Yang, Ian A/B-9609-2008; Duffy, David L/B-7392-2013; Fong, Kwun M/G-6369-2010	Yang, Ian A/0000-0001-8338-1993; Duffy, David L/0000-0001-7227-632X; 				[Anonymous], 1997, NIH PUBLICATION; Asano K, 2002, PHARMACOGENETICS, V12, P565, DOI 10.1097/00008571-200210000-00009; Bannenberg G, 1999, J BIOL CHEM, V274, P1994, DOI 10.1074/jbc.274.4.1994; Bigby TD, 1996, MOL MED, V2, P637, DOI 10.1007/BF03401647; Bleecker ER, 1998, CLIN EXP ALLERGY, V28, P6; Brauer JE, 1999, AM J RESP CRIT CARE, V159, pA650; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Hall I, 2002, THORAX, V57, P377, DOI 10.1136/thorax.57.5.377; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25; Iannuzzi MC, 2002, RESP RES, V3, DOI 10.1186/rr164; Ihaka Ross., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.1080/10618600.1996.10474713, 10.2307/1390807]; Kalyoncu AF, 1999, ALLERGY, V54, P428, DOI 10.1034/j.1398-9995.1999.00963.x; Karakaya G, 2000, Allergol Immunopathol (Madr), V28, P229; Kawagishi Y, 2002, J ALLERGY CLIN IMMUN, V109, P936, DOI 10.1067/mai.2002.124466; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Penrose JF, 1996, J BIOL CHEM, V271, P11356, DOI 10.1074/jbc.271.19.11356; SAMPSON AP, 2002, THORAX S2, V55, pS28; SAMPSON AP, 1999, DRUG INDUCED ASTHMA, P128; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sanak M, 2000, AM J RESP CELL MOL, V23, P290, DOI 10.1165/ajrcmb.23.3.4051; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; Sayers I, 2003, THORAX, V58, P417, DOI 10.1136/thorax.58.5.417; Schiavino D, 2000, THORAX, V55, pS66, DOI 10.1136/thorax.55.suppl_2.S66; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; Sturtevant Joanna, 1999, New Zealand Dental Journal, V95, P84; Szczeklik A, 2000, THORAX, V55, pS42, DOI 10.1136/thorax.55.suppl_2.S42; Szczeklik A, 1993, Allergol Immunopathol (Madr), V21, P35; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Szczeklik A, 2001, CURR OPIN ALLERGY CL, V1, P27, DOI 10.1097/01.all.0000010981.95396.58; Torres-Galvan MJ, 2001, ANN ALLERG ASTHMA IM, V87, P506, DOI 10.1016/S1081-1206(10)62265-X; Vally H, 2002, THORAX, V57, P569, DOI 10.1136/thorax.57.7.569; Van Sambeek R, 2000, J ALLERGY CLIN IMMUN, V106, P72, DOI 10.1067/mai.2000.107603	34	54	58	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					889	895		10.1016/j.jaci.2004.02.008	http://dx.doi.org/10.1016/j.jaci.2004.02.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131571				2022-12-18	WOS:000221269000011
J	Temkin, V; Aingorn, H; Puxeddu, I; Goldshmidt, O; Zcharia, E; Gleich, GJ; Vlodavsky, I; Levi-Schaffer, F				Temkin, V; Aingorn, H; Puxeddu, I; Goldshmidt, O; Zcharia, E; Gleich, GJ; Vlodavsky, I; Levi-Schaffer, F			Eosinophil major basic protein: First identified natural heparanase-inhibiting protein	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						heparanase; eosinophils; major basic protein; inflammation; angiogenesis; fibrosis; metastasis; allergic peritonitis	PERIPHERAL-BLOOD EOSINOPHILS; MAMMALIAN HEPARANASE; EXTRACELLULAR-MATRIX; HUMAN-NEUTROPHILS; CATIONIC PROTEIN; GROWTH-FACTOR; IN-VITRO; METASTASIS; EXPRESSION; RELEASE	Background: Heparanase and eosinophils are involved in several diseases, including inflammation, cancer, and angiogenesis. Objective: We sought to determine whether eosinophils produce active heparanase. Methods: Human peripheral blood eosinophils were isolated by immunoselection and tested for heparanase protein (immunocytochemistry. Western blot), mRNA (RT-PCR) and activity (Na-2 [S-35]O-4-labeled extracellular matrix degradation) before and after activation. Heparanase intracellular localization (confocal laser microscopy) and ability to bind to eosinophil major basic protein (MBP) were also evaluated (immunoprecipitation). A model of allergic peritonitis resulting in eosinophilia was induced in TNF knockout and wild-type mice for in vivo studies. Results: Eosinophils synthesized heparanase mRNA and contained heparanase in the active (50-kd) and latent (65-kd) forms. Heparanase partially co-localized with and was bound to NOR No heparanase enzymatic activity was detected in eosinophils resting or activated with various agonists, including GM-CSF/C5a. Eosinophil lysates and MBP inhibited recombinant heparanase activity in a concentration-dependent manner (100%, 2 x 10(-7) mol/L). Eosinophil peroxidase and eosinophil cationic protein, but not myelin basic protein or compound 48/ 80, partially inhibited heparanase activity. Poly-(L)-arginine at very high concentrations caused an almost complete inhibition. In allergic peritonitis, heparanase activity in the peritoneal fluid inversely correlated with eosinophil number. Conclusions: MBP is the first identified natural heparanase inhibiting protein. Its presence in the eosinophil granules might indicate a protective function of these cells in diseases associated with inflammation and cancer progression.	Hebrew Univ Jerusalem, Fac Med, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Med, Dept Oncol, IL-91120 Jerusalem, Israel; Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT USA; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Levi-Schaffer, F (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Pharmacol, POB 12065, IL-91120 Jerusalem, Israel.		Puxeddu, Ilaria/AAB-3263-2019	Levi-Schaffer, Francesca/0000-0003-0620-2810				CARLSON MGC, 1985, J IMMUNOL, V134, P1875; Chekhonin VP, 2000, VOP MED KHIM, V46, P549; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Goldshmidt O, 2002, EXP CELL RES, V281, P50, DOI 10.1006/excr.2002.5651; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Hallsworth MP, 1998, AM J RESP CELL MOL, V19, P910, DOI 10.1165/ajrcmb.19.6.3275; Hoenstein R, 2001, CELL IMMUNOL, V210, P116, DOI 10.1006/cimm.2001.1808; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; KUHRY JG, 1985, AGENTS ACTIONS, V16, P109, DOI 10.1007/BF01983114; Levi-Schaffer F, 1999, P NATL ACAD SCI USA, V96, P9660, DOI 10.1073/pnas.96.17.9660; Mallorqui-Fernandez G, 2000, J MOL BIOL, V300, P1297, DOI 10.1006/jmbi.2000.3939; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; Mollinedo F, 1997, BIOCHEM J, V327, P917, DOI 10.1042/bj3270917; Nadav L, 2002, J CELL SCI, V115, P2179; Nagler A, 1997, ARTERIOSCL THROM VAS, V17, P194, DOI 10.1161/01.ATV.17.1.194; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; Samoszuk M, 1997, HISTOL HISTOPATHOL, V12, P807; SHTEPER PJ, 2003, IN PRESS ONCOGENE; Simon HU, 2000, J IMMUNOL, V165, P4069, DOI 10.4049/jimmunol.165.7.4069; Solomon A, 2000, INVEST OPHTH VIS SCI, V41, P1038; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Temkin V, 2002, J IMMUNOL, V169, P2662, DOI 10.4049/jimmunol.169.5.2662; TEMKIN V, 2003, IN PRESS CYTOKINE; Thomas LL, 2001, IMMUNOL LETT, V78, P175, DOI 10.1016/S0165-2478(01)00249-8; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE, V1; WHITE SR, 1991, J IMMUNOL METHODS, V44, P257	38	54	58	1	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					703	709		10.1016/j.jaci.2003.11.038	http://dx.doi.org/10.1016/j.jaci.2003.11.038			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100677				2022-12-18	WOS:000220956600019
J	Crestani, E; Guerra, S; Wright, AL; Halonen, M; Martinez, FD				Crestani, E; Guerra, S; Wright, AL; Halonen, M; Martinez, FD			Parental asthma as a risk factor for the development of early skin test sensitization in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; skin test sensitization; wheezing; IgE; eosinophils	RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; SERUM IGE; ATOPY; PREVALENCE; ALLERGY; SCHOOLCHILDREN; POPULATION; CHILDHOOD; INFANCY	Background: Recent epidemiologic evidence has challenged the paradigm suggesting a direct causal relationship between allergic sensitization and asthma. Objective: We sought to investigate the role of a familial predisposition for asthma in the development of atopy in children. Methods: Subjects were participants in the Tucson Children's Respiratory Study. Skin tests to aeroallergens were performed in parents and in children at ages 6, 11, and 16 years. Parents were considered asthmatic if they reported physician-confirmed asthma. Parents were divided into 4 phenotypes on the basis of skin sensitization (Skt+ or Skt-) and asthma status (As+ or As-): Skt-/As-, Skt-/As+, Skt+/As-, and Skt+/As+. Results: Children's allergic sensitization differed among parental phenotypes at all ages (P < .0001). Children in the Skt+/As- and Skt+/As+ groups were significantly more likely to be allergic than children in the Skt-/As- group at all ages. Among children with allergic parents, those with at least one parent with asthma were significantly more likely to have positive skin test responses than those with nonasthmatic parents at age 6 years (52.4% vs 37.4%, P < .005) and 11 years (70.1% vs 55.6%, P < .005) but not at age 16 years (82.3% vs 75.1%, P =.180). Results were independent of wheezing in the child and of the characteristics of atopy in parents. The Skt-/As+ group had too few subjects for meaningful comparisons. Conclusion: Among children of atopic parents, parental asthma is a risk factor for allergic sensitization in early childhood. The strong association between allergic sensitization and asthma is at least in part explained by an increased susceptibility to allergen sensitization in subjects predisposed to asthma.	Univ Arizona, Arizona Resp Ctr, Ctr Hlth Sci, Coll Med, Tucson, AZ 85724 USA; Univ Arizona, Dept Pediat, Coll Med, Tucson, AZ 85724 USA; Univ Arizona, Dept Pharmacol, Tucson, AZ 85721 USA	University of Arizona; University of Arizona; University of Arizona	Martinez, FD (corresponding author), Univ Arizona, Arizona Resp Ctr, Ctr Hlth Sci, Coll Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA.			Halonen, Marilyn/0000-0001-9606-935X	NHLBI NIH HHS [HL 14136, HL 56177] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blease K, 2000, J IMMUNOL, V165, P1564, DOI 10.4049/jimmunol.165.3.1564; Blyth DI, 2000, AM J RESP CELL MOL, V23, P241, DOI 10.1165/ajrcmb.23.2.3999; Booth BW, 2001, AM J RESP CELL MOL, V25, P739, DOI 10.1165/ajrcmb.25.6.4659; BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1497, DOI 10.1164/ajrccm.152.5.7582283; CLOUGH JB, 1991, AM REV RESPIR DIS, V143, P755, DOI 10.1164/ajrccm/143.4_Pt_1.755; Doucet C, 2002, EUR J IMMUNOL, V32, P2437, DOI 10.1002/1521-4141(200209)32:9<2437::AID-IMMU2437>3.0.CO;2-N; Hardin J. W., 2013, GEN ESTIMATING EQUAT; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113, DOI 10.1164/ajrccm.162.supplement_2.ras-12; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; KELLY WJW, 1990, J ALLERGY CLIN IMMUN, V85, P548, DOI 10.1016/0091-6749(90)90092-I; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LEUNG R, 1994, THORAX, V49, P1205, DOI 10.1136/thx.49.12.1205; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; Patino CM, 2001, ALLERGY, V56, P279, DOI 10.1034/j.1398-9995.2001.00135.x; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; Riikjarv MA, 2000, EUR RESPIR J, V16, P86, DOI 10.1034/j.1399-3003.2000.16a15.x; Sherrill D, 1999, CLIN EXP ALLERGY, V29, P905; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; VANASPEREN PP, 1990, J ALLERGY CLIN IMMUN, V85, P790, DOI 10.1016/0091-6749(90)90200-N; von Mutius E, 2001, CLIN EXP ALLERGY, V31, P1651, DOI 10.1046/j.1365-2222.2001.01272.x; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; vonMutius E, 1996, AM J RESP CRIT CARE, V153, P1266, DOI 10.1164/ajrccm.153.4.8616552; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	28	54	55	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					284	290		10.1016/j.jaci.2003.11.009	http://dx.doi.org/10.1016/j.jaci.2003.11.009			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767443				2022-12-18	WOS:000188885700016
J	Fukuda, K; Fujitsu, Y; Seki, K; Kumagai, N; Nishida, T				Fukuda, K; Fujitsu, Y; Seki, K; Kumagai, N; Nishida, T			Differential expression of thymus- and activation-regulated chemokine (CCL17) and macrophage-derived chemokine (CCL22) by human fibroblasts from cornea, skin, and lung	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fibroblast; thymus- and activation-regulated chemokine; macrophage-derived chemokine; IL-4; IL-13; T(H)2 cell	CC-CHEMOKINE; ATOPIC-DERMATITIS; HUMAN NASAL; IN-VITRO; T-CELLS; EOTAXIN EXPRESSION; TNF-ALPHA; RECEPTOR; TARC; INFLAMMATION	Background: Allergic diseases of the ocular surface, skin, and lung are triggered by T(H)2 cells, which are recruited by thymus- and activation-regulated chemokine (TARC; CCL17) and macrophage-derived chemokine (MDC; CCL22). Resident fibroblasts are thought to contribute to inflammatory cell infiltration through chemokine production. Objective: We sought to provide insight into the clinical differences apparent among these allergic diseases of the eye, skin, and lung, and we compared the abilities of corneal, dermal, and lung fibroblasts to produce TARC and MDC. Methods: The amounts of chemokines released into the culture supernatant were determined by means of ELISA, and the intracellular abundance of chemokine mRNAs was quantitated by means of reverse transcription and real-time PCR analysis. Results: Neither TNF-alpha, IFN-gamma, IL-4, nor IL-13 alone induced the release of TARC from or affected the amount of TARC mRNA in corneal, dermal, or lung fibroblasts. The combination of TNF-a with either IL-4 or IL-13, however, markedly increased both TARC release and the abundance of TARC mRNA in corneal and dermal fibroblasts, but not in lung fibroblasts. Neither MDC release nor MDC mRNA was detected in any of the 3 types of fibroblasts stimulated with any of the cytokines examined. Conclusion: These results indicate that cytokine regulation of TARC expression differs among fibroblasts derived from the cornea, skin, or lung. Corneal and dermal fibroblasts might thus be important sources of TARC during allergic inflammation. (J Allergy Clin Immunol 2003; 111:520-6.).	Yamaguchi Univ, Sch Med, Dept Ocular Pathophysiol, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Biomol Recognit & Ophtalmol, Ube, Yamaguchi 7558505, Japan	Yamaguchi University; Yamaguchi University	Fukuda, K (corresponding author), Yamaguchi Univ, Sch Med, Dept Ocular Pathophysiol, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.		Fukuda, Ken/A-3076-2011	Fukuda, Ken/0000-0003-4990-6308				Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Brouty-Boye D, 2000, EUR J IMMUNOL, V30, P914, DOI 10.1002/1521-4141(200003)30:3<914::AID-IMMU914>3.0.CO;2-D; Buckley CD, 2001, TRENDS IMMUNOL, V22, P199, DOI 10.1016/S1471-4906(01)01863-4; Fukuda K, 2002, INVEST OPHTH VIS SCI, V43, P183; Galli G, 2000, EUR J IMMUNOL, V30, P204, DOI 10.1002/1521-4141(200001)30:1<204::AID-IMMU204>3.0.CO;2-G; Gonzalo JA, 1999, J IMMUNOL, V163, P403; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hogaboam CM, 1998, KIDNEY INT, V54, P2152, DOI 10.1046/j.1523-1755.1998.00176.x; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; Kawasaki S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/jimmunol.166.3.2055; KOMURO T, 1990, ANAT EMBRYOL, V182, P103; Kumagai N, 2000, INVEST OPHTH VIS SCI, V41, P1448; Kumagai N, 2000, BIOCHEM BIOPH RES CO, V279, P1, DOI 10.1006/bbrc.2000.3890; Lieberam I, 1999, EUR J IMMUNOL, V29, P2684, DOI 10.1002/(SICI)1521-4141(199909)29:09<2684::AID-IMMU2684>3.3.CO;2-P; MAGGI E, 1991, J IMMUNOL, V146, P1169; Minshall EM, 2000, CLIN EXP ALLERGY, V30, P301; Miyamasu M, 1999, CYTOKINE, V11, P751, DOI 10.1006/cyto.1999.0487; Miyamasu M, 1999, INT IMMUNOL, V11, P1001, DOI 10.1093/intimm/11.6.1001; Nagata K, 1999, J IMMUNOL, V162, P1278; Nonaka M, 1999, INT ARCH ALLERGY IMM, V119, P314, DOI 10.1159/000024209; PHIPPS RP, 1990, IMMUNOL RES, V9, P275, DOI 10.1007/BF02935527; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROLFE MW, 1991, AM J RESP CELL MOL, V5, P493, DOI 10.1165/ajrcmb/5.5.493; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; SAPPINO AP, 1990, LAB INVEST, V63, P144; SCHMITTGRAFF A, 1994, VIRCHOWS ARCH, V425, P3, DOI 10.1007/BF00193944; Sekiya T, 2000, J IMMUNOL, V165, P2205, DOI 10.4049/jimmunol.165.4.2205; SHINDO N, 1988, BIOMED ENVIRON MASS, V15, P25, DOI 10.1002/bms.1200150105; Smith RS, 1997, AM J PATHOL, V151, P317; Terada N, 2001, CLIN EXP ALLERGY, V31, P1923, DOI 10.1046/j.1365-2222.2001.01152.x; Teran LM, 1999, AM J RESP CELL MOL, V20, P777, DOI 10.1165/ajrcmb.20.4.3508; Teruya-Feldstein J, 1999, BLOOD, V93, P2463, DOI 10.1182/blood.V93.8.2463.408k02_2463_2470; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; Vestergaard C, 2000, J INVEST DERMATOL, V115, P640, DOI 10.1046/j.1523-1747.2000.00115.x; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; XING Z, 1993, AM J RESP CELL MOL, V9, P255, DOI 10.1165/ajrcmb/9.3.255; Yoneyama H, 1998, J CLIN INVEST, V102, P1933, DOI 10.1172/JCI4619; Zingoni A, 1998, J IMMUNOL, V161, P547	40	54	59	1	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					520	526		10.1067/mai.2003.59	http://dx.doi.org/10.1067/mai.2003.59			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642832	Bronze			2022-12-18	WOS:000181639500013
J	Panzer, SE; Dodge, AM; Kelly, EAB; Jarjour, NN				Panzer, SE; Dodge, AM; Kelly, EAB; Jarjour, NN			Circadian variation of sputum inflammatory cells in mild asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; induced sputum; circadian variations	BRONCHOALVEOLAR LAVAGE FLUID; EXPIRATORY FLOW VARIATION; NOCTURNAL ASTHMA; AIRWAY INFLAMMATION; ALVEOLAR TISSUE; PERIPHERAL-BLOOD; REPRODUCIBILITY; ALLERGEN; IL-5; EOSINOPHILS	Background: Asthma, like many conditions, demonstrates a cireadian rhythm with a worsening of lung function in the early morning hours compared with in the late afternoon. Objective: Because eosinophilic airway inflammation is a proposed mechanism for worsening asthma, we characterized circadian variation in airway eosinophils and determined its rela. tionship to variability in airway function. Methods: Pulmonary function testing, sputum induction, and phlebotomy were performed at 7 Am and 4 Pm in 11 allergic subjects with mild asthma. Sputum was analyzed for cell viability, differential, and eosinophil-derived neurotoxin levels. IL-5 levels in serum were measured by means of ELISA. Results: Subjects had a significant decrease in FEV1 (median [interquartile range] = 80% [70%-86%] vs 85% [82%-94%], P =.009) and a greater P-agonist reversibility (median [interquartile range] = 13% [7% -32 %] vs 8 % [5 %-14 %], P = .024) in the early morning compared with in the late afternoon. Sputum analysis showed an increase in early morning total sputum leukocytes (median [interquartile range] = 4.3 x 10(6) [2.3 x 10(6) to 6.1 X 10(6)] vs 2.6 x 10(6) [1.7 x 10(6) to 3.6 x 10(6)], P = .044) and eosinophils (median [interquartile range] = 7.0 x 104 [2.7 x 10(4) to 18.7 x 10(4)] vs 3.6 x 10(4) [1.0 X 10(4) to 8.2 x 10(4)], P =.024). Furthermore, sputum eosinophils correlated with beta-agonist reversibility (R-s = 0.665, P =.019). Finally, levels of IL5 in serum and eosinophil-derived neurotoxin in sputum were significantly increased at 7 Am. conclusion: These data suggest that circadian variability in pulmonary function in asthma could be related to changes in airway eosinophil recruitment and activation. (J Allergy Clin Immunol 2003;111:308-12.).	Univ Wisconsin, Dept Med, Pulm & Crit Care Sect, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Jarjour, NN (corresponding author), Univ Wisconsin, Dept Med, Pulm & Crit Care Sect, 600 Highland Ave,CSC K4-914, Madison, WI 53792 USA.			Kelly, Elizabeth/0000-0001-7335-6698	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064812] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 64812] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P577, DOI 10.1164/ajrccm/145.3.577; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; DALONZO GE, 1995, AM J RESP CRIT CARE, V152, P1097, DOI 10.1164/ajrccm.152.3.7663789; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470, DOI 10.1164/ajrccm.163.6.9901105; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; Glantz SA., 1997, PRIMER BIOSTATISTICS; JARJOUR NN, 1995, AM J RESP CRIT CARE, V152, P1474, DOI 10.1164/ajrccm.152.5.7582279; JARJOUR NN, 1992, AM REV RESPIR DIS, V146, P905, DOI 10.1164/ajrccm/146.4.905; Keatings VM, 1997, J ALLERGY CLIN IMMUN, V99, P693, DOI 10.1016/S0091-6749(97)70032-0; Kelly EAB, 1997, AM J RESP CRIT CARE, V156, P1421, DOI 10.1164/ajrccm.156.5.9703054; Kelly MM, 2000, J ALLERGY CLIN IMMUN, V105, P1162, DOI 10.1067/mai.2000.106375; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Kraft M, 1998, CHRONOBIOL INT, V15, P85, DOI 10.3109/07420529808998672; Lebowitz MD, 1997, EUR RESPIR J, V10, pS49; Liu LY, 2002, AM J RESP CRIT CARE, V165, P1062, DOI 10.1164/ajrccm.165.8.2109065; Liu LY, 2000, J ALLERGY CLIN IMMUN, V106, P1063; MACKAY TW, 1994, THORAX, V49, P257, DOI 10.1136/thx.49.3.257; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; MARTIN RJ, 1990, AM REV RESPIR DIS, V141, P33, DOI 10.1164/ajrccm/141.1.33; Martin RJ, 1998, AM J RESP CRIT CARE, V157, pS188, DOI 10.1164/ajrccm.157.5.rsaa-4; Olivenstein R, 1999, J ALLERGY CLIN IMMUN, V103, P238, DOI 10.1016/S0091-6749(99)70497-5; OOSTERHOFF Y, 1995, CLIN EXP ALLERGY, V25, P915, DOI 10.1111/j.1365-2222.1995.tb00392.x; OOSTERHOFF Y, 1995, J ALLERGY CLIN IMMUN, V96, P219, DOI 10.1016/S0091-6749(95)70011-0; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; POSTMA DS, 1994, AM J RESP CRIT CARE, V150, pS83, DOI 10.1164/ajrccm/150.5_Pt_2.S83; SHAMOO DA, 1994, J EXPO ANAL ENV EPID, V4, P133; Spanevello A, 1997, CLIN EXP ALLERGY, V27, P1138; Sulakvelidze I, 1998, EUR RESPIR J, V11, P821, DOI 10.1183/09031936.98.11040821; ten Hacken NHT, 1998, EUR RESPIR J, V11, P312, DOI 10.1183/09031936.98.11020312; ten Hacken NHT, 1998, EUR RESPIR J, V12, P546, DOI 10.1183/09031936.98.12030546; Thomas PS, 1999, J ASTHMA, V36, P335, DOI 10.3109/02770909909068226; Veen JCCMI, 1996, EUR RESPIR J, V9, P2441, DOI 10.1183/09031936.96.09122441; Wijnhoven HAH, 2001, CHEST, V119, P1034, DOI 10.1378/chest.119.4.1034; Wilson NM, 2000, THORAX, V55, P768, DOI 10.1136/thorax.55.9.768	38	54	55	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					308	312		10.1067/mai.2003.65	http://dx.doi.org/10.1067/mai.2003.65			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589350				2022-12-18	WOS:000180942700014
J	von Bubnoff, D; Geiger, E; Bieber, T				von Bubnoff, D; Geiger, E; Bieber, T			Antigen-presenting cells in allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						dendritic cell; atopic dermatitis; Fc epsilon RI	FC-EPSILON-RI; EPIDERMAL LANGERHANS CELLS; HIGH-AFFINITY RECEPTOR; EOSINOPHILIC AIRWAY INFLAMMATION; NECROSIS-FACTOR-ALPHA; GRASS-POLLEN ALLERGY; DENDRITIC CELLS; ATOPIC-DERMATITIS; CONTACT HYPERSENSITIVITY; ASTHMATIC REACTIONS	The complex interaction of the innate and adaptive immune system requires flexibility and cooperation among various cell pes. In this regard, antigen-presenting-cells (APCs) play a ty pivotal role in transferring information from the periphery of the organism to lymphoid organs, where they initiate the activation of naive T cells. Dendritic cells, Langerhans' cells (LCs), and macrophages are also critical in the induction of allergic inflammation by presenting allergens to T lymphocytes and by contributing to the local recruitment of effector cells. Because of a complex genetic background, atopic individuals exhibit a dysregulation of T cell-mediated immune mechanisms. Attempts to understand the role APCs play in these pathophysiologic conditions are in progress and may allow development of new treatment strategies. In this review we will focus on the biology of APCs and their unique role in the induction and control of allergic inflammation.	Univ Bonn, Dept Dermatol, D-53105 Bonn, Germany	University of Bonn	Bieber, T (corresponding author), Univ Bonn, Dept Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.							Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; AUBAS P, 1984, AM REV RESPIR DIS, V130, P875; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Banchereau J, 2000, J EXP MED, V192, pF39, DOI 10.1084/jem.192.12.F39; BERGSTRESSER PR, 1990, DERMATOL CLIN, V8, P3, DOI 10.1016/S0733-8635(18)30512-6; Bieber T, 1997, IMMUNOL TODAY, V18, P311, DOI 10.1016/S0167-5699(97)01046-3; Bieber T, 1998, J ALLERGY CLIN IMMUN, V102, P555, DOI 10.1016/S0091-6749(98)70270-2; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Bieber T, 1997, INT ARCH ALLERGY IMM, V113, P30, DOI 10.1159/000237500; Bieber T, 2000, J Dermatol, V27, P698; Bieber T, 1996, J DERMATOL SCI, V13, P71, DOI 10.1016/0923-1811(95)00504-8; BIEBER T, 1992, J INVEST DERMATOL, V99, pS10, DOI 10.1111/1523-1747.ep12668204; Blom B, 2000, J EXP MED, V192, P1785, DOI 10.1084/jem.192.12.1785; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Campbell JJ, 2001, J IMMUNOL, V166, P877, DOI 10.4049/jimmunol.166.2.877; Caux C, 1997, ADV EXP MED BIOL, V417, P21; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; de la Salle H, 1997, Int Rev Immunol, V16, P187, DOI 10.3109/08830189709045708; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; Donnadieu E, 2000, J IMMUNOL, V165, P3917, DOI 10.4049/jimmunol.165.7.3917; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Facchetti F, 1999, HISTOPATHOLOGY, V35, P88; FOKKENS WJ, 1990, INT ARCH ALLER A IMM, V93, P66, DOI 10.1159/000235281; FOKKENS WJ, 1991, IMMUNOBIOLOGY, V182, P135, DOI 10.1016/S0171-2985(11)80197-X; Geissmann F, 2001, J IMMUNOL, V166, P346, DOI 10.4049/jimmunol.166.1.346; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; JURGENS M, 1995, J IMMUNOL, V155, P5184; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Kauffmann F, 1997, AM J RESP CRIT CARE, V156, pS123, DOI 10.1164/ajrccm.156.4.12tac9; Kay AB, 2001, NEW ENGL J MED, V344, P109, DOI 10.1056/NEJM200101113440206; Kehren J, 1999, J EXP MED, V189, P779, DOI 10.1084/jem.189.5.779; Kraft S, 1998, J IMMUNOL, V161, P1000; Krasteva M, 1999, EUR J DERMATOL, V9, P144; Krasteva M, 1999, EUR J DERMATOL, V9, P65; Krasteva M, 1998, IMMUNOL TODAY, V19, P289, DOI 10.1016/S0167-5699(98)01272-9; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; LEUNG DYM, 1987, CLIN IMMUNOL IMMUNOP, V42, P328, DOI 10.1016/0090-1229(87)90021-3; Maurer D, 1996, J IMMUNOL, V157, P607; Maurer D, 1997, ADV EXP MED BIOL, V417, P175; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1111/j.1365-2222.1996.tb00571.x; ODOHERTY U, 1994, IMMUNOLOGY, V82, P487; Panhans-Gross A, 2001, J ALLERGY CLIN IMMUN, V107, P345, DOI 10.1067/mai.2001.112600; PATRY C, 1995, IMMUNOLOGY, V86, P1; POLAT GL, 1993, IMMUNOLOGY, V80, P287; Poulter LW, 1996, IMMUNOBIOLOGY, V195, P574, DOI 10.1016/S0171-2985(96)80023-4; POULTER LW, 1994, IMMUNOL TODAY, V15, P258, DOI 10.1016/0167-5699(94)90004-3; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Robert C, 1999, J EXP MED, V189, P627, DOI 10.1084/jem.189.4.627; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sallusto F, 1999, J EXP MED, V189, P611, DOI 10.1084/jem.189.4.611; Schuler G, 1997, INT ARCH ALLERGY IMM, V112, P317, DOI 10.1159/000237474; Sebastiani S, 2001, J IMMUNOL, V166, P996, DOI 10.4049/jimmunol.166.2.996; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P433, DOI 10.1016/S0091-6749(99)70389-1; Spits H, 2000, J EXP MED, V192, P1775, DOI 10.1084/jem.192.12.1775; Taams LS, 1999, PATHOBIOLOGY, V67, P249, DOI 10.1159/000028103; Takashima A, 2000, Ann N Y Acad Sci, V919, P205; Teraki Y, 2000, BRIT J DERMATOL, V143, P373, DOI 10.1046/j.1365-2133.2000.03665.x; Tighe H, 1998, IMMUNOL TODAY, V19, P89, DOI 10.1016/S0167-5699(97)01201-2; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Wollenberg A, 2001, J ALLERGY CLIN IMMUN, V107, P519, DOI 10.1067/mai.2001.112942	74	54	57	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					329	339		10.1067/mai.2001.117457	http://dx.doi.org/10.1067/mai.2001.117457			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544450	Bronze			2022-12-18	WOS:000171215400002
J	Chakir, J; Page, N; Hamid, Q; Laviolette, M; Boulet, LP; Rouabhia, M				Chakir, J; Page, N; Hamid, Q; Laviolette, M; Boulet, LP; Rouabhia, M			Bronchial mucose produced by tissue engineering: A new tool to study cellular interactions in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; resident cells; engineered bronchial tissue; T cells; fibroblasts; epithelial cells; IL-5	EPIDERMIS; CELLS	Background: The use of fiberoptic bronchial biopsies has improved our understanding of the immunopathology of asthma. However this approach offers a limited ability to perform mechanistic studies observing cell-cell and cell-matrix interactions, which are a key issue in the study of airway remodeling. Tissue engineering is a technique that combines the use of biology and engineering expertise to generate a limitless amount of tissue from small samples. This technology allows for the study of cell interactions under conditions as close as possible to the natural environment. Objective: The aim of this study was to evaluate the feasibility of an engineered human bronchial mucosa as a model to study cellular interactions in asthma, Methods: Human bronchial fibroblasts from normal and asthmatic donors were incorporated into collagen gel. Bronchial epithelial cells were seeded over this gel and then cultured in an air-liquid interface in the presence or the absence of T lymphocytes, Biopsy specimens from these engineered mucosa were taken for structural and ultrastructural analysis, and T lymphocytes were harvested and used to localize IL-5. Results: Histologic analysis showed that engineered mucosa with normal bronchial cells presented a pseudostratified ciliated epithelium with the presence of mucus secretory cells. The electron microscopy analysis confirmed these histologic results. These features were comparable with those observed in normal bronchial tissues. However, in engineered mucosa from asthmatic subjects, the tissue structure was disorganized, particularly the epithelial cell arrangement. The percentage of IL-5(+) lymphocytes was significantly (P =.03) higher in engineered bronchial mucosa from asthmatic subjects (87% +/- 2%) compared with mucosa from normal volunteers (2% +/- 0.3%). Conclusion: Using tissue engineering, we produced an in vitro model of bronchial mucosa from normal and asthmatic subjects, These models could be a valuable tool to better understand key mechanisms Involved in inflammation and airway repair.	Hop Laval, Ctr Rech, Inst Univ Crdiol & Pneumol, Ste Foy, PQ G1V 4G5, Canada; Univ Laval, CHUQ Hop St Francois Assise, Unite Biotechnol, Quebec City, PQ, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada	Laval University; Laval University; McGill University	Chakir, J (corresponding author), Hop Laval, Ctr Rech, Inst Univ Crdiol & Pneumol, 2725 Chemin St Foy, Ste Foy, PQ G1V 4G5, Canada.			Rouabhia, Mahmoud/0000-0003-2205-8281				ADAMS JC, 1993, DEVELOPMENT, V117, P1183; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; AUBOCK J, 1988, TRANSPLANTATION, V45, P730, DOI 10.1097/00007890-198804000-00013; Dube J, 1998, LAB INVEST, V78, P297; GAULDIE J, 1992, AM REV RESPIR DIS, V145, pS14, DOI 10.1164/ajrccm/145.2_Pt_2.S14; Goulet F, 1996, AM J RESP CELL MOL, V15, P312, DOI 10.1165/ajrcmb.15.3.8810634; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Larochelle F, 1998, LAB INVEST, V78, P1089; Lukacs NW, 1997, AM J PATHOL, V150, P1861; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; Ogle BM, 1999, TISSUE ENG, V5, P387, DOI 10.1089/ten.1999.5.387; Puddicombe S. M., 1998, European Respiratory Journal, V12, p29s; RAEBURN D, 1994, EUR RESPIR J, V7, P2226, DOI 10.1183/09031936.94.07122226; RICCIARDOLO FLM, 1999, EUR RESPIR J, V14, pS66; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; Wakitani S, 1998, TISSUE ENG, V4, P429, DOI 10.1089/ten.1998.4.429; Zhang SL, 1999, LAB INVEST, V79, P395	18	54	56	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					36	40		10.1067/mai.2001.111929	http://dx.doi.org/10.1067/mai.2001.111929			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11149988	Bronze			2022-12-18	WOS:000166533300007
J	Ott, VL; Cambier, JC				Ott, VL; Cambier, JC			Activating and inhibitory signaling in mast cells: New opportunities for therapeutic intervention?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						mast cell; Fc epsilon RI; Fc gamma RIIB; inhibitory receptors; signal transduction	INTEGRIN-ASSOCIATED PROTEIN; AFFINITY IGE RECEPTOR; FC-GAMMA-RIIB; FUNCTION-ASSOCIATED ANTIGEN; TYROSINE-PHOSPHATASE SHP-1; C-TYPE LECTIN; IMMUNOGLOBULIN-LIKE RECEPTORS; NATURAL-KILLER-CELLS; NEGATIVE REGULATION; B-CELL	Immune responses are tightly controlled by the activities of both activating and inhibitory signals. At the cellular level, these signals are generated through engagement of membrane-associated receptors and coreceptors. The high-affinity IgE receptor Fc epsilon RI is expressed on mast cells and basophils and, on cross-linking by multivalent antigen (allergen), stimulates the release of inflammatory mediators that induce acute allergic responses. Activation signals mediated by a variety of immune receptors (eg, B-cell receptor, T-cell receptor, and Fc epsilon RI) are subject to negative regulation by a growing family of structurally and functionally related inhibitory receptors, Recent studies indicate that mast cells express multiple inhibitory receptors that may regulate Fc epsilon RI-induced mast cell activation through similar mechanisms. The ability of inhibitory receptors to attenuate IgE-mediated allergic responses implicates them as potential targets for therapeutic intervention in the treatment of atopic disease. Indeed, coaggregation of activating and inhibitory receptors has been suggested as one possible mechanism to explain the beneficial effects of specific immunotherapy in the treatment of allergy. In this review we summarize the current knowledge of inhibitory receptors expressed in mast cells and the mechanisms through which they regulate mast cell function.	Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO USA; Natl Jewish Med & Res Ctr, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Cambier, JC (corresponding author), 1400 Jackson St,K1004, Denver, CO 80206 USA.			Cambier, John/0000-0002-7803-242X				Adams S, 1998, J IMMUNOL, V161, P1853; Aman MJ, 2000, MOL CELL BIOL, V20, P3576, DOI 10.1128/MCB.20.10.3576-3589.2000; ARM JP, 1991, J BIOL CHEM, V266, P15966; Ashman RF, 1996, J IMMUNOL, V157, P5; BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; Barnes PJ, 1999, NATURE, V402, pB31, DOI 10.1038/35037026; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Binsack R, 1997, EUR J IMMUNOL, V27, P2557, DOI 10.1002/eji.1830271014; Blaser C, 1998, J IMMUNOL, V161, P6451; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Brooke GP, 1998, EUR J IMMUNOL, V28, P1, DOI 10.1002/(SICI)1521-4141(199801)28:01&lt;1::AID-IMMU1&gt;3.0.CO;2-V; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Bruhns P, 1999, J IMMUNOL, V162, P3168; Buhl AM, 1999, J IMMUNOL, V162, P4438; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; Butcher S, 1998, EUR J IMMUNOL, V28, P3755, DOI 10.1002/(SICI)1521-4141(199811)28:11<3755::AID-IMMU3755>3.0.CO;2-3; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CASTELLS MC, 1994, J BIOL CHEM, V269, P8393; CHAN PL, 1971, IMMUNOLOGY, V21, P967; CHUANG W, 1990, DEV BIOL, V137, P219, DOI 10.1016/0012-1606(90)90249-I; Colonna M, 1999, J LEUKOCYTE BIOL, V66, P375, DOI 10.1002/jlb.66.3.375; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; Corne J, 1997, J CLIN INVEST, V99, P879, DOI 10.1172/JCI119252; Corral L, 2000, EUR J IMMUNOL, V30, P920, DOI 10.1002/1521-4141(200003)30:3<920::AID-IMMU920>3.0.CO;2-P; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Costello PS, 1996, ONCOGENE, V13, P2595; Daeron M, 1997, INT ARCH ALLERGY IMM, V113, P138, DOI 10.1159/000237528; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1993, INT IMMUNOL, V5, P1393, DOI 10.1093/intimm/5.11.1393; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAmbrosio D, 1996, IMMUNOL LETT, V54, P77, DOI 10.1016/S0165-2478(96)02653-3; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Dustin LB, 1999, J IMMUNOL, V162, P2717; Ebner C, 1999, INT ARCH ALLERGY IMM, V119, P1, DOI 10.1159/000024168; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Fleming TJ, 1997, J EXP MED, V186, P1307, DOI 10.1084/jem.186.8.1307; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; FOX CC, 1994, CELL IMMUNOL, V158, P253, DOI 10.1006/cimm.1994.1272; FRANDJI P, 1993, J IMMUNOL, V151, P6318; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; Gupta N, 1997, J EXP MED, V186, P473, DOI 10.1084/jem.186.3.473; GUTHMANN MD, 1995, INT ARCH ALLERGY IMM, V107, P82, DOI 10.1159/000236938; GUTHMANN MD, 1995, P NATL ACAD SCI USA, V92, P9397, DOI 10.1073/pnas.92.20.9397; Hanke T, 1998, EUR J IMMUNOL, V28, P4409, DOI 10.1002/(SICI)1521-4141(199812)28:12<4409::AID-IMMU4409>3.0.CO;2-3; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Ho LH, 1999, P NATL ACAD SCI USA, V96, P15086, DOI 10.1073/pnas.96.26.15086; Holgate ST, 1998, ALLERGY, V53, P83, DOI 10.1111/j.1398-9995.1998.tb04946.x; Huber M, 1999, CURR TOP MICROBIOL, V244, P29; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Jurgens L, 1996, EUR J IMMUNOL, V26, P84, DOI 10.1002/eji.1830260113; Katz HR, 1997, J IMMUNOL, V158, P5065; Katz HR, 1996, P NATL ACAD SCI USA, V93, P10809, DOI 10.1073/pnas.93.20.10809; Kawakami Y, 1999, J LEUKOCYTE BIOL, V65, P286, DOI 10.1002/jlb.65.3.286; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; KEPLEY CL, 2000, IN PRESS J ALLERGY C; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kimura T, 1996, J BIOL CHEM, V271, P27962, DOI 10.1074/jbc.271.44.27962; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kubagawa H, 1999, CURR TOP MICROBIOL, V244, P137; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; Kuroiwa A, 1998, J BIOL CHEM, V273, P1070, DOI 10.1074/jbc.273.2.1070; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Lienard H, 1999, J BIOL CHEM, V274, P32493, DOI 10.1074/jbc.274.45.32493; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Lu-Kuo JM, 1999, J BIOL CHEM, V274, P5791, DOI 10.1074/jbc.274.9.5791; MACHIELS JJ, 1993, AM REV RESPIR DIS, V147, P1407, DOI 10.1164/ajrccm/147.6_Pt_1.1407; Maeda A, 1999, ONCOGENE, V18, P2291, DOI 10.1038/sj.onc.1202552; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; Maeda A, 1998, J EXP MED, V188, P991, DOI 10.1084/jem.188.5.991; Malbec O, 1999, CURR TOP MICROBIOL, V244, P13; Malbec O, 1998, J IMMUNOL, V160, P1647; Malbec O, 1999, J IMMUNOL, V162, P4424; MAWBY WJ, 1994, BIOCHEM J, V304, P525, DOI 10.1042/bj3040525; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; MORTON HC, 1995, J BIOL CHEM, V270, P29781; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; Nadler MJS, 1997, J BIOL CHEM, V272, P20038, DOI 10.1074/jbc.272.32.20038; Ohnishi H, 1999, J NEUROCHEM, V72, P1402, DOI 10.1046/j.1471-4159.1999.721402.x; Ono M, 1999, J BIOL CHEM, V274, P30288, DOI 10.1074/jbc.274.42.30288; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; ORTEGA E, 1991, INT IMMUNOL, V3, P333, DOI 10.1093/intimm/3.4.333; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; Philosof-Oppenheimer R, 2000, EUR J BIOCHEM, V267, P703, DOI 10.1046/j.1432-1327.2000.01044.x; Reinhold MI, 1997, J EXP MED, V185, P1, DOI 10.1084/jem.185.1.1; Reischl IG, 1999, BIOCHEM PHARMACOL, V58, P1841, DOI 10.1016/S0006-2952(99)00226-9; Rohrschneider LR, 2000, GENE DEV, V14, P505; Rojo S, 1997, J IMMUNOL, V158, P9; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Sato K, 1998, J IMMUNOL, V161, P2716; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Schweitzer-Stenner R, 1999, IMMUNOL LETT, V68, P71, DOI 10.1016/S0165-2478(99)00032-2; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Ticchioni M, 1997, J IMMUNOL, V158, P677; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Todd SC, 1996, J EXP MED, V184, P2055, DOI 10.1084/jem.184.5.2055; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Wang LL, 1997, J IMMUNOL, V158, P13; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yamashita Y, 1998, J IMMUNOL, V161, P4042; Yamashita Y, 1998, J BIOCHEM-TOKYO, V123, P358, DOI 10.1093/oxfordjournals.jbchem.a021945; YANO H, 1993, J BIOL CHEM, V268, P25846; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yuasa T, 1999, J EXP MED, V189, P187, DOI 10.1084/jem.189.1.187	130	54	63	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					429	440		10.1067/mai.2000.109428	http://dx.doi.org/10.1067/mai.2000.109428			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984360				2022-12-18	WOS:000089471900003
J	Ahn, K; Takai, S; Pawankar, R; Kuramasu, A; Ohtsu, H; Kempuraj, D; Tomita, H; Iida, M; Matsumoto, K; Akasawa, A; Miyazaki, M; Saito, H				Ahn, K; Takai, S; Pawankar, R; Kuramasu, A; Ohtsu, H; Kempuraj, D; Tomita, H; Iida, M; Matsumoto, K; Akasawa, A; Miyazaki, M; Saito, H			Regulation of chymase production in human mast cell progenitors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; cell differentiation; chymase; tryptase; IL-4; stem cells	CORD-BLOOD; HISTAMINE-SECRETION; GENE-EXPRESSION; KINASE RECEPTOR; STEEL FACTOR; TRYPTASE; GROWTH; RAT; MOUSE; LUNG	Background: Although mature tryptase-positive mast cells (MCs) and tryptase and chymase double-positive MCs are recognized using in situ staining and are preferentially distributed in different tissues, recent findings suggest that tryptase-positive MCs can give rise to tryptase and chymase double-positive MCs, Objective: We investigated the regulation of chymase production in developing MCs. Methods: Human cord blood or peripheral blood cells were cultured in the presence of stem cell factor and IL-6 with or without IL-4 in methylcellulose or liquid medium. Intracellular chymase and tryptase were determined with immunocytochemistry, flow cytometry, and ELISA, Chymase messenger RNA expression was examined with 3 different methods, such as Northern blotting. Results: Flow cytometric analysis always showed a unimodal histogram of chymase-positive, as well as tryptase-positive, cells in the presence of various cytokines, even when chymase was not detected in some MCs with immunocytochemistry, The chymase protein expression increased by culture duration and was enhanced by cytokines, such as a high concentration of stem cell factor or IL-4. Chymase messenger RNA was expressed higher in immature MCs than mature chymase protein-rich MCs, We generated macroscopic MC colonies in methylcellulose by culturing CD34(+) cells for 10 weeks and measured cellular chymase, tryptase, and histamine. The chymase/histamine ratio widely varied (0.07-1.01) depending on MC colony, even under the same culture conditions, including IL-4, whereas the tryptase/histamine ratio was relatively constant (1.02-1.89), Conclusion: All human MCs in culture are capable of producing chymase, and the production is clonally regulated at their progenitors by cytokine-independent mechanisms, as well as being totally controlled by cytokine-dependent mechanisms accompanied by maturation.	Natl Childrens Med Res Ctr, Dept Allergy, Setagaya Ku, Tokyo 1548509, Japan; Osaka Med Coll, Dept Pharmacol, Osaka, Japan; Nippon Med Sch, Dept Otolaryngol, Tokyo 113, Japan; Tohoku Univ, Sch Med, Dept Cellular Pharmacol, Sendai, Miyagi 980, Japan	National Center for Child Health & Development - Japan; Osaka Medical College; Nippon Medical School; Tohoku University	Saito, H (corresponding author), Natl Childrens Med Res Ctr, Dept Allergy, Setagaya Ku, 3-35-31 Taishido, Tokyo 1548509, Japan.		Duraisamy, Kempuraj/AAC-5638-2022; duraisamy, kempuraj/R-3043-2019	Saito, Hirohisa/0000-0002-6630-8337				BEFUS AD, 1982, J IMMUNOL, V128, P2475; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Chen HX, 1998, J EXP MED, V188, P1657, DOI 10.1084/jem.188.9.1657; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH MK, 1982, J IMMUNOL, V129, P2116; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; CRAIG SS, 1986, AM J PATHOL, V124, P427; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P303, DOI 10.1111/apm.1966.66.3.303; IHLE JN, 1983, J IMMUNOL, V131, P282; IRANI AMA, 1987, J IMMUNOL, V138, P4381; KANAKURA Y, 1988, BLOOD, V72, P877; Kempuraj D, 1999, BLOOD, V93, P3338, DOI 10.1182/blood.V93.10.3338.410k05_3338_3346; Kinoshita T, 1999, BLOOD, V94, P496, DOI 10.1182/blood.V94.2.496.414k19_496_508; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; Kuramasu A, 1998, J BIOL CHEM, V273, P31607, DOI 10.1074/jbc.273.47.31607; LEARY AG, 1989, P NATL ACAD SCI USA, V86, P4535, DOI 10.1073/pnas.86.12.4535; LOWMAN MA, 1988, J ALLERGY CLIN IMMUN, V81, P574, DOI 10.1016/0091-6749(88)90199-6; MAYRHOFER G, 1980, HISTOCHEM J, V12, P513, DOI 10.1007/BF01011925; MILLER HRP, 1972, AM J PATHOL, V69, P195; MIYAZAWA K, 1995, BLOOD, V85, P641, DOI 10.1182/blood.V85.3.641.bloodjournal853641; Moss RB, 1996, J CLIN LAB ANAL, V10, P418, DOI 10.1002/(SICI)1098-2825(1996)10:6<418::AID-JCLA18>3.0.CO;2-#; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; OTSU K, 1987, J EXP MED, V165, P615, DOI 10.1084/jem.165.3.615; Pawankar R, 2000, J ALLERGY CLIN IMMUN, V105, pS67, DOI 10.1016/S0091-6749(00)90636-5; PEARCE FL, 1982, J IMMUNOL, V128, P2481; Saito H, 1996, J IMMUNOL, V157, P343; SCHWARTZ LB, 1994, J CLIN IMMUNOL, V14, P190, DOI 10.1007/BF01533368; Schwartz LB, 1998, ALLERGY PRINCIPLES P, V1, P261; STEVENS RL, 1982, J BIOL CHEM, V257, P253; Takai S, 1997, CLIN CHIM ACTA, V265, P13, DOI 10.1016/S0009-8981(97)00114-9; Toru H, 1998, BLOOD, V91, P187, DOI 10.1182/blood.V91.1.187.187_187_195; Xia ZN, 1996, J BIOL CHEM, V271, P8747, DOI 10.1074/jbc.271.15.8747; YANAGIDA M, 1995, BLOOD, V86, P3705, DOI 10.1182/blood.V86.10.3705.bloodjournal86103705; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	36	54	56	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					321	328		10.1067/mai.2000.108107	http://dx.doi.org/10.1067/mai.2000.108107			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932077				2022-12-18	WOS:000088708100016
J	Simons, FER; Peng, ZK				Simons, FER; Peng, ZK			Skeeter syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							WORLDWIDE DISTRIBUTION; IGE RESPONSES; SKIN; REACTIVITY; ANTIGENS		Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB, Canada	University of Manitoba	Simons, FER (corresponding author), Childrens Hosp, 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.							Peng Z, 1998, J ALLERGY CLIN IMMUN, V101, pS32; Peng ZK, 1996, ANN ALLERG ASTHMA IM, V77, P238, DOI 10.1016/S1081-1206(10)63262-0; Peng ZK, 1998, J ALLERGY CLIN IMMUN, V101, P284, DOI 10.1016/S0091-6749(98)70395-1; Peng ZK, 1998, J ALLERGY CLIN IMMUN, V101, P498, DOI 10.1016/S0091-6749(98)70357-4; Peng ZK, 1997, J ALLERGY CLIN IMMUN, V100, P192, DOI 10.1016/S0091-6749(97)70224-0; Peng ZK, 1996, ANN ALLERG ASTHMA IM, V77, P371, DOI 10.1016/S1081-1206(10)63335-2; Xu W, 1998, J ALLERGY CLIN IMMUN, V101, pS203	7	54	56	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				705	707		10.1016/S0091-6749(99)70348-9	http://dx.doi.org/10.1016/S0091-6749(99)70348-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482852	Bronze			2022-12-18	WOS:000082870000041
J	Peden, DB; Tucker, K; Murphy, P; Newlin-Clapp, L; Boehlecke, B; Hazucha, M; Bromberg, P; Reed, W				Peden, DB; Tucker, K; Murphy, P; Newlin-Clapp, L; Boehlecke, B; Hazucha, M; Bromberg, P; Reed, W			Eosinophil influx to the nasal airway after local, low-level LPS challenge in humans	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; air pollution; asthma; eosinophils; GM-CSF	COLONY-STIMULATING FACTOR; ATOPIC ASTHMATIC SUBJECTS; INHALED ENDOTOXIN; CD14 EXPRESSION; UP-REGULATION; TNF-ALPHA; GM-CSF; DUST; LIPOPOLYSACCHARIDE; INHALATION	Background: Recent observations show that atopic asthmatic subjects have increased sensitivity to respirable endotoxin (or LPS) compared with normal persons. In vitro studies demonstrate that LPS enhances eosinophil survival. These observations suggest that the effects of inhaled LPS in asthmatic subjects may include increases in the number of airway eosinophils. Objective: We sought to determine whether low-level nasal LPS challenge causes an increase in eosinophil numbers in the nasal airways of atopic or normal subjects. Methods: Sixteen volunteers (10 atopic asthmatic subjects and 6 normal subjects) underwent 2 nasal challenge sessions. In one session, one nostril was challenged with saline and the other with 0.1 mu g of LPS. During the second session, 0.3 mu g and 1.0 mu g of LPS was delivered to each nostril, respectively. Nasal lavage fluid was obtained from each nostril before challenge, as well as 4 and 24 hours after challenge, and examined for the percent of total cells that were eosinophils and neutrophils, as well as cytokine levels. Results: LPS (1.0 pg) increased the percent of eosinophils in nasal lavage fluid 4 hours after challenge in atopic subjects only. There was also a correlation between constitutive nasal GM-CSF and eosinophil response to LPS in atopic subjects. Conclusion: LPS challenge increases eosinophils in the airways of atopic subjects.	Univ N Carolina, Sch Med, Ctr Environm Med & Lung Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Peden, DB (corresponding author), Univ N Carolina, Sch Med, Ctr Environm Med & Lung Biol, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27599 USA.			Peden, David/0000-0003-4526-4627				Akin C, 1996, J INTERF CYTOK RES, V16, P479, DOI 10.1089/jir.1996.16.479; Baqui AAMA, 1998, CLIN DIAGN LAB IMMUN, V5, P341, DOI 10.1128/CDLI.5.3.341-347.1998; BASHA MA, 1994, CHEST, V106, P1757, DOI 10.1378/chest.106.6.1757; Bittleman DB, 1996, INFLAMM RES, V45, P89, DOI 10.1007/BF02265121; Blaski CA, 1996, AM J RESP CRIT CARE, V154, P334, DOI 10.1164/ajrccm.154.2.8756803; BOZZA PT, 1994, J LEUKOCYTE BIOL, V56, P151, DOI 10.1002/jlb.56.2.151; BOZZA PT, 1994, IMMUNOPHARMACOLOGY, V27, P131, DOI 10.1016/0162-3109(94)90047-7; BRUIJNZEEL PLB, 1993, J INVEST DERMATOL, V100, P137, DOI 10.1111/1523-1747.ep12462781; Bundschuh DS, 1997, J IMMUNOL, V158, P2862; CHRISTIANI DC, 1993, AM J IND MED, V23, P333, DOI 10.1002/ajim.4700230210; CHWARTZ DA, 1994, AM J PHYSIOL, V267, pL609; CLAPP WD, 1993, CHEST, V104, P825, DOI 10.1378/chest.104.3.825; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736, DOI 10.1152/ajplung.1996.270.5.L736; Gauvreau GM, 1998, AM J RESP CELL MOL, V19, P55, DOI 10.1165/ajrcmb.19.1.2871; HALLWORTH MP, 1994, EUR RESPIR J, V4, P1096; KITA H, 1995, J ALLERGY CLIN IMMUN, V95, P1261, DOI 10.1016/S0091-6749(95)70084-6; Kruger M, 1996, IMMUNOLOGY, V89, P89, DOI 10.1046/j.1365-2567.1996.d01-707.x; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352, DOI 10.1164/ajrccm/146.2.352; MICHEL O, 1992, THORAX, V47, P288, DOI 10.1136/thx.47.4.288; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; Nightingale JA, 1998, THORAX, V53, P563, DOI 10.1136/thx.53.7.563; NOAH TL, 1995, AM J RESP CRIT CARE, V152, P1290, DOI 10.1164/ajrccm.152.4.7551384; Peden DB, 1997, J ALLERGY CLIN IMMUN, V100, P802, DOI 10.1016/S0091-6749(97)70277-X; Peden DB, 1997, ALLERGY, V52, P37, DOI 10.1111/j.1398-9995.1997.tb04869.x; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336, DOI 10.1164/ajrccm.151.5.7735583; Saitou M, 1997, Fukushima J Med Sci, V43, P75; SANDSTROM T, 1994, AM J IND MED, V25, P103, DOI 10.1002/ajim.4700250127; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24, DOI 10.1164/ajrccm.154.1.8680687; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V152, P603, DOI 10.1164/ajrccm.152.2.7633714; Shute JK, 1997, AM J RESP CRIT CARE, V155, P1877, DOI 10.1164/ajrccm.155.6.9196089; Sullivan S, 1996, J ALLERGY CLIN IMMUN, V97, P966, DOI 10.1016/S0091-6749(96)80072-8; TEEUW KB, 1994, ARCH INTERN MED, V154, P2339, DOI 10.1001/archinte.154.20.2339; Virchow JC, 1998, EUR RESPIR J, V11, P317, DOI 10.1183/09031936.98.11020317; Wang Z, 1997, EUR RESPIR J, V10, P381, DOI 10.1183/09031936.97.10020381; WARRINGA RAJ, 1993, J ALLERGY CLIN IMMUN, V91, P1198, DOI 10.1016/0091-6749(93)90323-8; WEG VB, 1995, IMMUNOLOGY, V84, P36; WOOLLEY KL, 1995, AM J RESP CRIT CARE, V151, P1915, DOI 10.1164/ajrccm.151.6.7767540; 1998, AM J RESP CRIT CAR S, V158, pS1	39	54	54	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				388	394		10.1016/S0091-6749(99)70383-0	http://dx.doi.org/10.1016/S0091-6749(99)70383-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452761				2022-12-18	WOS:000082364800032
J	Wisnewski, AV; Lemus, R; Karol, MH; Redlich, CA				Wisnewski, AV; Lemus, R; Karol, MH; Redlich, CA			Isocyanate-conjugated human lung epithelial cell proteins: A link between exposure and asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						isocyanate; hexamethylene diisocyanate; occupational asthma; human lung epithelial cell antigens	HUMAN-SERUM-ALBUMIN; TOLUENE DIISOCYANATE; OCCUPATIONAL ASTHMA; T-CELLS; BRONCHIAL-MUCOSA; RESPONSES; MANUFACTURE; EOSINOPHILS; ACTIVATION; PAINTERS	Background: Isocyanates are a group of highly reactive cross-linking chemicals that cause airway inflammation and asthma in exposed individuals. Isocyanates have been detected along the airway epithelia of exposed workers and animals, prompting the hypothesis that isocyanates can directly bind to epithelial cell proteins. Objective: We tested the hypothesis that hexamethylene diisocyanate (HDI) binds directly to lung epithelial cell proteins and initiated studies to evaluate the immunostimulatory potential of HDI-conjugated lung epithelial cell proteins. Methods: Human lung epithelial cell lines were exposed to vapor- and liquid-phase HDI, and the cellular proteins were analyzed for HDI conjugation by Western blotting and tested for the ability to induce lymphocyte proliferation in vitro. Results: A number of epithelial cell polypeptides, ranging from 25 to 110 kd in apparent molecular weight, were conjugated with HDI after exposure of the human lung epithelial cell lines (A549 and NCI-H292) to HDI concentrations greater than 0.005% (vol/vol) in the liquid phase. Vapor-phase HDI exposure resulted in a more restricted HDI conjugation pattern, with major HDI-conjugated polypeptides migrating at 47, 71, and 91 kd, HDI-conjugated epithelial cell proteins specifically stimulated proliferation of PBMCs from subjects with isocyanate induced asthma but not HDI-exposed nonasthmatic individuals or atopic subjects with nonisocyanate-related asthma. Conclusions: The data demonstrate that epithelial cell proteins readily react with HDI and that HDI-conjugated epithelial cell proteins can stimulate lymphocyte proliferation. Further characterization and evaluation of HDI-conjugated epithelial cell proteins will elucidate their potential role in the pathogenesis of isocyanate-induced asthma.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA	Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wisnewski, AV (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,LCI-105, New Haven, CT 06510 USA.				NHLBI NIH HHS [1R01HL62622, R01 HL062622-01, R01 HL062622, 1P01HL56389] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062622, P01HL056389] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVERY SB, 1969, CLIN EXP IMMUNOL, V4, P585; Bernstein JA, 1997, J ALLERGY CLIN IMMUN, V99, P245, DOI 10.1016/S0091-6749(97)70104-0; BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411, DOI 10.1164/arrd.1977.116.3.411; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; COLIGAN JE, 1998, CURRENT PROTOCOLS IM; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Day BW, 1997, CHEM RES TOXICOL, V10, P424, DOI 10.1021/tx960201+; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; FABBRI LM, 1994, CLIN EXP ALLERGY, V24, P628, DOI 10.1111/j.1365-2222.1994.tb00966.x; Frew A, 1998, J ALLERGY CLIN IMMUN, V101, P841, DOI 10.1016/S0091-6749(98)70313-6; GRAMMAR LC, 1993, J ALLERGY CLIN IMMUN, V92, P857; JIN R, 1988, CHEM RES TOXICOL, V1, P281, DOI 10.1021/tx00005a005; Karol M H, 1982, Fundam Appl Toxicol, V2, P108, DOI 10.1016/S0272-0590(82)80090-0; KAROL MH, 1994, AM J RESP CRIT CARE, V149, P611, DOI 10.1164/ajrccm.149.3.8118626; KAY AB, 1992, AM REV RESPIR DIS, V145, pS22, DOI 10.1164/ajrccm/145.2_Pt_2.S22; KENNEDY AL, 1993, FUND APPL TOXICOL, V20, P57, DOI 10.1006/faat.1993.1007; LESAGE J, 1992, AM IND HYG ASSOC J, V53, P146, DOI 10.1202/0002-8894(1992)053<0146:WETI>2.0.CO;2; Lushniak BD, 1998, AM J IND MED, V33, P471, DOI 10.1002/(SICI)1097-0274(199805)33:5<471::AID-AJIM6>3.0.CO;2-V; MAESTRELLI P, 1994, SCAND J WORK ENV HEA, V20, P376, DOI 10.5271/sjweh.1383; Malo JL, 1996, OCCUPATIONAL ENV RES, P420; MCMURRY J, 1984, ORGANIC CHEM, P1158; Merk HF, 1997, INT ARCH ALLERGY IMM, V113, P173, DOI 10.1159/000237538; MOSCATO G, 1991, J OCCUP ENVIRON MED, V33, P720, DOI 10.1097/00043764-199106000-00014; MYER HE, 1993, AM IND HYG ASSOC J, V54, P663, DOI 10.1202/0002-8894(1993)054<0663:ASOAHH>2.0.CO;2; Redlich CA, 1996, CHEST, V109, pS6, DOI 10.1378/chest.109.3_Supplement.6S; Redlich CA, 1997, SCAND J WORK ENV HEA, V23, P227, DOI 10.5271/sjweh.203; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SAETTA M, 1992, AM REV RESPIR DIS, V145, P160, DOI 10.1164/ajrccm/145.1.160; SAETTA M, 1992, AM REV RESPIR DIS, V145, P169, DOI 10.1164/ajrccm/145.1.169; TORNLING G, 1990, AM J IND MED, V17, P299, DOI 10.1002/ajim.4700170302; Urlich H, 1996, CHEM TECHNOLOGY ISOC; VANDENPLAS O, 1993, BRIT J IND MED, V50, P213; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WELINDER H, 1988, CLIN ALLERGY, V18, P85, DOI 10.1111/j.1365-2222.1988.tb02847.x	34	54	56	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				341	347		10.1016/S0091-6749(99)70377-5	http://dx.doi.org/10.1016/S0091-6749(99)70377-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452755	Bronze			2022-12-18	WOS:000082364800026
J	Lemiere, C; Efthimiadis, A; Hargreave, FE				Lemiere, C; Efthimiadis, A; Hargreave, FE			Occupational eosinophilic bronchitis without asthma: An unknown occupational airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									St Josephs Hosp, Firestone Reg Chest & Allergy Unit, Dept Med, Hamilton, ON L8N 4A6, Canada; St Josephs Hosp, Asthma Res Grp, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Hamilton, ON, Canada	McGill University; McMaster University; McGill University; McMaster University; McMaster University	Hargreave, FE (corresponding author), St Josephs Hosp, Firestone Reg Chest & Allergy Unit, Dept Med, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.							FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; GIBSON PG, 1995, CLIN EXP ALLERGY, V25, P127, DOI 10.1111/j.1365-2222.1995.tb01017.x; Juniper E, 1994, HISTAMINE METHACHOLI; LOZEWICZ S, 1985, THORAX, V40, P836, DOI 10.1136/thx.40.11.836; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799	5	54	56	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				852	853		10.1016/S0091-6749(97)70286-0	http://dx.doi.org/10.1016/S0091-6749(97)70286-0			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438499				2022-12-18	WOS:000071353600023
J	Christiansen, SC; Martin, SB; Schleicher, NC; Koziol, JA; Mathews, KP; Zuraw, BL				Christiansen, SC; Martin, SB; Schleicher, NC; Koziol, JA; Mathews, KP; Zuraw, BL			Evaluation of a school-based asthma education program for inner-city children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; education; school; severity	MANAGEMENT	Background: We have previously reported a high prevalence of current asthma-related symptoms affecting predominantly Hispanic, socioeconomically disadvantaged schoolchildren in Southeast San Diego. Objective: We sought to assess the impact of a School-based education program on asthma outcomes. Methods: In cooperation with the San Diego Unified Schools, we developed and implemented a school-based asthma education program. Based on the National Heart, Lung, and Blood Institute consensus guidelines for asthma, the five-session bilingual, interactive curriculum was conducted in 20-minute segments. Asthma knowledge was tested before and after the education program, and asthma severity was prospectively assessed at monthly intervals, Outcome parameters were compared in educated and control (noneducated) fourth grade students with asthma by using nonparametric techniques. Results: After asthma education, students demonstrated improvement with increases in mean scores for: asthma knowledge quiz from 9.9 (SEM = 0.44, n = 34) to 13.7 (SEM = 0.30); peak flowmeter technique from 3.9 (SEM = 0.33, n = 32) to 6.4 (SEM = 0.29); and inhaler technique from 2.3 (SEM = 0.26, n = 32) to 4.3 (SEM = 0.26). All changes were highly significant (p less than or equal to 0.00001 as determined by Wilcoxon matched-pairs signed-rank test), Mean score comparisons for asthmatic control students given paired examinations after a time interval matched with the educated students, did not reach statistical significance: quiz score of 11.3 (SEM = 0.80, n = 11) versus 10.9 (SEM = 0.68), peak flowmeter technique score of 2.6 (SEM = 0.50, n = 18) versus 3.1 (SEM = 0.37), and inhaler technique score of 2.5 (SEM = 0.37, n = 18) versus 2.2 (SEM = 0.31). Prospective monthly data were collected on 27 educated and 15 control asthmatic subjects. Severity of asthma was not significantly different between groups at entry to the study. Symptom questionnaires, validated for functional asthma severity, revealed a significant reduction in mean symptom scores at 180 days for the educated (2.87, SEM = 0.447) versus the control (4.36, SEM = 0.573) groups (p = 0.0188 as determined by the Mann-Whitney U test). Conclusion: Child-centered asthma education can be successfully conducted in the school setting, resulting in increased asthma knowledge, improved skills for peak flowmeter andinhaler use, and a reduction in the severity of asthma symptoms.	Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA USA	Scripps Research Institute				Zuraw, Bruce/0000-0003-0640-6768	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032834] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32834] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUSSE WW, 1986, J ALLERGY CLIN IMMUN, V78, P525, DOI 10.1016/0091-6749(86)90099-0; Christiansen SC, 1996, J ASTHMA, V33, P17, DOI 10.3109/02770909609077759; CLARK NM, 1980, HEALTH EDUC QUART, V7, P278, DOI 10.1177/109019818000700403; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; EVANS D, 1987, HEALTH EDUC QUART, V14, P267, DOI 10.1177/109019818701400302; KAPLAN DL, 1986, J SCHOOL HEALTH, V56, P267, DOI 10.1111/j.1746-1561.1986.tb05748.x; KOTSES H, 1995, J ALLERGY CLIN IMMUN, V95, P529, DOI 10.1016/S0091-6749(95)70315-2; ROSIER MJ, 1994, AM J RESP CRIT CARE, V149, P1434, DOI 10.1164/ajrccm.149.6.8004295; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; STRUNK RC, 1987, J ALLERGY CLIN IMMUN, V80, P472, DOI 10.1016/0091-6749(87)90078-9; *US DHHS, 1991, NIH PUBL; WIGAL J K, 1990, Pediatric Asthma Allergy and Immunology, V4, P17, DOI 10.1089/pai.1990.4.17	12	54	56	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					613	617		10.1016/S0091-6749(97)70164-7	http://dx.doi.org/10.1016/S0091-6749(97)70164-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389290				2022-12-18	WOS:A1997YG20200007
J	Litwin, A; Flanagan, M; Entis, G; Gottschlich, G; Esch, R; Gartside, P; Michael, JG				Litwin, A; Flanagan, M; Entis, G; Gottschlich, G; Esch, R; Gartside, P; Michael, JG			Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: A double-blind study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						oral immunotherapy; microencapsulation; immunotherapy; short ragweed; nasal IgA antibodies	BOVINE SERUM-ALBUMIN; POLLEN HAY-FEVER; PEPTIC FRAGMENTS; IMMUNE-RESPONSE; IGG ANTIBODIES; GRASS-POLLEN; SECRETIONS; INDUCTION; EFFICACY; ANTIGEN	Background: In the past. oral immunotherapy with allergens has had limited clinical effectiveness, presumably because of gastrointestinal destruction of allergens. Objective: We have developed a new technique for microencapsulating protein antigens that permits them, when given orally, to bypass the stomach and be delivered to the small intestine in a highly immunogenic form. This study's purpose was to confirm the immunologic potency of orally administered short ragweed pollen extracts (SRW) microencapsulated (mSRW) by this new technique and to study the effectiveness of mSRW in controlling the symptoms of ragweed-induced hay fever. Methods: Twenty-one SRW-sensitive patients were treated with mSRW in a double-blind placebo-controlled study. Serum SRW Ige and IgE antibodies and nasal secretory IgA antibodies were determined. During the ragweed season, symptoms were quantified by symptom-medication scoring. Results: The treated patients had high titers of serum SRW IgG antibodies (1.15 mu g/ml at baseline, increasing to 21.21 mu g/ml), experienced regulation of the seasonal increase in serum SRW IgE antibodies (+9% vs +59% in placebo-treated patients), and produced a small amount of nasal SRW IgA antibodies. Despite an insubstantial pollen count, the symptom-medication scores in the treated group were lower than those in the placebo group (4.28 vs 6.18, p = 0.059), but the differences were statistically significant only in the subgroup that tolerated high doses (>20 mu g of Amb a 1 in 19 of 21 patients, p = 0.04). These effects were accomplished without inducing any systemic reactions with a dose of mSRW (mean, 23.8 mu g of Amb a 1) only slightly higher than that used in high-dose subcutaneous immunotherapy. Conclusion: Oral mSRW seems a safe, easily administered, and immunologically potent treatment for ragweed-induced hay fever, but its ultimate utility requires further study.	UNIV CINCINNATI, COLL MED, DEPT ENVIRONM HLTH, CINCINNATI, OH 45267 USA; GREER LABS INC, LENOIR, NC USA; UNIV CINCINNATI, COLL MED, DEPT PEDIAT, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT MED, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Litwin, A (corresponding author), UNIV CINCINNATI, COLL MED, DEPT MOL GENET BIOCHEM & MICROBIOL, 231 BETHESDA AVE, CINCINNATI, OH 45267 USA.							ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; [Anonymous], 1995, J ALLERGY CLIN IMMUN, V95, P652; BARCLAY WS, 1988, J MED VIROL, V25, P475, DOI 10.1002/jmv.1890250411; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; CRETICOS P S, 1990, Journal of Allergy and Clinical Immunology, V85, P165; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DEFILIPPI I, 1981, ANN ALLERGY, V46, P249; ELSON CO, 1984, J IMMUNOL METHODS, V67, P101, DOI 10.1016/0022-1759(84)90089-9; FERGUSON TA, 1983, CELL IMMUNOL, V78, P1, DOI 10.1016/0008-8749(83)90254-X; FLANAGAN M, 1994, J ALLERGY CLIN IMMUN, V93, P252; FLANAGAN MP, 1993, J IMMUNOL, V150, pA35; FRANKLAND AW, 1954, LANCET, V1, P1055; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; HALPERN GM, 1989, ALLERGOL IMMUNOPATH, V17, P271; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JAIN SL, 1995, ADV EXP MED BIOL, V371, P1245; Jain SL, 1996, CELL IMMUNOL, V167, P170, DOI 10.1006/cimm.1996.0024; Jain SL, 1996, VACCINE, V14, P42, DOI 10.1016/0264-410X(95)00158-W; LARSEN GL, 1987, FASEB J, V46, P105; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LITWIN A, 1991, CLIN EXP ALLERGY, V21, P457, DOI 10.1111/j.1365-2222.1991.tb01686.x; Litwin A, 1996, ANN ALLERG ASTHMA IM, V77, P132, DOI 10.1016/S1081-1206(10)63499-0; Loveless MH, 1943, J IMMUNOL, V47, P165; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; MESTECKY J, 1987, J CLIN IMMUNOL, V7, P265, DOI 10.1007/BF00915547; MICHAEL JG, 1989, IMMUNOL INVEST, V18, P1049, DOI 10.3109/08820138909030606; MORRISON DF, 1983, APPL LINEAR STAT MET, P407; MOSBECH H, 1987, ALLERGY, V42, P451, DOI 10.1111/j.1398-9995.1987.tb00362.x; NISH WA, 1994, J ALLERGY CLIN IMMUN, V93, P484, DOI 10.1016/0091-6749(94)90358-1; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OPPENHEIMER J, 1994, J ALLERGY CLIN IMMUN, V93, P61, DOI 10.1016/0091-6749(94)90233-X; PATTERSON R, 1985, J ALLERGY CLIN IMMUN, V76, P394, DOI 10.1016/0091-6749(85)90660-8; PENG ZK, 1992, J ALLERGY CLIN IMMUN, V89, P519, DOI 10.1016/0091-6749(92)90318-V; PESCE AJ, 1990, INT ARCH ALLER A IMM, V92, P88, DOI 10.1159/000235230; REED CE, 1991, INT ARCH ALLER A IMM, V94, P275, DOI 10.1159/000235382; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; TAUDORF E, 1989, J ALLERGY CLIN IMMUN, V83, P589, DOI 10.1016/0091-6749(89)90070-5; TAUDORF E, 1987, J ALLERGY CLIN IMMUN, V80, P153, DOI 10.1016/0091-6749(87)90124-2; URBANEK R, 1990, EUR J PEDIATR, V149, P545, DOI 10.1007/BF01957689; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VANNIEKERK CH, 1987, CLIN ALLERGY, V17, P507; WALDMAN RH, 1986, AM J MED SCI, V292, P367, DOI 10.1097/00000441-198612000-00006; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294; ZHANG ZY, 1987, CELL IMMUNOL, V104, P426, DOI 10.1016/0008-8749(87)90044-X	49	54	57	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					30	38		10.1016/S0091-6749(97)70191-X	http://dx.doi.org/10.1016/S0091-6749(97)70191-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257784				2022-12-18	WOS:A1997XP42800006
J	Allen, JN; Liao, ZM; Wewers, MD; Altenberger, EA; Moore, SA; Allen, ED				Allen, JN; Liao, ZM; Wewers, MD; Altenberger, EA; Moore, SA; Allen, ED			Detection of IL-5 and IL-1 receptor antagonist in bronchoalveolar lavage fluid in acute eosinophilic pneumonia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Il-5; Il-1ra; Il-3; GM-CSF; IL-1 beta; TNF-alpha; bronchoalveolar lavage; acute eosinophilic pneumonia; eosinophil	COLONY-STIMULATING FACTOR; MONONUCLEAR PHAGOCYTES; ANTI-IL-5 ANTIBODY; LUNG-DISEASES; GUINEA-PIGS; INTERLEUKIN-5; ACCUMULATION; MACROPHAGES; LYMPHOCYTE; MIGRATION	Background: Acute eosinophilic pneumonia is an idiopathic cause of respiratory failure characterized by very high numbers of alveolar eosinophils without significant blood eosinophilia. Objective: The purpose of this study was to determine which cytokines are associated with acute eosinophilic pneumonia. Methods: Soluble IL-1 type II receptor and the cytokines IL-1 beta. IL-1ra, IL-3, IL-5, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-alpha were measured in serum and in bronchoalveolar lavage fluid from two patients with acute eosinophilic pneumonia during both acute and convalescent phases. Results: Compared with patients with adult respiratory distress syndrome, the patients with acute eosinophilic pneumonia had high bronchoalveolar lavage fluid levels of IL-5, IL-1ra, and soluble type II IL-1 receptor but not IL-1 beta, tumor necrosis factor-alpha, IL-3, or granulocyte-macrophage colony-stimulating factor. Bronchoalveolar lavage fluid levels of IL-5 and IL-1ra fell after resolution of symptoms. In the serum of patients with acute eosinophilic pneumonia, IL-5 was not detectable, and IL-1ra was initially high but fell after corticosteroid treatment. Conclusion: Acute eosinophilic pneumonia is characterized by locally high levels of IL-5, IL-1ra, and soluble type II IL-1 receptor in the alveolar space.	OHIO STATE UNIV, MED CTR, DIV PEDIAT PULM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University	Allen, JN (corresponding author), OHIO STATE UNIV, MED CTR, DIV PULM & CRIT CARE MED, N-325 MEANS HALL, 1654 UPHAM DR, COLUMBUS, OH 43210 USA.		Wewers, Mark/AAB-6202-2021					ALLEN JN, 1990, AM REV RESPIR DIS, V142, P642, DOI 10.1164/ajrccm/142.3.642; ALLEN JN, 1994, AM J RESP CRIT CARE, V150, P1423, DOI 10.1164/ajrccm.150.5.7952571; ALLEN JN, 1989, NEW ENGL J MED, V321, P569, DOI 10.1056/NEJM198908313210903; ALLEN JN, 1991, AM J PHYSIOL, V261, pL315, DOI 10.1152/ajplung.1991.261.4.L315; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; ARZT E, 1994, ENDOCRINOLOGY, V134, P672, DOI 10.1210/en.134.2.672; BASTEN A, 1970, J EXP MED, V131, P1288, DOI 10.1084/jem.131.6.1288; BUTTERFIELD JH, 1992, BLOOD, V79, P688; CHAND N, 1992, EUR J PHARMACOL, V211, P121, DOI 10.1016/0014-2999(92)90273-7; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; DICKASON RR, 1994, CYTOKINE, V6, P647, DOI 10.1016/1043-4666(94)90053-1; EBISAWA M, 1994, J IMMUNOL, V153, P2153; ENOKIHARA H, 1990, BRIT J HAEMATOL, V75, P458, DOI 10.1111/j.1365-2141.1990.tb07782.x; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; HIDI R, 1992, J LEUKOCYTE BIOL, V51, P425, DOI 10.1002/jlb.51.5.425; KITA H, 1992, J IMMUNOL, V149, P629; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; LU L, 1990, EXP HEMATOL, V18, P1180; MARSH CB, 1994, J IMMUNOL, V152, P4604; MARSH CB, 1994, AM J RESP CELL MOL, V10, P521, DOI 10.1165/ajrcmb.10.5.8179914; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MIGITA M, 1991, CELL IMMUNOL, V133, P484, DOI 10.1016/0008-8749(91)90120-Z; MURALI PS, 1993, J LEUKOCYTE BIOL, V53, P264, DOI 10.1002/jlb.53.3.264; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; OHNISHI T, 1993, J ALLERGY CLIN IMMUN, V92, P607, DOI 10.1016/0091-6749(93)90085-T; OKUDAIRA H, 1991, INT ARCH ALLER A IMM, V94, P171, DOI 10.1159/000235354; PASQUALE CP, 1991, INT ARCH ALLER A IMM, V95, P244, DOI 10.1159/000235436; PISANI CV, 1991, BLOOD, V78, P1538, DOI 10.1182/blood.V78.6.1538.1538; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SANZ MJ, 1995, J IMMUNOL, V154, P1364; SAWYERS CL, 1992, CANCER, V69, P1342, DOI 10.1002/1097-0142(19920315)69:6<1342::AID-CNCR2820690607>3.0.CO;2-U; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SEHMI R, 1992, BLOOD, V79, P2952; Spry CJ, 1988, EOSINOPHILS COMPREHE; STERN M, 1992, J IMMUNOL, V148, P3543; TERADA N, 1992, J ALLERGY CLIN IMMUN, V90, P160, DOI 10.1016/0091-6749(92)90067-C; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548, DOI 10.1164/ajrccm/147.3.548; VILLAR MTA, 1993, AM REV RESPIR DIS, V147, pA242; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WARRINGA RAJ, 1991, BLOOD, V77, P2694; WEWERS MD, 1989, J IMMUNOL, V143, P1635; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	46	54	55	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1366	1374		10.1016/S0091-6749(96)70206-3	http://dx.doi.org/10.1016/S0091-6749(96)70206-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648034				2022-12-18	WOS:A1996VD60700026
J	Asero, R; Massironi, F; Velati, C				Asero, R; Massironi, F; Velati, C			Detection of prognostic factors for oral allergy syndrome in patients with birch pollen hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						oral allergy syndrome; food allergy; birch pollen allergy; skin prick tests	CROSS-REACTIVITY; FOOD HYPERSENSITIVITY; IGE ANTIBODIES; SENSITIVITY; APPLE; VEGETABLES; POLLINOSIS; FRUITS; RAST	To determine why a significant proportion of birch pollen-sensitive patients do not have the oral allergy syndrome (OAS), possible predictive in vivo or in vitro tests for OAS were sought in a large retrospective and prospective follow-np study performed in 283 patients with clinical evidence of birch pollen hypersensitivity. OAS was associated with more severe respiratory symptoms and with higher birch-specific and total IgE levels; moreover its onset was clearly related to duration of birch pollinosis. The prospective part of this study, performed in 63 patients without OAS, confirmed these findings and highlighted the very high negative predictive value of both skin prick tests with fresh foods and RAST with food allergens. This work suggests that about 15% of patients with birch pollen hypersensitivity are not prone to OAS and that their anti-birch IgE might be directed against determinants that do not cross-react with food allergens.			Asero, R (corresponding author), OSPED CADUTI BOLLATESI,AMBULATORIO ALLERGOL,VIA PIAVE 20,I-20021 BOLLATE,MILAN,ITALY.							ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; BESSOT JC, 1985, MED HYG, V43, P2704; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P419; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; CRIMI E, 1990, J ALLERGY CLIN IMMUN, V85, P1014, DOI 10.1016/0091-6749(90)90045-6; DEMARTINO M, 1988, ALLERGY, V43, P206; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; ENBERG RN, 1987, J ALLERGY CLIN IMMUN, V79, P867, DOI 10.1016/0091-6749(87)90234-X; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; ERIKSSON NE, 1983, ALLERGY, V38, P353, DOI 10.1111/j.1398-9995.1983.tb04130.x; FOGLEHANSSON M, 1993, ALLERGY, V48, P282, DOI 10.1111/j.1398-9995.1993.tb00729.x; Goldstein Laurence, 1987, PRINCIPLES INTERNAL, P5; HALMEPURO L, 1985, ALLERGY, V40, P264, DOI 10.1111/j.1398-9995.1985.tb00231.x; HALMEPURO L, 1984, INT ARCH ALLER A IMM, V74, P235, DOI 10.1159/000233550; LAHTI A, 1980, ALLERGY, V35, P297, DOI 10.1111/j.1398-9995.1980.tb01770.x; LOWENSTEIN H, 1983, ALLERGY, V38, P577, DOI 10.1111/j.1398-9995.1983.tb04143.x; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; Ortolani C., 1991, GIORN IT ALLERGOLO I, V1, P515; PASTORELLO EA, 1987, ANN ALLERGY, V59, P82; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x	24	54	54	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					611	616		10.1016/S0091-6749(96)70306-8	http://dx.doi.org/10.1016/S0091-6749(96)70306-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621846				2022-12-18	WOS:A1996TW08700006
J	Laitinen, LA; Laitinen, A				Laitinen, LA; Laitinen, A			Remodeling of asthmatic airways by glucocorticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EXTRACELLULAR-MATRIX; INFLAMMATION; BETA-2-AGONIST; EOSINOPHILS; TERBUTALINE; BUDESONIDE; BIOPSIES		UNIV HELSINKI,DEPT ANAT,SF-00290 HELSINKI,FINLAND	University of Helsinki	Laitinen, LA (corresponding author), HELSINKI UNIV,CENT HOSP,DEPT MED,HAARTMANINKATU,SF-00290 HELSINKI,FINLAND.							ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ALBELDA SM, 1989, AM J RESPIR CELL MOL, V1, P483; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; DUNNILL MS, 1989, THORAX, V24, P175; EKBLOM M, 1993, J CELL BIOL, V123, P1037, DOI 10.1083/jcb.123.4.1037; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; LAITINEN A, 1994, AM J RESP CRIT CARE, V150, pS14, DOI 10.1164/ajrccm/150.5_Pt_2.S14; LAITINEN A, 1994, AM J RESP CRIT CARE, V149, pA942; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MCGOWAN SE, 1992, FASEB J, V6, P2895, DOI 10.1096/fasebj.6.11.1644255; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; STONER GD, 1981, IN VITRO CELL DEV, V17, P877; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745	22	54	57	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	2	S			153	158		10.1016/S0091-6749(96)80215-6	http://dx.doi.org/10.1016/S0091-6749(96)80215-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT805	8568146	Bronze			2022-12-18	WOS:A1996TT80500002
J	SPECTOR, SL; NICODEMUS, CF; CORREN, J; SCHANKER, HM; RACHELEFSKY, GS; KATZ, RM; SIEGEL, SC				SPECTOR, SL; NICODEMUS, CF; CORREN, J; SCHANKER, HM; RACHELEFSKY, GS; KATZ, RM; SIEGEL, SC			COMPARISON OF THE BRONCHODILATORY EFFECTS OF CETIRIZINE, ALBUTEROL, AND BOTH TOGETHER VERSUS PLACEBO IN PATIENTS WITH MILD-TO-MODERATE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CETIRIZINE; ALBUTEROL; ANTIHISTAMINE; MILD-TO-MODERATE ASTHMA; BRONCHODILATION	SEASONAL ALLERGIC RHINITIS; CHRONIC IDIOPATHIC URTICARIA; POLLEN-INDUCED ASTHMA; DOUBLE-BLIND; PROPHYLACTIC TREATMENT; TERFENADINE; EFFICACY; ANTIHISTAMINE; ASTEMIZOLE; INHALATION	Background: Many potential users of the H-1 antihistamine cetirizine are asthmatic and may be using inhaled albuterol. This study was conducted to assess the possible bronchodilatory effect of cetirizine in patients with mild-to-moderate asthma and to determine whether cetirizine interacts with albuterol. Methods: In a randomized, double-blind, placebo-controlled, crossover study, the effects on pulmonary function of 5, 10, and 20 mg oral doses of cetirizine with and without inhaled albuterol (180 mu g) were determined in 12 patients at 11 time points over 8 hours. The primary measure of efficacy was forced expiratory volume in I second (FEY(1)). Results: Cetirizine with or without albuterol significantly increased FEV, peak expiratory flow rate, and forced expiratory flow rate between 25% and 75% of vital capacity relative to baseline and placebo but did not have a significant effect on forced vital capacity. The effect of 20 mg of cetirizine on FEV, was generally greater than that of IO or 5 mg, but the difference was statistically significant only at the 30-minute time point (p < 0.05). All three cetirizine doses produced significantly greater increases than placebo in FEV(1) and forced expiratory flow rate between 25% and 75% of vital capacity for 8 hours and in peak expiratory flow rate for 7 hours (p < 0.02). Albuterol alone had a significant effect on the four pulmonary function variables from 1 to 5 hours after baseline (p < 0.05), which is consistent with albuterol's recommended dosing frequency of every 4 to 6 hours. Albuterol alone increased FEV, significantly more than 5 mg of cetirizine alone but not 10 mg or 20 mg of cetirizine alone at 60, 90, and 120 minutes after baseline, but all three doses of cetirizine increased FEV(1) significantly more than albuterol 7 and 8 hours after baseline (p < 0.05), indicating that the bronchodilatory action of cetirizine lasts longer than that of albuterol. Cetirizine neither potentiated nor inhibited the bronchodilatory action of albuterol, but the two drugs appeared to have an additive bronchodilatory effect. None of the cetirizine treatments caused a worsening of pulmonary function, and all were well tolerated. Conclusions: Cetirizine has a significant bronchodilatory effect in patients with mild-to-moderate asthma and can be used to treat concomitant conditions (e.g., allergic rhinitis) without concern that it will interfere with the bronchodilatory effect of albuterol or cause worsening of asthma by itself	PFIZER INC,NEW YORK,NY	Pfizer	SPECTOR, SL (corresponding author), ALLERGY RES FDN INC,11620 WILSHIRE BLVD,SUITE 200,LOS ANGELES,CA 90025, USA.							ADVENIER C, 1991, J ALLERGY CLIN IMMUN, V88, P104, DOI 10.1016/0091-6749(91)90307-A; ALOMAR A, 1990, J INT MED RES, V18, P358, DOI 10.1177/030006059001800503; BOUSQUET J, 1990, ANN ALLERGY, V65, P504; BRIK A, 1987, J ALLERGY CLIN IMMUN, V80, P51, DOI 10.1016/S0091-6749(87)80190-2; BRUTTMANN G, 1990, ANN ALLERGY, V64, P224; CHAWEEWAN B, 1993, DRUG INVEST, V5, P222, DOI 10.1007/BF03258450; DAVIES BH, 1991, CLIN THER, V13, P87; DIJKMAN JH, 1990, CLIN EXP ALLERGY, V20, P483, DOI 10.1111/j.1365-2222.1990.tb03140.x; FALLIERS CJ, 1991, ANN ALLERGY, V66, P257; GHOSH SK, 1991, J ALLERGY CLIN IMMUN, V87, P1010, DOI 10.1016/0091-6749(91)90424-M; GO MJT, 1989, ACTA THERAP, V15, P77; HERXHEIMER H, 1949, BMJ-BRIT MED J, V2, P901, DOI 10.1136/bmj.2.4633.901; JUHLIN L, 1988, BRIT J DERMATOL, V119, P67, DOI 10.1111/j.1365-2133.1988.tb07103.x; KALIVAS J, 1990, J ALLERGY CLIN IMMUN, V86, P1014, DOI 10.1016/S0091-6749(05)80246-5; KOPFERSCHMITTKU.MC, 1990, ANN ALLERGY, V65, P501; KURZEJA A, 1989, LANCET, V1, P556; LOCKEY RF, 1993, ANN ALLERGY, V70, P311; MANSMANN HC, 1992, ANN ALLERGY, V68, P348; NOGRADY SG, 1978, THORAX, V33, P479, DOI 10.1136/thx.33.4.479; PANAYOTOPOULOS SM, 1988, ACTA THERAP, V14, P347; POPA VT, 1977, J ALLERGY CLIN IMMUN, V59, P54, DOI 10.1016/0091-6749(77)90177-4; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; REDIER H, 1992, J ALLERGY CLIN IMMUN, V90, P215, DOI 10.1016/0091-6749(92)90074-C; SCHMEISSER KJ, 1989, ACTA THERAP, V15, P87; SNYDER SH, 1987, ANN ALLERGY, V59, P4; SPECTOR S, 1992, ANN ALLERGY, V69, P212; WASSERFALLEN JB, 1993, J ALLERGY CLIN IMMUN, V91, P1189, DOI 10.1016/0091-6749(93)90322-7; WASSERMAN SI, 1991, CLIN THER, V13, P707; WOOD SG, 1987, ANN ALLERGY, V59, P31; WOODBAKER R, 1993, J ALLERGY CLIN IMMUN, V91, P1005, DOI 10.1016/0091-6749(93)90213-Y; 1991, 913042 NAT I HLTH PU	31	54	60	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					174	181		10.1016/S0091-6749(95)70005-6	http://dx.doi.org/10.1016/S0091-6749(95)70005-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636054				2022-12-18	WOS:A1995RQ00100005
J	LANG, DM; ALPERN, MB; VISINTAINER, PF; SMITH, ST				LANG, DM; ALPERN, MB; VISINTAINER, PF; SMITH, ST			GENDER RISK FOR ANAPHYLACTOID REACTION TO RADIOGRAPHIC CONTRAST-MEDIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANAPHYLACTOID REACTION; ANAPHYLAXIS; FEMALE GENDER; RADIOGRAPHIC CONTRAST MEDIA	ADVERSE REACTIONS; AGENTS; HEALTH; ASTHMA	Background: Female predominance has been re ported previously in series of anaphylaxis cases; however, no definite precedent has been established for greater risk of anaphylactoid reaction caused by contrast media infusion on the basis of gender. Objective: This study was designed to determine whether greater risk for anaphylactoid reaction caused by intravenous contrast media infusion exists in association with female gender. Methods: Rates of anaphylactoid and severe anaphylactoid reaction, according to gender, were determined in a sample of 5264 consecutive patients receiving conventional radiocontrast media during performance of computed tomography. Results: Of 80 adverse reactions caused by contrast media infusion, 73 (1.39%) were classified as anaphylactoid in nature. Among 5191 patients who received intravenous contrast media without experiencing an anaphylactoid reaction, there were 2642 male patients (51%) and 2549 female patients (49%); reactors included 22 male patients and 51 female patients (odds ratio = 2.40, 95% confidence interval = 1.42 - 4.10, p < 0.0005). Female patients also comprised 21 of 22 cases of severe anaphylactoid reaction (odds ratio = 21. 77, 95% confidence interval = 3.13 - 435.15 p < 0.0005). Conclusion: Greater risk for anaphylactoid and severe anaphylactoid reaction exists in association with female gender. Further studies are needed to identify mechanisms that can explain this risk. The importance of these findings for cost-effective use of lower osmolality contrast media need to be determined.	HENRY FORD HOSP,DEPT RADIOL,DIV COMPUTED TOMOG,DETROIT,MI 48202; NEW YORK MED COLL,GRAD SCH HLTH SCI,VALHALLA,NY; HENRY FORD HOSP,DEPT INTERNAL MED,DIV CARDIOVASC MED,DETROIT,MI	Henry Ford Health System; Henry Ford Hospital; New York Medical College; Henry Ford Health System; Henry Ford Hospital	LANG, DM (corresponding author), HAHNEMANN UNIV,DEPT MED,DIV ALLERGY IMMUNOL,MALL STOP 107,BROAD & VINE STS,PHILADELPHIA,PA 19102, USA.			Visintainer, Paul/0000-0002-2491-1242				ANSELL G, 1980, INVEST RADIOL, V15, pS32, DOI 10.1097/00004424-198011001-00010; DATTWYLER R, 1985, ALLERGY, P599; GOEL V, 1989, CAN MED ASSOC J, V140, P389; JACOBSON PD, 1988, JAMA-J AM MED ASSOC, V260, P1586, DOI 10.1001/jama.260.11.1586; KALIMO K, 1980, ANN ALLERGY, V45, P253; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; LANG DM, 1991, ANN INTERN MED, V115, P270, DOI 10.7326/0003-4819-115-4-270; LANG DM, 1993, ARCH INTERN MED, V153, P2033, DOI 10.1001/archinte.153.17.2033; LEARUM F, 1983, RADIOLOGY, V147, P681; LIEBERMAN P, 1991, ANN ALLERGY, V67, P91; MEGGS WJ, 1984, NEW ENGL J MED, V311, P1236, DOI 10.1056/NEJM198411083111907; OCHSNER SF, 1971, SOUTHERN MED J, V64, P907, DOI 10.1097/00007611-197108000-00002; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SETTIPANE RA, 1989, ANN ALLERGY, V63, P373; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; THRALL JH, 1990, PHARM MED IMAGING, P253; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WOLF GL, 1986, RADIOLOGY, V159, P557, DOI 10.1148/radiology.159.2.3961192; WONG S, 1990, ARCH INTERN MED, V150, P1323, DOI 10.1001/archinte.150.6.1323; YOCUM MW, 1994, MAYO CLIN PROC, V69, P16, DOI 10.1016/S0025-6196(12)61606-1; 1979, DHEW PHS791659 PUBL; 1971, VITAL HLTH STATIS 11, V211	23	54	56	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1995	95	4					813	817		10.1016/S0091-6749(95)70123-0	http://dx.doi.org/10.1016/S0091-6749(95)70123-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QT468	7722160				2022-12-18	WOS:A1995QT46800005
J	JUNG, CM; PRINZ, JC; RIEBER, EP; RING, J				JUNG, CM; PRINZ, JC; RIEBER, EP; RING, J			A REDUCTION IN ALLERGEN-INDUCED FC-EPSILON-R2/CD23 EXPRESSION ON PERIPHERAL B-CELLS CORRELATES WITH SUCCESSFUL HYPOSENSITIZATION IN GRASS POLLINOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HYPOSENSITIZATION; DESENSITIZATION IMMUNOLOGICAL; IMMUNOTHERAPY; CD23; LYMPHOCYTE STIMULATION; GRASS POLLEN; HAY-FEVER	FC-EPSILON RECEPTORS; HUMAN-LYMPHOCYTES; IGE PRODUCTION; MONOCLONAL-ANTIBODIES; ATOPIC PATIENTS; HAY-FEVER; IMMUNOTHERAPY; CD23; INHIBITION; ANTIGEN	Background: The cellular basis for the mechanism of specific hyposensitization is still unclear. Objective: We prospectively studied the effect of immunotherapy on allergen-induced proliferation and Fc epsilon R2/CD23 expression of lymphocytes. Methods: Mononuclear cells prepared from the peripheral blood of 22 patients with grass pollen (GP) allergy before, during, and after a preseasonal immunotherapy period with GP were stimulated with GP or control antigens. Tritiated thymidine uptake and percentage of CD23(+)B cells were determined daily during days 6 to 8 and compared with lymphocyte responsiveness of II only symptomatically treated atopic patients and 14 nonatopic individuals. Results: GP-induced lymphocyte proliferative response of both hyposensitized and symptomatically treated GP-allergic patients decreased markedly before the pollen season and rose again after seasonal allergen exposure, whereas a long-lived decrease in GP-induced Fc epsilon R2/CD23(+) B cells was only observed in GP-treated patients. Alterations in Fc epsilon R2/CD23 expression were closely related to changes in symptoms and medication requirement during the following pollen season. In contrast, immunotherapy had no effect on Fc epsilon R2/CD23 expression of B cells without stimulation or on B cells cultured in the presence of control antigens. Conclusion: Because Fc epsilon R2/CD23 expression on B cells is antagonistically regulated by the cytokines interleukin-4 and interferon-gamma, the decrease of allergen-induced Fc epsilon R2/CD23(+) B cells indicates an altered cytokine secretion pattern of the allergen-specific T lymphocytes with a predominance of interferon-gamma.	TECH UNIV MUNICH,DERMATOL KLIN & POLIKLIN,MUNICH,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,MUNICH,GERMANY; UNIV MUNICH,INST IMMUNOL,MUNICH,GERMANY; UNIV HAMBURG,HAUTKLIN,HAMBURG,GERMANY; UNIV HAMBURG,ALLERGOL ABT,HAMBURG,GERMANY	Technical University of Munich; University of Munich; University of Munich; University of Hamburg; University of Hamburg			Prinz, Jörg/AAP-9472-2021; Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BONNEFOY JY, 1990, EUR J IMMUNOL, V20, P139, DOI 10.1002/eji.1830200120; BROMAN P, 1988, ALLERGY, V43, P321, DOI 10.1111/j.1398-9995.1988.tb00425.x; CASTRACANE JM, 1988, INT ARCH ALLER A IMM, V86, P295, DOI 10.1159/000234587; COFFMAN RL, 1986, J IMMUNOL, V136, P949; COROMINAS M, 1993, CLIN EXP ALLERGY, V23, P612, DOI 10.1111/j.1365-2222.1993.tb00902.x; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; EISENBREY AB, 1985, J ALLERGY CLIN IMMUN, V75, P84; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; FORD CE, 1966, THYMUS EXPERIMENTAL, P131; GALIZZI JP, 1988, J IMMUNOL, V141, P1982; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; HSIEH KH, 1985, J ALLERGY CLIN IMMUN, V76, P188, DOI 10.1016/0091-6749(85)90700-6; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LEVY DA, 1967, J IMMUNOL, V99, P1068; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; Mossmann TR, 1986, J IMMUNOL, V136, P2348; NORMAN PS, 1988, J ALLERGY CLIN IMMUN, V81, P992, DOI 10.1016/0091-6749(88)90167-4; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PRINZ JC, 1987, HYBRIDOMA, V6, P1, DOI 10.1089/hyb.1987.6.1; PRINZ JC, 1987, EUR J IMMUNOL, V17, P757, DOI 10.1002/eji.1830170604; PRINZ JC, 1991, NEW TRENDS ALLERGY, V3, P105; PRINZ JC, 1990, ALLERGOLOGIE, V13, P35; RIEBER EP, 1991, NEW TRENDS ALLERGY, V3, P82; ROCKLIN RE, 1989, CLIN IMMUNOL IMMUNOP, V53, pS119, DOI 10.1016/0090-1229(89)90077-9; ROCKLIN RE, 1980, NEW ENGL J MED, V22, P1213; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199; Spiegelberg H L, 1987, Int Rev Immunol, V2, P63, DOI 10.3109/08830188709044747; STARR MS, 1970, INT ARCH ALLER A IMM, V38, P514, DOI 10.1159/000230304; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WILHELM M, 1986, J IMMUNOL METHODS, V90, P89, DOI 10.1016/0022-1759(86)90388-1	33	54	55	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				77	87		10.1016/S0091-6749(95)70155-9	http://dx.doi.org/10.1016/S0091-6749(95)70155-9			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822667				2022-12-18	WOS:A1995QC31200011
J	WILLIAMS, PB; BUHR, MP; WEBER, RW; VOLZ, MA; KOEPKE, JW; SELNER, JC				WILLIAMS, PB; BUHR, MP; WEBER, RW; VOLZ, MA; KOEPKE, JW; SELNER, JC			LATEX ALLERGEN IN RESPIRABLE PARTICULATE AIR-POLLUTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX; RUBBER TIRES; AIR POLLUTION; ASTHMA	DAILY MORTALITY; PULMONARY-FUNCTION; HEVEA-BRASILIENSIS; ADJUVANT ACTIVITY; UNITED-STATES; IGE ANTIBODY; CHILDREN; PREVALENCE; RUBBER; ASTHMA	Objective: Urban air samples contain numerous irregular respirable black particles which may be airborne tire fragments. A major component of tires is natural latex. Proteins of natural latex can act as adjuvants and as antigens capable of eliciting immediate hypersensitivity making their presence in particulate air pollution an important clinical issue. Methods: Particulate air pollutants were collected by volumetric sampling devices and characterized by optical microscopy, chemical solubility tests, and mass spectrometry. Extracts of rubber tire fragments were tested for elutable latex antigens by antibody inhibition assays. Results: Identification of latex in air samples and milled material from automobile tires was supported by mass spectrometry results and was further confirmed by physical appearance and chemical solubility studies. Competitive immunoassay confirmed the presence of extractable latex antigens from rubber tire fragments. Conclusions: Latex antigens are extractable from rubber tire fragments, which are abundant in urban air samples. Given the adjuvant and sensitizing effects of latex these airborne particles could contribute, through direct and indirect mechanisms, to the increase in both latex sensitization and asthma. The impact of these particles should be considered in the issue of morbidity and mortality rates associated with respiratory diseases and air pollution.	UNIV COLORADO, HLTH SCI CTR, DEPT IMMUNOL, DENVER, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WILLIAMS, PB (corresponding author), ALLERGY RESP INST COLORADO, 5800 E EVANS AVE, SUITE 100, DENVER, CO 80222 USA.							AKHTAR S, 1988, POLYM MATER SCI ENG, V59, P1135; BEHRENDT H, 1992, INT ARCH ALLERGY IMM, V99, P425, DOI 10.1159/000236303; BOGDAN L, 1981, PB82153586; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42, DOI 10.1164/ajrccm/145.1.42; CADLE SH, 1978, GM RES PUBLICAT GMRR, V2542; CHESTNUT LG, 1991, ARCH ENVIRON HEALTH, V46, P135, DOI 10.1080/00039896.1991.9937440; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; Dannis M.L., 1974, RUBBER CHEM TECHNOL, V47, P1011; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DOCKERY DW, 1982, JAPCA J AIR WASTE MA, V32, P937, DOI 10.1080/00022470.1982.10465494; EGHRARISABET JS, 1993, J RESPIR DIS, V14, P473; EVANS JV, 1971, M71166EPA PREL REP; FAIRLEY D, 1990, ENVIRON HEALTH PERSP, V89, P159, DOI 10.2307/3430912; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GREEK BF, 1991, CHEM ENG NEWS, V69, P37, DOI 10.1021/cen-v069n019.p037; HILDEMANN LM, 1991, ENVIRON SCI TECHNOL, V25, P744, DOI 10.1021/es00016a021; IACOBELLI AM, 1993, J ALLERGY CLIN IMMUN, V91, P216; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; KAGAMIMORI S, 1986, CLIN ALLERGY, V16, P299, DOI 10.1111/j.1365-2222.1986.tb01961.x; KAINKASTANICKE E, 1988, ALLERGY, V43, P57; KURUP VP, 1994, INT ARCH ALLERGY IMM, V103, P370, DOI 10.1159/000236656; KURUP VP, 1992, ALLERGY PROC, V13, P329, DOI 10.2500/108854192778816915; LIGHT DR, 1989, J BIOL CHEM, V264, P18589; MARIO RT, 1992, INT ARCH ALLER A IMM, V99, P165; MARTINI R, 1992, FUNDAMENTALS ANATOMY, P758; MONERETVAUTRIN DA, 1993, J ALLERGY CLIN IMMUN, V92, P668, DOI 10.1016/0091-6749(93)90009-5; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Pierson W.R., 1974, RUBBER CHEM TECHNOL, V47, P1275, DOI [10.5254/1.3540499., DOI 10.5254/1.3540499]; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211, DOI 10.1080/00039896.1992.9938351; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123, DOI 10.1164/ajrccm/145.5.1123; REISCH MS, 1993, CHEM ENG NEWS, V71, P24, DOI 10.1021/cen-v071n019.p024; RENNICK GJ, 1992, MED J AUSTRALIA, V156, P837, DOI 10.5694/j.1326-5377.1992.tb136995.x; SCHWARTZ J, 1992, AM J EPIDEMIOL, V135, P12, DOI 10.1093/oxfordjournals.aje.a116195; SCHWARTZ J, 1991, ENVIRON RES, V56, P204, DOI 10.1016/S0013-9351(05)80009-X; SMITH EG, 1984, SAMPLING IDENTIFYING, P22; STEPHENS HL, 1973, RUBBER TECHNOLOGY, P19; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; TAKAFUJI S, 1989, INT ARCH ALLER A IMM, V90, P1, DOI 10.1159/000234990; TSENG RYM, 1992, ANN ALLERGY, V68, P425; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WILLIAMS MH, 1989, NEW ENGL J MED, V320, P1015; WOLTERS JHB, 1987, BOT REV, V53, P372, DOI 10.1007/BF02858322; XU XP, 1991, ARCH ENVIRON HEALTH, V46, P198, DOI 10.1080/00039896.1991.9937448; YASSIN MS, 1992, ANN ALLERGY, V69, P207; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215; [No title captured]; 1990, MMWR-MORBID MORTAL W, V39, P493; 1986, EC COSTS RESPIRATORY	51	54	56	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				88	95		10.1016/S0091-6749(95)70156-7	http://dx.doi.org/10.1016/S0091-6749(95)70156-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822669				2022-12-18	WOS:A1995QC31200012
J	STANALAND, BE; FERNANDEZCALDAS, E; JACINTO, CM; TRUDEAU, WL; LOCKEY, RF				STANALAND, BE; FERNANDEZCALDAS, E; JACINTO, CM; TRUDEAU, WL; LOCKEY, RF			SENSITIZATION TO BLOMIA-TROPICALIS - SKIN-TEST AND CROSS-REACTIVITY STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BLOMIA TROPICALIS; DERMATOPHAGOIDES PTERONYSSINUS; DERMATOPHAGOIDES-FARINAE; ALLERGENS; MITES; HOUSE DUST; ALLERGIC RHINITIS; ASTHMA; CROSS-REACTIVITY	HOUSE-DUST MITES; EXPOSURE; ASTHMA; INDIVIDUALS; PREVALENCE; ALLERGENS; CHILDREN; FLORIDA; TAMPA; HOMES	This study evaluated the prevalence of positive percutaneous skin test results to Blomia tropicalis, Dermatophagoides pteronyssinus, and D. farinae in 167 consecutive persons (61 males, 106 females; mean age, 38.7 years; range 14 to 75 years) with asthma or rhinitis, or both, in Tampa Fla. Forty-nine had asthma with or without rhinitis, and 118 had rhinitis alone. RAST and RAST inhibition analysis of all three mite species were performed by using pooled patient sera. Prepared extracts of B. tropicalis and standardized D. pteronyssinus and D. farinae (1:50 wt/vol) were used for percutaneous skin tests. One hundred twelve subjects (67%) had a positive result to at least one mite species; 38%, 62%, and 60% reacted to B. tropicalis, D. pteronyssinus, and D. farinae, respectively. Positive skin test results to both D. pteronyssinus and D. farinae occurred in 96 subjects (57%); 56 of these subjects (58%) were also positive to B. tropicalis. Positive skin test results to B. tropicalis, D. pteronyssinus, or D. farinae alone occurred in four (2%), five (3%), and four (2%), respectively. RAST and RAST inhibition data indicate that B. tropicalis contains unique allergens. The high rate of skin test reactivity to B. tropicalis extracts, and its unique allergenic composition, warrants its use in the diagnosis and treatment of allergic disorders in Tampa.	UNIV S FLORIDA,JAMES A HALEY VET HOSP,COLL MED,DIV ALLERGY & IMMUNOL,TAMPA,FL 33612	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital								ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARLIAN LG, 1993, J ALLERGY CLIN IMMUN, V91, P1042, DOI 10.1016/0091-6749(93)90218-5; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; FERNANDEZCALDAS E, 1993, CLIN EXP ALLERGY, V23, P292, DOI 10.1111/j.1365-2222.1993.tb00325.x; FERNANDEZCALDAS E, 1993, J INVEST ALLERG CLIN, V3, P245; FERNANDEZCALDAS E, 1990, ALLERGY PROC, V11, P263, DOI 10.2500/108854190778879710; FERNANDEZCALDAS E, 1993, J ALLERGY CLIN IMMUN, V91, P327; FERNANDEZCALDAS E, 1991, ALLERGEN IMMUNOTHERA, P69; HURTADO I, 1987, ANN ALLERGY, V59, P128; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; LLERENA LP, 1991, J ALLERGY CLIN IMMUN, V88, P943, DOI 10.1016/0091-6749(91)90252-J; MULLA MS, 1980, ACAROS COLOMBIA BION; NETO J, 1980, REV BRAS ALERG IMUNO, V2, P140; PEAT JK, 1987, CLIN ALLERGY, V17, P297; PUERTA L, 1993, J INVEST ALLERG CLIN, V3, P198; SILTON RP, 1991, J ALLERGY CLIN IMMUN, V88, P595, DOI 10.1016/0091-6749(91)90153-F; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; VANHAGEHAMSTEN M, 1989, J ALLERGY CLIN IMMUN, V83, P581, DOI 10.1016/0091-6749(89)90069-9; [No title captured]	19	54	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				452	457		10.1016/0091-6749(94)90200-3	http://dx.doi.org/10.1016/0091-6749(94)90200-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	8083450				2022-12-18	WOS:A1994PG90700003
J	BARANIUK, JN				BARANIUK, JN			SENSORY, PARASYMPATHETIC, AND SYMPATHETIC NEURAL INFLUENCES IN THE NASAL-MUCOSA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	CONF ON INTRANASAL ANTICHOLINERGIC TREATMENT OF NASAL DISORDERS	MAR   06, 1991	SAN FRANCISCO, CA	BOEHRINGER INGELHEIM PHARM		VASOACTIVE INTESTINAL PEPTIDE; PARASYMPATHETIC REFLEXES; RHINITIS; NEUROPEPTIDE	VASOACTIVE INTESTINAL POLYPEPTIDE; GENE-RELATED PEPTIDE; NEUTRAL ENDOPEPTIDASE; SUBSTANCE-P; GUINEA-PIG; SECRETION; CAPSAICIN; RHINITIS; GLAND; HYPERRESPONSIVENESS	Neural mechanisms contribute to many nasal symptoms and syndromes. Sensory nerve stimulation by irritants, mast cell products, and inflammatory mediators leads to sneezing and other systemic reflexes. Parasympathetic reflexes and sensory axon responses combine to increase nasal bloodflow, fill venous sinusoids (which thickens the mucosa and reduces nasal patency), induce plasma extravasation, and stimulate glandular secretion of mucous and serous cell products. These putative roles for nerves and neuropeptides in pathologic events open new therapeutic avenues. Anticholinergic agents, peptide neurotransmitter agonists and antagonists, drugs to reduce or modulate sensory or parasympathetic nerve function, potent topically applied glucocorticosteroids, and agents to inactivate inflammatory, secretory, or vascular cells may be of use. Ablation of sensory nerves by topical application of the chili pepper neurotoxin capsaicin has been successful in reducing the symptoms of refractory vasomotor rhinitis.			BARANIUK, JN (corresponding author), GEORGETOWN UNIV,MED CTR,DEPT MED,LUNG BIOL LABS,3900 RESERVOIR RD,WASHINGTON,DC 20057, USA.			Baraniuk, James Nicholas/0000-0002-1866-4177				BARANIUK JN, 1990, AM J PHYSIOL, V258, pL81, DOI 10.1152/ajplung.1990.258.2.L81; BARANIUK JN, 1990, J ALLERGY CLIN IMMUN, V86, P620, DOI 10.1016/S0091-6749(05)80226-X; BARANIUK JN, 1990, AM J RESP CELL MOL, V3, P165, DOI 10.1165/ajrcmb/3.2.165; BARANIUK JN, 1990, J CLIN INVEST, V85, P998, DOI 10.1172/JCI114577; BARANIUK JN, 1991, AM J RESP CELL MOL, V4, P228, DOI 10.1165/ajrcmb/4.3.228; BARANIUK JN, 1990, J CLIN INVEST, V86, P825, DOI 10.1172/JCI114780; BARANIUK JN, 1991, PULM PHARMACOL THER, V4, P20, DOI 10.1016/0952-0600(91)90035-2; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CARSTAIRS JR, 1986, J PHARMACOL EXP THER, V239, P249; COLES SJ, 1981, AM REV RESPIR DIS, V124, P531; DUSSER DJ, 1989, J CLIN INVEST, V84, P900, DOI 10.1172/JCI114251; GEPPETTI P, 1988, BRIT J PHARMACOL, V93, P509, DOI 10.1111/j.1476-5381.1988.tb10305.x; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; JACOBY DB, 1988, J APPL PHYSIOL, V64, P2653, DOI 10.1152/jappl.1988.64.6.2653; KURIAN SS, 1983, CLIN BIOCHEM, V11, P425; LARSSON O, 1986, REGUL PEPTIDES, V13, P319, DOI 10.1016/0167-0115(86)90049-2; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; LINDGREN BR, 1988, ACTA PHYSIOL SCAND, V133, P1; LUNDBERG JM, 1984, NEUROSCI LETT, V52, P37, DOI 10.1016/0304-3940(84)90347-1; LUNDBERG JM, 1987, AM REV RESPIR DIS, V136, pS16, DOI 10.1164/ajrccm/136.6_Pt_2.S16; LUNDBERG JM, 1981, ACTA PHYSIOL SCAND, V113, P329, DOI 10.1111/j.1748-1716.1981.tb06903.x; MALM L, 1980, ACTA OTO-LARYNGOL, V90, P304, DOI 10.3109/00016488009131730; MCDONALD DM, 1988, AM REV RESPIR DIS, V137, P1432, DOI 10.1164/ajrccm/137.6.1432; OKAYAMA M, 1990, Journal of Allergy and Clinical Immunology, V85, P225; RAPHAEL G, 1989, J ALLERGY CLIN IMMUN, V83, P110, DOI 10.1016/0091-6749(89)90484-3; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; RAPHAEL GD, 1988, AM J RHINOL, V2, P8; STAMMBERGER H, 1989, ANN OTOL RHINOL S134, V97, P3; STJARNE P, 1989, BRIT J PHARMACOL, V96, P693, DOI 10.1111/j.1476-5381.1989.tb11870.x; Szolcsanyi J, 1990, CHEM SENSES, V2, P141; UDDMAN R, 1986, CLIN CHEST MED, V7, P201; WIDDICOMBE JG, 1986, CLIN CHEST MED, V7, P159	32	54	56	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	2	S			1045	1050		10.1016/0091-6749(92)90121-H	http://dx.doi.org/10.1016/0091-6749(92)90121-H			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD635	1460206				2022-12-18	WOS:A1992KD63500004
J	PALMGREN, MS; DESHAZO, RD; CARTER, RM; ZIMNY, ML; SHAH, SV				PALMGREN, MS; DESHAZO, RD; CARTER, RM; ZIMNY, ML; SHAH, SV			MECHANISMS OF NEUTROPHIL DAMAGE TO HUMAN ALVEOLAR EXTRACELLULAR-MATRIX - THE ROLE OF SERINE AND METALLOPROTEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EXTRACELLULAR MATRIX; NEUTROPHIL PROTEASES; REACTIVE OXYGEN SPECIES; LUNG-INJURY MECHANISMS	GLOMERULAR BASEMENT-MEMBRANE; RESPIRATORY-DISTRESS SYNDROME; POLYMORPHONUCLEAR-LEUKOCYTE; STIMULATED NEUTROPHILS; LUNG INJURY; DEGRADATION; COLLAGEN; GELATINASE; PROTEINASES; ACTIVATION	Many syndromes of lung injury are associated with accumulation of neutrophils within the pulmonary parenchyma. These neutrophils have the capacity to produce lung injury by products including proteases and reactive oxygen species (ROS). We examined the ability of activated neutrophils to solubilize human alveolar extracellular matrix (ECM), and by use of scavengers and inhibitors, evaluated the role of ROS and proteases in this process. Supernatants of phorbol myristate acetate-activated neutrophils routinely solubilized 10.2% +/- 0.8% (n = 30) of collagen in human alveolar ECM, as measured by hydroxyproline release. Scavengers of ROS had no significant effect on ECM solubilization. Inhibitors of metalloproteases partially inhibited ECM solubilization (38.5% +/- 4.6% inhibition by ethylenediaminetetraacetic acid [n = 6], and 37.0% +/- 14.7% by 1,10-phenanthroline [n = 6]; p < 0.05). Inhibitors of the neutrophil serine proteases, elastase and cathepsin G, markedly inhibited ECM solubilization (100.9% +/- 3.7% by alpha(1)-protease inhibitor [alpha(1)-PI][n = 6] and 81.9% +/- 0.1% by soybean trypsin inhibitor [n = 6]; p < 0.01). Since alpha(1)-PI completely inhibited solubilization, metalloprotease activity appeared to be related to serine protease activity. This finding was confirmed by the observation that addition of a metalloenzyme activator, p-aminophenylmercuric acetate, in the presence of alpha(1)-PI, restored solubilization to the same level as that inhibited by metal chelators. We conclude that human neutrophil metalloproteases and serine proteases directly solubilize human alveolar ECM. Furthermore, neutrophil serine proteases activate latent metalloproteases. However, ROS were not demonstrated to play a major role in ECM solubilization in our system.	UNIV SO ALABAMA,COLL MED,DEPT MED,2451 FILLINGIM ST,MOBILE,AL 36617; TULANE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA 70112; VET ADM MED CTR,RES SERV,NEW ORLEANS,LA 70146; LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT ANAT,NEW ORLEANS,LA 70112	University of South Alabama; Tulane University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Louisiana State University System					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL015092] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL 15092] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHANI Y, 1980, ANAL BIOCHEM, V109, P55, DOI 10.1016/0003-2697(80)90009-3; BOX GEP, 1978, STATISTICS EXPT; CAMPBELL EJ, 1988, J CELL BIOL, V106, P677; CHAPMAN HA, 1988, AM REV RESPIR DIS, V137, P412, DOI 10.1164/ajrccm/137.2.412; CHRISTNER P, 1985, AM REV RESPIR DIS, V131, P690; DAVIES M, 1978, CLIN SCI MOL MED, V54, P233, DOI 10.1042/cs0540233; DESHAZO RD, 1982, J ALLERGY CLIN IMMUN, V69, P429, DOI 10.1016/0091-6749(82)90117-8; FLIGIEL SEG, 1984, AM J PATHOL, V115, P375; FREEMAN BA, 1985, FED PROC, V44, P2591; GOLDSTEIN W, 1986, AM REV RESPIR DIS, V134, P49; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HIBBS MS, 1984, COLLAGEN REL RES, V4, P467; KALEBIC T, 1983, SCIENCE, V221, P281, DOI 10.1126/science.6190230; LAZARUS GS, 1968, J CLIN INVEST, V47, P2622, DOI 10.1172/JCI105945; LIOTTA LA, 1981, THROMB RES, V21, P663, DOI 10.1016/0049-3848(81)90268-1; MAINARDI CL, 1980, J BIOL CHEM, V255, P5435; MORRISON DF, 1976, MULTIVARIATE STATIST; PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322; RINALDO JE, 1982, NEW ENGL J MED, V306, P900, DOI 10.1056/NEJM198204153061504; SHAH SV, 1987, J CLIN INVEST, V79, P25, DOI 10.1172/JCI112790; SIBILLE Y, 1986, AM REV RESPIR DIS, V134, P134; STOSSEL TP, 1980, MANUAL CLIN IMMUNOLO, P309; SWITZER BR, 1971, ANAL BIOCHEM, V39, P487, DOI 10.1016/0003-2697(71)90438-6; TILL GO, 1985, AM J PATHOL, V119, P376; TIMPL R, 1979, EUR J BIOCHEM, V95, P255, DOI 10.1111/j.1432-1033.1979.tb12961.x; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; VANKUPPEVELT THMSM, 1985, EUR J CELL BIOL, V36, P74; VISSERS MCM, 1984, BIOCHIM BIOPHYS ACTA, V804, P154, DOI 10.1016/0167-4889(84)90144-7; VISSERS MCM, 1988, COLLAGEN REL RES, V8, P113; VISSERS MCM, 1988, BIOCHEM J, V249, P327, DOI 10.1042/bj2490327; VISSERS MCM, 1987, BIOCHEM J, V245, P277, DOI 10.1042/bj2450277; VISSERS MCM, 1986, BIOCHIM BIOPHYS ACTA, P277; WEISS SJ, 1986, J IMMUNOL, V136, P636; WEISS SJ, 1985, SCIENCE, V227, P747, DOI 10.1126/science.2982211; WEITZ JI, 1987, J EXP MED, V166, P1836, DOI 10.1084/jem.166.6.1836; ZIBRAK JD, 1985, EXP LUNG RES, V8, P15, DOI 10.3109/01902148509069677	36	54	54	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1992	89	4					905	915		10.1016/0091-6749(92)90447-A	http://dx.doi.org/10.1016/0091-6749(92)90447-A			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN860	1560171	Bronze			2022-12-18	WOS:A1992HN86000017
J	GRANT, JA; ALAM, R; LETTBROWN, MA				GRANT, JA; ALAM, R; LETTBROWN, MA			HISTAMINE-RELEASING FACTORS AND INHIBITORS - HISTORICAL PERSPECTIVES AND POSSIBLE IMPLICATIONS IN HUMAN ILLNESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HISTAMINE-RELEASING FACTOR; HISTAMINE; INTERLEUKINS; BASOPHILS; HYPERSENSITIVITY	HUMAN MONONUCLEAR-CELLS; COLONY-STIMULATING FACTOR; SLOW REACTING SUBSTANCE; HUMAN BASOPHILS; MAST-CELLS; ACTIVITY HRA; ASTHMATIC-PATIENTS; MEDIATOR RELEASE; LATE-PHASE; HUMAN-LEUKOCYTES	The initiation of allergic reactions with the bridging of surface-bound IgE antibodies on mast cells and basophils by allergens is well recognized. However, it is clear that other factors most likely play a role in regulating these cells. A number of cytokines have been identified that modulate the secretory response of mast cells and basophils. Among the well-characterized cytokines, interleukin-3 and connective tissue-activating peptide III (or its degradation product, neutrophil-activating peptide 2) can increase the secretory response, whereas interleukin-8 specifically inhibits the response to cytokines. Additional factors are currently under investigation. Preliminary studies suggest an important role for these histamine-releasing factors in atopic disorders, as well as in other conditions in which an IgE-dependent mechanism is not demonstrable. Furthermore, these cytokines may modulate the response of basophils and mast cells in physiologic conditions, such as tissue repair and host defense.			GRANT, JA (corresponding author), UNIV TEXAS, MED BRANCH, DEPT INTERNAL MED, DIV ALLERGY & IMMUNOL, ROUTE G-62, GALVESTON, TX 77550 USA.				NIAID NIH HHS [AI-22940, AI-27864] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027864, R01AI022940] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM R, 1988, CELL IMMUNOL, V115, P447, DOI 10.1016/0008-8749(88)90197-9; ALAM R, 1985, ANN ALLERGY, V55, P825; ALAM R, 1990, AM REV RESPIR DIS, V141, P666, DOI 10.1164/ajrccm/141.3.666; ALAM R, 1985, ALLERGY, V40, P124, DOI 10.1111/j.1398-9995.1985.tb02671.x; ALAM R, 1990, J ALLERGY CLIN IMMUN, V86, P73, DOI 10.1016/S0091-6749(05)80125-3; ALAM R, 1985, IMMUNOL LETT, V11, P111, DOI 10.1016/0165-2478(85)90152-X; ALAM R, 1986, AGENTS ACTIONS, V18, P163, DOI 10.1007/BF01988011; ALAM R, 1988, J ALLERGY CLIN IMMUN, V81, P580, DOI 10.1016/0091-6749(88)90200-X; ALAM R, 1989, J IMMUNOL, V142, P3431; ALAM R, 1989, J IMMUNOL, V142, P3951; ALAM R, 1984, ANN ALLERGY, V53, P66; ALAM R, 1988, J CLIN INVEST, V82, P2056, DOI 10.1172/JCI113826; ALAM R, 1990, Journal of Allergy and Clinical Immunology, V85, P257; ALAM R, 1987, INSIGHTS ALLERGY, V2, P1; ALAM R, 1989, J ALLERGY CLIN IMMUN, V43, P2280; ASKENASE PW, 1975, NATURE, V256, P52, DOI 10.1038/256052a0; ASKENASE PW, 1988, ALLERGY PRINCIPLES P, P247; BAEZA ML, 1988, J IMMUNOL, V141, P2688; BAEZA ML, 1989, J CLIN INVEST, V83, P1204, DOI 10.1172/JCI114002; BAEZA ML, 1990, J CLIN INVEST, V85, P1516, DOI 10.1172/JCI114598; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BROIDE DH, 1990, J IMMUNOL, V145, P1838; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CARRAWAY RE, 1989, J IMMUNOL, V143, P1680; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CHURCH MK, 1989, AGENTS ACTIONS, V27, P9, DOI 10.1007/BF02222185; COCCHIARA R, 1987, INT ARCH ALLER A IMM, V84, P321, DOI 10.1159/000234442; COCHRANE DE, 1988, INT ARCH ALLER A IMM, V87, P269, DOI 10.1159/000234684; COCKCROFT DW, 1985, ANN ALLERGY, V55, P857; COCKCROFT DW, 1988, CHEST, V94, P178, DOI 10.1378/chest.94.1.178; CORRIGAN CJ, 1988, LANCET, V1, P1129; COSTA JJ, 1990, INSIGHTS ALLERGY, V5, P1; DAHINDEN CA, 1989, INT ARCH ALLER A IMM, V90, P113, DOI 10.1159/000235011; DAHINDEN CA, 1989, J EXP MED, V170, P1787, DOI 10.1084/jem.170.5.1787; DVORAK AM, 1976, J IMMUNOL, V116, P687; DVORAK AM, 1984, CLIN IMMUNOL IMMUNOP, V32, P142, DOI 10.1016/0090-1229(84)90116-8; DVORAK AM, 1981, J IMMUNOL, V126, P523; DVORAK HF, 1974, LAB INVEST, V31, P111; DVORAK HF, 1970, J EXP MED, V132, P558, DOI 10.1084/jem.132.3.558; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; EZEAMUZIE IC, 1983, AGENTS ACTIONS, V13, P222, DOI 10.1007/BF01967337; EZEAMUZIE IC, 1985, AGENTS ACTIONS, V17, P21, DOI 10.1007/BF01966675; EZEAMUZIE IC, 1985, INT J IMMUNOPHARMACO, V7, P533, DOI 10.1016/0192-0561(85)90073-6; FILIPOWICZ AW, 1989, NATURE, V339, P150; FINDLAY SR, 1980, J IMMUNOL, V124, P238; FISHER R H, 1990, Journal of Allergy and Clinical Immunology, V85, P261; GOETZL EJ, 1984, IMMUNOLOGY, V53, P227; GRANT JA, 1972, J IMMUNOL, V109, P20; GRANT JA, 1986, FASEB J, V45, P2653; GUO C-B, 1990, Journal of Allergy and Clinical Immunology, V85, P172; HAAKFRENDSCHO M, 1988, J CLIN INVEST, V82, P17, DOI 10.1172/JCI113567; HAAKFRENDSCHO M, 1988, J ALLERGY CLIN IMMUN, V82, P218, DOI 10.1016/0091-6749(88)91002-0; HIRAI K, 1988, J IMMUNOL, V141, P3958; HSIEH K H, 1990, Journal of Allergy and Clinical Immunology, V85, P258; IDA S, 1977, J EXP MED, V145, P892, DOI 10.1084/jem.145.4.892; IIKURA Y, 1987, INT ARCH ALLER A IMM, V82, P341, DOI 10.1159/000234221; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KAPLAN AP, 1985, INT ARCH ALLER A IMM, V77, P64, DOI 10.1159/000233754; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; KURIMOTO Y, 1989, J EXP MED, V170, P467, DOI 10.1084/jem.170.2.467; LANGFORD MP, 1987, IMMUNOL INVEST, V16, P129, DOI 10.3109/08820138709030570; LEMANSKE RF, 1988, ALLERGY PRINCIPLES P, P224; Lett-Brown M A, 1989, Year Immunol, V5, P195; LETTBROWN MA, 1984, CELL IMMUNOL, V87, P434, DOI 10.1016/0008-8749(84)90012-1; LETTBROWN MA, 1984, CELL IMMUNOL, V87, P445, DOI 10.1016/0008-8749(84)90013-3; LETTBROWN MA, 1976, J IMMUNOL, V117, P246; LETTBROWN MA, 1981, J CLIN INVEST, V67, P547, DOI 10.1172/JCI110065; LICHTENSTEIN LM, 1988, J ALLERGY CLIN IMMUN, V81, P814, DOI 10.1016/0091-6749(88)90936-0; LIU MC, 1986, J IMMUNOL, V136, P2588; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MASSEY WA, 1989, J IMMUNOL, V143, P1875; MCCLEAN SP, 1989, J ALLERGY CLIN IMMUN, V83, P236; MORITA Y, 1987, ALLERGY, V42, P104, DOI 10.1111/j.1398-9995.1987.tb02367.x; NACLERIO RM, 1988, IMMUNOL INVEST, V16, P649; ORCHARD MA, 1986, J IMMUNOL, V136, P2240; OTTE RW, 1990, ANN ALLERGY, V64, P55; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RAZIN E, 1984, J IMMUNOL, V132, P1479; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SCHULMAN ES, 1988, J IMMUNOL, V140, P2369; SEDGWICK JD, 1981, CLIN EXP IMMUNOL, V45, P409; SIM T C, 1990, Journal of Allergy and Clinical Immunology, V85, P156; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SUBRAMANIAN N, 1987, J IMMUNOL, V138, P271; TANNO Y, 1987, EXP HEMATOL, V15, P24; THOMAS LL, 1989, IMMUNOLOGY, V66, P611; THUESON DO, 1979, J IMMUNOL, V123, P633; THUESON DO, 1979, J IMMUNOL, V123, P626; THUESON DO, 1982, HUMAN LYMPHOKINES BI, P229; VALENT P, 1989, BLOOD, V73, P1763; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; WALDEN SM, 1988, J ALLERGY CLIN IMMUN, V81, P940, DOI 10.1016/0091-6749(88)90157-1; WARNER JA, 1986, J IMMUNOL, V136, P2583; WHITE MV, 1989, IMMUNOL LETT, V22, P151, DOI 10.1016/0165-2478(89)90182-X; WHITE MV, 1987, J IMMUNOL, V139, P1624; WHITE MV, 1988, J IMMUNOL, V141, P3575; WHITE MV, 1989, J ALLERGY CLIN IMMUN, V84, P773, DOI 10.1016/0091-6749(89)90308-4	99	54	55	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					683	693		10.1016/0091-6749(91)90170-S	http://dx.doi.org/10.1016/0091-6749(91)90170-S			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1720148				2022-12-18	WOS:A1991GQ45200001
J	SAMPLE, S; CHERNOFF, DN; LENAHAN, GA; SERWONSKA, MH; RANGI, S; SHERMAN, JW; SOOY, CD; HOLLANDER, H; GOETZL, EJ				SAMPLE, S; CHERNOFF, DN; LENAHAN, GA; SERWONSKA, MH; RANGI, S; SHERMAN, JW; SOOY, CD; HOLLANDER, H; GOETZL, EJ			ELEVATED SERUM CONCENTRATIONS OF IGE ANTIBODIES TO ENVIRONMENTAL ANTIGENS IN HIV-SEROPOSITIVE MALE-HOMOSEXUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE-DEFICIENCY SYNDROME; INFECTION; MANIFESTATIONS; ALLERGY	Forty-five homosexual male subjects with human immunodeficiency virus (HIV) infection, who received care during a 4-month period in an ambulatory center for acquired immunodeficiency syndrome (AIDS), were classified according to their principal presentation with characteristic secondary infections (CDC group IV C, N = 28), cancers (IV D, N = 10), or limited or no symptoms (groups II, III, IV A, or IV B, N = 7). The incidence of allergic rhinitis and conjunctivitis increased after HIV seroconversion by approximately twofold in patients of groups IV C and IV D. The mean serum concentration of IgE was significantly higher for group IV C than for the other HIV-seropositive groups and for a control group of 45 HIV-seronegative homosexual male subjects from the same community who were studied concurrently. More patients in groups IV C and IV D had positive RASTs for a panel of environmental antigens than patients in the other HIV-seropositive groups and the HIV-seronegative control group. Patients with AIDS presenting with typical secondary infections thus have a high frequency of some clinical and laboratory manifestations of allergic diseases.	UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MED,533 PARNASSUS,RM U426,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT OTOLARYNGOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								BERG TLO, 1974, J ALLERGY CLIN IMMUN, V54, P209, DOI 10.1016/0091-6749(74)90063-3; CARINI C, 1988, P NATL ACAD SCI USA, V85, P9214, DOI 10.1073/pnas.85.23.9214; DUC J, 1988, ALLERGY, V43, P332, DOI 10.1111/j.1398-9995.1988.tb00426.x; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GRIECO MH, 1989, J ALLERGY CLIN IMMUN, V84, P1, DOI 10.1016/0091-6749(89)90170-X; JACKSON S, 1988, J CLIN IMMUNOL, V8, P390, DOI 10.1007/BF00917155; KAYE BR, 1989, ANN INTERN MED, V111, P158, DOI 10.7326/0003-4819-111-2-158; LOWENSTEIN W, 1988, 4TH P INT AIDS C STO, P188; PARKIN JM, 1987, BRIT MED J, V294, P1185, DOI 10.1136/bmj.294.6581.1185; PEDERSEN M, 1987, ALLERGY, V42, P291, DOI 10.1111/j.1398-9995.1987.tb02212.x; QUIRINO T, 1988, 4TH P INT AIDS C STO, P194; RING J, 1986, ACTA DERM-VENEREOL, V66, P530; WRIGHT DN, 1988, J ALLERGY CLIN IMMUN, V81, P216, DOI 10.1016/0091-6749(88)90426-5	13	54	54	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				876	880		10.1016/S0091-6749(05)80149-6	http://dx.doi.org/10.1016/S0091-6749(05)80149-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	2262644				2022-12-18	WOS:A1990EQ04500007
J	MAXWELL, DL; ATKINSON, BA; SPUR, BW; LESSOF, MH; LEE, TH				MAXWELL, DL; ATKINSON, BA; SPUR, BW; LESSOF, MH; LEE, TH			SKIN-RESPONSES TO INTRADERMAL HISTAMINE AND LEUKOTRIENE-C4 LEUKOTRIENE-D4, AND LEUKOTRIENE-E4 IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA AND IN NORMAL SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT ALLERGY & ALLIED RESP DISORDERS,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Spur, Bernd/0000-0002-7581-4741				BATEMAN DN, 1983, EUR J CLIN PHARMACOL, V25, P547, DOI 10.1007/BF00542126; BEDARD PM, 1986, J ALLERGY CLIN IMMUN, V78, P1121, DOI 10.1016/0091-6749(86)90260-5; BRUENT C, 1988, J ALLERGY CLIN IMMUN, V82, P398; CAMP RDR, 1983, BRIT J PHARMACOL, V80, P497, DOI 10.1111/j.1476-5381.1983.tb10721.x; COHEN RW, 1986, J ALLERGY CLIN IMMUN, V77, P802, DOI 10.1016/0091-6749(86)90377-5; COOK J, 1980, BRIT J PHARMACOL, V69, P579, DOI 10.1111/j.1476-5381.1980.tb07907.x; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P26; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KRAUSE LB, 1985, BR J CLIN PHARM, V20, P468; LESSOF MH, 1989, PROGRESS IN ALLERGY AND CLINICAL IMMUNOLOGY, P353; LESSOF MH, 1990, CLIN EXP ALLERGY, V20, P373, DOI 10.1111/j.1365-2222.1990.tb02796.x; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P371, DOI 10.1016/0091-6749(80)90215-8; PRASAD DN, 1967, INT ARCH ALLER A IMM, V31, P230, DOI 10.1159/000229872; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018	16	54	54	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1990	86	5					759	765		10.1016/S0091-6749(05)80180-0	http://dx.doi.org/10.1016/S0091-6749(05)80180-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EJ631	2172351				2022-12-18	WOS:A1990EJ63100008
J	MICAN, JAM; METCALFE, DD				MICAN, JAM; METCALFE, DD			ARTHRITIS AND MAST-CELL ACTIVATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MICAN, JAM (corresponding author), NIAID, CLIN INVEST LAB, MAST CELL PHYSIOL SECT, BLDG 10, RM 11C210, BETHESDA, MD 20892 USA.							ALTER SC, 1987, BIOCHEM J, V248, P821, DOI 10.1042/bj2480821; ATKINS FM, 1985, INT ARCH ALLER A IMM, V77, P96, DOI 10.1159/000233760; AZIZKHAN RG, 1980, J EXP MED, V152, P931, DOI 10.1084/jem.152.4.931; BARRETT KE, 1986, J IMMUNOL, V137, P2001; BARZU T, 1985, BIOCHIM BIOPHYS ACTA, V845, P196, DOI 10.1016/0167-4889(85)90177-6; BIERTHER M, 1974, Z RHEUMATOL, V33, P43; BROMLEY M, 1984, ARTHRITIS RHEUM, V27, P857, DOI 10.1002/art.1780270804; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; BURD PR, 1990, FASEB J, V4, pA1705; CASTOR CW, 1960, ARTHRITIS RHEUM, V3, P140, DOI 10.1002/art.1780030205; CAULFIELD JP, 1988, LAB INVEST, V59, P82; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CLAMAN HN, 1989, J INVEST DERMATOL, V92, P290, DOI 10.1111/1523-1747.ep12276876; CLAMAN HN, 1986, J IMMUNOL, V137, P2009; COSTA JJ, 1990, FASEB J, V4, pA1943; CRISP AJ, 1984, ARTHRITIS RHEUM, V27, P845, DOI 10.1002/art.1780270802; CRISP AJ, 1984, ANN RHEUM DIS, V43, P628, DOI 10.1136/ard.43.4.628; DALLDORF FG, 1988, AM J PATHOL, V132, P258; DAVATELIS G, 1989, SCIENCE, V243, P1066, DOI 10.1126/science.2646711; DAYTON ET, 1989, J IMMUNOL, V142, P4307; FONSECA E, 1985, ANN INTERN MED, V102, P864, DOI 10.7326/0003-4819-102-6-864_2; FRIERI M, 1983, J IMMUNOL, V131, P1942; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GAJDUSEK CM, 1984, J CELL PHYSIOL, V121, P13, DOI 10.1002/jcp.1041210104; GIORNO R, 1987, J IMMUNOL METHODS, V99, P163, DOI 10.1016/0022-1759(87)90121-9; GODFREY HP, 1984, ARTHRITIS RHEUM, V27, P852, DOI 10.1002/art.1780270803; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GOTO T, 1984, AM REV RESPIR DIS, V130, P797; GRENNAN DM, 1975, EUR J CLIN INVEST, V5, P75, DOI 10.1111/j.1365-2362.1975.tb00431.x; GRUBER B, 1988, CLIN EXP IMMUNOL, V71, P289; GRUBER B, 1989, MONOGR ALLERGY, V26, P120; GRUBER B, 1986, ARTHRITIS RHEUM, V29, P944, DOI 10.1002/art.1780290802; GRUBER BL, 1988, J IMMUNOL, V140, P3936; GRYFE A, 1971, ANN RHEUM DIS, V30, P24, DOI 10.1136/ard.30.1.24; HAAKFRENDSCHO M, 1988, J CLIN INVEST, V82, P17, DOI 10.1172/JCI113567; HAWKINS RA, 1985, ANN INTERN MED, V102, P182, DOI 10.7326/0003-4819-102-2-182; HUNDER GG, 1973, AM J MED, V54, P461, DOI 10.1016/0002-9343(73)90042-9; JAFFEE BD, 1983, CELL IMMUNOL, V77, P1, DOI 10.1016/0008-8749(83)90001-1; JANES J, 1948, ARCH PATHOL, V45, P622; KAHALEH MB, 1979, J EXP MED, V149, P1326, DOI 10.1084/jem.149.6.1326; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KAWANAMI O, 1979, LAB INVEST, V40, P717; KIRSCHER CW, 1972, TEX REP BIOL MED, V30, P327; KLOCKFORN RW, 1982, ARTHRITIS RHEUM, V25, P708; KOPICKYBURD JA, 1988, J RHEUMATOL, V15, P1326; LEROY EC, 1972, J EXP MED, V135, P1351, DOI 10.1084/jem.135.6.1351; LEVER JD, 1958, ANAT REC, V132, P525, DOI 10.1002/ar.1091320402; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; MAJNO G, 1969, J CELL BIOL, V42, P647, DOI 10.1083/jcb.42.3.647; MALONE DG, 1986, ARTHRITIS RHEUM, V29, P956, DOI 10.1002/art.1780290803; MALONE DG, 1988, ARTHRITIS RHEUM, V31, P1063, DOI 10.1002/art.1780310820; MALONE DG, 1989, ARTHRITIS RHEUM, V32, P357, DOI 10.1002/anr.1780320323; MALONE DG, 1987, ARTHRITIS RHEUM, V30, P130, DOI 10.1002/art.1780300202; MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; MIOSSEC P, 1987, J RHEUMATOL, V14, P372; MIYAWAKI S, 1974, J IMMUNOL, V113, P1346; Murata K, 1973, Acta Derm Venereol Suppl (Stockh), V73, P157; NAGPAL S, 1987, J IMMUNOL, V138, P4169; NISHIOKA K, 1987, ARCH DERMATOL, V123, P205, DOI 10.1001/archderm.123.2.205; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OKADA Y, 1989, FEBS LETT, V244, P473, DOI 10.1016/0014-5793(89)80586-1; OKADA Y, 1973, JPN J ORTHOP SURG, V47, P657; ORCHARD MA, 1986, J IMMUNOL, V136, P2240; PANUSH RS, 1986, ARTHRITIS RHEUM, V29, P220, DOI 10.1002/art.1780290210; PEARSON ME, 1988, ARTHRITIS RHEUM, V31, P672, DOI 10.1002/art.1780310514; PERMIN H, 1981, ALLERGY, V36, P435, DOI 10.1111/j.1398-9995.1981.tb01852.x; PERMIN H, 1978, ACTA PATH MICRO IM C, V86, P245; PERSINGER MA, 1983, BRIT J DERMATOL, V108, P179, DOI 10.1111/j.1365-2133.1983.tb00060.x; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RAO PVS, 1983, J IMMUNOL, V130, P341; ROCKLIN RE, 1981, J CLIN IMMUNOL, V1, P73, DOI 10.1007/BF00915479; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SHANAHAN F, 1985, J IMMUNOL, V135, P1331; SYLVEN B, 1945, ACTA RADIOL STOCKH S, V59, P1; TAKEDA K, 1989, ARCH DERMATOL RES, V281, P288, DOI 10.1007/BF00431065; TAYLOR DJ, 1985, BIOCHEM J, V225, P315, DOI 10.1042/bj2250315; TAYLOR DJ, 1987, ANN RHEUM DIS, V46, P425, DOI 10.1136/ard.46.6.425; TAYLOR DJ, 1987, ANN RHEUM DIS, V46, P431, DOI 10.1136/ard.46.6.431; TAYLOR DJ, 1986, ARTHRITIS RHEUM, V29, P160, DOI 10.1002/art.1780290202; THOMPSON HL, 1990, CLIN RES, V38, pA448; THOMPSON HL, 1988, J IMMUNOL, V140, P2708; THUESON DO, 1979, J IMMUNOL, V123, P626; WALLACH D, 1979, NOUV PRESSE MED, V8, P2981; WARD PA, 1971, J CLIN INVEST, V50, P606, DOI 10.1172/JCI106531; WASSERMAN SI, 1984, ARTHRITIS RHEUM, V27, P841, DOI 10.1002/art.1780270801; WHITE MV, 1988, J IMMUNOL, V141, P3575; WHITE MV, 1989, BIOCH ACUTE ALLERGIC, P83; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180	92	54	58	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	2	S			677	683		10.1016/S0091-6749(05)80240-4	http://dx.doi.org/10.1016/S0091-6749(05)80240-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH093	2229835	Bronze			2022-12-18	WOS:A1990EH09300021
J	BROOKS, SM; BERNSTEIN, IL; RAGHUPRASAD, PK; MACCIA, CA; MIECZKOWSKI, L				BROOKS, SM; BERNSTEIN, IL; RAGHUPRASAD, PK; MACCIA, CA; MIECZKOWSKI, L			ASSESSMENT OF AIRWAY HYPERRESPONSIVENESS IN CHRONIC STABLE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI, COLL MED, DEPT ENVIRONM HLTH, CINCINNATI, OH 45221 USA; UNIV CINCINNATI, COLL MED, DEPT MED, CINCINNATI, OH 45221 USA	University of Cincinnati; University of Cincinnati	BROOKS, SM (corresponding author), UNIV S FLORIDA, COLL PUBL HLTH, DEPT ENVIRONM & OCCUPAT HLTH, 13301 BRUCE B DOWNS BLVD, MHH 104, TAMPA, FL 33612 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000159] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00068-17] Funding Source: Medline; NHLBI NIH HHS [HL 22415] Funding Source: Medline; NIEHS NIH HHS [ES 00159] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMAROGALVEZ R, 1987, ANN ALLERGY, V59, P298; [Anonymous], 1979, AM REV RESPIR DIS, V119, P831; ANTIC R, 1976, AM REV RESPIR DIS, V114, P851; ARKINS JA, 1968, J ALLERGY, V41, P209, DOI 10.1016/0021-8707(68)90043-9; BENSON MK, 1977, J APPL PHYSIOL, V43, P643, DOI 10.1152/jappl.1977.43.4.643; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BROWN E A, 1954, Ann Allergy, V12, P14; BROWN R, 1977, J APPL PHYSIOL, V42, P221, DOI 10.1152/jappl.1977.42.2.221; CASALE TB, 1987, J APPL PHYSIOL, V62, P1888, DOI 10.1152/jappl.1987.62.5.1888; CHANYEUNG M, 1977, AM REV RESPIR DIS, V116, P1023; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P505; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1987, ANN ALLERGY, V59, P405; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; CROPP GJA, 1975, AM REV RESPIR DIS, V112, P599; DAHLEM NW, 1979, J ALLERGY CLIN IMMUN, V63, P23, DOI 10.1016/0091-6749(79)90157-X; DALES RE, 1987, AM REV RESPIR DIS, V135, P817, DOI 10.1164/arrd.1987.135.4.817; DAVIES RJ, 1982, PERSPECTIVES ASTHMA, P187; DESJARDINS A, 1988, AM REV RESPIR DIS, V137, P1020, DOI 10.1164/ajrccm/137.5.1020; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; ENARSON DA, 1987, AM REV RESPIR DIS, V136, P613, DOI 10.1164/ajrccm/136.3.613; GAYRARD P, 1975, AM REV RESPIR DIS, V111, P433; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HERBERT M, 1967, J PSYCHOSOM RES, V11, P195, DOI 10.1016/0022-3999(67)90007-4; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; HORTON DJ, 1978, AM REV RESPIR DIS, V117, P1029; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LEE LY, 1977, J APPL PHYSIOL, V43, P626, DOI 10.1152/jappl.1977.43.4.626; LITTLE JW, 1978, AM REV RESPIR DIS, V118, P295; LUPARELLO T, 1968, PSYCHOSOM MED, V30, P819, DOI 10.1097/00006842-196811000-00002; Moll HH, 1940, Q J MED, V9, P229; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; MORTAGY AK, 1986, BRIT MED J, V293, P525, DOI 10.1136/bmj.293.6546.525; NADEL JA, 1961, J APPL PHYSIOL, V16, P713, DOI 10.1152/jappl.1961.16.4.713; OUELLETTE JJ, 1965, J ALLERGY, V36, P558, DOI 10.1016/0021-8707(65)90193-0; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; POPA V, 1973, J ALLERGY CLIN IMMUN, V51, P344, DOI 10.1016/0091-6749(73)90073-0; RIJCKEN B, 1987, AM REV RESPIR DIS, V136, P62, DOI 10.1164/ajrccm/136.1.62; ROSENTHAL RR, 1977, J APPL PHYSIOL, V42, P600, DOI 10.1152/jappl.1977.42.4.600; RUFFIN RE, 1978, AM REV RESPIR DIS, V117, P485; SCHEFLER WC, 1979, STATISTICS BIOL SCI, P216; SHIM C, 1986, AM J MED, V80, P18, DOI 10.1016/0002-9343(86)90043-4; SNEDECOR GW, 1968, STATISTICAL METHODS, P268; SPECTOR S, 1976, AM REV RESPIR DIS, V113, P43; SPECTOR SL, 1979, ALLERGY, V34, P167, DOI 10.1111/j.1398-9995.1979.tb01564.x; Starr I, 1933, AM J MED SCI, V186, P313, DOI 10.1097/00000441-193309000-00001; STEIN M, 1958, PSYCHOSOM MED, V20, P60, DOI 10.1097/00006842-195801000-00007; STERLING GM, 1967, BRIT MED J, V3, P275, DOI 10.1136/bmj.3.5560.275; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; TOWNLEY RG, 1976, J ALLERGY CLIN IMMUN, V57, P358, DOI 10.1016/0091-6749(76)90093-2; VRIES KD, 1987, BRONCHIAL HYPERRESPO, P359; WILLIAMS MH, 1979, CHEST, V76, P3, DOI 10.1378/chest.76.1.3; WOOLCOCK AJ, 1988, TXB RESPIRATORY MED, P1030	56	54	54	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				17	26		10.1016/0091-6749(90)90216-Q	http://dx.doi.org/10.1016/0091-6749(90)90216-Q			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2405041				2022-12-18	WOS:A1990CM37800004
J	ROBERTS, NM; PAGE, CP; CHUNG, KF; BARNES, PJ				ROBERTS, NM; PAGE, CP; CHUNG, KF; BARNES, PJ			EFFECT OF A PAF ANTAGONIST, BN52063, ON ANTIGEN-INDUCED, ACUTE, AND LATE-ONSET CUTANEOUS RESPONSES IN ATOPIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV LONDON KINGS COLL,DEPT PHARMACOL,LONDON WC2R 2LS,ENGLAND	University of London; King's College London			Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Barnes, Peter/0000-0002-5122-4018				ARCHER CB, 1984, BRIT J DERMATOL, V110, P45, DOI 10.1111/j.1365-2133.1984.tb07310.x; ARCHER CB, 1985, BRIT J DERMATOL, V112, P285, DOI 10.1111/j.1365-2133.1985.tb04855.x; BARNES PJ, 1986, BRIT J PHARMACOL, V88, P741, DOI 10.1111/j.1476-5381.1986.tb16246.x; BARNES PJ, IN PRESS J ALLERGY C; BEDARD PM, 1983, J ALLERGY CLIN IMMUN, V71, P394, DOI 10.1016/0091-6749(83)90068-4; BRAQUET P, 1985, BLOOD VESSELS, V16, P559; BROSTOFF J, 1979, LANCET, V1, P1268; CASALSSTENZEL J, 1987, BRIT J PHARMACOL, V90, P139, DOI 10.1111/j.1476-5381.1987.tb16833.x; CHUNG KF, 1987, LANCET, V1, P248; COYLE A, 1987, CLIN RES, V35, pA254; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DOR PJ, 1983, J ALLERGY CLIN IMMUN, V71, P363, DOI 10.1016/0091-6749(83)90063-5; DORSCH W, 1982, J ALLERGY CLIN IMMUN, V70, P236, DOI 10.1016/0091-6749(82)90059-8; DORSCH W, 1980, ALLERGY, V35, P503, DOI 10.1111/j.1398-9995.1980.tb01797.x; FOREMAN JC, 1982, BRIT J PHARMACOL, V77, P531, DOI 10.1111/j.1476-5381.1982.tb09328.x; GUINOT P, 1986, PROSTAGLANDINS, V32, P160, DOI 10.1016/0090-6980(86)90161-9; GUINOT P, 1987, PAF PLATELETS ASTHMA, P239; HENOCQ E, 1986, LANCET, V1, P1378; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P26; LEMBECK F, 1982, EUR J PHARMACOL, V85, P171, DOI 10.1016/0014-2999(82)90462-9; MORLEY J, 1984, LANCET, V2, P1142; PAGE CP, 1985, INFLAMMATORY MEDIATO, P57; PHILLIPS MJ, 1983, BRIT J CLIN PHARMACO, V15, P277, DOI 10.1111/j.1365-2125.1983.tb01500.x; SHAIKH W, 1977, J ALLERGY CLIN IMMUN, V60, P242, DOI 10.1016/0091-6749(77)90138-5; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; STEVENSON JS, 1987, FED PROC, V46, pA1454; TERASHITA Z, 1983, LIFE SCI, V32, P1975, DOI 10.1016/0024-3205(83)90049-8; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; VALONE F, 1987, J ALLERGY CLIN IMMUN, V79, P248; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; ZETTERSTROM O, 1978, CLIN ALLERGY, V8, P77, DOI 10.1111/j.1365-2222.1978.tb00452.x; 1977, CHINESE PHARMACOPOEI	33	54	54	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					236	241		10.1016/0091-6749(88)91005-6	http://dx.doi.org/10.1016/0091-6749(88)91005-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	3403863				2022-12-18	WOS:A1988P874100015
J	GONG, H; SIMMONS, MS; CLARK, VA; TASHKIN, DP				GONG, H; SIMMONS, MS; CLARK, VA; TASHKIN, DP			METERED-DOSE INHALER USAGE IN SUBJECTS WITH ASTHMA - COMPARISON OF NEBULIZER CHRONOLOG AND DAILY DIARY RECORDINGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DIV BIOSTAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	GONG, H (corresponding author), UNIV CALIF LOS ANGELES,MED CTR,SCH MED,DIV PULM,LOS ANGELES,CA 90024, USA.							DIRKS JF, 1982, CLIN PHARMACOL THER, V31, P413, DOI 10.1038/clpt.1982.53; DIRKS JF, 1977, PSYCHOSOM MED, V39, P120, DOI 10.1097/00006842-197703000-00006; GONG H, 1986, AM REV RESPIR DIS, V133, pA217; JONES NF, 1979, MED CARE, V17, P1103, DOI 10.1097/00005650-197911000-00003; KINSMAN RA, 1977, PSYCHOSOM MED, V39, P102, DOI 10.1097/00006842-197703000-00005; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; MORRIS JF, 1976, WESTERN J MED, V125, P110; PERRY GB, 1983, AM J PUBLIC HEALTH, V73, P50, DOI 10.2105/AJPH.73.1.50; Polgar G, 1971, PULMONARY FUNCTION T; RAMSAY JA, 1982, MED CARE, V20, P615, DOI 10.1097/00005650-198206000-00007; SPECTOR SL, 1985, ANN ALLERGY, V55, P552; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8; SPIELBERGER CD, 1973, STAI MANUAL; 1962, AM REV RESPIR DIS, V85, P762	14	54	58	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					5	10		10.1016/0091-6749(88)90043-7	http://dx.doi.org/10.1016/0091-6749(88)90043-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	3392369				2022-12-18	WOS:A1988P400400002
J	MALBRAN, A; HAMMER, CH; FRANK, MM; FRIES, LF				MALBRAN, A; HAMMER, CH; FRANK, MM; FRIES, LF			ACQUIRED ANGIOEDEMA - OBSERVATIONS ON THE MECHANISM OF ACTION OF AUTOANTIBODIES DIRECTED AGAINST C1 ESTERASE INHIBITOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,BLDG 10,ROOM 11N-214,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Malbran, Alejandro/C-3410-2017	Malbran, Alejandro/0000-0003-4228-4892				ALSENZ J, 1987, NEW ENGL J MED, V316, P1360, DOI 10.1056/NEJM198705283162202; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; DONALDSON VH, 1985, J CLIN INVEST, V75, P124, DOI 10.1172/JCI111664; FRANK MM, 1987, CLIN RES, V35, P641; GEHA RS, 1985, NEW ENGL J MED, V312, P534, DOI 10.1056/NEJM198502283120902; Hames BD, 1986, GEL ELECTROPHORESIS, P1; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; JACKSON J, 1986, NATURE, V323, P722, DOI 10.1038/323722a0; KENDALL FE, 1938, COLD SPRING HARB SYM, V6, P376; Osler W, 1888, AM J MED SCI, V95, P362; PAPADOPOULOS NM, 1987, CLIN CHIM ACTA, V163, P231, DOI 10.1016/0009-8981(87)90027-1; PROGRAIS LJ, 1987, J IMMUNOL METHODS, V99, P113, DOI 10.1016/0022-1759(87)90039-1; STEINBUCH M, 1969, ARCH BIOCHEM BIOPHYS, V134, P279, DOI 10.1016/0003-9861(69)90285-9; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; ZURAW BL, 1986, J CLIN INVEST, V78, P567, DOI 10.1172/JCI112610	15	54	54	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1199	1204		10.1016/0091-6749(88)90891-3	http://dx.doi.org/10.1016/0091-6749(88)90891-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	2454251				2022-12-18	WOS:A1988P002300021
J	ARLIAN, LG; BERNSTEIN, IL; GEIS, DP; VYSZENSKIMOHER, DL; GALLAGHER, JS; MARTIN, B				ARLIAN, LG; BERNSTEIN, IL; GEIS, DP; VYSZENSKIMOHER, DL; GALLAGHER, JS; MARTIN, B			INVESTIGATIONS OF CULTURE MEDIUM-FREE HOUSE DUST MITES .3. ANTIGENS AND ALLERGENS OF BODY AND FECAL EXTRACT OF DERMATOPHAGOIDES-FARINAE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WRIGHT STATE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,DAYTON,OH 45435; UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267; WILFORD HALL USAF MED CTR,LACKLAND AFB,TX 78236	University System of Ohio; Wright State University Dayton; University System of Ohio; University of Cincinnati; United States Department of Defense; United States Air Force	ARLIAN, LG (corresponding author), WRIGHT STATE UNIV,DEPT BIOL SCI,DAYTON,OH 45435, USA.				NIAID NIH HHS [R01 AI 13702] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARLIAN L G, 1984, Journal of Allergy and Clinical Immunology, V73, P119; ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P172, DOI 10.1016/0091-6749(84)90282-3; ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P166, DOI 10.1016/0091-6749(84)90281-1; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; DALE S, 1984, ALLERGY, V39, P572, DOI 10.1111/j.1398-9995.1984.tb01977.x; HAIDA M, 1985, J ALLERGY CLIN IMMUN, V75, P686, DOI 10.1016/0091-6749(85)90094-6; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P132, DOI 10.1016/0091-6749(84)90275-6; LEMAO J, 1981, IMMUNOLOGY, V44, P239; LEMAO J, 1983, J ALLERGY CLIN IMMUN, V71, P588, DOI 10.1016/0091-6749(83)90441-4; LEMAO J, 1985, INT ARCH ALLERGY APP, V76, P189; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; LIND P, 1981, P SCAND ALLERGO C GO; STEWART GA, 1986, J ALLERGY CLIN IMMUN, V77, P14, DOI 10.1016/0091-6749(86)90316-7; STEWART GA, 1982, INT ARCH ALLER A IMM, V69, P224, DOI 10.1159/000233175; TOVEY ER, 1985, INT ARCH ALLER A IMM, V76, P82, DOI 10.1159/000233667; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; WAHN U, 1985, ALLERGY, V40, P389, DOI 10.1111/j.1398-9995.1985.tb02676.x	18	54	57	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1987	79	3					457	466		10.1016/0091-6749(87)90363-0	http://dx.doi.org/10.1016/0091-6749(87)90363-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G4795	3819227				2022-12-18	WOS:A1987G479500008
J	LASAGNA, L				LASAGNA, L			THE PLACEBO-EFFECT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LASAGNA, L (corresponding author), TUFTS UNIV, SACKLER SCH GRAD BIOMED SCI, 136 HARRISON AVE, BOSTON, MA 02111 USA.							ADER R, COMMUNICATION; BEECHER HK, 1961, JAMA-J AM MED ASSOC, V176, P1102, DOI 10.1001/jama.1961.63040260007008; BIANCHINE JR, 1968, AM J MED, V44, P390, DOI 10.1016/0002-9343(68)90110-1; IREY NS, 1968, DIAGNOSTIC PROBLEM 3; IREY NS, 1966, DIAGNOSTIC PROBLEM 1; IREY NS, 1967, DIAGNOSTIC PROBLEM 2; LASAGNA L, 1954, AM J MED, V16, P770, DOI 10.1016/0002-9343(54)90441-6; LASAGNA L, 1954, J PHARMACOL EXP THER, V111, P9; LASAGNA L, 1958, J CLIN INVEST, V37, P533, DOI 10.1172/JCI103635; Lasagna L, 1962, DOCTORS DILEMMAS; LIBERMAN R, 1964, J PSYCHIAT RES, V2, P233, DOI 10.1016/0022-3956(64)90010-X; MINTZ I, 1977, AM J PSYCHIAT, V134, P327; PARK LC, 1965, ARCH GEN PSYCHIAT, V12, P336; REIDENBERG NM, 1968, NEW ENGL J MED, V27, P678; VINAR O, 1969, BRIT J PSYCHIAT, V115, P1189, DOI 10.1192/bjp.115.527.1189; WOLF S, 1954, JAMA-J AM MED ASSOC, V155, P339, DOI 10.1001/jama.1954.03690220013004; WOLF S, 1947, HUMAN GASTRIC FUNCTI	17	54	55	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	2	S			161	165		10.1016/0091-6749(86)90008-4	http://dx.doi.org/10.1016/0091-6749(86)90008-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2997	3722643	Bronze			2022-12-18	WOS:A1986D299700008
J	COHEN, RW; ROSENSTREICH, DL				COHEN, RW; ROSENSTREICH, DL			DISCRIMINATION BETWEEN URTICARIA-PRONE AND OTHER ALLERGIC PATIENTS BY INTRADERMAL SKIN TESTING WITH CODEINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, CHANIN BLDG, RM 628, 1300 MORRIS PK AVE, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017934] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-13330] Funding Source: Medline; NIAID NIH HHS [R01 AI-17934] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEDARD PM, 1985, J ALLERGY CLIN IMMUN, V75, P126, DOI 10.1016/0091-6749(85)90222-2; BOONK WJ, 1981, DERMATOLOGICA, V163, P151, DOI 10.1159/000250152; CASALE TB, 1984, J ALLERGY CLIN IMMUN, V73, P775, DOI 10.1016/0091-6749(84)90447-0; COSTA TJ, 1978, ALLERGOL IMMUNOPATH, V6, P520; CURTIS AC, 1983, ARCH DERMATOL, V119, P438, DOI 10.1001/archderm.119.5.438; ELLIS HV, 1970, J PHARMACOL EXP THER, V175, P627; FELDBERG W, 1951, J PHYSIOL-LONDON, V114, P490, DOI 10.1113/jphysiol.1951.sp004639; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; GROSMAN N, 1981, AGENTS ACTIONS, V11, P196, DOI 10.1007/BF01967614; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; LEWIS T, 1927, BLOOD VESSELS HUMAN, P93; MISCH KJ, 1983, BRIT J DERMATOL, V109, P10; MONROE EW, 1977, ARCH DERMATOL, V113, P80, DOI 10.1001/archderm.113.1.80; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; NUMATA T, 1979, ANN ALLERGY, V43, P356; PARRATT JR, 1957, J PHYSIOL-LONDON, V137, P179, DOI 10.1113/jphysiol.1957.sp005805; PATON WDM, 1957, PHARMACOL REV, V9, P269; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P371, DOI 10.1016/0091-6749(80)90215-8; RHOADES RB, 1975, J ALLERGY CLIN IMMUN, V55, P180, DOI 10.1016/0091-6749(75)90014-7; Sollmann T, 1917, J PHARMACOL EXP THER, V9, P309; SOTER NA, 1980, J ALLERGY CLIN IMMUN, V66, P358, DOI 10.1016/0091-6749(80)90114-1; Swinny B, 1941, SOUTH MED J, V34, P855; ZAR JH, 1984, BIOSTAT ANAL, P36	24	54	54	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1986	77	6					802	807		10.1016/0091-6749(86)90377-5	http://dx.doi.org/10.1016/0091-6749(86)90377-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C8694	3711548				2022-12-18	WOS:A1986C869400004
J	TOPPING, MD; VENABLES, KM; LUCZYNSKA, CM; HOWE, W; TAYLOR, AJN				TOPPING, MD; VENABLES, KM; LUCZYNSKA, CM; HOWE, W; TAYLOR, AJN			SPECIFICITY OF THE HUMAN IGE RESPONSE TO INHALED ACID ANHYDRIDES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HLTH & SAFETY EXECUT,EMPLOYMENT MED ADVISORY SERV,DARLINGTON,ENGLAND; BROMPTON HOSP,DEPT OCCUPAT MED,LONDON SW3 6HP,ENGLAND	Royal Brompton Hospital	TOPPING, MD (corresponding author), HLTH & SAFETY EXECUT,OCCUPAT MED & HYG LAB,403 EDGWARE RD,LONDON NW2 6LN,ENGLAND.							AKIYAMA K, 1984, J IMMUNOL, V133, P3286; BERNSTEIN DI, 1982, J ALLERGY CLIN IMMUN, V69, P311, DOI 10.1016/S0091-6749(82)80009-2; BERNSTEIN DI, 1984, J ALLERGY CLIN IMMUN, V74, P794, DOI 10.1016/0091-6749(84)90181-7; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P146, DOI 10.1016/0091-6749(79)90049-6; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; HOWE W, 1983, J ALLERGY CLIN IMMUN, V71, P5, DOI 10.1016/0091-6749(83)90539-0; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1980, INT ARCH ALLER A IMM, V61, P380; ZEISS CR, 1982, J ALLERGY CLIN IMMUN, V70, P15, DOI 10.1016/0091-6749(82)90195-6	12	54	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1986	77	6					834	842		10.1016/0091-6749(86)90381-7	http://dx.doi.org/10.1016/0091-6749(86)90381-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C8694	3711550				2022-12-18	WOS:A1986C869400008
J	REED, CE				REED, CE			NEW THERAPEUTIC APPROACHES IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											REED, CE (corresponding author), MAYO CLIN, 200 1ST ST SW, ROCHESTER, MN 55901 USA.							ADELROTH E, 1985, ALLERGY, V40, P58, DOI 10.1111/j.1398-9995.1985.tb04155.x; ANDERSON G, 1983, POSTGRAD MED J, V59, P64; [Anonymous], 1983, ANN INTERN MED, V99, P612, DOI 10.7326/0003-4819-99-5-612; BECKER AB, 1983, J PEDIATR-US, V102, P465, DOI 10.1016/S0022-3476(83)80679-9; BELL JA, 1984, MT SINAI J MED, V51, P215; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; BOOJINOORD H, 1970, J ALLERGY, V46, P1; BUSSE WW, 1983, J ASTHMA, V20, P85, DOI 10.3109/02770908309077070; BUTCHER BT, 1982, J ALLERGY CLIN IMMUN, V70, P231, DOI 10.1016/0091-6749(82)90058-6; CUMMINGS NP, 1983, J ALLERGY CLIN IMMUN, V71, P245, DOI 10.1016/0091-6749(83)90106-9; DUNNILL MS, 1978, ALLERGY PRINCIPLES P, V2, P679; ESAU S, 1984, J ALLERGY CLIN IMMUN, V74, P270, DOI 10.1016/0091-6749(84)90257-4; FANTA CH, 1982, AM J MED, V72, P416, DOI 10.1016/0002-9343(82)90498-3; FLINT K, 1983, EUR J RESPIR DIS, V64, P548; GRIFFIN MP, 1983, J ALLERGY CLIN IMMUN, V71, P331, DOI 10.1016/0091-6749(83)90088-X; HINDIALEXANDER MC, 1984, J ALLERGY CLIN IMMUN, V74, P505, DOI 10.1016/0091-6749(84)90386-5; HIRATA F, 1976, P NATL ACAD SCI USA, V73, P1730; IRONS JS, 1975, J ALLERGY CLIN IMMUN, V56, P64, DOI 10.1016/0091-6749(75)90035-4; JACKSON RT, 1983, NEW ZEAL MED J, V96, P728; KATZ RM, 1983, ANN ALLERGY, V50, P23; KLEIN JJ, 1983, AM REV RESPIR DIS, V127, P413, DOI 10.1164/arrd.1983.127.4.413; KORDANSKY D, 1978, ANN INTERN MED, V88, P508, DOI 10.7326/0003-4819-88-4-508; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAW S, 1978, J ALLERGY CLIN IMMUN, V63, P28; MANN JS, 1985, J ALLERGY CLIN IMMUN, V76, P83, DOI 10.1016/0091-6749(85)90808-5; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; MIDDLETON E, 1985, CHEST, V87, pS79; MURANAKA M, 1981, J ALLERGY CLIN IMMUN, V67, P350, DOI 10.1016/0091-6749(81)90079-8; NELSON HS, 1983, J ALLERGY CLIN IMMUN, V72, P371, DOI 10.1016/0091-6749(83)90502-X; NORMAN PS, 1975, ANNU REV MED, V26, P337, DOI 10.1146/annurev.me.26.020175.002005; PATERSON JW, 1983, EUR J CLIN PHARMACOL, V25, P187, DOI 10.1007/BF00543789; PATTERSON R, 1979, J ALLERGY CLIN IMMUN, V64, P155, DOI 10.1016/0091-6749(79)90089-7; POUNSFORD JC, 1983, EUR J RESPIR DIS, V64, P536; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P858, DOI 10.1056/NEJM195205292462204; REBUCK AS, 1983, J ALLERGY CLIN IMMUN, V71, P317, DOI 10.1016/0091-6749(83)90086-6; REED CE, 1985, AM REV RESPIR DIS, V131, P48; ROSSING TH, 1980, AM REV RESPIR DIS, V122, P365; SHIM CS, 1984, J ALLERGY CLIN IMMUN, V73, P387, DOI 10.1016/0091-6749(84)90413-5; SMITH MJ, 1983, LANCET, V1, P265, DOI 10.1016/S0140-6736(83)91686-0; SPECTOR SL, 1985, CHEST, V87, pS73; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; WARNER JO, 1982, CLIN ALLERGY, V12, P21; 1984, LANCET, V2, P23	44	54	54	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1986	77	4					537	543		10.1016/0091-6749(86)90342-8	http://dx.doi.org/10.1016/0091-6749(86)90342-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A9381	2870096				2022-12-18	WOS:A1986A938100002
J	GENDREAUREID, L; SIMONS, KJ; SIMONS, FER				GENDREAUREID, L; SIMONS, KJ; SIMONS, FER			COMPARISON OF THE SUPPRESSIVE EFFECT OF ASTEMIZOLE, TERFENADINE, AND HYDROXYZINE ON HISTAMINE-INDUCED WHEALS AND FLARES IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC PHARM,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC MED,DEPT PEDIAT & CHILD HLTH,ALLERGY & CLIN IMMUNOL SECT,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; University of Manitoba								BAIN WA, 1951, ANALYST, V76, P573, DOI 10.1039/an9517600573; BATEMAN DN, 1983, EUR J CLIN PHARMACOL, V25, P547, DOI 10.1007/BF00542126; BETTS T, 1984, BRIT MED J, V288, P281, DOI 10.1136/bmj.288.6413.281; BIERMAN CW, 1980, PEDIATRIC PHARM THER, P213; BROBYN RD, 1983, HISTAMINE ALLERGIC D, P14; COOK CE, 1980, J PHARM SCI, V69, P1419, DOI 10.1002/jps.2600691218; COOK J, 1980, BRIT J PHARMACOL, V69, P579, DOI 10.1111/j.1476-5381.1980.tb07907.x; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; FOWLE ASE, 1971, EUR J CLIN PHARMACOL, V3, P215, DOI 10.1007/BF00565009; GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185; HOWARTH PH, 1984, BRIT J CLIN PHARMACO, V18, P1; HUTHER KJ, 1977, EUR J CLIN PHARMACOL, V12, P195, DOI 10.1007/BF00609860; LADURON PM, 1982, MOL PHARMACOL, V21, P294; MALMBERG H, 1983, ALLERGY, V38, P227, DOI 10.1111/j.1398-9995.1983.tb01615.x; MARTZ BL, 1982, ARZNEIMITTELFORSCH, V32-2, P1153; REINBERG A, 1978, EUR J CLIN PHARMACOL, V14, P245, DOI 10.1007/BF00560457; REINBERG A, 1965, J ALLERGY, V36, P273, DOI 10.1016/0021-8707(65)90086-9; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; ROEHRS TA, 1984, SLEEP, V7, P137, DOI 10.1093/sleep/7.2.137; SCHAAF L, 1979, J ALLERGY CLIN IMMUN, V63, P129, DOI 10.1016/0091-6749(79)90203-3; SIMONS FER, 1984, J ALLERGY CLIN IMMUN, V73, P69, DOI 10.1016/0091-6749(84)90486-X; SIMONS FER, 1983, PEDIATR CLIN N AM, V30, P899; SIMONS FER, 1984, J PEDIATR-US, V104, P123; Steel R.G.D., 1980, PRINCIPLES STAT; TRZECIAKOWSKI JP, 1983, ALLERGY PRINCIPLES P, P575; WOESTENBORGHS R, 1983, J CHROMATOGR, V278, P359, DOI 10.1016/S0378-4347(00)84795-7; WONG L, 1981, J ALLERGY CLIN IMMUN, V67, P223, DOI 10.1016/0091-6749(81)90065-8	27	54	54	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1986	77	2					335	340		10.1016/S0091-6749(86)80114-2	http://dx.doi.org/10.1016/S0091-6749(86)80114-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A0899	3080511	Bronze			2022-12-18	WOS:A1986A089900012
J	SCHWARTZ, HJ; SHER, TH				SCHWARTZ, HJ; SHER, TH			BISULFITE SENSITIVITY MANIFESTING AS ALLERGY TO LOCAL DENTAL-ANESTHESIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CASE WESTERN RESERVE UNIV HOSP,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV HOSP,DEPT PEDIAT,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University Hospital; Case Western Reserve University; Case Western Reserve University Hospital								BAKER GJ, 1981, MED J AUSTRALIA, V2, P614, DOI 10.5694/j.1326-5377.1981.tb113018.x; DESHAZO RD, 1979, J ALLERGY CLIN IMMUN, V63, P387, DOI 10.1016/0091-6749(79)90211-2; DESWARTE RD, 1980, ALLERGIC DISEASES DI, P557; GOLDFARB F, 1984, J ALLERGY CLIN IMMUN, V73, P135; INCAUDO G, 1978, J ALLERGY CLIN IMMUN, V61, P339, DOI 10.1016/0091-6749(78)90057-X; JACOBSEN D W, 1984, Journal of Allergy and Clinical Immunology, V73, P135; KRANTZ JC, 1951, PHARM PRINCIPLES MED, P347; NAGEL JE, 1977, JAMA-J AM MED ASSOC, V237, P1594; PRENNER BM, 1976, ANN ALLERGY, V37, P180; SCHWARTZ HJ, 1983, J ALLERGY CLIN IMMUN, V71, P487, DOI 10.1016/0091-6749(83)90466-9; SIMON R A, 1982, Journal of Allergy and Clinical Immunology, V69, P118; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6; VANARSDEL PP, 1978, ALLERGY PRINCIPLES P, P1154; VERILL PJ, 1975, PRACTITIONER, V214, P380; 1984, PHYSICIANS DESK REFE	15	54	54	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	4					525	527		10.1016/S0091-6749(85)80027-0	http://dx.doi.org/10.1016/S0091-6749(85)80027-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AFY44	3980886				2022-12-18	WOS:A1985AFY4400014
J	FOREMAN, JC; PIOTROWSKI, W				FOREMAN, JC; PIOTROWSKI, W			PEPTIDES AND HISTAMINE-RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											FOREMAN, JC (corresponding author), UNIV LONDON UNIV COLL, DEPT PHARMACOL, LONDON WC1E 6BT, ENGLAND.							ANAND P, 1983, BRIT J PHARMACOL, V78, P665, DOI 10.1111/j.1476-5381.1983.tb09418.x; Bayliss WM, 1901, J PHYSIOL-LONDON, V26, P173; Beaven M A, 1978, Monogr Allergy, V13, P1; BENNICH H, 1977, INT ARCH ALLER A IMM, V53, P459, DOI 10.1159/000231784; BERNSTEIN JE, 1981, J INVEST DERMATOL, V76, P394, DOI 10.1111/1523-1747.ep12520912; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BLANDINA P, 1980, J PHYSIOL-LONDON, V301, P281, DOI 10.1113/jphysiol.1980.sp013205; BONNEY G, 1954, BRAIN, V77, P588, DOI 10.1093/brain/77.4.588; Bruce AN, 1913, Q J EXP PHYSIOL, V6, P339, DOI 10.1113/expphysiol.1913.sp000144; CHAHL LA, 1979, N-S ARCH PHARMACOL, V309, P159, DOI 10.1007/BF00501224; FELDMAN M, 1977, NEW ENGL J MED, V297, P1427, DOI 10.1056/NEJM197712292972603; FOREMAN J, 1983, AGENTS ACTIONS, V13, P105, DOI 10.1007/BF01967311; FOREMAN JC, 1981, BRIT J PHARMACOL, V73, pP207; FOREMAN JC, 1983, J PHYSIOL-LONDON, V335, P449, DOI 10.1113/jphysiol.1983.sp014543; FOREMAN JC, 1984, J ALLERGY CLIN IMMUN, V73, P769, DOI 10.1016/0091-6749(84)90446-9; FOREMAN JC, 1982, BRIT J PHARMACOL, V77, P531, DOI 10.1111/j.1476-5381.1982.tb09328.x; GAMSE R, 1980, BRIT J PHARMACOL, V68, P207, DOI 10.1111/j.1476-5381.1980.tb10409.x; HAGERMARK O, 1978, J INVEST DERMATOL, V71, P233, DOI 10.1111/1523-1747.ep12515092; HAMBURGER RN, 1975, SCIENCE, V189, P389, DOI 10.1126/science.1145208; HEINE H, 1974, ACTA ANAT, V89, P387; HOKFELT T, 1975, BRAIN RES, V100, P235, DOI 10.1016/0006-8993(75)90481-3; ISHIZAKA T, 1978, J IMMUNOL, V120, P800; JASANI B, 1979, BIOCHEM J, V181, P623, DOI 10.1042/bj1810623; JASANI B, 1973, INT ARCH ALLER A IMM, V45, P74, DOI 10.1159/000231005; JOHNSON AR, 1973, P SOC EXP BIOL MED, V142, P1252; JOHNSON LR, 1971, GASTROENTEROLOGY, V61, P106; JORIZZO JL, 1983, EUR J PHARMACOL, V87, P67, DOI 10.1016/0014-2999(83)90051-1; KEEN P, 1982, CIBA F SYMP, V91, P145; KIERNAN JA, 1975, Q J EXP PHYSIOL CMS, V60, P123, DOI 10.1113/expphysiol.1975.sp002298; LAFFERTY K, 1983, LANCET, V2, P313; LEMBECK F, 1953, N-S ARCH EX PATH PH, V219, P197; Lewis T., 1927, BLOOD VESSELS HUMAN; LUNDBERG JM, 1983, ACTA PHYSIOL SCAND, V119, P243, DOI 10.1111/j.1748-1716.1983.tb07334.x; MACINTOSH FC, 1949, J PHYSIOL-LONDON, V109, P190, DOI 10.1113/jphysiol.1949.sp004385; MIZRAHI J, 1982, EUR J PHARMACOL, V82, P101, DOI 10.1016/0014-2999(82)90561-1; MORRISON DC, 1975, INT ARCH ALLER A IMM, V49, P172, DOI 10.1159/000231392; PIOTROWSKI W, 1984, AGENTS ACTIONS, V14, P420, DOI 10.1007/BF01973842; PIOTROWSKI W, 1983, SUBSTANCE P, P96; POWELL JR, 1976, AM J PHYSIOL, V231, P1002, DOI 10.1152/ajplegacy.1976.231.4.1002; RICHARDSON CT, 1978, GASTROENTEROLOGY, V74, P366; SARIA A, 1983, N-S ARCH PHARMACOL, V324, P212, DOI 10.1007/BF00503897; SOLL AH, 1978, J CLIN INVEST, V61, P381, DOI 10.1172/JCI108948; SOLL AH, 1979, ANNU REV PHYSIOL, V41, P35, DOI 10.1146/annurev.ph.41.030179.000343; SOLL AH, 1980, HYDROGEN ION TRANSPO, V1, P401; STACH W, 1961, Z MIKROSKOPISCHANAT, V67, P17; STANWORTH DR, 1979, BIOCHEM J, V180, P665, DOI 10.1042/bj1800665; STANWORTH DR, 1978, INT ARCH ALLER A IMM, V56, P409, DOI 10.1159/000232050; THARP MD, 1984, J ALLERGY CLIN IMMUN, V74, P159, DOI 10.1016/0091-6749(84)90280-X; THEOHARIDES TC, 1981, EUR J PHARMACOL, V69, P127, DOI 10.1016/0014-2999(81)90407-6; THUNBERG R, 1967, EXP CELL RES, V47, P108, DOI 10.1016/0014-4827(67)90214-5; TOREBJORK HE, 1974, BRAIN RES, V67, P387, DOI 10.1016/0006-8993(74)90489-2; WEBBER SE, 1984, AGENTS ACTIONS, V14, P425, DOI 10.1007/BF01973843; WILLIAMS TJ, 1982, BRIT J PHARMACOL, V77, P505, DOI 10.1111/j.1476-5381.1982.tb09324.x	53	54	54	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	2					127	131		10.1016/0091-6749(84)90274-4	http://dx.doi.org/10.1016/0091-6749(84)90274-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE226	6205034				2022-12-18	WOS:A1984TE22600002
J	NELSON, HS				NELSON, HS			GASTROESOPHAGEAL REFLUX AND PULMONARY-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											NELSON, HS (corresponding author), FITZSIMONS ARMY MED CTR, ALLERGY IMMUNOL SERV, AURORA, CO 80045 USA.							BABB RR, 1970, AM J GASTROENTEROL, V53, P230; Barnardo D E, 1975, Curr Med Res Opin, V3, P388, DOI 10.1185/03007997509114793; BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BEHAR J, 1976, GASTROENTEROLOGY, V71, P9; BEHAR J, 1975, NEW ENGL J MED, V293, P263, DOI 10.1056/NEJM197508072930602; BEHAR J, 1978, GASTROENTEROLOGY, V74, P441; BERQUIST WE, 1981, PEDIATRICS, V68, P29; BRAND DL, 1979, GASTROENTEROLOGY, V76, P1393; BRAY GW, 1935, BRIT MED J, V1, P118; BRIGHTASARE P, 1980, J CLIN GASTROENTEROL, V2, P149, DOI 10.1097/00004836-198006000-00008; CARRE IJ, 1959, ARCH DIS CHILD, V34, P344, DOI 10.1136/adc.34.176.344; CASTELL DO, 1978, SOUTHERN MED J, V71, P26; CHERNOW B, 1979, DIGEST DIS SCI, V24, P839, DOI 10.1007/BF01324899; CHRISTIE DL, 1978, J PEDIATR-US, V93, P23, DOI 10.1016/S0022-3476(78)80593-9; COHEN S, 1971, NEW ENGL J MED, V284, P1053, DOI 10.1056/NEJM197105132841902; DANUS O, 1976, J PEDIATR-US, V89, P220, DOI 10.1016/S0022-3476(76)80452-0; Davis M V, 1969, Ann Thorac Surg, V7, P120; DAVIS MV, 1972, NEW YORK STATE J MED, V72, P935; DAVIS RS, 1982, AM REV RESPIR DIS, V125, P190; DEMEESTER TR, 1976, ANN SURG, V184, P459, DOI 10.1097/00000658-197610000-00009; DEMEESTER TR, 1980, J THORAC CARDIOV SUR, V79, P656; DENT J, 1980, J CLIN INVEST, V65, P256, DOI 10.1172/JCI109667; DODDS WJ, 1982, NEW ENGL J MED, V307, P1547, DOI 10.1056/NEJM198212163072503; EASTWOOD GL, 1975, GASTROENTEROLOGY, V69, P146; EULER AR, 1981, GASTROENTEROLOGY, V80, P957; EULER AR, 1979, PEDIATRICS, V63, P47; EULER AR, 1980, J PEDIATR-US, V96, P321, DOI 10.1016/S0022-3476(80)80839-0; Friedland G W, 1973, Pediatr Radiol, V1, P156, DOI 10.1007/BF00974060; GHAED N, 1979, ANN ALLERGY, V42, P306; GOODALL RJR, 1981, THORAX, V36, P116, DOI 10.1136/thx.36.2.116; GRAHAM DY, 1977, CURR THER RES CLIN E, V22, P653; HARNSBERGER JK, 1983, J PEDIATR-US, V102, P505, DOI 10.1016/S0022-3476(83)80174-7; HERBST JJ, 1981, J PEDIATR-US, V98, P859, DOI 10.1016/S0022-3476(81)80576-8; HERBST JJ, 1981, PEDIATRICS, V68, P132; HERBST JJ, 1979, J PEDIATR-US, V95, P763, DOI 10.1016/S0022-3476(79)80733-7; HUGHES DM, 1983, J PEDIATR-US, V102, P666, DOI 10.1016/S0022-3476(83)80231-5; ISMAIL-BEIGI F, 1970, Gastroenterology, V58, P163; IVERSON LIG, 1973, AM J SURG, V126, P223, DOI 10.1016/S0002-9610(73)80156-4; JOHNSON LF, 1974, AM J GASTROENTEROL, V62, P325; JOHNSON LF, 1981, DIGEST DIS SCI, V26, P673, DOI 10.1007/BF01316854; JOLLEY SG, 1981, GASTROENTEROLOGY, V80, P1501; JOLLEY SG, 1980, J PEDIATR-US, V96, P194, DOI 10.1016/S0022-3476(80)80801-8; JOLLEY SG, 1978, SURGERY, V84, P16; KENNEDY JH, 1962, DIS CHEST, V42, P42; KJELLEN G, 1981, EUR J RESPIR DIS, V62, P190; KJELLEN G, 1981, EUR J RESPIR DIS, V62, P87; KJELLEN G, 1981, CLIN PHYSIOL, V1, P285, DOI 10.1111/j.1475-097X.1981.tb00897.x; LEAPE LL, 1977, PEDIATRICS, V60, P924; LEAPE LL, 1982, J PEDIATR-US, V101, P481, DOI 10.1016/S0022-3476(82)80095-4; LICHTER I, 1974, BRIT J SURG, V61, P253, DOI 10.1002/bjs.1800610402; MACFADYEN UM, 1983, ARCH DIS CHILD, V58, P87, DOI 10.1136/adc.58.2.87; MALMUD LS, 1978, SOUTHERN MED J, V71, P10, DOI 10.1097/00007611-197801001-00003; MANSFIELD LE, 1981, ANN ALLERGY, V47, P431; MANSFIELD LE, 1978, ANN ALLERGY, V41, P224; MARTIN ME, 1982, ANN ALLERGY, V49, P318; MAYS EE, 1976, JAMA-J AM MED ASSOC, V236, P2626, DOI 10.1001/jama.236.23.2626; MAYS EE, 1976, CHEST, V69, P512, DOI 10.1378/chest.69.4.512; MCCALLUM RW, 1977, NEW ENGL J MED, V296, P354, DOI 10.1056/NEJM197702172960702; MCHARDY G, 1978, SOUTHERN MED J, V71, P16, DOI 10.1097/00007611-197801001-00004; Meyer G W, 1980, Am J Otolaryngol, V1, P440, DOI 10.1016/S0196-0709(80)80025-1; MEYERS WF, 1982, PEDIATRICS, V69, P768; NEBEL OT, 1976, AM J DIG DIS, V21, P953, DOI 10.1007/BF01071906; ORRINGER MB, 1979, CHEST, V76, P618, DOI 10.1378/chest.76.6.618; OVERHOLT RH, 1966, DIS CHEST, V49, P464; OVERHOLT RH, 1966, NEW YORK STATE J MED, V66, P3030; PEARSON JEG, 1971, THORAX, V26, P300, DOI 10.1136/thx.26.3.300; PHELAN PD, 1982, J RESPIR DIS, V3, P65; PINDER RM, 1976, DRUGS, V12, P81, DOI 10.2165/00003495-197612020-00001; POPE CE, 1976, GASTROENTEROLOGY, V70, P445; POWELL J R, 1982, Clinical Pharmacology and Therapeutics, V31, P261; POWELLJACKSON P, 1978, LANCET, V2, P1068; REICH SB, 1977, J NUCL MED, V18, P1079; RICHARDSON CT, 1982, ANN INTERN MED, V97, P269, DOI 10.7326/0003-4819-97-2-269; RICHTER JE, 1982, ANN INTERN MED, V97, P93, DOI 10.7326/0003-4819-97-1-93; ROUFAIL WM, 1978, SOUTHERN MED J, V71, P43, DOI 10.1097/00007611-197801001-00011; SHAPIRO GG, 1983, CLIN REV ALLERG, V1, P39; SHAPIRO GG, 1979, PEDIATRICS, V63, P207; SPAULDING HS, 1982, J ALLERGY CLIN IMMUN, V69, P516, DOI 10.1016/0091-6749(82)90176-2; STANCIU C, 1974, LANCET, V1, P109; STEIN MR, 1980, ANN ALLERGY, V45, P238; TEMPLE JG, 1983, BRIT MED J, V286, P1863, DOI 10.1136/bmj.286.6381.1863; THANIK KD, 1980, ANN INTERN MED, V93, P805, DOI 10.7326/0003-4819-93-6-805; URSCHEL HC, 1967, J THORAC CARDIOV SUR, V53, P21, DOI 10.1016/S0022-5223(19)43238-8; VRANEY GA, 1979, CHEST, V76, P678, DOI 10.1378/chest.76.6.678; WESDORP E, 1978, GASTROENTEROLOGY, V74, P821; ZFASS AM, 1970, AM J DIG DIS, V15, P303, DOI 10.1007/BF02239282	86	54	55	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					547	556		10.1016/0091-6749(84)90509-8	http://dx.doi.org/10.1016/0091-6749(84)90509-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS045	6371102	Bronze			2022-12-18	WOS:A1984SS04500002
J	GEURKINK, N				GEURKINK, N			NASAL ANATOMY, PHYSIOLOGY, AND FUNCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GEURKINK, N (corresponding author), DARTMOUTH HITCHCOCK MED CTR,DARTMOUTH MED SCH,HITCHCOCK CLIN,HANOVER,NH 03756, USA.							BERGLUND B, 1982, NOSE UPPER AIRWAY PH, P283; COLE P, 1982, NOSE UPPER AIRWAY PH, P166; FAIRBANKS DNF, 1983, PEDIATRIC OTOLARYNGO, V2, P647; HOLLINGSHEAD WH, 1982, ANATOMY SURGEONS HEA, V1, pCH4; HOLMES TH, 1950, NOSE; MYGIND N, 1982, NOSE UPPER AIRWAY PH, P81; PROCTOR DF, 1982, NOSE UPPER AIRWAY PH, P245; PROETZ AW, 1953, ESSAYS APPLIED PHYSL, P153	8	54	54	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	2					123	128		10.1016/0091-6749(83)90518-3	http://dx.doi.org/10.1016/0091-6749(83)90518-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD959	6350406				2022-12-18	WOS:A1983RD95900003
J	NELSON, HS; SPECTOR, SL; WHITSETT, TL; GEORGE, RB; DWEK, JH				NELSON, HS; SPECTOR, SL; WHITSETT, TL; GEORGE, RB; DWEK, JH			THE BRONCHODILATOR RESPONSE TO INHALATION OF INCREASING DOSES OF AEROSOLIZED ALBUTEROL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NELSON, HS (corresponding author), FITZSIMMONS ARMY MED CTR,ALLERGY IMMUNOL SERV,AURORA,CO 80045, USA.							ALLIOTT RJ, 1972, BMJ-BRIT MED J, V1, P539, DOI 10.1136/bmj.1.5799.539; BLOOMFIELD P, 1979, BRIT MED J, V1, P848, DOI 10.1136/bmj.1.6167.848; CHALEB JA, 1974, CURR MED RES OPIN, V2, P275; DULFANO MJ, 1977, ANN ALLERGY, V39, P266; DWEK JH, UNPUB ALBUTEROL ISOP; EMIRGIL C, 1977, ANN ALLERGY, V39, P415; FRANCIS PWJ, 1980, PEDIATRICS, V66, P103; HEIMER D, 1980, J ALLERGY CLIN IMMUN, V66, P75, DOI 10.1016/0091-6749(80)90141-4; HETZEL MR, 1976, BRIT MED J, V2, P919, DOI 10.1136/bmj.2.6041.919; LARSSON S, 1977, AM REV RESPIR DIS, V116, P861; LIGHT RW, 1979, ARCH INTERN MED, V139, P639; NEWMAN SP, 1981, THORAX, V36, P52, DOI 10.1136/thx.36.1.52; PENNOCK BE, 1977, CHEST, V72, P731, DOI 10.1378/chest.72.6.731; POPA VT, 1976, CHEST, V70, P205, DOI 10.1378/chest.70.2.205; REMINGTON RD, 1970, STATISTICS APPLICATI, P228; RILEY DJ, 1979, CHEST, V76, P501, DOI 10.1378/chest.76.5.501; ROSSING TH, 1980, AM REV RESPIR DIS, V122, P365; RUFFIN RE, 1978, CLIN PHARMACOL THER, V23, P338; RUFFIN RE, 1978, THORAX, V33, P689, DOI 10.1136/thx.33.6.689; SACKNER MA, 1978, CHEST, V73, P802, DOI 10.1378/chest.73.6.802; SPECTOR SL, 1977, J ALLERGY CLIN IMMUN, V59, P280, DOI 10.1016/0091-6749(77)90048-3; TASHKIN DP, 1980, AM J MED, V68, P14, DOI 10.1016/0002-9343(80)90156-4; THIRINGER G, 1976, SCAND J RESPIR DIS, V57, P17; THIRINGER G, 1974, Scandinavian Journal of Respiratory Diseases Supplementum, V88, P56; WARRELL DA, 1970, BMJ-BRIT MED J, V1, P65, DOI 10.1136/bmj.1.5688.65; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V63, P116, DOI 10.1016/0091-6749(79)90201-X; WHITSETT TL, 1978, CHEST, V74, P251, DOI 10.1378/chest.74.3.251; WILLIAMS MH, 1975, AM REV RESPIR DIS, V111, P321	28	54	56	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	4					371	375		10.1016/0091-6749(83)90502-X	http://dx.doi.org/10.1016/0091-6749(83)90502-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RN330	6352780				2022-12-18	WOS:A1983RN33000007
J	REISMAN, RE; WYPYCH, JI; MUELLER, UR; GRANT, JA				REISMAN, RE; WYPYCH, JI; MUELLER, UR; GRANT, JA			COMPARISON OF THE ALLERGENICITY AND ANTIGENICITY OF POLISTES VENOM AND OTHER VESPID VENOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14260; UNIV TEXAS,MED BRANCH,ADULT ALLERGY SECT,GALVESTON,TX 77550	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Texas System; University of Texas Medical Branch Galveston					NIAID NIH HHS [AI-12621, AI-00110, AI 01303] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		FINDLAY SR, 1977, J ALLERGY CLIN IMMUN, V60, P230, DOI 10.1016/0091-6749(77)90135-X; KERN F, 1976, J ALLERGY CLIN IMMUN, V57, P554, DOI 10.1016/0091-6749(76)90006-3; LIGHT WC, 1976, CLIN ALLERGY, V6, P293, DOI 10.1111/j.1365-2222.1976.tb01909.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V68, P254, DOI 10.1016/0091-6749(81)90148-2; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V67, P290, DOI 10.1016/0091-6749(81)90024-5; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1; WICHER K, 1980, J ALLERGY CLIN IMMUN, V66, P244, DOI 10.1016/0091-6749(80)90047-0	8	54	54	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	4					281	287		10.1016/0091-6749(82)90064-1	http://dx.doi.org/10.1016/0091-6749(82)90064-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PL151	6811646				2022-12-18	WOS:A1982PL15100008
J	TWIGGS, JT; AGARWAL, MK; DAHLBERG, MJE; YUNGINGER, JW				TWIGGS, JT; AGARWAL, MK; DAHLBERG, MJE; YUNGINGER, JW			IMMUNOCHEMICAL MEASUREMENT OF AIRBORNE MOUSE ALLERGENS IN A LABORATORY-ANIMAL FACILITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERGY DIS RES LAB,ROCHESTER,MN 55905; UNIV MINNESOTA,MAYO GRAD SCH MED,DEPT PEDIAT,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; University of Minnesota System; University of Minnesota Rochester					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016791] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 16791] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; AWDEH ZL, 1968, NATURE, V219, P66, DOI 10.1038/219066a0; CHEN RF, 1967, J BIOL CHEM, V242, P173; COCKCROFT A, 1981, LANCET, V1, P827; FINLAYSON JS, 1965, SCIENCE, V149, P981, DOI 10.1126/science.149.3687.981; LEVY DA, 1975, INT ARCH ALLER A IMM, V49, P219, DOI 10.1159/000231399; LINCOLN TA, 1974, J OCCUP ENVIRON MED, V16, P465; LUTSKY II, 1975, ANN ALLERGY, V35, P201; NEWMANTAYLOR A, 1977, LANCET, V2, P847; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; RAJKA G, 1961, ACTA ALLERGOL, V16, P168, DOI 10.1111/j.1398-9995.1961.tb02891.x; SCHUMACHER MJ, 1980, MOL IMMUNOL, V17, P1087, DOI 10.1016/0161-5890(80)90105-4; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V63, P435, DOI 10.1016/0091-6749(79)90219-7; SLOVAK AJM, 1981, BRIT J IND MED, V38, P38; TAYLOR G, 1976, NATURE, V260, P280, DOI 10.1038/260280a0; WAHN U, 1980, J IMMUNOL, V125, P2544; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778	17	54	54	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	6					522	526		10.1016/0091-6749(82)90177-4	http://dx.doi.org/10.1016/0091-6749(82)90177-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT025	7076993	Bronze			2022-12-18	WOS:A1982NT02500008
J	MARSH, DG; HSU, SH; HUSSAIN, R; MEYERS, DA; FREIDHOFF, LR; BIAS, WB				MARSH, DG; HSU, SH; HUSSAIN, R; MEYERS, DA; FREIDHOFF, LR; BIAS, WB			GENETICS OF HUMAN IMMUNE-RESPONSE TO ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DIV CLIN IMMUNOL,HOWARD HUGHES MED INST LAB,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH MED,DIV MED GENET,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University			Hussain, Rabia/E-9982-2015					AMOS DB, 1969, TRANSPLANTATION, V7, P220, DOI 10.1097/00007890-196903000-00023; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BENACERR.B, 1972, SCIENCE, V175, P273, DOI 10.1126/science.175.4019.273; BENACERRAF B, 1978, IMMUNOL REV, V38, P70, DOI 10.1111/j.1600-065X.1978.tb00385.x; BIAS WB, 1975, SCIENCE, V188, P375, DOI 10.1126/science.1118733; BJORKSTEN F, 1975, CLIN ALLERGY, V5, P353; BLACK FL, 1975, SCIENCE, V187, P515, DOI 10.1126/science.163483; BLACK PL, 1976, IMMUNOGENETICS, V3, P349, DOI 10.1007/BF01576967; BODMER WF, 1973, HISTOCOMPATIBILITY T, P611; DAUSSET J, 1978, TISSUE ANTIGENS, V12, P297, DOI 10.1111/j.1399-0039.1978.tb01337.x; DAUSSET J, 1977, HLA DISEASE; EICHMANN K, 1971, J EXP MED, V134, P48, DOI 10.1084/jem.134.1.48; Fenner F., 1970, IMPACT CIVILIZATION, P48; FESTENSTEIN H, 1978, HISTOCOMPATIBILITY T, P85; FREIDHOFF LR, UNPUBLISHED; GERRARD JW, 1978, AM J HUM GENET, V30, P46; GOODFRIEND L, 1977, MONOGR ALLERGY, V11, P106; HALDANE JBS, 1957, ACTA GENET STAT MED, V6, P321; HAMBURGER RN, 1973, MECHANISMS ALLERGY R, P131; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P256, DOI 10.1016/0091-6749(75)90145-1; HUSSAIN R, 1979, J ALLERGY CLIN IMMUN, V63, P193; KATZ DH, 1977, LYMPHOCYTE DIFFERENT; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; KISSMEYE.F, 1971, TRANSPL P, V3, P1019; LAPKOFF CB, 1974, INT ARCH ALLER A IMM, V46, P215, DOI 10.1159/000231125; LOWENSTEIN H, 1978, J ALLERGY CLIN IMMUN, V61, P180, DOI 10.1016/0091-6749(78)90411-6; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; MACKAY IR, 1972, LANCET, V2, P793; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MARSH DG, 1979, P NATL ACAD SCI USA, V76, P2903, DOI 10.1073/pnas.76.6.2903; MARSH DG, 1973, SCIENCE, V179, P691, DOI 10.1126/science.179.4074.691; MARSH DG, 1975, IMMUNOCHEMISTRY, V12, P539, DOI 10.1016/0019-2791(75)90081-6; MARSH DG, 1977, IMMUNOGENETICS, V5, P235, DOI 10.1007/BF01570479; MARSH DG, 1977, IMMUNOGENETICS, V5, P217, DOI 10.1007/BF01570478; MARSH DG, 1976, 33 NOB S MOL BIOL AS, P23; MARSH DG, 1975, ANTIGENS, V3, P271; MARSH DG, 1978, IMMUNOLOGICAL DISEAS, P819; MICKEY M R, 1971, Tissue Antigens, V1, P57; MOTULSKY ARNO G., 1960, HUMAN BIOL, V32, P28; ORGEL HA, 1974, J ALLERGY CLIN IMMUN, V53, P213, DOI 10.1016/0091-6749(74)90083-9; SCHREFFLER DC, 1975, ADV IMMUNOL, V20, P125; SCHWARTZ M, 1952, ACTA ALLERGOL S2, V5; SHERMAN WB, 1965, MED CLIN N AM, V49, P1597, DOI 10.1016/S0025-7125(16)33248-5; SMITH JM, 1974, MED CLIN N AM, V58, P3; TERASAKI PI, 1975, TRANSPLANT REV, V22, P105; TERASAKI PI, 1971, DISEASE MONTH    DEC; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031; WILLCOX HNA, 1978, IMMUNOGENETICS, V6, P209, DOI 10.1007/BF01563911	48	54	56	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	5					322	332		10.1016/0091-6749(80)90208-0	http://dx.doi.org/10.1016/0091-6749(80)90208-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV955	6154725				2022-12-18	WOS:A1980JV95500002
J	COGEN, FC; NORMAN, ME; DUNSKY, E; HIRSHFELD, J; ZWEIMAN, B				COGEN, FC; NORMAN, ME; DUNSKY, E; HIRSHFELD, J; ZWEIMAN, B			HISTAMINE-RELEASE AND COMPLEMENT CHANGES FOLLOWING INJECTION OF CONTRAST-MEDIA IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,CARDIOL SECT,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	COGEN, FC (corresponding author), UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,PHILADELPHIA,PA 19104, USA.								0	54	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	4					299	303		10.1016/0091-6749(79)90148-9	http://dx.doi.org/10.1016/0091-6749(79)90148-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HQ469	90063	Bronze			2022-12-18	WOS:A1979HQ46900012
J	BUSH, RK; BUSSE, W; FLAHERTY, D; WARSHAUER, D; DICK, EC; REED, CE				BUSH, RK; BUSSE, W; FLAHERTY, D; WARSHAUER, D; DICK, EC; REED, CE			EFFECTS OF EXPERIMENTAL RHINOVIRUS 16 INFECTION ON AIRWAYS AND LEUKOCYTE FUNCTION IN NORMAL SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BLAIR HT, 1976, AM REV RESPIR DIS, V114, P95; Boyum A., 1967, SCAND J CLIN LAB INV, V97, P77; BUSSE WW, 1976, J ALLERGY CLIN IMMUN, V58, P586, DOI 10.1016/0091-6749(76)90205-0; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; BUSSE WW, 1977, J CLIN INVEST, V59, P1087; CABOUD PG, 1968, AM J CLIN PATHOL, V30, P234; CATE TR, 1973, AM REV RESPIR DIS, V108, P858; COONEY MK, 1977, J CLIN MICROBIOL, V5, P202; DALESSIO DJ, 1976, J INFECT DIS, V133, P28, DOI 10.1093/infdis/133.1.28; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FISHMAN WH, 1967, CLIN CHIM ACTA, V15, P435, DOI 10.1016/0009-8981(67)90008-3; FLAHERTY DK, 1977, J ALLERGY CLIN IMMUN, V59, P48, DOI 10.1016/0091-6749(77)90176-2; FRIDY WW, 1974, ANN INTERN MED, V80, P150, DOI 10.7326/0003-4819-80-2-150; LEE TP, 1977, J ALLERGY CLIN IMMUN, V59, P408, DOI 10.1016/0091-6749(77)90002-1; MANGI RJ, 1974, ANN INTERN MED, V81, P588; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; STORMS WW, 1976, J ALLERGY CLIN IMMUN, V58, P284, DOI 10.1016/0091-6749(76)90133-0; UTSINGER PD, 1975, ANN INTERN MED, V83, P82, DOI 10.7326/0003-4819-83-1-82_1; WYBRAN J, 1973, J CLIN INVEST, V52, P1026, DOI 10.1172/JCI107267; ZECK R T, 1977, American Review of Respiratory Disease, V115, P392; ZURIER RB, 1973, P NATL ACAD SCI USA, V70, P844, DOI 10.1073/pnas.70.3.844	26	54	54	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	2					80	87		10.1016/0091-6749(78)90229-4	http://dx.doi.org/10.1016/0091-6749(78)90229-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EL413	563883				2022-12-18	WOS:A1978EL41300003
J	CAVANAUGH, MJ; BRONSKY, EA; BUCKLEY, JM				CAVANAUGH, MJ; BRONSKY, EA; BUCKLEY, JM			CLINICAL VALUE OF BRONCHIAL PROVOCATION TESTING IN CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,DEPT PEDIAT,DENVER,CO 80206	National Jewish Health								AAS K, 1970, ARCH DIS CHILD, V45, P221, DOI 10.1136/adc.45.240.221; AAS K, 1975, BRONCHIAL PROVOCATIO, P40; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BRONSKY EA, 1969, PEDIATR CLIN N AM, V16, P85; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CSIMA A, 1961, TABLE TESTING SIGNIF; FINNEY DJ, 1948, BIOMETRIKA, V35, P145, DOI 10.2307/2332635; HOBDAY JD, 1972, MED J AUSTRALIA, V1, P161, DOI 10.5694/j.1326-5377.1972.tb46732.x; HOLMAN JG, 1972, ANN ALLERGY, V30, P250; ROSENTHAL RR, 1975, J ALLERGY CLIN IMMUN, V56, P338, DOI 10.1016/0091-6749(75)90127-X; SHELDON JM, 1967, MANUAL CLINICAL ALLE, P63; SPECTOR SL, 1974, MED CLIN N AM, V58, P71, DOI 10.1016/S0025-7125(16)32178-2; 1962, AM REV RESPIR DIS, V85, P762	17	54	54	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	1					41	47		10.1016/0091-6749(77)90175-0	http://dx.doi.org/10.1016/0091-6749(77)90175-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CS828	833374	Bronze			2022-12-18	WOS:A1977CS82800007
J	LIGHT, WC; REISMAN, RE; SHIMIZU, M; ARBESMAN, CE				LIGHT, WC; REISMAN, RE; SHIMIZU, M; ARBESMAN, CE			CLINICAL APPLICATION OF MEASUREMENTS OF SERUM LEVELS OF BEE VENOM-SPECIFIC IGE AND IGG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203; SUNY BUFFALO,DEPT MED,BUFFALO,NY 14214; SUNY BUFFALO,DEPT MICROBIOL,BUFFALO,NY 14214	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; LESSOF MH, 1976, J ALLERGY CLIN IMMUN, V57, P246; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LIGHT W C, 1975, Clinical Allergy, V5, P389, DOI 10.1111/j.1365-2222.1975.tb01878.x; REISMAN RE, 1975, J ALLERGY CLIN IMMUN, V56, P443, DOI 10.1016/0091-6749(75)90062-7; REISMAN RE, 1975, INT ARCH ALLER A IMM, V48, P721, DOI 10.1159/000231360; REISMAN RE, 1976, J ALLERGY CLIN IMMUN, V57, P547, DOI 10.1016/0091-6749(76)90005-1; SHIMIZO M, 1976, J ALLERGY CLIN IMMUN, V57, P211	9	54	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	3					247	253		10.1016/0091-6749(77)90158-0	http://dx.doi.org/10.1016/0091-6749(77)90158-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CZ249	838994				2022-12-18	WOS:A1977CZ24900011
J	BAER, H; MALONEY, CJ; NORMAN, PS; MARSH, DG				BAER, H; MALONEY, CJ; NORMAN, PS; MARSH, DG			POTENCY AND GROUP-I ANTIGEN CONTENT OF 6 COMMERCIALLY PREPARED GRASS POLLEN EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD; GOOD SAMARITAN HOSP,ONEILL MEM LABS,BALTIMORE,MD; US DEPT HEW,FDA,BUR BIOL,ROCKVILLE,MD 20852	Johns Hopkins University; US Food & Drug Administration (FDA)								BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; JOHNSON P, 1966, IMMUNOCHEMISTRY, V3, P101, DOI 10.1016/0019-2791(66)90291-6; JOHNSON P, 1966, IMMUNOCHEMISTRY, V3, P91, DOI 10.1016/0019-2791(66)90290-4; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; JOHNSON P, 1965, EUR POLYM J, V1, P63; LICHTENSTEIN LM, 1969, J ALLERGY, V44, P307, DOI 10.1016/0021-8707(69)90035-5; MARSH DG, 1966, INT ARCH ALLER A IMM, V29, P521, DOI 10.1159/000229739; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; NATELSON S, 1961, MICROTECHNIQUES CLIN; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P94, DOI 10.1016/0091-6749(73)90081-X; STULL ARTHUR, 1933, JOUR ALLERGY, V4, P455, DOI 10.1016/S0021-8707(33)90098-2	13	54	54	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	3					157	164		10.1016/0091-6749(74)90052-9	http://dx.doi.org/10.1016/0091-6749(74)90052-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U0308	4854999				2022-12-18	WOS:A1974U030800004
J	LOCKEY, RF				LOCKEY, RF			SYSTEMIC REACTIONS TO STINGING ANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV S FLORIDA,COLL MED,TAMPA,FL; USAF HOSP,ALLERGY CLIN,CARSWELL AFB,FT WORTH,TX; VET ADM HOSP,ALLERGY SECT,13000 N 30TH ST,TAMPA,FL 33612	State University System of Florida; University of South Florida								BARNARD JH, 1967, J ALLERGY, V40, P107, DOI 10.1016/0021-8707(67)90104-9; BARR SE, 1971, ANN ALLERGY, V29, P49; BARR SE, 1972, ANN ALLERGY, V30, P282; BOWEN R, 1951, South Med J, V44, P836, DOI 10.1097/00007611-195109000-00014; BRAND JM, 1972, TOXICON, V10, P259, DOI 10.1016/0041-0101(72)90011-6; BROWN LL, 1972, SOUTHERN MED J, V65, P273, DOI 10.1097/00007611-197203000-00003; BUFFKIN DC, 1972, TOXICON, V10, P526; BUREN W F, 1972, Journal of the Georgia Entomological Society, V7, P1; BUREN WF, PERSONAL COMMUNICATI; CARO MR, 1957, ARCH DERMATOL, V75, P475, DOI 10.1001/archderm.1957.01550160001001; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; CREIGHTON WS, 1950, B MUSEUM COMP ZOOL, V104; FAVORITE FG, 1958, PUBLIC HEALTH REP, V73, P445, DOI 10.2307/4590149; FERGUSON DE, 1970, SCIENCE, V169, P630, DOI 10.1126/science.169.3946.630; GREEN HB, 1952, J ECON ENTOMOL, V45, P593, DOI 10.1093/jee/45.4.593; GREEN HB, 1967, 737 MISS STAT U AGR, P23; Helmly R B, 1970, Hawaii Med J, V29, P368; JOUVENAZ DP, 1972, ANTIMICROB AGENTS CH, V2, P291, DOI 10.1128/AAC.2.4.291; MACCONNELL JG, 1970, SCIENCE, V168, P840, DOI 10.1126/science.168.3933.840; MACCONNELL JG, 1971, TETRAHEDRON, V26, P1129; MARKIN G P, 1971, Journal of the Georgia Entomological Society, V6, P145; MARKIN GP, 1972, ANN ENTOMOL SOC AM, V65, P1053, DOI 10.1093/aesa/65.5.1053; MARKIN GP, 1973, ANN ENTOMOL SOC AM, V66, P803, DOI 10.1093/aesa/66.4.803; MARKIN GP, 1972, INSECTICIDE MIREX TE; MICKS D W, 1960, Tex Rep Biol Med, V18, P624; OLIVE AT, 1960, J ECON ENTOMOL, V53, P646, DOI 10.1093/jee/53.4.646; PARRISH HM, 1963, AM J MED SCI, V245, P129; SHAPLEY D, 1971, SCIENCE, V172, P358, DOI 10.1126/science.172.3981.358; SMITH JD, 1971, ARCH DERMATOL, V103, P438, DOI 10.1001/archderm.103.4.438; SPENCE JE, 1962, COMPARISON ALLERGENI, V7; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; Vanselow N A, 1967, J Ark Med Soc, V63, P428; VANSELOW NA, 1967, MANUAL CLINICAL ALLE; 1968, 592 USDA PHAM; 1965, JAMA, V193, P115; 1971, SCIENCE, V171, P1131	36	54	54	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	3					132	146		10.1016/0091-6749(74)90050-5	http://dx.doi.org/10.1016/0091-6749(74)90050-5			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U0308	4854598				2022-12-18	WOS:A1974U030800002
J	ZWEIMAN, B; SCHOENWETTER, WF; PAPPANO, JE; TEMPEST, B; HILDRETH, EA				ZWEIMAN, B; SCHOENWETTER, WF; PAPPANO, JE; TEMPEST, B; HILDRETH, EA			PATTERNS OF ALLERGIC RESPIRATORY DISEASE IN CHILDREN WITH A PAST HISTORY OF BRONCHIOLITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BERKOVICH S, 1970, ANN ALLERGY, V28, P43; CHANOCK RM, 1970, ARCH ENVIRON HEALTH, V21, P347, DOI 10.1080/00039896.1970.10667249; CHANOCK RM, 1961, JAMA-J AM MED ASSOC, V176, P647; EISEN AH, 1963, PEDIATRICS, V31, P859; FONTANA VJ, 1963, J ALLERGY, V34, P348, DOI 10.1016/0021-8707(63)90052-2; FORD RM, 1967, ANN ALLERGY, V25, P20; GREEN GR, 1967, J ALLERGY, V40, P224, DOI 10.1016/0021-8707(67)90085-8; HIGH RH, 1957, PEDIATR CLIN N AM, V4, P183; Hyde J S, 1966, J Asthma Res, V4, P137, DOI 10.3109/02770906609100534; LEER JA, 1969, AM J DIS CHILD, V117, P495, DOI 10.1001/archpedi.1969.02100030497001; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; PARROTT RH, 1961, JAMA-J AM MED ASSOC, V176, P653; REYNOLDS EOR, 1967, DISORDERS RESPIRATOR; RHYNE MB, 1969, PEDIATR CLIN N AM, V16, P227; SIMON G, 1967, J PEDIATR-US, V70, P533, DOI 10.1016/S0022-3476(67)80036-2; SMITH JM, 1971, J ALLERGY, V47, P23, DOI 10.1016/S0091-6749(71)80314-7; WITTIG HJ, 1969, PEDIATR CLIN N AM, V16, P55; WITTIG HJ, 1959, J ALLERGY, V30, P19, DOI 10.1016/0021-8707(59)90054-1; ZWEIMAN B, 1966, J ALLERGY, V37, P48, DOI 10.1016/0021-8707(66)90109-2	19	54	54	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	5					283	+		10.1016/0091-6749(71)90029-7	http://dx.doi.org/10.1016/0091-6749(71)90029-7			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K7978	5285778				2022-12-18	WOS:A1971K797800005
J	Volpi, S; Cicalese, MP; Tuijnenburg, P; Tool, ATJ; Cuadrado, E; Abu-Halaweh, M; Ahanchian, H; Alzyoud, R; Akdemir, ZC; Barzaghi, F; Blank, A; Boisson, B; Bottino, C; Brigida, I; Caorsi, R; Casanova, JL; Chiesa, S; Chinn, IK; Duckers, G; Enders, A; Erichsen, HC; Forbes, LR; Gambin, T; Gattorno, M; Karimiani, EG; Giliani, S; Gold, MS; Jacobsen, EM; Jansen, MH; King, JR; Laxer, RM; Lupski, JR; Mace, E; Marcenaro, S; Maroofian, R; Meijer, AB; Niehues, T; Notarangelo, LD; Orange, J; Pannicke, U; Pearson, C; Picco, P; Quinn, PJ; Schulz, A; Seeborg, F; Stray-Pedersen, A; Tawamie, H; van Leeuwen, EMM; Aiuti, A; Yeung, R; Schwarz, K; Kuijpers, TW				Volpi, Stefano; Cicalese, Maria Pia; Tuijnenburg, Paul; Tool, Anton T. J.; Cuadrado, Eloy; Abu-Halaweh, Marwan; Ahanchian, Hamid; Alzyoud, Raed; Akdemir, Zeynep Coban; Barzaghi, Federica; Blank, Alexander; Boisson, Bertrand; Bottino, Cristina; Brigida, Immacolata; Caorsi, Roberta; Casanova, Jean-Laurent; Chiesa, Sabrina; Chinn, Ivan Kingyue; Dueckers, Gregor; Enders, Anselm; Erichsen, Hans Christian; Forbes, Lisa R.; Gambin, Tomasz; Gattorno, Marco; Karimiani, Ehsan Ghayoor; Giliani, Silvia; Gold, Michael S.; Jacobsen, Eva-Maria; Jansen, Machiel H.; King, Jovanka R.; Laxer, Ronald M.; Lupski, James R.; Mace, Emily; Marcenaro, Stefania; Maroofian, Reza; Meijer, Alexander B.; Niehues, Tim; Notarangelo, Luigi D.; Orange, Jordan; Pannicke, Ulrich; Pearson, Chris; Picco, Paolo; Quinn, Patrick J.; Schulz, Ansgar; Seeborg, Filiz; Stray-Pedersen, Asbjorg; Tawamie, Hasan; van Leeuwen, Ester M. M.; Aiuti, Alessandro; Yeung, Rae; Schwarz, Klaus; Kuijpers, Taco W.			A combined immunodeficiency with severe infections, inflammation, and allergy caused by ARPC1B deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Volpi, Stefano; Caorsi, Roberta; Chiesa, Sabrina; Gattorno, Marco] Ist Giannina Gaslini, Clin Pediat & Reumatol, Ctr Malattie Autoinfiammatorie & Immunodeficienze, Genoa, Italy; [Volpi, Stefano] Univ Genoa, DINOGMI, Genoa, Italy; [Cicalese, Maria Pia; Barzaghi, Federica; Brigida, Immacolata; Aiuti, Alessandro] Osped San Raffaele, Pediat Immunohematol, Milan, Italy; [Tuijnenburg, Paul; Jansen, Machiel H.; Kuijpers, Taco W.] Univ Amsterdam, Emma Childrens Hosp, Dept Pediat Immunol Rheumatol & Infect Dis, Amsterdam UMC, Amsterdam, Netherlands; [Tuijnenburg, Paul; Jansen, Machiel H.; van Leeuwen, Ester M. M.] Univ Amsterdam, Dept Expt Immunol, Amsterdam Infect & Immun Inst, Amsterdam UMC, Amsterdam, Netherlands; [Tool, Anton T. J.; Kuijpers, Taco W.] Univ Amsterdam, Dept Blood Cell Res, Sanquin Res & Landsteiner Lab AMC, Amsterdam, Netherlands; [Cuadrado, Eloy] Univ Amsterdam, Dept Immunopathol, Sanquin Res & Landsteiner Lab AMC, Amsterdam, Netherlands; [Ahanchian, Hamid] Mashhad Univ Med Sci, Sch Med, Dept Allergy & Immunol, Mashhad, Razavi Khorasan, Iran; [Alzyoud, Raed] Queen Rania Childrens Hosp, Immunol Allergy & Rheumatol Sect, Bone Marrow Transplantat Primary Immunodeficiency, Amman, Jordan; [Akdemir, Zeynep Coban; Gambin, Tomasz; Lupski, James R.] Baylor Coll Med, Baylor Hopkins Ctr Mendelian Genom, Dept Mol & Human Genet, Houston, TX 77030 USA; [Blank, Alexander; Jacobsen, Eva-Maria; Schulz, Ansgar] Univ Med Ctr Ulm, Dept Pediat, Ulm, Germany; [Boisson, Bertrand; Casanova, Jean-Laurent] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, 1230 York Ave, New York, NY 10021 USA; [Boisson, Bertrand; Casanova, Jean-Laurent] Necker Branch, Lab Human Genet Infect Dis, Paris, France; [Boisson, Bertrand; Casanova, Jean-Laurent] Paris Descartes Univ, Imagine Inst, Paris, France; [Bottino, Cristina] Univ Genoa, Dept Expt Med DIMES, Genoa, Italy; [Bottino, Cristina] Ist Giannina Gaslini, Genoa, Italy; [Casanova, Jean-Laurent] Necker Hosp Sick Children, APHP, Pediat Hematol Immunol & Rheumatol Unit, Paris, France; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA; [Chinn, Ivan Kingyue; Forbes, Lisa R.; Mace, Emily; Orange, Jordan; Seeborg, Filiz] Texas Childrens Hosp, Dept Pediat, Sect Allergy Immunol & Rheumatol, Houston, TX 77030 USA; [Chinn, Ivan Kingyue; Forbes, Lisa R.; Mace, Emily; Orange, Jordan; Seeborg, Filiz] Texas Childrens Hosp, Ctr Human Immunobiol, Houston, TX 77030 USA; [Dueckers, Gregor; Niehues, Tim] Helios Clin, Ctr Child & Adolescent Med, Krefeld, Germany; [Enders, Anselm] Australian Natl Univ, Dept Immunol & Infect Dis, John Curtin Sch Med Res, Canberra, ACT, Australia; [Enders, Anselm] Australian Natl Univ, Ctr Personalised Immunol, Canberra, ACT, Australia; [Erichsen, Hans Christian] Oslo Univ Hosp, Div Paediat & Adolescent Med, Sect Paediat Med & Transplantat, Oslo, Norway; [Gambin, Tomasz] Warsaw Univ Technol, Inst Comp Sci, Warsaw, Poland; [Karimiani, Ehsan Ghayoor] St Georges Univ London, Mol & Clin Sci Inst, Cranmer Terrace, London, England; [Karimiani, Ehsan Ghayoor] Islamic Azad Univ, Innovat Med Res Ctr, Mashhad Branch, Mashhad, Razavi Khorasan, Iran; [Giliani, Silvia] Univ Brescia, Med Genet Unit, Spedali Civili Hosp, Dept Mol & Translat Med, Brescia, Italy; [Giliani, Silvia] Univ Brescia, A Nocivelli Inst Mol Med, Spedali Civili Hosp, Dept Mol & Translat Med, Brescia, Italy; [Gold, Michael S.; King, Jovanka R.; Quinn, Patrick J.] Univ Adelaide, Discipline Pediat, Sch Med, Adelaide, SA, Australia; [Gold, Michael S.; King, Jovanka R.; Quinn, Patrick J.] Dept Allergy & Clin Immunol, Womens & Childrens Hlth Network, Adelaide, SA, Australia; [Abu-Halaweh, Marwan] Philadelphia Univ, Dept Biotechnol & Genet Engn, Amman, Jordan; [Laxer, Ronald M.; Yeung, Rae] Univ Toronto, Hosp Sick Children, Div Rheumatol, Dept Paediat, Toronto, ON, Canada; [Laxer, Ronald M.; Yeung, Rae] Univ Toronto, Hosp Sick Children, Dept Med, Toronto, ON, Canada; [Lupski, James R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Lupski, James R.] Texas Childrens Hosp, Houston, TX 77030 USA; [Marcenaro, Stefania] Ist Giannina Gaslini, Genoa, Italy; [Maroofian, Reza] Royal Devon & Exeter NHS Fdn Trust, RILD Welcome Wolfson Ctr, Med Res, Exeter Med Sch, Exeter, Devon, England; [Maroofian, Reza] St Georges Univ London, Genet & Mol Cell Sci Res Ctr, London, England; [Meijer, Alexander B.] Univ Amsterdam, Dept Plasma Prot, Sanquin Res & Landsteiner Lab AMC, Amsterdam, Netherlands; [Notarangelo, Luigi D.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Pannicke, Ulrich; Schwarz, Klaus] Univ Ulm, Inst Transfus Med, Ulm, Germany; [Pearson, Chris] Dept Gen Med, Womens & Childrens Hlth Network, Adelaide, SA, Australia; [Picco, Paolo] Ist Giannina Gaslini, Clin Pediat & Reumatol, Genoa, Italy; [Stray-Pedersen, Asbjorg] Oslo Univ Hosp, Div Pediat & Adolescent Med, Norwegian Natl Unit Newborn Screening, Oslo, Norway; [Tawamie, Hasan] Inst Human Genet Leipzig, Leipzig, Germany; [Yeung, Rae] Univ Toronto, Hosp Sick Children, Cell Biol Program, Inst Med Sci,Dept Paediat, Toronto, ON, Canada; [Yeung, Rae] Univ Toronto, Hosp Sick Children, Cell Biol Program, Inst Med Sci,Dept Immunol, Toronto, ON, Canada; [Schwarz, Klaus] German Red Cross Blood Serv Baden Wuerttemberg He, Inst Clin Transfus Med & Immunogenet Ulm, Ulm, Germany	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Emma Children's Hospital; University of Amsterdam; University of Amsterdam; University of Amsterdam; University of Amsterdam; Mashhad University Medical Science; Baylor College of Medicine; Ulm University; Rockefeller University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Australian National University; John Curtin School of Medical Research; Australian National University; University of Oslo; Warsaw University of Technology; St Georges University London; Islamic Azad University; Hospital Spedali Civili Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Brescia; University of Adelaide; Philadelphia University Jordan; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Baylor College of Medicine; Baylor College of Medicine; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Exeter; St Georges University London; University of Amsterdam; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Ulm University; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Oslo; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Volpi, S (corresponding author), Ist Giannina Gaslini, Clin Pediat & Reumatol, Ctr Malattie Autoinfiammatorie & Immunodeficienze, Genoa, Italy.; Volpi, S (corresponding author), Univ Genoa, DINOGMI, Genoa, Italy.	stefanovolpi@gaslini.org; t.w.kuijpers@amc.nl	Ghayoor Karimiani, Ehsan/AFS-7844-2022; Chiesa, Sabrina/AAN-7877-2020; Volpi, Stefano/O-3717-2014; Gattorno, Marco/AAL-2974-2020; Boisson, Bertrand/AAC-6058-2019; Gambin, Tomasz/HDN-5840-2022; Giliani, Silvia/AAX-8843-2020; Boisson, Bertrand/I-2485-2017; Enders, Anselm/B-1165-2011; Bottino, Cristina/J-9977-2016; Caorsi, Roberta/K-8608-2016	Volpi, Stefano/0000-0002-7129-868X; Gattorno, Marco/0000-0003-0704-1916; Boisson, Bertrand/0000-0001-5240-3555; Gambin, Tomasz/0000-0002-0941-4571; Giliani, Silvia/0000-0001-8137-4642; Boisson, Bertrand/0000-0001-5240-3555; Enders, Anselm/0000-0001-5933-6463; Chiesa, Sabrina/0000-0002-0392-1927; King, Jovanka/0000-0002-6783-4830; Picco, Paolo/0000-0003-0686-0725; Bottino, Cristina/0000-0001-6695-1739; Chinn, Ivan/0000-0001-5684-5457; orange, jordan/0000-0001-7117-7725; Stray-Pedersen, Asbjorg/0000-0002-9168-0878; Caorsi, Roberta/0000-0003-0131-7846	Italian Ministero della Salute [NET-2011-02350069]; European Commission [ERARE-3-JTC 2015 EUROCID]; Fondazione Telethon (TIGET Core grant C6); Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md; US National Institutes of Health, National Human Genome Research Institute/National Heart, Lung and Blood Institute [UM1 HG006542]; NIHNHGRI/NHLBI [UM1HG006542]; NIH [R01AI120989]; Bundesministerium fur Bildung und Forschung [01GM1517B]; University Hospital Ulm; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [UM1HG006542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI120989, ZIAAI001222] Funding Source: NIH RePORTER	Italian Ministero della Salute(Ministry of Health, Italy); European Commission(European CommissionEuropean Commission Joint Research Centre); Fondazione Telethon (TIGET Core grant C6)(Fondazione Telethon); Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); US National Institutes of Health, National Human Genome Research Institute/National Heart, Lung and Blood Institute; NIHNHGRI/NHLBI; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); University Hospital Ulm; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The study was partly supported by grants of the Italian Ministero della Salute (Programma di rete, NET-2011-02350069), the European Commission (ERARE-3-JTC 2015 EUROCID) and Fondazione Telethon (TIGET Core grant C6). L.D.N. is supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md, and also supported in part by a US National Institutes of Health, National Human Genome Research Institute/National Heart, Lung and Blood Institute grant to the Baylor Hopkins Center for Mendelian Genomics (UM1 HG006542) and by NIHNHGRI/NHLBI grant UM1HG006542 to the Baylor-Hopkins Center for Mendelian Genomics. J.S.O. is supported by NIH grant R01AI120989. The study was partly supported by a grant of the Bundesministerium fur Bildung und Forschung to the University of Ulm (PID NET3; 01GM1517B). This study was supported by a starting grant from the University Hospital Ulm to A.B., as well as by a grant for the Center of Immunodeficiencies Amsterdam (CIDA).	Brigida I, 2018, BLOOD, V132, P2362, DOI 10.1182/blood-2018-07-863431; Gismondi A, 2004, BLOOD, V104, P436, DOI 10.1182/blood-2003-07-2621; Kahr WHA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14816; Kuijpers TW, 2017, J ALLERGY CLIN IMMUN, V140, P273, DOI 10.1016/j.jaci.2016.09.061; Lanzi G, 2012, J EXP MED, V209, P29, DOI 10.1084/jem.20110896; Somech R, 2017, J IMMUNOL, V199, P4036, DOI 10.4049/jimmunol.1700460; Su HC, 2019, IMMUNOL REV, V287, P9, DOI 10.1111/imr.12723	7	53	55	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2296	+		10.1016/j.jaci.2019.02.003	http://dx.doi.org/10.1016/j.jaci.2019.02.003			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30771411	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000470113200037
J	Shamji, MH; Layhadi, JA; Achkova, D; Kouser, L; Perera-Webb, A; Couto-Francisco, NC; Parkin, RV; Matsuoka, T; Scadding, G; Ashton-Rickardt, PG; Durham, SR				Shamji, Mohamed H.; Layhadi, Janice A.; Achkova, Daniela; Kouser, Lubna; Perera-Webb, Alan; Couto-Francisco, Natalia C.; Parkin, Rebecca V.; Matsuoka, Tomokazu; Scadding, Guy; Ashton-Rickardt, Philip G.; Durham, Stephen R.			Role of IL-35 in sublingual allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Seasonal allergic rhinitis; sublingual immunotherapy; regulatory T cells; IL-35; IL-35-inducible regulatory T cells	INNATE LYMPHOID-CELLS; REGULATORY T-CELLS; HUMAN B-CELLS; MONOCLONAL-ANTIBODY; RHINITIS; RESPONSES; ASTHMA; TYPE-2; WORLD; INFLAMMATION	Background: Grass pollen-specific immunotherapy involves immunomodulation of allergen-specific TH2 responses and induction of IL-10(+) and/ or TGF-beta(+) CD4(+) CD25(+) regulatory T cells (induced Treg cells). IL-35(+) CD4(+) CD25(+) forkhead box protein 3-negative T (IL-35-inducible regulatory T [iTR35]) cells have been reported as a novel subset of induced Treg cells with modulatory characteristics. Objective: We sought to investigate mechanisms underlying the induction and maintenance of immunologic tolerance induced by IL-35 and iTR35 cells. Methods: The biological effects of IL-35 were assessed on group 2 innate lymphoid cells (ILC2s); dendritic cells primed with thymic stromal lymphopoietin, IL-25, and IL-33; and B and T(H)2 cells by using flow cytometry and quantitative RT-PCR. Grass pollen-driven T(H)2 cell proliferation and cytokine production were measured by using tritiated thymidine and Luminex MagPix, respectively. iTR35 cells were quantified in patients with grass pollen allergy (seasonal allergic rhinitis [SAR] group, n = 16), sublingual immunotherapy (SLIT)-treated patients (SLIT group, n =5 16), and nonatopic control subjects (NACs; NAC group, n = 16). Results: The SAR group had increased proportions of ILC2s (P = .002) and IL-5 1 cells (P = .042), IL-13(+) cells (P = .042), and IL-5(+) IL-13(+) ILC2s (P = .003) compared with NACs. IL-35 inhibited IL-5 and IL-13 production by ILC2s in the presence of IL-25 or IL-33 (P 5.031) and allergen-driven T(H)2 cytokines by effector T cells. IL-35 inhibited CD40 ligand-, IL-4-, and IL-21-mediated IgE production by B cells (P 5.015), allergen-driven T-cell proliferation (P = .001), and T(H)2 cytokine production mediated by primed dendritic cells. iTR35 cells suppressed T(H)2 cell proliferation and cytokine production. In addition, allergen-driven IL-35 levels and iTR35 cell counts were increased in patients receiving SLIT (all, P <.001) and NACs (all, P <.001) compared with patients with SAR. Conclusion: IL-35 and iTR35 cells are potential novel immune regulators induced by SLIT. The clinical relevance of SLIT can be underscored by restoration of protective iTR35 cells.	[Shamji, Mohamed H.; Layhadi, Janice A.; Achkova, Daniela; Kouser, Lubna; Perera-Webb, Alan; Couto-Francisco, Natalia C.; Parkin, Rebecca V.; Matsuoka, Tomokazu; Scadding, Guy; Durham, Stephen R.] Imperial Coll London, Natl Heart & Lung Inst, Immunomodulat & Tolerance Grp, Allergy & Clin Immunol,Inflammat Repair & Dev, 1st Floor,Rm 111,Sir Alexander Fleming Bldg, London SW7 2AZ, England; [Ashton-Rickardt, Philip G.] Imperial Coll London, Fac Med, Dept Med, Sect Immunobiol,Div Immunol & Inflammat, London, England	Imperial College London; Imperial College London	Shamji, MH (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Immunomodulat & Tolerance Grp, Allergy & Clin Immunol,Inflammat Repair & Dev, 1st Floor,Rm 111,Sir Alexander Fleming Bldg, London SW7 2AZ, England.	m.shamji@imperial.ac.uk	Shamji, Mohamed/AAD-1788-2019; Layhadi, Janice/AAU-8807-2020; Shamji, Mohamed/AAU-8811-2020	Shamji, Mohamed/0000-0003-3425-3463; Layhadi, Janice/0000-0002-5242-1806	Royal Brompton Hospital NHS Trust research funds; MRC [MC_PC_12015] Funding Source: UKRI	Royal Brompton Hospital NHS Trust research funds; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Royal Brompton Hospital NHS Trust research funds.	Akdis CA, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0063-2; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Baraniuk JN, 1997, J ALLERGY CLIN IMMUN, V99, pS763, DOI 10.1016/S0091-6749(97)70125-8; Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bettini M, 2009, CURR OPIN IMMUNOL, V21, P612, DOI 10.1016/j.coi.2009.09.011; Bird L, 2005, NAT REV IMMUNOL, V5, P747, DOI 10.1038/nri1727; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Cerutti A, 2002, J IMMUNOL, V169, P6594, DOI 10.4049/jimmunol.169.11.6594; Collison LW, 2007, NATURE, V450, P566, DOI 10.1038/nature06306; Collison LW, 2012, NAT IMMUNOL, V13, P290, DOI 10.1038/ni.2227; Collison LW, 2010, NAT IMMUNOL, V11, P1093, DOI 10.1038/ni.1952; Collison LW, 2009, J IMMUNOL, V182, P6121, DOI 10.4049/jimmunol.0803646; Cortez VS, 2015, CURR OPIN IMMUNOL, V32, P71, DOI 10.1016/j.coi.2015.01.004; Didier A, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0057-8; Doherty TA, 2014, J ALLERGY CLIN IMMUN, V133, P1203, DOI 10.1016/j.jaci.2013.12.1086; Dong J, 2015, ALLERGY, V70, P921, DOI 10.1111/all.12631; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Eberl G, 2015, NAT IMMUNOL, V16, P1, DOI 10.1038/ni.3059; Fear DJ, 2004, J IMMUNOL, V173, P4529, DOI 10.4049/jimmunol.173.7.4529; FUJIEDA S, 1995, J IMMUNOL, V155, P2318; Gueguen C, 2016, J ALLERGY CLIN IMMUN, V137, P545, DOI 10.1016/j.jaci.2015.09.015; Guttek K, 2013, CYTOKINE, V64, P46, DOI 10.1016/j.cyto.2013.04.037; Hams E, 2013, J IMMUNOL, V191, P5349, DOI 10.4049/jimmunol.1301176; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; Jin P, 2014, HUM IMMUNOL, V75, P29, DOI 10.1016/j.humimm.2013.09.018; Katelaris CH, 2012, CLIN EXP ALLERGY, V42, P186, DOI 10.1111/j.1365-2222.2011.03891.x; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Lao-Araya M, 2014, J ALLERGY CLIN IMMUN, V134, P1193, DOI 10.1016/j.jaci.2014.07.029; Liu JQ, 2012, J IMMUNOL, V188, P3099, DOI 10.4049/jimmunol.1100106; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Mjosberg J, 2016, J ALLERGY CLIN IMMUN, V138, P1265, DOI 10.1016/j.jaci.2016.09.009; Olson BM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00315; Ott H, 2009, ALLERGY, V64, P1394, DOI [10.1111/j.1398-9995.2008.01875.x, 10.1111/j.1398-9995.2009.02194.x]; Pillai MR, 2011, J IMMUNOL, V187, P4987, DOI 10.4049/jimmunol.1102173; Reinhardt RL, 2009, NAT IMMUNOL, V10, P385, DOI 10.1038/ni.1715; Robinson DS, 2009, CLIN EXP ALLERGY, V39, P1314, DOI 10.1111/j.1365-2222.2009.03301.x; Spits H, 2011, NAT IMMUNOL, V12, P21, DOI 10.1038/ni.1962; Tong H, 2010, IMMUNOL LETT, V128, P108, DOI 10.1016/j.imlet.2010.01.001; Varricchi G, 2016, ALLERGY, V71, P1086, DOI 10.1111/all.12878; Vignali DAA, 2012, NAT IMMUNOL, V13, P722, DOI 10.1038/ni.2366; Wang W, 2015, J ASTHMA, V52, P763, DOI 10.3109/02770903.2015.1038390; Wawrzyniak P, 2016, J ALLERGY CLIN IMMUN, V137, P1681, DOI 10.1016/j.jaci.2016.02.010; Whitehead GS, 2012, J ALLERGY CLIN IMMUN, V129, P207, DOI 10.1016/j.jaci.2011.08.009; Zhang YL, 2012, EUR J IMMUNOL, V42, P1735, DOI 10.1002/eji.201142123	48	53	55	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1131	+		10.1016/j.jaci.2018.06.041	http://dx.doi.org/10.1016/j.jaci.2018.06.041			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30053528	Green Published, hybrid, Green Submitted			2022-12-18	WOS:000460272900033
J	Gaffin, JM; Hauptman, M; Petty, CR; Sheehan, WJ; Lai, PS; Wolfson, JM; Gold, DR; Coull, BA; Koutrakis, P; Phipatanakul, W				Gaffin, Jonathan M.; Hauptman, Marissa; Petty, Carter R.; Sheehan, William J.; Lai, Peggy S.; Wolfson, Jack M.; Gold, Diane R.; Coull, Brent A.; Koutrakis, Petros; Phipatanakul, Wanda			Nitrogen dioxide exposure in school classrooms of inner-city children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; indoor air pollution; obstructive lung disease; nitrogen dioxide; spirometry; exhaled nitric oxide	BRONCHIAL EPITHELIAL-CELLS; AIR-POLLUTION; LUNG-FUNCTION; RESPIRATORY HEALTH; INFLAMMATORY RESPONSE; INHALED ALLERGEN; INDOOR; SYMPTOMS; POLLUTANTS; COHORT	Background: Ambient and home exposure to nitrogen dioxide (NO2) causes asthma symptoms and decreased lung function in children with asthma. Little is known about the health effects of school classroom pollution exposure. Objective: We aimed to determine the effect of indoor classroom NO2 on lung function and symptoms in inner-city school children with asthma. Methods: Children enrolled in the School Inner-City Asthma Study were followed for 1 academic year. Subjects performed spirometry and had fraction of exhaled nitric oxide values measured twice during the school year at school. Classroom NO2 was collected by means of passive sampling for 1-week periods twice per year, coinciding with lung function testing. Generalized estimating equation models assessed lung function and symptom relationships with the temporally nearest classroom NO2 level. Results: The mean NO2 value was 11.1 ppb (range, 4.3-29.7 ppb). In total, exposure data were available for 296 subjects, 188 of whom had complete spirometric data. At greater than a threshold of 8 ppb of NO2 and after adjusting for race and season (spirometry standardized by age, height, and sex), NO2 levels were associated highly with airflow obstruction, such that each 10-ppb increase inNO(2) level was associated with a 5% decrease in FEV1/ forced vital capacity ratio (b520.05; 95% CI, 20.08 to 20.02; P=.01). Percent predicted forced expiratory flow between the 25th and 75th percentile of forced vital capacity was also inversely associated with higher NO2 exposure (beta=222.8; 95% CI, 236.0 to 29.7; P=.01). There was no significant association of NO2 levels with percent predictedFEV1, fraction of exhaled nitric oxide, or asthma symptoms. Additionally, there was no effect modification of atopy on lung function or symptom outcomes. Conclusion: In children with asthma, indoor classroom NO2 levels can be associated with increased airflow obstruction.	[Gaffin, Jonathan M.] Boston Childrens Hosp, Div Resp Dis, Boston, MA USA; [Petty, Carter R.] Boston Childrens Hosp, Clin Res Ctr, Boston, MA USA; [Sheehan, William J.; Phipatanakul, Wanda] Boston Childrens Hosp, Div Allergy & Immunol, Boston, MA USA; [Hauptman, Marissa] Boston Childrens Hosp, Div Gen Pediat, Boston, MA USA; [Gaffin, Jonathan M.; Hauptman, Marissa; Sheehan, William J.; Lai, Peggy S.; Phipatanakul, Wanda] Harvard Med Sch, Boston, MA USA; [Lai, Peggy S.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Lai, Peggy S.; Wolfson, Jack M.; Gold, Diane R.; Coull, Brent A.; Koutrakis, Petros] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Gold, Diane R.] Brigham & Womens Hosp, Channing Inst Network Med, 75 Francis St, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Phipatanakul, W (corresponding author), Childrens Hosp Boston, Div Immunol, Fegan 6,300 Longwood Ave, Boston, MA 02115 USA.	wanda.phipatanakul@childrens.harvard.edu		Hauptman, Marissa/0000-0002-0028-8927; GAFFIN, JONATHAN/0000-0003-2213-4504	National Institutes of Health [K23AI106945, R01 AI 073964, R01AI 073964-02S1, K24 AI 106822, U01 AI 110397, U10HL098102]; NIH/NIEHS [K23ES023700, K23AI104780, P01 ES009825, P30ES000002]; US Environmental Protection Agency [RD-834798, RD-83587201]; Harvard Catalyst \ Harvard Clinical and Translational Science Center (National Center for Research Resources, NIH Award) [UL1 TR001102]; Harvard Catalyst \ Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, NIH Award) [UL1 TR001102]; Harvard University and its affiliated academic healthcare centers; EPA [RD-83479801, DW-75-92301301]; Agency for Toxic Substances and Disease Registry (ATSDR) [FAIN: U61TS000237]; AGENCY FOR TOXIC SUBSTANCES AND DISEASE REGISTRY [U61TS000237] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001102] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL098102, R01HL137192] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI106822, U01AI110397, U01AI126614, R01AI073964, K23AI106945, K23AI104780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, K23ES023700, P01ES009825] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); US Environmental Protection Agency(United States Environmental Protection Agency); Harvard Catalyst \ Harvard Clinical and Translational Science Center (National Center for Research Resources, NIH Award); Harvard Catalyst \ Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, NIH Award); Harvard University and its affiliated academic healthcare centers; EPA(United States Environmental Protection Agency); Agency for Toxic Substances and Disease Registry (ATSDR); AGENCY FOR TOXIC SUBSTANCES AND DISEASE REGISTRY(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health grants K23AI106945 (J.M.G.), R01 AI 073964, R01AI 073964-02S1, K24 AI 106822, U01 AI 110397, U10HL098102 (W.P.), NIH/NIEHS K23ES023700 (P.S.L.), K23AI104780 (W.J.S.), P01 ES009825, and P30ES000002 (D.R.G.). This study was also supported by US Environmental Protection Agency grants RD-834798 and RD-83587201. This work was conducted with support from Harvard Catalyst vertical bar Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH Award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic healthcare centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the NIH. This publication was also made possible by EPA grant RD-83479801 and was also funded (in part) by cooperative agreement award no. FAIN: U61TS000237 from the Agency for Toxic Substances and Disease Registry (ATSDR). The EPA supports the Pediatric Environmental Health Specialty Units by providing partial funding to the ATSDR under Inter-Agency Agreement number DW-75-92301301. Its contents are solely the responsibility of the grantee and do not necessarily represent the official views of the ATSDR or EPA. Furthermore, the EPA or ATSDR do not endorse the purchase of any commercial products or services mentioned in the publication. Additional acknowledgment goes to the Allergy and Asthma Awareness Initiative. We thank the following companies for their generous donations: Multi-Test II device, Lincoln Diagnostics, Decatur, Ill; allergenic extracts for skin testing, Greer Laboratories, Lenoir, NC; ImmunoCAP testing, Thermo Fisher, Waltham, Mass; aerochambers, Monaghan Medical, Plattsburgh, NY; and NIOX Machines, Aerocrine, Solna, Sweden.	[Anonymous], 2010, FACT SHEETS ADDITION; Ayyagari VN, 2007, INHAL TOXICOL, V19, P181, DOI 10.1080/08958370601052121; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Barck C, 2002, RESP MED, V96, P907, DOI 10.1053/rmed.2002.1374; Belanger K, 2006, AM J RESP CRIT CARE, V173, P297, DOI 10.1164/rccm.200408-1123OC; Belanger K, 2013, EPIDEMIOLOGY, V24, P320, DOI 10.1097/EDE.0b013e318280e2ac; Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Brunekreef B, 2007, J EXPO SCI ENV EPID, V17, pS61, DOI 10.1038/sj.jes.7500628; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Devlin RB, 1999, INHAL TOXICOL, V11, P89, DOI 10.1080/089583799197195; EPR3 NN, 2007, GUID DIAGN MAN ASTHM; Ezratty V, 2014, ENVIRON HEALTH PERSP, V122, P850, DOI 10.1289/ehp.1307240; Franklin PJ, 2007, PAEDIATR RESPIR REV, V8, P281, DOI 10.1016/j.prrv.2007.08.007; Gaffin JM, 2017, J EXPO SCI ENV EPID, V27, P451, DOI 10.1038/jes.2016.52; Gehring U, 2015, LANCET RESP MED, V3, P933, DOI 10.1016/S2213-2600(15)00426-9; Gillespie-Bennett J, 2011, EUR RESPIR J, V38, P303, DOI 10.1183/09031936.00115409; Guerriero C, 2016, J ENVIRON MANAGE, V181, P615, DOI 10.1016/j.jenvman.2016.06.039; Habre R, 2014, J EXPO SCI ENV EPID, V24, P380, DOI 10.1038/jes.2014.21; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hansel NN, 2008, ENVIRON HEALTH PERSP, V116, P1428, DOI 10.1289/ehp.11349; Ierodiakonou D, 2016, J ALLERGY CLIN IMMUN, V137, P390, DOI 10.1016/j.jaci.2015.05.028; Institute of Medicine; Division of Health Promotion and Disease Prevention; Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; Kattan M, 2007, J ALLERGY CLIN IMMUN, V120, P618, DOI 10.1016/j.jaci.2007.05.014; Lai PS, 2015, CHEST, V148, P1251, DOI 10.1378/chest.15-0098; Litonjua AA, 2016, AM J RESP CRIT CARE, V193, P110, DOI 10.1164/rccm.201510-1963ED; Mazaheri M, 2016, ENVIRON INT, V88, P142, DOI 10.1016/j.envint.2015.12.029; McConnell R, 2010, ENVIRON HEALTH PERSP, V118, P1021, DOI 10.1289/ehp.0901232; Mi YH, 2006, INDOOR AIR, V16, P454, DOI 10.1111/j.1600-0668.2006.00439.x; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Mirowsky JE, 2016, INHAL TOXICOL, V28, P374, DOI 10.1080/08958378.2016.1185199; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Neophytou AM, 2016, AM J RESP CRIT CARE, V193, P1271, DOI 10.1164/rccm.201508-1706OC; Nitschke M, 2006, J OCCUP ENVIRON MED, V48, P462, DOI 10.1097/01.jom.0000215802.43229.62; O'Connor GT, 2008, J ALLERGY CLIN IMMUN, V121, P1133, DOI 10.1016/j.jaci.2008.02.020; Ogawa & Co Inc. NO, 2006, NO2 NOX SO2 SAMPL PR; Phipatanakul W, 2011, J ASTHMA, V48, P1007, DOI 10.3109/02770903.2011.624235; Pilotto LS, 2004, INT J EPIDEMIOL, V33, P208, DOI 10.1093/ije/dyh018; Pilotto LS, 1997, INT J EPIDEMIOL, V26, P788, DOI 10.1093/ije/26.4.788; Rice MB, 2014, PEDIAT PULMONOL; Rivas I, 2014, ENVIRON INT, V69, P200, DOI 10.1016/j.envint.2014.04.009; Sheehan WJ, 2017, JAMA PEDIATR, V171, P31, DOI 10.1001/jamapediatrics.2016.2543; Smedje G, 2000, ARCH ENVIRON HEALTH, V55, P18, DOI 10.1080/00039890009603380; Strand V, 1997, AM J RESP CRIT CARE, V155, P881, DOI 10.1164/ajrccm.155.3.9117021; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Sunyer J, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001792; Viera L, 2009, CURR ALLERGY ASTHM R, V9, P327, DOI 10.1007/s11882-009-0046-x; Wallace LA, 2003, ENVIRON HEALTH PERSP, V111, P1265, DOI 10.1289/ehp.6135; Zheng XY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138146; Zwozdziak A, 2016, ENVIRON SCI POLLUT R, V23, P23892, DOI 10.1007/s11356-016-7605-1	49	53	54	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2249	+		10.1016/j.jaci.2017.08.028	http://dx.doi.org/10.1016/j.jaci.2017.08.028			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	28988796	Bronze, Green Accepted			2022-12-18	WOS:000434701600028
J	Trotta, L; Martelius, T; Siitonen, T; Hautala, T; Hamalainen, S; Juntti, H; Taskinen, M; Ilander, M; Andersson, EI; Zavialov, A; Kaustio, M; Keski-Filppula, R; Hershfield, M; Mustjoki, S; Tapiainen, T; Seppanen, M; Saarela, J				Trotta, Luca; Martelius, Timi; Siitonen, Timo; Hautala, Timo; Hamalainen, Sari; Juntti, Hanna; Taskinen, Mervi; Ilander, Mette; Andersson, Emma Irene h; Zavialov, Andrey; Kaustio, Meri; Keski-Filppula, Riikka; Hershfield, Michael; Mustjoki, Satu; Tapiainen, Terhi; Seppanen, Mikko; Saarela, Janna			ADA2 deficiency: Clonal lymphoproliferation in a subset of patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ADENOSINE-DEAMINASE 2; MUTATIONS; VARIANTS; TYPE-2		[Trotta, Luca; Kaustio, Meri; Saarela, Janna] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland; [Martelius, Timi; Seppanen, Mikko] Univ Helsinki, Inflammat Ctr, Dept Infect Dis, Adult Immunodeficiency Unit, Helsinki, Finland; [Seppanen, Mikko] Univ Helsinki, Childrens Hosp, Rare Dis Ctr, Helsinki, Finland; [Seppanen, Mikko] Helsinki Univ Hosp, Helsinki, Finland; [Siitonen, Timo] Oulu Univ Hosp, Dept Med, Div Hematol, Oulu, Finland; [Hautala, Timo] Oulu Univ Hosp, Dept Internal Med, Oulu, Finland; [Hamalainen, Sari] Kuopio Univ Hosp, Dept Internal Med, Kuopio, Finland; [Juntti, Hanna; Tapiainen, Terhi] Univ Oulu, Med Res Ctr, Dept Pediat, PEDEGO Res Unit, Oulu, Finland; [Juntti, Hanna; Tapiainen, Terhi] Oulu Univ Hosp, Dept Children & Adolescents, Oulu, Finland; [Taskinen, Mervi] Helsinki Univ Hosp, Div Pediat Hematol Oncol & Stem Cell Transplantat, Helsinki, Finland; [Ilander, Mette; Andersson, Emma Irene h; Mustjoki, Satu] Univ Helsinki, Dept Clin Chem & Hematol, Hematol Res Unit Helsinki, Helsinki, Finland; [Ilander, Mette; Andersson, Emma Irene h; Mustjoki, Satu] Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland; [Zavialov, Andrey] Guangzhou Women & Childrens Med Ctr, Guangzhou Inst Pediat, Guangzhou, Guangdong, Peoples R China; [Keski-Filppula, Riikka] Univ Oulu, Med Res Ctr Oulu, PEDEGO Res Unit, Oulu, Finland; [Keski-Filppula, Riikka] Oulu Univ Hosp, Dept Clin Genet, Oulu, Finland; [Hershfield, Michael] Duke Univ, Sch Med, Dept Med & Biochem, Durham, NC USA	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Oulu; University of Oulu; Kuopio University Hospital; University of Eastern Finland; University of Oulu; University of Oulu; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Oulu; University of Oulu; Duke University	Seppanen, M (corresponding author), Univ Helsinki, Inflammat Ctr, Dept Infect Dis, Adult Immunodeficiency Unit, Helsinki, Finland.; Seppanen, M (corresponding author), Univ Helsinki, Childrens Hosp, Rare Dis Ctr, Helsinki, Finland.; Seppanen, M (corresponding author), Helsinki Univ Hosp, Helsinki, Finland.	mikko.seppanen@hus.fi; janna.saarela@helsinki.fi	Mustjoki, Satu/AAD-9974-2020	Mustjoki, Satu/0000-0002-0816-8241; Seppanen, Mikko/0000-0001-9733-3650; Hautala, Timo/0000-0001-7889-1614; Saarela, Janna/0000-0002-0853-6219; Trotta, Luca/0000-0001-7162-2040; Martelius, Timi/0000-0002-3678-958X	Cancer Foundation Finland sr [140142, 130127] Funding Source: researchfish	Cancer Foundation Finland sr		Ben-Ami T, 2016, J PEDIATR-US, V177, P316, DOI 10.1016/j.jpeds.2016.06.058; Chang X, 2012, J MED GENET, V49, P433, DOI 10.1136/jmedgenet-2012-100918; Elkan PN, 2014, NEW ENGL J MED, V370, P921, DOI 10.1056/NEJMoa1307362; Hsu AP, 2016, J ALLERGY CLIN IMMUN, V138, P628, DOI 10.1016/j.jaci.2016.03.016; Koskela HLM, 2012, NEW ENGL J MED, V366, P1905, DOI 10.1056/NEJMoa1114885; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lim ET, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004494; Poswar FD, 2016, J NEUROL, V263, P818, DOI 10.1007/s00415-016-8070-y; Rajala HLM, 2013, BLOOD, V121, P4541, DOI 10.1182/blood-2012-12-474577; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Santiago TMG, 2015, JAMA DERMATOL, V151, P1230, DOI 10.1001/jamadermatol.2015.1635; Schepp J, 2016, J CLIN IMMUNOL, V36, P179, DOI 10.1007/s10875-016-0245-x; Sulonen AM, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r94; Trotta L, 2016, EUR J HUM GENET, V24, P1473, DOI 10.1038/ejhg.2016.37; Van Montfrans JM, 2016, RHEUMATOLOGY, V55, P902, DOI 10.1093/rheumatology/kev439; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Zhou Q, 2014, NEW ENGL J MED, V370, P911, DOI 10.1056/NEJMoa1307361	17	53	54	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1534	+		10.1016/j.jaci.2018.01.012	http://dx.doi.org/10.1016/j.jaci.2018.01.012			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29391253	Bronze			2022-12-18	WOS:000429197800052
J	Robinson, RK; Birrell, MA; Adcock, JJ; Wortley, MA; Dubuis, ED; Chen, S; McGilvery, CM; Hu, S; Shaffer, MSP; Bonvini, SJ; Maher, SA; Mudway, IS; Porter, AE; Carlsten, C; Tetley, TD; Belvisi, MG				Robinson, Ryan K.; Birrell, Mark A.; Adcock, John J.; Wortley, Michael A.; Dubuis, Eric D.; Chen, Shu; McGilvery, Catriona M.; Hu, Sheng; Shaffer, Milo S. P.; Bonvini, Sara J.; Maher, Sarah A.; Mudway, Ian S.; Porter, Alexandra E.; Carlsten, Chris; Tetley, Teresa D.; Belvisi, Maria G.			Mechanistic link between diesel exhaust particles and respiratory reflexes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pollution; oxidative stress; transient receptor potential ion channels; sensory nerves; vagus	ARYL-HYDROCARBON RECEPTOR; POLYCYCLIC AROMATIC-HYDROCARBONS; POTENTIAL TRP CHANNELS; AIRWAY SENSORY NERVES; SHORT-TERM EXPOSURE; MICE LACKING TRPV4; COVALENT MODIFICATION; PARTICULATE MATTER; PULMONARY TOXICITY; OXIDATIVE STRESS	Background: Diesel exhaust particles (DEPs) are a major component of particulate matter in Europe's largest cities, and epidemiologic evidence links exposure with respiratory symptoms and asthma exacerbations. Respiratory reflexes are responsible for symptoms and are regulated by vagal afferent nerves, which innervate the airway. It is not known how DEP exposure activates airway afferents to elicit symptoms, such as cough and bronchospasm. Objective: We sought to identify the mechanisms involved in activation of airway sensory afferents by DEPs. Methods: In this study we use in vitro and in vivo electrophysiologic techniques, including a unique model that assesses depolarization (a marker of sensory nerve activation) of human vagus. Results: We demonstrate a direct interaction between DEP and airway C-fiber afferents. In anesthetized guinea pigs intratracheal administration of DEPs activated airway C-fibers. The organic extract (DEP-OE) and not the cleaned particles evoked depolarization of guinea pig and human vagus, and this was inhibited by a transient receptor potential ankyrin-1 antagonist and the antioxidant N-acetyl cysteine. Polycyclic aromatic hydrocarbons, major constituents of DEPs, were implicated in this process through activation of the aryl hydrocarbon receptor and subsequent mitochondrial reactive oxygen species production, which is known to activate transient receptor potential ankyrin-1 on nociceptive C-fibers. Conclusions: This study provides the first mechanistic insights into how exposure to urban air pollution leads to activation of guinea pig and human sensory nerves, which are responsible for respiratory symptoms. Mechanistic information will enable the development of appropriate therapeutic interventions and mitigation strategies for those susceptible subjects who are most at risk.	[Robinson, Ryan K.; Birrell, Mark A.; Adcock, John J.; Wortley, Michael A.; Dubuis, Eric D.; Bonvini, Sara J.; Maher, Sarah A.; Belvisi, Maria G.] Imperial Coll London, Natl Heart & Lung Inst, Airway Dis, Resp Pharmacol Grp, Exhibit Rd, London SW7 2AZ, England; [Chen, Shu; McGilvery, Catriona M.; Shaffer, Milo S. P.; Porter, Alexandra E.] Imperial Coll London, Dept Mat, London, England; [Chen, Shu; McGilvery, Catriona M.; Hu, Sheng; Shaffer, Milo S. P.; Porter, Alexandra E.] Imperial Coll London, London Ctr Nanotechnol, London, England; [Hu, Sheng; Shaffer, Milo S. P.] Imperial Coll London, Dept Chem, London, England; [Tetley, Teresa D.] Imperial Coll London, Natl Heart & Lung Inst, Airways Dis, Lung Cell Biol, London, England; [Robinson, Ryan K.; Birrell, Mark A.; Belvisi, Maria G.] MRC, London, England; [Robinson, Ryan K.; Birrell, Mark A.; Belvisi, Maria G.] Asthma UK Ctr Allerg Mech Asthma, London, England; [Mudway, Ian S.] Kings Coll London, MRC PHE Ctr Environm & Hlth, London, England; [Mudway, Ian S.; Porter, Alexandra E.; Tetley, Teresa D.] NIHR Hlth Protect Res Unit Hlth Impact Environm H, London, England; [Carlsten, Chris] Univ British Columbia, Ctr Heart Lung Innovat, Vancouver, BC, Canada	Imperial College London; Imperial College London; Imperial College London; University of London; University College London; Imperial College London; Imperial College London; University of London; King's College London; University of London; King's College London; University of British Columbia	Belvisi, MG (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Airway Dis, Resp Pharmacol Grp, Exhibit Rd, London SW7 2AZ, England.; Tetley, TD (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Airways Dis, Dovehouse St, London SW3 6LY, England.	t.tetley@imperial.ac.uk; m.belvisi@imperial.ac.uk	Shaffer, Milo S P/C-5977-2008	Shaffer, Milo S P/0000-0001-9384-9043; Bonvini, Sara/0000-0002-5292-8316; McGilvery, Catriona/0000-0002-4849-0251	BBSRC; Medical Research Council (MRC, UK) MICA award [MR/K020293/1]; National Heart&Lung Institute (NHLI) studentship; North West Lung Centre Charity; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust; Medical Research Council [MR/K020293/1, G1000758B, G1000758] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre, MRC-Asthma UK Centre] Funding Source: researchfish; MRC [MR/K020293/1] Funding Source: UKRI	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council (MRC, UK) MICA award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Heart&Lung Institute (NHLI) studentship; North West Lung Centre Charity; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	R.K.R. was funded by a BBSRC Doctoral Training Programme. S.A.M. and E.D.B. were funded by a Medical Research Council (MRC, UK) MICA award (MR/K020293/1). S.J.B. was supported by a National Heart&Lung Institute (NHLI) studentship. M.A.W. was funded by the North West Lung Centre Charity. The human vagus experiments in this study were undertaken with the support of the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust.	Adcock JJ, 2003, BRIT J PHARMACOL, V138, P407, DOI 10.1038/sj.bjp.0705056; [Anonymous], Patent, Patent No. [PCT/ US2010/ 03738, 201003738]; [Anonymous], Patent, Patent No. [WO2010/ 141805, 2010141805]; Atkinson RW, 2016, J EXPO SCI ENV EPID, V26, P125, DOI 10.1038/jes.2015.65; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860, DOI 10.1164/ajrccm.164.10.2010138; Ball JC, 2000, J AIR WASTE MANAGE, V50, P1897, DOI 10.1080/10473289.2000.10464231; Belvisi MG, 2011, CHEST, V140, P1040, DOI 10.1378/chest.10-3327; Bernstein DI, 2012, ALLERGY ASTHMA IMMUN, V4, P178, DOI 10.4168/aair.2012.4.4.178; Bessac BF, 2008, J CLIN INVEST, V118, P1899, DOI 10.1172/JCI34192; Billiard SM, 2006, TOXICOL SCI, V92, P526, DOI 10.1093/toxsci/kfl011; Birger N, 2011, INHAL TOXICOL, V23, P219, DOI 10.3109/08958378.2011.562256; Birrell MA, 2009, AM J RESP CRIT CARE, V180, P1042, DOI 10.1164/rccm.200905-0665OC; Bonvini SJ, 2016, J ALLERGY CLIN IMMUN, V138, P249, DOI 10.1016/j.jaci.2015.10.044; Bonvini SJ, 2015, N-S ARCH PHARMACOL, V388, P1; Cames Michel, 2013, Environmental Sciences Europe, V25, P15, DOI 10.1186/2190-4715-25-15; Canning BJ, 2006, RESP PHYSIOL NEUROBI, V152, P223, DOI 10.1016/j.resp.2006.03.001; Canning BJ, 2014, CHEST, V146, P1633, DOI 10.1378/chest.14-1481; Carlsten C, 2016, THORAX, V71, P35, DOI 10.1136/thoraxjnl-2015-207399; Carlsten C, 2014, TOXICOL SCI, V139, P479, DOI 10.1093/toxsci/kfu040; Cvetkov TL, 2011, J BIOL CHEM, V286, P38168, DOI 10.1074/jbc.M111.288993; Deering-Rice CE, 2011, CHEM RES TOXICOL, V24, P950, DOI 10.1021/tx200123z; Gallo V, 2017, PEDIAT ALLERG IMM-UK, V28, P191, DOI 10.1111/pai.12673; Grace MS, 2014, BRIT J PHARMACOL, V171, P2593, DOI 10.1111/bph.12538; Grace M, 2012, THORAX, V67, P891, DOI 10.1136/thoraxjnl-2011-201443; Hadley SH, 2014, MOL PHARMACOL, V85, P839, DOI 10.1124/mol.113.091272; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; Hosseini A, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0114-z; Izawa H, 2007, J REPROD DEVELOP, V53, P1191, DOI 10.1262/jrd.19114; Kelly FJ, 2011, CLIN EXP ALLERGY, V41, P1059, DOI 10.1111/j.1365-2222.2011.03776.x; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Lewis AC, 2015, NATURE, V526, P195, DOI 10.1038/526195c; Li JJ, 2011, ENVIRON HEALTH PERSP, V119, P784, DOI 10.1289/ehp.1002807; Li N, 2002, J IMMUNOL, V169, P4531, DOI 10.4049/jimmunol.169.8.4531; Liu T, 2012, NEUROSCI BULL, V28, P145, DOI 10.1007/s12264-012-1207-9; Ma JYC, 2002, J ENVIRON SCI HEAL C, V20, P117, DOI 10.1081/GNC-120016202; Macpherson LJ, 2007, NATURE, V445, P541, DOI 10.1038/nature05544; Maher SA, 2009, AM J RESP CRIT CARE, V180, P923, DOI 10.1164/rccm.200903-0388OC; MCCLELLAN RO, 1987, ANNU REV PHARMACOL, V27, P279; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Misaki K, 2008, ARCH ENVIRON CON TOX, V55, P199, DOI 10.1007/s00244-007-9110-5; Mizuno A, 2003, AM J PHYSIOL-CELL PH, V285, pC96, DOI 10.1152/ajpcell.00559.2002; Nasra J, 2009, PHARMACOL THERAPEUT, V124, P354, DOI 10.1016/j.pharmthera.2009.09.006; Nesuashvili L, 2013, MOL PHARMACOL, V83, P1007, DOI 10.1124/mol.112.084319; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; Raemdonck K, 2012, THORAX, V67, P19, DOI 10.1136/thoraxjnl-2011-200365; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; Rudell B, 1996, OCCUP ENVIRON MED, V53, P658, DOI 10.1136/oem.53.10.658; Samoli E, 2016, OCCUP ENVIRON MED, V73, P300, DOI 10.1136/oemed-2015-103136; Senft AP, 2002, FREE RADICAL BIO MED, V33, P1268, DOI 10.1016/S0891-5849(02)01014-6; Shah SD, 2004, ENVIRON SCI TECHNOL, V38, P2544, DOI 10.1021/es0350583; Shinyashiki M, 2009, ENVIRON RES, V109, P239, DOI 10.1016/j.envres.2008.12.008; Singh P, 2004, ENVIRON HEALTH PERSP, V112, P820, DOI 10.1289/ehp.6579; Soontjens CD, 1997, ATMOS ENVIRON, V31, P219, DOI 10.1016/1352-2310(96)00211-7; Stenfors N, 2004, EUR RESPIR J, V23, P82, DOI 10.1183/09031936.03.00004603; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Taylor-Clark TE, 2015, PULM PHARMACOL THER, V35, P94, DOI 10.1016/j.pupt.2015.06.003; Totlandsdal AI, 2015, ENVIRON TOXICOL, V30, P188, DOI 10.1002/tox.21884; Totlandsdal AI, 2012, TOXICOL LETT, V208, P262, DOI 10.1016/j.toxlet.2011.10.025; Tseng CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131911; Tuyen LH, 2014, SCI TOTAL ENVIRON, V491, P246, DOI 10.1016/j.scitotenv.2014.01.086; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103	62	53	53	2	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1074	+		10.1016/j.jaci.2017.04.038	http://dx.doi.org/10.1016/j.jaci.2017.04.038			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	28532657	Green Published, hybrid			2022-12-18	WOS:000426974800027
J	Carter, MC; Desai, A; Komarow, HD; Bai, Y; Clayton, ST; Clark, AS; Ruiz-Esteves, KN; Long, LM; Cantave, D; Wilson, TM; Scott, LM; Simakova, O; Jung, MY; Hahn, J; Maric, I; Metcalfe, DD				Carter, Melody C.; Desai, Avanti; Komarow, Hirsh D.; Bai, Yun; Clayton, Sarah T.; Clark, Alicia S.; Ruiz-Esteves, Karina N.; Long, Lauren M.; Cantave, Daly; Wilson, Todd M.; Scott, Linda M.; Simakova, Olga; Jung, Mi-Yeon; Hahn, Jamie; Maric, Irina; Metcalfe, Dean D.			A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; mast cells; mastocytosis; monoclonal mast cell activation syndrome; mast cell activation; tryptase; KIT; allele-specific quantitative PCR	KIT D816V MUTATION; SYSTEMIC MASTOCYTOSIS; ACTIVATION SYNDROMES; PERIPHERAL-BLOOD; CLASSIFICATION; TRYPTASE; LINE; PREVALENCE; CRITERIA; PROPOSAL	Background: Clonal mast cell disorders are known to occur in a subset of patients with systemic reactions to Hymenoptera stings. This observation has prompted the question of whether clonal mast cell disorders also occur in patients with idiopathic anaphylaxis (IA). Objective: We sought to determine the prevalence of clonal mast cell disorders among patients with IA, criteria to identify those patients who require a bone marrow biopsy, and whether the pathogenesis of IA involves a hyperresponsive mast cell compartment. Methods: We prospectively enrolled patients with IA (>= 3 episodes/y) who then underwent a medical evaluation that included a serum tryptase determination, allele-specific quantitative PCR (ASqPCR) for the KIT D816V mutation, and a bone marrow examination. Mast cells were cultured from peripheral blood CD34(+) cells and examined for releasability after FceRI aggregation. Results: Clonal mast cell disease was diagnosed in 14% of patients referred with IA. ASqPCR for the KIT D816V mutation was a useful adjunct in helping identify those with systemic mastocytosis but not monoclonal mast cell activation syndrome. A modified overall clonal prediction model was developed by using clinical findings, a serum tryptase determination, and ASqPCR. There was no evidence of a hyperresponsive mast cell phenotype in patients with IA. Conclusion: Patients with clonal mast cell disease can present as having IA. Distinct clinical and laboratory features can be used to select those patients more likely to have an underlying clonal mast cell disorder (monoclonal mast cell activation syndrome or systemic mastocytosis) and thus candidates for a bone marrow biopsy.	[Carter, Melody C.; Desai, Avanti; Komarow, Hirsh D.; Bai, Yun; Clayton, Sarah T.; Clark, Alicia S.; Ruiz-Esteves, Karina N.; Long, Lauren M.; Wilson, Todd M.; Scott, Linda M.; Jung, Mi-Yeon; Metcalfe, Dean D.] NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Simakova, Olga; Hahn, Jamie; Maric, Irina] NIH, Hematol Sect, Dept Lab Med, Bldg 10, Bethesda, MD 20892 USA; [Cantave, Daly] NIH, Dept Nursing, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA; [Simakova, Olga] US FDA, Off Blood Res & Review, Ctr Biol Evaluat & Res, Silver Spring, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); US Food & Drug Administration (FDA)	Carter, MC (corresponding author), Bldg 10-11C207,10 Ctr Dr,MSC 1881, Bethesda, MD 20892 USA.	mcarter@niaid.nih.gov			Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001092] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL080005] Funding Source: NIH RePORTER	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	Supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.	Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Boyden SE, 2016, NEW ENGL J MED, V374, P656, DOI 10.1056/NEJMoa1500611; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Broesby-Olsen S, 2015, J ALLERGY CLIN IMMUN, V135, P262, DOI 10.1016/j.jaci.2014.06.031; De Matteis G, 2015, LEUKEMIA RES, V39, P273, DOI 10.1016/j.leukres.2014.11.029; de Olano DG, 2007, CLIN EXP ALLERGY, V37, P1547, DOI 10.1111/j.1365-2222.2007.02804.x; Erben P, 2014, ANN HEMATOL, V93, P81, DOI 10.1007/s00277-013-1964-1; Gulen T, 2014, CLIN EXP ALLERGY, V44, P121, DOI 10.1111/cea.12225; Jara-Acevedo M, 2015, MODERN PATHOL, V28, P1138, DOI 10.1038/modpathol.2015.72; Kristensen T, 2014, AM J HEMATOL, V89, P493, DOI 10.1002/ajh.23672; Kristensen T, 2011, J MOL DIAGN, V13, P180, DOI 10.1016/j.jmoldx.2010.10.004; Kuehn Hye Sun, 2010, Curr Protoc Immunol, VChapter 7, DOI 10.1002/0471142735.im0738s91; Lieberman P, 2015, ANN ALLERG ASTHMA IM, V115, P341, DOI 10.1016/j.anai.2015.07.019; Maric I, 2007, J ALLERGY CLIN IMMUN, V120, P680, DOI 10.1016/j.jaci.2007.05.024; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; Saleh R, 2014, BLOOD, V124, P111, DOI 10.1182/blood-2013-10-534685; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Soar J, 2008, RESUSCITATION, V77, P157, DOI 10.1016/j.resuscitation.2008.02.001; Sundstrom M, 2003, IMMUNOLOGY, V108, P89, DOI 10.1046/j.1365-2567.2003.01559.x; Teodosio C, 2010, J ALLERGY CLIN IMMUN, V125, P719, DOI 10.1016/j.jaci.2009.10.020; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2014, ALLERGY, V69, P1267, DOI 10.1111/all.12436; Valent P, 2013, ALLERGY, V68, P417, DOI 10.1111/all.12126; Valent P, 2017, BLOOD, V129, P1420, DOI 10.1182/blood-2016-09-731893; Valent P, 2012, INT ARCH ALLERGY IMM, V157, P215, DOI 10.1159/000328760	29	53	53	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					180	+		10.1016/j.jaci.2017.05.036	http://dx.doi.org/10.1016/j.jaci.2017.05.036			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28629749	Green Accepted, Bronze			2022-12-18	WOS:000419312200024
J	Konya, V; Czarnewski, P; Forkel, M; Rao, A; Kokkinou, E; Villablanca, EJ; Almer, S; Lindforss, U; Friberg, D; Hoog, C; Bergman, P; Mjosberg, J				Konya, Viktoria; Czarnewski, Paulo; Forkel, Marianne; Rao, Anna; Kokkinou, Efthymia; Villablanca, Eduardo J.; Almer, Sven; Lindforss, Ulrik; Friberg, Danielle; Hoeoeg, Charlotte; Bergman, Peter; Mjoesberg, Jenny			Vitamin D downregulates the IL-23 receptor pathway in human mucosal group 3 innate lymphoid cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate lymphoid cells; inflammatory bowel diseases; vitamin D receptor; IL-22	INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; COLON-CANCER; 1,25-DIHYDROXYVITAMIN D-3; INTESTINAL PATHOLOGY; T-CELLS; COLITIS; THERAPY; INTERLEUKIN-22; TUMORIGENESIS	Background: Vitamin D deficiency is a risk factor for inflammatory bowel disease (IBD). The IL-23-driven tissue-resident group 3 innate lymphoid cells (ILC3s) play essential roles in intestinal immunity, and targeting IL-23/12 is a promising approach in IBD therapy. Objective: We set out to define the role of 1 alpha,25-dihydroxy vitamin D3 (1,25D) in regulating functional responses of human mucosal ILC3s to IL-23 plus Il-1 beta stimulation. Methods: Transcriptomes of sorted tonsillar ILC3s were assessed by using microarray analysis. ILC3 cytokine production, proliferation, and differentiation were determined by means of flow cytometry, ELISA, and multiplex immunoassay. Intestinal cell suspensions and ILC3s sorted from gut biopsy specimens of patients with IBD were also analyzed along with plasma 25-hydroxy vitamin D3 (25D) detection. Results: ILC3s stimulated with IL-23 plus IL-1 beta upregulated the vitamin D receptor and responded to 1,25D with downregulation of the IL-23 receptor pathway. Consequently, 1,25D suppressed IL-22, IL-17F, and GM-CSF production from tonsillar and gut ILC3s. In parallel, 1,25D upregulated genes linked to the IL-1 beta signaling pathway, as well as the IL-1 beta-inducible cytokines IL-6, IL-8, and macrophage inflammatory protein IL/1 beta. The 1,25D-triggered skewing in ILC3 function was not accompanied or caused by changes in viability, proliferation, or phenotype. Finally, we confirmed low 25D plasma levels in patients with IBD with active inflammation. Conclusion: In light of the beneficial targeting of IL-23/12 in patients with IBD, 1,25D appears as an interesting therapeutic agent that inhibits the IL-23 receptor pathway, providing a novel mechanism for how ILC3s could be manipulated to regulate intestinal inflammation.	[Konya, Viktoria; Forkel, Marianne; Rao, Anna; Kokkinou, Efthymia; Bergman, Peter; Mjoesberg, Jenny] Karolinska Inst, Dept Med, Ctr Infect Med, Huddinge, Sweden; [Konya, Viktoria; Forkel, Marianne; Rao, Anna; Kokkinou, Efthymia; Almer, Sven; Lindforss, Ulrik; Friberg, Danielle; Hoeoeg, Charlotte; Bergman, Peter; Mjoesberg, Jenny] Karolinska Univ Hosp, Stockholm, Sweden; [Konya, Viktoria] Med Univ Graz, Inst Expt & Clin Pharmacol, Graz, Austria; [Czarnewski, Paulo; Villablanca, Eduardo J.] Sci Life Lab, Dept Med, Stockholm, Sweden; [Almer, Sven] Karolinska Inst, Dept Med, Ctr Digest Dis, Solna, Sweden; [Lindforss, Ulrik] Karolinska Inst, Dept Mol Med & Surg, Solna, Sweden; [Friberg, Danielle] Karolinska Inst, Dept Otorhinolaryngol, Dept Clin Sci Intervent & Technol, Stockholm, Sweden; [Hoeoeg, Charlotte] Karolinska Inst, Dept Med, Unit Inflammat Gastroenterol & Rheumatol, Huddinge, Sweden; [Bergman, Peter] Karolinska Inst, Clin Microbiol, Dept Lab Med, Huddinge, Sweden; [Mjoesberg, Jenny] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Medical University of Graz; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Linkoping University	Mjosberg, J (corresponding author), Karolinska Inst, Ctr Infect Med, F59, S-14186 Stockholm, Sweden.	jenny.mjosberg@ki.se	; Villablanca, Eduardo/E-1380-2016	Bergman, Peter/0000-0003-3306-3713; Friberg, Danielle/0000-0001-8327-1292; Almer, Sven/0000-0001-9334-1821; Czarnewski, Paulo/0000-0001-8150-4021; Mjosberg, Jenny/0000-0002-1119-0976; Villablanca, Eduardo/0000-0001-9522-9729	European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant [655677]; Austrian Science Fund FWF [P25531-B23]; Swedish Research Council; Swedish Cancer Foundation; Swedish Foundation for Strategic Research; Knut and Alice Wallenberg Foundation; Swedish Society for Medical Research	European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant; Austrian Science Fund FWF(Austrian Science Fund (FWF)); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Foundation; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Swedish Society for Medical Research	This project has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant (agreement no. 655677 to V.K.). Additional financial support was provided by the Austrian Science Fund FWF (grant P25531-B23 to V.K.), the Swedish Research Council, the Swedish Cancer Foundation, the Swedish Foundation for Strategic Research, the Knut and Alice Wallenberg Foundation, and the Swedish Society for Medical Research (to J.M.).	Ananthakrishnan AN, 2015, NAT REV GASTRO HEPAT, V12, P205, DOI 10.1038/nrgastro.2015.34; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Bjorklund AK, 2016, NAT IMMUNOL, V17, P451, DOI 10.1038/ni.3368; Bruce D, 2011, INT IMMUNOL, V23, P519, DOI 10.1093/intimm/dxr045; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Cella M, 2010, P NATL ACAD SCI USA, V107, P10961, DOI 10.1073/pnas.1005641107; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Chan IH, 2014, MUCOSAL IMMUNOL, V7, P842, DOI 10.1038/mi.2013.101; Chen J, 2015, MUCOSAL IMMUNOL, V8, P618, DOI 10.1038/mi.2014.94; Chen L, 2015, MUCOSAL IMMUNOL, V8, P390, DOI 10.1038/mi.2014.77; Choi JS, 2015, MUCOSAL IMMUNOL, V8, P1285, DOI 10.1038/mi.2015.19; Chun RF, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00151; Crellin NK, 2010, IMMUNITY, V33, P752, DOI 10.1016/j.immuni.2010.10.012; Eken A, 2014, MUCOSAL IMMUNOL, V7, P143, DOI 10.1038/mi.2013.33; Flanagan PK, 2015, INFLAMM BOWEL DIS, V21, P1499, DOI 10.1097/MIB.0000000000000387; Froicu M, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-5; Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707; Geremia A, 2011, J EXP MED, V208, P1127, DOI 10.1084/jem.20101712; Glatzer T, 2013, IMMUNITY, V38, P1223, DOI 10.1016/j.immuni.2013.05.013; Goc J, 2016, INT IMMUNOL, V28, P43, DOI 10.1093/intimm/dxv056; Hanash AM, 2012, IMMUNITY, V37, P339, DOI 10.1016/j.immuni.2012.05.028; Hoorweg K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00072; Huber S, 2012, NATURE, V491, P259, DOI 10.1038/nature11535; Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668; Ito H, 2004, GASTROENTEROLOGY, V126, P989, DOI 10.1053/j.gastro.2004.01.012; Kabbani TCA, 2016, AM J GASTROENTEROL, V111, P712, DOI 10.1038/ajg.2016.53; Kirchberger S, 2013, J EXP MED, V210, P917, DOI 10.1084/jem.20122308; Klampfer L, 2014, WORLD J GASTRO ONCOL, V6, P430, DOI 10.4251/wjgo.v6.i11.430; Kongsbak M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00148; Kuhn KA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114195; Lee JS, 2015, IMMUNITY, V43, P727, DOI 10.1016/j.immuni.2015.09.003; Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034; Liu PT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005810; Liu WC, 2013, J CLIN INVEST, V123, P3983, DOI 10.1172/JCI65842; Marks DJB, 2006, LANCET, V367, P668, DOI 10.1016/S0140-6736(06)68265-2; Meeker S, 2016, WORLD J GASTROENTERO, V22, P933, DOI 10.3748/wjg.v22.i3.933; Mielke LA, 2013, J EXP MED, V210, P1117, DOI 10.1084/jem.20121588; Mortha A, 2014, SCIENCE, V343, P1477, DOI 10.1126/science.1249288; Neurath MF, 2014, MUCOSAL IMMUNOL, V7, P6, DOI 10.1038/mi.2013.73; O'Sullivan M, 2015, P NUTR SOC, V74, P5, DOI 10.1017/S0029665114001621; Ouyang XS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1311; Pearson C, 2016, ELIFE, V5, DOI 10.7554/eLife.10066; Qiu J, 2012, IMMUNITY, V36, P92, DOI 10.1016/j.immuni.2011.11.011; Ramagopalan SV, 2010, GENOME RES, V20, P1352, DOI 10.1101/gr.107920.110; Reinisch W, 2010, INFLAMM BOWEL DIS, V16, P233, DOI 10.1002/ibd.21038; Reynders A, 2011, EMBO J, V30, P2934, DOI 10.1038/emboj.2011.201; Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704; Sadeghian M, 2016, NUTRITION, V32, P505, DOI 10.1016/j.nut.2015.11.008; Sandborn WJ, 2012, NEW ENGL J MED, V367, P1519, DOI 10.1056/NEJMoa1203572; Sanos SL, 2009, NAT IMMUNOL, V10, P83, DOI 10.1038/ni.1684; Sawa S, 2011, NAT IMMUNOL, V12, P320, DOI 10.1038/ni.2002; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Simmons KM, 2015, J CELL BIOCHEM, V116, P1693, DOI 10.1002/jcb.25129; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Sonnenberg GF, 2015, NAT MED, V21, P698, DOI 10.1038/nm.3892; Spekhorst LM, 2015, EXPERT REV CLIN IMMU, V11, P33, DOI 10.1586/1744666X.2015.990439; Spencer SP, 2014, SCIENCE, V343, P432, DOI 10.1126/science.1247606; Sutton ALM, 2005, MOL ENDOCRINOL, V19, P2234, DOI 10.1210/me.2005-0081; Takeuchi A, 1998, J IMMUNOL, V160, P209; Tillack C, 2014, GUT, V63, P567, DOI 10.1136/gutjnl-2012-302853; Uhlig HH, 2006, IMMUNITY, V25, P309, DOI 10.1016/j.immuni.2006.05.017; Verway M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003407; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1; Wils P, 2016, CLIN GASTROENTEROL H, V14, P242, DOI 10.1016/j.cgh.2015.09.018; Wobke TK, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00244; Wu SP, 2015, GUT, V64, P1082, DOI 10.1136/gutjnl-2014-307436; Zhao PC, 2014, J LEUKOCYTE BIOL, V95, P521, DOI 10.1189/jlb.0613331	68	53	55	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					279	292		10.1016/j.jaci.2017.01.045	http://dx.doi.org/10.1016/j.jaci.2017.01.045			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28433688				2022-12-18	WOS:000419312200033
J	Kolsum, U; Damera, G; Pham, TH; Southworth, T; Mason, S; Karur, P; Newbold, P; Singh, D				Kolsum, Umme; Damera, Gautam; Pham, Tuyet-Hang; Southworth, Thomas; Mason, Sarah; Karur, Pradeep; Newbold, Paul; Singh, Dave			Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DENDRITIC CELLS; ASTHMA; HAPTOGLOBIN; AIRWAYS		[Kolsum, Umme; Southworth, Thomas; Mason, Sarah; Karur, Pradeep; Singh, Dave] Univ Manchester, Div Infect Immun & Resp Med, Sch Biol Sci, Fac Biol Med & Hlth,Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Kolsum, Umme; Southworth, Thomas; Mason, Sarah; Karur, Pradeep; Singh, Dave] Univ Hosp South Manchester NHS Fdn Trust, Manchester, Lancs, England; [Kolsum, Umme; Karur, Pradeep; Singh, Dave] Med Evaluat Unit, Manchester, Lancs, England; [Damera, Gautam; Pham, Tuyet-Hang; Newbold, Paul] MedImmune LLC, Translat Med Resp Inflammat, Autoimmun, Gaithersburg, MD USA	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; AstraZeneca; Medimmune	Kolsum, U (corresponding author), Univ Manchester, Div Infect Immun & Resp Med, Sch Biol Sci, Fac Biol Med & Hlth,Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.; Kolsum, U (corresponding author), Univ Hosp South Manchester NHS Fdn Trust, Manchester, Lancs, England.; Kolsum, U (corresponding author), Med Evaluat Unit, Manchester, Lancs, England.	ukolsum@meu.org.uk	Singh, Dave/AAH-4342-2020	Singh, Dave/0000-0001-8918-7075; Southworth, Thomas/0000-0002-8127-565X	Almirall; AstraZeneca; Boehringer Ingleheim; Chiesi; Glenmark; Merck; NAPP; Novartis; Pfizer; Teva; Therevance; Verona; Genentech; Skyepharma; GlaxoSmithKline; Takeda	Almirall(Almirall); AstraZeneca(AstraZeneca); Boehringer Ingleheim; Chiesi(Chiesi Pharmaceuticals Inc); Glenmark; Merck(Merck & Company); NAPP; Novartis(Novartis); Pfizer(Pfizer); Teva(Teva Pharmaceutical Industries); Therevance; Verona; Genentech(Roche HoldingGenentech); Skyepharma; GlaxoSmithKline(GlaxoSmithKline); Takeda(Takeda Pharmaceutical Company Ltd)	G. Damera, T.-H. Pham, and P. Newbold are employed by and have stock options with MedImmune. D. Singh's institute has received a grant from Medimune. D. Singh has received consultancy fees from Almirall, AstraZeneca, Boehringer Ingleheim, Chiesi, Glenmark, Merck, NAPP, Novartis, Pfizer, Teva, Therevance, Verona, Genentech, and Skyepharma; has received grants from Almirall, AstraZeneca, Boehringer Ingleheim, Chiesi, GlaxoSmithKline, Glenmark, Merck, NAPP, Novartis, Pfizer, Takeda, Teva, Therevance, and Verona; and has received payment for lectures from AstraZeneca, Boehringer Ingleheim, Chiesi, GlaxoSmithKline, Glenmark, Merck, NAPP, Novartis, Pfizer, Takeda, Teva, Therevance, Verona, Skyepharma, and Genentech. The rest of the authors declare that they have no relevant conflicts of interest.	Bateman ED, 2015, LANCET RESP MED, V3, P719, DOI 10.1016/S2213-2600(15)00254-4; Belda J, 2000, AM J RESP CRIT CARE, V161, P475, DOI 10.1164/ajrccm.161.2.9903097; Brightling CE, 2014, LANCET RESP MED, V2, P891, DOI 10.1016/S2213-2600(14)70187-0; Christenson SA, 2015, AM J RESP CRIT CARE, V191, P758, DOI 10.1164/rccm.201408-1458OC; Demedts IK, 2007, AM J RESP CRIT CARE, V175, P998, DOI 10.1164/rccm.200608-1113OC; Dobryszycka W, 1997, EUR J CLIN CHEM CLIN, V35, P647; Eltboli O, 2015, RESPIROLOGY, V20, P667, DOI 10.1111/resp.12475; Goswami S, 2009, NAT IMMUNOL, V10, P496, DOI 10.1038/ni.1719; Gueders MM, 2006, EUR J PHARMACOL, V533, P133, DOI 10.1016/j.ejphar.2005.12.082; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Mesnil C, 2016, J CLIN INVEST, V126, P3279, DOI 10.1172/JCI85664; Siddiqui SH, 2015, AM J RESP CRIT CARE, V192, P523, DOI 10.1164/rccm.201502-0235LE; Singh D, 2016, AM J RESP CRIT CARE, V194, P541, DOI 10.1164/rccm.201606-1179PP; Sullivan P, 1998, EUR RESPIR J, V12, P811, DOI 10.1183/09031936.98.12040811; Tomasi VH, 2008, BIOTECH HISTOCHEM, V83, P147, DOI 10.1080/10520290802352424; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Watz H, 2016, LANCET RESP MED, V4, P390, DOI 10.1016/S2213-2600(16)00100-4; Yang FM, 2000, AM J RESP CELL MOL, V23, P277, DOI 10.1165/ajrcmb.23.3.4069	18	53	59	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1181	+		10.1016/j.jaci.2017.04.027	http://dx.doi.org/10.1016/j.jaci.2017.04.027			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28506852	Green Submitted, Bronze			2022-12-18	WOS:000412172900039
J	Feeney, M; Du Toit, G; Roberts, G; Sayre, PH; Lawson, K; Bahnson, HT; Sever, ML; Radulovic, S; Plaut, M; Lack, G				Feeney, Mary; Du Toit, George; Roberts, Graham; Sayre, Peter H.; Lawson, Kaitie; Bahnson, Henry T.; Sever, Michelle L.; Radulovic, Suzana; Plaut, Marshall; Lack, Gideon		Immune Tolerance Network Leap Stu	Impact of peanut consumption in the LEAP Study: Feasibility, growth, and nutrition	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; allergy prevention; peanut; infant feeding; breast-feeding; nutrition; growth; prospective food diary; protein homeostasis	HIGH-RISK INFANTS; CONSENSUS COMMUNICATION; ALLERGY; CHILDREN; ADOLESCENTS; PREVENTION; PREVALENCE; ACCEPTANCE; CHILDHOOD; FRUIT	Background: Early introduction of peanut is an effective strategy to prevent peanut allergy in high-risk infants; however, feasibility and effects on growth and nutritional intake are unknown. Objective: We sought to evaluate the feasibility of introducing peanut in infancy and explore effects on growth and nutritional intake up to age 60 months. Methods: In the Learning Early About Peanut Allergy trial, 640 atopic infants aged 4 to 11 months were randomly assigned to consume (6 g peanut protein per week) or avoid peanut until age 60 months. Peanut consumption and early feeding practices were assessed by questionnaire. Dietary intake was evaluated with prospective food diaries. Anthropometric measurements were taken at all study visits. Results: Peanut was successfully introduced and consumed until 60 months, with median peanut protein intake of 7.5 g/wk (interquartile range, 6.0-9.0 g/wk) in the consumption group compared with 0 g in the avoidance group. Introduction of peanut in breast-feeding infants did not affect the duration of breast-feeding. There were no differences in anthropometric measurements or energy intakes between groups at any visits. Regular peanut consumption led to differences in dietary intakes. Consumers had higher intakes of fat and avoiders had higher carbohydrate intakes; differences were greatest at the upper quartiles of peanut consumption. Protein intakes remained consistent between groups. Conclusions: Introduction of peanut proved feasible in infants at high risk of peanut allergy and did not affect the duration of breast-feeding nor impact negatively on growth or nutrition. Energy balance was achieved in both groups through variations in intakes from fat and carbohydrate while protein homeostasis was maintained.	[Feeney, Mary; Du Toit, George; Radulovic, Suzana; Lack, Gideon] Kings Coll London, Dept Pediat Allergy, Div Asthma Allergy & Lung Biol, London, England; [Feeney, Mary; Du Toit, George; Roberts, Graham; Radulovic, Suzana; Lack, Gideon] Guys & St Thomas NHS Fdn Trust, London, England; [Roberts, Graham] Univ Southampton, Southampton, Hants, England; [Roberts, Graham] Natl Inst Hlth, Res Resp Biomed Res Unit, Southampton, Hants, England; [Roberts, Graham] David Hide Ctr, Isle Of Wight, England; [Sayre, Peter H.] Immune Tolerance Network, San Francisco, CA USA; [Sayre, Peter H.] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA USA; [Lawson, Kaitie; Bahnson, Henry T.; Sever, Michelle L.] Rho Fed Syst Div, Chapel Hill, NC USA; [Plaut, Marshall] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of Southampton; Immune Tolerance Network; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lack, G (corresponding author), Guys & St Thomas NHS Fdn Trust, Childrens Allergy Unit, 2nd Fl,South Wing,Westminster Bridge Rd, London SE1 7EH, England.	gideon.lack@kcl.ac.uk		Du Toit, George/0000-0002-0321-2928; Lack, Gideon/0000-0001-7350-4021; Roberts, Graham/0000-0003-2252-1248	National Institute of Allergy and Infectious Diseases [UM1AI109565, NO1-AI-15416, HHSN272200800029C]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Food Allergy Research & Education (FARE), McLean, Virginia; Medical Research Council & Asthma UK Centre; UK Department of Health through the National Institute for Health Research comprehensive Biomedical Research Centre award; King's College London; King's College Hospital NHS Foundation Trust; National Peanut Board, Atlanta, Georgia; UK Food Standards Agency; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM2AI117870, UM1AI109565, N01AI015416] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy Research & Education (FARE), McLean, Virginia; Medical Research Council & Asthma UK Centre; UK Department of Health through the National Institute for Health Research comprehensive Biomedical Research Centre award; King's College London; King's College Hospital NHS Foundation Trust; National Peanut Board, Atlanta, Georgia; UK Food Standards Agency; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was funded by the National Institute of Allergy and Infectious Diseases (award nos. UM1AI109565, NO1-AI-15416, and HHSN272200800029C) and others. This research was performed as a project of the Immune Tolerance Network, an international clinical research consortium headquartered at the Benaroya Research Institute and supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional support came from Food Allergy Research & Education (FARE), McLean, Virginia; the Medical Research Council & Asthma UK Centre; the UK Department of Health through the National Institute for Health Research comprehensive Biomedical Research Centre award to Guy's & St Thomas' National Health Service (NHS) Foundation Trust, in partnership with King's College London and King's College Hospital NHS Foundation Trust. The clinical trials unit is supported by the National Peanut Board, Atlanta, Georgia. The UK Food Standards Agency provided additional support for the costs of phlebotomy.	[Anonymous], 2005, DIET REF INT EN CARB; Balolia Y, 2010, CARBS AND CALS; Christie L, 2002, J AM DIET ASSOC, V102, P1648, DOI 10.1016/S0002-8223(02)90351-2; Cooke LJ, 2004, PUBLIC HEALTH NUTR, V7, P295, DOI 10.1079/PHN2003527; Crawley H, 2002, FOOD STANDARDS AGENC; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Emmett P, 2009, PAEDIATR PERINAT EP, V23, P154, DOI 10.1111/j.1365-3016.2009.01015.x; Fleischer DM, 2016, PEDIATR DERMATOL, V33, P102, DOI 10.1111/pde.12685; Fleischer DM, 2015, PEDIATRICS, V136, P600, DOI 10.1542/peds.2015-2394; Forestell CA, 2007, PEDIATRICS, V120, P1247, DOI 10.1542/peds.2007-0858; Gardner HG, 2010, PEDIATRICS, V125, P601, DOI 10.1542/peds.2009-2862; Griel AE, 2004, J AM COLL NUTR, V23, P660, DOI 10.1080/07315724.2004.10719408; Griffioen-Roose S, 2012, AM J CLIN NUTR, V95, P32, DOI 10.3945/ajcn.111.020503; Grummer-Strawn LM, 2008, PEDIATRICS, V122, pS36, DOI 10.1542/peds.2008-1315d; Hornell A, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e38; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; JACKSON DA, 1992, BRIT J NUTR, V67, P149, DOI 10.1079/BJN19920019; Johnson L, 2008, AM J CLIN NUTR, V87, P846, DOI 10.1093/ajcn/87.4.846; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Livingstone MBE, 2004, BRIT J NUTR, V92, pS213, DOI 10.1079/BJN20041169; Maier A, 2007, FOOD QUAL PREFER, V18, P1023, DOI 10.1016/j.foodqual.2007.04.005; McAndrew F, 2012, INFANT FEEDING SURVE; Meyer R, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-31; Moreno JP, 2013, NUTR RES, V33, P552, DOI 10.1016/j.nutres.2013.05.005; Nelson M, 1997, PHOTOGRAPHIC ATLAS F; Noimark L, 2008, PEDIAT ALLERG IMM-UK, V19, P188, DOI 10.1111/j.1399-3038.2007.00700.x; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; [Public Health England Food Standards Agency], 2014, NAT DIET NUTR SURV H; Scientifc Advisory Committee on Nutrition, 2015, CARB HLTH; Scientific Advisory Committee on Nutrition, 2003, SALT HLTH; Sofianou-Katsoulis A, 2011, WORLD ALLERGY ORGAN, V4, P38, DOI 10.1097/WOX.0b013e318205ab27; The Caroline Walker Trust, 2010, EAT WELL 1 4 YEAR OL; The Caroline Walker Trust, 2010, EAT WELL 5 11 YEAR O; US Department of Agriculture and US Department of Health and Human Services, 2010, DIET GUID AM 2010; [Whitehead RG Panel on Dietary Reference Values Great Britain Department of Health Working Party on the Composition of Foods for Infants and Young Children], 1991, WORKING PARTY COMPOS; WHO Multicentre Growth Reference Study Group, 2006, WHO CHILD GROWTH STA; World Health Organization, 2009, INF YOUNG CHILD FEED; Wrieden WL, 2008, BRIT J NUTR, V99, P1344, DOI 10.1017/S0007114507868516	41	53	60	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1108	1118		10.1016/j.jaci.2016.04.016	http://dx.doi.org/10.1016/j.jaci.2016.04.016			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27297994	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000385499400016
J	Turner, S; Francis, B; Vijverberg, S; Pino-Yanes, M; Maitland-van der Zee, AH; Basu, K; Bignell, L; Mukhopadhyay, S; Tavendale, R; Palmer, C; Hawcutt, D; Pirmohamed, M; Burchard, EG; Lipworth, B				Turner, Steve; Francis, Ben; Vijverberg, Susanne; Pino-Yanes, Maria; Maitland-van der Zee, Anke H.; Basu, Kaninika; Bignell, Lauren; Mukhopadhyay, Somnath; Tavendale, Roger; Palmer, Colin; Hawcutt, Daniel; Pirmohamed, Munir; Burchard, Esteban G.; Lipworth, Brian		Pharmacogenomics Childhood Asthma	Childhood asthma exacerbations and the Arg16 beta(2)-receptor polymorphism: A meta-analysis stratified by treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adrenergic receptors; asthma; child; disease exacerbation; therapeutics	BETA(2)-ADRENERGIC RECEPTOR POLYMORPHISMS; GENOME-WIDE ASSOCIATION; BRONCHOPROTECTIVE SUBSENSITIVITY; GENETIC POLYMORPHISMS; RECEIVING SALMETEROL; COMBINATION THERAPY; BETA-AGONISTS; PACMAN COHORT; ADRB2 GENE; CHILDREN	Background: The Gly-to-Arg substitution at the 16 position (rs1042713) in the beta(2)-adrenoceptor gene (ADRB2) is associated with enhanced downregulation and uncoupling of beta(2)-receptors. Objectives: We sought to undertake a meta-analysis to test the hypothesis that there is an interaction between the A allele of rs1042713 (Arg16 amino acid) and long-acting beta-agonist (LABA) exposure for asthma exacerbations in children. Methods: Children with diagnosed asthma were recruited in 5 populations (BREATHE, Genes-Environments and Admixture in Latino Americans II, PACMAN, the Paediatric Asthma Gene Environment Study, and the Pharmacogenetics of Adrenal Suppression with Inhaled Steroid Study). A history of recent exacerbation and asthma treatment was determined from questionnaire data. DNA was extracted, and the Gly16Arg genotype was determined. Results: Data from4226 children of white Northern European and Latino origin were analyzed, and the odds ratio for exacerbation increased by 1.52 (95% CI, 1.17-1.99; P = .0021) for each copy of the A allele among the 637 children treated with inhaled corticosteroids (ICSs) plus LABAs but not for treatment with ICSs alone (n = 1758) or ICSs plus leukotriene receptor antagonist (LTRAs; n 5 354) or ICSs plus LABAs plus LTRAs (n = 569). Conclusions: The use of a LABA but not an LTRA as an "addon controller'' is associated with increased risk of asthma exacerbation in children carrying 1 or 2 A alleles at rs1042713. Prospective genotype-stratified clinical trials are now required to explore the potential role of rs1042713 genotyping for personalized asthma therapy in children.	[Turner, Steve] Univ Aberdeen, Child Hlth, Aberdeen, Scotland; [Francis, Ben] Univ Liverpool, Dept Biostat, Liverpool, Merseyside, England; [Vijverberg, Susanne; Maitland-van der Zee, Anke H.] Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [Pino-Yanes, Maria] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain; [Pino-Yanes, Maria] Hosp Univ NS Candelaria, Res Unit, Santa Cruz De Tenerife, Brazil; [Basu, Kaninika; Bignell, Lauren; Mukhopadhyay, Somnath] Royal Alexandra Hosp Children, Acad Dept Paediat, Brighton, E Sussex, England; [Basu, Kaninika; Bignell, Lauren; Mukhopadhyay, Somnath] Sussex Med Sch, Brighton, E Sussex, England; [Tavendale, Roger; Palmer, Colin] Univ Dundee, Populat Pharmacogenet Grp, Dundee, Scotland; [Lipworth, Brian] Univ Dundee, Asthma & Allergy Res Grp, Dundee, Scotland; [Hawcutt, Daniel] Univ Liverpool, Inst Translat Med, Dept Womens & Childrens Hlth, Liverpool, Merseyside, England; [Pirmohamed, Munir] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England; [Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci & Med, San Francisco, CA USA; [Burchard, Esteban G.] Univ Calif San Francisco, Ctr Genes Environm & Hlth, San Francisco, CA USA	University of Aberdeen; University of Liverpool; Utrecht University; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; University of Brighton; University of Brighton; University of Dundee; University of Dundee; University of Liverpool; University of Liverpool; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Turner, S (corresponding author), Royal Aberdeen Childrens Hosp, Child Hlth, Aberdeen AB25 2ZG, Scotland.	s.w.turner@abdn.ac.uk	Pirmohamed, Munir/H-6004-2011; Palmer, Colin NA/C-7053-2008; Pino-Yanes, Maria/C-8498-2017	Pirmohamed, Munir/0000-0002-7534-7266; Palmer, Colin NA/0000-0002-6415-6560; Pino-Yanes, Maria/0000-0003-0332-437X; Hawcutt, Dan/0000-0002-8120-6507; Vijverberg, Susanne/0000-0002-4579-4081; Francis, Ben/0000-0002-2130-5976	Scottish Enterprise Tayside; Gannochy Trust; Perth and Kinross City Council; Brighton and Sussex Medical School; National Institutes of Health; National Heart, Lung, and Blood Institute [HL088133, HL078885, HL004464, HL104608, HL117004]; National Institute of Environmental Health Sciences [ES015794]; National Institute on Minority Health and Health Disparities [MD006902]; National Institute of General Medical Sciences [GM007546]; American Asthma Foundation; RWJF Amos Medical Faculty Development Award; Sandler Foundation; Flight Attendant Medical Research Institute; Fundacion Ramon Areces; GlaxoSmithKline; Utrecht Institute for Pharmaceutical Sciences; Chief Scientist Officer for Scotland; UK Department of Health through the NHS Chair of Pharmacogenomics; Medical Research Council [G0700654] Funding Source: researchfish; National Institute for Health Research [NF-SI-0512-10064] Funding Source: researchfish; Chief Scientist Office [CZH/4/418] Funding Source: researchfish; MRC [G0700654] Funding Source: UKRI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078885, K23HL004464, R01HL088133, R01HL104608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [P60MD006902] Funding Source: NIH RePORTER	Scottish Enterprise Tayside; Gannochy Trust; Perth and Kinross City Council; Brighton and Sussex Medical School; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); American Asthma Foundation; RWJF Amos Medical Faculty Development Award; Sandler Foundation; Flight Attendant Medical Research Institute; Fundacion Ramon Areces; GlaxoSmithKline(GlaxoSmithKline); Utrecht Institute for Pharmaceutical Sciences; Chief Scientist Officer for Scotland; UK Department of Health through the NHS Chair of Pharmacogenomics; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Chief Scientist Office; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	Individual cohorts were funded as follows: BREATHE was funded by Scottish Enterprise Tayside, the Gannochy Trust, the Perth and Kinross City Council, and Brighton and Sussex Medical School. The contribution from GALA II to this work was supported by grants from the National Institutes of Health to E.G.B.: the National Heart, Lung, and Blood Institute (HL088133, HL078885, HL004464, HL104608, and HL117004); the National Institute of Environmental Health Sciences (ES015794); the National Institute on Minority Health and Health Disparities (MD006902); and the National Institute of General Medical Sciences (GM007546). E.G.B. was also funded by the American Asthma Foundation, the RWJF Amos Medical Faculty Development Award, the Sandler Foundation, and the Flight Attendant Medical Research Institute. M.P.-Y. was supported by a postdoctoral fellowship from Fundacion Ramon Areces (www.fundacionareces.es). PACMAN was funded by a strategic alliance between GlaxoSmithKline and the Utrecht Institute for Pharmaceutical Sciences. The Paediatric Asthma Gene Environment Study was funded by the Chief Scientist Officer for Scotland. The Pharmacogenetics of Adrenal Suppression with Inhaled Steroid Study was funded by the UK Department of Health through the NHS Chair of Pharmacogenomics.	Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109; Basu K, 2009, J ALLERGY CLIN IMMUN, V124, P1188, DOI 10.1016/j.jaci.2009.07.043; Bleecker ER, 2007, LANCET, V370, P2118, DOI 10.1016/S0140-6736(07)61906-0; Bleecker ER, 2010, AM J RESP CRIT CARE, V181, P676, DOI [10.1164/rccm.200809-1511OC, 10.1164/200809-1511OC]; British Thoracic Society Scottish Intercollegiate Guidelines Network, BRIT GUID MAN ASTHM; Carroll CL, 2012, J ASTHMA, V49, P563, DOI 10.3109/02770903.2012.701362; Carroll CL, 2012, PEDIATR PULM, V47, P233, DOI 10.1002/ppul.21544; Carroll CL, 2009, CHEST, V135, P1186, DOI 10.1378/chest.08-2041; Choudhry S, 2005, AM J RESP CRIT CARE, V171, P563, DOI 10.1164/rccm.200409-1286OC; Currie GP, 2003, AM J RESP CRIT CARE, V167, P1232, DOI 10.1164/rccm.200209-1116OC; Finkelstein Y, 2009, J ASTHMA, V46, P900, DOI 10.3109/02770900903199961; Galanter JM, 2014, J ALLERGY CLIN IMMUN, V134, P295, DOI 10.1016/j.jaci.2013.08.055; Giubergia V, 2013, ANN ALLERG ASTHMA IM, V110, P156, DOI 10.1016/j.anai.2012.12.018; Global Initiative for Asthma, POCK GUID ASTHM MAN; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; Hall IP, 2005, THORAX, V60, P357, DOI 10.1136/thx.2005.040790; Hawcutt DB, 2015, CLIN ENDOCRINOL, V82, P648, DOI 10.1111/cen.12655; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Kim SH, 2011, J CLIN PHARM THER, V36, P399, DOI 10.1111/j.1365-2710.2010.01196.x; Koster ES, 2009, PHARMACOGENOMICS, V10, P1351, DOI [10.2217/pgs.09.79, 10.2217/PGS.09.79]; Lee DKC, 2004, BRIT J CLIN PHARMACO, V57, P68, DOI 10.1046/j.1365-2125.2003.01955.x; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Lenney W, 1997, PEDIATR PULM, P13; Lima JJ, 1999, CLIN PHARMACOL THER, V65, P519, DOI 10.1016/S0009-9236(99)70071-8; Lipworth B, 2013, AM J RESP CRIT CARE, V188, P1386, DOI 10.1164/rccm.201311-1968ED; Lipworth BJ, 2013, CLIN SCI, V124, P521, DOI 10.1042/CS20120528; Lozano P, 1997, PEDIATRICS, V99, P757, DOI 10.1542/peds.99.6.757; Magi R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-288; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; Nishimura KK, 2013, AM J RESP CRIT CARE, V188, P309, DOI 10.1164/rccm.201302-0264OC; Ortega VE, 2014, LANCET RESP MED, V2, P204, DOI 10.1016/S2213-2600(13)70289-3; Ortega VE, 2014, J ALLERGY CLIN IMMUN, V133, P16, DOI 10.1016/j.jaci.2013.10.040; Palmer CNA, 2006, THORAX, V61, P940, DOI 10.1136/thx.2006.059386; Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149; Silverman EK, 2003, J ALLERGY CLIN IMMUN, V112, P870, DOI 10.1016/S0091-6749(03)02023-2; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; Turner S, 2009, ARCH DIS CHILD, V94, P16, DOI 10.1136/adc.2008.140681; Turner SW, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-107; Turner SW, 2009, MOL DIAGN THER, V13, P127, DOI 10.2165/01250444-200913020-00006; Turner SW, 2004, CLIN EXP ALLERGY, V34, P1043, DOI 10.1111/j.1365-2222.2004.02001.x; Vaessen-Verberne AAPH, 2010, AM J RESP CRIT CARE, V182, P1221, DOI 10.1164/rccm.201002-0193OC; Vijverberg SJH, 2015, CLIN EXP ALLERGY, V45, P1051, DOI 10.1111/cea.12492; Wang Li Yan, 2005, Prev Chronic Dis, V2, pA11; Wechsler ME, 2009, LANCET, V374, P1754, DOI 10.1016/S0140-6736(09)61492-6; Zuurhout MJL, 2013, PHARMACOGENOMICS, V14, P1965, DOI [10.2217/PGS.13.200, 10.2217/pgs.13.200]	47	53	55	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					107	+		10.1016/j.jaci.2015.10.045	http://dx.doi.org/10.1016/j.jaci.2015.10.045			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26774659	Green Accepted, Bronze, Green Submitted			2022-12-18	WOS:000379659100012
J	Hamilos, DL				Hamilos, Daniel L.			Drivers of chronic rhinosinusitis: Inflammation versus infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; nasal polyposis; T(H)2 inflammation; innate; adaptive	THYMIC STROMAL LYMPHOPOIETIN; NASAL POLYPS; EOSINOPHILIC INFLAMMATION; IMMUNE-RESPONSE; EXPRESSION; MODEL; INTERLEUKIN-33; SUPERANTIGENS; LACTOFERRIN; SINUSITIS	Studies of the underlying cause or causes of chronic rhinosinusitis (CRS) over the past 20 or more years have expanded from a focus on systemic immune and allergic mechanisms to an intense search for the underlying drivers of mucosal inflammation. These drivers involve mucosal inflammatory pathways that become activated by allergens, microbial stimuli, or poorly understood exogenous or endogenous stimuli. The holy grail in the study of CRS is to identify specific drivers of mucosal inflammation and translate these into more effective treatment for CRS. Certain deficiencies in local innate immunity have been described in patients with CRS that predispose to increased sinus mucosal bacterial colonization/infection, including deficient local production of antimicrobial lactoferrin and deficient functioning of the bitter taste receptor TAS2R38. Conversely, certain innate factors, namely IL-25, IL-33, and thymic stromal lymphopoietin (TSLP), are elaborated by sinus epithelial cells in response to microbial stimulation or airway injury and promote local T(H)2 inflammation. The precise physiologic role of these factors in innate or adaptive immunity is unclear, although IL-33 might function as an alarmin triggered by damage-associated molecular patterns. The cytokines IL-25 and TSLP, similarly promote proinflammatory tissue responses. Another feature of epithelial dysregulation in patients with CRS is overproduction of eosinophil-promoting C-C chemokines by sinus epithelium, perhaps driven in part through innate stimuli, as well as T(H)2 cytokines, such as IL-13. Strategies to reduce the microbial stimulation of maladaptive T(H)2 inflammation or to suppress the local elaboration of T(H)2-promoting epithelial factors, such as IL-33, have potential therapeutic benefit in patients with CRS, although the extent to which this is realized in patient care remains limited at present. This rostrum will summarize my views on the major microbial drivers of mucosal inflammation and dysregulation of innate T(H)2-promoting factors in patients with CRS based on recent experimental data.	[Hamilos, Daniel L.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Hamilos, DL (corresponding author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Bullfinch 422,55 Fruit St, Boston, MA 02114 USA.	dhamilos@partners.org			Sanofi; Regeneron; Merck	Sanofi; Regeneron(Regeneron); Merck(Merck & Company)	D. L. Hamilos has received consultancy fees from Sanofi and Regeneron; has received research support from Merck; and receives royalties from UpToDate.	Abreu NA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003783; Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; BAROODY FM, 1995, ARCH OTOLARYNGOL, V121, P1396; Bartemes KR, 2012, CLIN IMMUNOL, V143, P222, DOI 10.1016/j.clim.2012.03.001; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bernstein JM, 2003, AM J RHINOL, V17, P321, DOI 10.1177/194589240301700601; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Boita M, 2015, INNATE IMMUN-LONDON, V21, P167, DOI 10.1177/1753425914523460; Cantero D, 2013, INT FORUM ALLERGY RH, V3, P556, DOI 10.1002/alr.21146; Conley DB, 2006, AM J RHINOL, V20, P534, DOI 10.2500/ajr.2006.20.2941; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Ha KR, 2007, AM J RHINOL, V21, P339, DOI 10.2500/ajr.2007.21.3032; Hamilos DL, 2014, J ALLERGY CLIN IMMUN, V133, P640, DOI 10.1016/j.jaci.2013.06.049; Hamilos DL, 2011, J ALLERGY CLIN IMMUN, V128, P693, DOI 10.1016/j.jaci.2011.08.004; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Jardeleza C, 2013, INT FORUM ALLERGY RH, V3, P193, DOI 10.1002/alr.21114; Kato A, 2015, ALLERGOL INT, V64, P121, DOI 10.1016/j.alit.2014.12.006; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Lam M, 2015, AM J RHINOL ALLERGY, V29, P175, DOI 10.2500/ajra.2015.29.4176; Lee RJ, 2012, J CLIN INVEST, V122, P4145, DOI 10.1172/JCI64240; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Mfuna-Endam L, 2011, CURR ALLERGY ASTHM R, V11, P236, DOI 10.1007/s11882-011-0189-4; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Okano M, 2011, CLIN EXP ALLERGY, V41, P171, DOI 10.1111/j.1365-2222.2010.03584.x; Orlandi RR, 2009, OTOLARYNG HEAD NECK, V141, P750, DOI 10.1016/j.otohns.2009.09.016; Ouyang YH, 2013, ORL J OTO-RHINO-LARY, V75, P37, DOI 10.1159/000346929; Paris G, 2014, INT FORUM ALLERGY RH, V4, P15, DOI 10.1002/alr.21237; Patou J, 2008, J ALLERGY CLIN IMMUN, V121, P110, DOI 10.1016/j.jaci.2007.08.059; Perloff JR, 2005, AM J RHINOL, V19, P1; Peters AT, 2014, ANN ALLERG ASTHMA IM, V113, P347, DOI 10.1016/j.anai.2014.07.025; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; Psaltis AJ, 2008, LARYNGOSCOPE, V118, P895, DOI 10.1097/MLG.0b013e31816381d4; Psaltis AJ, 2007, LARYNGOSCOPE, V117, P2030, DOI 10.1097/MLG.0b013e31812e01ab; Ramanathan M, 2008, AM J RHINOL, V22, P115, DOI 10.2500/ajr.2008.22.3136; Reh DD, 2010, AM J RHINOL ALLERGY, V24, P105, DOI 10.2500/ajra.2010.24.3446; Schittek B, 2011, CURR PROBL DERMATOL, V41, P54, DOI 10.1159/000323296; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Tantilipikorn P, 2012, ASIAN PAC J ALLERGY, V30, P171; Tripathi A, 2005, AM J RHINOL, V19, P327, DOI 10.1177/194589240501900401; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Wilson MT, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0485-x; Zariwala MA, 2007, ANNU REV PHYSIOL, V69, P423, DOI 10.1146/annurev.physiol.69.040705.141301; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	46	53	53	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1454	1459		10.1016/j.jaci.2015.10.011	http://dx.doi.org/10.1016/j.jaci.2015.10.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26654194	Bronze			2022-12-18	WOS:000366044300003
J	Stuck, BA; Hummel, T				Stuck, Boris A.; Hummel, Thomas			Olfaction in allergic rhinitis: A systematic review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Allergy; rhinitis; smell; olfaction; hyposmia; anosmia	QUALITY-OF-LIFE; FUROATE NASAL SPRAY; NONALLERGIC RHINITIS; SUBLINGUAL IMMUNOTHERAPY; INTRANASAL STEROIDS; MOMETASONE FUROATE; SMELL DYSFUNCTION; ACOUSTIC RHINOMETRY; ODOR DISCRIMINATION; CLEFT INFLAMMATION	Olfactory dysfunction is a key symptom in patients with allergic rhinitis (AR). Despite the implications for quality of life, relatively few articles have tested olfactory function in their investigations. The current systematic review aimed to investigate the following 2 questions: (1) What does AR do to human olfaction? (2) How effective is the treatment of AR in restoring the sense of smell? A comprehensive literature search was performed, and human studies of any design were included. A total of 420 articles were identified, and 36 articles were considered relevant. Data indicate that the frequency of olfactory dysfunction increases with the duration of the disorder, and most studies report a frequency in the range of 20% to 40%. Although olfactory dysfunction does not appear to be very severe in patients with AR, its presence seems to increase with the severity of the disease. There is very limited evidence that antihistamines improve olfactory function. In addition, there is limited evidence that topical steroids improve the sense of smell, especially in patients with seasonal AR. This is also the case for specific immunotherapy. However, many questions remain unanswered because randomized controlled trials are infrequent and only a few studies rely on quantitative measurement of olfactory function.	[Stuck, Boris A.] Univ Hosp Essen, Dept Otorhinolaryngol Head & Neck Surg, D-45147 Essen, Germany; [Hummel, Thomas] Tech Univ Dresden, Dept Otorhinolaryngol Head & Neck Surg, Dresden, Germany	University of Duisburg Essen; Technische Universitat Dresden	Stuck, BA (corresponding author), Univ Hosp Essen, Dept Otorhinolaryngol Head & Neck Surg, Hufelandstr 55, D-45147 Essen, Germany.	boris.stuck@uk-essen.de			MedaPharm GmbH	MedaPharm GmbH	B. A. Stuck has received research support from MedaPharm GmbH. T. Hummel declares that he has no relevant conflicts of interest.	Apter AJ, 1999, ARCH OTOLARYNGOL, V125, P1005, DOI 10.1001/archotol.125.9.1005; APTER AJ, 1995, ANN ALLERG ASTHMA IM, V75, P311; APTER AJ, 1992, J ALLERGY CLIN IMMUN, V90, P670, DOI 10.1016/0091-6749(92)90141-N; Ashequr RM, 2005, INT IMMUNOPHARMACOL, V5, P1741, DOI 10.1016/j.intimp.2005.06.001; Bachert C, 1998, ALLERGOLOGIE, V21, pS17; Bachert C, 2002, ALLERGY, V57, P1208; Becker S, 2012, ACTA OTO-LARYNGOL, V132, P763, DOI 10.3109/00016489.2012.656764; BENDE M, 1995, CHEM SENSES, V20, P99; BENNINGER MS, 1992, AM J RHINOL, V6, P37, DOI 10.2500/105065892781874829; BINDER E, 1982, ALLERGY, V37, P389, DOI 10.1111/j.1398-9995.1982.tb02317.x; Blaiss M, 2004, CLIN THER, V26, P1876, DOI 10.1016/j.clinthera.2004.11.003; Borish L, 2002, ANN ALLERG ASTHMA IM, V88, P16, DOI 10.1016/S1081-1206(10)62024-8; CAIN WS, 1983, AM J OTOLARYNG, V4, P252, DOI 10.1016/S0196-0709(83)80068-4; Cardesin A, 2006, RHINOLOGY, V44, P83; Catana I, 2010, ALLERGY, V65, P719; Chaiyasate Saisawat, 2009, Journal of the Medical Association of Thailand, V92, P377; Chang H, 2009, CLIN EXP OTORHINOLAR, V2, P136, DOI 10.3342/ceo.2009.2.3.136; COWART BJ, 1993, J ALLERGY CLIN IMMUN, V91, P747, DOI 10.1016/0091-6749(93)90194-K; Croy I, 2014, CHEM SENSES, V39, P185, DOI 10.1093/chemse/bjt072; Di Lorenzo G, 2011, INT ARCH ALLERGY IMM, V155, P263, DOI 10.1159/000320050; Doty RL, 2001, LARYNGOSCOPE, V111, P409, DOI 10.1097/00005537-200103000-00008; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; DRUCE HM, 1995, ANN ALLERG ASTHMA IM, V75, P291; Eggers G, 1997, ALLERGOLOGIE, V20, P526; Elsberg CA, 1953, B NEUROL I N Y, V4, P5; FEIN BT, 1966, ANN ALLERGY, V24, P278; GAMBARDELLA R, 1993, J INT MED RES, V21, P268, DOI 10.1177/030006059302100505; Guilemany J, 2008, ALLERGY, V63, P72; Guilemany JM, 2009, LARYNGOSCOPE, V119, P233, DOI 10.1002/lary.20075; Guss J, 2009, ORL-J OTO-RHIN-LARYN, V71, P268, DOI 10.1159/000242429; HAGUENAUER JP, 1981, REV FR ALLERGOL, V21, P167, DOI 10.1016/S0335-7457(81)80039-1; Hellings PW, 2009, B-ENT, P71; Henkin RI, 2013, AM J OTOLARYNG, V34, P477, DOI 10.1016/j.amjoto.2013.04.006; Henkin RI, 2012, ARCH OTOLARYNGOL, V138, P1064, DOI 10.1001/2013.jamaoto.342; Higaki T, 2012, ANN ALLERG ASTHMA IM, V109, P458, DOI 10.1016/j.anai.2012.08.016; Hilberg O, 2002, ALLERGY, V57, P5, DOI 10.1046/j.0908-665x.2001.all.doc.x; HILBERG O, 1995, ALLERGY, V50, P683, DOI 10.1111/j.1398-9995.1995.tb02586.x; Hinriksdottir I, 1997, ORL J OTO-RHINO-LARY, V59, P36, DOI 10.1159/000276902; Hu KH, 2007, P ANN INT IEEE EMBS, P1479, DOI 10.1109/IEMBS.2007.4352580; Hummel T, 1997, CHEM SENSES, V22, P39, DOI 10.1093/chemse/22.1.39; Ikeda K, 2006, ACTA OTO-LARYNGOL, V126, P739, DOI 10.1080/00016480500472853; Incandela C, 2013, INDIAN J OTOLARYNGOL, V65, pS226, DOI 10.1007/s12070-011-0337-0; Jareoncharsri P, 1999, ASIAN PAC J ALLERGY, V17, P261; Kalpaklioglu AF, 2010, AM J RHINOL ALLERGY, V24, P29, DOI 10.2500/ajra.2010.24.3423; Katotomichelakis M, 2013, LARYNGOSCOPE, V123, pE10, DOI 10.1002/lary.24113; Katotomichelakis M, 2013, AM J RHINOL ALLERGY, V27, P293, DOI 10.2500/ajra.2013.27.3903; Kavut AB, 2013, ALLERGOL IMMUNOPATH, V41, P374, DOI 10.1016/j.aller.2012.05.006; Keith PK, 2012, ALLERGY ASTHMA CL IM, V8, DOI 10.1186/1710-1492-8-7; Khanna P, 2005, ANN ALLERG ASTHMA IM, V94, P60, DOI 10.1016/S1081-1206(10)61287-2; Klimek L, 1997, J ALLERGY CLIN IMMUN, V100, P158, DOI 10.1016/S0091-6749(97)70218-5; Klimek L, 2011, ALLERGY, V66, P632; Klimek L, 1996, ALLERGOLOGIE, V19, P382; Klimek L, 1998, Pneumologie, V52, P196; Kobal G, 2000, EUR ARCH OTO-RHINO-L, V257, P205, DOI 10.1007/s004050050223; Landis BN, 2003, CHEM SENSES, V28, P691, DOI 10.1093/chemse/bjg061; Lane AP, 1996, ANN OTO RHINOL LARYN, V105, P811; Lee W. C., 1996, Rhinology (Utrecht), V34, P130; Lee WH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062725; Lin HC, 2010, ARCH OTOLARYNGOL, V136, P892, DOI 10.1001/archoto.2010.135; Mann S. S., 2002, Indian Journal of Physiology and Pharmacology, V46, P186; Guilemany JM, 2012, INT ARCH ALLERGY IMM, V158, P184, DOI 10.1159/000331329; Meltzer Eli O, 2012, Allergy Asthma Proc, V33 Suppl 1, pS113, DOI 10.2500/aap.2012.33.3603; Meltzer EO, 1998, J ALLERGY CLIN IMMUN, V102, P39, DOI 10.1016/S0091-6749(98)70053-3; Moll B, 1998, ALLERGY, V53, P297, DOI 10.1111/j.1398-9995.1998.tb03890.x; Mun SJ, 2013, INT FORUM ALLERGY RH, V3, P177, DOI 10.1002/alr.21098; Olsson P, 2003, ACTA OTO-LARYNGOL, V123, P75, DOI 10.1080/0036554021000028071; Paparo B S, 1996, Riv Eur Sci Med Farmacol, V18, P157; Parida Pradipta Kumar, 2011, Indian J Med Sci, V65, P269; Passali GC, 2008, CURR OPIN ALLERGY CL, V8, P238, DOI 10.1097/ACI.0b013e3282ffd6bb; Pinto JM, 2008, J ALLERGY CLIN IMMUN, V121, pS277, DOI 10.1016/j.jaci.2007.12.1146; Radcliffe MJ, 1996, J INVEST ALLERG CLIN, V6, P242; Rhee CS, 2014, AM J RHINOL ALLERGY, V28, pE107, DOI 10.2500/ajra.2014.28.4040; Rydzewski B, 2000, ACTA OTO-LARYNGOL, V120, P323; Said SA, 2012, BMC EAR NOSE THROAT, V12, DOI 10.1186/1472-6815-12-13; SEIDEN A M, 1989, Chemical Senses, V14, P746; Shariat M, 2012, ALLERGY, V67, P492; Simola M, 1998, ALLERGY, V53, P190, DOI 10.1111/j.1398-9995.1998.tb03869.x; Sivam A, 2010, AM J RHINOL ALLERGY, V24, P286, DOI 10.2500/ajra.2010.24.3478; Stevenson RJ, 2010, CHEM SENSES, V35, P3, DOI 10.1093/chemse/bjp083; Stuck BA, 2003, ALLERGY, V58, P1195, DOI 10.1034/j.1398-9995.2003.00162.x; Tansuker D, 2014, J CRANIOFAC SURG, V25, pE339, DOI 10.1097/SCS.0000000000000599; Tsakiropoulou E, 2011, ALLERGY, V66, P353; Wober W, 1997, ARZNEIMITTEL-FORSCH, V47, P841; Yonekura Syuji, 2010, Allergology International, V59, P381, DOI 10.2332/allergolint.10-OA-0200; Zweiman B, 1997, J ALLERGY CLIN IMMUN, V100, P624, DOI 10.1016/S0091-6749(97)70166-0	86	53	60	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1460	1470		10.1016/j.jaci.2015.08.003	http://dx.doi.org/10.1016/j.jaci.2015.08.003			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26409662				2022-12-18	WOS:000366044300004
J	O'Gorman, WE; Hsieh, EWY; Savig, ES; Gherardini, PF; Hernandez, JD; Hansmann, L; Balboni, IM; Utz, PJ; Bendall, SC; Fantl, WJ; Lewis, DB; Nolan, GP; Davis, MM				O'Gorman, William E.; Hsieh, Elena W. Y.; Savig, Erica S.; Gherardini, Pier Federico; Hernandez, Joseph D.; Hansmann, Leo; Balboni, Imelda M.; Utz, Paul J.; Bendall, Sean C.; Fantl, Wendy J.; Lewis, David B.; Nolan, Garry P.; Davis, Mark M.			Single-cell systems-level analysis of human Toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mass cytometry; Toll-like receptors; systemic lupus erythematosus; inflammation; monocytes; monocyte chemotactic protein 1	MONOCYTE CHEMOATTRACTANT PROTEIN-1; PATTERN-RECOGNITION RECEPTORS; INNATE IMMUNE-SYSTEM; DENDRITIC CELLS; MASS CYTOMETRY; NK CELLS; TLR2; EXPRESSION; NEPHRITIS; MARKERS	Background: Activation of Toll-like receptors (TLRs) induces inflammatory responses involved in immunity to pathogens and autoimmune pathogenesis, such as in patients with systemic lupus erythematosus (SLE). Although TLRs are differentially expressed across the immune system, a comprehensive analysis of how multiple immune cell subsets respond in a system-wide manner has not been described. Objective: We sought to characterize TLR activation across multiple immune cell subsets and subjects, with the goal of establishing a reference framework against which to compare pathologic processes. Methods: Peripheral whole-blood samples were stimulated with TLR ligands and analyzed by means of mass cytometry simultaneously for surface marker expression, activation states of intracellular signaling proteins, and cytokine production. We developed a novel data visualization tool to provide an integrated view of TLR signaling networks with single-cell resolution. We studied 17 healthy volunteer donors and 8 patients with newly diagnosed and untreated SLE. Results: Our data revealed the diversity of TLR-induced responses within cell types, with TLR ligand specificity. Subsets of natural killer cells and T cells selectively induced nuclear factor k light chain enhancer of activated B cells in response to TLR2 ligands. CD14(hi) monocytes exhibited the most polyfunctional cytokine expression patterns, with more than 80 distinct cytokine combinations. Monocytic TLR-induced cytokine patterns were shared among a group of healthy donors, with minimal intraindividual and interindividual variability. Furthermore, autoimmune disease altered baseline cytokine production; newly diagnosed untreated SLE patients shared a distinct monocytic chemokine signature, despite clinical heterogeneity. Conclusion: Mass cytometry defined a systems-level reference framework for human TLR activation, which can be applied to study perturbations in patients with inflammatory diseases, such as SLE.	[O'Gorman, William E.; Hsieh, Elena W. Y.; Gherardini, Pier Federico; Hansmann, Leo; Fantl, Wendy J.; Nolan, Garry P.; Davis, Mark M.] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Hsieh, Elena W. Y.; Hernandez, Joseph D.; Balboni, Imelda M.; Lewis, David B.] Stanford Univ, Dept Pediat, Div Allergy Immunol & Rheumatol, Stanford, CA 94305 USA; [Savig, Erica S.] Stanford Univ, Canc Biol Program, Stanford, CA 94305 USA; [Hernandez, Joseph D.; Bendall, Sean C.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Utz, Paul J.] Stanford Univ, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA; [Utz, Paul J.; Nolan, Garry P.; Davis, Mark M.] Stanford Univ, Inst Immun Transplantat & Infect, Stanford, CA 94305 USA; [Fantl, Wendy J.] Stanford Univ, Dept Obstet & Gynecol, Div Gynecol Oncol, Stanford, CA 94305 USA; [Davis, Mark M.] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Nolan, GP (corresponding author), 269 Campus Dr,Ctr Clin Sci Res 3205, Stanford, CA 94305 USA.	gnolan@stanford.edu; mmdavis@stanford.edu	Nolan, Garry/AAE-7903-2019; Bendall, Sean/AGG-0126-2022; Hansmann, Leo/V-3748-2019	Hansmann, Leo/0000-0003-3790-0128; Bendall, Sean/0000-0003-1341-2453; Davis, Mark/0000-0001-6868-657X; Nolan, Garry/0000-0002-8862-9043	Eunice Kennedy Shriver National Institute of Child Health and Human Development [K12 HD000850]; Lucile Packard Foundation for Children's Health Stanford CTSA [UL1 TR001085]; Child Health Research Institute of Stanford University; American Academy of Allergy Asthma and Immunology Mylan Anaphylaxis Research Award; German Research Foundation DFG [HA 6772/1-1]; National Institutes of Health (NIH) [K08 AI080945]; Stanford Child Health Research Institute; Arthritis Foundation Postdoctoral Fellowship; NIH [R01 AI083757, R01 AI100121, R00 GM104148-03, U19AI057229, U19AI090019, U54CA149145, T32AI007290, N01 HV 00242, 1R01CA130826, R01GM109836, 1R01NS089533, P01 CA034233, 1U19AI100627, 5R01AI073724, R01CA184968]; Damon Runyon Cancer Research Foundation Fellowship [DRG-2017-09]; NIH-Northrop Grumman Corp [7500108142]; California Institute for Regenerative Medicine [DR1-01477]; US Food and Drug Administration [HHSF223201210194C]; Bill and Melinda Gates Foundation [OPP1113682]; European Commission [HEALTH.2010.1.2-1]; Alliance for Lupus Research [218518]; Entertainment Industry Foundation NWCRA grant; US Department of Defense [OC110674, 11491122]; Rachford and Carlota A. Harris Endowed Professorship; Howard Hughes Medical Institute;  [R33CA183654];  [R33CA183692];  [HHSN272201200028C];  [201303028];  [HHSN272200700038C];  [5U54CA143907];  [1149112];  [41000411217]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000850] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U54CA143907, R33CA183692, U54CA149145, R01CA130826, R01CA184968, T32CA009302, R33CA183654, P01CA034233] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290, U19AI110491, U19AI090019, U19AI057229, R01AI073724, U19AI100627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R00GM104148, R01GM109836, T32GM007276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS089533] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Lucile Packard Foundation for Children's Health Stanford CTSA; Child Health Research Institute of Stanford University; American Academy of Allergy Asthma and Immunology Mylan Anaphylaxis Research Award; German Research Foundation DFG(German Research Foundation (DFG)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stanford Child Health Research Institute; Arthritis Foundation Postdoctoral Fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Cancer Research Foundation Fellowship; NIH-Northrop Grumman Corp; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); US Food and Drug Administration; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); European Commission(European CommissionEuropean Commission Joint Research Centre); Alliance for Lupus Research; Entertainment Industry Foundation NWCRA grant; US Department of Defense(United States Department of Defense); Rachford and Carlota A. Harris Endowed Professorship; Howard Hughes Medical Institute(Howard Hughes Medical Institute); ; ; ; ; ; ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	E.W.Y.H. is a Fellow of the Pediatric Scientist Development Program; supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development grant K12 HD000850, the Lucile Packard Foundation for Children's Health Stanford CTSA UL1 TR001085, and the Child Health Research Institute of Stanford University. E.S.S. is a National Science Foundation Graduate Research Fellow and Gabilon Stanford Graduate Research Fellow. P.F.G. is a Howard Hughes Medical Institute Fellow of the Life Sciences Research Foundation. J.D.H. is funded by the American Academy of Allergy Asthma and Immunology Mylan Anaphylaxis Research Award. L.H. is funded by the German Research Foundation DFG, HA 6772/1-1. I.M.B. is supported by National Institutes of Health (NIH) grant K08 AI080945, the Stanford Child Health Research Institute, and the Arthritis Foundation Postdoctoral Fellowship. D.B.L. is supported by funds from NIH grants R01 AI083757 and R01 AI100121. S.C.B. is supported by the Damon Runyon Cancer Research Foundation Fellowship (DRG-2017-09) and NIH R00 GM104148-03. This work is supported by funds from NIH grants U19AI057229, U19AI090019, U54CA149145, T32AI007290, N01 HV 00242, 1R01CA130826, R01GM109836, 1R01NS089533, P01 CA034233, 1U19AI100627, 5R01AI073724, R01CA184968, R33CA183654, and R33CA183692; HHSN272201200028C, 201303028, HHSN272200700038C, 5U54CA143907, 1149112 NIH-Baylor Research Institute 41000411217; NIH-Northrop Grumman Corp 7500108142; the California Institute for Regenerative Medicine DR1-01477; the US Food and Drug Administration HHSF223201210194C; the Bill and Melinda Gates Foundation OPP1113682; the European Commission HEALTH.2010.1.2-1; the Alliance for Lupus Research 218518; an Entertainment Industry Foundation NWCRA grant; US Department of Defense grants OC110674 and 11491122; Rachford and Carlota A. Harris Endowed Professorship; and the Howard Hughes Medical Institute.	Abujam B, 2013, LUPUS, V22, P614, DOI 10.1177/0961203313484977; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Atamas SP, 2003, CURR OPIN RHEUMATOL, V15, P772, DOI 10.1097/00002281-200311000-00015; Bauer JW, 2006, PLOS MED, V3, P2274, DOI 10.1371/journal.pmed.0030491; Bekeredjian-Ding I, 2009, IMMUNOLOGY, V128, P311, DOI 10.1111/j.1365-2567.2009.03173.x; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Beutler B, 2007, NAT REV IMMUNOL, V7, P753, DOI 10.1038/nri2174; Bieneman AP, 2005, J ALLERGY CLIN IMMUN, V115, P295, DOI 10.1016/j.jaci.2004.10.018; Blasius AL, 2010, IMMUNITY, V32, P305, DOI 10.1016/j.immuni.2010.03.012; Brenner M, 2013, PHYSIOL GENOMICS, V45, P1109, DOI 10.1152/physiolgenomics.00108.2013; Chen Q, 2009, J IMMUNOL, V183, P4458, DOI 10.4049/jimmunol.0901465; Corbett NP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015041; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Esin S, 2013, SCAND J IMMUNOL, V77, P460, DOI 10.1111/sji.12052; Ferwerda G, 2008, CELL MICROBIOL, V10, P2058, DOI 10.1111/j.1462-5822.2008.01188.x; Finak G, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-546; Finck R, 2013, CYTOM PART A, V83A, P483, DOI 10.1002/cyto.a.22271; Fitzgerald KA, 2006, CELL, V125, P834, DOI 10.1016/j.cell.2006.05.014; Guiducci C, 2013, J EXP MED, V210, P2903, DOI 10.1084/jem.20131044; Hasegawa H, 2003, ARTHRITIS RHEUM, V48, P2555, DOI 10.1002/art.11231; Hausmann OV, 2011, ALLERGY, V66, P85, DOI 10.1111/j.1398-9995.2010.02431.x; Ishii KJ, 2008, CELL HOST MICROBE, V3, P352, DOI 10.1016/j.chom.2008.05.003; Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021; Jansen K, 2008, J IMMUNOL METHODS, V336, P183, DOI 10.1016/j.jim.2008.04.013; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kawasaki T, 2011, IMMUNOL REV, V243, P61, DOI 10.1111/j.1600-065X.2011.01048.x; Kim RY, 2014, J NEUROIMMUNOL, V274, P53, DOI 10.1016/j.jneuroim.2014.06.009; Koh YT, 2013, J IMMUNOL, V190, P4982, DOI 10.4049/jimmunol.1202986; Kulkarni O, 2007, J AM SOC NEPHROL, V18, P2350, DOI 10.1681/ASN.2006121348; Lancioni CL, 2011, INFECT IMMUN, V79, P663, DOI 10.1128/IAI.00806-10; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Luber CA, 2010, IMMUNITY, V32, P279, DOI 10.1016/j.immuni.2010.01.013; Lundberg AM, 2007, BLOOD, V110, P3245, DOI 10.1182/blood-2007-02-072934; Marcenaro E, 2008, INT IMMUNOL, V20, P1155, DOI 10.1093/intimm/dxn073; Marks SD, 2008, NEPHROL DIAL TRANSPL, V23, P3521, DOI 10.1093/ndt/gfn270; Martinez J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000811; Means TK, 2005, J CLIN INVEST, V115, P407, DOI 10.1172/JCI200523025; Meissner F, 2013, SCIENCE, V340, P475, DOI 10.1126/science.1232578; Milush JM, 2009, BLOOD, V114, P4823, DOI 10.1182/blood-2009-04-216374; Netea MG, 2012, NAT IMMUNOL, V13, P535, DOI 10.1038/ni.2284; Newell EW, 2012, IMMUNITY, V36, P142, DOI 10.1016/j.immuni.2012.01.002; O'Gorman WE, 2014, VACCINE, V32, P5989, DOI 10.1016/j.vaccine.2014.07.115; O'Neill LAJ, 2013, NAT REV IMMUNOL, V13, P453, DOI 10.1038/nri3446; Pascual V, 2008, IMMUNOL REV, V223, P39, DOI 10.1111/j.1600-065X.2008.00643.x; Pascual V, 2006, CURR OPIN IMMUNOL, V18, P676, DOI 10.1016/j.coi.2006.09.014; Poli A, 2009, IMMUNOLOGY, V126, P458, DOI 10.1111/j.1365-2567.2008.03027.x; Ronnblom L, 2008, LUPUS, V17, P394, DOI 10.1177/0961203308090020; Rovin BH, 2005, J AM SOC NEPHROL, V16, P467, DOI 10.1681/ASN.2004080658; Shirernan PK, 2007, J LEUKOCYTE BIOL, V81, P775, DOI 10.1189/jlb.0506356; Sieling PA, 2008, J IMMUNOL, V180, P5833, DOI 10.4049/jimmunol.180.9.5833; Sjoelund V, 2014, J PROTEOME RES, V13, P5185, DOI 10.1021/pr5002466; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Theofilopoulos AN, 2010, NAT REV RHEUMATOL, V6, P146, DOI 10.1038/nrrheum.2009.278; Weintz G, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.29; Yu C, 2014, J AUTOIMMUN, V48-49, P10, DOI 10.1016/j.jaut.2014.01.004; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	57	53	53	2	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1326	1336		10.1016/j.jaci.2015.04.008	http://dx.doi.org/10.1016/j.jaci.2015.04.008			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26037552	Green Accepted, hybrid			2022-12-18	WOS:000364787200023
J	Kiwamoto, T; Katoh, T; Evans, CM; Janssen, WJ; Brummet, ME; Hudson, SA; Zhu, Z; Tiemeyer, M; Bochner, BS				Kiwamoto, Takumi; Katoh, Toshihiko; Evans, Christopher M.; Janssen, William J.; Brummet, Mary E.; Hudson, Sherry A.; Zhu, Zhou; Tiemeyer, Michael; Bochner, Bruce S.			Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil; asthma; Siglec-F; mucin; Muc5b; Muc4; apoptosis; glycan ligands; epithelium; glands; lung; airway	OBSTRUCTIVE PULMONARY-DISEASE; TUMOR-PRODUCED MUCINS; EPITHELIAL-CELLS; T-CELLS; COUNTER-RECEPTOR; LIGAND FORMATION; DEFICIENT MICE; CANCER-CELLS; NK CELLS; B-CELLS	Background: Sialic acid-binding, immunoglobulin-like lectin (Siglec) F is a glycan-binding protein selectively expressed on mouse eosinophils. Its engagement induces apoptosis, suggesting a pathway for ameliorating eosinophilia in the setting of asthma and other eosinophil-associated diseases. Siglec-F recognizes sialylated sulfated glycans in glycan-binding assays, but the identities of endogenous sialoside ligands and their glycoprotein carriers in vivo are unknown. Objectives: To use mouse lung-derived materials to isolate, biochemically identify, and biologically characterize naturally occurring endogenous glycan ligands for Siglec-F. Methods: Lungs from normal and mucin-deficient mice, as well as mouse tracheal epithelial cells, were investigated in vitro and in vivo for the expression of Siglec-F ligands. Western blotting and cytochemistry used Siglec-F-Fc as a probe for directed purification, followed by liquid chromatography-tandem mass spectrometry of recognized glycoproteins. Purified components were tested in mouse eosinophil-binding assays and flow cytometry-based cell death assays. Results: We detected mouse lung glycoproteins that bound to Siglec-F; binding was sialic acid dependent. Proteomic analysis of Siglec-F binding material identified Muc5b and Muc4. Cross-affinity enrichment and histochemical analysis of lungs from mucin-deficient mice assigned and validated the identity of Muc5b as one glycoprotein ligand for Siglec-F. Purified mucin preparations carried sialylated and sulfated glycans, bound to eosinophils and induced their death in vitro. Mice conditionally deficient in Muc5b displayed exaggerated eosinophilic inflammation in response to intratracheal installation of IL-13. Conclusions: These data identify a previously unrecognized endogenous anti-inflammatory property of airway mucins by which their glycans can control lung eosinophilia through engagement of Siglec-F.	[Kiwamoto, Takumi; Brummet, Mary E.; Hudson, Sherry A.; Zhu, Zhou; Bochner, Bruce S.] Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD 21205 USA; [Katoh, Toshihiko; Tiemeyer, Michael] Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; [Evans, Christopher M.; Janssen, William J.] Univ Colorado, Sch Med, Dept Med, Div Pulm Med, Denver, CO USA; [Janssen, William J.] Natl Jewish Hlth, Dept Med, Div Pulm Crit Care & Sleep Med, Denver, CO USA	Johns Hopkins University; University System of Georgia; University of Georgia; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Bochner, BS (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, 240 E Huron St,Rm M-306, Chicago, IL 60611 USA.	mtiemeyer@ccrc.uga.edu; bruce.bochner@northwestern.edu	Kiwamoto, Takumi/AAX-8140-2021	Kiwamoto, Takumi/0000-0003-3918-9878	National Institutes of Health [AI72265, HL080396, ES023384, HL109517, P41 GM103490, HL107151]; American Heart Association [14GRNT19990040]; Grants-in-Aid for Scientific Research [26860596] Funding Source: KAKEN; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL109517, P01HL107151, R01HL080396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072265, R56AI072265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES023384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103490] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants AI72265 (to B.S.B. and Z.Z.), HL080396, ES023384 (to C.M.E.), HL109517 (to W.J.J.), P41 GM103490 (to M.T.), and HL107151 (to B.S.B., Z.Z., and M.T.) from the National Institutes of Health, as well as American Heart Association grant 14GRNT19990040 (to C.M.E.).	Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; ANUMULA KR, 1992, ANAL BIOCHEM, V203, P101, DOI 10.1016/0003-2697(92)90048-C; Bafna S, 2010, ONCOGENE, V29, P2893, DOI 10.1038/onc.2010.87; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Bax M, 2007, J IMMUNOL, V179, P8216, DOI 10.4049/jimmunol.179.12.8216; Belisle JA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-118; Bochner BS, 2010, J ALLERGY CLIN IMMUN, V126, P16, DOI 10.1016/j.jaci.2010.02.026; Button B, 2012, SCIENCE, V337, P937, DOI 10.1126/science.1223012; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Cho JY, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-154; Damera G, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-39; Damera G, 2006, BIOSCIENCE REP, V26, P55, DOI 10.1007/s10540-006-9000-5; Ellies LG, 2002, BLOOD, V100, P3618, DOI 10.1182/blood-2002-04-1007; Fahy JV, 2010, NEW ENGL J MED, V363, P2233, DOI 10.1056/NEJMra0910061; Feng YH, 2012, J ZHEJIANG UNIV-SC B, V13, P386, DOI 10.1631/jzus.B1100218; Guo JP, 2011, AM J RESP CELL MOL, V44, P238, DOI 10.1165/rcmb.2010-0007OC; Hasnain SZ, 2011, J EXP MED, V208, P893, DOI 10.1084/jem.20102057; Henke MO, 2004, AM J RESP CELL MOL, V31, P86, DOI 10.1165/rcmb.2003-0345OC; Hiraoka N, 2007, GLYCOBIOLOGY, V17, P277, DOI 10.1093/glycob/cwl077; Ishida A, 2008, PROTEOMICS, V8, P3342, DOI 10.1002/pmic.200800039; Jacobsen EA, 2008, J EXP MED, V205, P699, DOI 10.1084/jem.20071840; Janssen WJ, 2011, AM J RESP CRIT CARE, V184, P547, DOI 10.1164/rccm.201011-1891OC; Jonckheere N, 2013, BIOCHIMIE, V95, P1077, DOI 10.1016/j.biochi.2012.11.005; Kim DH, 2004, ARCH OTOLARYNGOL, V130, P747, DOI 10.1001/archotol.130.6.747; Kirkham S, 2008, AM J RESP CRIT CARE, V178, P1033, DOI 10.1164/rccm.200803-391OC; Kiwamoto T, 2014, J ALLERGY CLIN IMMUN, V133, P240, DOI 10.1016/j.jaci.2013.05.018; Kiwamoto T, 2013, CURR OPIN ALLERGY CL, V13, P106, DOI 10.1097/ACI.0b013e32835b594a; Kiwamoto T, 2012, PHARMACOL THERAPEUT, V135, P327, DOI 10.1016/j.pharmthera.2012.06.005; Kumagai T, 2013, ANAL CHEM, V85, P8692, DOI 10.1021/ac4015935; Lauc G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003225; Lee NA, 1997, J IMMUNOL, V158, P1332; Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737; Mao H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068143; Misharin AV, 2013, AM J RESP CELL MOL, V49, P503, DOI 10.1165/rcmb.2013-0086MA; Nath D, 1999, IMMUNOLOGY, V98, P213; Ohta M, 2010, BIOCHEM BIOPH RES CO, V402, P663, DOI 10.1016/j.bbrc.2010.10.079; Okubo T, 2005, DEVELOPMENT, V132, P1363, DOI 10.1242/dev.01678; Patnode ML, 2013, J BIOL CHEM, V288, P26533, DOI 10.1074/jbc.M113.485409; Roy MG, 2014, NATURE, V505, P412, DOI 10.1038/nature12807; Seibold MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058658; Seibold MA, 2011, NEW ENGL J MED, V364, P1503, DOI 10.1056/NEJMoa1013660; Suzukawa M, 2013, J IMMUNOL, V190, P5939, DOI 10.4049/jimmunol.1203455; Swanson BJ, 2007, CANCER RES, V67, P10222, DOI 10.1158/0008-5472.CAN-06-2483; Tanida S, 2013, J BIOL CHEM, V288, P31842, DOI 10.1074/jbc.M113.471318; Tateno H, 2005, GLYCOBIOLOGY, V15, P1125, DOI 10.1093/glycob/cwi097; Thornton DJ, 2008, ANNU REV PHYSIOL, V70, P459, DOI 10.1146/annurev.physiol.70.113006.100702; Toda M, 2008, BIOCHEM BIOPH RES CO, V372, P45, DOI 10.1016/j.bbrc.2008.04.175; Toda M, 2009, BIOCHEM J, V417, P673, DOI 10.1042/BJ20081241; Tyler C, 2012, AM J REPROD IMMUNOL, V68, P28, DOI 10.1111/j.1600-0897.2012.01113.x; Varki A, 2009, ESSENTIALS GLYCOBIOL, P1; Wagers AJ, 2000, J IMMUNOL, V165, P5011, DOI 10.4049/jimmunol.165.9.5011; Wechsler ME, 2012, J ALLERGY CLIN IMMUN, V130, P563, DOI 10.1016/j.jaci.2012.07.027; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wickstrom C, 1998, BIOCHEM J, V334, P685, DOI 10.1042/bj3340685; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; You YJ, 2002, AM J PHYSIOL-LUNG C, V283, pL1315, DOI 10.1152/ajplung.00169.2002; Young HWJ, 2007, AM J RESP CELL MOL, V37, P273, DOI 10.1165/rcmb.2005-0460OC; Zhang M, 2007, BLOOD, V109, P4280, DOI 10.1182/blood-2006-08-039255; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458	59	53	55	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1329	U366		10.1016/j.jaci.2014.10.027	http://dx.doi.org/10.1016/j.jaci.2014.10.027			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25497369	Green Accepted			2022-12-18	WOS:000353980700027
J	Ebisawa, M; Brostedt, P; Sjolander, S; Sato, S; Borres, MP; Ito, K				Ebisawa, Motohiro; Brostedt, Peter; Sjolander, Sigrid; Sato, Sakura; Borres, Magnus P.; Ito, Komei			Gly m 2S albumin is a major allergen with a high diagnostic value in soybean-allergic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							JAPANESE CHILDREN; GLYCINE-MAX; IGE; SOY		[Ebisawa, Motohiro; Sato, Sakura] Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan; [Brostedt, Peter; Sjolander, Sigrid; Borres, Magnus P.] Thermo Fisher Sci, Uppsala, Sweden; [Borres, Magnus P.] Univ Gothenburg, Sahlgrenska Acad, Dept Pediat, Gothenburg, Sweden; [Ito, Komei] Aichi Childrens Hlth & Med Ctr, Dept Allergy, Obu, Japan	Thermo Fisher Scientific; University of Gothenburg	Ebisawa, M (corresponding author), Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan.	m-ebisawa@sagamihara-hosp.gr.jp		Ebisawa, Motohiro/0000-0003-4117-558X				Ballmer-Weber BK, 2008, CURR OPIN ALLERGY CL, V8, P270, DOI 10.1097/ACI.0b013e3282ffb157; DeWitt AM, 2002, CLIN EXP ALLERGY, V32, P1329, DOI 10.1046/j.1365-2222.2002.01467.x; Ebisawa M, 2012, PEDIAT ALLERG IMM-UK, V23, P573, DOI 10.1111/j.1399-3038.2012.01332.x; Fukutomi Y, 2012, J ALLERGY CLIN IMMUN, V129, P860, DOI 10.1016/j.jaci.2012.01.031; Holzhauser T, 2009, J ALLERGY CLIN IMMUN, V123, P452, DOI 10.1016/j.jaci.2008.09.034; Ito K, 2011, J ALLERGY CLIN IMMUN, V128, P673, DOI 10.1016/j.jaci.2011.04.025; Ito Komei, 2009, Allergology International, V58, P467, DOI 10.2332/allergolint.09-RAI-0140; Lin J, 2006, INT ARCH ALLERGY IMM, V141, P91, DOI 10.1159/000094535; Moreno F Javier, 2008, Open Biochem J, V2, P16, DOI 10.2174/1874091X00802010016	9	53	57	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					976	+		10.1016/j.jaci.2013.04.028	http://dx.doi.org/10.1016/j.jaci.2013.04.028			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23763971				2022-12-18	WOS:000325096500028
J	Deniz, G; van de Veen, W; Akdis, M				Deniz, Gunnur; van de Veen, Willem; Akdis, Muebeccel			Natural killer cells in patients with allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Natural killer cells; allergic inflammation; NK1; NK2; NK22	HUMAN NK CELLS; T-CELLS; ATOPIC-DERMATITIS; DENDRITIC CELLS; IFN-GAMMA; ACTIVATING RECEPTOR; ADAPTIVE IMMUNITY; PERIPHERAL-BLOOD; GENE-EXPRESSION; INNATE IMMUNITY	Natural killer (NK) cells not only exert cytotoxic activity against tumor cells or infected cells but also act to regulate the function of other immune cells through secretion of cytokines and chemokines or cell contact-dependent mechanisms. NK cells are able to polarize in vitro into 2 functional distinct subsets, NK1 or NK2 cells, which are analogous to the T-cell subsets T(H)1 or T(H)2. In addition, a regulatory NK cell subset has been described that secretes IL-10, shows antigen-specific T-cell suppression, and suppresses IgE production. Although it has been demonstrated that NK cells play important roles in autoimmunity, cancer, transplantation, and pregnancy, the role of NK cells in allergy has not been extensively discussed. This review aims to discuss our understanding of NK cells and NK cell subsets in allergic inflammation and IgE regulation.	[Deniz, Gunnur] Istanbul Univ, Inst Expt Med DETAE, Dept Immunol, Istanbul, Turkey; [van de Veen, Willem; Akdis, Muebeccel] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland	Istanbul University; Swiss Institute of Allergy & Asthma Research; University of Zurich	Deniz, G (corresponding author), Istanbul Univ, Inst Expt Med DETAE, Istanbul, Turkey.	gdeniz@istanbul.edu.tr	Akdis, Cezmi/AAV-4844-2020; Deniz, Gunnur/AAC-2909-2020	Akdis, Cezmi/0000-0001-8020-019X; van de Veen, Willem/0000-0001-9951-6688	Swiss National Science Foundation [32-188226, 320030-140772]; Christine Kuhne Center for Allergy Research and Education (CK-CARE); European Commission's Seventh Framework Programme [261357 MEDALL, 260895 PreDICTA]; University of Istanbul [T-780/0703200, UDP-29187, BYP-2718, ONAP-870]; Swiss National Science Foundation Research on Regulation of Antigen-specific Immune Responses; MeDALL: European Commission's Seventh Framework Program	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Christine Kuhne Center for Allergy Research and Education (CK-CARE); European Commission's Seventh Framework Programme(European Commission); University of Istanbul(Istanbul University); Swiss National Science Foundation Research on Regulation of Antigen-specific Immune Responses; MeDALL: European Commission's Seventh Framework Program	Dr Akdis's laboratory is supported by the Swiss National Science Foundation (grants no. 32-188226 and 320030-140772), the Christine Kuhne Center for Allergy Research and Education (CK-CARE), and the European Commission's Seventh Framework Programme (grant agreement no. 261357 MEDALL and grant agreement no. 260895 PreDICTA). Dr Deniz's laboratory is supported by the Research Fund of the University of Istanbul (projects no. T-780/0703200, UDP-29187, BYP-2718, and ONAP-870).; M. Akdis is an employee of the Swiss Institute of Allergy and Asthma Research and the University of Zurich, Switzerland. Her institution has received grants or has grants pending for PREDICTA: European Commission's Seventh Framework for research on virus-induced exacerbations; from the Swiss National Science Foundation Research on Regulation of Antigen-specific Immune Responses; and from MeDALL: European Commission's Seventh Framework Program for research on early initiation of asthma. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis CA, 1999, INT ARCH ALLERGY IMM, V118, P140, DOI 10.1159/000024051; Akdis M, 1997, J IMMUNOL, V159, P4611; Aktas E, 2005, CLIN EXP IMMUNOL, V140, P301, DOI 10.1111/j.1365-2249.2005.02777.x; Al Omar S, 2013, CYTOKINE, V62, P123, DOI 10.1016/j.cyto.2013.02.005; Arnon TI, 2005, NAT IMMUNOL, V6, P515, DOI 10.1038/ni1190; Bernardini G, 2012, IMMUNOL LETT, V145, P39, DOI 10.1016/j.imlet.2012.04.014; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Blanca IR, 2001, J IMMUNOL, V167, P6132, DOI 10.4049/jimmunol.167.11.6132; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Brilot F, 2007, J CLIN INVEST, V117, P3316, DOI 10.1172/JCI31751; Bryceson YT, 2009, BLOOD, V114, P2657, DOI 10.1182/blood-2009-01-201632; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Canonica GW, 2002, ALLERGY, V57, P8, DOI 10.1034/j.1398-9995.57.s75.2.x; Carbone T, 2010, J IMMUNOL, V184, P1102, DOI 10.4049/jimmunol.0902518; Carrega P, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00347; Cella M, 2010, P NATL ACAD SCI USA, V107, P10961, DOI 10.1073/pnas.1005641107; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Ciccia F, 2012, ARTHRITIS RHEUM-US, V64, P1869, DOI 10.1002/art.34355; Colonna M, 2009, IMMUNITY, V31, P15, DOI 10.1016/j.immuni.2009.06.008; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Cooper MA, 2004, TRENDS IMMUNOL, V25, P47, DOI 10.1016/j.it.2003.10.012; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; De Maria A, 2011, P NATL ACAD SCI USA, V108, P728, DOI 10.1073/pnas.1012356108; Deniz G, 2002, EUR J IMMUNOL, V32, P879, DOI 10.1002/1521-4141(200203)32:3<879::AID-IMMU879>3.0.CO;2-2; Deniz G, 2008, J IMMUNOL, V180, P850, DOI 10.4049/jimmunol.180.2.850; Deniz G, 2011, EXPERT OPIN BIOL TH, V11, P833, DOI 10.1517/14712598.2011.572549; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Gineau L, 2012, J CLIN INVEST, V122, P821, DOI 10.1172/JCI61014; Hamerman JA, 2005, CURR OPIN IMMUNOL, V17, P29, DOI 10.1016/j.coi.2004.11.001; Hanna J, 2004, J IMMUNOL, V173, P6547, DOI 10.4049/jimmunol.173.11.6547; Harrington LE, 2006, CURR OPIN IMMUNOL, V18, P349, DOI 10.1016/j.coi.2006.03.017; Haworth O, 2011, J IMMUNOL, V186, P6129, DOI 10.4049/jimmunol.1004007; Hayakawa Y, 2006, J IMMUNOL, V176, P1517, DOI 10.4049/jimmunol.176.3.1517; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Hudspeth K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00069; Jonges LE, 2001, SCAND J IMMUNOL, V53, P103, DOI 10.1046/j.1365-3083.2001.00838.x; Koch J, 2013, TRENDS IMMUNOL, V34, P182, DOI 10.1016/j.it.2013.01.003; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Laroni A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026173; Lee SH, 2009, J EXP MED, V206, P2235, DOI 10.1084/jem.20082387; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Lo CKC, 2008, ARTHRITIS RHEUM, V58, P2700, DOI 10.1002/art.23760; Lopez-Verges S, 2010, BLOOD, V116, P3865, DOI 10.1182/blood-2010-04-282301; Loza MJ, 2001, NAT IMMUNOL, V2, P917, DOI 10.1038/ni1001-917; Lucas M, 2007, IMMUNITY, V26, P503, DOI 10.1016/j.immuni.2007.03.006; Lugini L, 2012, J IMMUNOL, V189, P2833, DOI 10.4049/jimmunol.1101988; Maintz L, 2011, J INNATE IMMUN, V3, P131, DOI 10.1159/000323963; Majewska-Szczepanik M, 2013, IMMUNOLOGY; Mandelboim O, 2001, INT J BIOCHEM CELL B, V33, P1147, DOI 10.1016/S1357-2725(01)00078-4; Marusina AI, 2008, J IMMUNOL, V180, P409, DOI 10.4049/jimmunol.180.1.409; Mesdaghi M, 2010, INT ARCH ALLERGY IMM, V153, P234, DOI 10.1159/000314363; Montaldo E, 2012, BLOOD, V119, P3987, DOI 10.1182/blood-2011-09-379693; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Moretta L, 2006, IMMUNOL REV, V214, P219, DOI 10.1111/j.1600-065X.2006.00450.x; Narni-Mancinelli E, 2013, CURR OPIN IMMUNOL, V25, P53, DOI 10.1016/j.coi.2012.11.005; Ni J, 2012, J EXP MED, V209, P2351, DOI 10.1084/jem.20120944; Noda M, 2011, BLOOD, V117, P451, DOI 10.1182/blood-2010-04-277897; O'Leary JG, 2006, NAT IMMUNOL, V7, P507, DOI 10.1038/ni1332; Orange JS, 2006, CLIN IMMUNOL, V118, P1, DOI 10.1016/j.clim.2005.10.011; Pandya AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026780; Paust S, 2011, NAT IMMUNOL, V12, P500, DOI 10.1038/ni.2032; Paust S, 2010, NAT IMMUNOL, V11, P1127, DOI 10.1038/ni.1953; Peritt D, 1998, J IMMUNOL, V161, P5821; Poli A, 2009, IMMUNOLOGY, V126, P458, DOI 10.1111/j.1365-2567.2008.03027.x; Raulet DH, 2006, SEMIN IMMUNOL, V18, P145, DOI 10.1016/j.smim.2006.03.003; Ren J, 2011, J RHEUMATOL, V38, P2112, DOI 10.3899/jrheum.101377; Romee R, 2013, BLOOD, V121, P3599, DOI 10.1182/blood-2012-04-425397; Satoskar AR, 1999, J IMMUNOL, V163, P5298; Scordamaglia F, 2008, J ALLERGY CLIN IMMUN, V121, P479, DOI 10.1016/j.jaci.2007.09.047; Shigeru S, 2008, J REPROD IMMUNOL, V77, P14, DOI 10.1016/j.jri.2007.04.007; Silva A, 2008, INT IMMUNOL, V20, P625, DOI 10.1093/intimm/dxn022; Sivori S, 1997, J EXP MED, V186, P1129, DOI 10.1084/jem.186.7.1129; Soderquest K, 2011, BLOOD, V117, P4511, DOI 10.1182/blood-2010-10-312264; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Tomasello E, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00344; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; Vitale M, 2005, BLOOD, V106, P566, DOI 10.1182/blood-2004-10-4035; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; von Bubnoff D, 2010, J ALLERGY CLIN IMMUN, V125, P60, DOI 10.1016/j.jaci.2009.11.020; Vossen MTM, 2008, J IMMUNOL, V180, P3739, DOI 10.4049/jimmunol.180.6.3739; Walzer T, 2005, BLOOD, V106, P2252, DOI 10.1182/blood-2005-03-1154; Walzer T, 2007, P NATL ACAD SCI USA, V104, P3384, DOI 10.1073/pnas.0609692104; WARREN HS, 1991, IMMUNOLOGY, V72, P150; WEHRMANN W, 1990, INT ARCH ALLER A IMM, V92, P318, DOI 10.1159/000235196; Wei HM, 2005, MOL IMMUNOL, V42, P1023, DOI 10.1016/j.molimm.2004.09.035; Wei HM, 2005, J ALLERGY CLIN IMMUN, V115, P841, DOI 10.1016/j.jaci.2004.11.026; Yu G, 2006, J EXP MED, V203, P1851, DOI 10.1084/jem.20060603; Yu JH, 2010, BLOOD, V115, P274, DOI 10.1182/blood-2009-04-215491; Zenewicz LA, 2008, EUR J IMMUNOL, V38, P3265, DOI 10.1002/eji.200838655; Zhang C, 2006, CELL MOL IMMUNOL, V3, P241; Zitvogel L, 2002, J EXP MED, V195, pf9, DOI 10.1084/jem.20012040	95	53	55	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					527	535		10.1016/j.jaci.2013.07.030	http://dx.doi.org/10.1016/j.jaci.2013.07.030			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23993354				2022-12-18	WOS:000323612000002
J	Kaiko, GE; Loh, Z; Spann, K; Lynch, JP; Lalwani, A; Zheng, ZL; Davidson, S; Uematsu, S; Akira, S; Hayball, J; Diener, KR; Baines, KJ; Simpson, JL; Foster, PS; Phipps, S				Kaiko, Gerard E.; Loh, Zhixuan; Spann, Kirsten; Lynch, Jason P.; Lalwani, Amit; Zheng, Zhenglong; Davidson, Sophia; Uematsu, Satoshi; Akira, Shizuo; Hayball, John; Diener, Kerrilyn R.; Baines, Katherine J.; Simpson, Jodie L.; Foster, Paul S.; Phipps, Simon			Toll-like receptor 7 gene deficiency and early-life Pneumovirus infection interact to predispose toward the development of asthma-like pathology in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Toll-like receptor 7; Pneumovirus; infection; type 2 innate lymphoid cell; nuocyte; asthma; IL-13; exacerbation; respiratory syncytial virus; bronchiolitis	PLASMACYTOID DENDRITIC CELLS; RESPIRATORY SYNCYTIAL VIRUS; INNATE IMMUNE-RESPONSE; INTERFERON-ALPHA; CYTOKINE RESPONSES; PERIPHERAL-BLOOD; VIRAL-INFECTIONS; HOST-DEFENSE; RISK; RHINOVIRUS	Background: Respiratory tract viruses are a major environmental risk factor for both the inception and exacerbations of asthma. Genetic defects in Toll-like receptor (TLR) 7-mediated signaling, impaired type I interferon responses, or both have been reported in asthmatic patients, although their contribution to the onset and exacerbation of asthma remains poorly understood. Objective: We sought to determine whether Pneumovirus infection in the absence of TLR7 predisposes to bronchiolitis and the inception of asthma. Methods: Wild-type and TLR7-deficient (TLR7(-/-)) mice were inoculated with the rodent-specific pathogen pneumonia virus of mice at 1 (primary), 7 (secondary), and 13 (tertiary) weeks of age, and pathologic features of bronchiolitis or asthma were assessed. In some experiments infected mice were exposed to low-dose cockroach antigen. Results: TLR7 deficiency increased viral load in the airway epithelium, which became sloughed and necrotic, and promoted an IFN-alpha/beta(low), IL-12p70(low), IL-1 beta(high), IL-25(high), and IL-33(high) cytokine microenvironment that was associated with the recruitment of type 2 innate lymphoid cells/nuocytes and increased T(H)2-type cytokine production. Viral challenge of TLR7(-/-) mice induced all of the cardinal pathophysiologic features of asthma, including tissue eosinophilia, mast cell hyperplasia, IgE production, airway smooth muscle alterations, and airways hyperreactivity in a memory CD4(+) T cell-dependent manner. Importantly, infections with pneumonia virus of mice promoted allergic sensitization to inhaled cockroach antigen in the absence but not the presence of TLR7. Conclusion: TLR7 gene defects and Pneumovirus infection interact to establish an aberrant adaptive response that might underlie virus-induced asthma exacerbations in later life.	[Kaiko, Gerard E.; Davidson, Sophia; Baines, Katherine J.; Simpson, Jodie L.; Foster, Paul S.] Univ Newcastle, Ctr Asthma & Resp Dis, Callaghan, NSW 2308, Australia; [Kaiko, Gerard E.; Davidson, Sophia; Foster, Paul S.] Univ Newcastle, Hunter Med Res Inst, Callaghan, NSW 2308, Australia; [Kaiko, Gerard E.; Foster, Paul S.] Cooperat Res Ctr CRC Asthma & Airways, Sydney, NSW, Australia; [Loh, Zhixuan; Lynch, Jason P.; Lalwani, Amit; Zheng, Zhenglong; Phipps, Simon] Univ Queensland, Sch Biomed Sci, S Lucia, Qld 4072, Australia; [Spann, Kirsten] Univ Queensland, Sir Albert Sakzewski Virus Res Ctr, S Lucia, Qld 4072, Australia; [Spann, Kirsten; Phipps, Simon] Univ Queensland, Australian Infect Dis Res Ctr, S Lucia, Qld 4072, Australia; [Uematsu, Satoshi; Akira, Shizuo] Osaka Univ, World Premier Int Immunol Frontier Res Ctr, Host Def Lab, Suita, Osaka 565, Japan; [Hayball, John; Diener, Kerrilyn R.] Univ S Australia, Sansom Inst, Expt Therapeut Lab, Adelaide, SA 5001, Australia; [Diener, Kerrilyn R.] Univ Adelaide, Robinson Inst, Adelaide, SA 5005, Australia; [Baines, Katherine J.; Simpson, Jodie L.] John Hunter Hosp, Hunter Med Res Inst, Dept Resp & Sleep Med, Newcastle, NSW, Australia	University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Queensland; University of Queensland; University of Queensland; Osaka University; University of South Australia; Robinson Research Institute; University of Adelaide; Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle	Phipps, S (corresponding author), Univ Queensland, Sch Biomed Sci, S Lucia, Qld 4072, Australia.	s.phipps@uq.edu.au	Lalwani, Amit/F-6158-2012; Lynch, Jason/G-2991-2016; Phipps, Simon/F-9170-2010; Kaiko, Gerard/ABC-2169-2021; BAINES, KATHERINE JOANNE/G-7654-2013; Foster, Paul/G-5057-2013; SIMPSON, JODIE LOUISE/G-7639-2013; Akira, Shizuo/C-3134-2009; Davidson, Sophia/AAA-4581-2022; Spann, Kirsten/B-4524-2013; Hayball, John D/F-4137-2013; Loh, Zhixuan/G-4104-2015	Lynch, Jason/0000-0003-0889-2616; Phipps, Simon/0000-0002-7388-3612; Kaiko, Gerard/0000-0002-3167-3174; BAINES, KATHERINE JOANNE/0000-0002-4240-6581; SIMPSON, JODIE LOUISE/0000-0002-3626-680X; Spann, Kirsten/0000-0003-0567-8382; Hayball, John D/0000-0002-3089-4506; Loh, Zhixuan/0000-0002-4124-9502; , Paul/0000-0002-0827-8299; Diener, Kerrilyn/0000-0001-8417-5542	National Health and Medical Research Council of Australia; National Health and Medical Research Council	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Supported by a National Health and Medical Research Council of Australia project grant (to S.P. and J.L.S.).; Disclosure of potential conflict of interest: G. E. Kaiko has received travel support from the Keystone Symposia. J. L. Simpson and S. Phipps have received grants from the National Health and Medical Research Council. The rest of the authors declare that they have no relevant conflicts of interest.	AHERNE W, 1970, J CLIN PATHOL, V23, P7, DOI 10.1136/jcp.23.1.7; Bem RA, 2011, AM J PHYSIOL-LUNG C, V301, pL148, DOI 10.1152/ajplung.00065.2011; Brasch-Andersen C, 2008, ALLERGY, V63, P1235, DOI 10.1111/j.1398-9995.2008.01699.x; Bufe A, 2002, INT ARCH ALLERGY IMM, V127, P82, DOI 10.1159/000048173; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Davidson S, 2011, J IMMUNOL, V186, P5938, DOI 10.4049/jimmunol.1002635; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Doull IJM, 1997, BMJ-BRIT MED J, V315, P858, DOI 10.1136/bmj.315.7112.858; Gehlhar K, 2006, CLIN EXP ALLERGY, V36, P331, DOI 10.1111/j.1365-2222.2006.02450.x; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Greiff L, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-53; Grissell TV, 2005, AM J RESP CRIT CARE, V172, P433, DOI 10.1164/rccm.200412-1621OC; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; Haagerup A, 2004, ALLERGY, V59, P88, DOI 10.1111/j.1398-9995.2004.00294.x; Hagendorens MM, 2003, CLIN EXP ALLERGY, V33, P633, DOI 10.1046/j.1365-2222.2003.01649.x; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Huber JP, 2010, J IMMUNOL, V185, P813, DOI 10.4049/jimmunol.1000469; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kaiko GE, 2010, J IMMUNOL, V185, P4681, DOI 10.4049/jimmunol.1001758; Kay AB, 2004, TRENDS IMMUNOL, V25, P477, DOI 10.1016/j.it.2004.07.006; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kroegel C, 2009, Pneumologie, V63, P307, DOI 10.1055/s-0029-1214738; Kusel MMH, 2012, EUR RESPIR J, V39, P876, DOI 10.1183/09031936.00193310; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Matsuda H, 2002, AM J RESP CRIT CARE, V166, P1050, DOI 10.1164/rccm.2110066; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Moller-Larsen S, 2008, THORAX, V63, P1064, DOI 10.1136/thx.2007.094128; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Parry DE, 2000, J ALLERGY CLIN IMMUN, V105, P692, DOI 10.1067/mai.2000.104785; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Pritchard AL, 2012, J IMMUNOL, V188, P5898, DOI 10.4049/jimmunol.1103507; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Roponen M, 2010, EUR RESPIR J, V35, P64, DOI 10.1183/09031936.00172008; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Schandene L, 1996, J CLIN INVEST, V97, P309, DOI 10.1172/JCI118417; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sly PD, 2011, CURR OPIN ALLERGY CL, V11, P24, DOI 10.1097/ACI.0b013e328342309d; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stetson DB, 2006, IMMUNITY, V25, P373, DOI 10.1016/j.immuni.2006.08.007; Swiecki M, 2010, IMMUNITY, V33, P955, DOI 10.1016/j.immuni.2010.11.020; Sykes A, 2012, J ALLERGY CLIN IMMUN, V129, P1506, DOI 10.1016/j.jaci.2012.03.044; Thomas PG, 2009, IMMUNITY, V30, P566, DOI 10.1016/j.immuni.2009.02.006; Upham JW, 2009, J ALLERGY CLIN IMMUN, V124, P707, DOI 10.1016/j.jaci.2009.07.009; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Zhang Q, 2009, J NANJING MED U, V23, P25	52	53	54	0	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1331	U132		10.1016/j.jaci.2013.02.041	http://dx.doi.org/10.1016/j.jaci.2013.02.041			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23561801				2022-12-18	WOS:000318912200009
J	Thyssen, JP; Thuesen, B; Huth, C; Standl, M; Carson, CG; Heinrich, J; Kramer, U; Kratzsch, J; Berg, ND; Menne, T; Johansen, JD; Carlsen, BC; Schwab, S; Thorand, B; Munk, M; Wallaschofski, H; Heickendorff, L; Meldgaard, M; Szecsi, PB; Stender, S; Bonnelykke, K; Weidinger, S; Bisgaard, H; Linneberg, A				Thyssen, Jacob P.; Thuesen, Betina; Huth, Cornelia; Standl, Marie; Carson, Charlotte G.; Heinrich, Joachim; Kraemer, Ursula; Kratzsch, Jurgen; Berg, Nikolaj D.; Menne, Torkil; Johansen, Jeanne D.; Carlsen, Berit C.; Schwab, Sigrid; Thorand, Barbara; Munk, Marianne; Wallaschofski, Henri; Heickendorff, Lene; Meldgaard, Michael; Szecsi, Pal B.; Stender, Steen; Bonnelykke, Klaus; Weidinger, Stephan; Bisgaard, Hans; Linneberg, Allan			Skin barrier abnormality caused by filaggrin (FLG) mutations is associated with increased serum 25-hydroxyvitamin D concentrations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							OF-FUNCTION VARIANTS; ATOPIC-DERMATITIS; SENSITIVITY		[Thyssen, Jacob P.; Menne, Torkil; Johansen, Jeanne D.; Carlsen, Berit C.] Univ Copenhagen, Gentofte Hosp, Natl Allergy Res Ctr, Dept Dermatoallergol, Hellerup, Denmark; [Meldgaard, Michael; Szecsi, Pal B.; Stender, Steen] Univ Copenhagen, Gentofte Hosp, Dept Clin Biochem, Hellerup, Denmark; [Thuesen, Betina; Berg, Nikolaj D.; Linneberg, Allan] Univ Copenhagen, Res Ctr Prevent & Hlth, Glostrup Hosp, Glostrup, Denmark; [Huth, Cornelia; Schwab, Sigrid; Thorand, Barbara] German Res Ctr Environm Hlth, Inst Epidemiol 2, Helmholtz Zentrum Muenchen, Neuherberg, Germany; [Standl, Marie; Heinrich, Joachim] German Res Ctr Environm Hlth, Inst Epidemiol 1, Helmholtz Zentrum Muenchen, Neuherberg, Germany; [Kraemer, Ursula] Univ Dusseldorf, IUF, Leibniz Inst Umweltmed Forsch, D-40225 Dusseldorf, Germany; [Kratzsch, Jurgen] Univ Hosp Leipzig, Fac Med, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany; [Munk, Marianne] Immunodiagnost Syst Nord, Herlev, Denmark; [Wallaschofski, Henri] Univ Med, Inst Clin Chem & Lab Med, Greifswald, Germany; [Heickendorff, Lene] Aarhus Univ Hosp, Dept Clin Biochem, DK-8000 Aarhus, Denmark; [Weidinger, Stephan] Univ Hosp Schleswig Holstein, Dept Dermatol Venereol & Allergy, Kiel, Germany; [Huth, Cornelia] German Ctr Diabet Res DZD eV, Neuherberg, Germany	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Heinrich Heine University Dusseldorf; Leibniz Institut fur Umweltmedizinische Forschung (IUF); Leipzig University; Aarhus University; University of Kiel; Schleswig Holstein University Hospital	Thyssen, JP (corresponding author), Univ Copenhagen, Gentofte Hosp, Natl Allergy Res Ctr, Dept Dermatoallergol, Hellerup, Denmark.	jacob.p.thyssen@regionh.dk	Bisgaard, Hans/N-4761-2016; Kronow, Joern/B-1054-2011; Thorand, Barbara/B-5349-2014; Heinrich, Joachim/N-1720-2013; Huth, Cornelia/B-5350-2014; Thyssen, Jacob/ABD-8517-2020; Johansen, Jeanne/AAM-6382-2021; Weidinger, Stephan/C-8461-2011	Bisgaard, Hans/0000-0003-4131-7592; Thorand, Barbara/0000-0002-8416-6440; Heinrich, Joachim/0000-0002-9620-1629; Huth, Cornelia/0000-0003-2421-433X; Johansen, Jeanne/0000-0002-3537-8463; Weidinger, Stephan/0000-0003-3944-252X; Standl, Marie/0000-0002-5345-2049; Szecsi, Pal/0000-0003-3446-0411; Thyssen, Jacob Pontoppidan/0000-0003-3770-1743; Thuesen, Betina/0000-0001-9772-4344; Linneberg, Allan/0000-0002-0994-0184; Bonnelykke, Klaus/0000-0003-2003-1018	Lundbeck Foundation [R108-2012-10225] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden)		Barresi C, 2011, J INVEST DERMATOL, V131, P188, DOI 10.1038/jid.2010.231; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Kezic S, 2011, ALLERGY, V66, P934, DOI 10.1111/j.1398-9995.2010.02540.x; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Mildner M, 2010, J INVEST DERMATOL, V130, P2286, DOI 10.1038/jid.2010.115; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; SCOTT IR, 1986, DEV BIOL, V115, P84, DOI 10.1016/0012-1606(86)90230-7; Winge MCG, 2011, BRIT J DERMATOL, V165, P1074, DOI 10.1111/j.1365-2133.2011.10475.x	9	53	54	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1204	1207		10.1016/j.jaci.2012.06.046	http://dx.doi.org/10.1016/j.jaci.2012.06.046			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	22921868				2022-12-18	WOS:000310571400026
J	Ashmole, I; Duffy, SM; Leyland, ML; Morrison, VS; Begg, M; Bradding, P				Ashmole, Ian; Duffy, S. Mark; Leyland, Mark L.; Morrison, Valerie S.; Begg, Malcolm; Bradding, Peter			CRACM/Orai ion channel expression and function in human lung mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CRACM; Orai; Ca2+; asthma; mast cell; histamine; leukotriene C-4; cytokine; GSK-7975A; Synta-66	K+ CHANNELS; MEDIATOR RELEASE; CALCIUM CURRENT; CA2+ CHANNELS; PORE SUBUNIT; CRAC CHANNEL; STORE; ACTIVATION; INFLUX; RESPONSES	Background: Influx of extracellular Ca2+ into human lung mast cells (HLMCs) is essential for the FceRI-dependent release of preformed granule-derived mediators and newly synthesized autacoids and cytokines. However, the identity of the ion channels underlying this Ca2+ influx is unknown. The recently discovered members of the CRACM/Orai ion channel family that carries the Ca2+ release-activated Ca2+ current are candidates. Objectives: To investigate the expression and function of CRACM channels in HLMCs. Methods: CRACM mRNA, protein, and functional expression were examined in purified HLMCs and isolated human bronchus. Results: CRACM1, -2, and -3 mRNA transcripts and CRACM1 and -2 proteins were detectable in HLMCs. A CRACM-like current was detected following FceRI-dependent HLMC activation and also in HLMCs dialyzed with 30 mu M inositol triphosphate. The Ca2+-selective current obtained under both conditions was blocked by 10 mu M La3+ and Gd3+, known blockers of CRACM channels, and 2 distinct and specific CRACM-channel blockers-GSK-7975A and Synta-66. Both blockers reduced FceRI-dependent Ca2+ influx, and 3 mu M GSK-7975A and Synta-66 reduced the release of histamine, leukotriene C-4, and cytokines (IL-5/-8/-13 and TNF alpha) by up to 50%. Synta-66 also inhibited allergen-dependent bronchial smooth muscle contraction in ex vivo tissue. Conclusions: The presence of CRACM channels, a CRACM-like current, and functional inhibition of HLMC Ca2+ influx, mediator release, and allergen-induced bronchial smooth muscle contraction by CRACM-channel blockers supports a role for CRACM channels in FceRI-dependent HLMC secretion. CRACM channels are therefore a potential therapeutic target in the treatment of asthma and related allergic diseases. (J Allergy Clin Immunol 2012;129:1628-35.)	[Ashmole, Ian; Duffy, S. Mark; Bradding, Peter] Univ Leicester, Dept Infect Immun & Inflammat, Inst Lung Hlth, Leicester, Leics, England; [Leyland, Mark L.] Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; [Morrison, Valerie S.; Begg, Malcolm] GlaxoSmithKline, Resp Therapy Area Unit, Stevenage, Herts, England	University of Leicester; University of Leicester; GlaxoSmithKline	Bradding, P (corresponding author), Glenfield Gen Hosp, Dept Resp Med, Groby Rd, Leicester LE3 9QP, Leics, England.	pbradding@hotmail.com		Begg, Malcolm/0000-0001-9508-3424; Bradding, Peter/0000-0001-8403-0319	Wellcome Trust [087499]; European Regional Development Fund [05567]; GlaxoSmithKline	Wellcome Trust(Wellcome TrustEuropean Commission); European Regional Development Fund(European Commission); GlaxoSmithKline(GlaxoSmithKline)	This work was supported by a Wellcome Trust Project Grant (grant no. 087499) and was conducted in laboratories part funded by European Regional Development Fund no. 05567.; P. Bradding has received travel grants from GlaxoSmithKline. The rest of the authors have declared that they have no conflict of interest.	Bradding P, 2005, CHEM IMMUNOL ALLERGY, V87, P163, DOI 10.1159/000087643; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Bradding P, 2003, J LEUKOCYTE BIOL, V73, P614, DOI 10.1189/jlb.1202602; BRADDING P, 2000, ASTHMA RHINITIS, P319; Bradding P, 2009, THORAX, V64, P278, DOI 10.1136/thx.2008.106427; Chandy KG, 2004, TRENDS PHARMACOL SCI, V25, P280, DOI 10.1016/j.tips.2004.03.010; CHONG LK, 1995, AM J RESP CELL MOL, V13, P540, DOI 10.1165/ajrcmb.13.5.7576689; CHURCH MK, 1982, J IMMUNOL, V129, P2116; Cruse G, 2006, THORAX, V61, P880, DOI 10.1136/thx.2006.060319; Di Capite J, 2009, J ALLERGY CLIN IMMUN, V124, P1014, DOI 10.1016/j.jaci.2009.08.030; Duffy SM, 2004, J ALLERGY CLIN IMMUN, V114, P66, DOI 10.1016/j.jaci.2004.04.005; Duffy SM, 2003, J ALLERGY CLIN IMMUN, V112, P965, DOI 10.1016/j.jaci.2003.07.004; Duffy SM, 2001, J IMMUNOL, V167, P4261, DOI 10.4049/jimmunol.167.8.4261; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Giannini D, 1996, CHEST, V110, P1452, DOI 10.1378/chest.110.6.1452; Gwack Y, 2007, J BIOL CHEM, V282, P16232, DOI 10.1074/jbc.M609630200; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Lewis RS, 2003, BIOCHEM SOC T, V31, P925; Lis A, 2007, CURR BIOL, V17, P794, DOI 10.1016/j.cub.2007.03.065; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Ng SW, 2008, J BIOL CHEM, V283, P31348, DOI 10.1074/jbc.M804942200; OKAYAMA Y, 1992, CLIN EXP ALLERGY, V22, P401, DOI 10.1111/j.1365-2222.1992.tb03102.x; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peel SE, 2008, AM J RESP CELL MOL, V38, P744, DOI 10.1165/rcmb.2007-0395OC; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Sanmugalingam D, 2000, J LEUKOCYTE BIOL, V68, P38; Shepherd MC, 2007, AM J RESP CELL MOL, V37, P525, DOI 10.1165/rcmb.2006-0358OC; Swystun VA, 2000, J ALLERGY CLIN IMMUN, V106, P57; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2008, NAT IMMUNOL, V9, P89, DOI 10.1038/ni1550; Wareham K, 2009, BRIT J PHARMACOL, V157, P1215, DOI 10.1111/j.1476-5381.2009.00287.x; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Yoshimaru T, 2009, MOL IMMUNOL, V46, P1267, DOI 10.1016/j.molimm.2008.11.011; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	36	53	53	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1628	+		10.1016/j.jaci.2012.01.070	http://dx.doi.org/10.1016/j.jaci.2012.01.070			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22409987	hybrid, Green Published			2022-12-18	WOS:000304764600025
J	Novak, N				Novak, Natalija			An update on the role of human dendritic cells in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; dendritic cells; inflammation; skin barrier; tolerance	THYMIC STROMAL LYMPHOPOIETIN; HISTAMINE H-4 RECEPTOR; FC-EPSILON-RI; ANTIGEN-PRESENTING CELLS; IFN-GAMMA RESPONSE; LANGERHANS CELLS; T-CELLS; ECZEMA HERPETICUM; GENE-EXPRESSION; IMMUNE-RESPONSES	Dendritic cells (DCs) are without a doubt important key skin cells that connect information from the environment with the innate and adaptive immune system. Their function is decisive for the initiation and inhibition of immune responses, and therefore they play a central role for both the healthy and diseased states of the skin. The type, maturation stage, and function of DCs, as well as the micromilieu in which they are located and their contact with cellular partners in the surrounding area, are important cofactors that direct maintenance of immune homeostasis or breakout of inflammatory reactions in patients with chronic inflammatory skin diseases, such as atopic dermatitis. Thus better knowledge about the exact proinflammatory and anti-inflammatory properties of DCs in patients with atopic dermatitis and the disease-specific roles of DC subtypes would allow us to target these important immune cells with versatile functions for therapeutic purpose. (J Allergy Clin Immunol 2012;129:879-86.)	Univ Bonn, Dept Dermatol & Allergy, D-53105 Bonn, Germany	University of Bonn	Novak, N (corresponding author), Univ Bonn, Dept Dermatol & Allergy, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Natalija.Novak@ukb.uni-bonn.de			Deutsche Forschungsgemeinschaft [SFB704 TPA4, FOR208 TPA1]; BONFOR of the University of Bonn	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); BONFOR of the University of Bonn	Supported by grants from the Deutsche Forschungsgemeinschaft (SFB704 TPA4 and FOR208 TPA1) and a BONFOR grant of the University of Bonn.	Alonso MN, 2011, BLOOD, V118, P3311, DOI 10.1182/blood-2011-03-341065; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Bin LH, 2011, J INVEST DERMATOL, V131, P2213, DOI 10.1038/jid.2011.202; Bobr A, 2010, J IMMUNOL, V185, P4724, DOI 10.4049/jimmunol.1001802; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; De BA, 2011, J ALLERGY CLIN IMMUN, V127, P773; Dijkstra D, 2008, J INVEST DERMATOL, V128, P1696, DOI 10.1038/sj.jid.5701250; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elser B, 2002, IMMUNITY, V17, P703, DOI 10.1016/S1074-7613(02)00471-5; Eyerich K, 2008, INT ARCH ALLERGY IMM, V145, P213, DOI 10.1159/000109290; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, P574, DOI 10.1016/j.jaci.2011.05.016; Fujita H, 2009, P NATL ACAD SCI USA, V106, P21795, DOI 10.1073/pnas.0911472106; Gabrielsson S, 2004, ACTA DERM-VENEREOL, V84, P339, DOI 10.1080/00015550410026957; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Gilles S, 2011, J ALLERGY CLIN IMMUN, V127, P454, DOI 10.1016/j.jaci.2010.12.1082; Gros E, 2011, J ALLERGY CLIN IMMUN, V128, P1015, DOI 10.1016/j.jaci.2011.05.043; Gros E, 2009, J ALLERGY CLIN IMMUN, V124, P753, DOI 10.1016/j.jaci.2009.07.004; Gschwandtner M, 2010, ALLERGY, V65, P840, DOI 10.1111/j.1398-9995.2009.02279.x; Gschwandtner M, 2008, J INVEST DERMATOL, V128, P2783, DOI 10.1038/jid.2008.153; Gschwandtner M, 2011, IMMUNOLOGY, V132, P49, DOI 10.1111/j.1365-2567.2010.03336.x; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Hatano Y, 2005, J INVEST DERMATOL, V124, P786, DOI 10.1111/j.0022-202X.2005.23651.x; Hinz T, 2011, ALLERGY, V66, P925, DOI 10.1111/j.1398-9995.2010.02538.x; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Hvid M, 2011, J INVEST DERMATOL, V131, P150, DOI 10.1038/jid.2010.277; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Kashyap M, 2011, J IMMUNOL, V187, P1207, DOI 10.4049/jimmunol.1100355; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P869, DOI 10.1067/mai.2003.1347; Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527; Kwiek B, 2008, J ALLERGY CLIN IMMUN, V122, P126, DOI 10.1016/j.jaci.2008.05.005; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Lundberg K, 2011, EUR J PHARMACOL, V651, P197, DOI 10.1016/j.ejphar.2010.10.065; Mandron M, 2006, J ALLERGY CLIN IMMUN, V117, P1141, DOI 10.1016/j.jaci.2005.12.1360; Merad M, 2008, NAT REV IMMUNOL, V8, P935, DOI 10.1038/nri2455; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Novak N, 2011, ALLERGY, V66, P830, DOI 10.1111/j.1398-9995.2011.02571.x; Novak N, 2010, CLIN EXP IMMUNOL, V161, P28, DOI 10.1111/j.1365-2249.2010.04162.x; O'Neill CA, 2011, EXP DERMATOL, V20, P88, DOI 10.1111/j.1600-0625.2010.01206.x; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Peng WM, 2011, ALLERGY, V66, P605, DOI 10.1111/j.1398-9995.2010.02524.x; Peng WM, 2007, J INVEST DERMATOL, V127, P1261, DOI 10.1038/sj.jid.5700657; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Silva NM, 2002, INFECT IMMUN, V70, P859, DOI 10.1128/IAI.70.2.859-868.2002; Simon D, 2005, ALLERGY, V60, P944, DOI 10.1111/j.1398-9995.2005.00798.x; Simon D, 2004, J ALLERGY CLIN IMMUN, V114, P887, DOI 10.1016/j.jaci.2004.05.066; Stary G, 2005, INT ARCH ALLERGY IMM, V138, P278, DOI 10.1159/000088865; Stary G, 2011, J IMMUNOL, V186, P103, DOI 10.4049/jimmunol.1002485; Steinbrink K, 2009, HUM IMMUNOL, V70, P289, DOI 10.1016/j.humimm.2009.02.003; Taher YA, 2008, J ALLERGY CLIN IMMUN, V121, P983, DOI 10.1016/j.jaci.2007.11.021; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; Voorhees T, 2011, CELL IMMUNOL, V267, P17, DOI 10.1016/j.cellimm.2010.10.010; Wollenberg A, 1999, CYTOMETRY, V37, P147, DOI 10.1002/(SICI)1097-0320(19991001)37:2<147::AID-CYTO8>3.0.CO;2-Y; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; WOLLENBERG A, 1995, LANCET, V346, P1626, DOI 10.1016/S0140-6736(95)91958-9; Zaba LC, 2009, J INVEST DERMATOL, V129, P302, DOI 10.1038/jid.2008.225; Ziegler SF, 2010, CURR OPIN IMMUNOL, V22, P795, DOI 10.1016/j.coi.2010.10.020	65	53	57	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					879	886		10.1016/j.jaci.2012.01.062	http://dx.doi.org/10.1016/j.jaci.2012.01.062			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22385631				2022-12-18	WOS:000302144600001
J	Bhan, I; Camargo, CA; Wenger, J; Ricciardi, C; Ye, J; Borregaard, N; Thadhani, R				Bhan, Ishir; Camargo, Carlos A., Jr.; Wenger, Julia; Ricciardi, Catherine; Ye, Jun; Borregaard, Niels; Thadhani, Ravi			Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VITAMIN-D; ANTIMICROBIAL PEPTIDE; PLASMA; HCAP18		[Bhan, Ishir; Ye, Jun; Thadhani, Ravi] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nephrol,Dept Med, Boston, MA 02115 USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol,Dept Med, Boston, MA USA; [Ricciardi, Catherine] MIT, Clin Res Ctr, Cambridge, MA 02139 USA; [Borregaard, Niels] Univ Copenhagen, Dept Hematol, Rigshosp, DK-1168 Copenhagen, Denmark	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Rigshospitalet; University of Copenhagen	Bhan, I (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nephrol,Dept Med, Boston, MA 02115 USA.	ibhan@partners.org	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK081677] Funding Source: NIH RePORTER; NIDDK NIH HHS [K23 DK081677, K23 DK081677-02, K23 1K23DK081677] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JS, 2009, J IMMUNOL, V182, P4289, DOI 10.4049/jimmunol.0803736; Bals R, 1999, INFECT IMMUN, V67, P6084, DOI 10.1128/IAI.67.11.6084-6089.1999; Gombart AF, 2009, CLIN INFECT DIS, V48, P418, DOI 10.1086/596314; Hata TR, 2008, J ALLERGY CLIN IMMUN, V122, P829, DOI 10.1016/j.jaci.2008.08.020; Hollis BW, 2005, J NUTR, V135, P317, DOI 10.1093/jn/135.2.317; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Martineau AR, 2007, AM J RESP CRIT CARE, V176, P208, DOI 10.1164/rccm.200701-007OC; Nilsson MF, 1999, INFECT IMMUN, V67, P2561, DOI 10.1128/IAI.67.5.2561-2566.1999; Sorensen O, 1997, J IMMUNOL METHODS, V206, P53, DOI 10.1016/S0022-1759(97)00084-7	9	53	60	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1302	1304		10.1016/j.jaci.2010.12.1097	http://dx.doi.org/10.1016/j.jaci.2010.12.1097			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21310475	Green Accepted			2022-12-18	WOS:000290018600030
J	Costa, DJ; Amouyal, M; Lambert, P; Ryan, D; Schunemann, HJ; Daures, JP; Bousquet, J; Bousquet, PJ				Costa, David J.; Amouyal, Michel; Lambert, Philippe; Ryan, Dermot; Schuenemann, Holger J.; Daures, Jean Pierre; Bousquet, Jean; Bousquet, Philippe J.		Languedoc-Roussillon Teaching Gen	How representative are clinical study patients with allergic rhinitis in primary care?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; randomized controlled trial; Allergic Rhinitis and its Impact on Asthma; Global Allergy and Asthma European Network; general practitioner; guidelines	ASTHMA; GUIDELINES; QUALITY; IMPACT; IMPLEMENTATION; MANAGEMENT; DIAGNOSIS; SEVERITY; GA(2)LEN; GRADE	Background: Guidelines are the cornerstone of health care decision making and are based on the best available evidence, ideally large randomized controlled trials (RCTs). Although guidelines target typical patients, RCTs are often based on narrow inclusion and exclusion criteria. Objectives: We explored to what extent typical patients, such as those consulting general practitioners for allergic rhinitis, differ from patients enrolled in RCTs. Methods: We conducted a prospective cohort study including all the consecutive patients with allergic rhinitis cared for by general practitioners in the Languedoc-Roussillon region of France within 2 weeks during the grass pollen season. We evaluated how the characteristics of these patients differed from those of patients included in the 4 largest placebo-controlled RCTs of persistent and intermittent allergic rhinitis. Results: Three hundred eleven patients seen by 48 general practitioners were enrolled in this study. Only 7.4% (95% CI, 4.5% to 10.3%) of the patients would have been enrolled in the RCTs. The primary reasons for this difference were as follows: diagnosis of allergy based on skin test results, serum specific IgE levels, or both (20.4%); severity of allergic rhinitis (11.5%); other chronic diseases (11.4%); history of sinusitis (10.4%); and asthma comorbidity (10.1%). A sensitivity analysis excluding contraception and the diagnosis of allergy showed that the percentage of representative patients increased to 20.2% (95% CI, 15.8% to 24.7%). Conclusion: Only a small proportion of patients with allergic rhinitis seen in the primary care setting for allergic rhinitis would be eligible for RCTs. Thus guideline developers and health decision makers need to make careful judgments about the directness of the evidence from RCTs conducted in highly controlled settings. (J Allergy Clin Immunol 2011;127:920-6.)	[Bousquet, Jean; Bousquet, Philippe J.] Hop Arnaud de Villeneuve, Serv Malad Resp, F-34295 Montpellier, France; [Costa, David J.; Amouyal, Michel; Lambert, Philippe] Univ Montpellier I, Dept Med Gen, Nimes, France; [Ryan, Dermot] Woodbrook Med Ctr, Loughborough, Leics, England; [Ryan, Dermot] Univ Aberdeen, Dept Gen Practice & Primary Care, Aberdeen, Scotland; [Schuenemann, Holger J.] McMaster Univ, Hamilton, ON, Canada; [Daures, Jean Pierre] Hop Caremeau, Dept Biostat Epidemiol Clin Sante Publ & Informat, Nimes, France; [Bousquet, Philippe J.] Inserm 1018, Ctr Rech Epidemiol & Sante Populat, Villejuif, France	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; University of Aberdeen; McMaster University; Universite de Montpellier; CHU de Nimes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Bousquet, J (corresponding author), Hop Arnaud de Villeneuve, Serv Malad Resp, F-34295 Montpellier, France.	Jean.bousquet@inserm.fr	Bousquet, Philippe Jean/AAW-8608-2021; Bousquet, Jean/O-4221-2019; Ryan, Dermot/AAJ-2329-2021; costa, david/AAA-1971-2020	Bousquet, Philippe Jean/0000-0002-0217-5483; Ryan, Dermot/0000-0002-4115-7376; Schunemann, Holger/0000-0003-3211-8479	European Union [FOOD-CT-2004-506378]; CHRU, Nimes, France	European Union(European Commission); CHRU, Nimes, France	Members of the Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN), supported by European Union Framework programme for research, contract no. FOOD-CT-2004-506378.; Supported by CHRU, Nimes, France.	Bachert C, 2004, J ALLERGY CLIN IMMUN, V114, P838, DOI 10.1016/j.jaci.2004.05.070; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2006, J ALLERGY CLIN IMMUN, V117, P158, DOI 10.1016/j.jaci.2005.09.047; Bousquet J, 2003, ALLERGY, V58, P733, DOI 10.1034/j.1398-9995.2003.00076.x; Bousquet J, 2009, ALLERGY, V64, P1516, DOI 10.1111/j.1398-9995.2009.02115.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet J, 2010, INT ARCH ALLERGY IMM, V153, P395, DOI 10.1159/000316351; Bousquet J, 2009, INT ARCH ALLERGY IMM, V150, P75, DOI 10.1159/000210383; Bousquet PJ, 2007, ALLERGY, V62, P367, DOI 10.1111/j.1398-9995.2006.01276.x; Bousquet PJ, 2009, J ALLERGY CLIN IMMUN, V123, P1349, DOI 10.1016/j.jaci.2009.02.033; Brozek JL, 2008, ALLERGY, V63, P38, DOI 10.1111/j.1398-9995.2007.01560.x; Costa David J, 2009, Prim Care Respir J, V18, P250, DOI 10.4104/pcrj.2009.00028; Fantin S, 2008, ALLERGY, V63, P924, DOI 10.1111/j.1398-9995.2008.01668.x; Guyatt G, 2006, CHEST, V129, P174, DOI 10.1378/chest.129.1.174; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE; Heinzerling L, 2005, ALLERGY, V60, P1287, DOI 10.1111/j.1398-9995.2005.00895.x; Herland K, 2005, RESP MED, V99, P11, DOI 10.1016/j.rmed.2004.03.026; Holgate S, 2008, EUR RESPIR J, V32, P1433, DOI 10.1183/09031936.00053108; Karanicolas PJ, 2009, J CLIN EPIDEMIOL, V62, P479, DOI 10.1016/j.jclinepi.2008.02.009; Levy Mark L, 2009, Prim Care Respir J, V18, P313, DOI 10.4104/pcrj.2009.00042; Ryan D, 2008, ALLERGY, V63, P981, DOI 10.1111/j.1398-9995.2008.01653.x; Ryan Dermot, 2005, Prim Care Respir J, V14, P204, DOI 10.1016/j.pcrj.2005.03.009; SACKETT DL, 1995, HEALTH ECON, V4, P249, DOI 10.1002/hec.4730040401; *SCOTT INT GUID NE, 2008, SIGN50 GUID DEV HDB; Smith HE, 2009, J ALLERGY CLIN IMMUN, V123, P646, DOI 10.1016/j.jaci.2008.11.005; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; van Weel C, 2008, ALLERGY, V63, P1005, DOI 10.1111/j.1398-9995.2008.01655.x; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; Ziegenfuss J T Jr, 1995, Am J Med Qual, V10, P213, DOI 10.1177/0885713X9501000408; Zwarenstein Merrick, 2009, Evid Based Med, V14, P101, DOI 10.1136/ebm.14.4.101	32	53	53	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					920	U144		10.1016/j.jaci.2010.10.058	http://dx.doi.org/10.1016/j.jaci.2010.10.058			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21269670				2022-12-18	WOS:000289055800013
J	Beebe, A; Gelfand, EW; Bender, B				Beebe, Anya; Gelfand, Erwin W.; Bender, Bruce			A randomized trial to test the effectiveness of art therapy for children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Children; asthma; art therapy	ILLNESS	Background: Art therapy has been used to help children cope with chronic illness but has not been specifically tested with children who have asthma. Objective: To test an art therapy intervention in a randomized controlled trial in children with asthma. Methods: Twenty-two children with asthma were randomized to an active art therapy or wait-list control group. Those in the active art therapy group participated in 60-minute art therapy sessions once a week for 7 weeks. Sessions included specific art therapy tasks designed to encourage expression, discussion, and problem-solving in response to the emotional burden of chronic illness. Measures taken at baseline, immediately after, and 6 months after the final art therapy session included the Formal Elements Art Therapy Scale applied to the Person Picking an Apple from a Tree assessment, the parent and child versions of the Pediatric Quality of Life Asthma Module, and the Beck Youth Inventories. Those children assigned to the wait-list control group completed all evaluations at the same intervals as the children receiving art therapy but did not receive the art therapy interventions. Results: Score changes from baseline to completion of art therapy indicated (1) improved problem-solving and affect drawing scores; (2) improved worry, communication, and total quality of life scores; and (3) improved Beck anxiety and self concept scores in the active group relative to the control group. At 6 months, the active group maintained some positive changes relative to the control group including (1) drawing affect scores, (2) the worry and quality of life scores, and (3) the Beck anxiety score. Frequency of asthma exacerbations before and after the 6-month study interval did not differ between the 2 groups. Conclusion: This was the first randomized trial demonstrating that children with asthma receive benefit from art therapy that includes decreased anxiety and increased quality of life. (J Allergy Clin Immunol 2010;126:263-6.)	[Beebe, Anya; Gelfand, Erwin W.; Bender, Bruce] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA	National Jewish Health	Bender, B (corresponding author), Natl Jewish Hlth, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	beebea@njhealth.com						Beck JS., 2005, BECK YOUTH INVENTORI; Bender BG, 1995, SCHOOL PSYCHOL QUART, V10, P274, DOI 10.1037/h0088309; Bender B, 2008, J ALLERGY CLIN IMMUN, V122, P490, DOI 10.1016/j.jaci.2008.05.041; Blackman JA, 2007, J DEV BEHAV PEDIATR, V28, P92, DOI 10.1097/01.DBP.0000267557.80834.e5; Gabriels RL, 2000, J ASTHMA, V37, P565, DOI 10.3109/02770900009090811; GANNT T, 2003, FORMAL ELEMENTS ART; MALCHIODI K, 1999, MED ART THERAPY CHIL; McQuaid EL, 2001, J DEV BEHAV PEDIATR, V22, P430, DOI 10.1097/00004703-200112000-00011; PERRIN EC, 1984, PEDIATR CLIN N AM, V31, P19; STRUNK R C, 1985, Journal of the American Medical Association, V254, P1193, DOI 10.1001/jama.254.9.1193; Varni JW, 2004, J BEHAV MED, V27, P297, DOI 10.1023/B:JOBM.0000028500.53608.2c; Weinberg D.J., 1985, ART THER, V2, P66, DOI [https://doi.org/10.1080/07421656.1985.10758788, DOI 10.1080/07421656.1985.10758788]	12	53	53	1	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					263	U14		10.1016/j.jaci.2010.03.019	http://dx.doi.org/10.1016/j.jaci.2010.03.019			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	642IL	20462632				2022-12-18	WOS:000281203800010
J	Makihara, S; Okano, M; Fujiwara, T; Kariya, S; Noda, Y; Higaki, T; Nishizaki, K				Makihara, Seiichiro; Okano, Mitsuhiro; Fujiwara, Tazuko; Kariya, Shin; Noda, Yohei; Higaki, Takaya; Nishizaki, Kazunori			Regulation and characterization of IL-17A expression in patients with chronic rhinosinusitis and its relationship with eosinophilic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Makihara, Seiichiro; Okano, Mitsuhiro; Fujiwara, Tazuko; Kariya, Shin; Noda, Yohei; Higaki, Takaya; Nishizaki, Kazunori] Okayama Univ, Dept Otolaryngol Head & Neck Surg, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan	Okayama University	Makihara, S (corresponding author), Okayama Univ, Dept Otolaryngol Head & Neck Surg, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan.	mokano@cc.okayama-u.ac.jp						Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Bachert Claus, 2007, Clin Allergy Immunol, V20, P163; Bousquet J, 2009, J ALLERGY CLIN IMMUN, V124, P428, DOI 10.1016/j.jaci.2009.06.027; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; Louten J, 2009, J ALLERGY CLIN IMMUN, V123, P1004, DOI 10.1016/j.jaci.2009.04.003; Napolitani G, 2009, EUR J IMMUNOL, V39, P1301, DOI 10.1002/eji.200838969; Okano M, 2009, J ALLERGY CLIN IMMUN, V123, P868, DOI 10.1016/j.jaci.2009.01.047; Saitoh T, 2010, INT ARCH ALLERGY IMM, V151, P8, DOI 10.1159/000232566; Su YC, 2008, J IMMUNOL, V180, P2600, DOI 10.4049/jimmunol.180.4.2600	9	53	57	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2								10.1016/j.jaci.2010.05.014	http://dx.doi.org/10.1016/j.jaci.2010.05.014			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20621345	Green Submitted			2022-12-18	WOS:000281203800032
J	Williams, LK; Peterson, EL; Wells, K; Campbell, J; Wang, MQ; Chowdhry, VK; Walsh, M; Enberg, R; Lanfear, DE; Pladevall, M				Williams, L. Keoki; Peterson, Edward L.; Wells, Karen; Campbell, Janis; Wang, Mingqun; Chowdhry, Vimal K.; Walsh, Matthew; Enberg, Robert; Lanfear, David E.; Pladevall, Manel			A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Medication adherence; inhaled corticosteroids; asthma; randomized controlled trial	OUTCOMES; ADULTS; FEEDBACK	Background: Inhaled corticosteroid (ICS) nonadherence is common among patients with asthma; however, interventions to improve adherence have often been complex and not easily applied to large patient populations. Objective: To assess the effect of supplying patient adherence information to primary care providers. Methods: Patients and providers were members of a health system serving southeast Michigan. Providers (88 intervention; 105 control) and patients (1335 intervention; 1363 control) were randomized together by practice. Patients were age 5 to 56 years, had a diagnosis of asthma, and had existing prescriptions for ICS medication. Adherence was estimated by using prescription and fill data. Unlike clinicians in the control arm, intervention arm providers could view updated ICS adherence information on their patients via electronic prescription software, and further details on patient ICS use could be viewed by selecting that option. The primary outcome was ICS adherence in last 3 months of the study period. Results: At the study end for the intention-to-treat analysis, ICS adherence was not different among patients in the intervention arm compared with those in the control arm (21.3% vs 23.3%, respectively; P = .553). However, adherence was significantly higher among patients whose clinician elected to view their detailed adherence information (35.7%) compared with both control arm patients (P = .026) and intervention arm patients whose provider did not view adherence data (P = .002). Conclusions: Overall, providing adherence information to clinicians did not improve ICS use among patients with asthma. However, patient use may improve when clinicians are sufficiently interested in adherence to view the details of this medication use. (J Allergy Clin Immunol 2010; 126: 225-31.)	[Williams, L. Keoki; Wells, Karen; Chowdhry, Vimal K.; Lanfear, David E.; Pladevall, Manel] Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI USA; [Williams, L. Keoki; Campbell, Janis; Wang, Mingqun; Enberg, Robert; Lanfear, David E.] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA; [Williams, L. Keoki; Peterson, Edward L.] Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital	Williams, LK (corresponding author), Henry Ford Hosp, Ctr Hlth Serv Res, 1 Ford Pl,3A CHSR, Detroit, MI 48202 USA.	kwillia5@hfhs.org			National Heart, Lung, and Blood Institute [HL79055]; National Institute of Allergy and Infectious Diseases [AI61774, AI79139]; National Institute of Diabetes and Digestive and Kidney Diseases [DK64695]; National Institutes of Health; Fund for Henry Ford Hospital; American Asthma Foundation; Merck; National Institutes of Health (NHLBI); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061774, R01AI079139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064695] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fund for Henry Ford Hospital; American Asthma Foundation; Merck(Merck & Company); National Institutes of Health (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants from the National Heart, Lung, and Blood Institute (HL79055), the National Institute of Allergy and Infectious Diseases (AI61774, AI79139), the National Institute of Diabetes and Digestive and Kidney Diseases (DK64695), National Institutes of Health; the Fund for Henry Ford Hospital; and the Strategic Program for Asthma Research of the American Asthma Foundation.; L. K. Williams has received research support from the National Institutes of Health and has served on an advisory board for Merck. E. L. Peterson has received research support from the National Institutes of Health. D. E. Lanfear has received research support from Merck and the National Institutes of Health (NHLBI). The rest of the authors have declared that they have no conflict of interest.	Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; Bender B, 2003, J ALLERGY CLIN IMMUN, V112, P489, DOI 10.1067/mai.2003.1680; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Cramer JA, 1999, J NERV MENT DIS, V187, P53, DOI 10.1097/00005053-199901000-00009; Donner A, 2004, AM J PUBLIC HEALTH, V94, P416, DOI 10.2105/AJPH.94.3.416; Eger M S, 2001, Health Mark Q, V19, P3, DOI 10.1300/J026v19n02_02; Haynes R B, 2002, Cochrane Database Syst Rev, pCD000011; Haynes RB, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub3; Ho PM, 2008, AM HEART J, V155, P772, DOI 10.1016/j.ahj.2007.12.011; Horne R, 1999, PSYCHOL HEALTH, V14, P1, DOI 10.1080/08870449908407311; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Menachemi N, 2009, PEDIATRICS, V123, pS92, DOI 10.1542/peds.2008-1755H; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Onyirimba F, 2003, ANN ALLERG ASTHMA IM, V90, P411, DOI 10.1016/S1081-1206(10)61825-X; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Paris J, 2008, ANN ALLERG ASTHMA IM, V101, P482, DOI 10.1016/S1081-1206(10)60286-4; Pladevall M, 2004, DIABETES CARE, V27, P2800, DOI 10.2337/diacare.27.12.2800; Reddel HK, 2002, BRIT MED J, V324, P146, DOI 10.1136/bmj.324.7330.146; Rigsby MO, 2000, J GEN INTERN MED, V15, P841, DOI 10.1046/j.1525-1497.2000.00127.x; Rosen MI, 2004, BEHAV RES THER, V42, P409, DOI 10.1016/S0005-7967(03)00149-9; SAS Institute Inc, 2004, SAS STAT US GUID VER; Schectman JM, 2004, AM J MED SCI, V327, P19, DOI 10.1097/00000441-200401000-00005; Schectman JM, 2002, DIABETES CARE, V25, P1015, DOI 10.2337/diacare.25.6.1015; Spahn J, 2009, J ALLERGY CLIN IMMUN, V124, P1197, DOI 10.1016/j.jaci.2009.08.042; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; Wells K, 2008, AM J RESP CRIT CARE, V178, P1194, DOI 10.1164/rccm.200808-1233OC; Williams LK, 2007, J ALLERGY CLIN IMMUN, V120, P1153, DOI 10.1016/j.jaci.2007.08.020; Williams LK, 2007, J ALLERGY CLIN IMMUN, V119, P168, DOI 10.1016/j.jaci.2006.09.029; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028	31	53	55	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					225	U6		10.1016/j.jaci.2010.03.034	http://dx.doi.org/10.1016/j.jaci.2010.03.034			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20569973	Green Accepted			2022-12-18	WOS:000281203800005
J	Tachdjian, R; Al Khatib, S; Schwinglshackl, A; Kim, HS; Chen, A; Blasioli, J; Mathias, C; Kim, HY; Umetsu, DT; Oettgen, HC; Chatila, TA				Tachdjian, Raffi; Al Khatib, Shadi; Schwinglshackl, Andreas; Kim, Hong Sook; Chen, Andrew; Blasioli, Julie; Mathias, Clinton; Kim, Hye Young; Umetsu, Dale T.; Oettgen, Hans C.; Chatila, Talal A.			In vivo regulation of the allergic response by the IL-4 receptor alpha chain immunoreceptor tyrosine-based inhibitory motif	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-4 receptor; IL-4; IL-13; immunoreceptor tyrosine-based inhibitory motif; Src homology 2 domain-containing protein tyrosine phosphatase 1; IgE; allergic airway inflammation; asthma	INTERLEUKIN-4 RECEPTOR; SIGNALING PATHWAYS; PHOSPHATASE SHP-1; AIRWAY HYPERREACTIVITY; ASTHMA PATHOGENESIS; GENE-EXPRESSION; MURINE LUNG; INFLAMMATION; PHOSPHORYLATION; SUSCEPTIBILITY	Background: Signaling by IL-4 and IL-13 through the IL-4 receptor a chain (IL-4R alpha) plays a critical role in the pathology of allergic diseases. The IL-4R alpha is endowed with an immunoreceptor tyrosine-based inhibitory motif (ITIM) centered on tyrosine 709 (Y709) in the cytoplasmic domain that binds a number of regulatory phosphatases. The function of the ITIM in the in vivo regulation of IL-4 receptor signaling remains unknown. Objective: We sought to determine the in vivo function of the IL-4R alpha ITIM by using mice in which the ITIM was inactivated by mutagenesis of the tyrosine Y709 residue into phenylalanine (F709). Methods: F709 ITIM mutant mice were derived by means of knock-in mutagenesis. Activation of intracellular signaling cascades by IL-4 and IL-13 was assessed by means of intracellular staining of phosphorylated signaling intermediates and gene expression analysis. In vivo responses to allergic sensitization were assessed by using models of allergic airway inflammation. Results: The F709 mutation increased signal transducer and activator of transcription 6 phosphorylation by IL-4 and, disproportionately, by IL-13. This was associated with exaggerated T(H)2 polarization, enhanced alternative macrophage activation by IL-13, augmented basal and antigen-induced IgE responses, and intensified allergen-induced eosinophilic airway inflammation and hyperreactivity. Conclusions: These results point to a physiologic negative regulatory role for the Y709 ITIM in signaling through IL-4R alpha, especially by IL-13. (J Allergy Clin Immunol 2010;125:1128-36.)	[Tachdjian, Raffi; Al Khatib, Shadi; Schwinglshackl, Andreas; Kim, Hong Sook; Chen, Andrew; Chatila, Talal A.] Univ Calif Los Angeles, Dept Pediat, David Geffen Sch Med, Div Immunol Allergy & Rheumatol, Los Angeles, CA 90095 USA; [Blasioli, Julie] Washington Univ, Sch Med, Dept Pathol, Howard Hughes Med Inst, St Louis, MO 63110 USA; [Mathias, Clinton; Kim, Hye Young; Umetsu, Dale T.; Oettgen, Hans C.] Harvard Univ, Sch Med, Div Immunol, Childrens Hosp, Boston, MA 02115 USA; [Mathias, Clinton; Kim, Hye Young; Umetsu, Dale T.; Oettgen, Hans C.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; Washington University (WUSTL); Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Chatila, TA (corresponding author), Univ Calif Los Angeles, Dept Pediat, David Geffen Sch Med, Div Immunol Allergy & Rheumatol, 12-430 MDCC,Mail Box 175217,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	tchatila@mednet.ucla.edu	Chen, Andrew/AAT-6318-2021	Chen, Andrew/0000-0002-6688-7674; Kim, Hye Young/0000-0001-5978-512X; Chatila, Talal/0000-0001-7439-2762; Mathias, Clinton/0000-0002-0223-4842	National Institutes of Health [2R0IAI065617, U19A1070453-, R01AI054471, R01 AI026322]; NIH/NICHD [T32 HD007512]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070453, R21AI087627, R01AI065617, R01AI026322, R21AI080002, R01AI054471] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants 2R0IAI065617 and U19A1070453- Project#3 (to T. A. Chatila), R01AI054471 (to H. C. Oettgen), and R01 AI026322 (to D. T. Umetsu) and by a March of Dimes grant (to T. A. Chatila). R. Tachdjian was supported by the Human and Molecular Development Training grant (NIH/NICHD T32 HD007512).	Blaeser F, 2003, J EXP MED, V198, P1189, DOI 10.1084/jem.20030471; Brewer JM, 1999, J IMMUNOL, V163, P6448; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Chatila TA, 2004, TRENDS MOL MED, V10, P493, DOI 10.1016/j.molmed.2004.08.004; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Daeron M, 2008, IMMUNOL REV, V224, P11, DOI 10.1111/j.1600-065X.2008.00666.x; Ford JG, 2001, J IMMUNOL, V167, P1769, DOI 10.4049/jimmunol.167.3.1769; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hanson EM, 2003, J BIOL CHEM, V278, P3903, DOI 10.1074/jbc.M211747200; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Heller NM, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1164795; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Hytonen AM, 2004, CLIN EXP ALLERGY, V34, P1570, DOI 10.1111/j.1365-2222.2004.02069.x; Kamata T, 2003, J CLIN INVEST, V111, P109, DOI 10.1172/JCI200315719; Kashiwada M, 2001, J IMMUNOL, V167, P6382, DOI 10.4049/jimmunol.167.11.6382; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Krutzik PO, 2004, CLIN IMMUNOL, V110, P206, DOI 10.1016/j.clim.2003.11.009; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Mishra A, 2007, AM J PHYSIOL-LUNG C, V293, pL305, DOI 10.1152/ajplung.00147.2007; Munitz A, 2008, P NATL ACAD SCI USA, V105, P7240, DOI 10.1073/pnas.0802465105; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Oh SY, 2007, J ALLERGY CLIN IMMUN, V119, P123, DOI 10.1016/j.jaci.2006.08.029; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Ramalingam TR, 2008, NAT IMMUNOL, V9, P25, DOI 10.1038/ni1544; Risma KA, 2002, J IMMUNOL, V169, P1604, DOI 10.4049/jimmunol.169.3.1604; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Ryan JJ, 1998, J IMMUNOL, V161, P1811; Sugiura H, 2007, AM J RESP CELL MOL, V37, P424, DOI 10.1165/rcmb.2007-0089OC; Sweeney MC, 2005, BIOCHEMISTRY-US, V44, P14932, DOI 10.1021/bi051408h; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wills-Karp M, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1.51.pe55; Wrighton N, 1992, GROWTH FACTORS, V6, P103, DOI 10.3109/08977199209011014	39	53	55	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1128	1136		10.1016/j.jaci.2010.01.054	http://dx.doi.org/10.1016/j.jaci.2010.01.054			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20392476	Green Accepted			2022-12-18	WOS:000277686700024
J	Upham, JW; Zhang, GC; Rate, A; Yerkovich, ST; Kusel, M; Sly, PD; Holt, PG				Upham, John W.; Zhang, Guicheng; Rate, Angela; Yerkovich, Stephanie T.; Kusel, Merci; Sly, Peter D.; Holt, Patrick G.			Plasmacytoid dendritic cells during infancy are inversely associated with childhood respiratory tract infections and wheezing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dendritic cells; respiratory infections; wheezing; childhood asthma; atopy	INTERFERON-GAMMA PRODUCTION; PERIPHERAL-BLOOD; SUBSEQUENT DEVELOPMENT; PREVENTION STRATEGIES; ALLERGEN CHALLENGE; IMMUNE-RESPONSES; INHALED ALLERGEN; BRONCHIAL-MUCOSA; VIRAL-INFECTION; SYNCYTIAL VIRUS	Background: It has been proposed that immune dysfunction during early childhood plays an important role in asthma pathogenesis. However, it is not known specifically whether changes in dendritic cells (DCs) during infancy antedate the development of respiratory tract infections, asthma, and related clinical phenotypes. Objectives: We sought to assess the association between the level of blood DCs during the first year and the subsequent development of respiratory tract infections, wheezing, and allergic sensitization. Methods: A community-based cohort of children with a family history of atopy was followed to age 5 years. Children were monitored intensively for respiratory tract infections. History of wheeze and asthma was collected annually, atopy was documented at 5 years, and flow cytometry was used to identify DC subsets in blood samples collected when children were well. Results: Levels of plasmacytoid DCs (pDCs) during infancy were inversely correlated with symptoms of lower respiratory tract infections, parent-reported wheezing, and the cumulative rate of physician-diagnosed asthma up to age 5 years. These relationships were independent of atopy, as determined by allergy skin test results and total and specific IgE levels. In contrast, levels of myeloid DCs were not associated with respiratory tract infections, asthma, or wheezing but were associated with total IgE levels at age 5 years. Conclusion: In children with a family history of atopy, relative deficiency of circulating pDCs during infancy appears to be a risk factor for more frequent and more severe respiratory tract infections, wheezing, and a diagnosis of asthma. Infants with higher numbers of pDCs are protected against these outcomes. (J Allergy Clin Immunol 2009;124:707-13.)	[Upham, John W.; Yerkovich, Stephanie T.] Univ Queensland, Sch Med, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia; [Upham, John W.; Zhang, Guicheng; Rate, Angela; Yerkovich, Stephanie T.; Kusel, Merci; Sly, Peter D.; Holt, Patrick G.] Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Upham, John W.; Zhang, Guicheng; Rate, Angela; Yerkovich, Stephanie T.; Kusel, Merci; Sly, Peter D.; Holt, Patrick G.] Telethon Inst Child Hlth Res, Perth, WA, Australia	University of Queensland; University of Western Australia; Telethon Kids Institute; University of Western Australia	Upham, JW (corresponding author), Univ Queensland, Sch Med, Princess Alexandra Hosp, 199 Ipswich Rd, Brisbane, Qld 4102, Australia.	j.upham@uq.edu.au	Sly, Peter D/F-1486-2010; Upham, John/F-4420-2010; Zhang, Brad/AAF-8719-2021; Holt, Patrick G/H-1548-2011; Yerkovich, Stephanie/A-9004-2011	Sly, Peter D/0000-0001-6305-2201; Upham, John/0000-0002-0017-3433; Holt, Patrick G/0000-0003-1193-0935; Yerkovich, Stephanie/0000-0003-4163-4782; Zhang, Guicheng/0000-0001-9888-5385	National Health and Medical Research Council (Australia)	National Health and Medical Research Council (Australia)(National Health and Medical Research Council (NHMRC) of Australia)	Supported by grants front the National Health and Medical Research Council (Australia).	Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Bufe A, 2002, INT ARCH ALLERGY IMM, V127, P82, DOI 10.1159/000048173; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Constant SL, 2002, J CLIN INVEST, V110, P1441, DOI 10.1172/JCI200216109; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Franklin PJ, 2003, THORAX, V58, P1048, DOI 10.1136/thorax.58.12.1048; Fujiwara D, 2008, J IMMUNOL, V180, P5843, DOI 10.4049/jimmunol.180.9.5843; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Gill MA, 2005, J INFECT DIS, V191, P1105, DOI 10.1086/428589; Grage-Griebenow E, 2007, IMMUNOL CELL BIOL, V85, P383, DOI 10.1038/sj.icb.7100048; Guerra S, 2004, AM J RESP CRIT CARE, V169, P70, DOI 10.1164/rccm.200304-499OC; Hagendorens MM, 2003, CLIN EXP ALLERGY, V33, P633, DOI 10.1046/j.1365-2222.2003.01649.x; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Kittan NA, 2007, J IMMUNOL, V179, P4219, DOI 10.4049/jimmunol.179.6.4219; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lund JM, 2006, J IMMUNOL, V177, P7510, DOI 10.4049/jimmunol.177.11.7510; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matsuda H, 2002, AM J RESP CRIT CARE, V166, P1050, DOI 10.1164/rccm.2110066; McCarthy NE, 2007, CLIN EXP ALLERGY, V37, P72, DOI 10.1111/j.1365-2222.2006.02631.x; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1111/j.1365-2222.1996.tb00571.x; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Pichyangkul S, 2003, J IMMUNOL, V171, P5571, DOI 10.4049/jimmunol.171.10.5571; Prescott SL, 2007, J ALLERGY CLIN IMMUN, V120, P200, DOI 10.1016/j.jaci.2007.03.045; SILVER E, 2008, PEDIAT ALLERGY IMMUN; Smit JJ, 2006, J EXP MED, V203, P1153, DOI 10.1084/jem.20052359; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Uchida Y, 2001, J ALLERGY CLIN IMMUN, V108, P1005, DOI 10.1067/mai.2001.119741; Upham JW, 2004, J ALLERGY CLIN IMMUN, V114, P1202, DOI 10.1016/j.jaci.2004.06.051; Upham JW, 2002, CLIN EXP ALLERGY, V32, P818, DOI 10.1046/j.1365-2222.2002.01375.x; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vuckovic S, 2007, CLIN IMMUNOL, V123, P281, DOI 10.1016/j.clim.2007.03.002; Zhang GC, 2009, AM J RESP CRIT CARE, V179, P205, DOI 10.1164/rccm.200803-438OC	40	53	55	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					707	713		10.1016/j.jaci.2009.07.009	http://dx.doi.org/10.1016/j.jaci.2009.07.009			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19733903				2022-12-18	WOS:000270802800013
J	Nakano, N; Nishiyama, C; Yagita, H; Koyanagi, A; Akiba, H; Chiba, S; Ogawa, H; Okumura, K				Nakano, Nobuhiro; Nishiyama, Chiharu; Yagita, Hideo; Koyanagi, Akemi; Akiba, Hisaya; Chiba, Shigeru; Ogawa, Hideoki; Okumura, Ko			Notch signaling confers antigen-presenting cell functions on mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; Notch; MHC class II; OX40 ligand; antigen presentation	GENE-EXPRESSION; NEUTROPHIL RECRUITMENT; OX40 LIGAND; T-CELLS; ACTIVATION; DIFFERENTIATION; PU.1; OVERPRODUCTION; INDUCTION; MOLECULES	Background: Notch signaling is involved in cell fate determination along with the development of the immune system. However, very little is known about the role for Notch signaling in mast cells. Objective: We investigated the role of Notch signaling in mast cell functions. Methods: After mouse bone marrow-derived mast cells (BMMCs) or peritoneal mast cells (PMCs) were cocultured with mouse Notch ligand-expressing chinese hamster ovary cells for 5 days, we examined the mast cell surface expressions of MHC-II molecules and OX40 ligand (OX40L), FC epsilon RI-mediated cytokine production, and the effects of the mast cells on proliferation and differentiation of naive CD4(+) T cells in vitro. Results: We showed that BMMCs and PMCs constitutively expressed Notch1 and Notch2 proteins on the cell surface. We also found that Delta-like 1 (Dll1)/Notch signaling induced the expression of MHC-II and upregulated the expression level of OX40L on the surface of the mast cells. Dll1/Notch signaling augmented FC epsilon RI-mediated IL-4, IL-6, IL-13, and TNF production by BMMCs. Dll1-stimulated MHC-II(+)OX40L(high) BMMCs promoted proliferation of naive CD4+ T cells and their differentiation into T(H)2 cells producing IL-4, IL-5, IL-10, and IL-13. Conclusion: Dll1/Notch signaling confers the functions as an antigen-presenting cell on mast cells, which preferentially induce the differentiation of TH2. (J Allergy Clin Immunol 2009;123:74-81.)	[Nakano, Nobuhiro; Nishiyama, Chiharu; Ogawa, Hideoki; Okumura, Ko] Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, Tokyo 1138421, Japan; [Yagita, Hideo; Akiba, Hisaya] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan; [Koyanagi, Akemi] Juntendo Univ, Sch Med, Biomed Res Ctr, Div Cell Biol, Tokyo 1138421, Japan; [Chiba, Shigeru] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Clin & Expt Hematol, Tsukuba, Ibaraki 305, Japan	Juntendo University; Juntendo University; Juntendo University; University of Tsukuba	Nakano, N (corresponding author), Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	nbnakano@med.juntendo.ac.jp	Nishiyama, Chiharu/GPW-9372-2022	Nakano, Nobuhiro/0000-0002-5317-5950	Ministry of Education, Culture, Sports, Science and Technology of Japan; Takeda Science Foundation	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF))	Supported in part by a Grant-in-aid for Young Scientists to N.N. and a Grant-in-aid for Scientific Research to C.N. from the Ministry of Education, Culture, Sports, Science and Technology of Japan and a grant from the Takeda Science Foundation to N.N.	Akiba H, 2000, J EXP MED, V191, P375, DOI 10.1084/jem.191.2.375; Araki Y, 2000, CLIN EXP IMMUNOL, V119, P264; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; FOX CC, 1994, CELL IMMUNOL, V158, P253, DOI 10.1006/cimm.1994.1272; FRANDJI P, 1993, J IMMUNOL, V151, P6318; Gaiano N, 2002, ANNU REV NEUROSCI, V25, P471, DOI 10.1146/annurev.neuro.25.030702.130823; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Geffers I, 2007, J CELL BIOL, V178, P465, DOI 10.1083/jcb.200702009; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Ito T, 2005, J IMMUNOL, V174, P376, DOI 10.4049/jimmunol.174.1.376; Jonsson JI, 2001, EUR J IMMUNOL, V31, P3240, DOI 10.1002/1521-4141(200111)31:11<3240::AID-IMMU3240>3.0.CO;2-E; Kambayashi T, 2008, BLOOD, V111, P1489, DOI 10.1182/blood-2007-07-102111; Kashiwakura J, 2004, J IMMUNOL, V173, P5247, DOI 10.4049/jimmunol.173.8.5247; KOCH N, 1984, J IMMUNOL, V132, P1361; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; Luo D, 2005, SEMIN CELL DEV BIOL, V16, P612, DOI 10.1016/j.semcdb.2005.07.002; Maillard I, 2003, IMMUNITY, V19, P781, DOI 10.1016/S1074-7613(03)00325-X; Marshall JS, 2004, J ALLERGY CLIN IMMUN, V114, P21, DOI 10.1016/j.jaci.2004.04.045; Metz M, 2007, IMMUNOL REV, V217, P304, DOI 10.1111/j.1600-065X.2007.00520.x; Monsalve E, 2006, J IMMUNOL, V176, P5362, DOI 10.4049/jimmunol.176.9.5362; Moriyama Y, 2008, INT IMMUNOL, V20, P763, DOI 10.1093/intimm/dxn034; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nakae S, 2006, J IMMUNOL, V176, P2238, DOI 10.4049/jimmunol.176.4.2238; Nakae S, 2007, BLOOD, V109, P3640, DOI 10.1182/blood-2006-09-046128; Nakano N, 2007, BLOOD, V109, P4846, DOI 10.1182/blood-2006-09-045641; Nishiyama C, 2004, BIOCHEM BIOPH RES CO, V313, P516, DOI 10.1016/j.bbrc.2003.11.145; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Ohshima Y, 1998, BLOOD, V92, P3338, DOI 10.1182/blood.V92.9.3338.421k19_3338_3345; Osborne BA, 2007, NAT REV IMMUNOL, V7, P64, DOI 10.1038/nri1998; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Robbie-Ryan M, 2002, CURR OPIN IMMUNOL, V14, P728, DOI 10.1016/S0952-7915(02)00394-1; Sayed BA, 2007, IMMUNOL REV, V217, P53, DOI 10.1111/j.1600-065X.2007.00524.x; Schroeder T, 2003, J IMMUNOL, V170, P5538, DOI 10.4049/jimmunol.170.11.5538; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Supajatura V, 2001, J IMMUNOL, V167, P2250, DOI 10.4049/jimmunol.167.4.2250; Tanigaki K, 2007, NAT IMMUNOL, V8, P451, DOI 10.1038/ni1453; Tanzola MB, 2003, J IMMUNOL, V171, P4385, DOI 10.4049/jimmunol.171.8.4385; Thelu Jacques, 2002, BMC Dermatol, V2, P7, DOI 10.1186/1471-5945-2-7; Wang HW, 1998, J CLIN INVEST, V102, P1617, DOI 10.1172/JCI3704; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455	44	53	57	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					74	81		10.1016/j.jaci.2008.10.040	http://dx.doi.org/10.1016/j.jaci.2008.10.040			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19130928	Bronze			2022-12-18	WOS:000262793900011
J	Griffith, LM; Cowan, MJ; Kohn, DB; Notarangelo, LD; Puck, JM; Schultz, KR; Buckley, RH; Eapen, M; Kamani, NR; O'Reilly, RJ; Parkman, R; Roifman, CM; Sullivan, KE; Filipovich, AH; Fleisher, TA; Shearer, WT				Griffith, Linda M.; Cowan, Morton J.; Kohn, Donald B.; Notarangelo, Luigi D.; Puck, Jennifer M.; Schultz, Kirk R.; Buckley, Rebecca H.; Eapen, Mary; Kamani, Naynesh R.; O'Reilly, Richard J.; Parkman, Robertson; Roifman, Chaim M.; Sullivan, Kathleen E.; Filipovich, Alexandra H.; Fleisher, Thomas A.; Shearer, William T.		Workshop Participants	Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: Current status and critical needs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allogeneic hematopoietic cell transplantation; primary immune deficiency; clinical trial	SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW-TRANSPLANTATION; CHRONIC GRANULOMATOUS-DISEASE; WISKOTT-ALDRICH-SYNDROME; TERM-FOLLOW-UP; EUROPEAN EXPERIENCE; CLINICAL-FEATURES; RECONSTITUTION; BLOOD; CHIMERISM	Allogeneic hematopoietic cell transplantation (HCT) has been used for 40 years to ameliorate or cure primary immune deficiency (PID) diseases, including severe combined immunodeficiency (SCID) and non-SCID PID. There is a critical need for evaluation of the North American experience of different HCT approaches for these diseases to identify best practices and plan future investigative clinical trials. Our survey of incidence and prevalence of PID in North American practice sites indicates that such studies are feasible. A conference of experts in HCT treatment of PID has recommended (1) a comprehensive cross-sectional and retrospective analysis of HCT survivors with SCID; (2) a prospective study of patients with SCID receiving HCT, with comparable baseline and follow-up testing across participating centers; (3) a pilot study of newborn screening for SCID to identify affected infants before compromise by infection; and (4) studies of the natural history of disease in patients who do or do not receive RCT for the non-SCID diseases of Wiskott-Aldrich syndrome and chronic granulomatous disease. To accomplish these goals, collaboration by a consortium of institutions in North America is proposed. Participation of immunologists and HCT physicians having interest in PID and experts in laboratory methods, clinical outcomes assessment, databases, and analysis will be required for the success of these studies. (J Allergy Clin Immunol 2008; 122:1087-96.)	[Shearer, William T.] Texas Childrens Hosp, Baylor Coll Med, Dept Allergy & Immunol, Houston, TX 77030 USA; [Griffith, Linda M.] NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; [Cowan, Morton J.] UCSF Childrens Hosp, Pediat Blood & Marrow Transplant Div, San Francisco, CA USA; [Kohn, Donald B.] Univ So Calif, Childrens Hosp Los Angeles, Div Res Immunol Bone Marrow Transplantat, Los Angeles, CA 90089 USA; [Notarangelo, Luigi D.] Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA; [Puck, Jennifer M.] Univ Calif San Francisco, Inst Human Genet, Dept Pediat, San Francisco, CA 94143 USA; [Schultz, Kirk R.] Univ British Columbia, British Columbia Childrens Hosp, Vancouver, BC V5Z 1M9, Canada; [Buckley, Rebecca H.] Duke Univ, Sch Med, Durham, NC 27706 USA; [Eapen, Mary] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA; [Kamani, Naynesh R.] Childrens Natl Med Ctr, Ctr Canc & Blood Disorders, Washington, DC 20010 USA; [O'Reilly, Richard J.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; [O'Reilly, Richard J.] Mem Sloan Kettering Canc Ctr, Dept Immunol, New York, NY 10021 USA; [Parkman, Robertson] Childrens Hosp Los Angeles, Div Immunol Res, BMT, Los Angeles, CA 90027 USA; [Roifman, Chaim M.] Univ Toronto, Hosp Sick Children, Div Immunol & Allergy, Toronto, ON M5S 1A1, Canada; [Sullivan, Kathleen E.] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Filipovich, Alexandra H.] Cincinnati Childrens Hosp, Med Ctr, Div Hematol Oncol, Cincinnati, OH USA; [Fleisher, Thomas A.] NIH, Ctr Clin, Dept Lab Med, Bethesda, MD 20892 USA	Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Francisco; UCSF Medical Center; Children's Hospital Los Angeles; University of Southern California; Harvard University; Boston Children's Hospital; Harvard Medical School; University of California System; University of California San Francisco; BC Childrens Hospital; University of British Columbia; Duke University; Center for International Blood & Marrow Transplant Research; Medical College of Wisconsin; Children's National Health System; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Children's Hospital Los Angeles; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Cincinnati Children's Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Shearer, WT (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Dept Allergy & Immunol, MC FC330-01,6621 Fannin St,Ste A-380, Houston, TX 77030 USA.	wtsheare@texaschildrenshospital.org	Notarangelo, Luigi D/F-9718-2016; Buckley, Rebecca/AAB-1578-2019; Kohn, Donald/N-5085-2016; Schultz, Kirk R/AAA-3440-2022	Notarangelo, Luigi D/0000-0002-8335-0262; Kohn, Donald/0000-0003-1840-6087; Schultz, Kirk/0000-0002-0001-6438; Eapen, Mary/0000-0001-6193-4243; Sullivan, Kathleen/0000-0003-4018-1646; Shearer, William/0000-0002-2483-2130	March of Dimes; Enzo Therapeutics; USIDNET; National Cancer Institute; Leukemia and Lymphoma Society; National Institutes of Health; Pediatric Blood and Marrow Transplant Consortium/Children's Oncology Group; NATIONAL CANCER INSTITUTE [U24CA076518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI082973] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL010304] Funding Source: NIH RePORTER	March of Dimes(March of Dimes); Enzo Therapeutics; USIDNET; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pediatric Blood and Marrow Transplant Consortium/Children's Oncology Group; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	M. J. Cowan has received research support from the March of Dimes and Enzo Therapeutics, J. NI. Puck has received research support from USIDNET and has provided legal consultation on primary immunodeficiency. K. R. Schultz has received research support from the National Cancer Institute and the Leukemia and Lymphoma Society and has served as an expert witness for DOIL BioPharma. R. H. Buckley has received research support from the National Institutes of Health. N. R. Kamani has received research Support from the Pediatric Blood and Marrow Transplant Consortium/Children's Oncology Group and has served as a member of the National Marrow Donor Program. R. J. O'Reilly has received research support from the National Institutes of Health and owns stock in Calibrant. R. Parkman has received research support from the National Institutes of Health. K. E. Sullivan has received research support front the National Institutes of Health and USIDNET, has served as an expert witness for Contocor-Psorusis, and has consulting arrangements with the Immune Deficiency Foundation. The rest of the authors have declared that they have no conflict of interest.	Antin JH, 2001, BIOL BLOOD MARROW TR, V7, P473, DOI 10.1053/bbmt.2001.v7.pm11669214; Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; BACH FH, 1968, LANCET, V2, P1364; Barge RMY, 2006, BONE MARROW TRANSPL, V37, P1129, DOI 10.1038/sj.bmt.1705385; Bolinger AM, 2001, BONE MARROW TRANSPL, V28, P1013, DOI 10.1038/sj.bmt.1703264; Booth C, 2006, BRIT J HAEMATOL, V135, P533, DOI 10.1111/j.1365-2141.2006.06333.x; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Cavazzana-Calvo M, 2007, BLOOD, V109, P4575, DOI 10.1182/blood-2006-07-029090; Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012; Conley ME, 2003, CLIN IMMUNOL, V109, P272, DOI 10.1016/j.clim.2003.08.005; DROR Y, 1993, BLOOD, V81, P2021; Dupuis-Girod S, 2003, PEDIATRICS, V111, pE622, DOI 10.1542/peds.111.5.e622; Dvorak C, 2008, BONE MARROW TRANSPL, V41, P119, DOI 10.1038/sj.bmt.1705890; Dvorak CC, 2008, BIOL BLOOD MARROW TR, V14, P1125, DOI 10.1016/j.bbmt.2008.07.008; Eggleston B, 2007, BRIT J HAEMATOL, V136, P673, DOI 10.1111/j.1365-2141.2006.06486.x; Filipovich AH, 2001, BLOOD, V97, P1598, DOI 10.1182/blood.V97.6.1598; FRIEDRICH W, 1985, EUR J PEDIATR, V144, P125, DOI 10.1007/BF00451897; GATTI RA, 1968, LANCET, V2, P1366; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Gurney JG, 2006, CANCER-AM CANCER SOC, V106, P1402, DOI 10.1002/cncr.21752; Horn B, 1999, BONE MARROW TRANSPL, V24, P1009, DOI 10.1038/sj.bmt.1702011; Horwitz ME, 2001, NEW ENGL J MED, V344, P881, DOI 10.1056/NEJM200103223441203; Knutsen AP, 2000, J CLIN IMMUNOL, V20, P466, DOI 10.1023/A:1026463900925; Li LY, 2002, J IMMUNOL, V168, P6323, DOI 10.4049/jimmunol.168.12.6323; Malech HL, 2007, CURR OPIN HEMATOL, V14, P29, DOI 10.1097/00062752-200701000-00007; Martire B, 2008, CLIN IMMUNOL, V126, P155, DOI 10.1016/j.clim.2007.09.008; Mazzolari E, 2007, J ALLERGY CLIN IMMUN, V120, P892, DOI 10.1016/j.jaci.2007.08.007; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Ozsahin H, 2008, BLOOD, V111, P439, DOI 10.1182/blood-2007-03-076679; Petersdorf EW, 2008, CURR OPIN IMMUNOL, V20, P588, DOI 10.1016/j.coi.2008.06.014; Puck JM, 2007, J ALLERGY CLIN IMMUN, V120, P760, DOI 10.1016/j.jaci.2007.08.043; Rao K, 2005, BLOOD, V105, P879, DOI 10.1182/blood-2004-03-0960; READ EJ, 2002, CELLULAR THERAPY NEW, P29; REISNER Y, 1983, BLOOD, V61, P341; Roifman CM, 2008, BONE MARROW TRANSPL, V41, P947, DOI 10.1038/bmt.2008.11; Seger RA, 2002, BLOOD, V100, P4344, DOI 10.1182/blood-2002-02-0583; Smogorzewska Elzbieta M., 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P111; SULLIVAN KE, 1994, J PEDIATR-US, V125, P876, DOI 10.1016/S0022-3476(05)82002-5	40	53	54	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1087	1096		10.1016/j.jaci.2008.09.045	http://dx.doi.org/10.1016/j.jaci.2008.09.045			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18992926	Green Accepted			2022-12-18	WOS:000261711800007
J	Munitz, A; Waddell, A; Seidu, L; Ahrens, R; Hogan, SP; Rothenberg, ME				Munitz, Ariel; Waddell, Amanda; Seidu, Luqman; Ahrens, Richard; Hogan, Simon P.; Rothenberg, Marc E.			Resistin-like molecule alpha enhances myeloid cell activation and promotes colitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Resistin-like molecule alpha; colitis; macrophages; eosinophils; LPS; inflammation; inflammatory bowel disease	NECROSIS-FACTOR-ALPHA; EOSINOPHIL PEROXIDASE; ULCERATIVE-COLITIS; INFLAMMATION; BETA; IMMUNITY; GLUCOSE; MACROPHAGES; MECHANISM; EPIDEMIC	Background: Resistin-like molecule (Relm) alpha is a secreted protein and a hallmark signature gene for alternatively activated macrophages. Relm-alpha is highly induced by allergic inflammatory triggers and perceived to promote tissue repair. Yet the function of Relm-alpha remains unknown. Objective: We sough to determine the role of Relm-alpha in dextran sodium sulfate (DSS)-induced colonic injury. Methods: The cellular source of Relm-alpha was determined after oral DSS-induced colitis. Retnla(-/-) mice were generated, subjected to DSS treatment, and monitored for disease progression (clinical and histopathologic features). Cytokine production in the supernatants of ex vivo colon cultures, and of LPS-stimulated macrophages incubated with Relm-alpha was assessed. Relm-alpha was administered intraperitoneally, and the cellular recruitment to the peritoneum was assessed. Results: After innate intestinal stimulation with DSS, Relm-alpha was highly expressed by eosinophils and epithelial cells. Retnla gene-targeted mice were protected from DSS-induced colitis (eg, decreased diarrhea, rectal bleeding, colon shortening, disease score, and histopathologic changes). Relm-alpha coactivated IL-6 and TNF-alpha release and inhibited IL-10 release from LPS-activated bone marrow-derived macrophages. Consistent with these finding, colon cultures of DSS-treated Retnla(-/-) mice produced decreased IL-6 and increased IL-10 ex vivo. Furthermore, Retnta-l- mice had substantially decreased c-Jun N-terminal kinase phosphorylation in vivo. In vivo administration of Relm-alpha initiated cellular recruitment to the peritoneum, and Relm-alpha was able to induce eosinophil chemotaxis in vitro. Conclusions: These findings demonstrate a central proinflammatory role for Relm-alpha in colonic innate immune responses, identifying a novel pathway for regulation of macrophage activation. Q Allergy Clin Immunol 2008;122:1200-7.)	[Munitz, Ariel; Waddell, Amanda; Seidu, Luqman; Ahrens, Richard; Hogan, Simon P.; Rothenberg, Marc E.] Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, 3333 Burnel Ave, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org			National Institutes of Health [P01 HL-076383, R01 AI057803]; Machiah Foundation; Jewish Community Endowment Fund; Alexander M. and June L. Maisin Foundation; Kanbar Charitable Trust; Campaign Urging Research for Eosinophilic Disorders (CURED); Food Allergy Project; Buckeye Foundation; Food Allergy and Anaphylaxis Network; Dana Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073553, R01AI057803] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Machiah Foundation; Jewish Community Endowment Fund; Alexander M. and June L. Maisin Foundation; Kanbar Charitable Trust; Campaign Urging Research for Eosinophilic Disorders (CURED); Food Allergy Project; Buckeye Foundation; Food Allergy and Anaphylaxis Network; Dana Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants P01 HL-076383 (M.E.R.) and R01 AI057803 (M.E.R.), a fellowship award (A.M) front the Machiah Foundation, a supporting foundation of the Jewish Community Endowment Fund. the generous support of the Alexander M. and June L. Maisin Foundation, and the Kanbar Charitable Trust, the Campaign Urging Research for Eosinophilic Disorders (CURED), the Food Allergy Project, and the Buckeye Foundation.; Disclosure of potential conflict of interest: M. E. Rothenberg is on the speakers' bureau for Merck has consulting arrangements with Merck, Ception Therapeutics, Novartis, and Nycomed; and has received research support from the National Institutes of Health. the Food Allergy and Anaphylaxis Network, and the Dana Foundation. The rest of the authors have declared that they have no conflict of interest.	Abelson P, 2004, SCIENCE, V304, P1413, DOI 10.1126/science.304.5676.1413; AHRENS R, 2008, J IMMUNOL IN PRESS; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Banerjee RR, 2001, J BIOL CHEM, V276, P25970, DOI 10.1074/jbc.M103109200; Bokarewa M, 2005, J IMMUNOL, V174, P5789, DOI 10.4049/jimmunol.174.9.5789; Calabro P, 2004, CIRCULATION, V110, P3335, DOI 10.1161/01.CIR.0000147825.97879.E7; Forbes E, 2004, J IMMUNOL, V172, P5664, DOI 10.4049/jimmunol.172.9.5664; Forbes E, 2006, J LEUKOCYTE BIOL, V80, P330, DOI 10.1189/jlb.1105643; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Hogan SP, 2006, J ALLERGY CLIN IMMUN, V118, P257, DOI 10.1016/j.jaci.2006.04.039; Kitowska K, 2008, AM J PHYSIOL-LUNG C, V294, pL34, DOI 10.1152/ajplung.00007.2007; Lampinen M, 2005, GUT, V54, P1714, DOI 10.1136/gut.2005.066423; Liu TJ, 2004, AM J PATHOL, V164, P1315, DOI 10.1016/S0002-9440(10)63218-X; MacDonald TT, 2005, SCIENCE, V307, P1920, DOI 10.1126/science.1106442; Mcvay LD, 2006, J CLIN INVEST, V116, P2914, DOI 10.1172/JCI28121; Mishra A, 2007, AM J PHYSIOL-LUNG C, V293, pL305, DOI 10.1152/ajplung.00147.2007; Moon B, 2003, AM J PHYSIOL-ENDOC M, V285, pE106, DOI 10.1152/ajpendo.00457.2002; Munitz A, 2008, BLOOD, V111, P5694, DOI 10.1182/blood-2007-12-126748; MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705; Nair MG, 2006, J IMMUNOL, V177, P1393, DOI 10.4049/jimmunol.177.3.1393; NATHAN CF, 1982, J EXP MED, V155, P1291, DOI 10.1084/jem.155.5.1291; Raes G, 2002, J LEUKOCYTE BIOL, V71, P597; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Sutherland TJT, 2008, AM J RESP CRIT CARE, V178, P469, DOI 10.1164/rccm.200802-301OC; Temkin V, 2001, CYTOKINE, V15, P20, DOI 10.1006/cyto.2001.0890; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; Voehringer D, 2007, J LEUKOCYTE BIOL, V81, P1434, DOI 10.1189/jlb.1106686; Yan ZQ, 2007, IMMUNOL REV, V219, P187, DOI 10.1111/j.1600-065X.2007.00554.x	31	53	53	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1200	1207		10.1016/j.jaci.2008.10.017	http://dx.doi.org/10.1016/j.jaci.2008.10.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	19084112	Green Accepted			2022-12-18	WOS:000261711800020
J	Apter, AJ; Schelleman, H; Walker, A; Addya, K; Rebbeck, T				Apter, Andrea J.; Schelleman, Hedi; Walker, Amy; Addya, Kathakali; Rebbeck, Timothy			Clinical and genetic risk factors of self-reported penicillin allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						penicillin; drug allergy; adverse drug reaction; immediate hypersensitivity; genetics; IL-4	IL-10 PROMOTER; HYPERSENSITIVITY; AMPLIFICATION; ANTIBIOTICS; ANAPHYLAXIS; DERIVATIVES; MECHANISMS; ANTIBODIES; RESPONSES; DISEASES	Background: Patients with self-reported penicillin allergy are frequently denied P-lactam antibiotics. Objective: To identify and correlate clinical and genetic risk factors of self-reported penicillin allergy. Methods: We conducted a case-control study of adults recruited from allergists' offices. Cases had a history of urticaria, angioedema, wheeze, hypotension, vomiting, or anaphylaxis after a dose of penicillin. DNA from buccal swabs was genotyped for variants associated with candidate genes linked to immediate hypersensitivity (IL4, IL4R, and IL10) and penicillin metabolism (LACTB). Logistic regression was used to calculate the association between penicillin allergy and clinical and genetic factors. Results: Seventeen allergists identified 76 adults. Complete data were available for 23 cases and 39 controls. Penicillin allergy was associated with a history of penicillin allergy in first-degree relatives (P =.002), a history of other adverse drug reactions (P =.008), and atopy (P =.039). However, in the multivariable analysis, only family history of penicillin allergy remained significant. IL4 single nucleotide polymorphisms (SNPs) rs11740584 (P =.012), rs10062446 (P =.021), and rs2070874 (P =.035) were associated and LACTB SNP rs2729835 (P =.058) was marginally associated with penicillin allergy. Adding rs11740584 or rs10062446 individually improved the clinical multivariable model (R-2 increased from 0.23 to 0.33). Haplotype analysis did not provide additional information to the SNP analysis. Conclusion: Self-reported penicillin allergy may be influenced by clinical and genetic factors such as IL4.	[Addya, Kathakali] Hosp Univ Penn, Mol Diag & Genotyping Facil, Philadelphia, PA 19104 USA; [Apter, Andrea J.] Hosp Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Apter, Andrea J.; Schelleman, Hedi; Walker, Amy; Rebbeck, Timothy] Hosp Univ Penn, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA; [Apter, Andrea J.; Schelleman, Hedi; Walker, Amy; Rebbeck, Timothy] Hosp Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Apter, Andrea J.] Hosp Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Apter, AJ (corresponding author), Hosp Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.	apter@mail.med.upenn.edu	Rebbeck, Timothy/GLU-8348-2022	Rebbeck, Timothy/0000-0002-4799-1900	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010399] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004337] Funding Source: NIH RePORTER; AHRQ HHS [HS10399] Funding Source: Medline; NCRR NIH HHS [P20RR02074] Funding Source: Medline; NHLBI NIH HHS [HL K23 04337-01] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbas AK, 2005, CELLULAR MOL IMMUNOL; ADKINSON NF, 2004, MIDDLETONS ALLERGY P; Apter AJ, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.10.052; Apter AJ, 2004, J ALLERGY CLIN IMMUN, V113, P764, DOI 10.1016/j.jaci.2003.11.032; Bergen AW, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-24; De La Vega Francisco M, 2006, Pac Symp Biocomput, P487, DOI 10.1142/9789812701626_0045; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Fontaine C, 2007, ALLERGY, V62, P47, DOI 10.1111/j.1398-9995.2006.01268.x; GADDE J, 1993, JAMA-J AM MED ASSOC, V270, P2456, DOI 10.1001/jama.270.20.2456; *GEN CARDS, 2008, REH ISR CROWN HUM GE; GILMAN AG, 2006, GOODMAN GILMANS PHAR, pCH44; Goldstein DB, 2007, AM J MED, V120, P21, DOI 10.1016/j.amjmed.2007.02.004; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; Greenberger PA, 2006, J ALLERGY CLIN IMMUN, V117, pS464, DOI 10.1016/j.jaci.2005.11.002; GREENBERGER PA, 2002, PATTERSONS ALLERGIC, P335; Guglielmi L, 2006, ALLERGY, V61, P921, DOI 10.1111/j.1398-9995.2006.01067.x; Kerdine S, 1996, MOL IMMUNOL, V33, P71, DOI 10.1016/0161-5890(95)00119-0; LEVINE BB, 1966, J CLIN INVEST, V45, P1895, DOI 10.1172/JCI105494; LEVINE BB, 1966, NEW ENGL J MED, V275, P1115, DOI 10.1056/NEJM196611172752009; Levins R, 1969, Symp Soc Exp Biol, V23, P1; LIVAK KJ, 1995, NAT GENET, V9, P341, DOI 10.1038/ng0495-341; Mazzaglia G, 2003, EUR J CLIN PHARMACOL, V59, P651, DOI 10.1007/s00228-003-0669-0; MELNICK SL, 1992, ANN PHARMACOTHER, V26, P1292, DOI 10.1177/106002809202601020; Murthy KK, 2005, HUM MUTAT, V26, P145, DOI 10.1002/humu.20199; Norris Pauline, 2005, N Z Med J, V118, pU1352; NOSEK L, 2007, WHOLE GENOME AMPLIFI; Park JS, 1997, J IMMUNOL, V158, P5002; Park MA, 2007, ANN ALLERG ASTHMA IM, V99, P54, DOI 10.1016/S1081-1206(10)60621-7; PARKER CW, 1962, J EXP MED, V115, P821, DOI 10.1084/jem.115.4.821; Qiao HL, 2007, EUR J CLIN PHARMACOL, V63, P263, DOI 10.1007/s00228-006-0245-5; REBBECK TR, 2004, BIOMARKERS PREV, V13, P681; Riedl MA, 2003, AM FAM PHYSICIAN, V68, P1781; Salkind AR, 2001, JAMA-J AM MED ASSOC, V285, P2498, DOI 10.1001/jama.285.19.2498; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; Strom BL, 2003, NEW ENGL J MED, V349, P1628, DOI 10.1056/NEJMoa022963; Yang J, 2005, EUR J CLIN PHARMACOL, V61, P803, DOI 10.1007/s00228-005-0047-1	38	53	55	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					152	158		10.1016/j.jaci.2008.03.037	http://dx.doi.org/10.1016/j.jaci.2008.03.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18538381				2022-12-18	WOS:000257605100025
J	Rogers, AJ; Celedon, JC; Lasky-Su, JA; Weiss, ST; Raby, BA				Rogers, Angela J.; Celedon, Juan C.; Lasky-Su, Jessica A.; Weiss, Scott T.; Raby, Benjamin A.			Filaggrin mutations confer susceptibility to atopic dermatitis but not to asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; genetics; asthma; filaggrin; association	OF-FUNCTION MUTATIONS; FAMILY-BASED ASSOCIATION; GENETIC ASSOCIATION; ICHTHYOSIS VULGARIS; EARLY-ONSET; PREDISPOSE; PHENOTYPES; CHILDHOOD; VARIANTS; CHILDREN	Background: Loss-of-function mutations in the filaggrin gene (FLG) have been strongly associated with atopic dermatitis and allergic phenotypes in multiple populations. The role of these mutations in the development of asthma is less clear, particularly in patients who do not have coincident atopic dermatitis. Objective: To determine whether FLG mutations are associated with asthma or asthma-related intermediate phenotypes. Methods: We genotyped 2 loss-of-function FLG mutations (R501X and 2282del4) in white children (age 5-12 years) with mild to moderate asthma in the Childhood Asthma Management Program. We assessed the relationship of these mutations to asthma and allergy-related phenotypes in children with and without atopic dermatitis using both population-based and family-based tests of association. Results: Nearly 113 (185/646) of the participating children had atopic dermatitis. Although strong associations were observed between FLG mutations and atopic dermatitis (odds ratio, 2.4; P = 7.6 X 10(-5)) and between the mutations and total serum IgE level (P = .009 in the atopic dermatitis cohort), no association was noted with either asthma or asthma-related phenotypes, including FEV1, FEV1/forced vital capacity, and methacholine PC20 (P > .1 for all tests). Conclusion: Although FLG loss-of-function mutations are consistently associated with atopic dermatitis and other allergic phenotypes, these mutations do not appear to influence either susceptibility to asthma or asthma severity phenotypes. Clinical implications: Filaggrin mutations that predispose to atopic dermatitis do not modulate the asthma phenotype.	[Rogers, Angela J.; Celedon, Juan C.; Lasky-Su, Jessica A.; Weiss, Scott T.; Raby, Benjamin A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab,Dept Med, Boston, MA 02115 USA; [Rogers, Angela J.; Celedon, Juan C.; Weiss, Scott T.; Raby, Benjamin A.] Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Raby, BA (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab,Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.	rebar@channing.harvard.edu	Raby, Benjamin/AAK-3866-2021	Rogers, Angela/0000-0001-6969-6200	DIVISION OF LUNG DISEASES [N01HR016049] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL074193, P50HL067664, T32HL007427] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL67664, N01-HR-16049, K08 HL074193, T32 HL07427] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barker JNWN, 2007, J INVEST DERMATOL, V127, P564, DOI 10.1038/sj.jid.5700587; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Lange C, 2002, GENET EPIDEMIOL, V23, P165, DOI 10.1002/gepi.209; Lange C, 2003, AM J HUM GENET, V73, P801, DOI 10.1086/378591; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Ruether A, 2006, BRIT J DERMATOL, V155, P1093, DOI 10.1111/j.1365-2133.2006.07500.x; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Stemmler S, 2007, J INVEST DERMATOL, V127, P722, DOI 10.1038/sj.jid.5700579; Strachan DP, 1996, BRIT MED J, V312, P1195; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630; Ying S, 2006, J ALLERGY CLIN IMMUN, V118, P1386, DOI 10.1016/j.jaci.2006.08.030	21	53	54	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1332	1337		10.1016/j.jaci.2007.09.037	http://dx.doi.org/10.1016/j.jaci.2007.09.037			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	18073125				2022-12-18	WOS:000251653800013
J	Gutermuth, J; Bewersdorff, M; Traidl-Hoffmann, C; Ring, J; Mueller, MJ; Behrendt, H; Jakob, T				Gutermuth, Jan; Bewersdorff, Mayte; Traidl-Hoffmann, Claudia; Ring, Johannes; Mueller, Martin J.; Behrendt, Heidrun; Jakob, Thilo			Immunomodulatory effects of aqueous birch pollen extracts and phytoprostanes on primary immune responses in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-H(1)/T-H(2) cells; T-cell polarization; pollen allergy; phytoprostanes; pollen-associated lipid mediators	ALPHA-LINOLENIC ACID; DENDRITIC CELLS; ACTIVATION; SIGNAL; INTERLEUKIN-12; CHALLENGE; PARTICLES; INDUCTION; MOUSE	Background: We recently demonstrated that pollen not only function as allergen carriers but also as rich sources of bioactive lipids, such as phytoprostanes, that modulate human dendritic cell (DC) function in a way that results in an enhanced T(H)2 polarization in vitro. Objective: Here we analyzed the immunomodulatory capacities of Betula alba (white birch) aqueous pollen extracts (Bet-APEs) and pollen-associated phytoprostanes in the murine system in vitro and in vivo. Methods: DC function was analyzed in vitro by using BALB/c bone marrow-derived DCs. T-cell responses were analyzed with DO11.10 peptide 323-339 from chicken ovalbumin (OVA)specific CD4 T cells as responder cells. For in vivo studies, OVA-specific CD4 T cells were adoptively transferred into BALB/c mice. Twenty-four hours later, mice were challenged by means of intranasal application of OVA in the absence or presence of Bet-APEs or phytoprostanes. Polarization of T-cell responses in vivo was analyzed in draining lymph node cells. Results: In vitro Bet-APEs and E-1-phytoprostanes dose-dependently inhibited LPS-induced IL-12p70 of DCs. In addition, Bet-APEs induced a TH2 polarization in vitro. Similarly, intranasal instillation of Bet-APEs in vivo, together with the antigen, lead to increased IL-4, IL-5, and IL-13 secretion and decreased IFN-gamma secretion from antigen-specific T cells in the draining lymph nodes. In contrast, intranasal E1- and F1-phytoprostanes downregulated both T(H)1 and T(H)2 cytokine production in vivo. Conclusion: Pollen release water-soluble factors that display T(H)2-polarizing capacities in vivo independently of E-1- and F-1-phytoprostanes. Clinical implications: Identification of the underlying mechanisms might open new approaches for pharmacologic intervention.	Univ Freiburg, Med Ctr, Dept Dermatol, Allergy Res Grp, D-79104 Freiburg, Germany; Tech Univ Munich, ZAUM Ctr Allergy & Environm, GSF Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergy GSF TUM, D-8000 Munich, Germany; Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-8000 Munich, Germany; Univ Wurzburg, Div Pharmaceut Biol, Julius von Sachs Inst Biosci, D-97070 Wurzburg, Germany	University of Freiburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich; Technical University of Munich; University of Wurzburg	Jakob, T (corresponding author), Univ Freiburg, Med Ctr, Dept Dermatol, Allergy Res Grp, Haupstr 7, D-79104 Freiburg, Germany.	thilo.jakob@uniklinik-freiburg.de	Ring, Johannes/GLN-4341-2022; mueller, martin j/C-7616-2019; Jakob, Thilo/J-1621-2012; Gutermuth, Jan/D-9487-2011	Ring, Johannes/0000-0001-8236-3152; Traidl-Hoffmann, Claudia/0000-0001-5085-5179				Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Bacsi A, 2005, J ALLERGY CLIN IMMUN, V116, P836, DOI 10.1016/j.jaci.2005.06.002; Behrendt H, 2001, INT ARCH ALLERGY IMM, V124, P121, DOI 10.1159/000053688; Bellinghausen I, 2000, J ALLERGY CLIN IMMUN, V105, P988, DOI 10.1067/mai.2000.105526; Bellinghausen I, 2003, IMMUNOLOGY, V108, P167, DOI 10.1046/j.1365-2567.2003.01576.x; BETZ M, 1991, J IMMUNOL, V146, P108; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Dharajiya N, 2007, J ALLERGY CLIN IMMUN, V119, P646, DOI 10.1016/j.jaci.2006.11.634; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P1468, DOI 10.1046/j.1365-2745.2002.01504.x; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hochrein H, 2000, J EXP MED, V192, P823, DOI 10.1084/jem.192.6.823; Imbusch R, 2000, FREE RADICAL BIO MED, V28, P720, DOI 10.1016/S0891-5849(00)00154-4; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Mueller MJ, 2004, CURR OPIN PLANT BIOL, V7, P441, DOI 10.1016/j.pbi.2004.04.001; Mueller MJ, 1998, CHEM BIOL, V5, pR323, DOI 10.1016/S1074-5521(98)90660-3; Parchmann S, 1998, J BIOL CHEM, V273, P32650, DOI 10.1074/jbc.273.49.32650; Plotz SG, 2004, J ALLERGY CLIN IMMUN, V113, P1152, DOI 10.1016/j.jaci.2004.03.011; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Schappi GF, 1997, J ALLERGY CLIN IMMUN, V100, P656, DOI 10.1016/S0091-6749(97)70170-2; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Traidl-Hoffmann C, 2003, INT ARCH ALLERGY IMM, V131, P1, DOI 10.1159/000070428; Traidl-Hoffmann C, 2002, J ALLERGY CLIN IMMUN, V109, P831, DOI 10.1067/mai.2002.124655; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	27	53	55	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					293	299		10.1016/j.jaci.2007.03.017	http://dx.doi.org/10.1016/j.jaci.2007.03.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17451798				2022-12-18	WOS:000248654900011
J	Balzar, S; Strand, M; Rhodes, D; Wenzel, SE				Balzar, Silvana; Strand, Matthew; Rhodes, Diane; Wenzel, Sally E.			IgE expression pattern in lung: Relation to systemic IgE and asthma phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; mucosal immune response; asthma exacerbation; mast cells; eosinophils; lymphocytes	FC-EPSILON-RI; ANTIBODY OMALIZUMAB; CELL ACTIVATION; NASAL-MUCOSA; MAST-CELLS; EXACERBATIONS; RESPONSES; ABSENCE; CHAIN; BETA	Background: IgE-mediated responses contribute to allergy and asthma. Little is understood regarding the relationship of tissue IgE to systemic IgE, inflammation or clinical outcomes. Objectives: To evaluate local IgE expression and cellular inflammation in the proximal and distal lung of normal subjects and subjects with asthma of varying severity and relate those tissue parameters to systemic IgE levels, atopy, lung function, and history of severe exacerbations of asthma. Methods: Tissue from more than 90 subjects with eosinophilic (SAeo(+)) and noneosinophilic (SAeo(-)) severe asthma, mild asthma and normal subjects were immunostained for IgE, signal-amplifying isoform of IgE receptor (Fc epsilon RI beta) and markers of mast cells, eosinophils, and lymphocytes. Tissue expression of IgE, Fc epsilon RI beta, cellular inflammation, serum IgE, and atopy were compared. Regression models were used to determine the relationship of local and systemic IgE to lung function and severe exacerbations of asthma. Results: Mast cell-bound IgE was present along airways but absent in lung parenchyma. Although the groups were similar in systemic/serum IgE and atopy, local/tissue IgE was highest in SAeo(+) and correlated with eosinophils and lymphocytes (r(s) = 0.52, P <.0001; and r(s) = 0.23, P =.03, respectively). Higher local IgE was associated with better lung function, but also with more severe exacerbations of asthma. Conclusion: Local IgE appears to be primarily a component of responses within the mucosal immune compartment and is related to cellular inflammation, lung function, and clinical outcomes in asthma. Clinical implications: Local/airway IgE-related processes rather than systemic markers of atopy may be relevant in determining clinical outcomes in asthma.	Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Sch Med, Pittsburgh, PA 15260 USA; Carnegie Mellon Univ, Div Pulm Allergy & Crit Care Med, Sch Med, Pittsburgh, PA 15213 USA; Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Balzar, S (corresponding author), Carnegie Mellon Univ, Div Pulm Allergy & Crit Care Med, Sch Med, UPMC Montefiore W626-3,3459 5th Ave, Pittsburgh, PA 15213 USA.	balzars@upmc.edu	Strand, Matt/AAU-3762-2021	Strand, Matt/0000-0002-9083-5989	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040600] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000005] Funding Source: Medline; NCRR NIH HHS [RR00051, M01 RR000051-40S21078, M01 RR000051] Funding Source: Medline; NHLBI NIH HHS [HL64087, R01 HL064087-04] Funding Source: Medline; NIAID NIH HHS [R01 AI040600, AI40600, R01 AI040600-10] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akadegawa K, 2005, J IMMUNOL, V174, P5499, DOI 10.4049/jimmunol.174.9.5499; Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Balzar S, 2006, INT ARCH ALLERGY IMM, V140, P96, DOI 10.1159/000092252; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Balzar S, 2002, EUR RESPIR J, V20, P254, DOI 10.1183/09031936.02.00261102; BALZAR S, 2004, AM J RESP CRIT CARE, V169, pA816; Bousquet J, 2005, ALLERGY, V60, P302, DOI 10.1111/j.1398-9995.2004.00770.x; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Chu H. W., 2002, Clinical and Experimental Allergy, V32, P1558, DOI 10.1046/j.1365-2222.2002.01477.x; Curran-Everett D, 2000, AM J PHYSIOL-REG I, V279, pR1, DOI 10.1152/ajpregu.2000.279.1.R1; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kleinbaum D, 1998, APPL REGRESSION ANAL; KleinJan A, 2000, EUR RESPIR J, V15, P491, DOI 10.1034/j.1399-3003.2000.15.11.x; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; MacPherson AJ, 2004, ANN NY ACAD SCI, V1029, P36, DOI 10.1196/annals.1309.005; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Powe DG, 2003, CLIN EXP ALLERGY, V33, P1374, DOI 10.1046/j.1365-2222.2003.01737.x; Powe DG, 2001, CLIN EXP ALLERGY, V31, P864, DOI 10.1046/j.1365-2222.2001.01106.x; Smurthwaite L, 2001, EUR J IMMUNOL, V31, P3422, DOI 10.1002/1521-4141(200112)31:12<3422::AID-IMMU3422>3.0.CO;2-T; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339; Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396; Zhou XX, 2005, AM J PHYSIOL-CELL PH, V288, pC435, DOI 10.1152/ajpcell.00035.2004	35	53	56	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					855	862		10.1016/j.jaci.2006.12.642	http://dx.doi.org/10.1016/j.jaci.2006.12.642			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17321582	Green Accepted			2022-12-18	WOS:000245729500013
J	Gibbs, BF; Rathling, A; Zillikens, D; Huber, M; Haas, H				Gibbs, Bernhard F.; Raethling, Anne; Zillikens, Detlef; Huber, Michael; Haas, Helmut			Initial Fc epsilon RI-mediated signal strength plays a key role in regulating basophil signaling and deactivation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; mast cells; signal transduction; allergy; IgE; Syk; p38 mitogen-activated protein kinase; extracellular signal-regulated kinase; src homology 2 domain-containing inositol 5 ' phosphatase	RBL-2H3 MAST-CELLS; HISTAMINE-RELEASE; LEUKEMIA-CELLS; IGE; SECRETION; DEGRANULATION; SHIP; ACTIVATION; KINASE; PHOSPHORYLATION	Background: Mediator releases after high-affinity IgE receptor (FCERI) cross-linking in basophils and mast cells crucially govern the symptoms of allergic disease and amplify underlying Tut-type responses. Interestingly, the dose-response curve for FCERI activation is bell-shaped, with supraoptimal stimulation leading to reduced mediator release. Objective: We sought to characterize the mechanisms responsible for this control of FCERI-triggered basophil activation. Methods: Human basophils were purified by means of Ficoll density centrifugation, elutriation, and negative selection with immunomagnetic beads. Various intracellular signal protein activities were assessed by means of Western blotting, and mediator releases were analyzed either spectrofluorometrically (histamine) or by means of ELISA (IL-4 and IL-13). Results: Supraoptimal anti-IgE concentrations led to lower mediator release than optimal concentrations but simultaneously to considerably faster histamine release kinetics. In parallel, basophil signaling proteins (Syk, p38 mitogen-activated protein kinase, and extracellular signal- regulated kinases 1 and 2) were more rapidly phosphorylated at higher anti-IgE concentrations but more transiently activated in the supraoptimal range. This endogenous regulation most likely-involved src homology 2 domain-containing inositol 5' phosphatase (SHIP), which was highly phosphorylated after supraoptimal anti-IgE triggering compared with lower stimulus concentrations. Conversely, N-formyl-methionyl-leucyl-phenylalanine-stimulated basophils failed to phosphorylate SHIP in the supraoptimal concentration range and did not display a bell-shaped dose-response curve. Conclusion: The kinetics of IgE-mediated signaling and mediator release in primary human Fc epsilon RI+ cells varies substantially according to the magnitude of stimulation, and SHIP most likely plays an important role in terminating these events. Clinical implications: The speed of allergic symptom generation depends on the degree of IgE receptor triggering, which is downregulated by SHIP, a potential target for allergy therapy.	Univ Freiburg, Dept Mol Immunol, D-7800 Freiburg, Germany; Univ Lubeck, Dept Dermatol, Lubeck, Germany; Max Planck Inst Immunobiol, D-7800 Freiburg, Germany; Forschungzentrum Borstel, Cellular Allergol, Borstel, Germany	University of Freiburg; University of Lubeck; Max Planck Society; Forschungszentrum Borstel	Gibbs, BF (corresponding author), Univ Kent, Sch Pharm, Cent Ave, Chatham ME4 4TB, Kent, England.	bfgibbs@gmx.de	Zillikens, Detlef/C-8572-2011; Sumbayev, Vadim/HCH-7696-2022					Bachelet I, 2005, J IMMUNOL, V175, P7989, DOI 10.4049/jimmunol.175.12.7989; CONROY MC, 1977, J IMMUNOL, V118, P1317; Falcone FH, 2000, BLOOD, V96, P4028; FEWTRELL C, 1980, J IMMUNOL, V125, P701; GADDY JN, 1986, AM REV RESPIR DIS, V134, P969, DOI 10.1164/arrd.1986.134.5.969; Gibbs BF, 1999, J LEUKOCYTE BIOL, V65, P883, DOI 10.1002/jlb.65.6.883; Gibbs BF, 2002, J LEUKOCYTE BIOL, V72, P391; Gibbs BF, 1996, EUR J IMMUNOL, V26, P2493, DOI 10.1002/eji.1830261033; Gimborn K, 2005, J IMMUNOL, V174, P507, DOI 10.4049/jimmunol.174.1.507; Haisch K, 1999, J IMMUNOL METHODS, V226, P129, DOI 10.1016/S0022-1759(99)00059-9; Hernandez-Hansen V, 2004, J IMMUNOL, V173, P100, DOI 10.4049/jimmunol.173.1.100; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Kepley CL, 2000, J IMMUNOL, V165, P5913, DOI 10.4049/jimmunol.165.10.5913; Kepley CL, 2004, J BIOL CHEM, V279, P35139, DOI 10.1074/jbc.M404318200; Lavens-Phillips SE, 2000, AM J RESP CELL MOL, V23, P566, DOI 10.1165/ajrcmb.23.4.4123; LICHTENSTEIN LM, 1986, J ALLERGY CLIN IMMUN, V77, P291, DOI 10.1016/S0091-6749(86)80106-3; MACGLASHAN DW, 1995, J LEUKOCYTE BIOL, V58, P177, DOI 10.1002/jlb.58.2.177; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MAGRO AM, 1974, J IMMUNOL, V112, P1762; Malbec O, 1998, J IMMUNOL, V160, P1647; Miura K, 2000, BLOOD, V96, P2199, DOI 10.1182/blood.V96.6.2199.h8002199_2199_2205; ORTEGA E, 1988, EMBO J, V7, P4101, DOI 10.1002/j.1460-2075.1988.tb03304.x; ROBERTSON D, 1986, J IMMUNOL, V136, P4565; Schroeder JT, 2001, ADV IMMUNOL, V77, P93, DOI 10.1016/S0065-2776(01)77015-0; SEAGRAVE J, 1991, J CELL PHYSIOL, V148, P139, DOI 10.1002/jcp.1041480117; SEAGRAVE J, 1990, J CELL PHYSIOL, V144, P128, DOI 10.1002/jcp.1041440117; Shiratori I, 2005, J IMMUNOL, V175, P4441, DOI 10.4049/jimmunol.175.7.4441; Voehringer D, 2004, J BIOL CHEM, V279, P54117, DOI 10.1074/jbc.M406997200; Vonakis BM, 2001, J ALLERGY CLIN IMMUN, V108, P822, DOI 10.1067/mai.2001.119159	30	53	57	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1060	1067		10.1016/j.jaci.2006.07.022	http://dx.doi.org/10.1016/j.jaci.2006.07.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088130				2022-12-18	WOS:000244282300010
J	Tawde, P; Venkatesh, YP; Wang, F; Teuber, SS; Sathe, SK; Roux, KH				Tawde, Pallavi; Venkatesh, Yeldur P.; Wang, Fang; Teuber, Suzanne S.; Sathe, Shridhar K.; Roux, Kenneth H.			Cloning and characterization of profilin (Pru du 4), a cross-reactive almond (Prunus dulcis) allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; almond allergy; profilin; food allergy; recombinant allergen; pan-allergen	BIRCH POLLEN PROFILIN; PLANT FOOD ALLERGENS; TREE NUT ALLERGY; MOLECULAR CHARACTERIZATION; MAJOR ALLERGEN; IGE-BINDING; IN-VITRO; RECOMBINANT ALLERGENS; PANALLERGEN PROFILIN; CELERY ALLERGENS	Background: The identity of allergenic almond proteins is incomplete. Objective: Our objective was to characterize patient IgE reactivity to a recombinant and corresponding native almond allergen. Methods: An almond cDNA library was screened with sera from patients with allergy for IgE binding proteins. Two reactive clones were sequenced, and 1 was expressed. The expressed recombinant allergen and its native counterpart (purified from unprocessed almond flour) were assayed by 1-dimensional and 2-dimensional gel electrophoresis, dot blot, and ELISA, and screened for cross-reactivity with grass profilin. Results: The 2 selected clones encoded profilin (designated Pru du 4) sequences that differed by 2 silent mutations. By dot-blot analyses, 6 of 18 patient sera (33%) reacted with the recombinant Pru du 4 protein, and 8 of 18 (44%) reacted with the native form. ELISA results were similar. Almond and ryegrass profilins were mutually inhibitable. Two-dimensional immunoblotting revealed the presence of more than I native almond profilin isoform. The strength of reactivity of some patients' serum IgE differed markedly between assays and between native and recombinant profilins. Conclusion: Almond nut profilin is an IgE-binding food protein that is cross-reactive with grass pollen profilin and is susceptible to denaturation, resulting in variable reactivity between assay types and between patients. Clinical implications: Serum IgE of nearly half of the tested patients with almond allergy reacts with almond nut profilin. Because most patients also had pollinosis, the well-known cross-this pattern of reactivity.	Florida State Univ, Biol Unit 1, Dept Biol Sci, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; Florida State Univ, Dept Nutr Food & Excercise Sci, Tallahassee, FL 32306 USA; Cent Food Technol Res Inst, Dept Biochem & Nutr, Mysore 570013, Karnataka, India	State University System of Florida; Florida State University; State University System of Florida; Florida State University; State University System of Florida; Florida State University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Food Technological Research Institute (CFTRI)	Roux, KH (corresponding author), Florida State Univ, Biol Unit 1, Dept Biol Sci, Tallahassee, FL 32306 USA.	roux@bio.fsu.edu						Asero R, 2003, J ALLERGY CLIN IMMUN, V112, P427, DOI 10.1067/mai.2003.1611; Asturias JA, 1997, J ALLERGY CLIN IMMUN, V100, P365, DOI 10.1016/S0091-6749(97)70250-1; Asturias JA, 1999, J IMMUNOL, V162, P4342; Asturias JA, 2005, CLIN EXP ALLERGY, V35, P374, DOI 10.1111/j.1365-2222.2005.02179.x; Asturias JA, 2002, INT IMMUNOL, V14, P993, DOI 10.1093/intimm/dxf070; Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; Breiteneder H, 2004, J ALLERGY CLIN IMMUN, V113, P821, DOI [10.1016/j.jaci.2004.01.779, 10.1016/j.jaci.2004.01.079]; Breiteneder H, 2001, CURR OPIN ALLERGY CL, V1, P261, DOI 10.1097/01.all.0000011024.76416.01; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Ebner C, 1998, ALLERGY, V53, P52, DOI 10.1111/j.1398-9995.1998.tb04961.x; *FAO, 1995, FOOD ALL REP TECHN C; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; GARCIAMAS J, 1995, PLANT MOL BIOL, V27, P205, DOI 10.1007/BF00019192; Hansen KS, 2003, ALLERGY, V58, P132, DOI 10.1034/j.1398-9995.2003.23959.x; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; Huang SR, 1996, PLANT PHYSIOL, V111, P115, DOI 10.1104/pp.111.1.115; Jankiewicz A, 1997, FOOD AGR IMMUNOL, V9, P203, DOI 10.1080/09540109709354951; Jankiewicz A, 1997, J SCI FOOD AGR, V75, P359, DOI 10.1002/(SICI)1097-0010(199711)75:3&lt;359::AID-JSFA889&gt;3.0.CO;2-Y; JANMEY PA, 1991, METHOD ENZYMOL, V196, P92; Jenkins JA, 2005, J ALLERGY CLIN IMMUN, V115, P163, DOI 10.1016/j.jaci.2004.10.026; Kelso JM, 2000, CLIN EXP ALLERGY, V30, P905, DOI 10.1046/j.1365-2222.2000.00872.x; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; Kleber-Janke T, 1999, INT ARCH ALLERGY IMM, V119, P265, DOI 10.1159/000024203; Kleber-Janke T, 2001, J CHROMATOGR B, V756, P295, DOI 10.1016/S0378-4347(01)00088-3; Koppelman SJ, 2005, J AGR FOOD CHEM, V53, P123, DOI 10.1021/jf0491355; Ledesma A, 1998, ALLERGY, V53, P520, DOI 10.1111/j.1398-9995.1998.tb04090.x; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; Mellon MB, 2002, J IMMUNOL, V168, P290, DOI 10.4049/jimmunol.168.1.290; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Poltronieri P, 2002, INT ARCH ALLERGY IMM, V128, P97, DOI 10.1159/000059399; Radauer C, 2004, PLANT FOOD ALLERGENS, P105; Rance F, 2002, ARCH PEDIATRIE, V9, p402S, DOI 10.1016/S0929-693X(02)00151-3; Reindl J, 2002, INT ARCH ALLERGY IMM, V128, P105, DOI 10.1159/000059400; Rihs HP, 1999, J ALLERGY CLIN IMMUN, V104, P1293, DOI 10.1016/S0091-6749(99)70027-8; Rodriguez-Perez R, 2003, ALLERGY, V58, P635, DOI 10.1034/j.1398-9995.2003.00198.x; Rodriguez-Perez R, 2003, J ALLERGY CLIN IMMUN, V111, P634, DOI 10.1067/mai.2003.74; Roux KH, 2003, INT ARCH ALLERGY IMM, V131, P234, DOI 10.1159/000072135; Roux KH, 2001, J AGR FOOD CHEM, V49, P2131, DOI 10.1021/jf001307k; ROZYCKI M, 1991, METHOD ENZYMOL, V196, P100; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sathe SK, 2002, J AGR FOOD CHEM, V50, P4333, DOI 10.1021/jf020007v; SATHE SK, 1993, J FOOD BIOCHEM, V16, P249, DOI 10.1111/j.1745-4514.1992.tb00450.x; Scheurer S, 2001, J CHROMATOGR B, V756, P315, DOI 10.1016/S0378-4347(01)00090-1; Schocker F, 2000, EUR J NUTR, V39, P172, DOI 10.1007/s003940070021; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; STAIGER CJ, 1993, PLANT J, V4, P631, DOI 10.1046/j.1365-313X.1993.04040631.x; Teuber SS, 2003, CURR ALLERGY ASTHM R, V3, P54, DOI 10.1007/s11882-003-0013-x; Vallverdu A, 1998, J ALLERGY CLIN IMMUN, V101, P363, DOI 10.1016/S0091-6749(98)70249-0; van Ree R, 1999, CLIN EXP ALLERGY, V29, P848, DOI 10.1046/j.1365-2222.1999.00521.x; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; Wang F, 2003, INT ARCH ALLERGY IMM, V132, P27, DOI 10.1159/000073262; Wang F, 2002, J ALLERGY CLIN IMMUN, V110, P160, DOI 10.1067/mai.2002.125208; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380; Westphal S, 2004, ALLERGY, V59, P526, DOI 10.1046/j.1398-9995.2003.00413.x; Witke W, 2004, TRENDS CELL BIOL, V14, P461, DOI 10.1016/j.tcb.2004.07.003	58	53	55	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					915	922		10.1016/j.jaci.2006.05.028	http://dx.doi.org/10.1016/j.jaci.2006.05.028			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030246				2022-12-18	WOS:000241434200020
J	Heinrich, J; Bedada, GB; Zock, JP; D Chinn, S; Norback, D; Olivieri, M; Svanes, C; Ponzio, M; Verlato, G; Villani, S; Jarvis, D; Luczynska, C				Heinrich, Joachim; Bedada, Getahun Bero; Zock, Jan-Paul; D Chinn, Susan; Norback, Dan; Olivieri, Mario; Svanes, Cecilie; Ponzio, Michela; Verlato, Giuseppe; Villani, Simona; Jarvis, Deborah; Luczynska, Christina		Indoor Working Grp European Comm	Cat allergen level: Its determinants and relationship to specific IgE to cat across European centers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cat allergen; Fel d 1; cat; mattress dust; indoor exposure; cat allergy; specific IgE to cat; ECRHS	FEL D 1; RESPIRATORY HEALTH SURVEY; IN-HOUSE DUST; COCKROACH ALLERGENS; ULTRAFINE PARTICLES; INDOOR ALLERGENS; GERMAN HOMES; EXPOSURE; SENSITIZATION; CHILDREN	Background: Cat allergen level in settled house dust and its determinants in Europe are unknown. Objective: The aim of this study is to quantify the level of cat allergens in mattress dust, to study its determinants, and to analyze the relationship with cat specific IgE on community level across European centers. Methods: Trained field workers collected dust from approximately 3000 mattresses during home visits in 22 European Community Respiratory Health Survey II centers. Sieved dust extracts were assayed for cat allergen using a mAb ELISA assay. Results: The overall geometric mean cat allergen was 0.94 mu g/g, ranging from 0.12 mu g/g in Huelva, Spain, to 3.76 mu g/g in Antwerp, Belgium. Current cat owners' homes showed substantially higher levels than past cat owners' and never cat owners' homes (geometric mean and 95% CI, 61.4 mu g/g [48.4-77.9] vs 1.37 mu g/g [0.97-1.9] vs 0.29 mu g/g [0.27-0.31]x). Community prevalence of cat ownership was moderately correlated with cat allergen levels in noncat owners (r(s) = 0.50), but not for past or current cat owners. The multilevel model identified community prevalence of cat keeping as the only statistically significant determinant of mattress cat allergen levels for noncat owners. However, averaged cat allergen levels per center were not related to community prevalence of detectable specific IgE to cat. Conclusion: Not having a cat in the home is associated with substantially lower Fel d 1 concentration, but does not protect against high Fel d 1 exposure in communities where cat ownership is common. Clinical implications: People (including patients with cat allergy) who do not own cats may be exposed to high levels of cat allergen in their home, particularly if they live in communities with high levels of cat ownership.	GSF, Inst Epidemiol, Natl Res Ctr Environm & Hlth, D-85758 Neuherberg, Germany; Municipal Inst Med Res, Ctr Res Environm Epidemiol, Barcelona, Spain; Kings Coll London, Dept Publ Hlth Sci, London WC2R 2LS, England; Uppsala Univ, Dept Med Sci Occupat & Environm Med, Uppsala, Sweden; Univ Verona, Unit Occupat Med, Dept Med & Publ Hlth, I-37100 Verona, Italy; Haukeland Hosp, Dept Thorac Med, N-5021 Bergen, Norway; Univ Pavia, Dept Hlth Sci, Sect Epidemiol & Med Stat, I-27100 Pavia, Italy; Univ Verona, Dept Med & Publ Hlth, Unit Epidemiol & Med Stat, I-37100 Verona, Italy; Univ London Imperial Coll Sci & Technol, Natl Heart & Lung Inst, Dept Resp Epidemiol & Publ Hlth, London, England	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of London; King's College London; Uppsala University; University of Verona; University of Bergen; Haukeland University Hospital; University of Pavia; University of Verona; Imperial College London	Heinrich, J (corresponding author), GSF, Inst Epidemiol, Natl Res Ctr Environm & Hlth, POB 1129, D-85758 Neuherberg, Germany.	joachim.heinrich@gsf.de	Zock, Jan-Paul/P-5034-2018; Jarvis, Deborah/E-6494-2011; Svanes, Cecilie/N-7556-2017; SESM, SESM/C-1440-2008; Heinrich, Joachim/N-1720-2013	Zock, Jan-Paul/0000-0002-2941-6259; Svanes, Cecilie/0000-0001-8512-5192; Heinrich, Joachim/0000-0002-9620-1629; Jarvis, Deborah/0000-0002-1753-3896; /0000-0003-2517-6515; Bero Bedada, Getahun/0000-0002-8184-4592; Norback, Dan/0000-0002-5174-6668				Afshari A, 2005, INDOOR AIR, V15, P141, DOI 10.1111/j.1600-0668.2005.00332.x; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Cullinan P, 2004, THORAX, V59, P855, DOI 10.1136/thx.2003.019877; Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; DABROWSKI AJ, 1990, J ALLERGY CLIN IMMUN, V86, P462, DOI 10.1016/S0091-6749(05)80200-3; ENBERG RN, 1993, ANN ALLERGY, V70, P471; Fahlbusch B, 2002, J INVEST ALLERG CLIN, V12, P12; Gehring U, 2004, INDOOR AIR, V14, P284, DOI 10.1111/j.1600-0668.2004.00244.x; Gehring U, 2004, ENVIRON HEALTH PERSP, V112, P834, DOI 10.1289/ehp.6685; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Heissenhuber A, 2003, ALLERGY, V58, P154, DOI 10.1034/j.1398-9995.2003.00037.x; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; Matson U, 2005, SCI TOTAL ENVIRON, V343, P169, DOI 10.1016/j.scitotenv.2004.10.002; Monn C, 1997, SCI TOTAL ENVIRON, V208, P15, DOI 10.1016/S0048-9697(97)00271-4; Munir A K, 1994, Pediatr Allergy Immunol, V5, P32, DOI 10.1111/j.1399-3038.1994.tb00216.x; MUNIR AKM, 1994, ALLERGY, V49, P508, DOI 10.1111/j.1398-9995.1994.tb01121.x; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; MUNIR AKM, 1993, ALLERGY, V48, P158, DOI 10.1111/j.1398-9995.1993.tb00706.x; Parvaneh S, 1999, ALLERGY, V54, P229, DOI 10.1034/j.1398-9995.1999.00855.x; Peterson EL, 1999, J ALLERGY CLIN IMMUN, V104, P348, DOI 10.1016/S0091-6749(99)70378-7; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Ritz BR, 2002, ALLERGY, V57, P357, DOI 10.1034/j.1398-9995.2002.1s3404.x; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Svanes C, 2003, J ALLERGY CLIN IMMUN, V112, P289, DOI 10.1067/mai.2003.1596; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wickman M, 1999, CLIN EXP ALLERGY, V29, P626	35	53	54	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					674	681		10.1016/j.jaci.2006.06.012	http://dx.doi.org/10.1016/j.jaci.2006.06.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950287				2022-12-18	WOS:000240649000021
J	Svanes, C; Zock, JP; Anto, J; Dharmage, S; Norback, D; Wjst, M; Heinrich, J; Jarvis, D; de Marco, R; Plana, E; Raherison, C; Sunyer, J				Svanes, Cecilie; Zock, Jan-Paul; Anto, Josep; Dharmage, Shyamali; Norback, Dan; Wjst, Matthias; Heinrich, Joachim; Jarvis, Deborah; de Marco, Roberto; Plana, Estel; Raherison, Chantal; Sunyer, Jordi		Early LIfe Working Grp European	Do asthma and allergy influence subsequent pet keeping? An analysis of childhood and adulthood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						selective avoidance; pets; cats; dogs; birds; asthma; allergy; atopy; ECRHS	RESPIRATORY-HEALTH-SURVEY; BRONCHIAL RESPONSIVENESS; CAT ALLERGEN; EXPOSURE; SENSITIZATION; CHILDREN; ATOPY; LIFE; SYMPTOMS; RISK	Background: Asthma and allergy might influence the choice of keeping pets, leading to apparent protective effects of pets on allergic disease. Objective: We investigated the effects of asthma and allergy on subsequent pet keeping in childhood and adulthood. Methods: Information about asthma and pet keeping at ages 0 to 4, 5 to 15, 20 to 44, and 26 to 56 years was provided by 9812 subjects participating in the 9-year follow-up of the European Community Respiratory Health Survey. Results: In childhood asthma debut at younger than 5 years was associated with less cat keeping at 5 to 15 years (odds ratio [OR], 0.60; 95% CI, 0.44-0.82), an effect only observed when the parents did not have asthma or allergy (P-interaction = .045). Childhood asthma did not influence adult pet ownership, unless there were adult symptoms. Adults less often acquired cats at follow-up if they had 3 or more asthma symptoms (OR, 0.78; 95% CI, 0.64-0.95), were taking asthma medication (OR, 0.48; 95% CI, 0.31-0.74), had hay fever (OR, 0.75; 95% CI, 0.620.91), had atopy (OR, 0.75; 95% CI, 0.61-0.91), or had specific IgE to cat (OR, 0.57; 95% CI, 0.39-0.82) at baseline. Adults who already had pets usually continued keeping the same type of pet, except that the presence of 3 or more asthma symptoms was associated with less subsequent dog keeping (OR, 0.69; 95% CI, 0.53-0.89). Pet removal between surveys to reduce allergen was reported by 4.7%. Conclusion: Selective avoidance subsequent to asthma or allergy was observed for childhood cat keeping and adult cat acquisition. Avoidance would produce an apparent protective effect of cats on childhood asthma (large OR, 0.83). Avoidance was generally not observed for dogs or birds. Clinical implications: A part of the protective effects of childhood cats on asthma and allergy can be attributed to selective avoidance.	Univ Bergen, Dept Thorac Med, Inst Med, Bergen, Norway; IMIM, Barcelona, Spain; Univ Melbourne, Ctr MEGA Epidemiol, Dept Publ Hlth, Melbourne, Vic, Australia; Uppsala Univ, Dept Med Sci Occupat & Environm Med, Uppsala, Sweden; GSF, Inst Epidemiol, Neuherberg, Germany; Kings Coll London, Dept Publ Hlth Sci, London WC2R 2LS, England; Univ Verona, Dept Med & Publ Hlth Epidemiol & Med Stat, I-37100 Verona, Italy; Univ Paris 07, INSERM Epidemiol U700, Paris, France	University of Bergen; Institut Hospital del Mar d'Investigacions Mediques (IMIM); University of Melbourne; Uppsala University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of London; King's College London; University of Verona; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Svanes, C (corresponding author), Haukeland Hosp, Dept Thorac Med, N-5021 Bergen, Norway.	cecilie.svanes@med.uib.no	Svanes, Cecilie/N-7556-2017; Heinrich, Joachim/N-1720-2013; Raherison, Chantal/T-3556-2019; Sunyer, Jordi/G-6909-2014; de Marco, Roberto/A-5470-2008; Jarvis, Deborah/E-6494-2011; Zock, Jan-Paul/P-5034-2018; Anto, J M/H-2676-2014; SESM, SESM/C-1440-2008	Svanes, Cecilie/0000-0001-8512-5192; Heinrich, Joachim/0000-0002-9620-1629; Sunyer, Jordi/0000-0002-2602-4110; Zock, Jan-Paul/0000-0002-2941-6259; Anto, J M/0000-0002-4736-8529; Jarvis, Deborah/0000-0002-1753-3896; Norback, Dan/0000-0002-5174-6668	NCRR NIH HHS [2 S07 RR05521-28] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005521] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; Baldini M, 2002, ALLERGY, V57, P188, DOI 10.1034/j.1398-9995.2002.1r152.x; Bornehag CG, 2003, ALLERGY, V58, P939, DOI 10.1034/j.1398-9995.2003.00050.x; Braback L, 2001, PEDIAT ALLERG IMM-UK, V12, P4, DOI 10.1034/j.1399-3038.2001.012001004.x; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Chinn S, 1998, THORAX, V53, P984, DOI 10.1136/thx.53.11.984; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Henriksen AH, 2001, RESP MED, V95, P122, DOI 10.1053/rmed.2000.1004; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holscher B, 2002, PEDIAT ALLERG IMM-UK, V13, P334, DOI 10.1034/j.1399-3038.2002.02063.x; Jaakkola JJK, 2002, J ALLERGY CLIN IMMUN, V109, P784, DOI 10.1067/mai.2002.123870; Jarvis D, 2005, J ALLERGY CLIN IMMUN, V116, P675, DOI 10.1016/j.jaci.2005.05.009; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829, DOI 10.1164/ajrccm.164.10.2103137; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Pekkanen J, 2005, EUR RESPIR J, V26, P28, DOI 10.1183/09031936.05.00120104; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Ronmark E, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e37; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Sunyer Y, 1997, EUR RESPIR J, V10, P2490, DOI 10.1183/09031936.97.10112490; Svanes C, 2003, J ALLERGY CLIN IMMUN, V112, P289, DOI 10.1067/mai.2003.1596; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785	32	53	53	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					691	698		10.1016/j.jaci.2006.06.017	http://dx.doi.org/10.1016/j.jaci.2006.06.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950289				2022-12-18	WOS:000240649000023
J	Trudeau, J; Hu, HZ; Chibana, K; Chu, HW; Westcott, JY; Wenzel, SE				Trudeau, John; Hu, Haizhen; Chibana, Kazuyuki; Chu, Hong Wei; Westcott, Jay Y.; Wenzel, Sally E.			Selective downregulation of prostaglandin E-2-related pathways by the T(H)2 cytokine IL-13	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-13; prostaglandin E-2; COX; asthma	ALLERGIC INFLAMMATION; INHALED PGE(2); PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED BRONCHOCONSTRICTION; AIRWAY RESPONSES; EPITHELIAL-CELLS; EXPRESSION; CYCLOOXYGENASE-2; E-2; DEHYDROGENASE	Background: Levels of COX-2 and downstream products, such as prostaglandin (PG) E-2, are increased in inflammatory settings after stimulation by IL-1 beta, LPS, and other innate factors. Although the T(H)2 cytokines IL-4 and IL-13 have been reported to decrease COX-2 levels in some cell types, neither the effect of these cytokines on other PGE(2)-related pathways nor their effect in primary human airway epithelial cells has been evaluated. Objective: To determine the impact of IL-13 on PGE(2) pathways in primary human airway epithelial cells. Methods: Because PGE(2) has anti-inflammatory, antifibrotic, and bronchodilating properties of relevance to asthma, the effect of IL-13 (10 ng/mL for 10 days) on PGE(2) pathway elements in first-passage air-liquid interface epithelial cells from 8 endobronchial brushings (5 asthmatic subjects and 3 healthy subjects) was evaluated. mRNA and protein levels for COX-1 and COX-2, membrane-bound PGE synthase 1, 15-PG dehydrogenase, and the receptors EP2 and EN were quantified by means of real-time PCR and Western blotting. PGE(2) levels in the supernatants were measured by means of enzyme immunoassay. Results: IL-13 significantly inhibited the PGE(2) synthetic pathways COX-2 and PGE synthase I while upregulating the PGE(2) metabolizing enzyme 15-PG dehydrogenase. These enzymatic changes associated and correlated with decreased supernatant PGE(2) levels. Significant reductions in the mRNA for EP2 (but not EP4) were also observed. Changes in the PG pathway were both time and dose dependent (n = 3). Conclusion: These data suggest that IL-13 induces systematic modulation of proteins related to the production, catabolism, and function of PGE(2), which might alter inflammatory and immune responses at the level of the epithelium and the submucosa below. Clinical implications: Modulation of PGE(2) pathways by IL-13 might alter inflammatory and repair processes in asthma.	Univ Colorado, Dept Med, Div Pulm & Crit Care Med, Hlth Sci Ctr, Denver, CO 80202 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wenzel, SE (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Div Pulm, 1400 Jackson St, Denver, CO 80206 USA.	wenzels@njc.org			NCRR NIH HHS [RR00051] Funding Source: Medline; NIAID NIH HHS [AI-40600] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040600] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGHOLTE JM, 1986, ARCH BIOCHEM BIOPHYS, V245, P308, DOI 10.1016/0003-9861(86)90221-3; Bonazzi A, 2000, AM J RESP CRIT CARE, V162, P2272, DOI 10.1164/ajrccm.162.6.2003127; Bonner JC, 2002, AM J PATHOL, V161, P459, DOI 10.1016/S0002-9440(10)64202-2; Challis JRG, 1999, J PERINAT MED, V27, P26, DOI 10.1515/JPM.1999.003; Chu HW, 2004, AM J PATHOL, V165, P1097, DOI 10.1016/S0002-9440(10)63371-8; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Endo T, 1996, J IMMUNOL, V156, P2240; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31, DOI 10.1164/ajrccm.159.1.9804030; GAUVREAU GM, 1998, PHARM MODULATION ALL, P83; Gyllfors P, 2003, J ALLERGY CLIN IMMUN, V111, P1116, DOI 10.1067/mai.2003.1450; Hapangama DK, 2002, J CLIN ENDOCR METAB, V87, P5229, DOI 10.1210/jc.2002-020429; Harbinson PL, 1997, EUR RESPIR J, V10, P1008, DOI 10.1183/09031936.97.10051008; Hashimoto K, 2005, J IMMUNOL, V174, P525, DOI 10.4049/jimmunol.174.1.525; Ikegami R, 2001, J IMMUNOL, V166, P4689, DOI 10.4049/jimmunol.166.7.4689; Kojima F, 2004, ARTHRITIS RES THER, V6, pR355, DOI 10.1186/ar1195; Lama V, 2002, AM J RESP CELL MOL, V27, P752, DOI 10.1165/rcmb.4857; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-509OC; Martinez-Moragon E, 2004, J ALLERGY CLIN IMMUN, V113, P242, DOI 10.1016/j.jaci.2003.11.002; MELILLO E, 1994, AM J RESP CRIT CARE, V149, P1138, DOI 10.1164/ajrccm.149.5.8173753; Mitchell MD, 2000, PROSTAG LEUKOTR ESS, V62, P1, DOI 10.1054/plef.1999.0117; Monick MM, 2002, J BIOL CHEM, V277, P32992, DOI 10.1074/jbc.M203218200; Nakata J, 2005, RESPIROLOGY, V10, P149, DOI 10.1111/j.1440-1843.2005.00687.x; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87; Peebles RS, 2002, AM J RESP CRIT CARE, V165, P1154, DOI 10.1164/rccm.2106025; Picado C, 1999, AM J RESP CRIT CARE, V160, P291, DOI 10.1164/ajrccm.160.1.9808048; Pierzchalska M, 2003, J ALLERGY CLIN IMMUN, V111, P1041, DOI 10.1067/mai.2003.1491; Pillinger MH, 2003, J IMMUNOL, V171, P6080, DOI 10.4049/jimmunol.171.11.6080; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; Sugiyama E, 1996, ANN RHEUM DIS, V55, P375, DOI 10.1136/ard.55.6.375; Vancheri C, 2004, TRENDS IMMUNOL, V25, P40, DOI 10.1016/j.it.2003.11.001; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 2002, J IMMUNOL, V169, P4613, DOI 10.4049/jimmunol.169.8.4613	36	53	54	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1446	1454		10.1016/j.jaci.2006.01.049	http://dx.doi.org/10.1016/j.jaci.2006.01.049			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751012				2022-12-18	WOS:000238332300038
J	Mitre, E; Nutman, TB				Mitre, E; Nutman, TB			IgE memory: Persistence of antigen-specific IgE responses years after treatment of human filarial infections	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; immunologic memory; histamine; IL-4; helminth; basophil; humoral immunity; filaria; parasite	FOLLICULAR DENDRITIC CELLS; TROPICAL PULMONARY EOSINOPHILIA; IMMUNOGLOBULIN-E; PLASMA-CELLS; B-CELLS; BANCROFTIAN FILARIASIS; TRICHINELLA-SPIRALIS; PERIPHERAL-BLOOD; IMMUNIZED MICE; MAST-CELLS	Background: The human immune response to helminth infections is characterized by elevated serum levels of antigen-specific IgE. Although it is well established that IgG Immoral immunity can persist for years, as yet there have been no longitudinal studies of antigen-specific IgE responses to helminth infection in the absence of re-exposure to pathogen. Objective: We sought to determine the presence of filaria-specific IgE responses years after treatment of human filarial infections in patients no longer living in a region endemic for filariasis. Methods: Filaria-specific IgE levels were measured in 34 filaria-infected patients before and I I to 178 (median = 33) months after anthelmintic therapy. Frequencies of filaria-specific IgE-producing cells and measures of filaria-specific IgE-mediated histamine and IL-4 release from basophils were measured in subsets of these patients. Results: At follow-up, all patients were asymptomatic without evidence of active infection, and none had travelled to filaria-endemic regions since initial evaluation. Although frequencies of Brugia malayi antigen (BmAg)-specitic IgE-producing cells and serum levels of BmAg-specific IgE decreased significantly over time, both remained detectable in the majority of patients years after initial treatment. Six of 10 patients' basophils released histamine in response to BmAg after treatment (vs 7 of 10 before treatment). Basophils also continued to release IL-4 after stimulation with BmAg years after treatment. Conclusion: These results demonstrate that filaria-specific IgE production and filaria-specific IgE-mediated basophil release of histamine and IL-4 persist for years after treatment of human filarial infections. Clinical implications: These findings suggest that (1) absolute allergen avoidance may not result in the loss of allergy, and (2) parasite-specific IgE-inducing vaccines, if effective, could potentially induce longstanding protection.	NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Mitre, E (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Room B4104, Bethesda, MD 20814 USA.	emitre@usuhs.mil			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000805, ZIAAI000805] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abraham D, 2004, INFECT IMMUN, V72, P810, DOI 10.1128/IAI.72.2.810-817.2004; AOKI I, 1995, P NATL ACAD SCI USA, V92, P2534, DOI 10.1073/pnas.92.7.2534; BENTASCONI NL, 2002, SCIENCE, V298, P2199; Bernardini R, 2000, ALLERGY, V55, P984, DOI 10.1034/j.1398-9995.2000.00791.x; Bethony J, 2005, FASEB J, V19, P1743, DOI 10.1096/fj.05-3936fje; Blanca M, 1999, J ALLERGY CLIN IMMUN, V103, P918, DOI 10.1016/S0091-6749(99)70439-2; Burger MS, 2004, J ALLERGY CLIN IMMUN, V114, P1301, DOI 10.1016/j.jaci.2004.08.013; Chapa-Ruiz MR, 2001, PARASITE, V8, pS163, DOI 10.1051/parasite/200108s2163; ESTAMBALE BBA, 1995, ANN TROP MED PARASIT, V89, P287, DOI 10.1080/00034983.1995.11812954; FISHER MM, 1992, ANAESTH INTENS CARE, V20, P143, DOI 10.1177/0310057X9202000203; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Gibbs BF, 1996, EUR J IMMUNOL, V26, P2493, DOI 10.1002/eji.1830261033; Gibbs BF, 2000, INFLAMM RES, V49, pS9; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Gray D, 2002, NAT REV IMMUNOL, V2, P60, DOI 10.1038/nri706; Gurish MF, 2004, J IMMUNOL, V172, P1139, DOI 10.4049/jimmunol.172.2.1139; HELM SLT, 1995, EUR J IMMUNOL, V25, P2362, DOI 10.1002/eji.1830250836; Horner AA, 2002, J ALLERGY CLIN IMMUN, V110, P706, DOI 10.1067/mai.2002.129122; Horst A, 2002, CLIN EXP IMMUNOL, V130, P370, DOI 10.1046/j.1365-2249.2002.02025.x; Hotez PJ, 2003, INT J PARASITOL, V33, P1245, DOI 10.1016/S0020-7519(03)00158-9; Hotez PJ, 2002, J PARASITOL, V88, P684, DOI 10.1645/0022-3395(2002)088[0684:EOVWRF]2.0.CO;2; Khodoun MV, 2004, J EXP MED, V200, P857, DOI 10.1084/jem.20040598; KING CL, 1991, J IMMUNOL, V146, P1478; King CL, 1997, J IMMUNOL, V158, P294; Kooyman FNJ, 2000, PARASITE IMMUNOL, V22, P13; LEE SJ, 1990, J INFECT DIS, V162, P529, DOI 10.1093/infdis/162.2.529; Lemiere C, 2003, ANN ALLERG ASTHMA IM, V90, P52, DOI 10.1016/S1081-1206(10)61650-X; Lobos E, 2003, INFECT IMMUN, V71, P747, DOI 10.1128/IAI.71.2.747-753.2003; MAEDA K, 1992, J IMMUNOL, V148, P2340; MANDEL TE, 1981, IMMUNOLOGY, V43, P353; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; MCCARTHY JS, 1994, J INFECT DIS, V170, P736, DOI 10.1093/infdis/170.3.736; Mitre E, 2005, INFECT IMMUN, V73, P4106, DOI 10.1128/IAI.73.7.4106-4111.2005; Mitre E, 2004, J IMMUNOL, V172, P2439, DOI 10.4049/jimmunol.172.4.2439; OTTESEN EA, 1992, ANNU REV MED, V43, P417, DOI 10.1146/annurev.med.43.1.417; Panum PL, 1847, VIRCHOWS ARCH PATH A, V1, P492, DOI [DOI 10.1007/BF02114472, 10.1007/BF02114472]; PAUL JR, 1951, AM J HYG, V54, P275, DOI 10.1093/oxfordjournals.aje.a119485; Poorafshar M, 2000, EUR J IMMUNOL, V30, P2660, DOI 10.1002/1521-4141(200009)30:9<2660::AID-IMMU2660>3.0.CO;2-I; Ramirez RM, 1996, MEM I OSWALDO CRUZ, V91, P593, DOI 10.1590/S0074-02761996000500010; Rossi Claudio L., 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P361, DOI 10.1590/S0036-46651993000400010; SAWYER W. A., 1931, JOUR PREV MED, V5, P413; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; STEEL C, 1991, J INFECT DIS, V164, P581, DOI 10.1093/infdis/164.3.581; Sur S, 1999, J IMMUNOL, V162, P6284; Tew JG, 1997, IMMUNOL REV, V156, P39, DOI 10.1111/j.1600-065X.1997.tb00957.x; Trujillo-Vargas CM, 2005, CLIN EXP ALLERGY, V35, P1003, DOI 10.1111/j.1365-2222.2005.02287.x; Turner JD, 2005, MICROBES INFECT, V7, P990, DOI 10.1016/j.micinf.2005.03.036; Yanagihara Y, 1998, CLIN EXP IMMUNOL, V111, P136	49	53	53	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					939	945		10.1016/j.jaci.2005.12.1341	http://dx.doi.org/10.1016/j.jaci.2005.12.1341			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630955				2022-12-18	WOS:000236862800033
J	Nockher, WA; Renz, H				Nockher, WA; Renz, H			Neurotrophins and asthma: Novel insight into neuroimmune interaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; neurotrophins; airway inflammation; airway hyperresponsiveness; neuroimmune interaction	NERVE GROWTH-FACTOR; MAST-CELLS; AIRWAY HYPERRESPONSIVENESS; NEUROGENIC INFLAMMATION; SENSORY NEURONS; MOUSE MODEL; GUINEA-PIGS; EXPRESSION; RECEPTOR; LUNG	There is increasing evidence that neuronal dysfunction and dysregulation contribute to the pathogenesis of allergic asthma. Many functional aspects of peripheral neurons strongly depend on the activity of neurotrophins, a family of mediators originally defined by their neuronal growth activity. More recently, it has been discovered that neurotrophins (eg, nerve growth factor, brain-derived neurotrophin factor, and neurotrophin 3) have profound activities on various immune cells involved in the pathogenesis or allergic disease. Furthermore, immune cells themselves can produce neurotrophins under certain conditions, and the levels of neurotrophins, as well as neurotrophic activities, are strongly upregulated in allergic conditions. Animal data demonstrate that a number of pathomechanisms controlling allergic diseases are directly related to neurotrophin function, including the development of airway hyperresponsiveness. These findings now lead to a much better understanding concerning the regulatory loop between immunologic and neurogenic dysregulation. In this review we will provide an overview of how neurotrophins connect the pathobiology of airway inflammation and hyperresponsiveness, which are the hallmarks of allergic asthma.	Klinikum Univ Marburg, Abt Klin Chem & Mol Diagnost, D-35033 Marburg, Germany		Nockher, WA (corresponding author), Klinikum Univ Marburg, Abt Klin Chem & Mol Diagnost, Baldingerstr, D-35033 Marburg, Germany.	nockher@med.uni-marburg.de						Bachar O, 2004, CLIN EXP ALLERGY, V34, P1137, DOI 10.1111/j.1365-2222.2004.1868.x; BARNES PJ, 1992, J ASTHMA, V29, P165, DOI 10.3109/02770909209099025; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; Braun A, 2002, CURR OPIN PHARMACOL, V2, P229, DOI 10.1016/S1471-4892(02)00150-9; Braun A, 1998, EUR J IMMUNOL, V28, P3240, DOI 10.1002/(SICI)1521-4141(199810)28:10<3240::AID-IMMU3240>3.0.CO;2-U; Braun A, 1999, AM J RESP CELL MOL, V21, P537, DOI 10.1165/ajrcmb.21.4.3670; de Vries A, 1999, AM J RESP CRIT CARE, V159, P1541, DOI 10.1164/ajrccm.159.5.9808058; de Vries A, 2001, BRIT J PHARMACOL, V134, P771, DOI 10.1038/sj.bjp.0704310; Fox AJ, 2001, EUR J PHARMACOL, V424, P159, DOI 10.1016/S0014-2999(01)01138-4; Freund V, 2004, PROG BRAIN RES, V146, P335; Graham RM, 2001, AM J RESP CRIT CARE, V164, P307, DOI 10.1164/ajrccm.164.2.2007115; Hikawa S, 2002, HISTOCHEM CELL BIOL, V118, P51, DOI 10.1007/s00418-002-0426-y; HORIGOME K, 1993, J BIOL CHEM, V268, P14881; Hoyle GW, 1998, AM J RESP CELL MOL, V18, P149, DOI 10.1165/ajrcmb.18.2.2803m; Hunter DD, 2000, AM J RESP CRIT CARE, V161, P1985, DOI 10.1164/ajrccm.161.6.9908051; James DE, 1999, CLIN EXP ALLERGY, V29, P1309; Joos GF, 2000, CLIN EXP ALLERGY, V30, P60; Kanbe N, 2000, CLIN EXP ALLERGY, V30, P1113; Kassel O, 2001, CLIN EXP ALLERGY, V31, P1432, DOI 10.1046/j.1365-2222.2001.01177.x; Kerzel S, 2003, AM J RESP CELL MOL, V28, P170, DOI 10.1165/rcmb.4811; Kobayashi H, 2002, BLOOD, V99, P2214, DOI 10.1182/blood.V99.6.2214; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; Lommatzsch M, 1999, AM J PATHOL, V155, P1183, DOI 10.1016/S0002-9440(10)65221-2; NADEL JA, 1991, EUR RESPIR J, V4, P745; Nassenstein C, 2003, J EXP MED, V198, P455, DOI 10.1084/jem.20010897; Nockher WA, 2003, CYTOKINE GROWTH F R, V14, P559, DOI 10.1016/S1359-6101(03)00071-6; O'Connor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061; Path G, 2002, AM J RESP CRIT CARE, V166, P818, DOI 10.1164/rccm.200202-134OC; Pattarawarapan M, 2003, J MED CHEM, V46, P5277, DOI 10.1021/jm030221q; Sariola H, 2001, CELL MOL LIFE SCI, V58, P1061, DOI 10.1007/PL00000921; Sawada J, 2000, BLOOD, V95, P2052, DOI 10.1182/blood.V95.6.2052; Sekimoto M, 2003, IMMUNOL LETT, V88, P221, DOI 10.1016/S0165-2478(03)00080-4; Szallasi A, 1999, PHARMACOL REV, V51, P159; Undem BJ, 1999, INT ARCH ALLERGY IMM, V118, P150, DOI 10.1159/000024053; Undem Bradley J, 2002, Curr Allergy Asthma Rep, V2, P159, DOI 10.1007/s11882-002-0011-4; Virchow JC, 1998, AM J RESP CRIT CARE, V158, P2002, DOI 10.1164/ajrccm.158.6.9803023	37	53	61	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					67	71		10.1016/j.jaci.2005.08.029	http://dx.doi.org/10.1016/j.jaci.2005.08.029			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387586				2022-12-18	WOS:000235687100011
J	Fei, MJ; Wu, XF; Xu, Q				Fei, MJ; Wu, XF; Xu, Q			Astilbin inhibits contact hypersensitivity through negative cytokine regulation distinct from cyclosporin A	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						astilbin; immunosuppressant; contact hypersensitivity; picryl chloride; IL-10; TNF-alpha; IFN-gamma	DELAYED-TYPE HYPERSENSITIVITY; INDUCED LIVER-INJURY; T-CELLS; ATOPIC-DERMATITIS; INTERLEUKIN-10; INDUCTION; APOPTOSIS; DAMAGE; TH1	Background: IL-10 is known as a negative regulator for inflammatory diseases, including contact dermatitis. However, only a few drug candidates are reported to induce endogenous IL-10. Objective: We sought to elucidate a new mechanism underlying the immunosuppressive properties of astilbin through negative cytokine regulation in comparison with the effective pattern with cyclosporin A. Methods: Contact hypersensitivity was induced in mice with picryl chloride. Lymph node cells were isolated for adoptive transfer and cytokine assays. Results: Astilbin significantly inhibited contact hypersensitivity when given in the elicitation phase but not in the sensitization phase, whereas cyclosporin A inhibited both phases. Lymph node cells from donor mice administered astilbin failed to adoptively transfer the hypersensitivity. Astilbin in vivo remarkably induced IL-10 expression in lymph node cells at an earlier time and decreased TNF-alpha and IFN-gamma expression at a later time. Furthermore, the in vivo neutralization of IL-10 significantly impaired the effect of astilbin on contact hypersensitivity. In the isolated lymphocytes sensitized with picryl chloride in vivo and challenged with trinitrobenzenesulfonic acid in vitro, astilbin did not affect the cell proliferation but modulated the above cytokine profiles as its in vivo effect in a concentration-dependent manner and furthermore significantly enhanced the expressions of suppressor of cytokine signaling 1 and 3. On the other band, cyclosporin A strongly inhibited proinflammatory cytokine production but influenced neither IL-10 nor downstream suppressor of cytokine signaling 1 and 3 expression. Conclusion: Astilbin alleviates contact hypersensitivity through a unique mechanism involving a negative cytokine regulation through stimulating IL-10, which is distinct from the immunosuppressant cyclosporin A.	Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Peoples R China	Nanjing University	Xu, Q (corresponding author), Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, 22 Han Kou Rd, Nanjing 210093, Peoples R China.	molpharm@163.com						Allison AC, 2000, IMMUNOPHARMACOLOGY, V47, P63, DOI 10.1016/S0162-3109(00)00186-7; Arnon R, 2004, P NATL ACAD SCI USA, V101, P14593, DOI 10.1073/pnas.0404887101; Aubin F, 2004, TRANSPLANTATION, V77, pS29, DOI 10.1097/01.TP.0000112969.24120.64; BERG DJ, 1995, J EXP MED, V182, P99, DOI 10.1084/jem.182.1.99; Cai Y, 2003, INFLAMM RES, V52, P334, DOI 10.1007/s00011-003-1179-3; Cai Y, 2003, J PHARM PHARMACOL, V55, P691, DOI 10.1211/002235703765344612; Cavani A, 2000, J INVEST DERMATOL, V114, P295, DOI 10.1046/j.1523-1747.2000.00881.x; Cavani A, 2001, TRENDS IMMUNOL, V22, P118, DOI 10.1016/S1471-4906(00)01815-9; Cechinel V, 2000, ARZNEIMITTELFORSCH, V50, pE281; Ding YZ, 2003, J IMMUNOL, V170, P1383, DOI 10.4049/jimmunol.170.3.1383; Haraguchi H, 1996, BIOSCI BIOTECH BIOCH, V60, P945, DOI 10.1271/bbb.60.945; Kalish RS, 1999, J ALLERGY CLIN IMMUN, V103, P192, DOI 10.1016/S0091-6749(99)70489-6; Lavon I, 2003, MOL PHARMACOL, V64, P1334, DOI 10.1124/mol.64.6.1334; Maurer M, 2003, J CLIN INVEST, V112, P432, DOI 10.1172/JCI200318106; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Pereira LGB, 2002, PEST MANAG SCI, V58, P503, DOI 10.1002/ps.478; SCHWARZ A, 1994, J INVEST DERMATOL, V103, P211, DOI 10.1111/1523-1747.ep12393073; Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896; Trautmann A, 2001, J ALLERGY CLIN IMMUN, V108, P839, DOI 10.1067/mai.2001.118796; Wang BH, 2000, J IMMUNOL, V165, P6783, DOI 10.4049/jimmunol.165.12.6783; Wang J, 2004, J PHARM PHARMACOL, V56, P495, DOI 10.1211/0022357023033; Xu Q, 1997, PHARMACOL RES, V36, P401, DOI 10.1006/phrs.1997.0249; XU Q, 1993, PHARM CLIN CHIN MAT, V9, P25; XU Q, 1991, J CHINA PHARM U, V22, P12; XU Q, 2001, EUR J PHARMACOL, V377, P93; Yan R, 2001, PHARMACOL RES, V44, P135, DOI 10.1006/phrs.2001.0838; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	27	53	58	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1350	1356		10.1016/j.jaci.2005.08.032	http://dx.doi.org/10.1016/j.jaci.2005.08.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337470				2022-12-18	WOS:000235687000029
J	Alford, SH; Zoratti, E; Peterson, EL; Maliarik, M; Ownby, DR; Johnson, CC				Alford, SH; Zoratti, E; Peterson, EL; Maliarik, M; Ownby, DR; Johnson, CC			Parental history of atopic disease: Disease pattern and risk of pediatric atopy in offspring	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; pediatric; family history	CORD SERUM IGE; MATERNAL SMOKING; EARLY-CHILDHOOD; BIRTH COHORT; 1ST YEAR; ASTHMA; LIFE; AGE; SENSITIZATION; PREVALENCE	Background: Family history is an important risk factor for atopic disease. However, most studies assess only limited information on family history. Because atopic disease can exhibit transient or persistent patterns, it may be useful to assess information on patterns of disease within families. This approach has been applied in other diseases, such as cancer, to discriminate between predominately inherited versus environmentally caused (sporadic) cases. Objective: In a cohort of children who were followed from birth until age 6 to 7 years, we examined the relationship between parental onset (ie, childhood and adulthood) and duration of atopic disease (ie, persistent disease) and the risk of pediatric atopic disease. Our hypothesis was that different parental disease patterns would be important to pediatric risk of disease. Methods: Data from 476 families in the ongoing Childhood Allergy Study in Detroit, Mich, were analyzed by using logistic regression. We examined the association between parental patterns of disease and disease onset in their children. Results: Father's disease history, particularly asthma history, was more strongly related to pediatric outcomes than mother's history. Asthma status in the fathers, whether it was childhood-only, adulthood-only, or persistent, was associated with current asthma in the children. Childhood-only and persistent asthma in fathers conferred a higher risk of atopy in the study children, whereas adulthood-only disease did not. There was also a significant relationship between persistent allergy in the father and atopy in the study children. Conclusion: Our data support the hypothesis that there are complex inheritance patterns for allergy and asthma. Therefore, a detailed family history of atopy, including childhood and adulthood experiences, is critical to identifying and classifying risk and disease phenotypes.	Henry Ford Hlth Syst, Detroit, MI 48202 USA; Med Coll Georgia, Augusta, GA 30912 USA	Henry Ford Health System; Henry Ford Hospital; University System of Georgia; Augusta University	Alford, SH (corresponding author), Henry Ford Hlth Syst, 1 Ford Place,5C, Detroit, MI 48202 USA.			Johnson, Christine Cole/0000-0002-6864-6604	NHLBI NIH HHS [HL 68971, HL 68245, HL 67427] Funding Source: Medline; NIAID NIH HHS [AI 50681] Funding Source: Medline; NIEHS NIH HHS [P03 ES 06639] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL068245, R01HL068971, R03HL067427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050681, R56AI050681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; CRONER S, 1990, PEDIATR ALLERGY IMMU, V1, P14, DOI DOI 10.1111/J.1399-3038.1990.TB00003.X; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; HIDE DW, 1991, CLIN EXP ALLERGY, V21, P739, DOI 10.1111/j.1365-2222.1991.tb03204.x; Kulig M, 2000, J ALLERGY CLIN IMMUN, V105, P274, DOI 10.1016/S0091-6749(00)90076-9; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Oddy WH, 2002, J ALLERGY CLIN IMMUN, V110, P65, DOI 10.1067/mai.2002.125296; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; OWNBY DR, 1991, J ALLERGY CLIN IMMUN, V88, P555, DOI 10.1016/0091-6749(91)90148-H; Pekkanen J, 2001, CLIN EXP ALLERGY, V31, P95, DOI 10.1046/j.1365-2222.2001.00930.x; POSONBY AL, 2002, J CLIN EPIDEMIOL, V55, P556; POSONBY AL, 2001, CLIN EXP ALLERGY, V3, P1544; Sears MR, 1996, ARCH DIS CHILD, V75, P392, DOI 10.1136/adc.75.5.392; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; Tariq SM, 1999, CLIN EXP ALLERGY, V29, P1042; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Turner KJ, 1987, ALLERGY INT TXB, P337; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	18	53	54	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1046	1050		10.1016/j.jaci.2004.08.036	http://dx.doi.org/10.1016/j.jaci.2004.08.036			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536408				2022-12-18	WOS:000225047800008
J	Silverman, ES; Breault, DT; Vallone, J; Subramanian, S; Yilmaz, AD; Mathew, S; Subramaniam, V; Tantisira, K; Pacak, K; Weiss, ST; Majzoub, JA				Silverman, ES; Breault, DT; Vallone, J; Subramanian, S; Yilmaz, AD; Mathew, S; Subramaniam, V; Tantisira, K; Pacak, K; Weiss, ST; Majzoub, JA			Corticotropin-releasing hormone deficiency increases allergen-induced airway inflammation in a mouse model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						corticotropin-releasing hormone; asthma; airway responsiveness; glucocorticoids; rodent; eosinophils; knockout; lung; ovalbumin; catecholamines	IMPAIRED STRESS-RESPONSE; PITUITARY-ADRENAL AXIS; RECEPTOR ANTAGONIST; IMMUNOGLOBULIN-E; MURINE MODEL; IN-VIVO; CRH; GLUCOCORTICOIDS; MICE; CYTOKINES	Background: Corticotropin-releasing hormone (CRH) is a major regulator of adrenocorticotropic hormone and the production of glucocorticoids by the adrenal gland. Abnormal regulation of CRH and endogenous glucocorticoids has been implicated in the pathogenesis of asthma. Objective: We postulated that CRH deficiency could increase asthma severity by disrupting hypothalamus-pituitary-adrenal axis function and the induction of glucocorticoids through inflammatory and physiologic stress. However, CRH is expressed by several types of immune cells and might be induced at sites of inflammation, where it has local immunostimulatory actions. Thus CRH deficiency could decrease asthma severity. Methods: To test these possibilities, we subjected CRH-knockout mice to an ovalbumin-induced airway inflammation protocol that mimics many features of asthma. Results: CRH-knockout mice had an increase in airway inflammation of approximately 80% to 300% and an increase in goblet cell hyperplasia of approximately 70% compared with wild-type mice. In contrast, IgE induction was unaffected by CRH deficiency. The increased inflammation in knockout mice was associated with increased tissue resistance, elastance, and hysteresivity. Levels of IL-4, IL-5, IL-13, RANTES, IFN-gamma, and eotaxin were all increased in knockout mice. Serum corticosterone levels were decreased in knockout mice and might account for some of the differences between knockout and wild-type mice. Conclusion: We conclude that CRH deficiency disrupts endogenous glucocorticoid production and enhances allergen-induced airway inflammation and lung mechanical dysfunction in mice. Thus inherited or acquired CRH deficiency could increase asthma severity in human subjects.	Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Physiol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA; Harvard Univ, Sch Med, Childrens Hosp, Div Endocrinol, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Silverman, ES (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Physiol Program, 665 Huntington Ave, Boston, MA 02115 USA.	esilverm@HSPH.harvard.edu	Breault, David/HDN-6048-2022; yilmaz, ayça dilara/N-7041-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL065899, R01HL070573] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL70573, U01 HL065899, HL65899, HL03827] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGIONI S, 1993, LIFE SCI, V53, P1735, DOI 10.1016/0024-3205(93)90160-5; Baigent SM, 2001, PEPTIDES, V22, P809, DOI 10.1016/S0196-9781(01)00395-3; BARNES PJ, 2002, ASTHMA COPD, P547; Beeson P B, 1977, Major Probl Intern Med, V14, P1; Bornstein SR, 1998, ENDOCRINOLOGY, V139, P1546, DOI 10.1210/en.139.4.1546; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; DeBie JJ, 1996, BRIT J PHARMACOL, V119, P1484; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; HANTOS Z, 1992, J APPL PHYSIOL, V72, P168, DOI 10.1152/jappl.1992.72.1.168; Karalis K, 1997, J NEUROIMMUNOL, V72, P131, DOI 10.1016/S0165-5728(96)00178-6; KARALIS K, 1991, SCIENCE, V254, P421, DOI 10.1126/science.1925600; Karalis KP, 1999, P NATL ACAD SCI USA, V96, P7093, DOI 10.1073/pnas.96.12.7093; MUGLIA L, 1995, NATURE, V373, P427, DOI 10.1038/373427a0; Muglia LJ, 2000, ENDOCR RES, V26, P1057, DOI 10.3109/07435800009048638; Muglia LJ, 2001, PEPTIDES, V22, P725, DOI 10.1016/S0196-9781(01)00385-0; PACAK K, 1995, ENDOCRINOLOGY, V136, P4814, DOI 10.1210/en.136.11.4814; Pullerits T, 2002, CLIN EXP ALLERGY, V32, P345, DOI 10.1046/j.1365-2222.2002.01336.x; Salvi SS, 2000, CLIN EXP ALLERGY, V30, P1499, DOI 10.1046/j.1365-2222.2000.00990.x; Silverman ES, 2001, AM J RESP CRIT CARE, V163, P778, DOI 10.1164/ajrccm.163.3.2003123; SMITH DL, 1993, AM REV RESPIR DIS, V148, P523, DOI 10.1164/ajrccm/148.2.523; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; THEOHARIDES TC, 1995, ENDOCRINOLOGY, V136, P5745, DOI 10.1210/en.136.12.5745; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; Tomioka S, 2002, J APPL PHYSIOL, V93, P263, DOI 10.1152/japplphysiol.01129.2001; Trifilieff A, 2000, AM J PHYSIOL-LUNG C, V279, pL1120, DOI 10.1152/ajplung.2000.279.6.L1120; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; Venihaki M, 2000, P NATL ACAD SCI USA, V97, P7336, DOI 10.1073/pnas.97.13.7336; WALLEN N, 1991, J IMMUNOL, V147, P3490; Walsh GM, 2003, J ENDOCRINOL, V178, P37, DOI 10.1677/joe.0.1780037; Webster EL, 1998, ANN NY ACAD SCI, V840, P21, DOI 10.1111/j.1749-6632.1998.tb09545.x; Webster EL, 2002, J RHEUMATOL, V29, P1252; Webster EL, 1996, ENDOCRINOLOGY, V137, P5747, DOI 10.1210/en.137.12.5747	33	53	57	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					747	754		10.1016/j.jaci.2004.06.055	http://dx.doi.org/10.1016/j.jaci.2004.06.055			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480311				2022-12-18	WOS:000224439100005
J	Ciacci, C; Cavallaro, R; Iovino, P; Sabbatini, F; Palumbo, A; Amoruso, D; Tortora, R; Mazzacca, G				Ciacci, C; Cavallaro, R; Iovino, P; Sabbatini, F; Palumbo, A; Amoruso, D; Tortora, R; Mazzacca, G			Allergy prevalence in adult celiac disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Celiac disease; allergy; atopy; atopic dermatitis; adult; eczema; intestine; gastrointestinal disease; intestinal biopsy	INTESTINAL PERMEABILITY; ATOPIC-DERMATITIS; CHRONIC URTICARIA; DISORDERS; IMMUNOLOGY; ANTIGENS; CHILDREN	Background: Celiac disease is considered to arise from an inappropriate T-cell-mediated immune response against ingested gluten in genetically predisposed people, whereas the T(H)2-type lymphocytes are mostly involved in IgE-mediated reactions. The matter of possible coexistence of T(H)1- and T(H)2-type diseases is still debated. Objective: This study was aimed to evaluate the allergy prevalence in a large series of adults with untreated celiac disease and their families at the moment of diagnosis. We also evaluated whether 1 year of gluten-free diet had any effect on allergy prevalence in our cohort. Methods: At the moment of celiac disease diagnosis a standardized questionnaire was administered for detailed information on presence and type of any allergy symptoms in 1044 adult patients with celiac disease, 2752 relatives, and 318 spouses. Those reporting any allergy underwent tests with dosage of serum levels of total IgE and search for serum specific IgE with a standard makeup of 20 antigens and PRICK tests in selected individuals. At follow-up visit patients with celiac disease were administered the same allergy questionnaire. Results: One hundred seventy-three patients with celiac disease (16.6%), 523 relative (19%), and 43 spouses (13.5%) had at least 1 allergy (P = not significant). Atopic dermatitis was more frequent in patients with celiac disease (3.8%) and their relatives (2.3%) than in spouses (1.3%). The presence of allergy in general and atopic dermatitis was not affected by presence of overt malabsorption or duration of undiagnosed disease. Follow-up data showed no change in allergy prevalence in the cohort examined. Conclusion: Allergy prevalence in a large series of patients with celiac disease is not different from that of their relatives and spouses. However, atopic dermatitis was about 3 times more frequent in patients with celiac disease and 2 times more frequent in their relatives than in spouses. One year of gluten-free diet did not change allergy prevalence in the celiac group under investigation.	Univ Naples Federico II, Gastrointestinal Unit, Naples, Italy	University of Naples Federico II	Ciacci, C (corresponding author), Gastroenterol, Via Pansini 5, I-80131 Naples, Italy.	ciacci@unina.it	carolina, ciacci/A-2594-2012; IOVINO, PAOLA/G-6195-2011	carolina, ciacci/0000-0002-7426-1145; IOVINO, PAOLA/0000-0002-9568-0680				Barbato M, 1999, GASTROENTEROLOGY, V116, P778, DOI 10.1016/S0016-5085(99)70211-8; Benn CS, 2002, J ALLERGY CLIN IMMUN, V110, P328, DOI 10.1067/mai.2002.126480; Bischoff SC, 2000, INT ARCH ALLERGY IMM, V121, P270, DOI 10.1159/000024340; BJARNASON I, 1995, GASTROENTEROLOGY, V108, P1566, DOI 10.1016/0016-5085(95)90708-4; Bode S, 1996, SCAND J GASTROENTERO, V31, P54, DOI 10.3109/00365529609031627; Bos JD, 1998, EXP DERMATOL, V7, P132, DOI 10.1111/j.1600-0625.1998.tb00313.x; CIACCI C, 1995, SCAND J GASTROENTERO, V30, P1077, DOI 10.3109/00365529509101610; COLLIN P, 1994, GUT, V35, P1215, DOI 10.1136/gut.35.9.1215; COOPER BT, 1978, BRIT MED J, V1, P537, DOI 10.1136/bmj.1.6112.537; DELPRETE G, 1992, ALLERGY, V47, P450; DeMeo MT, 2002, J CLIN GASTROENTEROL, V34, P385, DOI 10.1097/00004836-200204000-00003; GRECO L, 1990, ACTA PAEDIATR SCAND, V79, P670, DOI 10.1111/j.1651-2227.1990.tb11533.x; HAUTEKEETE ML, 1987, LANCET, V1, P157, DOI 10.1016/S0140-6736(87)91986-6; HODGSON HJF, 1976, LANCET, V1, P115; KELLY CP, 1987, LANCET, V2, P109; Kero J, 2001, J ALLERGY CLIN IMMUN, V108, P781, DOI 10.1067/mai.2001.119557; KOLGNOFF MF, 1996, GASTROINTESTINAL DIS, P113; Levine A, 1999, PEDIATRICS, V104, part. no., DOI 10.1542/peds.104.2.e25; MARSH MN, 1992, COELIAC DIS; Mowat AM, 2003, LANCET, V361, P1290; Perichon B, 1991, Allerg Immunol (Paris), V23, P301; Romagnani S, 1997, CURR OPIN IMMUNOL, V9, P773, DOI 10.1016/S0952-7915(97)80176-8; Romagnani S, 1997, INT ARCH ALLERGY IMM, V113, P153, DOI 10.1159/000237532; Scala E, 1999, ALLERGY, V54, P1008, DOI 10.1034/j.1398-9995.1999.00216.x; Schuppan D, 2000, GASTROENTEROLOGY, V119, P234, DOI 10.1053/gast.2000.8521; Sheikh A, 2003, J ALLERGY CLIN IMMUN, V111, P131, DOI 10.1067/mai.2003.8; VANELBURG RM, 1993, GUT, V34, P354, DOI 10.1136/gut.34.3.354; Varjonen E, 1996, INT ARCH ALLERGY IMM, V111, P55, DOI 10.1159/000237346; VERKASALO M, 1983, GUT, V24, P306, DOI 10.1136/gut.24.4.306; WILLIAMS AJ, 1987, LANCET, V1, P808; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P1; Zauli D, 2000, DIGEST LIVER DIS, V32, P775, DOI 10.1016/S1590-8658(00)80354-0	32	53	55	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1199	1203		10.1016/j.jaci.2004.03.012	http://dx.doi.org/10.1016/j.jaci.2004.03.012			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208605				2022-12-18	WOS:000222091000029
J	Duffy, SM; Lawley, WJ; Kaur, D; Yang, WD; Bradding, P				Duffy, SM; Lawley, WJ; Kaur, D; Yang, WD; Bradding, P			Inhibition of human mast cell proliferation and survival by tamoxifen in association with ion channel modulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; mast cells; ion channels; cellular proliferation; tamoxifen	C-KIT; CHLORIDE CHANNEL; ACTIVATION; CURRENTS; LIGAND; CLC-5; CYCLE; LINE; RAT; IDENTIFICATION	Background: Human lung mast cells (HLMCs) and the human mast cell line HMC-1 express a strongly outwardly rectifying Cl- current characteristic of that carried by the voltage-dependent Cl- channel CIC-5. A similar but distinct current has been implicated in the control of cell proliferation in astrocytes. Objective: In this study, we have examined the effects of the Cl- channel blocker tamoxifen on ion channel activity and cell proliferation in both HMC-1 and HLMCs. Methods: We used the whole-cell patch-clamp technique to characterize macroscopic ion currents in mast cells before and after addition of tamoxifen. HMC-1 proliferation was assessed by incorporation of tritiated thymidine, HLMC proliferation was determined by counting cells in long-term culture, and cell viability was assessed by annexin V binding and propidium iodide uptake. Results: In HMC-1, tamoxifen reduced the outward Cl- current at +130 mV by 73% +/- 9% at a concentration of 3 mumol/L and simultaneously opened a novel inwardly rectifying nonselective cation current with a mean inward current of 153 18 pA at -130 mV. Tamoxifen produced a dose-dependent inhibition of HMC-1 proliferation (90.3% +/- 4.0% inhibition at 30 mumol/L) without altering cell viability. Tamoxifen inhibited the outward CIC-5-like current in HLMCs, did not open an inward current, and produced a dose-dependent inhibition of HLMC proliferation in long-term culture. Conclusion: Tamoxifen inhibits HMC proliferation, possibly through ion channel modulation. This suggests that tamoxifen might be useful in the treatment of mast-cell-mediated diseases, including mastocytosis, asthma, and pulmonary fibrosis.	Glenfield Gen Hosp, Dept Resp Med, Leicester LE3 9QP, Leics, England; Univ Leicester, Sch Med, Inst Lung Hlth, Div Resp Med, Leicester, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University of Leicester	Bradding, P (corresponding author), Glenfield Gen Hosp, Dept Resp Med, Groby Rd, Leicester LE3 9QP, Leics, England.			Bradding, Peter/0000-0001-8403-0319				Altan N, 1999, P NATL ACAD SCI USA, V96, P4432, DOI 10.1073/pnas.96.8.4432; AMIGORENA S, 1990, J IMMUNOL, V144, P2038; BRADDING P, 1995, IMMUNOPHARMACOLOGY R, P53; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Duffy SM, 2001, J IMMUNOL, V167, P4261, DOI 10.4049/jimmunol.167.8.4261; Duffy SM, 2001, J LEUKOCYTE BIOL, V70, P233; Frenz AM, 1997, INFLAMM RES, V46, P35, DOI 10.1007/s000110050045; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GARRIGA MM, 1988, J ALLERGY CLIN IMMUN, V82, P425, DOI 10.1016/0091-6749(88)90015-2; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Jensen BS, 1999, P NATL ACAD SCI USA, V96, P10917, DOI 10.1073/pnas.96.19.10917; KAWANAMI O, 1979, LAB INVEST, V40, P717; Koo GC, 1997, J IMMUNOL, V158, P5120; LIEN EA, 1991, CANCER RES, V51, P4837; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; MALONE DG, 1986, ARTHRITIS RHEUM, V29, P956, DOI 10.1002/art.1780290803; O'Day SJ, 2001, CANCER, V92, P609, DOI 10.1002/1097-0142(20010801)92:3<609::AID-CNCR1361>3.0.CO;2-U; OBRIAN CA, 1985, CANCER RES, V45, P2462; Sanmugalingam D, 2000, J LEUKOCYTE BIOL, V68, P38; Schulman ES, 2001, J ALLERGY CLIN IMMUN, V107, pS288; Shen MR, 2000, J PHYSIOL-LONDON, V529, P385, DOI 10.1111/j.1469-7793.2000.00385.x; Shirihai O, 1996, PFLUG ARCH EUR J PHY, V431, P632, DOI 10.1007/s004240050045; Smitherman KA, 2001, J MEMBRANE BIOL, V181, P125, DOI 10.1007/s00232-001-0016-2; Ullrich N, 1996, AM J PHYSIOL-CELL PH, V270, pC1511; Ullrich N, 1997, AM J PHYSIOL-CELL PH, V273, pC1290, DOI 10.1152/ajpcell.1997.273.4.C1290; VALENT P, 1992, BLOOD, V80, P2237; Vandewalle A, 2001, AM J PHYSIOL-CELL PH, V280, pC373, DOI 10.1152/ajpcell.2001.280.2.C373; VLIAGOFTIS H, 1992, INT ARCH ALLERGY IMM, V98, P398, DOI 10.1159/000236217; VOETS T, 1995, PFLUG ARCH EUR J PHY, V431, P132, DOI 10.1007/BF00374387; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WISEMAN H, 1992, BIOCHIM BIOPHYS ACTA, V1138, P197, DOI 10.1016/0925-4439(92)90038-O; ZHANG JJ, 1994, J CLIN INVEST, V94, P1690, DOI 10.1172/JCI117514	36	53	56	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					965	972		10.1016/j.jaci.2003.07.004	http://dx.doi.org/10.1016/j.jaci.2003.07.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610489	Bronze			2022-12-18	WOS:000186553300021
J	Eichenfield, LF; Beck, L				Eichenfield, LF; Beck, L			Elidel (pimecrolimus) cream 1%: A nonsteroidal topical agent for the treatment of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; pruritus; corticosteroid; topical immunomodulator; eczema; cytokines; ascomycin; pimecrolimus; Elidel; inflammation; T cells	LONG-TERM MANAGEMENT; ANTIINFLAMMATORY DRUG; TACROLIMUS OINTMENT; PERIPHERAL-BLOOD; NATURAL-HISTORY; SKIN DISEASES; DOUBLE-BLIND; SDZ ASM-981; SDZ-ASM-981; EFFICACY	Elidel is a steroid-free cream containing a 1% strength of the topical immunomodulator pimecrolimus. Elidel was specifically developed as a treatment for atopic dermatitis (AD) and is approved for use in children as young as 2 years of age. The production of inflammatory cytokines by activated T cells in skin is thought to play an important role in the pathogenesis of AD. Elidel potently suppresses cytokine production by dermal T cells without significantly impairing systemic immune responses. Elidel does not cause steroid-associated local effects, such as dermal atrophy, striae, or telangiectasia. In randomized controlled clinical studies, twice-daily application of Elidel was shown to significantly improve the signs and symptoms of AD in infants, children, and adults. The clinical effect of Elidel on pruritus, the most troublesome symptom of AD, can be observed within 1 week of therapy and is maintained for the duration of treatment. Elidel is well tolerated; the risk of application-site reactions, such as itching or burning, is comparable with that of the vehicle. Adverse effects were generally mild in patients receiving Elidel and occurred at rates comparable with those in patients receiving vehicle treatment. In a 1-year study, Elidel significantly reduced the incidence of flares when used at the first signs and symptoms of acute AD. As a result overall corticosteroid use to treat flares was significantly lower in patients using Elidel for early intervention.	Childrens Hosp, Dept Pediat & Adolescent Dermatol, San Diego, CA 92123 USA; Univ Calif San Diego, Dept Pediat & Med Dermatol, Sch Med, San Diego, CA 92103 USA; Johns Hopkins Univ, Sch Med, Dept Dermatol & Med, Baltimore, MD USA	Children's Hospital Los Angeles; University of California System; University of California San Diego; Johns Hopkins University	Eichenfield, LF (corresponding author), Childrens Hosp, Div Pediat Dermatol, 8010 Frost St,Suite 602, San Diego, CA 92123 USA.							Akdis M, 1999, J IMMUNOL, V163, P466; Bekersky I, 2001, J AM ACAD DERMATOL, V44, pS17, DOI 10.1067/mjd.2001.109816; BerthJones J, 1997, BRIT J DERMATOL, V136, P76, DOI 10.1046/j.1365-2133.1997.d01-1146.x; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; Boguniewicz M, 2001, SEMIN CUTAN MED SURG, V20, P217, DOI 10.1053/sder.2001.29379; Boguniewicz Mark, 1996, Comprehensive Therapy, V22, P144; BRUIJNZEEL PLB, 1993, CLIN EXP ALLERGY, V23, P97, DOI 10.1111/j.1365-2222.1993.tb00304.x; Charman CR, 2000, BRIT J DERMATOL, V142, P931, DOI 10.1046/j.1365-2133.2000.03473.x; DERIE MA, 1991, ACTA DERM-VENEREOL, V71, P452; DOUGADOS M, 1988, ANN RHEUM DIS, V47, P127, DOI 10.1136/ard.47.2.127; Dworzak MN, 1999, J ALLERGY CLIN IMMUN, V103, P901, DOI 10.1016/S0091-6749(99)70436-7; Eichenfield LF, 2002, J AM ACAD DERMATOL, V46, P495, DOI 10.1067/mjd.2002.122187; Eichenfield LF, 2001, SEMIN CUTAN MED SURG, V20, P215, DOI 10.1053/sder.2001.29238; Ellison JA, 2000, PEDIATRICS, V105, P794, DOI 10.1542/peds.105.4.794; *FUJ HEALTHC INC, PROT; Grassberger M, 1999, BRIT J DERMATOL, V141, P264; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hanifin JM, 1999, J AM ACAD DERMATOL, V41, P72, DOI 10.1016/S0190-9622(99)70410-X; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; HARDIE RA, 1977, PRACTITIONER, V219, P376; Ho VC, 2003, J PEDIATR-US, V142, P155, DOI 10.1067/mpd.2003.65; JAMES JM, 1993, J ALLERGY CLIN IMMUN, V91, P1155, DOI 10.1016/0091-6749(93)90318-A; Jonas S, 1996, Transpl Int, V9 Suppl 1, pS164, DOI 10.1111/j.1432-2277.1996.tb01598.x; Kapp A, 2002, J ALLERGY CLIN IMMUN, V110, P277, DOI 10.1067/mai.2002.126500; Koblenzer CS, 1999, J ALLERGY CLIN IMMUN, V104, pS109, DOI 10.1016/S0091-6749(99)70052-7; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Leung DYM, 1997, ANN ALLERG ASTHMA IM, V79, P197, DOI 10.1016/S1081-1206(10)63003-7; Loden M, 1999, BRIT J DERMATOL, V140, P264; Lutgemeier M D, 1987, Derm Beruf Umwelt, V35, P55; McAlister RO, 2002, CUTIS, V69, P461; Meingassner J, 2001, J INVEST DERMATOL, V117, P532; Meingassner J., 2000, Journal of Investigative Dermatology, V114, P832; Meingassner JG, 1997, BRIT J DERMATOL, V137, P568, DOI 10.1111/j.1365-2133.1997.tb03788.x; Mrowietz U, 1998, BRIT J DERMATOL, V139, P992; *NOV PHARM CORP, EL; OIKARINEN A, 1991, CLIN EXP DERMATOL, V16, P416, DOI 10.1111/j.1365-2230.1991.tb01225.x; Paller A, 2001, J AM ACAD DERMATOL, V44, pS47, DOI 10.1067/mjd.2001.109813; Patrizi A, 2000, PEDIATR DERMATOL, V17, P261, DOI 10.1046/j.1525-1470.2000.01771.x; Queille-Roussel C, 2001, BRIT J DERMATOL, V144, P507, DOI 10.1046/j.1365-2133.2001.04076.x; RAJKA G, 1986, CLIN REV ALLERG, V4, P3; Rappersberger K, 2002, J INVEST DERMATOL, V119, P876, DOI 10.1046/j.1523-1747.2002.00694.x; Reitamo S, 2002, J ALLERGY CLIN IMMUN, V109, P547, DOI 10.1067/mai.2002.121832; Reitamo S, 2002, J ALLERGY CLIN IMMUN, V109, P539, DOI 10.1067/mai.2002.121831; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; SAURAT JH, 1987, ANN NESTLE, V45, P9; SERUP J, 1992, ACTA DERM-VENEREOL, P14; Stuetz A, 2001, SEMIN CUTAN MED SURG, V20, P233, DOI 10.1053/sder.2001.29066; SVENSSON A, 1988, ACTA DERM-VENEREOL, V68, P509; THACI D, 2001, J EUR ACAD DERMAT S2, V15, P196; Van Leent EJM, 2002, DERMATOLOGY, V204, P63, DOI 10.1159/000051813; Van Leent EJM, 1998, ARCH DERMATOL, V134, P805, DOI 10.1001/archderm.134.7.805; Wahn U, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e2; WAHN U, 2001, 59 ANN M AM AC DERM; YAMAGUCHI Y, 1991, BLOOD, V78, P2542; Yamamoto S, 1997, ANN ALLERG ASTHMA IM, V78, P517, DOI 10.1016/S1081-1206(10)63241-3; Zuberbier T, 2001, J ALLERGY CLIN IMMUN, V108, P275, DOI 10.1067/mai.2001.116865	60	53	57	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1154	1168		10.1067/mai.2003.1492	http://dx.doi.org/10.1067/mai.2003.1492			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743593				2022-12-18	WOS:000182904500044
J	Konduri, KS; Nandedkar, S; Duzgunes, N; Suzara, V; Artwohl, J; Bunte, R				Konduri, KS; Nandedkar, S; Duzgunes, N; Suzara, V; Artwohl, J; Bunte, R			Efficacy of liposomal budesonide in experimental asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						budesonide; asthma; liposomes; lung inflammation; inhaled glucocorticoids; lung inflammation	INHALED CORTICOSTEROIDS; EOSINOPHIL; CIRCULATION; AEROSOL; AIRWAY; SAFETY; BLOOD; INFLAMMATION; VOLUNTEERS; IMPACT	Background: Inhaled corticosteroids, such as budesonide, attenuate the inflammatory response in asthma. However, patient noncompliance and side effects of available inhaled corticosteroids limit their use. Liposomes are currently used in medicine to deliver a variety of drugs. Objective: The objective of our study was to determine whether weekly therapy with budesonide encapsulated in sterically stabilized (stealth) liposomes would be comparable to daily budesonide therapy in reducing allergic inflammation. Methods: Ovalbumin-sensitized C57/Black 6 mice received aerosolized (1) budesonide encapsulated in stealth or conventional liposomes, administered weekly, (2) budesonide (without liposomes), administered either daily or weekly, or (3) empty stealth liposomes, administered weekly. All treatment groups were compared with sensitized untreated or unsensitized mice. Histopathologic examination of the lung tissues and measurements of eosinophil peroxidase activity, peripheral blood eosinophil counts, and total serum IgE levels were done weekly for 4 weeks. Results: Weekly therapy with budesonide encapsulated in stealth liposomes was as effective as daily budesonide therapy in decreasing lung inflammation and lowering eosinophil peroxidase activity, peripheral blood eosinophils, and total serum IgE levels. In none of the other groups was there a significant decrease in the inflammatory parameters evaluated. Conclusion: We conclude that weekly therapy with budesonide encapsulated in stealth liposomes is as effective as daily budesonide in reducing markers of lung inflammation in experimental asthma. This novel strategy offers an effective alternative to standard daily budesonide therapy in asthma and has the potential to reduce toxicity and improve compliance. (J Allergy Clin Immunol 2003;111:321-7.)	Med Coll Wisconsin, Div Allergy & Immunol, Dept Pediat, Milwaukee, WI 53201 USA; Univ Pacific, Dept Microbiol, San Francisco, CA 94115 USA; Univ Illinois, Dept Internal Med, Chicago, IL USA; Univ Illinois, Biol Resource Lab, Chicago, IL USA	Medical College of Wisconsin; University of the Pacific; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Konduri, KS (corresponding author), Med Coll Wisconsin, Div Allergy & Immunol, Dept Pediat, 9000 W Wisconsin Ave,POB 1997, Milwaukee, WI 53201 USA.		Duzgunes, Nejat/T-5478-2019; Duzgunes, Nejat/V-5058-2019					ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1066, P29, DOI 10.1016/0005-2736(91)90246-5; BAKKERWOUDENBERG IAJM, 1993, J INFECT DIS, V168, P164, DOI 10.1093/infdis/168.1.164; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; BROWN PH, 1991, RESP MED, V85, P511, DOI 10.1016/S0954-6111(06)80269-6; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; deSiqueira ALP, 1997, J ALLERGY CLIN IMMUN, V100, P383, DOI 10.1016/S0091-6749(97)70253-7; DIJKSTRA J, 1984, EXP CELL RES, V150, P161, DOI 10.1016/0014-4827(84)90711-0; Duzgunes N, 1998, MEDICAL APPLICATIONS OF LIPOSOMES, P189, DOI 10.1016/B978-044482917-7/50012-0; FARR SJ, 1989, INT J PHARM, V51, P39, DOI 10.1016/0378-5173(89)90072-0; GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949; GANGADHARAM PRJ, 1995, ANTIMICROB AGENTS CH, V39, P725, DOI 10.1128/AAC.39.3.725; GONDA I, 1990, CRC CRIT R THER DRUG, V6, P272; GonzalezRothi RJ, 1996, PHARMACEUT RES, V13, P1699, DOI 10.1023/A:1016448908909; HUANG SK, 1995, STEALTH LIPOSOMES, P119; Lonnkvist K, 2001, J ALLERGY CLIN IMMUN, V107, P812, DOI 10.1067/mai.2001.114246; MAYER LB, 1998, MED APPL LIPOSOMES, P242; Nandedkar SD, 2001, J ALLERGY CLIN IMMUN, V107, pS176; O'Byrne PM, 1998, J ALLERGY CLIN IMMUN, V102, P879, DOI 10.1016/S0091-6749(98)70322-7; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; Schreier H, 1994, P INT S CONTR REL BI, V21, P228; STRATH M, 1985, J IMMUNOL METHODS, V83, P209, DOI 10.1016/0022-1759(85)90242-X; TAYLOR KMG, 1989, PHARMACEUT RES, V6, P633, DOI 10.1023/A:1015917918130; TAYLOR KMG, 1990, INT J PHARM, V58, P57, DOI 10.1016/0378-5173(90)90287-E; Toogood J H, 1994, Int J Risk Saf Med, V5, P1, DOI 10.3233/JRS-1994-5102; *US PHS, 1997, NIH PUBL; VIDGREN M, 1995, INT J PHARM, V115, P209, DOI 10.1016/0378-5173(94)00265-7; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; WALDREP JC, 1994, CHEST, V105, P106, DOI 10.1378/chest.105.1.106; Waldrep JC, 1997, CHEST, V111, P316, DOI 10.1378/chest.111.2.316; WARDLAW AJ, 1987, ALLERGY, V42, P321, DOI 10.1111/j.1398-9995.1987.tb02218.x; Wasan KM, 1998, MEDICAL APPLICATIONS OF LIPOSOMES, P165, DOI 10.1016/B978-044482917-7/50010-7; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; WONG J, 1992, BRIT MED J, V304, P1415, DOI 10.1136/bmj.304.6839.1415-a; WOOLLEY MJ, 1994, AM J RESP CELL MOL, V11, P600, DOI 10.1165/ajrcmb.11.5.7946389	35	53	58	2	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					321	327		10.1067/mai.2003.104	http://dx.doi.org/10.1067/mai.2003.104			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589352	Bronze			2022-12-18	WOS:000180942700016
J	Victor, JR; Fusaro, AE; Duarte, AJD; Sato, MN				Victor, JR; Fusaro, AE; Duarte, AJD; Sato, MN			Preconception maternal immunization to dust mite inhibits the type I hypersensitivity response of offspring	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HUMAN IMMUNE-SYSTEM; ENVIRONMENTAL ALLERGENS; EFFECTOR FUNCTION; T-CELLS; ANTIGEN; SUPPRESSION; ANTIBODIES; IGG	Background: The maternal immunologic experience associated with early life exposure to allergens might contribute to the development of allergy during infancy. Objectives: We sought to analyze the effect of the mother's immunization before conception with the dust mite Dermatophagoides pteronyssinus on the allergen priming an hypersensitivity response in early immunized offspring. The kinetics of D pteronyssinus immunization were observed from newborn to adult age, and the secondary response to D pteronyssinus was followed in offspring immunized in early life. Methods: Female A/Sn mice were immunized or not with D pteronyssinus and mated with male C57BL/6 mice. The hybrid offspring were immunized to investigate allotypes and subclasses of anti-D pteronyssinus antibody, as well as total IgE levels, by using ELISA and anti-D pteronyssinus IgE antibody by using the passive cutaneous anaphylaxis reaction. Ovalbumin was used for heterologous; immunization. Cytokines; were measured in the cell-culture supernatant by means of ELISA, and CD4(+)CD25(+) cells were analyzed by means of flow cytometry. Results: Offspring from immune mothers have not shown evidence of prenatal or postnatal allergen priming with respect to humoral level. Immunization with D pteronyssinus of offspring at very early life and in the postweaning period inhibited anti-D pteronyssinus IgE and IgG1 antibody production, along with the expected presence of maternal antibody. Furthermore, offspring antibody responsiveness from immune mothers has remained quiescent on secondary allergenic challenge. is maternal influence on the offspring antibody response was specific to D pteronyssinus because the immunization with a heterologous; antigen did not alter IgE response. Maternal D pteronyssinus immunization induced a significant decrease of the IFN-y level in the offspring, avoided an exacerbation of T(H)2 cytokine secretion, and, concomitantly, upregulated the number of CD4(+)CD25(+) T cells. Conclusion: Maternal immunization to D pteronyssinus seems to protect offspring from the development of allergy. (J Allergy Clin Immunol 2003;111:269-77.).	Univ Sao Paulo, Sch Med, Lab Clin & Expt Allergy & Immunol, Sao Paulo, Brazil	Universidade de Sao Paulo	Sato, MN (corresponding author), Univ Sao Paulo, Lab Alergia & Imunol Clin & Expt, Fac Med, Av Dr Arnaldo 455,Sala 2345, BR-01246903 Cerqueira Cesar Sao Paul, Brazil.		Duarte, Alberto J S/D-4382-2012; Victor, Jefferson Russo/D-1402-2012; Sato, Maria N/C-1196-2012; Sato, Maria N/C-2853-2012	Victor, Jefferson Russo/0000-0001-6092-8394; Sato, Maria N/0000-0002-7911-1824; 				Adkins B, 2000, J IMMUNOL, V164, P2347, DOI 10.4049/jimmunol.164.5.2347; Adkins P, 2001, J IMMUNOL, V166, P918, DOI 10.4049/jimmunol.166.2.918; ALBRECHT P, 1977, J PEDIATR-US, V91, P715, DOI 10.1016/S0022-3476(77)81021-4; Astori M, 1999, INT IMMUNOL, V11, P445, DOI 10.1093/intimm/11.3.445; Barrios C, 1996, EUR J IMMUNOL, V26, P2666, DOI 10.1002/eji.1830261118; ELLIOTT M, 1992, ANN NY ACAD SCI, V651, P336; Fusaro AE, 2002, INT ARCH ALLERGY IMM, V127, P208, DOI 10.1159/000053865; Herz U, 2000, EUR J IMMUNOL, V30, P714, DOI 10.1002/1521-4141(200002)30:2<714::AID-IMMU714>3.0.CO;2-P; JARRETT E, 1979, NATURE, V280, P145, DOI 10.1038/280145a0; JARRETT EEE, 1983, IMMUNOLOGY, V48, P49; JARRETT EEE, 1984, IMMUNOLOGY, V53, P365; Lundin BS, 1999, SCAND J IMMUNOL, V50, P651; Marshall-Clarke S, 2000, IMMUNOL TODAY, V21, P35, DOI 10.1016/S0167-5699(99)01548-0; MURPHY BR, 1988, J VIROL, V62, P3907, DOI 10.1128/JVI.62.10.3907-3910.1988; OVARY Z, 1958, J IMMUNOL, V81, P325; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P441; Prescott SL, 1998, J IMMUNOL, V160, P4730; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Sato MN, 1999, IMMUNOLOGY, V98, P338, DOI 10.1046/j.1365-2567.1999.00869.x; Seeger M, 1998, EUR J IMMUNOL, V28, P2124, DOI 10.1002/(SICI)1521-4141(199807)28:07<2124::AID-IMMU2124>3.0.CO;2-A; Shevach EM, 2001, IMMUNOL REV, V182, P58, DOI 10.1034/j.1600-065X.2001.1820104.x; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; Szepfalusi Z, 2000, J ALLERGY CLIN IMMUN, V106, P530	23	53	53	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					269	277		10.1067/mai.2003.39	http://dx.doi.org/10.1067/mai.2003.39			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589344				2022-12-18	WOS:000180942700008
J	Arvidsson, MB; Lowhagen, O; Rak, S				Arvidsson, MB; Lowhagen, O; Rak, S			Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						specific allergen immunotherapy; birch pollen allergy.; placebo-controlled study	DOUBLE-BLIND; CONTROLLED TRIAL; DERMATOPHAGOIDES-PTERONYSSINUS; RUSH IMMUNOTHERAPY; CAT-DANDER; RHINITIS; ASTHMA; EXTRACTS; HYPOSENSITIZATION; EPIDEMIOLOGY	Background: Birch pollen is a common allergen in northern, central, and eastern Europe. Earlier studies of specific immunotherapy using birch pollen extract were not placebo-controlled or were only preseasonal. Long-term, placebo-controlled studies with subcutaneously administered standardized birch pollen extract are lacking. Objective: The aim of this study was to evaluate the effect of immunotherapy with birch pollen extract on airway symptoms and use of medication in adult birch pollen-allergic patients in a double-blind, placebo-controlled trial. Methods: Forty-nine patients with histories of birch pollen allergy from the upper and lower airways, positive skin prick test and conjunctival provocation test results, and in vitro specific IgE to birch pollen (Betula verrucosa) extract were included. Immunotherapy with birch pollen extract was given during 2 consecutive years in a double-blind, randomized, placebo-controlled study. Clinical symptom scores from the upper and lower airways and use of rescue medication were registered throughout the pollen season. Results: Forty-six patients reached the maintenance dose and were maintained on that dose during the 2-year study. The median symptom scores during the 1997 and 1998 seasons were 1.3 and 2.6, respectively, in the specific immunotherapy group and 2.1 and 4.3, respectively, in the placebo group. The differences between the groups were significant (P = .05 in 1997 and P = .005 in 1998). The placebo group used significantly more rescue medication during both seasons than the specific immunotherapy group (P = .004 for 1997 and P = .004 for 1998). Conclusion: Specific immunotherapy with birch pollen extract is an effective and safe treatment for reducing clinical allergy symptoms and medication use in birch pollen-allergic patients during the pollen season.	Sahlgrens Univ Hosp, Dept Resp Med & Allergol, Asthma & Allergy Res Grp, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital	Rak, S (corresponding author), Sahlgrens Univ Hosp, Dept Resp Med & Allergol, Asthma & Allergy Res Grp, S-41345 Gothenburg, Sweden.							Balda BR, 1998, ALLERGY, V53, P740; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; Chanez P, 1996, ALLERGY, V51, P850; CHARPIN D, 1993, CLIN EXP ALLERGY, V23, P435, DOI 10.1111/j.1365-2222.1993.tb00350.x; COCKCROFT DW, 1977, J ALLERGY CLIN IMMUN, V60, P56, DOI 10.1016/0091-6749(77)90083-5; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb00166.x; Dreborg S, 1989, ALLERGY S, V44, P22; FROST L, 1985, ALLERGY, V40, P368, DOI 10.1111/j.1398-9995.1985.tb00249.x; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; LINNA O, 1992, ACTA PAEDIATR, V81, P100, DOI 10.1111/j.1651-2227.1992.tb12182.x; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; MALMBERG CHO, 1978, CLIN ALLERGY, V8, P397, DOI 10.1111/j.1365-2222.1978.tb00475.x; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Noon L, 1911, LANCET, V1, P1572; NUCHELPETERSEN B, 1988, ALLERGY, V43, P353; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; PILCHER CE, 1997, ALLERGY, V52, P274; Plaschke P, 1996, ALLERGY, V51, P461, DOI 10.1111/j.1398-9995.1996.tb00163.x; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; TROISE C, 1992, J INVEST ALLERG CLIN, V2, P313; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; Vignola AM, 1998, ALLERGY, V53, P833, DOI 10.1111/j.1398-9995.1998.tb03988.x; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; WARNER JO, 1978, LANCET, V2, P912; *WHO, 1998, ALLERGY S44, V53, P6; Winther L, 2000, ALLERGY, V55, P818, DOI 10.1034/j.1398-9995.2000.00367.x	32	53	56	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					777	783		10.1067/mai.2002.123868	http://dx.doi.org/10.1067/mai.2002.123868			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994699				2022-12-18	WOS:000175687800005
J	Vizi, E; Huszar, E; Csoma, Z; Boszormenyi-Nagy, G; Barat, E; Horvath, I; Herjavecz, I; Kollai, M				Vizi, E; Huszar, E; Csoma, Z; Boszormenyi-Nagy, G; Barat, E; Horvath, I; Herjavecz, I; Kollai, M			Plasma adenosine concentration increases during exercise: A possible contributing factor in exercise-induced bronchoconstriction in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exercise-induced bronchoconstriction; adenosine; asthma	RELEASE	We investigated whether the level of plasma adenosine (ADO) changed during exercise and whether this could be related to exercise-induced broncho constriction. Baseline levels of ADO did not differ, but exercise resulted in higher ADO in patients with asthma than in healthy subjects (86 +/- 35 vs 59 +/- 16 nmoL/L; P < .001). In patients with asthma, the increase in ADO was related to decreases in FEV1 (r(2) = 0.475; P < .05) and SaO(2) (r(2) = 0,693; P < .05). These data suggest that adenosine might be involved in the development of exercise-induced broncho constriction.	Natl Koranyi Inst TB & Pulm, Dept Pathophysiol, H-1529 Budapest, Hungary		Huszar, E (corresponding author), Natl Koranyi Inst TB & Pulm, Dept Pathophysiol, Budapest Piheno U 1,POB 1, H-1529 Budapest, Hungary.		Horváth, Ildikó/GPP-6088-2022; Horvath, Ildiko/M-7874-2019	Horvath, Ildiko/0000-0001-6891-1044				Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P419, DOI 10.1067/mai.2000.108914; CUSLEY MJ, 1983, BR J CLIN PHARM, V15, P161; Feoktistov I, 1998, TRENDS PHARMACOL SCI, V19, P148, DOI 10.1016/S0165-6147(98)01179-1; FINNERTY JP, 1990, J ALLERGY CLIN IMMUN, V86, P353, DOI 10.1016/S0091-6749(05)80098-3; FULLER RW, 1987, BRIT J CLIN PHARMACO, V24, P309; Huszar E, 1998, J ALLERGY CLIN IMMUN, V102, P687, DOI 10.1016/S0091-6749(98)70288-X; Huszar E, 1996, CHROMATOGRAPHIA, V42, P318, DOI 10.1007/BF02290317; MANN JS, 1986, J APPL PHYSIOL, V61, P1667, DOI 10.1152/jappl.1986.61.5.1667; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; VanSchoor J, 1997, AM J RESP CRIT CARE, V155, P875, DOI 10.1164/ajrccm.155.3.9117020	10	53	55	0	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					446	448		10.1067/mai.2002.121955	http://dx.doi.org/10.1067/mai.2002.121955			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897989				2022-12-18	WOS:000174586400010
J	Stelmach, I; Jerzynska, J; Kuna, P				Stelmach, I; Jerzynska, J; Kuna, P			A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						markers of inflammation; childhood asthma; bronchial hyperreactivity; montelukast	INHALED CORTICOSTEROIDS; ANTAGONIST; LEUKOTRIENES; RESPONSIVENESS; SALMETEROL; PRANLUKAST; COUNTS	Background: Anti-inflammatory properties of leukotriene modifiers and their effect on bronchial hyperresponsiveness have not been studied in children with asthma. Objective: The primary objective of this study was to determine the changes in serum levels of inflammatory mediators, clinical efficacy, and bronchial hyperresponsiveness after treatment with montelukast. Methods: In this double-blind, randomized, placebo-controlled trial, 39 children with mild-to-moderate atopic asthma were randomly allocated to receive montelukast or placebo for 6 weeks. Main outcome measures were changes in serum concentrations of soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule I (sICAM-1); peripheral blood eosinophil count; and eosinophilic cationic protein (ECP). Asthma severity score, FEV1, and bronchial hyperreactivity (BHR) for histamine were secondary end points. Results: Compared to placebo, serum concentrations of IL-4, sICAM-1, and ECP and eosinophil blood counts significantly decreased after 6 weeks of treatment with montelukast. Montelukast significantly improved asthma control and FEV1. Montelukast resulted in within-group significant decrease in levels of serum sIL-2R (611 vs 483 pg/mL), IL-4 (0.123 vs 0.102 pg/mL), sICAM-1 (280 vs 244 ng/mL), and ECP (74 Vs 59 mug/mL) and in eosinophil blood counts (349 vs 310 cells/mm(3)). Mean FEV1 value changed from 85% of predicted to 95% (P < .001) and for histamine (PC20H) from 2.8 mg/mL to 3.8 mg/mL (P < .001) after treatment with montelukast.: There was no significant difference between montelukast and placebo recipients in the serum concentrations of sIL-2R and PC20H after treatment. Conclusion: Montelukast provides clinical benefit to patients with chronic asthma and decreases bronchial hyperresponsiveness. Montelukast caused a statistically significant decrease of serum concentrations in cytokine, ICAM-1, and ECP and peripheral blood eosinophil counts over the 6-week treatment period. This observation raises the possibility that leukotriene receptor antagonists, such as montelukast, may have effects on parameters of asthmatic inflammation.	M Curie Hosp, Dept Pediat & Allergy, PL-95100 Zgierz, Poland; Med Univ Lodz, Dept Allergy & Pneumonol, Lodz, Poland	Medical University Lodz	Stelmach, I (corresponding author), M Curie Hosp, Dept Pediat & Allergy, 35 Parzeczewska Str, PL-95100 Zgierz, Poland.		Jerzynska, Joanna/S-9691-2016; Stelmach, Iwona/S-9796-2016	Kuna, Piotr/0000-0003-2401-0070; Stelmach, Iwona/0000-0002-1475-8221				ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; Altman LC, 1998, J ALLERGY CLIN IMMUN, V102, P50, DOI 10.1016/S0091-6749(98)70054-5; [Anonymous], 1999, AM J RESP CRIT CARE, V160, P1778; Bisgaard H, 2000, AM J RESP CRIT CARE, V162, P187, DOI 10.1164/ajrccm.162.1.9910039; BOUSQUET J, 1998, EUR RESPIR J, V26, P42; Cengizlier R, 2000, ANN ALLERG ASTHMA IM, V84, P539, DOI 10.1016/S1081-1206(10)62519-7; CHRISTIANVIRCHO.JC, 2000, AM J RESP CRIT CARE, V162, P578; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; CRAPO RO, 1995, AM J RESP CRIT CARE, V152, P1107, DOI DOI 10.1164/AJRCCM.152.3.7663792; DAHER S, 1995, J INVEST ALLERG CLIN, V5, P251; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; Dempsey OJ, 2000, CHEST, V117, P950, DOI 10.1378/chest.117.4.950; Diamant Z, 1999, CLIN EXP ALLERGY, V29, P42; Edelman JM, 2000, ANN INTERN MED, V132, P97, DOI 10.7326/0003-4819-132-2-200001180-00002; El-Sawy IH, 1999, INT ARCH ALLERGY IMM, V119, P126, DOI 10.1159/000024187; Ishioka Shinichi, 1999, Hiroshima Journal of Medical Sciences, V48, P105; Ishioka Shinichi, 2000, Hiroshima Journal of Medical Sciences, V49, P105; Jansen DF, 1999, AM J RESP CRIT CARE, V159, P924, DOI 10.1164/ajrccm.159.3.9804024; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; LAI CKW, 1993, CHEST, V103, P782, DOI 10.1378/chest.103.3.782; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Lofdahl CG, 1999, BMJ-BRIT MED J, V319, P87, DOI 10.1136/bmj.319.7202.87; Markham A, 1998, DRUGS, V56, P251, DOI 10.2165/00003495-199856020-00010; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; Matsumoto H, 2001, CLIN EXP ALLERGY, V31, P637, DOI 10.1046/j.1365-2222.2001.01034.x; MONTEFORT S, 1994, AM J RESP CRIT CARE, V149, P1149, DOI 10.1164/ajrccm.149.5.7513593; MOTOJIMA S, 1995, J ASTHMA, V32, P151, DOI 10.3109/02770909509083237; *NIH, 1997, NIH PUBL; PARK CS, 1993, J ALLERGY CLIN IMMUN, V91, P623, DOI 10.1016/0091-6749(93)90268-K; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Santanello NC, 1997, EUR RESPIR J, V10, P646; Shiota Y, 1996, CHEST, V109, P94, DOI 10.1378/chest.109.1.94; Stolpe A.V., 1996, J MOL MED, V74, P13; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; Tohda Y, 1999, CLIN EXP ALLERGY, V29, P1532; TSAI LC, 1990, J ASTHMA, V27, P307, DOI 10.3109/02770909009073343; Underwood DC, 1996, AM J RESP CRIT CARE, V154, P850, DOI 10.1164/ajrccm.154.4.8887574; Virchow J. C., 1997, European Respiratory Journal Supplement, V10, p437S; Volovitz B, 1999, J ALLERGY CLIN IMMUN, V104, P1162, DOI 10.1016/S0091-6749(99)70008-4; WALKER C, 1991, J IMMUNOL, V146, P1829; WOODWARD DF, 1983, PROSTAGLANDINS, V25, P131, DOI 10.1016/0090-6980(83)90142-9; Yoshida S, 2000, CLIN EXP ALLERGY, V30, P64	43	53	59	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					257	263		10.1067/mai.2002.121456	http://dx.doi.org/10.1067/mai.2002.121456			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842294				2022-12-18	WOS:000174232600008
J	Alenius, H; Laouini, D; Woodward, A; Mizoguchi, E; Bhan, AK; Castigli, E; Oettgen, HC; Geha, RS				Alenius, H; Laouini, D; Woodward, A; Mizoguchi, E; Bhan, AK; Castigli, E; Oettgen, HC; Geha, RS			Mast cells regulate IFN-gamma expression in the skin and circulating IgE levels in allergen-induced skin inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; mast cells; inflammation; antibodies; cytokines; in vivo animal models	ATOPIC-DERMATITIS; IN-VIVO; AIRWAY HYPERRESPONSIVENESS; HUMAN KERATINOCYTES; DENDRITIC CELLS; DEFICIENT W/WV; T-CELLS; ADHESION MOLECULE-1; INTERFERON-GAMMA; CONTROLLED-TRIAL	Background: Mast cells are important effector cells in IgE-mediated allergic reactions. They are present in normal skin and increased in skin lesions of patients with atopic dermatitis (AD). Objective: We used mice deficient in mast cells (W/W-v) to assess, the role of these cells in a marine model of allergen-induced skin inflammation induced by repeated epicutaneous sensitization with ovalbumin (OVA); the model exhibits many of the characteristics of AD. Methods: Mice deficient in mast cells were sensitized with OVA. Histologic and immunohistochemical examinations, as well as measurements of IL-4 and IFN-gamma mRNA, were performed on OVA-sensitized skin. Total and antigen-specific serum IgE levels were determined. Results. Infiltration in W/W-v mice by mononuclear cells, T cells, and eosinophils in OVA-sensitized skin was comparable to that in wild-type (WT) controls. Expression of IL-4 mRNA in sensitized skin sites was similarly increased in WT and W/W-v mice. However. IFN-gamma mRNA expression was significantly increased in sensitized skin of W/W-v mice but not in that of WT controls. IL-4 mRNA was readily detectable in unsensitized skin of WT controls but not in that of W/W-v mice, whereas expression of IL-12 p40 mRNA was significantly increased in unsensitized skin of W/W-v mice in comparison with WT controls. Total serum IgE levels were. significantly increased after epicutancous sensitization in W/W-v mice in comparison with WT controls. Conclusion: These results suggest that mast cells regulate IFN-gamma expression in the skin and IgE levels in the circulation in a model of allergen-induced skin inflammation with similarities to AD. This is important, given the role of IFN-gamma in keratinocyte injury in AD and the role of IgE-mediated reactions in exacerbating AD.	Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Immunopathol Unit, Boston, MA 02114 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital	Geha, RS (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Enders 8,300 Longwood Ave, Boston, MA 02115 USA.		Laouini, Dhafer/Q-6535-2019	Laouini, Dhafer/0000-0003-1222-4880; Alenius, Harri/0000-0003-0106-8923	NIAID NIH HHS [AI-31541] Funding Source: Medline; NIAMS NIH HHS [AR-47417] Funding Source: Medline; NIDDK NIH HHS [DK47677, DK43351] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031541, U19AI031541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047677, P30DK043351] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Ackermann L, 1999, BRIT J DERMATOL, V140, P624; ARAGANE Y, 1994, J IMMUNOL, V153, P5366; Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Askenase P W, 1977, Prog Allergy, V23, P199, DOI 10.1159/000314242; Bressler RB, 1997, J ALLERGY CLIN IMMUN, V99, P508, DOI 10.1016/S0091-6749(97)70078-2; CHERVENI.PA, 1969, J CELL PHYSIOL, V73, P25, DOI 10.1002/jcp.1040730104; Coffman RL, 1997, J EXP MED, V185, P373, DOI 10.1084/jem.185.3.373; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; Enk CD, 1996, PHOTOCHEM PHOTOBIOL, V63, P854, DOI 10.1111/j.1751-1097.1996.tb09642.x; GALLI SJ, 1989, CIBA F SYMP, V147, P53; GALLI SJ, 1987, AM J PATHOL, V127, P191; GALLI SJ, 1987, BLOOD, V69, P1661; GROVES RW, 1993, J AM ACAD DERMATOL, V29, P67, DOI 10.1016/0190-9622(93)70154-L; HA TY, 1986, INT ARCH ALLER A IMM, V80, P85, DOI 10.1159/000234031; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; Jakob T, 1999, INT ARCH ALLERGY IMM, V118, P457, DOI 10.1159/000024163; JONES SM, 1993, CLIN REV ALLERG, V11, P471; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kobayashi T, 2000, J IMMUNOL, V164, P3855, DOI 10.4049/jimmunol.164.7.3855; Kondo S, 1998, J CELL PHYSIOL, V177, P493, DOI 10.1002/(SICI)1097-4652(199812)177:3<493::AID-JCP12>3.0.CO;2-B; Kruger-Krasagakes S, 1995, Exp Dermatol, V4, P250, DOI 10.1111/j.1600-0625.1995.tb00253.x; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404, DOI 10.1165/ajrcmb.12.4.7695919; Lantz CS, 1997, J IMMUNOL, V158, P2517; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Leung DYM, 1999, J ALLERGY CLIN IMMUN, V104, pS99, DOI 10.1016/S0091-6749(99)70051-5; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; Lever R, 1998, PEDIATR ALLERGY IMMU, V9, P13, DOI 10.1111/j.1399-3038.1998.tb00294.x; Levings MK, 1999, J IMMUNOL, V162, P5224; Lorentz A, 2001, IMMUNOL REV, V179, P57, DOI 10.1034/j.1600-065X.2001.790106.x; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; METCALFE D, 1992, MAST CELLS BASOPHILS; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; MUSIAL J, 1995, ALLERGY, V50, P520, DOI 10.1111/j.1398-9995.1995.tb01190.x; Nagai H, 1996, CLIN EXP ALLERGY, V26, P642, DOI 10.1046/j.1365-2222.1996.993357.x; NAKANO T, 1987, FASEB J, V46, P1920; NICKOLOFF BJ, 1989, BRIT J DERMATOL, V121, P161, DOI 10.1111/j.1365-2133.1989.tb01795.x; Pastore S, 1998, J ALLERGY CLIN IMMUN, V101, P538, DOI 10.1016/S0091-6749(98)70361-6; Pawankar R, 1998, CLIN EXP ALLERGY, V28, P6; PLATTSMILLS TAE, 1991, ROLE INHALANT ALLERG; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; Scalabrin DMF, 1999, J ALLERGY CLIN IMMUN, V104, P1273, DOI 10.1016/S0091-6749(99)70024-2; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; SEDER RA, 1991, INT ARCH ALLER A IMM, V94, P137, DOI 10.1159/000235345; SHIRE D, 1993, EUR CYTOKINE NETW, V4, P161; SHIRE D, 1995, GENE EXPRESSION ANAL, V3; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, pS114, DOI 10.1016/S0091-6749(99)70053-9; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; SUTHERLA.DJ, 1970, J CELL PHYSIOL, V75, P267, DOI 10.1002/jcp.1040750302; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Thoma-Uszynski S, 2000, J IMMUNOL, V165, P3804, DOI 10.4049/jimmunol.165.7.3804; Toru H, 1998, J ALLERGY CLIN IMMUN, V102, P491, DOI 10.1016/S0091-6749(98)70140-X; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; van der Pouw Kraan TCTM, 1998, J CLIN INVEST, V102, P1866, DOI 10.1172/JCI3692; Vestergaard C, 2001, J DERMATOL SCI, V26, P46, DOI 10.1016/S0923-1811(00)00160-2; Wang M, 1999, CLIN IMMUNOL, V90, P47, DOI 10.1006/clim.1998.4628; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Woodward AL, 2001, J ALLERGY CLIN IMMUN, V107, P359, DOI 10.1067/mai.2001.112695; Yawalkar N, 1996, ARCH DERMATOL RES, V288, P79, DOI 10.1007/s004030050027	68	53	54	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					106	113		10.1067/mai.2002.120553	http://dx.doi.org/10.1067/mai.2002.120553			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799374				2022-12-18	WOS:000173739300017
J	Lacy, P; Logan, MR; Bablitz, B; Moqbel, R				Lacy, P; Logan, MR; Bablitz, B; Moqbel, R			Fusion protein vesicle-associated membrane protein 2 is implicated in IFN-gamma-induced piecemeal degranulation in human eosinophils from atopic individuals	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; vesicle-associated membrane protein; soluble N-ethylmaleimide-sensitive factor attachment protein receptor; confocal microscopy; RANTES; tetanus toxin	MEMBRANE-PROTEIN; EXPRESSION; SYNTAXIN; SNAP-23; BINDING; LOCALIZATION; CELLUBREVIN; NEUROTOXINS; EXOCYTOSIS; CYTOLYSIS	Background: Exocytosis is an integral event during IFN-gamma -induced piecemeal degranulation in eosinophils. In many tissues soluble N-ethylmaleimide-sensitive Factor attachment protein receptors (SNAREs), including vesicle-associated membrane protein (VAMP), act as specific intracellular receptors to allow granule fusion with the membrane during degranulation. However, the mechanisms underlying eosinaphil piecemeal degranulation induced by IFN-gamma are not well understood. Objective: We sought to assess whether eosinophils express the vesicular SNARE protein VAMP-2 and to determine the involvement of VAMP-2 in IFN-gamma -induced piecemeal degranulation, Methods: Human peripheral blood eosinophils (greater than or equal to 97%) from atopic subjects were subjected to RT-PCR and sequence analysis with specific primers for VAMP-2 mRNA. Western blotting and flow cytometric analysis were carried out to confirm the identity of VAMP-2 and its susceptibility to cleavage by tetanus toxin. Confocal laser scanning microscopy imaging was conducted on double-labeled cytospin preparations of eosinophils at 0, 5, 10, 30, and 60 minutes and 16 hours of IFN-gamma (500 U/mL) stimulation. Results: Eosinophils expressed VAMP-2 mRNA (n = 4 donors), which exhibited 100% homology with human VAMP-2, cDNA on sequencing. Eosinophils were also found to express tetanus toxin-sensitive VAMP-2 protein. RANTES and VAMP-2 immunofluorescence were observed to colocalize to similar intracellular structures by means of confocal imaging. IFN-gamma induced a rapid translocation of VAMP-2(+) organelles toward the cell membrane in correlation with RANTES. Conclusions: These findings suggest that exocytosis in human eosinophils is regulated by SNAREs, with a specific role indicated for VAMP-2 in piecemeal degranulation.	Univ Alberta, Heritage Med Res Ctr 574, Pulm Res Grp, Dept Med, Edmonton, AB T6G 2S2, Canada	University of Alberta	Moqbel, R (corresponding author), Univ Alberta, Heritage Med Res Ctr 574, Pulm Res Grp, Dept Med, Edmonton, AB T6G 2S2, Canada.		Lacy, Paige/A-6021-2010	Lacy, Paige/0000-0001-8885-6011				BRUMELL JH, 1995, J IMMUNOL, V155, P5750; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Edwardson JM, 1998, CURR BIOL, V8, pR390, DOI 10.1016/S0960-9822(98)70245-3; Egesten A, 1996, BLOOD, V87, P3910, DOI 10.1182/blood.V87.9.3910.bloodjournal8793910; Erjefalt JS, 1998, J ALLERGY CLIN IMMUN, V102, P286, DOI 10.1016/S0091-6749(98)70098-3; Erjefalt JS, 1999, AM J RESP CRIT CARE, V160, P304, DOI 10.1164/ajrccm.160.1.9809048; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; GOMPERTS BD, 1992, METHOD ENZYMOL, V219, P178; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; Hua SY, 1999, NAT NEUROSCI, V2, P1078, DOI 10.1038/16005; Jagadish MN, 1996, BIOCHEM J, V317, P945, DOI 10.1042/bj3170945; LACY P, 1995, J CELL SCI, V108, P3547; Lacy P, 1999, IMMUNOLOGY, V98, P244; Lacy P, 1999, BLOOD, V94, P23, DOI 10.1182/blood.V94.1.23.413k13_23_32; Lacy P, 2000, J ALLERGY CLIN IMMUN, V105, pS252, DOI 10.1016/S0091-6749(00)91177-1; Lacy P, 1998, BLOOD, V91, P2508, DOI 10.1182/blood.V91.7.2508.2508_2508_2516; LACY P, 2000, AM J RESP CRIT CARE, V161, pA539; Mahmudi-Azer S, 2000, J ALLERGY CLIN IMMUN, V105, pS257, DOI 10.1016/S0091-6749(00)91192-8; MCLAREN DJ, 1978, PARASITOLOGY, V77, P313, DOI 10.1017/S0031182000050277; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MONTECUCCO C, 1993, TRENDS BIOCHEM SCI, V18, P324, DOI 10.1016/0968-0004(93)90065-U; MOQBEL R, 1992, CLIN EXP ALLERGY, V22, P265, DOI 10.1111/j.1365-2222.1992.tb03082.x; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; Rossetto O, 1996, J CELL BIOL, V132, P167, DOI 10.1083/jcb.132.1.167; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Velazquez JR, 2000, IMMUNOLOGY, V99, P591, DOI 10.1046/j.1365-2567.2000.00012.x; Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6	32	53	53	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					671	678		10.1067/mai.2001.113562	http://dx.doi.org/10.1067/mai.2001.113562			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295657	Bronze			2022-12-18	WOS:000168190100020
J	Martin, L; Degenne, D; Toutain, A; Ponard, D; Watier, H				Martin, L; Degenne, D; Toutain, A; Ponard, D; Watier, H			Hereditary angioedema type III: An additional French pedigree with autosomal dominant transmission	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Hosp, Dept Dermatol, F-37044 Tours 01, France; Univ Hosp, Immunol Lab, F-38042 Tours, France; Univ Hosp, Immunol Lab, F-37044 Tours 01, France; Univ Hosp, Dept Genet, F-37044 Tours 01, France	CHU Tours; CHU Tours; CHU Tours; CHU Tours	Martin, L (corresponding author), Univ Hosp, Dept Dermatol, F-37044 Tours 01, France.			Toutain, Annick/0000-0002-5999-5300				Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1	2	53	53	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					747	747		10.1067/mai.2001.114242	http://dx.doi.org/10.1067/mai.2001.114242			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295676				2022-12-18	WOS:000168190100038
J	Merget, R; Caspari, C; Dierkes-Globisch, A; Kulzer, R; Breitstadt, R; Kniffka, A; Degens, P; Schultze-Werninghaus, G				Merget, R; Caspari, C; Dierkes-Globisch, A; Kulzer, R; Breitstadt, R; Kniffka, A; Degens, P; Schultze-Werninghaus, G			Effectiveness of a medical surveillance program for the prevention of occupational asthma caused by platinum salts: A nested case-control study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						platinum; allergy; asthma; occupational; prevention	EXPOSURE; DIISOCYANATE; WORKERS; PLANT	Background: Exposure reduction has proven to be effective in the prevention of occupational asthma, Few data are available on the effectiveness of secondary prevention programs, including medical examinations and removal of workers from exposure sources after detecting symptoms or signs indicative of a beginning disease. Objective: We sought to assess the effectiveness of a medical surveillance program in workers with exposure to platinum salts. Methods: A nested case-control study was performed in 14 workers of a catalyst production plant whose skin prick test (SPT) responses to platinum salt converted from negative to positive during a 5-year prospective cohort study with yearly medical examinations and 42 matched control subjects from the plant who did not experience SPT response conversion. With the exception of 2 subjects, the workers showing SPT response conversion were removed completely from exposure sources and followed for up to 42 months. Results: Work-related new symptoms were reported by 9 of the 14 subjects, and new symptoms without relation to work were reported by 3 subjects at the time of SPT response conversion, Symptoms were not accompanied by a change in FEV1 or bronchial responsiveness to histamine. Symptoms resolved after transferral, but occasional shortness of breath or wheeze persisted in 4 subjects. SPT reactions decreased or became negative in all workers after complete removal but remained unchanged in a craftsman with ongoing occasional exposure to contaminated materials. Conclusion: Although no randomized intervention was performed, this study proves the effectiveness of a medical surveillance program for the prevention of occupational asthma caused by platinum salts.	Res Inst Occupat Med, Bochum, Germany; Degussa Huls AG, Dept Med, Frankfurt, Germany; Univ Hosp Bergmannsheil, Div Pneumol Allergol & Sleep Med, Dept Internal Med, Bochum, Germany	Ruhr University Bochum; Evonik Industries; Ruhr University Bochum	Merget, R (corresponding author), BGFA, Burkle de la Camp Pl 1, D-44789 Bochum, Germany.							ALT F, 1993, FRESEN J ANAL CHEM, V346, P693, DOI 10.1007/BF00321274; BERNSTEIN DI, 1993, J ALLERGY CLIN IMMUN, V92, P387, DOI 10.1016/0091-6749(93)90117-X; BERNSTEIN DI, 1999, ASTHMA WORKPLACE; CALVERLEY AE, 1995, OCCUP ENVIRON MED, V52, P661, DOI 10.1136/oem.52.10.661; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1987, AM REV RESPIR DIS, V135, P950, DOI 10.1164/arrd.1987.135.4.950; HUDSON P, 1985, J ALLERGY CLIN IMMUN, V76, P682, DOI 10.1016/0091-6749(85)90671-2; Merget R, 1999, INT ARCH OCC ENV HEA, V72, P33, DOI 10.1007/s004200050331; MERGET R, 1994, AM J RESP CRIT CARE, V150, P1146, DOI 10.1164/ajrccm.150.4.7921450; Merget R, 2000, J ALLERGY CLIN IMMUN, V105, P364, DOI 10.1016/S0091-6749(00)90089-7; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PISATI G, 1993, BRIT J IND MED, V50, P60; Tarlo SM, 1997, OCCUP ENVIRON MED, V54, P756, DOI 10.1136/oem.54.10.756; VEDAL S, 1986, ARCH ENVIRON HEALTH, V41, P179, DOI 10.1080/00039896.1986.9935774	14	53	54	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					707	712						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295662				2022-12-18	WOS:000168190100025
J	Kearns, GL				Kearns, GL			Impact of developmental pharmacology on pediatric study design: Overcoming the challenges	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pharmacokinetics; pharmacodynamics; cytochromes; generic polymorphism	SINGLE-DOSE PHARMACOKINETICS; VP63843 ORAL SOLUTION; HUMAN LIVER; POPULATION PHARMACOKINETICS; THEOPHYLLINE METABOLISM; CHILDREN; PHARMACODYNAMICS; AGE; CYCLOSPORINE; ADOLESCENTS	The need to establish drug-dosing guidelines in children highlights the challenges associated with the development of phases I and II pediatric clinical trials. These challenges are the consequence of significant developmental changes that characterize childhood and adolescence and can affect drug absorption, binding, renal elimination, and, especially, metabolism. In addition, genetic polymorphism can contribute to the variations in the expression of activity for specific drug-metabolizing enzymes. These developmental and genetic variations in pharmacokinetics are the major determinants of drug exposure over time and are thus directly related to the safety, efficacy, and toxicity of a drug dose. Therefore, in the development of pediatric protocols and appropriate dosing in children, it is essential to develop a strategy for addressing the developmental variables that affect drug exposure and to incorporate them into study design.	Childrens Mercy Hosp & Clin, Div Pediat Clin Pharmacol & Toxicol, Kansas City, MO USA; Univ Missouri, Dept Pediat, Kansas City, KS USA; Univ Missouri, Dept Pharmacol, Kansas City, KS USA	Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City	Kearns, GL (corresponding author), Childrens Mercy Hosp, Div Pediat Clin Pharmacol & Toxicol, 2401 Gillham Rd, Kansas City, MO 64108 USA.							Abdel-Rahman SM, 1998, PEDIATR INFECT DIS J, V17, P1171, DOI 10.1097/00006454-199812000-00018; Abdel-Rahman SM, 1998, ANTIMICROB AGENTS CH, V42, P2706, DOI 10.1128/AAC.42.10.2706; BURTIN P, 1994, CLIN PHARMACOL THER, V56, P615, DOI 10.1038/clpt.1994.186; CHIBA K, 1980, J PEDIATR-US, V96, P479; de Wildt SN, 1999, CLIN PHARMACOKINET, V36, P439, DOI 10.2165/00003088-199936060-00005; de Wildt SN, 1999, CLIN PHARMACOKINET, V37, P485, DOI 10.2165/00003088-199937060-00004; GILMAN JT, 1992, CLIN PHARMACOKINET, V23, P1, DOI 10.2165/00003088-199223010-00001; GOTSCHALL RR, 1999, PEDIAT PULMONOL, V28, P210; James LP, 1998, J CLIN PHARMACOL, V38, P1089; James LP, 1996, J CLIN PHARMACOL, V36, P48, DOI 10.1002/j.1552-4604.1996.tb04151.x; Kashuba ADM, 1998, CLIN PHARMACOL THER, V64, P257, DOI 10.1016/S0009-9236(98)90174-6; Kearns GL, 1999, CLIN PHARMACOL THER, V65, P140, DOI 10.1016/S0009-9236(99)80091-5; Kearns GL, 1999, ANTIMICROB AGENTS CH, V43, P634, DOI 10.1128/AAC.43.3.634; KEARNS GL, 1999, PEDIAT PULMONOL, V28, P208; KORINTHENBERG R, 1994, NEUROPEDIATRICS, V25, P214, DOI 10.1055/s-2008-1073024; KRAUS DM, 1993, CLIN PHARMACOL THER, V54, P351, DOI 10.1038/clpt.1993.160; KROETZ DL, 1993, CLIN PHARMACOL THER, V53, P306, DOI 10.1038/clpt.1993.26; Lacroix D, 1997, EUR J BIOCHEM, V247, P625, DOI 10.1111/j.1432-1033.1997.00625.x; LAMBERT GH, 1986, DEV PHARMACOL THERAP, V9, P375, DOI 10.1159/000457262; Leeder JS, 1999, CLIN PHARMACOL THER, V65, P176, DOI 10.1016/S0009-9236(99)80235-5; Leeder JS, 1999, CLIN PHARMACOL THER, V65, P194, DOI 10.1016/S0009-9236(99)80306-3; Leeder JS, 1997, PEDIATR CLIN N AM, V44, P55, DOI 10.1016/S0031-3955(05)70463-6; Mamiya K, 1998, EPILEPSIA, V39, P1317, DOI 10.1111/j.1528-1157.1998.tb01330.x; Marshall JD, 1999, CLIN PHARMACOL THER, V66, P66, DOI 10.1016/S0009-9236(99)70055-X; MCLEOD HL, 1995, PHARMACOGENETICS, V5, P281, DOI 10.1097/00008571-199510000-00003; MURRY DJ, 1995, DRUG METAB DISPOS, V23, P1110; NASSIF EG, 1981, J PEDIATR-US, V98, P158; PARIENTEKHAYAT A, 1991, PEDIATR RES, V29, P492, DOI 10.1203/00006450-199105010-00015; Poulsen L, 1996, CLIN PHARMACOL THER, V60, P636, DOI 10.1016/S0009-9236(96)90211-8; Relling MV, 1999, CLIN PHARMACOL THER, V65, P139, DOI 10.1016/S0009-9236(99)80087-3; RITSCHEL WA, 1999, HDB BASIC PHARMACOKI, P304; Tateishi T, 1999, PEDIATR RES, V45, P66, DOI 10.1203/00006450-199901000-00011; Thummel KE, 1996, CLIN PHARMACOL THER, V59, P491, DOI 10.1016/S0009-9236(96)90177-0; Tjia JF, 1996, J PHARMACOL EXP THER, V276, P912; Transon C, 1996, EUR J CLIN PHARMACOL, V51, P79, DOI 10.1007/s002280050164; WANDSTRAT TL, 1989, THER DRUG MONIT, V11, P493; ZENK KE, 1994, AM J HOSP PHARM, V51, P688, DOI 10.1093/ajhp/51.5.688	37	53	57	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3		S			S128	S138						11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	357XB	10984393				2022-12-18	WOS:000089525400004
J	Reindl, J; Anliker, MD; Karamloo, F; Vieths, S; Wuthrich, B				Reindl, J; Anliker, MD; Karamloo, F; Vieths, S; Wuthrich, B			Allergy caused by ingestion of zucchini (Cucurbita pepo): Characterization of allergens and cross-reactivity to pollen and other foods	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						zucchini; allergy; cross-reactivity; double-blind, placebo-controlled, food challenge; cross-reacting carbohydrate determinant; profilin	PROFILIN; WATERMELON; CELERY; APPLE	Background: Allergy to zucchini (Cucurbita pepo), a member of the Cucurbitaceae family, has not previously been reported. We examined 4 patients complaining of allergic symptoms, such as oral allergy syndrome, nausea, diarrhea, or pruritus, after the intake of zucchini Objective: After the confirmation of food allergy, we wanted to characterize zucchini allergens and examine possible cross-reactions to pollen and food. Methods: The patients underwent skin prick and prick-to-prick-testing with different allergens, including zucchini, latex, and birch, ragweed, and grass pollen, Moreover a double-blind, placebo-controlled, food challenge was performed to confirm food allergy, Total and specific serum IgE levels were determined by using CAP-FEIA and the enzyme allergo-sorbent test method (EAST), respectively. Proteins from zucchini reacting with patient IgE were detected by means of immunoblotting. To characterize cross-reacting IgE antibodies, immunoblot- and EAST-inhibition assays were carried out. Results: All patients in this study had positive reactions to zucchini both in prick-to-prick tests and double-blind, placebo-controlled, food challenges. Specific serum IgE levels to zucchini were found in all cases. In blot- and EAST-inhibition assays IgE from two patients revealed binding to zucchini profilin at about 15 kd. Furthermore, in two cases, including one of the profilin-positive patients, IgE directed against cross-reacting carbohydrate determinants was detected. For one patient, no cross-reacting IgE could be found, but IgE from this patient reacted strongly with a zucchini protein at 17 kd. Conclusions: We report the first 4 cases of food allergy to zucchini, Zucchini allergens can cause systemic reactions and are at least partially heat stable. We suggest that allergy to zucchini can occur as a result of primary sensitization to zucchini, as well as to cross-reactions to the panallergen profilin and crossreacting carbohydrate determinants.	Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; Paul Ehrlich Inst, Dept Allergol, Fed Agcy Sera & Vaccines, D-63225 Langen, Germany	University of Zurich; University Zurich Hospital; Paul Ehrlich Institute	Wuthrich, B (corresponding author), Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Gloriastr 31, CH-8091 Zurich, Switzerland.							Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; BALLMERWEBER BK, IN PRESS J ALLERGY C; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; ENBERG RN, 1987, J ALLERGY CLIN IMMUN, V79, P867, DOI 10.1016/0091-6749(87)90234-X; FAH J, 1995, CLIN EXP ALLERGY, V25, P1018, DOI 10.1111/j.1365-2222.1995.tb00405.x; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; Fritsch R, 1997, ALLERGY, V52, P335, DOI 10.1111/j.1398-9995.1997.tb01000.x; JORDANWAGNER DL, 1993, ANN ALLERGY, V71, P70; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; ORTIZ JCG, 1995, ALLERGY, V50, P269, DOI 10.1111/j.1398-9995.1995.tb01145.x; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; VIETHS S, 1992, DEUT LEBENSM-RUNDSCH, V88, P239; Vieths S, 1999, EUR FOOD RES TECHNOL, V209, P379, DOI 10.1007/s002170050513; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651	21	53	54	3	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					379	385		10.1067/mai.2000.107602	http://dx.doi.org/10.1067/mai.2000.107602			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932084				2022-12-18	WOS:000088708100023
J	Eppinger, TM; Greenberger, PA; White, DA; Brown, AE; Cunningham-Rundles, C				Eppinger, TM; Greenberger, PA; White, DA; Brown, AE; Cunningham-Rundles, C			Sensitization to Aspergillus species in the congenital neutrophil disorders chronic granulomatous disease and hyper-IgE syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	AAAAI Annual Meeting	1997	WASHINGTON, D.C.	AAAAI		allergic bronchopulmonary aspergillosis; Aspergillus fumigatus; neutrophil disorder; chronic granulomatous disease; hyper-IgE syndrome; corticosteroids	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; HYPERIMMUNOGLOBULIN-E-SYNDROME; INFECTION; ITRACONAZOLE; MANAGEMENT; INTERFERON; DIAGNOSIS; DEFENSE; GAMMA	Background: Hyper-IgE syndrome (HIE) and chronic granulomatous disease (CGD) are congenital immunodeficiency diseases with increased susceptibility to bacterial and fungal infections. Both carry significant morbidity and mortality rates because of invasive infections by Aspergillus species. We encountered 2 patients, one with HIE and one with CGD, in whom detection of sensitization to Aspergillus species preceded the diagnosis of immunodeficiency, With high-dose systemic corticosteroids for allergic bronchopulmonary aspergillosis (ABPA), an inflammatory disorder caused by sensitization to Aspergillus species, pulmonary abscesses developed in the patient with HIE, and the patient with CGD succumbed to an overwhelming Aspergillus species-induced pneumonia. Objective: We sought to assess the prevalence of sensitization to Aspergillus fumigatus and the presence of diagnostic criteria for ABPA in patients with CGD and HIE. Methods: We measured A fumigatus-specific serum IgE, IgG, and precipitating antibodies as indicators for A fumigatus sensitization in the sera of 18 patients with neutrophil disorders (7 with HIE and 11 with CGD), Hospital records were reviewed for the presence of other diagnostic criteria for ABPA (asthma, elevated total serum IgE concentration, and radiographic abnormalities). Results: Twelve (67%) of 18 patients were sensitized to A fumigatus, as evidenced by precipitating A fumigatus-specific antibodies. Sis (33%) of 18 patients had serologic evidence of ABPA. Five of those 6 patients had radiologic abnormalities consistent with a diagnosis of ABPA. One patient with HIE also had asthma, thus fulfilling minimal essential criteria for concurrent ABPA. Conclusions: Patients with HIE syndrome and CGD have a high incidence of sensitization to Aspergillus species. A clinical picture indistinguishable from ABPA may coexist or emerge in patients with CGD or HIE and create a major management dilemma because systemic corticosteroids may accelerate tissue damage and invasive fungal infections. It is important to distinguish individuals with congenital neutrophil disorders from uncomplicated classic ABPA.	CUNY, Mt Sinai Med Ctr, Div Clin Immunol, Dept Med, New York, NY 10029 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Div Allergy Immunol Rheumatol, Los Angeles, CA USA; Northwestern Univ, Med Ctr, Dept Med, Div Allergy & Immunol, Chicago, IL 60611 USA; Mem Sloan Kettering Canc Ctr, Pulm Serv, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Infect Dis Serv, New York, NY 10021 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Northwestern University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Cunningham-Rundles, C (corresponding author), CUNY, Mt Sinai Med Ctr, Div Clin Immunol, Dept Med, Box 1089,1425 Madison Ave, New York, NY 10029 USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NIAID NIH HHS [AI42349] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042349] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANNATYNE M, 1969, J PEDIATR, V75, P236; BUCKLEY RH, 1996, IMMUNOLOGIC DISORDER, P409; CHIN TW, 1987, J PEDIATR-US, V111, P349, DOI 10.1016/S0022-3476(87)80452-3; CHUDWIN DS, 1982, ACTA PAEDIATR SCAND, V71, P915, DOI 10.1111/j.1651-2227.1982.tb09548.x; COHEN MS, 1981, AM J MED, V71, P59, DOI 10.1016/0002-9343(81)90259-X; CONRAD DJ, 1992, AM J IND MED, V22, P411, DOI 10.1002/ajim.4700220313; CURNUTTE J, 1992, HEMATOLOGY INFANCY C, P904; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2, DOI 10.1006/clin.1993.1078; DAVIS SD, 1970, J PEDIATR-US, V76, P159, DOI 10.1016/S0022-3476(70)80152-4; DENNING DW, 1991, CHEST, V100, P813, DOI 10.1378/chest.100.3.813; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; EPLING CL, 1992, CYTOMETRY, V13, P615, DOI 10.1002/cyto.990130609; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; GALLIN JI, 1983, ANN INTERN MED, V99, P657, DOI 10.7326/0003-4819-99-5-657; GREENBERGER PA, 1993, ANN ALLERGY, V70, P333; GREENBERGER PA, 1994, ALLERGY PROC, V15, P335, DOI 10.2500/108854194778816463; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; HALL RA, 1995, ANN THORAC SURG, V59, P759, DOI 10.1016/0003-4975(94)00730-6; JENNINGS TS, 1993, ANN PHARMACOTHER, V27, P1206, DOI 10.1177/106002809302701011; JEPPSON J, 1991, J PEDIATR, V188, P383; KELLY JK, 1986, AM J CLIN PATHOL, V86, P235, DOI 10.1093/ajcp/86.2.235; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; Liese JG, 1996, LANCET, V347, P220, DOI 10.1016/S0140-6736(96)90403-1; MARGOLIS DM, 1990, J INFECT DIS, V162, P723, DOI 10.1093/infdis/162.3.723; MILLS E, 1978, PEDIATR RES, V12, P543; Morgenstern DE, 1997, J EXP MED, V185, P207, DOI 10.1084/jem.185.2.207; PARK BH, 1969, LANCET, V1, P157; ROBINSON MF, 1982, AM J MED, V73, P63, DOI 10.1016/0002-9343(82)90927-5; RODEY GE, 1970, J PEDIATR-US, V76, P160, DOI 10.1016/S0022-3476(70)80153-6; SCHAFFNER A, 1985, J CLIN INVEST, V76, P1755, DOI 10.1172/JCI112166; van der Meer JWM, 1998, CLIN INFECT DIS, V27, P1337, DOI 10.1093/clinids/27.5.1337; Wolach B, 1998, CLIN INFECT DIS, V26, P204, DOI 10.1086/516254	33	53	55	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1265	1272		10.1016/S0091-6749(99)70023-0	http://dx.doi.org/10.1016/S0091-6749(99)70023-0			8	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589011				2022-12-18	WOS:000084289200023
J	Lamblin, C; Gosset, P; Salez, F; Vandezande, LM; Perez, T; Darras, J; Janin, A; Tonnel, AB; Wallaert, B				Lamblin, C; Gosset, P; Salez, F; Vandezande, LM; Perez, T; Darras, J; Janin, A; Tonnel, AB; Wallaert, B			Eosinophilic airway inflammation in nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyposis; bronchial hyperresponsiveness; eosinophil; bronchial inflammation; bronchial lavage; bronchial biopsy	SEASONAL ALLERGIC RHINITIS; BRONCHIAL HYPERRESPONSIVENESS; BRONCHOALVEOLAR LAVAGE; MILD ASTHMA; MAST-CELLS; FOLLOW-UP; RESPONSIVENESS; METHACHOLINE; STANDARDIZATION; POPULATIONS	Background: Asthma and asymptomatic bronchial hyperresponsiveness (BHR) are frequent findings in patients with nasal polyposis (NP), Objective: To elucidate mechanisms responsible for the development of BHR, we initiated a prospective study of bronchial inflammation as assessed by bronchial lavage (BL) and bronchial biopsy specimens in 35 patients with noninfectious NP. Methods: BHR was determined with methacholine provocation testing. Differential cell count, ECP, and histamine and tryptase levels were determined in BLs, Pathologic examination of bronchial biopsy specimens was performed with May-Grunwald-Giemsa stain to assess the number of lymphocytes, Indirect immunoenzymatic methods were used to identify eosinophils and mast cells, Results: Fourteen patients did not exhibit BHR (group A); 7 patients had asymptomatic BHR (group B); and 14 patients had BHR associated with asthma (group C), Patients of group C tended to have a longer duration of nasal symptoms than those of groups A and B. FEV1 (L) was significantly lower in group C than in groups A and B, The number and percentage of eosinophils were significantly higher in BLs in groups B and C than in group A (P <.05). Patients of groups B and C had a significantly higher number of eosinophils in bronchial submucosa (14.0 +/- 1.5/mm(2) and 19.0 +/- 1.9/mm(2), respectively) than patients of group A (0.1 +/- 0.1/mm(2)). The number of lymphocytes was also higher in groups B and C than in group A. FEV1 (percent of predicted value) and eosinophil number within bronchial mucosa correlated negatively. Conclusion: Our results demonstrate that patients with NP and asymptomatic BHR had an eosinophilic bronchial inflammation similar to that observed in asthmatic patients with NP, whereas patients with NP without BHR do not feature eosinophilic lower airways inflammation. The clinical relevance of these results requires careful follow-up to determine whether eosinophilic inflammation in these patients precedes and is responsible for the development of obvious asthma.	Hop A Calmette, Clin Malad Resp, F-59037 Lille, France; Inst Pasteur, INSERM, U416, F-59019 Lille, France; Hop Claude Huriez, Serv Otorhinolaryngol, Lille, France; Hop St Louis, Lab Rech, EA 2378, Paris, France	Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Wallaert, B (corresponding author), Hop A Calmette, Clin Malad Resp, Blvd Pr J Leclerc, F-59037 Lille, France.		Gosset, Philippe/C-6174-2018	Gosset, Philippe/0000-0002-4043-6429				AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; ADINOFF AD, 1987, SEMIN RESPIR MED, V8, P308, DOI 10.1055/s-2007-1012669; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Bachert C, 1998, ALLERGY, V53, P2, DOI 10.1111/j.1398-9995.1998.tb03767.x; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BOULET LP, 1995, EUR RESPIR J, V8, P913; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; CHANYEUNG M, 1988, CLIN ALLERGY, V18, P359, DOI 10.1111/j.1365-2222.1988.tb02883.x; Corren J, 1997, J ALLERGY CLIN IMMUN, V99, pS781, DOI 10.1016/S0091-6749(97)70127-1; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; DOWNING E, 1982, J ALLERGY CLIN IMMUN, V69, P148; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; Foresi A, 1997, J ALLERGY CLIN IMMUN, V100, P58, DOI 10.1016/S0091-6749(97)70195-7; HURD S, 1992, EUR RESPIR J, V5, P115; JACOBS RL, 1983, ANN ALLERGY, V51, P500; Jansen DF, 1997, RESP MED, V91, P121, DOI 10.1016/S0954-6111(97)90048-2; KANAI N, 1994, AM J RESP CRIT CARE, V150, P1094, DOI 10.1164/ajrccm.150.4.7921442; Lamblin C, 1997, AM J RESP CRIT CARE, V155, P99, DOI 10.1164/ajrccm.155.1.9001296; Laprise C, 1997, AM J RESP CRIT CARE, V156, P403, DOI 10.1164/ajrccm.156.2.9606053; Larsen K, 1996, ALLERGY ASTHMA PROC, V17, P243, DOI 10.2500/108854196778662255; Leone C, 1997, J ALLERGY CLIN IMMUN, V100, P775, DOI 10.1016/S0091-6749(97)70273-2; MILES-LAWRENCE R, 1982, Journal of Allergy and Clinical Immunology, V69, P102; MOLONEY JR, 1977, BRIT J DIS CHEST, V71, P1; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90, DOI 10.1164/ajrccm.153.1.8542168; PIN I, 1993, EUR RESPIR J, V6, P1249; POWER C, 1993, THORAX, V48, P1125, DOI 10.1136/thx.48.11.1125; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Rolla G, 1997, J ALLERGY CLIN IMMUN, V100, P52, DOI 10.1016/S0091-6749(97)70194-5; Settipane GA, 1996, ALLERGY ASTHMA PROC, V17, P231, DOI 10.2500/108854196778662246; SODERBERG M, 1993, ALLERGY, V48, P173, DOI 10.1111/j.1398-9995.1993.tb00709.x; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; ZHONG NS, 1992, CHEST, V102, P1104, DOI 10.1378/chest.102.4.1104	37	53	55	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					85	92		10.1016/S0091-6749(99)70118-1	http://dx.doi.org/10.1016/S0091-6749(99)70118-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400844				2022-12-18	WOS:000081738900013
J	Melen, E; Pomes, A; Vailes, LD; Arruda, LK; Chapman, MD				Melen, E; Pomes, A; Vailes, LD; Arruda, LK; Chapman, MD			Molecular cloning of Per a 1 and definition of the cross-reactive Group 1 cockroach allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	54th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 13-18, 1998	WASHINGTON, D.C.	Amer Acad Allergy Asthma & Immunol		allergen; amino acid sequence; American cockroach; asthma	AMERICAN PERIPLANETA-AMERICANA; IGE ANTIBODY-RESPONSES; BLATTELLA-GERMANICA; MONOCLONAL-ANTIBODIES; ASTHMA; IDENTIFICATION; EXPOSURE; HYPERSENSITIVITY; PURIFICATION; PROTEINS	Background: Sensitization to allergens produced by German and American cockroaches is strongly associated with the cause of asthma, Most of the cockroach allergens identified to date have been species specific. Objective: The aim of this study was to identify and sequence cross-reactive cockroach allergens. Methods: A Periplaneta americana cDNA library was screened with IgE antibody from patients in the United States who were allergic to cockroach and who were sensitized to Blattella germanica. Results: A cDNA clone was isolated that contained an 870-bp sequence with a 695-bp open reading frame, encoding a 231 amino acid protein, molecular weight 26.2 kd, Plaque immunoassays using anti-Bla gl and anti-Per a 1 mAbs and a panel of human IgE antibodies showed that the protein expressed by these clones was Per a 1. Sequence homology searches showed that Per a 1 was homologous to 5 previously reported, but unidentified, sequences from B germanica and P americana. These sequences encoded proteins with multiple molecular sizes containing approximately 100 amino acid repeats. The Per a 1 sequence also showed 31% identity to a mosquito precursor protein, ANG12, which may be involved in digestion. The Per a 1 cDNA was expressed in Pichia pastoris to produce purified recombinant allergen (yield, 14 mg/L). Conclusion: The results define the molecular structure and antigenic relationships between a new family of cross-reactive "Group 1" allergens produced by both P americana and B germanica. These recombinant allergens and specific mAbs will provide toots to improve the diagnosis and treatment of allergic diseases caused by cockroaches.	Univ Virginia, Asthma & Allerg Dis Ctr, Dept Med, Charlottesville, VA 22908 USA	University of Virginia	Chapman, MD (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, Dept Med, Box 225, Charlottesville, VA 22908 USA.		Arruda, L. Karla/D-5845-2013; Pomés, Anna/H-7010-2019	Arruda, L. Karla/0000-0002-7505-210X; Pomés, Anna/0000-0002-8729-1829; Chapman, Martin/0000-0002-0845-3632	NIAID NIH HHS [AI 32557] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032557] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; Arruda LK, 1998, J ALLERGY CLIN IMMUN, V101, pS29; ASTURIAS JA, 1998, ALLERGY, V43, P29; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; CHAPMAN MD, 1997, ALLERGY ALLERGIC DIS, P942; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; MENON P, 1991, ANN ALLERGY, V67, P573; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sakaguchi Masahiro, 1994, Japanese Journal of Allergology, V43, P1309; Sarpong SB, 1997, J ALLERGY CLIN IMMUN, V99, P486, DOI 10.1016/S0091-6749(97)70074-5; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V81, P548, DOI 10.1016/0091-6749(88)90195-9; Vailes LD, 1998, J ALLERGY CLIN IMMUN, V101, P274, DOI 10.1016/S0091-6749(98)70393-8; Wu CH, 1996, ANN ALLERG ASTHMA IM, V76, P195, DOI 10.1016/S1081-1206(10)63422-9; Wu CH, 1996, J BIOL CHEM, V271, P17937, DOI 10.1074/jbc.271.30.17937; Wu CH, 1998, J ALLERGY CLIN IMMUN, V101, P832, DOI 10.1016/S0091-6749(98)70312-4; WU CH, 1995, J ALLERGY CLIN IMMUN, V96, P352, DOI 10.1016/S0091-6749(95)70054-4	28	53	54	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				859	864		10.1016/S0091-6749(99)70430-6	http://dx.doi.org/10.1016/S0091-6749(99)70430-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	199FP	10329820				2022-12-18	WOS:000080470200021
J	Becker, JM; Arora, A; Scarfone, RJ; Spector, ND; Fontana-Penn, ME; Gracely, E; Joffe, MD; Goldsmith, DP; Malatack, JJ				Becker, JM; Arora, A; Scarfone, RJ; Spector, ND; Fontana-Penn, ME; Gracely, E; Joffe, MD; Goldsmith, DP; Malatack, JJ			Oral versus intravenous corticosteroids in children hospitalized with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						children; prednisone; methylprednisolone; asthma; hospitalized; status asthmaticus; length of stay	CONTROLLED TRIAL; METHYLPREDNISOLONE; PREDNISONE; EMERGENCY; THERAPY; MANAGEMENT; CHILDHOOD; EFFICACY	Background: Previous studies have demonstrated that in the emergency treatment of an asthma exacerbation, corticosteroids used in conjunction with beta-agonists result in lower hospitalization rates for children and adults. Furthermore, orally administered corticosteroids have been found to be effective in the treatment of outpatients with asthma, However, similar data in inpatients is lacking. Objective: The purpose of this study was to determine the efficacy of oral prednisone versus intravenous methylprednisolone in equivalent doses for the treatment of an acute asthma exacerbation in hospitalized children. Methods: We conducted a randomized, double-blind, double-placebo study comparing oral prednisone at 2 mg/kg/dose (maximum 120 mg/dose) twice daily versus intravenous methylprednisolone at 1 mg/kg/dose (maximum 60 mg/dose) four times daily in a group of patients 2 through 18 years of age hospitalized for an acute asthma exacerbation. All patients were assessed by a clinical asthma score 3 times a day. The main study outcome was length of hospitalization; total length of stay and time elapsed before beta-agonists could be administered at 6-hour intervals. Duration of supplemental oxygen administration and peak flow measurements were secondary outcome measures. Results: Sixty-six patients were evaluated. Children in the prednisone group had a mean length of stay of 70 hours compared with 78 hours for the methylprednisolone group (P = .52). Children in the prednisone group were successfully weaned to beta-agonists in 6-hour intervals after 59 hours compared with 68 hours for the methylprednisolone group (P = .47). Patients receiving prednisone required supplemental oxygen for 30 hours compared with 52 hours for the methylprednisolone group (P = .04). Conclusion: There was no difference in length of hospital stay between asthmatic patients receiving oral prednisone and those receiving intravenous methylprednisolone. Because hospitalization charges are approximately 10 times greater for intravenous methylprednisolone compared with oral prednisone, the use of oral prednisone to treat inpatients with acute asthma would result in substantial savings.	MCP Hahnemann Sch Med, Dept Pediat, Philadelphia, PA USA; Thomas Jefferson Univ, Dept Pediat, Philadelphia, PA 19107 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	Drexel University; Jefferson University; University of Pennsylvania	Becker, JM (corresponding author), St Christophers Hosp Children, Sect Allergy, Front & Erie St, Philadelphia, PA 19134 USA.							BRUNETTE MG, 1988, PEDIATRICS, V81, P624; CHAPMAN KR, 1991, NEW ENGL J MED, V324, P788, DOI 10.1056/NEJM199103213241202; ELLIS EF, 1988, ALLERGY PRINCIPLES P, P1037; FIEL SB, 1983, AM J MED, V75, P259, DOI 10.1016/0002-9343(83)91202-0; Grant CC, 1996, ARCH PEDIAT ADOL MED, V150, P58, DOI 10.1001/archpedi.1996.02170260062010; HARRIS JB, 1987, J PEDIATR-US, V110, P627, DOI 10.1016/S0022-3476(87)80567-X; HARRISON BDW, 1986, LANCET, V1, P181; HENRY RL, 1993, J PAEDIATR CHILD H, V29, P101; LARSEN GL, 1992, NEW ENGL J MED, V326, P1540; LITTENBERG B, 1986, NEW ENGL J MED, V314, P150, DOI 10.1056/NEJM198601163140304; MCFADDEN ER, 1993, AM REV RESPIR DIS, V147, P1306, DOI 10.1164/ajrccm/147.5.1306; NALL M, 1992, ANN ALLERGY, V69, P218; *NIH, 1997, NIH PUBL; PIERSON WE, 1974, PEDIATRICS, V54, P282; RATTO D, 1988, JAMA-J AM MED ASSOC, V260, P527, DOI 10.1001/jama.260.4.527; SCARFONE RJ, 1993, PEDIATRICS, V92, P513; Schimmer B, 1996, GOODMAN GILMANS PHAR, P1459; SHAPIRO GG, 1983, PEDIATRICS, V71, P510; Spahn J D, 1995, Pediatr Rev, V16, P266, DOI 10.1542/pir.16-7-266; STEMPEL DA, 1992, PEDIATR CLIN N AM, V39, P1293; TAL A, 1990, PEDIATRICS, V86, P350; VICHYANOND P, 1989, J ALLERGY CLIN IMMUN, V84, P867, DOI 10.1016/0091-6749(89)90381-3; WOOD DW, 1972, AM J DIS CHILD, V123, P227, DOI 10.1001/archpedi.1972.02110090097011; YOUNGER RE, 1987, PEDIATRICS, V80, P225	24	53	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					586	590		10.1016/S0091-6749(99)70228-9	http://dx.doi.org/10.1016/S0091-6749(99)70228-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200005	Bronze			2022-12-18	WOS:000079723900008
J	Barbee, RA; Murphy, S				Barbee, RA; Murphy, S			The natural history of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						natural history; asthma; risk factors; atopic hypersensitivity; air pollution; prevalence; occupational diseases	SKIN-TEST REACTIVITY; COMMUNITY POPULATION-SAMPLE; SERUM IMMUNOGLOBULIN-E; RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; OCCUPATIONAL ASTHMA; PULMONARY-FUNCTION; LUNG-FUNCTION; YOUNG-ADULTS; BRONCHIAL HYPERRESPONSIVENESS	Our understanding of the natural history of asthma is improving through the establishment of a more precise definition of asthma Linked with information from large-scale longitudinal studies. Risk factors for the development of childhood asthma including sex, atopic status, genetic and familial factors, respiratory infections, and outdoor and indoor pollution are now more clearly understood. New information on the relation of viral wheezing episodes in infancy to later childhood asthma is evolving. We now know that children who start wheezing early in life and continue to wheeze at age 6 years are more likely to have a maternal history of asthma, elevated serum IgE levels, and normal lung function in the first year of life. However, at age 6 years they have both elevated Serum IgE levels and diminished lung function, Approximately 50% of adults who report having had childhood asthma no longer have symptoms, Airway responsiveness in childhood tends to predict airway responsiveness in adulthood and to be greater in asthmatics with persistent symptoms. Studies of the natural history of asthma support the hypothesis that early therapeutic intervention in mild disease may lead to an improved clinical outcome. Adults exposed to specific occupational environments are at additional risk for the development of asthma, As we learn more about the natural history of asthma, we will have a better understanding of the effect of early diagnosis, environmental control, and therapy on the outcome of the disease.	Univ Arizona, Hlth Sci Ctr, Dept Med, Pulm & Crit Care Med Sect, Tucson, AZ 85724 USA; Univ New Mexico, Sch Med, Dept Pediat, Albuquerque, NM 87131 USA	University of Arizona; University of Arizona Health Sciences; University of New Mexico	Barbee, RA (corresponding author), Univ Arizona, Hlth Sci Ctr, Dept Med, Pulm & Crit Care Med Sect, 1501 N Campbell Ave, Tucson, AZ 85724 USA.							ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; AUERBACH I, 1993, THORAX, V48, P139, DOI 10.1136/thx.48.2.139; Balboni A, 1996, EUR RESPIR J, V9, P207, DOI 10.1183/09031936.96.09020207; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; Bodner CH, 1998, AM J RESP CRIT CARE, V157, P35, DOI 10.1164/ajrccm.157.1.9702062; BUFFUM WP, 1966, AM J DIS CHILD, V112, P214, DOI 10.1001/archpedi.1966.02090120082007; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURROWS B, 1977, AM REV RESPIR DIS, V115, P751; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BURROWS B, 1982, J ALLERGY CLIN IMMUN, V70, P199, DOI 10.1016/0091-6749(82)90042-2; Ciba Guest Symposium, 1959, THORAX, V14, P286, DOI 10.1136/thx.14.4.286; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; COULTAS DB, 1993, CHILDHOOD ASTHMA, P71; DEES SC, 1957, AMA J DIS CHILD, V93, P228, DOI 10.1001/archpedi.1957.02060040230004; DEGOOIJER A, 1993, EUR RESPIR J, V6, P848; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; DUNNILL MS, 1971, IDENTIFICATION ASTHM, P35; ENARSON DA, 1987, AM REV RESPIR DIS, V136, P613, DOI 10.1164/ajrccm/136.3.613; FRANDSEN S, 1958, Acta Allergol, V12, P341, DOI 10.1111/j.1398-9995.1958.tb03090.x; GERSTMAN BB, 1989, J ALLERGY CLIN IMMUN, V83, P1032, DOI 10.1016/0091-6749(89)90444-2; GODDEN DJ, 1994, AM J RESP CRIT CARE, V149, P106, DOI 10.1164/ajrccm.149.1.8111567; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129, DOI 10.1164/ajrccm/145.5.1129; JAAKKOLA MS, 1993, AM REV RESPIR DIS, V147, P359, DOI 10.1164/ajrccm/147.2.359; KELLY WJW, 1990, J ALLERGY CLIN IMMUN, V85, P548, DOI 10.1016/0091-6749(90)90092-I; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26, DOI 10.1164/ajrccm/138.1.26; KOKKONEN J, 1993, EUR RESPIR J, V6, P657; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; Magnus P, 1997, BRIT MED J, V314, P1795, DOI 10.1136/bmj.314.7097.1795; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; MANFREDA J, 1993, CHEST, V103, P151, DOI 10.1378/chest.103.1.151; Marsh DG, 1997, NAT GENET, V15, P389; MARTIN AJ, 1980, AM REV RESPIR DIS, V122, P609; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MURPHY SJ, IN PRESS PEDIAT ASTH; *NAT ASTHM ED PREV, 1991, NIH NAT HEART LUNG B; *NAT ASTHM ED PREV, 1997, NIH NAT HEART LUNG B; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; OGILVIE A. G., 1962, THORAX, V17, P183, DOI 10.1136/thx.17.3.183; OHMAN JL, 1993, J ALLERGY CLIN IMMUN, V91, P752, DOI 10.1016/0091-6749(93)90195-L; PARK ES, 1986, ARCH DIS CHILD, V61, P642, DOI 10.1136/adc.61.7.642; PEAT JK, 1992, EUR RESPIR J, V5, P921; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P815, DOI 10.1056/NEJM195205222462104; ROORDA RJ, 1994, J ALLERGY CLIN IMMUN, V93, P575, DOI 10.1016/S0091-6749(94)70069-9; ROORDA RJ, 1993, AM REV RESPIR DIS, V148, P1490, DOI 10.1164/ajrccm/148.6_Pt_1.1490; SCHACHTER EN, 1984, CHEST, V85, P623, DOI 10.1378/chest.85.5.623; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SKARPAAS IJK, 1985, ALLERGY, V40, P295, DOI 10.1111/j.1398-9995.1985.tb00235.x; SPORIK R, 1991, ARCH DIS CHILD, V66, P1050, DOI 10.1136/adc.66.9.1050; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1996, AM J RESP CRIT CARE, V154, P1629, DOI 10.1164/ajrccm.154.6.8970346; SUNYER J, 1989, LANCET, V1, P179; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Venables KM, 1997, LANCET, V349, P1465, DOI 10.1016/S0140-6736(96)07219-4; WEISS ST, 1992, AM REV RESPIR DIS, V145, P58, DOI 10.1164/ajrccm/145.1.58; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; WOOLCOCK AJ, 1983, EUR J RESPIR DIS, V64, P571	68	53	53	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	2				S65	S72		10.1016/S0091-6749(98)70006-5	http://dx.doi.org/10.1016/S0091-6749(98)70006-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	133CT	9798724	Bronze			2022-12-18	WOS:000076669400008
J	Slater, JE; Paupore, E; Zhang, YT; Colberg-Poley, AM				Slater, JE; Paupore, E; Zhang, YT; Colberg-Poley, AM			The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rodent; allergy; vaccination; immunotherapy; latex	DIRECT GENE-TRANSFER; IMMUNE-RESPONSE; PLASMID DNA; IN-VIVO; DENDRITIC CELLS; SURFACE-ANTIGEN; MOUSE MUSCLE; IMMUNIZATION; VIRUS; PROTECTION	Background: DNA vaccines reduce IgE responses to selected allergens, but severe reactions to the expressed antigen may limit the usefulness of the technique in allergen immunotherapy. Objective: We sought to determine the extent of spread of an injected DNA vaccine in mice. Methods: We placed the gene encoding the potent Hevea latex allergen Hev b 5 in a mammalian expression vector and injected this DNA vaccine subcutaneously into BALB/c mice. At several times after injection, the presence of Hev b 5 transcript was determined in multiple tissues by RT-PCR, The identity of the amplification product was confirmed by Southern hybridization and restriction analyses. Results: Hev b 5 RNA appeared at the injection site and in the lymph nodes, spleen, and lungs within 1 day after injection and persisted for at least 14 days. Hev b 5 RNA was also identified in the blood and tongue 14 days after injection. Antibody and cell-mediated responses to Hev b 5 were also noted in the immunized animals at later time points. As expected, animals injected with the identical plasmid containing the Hev b 5 DNA in the antisense orientation mounted no immune response to Hev b 5. Conclusions: The rapid and widespread appearance of the Hev b 5 transcript in the injected mice confirms that DNA is translocated from the injection site, transcribed, and expressed in immune and nonimmune tissues after injection. Controlling the extent and degree of expression in specific target tissues may allow therapeutic DNA vaccination with plasmids that encode potentially toxic allergens.	Childrens Natl Med Ctr, Dept Allergy Immunol & Pulm Med, Childrens Res Inst, Ctr Mol Mechanisms Dis Res, Washington, DC 20010 USA; George Washington Univ, Sch Med, Washington, DC USA; Childrens Natl Med Ctr, Childrens Res Inst, Ctr Virol Immunol & Infect Dis Res, Washington, DC 20010 USA	Children's National Health System; George Washington University; Children's National Health System	Slater, JE (corresponding author), US FDA, Lab Immunobiochem, Ctr Biol Evaluat & Res, 1401 Rockville Pike, Rockville, MD 20852 USA.							Casares S, 1997, J EXP MED, V186, P1481, DOI 10.1084/jem.186.9.1481; Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122; CONRY RM, 1994, CANCER RES, V54, P1164; DAVIS HL, 1994, VACCINE, V12, P1503, DOI 10.1016/0264-410X(94)90073-6; FELQUATE DM, 1997, J IMMUNOL, V158, P2278; FURTH PA, 1995, HYBRIDOMA, V14, P149, DOI 10.1089/hyb.1995.14.149; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; HAYNES JR, 1994, AIDS RES HUM RETROV, V10, pS43; Hsu CH, 1996, INT IMMUNOL, V8, P1405, DOI 10.1093/intimm/8.9.1405; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; HUI KM, 1994, J IMMUNOL METHODS, V171, P147, DOI 10.1016/0022-1759(94)90035-3; PLAUTZ GE, 1993, P NATL ACAD SCI USA, V90, P4645, DOI 10.1073/pnas.90.10.4645; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; RHODES GH, 1993, VACCINES93 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P137; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; Slater J. E., 1997, Journal of Allergy and Clinical Immunology, V99, pS504; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V93, P825, DOI 10.1016/0091-6749(94)90372-7; SLATER JE, 1997, REGULATORY CONTROL S, P230; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WANG B, 1993, DNA CELL BIOL, V12, P799, DOI 10.1089/dna.1993.12.799; WHALEN RG, 1995, CLIN IMMUNOL IMMUNOP, V75, P1, DOI 10.1006/clin.1995.1045; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105; YOKOYAMA M, 1995, J VIROL, V69, P2684, DOI 10.1128/JVI.69.4.2684-2688.1995	29	53	57	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					469	475		10.1016/S0091-6749(98)70137-X	http://dx.doi.org/10.1016/S0091-6749(98)70137-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768590				2022-12-18	WOS:000076212800023
J	Blanc, PD; Kuschner, WG; Katz, PP; Smith, S; Yelin, EH				Blanc, PD; Kuschner, WG; Katz, PP; Smith, S; Yelin, EH			Use of herbal products, coffee or black tea, and over-the-counter medications as self-treatments among adults with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; outcomes; herbal therapy; coffee; tea	PREVALENCE; DISABILITY; INHALERS	Background: There are few data on the use. of alternative therapies in adult asthma and their impact on health outcomes. Objective: The objective of this study was to study the prevalence and morbidity of asthma self-treatment with herbs, coffee or black tea, and over-the-counter (OTC) medications containing ephedrine or epinephrine. Methods: We carried out a cross-sectional analysis of interview data for 601 adults with asthma recruited from a random sample of pulmonary and allergy specialists. We estimated the 12-month prevalence of reported use of herbal products, coffee or black tea, or OTC products to self-treat asthma and their association with emergency department visits and hospitalization. Results: Herbal asthma self-treatment was reported by 46 (8%; 95% confidence interval [CI] 6% to 10%); coffee or black tea self-treatment by 36 (6%; 95% CI 4% to 8%), epinephrine or ephedrine OTC use by 36 (6%; 95% CI 4% to 8%), and any of the three practices by 98 subjects (16%; 95% CI 13% to 19%). Adjusting for demographic and illness covariates, herbal use (odds ratio [OR] 2.5; 95% CI 1.1 to 5.6) and coffee or black tea use (OR 3.1; 95% CI 1.2 to 7.8) were associated with asthma hospitalization; OTC use was not (OR 0.8; 95% CI 0.3 to 2.5). Conclusions: Even among adults with access to specialty care for asthma, self-treatment with nonprescription products was common and was associated with increased risk of reported hospitalization. This association does not appear to be accounted for by illness severity or other disease covariates. It may reflect delay in utilization of more efficacious treatments.	Univ Calif San Francisco, Dept Med, Div Environm & Occupat Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Arthrit Res Grp, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Blanc, PD (corresponding author), Univ Calif San Francisco, Dept Med, Div Environm & Occupat Med, Box 0924, San Francisco, CA 94143 USA.			Kuschner, Ware/0000-0002-9732-1366	NHLBI NIH HHS [KO4-HL03225, R29-HL48959] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL048959, K04HL003225] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blanc PD, 1996, CHEST, V109, P688, DOI 10.1378/chest.109.3.688; BLANC PD, 1993, CHEST, V104, P1371, DOI 10.1378/chest.104.5.1371; BORKAN J, 1994, J FAM PRACTICE, V39, P545; *CDC, 1995, MMWR-MORBID MORTAL W, V44, P204; COMINO EJ, 1995, AUST NZ J MED, V25, P496, DOI 10.1111/j.1445-5994.1995.tb01494.x; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; GIBSON P, 1993, BRIT MED J, V306, P1514, DOI 10.1136/bmj.306.6891.1514; HENRY DA, 1989, MED J AUSTRALIA, V150, P445; KASSLER WJ, 1991, ARCH INTERN MED, V151, P2281, DOI 10.1001/archinte.151.11.2281; Katz PP, 1997, AM J RESP CRIT CARE, V155, P577, DOI 10.1164/ajrccm.155.2.9032197; KUSCHNER W, IN PRESS CHEST; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; PAGANO R, 1988, CHEST, V94, P386, DOI 10.1378/chest.94.2.386; Schwartz J, 1992, Ann Epidemiol, V2, P627, DOI 10.1016/1047-2797(92)90007-D; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; Ware J.E., 1993, LINC RI QUAL METR IN	16	53	57	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				789	791		10.1016/S0091-6749(97)70275-6	http://dx.doi.org/10.1016/S0091-6749(97)70275-6			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438488	Bronze			2022-12-18	WOS:000071353600012
J	Kim, YK; Nakagawa, N; Nakano, K; Sulakvelidze, I; Dolovich, J; Denburg, J				Kim, YK; Nakagawa, N; Nakano, K; Sulakvelidze, I; Dolovich, J; Denburg, J			Stem cell factor in nasal polyposis and allergic rhinitis: Increased expression by structural cells is suppressed by in vivo topical corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyposis; allergic rhinitis; mast cells; stem cell factor; corticosteroids	HUMAN MAST-CELLS; BRONCHIAL EPITHELIAL-CELLS; C-KIT LIGAND; COLONY-STIMULATING ACTIVITY; FETAL LIVER-CELLS; ENDOTHELIAL-CELLS; RECOMBINANT HUMAN; GROWTH-FACTOR; BONE-MARROW; CHEMOTACTIC FACTOR	Background: Mast cells are increased in nasal polyp (Np) and allergic rhinitis (AR) tissue and are suppressed by topical corticosteroid treatment. Stem cell factor (SCF), a mast cell growth and survival factor, may explain these phenomena. Objective: We investigated structural cell gene expression and production of SCF in nasal tissues in patients who had received and who had not received in vivo intranasal corticosteroid therapy. Methods: Northern blot analyses for messenger RNA and ELISA for biologically active SCF protein from cultured Np epithelial cells and fibroblasts mere performed. Immunostaining for SCF in cultured and tissue nasal structural cells in the presence or absence of steroid treatment was also performed. Results: We detected significant expression of SCF mRNA and protein by cultured Np epithelial cells and Np fibroblasts; Np fibroblast SCF supported the differentiation of mast cells in vitro. There were more immunoreactive SCF-positive Np epithelial cells in patients with AR than in control subjects (97.2 +/- 2.8 vs 45.6 +/- 22.0%; p < 0.0001). SCF that could be immunostained was significantly diminished overall in Np structural cells in the group given in vivo steroid treatment, with a modest (trend to significant) effect on any given cell type analyzed. In vitro treatment with budesonide of SCF-producing fibroblasts demonstrated inhibition of unstimulated, primary Np fibroblasts but not of IL-l-stimulated fibroblasts or transformed cell lines. Conclusions: Human Np and AR tissue structural cells express and produce increased SCF. Our in vitro studies suggest that intranasal steroids blunt SCP expression in Nps, an effect that may be responsible for a decrease in mast cells and symptoms.	MCMASTER UNIV,MED CTR,DEPT MED,HAMILTON,ON L8N 3Z5,CANADA; MCMASTER UNIV,DEPT PEDIAT,HAMILTON,ON L8N 3Z5,CANADA	McMaster University; McMaster University								ADACHI S, 1992, BLOOD, V79, P650; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; AYE MT, 1992, EXP HEMATOL, V20, P523; BLACK PN, 1989, FEBS LETT, V255, P129, DOI 10.1016/0014-5793(89)81075-0; CASTLEMAN WL, 1995 ATS INT C SEATT, pA368; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; DASTYCH J, 1994, J IMMUNOL, V152, P213; DENBURG JA, 1991, INT ARCH ALLER A IMM, V94, P127, DOI 10.1159/000235343; DVORAK AM, 1994, CLIN EXP ALLERGY, V24, P649, DOI 10.1111/j.1365-2222.1994.tb00969.x; FINOTTO S, 1994, CLIN EXP IMMUNOL, V95, P343; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FOKKENS WJ, 1992, CLIN EXP ALLERGY, V22, P701, DOI 10.1111/j.1365-2222.1992.tb00194.x; FUJIO K, 1994, LAB INVEST, V70, P511; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GO S, 1980, J HERED, V71, P41, DOI 10.1093/oxfordjournals.jhered.a109308; GUYGRAND D, 1984, J EXP MED, V160, P12, DOI 10.1084/jem.160.1.12; HEARD BE, 1992, J PATHOL, V166, P303, DOI 10.1002/path.1711660314; HIBI K, 1991, ONCOGENE, V6, P2291; HOLTZMAN MJ, 1988, BIOCHIM BIOPHYS ACTA, V963, P401, DOI 10.1016/0005-2760(88)90308-6; IEMURA A, 1994, AM J PATHOL, V144, P321; INOUE M, 1994, CANCER RES, V54, P3049; IRANI AA, 1995, IMMUNOLOGY, V84, P72; IRANI AMA, 1992, BLOOD, V80, P3009; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; JOZAKI K, 1991, EXP HEMATOL, V19, P185; JULIUSSON S, 1993, CLIN EXP ALLERGY, V23, P591, DOI 10.1111/j.1365-2222.1993.tb00899.x; KEPPEL G, 1982, DESIGN ANAL; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; KOENIG A, 1994, BLOOD, V83, P2836, DOI 10.1182/blood.V83.10.2836.2836; LANGLEY KE, 1993, BLOOD, V81, P656; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MATTOLI S, 1991, J CELL PHYSIOL, V149, P260, DOI 10.1002/jcp.1041490212; MAYRHOFER G, 1987, IMMUNOL CELL BIOL, V65, P241, DOI 10.1038/icb.1987.27; MEININGER CJ, 1995, LAB INVEST, V72, P166; MITSUI H, 1993, P NATL ACAD SCI USA, V90, P735, DOI 10.1073/pnas.90.2.735; MULLOL J, 1995, CLIN EXP ALLERGY, V25, P607, DOI 10.1111/j.1365-2222.1995.tb01108.x; MUTA K, 1993, J CELL PHYSIOL, V156, P264, DOI 10.1002/jcp.1041560207; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; NILSSON G, 1994, J IMMUNOL, V153, P3717; Nonaka M, 1996, AM J RESP CRIT CARE, V153, P1675, DOI 10.1164/ajrccm.153.5.8630619; OHNISHI M, 1988, AM REV RESPIR DIS, V138, P560, DOI 10.1164/ajrccm/138.3.560; OTSUKA H, 1986, CLIN ALLERGY, V16, P589, DOI 10.1111/j.1365-2222.1986.tb01998.x; PESCE M, 1993, DEVELOPMENT, V118, P1089; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; RENNARD SI, 1991, LUNG SCI F, V1, P157; ROCHESTER CL, 1995, CHEST, V107, pS117, DOI 10.1378/chest.107.3_Supplement.117S; SACCO O, 1992, J CLIN INVEST, V90, P1379, DOI 10.1172/JCI116004; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; SEGAL GM, 1987, J IMMUNOL, V138, P1772; SHOJI S, 1989, AM J RESP CELL MOL, V1, P13, DOI 10.1165/ajrcmb/1.1.13; SMITH SM, 1990, AM J RESP CELL MOL, V2, P59, DOI 10.1165/ajrcmb/2.1.59; SPERR WR, 1993, INT ARCH ALLERGY IMM, V102, P170, DOI 10.1159/000236568; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; VALENT P, 1992, BLOOD, V80, P2237; WERSHIL BK, 1995, INT ARCH ALLERGY IMM, V107, P323, DOI 10.1159/000237015; WIDDICOMBE JG, 1995, ASTHMA RHINITIS, P722; YANKASKAS JR, 1985, AM REV RESPIR DIS, V132, P1281	61	53	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					389	399		10.1016/S0091-6749(97)70254-9	http://dx.doi.org/10.1016/S0091-6749(97)70254-9			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314353				2022-12-18	WOS:A1997XX47900018
J	Matsumoto, K; Sterbinsky, SA; Bickel, CA; Zhou, DFH; Kovach, NL; Bochner, BS				Matsumoto, K; Sterbinsky, SA; Bickel, CA; Zhou, DFH; Kovach, NL; Bochner, BS			Regulation of alpha(4) integrin-mediated adhesion of human eosinophils to fibronectin and vascular cell adhesion molecule-1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; adhesion; integrin; fibronectin; vascular cell adhesion molecule-1; integrin function	PLATELET-ACTIVATING-FACTOR; ENDOTHELIAL-CELLS; TRANSENDOTHELIAL MIGRATION; PLASMA FIBRONECTIN; MATRIX COMPONENTS; VLA-4; ADHERENCE; RECEPTOR; NEUTROPHILS; EXPRESSION	Background: Eosinophils selectively accumulate at sites of allergic inflammation. Their recruitment is dependent on both the expression and functional activity of cell adhesion molecules. How the functional activity of cell adhesion molecules on eosinophils is regulated is poorly understood, Objective: Our objective was to examine the functional activity of alpha(4) integrins on human eosinophils and its regulation by various agents. Methods: Function of alpha(4) integrins on human eosinophils was examined by testing adhesion to immobilized fibronectin and vascular cell adhesion molecule-1 (VCAM-1) in the presence or absence of a monoclonal antibody (mAb) (8A2) that activates beta(perpendicular to) integrin function, Results: Spontaneous eosinophil adhesion to VCAM-1 was enhanced by 8A2, but adhesion to fibronectin could only he detected in the presence of 8A2. Concentrations of 8A2 that were approximately 100-fold less than saturating induced maximal eosinophil adhesion, Adhesion to VCAM-1 in the presence of 8A2 was effectively inhibited by alpha(4) and beta(1) integrin mAbs; beta(7) mAb had partial inhibitory activity, Connecting segment-1 peptide and alpha(4) mAb blocked 8A2-dependent fibronectin binding; beta(1), beta(2), and beta(7) integrin mAbs had partial inhibitory activity, Eosinophils obtained from bronchoalveolar lavage fluids and blood eosinophils stimulated with IL-5, platelet-activating factor, or RANTES displayed increased beta(2) integrin-dependent not alpha(4) integrin-dependent, attachment. Spontaneous adhesion of eosinophils to VCAM-1 was significantly reduced by the tyrosine kinase inhibitor tyrphostin B46 (inhibitory concentration of 50% congruent to 20 mu mol/L); this effect was reversed by 8A2. Conclusions: The functional activity of integrins on eosinophils can be positively and negatively regulated. Altered integrin avidity may influence eosinophil recruitment in vivo.	JOHNS HOPKINS ASTHMA & ALLERGY CTR, BALTIMORE, MD 21224 USA; OTSUKA AMER PHARMACEUT INC, ROCKVILLE, MD USA; UNIV WASHINGTON, DEPT MED, DIV HEMATOL, SEATTLE, WA 98195 USA	Johns Hopkins University; Johns Hopkins Medicine; University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL49545] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049545] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANWAR ARE, 1994, IMMUNOLOGY, V82, P222; ANWAR ARF, 1993, J EXP MED, V177, P839, DOI 10.1084/jem.177.3.839; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; CARLOS TM, 1994, BLOOD, V84, P2068; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; DRI P, 1991, J IMMUNOL, V147, P613; EBISAWA M, 1994, J IMMUNOL, V152, P4590; EBISAWA M, 1994, J IMMUNOL, V153, P2153; Ebisawa M, 1995, LEUKOCYTE TYPING, Vone, P1036; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; GEORAS SN, 1993, BLOOD, V82, P2872; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HILDRETH JEK, 1985, J IMMUNOL, V134, P3272; HORIE S, 1994, J IMMUNOL, V152, P5457; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIMANI G, 1988, J IMMUNOL, V140, P3161; Kita H, 1996, J IMMUNOL, V156, P1174; KOVACH NL, 1995, BLOOD, V85, P159, DOI 10.1182/blood.V85.1.159.bloodjournal851159; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; LAMAS AM, 1988, J IMMUNOL, V140, P1500; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; LOBB RR, 1992, ADHESION ITS ROLE IN, P1; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; NAGATA M, 1995, J IMMUNOL, V155, P2194; NEELEY SP, 1994, AM J RESP CELL MOL, V11, P206, DOI 10.1165/ajrcmb.11.2.8049081; PICKER LJ, 1993, EUR J IMMUNOL, V23, P2751, DOI 10.1002/eji.1830231105; PULIDO R, 1991, J BIOL CHEM, V266, P10241; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SHAW S, 1995, LEUKOCYTE TYPING, V5, P16; SMYTH SS, 1993, BLOOD, V81, P2827; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; THORNHILL MH, 1990, J IMMUNOL, V144, P3060; WALSH GM, 1995, CLIN EXP ALLERGY, V25, P1128, DOI 10.1111/j.1365-2222.1995.tb03260.x; Walsh GM, 1996, IMMUNOLOGY, V89, P112, DOI 10.1046/j.1365-2567.1996.d01-713.x; WALSH GM, 1991, J IMMUNOL, V146, P3419; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WARDLAW A J, 1992, American Review of Respiratory Disease, V145, pA664; WARDLAW AJ, 1993, EOSINOPHILS ALLERGY, P15; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; Werfel SJ, 1996, AM J RESP CELL MOL, V14, P44, DOI 10.1165/ajrcmb.14.1.8534485; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	54	53	54	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					648	656		10.1016/S0091-6749(97)70027-7	http://dx.doi.org/10.1016/S0091-6749(97)70027-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155832	hybrid			2022-12-18	WOS:A1997WY60000013
J	Mazon, A; Nieto, A; Estornell, F; Nieto, A; Reig, C; GarciaIbarra, F				Mazon, A; Nieto, A; Estornell, F; Nieto, A; Reig, C; GarciaIbarra, F			Factors that influence the presence of symptoms caused by latex allergy in children with spina bifida	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex; spina bifida; hypersensitivity; atopy; exposure symptoms; risk factors	INTRAOPERATIVE ANAPHYLAXIS; RISK-FACTORS; RUBBER; HYPERSENSITIVITY; CONTACT	Background: Some children with spins bifida who are sensitized to lates can ha Objective: Our aim was to study the differences between these two groups of patients, Material and methods: In 110 consecutive children with spina bifida, we identified by means of skin prick tests and serum latex-specific IgE 32 patients sensitized to latex, In these 32 patients, data were collected for ser;, age, personal and familial history of atopy, number of cystourethrograms and number of operations, history of intermittent bladder catheterization, serum levels of total IgE in units per milliliter and in z units, levels of latex-specific IgE, and results of skin prick tests. Results: Sixteen patients (50%) had clinical symptoms related to latex. These patients had significantly higher levels of serum specific IgE (32.8 +/- 30.7 U/ml vs. 12.5 +/- 16.5 U/ml), were more Likely to have positive responses on skin tests (100% vs. 75%), had a higher number of operations (10.5 +/- 6.9 vs. 5.8 +/- 2.7), and were more likely to have a personal history of atopy (41% vs. 6%) in comparison with findings for patients who did not have symptoms (p < 0.05 in all cases). A multivariate logistic regression analysis identified the latter two factors as independent synergistic variables to predict symptoms. Conclusions: The number of operations is the main risk factor for latex-related symptoms in sensitized children. Atopy seems to lower the threshold both for sensitization and for the presentation of clinical reactions.	HOSP INFANTIL LA FE, DEPT PEDIAT ALLERGY, VALENCIA 46009, SPAIN; HOSP INFANTIL LA FE, DEPT PEDIAT UROL, VALENCIA 46009, SPAIN				Mazon, Angel/ABG-8016-2020	Mazon, Angel/0000-0001-5639-1037				ELLSWORTH PI, 1993, J UROLOGY, V150, P691, DOI 10.1016/S0022-5347(17)35587-8; GERBER AC, 1989, ANESTHESIOLOGY, V71, P800, DOI 10.1097/00000542-198911000-00031; GOLD M, 1991, J ALLERGY CLIN IMMUN, V87, P662, DOI 10.1016/0091-6749(91)90385-2; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; KONZ KR, 1995, J ALLERGY CLIN IMMUN, V95, P950, DOI 10.1016/S0091-6749(95)70094-3; MONERETVAUTRIN DA, 1990, ANESTHESIOLOGY, V73, P556, DOI 10.1097/00000542-199009000-00032; MONERETVAUTRIN DA, 1993, J ALLERGY CLIN IMMUN, V92, P668, DOI 10.1016/0091-6749(93)90009-5; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; Nieto A, 1996, J ALLERGY CLIN IMMUN, V98, P501, DOI 10.1016/S0091-6749(96)70082-9; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; PASQUARIELLO CA, 1993, PEDIATRICS, V91, P983; PEARSON ML, 1994, DEV MED CHILD NEUROL, V36, P64, DOI 10.1111/j.1469-8749.1994.tb11767.x; SCHWARTZ HA, 1993, J ALLERGY CLIN IMMUN, V92, P358, DOI 10.1016/0091-6749(93)90181-E; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; *TASK FORC ALL REA, 1993, J ALLERGY CLIN IMMUN, V92, P16; TOSI LL, 1993, J PEDIATR ORTHOPED, V13, P709, DOI 10.1097/01241398-199311000-00003; TURJANMAA K, 1995, IMMUNOL ALLERGY CLIN, V15, P71	19	53	54	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					600	604		10.1016/S0091-6749(97)70019-8	http://dx.doi.org/10.1016/S0091-6749(97)70019-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155824				2022-12-18	WOS:A1997WY60000005
J	Monroe, EW; Daly, AF; Shalhoub, RF				Monroe, EW; Daly, AF; Shalhoub, RF			Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						histamine-induced wheal and flare; antihistamines; seasonal allergic rhinitis; chronic urticaria; antiallergic efficacy	SEASONAL ALLERGIC RHINITIS; CHRONIC IDIOPATHIC URTICARIA; NON-SEDATING ANTIHISTAMINE; DOUBLE-BLIND; HAY-FEVER; PROPHYLACTIC TREATMENT; LORATADINE SCH-29851; SKIN REACTION; TERFENADINE; CETIRIZINE	Antihistaminic drugs have been used successfully for many years in the treatment of allergic diseases. Second-generation antihistamines have fewer sedating side effects than first-generation agents, and the number of newer drugs available for clinical use is growing. Various methods have been used to assess antihistaminic activity, the most popular of which is the epicutaneous histamine-induced wheal and flare. This test relies on the ability of epicutaneously injected histamine to bring about the wheal and flare, a neurovascular response that involves reflex vasodilation (flare) and local swelling caused by plasma extravasation (wheal). Antihistamines have been compared on the basis of their ability to block the histamine-induced wheal and flare in the skin. Results of these trials have been applied to predict the global antiallergic efficacy of various antihistamines. This review has examined the reliability of suppression of the histamine wheal and flare reaction in the skin to predict an antihistamine's clinical efficacy in two common allergic diseases, seasonal allergic rhinitis and chronic idiopathic urticaria. Although histamine is one mediator in the allergic response in the skin and nasal mucosa, many other agents are important modulators of the allergic response. In addition, the major structural and functional differences that exist between the nasal mucosa and the skin affect the type of local response. These manifest themselves as differences between the responses to antigen and histamine challenge in the skin and the nose. The allergic responses in these tissues are not simply the consequence of one chemical but are the result of a cascade of interactions among various cells and mediators. The clinical manifestations of these complex interactions obviously cannot be fully replicated by injection of one chemical mediator, histamine, into the outer layer of the skin. Studies with antihistamines have shown that certain drugs, such as cetirizine, are more suppressive than others (loratadine, terfenadine) in controlling the histamine-induced wheal and flare reaction in the skin. When the clinical efficacy of these medications is compared in clinical trials in seasonal allergic rhinitis and chronic idiopathic urticaria, all are equally efficacious in controlling symptoms. Although the histamine-induced wheal and flare reaction can serve as a useful clinical pharmacologic test to assess dose-response relations for antihistamine, its lack of correlation with clinical responses among antihistamines indicates that this model should not be used to predict or compare clinical efficacies of antihistamines in seasonal allergic rhinitis and chronic idiopathic urticaria.	MED COLL WISCONSIN, MILWAUKEE, WI 53217 USA; ROYAL COLL SURGEONS IRELAND, SCH MED, DUBLIN 2, IRELAND	Medical College of Wisconsin; Royal College of Surgeons - Ireland	Monroe, EW (corresponding author), MILWAUKEE MED CLIN, DEPT DERMATOL, 3003 W GOOD HOPE RD, MILWAUKEE, WI 53217 USA.		Daly, Adrian F/E-2178-2011	Daly, Adrian F/0000-0001-6130-2975				ALEXANDER M, 1994, J ALLERGY CLIN IMMUN, V93, P163; ALOMAR A, 1990, J INT MED RES, V18, P358, DOI 10.1177/030006059001800503; ANGGARD A, 1983, EUR J RESPIR DIS, V64, P143; BACKHOUSE CI, 1987, BRIT J CLIN PRACT, V41, P995; BACKHOUSE CI, 1982, PRACTITIONER, V226, P347; BACKHOUSE CI, 1990, BRIT J CLIN PRACT, V44, P88; BAROODY F, 1989, ANN ALLERGY, V63, P551; BELAICH S, 1990, ANN ALLERGY, V64, P191; BOUSQUET J, 1987, P 44 ANN C AM COLL A; Bovet D, 1937, CR SOC BIOL, V124, P547; BRANDON ML, 1980, ANN ALLERGY, V44, P71; BRENEMAN D, 1992, J ALLERGY CLIN IMMUN, V89, P249; BROSTOFF J, 1982, POSTGRAD MED J, V58, P422, DOI 10.1136/pgmj.58.681.422; BUCKLEY CE, 1988, ANN ALLERGY, V60, P123; CAIAFFA MF, 1992, J INVEST ALLERG CLIN, V2, P162; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; D'AMATO G, 1990, Clinical and Experimental Allergy, V20, P101; DAMBROSIO FP, 1991, SCHWEIZERISCHE MED W, V121, P11; DAVIES BH, 1989, CLIN TRIALS J, V26, P100; DAVIES BH, 1991, CLIN THER, V13, P87; DECARPIO J, 1989, J ALLERGY CLIN IMMUN, V84, P741; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOCKHORN RJ, 1987, ANN ALLERGY, V58, P407; DOCKX P, 1988, S CET ALL BRUSS MARC, P23; FADEL R, 1990, J INT MED RES, V18, P366, DOI 10.1177/030006059001800504; GO MJT, 1989, ACTA THERAP, V15, P77; GRANT JA, 1988, J ALLERGY CLIN IMMUN, V81, P563, DOI 10.1016/0091-6749(88)90197-2; GROSSMAN J, 1988, N ENGL REGIONAL ALLE, V9, P370; GUERRA L, 1991, P 2 C EUR AC VEN ATH, P206; GUILETT G, 1992, ABSTR DERM, V138, P1; HALTOM JR, 1992, ANN ALLERGY, V68, P110; HARCUP JW, 1993, BRIT J CLIN PRACT, V47, P131; HERMANN K, 1990, CLIN EXP ALLERGY, V20, P569, DOI 10.1111/j.1365-2222.1990.tb03151.x; HORAK F, 1988, ARZNEIMITTEL-FORSCH, V38-1, P124; HOWARTH PH, 1984, BRIT J CLIN PHARMACO, V18, P1; HUMPHREYS F, 1991, BRIT J DERMATOL, V125, P364, DOI 10.1111/j.1365-2133.1991.tb14173.x; HUSTON DP, 1992, MED CLIN N AM, V76, P805, DOI 10.1016/S0025-7125(16)30327-3; KAPLAN AP, 1993, ALLERGY PRINCIPLES P, V2, P1553; KATELARIS C, 1990, ASIAN PAC J ALLERGY, V8, P103; KEMP JP, 1985, ANN ALLERGY, V54, P502; KEMP JP, 1987, AM J RHINOL, V1, P151; KINT A, 1989, ACTA THERAP, V15, P65; KONTOUFILI K, 1989, EUR J CLIN PHARMACOL, V36, P617, DOI 10.1007/BF00637746; LEVER LR, 1992, SKIN PHARMACOL, V5, P29; LOCKEY RF, 1993, ANN ALLERGY, V70, P311; MARCHER E, 1989, P 14 C EUR AC ALL CL, P91; MAURACHER EH, 1992, IMMUNOL ALLERGY PRAC, V14, P223; OEI HD, 1988, ANN ALLERGY, V61, P436; OLSEN OT, 1992, ARZNEIMITTEL-FORSCH, V42-2, P1227; PAUL E, 1994, ALLERGOLOGIE, V17, P486; PECHADRE JC, 1988, EUR J CLIN PHARMACOL, V35, P255, DOI 10.1007/BF00558262; PERSI L, IN PRESS J ALLERGY C; REED C E, 1991, Annals of Allergy, V66, P104; RIHOUX JP, 1987, ANN ALLERGY, V59, P235; RIJNTJES E, 1990, J INT MED RES, V18, P219, DOI 10.1177/030006059001800306; ROMAN IJ, 1986, ANN ALLERGY, V57, P253; Rosenzweig P., 1994, British Journal of Clinical Pharmacology, V37, p116P; ROSSI O, 1991, ALLERGY CLIN IMMUN S, P358; SHALL L, 1992, CLIN EXP ALLERGY, V22, P711, DOI 10.1111/j.1365-2222.1992.tb00195.x; SIEGAL S, 1988, ALLERGY S, V7, P5; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540; SKASSABROCIEK W, 1988, J ALLERGY CLIN IMMUN, V81, P725, DOI 10.1016/0091-6749(88)91045-7; SMALL P, 1993, J ALLERGY CLIN IMMUN, V91, P244; TJWA MKT, 1992, ALLERGY S, V47, P174; VANROOY P, 1991, J ALLERGY CLIN IMMUN, V87, P51	65	53	57	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					S798	S806		10.1016/S0091-6749(97)70128-3	http://dx.doi.org/10.1016/S0091-6749(97)70128-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042073				2022-12-18	WOS:A1997WH83100041
J	Benessiano, J; Crestani, B; Mestari, F; Klouche, W; Neukirch, F; HaceinBey, S; Durand, G; Aubier, M				Benessiano, J; Crestani, B; Mestari, F; Klouche, W; Neukirch, F; HaceinBey, S; Durand, G; Aubier, M			High frequency of a deletion polymorphism of the angiotensin-converting enzyme gene in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						genetics; bradykinin; substance P; tachykinin	BRONCHIAL HYPERRESPONSIVENESS; MYOCARDIAL-INFARCTION; CELLS; PREDISPOSITION; TISSUE	Background: An insertion-deletion polymorphism of the angiotensis-converting enzyme (ACE) gene has been shown to be associated with levels of ACE. Because ACE is heavily expressed in the lungs and plays a key role in the metabolism of angiotensin II and bradykinin, which are potentially il2volved in the pathogenesis of asthma, we rested the hypothesis of an association between the polymorphism of the ACE gene and asthma. Methods: Seventy-nine patients with asthma, 54 healthy subjects, and 33 patients with nonasthmatic lung disease were studied. Pulmonary function tests were performed in patients with asthma, and the ACE genotypes were determined in all subjects by the polymerase chain reaction. Results: The ACE genotype distribution was similar in healthy subjects and in patients without asthma. By cona ast, the population of patients with asthma was characterized by a higher prevalence of the DD genotype of ACE (odds ratio, 2.09; 95% confidence interval, 1.05 to 4.16; p = 0.023). No difference in pulmonary function test results was detected in asthmatic patients according to the distribution of ACE genotypes. Conclusion: This study reports an association between the DD genotype of ACE and asthma, which is not related to the degree of ail-way obstruction. These results need to be confirmed by a larger case-control study.	HOP BICHAT, INSERM UNIT 408, SERV BIOCHIM A, PARIS, FRANCE; HOP BICHAT, INSERM UNIT 408, SERV PNEUMOL, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)								ABE K, 1967, EXPERIENTIA, V23, P626, DOI 10.1007/BF02144161; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BARNES PJ, 1988, PHARMACOL REV, V40, P49; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CAMBIEN F, 1988, AM J HUM GENET, V43, P774; CAMPBELLBOSWELL M, 1981, EXP MOL PATHOL, V35, P265, DOI 10.1016/0014-4800(81)90066-6; CHRISTIANSEN SC, 1987, J CLIN INVEST, V79, P188, DOI 10.1172/JCI112782; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; ERDOS E. G., 1967, LIFE SCI, V6, P569, DOI 10.1016/0024-3205(67)90090-2; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; EVANS AE, 1994, Q J MED, V87, P211; HARRAP SB, 1993, HYPERTENSION, V21, P455, DOI 10.1161/01.HYP.21.4.455; JOHNSON AR, 1985, AM REV RESPIR DIS, V132, P564; KOHNO M, 1992, HYPERTENSION, V19, P320, DOI 10.1161/01.HYP.19.4.320; LEADON SA, 1982, ANAL BIOCHEM, V120, P282, DOI 10.1016/0003-2697(82)90349-9; MILLAR EA, 1994, THORAX, V49, P492, DOI 10.1136/thx.49.5.492; PAOLETTI P, 1992, EUR RESPIR J, V5, P910; REDLINE S, 1989, CLIN EPIDEMIOLOGY CH, P139; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; TIRET L, 1993, LANCET, V341, P991, DOI 10.1016/0140-6736(93)91075-W	25	53	56	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				53	57		10.1016/S0091-6749(97)70300-2	http://dx.doi.org/10.1016/S0091-6749(97)70300-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003211				2022-12-18	WOS:A1997WD06100008
J	Yamaguchi, M; Hirai, K; Ohta, K; Suzuki, K; Kitani, S; Takaishi, T; Ito, K; Ra, C; Morita, Y				Yamaguchi, M; Hirai, K; Ohta, K; Suzuki, K; Kitani, S; Takaishi, T; Ito, K; Ra, C; Morita, Y			Nonreleasing basophils convert to releasing basophils by culturing with IL-3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; anti-IgE; releasability; Fc epsilon RI; DNA sequence; IL-3; histamine release	HEMATOPOIETIC GROWTH-FACTORS; AFFINITY IGE RECEPTOR; PROTEIN-KINASE-C; HISTAMINE-RELEASE; SIGNAL TRANSDUCTION; DIFFERENTIATION FACTOR; TYROSINE KINASE; RELEASABILITY; GENE; IDENTIFICATION	The extent of basophil histamine release initiated by IgE cross-linking stimuli has been known to vary greatly among donors. Studies on anti-IgE nonreleasing basophils are useful in understanding the IgE-specific control mechanism of mediator release. We attempted to determine (1) whether a mutation of Fc epsilon RI is present in nonreleasing basophils and (2) whether treatment with IL-3 converts anti-IgE nonreleasing basophils to releasing basophils. Basophils were purified from normal human blood and donors were divided into releasers (maximal histamine release >5%) and nonreleasers (<5%). The mutation of Fc epsilon RI alpha, beta, and gamma was evaluated by reverse transcriptase-polymerase chain reaction, and the DNA sequence was determined from amplified polymerase chain reaction products. Although antibodies against Fc epsilon RI failed to cause histamine release in anti-IgE nonreleasing basophils, no primary structural change of Fc epsilon RI was observed in nonreleaser basophils. After culturing with IL-3 for 7 days, nonreleasing basophils released histamine in response to anti-IgE, and dose-response curves of anti-IgE were equal in both releasers and nonreleasers. The conversion of nonreleasing basophils to releasing basophils was evident after 3 days of culture with IL-3. These findings indicate that nonreleasing basophils have recover able defect(s) in the signal transduction pathway after IgE cross-linking.	UNIV TOKYO,SCH MED,DEPT MED & PHYS THERAPY,BUNKYO KU,TOKYO 113,JAPAN; TEIKYO UNIV,SCH MED,DEPT MED 2,TOKYO 173,JAPAN; JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,TOKYO 113,JAPAN	University of Tokyo; Teikyo University; Juntendo University			Kitani, Seiichi/O-1848-2014					BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; CONROY MC, 1977, J IMMUNOL, V118, P1317; EISEMAN E, 1992, NATURE, V355, P78; HIRAI K, 1988, J IMMUNOL, V141, P3958; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; HIRAI K, 1993, J IMMUNOL, V150, P1503; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; KNOL EF, 1992, J ALLERGY CLIN IMMUN, V90, P92, DOI 10.1016/S0091-6749(06)80015-1; KOCHAN J, 1988, NUCLEIC ACIDS RES, V16, P3584, DOI 10.1093/nar/16.8.3584; KRIEGER M, 1992, EUR J IMMUNOL, V22, P2907, DOI 10.1002/eji.1830221123; KUROMITSU S, 1992, P JPN SOC IMMUNOL, V22, P541; KUSTER H, 1990, J BIOL CHEM, V265, P6448; KUSTER H, 1992, J BIOL CHEM, V267, P12782; LICHTENSTEIN LM, 1986, J ALLERGY CLIN IMMUN, V77, P291, DOI 10.1016/S0091-6749(86)80106-3; MACGLASHAN D, 1991, J LEUKOCYTE BIOL, V49, P29, DOI 10.1002/jlb.49.1.29; MACGLASHAN DW, 1993, J IMMUNOL, V151, P6358; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MAEYAMA K, 1988, J IMMUNOL, V140, P3919; MARONE G, 1986, J ALLERGY CLIN IMMUN, V78, P974, DOI 10.1016/0091-6749(86)90288-5; MAYER P, 1989, BLOOD, V74, P613; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NGUYEN KL, 1990, J ALLERGY CLIN IMMUN, V85, P1020, DOI 10.1016/0091-6749(90)90046-7; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SIRAGANIAN RP, 1981, CELLULAR FUNCTIONS I, P323; VALENT P, 1989, BLOOD, V73, P1763; WARNER JA, 1990, J IMMUNOL, V145, P1897; YAMAGUCHI M, 1992, INT ARCH ALLERGY IMM, V97, P322, DOI 10.1159/000236140; YAMAGUCHI M, 1992, CLIN EXP ALLERGY, V22, P379, DOI 10.1111/j.1365-2222.1992.tb03099.x; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0	33	53	56	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1279	1287		10.1016/S0091-6749(96)70196-3	http://dx.doi.org/10.1016/S0091-6749(96)70196-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648024				2022-12-18	WOS:A1996VD60700016
J	Piacentini, GL; Martinati, L; Mingoni, S; Boner, AL				Piacentini, GL; Martinati, L; Mingoni, S; Boner, AL			Influence of allergen avoidance on the eosinophil phase of airway inflammation in children with allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; antigen avoidance; bronchial hyperreactivity; sputum; eosinophil; inflammation; altitude	BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE; INDUCED SPUTUM; MILD ASTHMA; MAST-CELLS; RESPONSIVENESS; ACTIVATION; CHALLENGE; HISTAMINE; DISEASE	Background: Exposure to relevant alla gens causes an increase in bronchial hyperresponsiveness, as well as an inflammatory reaction at the site of the bronchial mucosa in patients with asthma. Objective: The purpose of this study was to determine whether antigen avoidance can evert an antiinflammatory effect on the eosinophil phase of airway inflammation in children with asthma. Methods: The level of bronchial hyperreactivity and the percentage of eosinophils in sputum samples obtained by inhalation of hypertonic saline solution, were evaluated in a group of asthmatic children allergic to house dust mite before and after a period of antigen avoidance in art Alpine environment (1756 m). Results: At the end of the avoidance period PC20 increased from a median value (lower and upper quartile: Q1, Q3) of 1.17 (0.74, 4.75) to 3.5 (1.18, 8.87) mg/ml (p = 0.02), and eosinophil percentage in the sputum decreased from a median value (Q1, Q3) of 14.02 (3.34, 25.24) to 2.05 (0, 7.4) (p < 0.01). Conclusion: A 3-month period of antigen avoidance can significantly reduce the eosinophil phase of airway inflammation, along with bronchial hyperresponsiveness, in patients with asthma.	UNIV VERONA, PEDIAT CLIN, I-37100 VERONA, ITALY; IST PIO XII, MISURINA, ITALY	University of Verona								AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; ACKERMAN SJ, 1980, J IMMUNOL, V125, P2118; AYARS GH, 1985, J ALLERGY CLIN IMMUN, V76, P595, DOI 10.1016/0091-6749(85)90781-X; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BONER AL, 1985, ANN ALLERGY, V54, P42; BONER AL, 1993, CLIN EXP ALLERGY, V23, P1021, DOI 10.1111/j.1365-2222.1993.tb00294.x; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P649, DOI 10.1016/0091-6749(91)90159-L; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; CARLSON M, 1992, J ALLERGY CLIN IMMUN, V89, P131, DOI 10.1016/S0091-6749(05)80050-8; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAPMAN MD, 1993, ALLERGY, V48, P301, DOI 10.1111/j.1398-9995.1993.tb02395.x; COCKCROFT DW, 1983, LANCET, V2, P253; Dahl R, 1988, ASTHMA BASIC MECHANI, P115; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; FERGUSON AC, 1992, J ALLERGY CLIN IMMUN, V90, P609, DOI 10.1016/0091-6749(92)90133-M; GIBSON PG, 1989, THORAX, V44, P693, DOI 10.1136/thx.44.9.693; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GRIFFIN E, 1991, J ALLERGY CLIN IMMUN, V87, P548, DOI 10.1016/0091-6749(91)90014-F; HANSEL TT, 1992, CLIN EXP ALLERGY, V22, P345, DOI 10.1111/j.1365-2222.1992.tb03096.x; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; LEE TH, 1989, RESP MED, V83, P453, DOI 10.1016/S0954-6111(89)80124-6; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; PERONI DG, 1994, AM J RESP CRIT CARE, V149, P1442, DOI 10.1164/ajrccm.149.6.8004296; PIACENTINI GL, 1993, J ALLERGY CLIN IMMUN, V92, P644, DOI 10.1016/0091-6749(93)90006-2; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1995, ADV ALLERGOLOGY CLIN, P367; REES DG, 1989, ESSENTIAL STAT, P34; ROSENTHAL RR, 1979, J ALLERGY CLIN IMMUN, V64, P564, DOI 10.1016/0091-6749(79)90013-7; VENGE P, 1985, INFLAMMATION, P85; VIEIRA VG, 1979, J CLIN PATHOL, V32, P1054, DOI 10.1136/jcp.32.10.1054; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WARNER JA, 1993, EUR RESPIR J, V6, pS538	36	53	54	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1079	1084		10.1016/S0091-6749(96)70261-0	http://dx.doi.org/10.1016/S0091-6749(96)70261-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626985				2022-12-18	WOS:A1996UL26100008
J	Bhagat, R; Swystun, VA; Cockcroft, DW				Bhagat, R; Swystun, VA; Cockcroft, DW			Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: Dose response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beta(2)-agonist tolerance; allergen inhalation test; methacholine inhalation test	BRONCHIAL RESPONSIVENESS; INHALED SALBUTAMOL; BETA-AGONISTS; ASTHMA; HISTAMINE; TERBUTALINE	Background: Two adverse effects of inhaled beta(2)-agonists are increased airway responsiveness to allergen and tolerance to the bronchoprotective effect of beta(2)-agonists versus bronchoconstrictors (e.g., methacholine). Objective: We studied three doses of inhaled salbutamol, 200, 400, and 800 mu g/day, to determine dose-response curves for these two adverse effects. Methods: Ten atopic patients with mild, stable asthma free of all asthma medications, allergen exposure, and respiratory tract infection for at least 4 weeks participated in a double-blind random-order, crossover study. There were four 1-week treatment periods with a 1-week washout period: placebo, salbutamol 200 mu g 400 mu g and 800 mu g per day. After each treatment, we assessed FEV(1), bronchodilation 10 minutes after administration of 200 mu g of salbutamol, methacholine PC20, methacholine dose-shift after administration of 200 mu g of salbutamol, and allergen PC20. Results: There was no significant different in baseline FEV(1), bronchodilation, or methacholine PC20. The methacholine nose shift was maximum after the placebo (3.4 +/- 0.22 doubling doses) and was significantly greater (p < 0.01) than all salbutamol regimens (2.2 to 2.6), which were not significantly different from each other (p > 0.05). Allergen PC20 was significantly lower (p < 002) after salbutamol 800 mu g/day (geometric mean = 288 protein nitrogen units [PNU]/ml) than each of the other treatments (447 to 550 PNU/ml), which were not significantly different from each other (p > 0.05). Conclusion: Significant increase in ail-way responsiveness to allergen occurred only with the largest dose of inhaled salbutamol (800 mu g/d); however, tolerance to the acute bronchoprotective effect of salbutamol was observed with all the three salbutamol regimens, even 200 mu g/day. This suggests different mechanisms may be operative in producing these two effects.	ROYAL UNIV HOSP,DEPT MED,DIV RESP MED,SASKATOON,SK S7N 0W8,CANADA	University of Saskatchewan								CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; COCKCROFT DW, 1995, J ALLERGY CLIN IMMUN, V96, P44, DOI 10.1016/S0091-6749(95)70031-5; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1995, IN PRESS AM J RESPIR; Davies R. J., 1993, Thorax, V48, P1060; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; Gauvreau GM, 1995, AM J RESP CRIT CARE, V151, pA39; GIBSON GJ, 1978, BRIT J DIS CHEST, V72, P199, DOI 10.1016/0007-0971(78)90042-6; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; VATHENEN AS, 1988, LANCET, V1, P554	21	53	53	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	1				47	52		10.1016/S0091-6749(96)70282-8	http://dx.doi.org/10.1016/S0091-6749(96)70282-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TR947	8568137				2022-12-18	WOS:A1996TR94700007
J	LEIFERMAN, KM				LEIFERMAN, KM			EOSINOPHILS IN ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EPIDERMAL LANGERHANS CELLS; MAJOR BASIC-PROTEIN; LATE-PHASE REACTION; FC-EPSILON-RI; IMMUNOGLOBULIN-E; CATIONIC PROTEIN; CLINICAL ACTIVITY; PERIPHERAL-BLOOD; INTERFERON-GAMMA; GRANULE PROTEINS				LEIFERMAN, KM (corresponding author), MAYO CLIN & MAYO FDN,DEPT DERMATOL,200 1ST ST SW,ROCHESTER,MN 55905, USA.				NIAID NIH HHS [AI 15231, AI 34577] Funding Source: Medline; NIAMS NIH HHS [AR 36008] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034577, R01AI015231, R37AI015231, U19AI034577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R23AR036008, R01AR036008] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BRUIJNZEEL PLB, 1993, CLIN EXP ALLERGY, V23, P97, DOI 10.1111/j.1365-2222.1993.tb00304.x; BRUIJNZEEL PLB, 1993, J INVEST DERMATOL, V100, P137, DOI 10.1111/1523-1747.ep12462781; BRUIJNZEELKOOMEN C, 1992, J ALLERGY CLIN IMMUN, V89, P52, DOI 10.1016/S0091-6749(05)80040-5; BURKE JF, 1979, DERMATOLOGY GENERAL, P932; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CHENG J, 1993, J INVEST DERMATOL, V100, P545; CLARK RAF, 1989, CLIN IMMUNOL IMMUNOP, V53, pS132, DOI 10.1016/0090-1229(89)90078-0; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; CZECH W, 1992, BRIT J DERMATOL, V126, P351, DOI 10.1111/j.1365-2133.1992.tb00677.x; DAHL M V, 1990, Journal of Dermatological Science, V1, P311, DOI 10.1016/0923-1811(90)90587-4; DIEPGEN TL, 1992, ACTA DERM VENER S176, V13, P13; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FOKKENS WJ, 1990, CLIN EXP ALLERGY, V20, P627, DOI 10.1111/j.1365-2222.1990.tb02701.x; FORSTEN Y, 1991, INT J DERMATOL, V30, P563; FUJISAWA T, 1990, J IMMUNOL, V144, P642; FULLER RW, 1986, CLIN EXP IMMUNOL, V65, P416; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GLEICH GJ, 1992, INFLAMMATION BASIC P, P663; GUNDEL RH, 1990, J APPL PHYSIOL, V68, P779, DOI 10.1152/jappl.1990.68.2.779; HANIFIN JM, 1991, J AM ACAD DERMATOL, V24, P1097, DOI 10.1016/0190-9622(91)70165-X; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; JUHLIN L, 1991, ACTA DERM-VENEREOL, V71, P495; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; KAGI MK, 1992, DERMATOLOGY, V185, P88, DOI 10.1159/000247419; KAPP A, 1991, BRIT J DERMATOL, V125, P108, DOI 10.1111/j.1365-2133.1991.tb06056.x; KAPP A, 1993, ALLERGY, V48, P1, DOI 10.1111/j.1398-9995.1993.tb02167.x; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KRAFCHIK BR, 1983, PEDIATR CLIN N AM, V30, P669; KRUTMANN J, 1992, J AM ACAD DERMATOL, V26, P225, DOI 10.1016/0190-9622(92)70031-A; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; LEIFERMAN KM, 1990, LAB INVEST, V62, P579; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LEUNG DYM, 1992, SPRINGER SEMIN IMMUN, V13, P427; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEVER R, 1987, J INVEST DERMATOL, V89, P4, DOI 10.1111/1523-1747.ep12579727; MAEDA K, 1992, Journal of Dermatological Science, V3, P151, DOI 10.1016/0923-1811(92)90029-B; MITCHELL EB, 1982, LANCET, V1, P127; MIYASATO M, 1988, J INVEST DERMATOL, V90, P589; MORITA E, 1989, Journal of Dermatology (Tokyo), V16, P348; MOSER R, 1992, J IMMUNOL, V149, P1432; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; OTT NL, 1994, J ALLERGY CLIN IMMUN, V94, P120, DOI 10.1016/0091-6749(94)90078-7; OYAMA K, 1993, DERMATOLOGY, V187, P182, DOI 10.1159/000247239; PAGANELLI R, 1991, INT ARCH ALLER A IMM, V96, P175, DOI 10.1159/000235490; QUINTI I, 1986, J ALLERGY CLIN IMMUN, V77, P586, DOI 10.1016/0091-6749(86)90350-7; RAJKA G, 1975, MAJOR PROBL DERMATOL, V3, P42; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; ROUZER CA, 1982, J EXP MED, V156, P1077, DOI 10.1084/jem.156.4.1077; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; SAMPSON HA, 1987, HOSP PRAC, V15, P111; SAMPSON HA, 1992, ACTA DERM-VENEREOL S, V176, P34; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SILBERSTEIN DS, 1989, HEMATOL ONCOL CLIN N, V3, P511, DOI 10.1016/S0889-8588(18)30545-8; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; STONE SP, 1973, ARCH DERMATOL, V108, P806, DOI 10.1001/archderm.108.6.806; TSUDA S, 1992, J DERMATOL, V91, P208; TUFT L, 1950, J ALLERGY, V21, P181, DOI 10.1016/0021-8707(50)90125-0; TUFT L, 1952, J ALLERGY, V23, P528, DOI 10.1016/0021-8707(52)90040-3; UEHARA M, 1990, CLIN EXP DERMATOL, V15, P264, DOI 10.1111/j.1365-2230.1990.tb02086.x; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; VERCELLI D, 1990, J IMMUNOL, V144, P570; WALKER C, 1993, CLIN EXP ALLERGY, V23, P145, DOI 10.1111/j.1365-2222.1993.tb00310.x; Walker IC, 1918, J AMER MED ASSOC, V70, P897; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; WUTHRICH B, 1992, ARCH DERMATOL RES, V284, P339, DOI 10.1007/BF00372036; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; [No title captured]	71	53	56	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1310	1317		10.1016/0091-6749(94)90347-6	http://dx.doi.org/10.1016/0091-6749(94)90347-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798571	Bronze			2022-12-18	WOS:A1994QA02000027
J	ORFAN, NA; REED, R; DYKEWICZ, MS; GANZ, M; KOLSKI, GB				ORFAN, NA; REED, R; DYKEWICZ, MS; GANZ, M; KOLSKI, GB			OCCUPATIONAL ASTHMA IN A LATEX DOLL MANUFACTURING PLANT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						OCCUPATIONAL ASTHMA; AIRBORNE LATEX; DOLL MANUFACTURING; SANDING DUST	GLOVES; ANTIGENS	Background: Occupational asthma caused by later has been reported in health care workers and workers in glove manufacturing plants. Objective: We report occupational asthma from later in a newly identified occupational setting, a latex doll manufacturing plant. Methods: We evaluated an index case of asthma associated with work in a Inter doll manufacturing plant by performing a workplace challenge and evaluating the work environment. We then performed an occupational survey and skin testing of 22 workers in the doll manufacturing plant. Results: The patient, a 21-year-old woman, had severe immediate bronchospasm within minutes of beginning a workplace challenge where sanding of latex parts was performed. Two of 22 workers surveyed (including the patient) reported flushing, rhinoconjunctivitis, and wheering on exposure to sanded doll parts. These two workers were the only subjects surveyed to have a history of atopy and positive immediate-type skin test responses to a raw later extract and to common aeroallergens. Conclusions: Sanding or grinding of solid later during the manufacturing process may result in a significant incidence of occupational asthma and rhinoconjunctivitis from later sensitization. Atopic workers appear to be most susceptible to developing latex sensitivity in this setting.	ST LOUIS UNIV,SCH MED,DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,ST LOUIS,MO; RACINE MED CLIN,DEPT ALLERGY IMMUNOL,RACINE,WI; CROZER CHESTER MED CTR,DEPT PEDIAT,UPLAND,PA	Saint Louis University	ORFAN, NA (corresponding author), MARY IMOGENE BASSETT HOSP,RES INST,DIV ALLERGY & IMMUNOL,1 ATWELL RD,COOPERSTOWN,NY 13326, USA.							BAUR X, 1990, LANCET, V335, P912, DOI 10.1016/0140-6736(90)90508-3; BEEZHOLD D, 1992, ARCH SURG-CHICAGO, V127, P1354; Hamann CP, 1993, AM J CONTACT DERMATI, V4, P4, DOI DOI 10.1097/01634989-199303000-00003; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; MARCOS C, 1991, ANN ALLERGY, V67, P319; SLATER JE, 1992, ANN ALLERGY, V68, P203; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x	9	53	56	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1994	94	5					826	830		10.1016/0091-6749(94)90149-X	http://dx.doi.org/10.1016/0091-6749(94)90149-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PR240	7963151				2022-12-18	WOS:A1994PR24000006
J	SCHWEITZER, PK; MUEHLBACH, MJ; WALSH, JK				SCHWEITZER, PK; MUEHLBACH, MJ; WALSH, JK			SLEEPINESS AND PERFORMANCE DURING 3-DAY ADMINISTRATION OF CETIRIZINE OR DIPHENHYDRAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SLEEPINESS; PERFORMANCE; CETIRIZINE DIPHENHYDRAMINE	PSYCHOMOTOR PERFORMANCE; MENTAL PERFORMANCE; ANTIHISTAMINES; TERFENADINE; HYDROXYZINE; HISTAMINE; TOLERANCE; SINGLE	Objective: The sedative effects of cetirizine (10 mg once daily), diphenhydramine (50 mg three times daily), and placebo each administered during a 3-day period, were compared with objective measures of sleepiness and performance. Methods: Twelve atopic subjects received each of the three treatments for 3 consecutive days in a double-blind Latin square design. Subjects received either cetirizine at 8:00 AM and placebo at 3:00 PM and 10:00 PM; diphenhydramine at 8:00 AM, 3:00 PM, and 10:00 PM; or placebo at all three times. Sleepiness was measured on days 1 and 3 with the multiple sleep latency test at 9:00 AM, 11:00 AM, 1:00 pns 3:00 PM and 5:00 PM. performance was assessed with a 60-minute simulated assembly line task at 9:30 AM, 11:30 AM, 1:30 PM, and 3:30 PM. Nightly sleep duration was estimated with actigraphy. Results: Compared with placebo and cetirizine diphenhydramine produced marked impairment only on the first day of drug administration, The multiple sleep latency test and the simulated assembly line task values remained stable across days with cetirizine and placebo but improved with diphenhydramine, resulting in no differences among the three conditions on the third day. Conclusion: Unlike cetirizine, diphenhydramine produced acute impairment of alertness and performance. By the third day of administration, however this impairment was no longer present, apparently because of development of tolerance to the sedative effects.			SCHWEITZER, PK (corresponding author), ST LUKES HOSP,SLEEP MED & RES CTR,232 S WOODS MILL RD,CHESTERFIELD,MO 63017, USA.							BYE CE, 1977, EUR J CLIN PHARMACOL, V12, P181, DOI 10.1007/BF00609857; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; COHEN AF, 1984, EUR J CLIN PHARMACOL, V27, P477, DOI 10.1007/BF00549598; DOMS M, 1988, EUR J CLIN PHARMACOL, V34, P619, DOI 10.1007/BF00615227; GARRISON JC, 1990, GOODMAN GILMANS PHAR, P584; GENGO F, 1989, CLIN PHARMACOL THER, V45, P15, DOI 10.1038/clpt.1989.3; GENGO FM, 1987, CLIN PHARMACOL THER, V42, P265, DOI 10.1038/clpt.1987.145; GENGO FM, 1990, ANN ALLERGY, V64, P520; GENGO FM, 1987, ANN ALLERGY, V59, P53; GENGO FM, 1990, J ALLERGY CLIN IMMUN, V186, P1034; MANNING C, 1992, J CLIN PHARMACOL, V32, P996, DOI 10.1002/j.1552-4604.1992.tb03801.x; Muehlbach MJ, 1993, SLEEP RES, V22, P412; MULLER FO, 1988, EUR J CLIN PHARMACOL, V35, P319, DOI 10.1007/BF00558272; NICHOLSON AN, 1979, BRIT J CLIN PHARMACO, V8, P321, DOI 10.1111/j.1365-2125.1979.tb04712.x; NICHOLSON AN, 1986, EUR J CLIN PHARMACOL, V30, P27, DOI 10.1007/BF00614191; PECHADRE JC, 1988, EUR J CLIN PHARMACOL, V35, P255, DOI 10.1007/BF00558262; RAMAEKERS JG, 1992, EUR J CLIN PHARMACOL, V42, P363; RIEDEL W J, 1990, Clinical and Experimental Allergy, V20, P97; RIHOUX JP, 1987, ANN ALLERGY, V59, P235; ROEHRS T, 1993, SLEEP, V16, P301, DOI 10.1093/sleep/16.4.301; ROTH T, 1987, J ALLERGY CLIN IMMUN, V80, P94, DOI 10.1016/S0091-6749(87)80197-5; ROTH T, 1989, PRINCIPLES PRACTICE, P12; SCHWEITZER PK, 1992, WORK STRESS, V6, P355, DOI 10.1080/02678379208259966; SEIDEL WF, 1987, ANN ALLERGY, V59, P58; SEPPALA T, 1981, BRIT J CLIN PHARMACO, V12, P179; THESSING VC, 1993, SLEEP RES, V22, P418; WALSH JK, 1992, ANN ALLERGY, V69, P195; WITEK TJ, 1992, J ALLERGY CLIN IMMUN, V90, P953, DOI 10.1016/0091-6749(92)90468-H; 1993, WAKE AM NATIONAL SLE	29	53	66	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					716	724		10.1016/0091-6749(94)90179-1	http://dx.doi.org/10.1016/0091-6749(94)90179-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7930305				2022-12-18	WOS:A1994PM27300010
J	NGUYEN, KL; CORBETT, ML; GARCIA, DP; EBERLY, SM; MASSEY, EN; LE, HT; SHEARER, LT; KARIBO, JM; PENCE, HL				NGUYEN, KL; CORBETT, ML; GARCIA, DP; EBERLY, SM; MASSEY, EN; LE, HT; SHEARER, LT; KARIBO, JM; PENCE, HL			CHRONIC SINUSITIS AMONG PEDIATRIC-PATIENTS WITH CHRONIC RESPIRATORY COMPLAINTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SINUS COMPUTED TOMOGRAPHIC (CT) SCANS; CHRONIC SINUSITIS; RISK FACTORS; PEDIATRIC PATIENTS; ALLERGY SKIN TESTS	PARA-NASAL SINUSES; CHILDREN; DIAGNOSIS; CT; ALLERGY; ABNORMALITIES; INFECTIONS; PREVALENCE; RECURRENT; DISEASE	We examined the prevalence of chronic sinusitis among children who presented to allergy clinics with chronic ( a 3 months) respiratory symptoms. Ninety-one patients, ranging from 2 to 17 years of age with 62% male and 72% white, completed the study. Fifty-nine percent of patients had positive skin test results, and 25.3% had chronic asthma. Paranasal sinuses were examined by coronal sinus computed tomographic scan. Sixty-three percent (58 of 91) had chronic sinusitis, 5.5% (5 of 91) had concha bullosa, 1% (I of 91) had foreign body, and 19% (19 of 91) had deviated nasal septums. Among symptoms of sneezing, nasal congestion, postnasal drip, coughing, wheezing, rhinorrhea, and headache, no single symptom was an acceptable predictor of abnormality on computed tomographic scan examinations. Combining the symptoms of moderate to severe rhinorrhea and cough with minimum sneezing had a specificity of 95% and a sensitivity of 38% in predicting the presence of chronic sinusitis. Allergic rhinitis (p = 0.27), mild deviated nasal septum (p = 0.11), unobstructive concha bullosa (p = 0.13), and passive exposure to cigarette smoke (p = 0. 53) were not risk factors associated with sinus abnormalities. Age (r = 0.30, p = 0. 004) in pediatric patients with chronic respiratory symptoms was the single risk factor significantly associated with abnormalities on sinus computed tomographic scan. Seventy-three percent of children 2 to 6 years of age, 74% of children 6 to 10 years of age, and 38% of children older than 10 had chronic sinusitis. Chronic sinusitis is common among pediatric patients with chronic respiratory symptoms. Because the clinical symptoms are not acceptably sensitive, imaging studies of the sinus such as a Waters' view roentgenogram should be considered as part of an allergy evaluation, especially in a high-risk group of patients from 2 to 10 years of age.	UNIV LOUISVILLE, HLTH SCI CTR, SCH MED, DEPT INTERNAL MED, LOUISVILLE, KY 40202 USA; UNIV LOUISVILLE, HLTH SCI CTR,SCH MED,DEPT PEDIAT, ALLERGY & IMMUNOL SECT, LOUISVILLE, KY 40202 USA	University of Louisville; University of Louisville								BLUESTONE CB, 1985, PEDIATR INFECT DIS J, V6, pS49; CARTER BL, 1988, OTOLARYNG CLIN N AM, V21, P395; CASTELLANOS J, 1989, J ALLERGY CLIN IMMUN, V83, P91, DOI 10.1016/0091-6749(89)90481-8; DIAMENT MJ, 1987, J COMPUT ASSIST TOMO, V11, P426, DOI 10.1097/00004728-198705000-00011; FURUKAWA CT, 1992, J ALLERGY CLIN IMMUN, V89, P332; GLASIER CM, 1986, AM J NEURORADIOL, V7, P861; KERN EB, 1984, J ALLERGY CLIN IMMUN, V73, P25, DOI 10.1016/0091-6749(84)90480-9; LEVINE H, 1978, ARCH OTOLARYNGOL, V104, P585; LEW D, 1983, NEW ENGL J MED, V309, P1149, DOI 10.1056/NEJM198311103091904; LUSK RP, 1989, PEDIATR CLIN N AM, V36, P1411; MAGANIAS NH, 1984, IMMUNOL ALLERGY PRAC, V6, P393; MALLING HJ, 1985, ALLERGY, V40, P354, DOI 10.1111/j.1398-9995.1985.tb00247.x; MCALISTER WH, 1989, AM J ROENTGENOL, V153, P1259, DOI 10.2214/ajr.153.6.1259; MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V82, P900, DOI 10.1016/0091-6749(88)90032-2; NASS RL, 1989, LARYNGOSCOPE, V99, P1158; OROBELLO PW, 1991, ARCH OTOLARYNGOL, V117, P980; OTT NL, 1991, MAYO CLIN PROC, V66, P1238, DOI 10.1016/S0025-6196(12)62475-6; PATTERSON R, 1985, ALLERGIC DISEASES DI, P207; PATTERSON R, 1985, ALLERGIC DISEASES DI, P102; Pepys J., 1975, BR J HOSP MED, V14, P412; RACHELEFSKY GS, 1988, PEDIATR CLIN N AM, V35, P1091; RACHELEFSKY GS, 1989, AM J DIS CHILD, V143, P886, DOI 10.1001/archpedi.1989.02150200030013; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; RICHARDS W, 1991, CLIN PEDIATR, V30, P88, DOI 10.1177/000992289103000205; RICHARDSON M, 1990, Journal of Allergy and Clinical Immunology, V85, P286; RICHARDSON MA, 1988, J ALLERGY CLIN IMMUN, V81, P1032, DOI 10.1016/0091-6749(88)90175-3; SHAPIRO GG, 1988, J ALLERGY CLIN IMMUN, V81, P1025, DOI 10.1016/0091-6749(88)90173-X; SHAPIRO GG, 1992, J ALLERGY CLIN IMMUN, V90, P417, DOI 10.1016/0091-6749(92)90160-4; SHAPIRO GG, 1985, PEDIATR INFECT DIS J, V4, pS55, DOI 10.1097/00006454-198511001-00003; SLAVIN RG, 1984, J ALLERGY CLIN IMMUN, V73, P712, DOI 10.1016/0091-6749(84)90312-9; Swischuk L. E., 1982, RADIOGRAPHICS, V2, P241; TINKELMAN DG, 1989, AM J DIS CHILD, V143, P938, DOI 10.1001/archpedi.1989.02150200098025; Towbin R, 1982, RADIOGRAPHICS, V2, P253; van der Veken P J, 1990, Rhinology, V28, P177; WALD ER, 1991, PEDIATRICS, V87, P129; WALD ER, 1988, PEDIATR INFECT DIS J, V7, pS150, DOI 10.1097/00006454-198811001-00006; ZIMMERMAN B, 1987, J ALLERGY CLIN IMMUN, V80, P268, DOI 10.1016/0091-6749(87)90029-7; ZINREICH SJ, 1987, RADIOLOGY, V163, P769, DOI 10.1148/radiology.163.3.3575731	38	53	53	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1993	92	6					824	830		10.1016/0091-6749(93)90059-O	http://dx.doi.org/10.1016/0091-6749(93)90059-O			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML893	8258616	Bronze			2022-12-18	WOS:A1993ML89300007
J	KALINER, MA				KALINER, MA			HUMAN NASAL HOST DEFENSE AND SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		HOST DEFENSE; SECRETORY IGA; MUCOUS MEMBRANES; SINUSITIS	PATHO-PHYSIOLOGY; RHINITIS; SECRETIONS; MUCOSA; BRADYKININ; PROTEIN; PEPTIDE	Sinusitis is an exceptionally common disorder that affects an estimated 35 million Americans per year. The development of sinusitis requires both the presence of a virulent pathogen and the failure of the local immune system to prevent or effectively combat the infection. Identification of the components of the immune defense system of the upper respiratory tract and the possible areas of dysfunction that predispose to sinusitis may be important steps in the eventual prevention of this common disease. The nasal and sinus passages are lined by respiratory mucous membranes. Recent studies have identified some of the constituents found in mucus and their roles in human health and disease. However, the local immune system of the respiratory mucosa is largely unknown, and its role in sinusitis is conjectural. Nasal secretions include many proteins that serve important functions in local mucosal host defense. Most of these host-defense molecules are synthesized and secreted by serous cells in the submucous glands, and it appears that the serous cell is the resident antimicrobial cell in mucous membranes. Currently data suggest that serous cell secretion is abnormal in patients with recurrent sinusitis and that effective treatment leads to correction of the secretory abnormality along with improvement in sinusitis.			KALINER, MA (corresponding author), NIAID,ALLERG DIS SECT,BLDG 10,ROOM 11C205,BETHESDA,MD 20892, USA.							BARANIUK JN, 1990, J CLIN INVEST, V85, P998, DOI 10.1172/JCI114577; BARANIUK JN, 1991, AM J RESP CELL MOL, V4, P228, DOI 10.1165/ajrcmb/4.3.228; BARANIUK JN, 1990, J CLIN INVEST, V86, P825, DOI 10.1172/JCI114780; BARANIUK JN, 1990, IMMUNOL ALLERGY CLIN, V10, P383; BARANIUK JN, 1990, AM REV RESPIR DIS, V141, P706, DOI 10.1164/ajrccm/141.3.706; BARANIUK JN, 1990, J APPL PHYSIOL, V258, P81; Fleming A, 1922, P R SOC LOND B-CONTA, V93, P306, DOI 10.1098/rspb.1922.0023; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HOLMBERG K, 1990, EUR J PHARMACOL, V175, P35, DOI 10.1016/0014-2999(90)90149-Z; IGARASHI Y, 1991, American Review of Respiratory Disease, V143, pA757; IGARASHI Y, 1992, J ALLERGY CLIN IMMUN, V89, P204; JENEY EVM, 1990, J ALLERGY CLIN IMMUN, V86, P10, DOI 10.1016/S0091-6749(05)80117-4; KALINER M, 1986, AM REV RESPIR DIS, V134, P612; MASSON PL, 1966, CLIN CHIM ACTA, V14, P735, DOI 10.1016/0009-8981(66)90004-0; MEREDITH SD, 1989, J ALLERGY CLIN IMMUN, V84, P920, DOI 10.1016/0091-6749(89)90390-4; MULLOL J, 1992, J APPL PHYSIOL, V89, P684; OHASHI Y, 1983, ACTA OTOLARYNGOL S S, V397, P11; OHKUBO K, 1991, Journal of Allergy and Clinical Immunology, V87, P145, DOI 10.1016/0091-6749(91)91310-P; PATOW CA, 1984, AM J OTOLARYNG, V5, P334, DOI 10.1016/S0196-0709(84)80003-4; PERSSON CGA, 1991, CLIN EXP ALLERGY, V21, P17, DOI 10.1111/j.1365-2222.1991.tb00799.x; PROUD D, 1987, J IMMUNOL, V138, P428; RAPHAEL G, 1989, J ALLERGY CLIN IMMUN, V83, P110, DOI 10.1016/0091-6749(89)90484-3; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V88, P33, DOI 10.1016/0091-6749(91)90298-3; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V87, P457, DOI 10.1016/0091-6749(91)90001-5; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; Raphael GD, 1988, AM J RHINOL, V2, P109	28	53	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			424	430		10.1016/0091-6749(92)90162-U	http://dx.doi.org/10.1016/0091-6749(92)90162-U			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527331				2022-12-18	WOS:A1992JP52100003
J	MELTZER, EO; ORGEL, HA; BRONSKY, EA; FINDLAY, SR; GEORGITIS, JW; GROSSMAN, J; RATNER, P; WOOD, CC				MELTZER, EO; ORGEL, HA; BRONSKY, EA; FINDLAY, SR; GEORGITIS, JW; GROSSMAN, J; RATNER, P; WOOD, CC			IPRATROPIUM BROMIDE AQUEOUS NASAL SPRAY FOR PATIENTS WITH PERENNIAL ALLERGIC RHINITIS - A STUDY OF ITS EFFECT ON THEIR SYMPTOMS, QUALITY-OF-LIFE, AND NASAL CYTOLOGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PERENNIAL ALLERGIC RHINITIS; IPRATROPIUM BROMIDE THERAPY; TOPICAL INTRANASAL AEROSOL; NASAL CYTOLOGY; QUALITY OF LIFE	VASOMOTOR RHINITIS; AEROSOL	Ipratropium bromide is an anticholinergic agent with topical activity that has been studied as a freon-propelled aerosol spray for therapy of nonallergic rhinitis. This is the first report of its use both as an aqueous nasal spray and in perennial allergic rhinitis. In this study 12.3 patients who had symptoms of perennial allergic rhinitis were randomized to receive ipratropium bromide 21-mu-g or 42-mu-g or placebo, one spray per nostril three times a day for 4 weeks. Patients maintained daily diaries of duration and severity of nasal symptoms and were evaluated weekly. Mean duration and severity of rhinorrhea was decreased in both ipratropium bromide treatment groups by comparison with placebo, with consistently greatest improvement in the group treated with ipratropium bromide 42-mu-g per nostril three times a day. No statistically significant differences occurred among treatment groups in duration or severity of postnasal drip, congestion, or sneezing. Seventy percent of patients treated with 42-mu-g of ipratropium bromide thought it had good or excellent effect on rhinorrhea (p < 0.05 vs placebo); significantly more patients thought that it had improved the quality of life (p = 0.02). No changes occurred in nasal cytology, and no significant local or systemic adverse events occurred. These data indicate that ipratropium bromide significantly decreases the rhinorrhea of perennial allergic rhinitis.	ALLERGY & ASTHMA MED GRP & RES CTR,SAN DIEGO,CA; INTERMT ALLERGY & ASTHMA CLIN,SALT LAKE CITY,UT; HEALTHQUEST RES,AUSTIN,TX; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC 27103; UNION UNIV,ALBANY,NY 12208; SYLVANA RES,SAN ANTONIO,TX; BOEHRINGER INGELHEIM,RIDGEFIELD,CT	Wake Forest University; Wake Forest Baptist Medical Center; Union College; Boehringer Ingelheim								Andersen, 1982, NOSE UPPER AIRWAY PH, P45; BORUM P, 1978, Rhinology (Utrecht), V16, P225; DOLOVICH J, 1987, J ALLERGY CLIN IMMUN, V80, P274, DOI 10.1016/0091-6749(87)90031-5; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; KIRKEGAARD J, 1987, J ALLERGY CLIN IMMUN, V79, P585, DOI 10.1016/S0091-6749(87)80153-7; KNIGHT A, 1986, ANN ALLERGY, V57, P348; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; Meltzer EO, 1988, AM J RHINOL, V2, P47, DOI DOI 10.2500/105065888781693212; MYGIND N, 1983, EUR J RESPIR DIS, V64, P167; ORGEL HA, 1986, J ALLERGY CLIN IMMUN, V77, P858, DOI 10.1016/0091-6749(86)90384-2; SANWIKARJA S, 1986, ANN ALLERGY, V56, P162; SMITH JM, 1988, ALLERGY PRINCIPLES P, V2, P891; SPECTOR SL, 1982, CLIN ALLERGY, V12, P187, DOI 10.1111/j.1365-2222.1982.tb01638.x; TOS M, 1976, Rhinology (Utrecht), V14, P155	14	53	53	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					242	249		10.1016/0091-6749(92)90078-G	http://dx.doi.org/10.1016/0091-6749(92)90078-G			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1386857				2022-12-18	WOS:A1992JJ42300015
J	SMITH, HR; LARSEN, GL; CHERNIACK, RM; WENZEL, SE; VOELKEL, NF; WESTCOTT, JY; BETHEL, RA				SMITH, HR; LARSEN, GL; CHERNIACK, RM; WENZEL, SE; VOELKEL, NF; WESTCOTT, JY; BETHEL, RA			INFLAMMATORY CELLS AND EICOSANOID MEDIATORS IN SUBJECTS WITH LATE ASTHMATIC RESPONSES AND INCREASES IN AIRWAY RESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; LATE ASTHMATIC RESPONSE; AIRWAY HYPERRESPONSIVENESS; BRONCHOALVEOLAR LAVAGE; INFLAMMATION; MEDIATORS	BRONCHOALVEOLAR LAVAGE; ALLERGEN CHALLENGE	To determine the relationship of inflammatory cells and eicosanoid mediators to the pathogenesis of the late asthmatic response (LAR) and increases in nonspecific airway responsiveness, we studied bronchoalveolar lavage (BAL) cells and fluid in 27 subjects 12 hours after inhaled antigen challenge. Methacholine challenge was performed before antigen challenge and 24 hours later (12 hours after BAL). Eight subjects had no LAR (-LAR, less-than-or-equal-to 10% fall in FEV1), nine subjects had an equivocal LAR (+/- LAR, 11% 25% fall in FEV1), and 10 subjects had a definite LAR (+LAR, >25% fall in FEV1). Subjects developing +LAR had increased airway responsiveness at baseline compared with that of subjects developing an +/-LAR, but not with subjects having -LAR. If airway responsiveness was markedly increased at baseline, further increases after antigen challenge were often not observed. We found that both percent neutrophils and eosinophils increased in BAL as the severity of the LAR increased, but significant differences between the groups with -LAR and +LAR were only observed when both cell types were considered together. In addition, there was a significant correlation between the combined cell percentages and the severity of the LAR as determined by fall in FEV1. Likewise, increases in airway responsiveness were associated with significant increases in both neutrophil and eosinophil numbers, but only neutrophils correlated with the change in airway responsiveness after antigen challenge. However, despite the significant physiologic and cellular differences that we found between our groups, no significant differences could be found in BAL eicosanoid-mediator concentrations. These data suggest that both neutrophils and eosinophils are important to the development of the LAR and increased airway hyperresponsiveness. Changes in eicosanoid mediators cannot be detected in BAL fluid after inhaled antigen challenge despite significant physiologic and cellular changes.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT CARDIOVASC PULM RES,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,WEBB WARING LUNG INST,DIV PULM SCI,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	SMITH, HR (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED & PEDIAT,1400 JACKSON ST,DENVER,CO 80206, USA.				NHLBI NIH HHS [HL-36577] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNSTEIN L, 1985, AM REV RESPIR DIS, V132, P180; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; DOLOVICH J, 1989, J ALLERGY CLIN IMMUN, V83, P521, DOI 10.1016/0091-6749(89)90032-8; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, pS35, DOI 10.1164/ajrccm/136.4_Pt_2.S35; PARDELLES P, 1985, ANAL CHEM, V57, P1170; PRICE JF, 1982, CLIN EXP IMMUNOL, V47, P587; SMITH HR, 1987, SEMIN RESPIR MED, V8, P287, DOI 10.1055/s-2007-1012667; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WENZEL SE, 1991, J ALLERGY CLIN IMMUN, V87, P540, DOI 10.1016/0091-6749(91)90013-E; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450; WESTCOTT JY, 1990, J APPL PHYSIOL, V68, P2640, DOI 10.1152/jappl.1990.68.6.2640; WESTCOTT JY, 1991, AM REV RESPIR DIS, V143, P1322, DOI 10.1164/ajrccm/143.6.1322	18	53	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1076	1084		10.1016/0091-6749(92)90291-9	http://dx.doi.org/10.1016/0091-6749(92)90291-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1607546	Bronze			2022-12-18	WOS:A1992HZ74800002
J	LIEBERMAN, P				LIEBERMAN, P			THE USE OF ANTIHISTAMINES IN THE PREVENTION AND TREATMENT OF ANAPHYLAXIS AND ANAPHYLACTOID REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	MEETING ON HISTAMINE AND DISEASE : A FORUM ON CURRENT AND FUTURE MANAGEMENT	AUG 25-26, 1989	CARLSBAD, CA	MERRELL DOW PHARM					UNIV TENNESSEE,CTR HLTH SCI,COLL MED,DEPT MED & PEDIAT,DIV ALLERGY & IMMUNOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								GINSBURG R, 1980, LIFE SCI, V26, P2245, DOI 10.1016/0024-3205(80)90209-X; GREENBERGER PA, 1985, ARCH INTERN MED, V145, P2197, DOI 10.1001/archinte.145.12.2197; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; MOSS J, 1983, ANESTHESIOLOGY, V59, P330, DOI 10.1097/00000542-198310000-00011; MOSS J, 1985, ANESTH ANALG, V64, P1197; PHILBIN DM, 1981, ANESTHESIOLOGY, V55, P292, DOI 10.1097/00000542-198109000-00019; RING J, 1989, INT ARCH ALLER A IMM, V78, P9	7	53	57	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	2	S			684	686		10.1016/S0091-6749(05)80241-6	http://dx.doi.org/10.1016/S0091-6749(05)80241-6			3	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH093	1977785				2022-12-18	WOS:A1990EH09300022
J	SHALIT, M; VALONE, FH; ATKINS, PC; RATNOFF, WD; GOETZL, EJ; ZWEIMAN, B				SHALIT, M; VALONE, FH; ATKINS, PC; RATNOFF, WD; GOETZL, EJ; ZWEIMAN, B			LATE APPEARANCE OF PHOSPHOLIPID PLATELET-ACTIVATING FACTOR AND LEUKOTRIENE-B4 IN HUMAN-SKIN AFTER REPEATED ANTIGEN CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,5TH FLOOR JOHNSON PAVILION,PHILADELPHIA,PA 19104; UNIV CALIF SAN FRANCISCO,VET ADM MED CTR,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MED,ALLERGY & IMMUNOL SECT,SAN FRANCISCO,CA 94143	University of Pennsylvania; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco					NIAID NIH HHS [AI 14332, AI 19784, AI 22141] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019784, R01AI014332, R01AI022141] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM I, 1983, THROMB RES, V30, P71, DOI 10.1016/0049-3848(83)90398-5; ARCHER CB, 1984, BRIT J DERMATOL, V110, P45, DOI 10.1111/j.1365-2133.1984.tb07310.x; ATKINS PC, 1987, J IMMUNOL, V139, P2744; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; CAMP RDR, 1982, BRIT J PHARMACOL, V75, P168; CLARK PO, 1980, BIOCHIM BIOPHYS ACTA, V628, P69, DOI 10.1016/0304-4165(80)90352-9; FLEEKOP PD, 1987, J ALLERGY CLIN IMMUN, V50, P140; FORDHUTCHINSON AW, 1985, FED PROC, V44, P25; FRIEDMAN BF, 1986, CLIN RES, V34, pA625; GRANDEL KE, 1985, NEW ENGL J MED, V313, P405, DOI 10.1056/NEJM198508153130702; JACKSON EM, 1984, J LIPID RES, V25, P753; KLICKSTEIN LB, 1980, J CLIN INVEST, V66, P1166, DOI 10.1172/JCI109947; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; LEE TC, 1984, J BIOL CHEM, V259, P5526; LILES WC, 1987, J IMMUNOL, V138, P3396; LYNCH JM, 1986, J IMMUNOL, V137, P2653; PALMER RMJ, 1983, IMMUNOLOGY, V50, P65; RYLANDER R, 1987, AM REV RESPIR DIS, V135, P83; SCHLEIMER RP, 1986, AM REV RESPIR DIS, V133, P614; SCHUL JL, 1984, CLIN RES, V32, pA659; SHALIT M, 1987, J ALLERGY CLIN IMMUN, V80, P87, DOI 10.1016/S0091-6749(87)80196-3; SHAW JO, 1981, J IMMUNOL, V127, P1250; SHEN TY, 1985, P NATL ACAD SCI USA, V82, P672, DOI 10.1073/pnas.82.3.672; SILBERSTEIN D, 1986, J IMMUNOL, V136, P3829; SISSON JH, 1987, J IMMUNOL, V138, P3918; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4; VALONE FH, 1982, J IMMUNOL, V129, P1637; WILLIAMS JD, 1985, J IMMUNOL, V134, P2624; ZIMMERMAN GA, 1987, AM REV RESPIR DIS, V136, P204, DOI 10.1164/ajrccm/136.1.204	30	53	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1989	83	3					691	696		10.1016/0091-6749(89)90084-5	http://dx.doi.org/10.1016/0091-6749(89)90084-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T8596	2538500				2022-12-18	WOS:A1989T859600018
J	CASALE, TB; SAMPSON, HA; HANIFIN, J; KAPLAN, AP; KULCZYCKI, A; LAWRENCE, ID; LEMANSKE, RF; LEVINE, MI; LILLIE, MA				CASALE, TB; SAMPSON, HA; HANIFIN, J; KAPLAN, AP; KULCZYCKI, A; LAWRENCE, ID; LEMANSKE, RF; LEVINE, MI; LILLIE, MA			GUIDE TO PHYSICAL URTICARIAS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CASALE, TB (corresponding author), AMER ACAD ALLERGY & IMMUNOL,EXECUT OFF,611 E WELLS ST,MILWAUKEE,WI 53202, USA.		Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377; Xie, Hui/0000-0002-8312-891X				ATKINS PC, 1981, J ALLERGY CLIN IMMUN, V68, P286, DOI 10.1016/0091-6749(81)90153-6; BREATHNACH SM, 1983, CLIN EXP DERMATOL, V8, P463, DOI 10.1111/j.1365-2230.1983.tb01814.x; CASALE TB, 1986, JAMA-J AM MED ASSOC, V255, P2049, DOI 10.1001/jama.255.15.2049; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; COMMENS CA, 1978, BRIT J DERMATOL, V98, P47, DOI 10.1111/j.1365-2133.1978.tb07332.x; CZARNETZKI BM, 1986, J AM ACAD DERMATOL, V15, P623, DOI 10.1016/S0190-9622(86)70215-6; DAMAN L, 1978, J ALLERGY CLIN IMMUN, V61, P273, DOI 10.1016/0091-6749(78)90203-8; DAVIS KC, 1986, J ALLERGY CLIN IMMUN, V77, P566, DOI 10.1016/0091-6749(86)90346-5; DAVIS RS, 1981, J ALLERGY CLIN IMMUN, V68, P479, DOI 10.1016/0091-6749(81)90202-5; DELORME P, 1969, J ALLERGY, V43, P284, DOI 10.1016/0021-8707(69)90149-X; DOEGLAS HMG, 1974, ARCH DERMATOL, V110, P382, DOI 10.1001/archderm.110.3.382; EBKEN RK, 1968, J ALLERGY, V41, P338, DOI 10.1016/0021-8707(68)90076-2; ESTES SA, 1981, J AM ACAD DERMATOL, V5, P25, DOI 10.1016/S0190-9622(81)70073-2; GOREVIC PD, 1980, INT J DERMATOL, V19, P417, DOI 10.1111/j.1365-4362.1980.tb05893.x; HARBER M, 1981, PHOTOSENSITIVITY DIS, P160; HORIO T, 1984, J AM ACAD DERMATOL, V11, P1094, DOI 10.1016/S0190-9622(84)70265-9; JORIZZO JL, 1982, ARCH DERMATOL, V118, P194, DOI 10.1001/archderm.118.3.194; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P319, DOI 10.1016/0091-6749(81)90158-5; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KAPLAN AP, 1981, NEW ENGL J MED, V18, P1074; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; KOBZA-BLACK A, 1980, British Journal of Dermatology Supplement, V103, P18; KOBZABLACK A, 1979, LANCET, V2, P1979; KOBZABLACK A, 1985, URTICARIAS, P168; LIM HW, 1987, J AM ACAD DERMATOL, V17, P293, DOI 10.1016/S0190-9622(87)80317-1; METZGER WJ, 1976, J ALLERGY CLIN IMMUN, V57, P605, DOI 10.1016/0091-6749(76)90012-9; NOVEY HS, 1983, J ALLERGY CLIN IMMUN, V71, P498, DOI 10.1016/0091-6749(83)90468-2; PATTERSON R, 1972, J ALLERGY CLIN IMMUN, V50, P174, DOI 10.1016/0091-6749(72)90048-6; RAMSAY CA, 1977, ARCH DERMATOL, V113, P1222, DOI 10.1001/archderm.113.9.1222; RYAN TJ, 1968, BRIT J DERMATOL, V80, P485, DOI 10.1111/j.1365-2133.1968.tb12334.x; SAMS WM, 1969, ARCH DERMATOL, V99, P390, DOI 10.1001/archderm.99.4.390; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SIBBALD RG, 1981, BRIT J DERMATOL, V105, P297, DOI 10.1111/j.1365-2133.1981.tb01289.x; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1977, J ALLERGY CLIN IMMUN, V59, P294, DOI 10.1016/0091-6749(77)90050-1; SUSSMAN GL, 1982, J ALLERGY CLIN IMMUN, V70, P337, DOI 10.1016/0091-6749(82)90022-7; TINDALL JP, 1969, ARCH INTERN MED, V124, P129, DOI 10.1001/archinte.124.2.129; TING S, 1983, J ALLERGY CLIN IMMUN, V71, P546, DOI 10.1016/0091-6749(83)90435-9; WENER MH, 1983, ANN INTERN MED, V98, P44, DOI 10.7326/0003-4819-98-1-44; WONG RC, 1984, J AM ACAD DERMATOL, V11, P643, DOI 10.1016/S0190-9622(84)70222-2	41	53	53	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				758	763		10.1016/0091-6749(88)90076-0	http://dx.doi.org/10.1016/0091-6749(88)90076-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	3057040				2022-12-18	WOS:A1988R170800008
J	WAHN, U; SCHWETER, C; LIND, P; LOWENSTEIN, H				WAHN, U; SCHWETER, C; LIND, P; LOWENSTEIN, H			PROSPECTIVE-STUDY ON IMMUNOLOGICAL CHANGES INDUCED BY 2 DIFFERENT DERMATOPHAGOIDES-PTERONYSSINUS EXTRACTS PREPARED FROM WHOLE MITE CULTURE AND MITE BODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COPENHAGEN,PROT LAB,DK-1168 COPENHAGEN K,DENMARK; ALK RES GRP,COPENHAGEN,DENMARK	University of Copenhagen	WAHN, U (corresponding author), UNIV CHILDRENS HOSP BERLIN,HEUBNERWEG 6,D-1000 BERLIN 19,FED REP GER.							AALBERSE RC, 1983, J IMMUNOL, V130, P722; BLAINEY AD, 1984, ALLERGY, V39, P521, DOI 10.1111/j.1398-9995.1984.tb00873.x; CHAPMAN MD, 1980, INT ARCH ALLER A IMM, V61, P431, DOI 10.1159/000232471; COCKCROFT DW, 1983, LANCET, V2, P253; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; DJURUP R, 1985, J ALLERGY CLIN IMMUN, V76, P46, DOI 10.1016/0091-6749(85)90803-6; DJURUP R, 1984, ALLERGY, V39, P433, DOI 10.1111/j.1398-9995.1984.tb01965.x; FINK JN, 1985, J ALLERGY CLIN IMMUN, V76, P402, DOI 10.1016/0091-6749(85)90662-1; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; FORMGREN H, 1985, ANN ALLERGY, V55, P312; FROLUND L, 1987, CLIN ALLERGY, V17, P217, DOI 10.1111/j.1365-2222.1987.tb02006.x; GRANT IWB, 1986, CLIN ALLERGY, V16, P7, DOI 10.1111/j.1365-2222.1986.tb01947.x; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; LEMAO J, 1983, J ALLERGY CLIN IMMUN, V71, P588, DOI 10.1016/0091-6749(83)90441-4; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWENSTEIN H, 1975, SCAND J IMMUNOL   S3, V4, P459; MAASCH HJ, 1984, INT ARCH ALLER A IMM, V73, P314, DOI 10.1159/000233491; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; MOSBECH H, 1985, ALLERGY, V40, P81, DOI 10.1111/j.1398-9995.1985.tb02665.x; MOSBECH H, 1986, CLIN ALLERGY, V16, P11; MURRAY AB, 1985, J ALLERGY CLIN IMMUN, V76, P108, DOI 10.1016/0091-6749(85)90812-7; OSTERBALLE O, 1982, ALLERGY, V37, P379, DOI 10.1111/j.1398-9995.1982.tb02316.x; PATTERSON R, 1985, J ALLERGY CLIN IMMUN, V76, P394, DOI 10.1016/0091-6749(85)90660-8; PAULI G, 1984, J ALLERGY CLIN IMMUN, V74, P524, DOI 10.1016/0091-6749(84)90389-0; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; Polgar G, 1971, PULMONARY FUNCTION T; RIEDEL F, 1986, PEDIATR PULM, V2, P15, DOI 10.1002/ppul.1950020107; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P393; STAFANGER G, 1986, ALLERGY, V41, P110, DOI 10.1111/j.1398-9995.1986.tb00286.x; STUCKEY MS, 1985, J ALLERGY CLIN IMMUN, V76, P373; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; TURNER MW, 1984, CLIN ALLERGY, V14, P221, DOI 10.1111/j.1365-2222.1984.tb02201.x; WAHN U, 1980, J IMMUNOL, V6, P2544; WARNER JO, 1978, LANCET, V2, P912; WIDE L, 1967, LANCET, V2, P1105	40	53	55	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				360	370		10.1016/0091-6749(88)90007-3	http://dx.doi.org/10.1016/0091-6749(88)90007-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3170985				2022-12-18	WOS:A1988Q322900007
J	GREENBERGER, PA; SMITH, LJ; HSU, CCS; ROBERTS, M; LIOTTA, JL				GREENBERGER, PA; SMITH, LJ; HSU, CCS; ROBERTS, M; LIOTTA, JL			ANALYSIS OF BRONCHOALVEOLAR LAVAGE IN ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS - DIVERGENT RESPONSES OF ANTIGEN-SPECIFIC ANTIBODIES AND TOTAL IGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT MED,INFECT DIS SECT,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT MED,PULM MED SECT,CHICAGO,IL 60611	Northwestern University; Northwestern University; Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498; Smith, Lewis J/0000-0002-4728-1562	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00048] Funding Source: Medline; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CALLERAME ML, 1971, J ALLERGY, V47, P187, DOI 10.1016/S0091-6749(71)80464-5; CRIMI E, 1983, ALLERGY, V38, P553, DOI 10.1111/j.1398-9995.1983.tb04139.x; FORMAN SR, 1978, J ALLERGY CLIN IMMUN, V62, P131, DOI 10.1016/0091-6749(78)90096-9; GEHA RS, 1984, J ALLERGY CLIN IMMUN, V74, P109, DOI 10.1016/0091-6749(84)90270-7; GHORY AC, 1980, CLIN EXP IMMUNOL, V40, P581; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P645, DOI 10.1016/0091-6749(84)90223-9; GREENBERGER PA, 1980, J ALLERGY CLIN IMMUN, V66, P327, DOI 10.1016/0091-6749(80)90029-9; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; HSU CCS, 1984, IMMUNOL COMMUN, V13, P403, DOI 10.3109/08820138409033887; HUNNINGHAKE GW, 1979, AM J PATHOL, V97, P149; ISHIZAKA T, 1976, J ALLERGY CLIN IMMUN, V58, P523, DOI 10.1016/0091-6749(76)90196-2; KAUFFMAN HF, 1984, J ALLERGY CLIN IMMUN, V74, P835, DOI 10.1016/0091-6749(84)90187-8; KORSRUD FR, 1980, CLIN EXP IMMUNOL, V39, P361; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; MERRILL WW, 1980, J LAB CLIN MED, V96, P494; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; METZGER WJ, 1984, CHEST, V87, pS16; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; PATTERSON R, 1980, CLIN EXP IMMUNOL, V42, P395; PATTERSON R, 1977, J CLIN INVEST, V59, P217, DOI 10.1172/JCI108631; PATTERSON R, 1977, AM J MED, V63, P257, DOI 10.1016/0002-9343(77)90240-6; POSEY WC, 1978, J ALLERGY CLIN IMMUN, V62, P340, DOI 10.1016/0091-6749(78)90134-3; RANKIN JA, 1984, CHEST, V85, P723, DOI 10.1378/chest.85.6.723; RANKIN JA, 1987, J ALLERGY CLIN IMMUN, V79, P371, DOI 10.1016/0091-6749(87)90158-8; RICKETTI AJ, 1984, J ALLERGY CLIN IMMUN, V74, P68, DOI 10.1016/0091-6749(84)90089-7; RICKETTI AJ, 1983, J ALLERGY CLIN IMMUN, V72, P386, DOI 10.1016/0091-6749(83)90504-3; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; TADA T, 1970, Journal of Immunology, V104, P377; TOMASI TB, 1984, BASIC CLIN IMMUNOL, P187; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917; WANG JLF, 1979, AM REV RESPIR DIS, V120, P87	33	53	55	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					164	170		10.1016/0091-6749(88)90995-5	http://dx.doi.org/10.1016/0091-6749(88)90995-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	3042837				2022-12-18	WOS:A1988P874100005
J	FOX, CC; WOLF, EJ; KAGEYSOBOTKA, A; LICHTENSTEIN, LM				FOX, CC; WOLF, EJ; KAGEYSOBOTKA, A; LICHTENSTEIN, LM			COMPARISON OF HUMAN-LUNG AND INTESTINAL MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI07290, AI00703, AI08270] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008270, K11AI000703, R01AI008270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRETT KE, 1985, J IMMUNOL, V135, P2020; BEFUS AD, 1987, J IMMUNOL, V138, P2604; BEFUS AD, 1984, FED P, V43, P1973; BEFUS D, 1985, INT ARCH ALLER A IMM, V76, P232, DOI 10.1159/000233697; DVORAK AM, 1978, IMMEDIATE HYPERSENSI, P369; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P303, DOI 10.1111/apm.1966.66.3.303; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P313, DOI 10.1111/apm.1966.66.3.313; FOX CC, 1984, J IMMUNOL, V132, P2177; FOX CC, 1985, J IMMUNOL, V135, P483; GILBERT HS, 1975, BLOOD, V46, P279; HOOK WA, 1976, J IMMUNOL, V117, P594; Lichtenstein LM., 1979, MAST CELL ITS ROLE H, P83; MARONE G, 1979, J IMMUNOL, V123, P1669; MIDDLETON E, 1981, J IMMUNOL, V127, P546; PATTERSON R, 1980, J ALLERGY CLIN IMMUN, V65, P278, DOI 10.1016/0091-6749(80)90156-6; PEARCE FL, 1984, J ALLERGY CLIN IMMUN, V73, P819, DOI 10.1016/0091-6749(84)90453-6; PEARCE FL, 1982, J IMMUNOL, V128, P2481; PETERS SP, 1983, BIOL RESPONSE MEDIAT, P83; SCHULMAN ES, 1982, J IMMUNOL, V129, P2662; SCHULMAN ES, 1983, J IMMUNOL, V131, P1936; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; SULLIVAN TJ, 1979, J IMMUNOL, V122, P431; THARP MD, 1983, J IMMUNOL, V130, P1896	25	53	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					89	94		10.1016/0091-6749(88)90225-4	http://dx.doi.org/10.1016/0091-6749(88)90225-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	2448357				2022-12-18	WOS:A1988M027400014
J	BERNSTEIN, DI; SMITH, AB; MOLLER, DR; GALLAGHER, JS; AW, TC; LONDON, M; KOPP, S; CARSON, G				BERNSTEIN, DI; SMITH, AB; MOLLER, DR; GALLAGHER, JS; AW, TC; LONDON, M; KOPP, S; CARSON, G			CLINICAL AND IMMUNOLOGICAL STUDIES AMONG EGG-PROCESSING WORKERS WITH OCCUPATIONAL ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,MED CTR,DEPT ENVIRONM HLTH,DIV IMMUNOL,CINCINNATI,OH 45267; NIOSH,CINCINNATI,OH 45226	University System of Ohio; University of Cincinnati; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	BERNSTEIN, DI (corresponding author), UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,231 BETHESDA AVE,CINCINNATI,OH 45267, USA.				PHS HHS [85-34633] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BLEUMINK E, 1969, INT ARCH ALLER A IMM, V35, P1; EDWARDS JH, 1983, CLIN ALLERGY, V13, P427, DOI 10.1111/j.1365-2222.1983.tb02618.x; HETZEL MR, 1980, THORAX, V35, P732, DOI 10.1136/thx.35.10.732; LANGELAND T, 1983, ALLERGY, V38, P131, DOI 10.1111/j.1398-9995.1983.tb01597.x; LANGELAND T, 1982, ALLERGY, V37, P521, DOI 10.1111/j.1398-9995.1982.tb02335.x; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; Schloss OM, 1912, AM J DIS CHILD, V3, P341; SMITH AB, 1986, 841631657 NAT I OCC; VIRTUE C M, 1970, Federation Proceedings, V29, P576; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WIDE L, 1967, LANCET, V2, P1105	11	53	54	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1987	80	6					791	797		10.1016/S0091-6749(87)80267-1	http://dx.doi.org/10.1016/S0091-6749(87)80267-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5020	3693757				2022-12-18	WOS:A1987L502000004
J	DOLAN, LM; KESARWALA, HH; HOLROYDE, JC; FISCHER, TJ				DOLAN, LM; KESARWALA, HH; HOLROYDE, JC; FISCHER, TJ			SHORT-TERM, HIGH-DOSE, SYSTEMIC STEROIDS IN CHILDREN WITH ASTHMA - THE EFFECT ON THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP MED CTR,DIV ALLERGY & CLIN IMMUNOL,CINCINNATI,OH 45229; UNIV CINCINNATI,DIV EPIDEMIOL & BIOSTAT,CINCINNATI,OH 45221	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	DOLAN, LM (corresponding author), CHILDRENS HOSP MED CTR,DIV ENDOCRINOL,ELLAND & BETHESDA AVE,CINCINNATI,OH 45229, USA.		Khoury, Jane/O-2068-2015		NCRR NIH HHS [RR00123] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000123] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AXELROD L, 1976, MEDICINE, V55, P39, DOI 10.1097/00005792-197601000-00003; CHAMBERLIN P, 1981, PEDIATRICS, V67, P245; COLLINS JV, 1975, Q J MED, V44, P259; FIEL SB, 1983, AM J MED, V75, P259, DOI 10.1016/0002-9343(83)91202-0; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; GOLDSTEIN DE, 1983, PEDIATRICS, V72, P60; GREENWOO.FC, 1966, J CLIN INVEST, V45, P429, DOI 10.1172/JCI105357; KERSHNAR H, 1978, PEDIATRICS, V62, P189; KLAUSTERMEYER WB, 1976, ANN ALLERGY, V37, P80; KLEIN R, 1977, PEDIATRICS, V60, P7; KRIEGER DT, 1972, AM J MED, V52, P25, DOI 10.1016/0002-9343(72)90005-8; LINDHOLM J, 1978, J CLIN ENDOCR METAB, V47, P272, DOI 10.1210/jcem-47-2-272; MCFADDEN ER, 1976, AM J MED, V60, P52, DOI 10.1016/0002-9343(76)90533-7; MORRIS HG, 1974, J ALLERGY CLIN IMMUN, V54, P350, DOI 10.1016/0091-6749(74)90025-6; MORRIS HG, 1971, J PEDIATR-US, V79, P480, DOI 10.1016/S0022-3476(71)80163-4; NELSON JC, 1978, AM J MED SCI, V275, P165, DOI 10.1097/00000441-197803000-00006; PLUMPTON FS, 1969, ANAESTHESIA, V24, P3, DOI 10.1111/j.1365-2044.1969.tb02798.x; RACHELEFSKY GS, 1983, PEDIATRICS, V72, P130; SHERIDAN P, 1975, LANCET, V2, P676; Siri W.E., 1961, TECHNIQUES MEASURING, P223; STRECK WF, 1979, AM J MED, V66, P910, DOI 10.1016/0002-9343(79)90444-3; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; TOOGOOD JH, 1978, J ALLERGY CLIN IMMUN, V61, P355, DOI 10.1016/0091-6749(78)90114-8; VAZ R, 1982, J PEDIATR-US, V100, P660, DOI 10.1016/S0022-3476(82)80781-6; WEBB J, 1981, THORAX, V36, P22, DOI 10.1136/thx.36.1.22; WILLIAMS MH, 1981, ANN INTERN MED, V95, P464, DOI 10.7326/0003-4819-95-4-464; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504; ZORA JA, 1986, J ALLERGY CLIN IMMUN, V77, P9, DOI 10.1016/0091-6749(86)90315-5	28	53	56	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1987	80	1					81	87		10.1016/S0091-6749(87)80195-1	http://dx.doi.org/10.1016/S0091-6749(87)80195-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J2194	3598031				2022-12-18	WOS:A1987J219400013
J	HENDERSON, WR				HENDERSON, WR			LIPID-DERIVED AND OTHER CHEMICAL MEDIATORS OF INFLAMMATION IN THE LUNG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											HENDERSON, WR (corresponding author), UNIV WASHINGTON, SCH MED, DEPT MED, DIV ALLERGY & INFECT DIS, RM-16, SEATTLE, WA 98195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL030542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017758, R01AI023713] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30542] Funding Source: Medline; NIAID NIH HHS [AI23713, AI17758] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; ALBERT RK, 1987, J APPL PHYSIOL, V62, P1; ANDERSON ME, 1982, P NATL ACAD SCI-BIOL, V79, P1088, DOI 10.1073/pnas.79.4.1088; BABIOR BM, 1984, J CLIN INVEST, V73, P599, DOI 10.1172/JCI111249; BERENBERG JL, 1973, J CLIN INVEST, V52, P1200, DOI 10.1172/JCI107287; BOKISCH VA, 1970, J CLIN INVEST, V49, P2427, DOI 10.1172/JCI106462; BORGEAT P, 1979, J BIOL CHEM, V254, P2643; CAMP RDR, 1982, PROSTAGLANDINS, V23, P631, DOI 10.1016/S0090-6980(82)80003-8; CAMUSSI G, 1983, J IMMUNOL, V131, P1802; CHILTON FH, 1982, J BIOL CHEM, V257, P5402; CLANCY RM, 1983, P NATL ACAD SCI-BIOL, V80, P7200, DOI 10.1073/pnas.80.23.7200; CLARK RA, 1979, J CLIN INVEST, V64, P913, DOI 10.1172/JCI109557; Corey E J, 1980, Adv Prostaglandin Thromboxane Res, V6, P19; COTRAN RS, 1969, J EXP MED, V129, P1291, DOI 10.1084/jem.129.6.1291; CRADDOCK PR, 1977, NEW ENGL J MED, V296, P769, DOI 10.1056/NEJM197704072961401; CRADDOCK PR, 1977, J CLIN INVEST, V59, P879, DOI 10.1172/JCI108710; CROMWELL O, 1981, LANCET, V2, P164; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DUSTING GJ, 1979, PROG CARDIOVASC DIS, V21, P405, DOI 10.1016/0033-0620(79)90024-0; EDELSON PJ, 1973, J EXP MED, V138, P318, DOI 10.1084/jem.138.1.318; FARRUKH I S, 1985, American Review of Respiratory Disease, V131, pA423; FELS AOS, 1982, P NATL ACAD SCI-BIOL, V79, P7866, DOI 10.1073/pnas.79.24.7866; FERNANDEZ HN, 1978, J IMMUNOL, V120, P109; FERNANDEZ HN, 1978, J BIOL CHEM, V253, P6955; GIMBRONE MA, 1984, J CLIN INVEST, V74, P1552, DOI 10.1172/JCI111570; GOETZL EJ, 1982, BIOCHEM BIOPH RES CO, V106, P270, DOI 10.1016/0006-291X(82)91105-6; GOETZL EJ, 1981, J EXP MED, V153, P482, DOI 10.1084/jem.153.2.482; GOLDMAN DW, 1984, J EXP MED, V159, P1027, DOI 10.1084/jem.159.4.1027; GOLDYNE ME, 1984, J BIOL CHEM, V259, P8815; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3824, DOI 10.1073/pnas.71.10.3824; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HANNA CJ, 1981, NATURE, V290, P343, DOI 10.1038/290343a0; HANSEN HS, 1976, PROSTAGLANDINS, V12, P647, DOI 10.1016/0090-6980(76)90044-7; HANSSON G, 1981, FEBS LETT, V130, P107, DOI 10.1016/0014-5793(81)80676-X; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; HARTUNG HP, 1983, J IMMUNOL, V130, P1345; HELLEWELL PG, 1986, J IMMUNOL, V137, P302; HENDERSON WR, 1982, J IMMUNOL, V128, P2609; HENDERSON WR, 1983, BIOCHEM BIOPH RES CO, V110, P266, DOI 10.1016/0006-291X(83)91290-1; HENDERSON WR, 1981, J EXP MED, V153, P520, DOI 10.1084/jem.153.3.520; HENDERSON WR, 1980, J EXP MED, V152, P265, DOI 10.1084/jem.152.2.265; HENDERSON WR, 1983, J BIOL CHEM, V258, P3522; HENDERSON WR, 1979, J IMMUNOL, V122, P1322; HENDERSON WR, 1978, J CLIN INVEST, V61, P187, DOI 10.1172/JCI108917; HENDERSON WR, 1986, J IMMUNOL, V137, P2695; HENDERSON WR, 1984, IMMUNOLOGY, V51, P679; HENDERSON WR, IN PRESS AM REV RESP; HENDERSON WR, 1985, DRUGS AFFECTING LEUK, P339; HENSON PM, 1970, J EXP MED, V131, P287, DOI 10.1084/jem.131.2.287; HOLTZMAN MJ, 1983, BIOCHEM BIOPH RES CO, V114, P1071, DOI 10.1016/0006-291X(83)90671-X; HUGLI TE, 1975, J BIOL CHEM, V250, P8293; HUNNINGHAKE GW, 1980, J CLIN INVEST, V66, P473, DOI 10.1172/JCI109878; IMAGAWA DK, 1983, P NATL ACAD SCI-BIOL, V80, P6647, DOI 10.1073/pnas.80.21.6647; IMAGAWA DK, 1986, J IMMUNOL, V136, P4637; JOHNSON KJ, 1981, J CLIN INVEST, V67, P983, DOI 10.1172/JCI110149; KAZMIEROWSKI JA, 1977, J CLIN INVEST, V59, P273, DOI 10.1172/JCI108638; Klebanoff S.J., 1982, ADV HOST DEFENSE MEC, P111; KLEBANOFF SJ, 1980, EOSINOPHIL HLTH DISE, P99; KREISLE RA, 1983, J EXP MED, V157, P628, DOI 10.1084/jem.157.2.628; LANDS WEM, 1979, ANNU REV PHYSIOL, V41, P633, DOI 10.1146/annurev.ph.41.030179.003221; LEE CW, 1983, J BIOL CHEM, V258, P5004; LEE TC, 1984, J BIOL CHEM, V259, P5526; LICHEY J, 1984, J APPL PHYSIOL, V57, P1039, DOI 10.1152/jappl.1984.57.4.1039; LIN AH, 1982, J CLIN INVEST, V70, P1058, DOI 10.1172/JCI110693; LISTON TE, 1985, J BIOL CHEM, V260, P3172; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MALIK AB, 1985, FED PROC, V44, P36; MALONE B, 1985, J BIOL CHEM, V260, P1531; MAROM Z, 1984, PROSTAGLANDINS, V28, P79, DOI 10.1016/0090-6980(84)90115-1; MAROM Z, 1984, J EXP MED, V159, P844, DOI 10.1084/jem.159.3.844; MAROM Z, 1985, J EXP MED, V161, P657, DOI 10.1084/jem.161.4.657; MAROM Z, 1985, J CLIN INVEST, V75, P191, DOI 10.1172/JCI111674; MARTIN T R, 1985, American Review of Respiratory Disease, V131, pA37; MARTIN TR, 1984, AM REV RESPIR DIS, V129, P106; MATHESON NR, 1979, BIOCHEM BIOPH RES CO, V88, P402, DOI 10.1016/0006-291X(79)92062-X; MATTHAY MA, 1984, J CLIN IMMUNOL, V4, P479, DOI 10.1007/BF00916578; MCMANUS LM, 1980, J IMMUNOL, V124, P2919; MCMANUS LM, 1981, J CLIN INVEST, V67, P903, DOI 10.1172/JCI110108; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; ODRISCOLL BRC, 1984, CLIN EXP IMMUNOL, V55, P397; PAREDES JM, 1982, J BIOL CHEM, V257, P2738; PARENTE L, 1985, BIOCH ARACHIDONIC AC, P195; PARKER CW, 1980, PROSTAGLANDINS, V20, P863, DOI 10.1016/0090-6980(80)90139-2; PETERS SP, 1984, J IMMUNOL, V132, P1972; PINCKARD RN, 1979, J IMMUNOL, V123, P1847; PLATSHON LF, 1978, J CLIN INVEST, V62, P1113, DOI 10.1172/JCI109230; POWELL WS, 1984, J BIOL CHEM, V259, P3082; RADMARK O, 1984, J BIOL CHEM, V259, P2339; RIBBES G, 1985, FEBS LETT, V191, P195, DOI 10.1016/0014-5793(85)80007-7; ROBINSON DR, 1986, J EXP MED, V163, P1509, DOI 10.1084/jem.163.6.1509; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; ROUZER CA, 1982, J EXP MED, V156, P1077, DOI 10.1084/jem.156.4.1077; SALARI H, 1985, J EXP MED, V162, P1904, DOI 10.1084/jem.162.6.1904; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCHOENE RB, 1986, JAMA-J AM MED ASSOC, V256, P63, DOI 10.1001/jama.256.1.63; SCHULMAN ES, 1982, J APPL PHYSIOL, V53, P589, DOI 10.1152/jappl.1982.53.3.589; SERAFIN WE, 1984, PROSTAGLANDINS, V27, P899, DOI 10.1016/S0090-6980(84)80009-X; SHAK S, 1984, J BIOL CHEM, V259, P181; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; SHELHAMER JH, 1982, CHEST, V81, pS36, DOI 10.1378/chest.81.5_Supplement.36S; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; STEEL L, 1981, J BIOL CHEM, V256, P2692; STEEL LK, 1982, J IMMUNOL, V129, P1233; STENMARK KR, 1983, NEW ENGL J MED, V309, P77, DOI 10.1056/NEJM198307143090204; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; STIMLER NP, 1980, AM J PATHOL, V100, P327; STIMLER NP, 1982, J IMMUNOL, V128, P2247; STIMLER NP, 1981, AM J PATHOL, V105, P64; VANDERHOEK JY, 1984, J BIOL CHEM, V259, P6752; VOELKEL NF, 1982, SCIENCE, V218, P286, DOI 10.1126/science.7123233; VOELKEL NF, 1984, J APPL PHYSIOL, V57, P860, DOI 10.1152/jappl.1984.57.3.860; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0; WHITTLE BJR, 1983, BRIT MED BULL, V39, P232, DOI 10.1093/oxfordjournals.bmb.a071825; WILLIAMS JD, 1984, J IMMUNOL, V132, P3034; WOOD RE, 1976, AM REV RESPIR DIS, V113, P833; ZASLOW MC, 1983, AM REV RESPIR DIS, V128, P434, DOI 10.1164/arrd.1983.128.3.434	122	53	54	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1987	79	4					543	553		10.1016/S0091-6749(87)80146-X	http://dx.doi.org/10.1016/S0091-6749(87)80146-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G9720	3031147				2022-12-18	WOS:A1987G972000001
J	KONNO, A; TERADA, N; OKAMOTO, Y; TOGAWA, K				KONNO, A; TERADA, N; OKAMOTO, Y; TOGAWA, K			THE ROLE OF CHEMICAL MEDIATORS AND MUCOSAL HYPERREACTIVITY IN NASAL HYPERSECRETION IN NASAL ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KONNO, A (corresponding author), AKITA UNIV,SCH MED,DEPT OTORHINOLARYNGOL,1-1-1 HONDO,AKITA 010,JAPAN.							BOREUS LO, 1961, ACTA PHYSIOL SCAND, V52, P309, DOI 10.1111/j.1748-1716.1961.tb02227.x; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; ISHIBE T, 1983, ARCH OTO-RHINO-LARYN, V238, P167, DOI 10.1007/BF00454309; JACKSON RT, 1977, ARCH OTOLARYNGOL, V103, P441; KONNO A, 1979, ARCH OTO-RHINO-LARYN, V225, P67, DOI 10.1007/BF00455877; KONNO A, 1983, EUR J RESPIR DIS, V64, P155; KONNO A, 1981, ARCH OTO-RHINO-LARYN, V232, P253, DOI 10.1007/BF00457450; KONNO A, 1979, ANN OTO RHINOL LARYN, V88, P258, DOI 10.1177/000348947908800219; KONNO A, 1985, OTOLOGICA FUKUOKA, V31, P1263; MCCAFFREY T, 1983, P S NASAL HYPERREACT, P29; MYGIND N, 1982, J ALLERGY CLIN IMMUN, V70, P149, DOI 10.1016/0091-6749(82)90036-7; MYGIND N, 1975, INT ARCH ALLER A IMM, V49, P99, DOI 10.1159/000231383; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OKUDA M, 1974, OTOLOGIA FUKUOKA, V20, P297; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; WIHL JA, 1977, ACTA OTO-LARYNGOL, V84, P281, DOI 10.3109/00016487709123968	18	53	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1987	79	4					620	627		10.1016/S0091-6749(87)80158-6	http://dx.doi.org/10.1016/S0091-6749(87)80158-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G9720	3558999	Bronze			2022-12-18	WOS:A1987G972000011
J	BARNES, PJ				BARNES, PJ			ENDOGENOUS CATECHOLAMINES AND ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											BARNES, PJ (corresponding author), BROMPTON HOSP,INST CARDIOTHORAC,DEPT CLIN PHARMACOL,LONDON SW3 6HP,ENGLAND.			Barnes, Peter/0000-0002-5122-4018				ADAMS GK, 1984, ASTHMA PHYSL IMMUNOP, P101; ARIENS EJ, 1983, BIOCHEM PHARMACOL, V32, P1539, DOI 10.1016/0006-2952(83)90324-6; ASSEM ESK, 1969, INT ARCH ALLER A IMM, V45, P62; BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BARNES PJ, 1981, THORAX, V36, P435, DOI 10.1136/thx.36.6.435; BARNES PJ, 1985, AM J MED, V79, P5, DOI 10.1016/0002-9343(85)90080-4; BARNES PJ, 1982, CLIN SCI, V62, P349, DOI 10.1042/cs0620349; BARNES PJ, 1983, J PHARMACOL EXP THER, V225, P456; BARNES PJ, 1982, CLIN SCI, V62, P661, DOI 10.1042/cs0620661; BARNES PJ, 1983, EUR J RESPIR DIS, V64, P559; BERKIN KE, 1985, Q J EXP PHYSIOL CMS, V70, P203, DOI 10.1113/expphysiol.1985.sp002903; BERKIN KE, 1986, CLIN SCI, V70, P347, DOI 10.1042/cs0700347; BROWN MJ, 1981, CLIN SCI, V61, P585, DOI 10.1042/cs0610585; BUTCHERS PR, 1980, BRIT J PHARMACOL, V71, P663, DOI 10.1111/j.1476-5381.1980.tb10987.x; CANNON W. B., 1931, AMER JOUR PHYSIOL, V98, P447; CARSTAIRS JR, 1984, EUR J PHARMACOL, V103, P189, DOI 10.1016/0014-2999(84)90211-5; CARSTAIRS JR, 1985, AM REV RESPIR DIS, V132, P541; CHRYSSANTHOPOULOS C, 1978, J ALLERGY CLIN IMMUN, V61, P17, DOI 10.1016/0091-6749(78)90468-2; CLARKE B, 1985, CLIN SCI, V69, P35; COLLIER HOJ, 1967, BRIT J PHARM CHEMOTH, V30, P283, DOI 10.1111/j.1476-5381.1967.tb02135.x; CRYER PE, 1980, NEW ENGL J MED, V303, P436; DAVIS C, 1982, J APPL PHYSIOL, V53, P1080, DOI 10.1152/jappl.1982.53.5.1080; DRAZEN JM, 1978, J APPL PHYSIOL, V44, P340, DOI 10.1152/jappl.1978.44.3.340; FITZGERALD GA, 1980, EUR J CLIN INVEST, V10, P401, DOI 10.1111/j.1365-2362.1980.tb00052.x; GOLDIE RG, 1984, BRIT J PHARMACOL, V81, P611, DOI 10.1111/j.1476-5381.1984.tb16125.x; GRIECO MH, 1971, J ALLERGY CLIN IMMUN, V48, P143, DOI 10.1016/0091-6749(71)90009-1; HARTLEY JPR, 1981, THORAX, V36, P823, DOI 10.1136/thx.36.11.823; IND PW, 1985, THORAX, V40, P903, DOI 10.1136/thx.40.12.903; IND PW, 1983, THORAX, V38, P702; IND PW, 1985, BRIT MED J, V290, P267, DOI 10.1136/bmj.290.6464.267; IND PW, 1984, ANN REV RESP DIS SA, V129, P10; IND PW, 1983, BR J CLIN PHARM, V15, P145; IND PW, 1983, CLIN SCI, V64, P9; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; LARSSON K, 1985, J ALLERGY CLIN IMMUN, V75, P586, DOI 10.1016/0091-6749(85)90034-X; LARSSON K, 1982, CHEST, V82, P561; LEFF AR, 1982, J APPL PHYSIOL, V53, P21, DOI 10.1152/jappl.1982.53.1.21; MACLAGAN J, 1979, BRIT J PHARMACOL, V66, P409, DOI 10.1111/j.1476-5381.1979.tb10846.x; MASUDA M, 1966, J PSYCHOSOM RES, V10, P255, DOI 10.1016/0022-3999(66)90092-4; MATHE AA, 1969, NEW ENGL J MED, V281, P234, DOI 10.1056/NEJM196907312810503; MATHE AA, 1971, J PSYCHOSOM RES, V15, P349, DOI 10.1016/0022-3999(71)90048-1; MCNEILL RS, 1964, LANCET, V2, P1101; MICHOUD MC, 1984, AM REV RESPIR DIS, V130, P755; MORRIS HG, 1972, J ALLERGY CLIN IMMUN, V50, P138, DOI 10.1016/0091-6749(72)90044-9; NADEL JA, 1984, ANNU REV MED, V35, P451, DOI 10.1146/annurev.med.35.1.451; PARTANEN M, 1982, HISTOCHEMISTRY, V76, P175, DOI 10.1007/BF00501920; PICHURKO BM, 1986, J ALLERGY CLIN IMMUN, V77, P798; PIPER PJ, 1967, NATURE, V213, P838, DOI 10.1038/213838a0; RICHARDSON JB, 1979, AM REV RESPIR DIS, V119, P785; RUFFIN RE, 1979, CLIN PHARMACOL THER, V25, P536; SANDS MF, 1985, AM REV RESPIR DIS, V132, P993; SCHNALL RP, 1980, THORAX, V35, P828, DOI 10.1136/thx.35.11.828; SHEPPARD MN, 1983, THORAX, V38, P333, DOI 10.1136/thx.38.5.333; SILVERBERG AB, 1978, AM J PHYSIOL, V234, P252; Solis-Cohen S., 1900, J AM MED ASS, V34, P1164, DOI [10.1001/jama.1900.24610190014001c, DOI 10.1001/JAMA.1900.24610190014001C]; TAKAMINE J, 1902, SCOTT MED SURG J, V10, P131; TATTERSFIELD AE, 1973, J APPL PHYSIOL, V35, P613, DOI 10.1152/jappl.1973.35.5.613; TAYLOR SM, 1984, J APPL PHYSIOL, V56, P958, DOI 10.1152/jappl.1984.56.4.958; TOWNLEY RG, 1976, J ALLERGY CLIN IMMUN, V57, P358, DOI 10.1016/0091-6749(76)90093-2; VANHERWAARDEN CL, 1983, J CARDIOVASC PHARM, V5, P46; VERMEIRE PA, 1979, J APPL PHYSIOL, V46, P787, DOI 10.1152/jappl.1979.46.4.787; WARREN JB, 1984, J ALLERGY CLIN IMMUN, V74, P683, DOI 10.1016/0091-6749(84)90230-6; WARREN JB, 1984, CLIN SCI, V66, P87, DOI 10.1042/cs0660087; WARREN JB, 1982, BRIT J DIS CHEST, V76, P147, DOI 10.1016/S0007-0971(82)80050-8; WARREN JB, 1983, CLIN SCI, V64, P475, DOI 10.1042/cs0640475; WARREN JB, 1984, CLIN SCI, V66, P79, DOI 10.1042/cs0660079; WORSTMAN J, 1984, AM J MED, V77, P779; ZAAGSMA J, 1983, J RECEPTOR RES, V3, P89, DOI 10.3109/10799898309041925; ZAID G, 1966, NEW ENGL J MED, V275, P580, DOI 10.1056/NEJM196609152751103; ZIELINSKI J, 1980, THORAX, V35, P823, DOI 10.1136/thx.35.11.823	70	53	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1986	77	6					791	795		10.1016/0091-6749(86)90375-1	http://dx.doi.org/10.1016/0091-6749(86)90375-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C8694	2872246	Bronze			2022-12-18	WOS:A1986C869400002
J	HABENICHT, HA; BURGE, HA; MUILENBERG, ML; SOLOMON, WR				HABENICHT, HA; BURGE, HA; MUILENBERG, ML; SOLOMON, WR			ALLERGEN CARRIAGE BY ATMOSPHERIC AEROSOL .2. RAGWEED-POLLEN DETERMINANTS IN SUBMICRONIC ATMOSPHERIC FRACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,DIV ALLERGY,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan					NIAID NIH HHS [AI-10181] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; D'AMATO G, 1981, Zeitschrift fuer Erkrankungen der Atmungsorgane, V157, P281; HATCH TF, 1964, PULMONARY DEPOSITION, P37; HOWLETT BJ, 1973, J CELL SCI, V13, P603; HUSSAIN R, 1981, J ALLERGY CLIN IMMUN, V67, P217, DOI 10.1016/0091-6749(81)90064-6; LICHTENSTEIN LM, 1977, ASTHMA PHYSL IMMUNOP; REBHUN J, 1954, J ALLERGY, V25, P407, DOI 10.1016/0021-8707(54)90005-2; SCHLICHTING HE, 1974, J ALLERGY CLIN IMMUN, V53, P185, DOI 10.1016/0091-6749(74)90006-2; SHAFIEE A, 1973, J PHARM SCI, V62, P1654, DOI 10.1002/jps.2600621015; SOLOMON WR, 1983, J ALLERGY CLIN IMMUN, V71, P101; SOUTHWORTH D, COMMUNICATION; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006	12	53	54	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	1					64	67		10.1016/0091-6749(84)90088-5	http://dx.doi.org/10.1016/0091-6749(84)90088-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SZ648	6203953				2022-12-18	WOS:A1984SZ64800009
J	FRIEDMAN, RA; DOYLE, WJ; CASSELBRANT, ML; BLUESTONE, C; FIREMAN, P				FRIEDMAN, RA; DOYLE, WJ; CASSELBRANT, ML; BLUESTONE, C; FIREMAN, P			IMMUNOLOGIC-MEDIATED EUSTACHIAN-TUBE OBSTRUCTION - A DOUBLE-BLIND CROSSOVER STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURGH,SCH MED,DEPT ALLERGY & IMMUNOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURGH,SCH MED,DEPT OTOLARYNGOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016337] Funding Source: NIH RePORTER; NCRR NIH HHS [BRS-G SO7 RR20] Funding Source: Medline; NIAID NIH HHS [1 ROL-AI 19262] Funding Source: Medline; NINDS NIH HHS [1 PO1-NS-16337] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMAN M, 1983, J ALLERGY CLIN IMMUN, V71, P155, DOI 10.1016/0091-6749(83)90391-3; BENNETT FC, 1980, PEDIATRICS, V66, P254; BERNSTEIN JM, 1981, OTOLARYNG HEAD NECK, V89, P874, DOI 10.1177/019459988108900534; BLUESTONE CD, 1975, LARYNGOSCOPE, V85, P113, DOI 10.1288/00005537-197501000-00009; BLUESTONE CD, 1981, ANN OTO RHINOL LARYN, V90, P552, DOI 10.1177/000348948109000608; BLUESTONE CD, 1978, PEDIATRICS, V61, P753; BLUESTONE CD, 1974, ANN OTO RHINOL LARYN, V83, P27, DOI 10.1177/0003489474083S1103; BLUESTONE CD, 1977, LARYNGOSCOPE, V87, P493; BLUESTONE CD, 1975, HDB CLIN IMPEDANCE A, P127; BLUESTONE CD, 1978, ALLERGY PRINCIPLES P, P1023; CANTEKIN EI, 1980, ANN OTO RHINOL LARYN, V89, P71, DOI 10.1177/00034894800890S320; CLEMIS JD, 1976, ANN OTO RHINOL LARYN, V85, P234, DOI 10.1177/00034894760850S243; DERLACKI EL, 1965, ANN ALLERGY, V23, P288; FRIEDMAN R, 1981, PEDIATR RES, V15, P594, DOI 10.1203/00006450-198104001-00937; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; JORDAN RE, 1952, AMA ARCH OTOLARYNGOL, V55, P363; KING JT, 1959, ANN OTOL RHINOL LARY, V62, P496; LIM DJ, 1976, ANN OTO RHINOL LARYN, V85, P117, DOI 10.1177/00034894760850S222; MIGLETS A, 1973, LARYNGOSCOPE, V83, P1355, DOI 10.1288/00005537-197309000-00001; MOGI G, 1976, ANN OTO RHINOL LARYN, V85, P97, DOI 10.1177/00034894760850S219; ORT H, 1981, PEDIATR RES, V13, P555; SENTURIA BH, 1960, LARYNGOSCOPE, V70, P2877; VISCOMI GJ, 1979, J CONT ED ORL ALLERG, V41, P37; WIHL JA, 1977, ACTA OTO-LARYNGOL, V84, P281, DOI 10.3109/00016487709123968	24	53	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	5					442	447		10.1016/0091-6749(83)90459-1	http://dx.doi.org/10.1016/0091-6749(83)90459-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QQ742	6341435				2022-12-18	WOS:A1983QQ74200002
J	MILLER, JR; ORGEL, HA; MELTZER, EO				MILLER, JR; ORGEL, HA; MELTZER, EO			THE SAFETY OF EGG-CONTAINING VACCINES FOR EGG-ALLERGIC PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		Baker HM, 1920, AM J DIS CHILD, V19, P114; BELLANTI JA, 1978, ALLERGY PRINCIPLES P; BIERMAN CW, 1977, J INFECT DIS, V136, pS652, DOI 10.1093/infdis/136.Supplement_3.S652; BLOOM S, 1953, J ALLERGY, V24, P64, DOI 10.1016/0021-8707(53)90062-8; BOCK SA, 1978, CLIN ALLERGY, V8, P559, DOI 10.1111/j.1365-2222.1978.tb01509.x; BROWN FR, 1967, PEDIATRICS, V71, P868; COHEN SG, 1958, J ALLERGY, V29, P479, DOI 10.1016/0021-8707(58)90019-4; COLEMAN M, 1957, J ALLERGY, V28, P494, DOI 10.1016/0021-8707(57)90079-5; FRIES JOSEPH H., 1960, ANN ALLERGY, V18, P1130; GOLD HERMAN, 1941, JOUR ALLERGY, V12, P138, DOI 10.1016/S0021-8707(41)90159-4; HAMPTON SF, 1947, J LAB CLIN MED, V32, P109; HEGGIE AD, 1960, NEW ENGL J MED, V263, P959, DOI 10.1056/NEJM196011102631909; Kailin E W, 1970, Med Ann Dist Columbia, V39, P437; KAMIN PB, 1963, JAMA-J AM MED ASSOC, V185, P647, DOI 10.1001/jama.1963.03060080043012; KAMIN PB, 1965, J AMER MED ASSOC, V193, P1125; LERNER RA, 1981, HOSP PRACT, V16, P55, DOI 10.1080/21548331.1981.11946879; MAY CD, 1982, J ALLERGY CLIN IMMUN, V69, P225; OBRIEN TC, 1971, APPL MICROBIOL, V21, P780, DOI 10.1128/AEM.21.4.780-782.1971; PARK RG, 1945, BRIT MED J, V2, P570, DOI 10.1136/bmj.2.4425.570-a; PESKIN MD, 1922, AM J DIS CHILD, V23, P51; PLOTZ H, 1946, J IMMUNOL, V53, P315; RAFKIN H, 1946, ANN INTERN MED, V25, P346; RATNER B, 1952, AMA AM J DIS CHILD, V83, P608, DOI 10.1001/archpedi.1952.02040090054005; RATNER B, 1946, JAMA-J AM MED ASSOC, V132, P899, DOI 10.1001/jama.1946.02870500005002; RATNER B, 1952, NEW ENGL J MED, V246, P533, DOI 10.1056/NEJM195204032461403; RATNER B, 1952, AMA AM J DIS CHILD, V83, P309, DOI 10.1001/archpedi.1952.02040070055006; RATNER B, 1950, ANN ALLERGY, V8, P699; RAYNOLDS AH, 1945, JAMA-J AM MED ASSOC, V128, P613, DOI 10.1001/jama.1945.02860250059020; ROWE AH, 1959, JAMA, V169, P1159; ROWE ALBERT H., 1934, JOUR ALLERGY, V5, P135, DOI 10.1016/S0021-8707(34)80006-8; RUBIN SS, 1946, J ALLERGY, V17, P21, DOI 10.1016/0021-8707(46)90017-2; SPRAGUE HB, 1945, US NAV M B, V45, P71; STULL A, 1946, J IMMUNOL, V53, P343; Sulzberger MB, 1942, US NAV M B, V40, P411; Swartz H, 1943, J LAB CLIN MED, V28, P1663; WALKER RUSSEL H., 1948, U S NAVAL MED BULL, V48, P303; 1968, BR MED J, V4, P469; 1969, RUBELLA VIRUS VACCIN; 1969, INFLUENZA VIRUS VACC; 1977, REPORT COMMITTEE INF; 1968, INFLUENZA VIRUS VACC; 1967, MEASLES VIRUS VACCIN	42	53	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	6					568	573						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QV139	6853925				2022-12-18	WOS:A1983QV13900008
J	SANO, Y; WATT, G; TOWNLEY, RG				SANO, Y; WATT, G; TOWNLEY, RG			DECREASED MONONUCLEAR CELL BETA-ADRENERGIC RECEPTORS IN BRONCHIAL-ASTHMA - PARALLEL STUDIES OF LYMPHOCYTE AND GRANULOCYTE DESENSITIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,CTR ALLERG DIS,DEPT MED,OMAHA,NE 68178	Creighton University					NHLBI NIH HHS [HL 24396] Funding Source: Medline; NIAID NIH HHS [AI 12029] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; BISHOPRIC NH, 1980, J ALLERGY CLIN IMMUN, V65, P29, DOI 10.1016/0091-6749(80)90173-6; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; CHENG JB, 1980, ENDOCRINOLOGY, V107, P1646, DOI 10.1210/endo-107-5-1646; COFFEY RG, 1977, IMMUNOPHARMACOLOGY, V3, P203; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; DAVIES AO, 1980, J CLIN ENDOCR METAB, V51, P599, DOI 10.1210/jcem-51-3-599; DAVIES AO, 1981, J CLIN ENDOCR METAB, V53, P703, DOI 10.1210/jcem-53-4-703; GALANT SP, 1978, J LAB CLIN MED, V92, P613; GALANT SP, 1979, J INVEST DERMATOL, V72, P330, DOI 10.1111/1523-1747.ep12531768; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GALANT SP, 1980, J CLIN INVEST, V65, P577, DOI 10.1172/JCI109702; GILLESPIE E, 1974, J ALLERGY CLIN IMMUN, V53, P27, DOI 10.1016/0091-6749(74)90096-7; HARDEN TK, 1976, MOL PHARMACOL, V12, P1; HASEGAWA M, 1983, J ALLERGY CLIN IMMUN, V71, P230, DOI 10.1016/0091-6749(83)90104-5; HENDERSON WR, 1979, NEW ENGL J MED, V300, P642, DOI 10.1056/NEJM197903223001203; HOFFMAN BB, 1980, ANNU REV PHARMACOL, V20, P581, DOI 10.1146/annurev.pa.20.040180.003053; KALINER M, 1973, J EXP MED, V138, P1077, DOI 10.1084/jem.138.5.1077; KARIMAN K, 1980, LUNG, V158, P41, DOI 10.1007/BF02713701; LEFKOWITZ RJ, 1979, ANN INTERN MED, V91, P450, DOI 10.7326/0003-4819-91-3-450; LOGSDON PJ, 1973, J ALLERGY CLIN IMMUN, V53, P148; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGUIRE ME, 1976, J BIOL CHEM, V251, P1221; MANO K, 1979, LIFE SCI, V25, P195; MCNEILL RS, 1966, AM J CARDIOL, V18, P473, DOI 10.1016/0002-9149(66)90072-5; Middleton E Jr, 1972, Adv Intern Med, V18, P177; MORRIS HG, 1977, CLIN PHARMACOL THER, V22, P352; MORRIS HG, 1977, J CYCLIC NUCL PROT, V3, P439; MUERS H, 1982, J ALLERGY CLIN IMMUN, V70, P272; OUELLETTE J J, 1967, Journal of Allergy, V39, P160, DOI 10.1016/0021-8707(67)90033-0; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; POCHET R, 1979, CLIN EXP IMMUNOL, V38, P578; ROBERTS JM, 1977, NATURE, V270, P624, DOI 10.1038/270624a0; RUOHO AE, 1980, J ALLERGY CLIN IMMUN, V66, P46, DOI 10.1016/0091-6749(80)90137-2; RYO UY, 1976, J ALLERGY CLIN IMMUN, V57, P12, DOI 10.1016/0091-6749(76)90074-9; SANO Y, 1980, CLIN RES, V28, pA431; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHEPPARD JR, 1977, NATURE, V269, P693, DOI 10.1038/269693a0; Steiner A L, 1974, Methods Enzymol, V38, P96; Szentivanyi A, 1979, Ann N Y Acad Sci, V332, P295, DOI 10.1111/j.1749-6632.1979.tb47123.x; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TASKIN DP, 1982, AM REV RESPIR DIS, V125, P185; WESSELS MR, 1979, MOL PHARMACOL, V16, P10; WILLIAMS LT, 1976, J CLIN INVEST, V57, P149, DOI 10.1172/JCI108254; WILLIAMS LT, 1977, J CLIN INVEST, V60, P815, DOI 10.1172/JCI108835; WOLFE RN, 1982, J ALLERGY CLIN IMMUN, V69, P46, DOI 10.1016/0091-6749(82)90086-0	46	53	53	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					495	503		10.1016/0091-6749(83)90587-0	http://dx.doi.org/10.1016/0091-6749(83)90587-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RR916	6313791	Bronze			2022-12-18	WOS:A1983RR91600011
J	ANDERSON, MC; BAER, H				ANDERSON, MC; BAER, H			ANTIGENIC AND ALLERGENIC CHANGES DURING STORAGE OF A POLLEN EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									US FDA,BUR BIOL,8800 ROCKVILLE PIKE,BETHESDA,MD 20205	US Food & Drug Administration (FDA)								ANDERSON MC, 1978, J ALLERGY CLIN IMMUN, V61, P178, DOI 10.1016/0091-6749(78)90405-0; ANDERSON MC, 1981, RAST INHIBITION PROC; AUGUSTIN R, 1959, IMMUNOLOGY, V2, P230; AUGUSTIN R, 1955, Q Rev Allergy Appl Immunol, V9, P504; AUKRUST L, 1978, INT ARCH ALLER A IMM, V57, P183, DOI 10.1159/000232101; AXELSEN NH, 1973, SCAND J IMMUNOL   S1, V2, P1; BAER H, 1980, J ALLERGY CLIN IMMUN, V66, P281, DOI 10.1016/0091-6749(80)90022-6; BOUSQUET J, 1978, REV FRANC ALLERGOL, V18, P3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CENTER JG, 1974, J ALLERGY CLIN IMMUN, V54, P305, DOI 10.1016/0091-6749(74)90016-5; FRANKLIN RM, 1976, J ALLERGY CLIN IMMUN, V58, P51, DOI 10.1016/0091-6749(76)90106-8; GLEICH GJ, 1980, MANUAL CLIN IMMUNOLO; HIATT CW, 1977, J BIOL STAND, V5, P39, DOI 10.1016/0092-1157(77)90017-8; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; LOWENSTEIN H, 1978, ALLERGY, V33, P30, DOI 10.1111/j.1398-9995.1978.tb01504.x; LOWENSTEIN H, ADV ALLERGOLOGY CLIN, P505; NELSON HS, 1979, J ALLERGY CLIN IMMUN, V63, P417, DOI 10.1016/0091-6749(79)90216-1; NIELSEN L, 1974, ACTA ALLERGOL, V29, P385, DOI 10.1111/j.1398-9995.1974.tb01660.x; RANCOUR JM, 1973, J ALLERGY CLIN IMMUN, V51, P114, DOI 10.1016/S0091-6749(73)80078-8; RIGHETTI PG, 1974, J CHROMATOGR, V98, P272; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; VARGA JM, 1972, J ALLERGY CLIN IMMUN, V49, P274, DOI 10.1016/0091-6749(72)90095-4; WEEKE B, 1974, ACTA ALLERGOL, V29, P402, DOI 10.1111/j.1398-9995.1974.tb01661.x	23	53	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	1					3	10		10.1016/0091-6749(82)90080-X	http://dx.doi.org/10.1016/0091-6749(82)90080-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ377	7054252				2022-12-18	WOS:A1982MZ37700002
J	BUTCHER, BT; ONEIL, CE; REED, MA; SALVAGGIO, JE; WEILL, H				BUTCHER, BT; ONEIL, CE; REED, MA; SALVAGGIO, JE; WEILL, H			DEVELOPMENT AND LOSS OF TOLUENE DIISOCYANATE REACTIVITY - IMMUNOLOGICAL, PHARMACOLOGIC, AND PROVOCATIVE CHALLENGE STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,MED CTR,DEPT MED,NEW ORLEANS,LA 70118	Tulane University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL015092] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-15092] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boyum A, 1968, SCAND J CLIN LAB S97, V21, P7; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411, DOI 10.1164/arrd.1977.116.3.411; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P146, DOI 10.1016/0091-6749(79)90049-6; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P655, DOI 10.1016/0091-6749(79)90031-9; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; DAVIES RJ, 1977, J ALLERGY CLIN IMMUN, V60, P233; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; MITCHELL JC, 1974, BRIT J DERMATOL, V91, P183, DOI 10.1111/j.1365-2133.1974.tb15864.x	10	53	53	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	4					231	235		10.1016/0091-6749(82)90058-6	http://dx.doi.org/10.1016/0091-6749(82)90058-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PL151	6288789	Bronze			2022-12-18	WOS:A1982PL15100002
J	PHANUPHAK, P; SCHOCKET, AL; ARROYAVE, CM; KOHLER, PF				PHANUPHAK, P; SCHOCKET, AL; ARROYAVE, CM; KOHLER, PF			SKIN HISTAMINE IN CHRONIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,MED CTR,DIV RHEUMATOL,DENVER,CO 80262; UNIV COLORADO,MED CTR,DEPT MED,DIV CLIN IMMUNOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BEALL GN, 1963, J ALLERGY, V34, P8, DOI 10.1016/0021-8707(63)90080-7; BEAVEN MA, 1976, NEW ENGL J MED, V294, P30, DOI 10.1056/NEJM197601012940108; Beaven MA., 1975, HDB PSYCHOPHARMACOLO, V1, P253; DVORAK HF, 1972, J EXP MED, V135, P235, DOI 10.1084/jem.135.2.235; GALANT SP, 1972, J ALLERGY CLIN IMMUN, V49, P119; JOHNSON HH, 1957, ARCH DERMATOL, V76, P726, DOI 10.1001/archderm.1957.01550240044008; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P26; JUHLIN L, 1967, ACTA DERM-VENEREOL, V47, P383; KAPLAN AP, 1977, J ALLERGY CLIN IMMUN, V60, P324, DOI 10.1016/0091-6749(77)90113-0; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; Lewis T., 1927, BLOOD VESSELS HUMAN; MATHISON DA, 1977, ANN INTERN MED, V86, P534, DOI 10.7326/0003-4819-86-5-534; PORTER JF, 1972, PHYSIOL REV, V52, P361, DOI 10.1152/physrev.1972.52.2.361; RHOADES RB, 1975, J ALLERGY CLIN IMMUN, V55, P180, DOI 10.1016/0091-6749(75)90014-7; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; WARIN RP, 1974, URTICARIA, P15; ZACHARIAE H, 1963, ACTA DERM VENEREOL S, V47, P383	19	53	53	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	5					371	375		10.1016/0091-6749(80)90215-8	http://dx.doi.org/10.1016/0091-6749(80)90215-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV955	7372956				2022-12-18	WOS:A1980JV95500009
J	SAAVEDRADELGADO, AMP; MATHEWS, KP; PAN, PM; KAY, DR; MUILENBERG, ML				SAAVEDRADELGADO, AMP; MATHEWS, KP; PAN, PM; KAY, DR; MUILENBERG, ML			DOSE-RESPONSE STUDIES OF THE SUPPRESSION OF WHOLE-BLOOD HISTAMINE AND BASOPHIL COUNTS BY PREDNISONE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020557] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00042] Funding Source: Medline; NIADDK NIH HHS [AM 20557] Funding Source: Medline; NIAID NIH HHS [AI 14950] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABEYOGLU IT, 1979, EUR J CLIN PHARMACOL, V16, P399, DOI 10.1007/BF00568200; ARROYAVE CM, 1976, J IMMUNOL, V117, P1866; BALDWA VS, 1977, JPN J PHYSIOL, V27, P13; BHAT KN, 1976, ANN ALLERGY, V37, P169; BRASCH RC, 1970, INVEST RADIOL, V5, P510, DOI 10.1097/00004424-197011000-00017; COGEN FC, 1979, J ALLERGY CLIN IMMUN, V64, P299, DOI 10.1016/0091-6749(79)90148-9; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; DUNSKY EH, 1979, J ALLERGY CLIN IMMUN, V63, P426, DOI 10.1016/0091-6749(79)90217-3; ENGELMAN K, 1968, AM J MED SCI, V255, P259, DOI 10.1097/00000441-196804000-00007; GILBERT HS, 1975, BLOOD, V46, P279; HIRSCH SR, 1974, J ALLERGY CLIN IMMUN, V53, P303, DOI 10.1016/0091-6749(74)90110-9; IZHIZAKA T, 1972, J IMMUNOL, V108, P1000; KELLY JF, 1978, J ALLERGY CLIN IMMUN, V62, P181, DOI 10.1016/0091-6749(78)90104-5; KOLB WP, 1978, J IMMUNOL, V121, P1232; LASSER EC, 1974, RADIOLOGY, V110, P49, DOI 10.1148/110.1.49; PARRILLO JE, 1979, ANNU REV PHARMACOL, V19, P179, DOI 10.1146/annurev.pa.19.040179.001143; RING J, 1978, CLIN EXP IMMUNOL, V32, P105; ROCKOFF SD, 1971, INVEST RADIOL, V6, P110, DOI 10.1097/00004424-197103000-00004; ROCKOFF SD, 1972, INVEST RADIOL, V7, P177; SALBERG DJ, 1977, LIFE SCI, V21, P1439, DOI 10.1016/0024-3205(77)90198-9; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SIEGLE RL, 1976, INVEST RADIOL, V11, P98, DOI 10.1097/00004424-197603000-00004; SIMON RA, 1979, J ALLERGY CLIN IMMUN, V63, P281, DOI 10.1016/0091-6749(79)90114-3; TILL G, 1978, INT ARCH ALLER A IMM, V56, P543, DOI 10.1159/000232070; ZWEIMAN B, 1975, ANN INTERN MED, V83, P159, DOI 10.7326/0003-4819-83-2-159	25	53	53	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	6					464	471		10.1016/0091-6749(80)90007-X	http://dx.doi.org/10.1016/0091-6749(80)90007-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KV363	7430504				2022-12-18	WOS:A1980KV36300006
J	SCHUMACHER, MJ; PAIN, MCF				SCHUMACHER, MJ; PAIN, MCF			NASAL CHALLENGE TESTING IN GRASS-POLLEN HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL MELBOURNE HOSP,RESP UNIT,MELBOURNE 3050,VICTORIA,AUSTRALIA	Royal Melbourne Hospital	SCHUMACHER, MJ (corresponding author), WALTER & ELIZA HALL INST MED RES,CLIN RES UNIT,MELBOURNE 3050,VICTORIA,AUSTRALIA.							BERG TLO, 1974, J ALLERGY CLIN IMMUN, V54, P209, DOI 10.1016/0091-6749(74)90063-3; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CONNELL JT, 1967, J ALLERGY, V39, P358, DOI 10.1016/0021-8707(67)90048-2; DERRICK E, 1966, AUST J BOT, V14, P49, DOI 10.1071/BT9660049; ERIKSSON NE, 1976, INT ARCH ALLER A IMM, V52, P335, DOI 10.1159/000231700; HALPERN SR, 1961, ANN ALLERGY, V19, P1407; HOLOPAINEN E, 1976, Rhinology (Utrecht), V14, P181; LEVY DA, 1967, J IMMUNOL, V99, P1068; MCLEAN JA, 1976, J ALLERGY CLIN IMMUN, V57, P153, DOI 10.1016/0091-6749(76)90034-8; MUNRO D, COMMUNICATION; MUNRO DA, 1976, CLEAN AIR, V10, P42; PEPYS J, 1975, Clinical Allergy, V5, P431, DOI 10.1111/j.1365-2222.1975.tb01882.x; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SOLOMON WR, 1965, J ALLERGY, V36, P62, DOI 10.1016/0021-8707(65)90033-X; TAYLOR G, 1971, Clinical Allergy, V1, P407, DOI 10.1111/j.1365-2222.1971.tb00792.x; TAYLOR G, 1972, Clinical Allergy, V2, P125, DOI 10.1111/j.1365-2222.1972.tb01277.x; TAYLOR G, 1971, Clinical Allergy, V1, P63, DOI 10.1111/j.1365-2222.1971.tb02448.x	17	53	53	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	3					202	208		10.1016/0091-6749(79)90096-4	http://dx.doi.org/10.1016/0091-6749(79)90096-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HL221	469119				2022-12-18	WOS:A1979HL22100008
J	CHUA, YY; BREMNER, K; LAKDAWALLA, N; LLOBET, JL; KOKUBU, HL; ORANGE, RP; COLLINSWILLIAMS, C				CHUA, YY; BREMNER, K; LAKDAWALLA, N; LLOBET, JL; KOKUBU, HL; ORANGE, RP; COLLINSWILLIAMS, C			INVIVO AND INVITRO CORRELATES OF FOOD ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP SICK CHILDREN, DEPT PEDIAT, TORONTO M5G 1X8, ONTARIO, CANADA; HOSP SICK CHILDREN, DEPT IMMUNOL, TORONTO M5G 1X8, ONTARIO, CANADA; UNIV TORONTO, DEPT PEDIAT, TORONTO, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ASSEM ESK, 1968, BMJ-BRIT MED J, V3, P272, DOI 10.1136/bmj.3.5613.272; ASSEM ESK, 1970, BRIT MED J, V2, P504, DOI 10.1136/bmj.2.5708.504; ASSEM ESK, 1972, MECHANISMS DRUG ALLE, P112; AUGUSTIN R, 1967, HDB EXPT IMMUNOLOGY, P1076; BARRICK RH, 1965, J ALLERGY, V36, P374, DOI 10.1016/0021-8707(65)90044-4; BLACK AP, 1956, PEDIATRICS, V17, P716; BOYDEN SV, 1951, J EXP MED, V93, P107, DOI 10.1084/jem.93.2.107; BROCKELHURST WE, 1968, BIOCHEMISTRY ACUTE A, P11; Bryan W T, 1971, Otolaryngol Clin North Am, V4, P523; BUKHARI AQS, 1967, THESIS EDINBURGH U; BULLOCK JD, 1970, ANN ALLERGY, V28, P127; BULLOCK JD, 1968, ANN ALLERGY, V26, P177; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; COCA AF, 1943, FAMILIAL NON REAGINI, P96; COLLINS-WILLIAMS C., 1955, ANN ALLERGY, V13, P415; COLLINSW.C, 1965, INT ARCH ALLER A IMM, V27, P110, DOI 10.1159/000229604; COLLINSWILLIAMS C, 1962, INT ARCH ALLER A IMM, V20, P38, DOI 10.1159/000229241; Cooke RA, 1947, ALLERGY THEORY PRACT; DEES SC, 1972, PEDIATRICS, V50, P420; DOCKHORN RJ, 1969, ANN ALLERGY, V27, P409; DONOVAN R, 1970, INT ARCH ALLER A IMM, V37, P154, DOI 10.1159/000230229; FALLSTRO.SP, 1965, ACTA PAEDIATR SCAND, V54, P101, DOI 10.1111/j.1651-2227.1965.tb06352.x; GALANT S P, 1972, Clinical Research, V20, P266; GALANT SP, 1973, CLIN ALLERGY, V3, P363, DOI 10.1111/j.1365-2222.1973.tb01343.x; GOLBERT TM, 1969, J ALLERGY, V44, P96, DOI 10.1016/0021-8707(69)90005-7; HADDAD ZH, 1972, J ALLERGY CLIN IMMUN, V49, P210, DOI 10.1016/0091-6749(72)90084-X; HEINER DC, 1962, AM J DIS CHILD, V103, P634, DOI 10.1001/archpedi.1962.02080020649003; ISHIZAKA K, 1970, J ALLERGY, V46, P197, DOI 10.1016/0021-8707(70)90023-7; ISHIZAKA T, 1970, J IMMUNOL, V104, P854; KLETTER B, 1971, Clinical Allergy, V1, P249; LIEBERMAN P, 1975, JAMA-J AM MED ASSOC, V231, P728; LOCKEY SD, 1971, ANN ALLERGY, V29, P461; LOCKEY SD, 1972, ANN ALLERGY, V30, P638; MATTHEWS TS, 1970, LANCET, V2, P893; May C D, 1972, Clin Allergy, V2, P335, DOI 10.1111/j.1365-2222.1972.tb01298.x; ORANGE RP, 1971, J EXP MED          2, V134, pS1; PARISH VE, 1971, CLIN ALLERGY, V1, P369; PARISH WE, 1970, LANCET, V2, P591; PARISH WE, 1967, NATURE, V215, P738, DOI 10.1038/215738a0; PETERSON RD, 1963, PEDIATRICS, V31, P209; POCKSTEEN OC, 1973, CLIN ALLERGY, V3, P373, DOI 10.1111/j.1365-2222.1973.tb01344.x; POPA V, 1968, J ALLERGY, V42, P130, DOI 10.1016/0021-8707(68)90086-5; ROSENSWE.NS, 1969, J DAIRY SCI, V52, P585, DOI 10.3168/jds.S0022-0302(69)86611-7; Rowe A., 1944, ELIMINATION DIETS PA; SCHWARTZ J, 1965, INT ARCH ALLER A IMM, V26, P333, DOI 10.1159/000229586; SHEARD P, 1967, NATURE, V216, P283, DOI 10.1038/216283a0; SHELDON JM, 1967, MANUAL CLINICAL ALLE, P216; SHELLEY WB, 1962, NATURE, V195, P1181, DOI 10.1038/1951181a0; SHIODA H, 1966, J ALLERGY, V37, P321, DOI 10.1016/0021-8707(66)90131-6; SPIES JR, 1970, J ALLERGY, V45, P208, DOI 10.1016/0021-8707(70)90132-2; SPIES JR, 1972, J ALLERGY CLIN IMMUN, V50, P82, DOI 10.1016/0091-6749(72)90003-6; STAVITSKY AB, 1955, J IMMUNOL, V74, P306; STECHSCHULTE DJ, 1967, J EXP MED, V125, P127, DOI 10.1084/jem.125.1.127; TADA T, 1970, Journal of Immunology, V104, P377; ULETT GA, 1974, ANN ALLERGY, V33, P23; Vaughan WT, 1936, J LAB CLIN MED, V21, P1278; VISAKORPI JK, 1967, ACTA PAEDIATR SCAND, V56, P49, DOI 10.1111/j.1651-2227.1967.tb15343.x; WICHER K, 1969, J AMER MED ASSOC, V208, P143, DOI 10.1001/jama.208.1.143; WILLOUGHBY JW, 1965, ANN ALLERGY, V23, P543	60	53	53	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	2					299	307		10.1016/0091-6749(76)90135-4	http://dx.doi.org/10.1016/0091-6749(76)90135-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA661	59744				2022-12-18	WOS:A1976CA66100007
J	TOWNLEY, RG; MCGEADY, S; BEWTRA, A				TOWNLEY, RG; MCGEADY, S; BEWTRA, A			EFFECT OF BETA-ADRENERGIC BLOCKADE ON BRONCHIAL SENSITIVITY TO ACETYL-BETA-METHACHOLINE IN NORMAL AND ALLERGIC RHINITIS SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,SCH MED,OMAHA,NB 68178	Creighton University								ADOLPHSON RL, 1971, CLIN RES, V19, P506; BEUMER H M, 1969, Pharmacologia Clinica, V1, P172, DOI 10.1007/BF00456941; COOKSON DV, 1968, AM REV RESPIR DIS, V88, P636; GILES RE, 1971, EUR J PHARMACOL, V16, P156, DOI 10.1016/0014-2999(71)90005-7; GRIECO MH, 1971, J ALLERGY CLIN IMMUN, V48, P143, DOI 10.1016/0091-6749(71)90009-1; HERXHEIMER H, 1967, J PHYSIOL-LONDON, V190, P41; LANGER I, 1967, J PHYSIOL-LONDON, V190, pP41; MACDONALD AG, 1968, BRIT J ANAESTH, V40, P508, DOI 10.1093/bja/40.7.508; MCNEILL RS, 1964, LANCET, V2, P1101; OUELLETTE J J, 1967, Journal of Allergy, V39, P160, DOI 10.1016/0021-8707(67)90033-0; RYO UY, 1976, J ALLERGY CLIN IMMUN, V57, P12, DOI 10.1016/0091-6749(76)90074-9; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TIVENIUS L, 1969, Pharmacologia Clinica, V2, P51, DOI 10.1007/BF00404187; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1973, J ALLERGY CLIN IMMUN, V51, P121, DOI 10.1016/S0091-6749(73)80092-2; TOWNLEY RG, 1972, PRACT MED, V1, pCH40; TOWNLEY RG, 1973, CHEST, V63, P65; TOWNLEY RG, UNPUBLISHED DATA; TOWNLEY RG, 1968, J ALLERGY, V29, P177; ZAID G, 1966, NEW ENGL J MED, V275, P580, DOI 10.1056/NEJM196609152751103	20	53	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	4					358	366		10.1016/0091-6749(76)90093-2	http://dx.doi.org/10.1016/0091-6749(76)90093-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BM689	4483				2022-12-18	WOS:A1976BM68900010
J	BERMAN, SZ; MATHISON, DA; STEVENSON, DD; TAN, EM; VAUGHAN, JH				BERMAN, SZ; MATHISON, DA; STEVENSON, DD; TAN, EM; VAUGHAN, JH			TRANSTRACHEAL ASPIRATION STUDIES IN ASTHMATIC-PATIENTS IN RELAPSE WITH INFECTIVE ASTHMA AND IN SUBJECTS WITHOUT RESPIRATORY-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN, DIV ALLERGY & IMMUNOL, 476 PROSPECT ST, LA JOLLA, CA 92037 USA	Scripps Research Institute								AARONSON DW, 1972, ALLERGIC DISEASES DI, P197; [Anonymous], 1965, LANCET, V1, P775; BEATY HN, 1970, ANN INTERN MED, V73, P144, DOI 10.7326/0003-4819-72-2-183; BERGMAN S, 1955, Acta Allergol, V8, P163, DOI 10.1111/j.1398-9995.1955.tb03563.x; BERMAN SZ, 1974, J ALLERGY CLIN IMMUN, V53, P311, DOI 10.1016/0091-6749(74)90111-0; Cooke RA, 1932, AM J MED SCI, V183, P309; COOKE RA, 1947, ALLERGY THEORY PRACT, P445; EISEN AH, 1967, INT ARCH ALLER A IMM, V31, P14, DOI 10.1159/000229851; HAMPTON SF, 1963, J ALLERGY, V34, P63, DOI 10.1016/0021-8707(63)90086-8; KALINSKE RW, 1967, NEW ENGL J MED, V276, P604, DOI 10.1056/NEJM196703162761103; LAMBERT HP, 1972, BMJ-BRIT MED J, V3, P323, DOI 10.1136/bmj.3.5822.323; LAPINSKI EM, 1964, AM REV RESPIR DIS, V89, P760; LAURENZI GA, 1961, NEW ENGL J MED, V265, P1273, DOI 10.1056/NEJM196112282652601; LEES AW, 1959, LANCET, V2, P1112; MATHISON DA, 1973, JAMA-J AM MED ASSOC, V224, P1134, DOI 10.1001/jama.224.8.1134; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; Meltzer SJ, 1910, J AMER MED ASSOC, V55, P1021, DOI 10.1001/jama.1910.04330120043014; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; PECORA DV, 1963, NEW ENGL J MED, V269, P664, DOI 10.1056/NEJM196309262691304; PECORA DV, 1958, NEW ENGL J MED, V258, P71, DOI 10.1056/NEJM195801092580204; PEPYS J, 1969, MONOGR ALLERGY, V4, P20; POTTER RT, 1968, AM REV RESPIR DIS, V97, P1051; Rackemann FM, 1918, ARCH INTERN MED, V22, P517; RIES K, 1974, ARCH INTERN MED, V133, P453, DOI 10.1001/archinte.133.3.453; ROSE B, 1971, IMMUNOLOGICAL DISEAS, P860; SCHREINER A, 1972, Scandinavian Journal of Infectious Diseases, V4, P49; SHAPIRO GG, 1973, J ALLERGY CLIN IMMUN, V51, P96, DOI 10.1016/S0091-6749(73)80041-7; SWINEFORD O, 1949, J ALLERGY, V20, P420, DOI 10.1016/0021-8707(49)90054-4; VIRTUE CM, 1971, J ALLERGY CLIN IMMUN, V48, P321, DOI 10.1016/0091-6749(71)90078-9	29	53	53	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	3					206	214		10.1016/0091-6749(75)90091-3	http://dx.doi.org/10.1016/0091-6749(75)90091-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ290	807610	Bronze			2022-12-18	WOS:A1975AQ29000005
J	NELSON, HS; BLACK, JW; BRANCH, LB; PFUETZE, B; SPAULDING, H; SUMMERS, R; WOOD, D				NELSON, HS; BLACK, JW; BRANCH, LB; PFUETZE, B; SPAULDING, H; SUMMERS, R; WOOD, D			SUBSENSITIVITY TO EPINEPHRINE FOLLOWING ADMINISTRATION OF EPINEPHRINE AND EPHEDRINE TO NORMAL INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FITZSIMONS ARMY MED CTR,ALLERGY IMMUNOL SERV,DENVER,CO 80240									ANTONIS A, 1965, J LIPID RES, V6, P307; BALL JH, 1972, J CLIN INVEST, V51, P2124, DOI 10.1172/JCI107019; BARBORIAK JJ, 1972, J ALLERGY CLIN IMMUN, V49, P116; BERNSTEIN RA, 1972, J LAB CLIN MED, V80, P772; BERNSTEIN RA, 1973, J ALLERGY CLIN IMMUN, V51, P89, DOI 10.1016/S0091-6749(73)80025-9; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; FIREMAN P, 1970, J ALLERGY, V45, P117; FLEMING WW, 1973, PHYSIOL REV, V68, P56; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; HERXHEIMER H, 1946, BMJ-BRIT MED J, V1, P350, DOI 10.1136/bmj.1.4444.350; INOUE S, 1967, J ALLERGY, V40, P337, DOI 10.1016/0021-8707(67)90023-8; IZARD SR, 1971, J ALLERGY, V47, P309, DOI 10.1016/S0091-6749(71)80134-3; KIRKPATRICK CH, 1967, AM REV RESPIR DIS, V96, P692; LOCKEY SD, 1967, J ALLERGY, V40, P337; MASELLI R, 1970, J ALLERGY, V45, P117; MCDONOUGH JR, 1970, CIRCULATION, V41, P743, DOI 10.1161/01.CIR.41.5.743; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; NELSON HS, 1973, J ALLERGY CLIN IMMUN, V51, P191, DOI 10.1016/0091-6749(73)90138-3; PATERSON JW, 1968, LANCET, V2, P427; REED CE, 1970, J ALLERGY, V46, P90, DOI 10.1016/0021-8707(70)90076-6; SCHOLZ R, 1959, BIOCHEM Z, V331, P71; SCHWARTZ HJ, 1973, J ALLERGY CLIN IMMUN, V51, P88, DOI 10.1016/S0091-6749(73)80024-7; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; ZAID G, 1968, J ALLERGY, V42, P177, DOI 10.1016/S0021-8707(68)90113-5	24	53	53	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	5					299	309		10.1016/0091-6749(75)90002-0	http://dx.doi.org/10.1016/0091-6749(75)90002-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AB754	164490				2022-12-18	WOS:A1975AB75400002
J	ROBBINS, JB; SCHNEERSON, R; GLODE, MP; VANN, W; SCHIFFER, MS; LIU, TY; PARKE, JC; HUNTLEY, C				ROBBINS, JB; SCHNEERSON, R; GLODE, MP; VANN, W; SCHIFFER, MS; LIU, TY; PARKE, JC; HUNTLEY, C			CROSS-REACTIVE ANTIGENS AND IMMUNITY TO DISEASES CAUSED BY ENCAPSULATED BACTERIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHARLOTTE MEM HOSP,CHARLOTTE,NC; BOWMAN GRAY SCH MED,DEPT PEDIAT,WINSTON SALEM,NC; FDA,BUR BIOL,DIV BACTERIAL PROD,BETHESDA,MD 20014	Carolinas Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; US Food & Drug Administration (FDA)								ANDERSON P, 1972, J CLIN INVEST, V51, P39, DOI 10.1172/JCI106794; ARGMAN M, 1974, J IMMUNOL, V111, P649; ARTENSTEIN MS, 1970, NEW ENGL J MED, V282, P417, DOI 10.1056/NEJM197002192820803; BRADSHAW MW, 1971, LANCET, V1, P1095; DAVIES JAV, 1937, J IMMUNOL, V23, P1; Feldman H A, 1972, Adv Intern Med, V18, P117; Finland M, 1942, J IMMUNOL, V45, P215; FINLAND M, 1932, J EXP MED, V57, P95; Fothergill LD, 1933, J IMMUNOL, V24, P273; GERSHON RK, 1973, CONTEMP TOP IMMUNOBI, V3, P1; GLODE MP, IN PRESS; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327; GOLDSCHNEIDER I, 1972, J INFECT DIS, V125, P509, DOI 10.1093/infdis/125.5.509; GOTSCHLICH EC, 1972, J CLIN INVEST, V51, P89, DOI 10.1172/JCI106801; GOTSCHLICH EC, 1969, J EXP MED, V129, P1367, DOI 10.1084/jem.129.6.1367; GRADOS O, 1970, J INFECT DIS, V122, P100, DOI 10.1093/infdis/122.1-2.100; HANDZEL ZT, IN PRESS; HEIDELBERGER M, 1946, J EXP MED, V83, P303, DOI 10.1084/jem.83.4.303; HEIDELBERGER M, 1968, J BACTERIOL, V96, P2415; HEIDELBERGER M, 1953, NATURE SIGNIFICANCE; HEINER DC, 1956, NEW ENGL J MED, V254, P629, DOI 10.1056/NEJM195604052541401; Hodes HL, 1944, J PEDIATR-US, V24, P641, DOI 10.1016/S0022-3476(44)80089-0; HUNTLEY CC, 1965, PEDIATRICS, V36, P523; HUNTLEY CC, 1969, J AMER MED ASSOC, V208, P1145, DOI 10.1001/jama.208.7.1145; HUNTLEY CC, 1975, CLIN RES, V23, pA66; HUNTLEY CC, 1974, CLIN RES, V22, pA86; JOHNSTON RB, 1973, CLIN IMMUNOL IMMUNOP, V1, P234, DOI 10.1016/0090-1229(73)90024-X; Kabat EA, 1956, BLOOD GROUP SUBSTANC; KASPER DL, 1973, J IMMUNOL, V110, P262; LIU TY, 1971, J BIOL CHEM, V246, P2849; LIU TY, 1971, J BIOL CHEM, V246, P4703; MACLEOD CM, 1945, J EXP MED, V82, P445, DOI 10.1084/jem.82.6.445; MCCRACKEN GH, 1974, LANCET, V2, P246; MCCRACKEN GH, IN PRESS; MOSIER DE, 1975, J EXP MED, V141, P216, DOI 10.1084/jem.141.1.216; MUSCHEL LH, 1959, P SOC EXP BIOL MED, V101, P614, DOI 10.3181/00379727-101-25036; MYEROWITZ RL, 1973, INFECT IMMUN, V7, P137, DOI 10.1128/IAI.7.2.137-140.1973; MYEROWITZ RL, 1973, INFECT IMMUN, V8, P896, DOI 10.1128/IAI.8.6.896-900.1973; MYEROWITZ RL, 1973, LANCET, V1, P567; Neter Erwin, 1943, PROC SOC EXP BIOL AND MED, V52, P289, DOI 10.3181/00379727-52-14125; NETO VA, 1974, SEROLOGIC RESPONSE S; NORDEN CW, 1973, J INFECT DIS, V128, P777, DOI 10.1093/infdis/128.6.777; OLIVERGONZALEZ J, 1949, J INFECT DIS, V85, P66, DOI 10.1093/infdis/85.1.66; OLIVERGONZALEZ J, 1944, J INFECT DIS, V78, P232; RANDOLPH M, 1973, J INFECT DIS, V128, P769; ROBBINS JB, 1972, INFECT IMMUN, V6, P651, DOI 10.1128/IAI.6.5.651-656.1972; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROBBINS JB, 1973, PEDIATR RES, V7, P103, DOI 10.1203/00006450-197303000-00001; ROBBINS JB, 1974, 4TH MIL INT S; ROBBINS JB, 1974, 4TH INT CONV IMM; ROSEN FS, 1966, NEW ENGL J MED, V275, P709, DOI 10.1056/NEJM196609292751307; SCHNEERSON R, 1971, J IMMUNOL, V107, P1081; SCHNEERSON R, 1972, J IMMUNOL, V108, P1551; SCHNEERSON R, IN PRESS; SMITH DH, 1973, PEDIATRICS, V52, P637; SPEAR PG, 1973, J EXP MED, V138, P557, DOI 10.1084/jem.138.3.557; SPRINGER GEORG F., 1967, P29; SPRINGER GF, 1969, J CLIN INVEST, V48, P1280, DOI 10.1172/JCI106094; SPRINGER GF, 1959, J EXP MED, V110, P221, DOI 10.1084/jem.110.2.221; SPRINGER GF, 1961, J EXP MED, V113, P1077, DOI 10.1084/jem.113.6.1077; Sutliff WD, 1932, J EXP MED, V55, P837, DOI 10.1084/jem.55.6.837; Sutliff WD, 1937, J IMMUNOL, V32, P43; Thomsen O, 1929, Z IMMUNITAETFORSCH, V63, P67; Trask JD, 1930, J CLIN INVEST, V8, P623, DOI 10.1172/JCI100284; VANN W, IN PRESS; WEBSTER ME, 1952, J IMMUNOL, V69, P135; WEINER AS, 1943, BLOOD GROUPS TRANSFU, P22; WHYLE FA, 1970, J INFECT DIS, V122, P100; YOUNT WJ, 1968, J EXP MED, V127, P633, DOI 10.1084/jem.127.3.633; ZEPP HD, 1943, P SOC EXP BIOL MED, V53, P315	70	53	56	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	2					141	151		10.1016/0091-6749(75)90119-0	http://dx.doi.org/10.1016/0091-6749(75)90119-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AM325	239050				2022-12-18	WOS:A1975AM32500008
J	Rojahn, TB; Vorstandlechner, V; Krausgruber, T; Bauer, WM; Alkon, N; Bangert, C; Thaler, FM; Sadeghyar, F; Fortelny, N; Gernedl, V; Rindler, K; Elbe-Burger, A; Bock, C; Mildner, M; Brunner, PM				Rojahn, Thomas B.; Vorstandlechner, Vera; Krausgruber, Thomas; Bauer, Wolfgang M.; Alkon, Natalia; Bangert, Christine; Thaler, Felix M.; Sadeghyar, Farzaneh; Fortelny, Nikolaus; Gernedl, Victoria; Rindler, Katharina; Elbe-Buerger, Adelheid; Bock, Christoph; Mildner, Michael; Brunner, Patrick M.			Single-cell transcriptomics combined with interstitial fluid proteomics defines cell type-specific immune regulation in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						single-cell RNA sequencing; Olink proteomics; atopic dermatitis; suction blistering	INNATE LYMPHOID-CELLS; HUMAN SKIN; LESIONAL SKIN; T-CELLS; EXPRESSION; DUPILUMAB; INSIGHTS; EPIDEMIOLOGY; POPULATIONS; MECHANISMS	Background: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, but its complex pathogenesis is only insufficiently understood, resulting in still limited treatment options. Objective: We sought to characterize AD on both transcriptomic and proteomic levels in humans. Methods: We used skin suction blistering, a painless and nonscarring procedure that can simultaneously sample skin cells and interstitial fluid. We then compared results with conventional biopsies. Results: Suction blistering captured epidermal and most immune cells equally well as biopsies, except for mast cells and nonmigratory CD163+ macrophages that were only present in biopsy isolates. Using single-cell RNA sequencing, we found comparable transcriptional profiles of key inflammatory pathways between blister and biopsy AD, but suction blistering was superior in cell-specific resolution for high-abundance transcripts (KRT1/KRT10, KRT16/KRT6A, S100A8/S100A9), which showed some background signals in biopsy isolates. Compared with healthy controls, we found characteristic upregulation of AD-typical cytokines such as IL13 and IL22 in T(H)2 and T(H)22 cells, respectively, but we also discovered these mediators in proliferating T cells and natural killer T cells, that also expressed the antimicrobial cytokine IL26. Overall, not T cells, but myeloid cells were most strongly enriched in AD, and we found dendritic cell (CLEC7A, amphiregulin/AREG, EREG) and macrophage products (CCL13) among the top upregulated proteins in AD blister fluid proteomic analyses. Conclusion: These data show that by using cutting-edge technology, suction blistering offers several advantages over conventional biopsies, including better transcriptomic resolution of skin cells, combined with proteomic information from interstitial fluid, unraveling novel inflammatory players that shape the cellular and proteomic microenvironment of AD.	[Rojahn, Thomas B.; Vorstandlechner, Vera; Bauer, Wolfgang M.; Alkon, Natalia; Bangert, Christine; Thaler, Felix M.; Sadeghyar, Farzaneh; Rindler, Katharina; Elbe-Buerger, Adelheid; Mildner, Michael; Brunner, Patrick M.] Med Univ Vienna, Dept Dermatol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria; [Vorstandlechner, Vera] Med Univ Vienna, Dept Surg, Res Lab Thorac Surg, Vienna, Austria; [Krausgruber, Thomas; Fortelny, Nikolaus; Gernedl, Victoria; Bock, Christoph] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Bock, Christoph] Med Univ Vienna, Dept Lab Med, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Medical University of Vienna	Brunner, PM (corresponding author), Med Univ Vienna, Dept Dermatol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	patrick.brunner@meduniwien.ac.at	Krausgruber, Thomas/H-8490-2018; Bock, Christoph/AAE-7618-2019	Krausgruber, Thomas/0000-0002-1374-0329; Bock, Christoph/0000-0001-6091-3088; Fife, Victoria/0000-0003-0052-5731; Fortelny, Nikolaus/0000-0003-4025-9968; Bauer, Wolfgang/0000-0002-0155-1176; Rindler, Katharina/0000-0002-2142-8490; Vorstandlechner, Vera/0000-0002-5938-1552; Mildner, Michael/0000-0002-6892-925X	LEO Foundation, Copenhagen, Denmark; Vienna Business Agency (Vienna, Austria) [2343727]; Aposcience AG; Austrian Science Fund [FWF M2403]; FWF [P31485-B30, DK-W1248-B30]; Austrian Academy of Sciences; ERC (European Union) [679146]	LEO Foundation, Copenhagen, Denmark(LEO Pharma); Vienna Business Agency (Vienna, Austria); Aposcience AG; Austrian Science Fund(Austrian Science Fund (FWF)); FWF(Austrian Science Fund (FWF)); Austrian Academy of Sciences; ERC (European Union)(European Research Council (ERC))	This work was funded by a research grant to P.M.B. from the LEO Foundation, Copenhagen, Denmark. V.V. is supported by the Vienna Business Agency (Vienna, Austria; grant "APOSEC to clinic'' 2343727), and the Aposcience AG. T.K. is supported by a Lise-Meitner fellowship from the Austrian Science Fund (FWF M2403). A.E.B. is supported by the FWF (P31485-B30 and DK-W1248-B30). C. Bock is supported by a New Frontiers Group award of the Austrian Academy of Sciences and by an ERC Starting Grant (European Union's Horizon 2020 research and innovation program, grant agreement no. 679146).	Alexander H, 2019, F1000RES, V8, pF1000; Assarsson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095192; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Boniface K, 2010, J IMMUNOL, V185, P679, DOI 10.4049/jimmunol.1000366; Braud VM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1423184; Bruggen MC, 2016, J INVEST DERMATOL, V136, P2396, DOI 10.1016/j.jid.2016.07.017; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cheng JB, 2018, CELL REP, V25, P871, DOI 10.1016/j.celrep.2018.09.006; Clark RA, 2007, BLOOD, V109, P194, DOI 10.1182/blood-2006-02-002873; Czarnowicki T, 2019, J ALLERGY CLIN IMMUN, V143, P1, DOI 10.1016/j.jaci.2018.10.032; Dang AT, 2019, J CLIN INVEST, V129, P1926, DOI 10.1172/JCI99550; Deleuran M, 2014, BRIT J DERMATOL, V170, P2, DOI 10.1111/bjd.12933; Dyjack N, 2018, J ALLERGY CLIN IMMUN, V141, P1298, DOI 10.1016/j.jaci.2017.10.046; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Ewald DA, 2017, J ALLERGY CLIN IMMUN, V139, P562, DOI 10.1016/j.jaci.2016.08.029; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Flohr C, 2014, ALLERGY, V69, P3, DOI 10.1111/all.12270; Florian P, 2020, EXP DERMATOL, V29, P4, DOI 10.1111/exd.13942; Freytag Saskia, 2018, F1000Res, V7, P1297, DOI 10.12688/f1000research.15809.2; Gunther C, 2011, AM J PATHOL, V179, P1434, DOI 10.1016/j.ajpath.2011.05.040; Guerrero-Juarez CF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08247-x; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Hafemeister C, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1874-1; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Harden JL, 2016, J ALLERGY CLIN IMMUN, V137, P1830, DOI 10.1016/j.jaci.2015.09.055; He H, 2020, J ALLERGY CLIN IMMUN; Tran HTN, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-019-1850-9; Hutter C, 2012, BLOOD, V120, P5199, DOI 10.1182/blood-2012-02-410241; Itoh T, 2019, J INVEST DERMATOL, V139, P878, DOI 10.1016/j.jid.2018.09.037; Jha P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112383; Kamijo H, 2020, J INVEST DERMATOL, V140, P636, DOI 10.1016/j.jid.2019.07.713; Leonard A, 2020, J ALLER CL IMM-PRACT, V8, P236, DOI 10.1016/j.jaip.2019.08.013; Lessard JC, 2013, P NATL ACAD SCI USA, V110, P19537, DOI 10.1073/pnas.1309576110; Leung DYM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav2685; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Lind L, 2015, ATHEROSCLEROSIS, V242, P205, DOI 10.1016/j.atherosclerosis.2015.07.023; Lood C, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3314; Lopez R, 2018, NAT METHODS, V15, P1053, DOI 10.1038/s41592-018-0229-2; Luecken MD, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188746; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Meller S, 2015, NAT IMMUNOL, V16, P970, DOI 10.1038/ni.3211; Mitsui H, 2012, J INVEST DERMATOL, V132, P1615, DOI 10.1038/jid.2012.33; Moyle M, 2019, EXP DERMATOL, V28, P756, DOI 10.1111/exd.13911; Muller AC, 2012, J PROTEOME RES, V11, P3715, DOI 10.1021/pr3002035; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nurjadi D, 2013, J INFECT DIS, V207, P666, DOI 10.1093/infdis/jis735; Nystrom A, 2013, J CLIN INVEST, V123, P3498, DOI 10.1172/JCI68127; Pasha MA, 2019, ALLERGY ASTHMA PROC, V40, P138, DOI 10.2500/aap.2019.40.4217; Pavel AB, 2020, J AM ACAD DERMATOL, V82, P690, DOI 10.1016/j.jaad.2019.10.039; Rakita A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-56847-4; Rea H, 2019, ACTA DERM-VENEREOL, V99, P945, DOI 10.2340/00015555-3223; Reindeiro AF, PREPRINT, DOI [10.1101/597005, DOI 10.1101/597005]; Renert-Yuval Y, 2018, CURR OPIN ALLERGY CL, V18, P356, DOI 10.1097/ACI.0000000000000455; ROSSING N, 1981, CLIN PHYSIOL, V1, P275, DOI 10.1111/j.1475-097X.1981.tb00896.x; Silverberg JI, 2017, DERMATOL CLIN, V35, P283, DOI 10.1016/j.det.2017.02.002; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Soderlund S, 2016, LEUKEMIA RES, V50, P95, DOI 10.1016/j.leukres.2016.09.019; Stoll SW, 2016, J INVEST DERMATOL, V136, P444, DOI 10.1016/j.jid.2015.10.061; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Sugaya M, 2012, J DERMATOL SCI, V68, P45, DOI 10.1016/j.jdermsci.2012.07.007; Tabib T, 2018, J INVEST DERMATOL, V138, P802, DOI 10.1016/j.jid.2017.09.045; Tanita K, 2018, EXP DERMATOL, V27, P1268, DOI 10.1111/exd.13779; Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185; Wang SW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01298; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Wolk K, 2014, CLIN CANCER RES, V20, P5507, DOI 10.1158/1078-0432.CCR-14-0707; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Zaba LC, 2007, J CLIN INVEST, V117, P2517, DOI 10.1172/JCI32282	73	52	54	4	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2020	146	5					1056	1069		10.1016/j.jaci.2020.03.041	http://dx.doi.org/10.1016/j.jaci.2020.03.041			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OP5VH	32344053				2022-12-18	WOS:000588153700010
J	Dykewicz, MS; Wallace, DV; Amrol, DJ; Baroody, FM; Bernstein, JA; Craig, TJ; Dinakar, C; Ellis, AK; Finegold, I; Golden, DBK; Greenhawt, MJ; Hagan, JB; Horner, CC; Khan, DA; Lang, DM; Larenas-Linnemann, DES; Lieberman, JA; Meltzer, EO; Oppenheimer, JJ; Rank, MA; Shaker, MS; Shaw, JL; Steven, GC; Stukus, DR; Wang, JL				Dykewicz, Mark S.; Wallace, Dana, V; Amrol, David J.; Baroody, Fuad M.; Bernstein, Jonathan A.; Craig, Timothy J.; Dinakar, Chitra; Ellis, Anne K.; Finegold, Ira; Golden, David B. K.; Greenhawt, Matthew J.; Hagan, John B.; Horner, Caroline C.; Khan, David A.; Lang, David M.; Larenas-Linnemann, Desiree E. S.; Lieberman, Jay A.; Meltzer, Eli O.; Oppenheimer, John J.; Rank, Matthew A.; Shaker, Marcus S.; Shaw, Jeffrey L.; Steven, Gary C.; Stukus, David R.; Wang, Julie			Rhinitis 2020: A practice parameter update	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; nonallergic rhinitis; vasomotor rhinitis; local allergic rhinitis; food allergy antihistamines; corticosteroids; ipratropium; allergen immunotherapy; decongestants	SEASONAL ALLERGIC RHINITIS; AZELASTINE NASAL SPRAY; QUALITY-OF-LIFE; LEUKOTRIENE RECEPTOR ANTAGONISTS; PERENNIAL NONALLERGIC RHINITIS; PLACEBO-CONTROLLED TRIAL; RESPIRATORY-TRACT INFECTIONS; ONCE-DAILY TREATMENT; INTRANASAL FLUTICASONE PROPIONATE; IMPORTANT RESEARCH QUESTIONS	This comprehensive practice parameter for allergic rhinitis (AR) and nonallergic rhinitis (NAR) provides updated guidance on diagnosis, assessment, selection of monotherapy and combination pharmacologic options, and allergen immunotherapy for AR. Newer information about local AR is reviewed. Cough is emphasized as a common symptom in both AR and NAR. Food allergy testing is not recommended in the routine evaluation of rhinitis. Intranasal corticosteroids (INCS) remain the preferred monotherapy for persistent AR, but additional studies support the additive benefit of combination treatment with INCS and intranasal antihistamines in both AR and NAR. Either intranasal antihistamines or INCS may be offered as first-line monotherapy for NAR. Montelukast should only be used for AR if there has been an inadequate response or intolerance to alternative therapies. Depot parenteral corticosteroids are not recommended for treatment of AR due to potential risks. While intranasal decongestants generally should be limited to short-term use to prevent rebound congestion, in limited circumstances, patients receiving regimens that include an INCS may be offered, in addition, an intranasal decongestant for up to 4 weeks. Neither acupuncture nor herbal products have adequate studies to support their use for AR. Oral decongestants should be avoided during the first trimester of pregnancy. Recommendations for use of subcutaneous and sublingual tablet allergen immunotherapy in AR are provided. Algorithms based on a combination of evidence and expert opinion are provided to guide in the selection of pharmacologic options for intermittent and persistent AR and NAR.	[Dykewicz, Mark S.] St Louis Univ, Sch Med, Sect Allergy & Immunol, Div Infect Dis Allergy & Immunol,Dept Internal Me, St Louis, MO 63104 USA; [Wallace, Dana, V] Nova Southeastern Allopath Med Sch, Dept Med, Ft Lauderdale, FL USA; [Amrol, David J.] Univ South Carolina, Dept Internal Med, Sch Med, Columbia, SC 29208 USA; [Baroody, Fuad M.] Univ Chicago, Dept Otolaryngol Head & Neck Surg, Pritzker Sch Med, Chicago, IL 60637 USA; [Bernstein, Jonathan A.] Univ Cincinnati, Coll Med, Dept Internal Med, Allergy Sect,Div Immunol, Cincinnati, OH 45221 USA; [Craig, Timothy J.] Penn State Univ, Dept Med, Hershey, PA USA; [Craig, Timothy J.] Penn State Univ, Dept Pediat, Hershey, PA USA; [Dinakar, Chitra] Stanford Univ, Div Pulm Allergy & Crit Care Med, Dept Med, Stanford, CA 94305 USA; [Ellis, Anne K.] Queens Univ, Dept Med, Div Allergy & Immunol, Kingston, ON, Canada; [Finegold, Ira] Mt Sinai West, Div Allergy & Immunol, Dept Med, New York, NY USA; [Golden, David B. K.] Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Greenhawt, Matthew J.] Univ Colorado, Childrens Hosp Colorado, Sch Med, Sect Allergy & Immunol,Dept Pediat, Aurora, CO USA; [Hagan, John B.] Mayo Clin, Div Allerg Dis, Rochester, MN USA; [Horner, Caroline C.] Washington Univ, Sch Med, Dept Pediat, Div Allergy Immunol & Pulm Med, St Louis, MO 63110 USA; [Khan, David A.] Univ Texas Southwestern Med Ctr Dallas, Div Allergy & Immunol, Dept Internal Med, Dallas, TX 75390 USA; [Lang, David M.] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Allergy & Clin Immunol,Resp Inst, Cleveland, OH 44106 USA; [Larenas-Linnemann, Desiree E. S.] Hosp Med Sur, Ctr Excellence Asthma & Allergy, Mexico City, DF, Mexico; [Lieberman, Jay A.] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Div Pulmonol Allergy & Immunol, Memphis, TN USA; [Meltzer, Eli O.] Univ Calif San Diego, Sch Med, Dept Pediat, Div Allergy & Immunol, San Diego, CA 92103 USA; [Meltzer, Eli O.] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; [Oppenheimer, John J.] Univ Med & Dent New Jersey, Rutgers New Jersey Med Sch, Dept Internal Med, Div Pulm & Crit Care Med & Allerg & Immunol Dis, New Brunswick, NJ USA; [Oppenheimer, John J.] Pulm & Allergy Associates, Morristown, NJ USA; [Rank, Matthew A.] Mayo Clin Arizona, Div Allergy Asthma & Clin Immunol, Scottsdale, AZ USA; [Shaker, Marcus S.] Dartmouth Hitchcock Med Ctr, Dept Pediat, Lebanon, NH 03766 USA; [Shaw, Jeffrey L.] Prevea Hlth, Green Bay, WI USA; [Steven, Gary C.] Allergy Asthma & Sinus Ctr, Greenfield, IN USA; [Stukus, David R.] Nationwide Childrens Hosp, Div Allergy & Immunol, Columbus, OH USA; [Stukus, David R.] Ohio State Univ, Dept Pediat, Coll Med, Columbus, OH 43210 USA; [Wang, Julie] Icahn Sch Med Mt Sinai, Elliot & Roslyn Jaffe Food Allergy Inst, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA	Saint Louis University; University of South Carolina System; University of South Carolina Columbia; University of Chicago; University System of Ohio; University of Cincinnati; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Stanford University; Queens University - Canada; Mount Sinai West; Johns Hopkins University; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Mayo Clinic; Washington University (WUSTL); University of Texas System; University of Texas Southwestern Medical Center Dallas; Case Western Reserve University; Cleveland Clinic Foundation; Tecnologico de Monterrey; University of Tennessee System; University of Tennessee Health Science Center; University of California System; University of California San Diego; Rutgers State University New Brunswick; Rutgers State University Medical Center; Mayo Clinic; Mayo Clinic Phoenix; Dartmouth College; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; Icahn School of Medicine at Mount Sinai	Dykewicz, MS (corresponding author), St Louis Univ, Sect Allergy & Immunol, Dept Internal Med, Sch Med, 1402 S Grand Blvd,M157, St Louis, MO 63104 USA.	mark.dykewicz@health.slu.edu		Bernstein, Jonathan/0000-0002-3476-1196				Aasbjerg K, 2013, RESP MED, V107, P1852, DOI 10.1016/j.rmed.2013.09.007; Abou-Elfadl M, 2015, EUR ANN OTORHINOLARY, V132, P343, DOI 10.1016/j.anorl.2015.08.006; Abrams EM, 2016, CAN MED ASSOC J, V188, P1087, DOI 10.1503/cmaj.160124; Abrich V, 2014, MAYO CLIN PROC, V89, P1636, DOI 10.1016/j.mayocp.2014.09.009; Abtahi SM, 2013, J RES MED SCI, V18, P400; Adedeji Taiwo Olugbemiga, 2016, Afr J Paediatr Surg, V13, P14, DOI 10.4103/0189-6725.181701; Adinoff AD, 2015, J ALLERGY CLIN IMMUN, V135, pAB190, DOI 10.1016/j.jaci.2014.12.1555; Aguirre N, 2013, INT J INTEGR CARE, V13; Ahmad A, 2015, J RES PHARM PRACT, V4, P37, DOI 10.4103/2279-042X.150057; Ahmed MN, 2010, CLIN PEDIATR, V49, P542, DOI 10.1177/0009922809357786; Al-Rabia Mohammed W, 2016, J Microsc Ultrastruct, V4, P69, DOI 10.1016/j.jmau.2015.11.004; Alabid AHMA, 2014, J CLIN DIAGN RES, V8, P119, DOI 10.7860/JCDR/2014/6199.3923; Perona AA, 2016, DRUG SAFETY, V39, P69, DOI 10.1007/s40264-015-0360-2; Andrews CP, 2020, ANN ALLERG ASTHMA IM, V124, P171, DOI 10.1016/j.anai.2019.11.007; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; [Anonymous], 1999, NASALCROM PACKAGE IN; Archontaki M, 2009, B-ENT, V5, P159; Assanasen P, 2000, AM J RESP CRIT CARE, V162, P1031, DOI 10.1164/ajrccm.162.3.9912055; Auge J, 2018, ALLERGY, V73, P1597, DOI 10.1111/all.13416; Autio TJ, 2015, LARYNGOSCOPE, V125, pE1, DOI 10.1002/lary.24862; Awad A, 2018, INT ARCH OTORHINOLAR, V22, P146, DOI 10.1055/s-0037-1603922; Bachert C, 2009, ALLERGY, V64, P520, DOI 10.1111/j.1398-9995.2009.01964.x; BADHWAR AK, 1992, MED CLIN N AM, V76, P789, DOI 10.1016/S0025-7125(16)30326-1; Bakhireva LN, 2007, J ALLERGY CLIN IMMUN, V119, P618, DOI 10.1016/j.jaci.2006.12.618; Banov CH, 2001, ANN ALLERG ASTHMA IM, V86, P28, DOI 10.1016/S1081-1206(10)62352-6; Baraniuk J N, 2001, Curr Allergy Asthma Rep, V1, P252; BARANIUK JN, 1992, J ALLERGY CLIN IMMUN, V90, P1045, DOI 10.1016/0091-6749(92)90121-H; Barnes ML, 2007, ALLERGY, V62, P73, DOI 10.1111/j.1398-9995.2006.01263.x; Barnes ML, 2005, RHINOLOGY, V43, P291; Baroody FM, 2011, J ALLERGY CLIN IMMUN, V127, P927, DOI 10.1016/j.jaci.2011.01.037; Bayonne E, 2009, RHINOLOGY, V47, P59; Becker B, 1997, CLIN OTOLARYNGOL, V22, P132, DOI 10.1046/j.1365-2273.1997.00875.x; Bedotta-Barajas M, 2017, ALLERGOL IMMUNOPATH, V45, P127, DOI 10.1016/j.aller.2016.04.017; Beltrani Vincent S, 2003, Dermatol Online J, V9, P1; Beltrani VS, 1999, J ALLERGY CLIN IMMUN, V104, pS87, DOI 10.1016/S0091-6749(99)70050-3; Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P770, DOI 10.1067/mai.2003.1408; Benninger MS, 2006, OTOLARYNG HEAD NECK, V134, P3, DOI 10.1016/j.otohns.2005.10.010; Berard A, 2016, J ALLERGY CLIN IMMUN, V138, P97, DOI 10.1016/j.jaci.2016.01.021; Berger W, 2016, ALLERGY, V71, P1219, DOI 10.1111/all.12903; Berger WE, 2003, ANN ALLERG ASTHMA IM, V91, P205, DOI 10.1016/S1081-1206(10)62179-5; Berger W, 2006, ANN ALLERG ASTHMA IM, V97, P375, DOI 10.1016/S1081-1206(10)60804-6; Berger WE, 2014, J ALLER CL IMM-PRACT, V2, P179, DOI 10.1016/j.jaip.2013.09.019; Berger WE, 2009, EXPERT OPIN DRUG MET, V5, P91, DOI [10.1517/17425250802670474 , 10.1517/17425250802670474]; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Bernstein JA, 2007, CURR MED RES OPIN, V23, P2441, DOI 10.1185/030079907X226302; Bernstein JA, 2013, CURR OPIN ALLERGY CL, V13, P410, DOI 10.1097/ACI.0b013e3283630cd8; Bernstein JA, 2011, ANN ALLERG ASTHMA IM, V107, P171, DOI 10.1016/j.anai.2011.05.016; Bernstein JA, 2009, WORLD ALLERGY ORGAN, V2, P102, DOI 10.1097/WOX.0b013e3181a8e389; Bernstein JA, 2010, ALLERGY ASTHMA PROC, V31, P365, DOI 10.2500/aap.2010.31.3380; Bhargava R, 2014, J LARYNGOL OTOL, V128, P1060, DOI 10.1017/S0022215114002503; Bielory L, 2011, ALLERGY, V66, P686, DOI 10.1111/j.1398-9995.2010.02543.x; Biggs TC, 2013, J LARYNGOL OTOL, V127, P483, DOI 10.1017/S0022215113000492; Bisgaard H, 2009, PEDIATR PULM, V44, P568, DOI 10.1002/ppul.21018; Blaiss MS, 2007, ALLERGY ASTHMA PROC, V28, pS4; Blaiss MS, 2010, ALLERGY ASTHMA PROC, V31, P375, DOI 10.2500/aap.2010.31.3329; BLANCA M, 2015, WORLD ALLERGY ORG S1, V8, pA262; Blom HM, 1997, CLIN EXP ALLERGY, V27, P796, DOI 10.1046/j.1365-2222.1997.670842.x; Bonadonna P, 2001, AM J RHINOL, V15, P297, DOI 10.1177/194589240101500502; Bousquet J, 2008, ALLERGY, V63, P842, DOI 10.1111/j.1398-9995.2008.01715.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; Bousquet J, 2005, CLIN EXP ALLERGY, V35, P728, DOI 10.1111/j.1365-2222.2005.02274.x; Bousquet J, 2017, ALLERGY, V72, P1475, DOI 10.1111/all.13177; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet J, 2018, J ALLER CL IMM-PRACT, V6, P1726, DOI 10.1016/j.jaip.2018.01.031; Bousquet PJ, 2007, ALLERGY, V62, P367, DOI 10.1111/j.1398-9995.2006.01276.x; Boyle J, 2006, CURR MED RES OPIN, V22, P1343, DOI 10.1185/030079906X112660; Bozek A, 2018, ANN ALLERG ASTHMA IM, V120, P53, DOI 10.1016/j.anai.2017.10.009; Bozek A, 2017, DRUG AGING, V34, P21, DOI 10.1007/s40266-016-0425-7; Brandt D, 2006, ANN ALLERG ASTHMA IM, V96, P526, DOI 10.1016/S1081-1206(10)63546-6; Braun T, 2012, AM J OTOLARYNG, V33, P64, DOI 10.1016/j.amjoto.2011.01.004; Braunstahl GJ, 2003, ALLERGY, V58, P1235, DOI 10.1046/j.0105-4538.2003.00354.x; Brinkhaus B, 2013, ANN INTERN MED, V158, P225, DOI 10.7326/0003-4819-158-4-201302190-00002; Broersen LHA, 2015, J CLIN ENDOCR METAB, V100, P2171, DOI 10.1210/jc.2015-1218; BRONSKY EA, 1995, J ALLERGY CLIN IMMUN, V95, P1117, DOI 10.1016/S0091-6749(95)70215-6; Brook I, 2006, J MED MICROBIOL, V55, P943, DOI 10.1099/jmm.0.46346-0; Brown CEB, 2014, J PAEDIATR CHILD H, V50, P795, DOI 10.1111/jpc.12658; Brozek JL, 2017, J ALLERGY CLIN IMMUN, V140, P950, DOI 10.1016/j.jaci.2017.03.050; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Caimmi D, 2017, CLIN EXP ALLERGY, V47, P1526, DOI 10.1111/cea.13025; Calais CJ, 2015, ANN ALLERG ASTHMA IM, V114, P429, DOI 10.1016/j.anai.2015.02.013; Calapai G, 2014, PHARMACOLOGY, V94, P60, DOI 10.1159/000366164; Calderon MA, 2014, CLIN EXP ALLERGY, V44, P1228, DOI 10.1111/cea.12331; Campo P, 2019, CLIN EXP ALLERGY, V49, P6, DOI 10.1111/cea.13192; Fernandes SDC, 2014, RHINOLOGY, V52, P133, DOI 10.4193/Rhino13.158; Campos G, 2011, ALLERGY, V66, P31; Canning BJ, 2014, CHEST, V146, P1633, DOI 10.1378/chest.14-1481; Caparroz FA, 2016, BRAZ J OTORHINOLAR, V82, P105, DOI 10.1016/j.bjorl.2015.04.011; Cardet JC, 2014, J ALLER CL IMM-PRACT, V2, P208, DOI 10.1016/j.jaip.2013.12.003; Carney AS, 2002, CLIN EXP ALLERGY, V32, P1436, DOI 10.1046/j.1365-2745.2002.01465.x; Carney AS, 1996, CLIN OTOLARYNGOL, V21, P198, DOI 10.1111/j.1365-2273.1996.tb01724.x; Carr W, 2012, J ALLERGY CLIN IMMUN, V129, P1282, DOI 10.1016/j.jaci.2012.01.077; Carr WW, 2012, ALLERGY ASTHMA PROC, V33, P450, DOI 10.2500/aap.2012.33.3626; Casale TB, 2003, J ALLERGY CLIN IMMUN, V111, pS835, DOI 10.1067/mai.2003.1550; CASALE TB, 1989, J ALLERGY CLIN IMMUN, V83, P771, DOI 10.1016/0091-6749(89)90013-4; Castano R, 2017, CLIN EXP ALLERGY, V47, P1566, DOI 10.1111/cea.13039; Cavero-Carbonell C, 2017, BIRTH DEFECTS RES, V109, P452, DOI 10.1002/bdra.23621; Centers for Disease Control and Prevention, 2017, SIN RINS HLTH REL PR; Centre for Clinical Practice at NICE, 2008, RESP TRACT INF AN PR, V69; Chakir J, 2000, J ALLERGY CLIN IMMUN, V106, P904, DOI 10.1067/mai.2000.110100; Chakir J, 1996, LAB INVEST, V75, P735; Chang AB, 2006, CHEST, V129, p260S, DOI 10.1378/chest.129.1_suppl.260S; CHATELAIN C, 1995, EUR ARCH OTO-RHINO-L, V252, P83; Chen JR, 2014, INT J PEDIATR OTORHI, V78, P1115, DOI 10.1016/j.ijporl.2014.04.026; Cheng KJ, 2013, AM J RHINOL ALLERGY, V27, P8, DOI 10.2500/ajra.2013.27.3845; Chervinsky P, 2005, ALLERGY ASTHMA PROC, V26, P391; Cho SH, 2016, ALLERGY ASTHMA PROC, V37, P131, DOI 10.2500/aap.2016.37.3925; Chohan A, 2015, INT J PEDIATR OTORHI, V79, P1599, DOI 10.1016/j.ijporl.2015.07.009; Church MK, 2010, ALLERGY, V65, P459, DOI 10.1111/j.1398-9995.2009.02325.x; Ciabatti PG, 2009, ACTA OTO-LARYNGOL, V129, P367, DOI 10.1080/00016480802510186; Ciebiada M, 2008, J INVEST ALLERG CLIN, V18, P343; Ciebiada M, 2013, AM J RHINOL ALLERGY, V27, pE58, DOI 10.2500/ajra.2013.27.3881; Ciebiada M, 2011, AM J RHINOL ALLERGY, V25, pE1, DOI 10.2500/ajra.2011.25.3540; Ciftci Z, 2015, EUR ARCH OTO-RHINO-L, V272, P2587, DOI 10.1007/s00405-014-3182-4; CIMBURA G, 1982, J FORENSIC SCI, V27, P855; Cingi C, 2010, LARYNGOSCOPE, V120, P1718, DOI 10.1002/lary.20941; Ciprandi G, 2002, ALLERGY, V57, P586, DOI 10.1034/j.1398-9995.2002.03228.x; Clark DW, 2018, ENT-EAR NOSE THROAT, V97, P173, DOI 10.1177/014556131809700615; Clarke Tainya C, 2015, Natl Health Stat Report, P1; COHAN RH, 1976, J ALLERGY CLIN IMMUN, V58, P121, DOI 10.1016/0091-6749(76)90147-0; Collamati A, 2016, AGING CLIN EXP RES, V28, P25, DOI 10.1007/s40520-015-0359-7; Comoglu S, 2012, AM J RHINOL ALLERGY, V26, pE55, DOI 10.2500/ajra.2012.26.3725; Cornelius RS, 2013, J AM COLL RADIOL, V10, P241, DOI 10.1016/j.jacr.2013.01.001; Corren J, 2005, CLIN THER, V27, P543, DOI 10.1016/j.clinthera.2005.04.012; Costa DJ, 2011, J ALLERGY CLIN IMMUN, V127, P920, DOI 10.1016/j.jaci.2010.10.058; Couroux P, 2009, ANN ALLERG ASTHMA IM, V102, P62, DOI 10.1016/S1081-1206(10)60110-X; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Cronin MJ, 2013, ARCH DIS CHILD, V98, P299, DOI 10.1136/archdischild-2012-302983; Cruz AA, 2006, J ALLERGY CLIN IMMUN, V117, P1351, DOI 10.1016/j.jaci.2006.01.054; Cruz ND, 2012, J ALLERGY CLIN IMMUN, V129, pAB111; DAVIES HJ, 1985, CLIN ALLERGY, V15, P419, DOI 10.1111/j.1365-2222.1985.tb02291.x; Day J, 1998, J ALLERGY CLIN IMMUN, V102, P902, DOI 10.1016/S0091-6749(98)70326-4; Day JH, 2008, ALLERGY ASTHMA PROC, V29, P304, DOI 10.2500/aap.2008.29.3109; Day JH, 2000, J ALLERGY CLIN IMMUN, V105, P489, DOI 10.1067/mai.2000.104550; Day JH, 2006, ANN ALLERG ASTHMA IM, V96, P263, DOI 10.1016/S1081-1206(10)61235-5; De Corso E, 2019, LARYNGOSCOPE, V129, P551, DOI 10.1002/lary.27576; de la Roca F, 2012, J ALLERGY CLIN IMMUN, V129, pAB111, DOI 10.1016/j.jaci.2011.12.546; De Schryver E, 2017, CLIN EXP ALLERGY, V47, P245, DOI 10.1111/cea.12836; Demir D, 2015, EUR ARCH OTO-RHINO-L, V272, P2847, DOI 10.1007/s00405-014-3387-6; Demirturk M, 2013, ALLERGY, V68, P185; Demoly P, 2013, CLIN EXP ALLERGY, V43, P881, DOI 10.1111/cea.12121; Demoly P, 2011, CLIN EXP ALLERGY, V41, P860, DOI 10.1111/j.1365-2222.2011.03734.x; Demoly P, 2003, ALLERGY, V58, P672, DOI 10.1034/j.1398-9995.2003.t01-1-00202.x; Demoly Pascal, 2013, Clin Transl Allergy, V3, P7, DOI 10.1186/2045-7022-3-7; Department of Health and Human Services, 1994, FED REG, V59; Department of Health and Human Services Food and Drug Administration, LAB NAS DEC DRUG PRO; Derendorf H, 2008, ALLERGY, V63, P1292, DOI 10.1111/j.1398-9995.2008.01750.x; DEVILLIER P, 1988, EUR RESPIR J, V1, P356; Dhami S, 2017, ALLERGY, V72, P1597, DOI 10.1111/all.13201; Di Bona D, 2010, J ALLERGY CLIN IMMUN, V126, P558, DOI 10.1016/j.jaci.2010.06.013; Di Lorenzo G, 2004, CLIN EXP ALLERGY, V34, P259, DOI 10.1111/j.1365-2222.2004.01877.x; Dockhorn R, 1999, ANN ALLERG ASTHMA IM, V82, P349, DOI 10.1016/S1081-1206(10)63284-X; Dondi A, 2013, PEDIAT ALLERG IMM-UK, V24, P742, DOI 10.1111/pai.12136; Donovan R, 1972, J Laryngol Otol, V86, P731; DRUCE HM, 1992, ANN ALLERGY, V69, P53; Duman H, 2013, ALLERGY, V68, P274; Dykewicz MS, 2017, ANN ALLERG ASTHMA IM, V119, P489, DOI 10.1016/j.anai.2017.08.012; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; DYMENT PG, 1970, PEDIATRICS, V46, P136; Dzieciolowska-Baran E, 2013, ADV EXP MED BIOL, V755, P213, DOI 10.1007/978-94-007-4546-9_27; Eccles R, 2008, AM J RHINOL, V22, P491, DOI 10.2500/ajr.2008.22.3202; Eccles R, 2007, BRIT J CLIN PHARMACO, V63, P10, DOI 10.1111/j.1365-2125.2006.02833.x; Eccles R, 2010, CURR MED RES OPIN, V26, P889, DOI 10.1185/03007991003648015; Eckel N, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-44; Edelstein DR, 1996, LARYNGOSCOPE, V106, P1, DOI 10.1097/00005537-199609001-00001; El Sayed MF, 2009, EUR J PEDIATR, V168, P667, DOI 10.1007/s00431-008-0815-x; Ellis AK, 2006, CURR ALLERGY ASTHM R, V6, P215, DOI 10.1007/s11882-006-0037-0; Ellis AK, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-16; Ellis AK, 2013, ANN ALLERG ASTHMA IM, V111, P323, DOI 10.1016/j.anai.2013.07.019; ENBERG RN, 1989, ANN ALLERGY, V63, P513; Epstein TG, 2014, J ALLER CL IMM-PRACT, V2, P161, DOI 10.1016/j.jaip.2014.01.004; Erel F, 2017, IRAN J ALLERGY ASTHM, V16, P193; Eskiizmir G, 2011, EUR J CLIN PHARMACOL, V67, P19, DOI 10.1007/s00228-010-0941-z; Esposito S, 2012, PEDIAT ALLERG IMM-UK, V23, P17, DOI 10.1111/j.1399-3038.2012.01319.x; Esteitie R, 2010, ANN ALLERG ASTHMA IM, V105, P155, DOI 10.1016/j.anai.2010.05.017; Etwel F, 2014, J OBSTET GYNAECOL, V34, P392, DOI 10.3109/01443615.2014.896887; Fairchild CJ, 2007, ALLERGY ASTHMA PROC, V28, P716, DOI 10.2500/aap.2007.28.3062; Feldman EM, 2010, AESTHET SURG J, V30, P672, DOI 10.1177/1090820X10381988; Feng SY, 2015, AM J RHINOL ALLERGY, V29, P57, DOI 10.2500/ajra.2015.29.4116; Fernandez-Rivas M, 1997, J ALLERGY CLIN IMMUN, V100, P728, DOI 10.1016/S0091-6749(97)70265-3; Filiaci F, 1994, Allergol Immunopathol (Madr), V22, P264; Fokkens WJ, 2002, ANN ALLERG ASTHMA IM, V89, P279, DOI 10.1016/S1081-1206(10)61955-2; Fonseca JA, 2010, ALLERGY, V65, P1042, DOI 10.1111/j.1398-9995.2009.02310.x; Fonseca Joao A, 2012, Clin Transl Allergy, V2, P16, DOI 10.1186/2045-7022-2-16; GANDERTON MA, 1970, BMJ-BRIT MED J, V1, P267, DOI 10.1136/bmj.1.5691.267; Gao F, 2019, CHINESE MED J-PEKING, V132, P653, DOI 10.1097/CM9.0000000000000118; Garavello W, 2010, INT ARCH ALLERGY IMM, V151, P137, DOI 10.1159/000236003; Gawchik S, 2003, ANN ALLERG ASTHMA IM, V90, P416, DOI 10.1016/S1081-1206(10)61826-1; Gawlik R, 2013, AM J RHINOL ALLERGY, V27, P514, DOI 10.2500/ajra.2013.27.3955; Georgalas C, 2012, CURR OPIN OTOLARYNGO, V20, P9, DOI 10.1097/MOO.0b013e32834dfb52; Georgitis JW, 2000, ANN ALLERG ASTHMA IM, V84, P451, DOI 10.1016/S1081-1206(10)62280-6; GEORGITIS JW, 1994, CLIN EXP ALLERGY, V24, P1049, DOI 10.1111/j.1365-2222.1994.tb02742.x; Gevorgyan A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010591.pub2; Gilboa SM, 2014, EXPERT OPIN DRUG SAF, V13, P1667, DOI 10.1517/14740338.2014.970164; Golembesky A, 2018, J OBSTET GYNAECOL, V38, P940, DOI 10.1080/01443615.2018.1441271; Gomez E, 2013, J ALLERGY CLIN IMMUN, V132, P975, DOI 10.1016/j.jaci.2013.07.016; Gomez F, 2015, CURR OPIN ALLERGY CL, V15, P111, DOI 10.1097/ACI.0000000000000150; Gomez-Hervas J, 2015, LARYNGOSCOPE, V125, P1301, DOI 10.1002/lary.25107; Gonyeau MJ, 2003, CLIN REV MONTELUKAST; Grainger J, 2006, CLIN OTOLARYNGOL, V31, P360, DOI 10.1111/j.1749-4486.2006.01276.x; Gray SL, 2015, JAMA INTERN MED, V175, P401, DOI 10.1001/jamainternmed.2014.7663; Greenhawt M, 2017, ANN ALLERG ASTHMA IM, V118, P276, DOI 10.1016/j.anai.2016.12.009; Greiner AN, 2006, J ALLERGY CLIN IMMUN, V118, P985, DOI 10.1016/j.jaci.2006.06.029; Greiner Alexander N, 2011, Proc Am Thorac Soc, V8, P121, DOI 10.1513/pats.201004-033RN; Gross GN, 2019, ANN ALLERG ASTHMA IM, V122, P630, DOI 10.1016/j.anai.2019.03.017; Grubbe RE, 2009, J INVEST ALLERG CLIN, V19, P117; Guerra S, 2005, ALLERGY, V60, P343, DOI 10.1111/j.1398-9995.2005.00717.x; Gulliford MC, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006245; Guo Limin, 2015, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V29, P243; Guo R, 2007, ANN ALLERG ASTHMA IM, V99, P483, DOI 10.1016/S1081-1206(10)60375-4; GUTKOWSKI A, 1988, J ALLERGY CLIN IMMUN, V81, P902, DOI 10.1016/0091-6749(88)90948-7; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; Halderman A, 2015, AM J RHINOL ALLERGY, V29, P128, DOI 10.2500/ajra.2015.29.4141; Halvorsen KH, 2017, PHARMACOEPIDEM DR S, V26, P192, DOI 10.1002/pds.4142; Hammersley VS, 2017, BRIT J GEN PRACT, V67, pE293, DOI 10.3399/bjgp17X689869; Hampel FC, 2019, ALLERGY ASTHMA PROC, V40, P261, DOI 10.2500/aap.2019.40.4223; Hampel FC, 2010, ANN ALLERG ASTHMA IM, V105, P168, DOI 10.1016/j.anai.2010.06.008; Hampel FC, 2006, ALLERGY ASTHMA PROC, V27, P202, DOI 10.2500/aap.2006.27.2862; Han JK, 2015, OTOLARYNG HEAD NECK, V153, P708, DOI 10.1177/0194599815606435; HANDELMAN NI, 1977, J ALLERGY CLIN IMMUN, V59, P237, DOI 10.1016/0091-6749(77)90156-7; Hankin CS, 2013, J ALLERGY CLIN IMMUN, V131, P1084, DOI 10.1016/j.jaci.2012.12.662; Harlor Evan J, 2012, Ear Nose Throat J, V91, pE4; Harvey RP, 1996, J ALLERGY CLIN IMMUN, V97, P1233, DOI 10.1016/S0091-6749(96)70190-2; He JS, 2006, SYMMETRY INTEGR GEOM, V2, DOI 10.3842/SIGMA.2006.060; He S, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15028118; Head Karen, 2018, Cochrane Database Syst Rev, V6, pCD012597, DOI 10.1002/14651858.CD012597.pub2; Health Quality Ontario, 2016, Ont Health Technol Assess Ser, V16, P1; Heatley DG, 2001, OTOLARYNG HEAD NECK, V125, P44, DOI 10.1067/mhn.2001.115909; HEDNER P, 1981, ANN ALLERGY, V47, P176; Hellgren Johan, 2007, Clin Allergy Immunol, V19, P241; Hellings PW, 2017, ALLERGY, V72, P1657, DOI 10.1111/all.13200; Hermelingmeier KE, 2012, AM J RHINOL ALLERGY, V26, pE119, DOI 10.2500/ajra.2012.26.3787; Hildenbrand T, 2011, EUR ARCH OTO-RHINO-L, V268, P17, DOI 10.1007/s00405-010-1391-z; Ho CY, 2007, AM J RHINOL, V21, P439, DOI 10.2500/ajr.2007.21.3044; Ho JC, 2001, AM J RESP CRIT CARE, V163, P983, DOI 10.1164/ajrccm.163.4.9909121; Hoa NQ, 2009, TROP MED INT HEALTH, V14, P546, DOI 10.1111/j.1365-3156.2009.02267.x; Horak F, 2006, CURR MED RES OPIN, V22, P151, DOI 10.1185/030079906X80305; Horak F, 2002, J ALLERGY CLIN IMMUN, V109, P956, DOI 10.1067/mai.2002.124657; Horak Friedrich, 2008, Ther Clin Risk Manag, V4, P1009; Horak F, 2009, ANN ALLERG ASTHMA IM, V102, P116, DOI 10.1016/S1081-1206(10)60240-2; Houser SM, 2006, OTOLARYNG HEAD NECK, V135, P972, DOI 10.1016/j.otohns.2005.04.017; Howarth Peter H, 2005, J Allergy Clin Immunol, V115, pS414, DOI 10.1016/j.jaci.2004.12.1134; Hox V, 2014, ALLERGY, V69, P282, DOI 10.1111/all.12347; Huang T, 2018, WORLD J PEDIATR, V14, P570, DOI 10.1007/s12519-018-0188-9; Ibanez MD, 1996, ANN ALLERG ASTHMA IM, V77, P185, DOI 10.1016/S1081-1206(10)63252-8; Ichimaru Y, 2008, J INT MED RES, V36, P559, DOI 10.1177/147323000803600322; Incorvaia C, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-11; Irwin RS, 2018, CHEST, V153, P196, DOI 10.1016/j.chest.2017.10.016; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640; Jackson CL, 2016, EUR RESPIR J, V47, P837, DOI 10.1183/13993003.00749-2015; JACOBS MB, 1986, POSTGRAD MED, V80, P159, DOI 10.1080/00325481.1986.11699543; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; Jacobs R, 2009, ALLERGY ASTHMA PROC, V30, P120, DOI 10.2500/aap.2009.30.3206; Jauregui I, 2009, J INVEST ALLERG CLIN, V19, P32; Jauregui I, 2011, PEDIAT ALLERG IMM-UK, V22, P388, DOI 10.1111/j.1399-3038.2010.01108.x; Jiang ZY, 2018, J NEUROL SURG PART B, V79, P193, DOI 10.1055/s-0037-1606306; Jones NS, 1998, J LARYNGOL OTOL, V112, P1019, DOI 10.1017/S0022215100142380; Jose J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005235.pub2; Joseph RM, 2016, SEMIN ARTHRITIS RHEU, V46, P133, DOI 10.1016/j.semarthrit.2016.03.001; Jovancevic L, 2010, RHINOLOGY, V48, P7, DOI 10.4193/Rhin07.153; Jun BC, 2009, EUR ARCH OTO-RHINO-L, V266, P975, DOI 10.1007/s00405-008-0855-x; Kaiser HB, 2007, J ALLERGY CLIN IMMUN, V119, P1430, DOI 10.1016/j.jaci.2007.02.022; Kaiser HB, 1998, ALLERGY ASTHMA PROC, V19, P23, DOI 10.2500/108854198778557962; KAISER HB, 1995, J ALLERGY CLIN IMMUN, V95, P1128, DOI 10.1016/S0091-6749(95)70217-2; Kaliner MA, 2011, ANN ALLERG ASTHMA IM, V106, pS6, DOI 10.1016/j.anai.2010.08.010; Kaliner MA, 2009, WORLD ALLERGY ORGAN, V2, P98, DOI 10.1097/WOX.0b013e3181a9d55b; Kaliner MA, 2009, WORLD ALLERGY ORGAN, V2, P119, DOI 10.1097/WOX.0b013e3181a8e15a; Kaliner MA, 2009, ANN ALLERG ASTHMA IM, V103, P373, DOI 10.1016/S1081-1206(10)60355-9; Kallen BAJ, 2006, AM J OBSTET GYNECOL, V194, P480, DOI 10.1016/j.ajog.2005.06.087; Kallen Bengt, 2006, Int J Med Sci, V3, P106; Kalpaklioglu AF, 2010, AM J RHINOL ALLERGY, V24, P29, DOI 10.2500/ajra.2010.24.3423; KAPER NM, 2013, OTOLARYNG HEAD NECK, V149, P664, DOI DOI 10.1177/0194599813505841; Kaplan A, 2014, CAN FAM PHYSICIAN, V60, P227; Kaszuba SM, 2001, ARCH INTERN MED, V161, P2581, DOI 10.1001/archinte.161.21.2581; KAUFMAN HS, 1986, ARCH OPHTHALMOL-CHIC, V104, P967; Kavut AB, 2013, INT ARCH ALLERGY IMM, V160, P184, DOI 10.1159/000339739; Keith PK, 2012, ALLERGY ASTHMA CL IM, V8, DOI 10.1186/1710-1492-8-7; Keskin O, 2006, PEDIAT ALLERG IMM-UK, V17, P259, DOI 10.1111/j.1399-3038.2006.00397.x; KIRKEGAARD J, 1988, ACTA OTO-LARYNGOL, P93; KIRKEGAARD J, 1987, J ALLERGY CLIN IMMUN, V79, P585, DOI 10.1016/S0091-6749(87)80153-7; Kirtsreesakul V, 2015, AM J RHINOL ALLERGY, V29, P343, DOI 10.2500/ajra.2015.29.4234; KNIGHT A, 1976, J ALLERGY CLIN IMMUN, V58, P278, DOI 10.1016/0091-6749(76)90132-9; KOLLY M, 1986, BRIT J CLIN PHARMACO, V22, P389, DOI 10.1111/j.1365-2125.1986.tb02907.x; Konradsen JR, 2011, PEDIAT ALLERG IMM-UK, V22, P9, DOI 10.1111/j.1399-3038.2010.01098.x; Korkut AY, 2012, J LARYNGOL OTOL, V126, P784, DOI 10.1017/S0022215112001260; Kotwani A, 2014, TROP MED INT HEALTH, V19, P761, DOI 10.1111/tmi.12327; Kowalski ML, 2013, ALLERGY, V68, P1219, DOI 10.1111/all.12260; Kremer B, 2004, CURR OPIN ALLERGY CL, V4, P171, DOI 10.1097/01.all.0000129446.88974.48; Kristiansen M, 2017, PEDIAT ALLERG IMM-UK, V28, P18, DOI 10.1111/pai.12661; Krzych-Falta E, 2015, IRAN J ALLERGY ASTHM, V14, P581; Kuan EC, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-014-0493-x; Kurowski M, 2004, ALLERGY, V59, P280, DOI 10.1046/j.1398-9995.2003.00416.x; LaForce C, 1996, ANN ALLERG ASTHMA IM, V76, P181, DOI 10.1016/S1081-1206(10)63420-5; LaForce CF, 2004, ANN ALLERG ASTHMA IM, V93, P154, DOI 10.1016/S1081-1206(10)61468-8; LaForce CF, 2010, ALLERGY ASTHMA PROC, V31, P132, DOI 10.2500/aap.2010.31.3326; Lambert EM, 2013, INT FORUM ALLERGY RH, V3, P795, DOI 10.1002/alr.21184; Laohasiriwong S, 2013, LARYNGOSCOPE, V123, P3233, DOI 10.1002/lary.24236; Larenas-Linnemann D, 2014, AM J RHINOL ALLERGY, V28, P232, DOI 10.2500/ajra.2014.28.4035; Larenas-Linnemann D, 2013, AM J RHINOL ALLERGY, V27, P495, DOI 10.2500/ajra.2013.27.3957; Larenas-Linnemann DES, 2016, ALLERGY ASTHMA PROC, V37, pE112, DOI 10.2500/aap.2016.37.3981; Larenas-Linnemann DES, 2012, ANN ALLERG ASTHMA IM, V108, P373, DOI 10.1016/j.anai.2012.03.009; Lau J, 1999, AHRQ EVIDENCE REPORT, V9; Law SWY, 2018, DRUG SAFETY, V41, P253, DOI 10.1007/s40264-017-0607-1; Lee M, 2011, CLIN THER, V33, P1590, DOI 10.1016/j.clinthera.2011.09.029; Lee MS, 2009, ANN ALLERG ASTHMA IM, V102, P269; Lee MS, 2009, ANN ALLERG ASTHMA IM, V102, P269, DOI 10.1016/S1081-1206(10)60330-4; Lemiengre MB, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006089.pub4; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Li Q, 2013, J ALLER CL IMM-PRACT, V1, P666, DOI 10.1016/j.jaip.2013.07.008; Lieberman JA, 2011, CURR ALLERGY ASTHM R, V11, P58, DOI 10.1007/s11882-010-0149-4; Lieberman P, 1999, J ALLERGY CLIN IMMUN, V103, pS400, DOI 10.1016/S0091-6749(99)70220-4; Lieberman P, 2011, ALLERGY ASTHMA PROC, V32, P151, DOI 10.2500/aap.2011.32.3439; Lieberman PL, 2003, ALLERGY ASTHMA PROC, V24, P95; Lin L, 2017, AM J RHINOL ALLERGY, V31, P96, DOI 10.2500/ajra.2017.31.4418; Lin SY, 2013, AHRQ COMP EFFECTIVEN; Lindstrand A, 2014, PEDIATRICS, V134, pE1528, DOI 10.1542/peds.2013-4177; Linneberg A, 2008, CLIN EXP ALLERGY, V38, P145, DOI 10.1111/j.1365-2222.2007.02837.x; Lobo BC, 2017, LARYNGOSCOPE INVEST, V2, P215, DOI 10.1002/lio2.75; Lockey RF, 1996, ANN ALLERG ASTHMA IM, V76, P448, DOI 10.1016/S1081-1206(10)63462-X; Loehrl TA, 2012, FACIAL PLAST SURG CL, V20, P83, DOI 10.1016/j.fsc.2011.10.009; LOFKVIST T, 1977, ACTA ALLERGOL, V32, P35; Lopardo G, 2012, MEDICINA-BUENOS AIRE, V72, P484; Lopez S, 2010, CLIN EXP ALLERGY, V40, P1007, DOI 10.1111/j.1365-2222.2010.03492.x; Loureiro G, 2011, ALLERGY, V66, P352; Lu S, 2009, J ASTHMA, V46, P878, DOI 10.3109/02770900903104540; Lucas JS, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01090-2016; Lumry W, 2007, ANN ALLERG ASTHMA IM, V99, P267, DOI 10.1016/S1081-1206(10)60663-1; Luo QL, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1988-5; Lupa M, 2012, OTOLARYNG CLIN N AM, V45, P983, DOI 10.1016/j.otc.2012.06.004; LURIE A, 1994, AM J RESP CRIT CARE, V149, P113, DOI 10.1164/ajrccm.149.1.7509244; Major MP, 2014, J AM DENT ASSOC, V145, P247, DOI 10.14219/jada.2013.31; MALMBERG H, 1983, CLIN OTOLARYNGOL, V8, P273, DOI 10.1111/j.1365-2273.1983.tb01441.x; MARABINI S, 1991, EUR ARCH OTO-RHINO-L, V248, P191; Marchiano E, 2017, J NEUROL SURG PART B, V78, P18, DOI 10.1055/s-0036-1584297; Marinetti L, 2005, J ANAL TOXICOL, V29, P738, DOI 10.1093/jat/29.7.738; Marshak T, 2016, J LARYNGOL OTOL, V130, pS7, DOI 10.1017/S0022215116008008; Mathias T, 2016, OCHSNER J, V16, P136; McCrory D C, 2003, Evid Rep Technol Assess (Summ), P1; Meadows A, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17270; Meggs WJ, 1996, J TOXICOL-CLIN TOXIC, V34, P383, DOI 10.3109/15563659609013808; Mehuys E, 2014, J ALLER CL IMM-PRACT, V2, P313, DOI 10.1016/j.jaip.2014.01.009; Mello CJ, 1996, ARCH INTERN MED, V156, P997, DOI 10.1001/archinte.156.9.997; Meltzer E, 2013, INT ARCH ALLERGY IMM, V161, P369, DOI 10.1159/000351404; Meltzer EO, 2007, ANN ALLERG ASTHMA IM, V98, P12, DOI 10.1016/S1081-1206(10)60854-X; Meltzer EO, 2016, ANN ALLERG ASTHMA IM, V116, P66, DOI 10.1016/j.anai.2015.10.022; Meltzer EO, 2015, J ALLER CL IMM-PRACT, V3, P702, DOI 10.1016/j.jaip.2015.05.007; Meltzer EO, 2013, AM J RHINOL ALLERGY, V27, P102, DOI 10.2500/ajra.2013.27.3864; Meltzer EO, 2013, J ALLERGY CLIN IMMUN, V131, P379, DOI 10.1016/j.jaci.2012.10.022; Meltzer Eli O, 2012, Allergy Asthma Proc, V33 Suppl 1, pS113, DOI 10.2500/aap.2012.33.3603; Meltzer EO, 2012, ALLERGY ASTHMA PROC, V33, P249, DOI 10.2500/aap.2012.33.3571; Meltzer EO, 2011, IMMUNOL ALLERGY CLIN, V31, P545, DOI 10.1016/j.iac.2011.05.004; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; Meltzer EO, 2005, ANN ALLERG ASTHMA IM, V95, P600, DOI 10.1016/S1081-1206(10)61025-3; Meltzer EO, 1996, J ALLERGY CLIN IMMUN, V97, P617, DOI 10.1016/S0091-6749(96)70307-X; Meltzer EO, 2002, CLIN THER, V24, P942, DOI 10.1016/S0149-2918(02)80009-1; Meltzer EO, 2001, ANN ALLERG ASTHMA IM, V86, P286, DOI 10.1016/S1081-1206(10)63300-5; Meltzer EO, 1999, J ALLERGY CLIN IMMUN, V104, P107, DOI 10.1016/S0091-6749(99)70121-1; Mener DJ, 2015, INT FORUM ALLERGY RH, V5, P95, DOI 10.1002/alr.21430; Meng YF, 2019, ALLERGY, V74, P720, DOI 10.1111/all.13640; Menger H, 1997, AM J MED GENET, V72, P129, DOI 10.1002/(SICI)1096-8628(19971017)72:2<129::AID-AJMG2>3.3.CO;2-8; Mishra AK, 2012, AIP ADV, V2, DOI 10.1063/1.4717490; Modgill V, 2010, METHOD FIND EXP CLIN, V32, P669, DOI 10.1358/mf.2010.32.9.1533686; MOLLER C, 1989, ANN ALLERGY, V62, P343; Moneret-Vautrin D A, 1989, Ann Otolaryngol Chir Cervicofac, V106, P47; Montoro J, 2012, ALLERGY, V67, P1437, DOI 10.1111/all.12011; Moore EJ, 2001, AM J RHINOL, V15, P355, DOI 10.1177/194589240101500601; Moote W, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0282-5; Morais-Almeida M, 2013, ALLERGY, V68, P1150, DOI 10.1111/all.12207; Morris S, 1997, AM J RHINOL, V11, P109, DOI 10.2500/105065897782537197; Moscato G, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-16; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; MULLARKEY MF, 1988, J ALLERGY CLIN IMMUN, V82, P941, DOI 10.1016/0091-6749(88)90037-1; Murphy TF, 2009, PEDIATR INFECT DIS J, V28, P43, DOI 10.1097/INF.0b013e318184dba2; Naclerio RM, 2010, INT J GEN MED, V3, P47; Naini AS, 2016, INDIAN J OTOLARYNGOL, V68, P329, DOI 10.1007/s12070-014-0753-z; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Nathan RA, 2006, ANN ALLERG ASTHMA IM, V97, P389, DOI 10.1016/S1081-1206(10)60806-X; Nathan RA, 2014, CURR OPIN ALLERGY CL, V14, P13, DOI 10.1097/ACI.0000000000000020; Nathan RA, 2010, PATIENT, V3, P91, DOI 10.2165/11318410-000000000-00000; National Center for Complementary and Integrative Health, 2017, BUTT; Nayak A, 2007, DRUGS, V67, P887, DOI 10.2165/00003495-200767060-00005; Nelsen LM, 2012, J ALLERGY CLIN IMMUN, V129, P251, DOI 10.1016/j.jaci.2011.09.003; NELSON BL, 1982, J ALLERGY CLIN IMMUN, V70, P125, DOI 10.1016/0091-6749(82)90240-8; Nelson H, 2015, J ALLER CL IMM-PRACT, V3, P256, DOI 10.1016/j.jaip.2014.09.018; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V97, P1193, DOI 10.1016/S0091-6749(96)70184-7; Ng DK, 2004, PEDIATRICS, V114, P1242, DOI 10.1542/peds.2004-0744; Ng MLS, 2000, CLIN EXP ALLERGY, V30, P1314; Ng TT, 2017, OPEN ACCESS EMERG M, V9, P107, DOI 10.2147/OAEM.S150503; NOBLE SL, 1995, AM FAM PHYSICIAN, V51, P837; Nogueira-Silva L, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-52; Noon L, 1911, LANCET, V1, P1572; Norlander T, 1996, EUR ARCH OTO-RHINO-L, V253, P205; Nurmatov U, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0159-6; OHANLON JF, 1995, ALLERGY, V50, P234, DOI 10.1111/j.1398-9995.1995.tb01140.x; OHanlon JF, 1998, I DRUGS SAFETY BEHAV, V42, P10; Olarte L, 2014, PEDIATR INFECT DIS J, V33, P1033, DOI 10.1097/INF.0000000000000387; OPATOWSKY I, 1995, OPHTHALMOLOGY, V102, P177; Orban N, 2013, RHINOLOGY, V51, P111, DOI [10.4193/Rhin12.045, 10.4193/Rhino12.045]; ORGEL HA, 1991, ANN ALLERGY, V66, P237; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; OSTBERG B, 1987, ARCH OTOLARYNGOL, V113, P160; Ozcan C, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0636-3; Palombini BC, 1999, CHEST, V116, P279, DOI 10.1378/chest.116.2.279; Panasiuk L, 2010, J CLIN PHARM THER, V35, P665, DOI 10.1111/j.1365-2710.2009.01136.x; Parashar R, 2016, J CLIN DIAGN RES, V10, pCC11, DOI 10.7860/JCDR/2016/16889.7497; Patel D, 2007, ALLERGY ASTHMA PROC, V28, P592, DOI 10.2500/aap2007.28.3033; Patel P, 2008, ANN ALLERG ASTHMA IM, V101, P287, DOI 10.1016/S1081-1206(10)60494-2; Patel P, 2007, OTOLARYNG HEAD NECK, V137, P918, DOI 10.1016/j.otohns.2007.08.005; Patel P, 2007, AM J RHINOL, V21, P499, DOI 10.2500/ajr.2007.21.3058; Patel P, 2019, ANN ALLERG ASTHMA IM, V122, P160, DOI 10.1016/j.anai.2018.10.011; Patel P, 2008, ENT-EAR NOSE THROAT, V87, P340, DOI 10.1177/014556130808700612; Pecova R, 2005, J Physiol Pharmacol, V56 Suppl 4, P171; Pecova R, 2008, J PHYSIOL PHARMACOL, V59, P557; PELIKAN Z, 1983, ANN ALLERGY, V51, P395; PENTEL P, 1984, JAMA-J AM MED ASSOC, V252, P1898, DOI 10.1001/jama.252.14.1898; Pepper AN, 2018, J ALLERGY CLIN IMMUN, V141, P1570, DOI 10.1016/j.jaci.2017.11.066; Pereira L, 2018, SLEEP MED REV, V38, P101, DOI 10.1016/j.smrv.2017.06.001; Peters AT, 2014, ANN ALLERG ASTHMA IM, V113, P347, DOI 10.1016/j.anai.2014.07.025; PETRUSON B, 1981, Rhinology (Utrecht), V19, P167; Philip G, 2004, CURR MED RES OPIN, V20, P1549, DOI 10.1185/030079904X3348; Pinargote Paulette, 2014, BMJ Case Rep, V2014, DOI 10.1136/bcr-2014-205462; Pinto Jayant M, 2010, Allergy Asthma Clin Immunol, V6, P10, DOI 10.1186/1710-1492-6-10; Pleskow W, 2005, ANN ALLERG ASTHMA IM, V94, P348, DOI 10.1016/S1081-1206(10)60986-6; Powe DG, 2003, CLIN EXP ALLERGY, V33, P1374, DOI 10.1046/j.1365-2222.2003.01737.x; PRATTER MR, 1993, ANN INTERN MED, V119, P977, DOI 10.7326/0003-4819-119-10-199311150-00003; Pratter MR, 2006, CHEST, V129, p59S, DOI 10.1378/chest.129.1_suppl.59S; Price D, 2013, J INVEST ALLERG CLIN, V23, P495; PROUD D, 1990, INT ARCH ALLER A IMM, V93, P165, DOI 10.1159/000235296; Pullerits T, 2002, J ALLERGY CLIN IMMUN, V109, P949, DOI 10.1067/mai.2002.124467; Rabago D, 2006, ANN FAM MED, V4, P295, DOI 10.1370/afm.552; Radulovic S, 2011, ALLERGY, V66, P740, DOI 10.1111/j.1398-9995.2011.02583.x; RAMAEKERS JG, 1992, EUR J CLIN PHARMACOL, V42, P363; Rao SUP, 2017, J CLIN DIAGN RES, V11, DOI 10.7860/JCDR/2017/24861.9850; Ratner PH, 2008, ANN ALLERG ASTHMA IM, V100, P74, DOI 10.1016/S1081-1206(10)60408-5; Ratner PH, 2006, J ALLERGY CLIN IMMUN, V118, P1142, DOI 10.1016/j.jaci.2006.07.050; Ratner PH, 2012, ALLERGY ASTHMA PROC, V33, P27, DOI 10.2500/aap.2012.33.3490; RATNER PH, 1994, J ALLERGY CLIN IMMUN, V94, P818, DOI 10.1016/0091-6749(94)90148-1; Ratner PH, 2005, ANN ALLERG ASTHMA IM, V95, P474, DOI 10.1016/S1081-1206(10)61174-X; Ratner PH, 2002, MAYO CLIN PROC, V77, P350, DOI 10.4065/77.4.350; Ray W A, 1993, Clin Geriatr Med, V9, P413; Raza SN, 2011, J OTOLARYNGOL-HEAD N, V40, P407, DOI 10.2310/7070.2011.110003; Refaat M, 2015, J ALLERGY CLIN IMMUN, V135, pAB140, DOI 10.1016/j.jaci.2014.12.1394; Reinecke S, 2005, MMW Fortschr Med, V147, P46; Reisacher WR, 2014, INT FORUM ALLERGY RH, V4, P292, DOI 10.1002/alr.21281; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Rinder J, 1996, Acta Physiol Scand Suppl, V632, P1; Risacher SL, 2016, JAMA NEUROL, V73, P721, DOI 10.1001/jamaneurol.2016.0580; Roberge RJ, 1999, J EMERG MED, V17, P285, DOI 10.1016/S0736-4679(98)00193-0; Roberts G, 2013, ALLERGY, V68, P1102, DOI 10.1111/all.12235; Rodrigo GJ, 2011, CLIN EXP ALLERGY, V41, P160, DOI 10.1111/j.1365-2222.2010.03654.x; Rodrigo GJ, 2006, ANN ALLERG ASTHMA IM, V96, P779, DOI 10.1016/S1081-1206(10)61339-7; Rodriguez K, 2015, INT FORUM ALLERGY RH, V5, P1063, DOI 10.1002/alr.21583; Rohrbach Saskia, 2009, Head Face Med, V5, P18, DOI 10.1186/1746-160X-5-18; Rondon C, 2018, ALLERGY, V73, P905, DOI 10.1111/all.13350; Rondon C, 2018, ALLERGY, V73, P470, DOI 10.1111/all.13272; Rondon C, 2014, ALLERGY, V69, P65; Rondon C, 2012, ALLERGY, V67, P1282, DOI 10.1111/all.12002; Rondon C, 2015, WORLD ALLERGY ORGAN, V8, pA263; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Rondon C, 2018, CURR OPIN ALLERGY CL, V18, P342, DOI 10.1097/ACI.0000000000000456; Rondon C, 2015, J ALLERGY CLIN IMMUN, V135, pAB171, DOI 10.1016/j.jaci.2014.12.1495; Rondon C, 2014, J ALLERGY CLIN IMMUN, V133, P1026, DOI 10.1016/j.jaci.2013.10.034; Rondon C, 2014, J ALLERGY CLIN IMMUN, V133, pAB75, DOI 10.1016/j.jaci.2013.12.290; Rondon C, 2011, J ALLERGY CLIN IMMUN, V127, P1069, DOI 10.1016/j.jaci.2010.12.013; Rondon C, 2009, J ALLERGY CLIN IMMUN, V124, P1005, DOI 10.1016/j.jaci.2009.07.018; Rosenfeld RM, 2015, OTOLARYNG HEAD NECK, V152, pS1, DOI 10.1177/0194599815572097; RUPP GH, 1982, PEDIATRICS, V70, P437; Salapatek AM, 2011, ALLERGY ASTHMA PROC, V32, P221, DOI 10.2500/aap.2011.32.3444; Salerno SM, 2005, ARCH INTERN MED, V165, P1686, DOI 10.1001/archinte.165.15.1686; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sansone Randy A, 2011, Innov Clin Neurosci, V8, P12; Santos CB, 2008, ALLERGY ASTHMA PROC, V29, P140, DOI 10.2500/aap.2008.29.3097; SANWIKARJA S, 1986, ANN ALLERGY, V56, P162; Sapd T, 2008, RHINOLOGY, V46, P45; Sarkar M, 2009, EUR J CLIN PHARMACOL, V65, P1259, DOI 10.1007/s00228-009-0713-9; Sauder KL, 1997, AM J EMERG MED, V15, P521, DOI 10.1016/S0735-6757(97)90200-X; Scadding GK, 2017, CLIN EXP ALLERGY, V47, P856, DOI 10.1111/cea.12953; Scadding GW, 2017, JAMA-J AM MED ASSOC, V317, P615, DOI 10.1001/jama.2016.21040; SCHATA M, 1991, J ALLERGY CLIN IMMUN, V87, P873, DOI 10.1016/0091-6749(91)90136-C; Schatz M, 2007, ALLERGY, V62, P9, DOI 10.1111/j.1398-9995.2007.01548.x; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; Schatz M, 2010, ANN ALLERG ASTHMA IM, V104, P118, DOI 10.1016/j.anai.2009.11.063; Schoenwetter WF, 2004, CURR MED RES OPIN, V20, P305, DOI 10.1185/030079903125003053; Schrodter S, 2003, ANAT EMBRYOL, V207, P19, DOI 10.1007/s00429-003-0326-5; Schumock GT, 2012, J ALLERGY CLIN IMMUN, V130, P368, DOI 10.1016/j.jaci.2012.04.035; Schwartz RH, 2001, OTOLARYNG HEAD NECK, V124, P160, DOI 10.1067/mhn.2001.112879; Segall N, 2019, ALLERGY ASTHMA PROC, V40, P301, DOI 10.2500/aap.2019.40.4233; Segboer C, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010592.pub2; Seidman MD, 2015, OTOLARYNG HEAD NECK, V152, P197, DOI 10.1177/0194599814562166; SETTIPANE GA, 1985, NEW ENGL REG ALLERGY, V6, P363; Settipane RA, 2001, ANN ALLERG ASTHMA IM, V86, P494, DOI 10.1016/S1081-1206(10)62896-7; SETTIPANE RA, 2001, ANN ALLERG ASTHMA IM, V86, P507, DOI DOI 10.1016/S1081-1206(10)62896-7; US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2018, ALL RHIN DEV DRUG PR; US Food and Drug Administration, IS RINS YOUR SIN NET; US Food and Drug Administration, 2020, FDA REQ BOX WARN SER; Wustenberg E, 2017, ALLERGO J, V26, P14; Shah S, 2009, ALLERGY ASTHMA PROC, V30, P628, DOI 10.2500/aap.2009.30.3296; Shah SR, 2009, CLIN THER, V31, P99, DOI 10.1016/j.clinthera.2009.01.016; Shahar E, 2014, CURR DRUG SAF, V9, P159, DOI 10.2174/1574886309666140527112408; Shaikh WA, 2012, ALLERGY, V67, P741, DOI 10.1111/j.1398-9995.2012.02815.x; Shamsi Z, 2000, HUM PSYCHOPHARM CLIN, V15, pS3, DOI 10.1002/1099-1077(200010)15:1+<::AID-HUP247>3.0.CO;2-S; Shapiro AJ, 2018, AM J RESP CRIT CARE, V197, pE24, DOI 10.1164/rccm.201805-0819ST; Sheikh A, 2009, BMJ CLIN EVID, V2009, P0509; Shin YS, 2018, CURR OPIN ALLERGY CL, V18, P10, DOI 10.1097/ACI.0000000000000413; Shusterman D, 2004, NEUROPEPTIDES, V38, P351, DOI 10.1016/j.npep.2004.08.002; Silvers WS, 2006, ANN ALLERG ASTHMA IM, V96, P334, DOI 10.1016/S1081-1206(10)61244-6; Simons FER, 2011, J ALLERGY CLIN IMMUN, V128, P1139, DOI 10.1016/j.jaci.2011.09.005; SIMONS FER, 1994, J PEDIATR-US, V124, P979; Singh U, 2017, INT ARCH ALLERGY IMM, V173, P153, DOI 10.1159/000478698; Singh U, 2014, AM J RHINOL ALLERGY, V28, P215, DOI 10.2500/ajra.2014.28.4059; Sinikumpu JJ, 2017, SCAND J SURG, V106, P350, DOI 10.1177/1457496916688139; SJOGREN I, 1988, ACTA OTO-LARYNGOL, V106, P453, DOI 10.3109/00016488809122270; SKONER DP, 1986, ARCH OTOLARYNGOL, V112, P840; Slavin Raymond G, 2009, Allergy Asthma Clin Immunol, V5, P9, DOI 10.1186/1710-1492-5-9; Smith J, 2011, J LARYNGOL OTOL, V125, P38, DOI 10.1017/S0022215110001921; Smith PK, 2011, AM J RHINOL ALLERGY, V25, pE149, DOI 10.2500/ajra.2011.25.3620; SMYRNIOS NA, 1995, CHEST, V108, P991, DOI 10.1378/chest.108.4.991; Soylu A, 2016, EUR REV MED PHARMACO, V20, P2315; Stern MA, 1998, ANN ALLERG ASTHMA IM, V81, P354, DOI 10.1016/S1081-1206(10)63128-6; Storms W W, 1994, Ear Nose Throat J, V73, P382; Stubner P, 2004, CURR MED RES OPIN, V20, P891, DOI 10.1185/030079904125003700; Stubner UP, 1999, ALLERGY, V54, P865, DOI 10.1034/j.1398-9995.1999.00961.x; Stuck BA, 2015, J ALLERGY CLIN IMMUN, V136, P1460, DOI 10.1016/j.jaci.2015.08.003; Szeinbach Sheryl L, 2007, Prim Care Respir J, V16, P98, DOI 10.3132/pcrj.2007.00015; Tabatabaei SA, 2012, J RES MED SCI, V17, P182; Tannenbaum C, 2012, DRUG AGING, V29, P639, DOI 10.2165/11633250-000000000-00000; Tatar M, 2009, PULM PHARMACOL THER, V22, P121, DOI 10.1016/j.pupt.2008.11.014; Tatekawa H, 2018, JPN J RADIOL, V36, P361, DOI 10.1007/s11604-018-0739-y; TAYLOR G, 1971, Clinical Allergy, V1, P189, DOI 10.1111/j.1365-2222.1971.tb03018.x; Tenn MW, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-017-0227-4; Thompson LDR, 2018, VIRCHOWS ARCH, V472, P315, DOI 10.1007/s00428-017-2116-0; Thongngarm T, 2016, ASIAN PAC J ALLERGY, V34, P30, DOI 10.12932/AP0649.34.1.2016; Tille KS, 2015, ANN ALLERG ASTHMA IM, V115, P258, DOI 10.1016/j.anai.2015.07.007; TOGIAS A, 1985, AM J MED, V79, P26, DOI 10.1016/0002-9343(85)90084-1; Torfs CP, 1996, TERATOLOGY, V54, P84, DOI 10.1002/(SICI)1096-9926(199606)54:2<84::AID-TERA4>3.0.CO;2-4; Tuhanioglu B, 2017, TURK J MED SCI, V47, P1736, DOI 10.3906/sag-1701-179; Vaidyanathan S, 2010, AM J RESP CRIT CARE, V182, P19, DOI 10.1164/rccm.200911-1701OC; Valenzuela CV, 2019, LARYNGOSCOPE, V129, P6, DOI 10.1002/lary.27209; van Adelsberg J, 2003, ALLERGY, V58, P1268, DOI 10.1046/j.1398-9995.2003.00261.x; van Bavel JH, 2012, ALLERGY ASTHMA PROC, V33, P386, DOI 10.2500/aap.2012.33.3593; van den Broek MFM, 2014, OTOLARYNG HEAD NECK, V150, P533, DOI 10.1177/0194599814522595; van Egmond MMHT, 2018, RHINOLOGY, V56, P195, DOI 10.4193/Rhin18.016; Van Gerven L, 2018, ALLERGY, V73, P248, DOI 10.1111/all.13245; Van Gerven L, 2017, J ALLERGY CLIN IMMUN, V140, P437, DOI 10.1016/j.jaci.2017.03.014; Van Gerven L, 2014, J ALLERGY CLIN IMMUN, V133, P1332, DOI 10.1016/j.jaci.2013.08.026; Van Gerven L, 2012, LARYNGOSCOPE, V122, P2615, DOI 10.1002/lary.23495; Van Rijswijk JB, 2003, ALLERGY, V58, P754, DOI 10.1034/j.1398-9995.2003.00203.x; Van Wijk RG, 2000, CLIN EXP ALLERGY, V30, P1792, DOI 10.1046/j.1365-2222.2000.00920.x; Varghese M, 2010, CLIN EXP ALLERGY, V40, P381, DOI 10.1111/j.1365-2222.2009.03450.x; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; Vimala LR, 2016, POL J RADIOL, V81, P80, DOI 10.12659/PJR.895698; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; WAGENMANN M, 1994, CLIN EXP ALLERGY, V24, P288, DOI 10.1111/j.1365-2222.1994.tb00233.x; Walgama E, 2013, INT FORUM ALLERGY RH, V3, P726, DOI 10.1002/alr.21170; Wallace G, 2008, ANTIGONISH REV, P122; Wang DY, 2000, AM J RHINOL, V14, P325, DOI 10.2500/105065800781329483; Wang SJ, 2012, ALLERGY, V67, P583, DOI 10.1111/j.1398-9995.2012.02806.x; WARLAND A, 1977, ACTA ALLERGOL, V32, P195, DOI 10.1111/j.1398-9995.1977.tb01350.x; Warren RSH, 1981, ALCOHOL DRUGS TRAFFI, P203; WASS U, 1988, J ALLERGY CLIN IMMUN, V81, P750, DOI 10.1016/0091-6749(88)91049-4; Watanabe H, 2003, RHINOLOGY, V41, P167; Watts AM, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00294; Webb DR, 2002, ANN ALLERG ASTHMA IM, V88, P385, DOI 10.1016/S1081-1206(10)62369-1; Webber CM, 2010, ANN ALLERG ASTHMA IM, V104, P101, DOI 10.1016/j.anai.2009.11.007; Wedback A, 2005, RHINOLOGY, V43, P86; Wei JX, 2015, ANN ALLERG ASTHMA IM, V115, P21, DOI 10.1016/j.anai.2015.04.019; Weiler JM, 2000, ANN INTERN MED, V132, P354, DOI 10.7326/0003-4819-132-5-200003070-00004; WEILER JM, 1988, J ALLERGY CLIN IMMUN, V82, P801, DOI 10.1016/0091-6749(88)90082-6; Weinstein SF, 2005, ALLERGY ASTHMA PROC, V26, P41; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; WERLER MM, 1992, TERATOLOGY, V45, P361, DOI 10.1002/tera.1420450407; Wierzbicki DA, 2008, ANN ALLERG ASTHMA IM, V100, P533, DOI 10.1016/S1081-1206(10)60051-8; Wild DC, 2008, J LARYNGOL OTOL, V122, P707, DOI 10.1017/S0022215107001612; Wilson AM, 2004, AM J MED, V116, P338, DOI 10.1016/j.amjmed.2003.10.030; Wilson AM, 2001, CLIN EXP ALLERGY, V31, P61, DOI 10.1046/j.1365-2222.2001.00964.x; Wise SK, 2018, INT FORUM ALLERGY RH, V8, P85, DOI 10.1002/alr.22070; Wolstenholme CR, 2006, AM J RHINOL, V20, P238, DOI 10.1177/194589240602000225; Wong IYZ, 2010, PEDIAT ALLERG IMM-UK, V21, P1146, DOI 10.1111/j.1399-3038.2010.01015.x; WONG L, 1981, J ALLERGY CLIN IMMUN, V67, P223, DOI 10.1016/0091-6749(81)90065-8; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7; Xue CC, 2015, ANN ALLERG ASTHMA IM, V115, P317, DOI 10.1016/j.anai.2015.05.017; Yamamoto H, 2012, ALLERGY ASTHMA PROC, V33, pE17, DOI 10.2500/aap.2012.33.3514; Yanez A, 2002, ANN ALLERG ASTHMA IM, V89, P479, DOI 10.1016/S1081-1206(10)62085-6; Yanni JM, 1996, J OCUL PHARMACOL TH, V12, P389, DOI 10.1089/jop.1996.12.389; Yau WP, 2013, AM J EPIDEMIOL, V178, P198, DOI 10.1093/aje/kws427; Yoo JK, 1997, LARYNGOSCOPE, V107, P40, DOI 10.1097/00005537-199701000-00010; Zambetti G, 2015, ALLERGY RHINOL, V6, pE94, DOI 10.2500/ar.2015.6.0125; Zhang T, 2016, EUR J PHARMACOL, V778, P158, DOI 10.1016/j.ejphar.2015.05.071; Zhang X, 2018, ALLERGY ASTHMA IMMUN, V10, P34, DOI 10.4168/aair.2018.10.1.34; Zhao GQ, 2018, EUR ARCH OTO-RHINO-L, V275, P1579, DOI 10.1007/s00405-018-4984-6; Zheng CQ, 2000, ACTA OTO-LARYNGOL, V120, P62; Zhou F, 2015, CLIN OTOLARYNGOL, V40, P551, DOI 10.1111/coa.12410; ZOHAR Y, 1990, J OTOLARYNGOL, V19, P345; Zuidmeer L, 2008, J ALLERGY CLIN IMMUN, V121, P1210, DOI 10.1016/j.jaci.2008.02.019	598	52	58	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2020	146	4					721	767		10.1016/j.jaci.2020.07.007	http://dx.doi.org/10.1016/j.jaci.2020.07.007			47	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OH2JO	32707227				2022-12-18	WOS:000582395800004
J	Ward, S; Lindsley, A; Courter, J; Assa'ad, A				Ward, Stephanie; Lindsley, Andrew; Courter, Josh; Assa'ad, Amal			Clinical testing for COVID-19	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19; coronavirus; SARS-CoV-2; viral genes; S protein; N protein; E protein; M protein; RT-PCR; test; point-of-care; prioritization; guidance; Centers for Disease Control and Prevention; Food and Drug Administration; World Health Organization; nucleic acid test; serologic test	IGA	As the novel coronavirus severe acute respiratory syndrome coronavirus 2 caused coronavirus disease 2019 cases in the United States, the initial test was developed and performed at the Centers for Disease Control and Prevention. As the number of cases increased, the demand for tests multiplied, leading the Centers for Disease Control and Prevention to use the Emergency Utilization Authorization to allow clinical and commercial laboratories to develop tests to detect the presence of the virus. Many nucleic acid tests based on RT-PCR were developed, each with different techniques, specifications, and turnaround time. As the illnesses turned into a pandemic, testing became more crucial. The test supply became inadequate to meet the need and so it had to be prioritized according to guidance. For surveillance, the need for serologic tests emerged. Here, we review the timeline of test development, the turnaround times, and the various approved tests, and compare them as regards the genes they detect. We concentrate on the point-of-care tests and discuss the basis for new serologic tests. We discuss the testing guidance for prioritization and their application in a hospital setting.	[Ward, Stephanie; Lindsley, Andrew; Assa'ad, Amal] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Courter, Josh] Cincinnati Childrens Hosp Med Ctr, Div Pharm, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Assa'ad, A (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	amal.assaad@cchmc.org						Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062; Benneyan JC, 2003, QUAL SAF HEALTH CARE, V12, P458, DOI 10.1136/qhc.12.6.458; Brady PW, 2018, J PEDIAT INF DIS SOC, V7, P100, DOI 10.1093/jpids/pix077; Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902; Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310; Hsueh PR, 2004, CLIN MICROBIOL INFEC, V10, P1062, DOI 10.1111/j.1469-0691.2004.01009.x; Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727; Matricardi PM, 2020, PEDIAT ALLERG IMM-UK, V31, P454, DOI 10.1111/pai.13271; Miller JM, 2018, CLIN INFECT DIS, V67, P813, DOI 10.1093/cid/ciy584; Mousavizadeh L, 2021, J MICROBIOL IMMUNOL, V54, P159, DOI 10.1016/j.jmii.2020.03.022; Nie SP, 2014, J CLIN MICROBIOL, V52, P3339, DOI 10.1128/JCM.01132-14; Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841; Padoan A, 2020, CLIN CHEM LAB MED, V58, P1081, DOI 10.1515/cclm-2020-0443; Provost LP., 2011, HLTH CARE DATA GUIDE; Shatizadeh Malekshahi S, 2016, INFECT DIS-NOR, V5, DOI [10.5812/pedinfect.36953., DOI 10.1093/CID/CIAA344, DOI 10.1093/cid/ciaa344]; Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316; To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1; Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624; Wolfel R, 2020, NATURE, V588, pE35, DOI 10.1038/s41586-020-2984-3; World Health Organization, 2020, RISK COMM COMM ENG R; Wyllie A.L., 2020, SALIVA IS MORE SENSI, DOI [10.1101/2020.04.16.20067835, DOI 10.1101/2020.04.16.20067835]; Zhang YC, 2020, EMERG MICROBES INFEC, V9, P833, DOI 10.1080/22221751.2020.1756699; Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443	27	52	54	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					23	34		10.1016/j.jaci.2020.05.012	http://dx.doi.org/10.1016/j.jaci.2020.05.012			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32445839	Green Published, Bronze			2022-12-18	WOS:000579170500004
J	Takabayashi, T; Schleimer, RP				Takabayashi, Tetsuji; Schleimer, Robert P.			Formation of nasal polyps: The roles of innate type 2 inflammation and deposition of fibrin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; nasal polyps; mast cell; tryptase; fibrin; coagulation cascade; fibrinolysis; tissue plasminogen activator	EOSINOPHILIC CHRONIC RHINOSINUSITIS; THYMIC STROMAL LYMPHOPOIETIN; TISSUE-PLASMINOGEN ACTIVATOR; ENDOSCOPIC SINUS SURGERY; AIRWAY EPITHELIAL-CELLS; POSITIVE MAST-CELLS; CYTOKINE PROFILES; SCORING SYSTEM; NITRIC-OXIDE; FACTOR-XIII	Chronic rhinosinusitis (CRS) is one of the most common chronic diseases worldwide. It is a heterogeneous disease, and geographical or ethnic differences in inflammatory pattern in nasal mucosa are major issues. Tissue eosinophilia in CRS is highly associated with extensive sinus disease, recalcitrance, and a higher nasal polyp (NP) recurrence rate after surgery. The prevalence of eosinophilic CRS (ECRS) is increasing in Asian countries within the last 2 decades, and this trend appears to be occurring across the world. International consensus criteria for ECRS are required for the accurate understanding of disease pathology and precision medicine. In a multicenter large-scale epidemiological survey, the "Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis study,'' ECRS was definitively defined when the eosinophil count in nasal mucosa is greater than or equal to 70 eosinophils/hpf (magnification, 3400), and this study proposed an algorithm that classifies CRS into 4 groups according to disease severity. The main therapeutic goal with ECRS is to eliminate or diminish the bulk of NP tissue. NPs are unique abnormal lesions that grow from the lining of the nasal and paranasal sinuses, and type 2 inflammation plays a critical role in NP development in patients with ECRS. An imbalance between protease and endogenous protease inhibitors might play a pivotal role in the initiation and exacerbation of type 2 inflammation in ECRS. Intraepithelial mast cells in NPs, showing a tryptase+, chymase- phenotype, may also enhance type 2 inflammation. Intense edema and reduced fibrosis are important histological features of eosinophilic NPs. Mucosal edema mainly consists of exuded plasma protein, and excessive fibrin deposition would be expected to contribute to the retention of proteins from capillaries and thereby perpetuate mucosal edema that may play an etiological role in NPs. Upregulation of the coagulation cascade and downregulation of fibrinolysis strongly induce abnormal fibrin deposition in nasal mucosa, and type 2 inflammation plays a central role in the imbalance of coagulation and fibrinolysis.	[Takabayashi, Tetsuji] Univ Fukui, Dept Sensory & Locomotor Med, Div Otorhinolaryngol Head & Neck Surg, 23 Shimoaizuki, Fukui 9101193, Japan; [Schleimer, Robert P.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Allergy & Immunol, Chicago, IL 60611 USA; [Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA	University of Fukui; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Takabayashi, T (corresponding author), Univ Fukui, Dept Sensory & Locomotor Med, Div Otorhinolaryngol Head & Neck Surg, 23 Shimoaizuki, Fukui 9101193, Japan.	tetsuji@u-fukui.ac.jp			KAKENHI [16K11207]; NIH [AI137174, PO1AI145818]; Ernest S. Bazley Charitable Fund	KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Charitable Fund	This research was supported in part by a Grant-in-Aid for Scientific Research (KAKENHI) (C) grant number 16K11207. R. P. Schleimer was supported in part by grants AI137174 on AERD and PO1AI145818 (Chronic Rhinosinusitis Integrative Studies Program 2 [CRISP2]) from the NIH and by The Ernest S. Bazley Charitable Fund.	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Akassoglou K, 2004, P NATL ACAD SCI USA, V101, P6698, DOI 10.1073/pnas.0303859101; Amin K, 2012, RESP MED, V106, P9, DOI 10.1016/j.rmed.2011.09.007; Baba S, 2014, CLIN EXP ALLERGY, V44, P701, DOI 10.1111/cea.12287; Baba S, 2017, ANN ALLERG ASTHMA IM, V119, P120, DOI 10.1016/j.anai.2017.05.019; Bachert C, 2000, AM J RHINOL, V14, P279, DOI 10.2500/105065800781329573; Bachert C, 2019, LANCET, V394, P1638, DOI 10.1016/S0140-6736(19)31881-1; Bachert C, 2018, J ALLERGY CLIN IMMUN, V141, P1543, DOI 10.1016/j.jaci.2018.03.004; Bagoly Z, 2012, THROMB RES, V129, pS77, DOI 10.1016/j.thromres.2012.02.040; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Batra PS, 2013, LARYNGOSCOPE, V123, pS1, DOI 10.1002/lary.24418; Cao PP, 2014, CLIN EXP ALLERGY, V44, P690, DOI 10.1111/cea.12304; Cao PP, 2019, ANN ALLERG ASTHMA IM, V122, P33, DOI 10.1016/j.anai.2018.10.014; Choi JH, 2014, CURR OPIN ALLERGY CL, V14, P1, DOI 10.1097/ACI.0000000000000021; de Boer JD, 2012, BLOOD, V119, P3236, DOI 10.1182/blood-2011-11-391532; Dejima K, 2005, INT ARCH ALLERGY IMM, V138, P97, DOI 10.1159/000088430; Del Rosso M, 2008, FRONT BIOSCI-LANDMRK, V13, P4667, DOI 10.2741/3032; Dinh QT, 2006, CLIN EXP ALLERGY, V36, P1039, DOI 10.1111/j.1365-2222.2006.02537.x; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Ebbo M, 2017, NAT REV IMMUNOL, V17, P665, DOI 10.1038/nri.2017.86; Fokkens W, 2019, RHINOLOGY, V57, P162, DOI 10.4193/Rhin19.080; Fujieda S, 2019, ALLERGOL INT, V68, P403, DOI 10.1016/j.alit.2019.07.002; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Hamblin SE, 2010, PHARMACOTHERAPY, V30, P855, DOI 10.1592/phco.30.8.855; Hu K, 2007, J CLIN INVEST, V117, P3821, DOI 10.1172/JCI32301; Hulse KE, 2015, CLIN EXP ALLERGY, V45, P328, DOI 10.1111/cea.12472; Imoto Y, 2018, CLIN EXP ALLERGY, V48, P544, DOI 10.1111/cea.13119; Imoto Y, 2019, J ALLERGY CLIN IMMUN, V144, P1566, DOI 10.1016/j.jaci.2019.08.040; Jennewein C, 2011, MOL MED, V17, P568, DOI 10.2119/molmed.2010.00146; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Jiang N, 2013, AM J RHINOL ALLERGY, V27, P396, DOI 10.2500/ajra.2013.27.3916; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Kato A, 2015, ALLERGOL INT, V64, P121, DOI 10.1016/j.alit.2014.12.006; Kato Y, 2018, AM J RESP CELL MOL, V59, P448, DOI 10.1165/rcmb.2017-0325OC; Katotomichelakis M, 2013, AM J RHINOL ALLERGY, V27, P354, DOI 10.2500/ajra.2013.27.3922; Kidoguchi M, 2018, AM J RHINOL ALLERGY, V32, P374, DOI 10.1177/1945892418782236; Kim DK, 2018, ALLERGY ASTHMA IMMUN, V10, P490, DOI 10.4168/aair.2018.10.5.490; Kim SJ, 2013, OTOLARYNG HEAD NECK, V149, P431, DOI 10.1177/0194599813495363; Kountakis SE, 2004, LARYNGOSCOPE, V114, P1895, DOI 10.1097/01.mlg.0000147917.43615.c0; Kouzaki H, 2017, AM J RESP CRIT CARE, V195, P737, DOI 10.1164/rccm.201603-0529OC; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Kowalski ML, 2019, ALLERGY, V74, P28, DOI 10.1111/all.13599; Kruithof EKO, 2014, THROMB HAEMOSTASIS, V112, P243, DOI 10.1160/TH13-06-0517; Krysko O, 2011, ALLERGY, V66, P396, DOI 10.1111/j.1398-9995.2010.02498.x; Laidlaw TM, 2015, J ALLERGY CLIN IMMUN, V135, P1407, DOI 10.1016/j.jaci.2015.02.005; Langdon C, 2016, J ASTHMA ALLERGY, V9, P45, DOI 10.2147/JAA.S86251; Lemarchant S, 2012, NEUROPHARMACOLOGY, V62, P749, DOI 10.1016/j.neuropharm.2011.10.020; Levi-Schaffer F, 2003, TRENDS IMMUNOL, V24, P158, DOI 10.1016/S1471-4906(03)00058-9; Liao B, 2018, ALLERGY, V73, P1459, DOI 10.1111/all.13411; Lindberg S, 1997, ACTA OTO-LARYNGOL, V117, P728, DOI 10.3109/00016489709113468; Lou HF, 2018, INT FORUM ALLERGY RH, V8, P1218, DOI 10.1002/alr.22214; Mahdavinia M, 2015, J ALLERGY CLIN IMMUN, V135, P576, DOI 10.1016/j.jaci.2014.08.031; Maniscalco M, 2007, INFLAMM RES, V56, P58, DOI 10.1007/s00011-006-6111-1; Mitsui C, 2016, J ALLERGY CLIN IMMUN, V137, P400, DOI 10.1016/j.jaci.2015.05.041; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Nakayama T, 2019, AURIS NASUS LARYNX, V46, P374, DOI 10.1016/j.anl.2018.09.004; Nicodemus-Johnson J, 2016, AM J RESP CRIT CARE, V193, P376, DOI 10.1164/rccm.201506-1243OC; Ninomiya T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29612-2; Noguchi T, 2016, J ALLERGY CLIN IMMUN, V138, P1449, DOI 10.1016/j.jaci.2016.05.020; Nonaka M, 2008, CLIN EXP ALLERGY, V38, P812, DOI 10.1111/j.1365-2222.2008.02959.x; Ogasawara N, 2018, ALLERGY, V73, P2251, DOI 10.1111/all.13552; Ogawa T, 2008, INT ARCH ALLERGY IMM, V146, P27, DOI 10.1159/000112500; Okano M, 2015, ALLERGOL INT, V64, P131, DOI 10.1016/j.alit.2015.01.004; Okuda M, 1969, Monatsschr Ohrenheilkd Laryngorhinol, V103, P56; Orlandi RR, 2016, INT FORUM ALLERGY RH, V6, pS3, DOI 10.1002/alr.21694; Otto BA, 2008, CURR OPIN OTOLARYNGO, V16, P270, DOI 10.1097/MOO.0b013e3282fb2885; Owczarek D, 2012, J CROHNS COLITIS, V6, P13, DOI 10.1016/j.crohns.2011.06.005; Park SK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181806; Proimos E, 2010, RHINOLOGY, V48, P331, DOI [10.4193/Rhin09.123, 10.4193/Rhino09.123]; Richer SL, 2008, AM J RHINOL, V22, P228, DOI 10.2500/ajr.2008.22.3162; Roy A, 2014, J BIOL CHEM, V289, P237, DOI 10.1074/jbc.M112.435156; Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401; Sejima T, 2012, ALLERGOL INT, V61, P115, DOI 10.2332/allergolint.10-OA-0290; Seshadri S, 2012, ALLERGY, V67, P920, DOI 10.1111/j.1398-9995.2012.02848.x; Shaw JL, 2012, INT FORUM ALLERGY RH, V2, P233, DOI 10.1002/alr.21021; Shi LL, 2013, ALLERGY, V68, P101, DOI 10.1111/all.12064; Shimizu S, 2015, AM J RHINOL ALLERGY, V29, P235, DOI 10.2500/ajra.2015.29.4183; Sivaprakasam S, 2016, PHARMACOL THERAPEUT, V164, P144, DOI 10.1016/j.pharmthera.2016.04.007; Soyka MB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123163; Stevens WW, 2015, AM J RESP CRIT CARE, V192, P682, DOI 10.1164/rccm.201412-2278OC; Szucs E, 2002, AM J RHINOL, V16, P131, DOI 10.1177/194589240201600301; Takabayashi T, 2019, ALLERGY, V74, P1307, DOI 10.1111/all.13677; Takabayashi T, 2017, ALLERGOL INT, V66, P594, DOI 10.1016/j.alit.2017.03.007; Takabayashi T, 2013, J ALLERGY CLIN IMMUN, V132, P584, DOI 10.1016/j.jaci.2013.02.003; Takabayashi T, 2013, AM J RESP CRIT CARE, V187, P49, DOI 10.1164/rccm.201207-1292OC; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; Takeno Sachio, 2010, Allergol Int, V59, P247, DOI 10.2332/allergolint.10-RAI-0202; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045; Tokunaga T, 2015, ALLERGY, V70, P995, DOI 10.1111/all.12644; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Van Bruaene N, 2009, J ALLERGY CLIN IMMUN, V124, P253, DOI 10.1016/j.jaci.2009.04.013; Waern I, 2013, MUCOSAL IMMUNOL, V6, P911, DOI 10.1038/mi.2012.129; Waern I, 2009, J IMMUNOL, V183, P6369, DOI 10.4049/jimmunol.0900180; Wang ET, 2014, WORLD J CLIN CASES, V2, P873, DOI 10.12998/wjcc.v2.i12.873; Wang WQ, 2019, INT FORUM ALLERGY RH, V9, P149, DOI 10.1002/alr.22234; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Yan B, 2019, J ALLERGY CLIN IMMUN, V144, P455, DOI 10.1016/j.jaci.2019.03.026; Yoshida K, 2019, ALLERGOL INT, V68, P225, DOI 10.1016/j.alit.2018.09.005; Zanini A, 2007, J ALLERGY CLIN IMMUN, V120, P329, DOI 10.1016/j.jaci.2007.04.021; Zhang N, 2011, ALLERGY, V66, P141, DOI 10.1111/j.1398-9995.2010.02448.x; Zhao W, 2005, J IMMUNOL, V175, P2635, DOI 10.4049/jimmunol.175.4.2635	101	52	56	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					740	750		10.1016/j.jaci.2020.01.027	http://dx.doi.org/10.1016/j.jaci.2020.01.027			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	32145873	Green Accepted, Bronze			2022-12-18	WOS:000518756700002
J	Su, JR; Moro, PL; Ng, CS; Lewis, PW; Said, MA; Cano, MV				Su, John R.; Moro, Pedro L.; Ng, Carmen S.; Lewis, Paige W.; Said, Maria A.; Cano, Maria V.			Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vaccine Adverse Event Reporting System; vaccine; adverse event; anaphylaxis; hypersensitivity; epidemiology; Brighton	UNITED-STATES; EMERGENCY-DEPARTMENT; ADVISORY-COMMITTEE; IMMUNIZATION; SAFETY; CHILDHOOD; CHILDREN; ASTHMA; RISK; UK	Background: Anaphylaxis, a rare and potentially life-threatening hypersensitivity reaction, can occur after vaccination. Objective: We sought to describe reports of anaphylaxis after vaccination made to the Vaccine Adverse Event Reporting System (VAERS) during 1990-2016. Methods: We identified domestic reports of anaphylaxis within VAERS using a combination of Medical Dictionary for Regulatory Activity queries and Preferred Terms. We performed a descriptive analysis, including history of hypersensitivity (anaphylaxis, respiratory allergies, and drug allergies) and vaccines given. We reviewed all serious reports and all nonserious reports with available medical records to determine if they met the Brighton Collaboration case definition for anaphylaxis or received a physician's diagnosis. Results: During the analytic period, VAERS received 467,960 total reports; 828 met the Brighton Collaboration case definition or received a physician's diagnosis of anaphylaxis: 654 (79%) were classified as serious, and 669 (81%) had medical records available. Of 478 reports in children aged less than 19 years, 65% were male; childhood vaccines were most commonly reported. Of 350 reports in persons aged 19 years or greater, 80% were female, and influenza vaccines were most frequently reported. Overall, 41% of reports described persons with no history of hypersensitivity. We identified 8 deaths, 4 among persons with no history of hypersensitivity. Conclusion: Anaphylaxis after vaccination is rare in the United States and can occur among persons with no history of hypersensitivity. Most persons recover fully with treatment, but serious complications, including death, can occur.	[Su, John R.; Moro, Pedro L.; Ng, Carmen S.; Lewis, Paige W.; Cano, Maria V.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA; [Said, Maria A.] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Silver Spring, MD USA	Centers for Disease Control & Prevention - USA; US Food & Drug Administration (FDA)	Su, JR (corresponding author), Ctr Dis Control & Prevent, Immunizat Safety Off, 1600 Clifton Rd,MS D-26, Atlanta, GA 30333 USA.	ezu2@cdc.gov		Ng, Carmen/0000-0003-4219-3907	Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; [Anonymous], 2015, EPIDEMIOLOGY PREVENT; [Anonymous], 2018, VACCINES LICENSED US; Bohlke K, 2003, PEDIATRICS, V112, P815, DOI 10.1542/peds.112.4.815; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Campbell RL, 2015, J ALLER CL IMM-PRACT, V3, P88, DOI 10.1016/j.jaip.2014.07.011; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P577; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P1007; Chaves SS, 2008, J INFECT DIS, V197, pS170, DOI 10.1086/522161; Cheng DR, 2015, VACCINE, V33, P1602, DOI 10.1016/j.vaccine.2015.02.008; Criado PR, 2004, J EUR ACAD DERMATOL, V18, P603, DOI 10.1111/j.1468-3083.2004.00989.x; DAVID TJ, 1984, ARCH DIS CHILD, V59, P983, DOI 10.1136/adc.59.10.983; de Marco R, 2000, AM J RESP CRIT CARE, V162, P68, DOI 10.1164/ajrccm.162.1.9907008; Erlewyn-Lajeunesse M, 2012, ARCH DIS CHILD, V97, P487, DOI 10.1136/archdischild-2011-301163; Ewan PW, 1998, BRIT MED J, V316, P1442, DOI 10.1136/bmj.316.7142.1442; Fineman SM, 2015, ANN ALLERG ASTHMA IM, V115, P301, DOI 10.1016/j.anai.2015.07.008; Hu Y, 2013, CLIN VACCINE IMMUNOL, V20, P211, DOI 10.1128/CVI.00541-12; Institute of Medicine, 2012, ADVERSE EFFECTS VACC; Jerschow E, 2014, J ALLERGY CLIN IMMUN, V134, P1318, DOI 10.1016/j.jaci.2014.08.018; Kim DK, 2016, MMWR-MORBID MORTAL W, V65, P88, DOI 10.15585/mmwr.mm6504a5; Lee JK, 2011, CLIN EXP ALLERGY, V41, P923, DOI 10.1111/j.1365-2222.2011.03779.x; Macdougall CF, 2002, ARCH DIS CHILD, V86, P236, DOI 10.1136/adc.86.4.236; McNeil MM, 2015, ALERGOL POL, V2, pT37, DOI 10.1016/j.jaci.2015.07.048; Moro PL, 2015, CLIN INFECT DIS, V61, P980, DOI 10.1093/cid/civ423; Patja A, 2000, PEDIATR INFECT DIS J, V19, P1127, DOI 10.1097/00006454-200012000-00002; Pool V, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e71; Robinson CL, 2016, MMWR-MORBID MORTAL W, V65, P86, DOI 10.15585/mmwr.mm6504a4; Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064; Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035; Tejedor-Alonso MA, 2015, J INVEST ALLERG CLIN, V25, P163; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Varricchio F, 2004, PEDIATR INFECT DIS J, V23, P287, DOI 10.1097/00006454-200404000-00002; World Allergy Organization, AN SYN; Zafack JG, 2017, J ALLER CL IMM-PRACT, V5, P718, DOI 10.1016/j.jaip.2016.09.048	34	52	57	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1465	1473		10.1016/j.jaci.2018.12.1003	http://dx.doi.org/10.1016/j.jaci.2018.12.1003			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30654049	Green Accepted, Bronze			2022-12-18	WOS:000463348900022
J	Zhu, J; Message, SD; Mallia, P; Kebadze, T; Contoli, M; Ward, CK; Barnathan, ES; Mascelli, MA; Kon, OM; Papi, A; Stanciu, LA; Edwards, MR; Jeffery, PK; Johnston, SL				Zhu, Jie; Message, Simon D.; Mallia, Patrick; Kebadze, Tatiana; Contoli, Marco; Ward, Christine K.; Barnathan, Elliot S.; Mascelli, Mary Ann; Kon, Onn M.; Papi, Alberto; Stanciu, Luminita A.; Edwards, Michael R.; Jeffery, Peter K.; Johnston, Sebastian L.			Bronchial mucosal IFN-alpha/beta and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma exacerbation; rhinovirus infection; type I interferon; pattern recognition receptors	DOUBLE-STRANDED-RNA; EPITHELIAL-CELLS; AIRWAY INFLAMMATION; TYPE-2 INFLAMMATION; VIRAL-INFECTIONS; RIG-I; DEFICIENT; INTERFERONS; VIRUS; BETA	Background: The innate immune system senses viral infection through pattern recognition receptors (PRRs), leading to type I interferon production. The role of type I interferon and PPRs in rhinovirus-induced asthma exacerbations in vivo are uncertain. Objectives: We sought to compare bronchial mucosal type I interferon and PRR expression at baseline and after rhinovirus infection in atopic asthmatic patients and control subjects. Methods: Immunohistochemistry was used to detect expression of IFN-alpha, IFN-beta, and the PRRs: Toll-like receptor 3, melanoma differentiation-associated gene 5, and retinoic acid-inducible protein I in bronchial biopsy specimens from 10 atopic asthmatic patients and 15 nonasthmatic nonatopic control subjects at baseline and on day 4 and 6 weeks after rhinovirus infection. Results: We observed IFN-alpha/beta deficiency in the bronchial epithelium at 3 time points in asthmatic patients in vivo. Lower epithelial IFN-alpha/beta expression was related to greater viral load, worse airway symptoms, airway hyperresponsiveness, and reductions in lung function during rhinovirus infection. We found lower frequencies of bronchial subepithelial monocytes/macrophages expressing IFN-alpha/beta in asthmatic patients during infection. Interferon deficiency at baseline was not accompanied by deficient PRR expression in asthmatic patients. Both epithelial and subepithelial PRR expression were induced during rhinovirus infection. Rhinovirus infection-increased numbers of subepithelial interferon/PRR-expressing inflammatory cells were related to greater viral load, airway hyperresponsiveness, and reductions in lung function. Conclusions: Bronchial epithelial IFN-alpha/beta expression and numbers of subepithelial IFN-alpha/beta-expressing monocytes/macrophages during infection were both deficient in asthmatic patients. Lower epithelial IFN-alpha/beta expression was associated with adverse clinical outcomes after rhinovirus infection in vivo. Increases in numbers of subepithelial cells expressing interferon/PRRs during infection were also related to greater viral load/illness severity.	[Zhu, Jie; Message, Simon D.; Mallia, Patrick; Kebadze, Tatiana; Contoli, Marco; Stanciu, Luminita A.; Edwards, Michael R.; Jeffery, Peter K.; Johnston, Sebastian L.] Imperial Coll London, Natl Heart & Lung Inst, Med Res Council, Airway Dis Infect, London, England; [Zhu, Jie; Message, Simon D.; Mallia, Patrick; Kebadze, Tatiana; Contoli, Marco; Stanciu, Luminita A.; Edwards, Michael R.; Jeffery, Peter K.; Johnston, Sebastian L.] Imperial Coll London, Asthma UK Ctr Allerg Mech Asthma, London, England; [Message, Simon D.; Mallia, Patrick; Contoli, Marco; Kon, Onn M.; Johnston, Sebastian L.] Imperial Coll Healthcare NHS Trust, London, England; [Contoli, Marco; Papi, Alberto] Univ Ferrara, Res Ctr Asthma, Ferrara, Italy; [Contoli, Marco; Papi, Alberto] Univ Ferrara, COPD, Ferrara, Italy; [Ward, Christine K.; Barnathan, Elliot S.; Mascelli, Mary Ann] Centocor Inc, Malvern, PA USA	Imperial College London; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); Imperial College London; University of London; King's College London; Imperial College London; University of Ferrara; University of Ferrara; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Johnston, SL (corresponding author), Imperial Coll London, Dept Airway Dis Infect, St Marys Campus,Norfolk Pl, London W2 1PG, England.	s.johnston@imperial.ac.uk	Johnston, Sebastian Lennox/I-2423-2012; Papi, alberto/AAC-1888-2019; Stanciu, Luminita A/B-8384-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200; 	Medical Research Council (MRC) Clinical Research Fellowship; British Medical Association HC Roscoe Fellowship; British Lung Foundation/Severin Wunderman Family Foundation Lung Research Programme [P00/2]; Asthma UK [02/027, 05/067, CH11SJ]; National Institute of Health Research (NIHR) Biomedical Research Centre; National Institute of Health Research (NIHR) Clinical Lecturer funding schemes; Centocor; MRC Centre grant [G1000758]; ERC FP7 Advanced grant [233015]; MRC [G0601236] Funding Source: UKRI	Medical Research Council (MRC) Clinical Research Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Medical Association HC Roscoe Fellowship; British Lung Foundation/Severin Wunderman Family Foundation Lung Research Programme; Asthma UK; National Institute of Health Research (NIHR) Biomedical Research Centre(National Institute for Health Research (NIHR)); National Institute of Health Research (NIHR) Clinical Lecturer funding schemes(National Institute for Health Research (NIHR)); Centocor; MRC Centre grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); ERC FP7 Advanced grant; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by a Medical Research Council (MRC) Clinical Research Fellowship and a British Medical Association HC Roscoe Fellowship (SDM), British Lung Foundation/Severin Wunderman Family Foundation Lung Research Programme grant no. P00/2, Asthma UK project grant nos. 02/027 and 05/067, the National Institute of Health Research (NIHR) Biomedical Research Centre and Clinical Lecturer funding schemes, Centocor, MRC Centre grant G1000758, and ERC FP7 Advanced grant 233015. S.L.J. is the Asthma UK Clinical Chair (grant CH11SJ) and is an NIHR Senior Investigator.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Baraldo S, 2012, J ALLERGY CLIN IMMUN, V130, P1307, DOI 10.1016/j.jaci.2012.08.005; Bardin PG, 2000, EUR RESPIR J, V16, P980, DOI 10.1183/09031936.00.16598000; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; CHEUNG D, 1995, AM J RESP CRIT CARE, V152, P1490, DOI 10.1164/ajrccm.152.5.7582282; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Denny MR, 2010, J IMMUNOL, V184, P3284, DOI 10.4049/jimmunol.0902199; Djukanovic R, 2014, AM J RESP CRIT CARE, V190, P145, DOI 10.1164/rccm.201312-2235OC; Dziadziuszko R, 2012, J THORAC ONCOL, V7, P340, DOI 10.1097/JTO.0b013e318240ca0d; Edwards MR, 2013, MUCOSAL IMMUNOL, V6, P797, DOI 10.1038/mi.2012.118; Ganesan S, 2016, J IMMUNOL, V197, P2409, DOI 10.4049/jimmunol.1502702; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Goritzka M, 2015, J EXP MED, V212, P699, DOI 10.1084/jem.20140825; Grunberg K, 1999, AM J RESP CRIT CARE, V160, P1375; Han MY, 2016, J ALLERGY CLIN IMMUN, V138, P1619, DOI 10.1016/j.jaci.2016.01.037; Hansel TT, 2017, EBIOMEDICINE, V19, P128, DOI 10.1016/j.ebiom.2017.03.033; Hewson CA, 2005, J VIROL, V79, P12273, DOI 10.1128/JVI.79.19.12273-12279.2005; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Khaitov MR, 2009, ALLERGY, V64, P375, DOI 10.1111/j.1398-9995.2008.01826.x; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852, DOI 10.1164/ajrccm.155.3.9117016; Patel DA, 2014, J ALLERGY CLIN IMMUN, V134, P1402, DOI 10.1016/j.jaci.2014.07.013; Pritchard AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106501; Qiu Y, 2009, AM J RESP CRIT CARE, V179; Rothenfusser S, 2005, J IMMUNOL, V175, P5260, DOI 10.4049/jimmunol.175.8.5260; SHIRAFUJI N, 1990, BLOOD, V75, P17; Slater L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001178; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Sykes A, 2014, THORAX, V69, P240, DOI 10.1136/thoraxjnl-2012-202909; Sykes A, 2012, J ALLERGY CLIN IMMUN, V129, P1506, DOI 10.1016/j.jaci.2012.03.044; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Triantafilou K, 2011, VIRULENCE, V2, P22, DOI 10.4161/viru.2.1.13807; Unger BL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002969; Von der Ohe M, 2001, J INTERF CYTOK RES, V21, P241, DOI 10.1089/107999001750169899; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhu J, 2014, CHEST, V145, P1219, DOI 10.1378/chest.13-1567	46	52	52	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					114	+		10.1016/j.jaci.2018.04.003	http://dx.doi.org/10.1016/j.jaci.2018.04.003			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	29698627	Green Published, hybrid			2022-12-18	WOS:000454918300018
J	Vargas-Hernandez, A; Mace, EM; Zimmerman, O; Zerbe, CS; Freeman, AF; Rosenzweig, S; Leiding, JW; Torgerson, T; Altman, MC; Schussler, E; Cunningham-Rundles, C; Chinn, IK; Carisey, AF; Hanson, IC; Rider, NL; Holland, SM; Orange, JS; Forbes, LR				Vargas-Hernandez, Alexander; Mace, Emily M.; Zimmerman, Ofer; Zerbe, Christa S.; Freeman, Alexandra F.; Rosenzweig, Sergio; Leiding, Jennifer W.; Torgerson, Troy; Altman, Matthew C.; Schussler, Edith; Cunningham-Rundles, Charlotte; Chinn, Ivan K.; Carisey, Alexandre F.; Hanson, Imelda C.; Rider, Nicholas L.; Holland, Steven M.; Orange, Jordan S.; Forbes, Lisa R.			Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Signal transducer and activator of transcription 1; gain of function; natural killer cell deficiency; perforin; Janus kinase inhibition; ruxolitinib; natural killer cell maturation	NK CELLS; PERFORIN GENE; CD56(BRIGHT); EXPRESSION; RECEPTORS; SUBSET; IL-15; ACQUISITION; RESPONSES; IMMUNITY	Background: Natural killer (NK) cells are critical innate effector cells whose development is dependent on the Janus kinase-signal transducer and activator of transcription (STAT) pathway. NK cell deficiency can result in severe or refractory viral infections. Patients with STAT1 gain-of-function (GOF) mutations have increased viral susceptibility. Objective: We sought to investigate NK cell function in patients with STAT1 GOF mutations. Methods: NK cell phenotype and function were determined in 16 patients with STAT1 GOF mutations. NK cell lines expressing patients' mutations were generated with clustered regularly interspaced short palindromic repeats (CRISPR-Cas9)-mediated gene editing. NK cells from patients with STAT1 GOF mutations were treated in vitro with ruxolitinib. Results: Peripheral blood NK cells from patients with STAT1 GOF mutations had impaired terminal maturation. Specifically, patients with STAT1 GOF mutations have immature CD56 dim NK cells with decreased expression of CD16, perforin, CD57, and impaired cytolytic function. STAT1 phosphorylation was increased, but STAT5 was aberrantly phosphorylated in response to IL-2 stimulation. Upstream inhibition of STAT1 signaling with the small-molecule Janus kinase 1/2 inhibitor ruxolitinib in vitro and in vivo restored perforin expression in CD56 dim NK cells and partially restored NK cell cytotoxic function. Conclusions: Properly regulated STAT1 signaling is critical for NK cell maturation and function. Modulation of increased STAT1 phosphorylation with ruxolitinib is an important option for therapeutic intervention in patients with STAT1 GOF mutations.	[Vargas-Hernandez, Alexander; Mace, Emily M.; Chinn, Ivan K.; Carisey, Alexandre F.; Hanson, Imelda C.; Rider, Nicholas L.; Orange, Jordan S.; Forbes, Lisa R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Vargas-Hernandez, Alexander; Mace, Emily M.; Chinn, Ivan K.; Carisey, Alexandre F.; Rider, Nicholas L.; Orange, Jordan S.; Forbes, Lisa R.] Texas Childrens Hosp, Ctr Human Immunobiol, Dept Allergy Immunol & Rheumatol, Houston, TX 77030 USA; [Zimmerman, Ofer; Zerbe, Christa S.; Freeman, Alexandra F.; Rosenzweig, Sergio; Holland, Steven M.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Zerbe, Christa S.; Freeman, Alexandra F.; Rosenzweig, Sergio; Holland, Steven M.] NIH, Ctr Clin, Bethesda, MD 20892 USA; [Leiding, Jennifer W.] Univ S Florida, Johns Hopkins All Childrens Hosp, Div Allergy & Immunol, Dept Pediat, St Petersburg, FL USA; [Torgerson, Troy; Altman, Matthew C.] Univ Washington, Ctr Allergy & Inflammat, Seattle, WA 98195 USA; [Schussler, Edith; Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Div Allergy & Immunol, New York, NY 10029 USA; [Schussler, Edith; Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Dept Med & Pediat, Inst Immunol, New York, NY 10029 USA	Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Johns Hopkins University; Johns Hopkins Medicine; State University System of Florida; University of South Florida; University of Washington; University of Washington Seattle; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Forbes, LR (corresponding author), Ctr Human Immunobiol, Dept Pediat Immunol Allergy & Rheumatol, 1102 Bates,Suite 330, Houston, TX 77030 USA.	lisa.forbes@bcm.edu	Zimmerman, Ofer/GRT-0020-2022; Carisey, Alexandre F/A-5026-2015	Zimmerman, Ofer/0000-0002-1684-4684; Carisey, Alexandre F/0000-0003-1326-2205; Chinn, Ivan/0000-0001-5684-5457; orange, jordan/0000-0001-7117-7725; Mace, Emily/0000-0003-0226-7393	Chao Physician Scientist Junior Faculty Award; National Institute of Allergy and Infectious Diseases [R01 AI120989]; Jeffrey Modell Foundation Diagnostic and Research Center for Primary Immunodeficiencies; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R18AI048693, R01AI120989, U24AI086037, ZIAAI000647, ZIAAI001247, P01AI061093, ZIAAI001122, ZIAAI000646] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL010304] Funding Source: NIH RePORTER	Chao Physician Scientist Junior Faculty Award; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Jeffrey Modell Foundation Diagnostic and Research Center for Primary Immunodeficiencies; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	Supported by a Chao Physician Scientist Junior Faculty Award (to L.R.F.), National Institute of Allergy and Infectious Diseases grant R01 AI120989 (to J.S.O.), and the Jeffrey Modell Foundation Diagnostic and Research Center for Primary Immunodeficiencies.	Addison EG, 2005, IMMUNOLOGY, V116, P354, DOI 10.1111/j.1365-2567.2005.02235.x; Becknell B, 2005, ADV IMMUNOL, V86, P209, DOI 10.1016/S0065-2776(04)86006-1; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Bjorkstrom NK, 2010, BLOOD, V116, P3853, DOI 10.1182/blood-2010-04-281675; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Cichocki F, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00055; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Cooper MA, 2001, BLOOD, V97, P3146, DOI 10.1182/blood.V97.10.3146; Fan YY, 2008, CELL BIOL INT, V32, P188, DOI 10.1016/j.cellbi.2007.08.025; Freud AG, 2006, J EXP MED, V203, P1033, DOI 10.1084/jem.20052507; Freud AG, 2005, IMMUNITY, V22, P295, DOI 10.1016/j.immuni.2005.01.013; Freud AG, 2006, IMMUNOL REV, V214, P56, DOI 10.1111/j.1600-065X.2006.00451.x; Frey M, 1998, J IMMUNOL, V161, P400; Gineau L, 2012, J CLIN INVEST, V122, P821, DOI 10.1172/JCI61014; GONG JH, 1994, LEUKEMIA, V8, P652; Gotthardt D, 2016, FRONT IMMUNOL, V7, P694, DOI [DOI 10.3389/fimmu.2016.00694, DOI 10.3389/FIMMU.2016.00694]; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Grier JT, 2012, J CLIN INVEST, V122, P3769, DOI 10.1172/JCI64837; Grzywacz B, 2006, BLOOD, V108, P3824, DOI 10.1182/blood-2006-04-020198; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; Higgins E, 2015, J ALLERGY CLIN IMMUN, V135, P551, DOI 10.1016/j.jaci.2014.12.1867; Hughes CR, 2012, J CLIN INVEST, V122, P814, DOI 10.1172/JCI60224; Huntington ND, 2009, J EXP MED, V206, P25, DOI 10.1084/jem.20082013; Hwa V, 2011, BEST PRACT RES CL EN, V25, P61, DOI 10.1016/j.beem.2010.09.003; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Juelke K, 2010, BLOOD, V116, P1299, DOI 10.1182/blood-2009-11-253286; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Lopez-Verges S, 2010, BLOOD, V116, P3865, DOI 10.1182/blood-2010-04-282301; Ma A, 2006, ANNU REV IMMUNOL, V24, P657, DOI 10.1146/annurev.immunol.24.021605.090727; Mace EM, 2017, J CLIN INVEST, V127, P306, DOI 10.1172/JCI86276; Mace EM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00545; Mace EM, 2013, BLOOD, V121, P2669, DOI 10.1182/blood-2012-09-453969; Miller JS, 2001, BLOOD, V98, P705, DOI 10.1182/blood.V98.3.705; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Mossner R, 2016, CLIN INFECT DIS, V62, DOI 10.1093/cid/ciw020; Orange JS, 2008, NAT REV IMMUNOL, V8, P713, DOI 10.1038/nri2381; Orange JS, 2013, J ALLERGY CLIN IMMUN, V132, P515, DOI 10.1016/j.jaci.2013.07.020; Orange JS, 2002, P NATL ACAD SCI USA, V99, P11351, DOI 10.1073/pnas.162376099; Poli A, 2009, IMMUNOLOGY, V126, P458, DOI 10.1111/j.1365-2567.2008.03027.x; Reich NC, 2007, CYTOKINE GROWTH F R, V18, P511, DOI 10.1016/j.cytogfr.2007.06.021; Rochman Y, 2009, NAT REV IMMUNOL, V9, P480, DOI 10.1038/nri2580; Sampaio EP, 2013, J ALLERGY CLIN IMMUN, V131, P1624, DOI 10.1016/j.jaci.2013.01.052; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Shaw RK, 2012, BLOOD, V119, P4009, DOI 10.1182/blood-2011-10-385377; Sivori S, 2003, EUR J IMMUNOL, V33, P3439, DOI 10.1002/eji.200324533; Stray-Pedersen A, 2017, J ALLERGY CLIN IMMUN, V139, P232, DOI 10.1016/j.jaci.2016.05.042; Tabellini G, 2017, J ALLERGY CLIN IMMUN, V140, P553, DOI 10.1016/j.jaci.2016.10.051; Takezaki S, 2012, J IMMUNOL, V189, P1521, DOI 10.4049/jimmunol.1200926; Tamzalit F, 2014, P NATL ACAD SCI USA, V111, P8565, DOI 10.1073/pnas.1405514111; Toth B, 2012, LANCET, V379, P2500, DOI 10.1016/S0140-6736(12)60365-1; Toubiana J, 2016, BLOOD, V127, P3154, DOI 10.1182/blood-2015-11-679902; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; Uzel G, 2013, J ALLERGY CLIN IMMUN, V131, P1611, DOI 10.1016/j.jaci.2012.11.054; Vairo D, 2011, BLOOD, V118, P1806, DOI 10.1182/blood-2011-01-330571; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Vignesh P, 2017, CLIN REV ALLERG IMMU, V52, P287, DOI 10.1007/s12016-016-8591-2; Villarino AV, 2015, J IMMUNOL, V194, P21, DOI 10.4049/jimmunol.1401867; Weinacht KG, 2017, J ALLERGY CLIN IMMUN, V139, P1629, DOI 10.1016/j.jaci.2016.11.022; Wilk E, 2008, IMMUNOBIOLOGY, V213, P271, DOI 10.1016/j.imbio.2007.10.012; Yamamoto K, 2002, BIOCHEM BIOPH RES CO, V297, P1245, DOI 10.1016/S0006-291X(02)02378-1; Yang XP, 2011, NAT IMMUNOL, V12, P247, DOI 10.1038/ni.1995; YODOI J, 1985, J IMMUNOL, V134, P1623; Yu CR, 1999, J IMMUNOL, V162, P2785; Yu JH, 2010, BLOOD, V115, P274, DOI 10.1182/blood-2009-04-215491; Zhang J, 1999, J EXP MED, V190, P1297, DOI 10.1084/jem.190.9.1297	66	52	54	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2142	+		10.1016/j.jaci.2017.08.040	http://dx.doi.org/10.1016/j.jaci.2017.08.040			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29111217	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000434701600020
J	Wolsk, HM; Harshfield, BJ; Laranjo, N; Carey, VJ; O'Connor, G; Sandel, M; Strunk, RC; Bacharier, LB; Zeiger, RS; Schatz, M; Hollis, BW; Weiss, ST; Litonjua, AA				Wolsk, Helene M.; Harshfield, Benjamin J.; Laranjo, Nancy; Carey, Vincent J.; O'Connor, George; Sandel, Megan; Strunk, Robert C.; Bacharier, Leonard B.; Zeiger, Robert S.; Schatz, Michael; Hollis, Bruce W.; Weiss, Scott T.; Litonjua, Augusto A.			Vitamin D supplementation in pregnancy, prenatal 25(OH)D levels, race, and subsequent asthma or recurrent wheeze in offspring: Secondary analyses from the Vitamin D Antenatal Asthma Reduction Trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D; asthma; allergy; randomized controlled trial; prenatal	RANDOMIZED CLINICAL-TRIAL; AFRICAN-AMERICAN WOMEN; PREVENTION; CHILDHOOD; CHILDREN; ORIGINS; DESIGN; WHITE; LIFE	Background: Nutrient trials differ from drug trials because participants have varying circulating levels at entry into the trial. Objective: We sought to study the effect of a vitamin D intervention in pregnancy between subjects of different races and the association between 25-hydroxyvitamin D-3 (25[OH] D) levels in pregnancy and the risk of asthma/recurrent wheeze in offspring. Methods: The Vitamin D Antenatal Asthma Reduction Trial is a randomized trial of pregnant women at risk of having children with asthma randomized to 4400 international units/d vitamin D or placebo plus 400 international units/d vitamin D. Asthma and recurrent wheezing until age 3 years were recorded. Results: African American (AA) women (n = 312) had lower initial levels of 25(OH) D (mean [SD], 17.6 ng/mL [8.3 ng/mL]) compared with non-AA women (n = 400; 27.1 ng/mL [9.7 ng/mL], P < .001). No racial difference was found from vitamin D supplementation in pregnancy on asthma/recurrent wheezing in offspring (P for interaction = .77). Having an initial level of greater than 30 ng/mL and being randomized to the intervention group was associated with the lowest risk for asthma/recurrent wheeze by age 3 years compared with having an initial level of less than 20 ng/mL and receiving placebo (adjusted odds ratio, 0.42; 95% CI, 0.19-0.91). Conclusions: We did not find differences between AA and non-AA mothers in the effect of maternal vitamin D supplementation and asthma/recurrent wheeze in offspring at 3 years. Maternal supplementation of vitamin D, particularly in mothers with initial 25(OH) D levels of greater than 30 ng/mL, reduced asthma/recurrent wheeze in the offspring through age 3 years, suggesting that higher vitamin D status beginning in early pregnancy is necessary for asthma/recurrent wheeze prevention in early life.	[Wolsk, Helene M.; Harshfield, Benjamin J.; Laranjo, Nancy; Carey, Vincent J.; Weiss, Scott T.; Litonjua, Augusto A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA; [Wolsk, Helene M.] Univ Copenhagen, Herlev & Gentofte Hosp, COPSAC, Copenhagen Prospect Studies Asthma Childhood, Copenhagen, Denmark; [Carey, Vincent J.; Weiss, Scott T.; Litonjua, Augusto A.] Harvard Med Sch, Boston, MA USA; [O'Connor, George] Boston Univ, Sch Med, Dept Med, Pulm Ctr, Boston, MA 02118 USA; [Sandel, Megan] Boston Med Ctr, Dept Pediat, Boston, MA USA; [Strunk, Robert C.; Bacharier, Leonard B.] Washington Univ, Sch Med, Dept Pediat, Div Pediat Allergy,Immunol & Pulm Med, St Louis, MO 63110 USA; [Strunk, Robert C.; Bacharier, Leonard B.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Zeiger, Robert S.; Schatz, Michael] Kaiser Permanente Southern Calif, Dept Allergy & Res Evaluat, San Diego, CA USA; [Zeiger, Robert S.; Schatz, Michael] Kaiser Permanente Southern Calif, Dept Allergy & Res Evaluat, Pasadena, CA USA; [Hollis, Bruce W.] Med Univ South Carolina, Dept Pediat, Charleston, SC 29425 USA	Harvard University; Brigham & Women's Hospital; University of Copenhagen; Harvard University; Harvard Medical School; Boston University; Boston Medical Center; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Kaiser Permanente; Kaiser Permanente; Medical University of South Carolina	Litonjua, AA (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.	augusto.litonjua@channing.harvard.edu		Zeiger, Robert/0000-0001-5788-5063; Bacharier, Leonard/0000-0003-0432-2704	National Heart, Lung, and Blood Institute [U01HL091528]; National Centers for Advancing Translational Sciences for participant visits at Boston Medical Center [U54TR001012]; Lundbeck Foundation [R191-2015-1571]	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Centers for Advancing Translational Sciences for participant visits at Boston Medical Center; Lundbeck Foundation(Lundbeckfonden)	The Vitamin D Antenatal Asthma Reduction Trial was supported by U01HL091528 from the National Heart, Lung, and Blood Institute. Additional support was provided by U54TR001012 from the National Centers for Advancing Translational Sciences for participant visits at Boston Medical Center. H.M.W. was supported by the Lundbeck Foundation (R191-2015-1571).	Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Bhagatwala Jigar, 2015, BMC Obes, V2, P27, DOI 10.1186/s40608-015-0056-2; Bisgaard H, 2007, PEDIATR PULM, V42, P1234, DOI 10.1002/ppul.20723; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bodnar LM, 2007, J NUTR, V137, P447, DOI 10.1093/jn/137.2.447; Castro M, 2014, JAMA-J AM MED ASSOC, V311, P2083, DOI 10.1001/jama.2014.5052; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Ersfeld DL, 2004, CLIN BIOCHEM, V37, P867, DOI 10.1016/j.clinbiochem.2004.06.006; Ferreira GB, 2015, CELL REP, V10, P711, DOI 10.1016/j.celrep.2015.01.013; Gallagher JC, 2014, J BONE MINER RES, V29, P173, DOI 10.1002/jbmr.2010; Gallagher JC, 2013, J CLIN ENDOCR METAB, V98, P1137, DOI 10.1210/jc.2012-3106; Heaney RP, 2014, NUTR REV, V72, P48, DOI 10.1111/nure.12090; Henderson AJ, 2012, SEMIN FETAL NEONAT M, V17, P82, DOI 10.1016/j.siny.2012.01.006; Hollis BW, 2007, J BONE MINER RES, V22, pV39, DOI 10.1359/JBMR.07S215; Litonjua AA, 2016, JAMA-J AM MED ASSOC, V315, P362, DOI 10.1001/jama.2015.18589; Litonjua AA, 2014, CONTEMP CLIN TRIALS, V38, P37, DOI 10.1016/j.cct.2014.02.006; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; Ng K, 2014, AM J CLIN NUTR, V99, P587, DOI 10.3945/ajcn.113.067777; Sharma S, 2014, THORAX, V69, P481, DOI 10.1136/thoraxjnl-2014-205166; Wegienka G, 2012, CLIN EXP ALLERGY, V42, P909, DOI 10.1111/j.1365-2222.2011.03946.x; WEISS ST, 1980, AM REV RESPIR DIS, V122, P697, DOI 10.1164/arrd.1980.122.5.697; Zosky GR, 2011, AM J RESP CRIT CARE, V183, P1336, DOI 10.1164/rccm.201010-1596OC	22	52	54	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1423	+		10.1016/j.jaci.2017.01.013	http://dx.doi.org/10.1016/j.jaci.2017.01.013			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28285844				2022-12-18	WOS:000414304300022
J	Galli, SJ				Galli, Stephen Joseph			Toward precision medicine and health: Opportunities and challenges in allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma; atopic dermatitis; exposome; gene-environment interactions; metabolome; microbiome; personalized medicine; pharmacogenomics; stratified medicine	ASTHMATIC-PATIENTS; VITAMIN-D; EOSINOPHILIC ASTHMA; ORAL IMMUNOTHERAPY; GUT MICROBIOME; FOOD ALLERGY; RISK; PEANUT; PERIOSTIN; EXPOSURE	Precision medicine (also called personalized, stratified, or P4 medicine) can be defined as the tailoring of preventive measures and medical treatments to the characteristics of each patient to obtain the best clinical outcome for each person while ideally also enhancing the cost-effectiveness of such interventions for patients and society. Clearly, the best clinical outcome for allergic diseases is not to get them in the first place. To emphasize the importance of disease prevention, a critical component of precision medicine can be referred to as precision health, which is defined herein as the use of all available information pertaining to specific subjects (including family history, individual genetic and other biometric information, and exposures to risk factors for developing or exacerbating disease), as well as features of their environments, to sustain and enhance health and prevent the development of disease. In this article I will provide a personal perspective on how the precision health-precision medicine approach can be applied to the related goals of preventing the development of allergic disorders and providing the most effective diagnosis, disease monitoring, and care for those with these prevalent diseases. I will also mention some of the existing and potential challenges to achieving these ambitious goals.	[Galli, Stephen Joseph] Sean N Parker Ctr Allergy & Asthma Res, Dept Pathol, Stanford, CA USA; [Galli, Stephen Joseph] Sean N Parker Ctr Allergy & Asthma Res, Dept Microbiol & Immunol, Stanford, CA USA; [Galli, Stephen Joseph] Stanford Ctr Genom & Personalized Med, Stanford, CA USA		Galli, SJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr L-235, Stanford, CA 94305 USA.	sgalli@stanford.edu			National Institutes of Health [U19AI104209, R01AR067145]; Department of Pathology of Stanford University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI104209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR067145] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Pathology of Stanford University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health grants U19AI104209 and R01AR067145 and the Department of Pathology of Stanford University.	Agache I, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0529-x; Akdis CA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7390; Ballmer-Weber BK, 2015, J ALLERGY CLIN IMMUN, V135, P964, DOI 10.1016/j.jaci.2014.10.047; Berry A, 2016, J ALLERGY CLIN IMMUN, V137, P1317, DOI 10.1016/j.jaci.2016.03.009; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Canani RB, 2016, ISME J, V10, P742, DOI 10.1038/ismej.2015.151; Canani RB, 2015, CURR OPIN ALLERGY CL, V15, P243, DOI 10.1097/ACI.0000000000000157; Cardet JC, 2015, EXPERT OPIN BIOL TH, V15, P1531, DOI 10.1517/14712598.2015.1090972; Castro M, 2014, LANCET RESP MED, V2, P879, DOI 10.1016/S2213-2600(14)70201-2; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Chawes BL, 2016, JAMA-J AM MED ASSOC, V315, P353, DOI 10.1001/jama.2015.18318; Chinthrajah RS, 2016, J ALLERGY CLIN IMMUN, V137, P984, DOI 10.1016/j.jaci.2016.02.004; Cho I, 2012, NAT REV GENET, V13, P260, DOI 10.1038/nrg3182; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Cussins J, 2015, PHARM J; Desmond-Helmann S, 2011, PRECISION MED BUILDI; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ferkol T, 2015, AM J RESP CRIT CARE, V192, P658, DOI 10.1164/rccm.201507-1428ED; Fleischer DM, 2015, J ALLERGY CLIN IMMUN, V136, P258, DOI 10.1016/j.jaci.2015.06.001; Freeman J, 1914, LANCET, V1, P1178; Freeman J, 1911, LANCET, V2, P814; Frew AJ, 2010, J ALLERGY CLIN IMMUN, V125, pS306, DOI 10.1016/j.jaci.2009.10.064; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hamilton RG, 2014, J ALLERGY CLIN IMMUN, V134, P360, DOI 10.1016/j.jaci.2014.02.022; Hefle Susan L, 2002, Curr Allergy Asthma Rep, V2, P63, DOI 10.1007/s11882-002-0041-y; Hood L, 2013, GENOME MED, V5, DOI 10.1186/gm514; Hood L, 2013, RAMBAM MAIMONIDES ME, V4, DOI 10.5041/RMMJ.10112; Hudson KL, 2015, NEW ENGL J MED, V373, P2293, DOI 10.1056/NEJMp1512205; Inoue Y, 2015, ALLERGOL INT, V64, P289, DOI 10.1016/j.alit.2015.04.001; Izuhara K, 2015, ALLERGOL INT, V64, pS3, DOI 10.1016/j.alit.2015.04.012; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Joyner MJ, 2015, JAMA-J AM MED ASSOC, V314, P999, DOI 10.1001/jama.2015.7725; Jutel M, 2014, CURR OPIN ALLERGY CL, V14, P557, DOI 10.1097/ACI.0000000000000121; Kau AL, 2014, CURR OPIN ALLERGY CL, V14, P570, DOI 10.1097/ACI.0000000000000108; Khoury MJ, 2003, GENET MED, V5, P261, DOI 10.1097/01.GIM.0000076977.90682.A5; Kim KS, 2016, SCIENCE, V351, P858, DOI 10.1126/science.aac5560; Kim TB, 2013, EUR RESPIR J, V41, P1308, DOI 10.1183/09031936.00100811; Konradsen JR, 2015, PEDIAT ALLERG IMM-UK, V26, P772, DOI 10.1111/pai.12457; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Litonjua AA, 2016, JAMA-J AM MED ASSOC, V315, P362, DOI 10.1001/jama.2015.18589; Lodge CJ, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/176484; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Marsland BJ, 2015, CURR OPIN IMMUNOL, V36, P94, DOI 10.1016/j.coi.2015.07.005; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P26, DOI 10.1513/pats.200607-144JG; Matsusaka M, 2015, ALLERGOL INT, V64, P175, DOI 10.1016/j.alit.2014.07.003; Meyers DA, 2014, LANCET RESP MED, V2, P405, DOI 10.1016/S2213-2600(14)70012-8; Mothes N, 2006, CLIN CHEM LAB MED, V44, P125, DOI 10.1515/CCLM.2006.024; Nair P, 2013, J ALLERGY CLIN IMMUN, V132, P81, DOI 10.1016/j.jaci.2013.05.007; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nieto A, 2014, PEDIAT ALLERG IMM-UK, V25, P516, DOI 10.1111/pai.12272; Noon L, 1911, LANCET, V1, P1572; Noonan M, 2013, J ALLERGY CLIN IMMUN, V132, P567, DOI 10.1016/j.jaci.2013.03.051; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Platts-Mills TAE, 2015, J ALLERGY CLIN IMMUN, V136, P3, DOI 10.1016/j.jaci.2015.03.048; Portelli MA, 2015, CLIN EXP ALLERGY, V45, P21, DOI 10.1111/cea.12327; Potaczek DP, 2016, J ALLERGY CLIN IMMUN, V137, P1334, DOI 10.1016/j.jaci.2015.12.1344; Ryan JF, 2016, P NATL ACAD SCI USA, V113, pE1286, DOI 10.1073/pnas.1520180113; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Schaub B, 2015, CURR OPIN IMMUNOL, V36, P88, DOI 10.1016/j.coi.2015.07.004; Sears MR, 2015, J ALLERGY CLIN IMMUN, V136, P829, DOI 10.1016/j.jaci.2015.04.048; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Simpson JL, 2014, EUR RESPIR J, V43, P1067, DOI 10.1183/09031936.00105013; Slager RE, 2010, J ALLERGY CLIN IMMUN, V126, P875, DOI 10.1016/j.jaci.2010.08.001; Smith PK, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0081-0; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Tanno LK, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-42; Treudler R, 2013, CURR ALLERGY ASTHM R, V13, P110, DOI 10.1007/s11882-012-0318-8; Tuano KS, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0534-0; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Wang LW, 2011, NEW ENGL J MED, V364, P1144, DOI 10.1056/NEJMra1010600; Weiss ST, 2015, AM J RESP CRIT CARE, V191, P492, DOI 10.1164/rccm.201501-0117ED; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Zhang YX, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad4322	88	52	52	1	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1289	1300		10.1016/j.jaci.2016.03.006	http://dx.doi.org/10.1016/j.jaci.2016.03.006			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	27155026	Bronze, Green Accepted			2022-12-18	WOS:000376180200001
J	Lindsley, AW; Saal, HM; Burrow, TA; Hopkin, RJ; Shchelochkov, O; Khandelwal, P; Xie, CC; Bleesing, J; Filipovich, L; Risma, K; Assa'ad, AH; Roehrs, PA; Bernstein, JA				Lindsley, Andrew W.; Saal, Howard M.; Burrow, Thomas A.; Hopkin, Robert J.; Shchelochkov, Oleg; Khandelwal, Pooja; Xie, Changchun; Bleesing, Jack; Filipovich, Lisa; Risma, Kimberly; Assa'ad, Amal H.; Roehrs, Phillip A.; Bernstein, Jonathan A.			Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Kabuki syndrome; KMT2D; KDM6A; hypogammaglobulinemia; memory B cells; CD21(lo) B cells; class-switch recombination; somatic hypermutation; PTIP; AICDA; AID; polymerase eta	CLASS SWITCH RECOMBINATION; COMMON VARIABLE IMMUNODEFICIENCY; MAKE-UP-SYNDROME; PHENOTYPIC SPECTRUM; MENTAL-RETARDATION; MLL2; MUTATION; IMMUNOGLOBULIN; PATHWAYS; COMPLEX	Background: Kabuki syndrome (KS) is a complex multisystem developmental disorder associated with mutation of genes encoding histone-modifying proteins. In addition to craniofacial, intellectual, and cardiac defects, KS is also characterized by humoral immune deficiency and autoimmune disease, yet no detailed molecular characterization of the KS-associated immune phenotype has been reported. Objective: We sought to characterize the humoral immune defects found in patients with KS with lysine methyltransferase 2D (KMT2D) mutations. Methods: We comprehensively characterized B-cell function in a cohort (n = 13) of patients with KS (age, 4 months to 27 years). Results: Three quarters (77%) of the cohort had a detectable heterozygous KMT2D mutation (50% nonsense, 20% splice site, and 30% missense mutations), and 70% of the reported mutations are novel. Among the patients with KMT2D mutations (KMT2D(Mut/+)), hypogammaglobulinemia was detected in all but 1 patient, with IgA deficiency affecting 90% of patients and a deficiency in at least 1 other isoform seen in 40% of patients. Numbers of total memory (CD27(+)) and class-switched memory B cells (IgM(-)) were significantly reduced in patients with KMT2D(Mut/+) mutations compared with numbers in control subjects (P < .001). Patients with KMT2D(Mut/+) mutations also had significantly reduced rates of somatic hypermutation in IgG (P = .003) but not IgA or IgM heavy chain sequences. Impaired terminal differentiation was noted in primary B cells from patients with KMT2D(Mut/+) mutations. Autoimmune pathology was observed in patients with missense mutations affecting the SET domain and its adjacent domains. Conclusions: In patients with KS, autosomal dominant KMT2D mutations are associated with dysregulation of terminal B-cell differentiation, leading to humoral immune deficiency and, in some cases, autoimmunity. All patients with KS should undergo serial clinical immune evaluations.	[Lindsley, Andrew W.; Risma, Kimberly; Assa'ad, Amal H.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Saal, Howard M.; Burrow, Thomas A.; Hopkin, Robert J.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA; [Khandelwal, Pooja; Bleesing, Jack; Filipovich, Lisa] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat, Cincinnati, OH 45229 USA; [Lindsley, Andrew W.; Saal, Howard M.; Burrow, Thomas A.; Hopkin, Robert J.; Khandelwal, Pooja; Bleesing, Jack; Filipovich, Lisa; Risma, Kimberly; Assa'ad, Amal H.] Univ Cincinnati, Dept Pediat, Cincinnati, OH 45221 USA; [Xie, Changchun] Univ Cincinnati, Div Biostatist & Bioinformat, Dept Environm Hlth, Cincinnati, OH 45221 USA; [Shchelochkov, Oleg] Univ Iowa Hosp & Clin, Dept Pediat, Div Genet, Iowa City, IA 52242 USA; [Roehrs, Phillip A.] Univ N Carolina, Div Pediat Hematol Oncol, Chapel Hill, NC USA; [Bernstein, Jonathan A.] Univ Cincinnati, Div Immunol Allergy & Rheumatol, Dept Internal Med, Coll Med, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Iowa; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; University of Cincinnati	Lindsley, AW (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	andrew.lindsley@cchmc.org	Risma, Kimberly/ABE-5905-2020	Bernstein, Jonathan/0000-0002-3476-1196; Saal, Howard/0000-0002-0277-4777; /0000-0003-0671-4859	CSL Behring; National Institutes of Health [HD028827]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD028827, K12HD000850] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060515] Funding Source: NIH RePORTER	CSL Behring; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	A.W.L. received investigator- initiated funding from CSL Behring for this study. A.W.L. was also supported by National Institutes of Health K12 (HD028827) Child Health Research Career Development Award.	Ansari KI, 2010, FEBS J, V277, P1790, DOI 10.1111/j.1742-4658.2010.07606.x; Armstrong L, 2005, AM J MED GENET A, V132A, P265, DOI 10.1002/ajmg.a.30340; Banka S, 2012, EUR J HUM GENET, V20, P381, DOI 10.1038/ejhg.2011.220; Beguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011; Begum NA, 2012, J BIOL CHEM, V287, P32415, DOI 10.1074/jbc.M112.351569; Bemark M, 2012, ANN NY ACAD SCI, V1247, P97, DOI 10.1111/j.1749-6632.2011.06378.x; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Bogershausen N, 2013, CLIN GENET, V83, P201, DOI 10.1111/cge.12051; Borchert GM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011641; Brackmann F, 2013, J PEDIAT HEMATOL ONC, V35, pE314, DOI 10.1097/MPH.0b013e3182707fa8; Bradley SP, 2006, J IMMUNOL, V177, P1179, DOI 10.4049/jimmunol.177.2.1179; Cho YW, 2007, J BIOL CHEM, V282, P20395, DOI 10.1074/jbc.M701574200; Chong Y, 2003, CLIN EXP IMMUNOL, V133, P59, DOI 10.1046/j.1365-2249.2003.02185.x; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Cunningham-Rundles C, 2008, J CLIN IMMUNOL, V28, pS42, DOI 10.1007/s10875-008-9182-7; Daniel JA, 2010, SCIENCE, V329, P917, DOI 10.1126/science.1187942; Ettinger R, 2005, J IMMUNOL, V175, P7867, DOI 10.4049/jimmunol.175.12.7867; Fecteau JF, 2006, J IMMUNOL, V177, P3728, DOI 10.4049/jimmunol.177.6.3728; Giordano P, 2014, ITAL J PEDIATR, V40, DOI 10.1186/1824-7288-40-10; Guo CC, 2012, P NATL ACAD SCI USA, V109, P17603, DOI 10.1073/pnas.1208807109; Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751; Hoffman JD, 2005, AM J MED GENET A, V135A, P278, DOI 10.1002/ajmg.a.30722; Hu DQ, 2013, MOL CELL BIOL, V33, P4745, DOI 10.1128/MCB.01181-13; Issaeva I, 2007, MOL CELL BIOL, V27, P1889, DOI 10.1128/MCB.01506-06; Kawame H, 1999, J PEDIATR-US, V134, P480, DOI 10.1016/S0022-3476(99)70207-6; Klein U, 1997, BLOOD, V89, P1288, DOI 10.1182/blood.V89.4.1288; KUROKI Y, 1981, J PEDIATR-US, V99, P570, DOI 10.1016/S0022-3476(81)80256-9; Lederer D, 2012, AM J HUM GENET, V90, P119, DOI 10.1016/j.ajhg.2011.11.021; Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042; Li GD, 2013, TRENDS IMMUNOL, V34, P460, DOI 10.1016/j.it.2013.03.006; Li Y, 2011, HUM GENET, V130, P715, DOI 10.1007/s00439-011-1004-y; Lin J.L., 2014, CLIN GENET; MacCarthy T, 2009, DNA REPAIR, V8, P137, DOI 10.1016/j.dnarep.2008.09.006; Matsumoto N, 2003, AM J MED GENET C, V117C, P57, DOI 10.1002/ajmg.c.10020; Micale L, 2014, HUM MUTAT, V35, P841, DOI 10.1002/humu.22547; Micale L, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-38; Ming JE, 2005, AM J MED GENET A, V132A, P260, DOI 10.1002/ajmg.a.30332; Ng SB, 2010, NAT GENET, V42, P790, DOI 10.1038/ng.646; NIIKAWA N, 1988, AM J MED GENET, V31, P565, DOI 10.1002/ajmg.1320310312; NIIKAWA N, 1981, J PEDIATR-US, V99, P565, DOI 10.1016/S0022-3476(81)80255-7; Orange JS, 2012, J ALLERGY CLIN IMMUN, V130, pS1, DOI 10.1016/j.jaci.2012.07.002; Reese MG, 1997, J COMPUT BIOL, V4, P311, DOI 10.1089/cmb.1997.4.311; Ruminy P, 2011, LEUKEMIA, V25, P681, DOI 10.1038/leu.2010.302; Schrander-Stumpel CTRM, 2005, AM J MED GENET A, V132A, P234, DOI 10.1002/ajmg.a.30331; Schwab KR, 2011, MOL CELL BIOL, V31, P1503, DOI 10.1128/MCB.00990-10; Shinsky SA, 2014, J MOL BIOL, V426, P2283, DOI 10.1016/j.jmb.2014.03.011; Smith E, 2011, GENE DEV, V25, P661, DOI 10.1101/gad.2015411; Stanlie A, 2010, P NATL ACAD SCI USA, V107, P22190, DOI 10.1073/pnas.1016923108; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Weill JC, 2009, ANNU REV IMMUNOL, V27, P267, DOI 10.1146/annurev.immunol.021908.132607; Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382	52	52	55	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					179	+		10.1016/j.jaci.2015.06.002	http://dx.doi.org/10.1016/j.jaci.2015.06.002			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26194542	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000367724300008
J	Persson, H; Kwon, AT; Ramilowski, JA; Silberberg, G; Soderhall, C; Orsmark-Pietras, C; Nordlund, B; Konradsen, JR; de Hoon, MJL; Melen, E; Hayashizaki, Y; Hedlin, G; Kere, J; Daub, CO				Persson, Helena; Kwon, Andrew T.; Ramilowski, Jordan A.; Silberberg, Gilad; Soderhall, Cilla; Orsmark-Pietras, Christina; Nordlund, Bjorn; Konradsen, Jon R.; de Hoon, Michiel J. L.; Melen, Erik; Hayashizaki, Yoshihide; Hedlin, Gunilla; Kere, Juha; Daub, Carsten O.			Transcriptome analysis of controlled and therapy-resistant childhood asthma reveals distinct gene expression profiles	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Therapy-resistant asthma; childhood asthma; peripheral blood leukocytes; transcriptome; long noncoding RNA	PROBLEMATIC SEVERE ASTHMA; GENOME-WIDE ASSOCIATION; DIFFERENTIAL EXPRESSION; CHILDREN; CELLS; LOCI; SETS	Background: Children with problematic severe asthma have poor disease control despite high doses of inhaled corticosteroids and additional therapy, leading to personal suffering, early deterioration of lung function, and significant consumption of health care resources. If no exacerbating factors, such as smoking or allergies, are found after extensive investigation, these children are given a diagnosis of therapy-resistant (or therapy-refractory) asthma (SA). Objective: We sought to deepen our understanding of childhood SA by analyzing gene expression and modeling the underlying regulatory transcription factor networks in peripheral blood leukocytes. Methods: Gene expression was analyzed by using Cap Analysis of Gene Expression in children with SA (n = 13), children with controlled persistent asthma (n = 15), and age-matched healthy control subjects (n = 9). Cap Analysis of Gene Expression sequencing detects the transcription start sites of known and novel mRNAs and noncoding RNAs. Results: Sample groups could be separated by hierarchical clustering on 1305 differentially expressed transcription start sites, including 816 known genes and several novel transcripts. Ten of 13 tested novel transcripts were validated by means of RT-PCR and Sanger sequencing. Expression of RAR-related orphan receptor A (RORA), which has been linked to asthma in genome-wide association studies, was significantly upregulated in patients with SA. Gene network modeling revealed decreased glucocorticoid receptor signaling and increased activity of the mitogen-activated protein kinase and Jun kinase cascades in patients with SA. Conclusion: Circulating leukocytes from children with controlled asthma and those with SA have distinct gene expression profiles, demonstrating the possible development of specific molecular biomarkers and supporting the need for novel therapeutic approaches.	[Persson, Helena; Soderhall, Cilla; Orsmark-Pietras, Christina; Kere, Juha; Daub, Carsten O.] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Persson, Helena; Soderhall, Cilla; Orsmark-Pietras, Christina; Kere, Juha; Daub, Carsten O.] Karolinska Inst, Ctr Innovat Med CIMED, Stockholm, Sweden; [Silberberg, Gilad] Karolinska Inst, Unit Computat Med, Dept Med, Stockholm, Sweden; [Soderhall, Cilla; Nordlund, Bjorn; Konradsen, Jon R.; Melen, Erik; Hedlin, Gunilla; Kere, Juha] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Nordlund, Bjorn; Konradsen, Jon R.; Hedlin, Gunilla] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Melen, Erik] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Kwon, Andrew T.; Ramilowski, Jordan A.; de Hoon, Michiel J. L.; Hayashizaki, Yoshihide; Daub, Carsten O.] Omics Sci Ctr, Yokohama, Kanagawa, Japan; RIKEN Yokohama Inst, Yokohama, Kanagawa, Japan; [Kwon, Andrew T.; Ramilowski, Jordan A.; de Hoon, Michiel J. L.; Daub, Carsten O.] RIKEN Ctr Life Sci Technol, Div Genom Technol, Yokohama, Kanagawa, Japan; [Nordlund, Bjorn; Konradsen, Jon R.; Hedlin, Gunilla] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Melen, Erik] Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden; [Hayashizaki, Yoshihide] RIKEN Res Cluster Innovat, Prevent Med & Diag Innovat Program, Wako, Saitama, Japan; [Kere, Juha] Folkhalsan Inst Genet, Helsinki, Finland; [Kere, Juha] Univ Helsinki, Res Programs Unit, FIN-00014 Helsinki, Finland	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; RIKEN; RIKEN; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; RIKEN; University of Helsinki	Kere, J (corresponding author), Karolinska Inst, Dept Biosci & Nutr, Halsovagen 7-9, SE-14183 Huddinge, Sweden.	juha.kere@ki.se	Ramilowski, Jordan A./Z-3103-2019; de Hoon, Michiel/A-6443-2013; Kere, Juha/A-9179-2008; Konradsen, Jon/AAD-5620-2021; Nordlund, Björn/AAF-6037-2019; Persson, Helena/ABE-5003-2020; Kere, Juha/AAX-9117-2021; Kwon, Andrew/D-4625-2017; Hayashizaki, Yoshihide/N-6590-2015; Daub, Carsten O/A-7436-2010	Ramilowski, Jordan A./0000-0002-3156-6416; Kere, Juha/0000-0003-1974-0271; Konradsen, Jon/0000-0001-7745-8624; Nordlund, Björn/0000-0001-9888-1659; Kere, Juha/0000-0003-1974-0271; Kwon, Andrew/0000-0001-5019-8156; Daub, Carsten O/0000-0002-3295-8729; Orsmark-Pietras, Christina/0000-0002-6533-0305; Persson, Helena/0000-0002-5187-6446; de Hoon, Michiel/0000-0003-0489-2352	MEXT; Swedish Foundation for Strategic Research [RBc08-0027]; Swedish Research Council [2009-5091]; Freemason Child House Foundation in Stockholm; Konsul Th. C. Bergh's Foundation; Swedish Asthma and Allergy Association's Research Foundation; Centre for Allergy Research at Karolinska Institutet; Swedish Heart-Lung Foundation; Karolinska Institutet; Bernard Osher Initiative for Research on Severe Asthma	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Research Council(Swedish Research CouncilEuropean Commission); Freemason Child House Foundation in Stockholm; Konsul Th. C. Bergh's Foundation; Swedish Asthma and Allergy Association's Research Foundation; Centre for Allergy Research at Karolinska Institutet(Karolinska Institutet); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Karolinska Institutet(Karolinska Institutet); Bernard Osher Initiative for Research on Severe Asthma	Supported by a research grant for the RIKEN Omics Science Center from MEXT (to Y.H.) and grants from the Swedish Foundation for Strategic Research (RBc08-0027) and the Swedish Research Council (2009-5091; to J.K.). Patient sample collection was supported by grants from the Freemason Child House Foundation in Stockholm, the Konsul Th. C. Bergh's Foundation, the Swedish Asthma and Allergy Association's Research Foundation, the Centre for Allergy Research at Karolinska Institutet, the Swedish Heart-Lung Foundation, Karolinska Institutet, and the Bernard Osher Initiative for Research on Severe Asthma.	[Anonymous], 2013, CHRON RESP DIS ASTHM; Aoki T, 2009, CLIN EXP ALLERGY, V39, P213, DOI 10.1111/j.1365-2222.2008.03186.x; Baines KJ, 2010, EUR RESPIR J, V35, P522, DOI 10.1183/09031936.00027409; Bjornsdottir US, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021902; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Bosco A, 2012, J ALLERGY CLIN IMMUN, V129, P88, DOI 10.1016/j.jaci.2011.10.038; Chamberland A, 2009, EXP LUNG RES, V35, P399, DOI 10.1080/01902140902745174; Chen E, 2009, THORAX, V64, P38, DOI 10.1136/thx.2007.095091; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Costa C, 2011, BLOOD, V118, P1099, DOI 10.1182/blood-2010-12-324756; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Fleming L, 2007, CURR OPIN ALLERGY CL, V7, P190, DOI 10.1097/ACI.0b013e3280895d0c; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Global Initiative for Asthma (GINA), 2012, GLOB STRAT ASTHM MAN; Hakonarson H, 2005, P NATL ACAD SCI USA, V102, P14789, DOI 10.1073/pnas.0409904102; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Hedlin G, 2010, EUR RESPIR J, V36, P196, DOI 10.1183/09031936.00104809; Hindorff LA, CATALOG PUBLISHED GE; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Hudson NJ, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-356; Just J, 2012, EUR RESPIR J, V40, P55, DOI 10.1183/09031936.00123411; Kanamori-Katayama M, 2011, GENOME RES, V21, P1150, DOI 10.1101/gr.115469.110; Kicic A, 2010, AM J RESP CRIT CARE, V181, P889, DOI 10.1164/rccm.200907-1071OC; Konradsen JR, 2011, PEDIAT ALLERG IMM-UK, V22, P9, DOI 10.1111/j.1399-3038.2010.01098.x; Lang A, 2008, ALLERGY, V63, P1054, DOI 10.1111/j.1398-9995.2008.01672.x; Laprise C, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-21; Marin-Bejar O, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r104; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Melen E, 2012, J INTERN MED, V272, P108, DOI 10.1111/j.1365-2796.2012.02555.x; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046; Orsmark-Pietrast C, 2013, EUR RESPIR J, V42, P65, DOI 10.1183/09031936.00077712; Portales-Casamar E, 2010, NUCLEIC ACIDS RES, V38, pD105, DOI 10.1093/nar/gkp950; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Suzuki H, 2009, NAT GENET, V41, P553, DOI 10.1038/ng.375; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tsitsiou E, 2012, J ALLERGY CLIN IMMUN, V129, P95, DOI 10.1016/j.jaci.2011.08.011; Vitezic M, 2010, NUCLEIC ACIDS RES, V38, P8141, DOI 10.1093/nar/gkq729; Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917; Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r14	40	52	54	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					638	648		10.1016/j.jaci.2015.02.026	http://dx.doi.org/10.1016/j.jaci.2015.02.026			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25863981	hybrid, Green Published			2022-12-18	WOS:000360913300014
J	Hasegawa, K; Tsugawa, Y; Chang, YC; Camargo, CA				Hasegawa, Kohei; Tsugawa, Yusuke; Chang, Yuchiao; Camargo, Carlos A., Jr.			Risk of an asthma exacerbation after bariatric surgery in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Acute asthma; emergency department; hospitalization; obesity; bariatric surgery; weight reduction; self-controlled case series study	BODY-MASS INDEX; CLINICAL-PRACTICE; PULMONARY-FUNCTION; WEIGHT-LOSS; OBESITY; ASSOCIATION; GUIDELINES; SEVERITY; TRIALS; IMPACT	Background: Research on nonsurgical weight loss interventions has failed to demonstrate consistent efficacy on asthma control, although these interventions resulted in only modest weight reductions. Objective: We sought to test the hypothesis that bariatric surgery is associated with a rapid and sustained decrease in risk of asthma exacerbation. Methods: We performed a self-controlled case series study of 2261 obese patients with asthma aged 18 to 54 years who underwent bariatric surgery using the population-based emergency department (ED) and inpatient sample in 3 states (California, Florida, and Nebraska). The primary outcome was an ED visit or hospitalization for asthma exacerbation from 2005 through 2011. We used conditional logistic regression to compare each patient's risk of the outcome event during sequential 12-month periods using presurgery months 13 to 24 as the reference period. Results: During the reference period, 22.0% (95% CI, 20.3% to 23.7%) of patients had an ED visit or hospitalization for asthma exacerbation. In the subsequent 12-month presurgery period, the risk did not materially change (21.7%; 95% CI, 20.0% to 23.4%), with an odds ratio (OR) of 0.98 (95% CI, 0.85-1.13) compared with the reference period. By contrast, significantly fewer ED visits or hospitalizations for asthma exacerbation occurred within 12 months after bariatric surgery (10.9%; 95% CI, 9.6% to 12.2%), corresponding to an OR of 0.42 (95% CI, 0.35-0.50). Similarly, in the subsequent period of 13 to 24 months after bariatric surgery, the risk remained significantly lower (10.9%; 95% CI, 9.6% to 12.2%), corresponding to an OR of 0.42 (95% CI, 0.35-0.50). Conclusion: In obese patients the risk of an ED visit or hospitalization for asthma exacerbation decreased by half after bariatric surgery. This reduction suggests the effectiveness of significant weight loss on asthma morbidity.	[Hasegawa, Kohei; Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Chang, Yuchiao] Harvard Univ, Massachusetts Gen Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02115 USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; [Tsugawa, Yusuke] Harvard Interfac Initiat Hlth Policy, Cambridge, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Hasegawa, K (corresponding author), Massachusetts Gen Hosp, Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA.	khasegawa1@partners.org	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654; Tsugawa, Yusuke/0000-0002-1937-4833; Hasegawa, Kohei/0000-0002-5739-7999	Eleanor and Miles Shore Fellowship Program (Boston, Mass)	Eleanor and Miles Shore Fellowship Program (Boston, Mass)	K.H. was supported in part by the Eleanor and Miles Shore Fellowship Program (Boston, Mass).	Adeniyi FB, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009339.pub2; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Boulet LP, 2012, RESP MED, V106, P651, DOI 10.1016/j.rmed.2011.12.012; Buchwald H, 2004, JAMA-J AM MED ASSOC, V292, P1724, DOI 10.1001/jama.292.14.1724; Burguera B, 2007, J ENDOCRINOL INVEST, V30, P844, DOI 10.1007/BF03349226; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Dixon AE, 2011, J ALLERGY CLIN IMMUN, V128, P508, DOI 10.1016/j.jaci.2011.06.009; Dixon Anne E, 2010, Proc Am Thorac Soc, V7, P325, DOI 10.1513/pats.200903-013ST; Dixon JB, 1999, OBES SURG, V9, P385, DOI 10.1381/096089299765552981; Eneli IU, 2008, THORAX, V63, P671, DOI 10.1136/thx.2007.086470; Gibson Peter G, 2013, Ann Am Thorac Soc, V10 Suppl, pS138, DOI 10.1513/AnnalsATS.201302-038AW; Gloy VL, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5934; Hasegawa Kohei, 2014, Ann Am Thorac Soc, V11, P1439, DOI 10.1513/AnnalsATS.201406-270BC; Hasegawa Kohei, 2014, Ann Am Thorac Soc, V11, P158, DOI 10.1513/AnnalsATS.201306-166OC; Hewitt S, 2014, OBES SURG, V24, P705, DOI 10.1007/s11695-013-1159-9; Lombardi C, 2011, J ASTHMA, V48, P553, DOI 10.3109/02770903.2011.587581; Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132; Maasland L, 2009, STROKE, V40, P2662, DOI 10.1161/STROKEAHA.109.551812; Mechanick JI, 2013, OBESITY, V21, pS1, DOI 10.1002/oby.20461; Moorman Jeanne E, 2012, Vital Health Stat 3, P1; Moreira A, 2013, ALLERGY, V68, P425, DOI 10.1111/all.12106; Mosen DM, 2008, J ALLERGY CLIN IMMUN, V122, P507, DOI 10.1016/j.jaci.2008.06.024; Nguyen GC, 2013, OBES SURG, V23, P1508, DOI 10.1007/s11695-013-0957-4; Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732; Overview of the State Emergency Department Databases (SEDD), HEALTHCARE COST AND; Overview of the State Inpatient Databases (SID), OV STAT INP DAT SID; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Quinto KB, 2011, J ALLERGY CLIN IMMUN, V128, P964, DOI 10.1016/j.jaci.2011.06.031; Reddy RC, 2011, OBES SURG, V21, P200, DOI 10.1007/s11695-010-0155-6; Schatz M, 2013, J ALLER CL IMM-PRACT, V1, P618, DOI 10.1016/j.jaip.2013.07.009; Scott HA, 2011, EUR RESPIR J, V38, P594, DOI 10.1183/09031936.00139810; Sideleva O, 2012, AM J RESP CRIT CARE, V186, P598, DOI 10.1164/rccm.201203-0573OC; Sikka N, 2010, ANN ALLERG ASTHMA IM, V104, P326, DOI 10.1016/j.anai.2009.12.009; Van Spall HGC, 2007, JAMA-J AM MED ASSOC, V297, P1233, DOI 10.1001/jama.297.11.1233; Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302	35	52	52	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					288	+		10.1016/j.jaci.2014.12.1931	http://dx.doi.org/10.1016/j.jaci.2014.12.1931			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25670012				2022-12-18	WOS:000359004900009
J	Savvatianos, S; Konstantinopoulos, AP; Borga, A; Stavroulakis, G; Lidholm, J; Borres, MP; Manousakis, E; Papadopoulos, NG				Savvatianos, Savvas; Konstantinopoulos, Anastasios P.; Borga, Ase; Stavroulakis, George; Lidholm, Jonas; Borres, Magnus P.; Manousakis, Emmanouil; Papadopoulos, Nikolaos G.			Sensitization to cashew nut 2S albumin, Ana o 3, is highly predictive of cashew and pistachio allergy in Greek children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATOPIC-DERMATITIS; TOPICAL PIMECROLIMUS; PEANUT; MILD; IGE		[Savvatianos, Savvas; Konstantinopoulos, Anastasios P.; Stavroulakis, George; Manousakis, Emmanouil; Papadopoulos, Nikolaos G.] Univ Athens, Pediat Clin 2, Dept Allergy, Athens, Greece; [Borga, Ase; Lidholm, Jonas; Borres, Magnus P.] Thermo Fisher Sci, Uppsala, Sweden; [Borres, Magnus P.] Uppsala Univ, Dept Maternal & Child Hlth, Uppsala, Sweden; [Papadopoulos, Nikolaos G.] Univ Manchester, Inst Human Dev, Ctr Paediat & Child Hlth, Manchester, Lancs, England	National & Kapodistrian University of Athens; Thermo Fisher Scientific; Uppsala University; University of Manchester	Savvatianos, S (corresponding author), Univ Athens, Pediat Clin 2, Dept Allergy, Athens, Greece.	ss@allergy.gr	Papadopoulos, Nikolaos/ABE-1774-2021; N.G., Papadopoulos/L-8670-2013	Papadopoulos, Nikolaos/0000-0002-4448-3468; N.G., Papadopoulos/0000-0002-4448-3468; Lidholm, Jonas/0000-0002-7779-3411				Clark AT, 2007, ALLERGY, V62, P913, DOI 10.1111/j.1398-9995.2007.01447.x; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; Ebisawa M, 2013, J ALLERGY CLIN IMMUN, V132, P976, DOI 10.1016/j.jaci.2013.04.028; Eichenfield LF, 2002, J AM ACAD DERMATOL, V46, P495, DOI 10.1067/mjd.2002.122187; FAN JQ, 1992, J AM STAT ASSOC, V87, P998, DOI 10.2307/2290637; Hourihane JO, 2001, ALLERGY, V56, P252, DOI 10.1034/j.1398-9995.2001.056003252.x; Kapoor R, 2009, PEDIATR DERMATOL, V26, P682, DOI 10.1111/j.1525-1470.2009.01013.x; Kapp A, 2002, J ALLERGY CLIN IMMUN, V110, P277, DOI 10.1067/mai.2002.126500; Klemans RJB, 2015, CLIN EXP ALLERGY, V45, P720, DOI 10.1111/cea.12412; Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014; Masthoff LJN, 2013, J ALLERGY CLIN IMMUN, V132, P393, DOI 10.1016/j.jaci.2013.02.024; Rabe-Hesketh S, 2012, MULTILEVEL LONGITUDI; Schmitt J, 2013, J ALLERGY CLIN IMMUN, V132, P1337, DOI 10.1016/j.jaci.2013.07.008; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Vetander M, 2012, CLIN EXP ALLERGY, V42, P568, DOI 10.1111/j.1365-2222.2011.03954.x; Vissing NH, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-160; Williams HC, 2005, NEW ENGL J MED, V352, P2314, DOI 10.1056/NEJMcp042803; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x	18	52	53	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					192	194		10.1016/j.jaci.2015.03.037	http://dx.doi.org/10.1016/j.jaci.2015.03.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25959668				2022-12-18	WOS:000357542200023
J	Idzko, M; Pitchford, S; Page, C				Idzko, Marco; Pitchford, Simon; Page, Clive			Role of platelets in allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Platelets; asthma pathophysiology; leukocyte recruitment; dendritic cells; T(H)2 sensitization; airway remodeling	INDUCED BRONCHIAL HYPERRESPONSIVENESS; NEUTROPHIL EXTRACELLULAR TRAPS; P-SELECTIN; LEUKOCYTE RECRUITMENT; DENDRITIC CELLS; IMMUNE CELLS; HOST-DEFENSE; MURINE MODEL; DOUBLE-BLIND; ASTHMA	Increasing evidence suggests an important role for platelets and their products (eg, platelet factor 4, beta-thromboglobulin, RANTES, thromboxane, or serotonin) in the pathogenesis of allergic diseases. A variety of changes in platelet function have been observed in patients with asthma, such as alterations in platelet secretion, expression of surface molecules, aggregation, and adhesion. Moreover, platelets have been found to actively contribute to most of the characteristic features of asthma, including bronchial hyperresponsiveness, bronchoconstriction, airway inflammation, and airway remodeling. This review brings together the current available data from both experimental and clinical studies that have investigated the role of platelets in allergic airway inflammation and asthma. It is anticipated that a better understanding of the role of platelets in the pathogenesis of asthma might lead to novel promising therapeutic approaches in the treatment of allergic airway diseases.	[Idzko, Marco] Univ Hosp Freiburg, Dept Pulm Med, D-79106 Freiburg, Germany; [Pitchford, Simon; Page, Clive] Kings Coll London, Inst Pharmaceut Sci, Sackler Inst Pulm Pharmacol, London WC2R 2LS, England	University of Freiburg; University of London; King's College London	Idzko, M (corresponding author), Univ Hosp Freiburg, Dept Pulm Med, Killianstr 5, D-79106 Freiburg, Germany.	marco.idzko@uniklinik-freiburg.de		Pitchford, Simon/0000-0003-3961-0407	DFG	DFG(German Research Foundation (DFG))	M. Idzko has received research support from DFG. The rest of the authors declare that they have no relevant conflicts of interest.	Amison RT, 2015, J ALLERGY CLIN IMMUN, V135, P528, DOI 10.1016/j.jaci.2014.09.032; AVERILL FJ, 1992, AM REV RESPIR DIS, V145, P571, DOI 10.1164/ajrccm/145.3.571; Boilard E, 2010, SCIENCE, V327, P580, DOI 10.1126/science.1181928; Broide DH, 1998, AM J RESP CELL MOL, V18, P218, DOI 10.1165/ajrcmb.18.2.2829; Capron M, 1991, Monogr Allergy, V29, P63; CARDOT E, 1992, INT ARCH ALLERGY IMM, V98, P127, DOI 10.1159/000236175; Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303; Cazzola M, 2013, CURR OPIN PULM MED, V19, P36, DOI 10.1097/MCP.0b013e32835b113a; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Cognasse F, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00083; COYLE AJ, 1994, AM J RESP CRIT CARE, V150, pS63, DOI 10.1164/ajrccm/150.5_Pt_2.S63; COYLE AJ, 1990, AM REV RESPIR DIS, V142, P587, DOI 10.1164/ajrccm/142.3.587; COYLE AJ, 1990, BRIT J PHARMACOL, V101, P31, DOI 10.1111/j.1476-5381.1990.tb12084.x; de Boer JD, 2012, BLOOD, V119, P3236, DOI 10.1182/blood-2011-11-391532; de Stoppelaar SF, 2014, BLOOD, V124, P3781, DOI 10.1182/blood-2014-05-573915; Durk T, 2013, AM J RESP CRIT CARE, V187, P476, DOI 10.1164/rccm.201208-1440OC; ENDRESEN GKM, 1989, RHEUMATOL INT, V9, P19, DOI 10.1007/BF00270285; Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871; HALONEN M, 1981, AM REV RESPIR DIS, V124, P416; Hamzeh-Cognasse H, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00082; HERD CM, 1994, EUR RESPIR J, V7, P1145; Holm ACBS, 2014, PLATELETS, V25, P111, DOI 10.3109/09537104.2013.783688; Idzko M, 2004, J IMMUNOL, V172, P6011, DOI 10.4049/jimmunol.172.10.6011; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Idzko M, 2014, NATURE, V509, P310, DOI 10.1038/nature13085; IND PW, 1991, CLIN EXP ALLERGY, V21, P395, DOI 10.1111/j.1365-2222.1991.tb01677.x; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Johansson MW, 2014, CLIN EXP ALLERGY, V44, P482, DOI 10.1111/cea.12292; Johansson MW, 2012, AM J RESP CRIT CARE, V185, P498, DOI 10.1164/rccm.201109-1712OC; JOSEPH M, 1993, J ALLERGY CLIN IMMUN, V92, P165, DOI 10.1016/0091-6749(93)90100-T; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; Klouche M, 1997, J ALLERGY CLIN IMMUN, V100, P235, DOI 10.1016/S0091-6749(97)70230-6; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; Kornerup KN, 2007, PLATELETS, V18, P319, DOI 10.1080/09537100701230436; Kowal K, 2006, CLIN EXP ALLERGY, V36, P426, DOI 10.1111/j.1365-2222.2006.02446.x; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021; Lambrecht BN, 2010, LANCET, V376, P835, DOI 10.1016/S0140-6736(10)61226-3; LASSER EC, 1987, ALLERGY, V42, P549, DOI 10.1111/j.1398-9995.1987.tb00381.x; Lechin F, 1998, CLIN PHARMACOL THER, V64, P223, DOI 10.1016/S0009-9236(98)90156-4; Lommatzsch M, 2009, THORAX, V64, P763, DOI 10.1136/thx.2008.110916; Lukacs NW, 2002, J IMMUNOL, V169, P2120, DOI 10.4049/jimmunol.169.4.2120; Lussana F, 2015, J THROMB HAEMOST, V13, P136, DOI 10.1111/jth.12779; Mehlhop PD, 2000, AM J RESP CELL MOL, V23, P646, DOI 10.1165/ajrcmb.23.5.3954; Morrell CN, 2014, BLOOD, V123, P2759, DOI 10.1182/blood-2013-11-462432; Muller T, 2010, ALLERGY, V65, P1545, DOI 10.1111/j.1398-9995.2010.02426.x; Muller T, 2011, AM J RESP CELL MOL, V44, P456, DOI 10.1165/rcmb.2010-0129OC; Page C, 2014, CLIN EXP ALLERGY, V44, P901, DOI 10.1111/cea.12322; Page C, 2013, AM J RESP CRIT CARE, V187, P459, DOI 10.1164/rccm.201301-0085ED; PAGE CP, 1988, TRENDS PHARMACOL SCI, V9, P66, DOI 10.1016/0165-6147(88)90120-4; Page CP, 2006, ENCY RESP MED, P347; Page G, 2013, INT IMMUNOPHARMACOL, V17, P1176, DOI 10.1016/j.intimp.2013.06.004; Pan DX, 2015, BLOOD, V125, P1146, DOI 10.1182/blood-2014-07-591040; Pitchford SC, 2005, BLOOD, V105, P2074, DOI 10.1182/blood-2004-06-2282; Pitchford SC, 2004, BLOOD, V103, P639, DOI 10.1182/blood-2003-05-1707; Pitchford SC, 2003, J ALLERGY CLIN IMMUN, V112, P109, DOI 10.1067/mai.2003.1514; Pitchford SC, 2008, AM J RESP CRIT CARE, V177, P604, DOI 10.1164/rccm.200702-214OC; Rossaint J, 2015, CARDIOVASC RES; SLATER D, 1985, LANCET, V1, P110; Sprague DL, 2008, BLOOD, V111, P5028, DOI 10.1182/blood-2007-06-097410; Sreeramkumar V, 2014, SCIENCE, V346, P1234, DOI 10.1126/science.1256478; Tian J, 2014, CELL MOL IMMUNOL; TUNONDELARA JM, 1992, J ALLERGY CLIN IMMUN, V89, P994, DOI 10.1016/0091-6749(92)90222-N; Ulfman LH, 2003, AM J RESP CELL MOL, V28, P512, DOI 10.1165/rcmb.4806; van Rift LS, 2004, J ALLERGY CLIN IMMUN, V114, P166, DOI 10.1016/j.jaci.2004.03.044; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; von Hundelshausen P, 2007, THROMB HAEMOSTASIS, V97, P704, DOI 10.1160/TH07-01-0066; von Hundelshausen P, 2007, CIRC RES, V100, P27, DOI 10.1161/01.RES.0000252802.25497.b7; Willemssen R, 2009, PLOS ONE, V4, DOI [10.1371/journal.pone.0006453, 10.1371/journal.pone.0004898]; Yeaman MR, 2014, NAT REV MICROBIOL, V12, P426, DOI 10.1038/nrmicro3269; Youssefian T, 2002, BLOOD, V99, P4021, DOI 10.1182/blood-2001-12-0191	71	52	55	2	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1416	1423		10.1016/j.jaci.2015.04.028	http://dx.doi.org/10.1016/j.jaci.2015.04.028			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	26051948				2022-12-18	WOS:000355933400002
J	Gueant, JL; Romano, A; Cornejo-Garcia, JA; Oussalah, A; Chery, C; Blanca-Lopez, N; Gueant-Rodriguez, RM; Gaeta, F; Rouyer, P; Josse, T; Canto, G; Carmona, FD; Bossini-Castillo, L; Martin, J; Laguna, JJ; Fernandez, J; Feo, F; Ostrov, DA; Plasencia, PC; Mayorga, C; Torres, MJ; Blanca, M				Gueant, Jean-Louis; Romano, Antonino; Cornejo-Garcia, Jose-Antonio; Oussalah, Abderrahim; Chery, Celine; Blanca-Lopez, Natalia; Gueant-Rodriguez, Rosa-Maria; Gaeta, Francesco; Rouyer, Pierre; Josse, Thomas; Canto, Gabriella; David Carmona, F.; Bossini-Castillo, Lara; Martin, Javier; Laguna, Jose-Julio; Fernandez, Javier; Feo, Francisco; Ostrov, David A.; Plasencia, Pablo C.; Mayorga, Cristobalina; Torres, Maria-Jose; Blanca, Miguel			HLA-DRA variants predict penicillin allergy in genome-wide fine-mapping genotyping	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Drug allergy; immediate-type reactions; anaphylaxis; beta-lactams; penicillins; amoxicillin; genome-wide association; HLA-DRA	MHC CLASS-II; BETA-LACTAMS; SWISS-MODEL; SERUM IGE; IMMEDIATE; CEPHALOSPORINS; IDENTIFICATION; VISUALIZATION; SENSITIZATION; DETERMINANTS	Background: Immediate reactions to b-lactams are the most common causes of anaphylactic reactions and can be life-threatening. The few known genetic factors influencing these reactions suggest a link with atopy and inflammation. Objective: We performed a fine-mapping genome-wide association study of the genetic predictors of b-lactam allergy to better understand the underlying mechanisms. Methods: We studied 387 patients with immediate allergic reactions to b-lactams and 1124 paired control subjects from Spain. We replicated the results in 299 patients and 362 paired control subjects from Italy. Results: We found significant associations with the single nucleotide polymorphisms rs4958427 of ZNF300 (c. 64-471G> A, P 5 9.9 3 10 29), rs17612 of C5 (c. 4311A> C [p. Glu1437Asp], P 5 7.5 3 10 27), rs7754768 and rs9268832 of the HLA-DRA j HLA-DRB5 interregion (P 5 1.6 3 10 26 and 4.9 3 10 26), and rs7192 of HLA-DRA (c. 724T> G [p. Leu242Val], P 5 7.4 3 10 26) in an allelic model, with similar results in an additive model. Single nucleotide polymorphisms of HLA-DRA and ZNF300 predicted skin test positivity to amoxicillin and other penicillins but not to cephalosporins. A haplotype block in HLA-DRA and the HLA-DRA j HLA-DRB5 interregion encompassed a motif involved in balanced expression of the a-and b-chains of MHC class II, whereas rs7192 was predicted to influence a-chain conformation. HLA-DRA rs7192 and rs8084 were significantly associated with allergy to penicillins and amoxicillin (P 5 6.0 3 10 24 and P 5 4.0 3 10 24, respectively) but not to cephalosporins in the replication study. Conclusions: Gene variants of HLA-DRA and the HLA-DRA j HLA-DRB5 interregion were significant predictors of allergy to penicillins but not to cephalosporins. These data suggest complex gene-environment interactions in which genetic susceptibility of HLA type 2 antigen presentation	[Gueant, Jean-Louis; Cornejo-Garcia, Jose-Antonio; Oussalah, Abderrahim; Chery, Celine; Gueant-Rodriguez, Rosa-Maria; Rouyer, Pierre; Josse, Thomas; Blanca, Miguel] Univ Lorraine, INSERM, Fac Med, U954, Nancy, France; [Gueant, Jean-Louis; Cornejo-Garcia, Jose-Antonio; Oussalah, Abderrahim; Chery, Celine; Gueant-Rodriguez, Rosa-Maria; Rouyer, Pierre; Josse, Thomas; Blanca, Miguel] Univ Hosp Ctr CHU Nancy, Nancy, France; [Romano, Antonino; Gaeta, Francesco] UCSC, Dept Internal Med & Geriatr, Allergy Unit, Rome, Italy; [Romano, Antonino] IRCCS Mental Retardat & Brain Aging, Oasi Maria SS, Troina, Italy; [Cornejo-Garcia, Jose-Antonio; Mayorga, Cristobalina; Torres, Maria-Jose; Blanca, Miguel] IBIMA Hosp Reg Univ Malaga, Carlos Haya Hosp, Allergy Serv, Malaga, Spain; [Blanca-Lopez, Natalia; Canto, Gabriella] Infanta Leonor Hosp, Allergy Serv, Madrid, Spain; [David Carmona, F.; Bossini-Castillo, Lara; Martin, Javier] Inst Parasitol & Biomed Lopez Neyra, Granada, Spain; [Laguna, Jose-Julio] Hosp la Cruz Roja, Allergy Unit, Madrid, Spain; [Fernandez, Javier] Hosp Alicante, Allergy Serv, Alicante, Spain; [Feo, Francisco] Hosp Ciudad Real, Allergy Serv, Ciudad Real, Spain; [Ostrov, David A.; Plasencia, Pablo C.] Univ Florida, Coll Med, Gainesville, FL USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; CHU de Nancy; Catholic University of the Sacred Heart; IRCCS Oasi Maria SS; Hospital Carlos Haya; Hospital Universitario Infanta Leonor; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); General University Hospital of Alicante; State University System of Florida; University of Florida	Gueant, JL (corresponding author), INSERM, Nutr Genet Environm Exposure UMRS 954, Ave Foret Haye, Vandoeuvre Les Nancy, France.	jean-louis.gueant@univ-lorraine.fr	Carmona, F. David/F-9953-2016; Martín, Javier/AAV-5209-2021; Romano, Antonino/D-3102-2017; Torres, María José/T-3518-2017; Fernandez, Javier/B-6425-2018; Torres, Maria/GVU-3391-2022; Martín, María/HDL-9512-2022; Mayorga, Lina/FBO-7730-2022; Martin, Javier/B-8141-2008; Gaeta, Francesco/AAC-7107-2020; Martinez, Jose Julio Laguna/L-6891-2017; Cornejo-García, Jose Antonio/S-7726-2016; Bossini-Castillo, Lara/G-1234-2016; Mayorga, Cristobalina/D-7167-2018; Abderrahim, OUSSALAH/F-9821-2014	Carmona, F. David/0000-0002-1427-7639; Romano, Antonino/0000-0001-9742-9898; Torres, María José/0000-0001-5228-471X; Fernandez, Javier/0000-0003-1065-7199; Martin, Javier/0000-0002-2202-0622; Gaeta, Francesco/0000-0003-2942-7633; Martinez, Jose Julio Laguna/0000-0001-5909-8979; Cornejo-García, Jose Antonio/0000-0003-3465-8735; Bossini-Castillo, Lara/0000-0002-5471-5824; Mayorga, Cristobalina/0000-0001-8852-8077; Abderrahim, OUSSALAH/0000-0002-9731-4529; Feo-Brito, Francisco/0000-0003-1886-9620	French Ministry of Health (National Program for Clinical Research) [PHRC 189]; ''Chercheur d'excellence'' of the Region of Lorraine (France); Carlos III Institute (ISCIII) of the Spanish Health Ministry: network RIRAAF [RD12/0013/0001, PI10/01598, PI12/02247]; Government of Andalucia [PI-0279-2012, PI-0352-2012]; Juan de la Cierva Program	French Ministry of Health (National Program for Clinical Research); ''Chercheur d'excellence'' of the Region of Lorraine (France)(Region Grand-Est); Carlos III Institute (ISCIII) of the Spanish Health Ministry: network RIRAAF; Government of Andalucia; Juan de la Cierva Program	Supported by a grant from the French Ministry of Health (National Program for Clinical Research, PHRC 189); a grant ''Chercheur d'excellence'' of the Region of Lorraine (France); grants from the Carlos III Institute (ISCIII) of the Spanish Health Ministry: network RIRAAF (RD12/0013/0001), PI10/01598, and PI12/02247; and the Government of Andalucia, PI-0279-2012 and PI-0352-2012. J.-A. C.-G. was a postdoctoral researcher of the Juan de la Cierva Program (Spanish Ministry of Science and Innovation) and is currently a postdoctoral researcher of the Andalusian Health Service. M. B. is a visiting full professor at the Medical Faculty, University of Nancy.	Apter AJ, 2008, J ALLERGY CLIN IMMUN, V122, P152, DOI 10.1016/j.jaci.2008.03.037; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bursztejn AC, 2013, ALLERGY, V68, P1076, DOI 10.1111/all.12196; Buschow SI, 2010, IMMUNOL CELL BIOL, V88, P851, DOI 10.1038/icb.2010.64; Cornejo-Garcia JA, 2012, ALLERGY, V67, P1181, DOI 10.1111/j.1398-9995.2012.02867.x; Dona I, 2012, J INVEST ALLERG CLIN, V22, P363; Gou DM, 2004, BBA-GENE STRUCT EXPR, V1676, P203, DOI 10.1016/j.bbaexp.2003.11.011; Grammatikos AP, 2008, ANN MED, V40, P482, DOI 10.1080/07853890802082096; Gueant JL, 2008, CURR PHARM DESIGN, V14, P2770, DOI 10.2174/138161208786369795; Gueant-Rodriguez RM, 2008, PHARMACOGENOMICS J, V8, P162, DOI 10.1038/sj.tpj.6500456; Gueant-Rodriguez RM, 2006, PHARMACOGENET GENOM, V16, P713, DOI 10.1097/01.fpc.0000230409.00276.44; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guglielmi L, 2006, ALLERGY, V61, P921, DOI 10.1111/j.1398-9995.2006.01067.x; Hartshorn MJ, 2002, J COMPUT AID MOL DES, V16, P871, DOI 10.1023/A:1023813504011; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kiefer Florian, 2009, Nucleic Acids Res, V37, pD387, DOI 10.1093/nar/gkn750; Kohl J, 2006, J CLIN INVEST, V116, P783, DOI 10.1172/JCI26582; Lapaque N, 2009, J BIOL CHEM, V284, P7007, DOI 10.1074/jbc.M805736200; Letunic I, 2012, NUCLEIC ACIDS RES, V40, pD302, DOI 10.1093/nar/gkr931; Nam YH, 2012, J KOREAN MED SCI, V27, P1292, DOI 10.3346/jkms.2012.27.11.1292; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Park MA, 2010, INT ARCH ALLERGY IMM, V153, P268, DOI 10.1159/000314367; Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061; Pisapia L, 2013, NUCLEIC ACIDS RES, V41, P3772, DOI 10.1093/nar/gkt059; Qiao HL, 2005, ALLERGY, V60, P1053, DOI 10.1111/j.1398-9995.2005.00816.x; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Rawlins M., 1977, TXB ADVERSE DRUG REA, P10; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Stephan V, 1999, CLIN EXP ALLERGY, V29, P1049, DOI 10.1046/j.1365-2222.1999.00610.x; Thibodeau J, 2008, EUR J IMMUNOL, V38, P1225, DOI 10.1002/eji.200737902; Torres MJ, 2003, ALLERGY, V58, P961, DOI 10.1034/j.1398-9995.2003.00280.x; Torres MJ, 2002, CLIN EXP ALLERGY, V32, P270, DOI 10.1046/j.1365-2222.2002.01296.x; van den Hoorn T, 2011, CURR OPIN IMMUNOL, V23, P88, DOI 10.1016/j.coi.2010.11.002; Wang T, 2012, J CELL MOL MED, V16, P1134, DOI 10.1111/j.1582-4934.2011.01388.x; Yang ZQ, 2012, J BIOL CHEM, V287, P9972, DOI 10.1074/jbc.M111.288498; Zhang X, 2010, EXPERT REV CLIN IMMU, V6, P269, DOI 10.1586/ECI.09.84	37	52	52	0	46	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					253	+		10.1016/j.jaci.2014.07.047	http://dx.doi.org/10.1016/j.jaci.2014.07.047			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25224099				2022-12-18	WOS:000347298200030
J	Erlich, TH; Yagil, Z; Kay, G; Peretz, A; Migalovich-Sheikhet, H; Tshori, S; Nechushtan, H; Levi-Schaffer, F; Saada, A; Razin, E				Erlich, Tal Hadad; Yagil, Zohar; Kay, Gillian; Peretz, Alona; Migalovich-Sheikhet, Helena; Tshori, Sagi; Nechushtan, Hovav; Levi-Schaffer, Francesca; Saada, Ann; Razin, Ehud			Mitochondrial STAT3 plays a major role in IgE-antigen-mediated mast cell exocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; mast cells; degranulation; cytokines; PIAS3; STAT3; mitochondria	MICROPHTHALMIA TRANSCRIPTION FACTOR; SIGNAL-REGULATED KINASE; PROTEIN INHIBITOR; ACTIVATION; PIAS3; PATHWAYS; RELEASE; EPSILON; PHOSPHORYLATION; DEGRANULATION	Background: The involvement of mitochondrial oxidative phosphorylation (OXPHOS) in mast cell exocytosis was recently suggested by the finding that mitochondria translocate to exocytosis sites upon mast cell activation. In parallel, mitochondrial signal transducer and activator of transcription 3 (STAT3) was found to be involved in ATP production. However, the regulation of mitochondrial STAT3 function and its connection to mast cell exocytosis is unknown. Objective: We sought to explore the role played by mitochondrial STAT3 in mast cell exocytosis. Methods: Experiments were performed in vitro with human and mouse mast cells and rat basophilic leukemia (RBL) cells and in vivo in mice. OXPHOS activity was measured after immunologic activation. The expression of STAT3, extracellular signal-regulated kinase 1/2, and protein inhibitor of activated STAT3 in the mitochondria during mast cell activation was determined, as was the effect of STAT3 inhibition on OXPHOS activity and mast cell function. Results: Here we show that mitochondrial STAT3 is essential for immunologically mediated degranulation of human and mouse mast cells and RBL cells. Additionally, in IgE-antigen-activated RBL cells, mitochondrial STAT3 was phosphorylated on serine 727 in an extracellular signal-regulated kinase 1/2-dependent manner, which was followed by induction of OXPHOS activity. Furthermore, the endogenous inhibitor of STAT3, protein inhibitor of activated STAT3, was found to inhibit OXPHOS activity in the mitochondria, resulting in inhibition of mast cell degranulation. Moreover, mice injected with Stattic, a STAT3 inhibitor, had a significant decrease in histamine secretion. Conclusion: These results provide the first evidence of a regulatory role for mitochondrial STAT3 in mast cell functions, and therefore mitochondrial STAT3 could serve as a new target for the manipulation of allergic diseases.	[Erlich, Tal Hadad; Yagil, Zohar; Kay, Gillian; Peretz, Alona; Razin, Ehud] Hebrew Univ Jerusalem, Inst Med Res Israel Canada, Dept Biochem & Mol Biol, Fac Med, IL-91120 Jerusalem, Israel; [Migalovich-Sheikhet, Helena; Levi-Schaffer, Francesca] Hebrew Univ Jerusalem, Dept Pharmacol & Expt Therapeut, Sch Pharm, Inst Drug Res,Fac Med, IL-91120 Jerusalem, Israel; [Tshori, Sagi] Hadassah Hebrew Univ Med Ctr, Dept Nucl Med, IL-91120 Jerusalem, Israel; [Nechushtan, Hovav] Hadassah Hebrew Univ Med Ctr, Dept Oncol, IL-91120 Jerusalem, Israel; [Saada, Ann] Hadassah Hebrew Univ Med Ctr, Monique & Jacques Roboh Dept Genet Res, IL-91120 Jerusalem, Israel; [Saada, Ann] Hadassah Hebrew Univ Med Ctr, Dept Genet & Metab Dis, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Razin, E (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Biochem & Mol Biol, POB 12272, IL-91120 Jerusalem, Israel.	annsr@hadassah.org.il; ehudr@ekmd.huji.ac.il	Saada, Ann/J-6864-2017; Kay, Gillian/F-3474-2014; nechushtan, hovav/Z-3564-2019	Saada, Ann/0000-0003-2951-0656; Kay, Gillian/0000-0003-0966-2388; Levi-Schaffer, Francesca/0000-0003-0620-2810; Erlich, Tal/0000-0003-0601-2574	United States Binational Science Foundation; Israeli Academy of Science; German-Israel Foundation for Scientific Research and Development; National Research Foundation of Singapore (HUJ-CREATE); Morasha Foundation; Canadian Friends of Hebrew University	United States Binational Science Foundation; Israeli Academy of Science; German-Israel Foundation for Scientific Research and Development(German-Israeli Foundation for Scientific Research and Development); National Research Foundation of Singapore (HUJ-CREATE); Morasha Foundation; Canadian Friends of Hebrew University	Supported by the United States Binational Science Foundation (to E. R.), the Israeli Academy of Science (to E. R.), The German-Israel Foundation for Scientific Research and Development (to E. R.), the National Research Foundation of Singapore (HUJ-CREATE; to E. R.), and the Morasha Foundation Fund (to H.N.). Z.Y. was supported by the Canadian Friends of Hebrew University.	Alonso M, 2004, J NEUROCHEM, V89, P248, DOI 10.1111/j.1471-4159.2004.02323.x; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Duan W, 2004, J IMMUNOL, V172, P7053, DOI 10.4049/jimmunol.172.11.7053; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Jang HD, 2004, J BIOL CHEM, V279, P24873, DOI 10.1074/jbc.M313018200; Jeong K, 2009, EXP MOL MED, V41, P226, DOI 10.3858/emm.2009.41.4.025; Kimata M, 2000, BIOCHEM PHARMACOL, V60, P589, DOI 10.1016/S0006-2952(00)00354-3; Kitahata Y, 2010, INT ARCH ALLERGY IMM, V152, P22, DOI 10.1159/000312122; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kuroki M, 1999, BIOCHEM J, V341, P691, DOI 10.1042/0264-6021:3410691; Lee HK, 2009, KOREAN J PHYSIOL PHA, V13, P161, DOI 10.4196/kjpp.2009.13.3.161; Levy C, 2002, J BIOL CHEM, V277, P1962, DOI 10.1074/jbc.M109236200; Liao BC, 2006, J BIOMED SCI, V13, P613, DOI 10.1007/s11373-006-9099-1; Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100; McMurray JS, 2006, CHEM BIOL, V13, P1123, DOI 10.1016/j.chembiol.2006.11.001; Monick MM, 2008, J IMMUNOL, V180, P7485, DOI 10.4049/jimmunol.180.11.7485; Mor A, 2010, INFLAMMATION, V33, P119, DOI 10.1007/s10753-009-9165-8; Nagai K, 2012, EUR J PHARMACOL, V687, P39, DOI 10.1016/j.ejphar.2012.04.038; Piliponsky AM, 2003, BLOOD, V101, P1898, DOI 10.1182/blood-2002-05-1488; Potla R, 2006, MOL CELL BIOL, V26, P8562, DOI 10.1128/MCB.00497-06; Quintana A, 2007, P NATL ACAD SCI USA, V104, P14418, DOI 10.1073/pnas.0703126104; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; RAZIN E, 1984, J IMMUNOL, V132, P1479; Redell MS, 2011, BLOOD, V117, P5701, DOI 10.1182/blood-2010-04-280123; Reisch AS, 2007, METHOD CELL BIOL, V80, P199, DOI 10.1016/S0091-679X(06)80010-5; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Sena LA, 2013, IMMUNITY, V38, P225, DOI 10.1016/j.immuni.2012.10.020; Siegel AM, 2013, J ALLERGY CLIN IMMUN, V132, P1388, DOI 10.1016/j.jaci.2013.08.045; Sonnenblick A, 2005, J IMMUNOL, V175, P1450, DOI 10.4049/jimmunol.175.3.1450; Sonnenblick A, 2004, MOL CELL BIOL, V24, P10584, DOI 10.1128/MCB.24.24.10584-10592.2004; Suzuki H, 1997, J IMMUNOL, V159, P5881; TAKEI M, 1994, PROSTAG LEUKOTR ESS, V50, P357, DOI 10.1016/0952-3278(94)90247-X; Venkatesha RT, 2005, MOL IMMUNOL, V42, P581, DOI 10.1016/j.molimm.2004.09.009; Yagil Z, 2012, J ALLERGY CLIN IMMUN, V129, P1357, DOI 10.1016/j.jaci.2011.11.051; Yagil Z, 2010, TRENDS IMMUNOL, V31, P199, DOI 10.1016/j.it.2010.01.005; Zhang BD, 2012, INT ARCH ALLERGY IMM, V159, P23, DOI 10.1159/000335178; Zhang BD, 2011, J ALLERGY CLIN IMMUN, V127, P1522, DOI 10.1016/j.jaci.2011.02.005; Zhang SL, 2004, J IMMUNOL, V173, P6786, DOI 10.4049/jimmunol.173.11.6786; Zhu JH, 2003, BRAIN PATHOL, V13, P473	41	52	52	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					460	+		10.1016/j.jaci.2013.12.1075	http://dx.doi.org/10.1016/j.jaci.2013.12.1075			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24582310				2022-12-18	WOS:000341370800027
J	Porter, PC; Lim, DJ; Maskatia, ZK; Mak, G; Tsai, CL; Citardi, MJ; Fakhri, S; Shaw, JL; Fothergil, A; Kheradmand, F; Corry, DB; Luong, A				Porter, Paul C.; Lim, Dae Jun; Maskatia, Zahida Khan; Mak, Garbo; Tsai, Chu-Lin; Citardi, Martin J.; Fakhri, Samer; Shaw, Joanne L.; Fothergil, Annette; Kheradmand, Farrah; Corry, David B.; Luong, Amber			Airway surface mycosis in chronic T(H)2-associated airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic; airway; mycosis; fungal; asthma; chronic rhinosinusitis; T(H)2-associated airway disease	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; CHRONIC RHINOSINUSITIS; SEVERE ASTHMA; SENSITIZATION; ASSOCIATION; RESPONSES; CELLS	Background: Environmental fungi have been linked to T(H)2 cell-related airway inflammation and the T(H)2-associated chronic airway diseases asthma, chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), and allergic fungal rhinosinusitis (AFRS), but whether these organisms participate directly or indirectly in disease pathology remains unknown. Objective: To determine the frequency of fungus isolation and fungus-specific immunity in patients with T(H)2-associated and non-T(H)2-associated airway disease. Methods: Sinus lavage fluid and blood were collected from sinus surgery patients (n = 118) including patients with CRSwNP, patients with CRS without nasal polyps, patients with AFRS, and non-CRS/nonasthmatic control patients. Asthma status was determined from medical history. Sinus lavage fluids were cultured and directly examined for evidence of viable fungi. PBMCs were restimulated with fungal antigens in an enzyme-linked immunocell spot assay to determine total memory fungus-specific IL-4-secreting cells. These data were compared with fungus-specific IgE levels measured from plasma by ELISA. Results: Filamentous fungi were significantly more commonly cultured in patients with T(H)2-associated airway disease (asthma, CRSwNP, or AFRS: n = 68) than in control patients with non-T(H)2-associated disease (n = 31): 74% vs 16%, respectively (P < .001). Both fungus-specific IL-4 enzyme-linked immunocell spot (n = 48) and specific IgE (n = 70) data correlated with T(H)2-associated diseases (sensitivity 73% and specificity 100% vs 50% and 77%, respectively). Conclusions: The frequent isolation of fungi growing directly within the airways accompanied by specific immunity to these organisms only in patients with T(H)2-associated chronic airway diseases suggests that fungi participate directly in the pathogenesis of these conditions. Efforts to eradicate airway fungi from the airways should be considered in selected patients.	[Porter, Paul C.; Maskatia, Zahida Khan; Mak, Garbo; Kheradmand, Farrah; Corry, David B.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Kheradmand, Farrah; Corry, David B.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Lim, Dae Jun] Konkuk Univ, Dept Otolaryngol Head & Neck Surg, Chungbuk, South Korea; [Tsai, Chu-Lin] Univ Texas Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, Houston, TX USA; [Citardi, Martin J.; Fakhri, Samer; Shaw, Joanne L.; Luong, Amber] Univ Texas Med Sch Houston, Dept Otorhinolaryngolgy Head & Neck Surg, Houston, TX USA; [Shaw, Joanne L.; Luong, Amber] Univ Texas Med Sch Houston, Brown Fdn Inst Mol Med Prevent Human Dis, Ctr Immunol & Autoimmune Dis, Houston, TX USA; [Fothergil, Annette] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA; [Kheradmand, Farrah; Corry, David B.] Michael E Debakey VA Ctr Translat Res Inflammator, Houston, TX USA	Baylor College of Medicine; Baylor College of Medicine; Konkuk University; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health San Antonio	Corry, DB (corresponding author), Baylor Coll Med, Dept Med, BCM285,1 Baylor Plaza, Houston, TX 77030 USA.	dcorry@bcm.edu; Amber.U.Luong@uth.tmc.edu		TSAI, CHU-LIN/0000-0003-4639-1513	Papadopoulos Family Fund for Allergic Disease Research from the Biology of Inflammation Center; National Institutes of Health [U19AI070973]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211, U19AI070973] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002221] Funding Source: NIH RePORTER	Papadopoulos Family Fund for Allergic Disease Research from the Biology of Inflammation Center; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by the Papadopoulos Family Fund for Allergic Disease Research from the Biology of Inflammation Center (to D. B. C.) and the National Institutes of Health (grant no. U19AI070973 to D. B. C. and F. K.).	Agarwal R, 2011, CURR ALLERGY ASTHM R, V11, P403, DOI 10.1007/s11882-011-0217-4; Agbetile J, 2014, J ALLERGY CLIN IMMUN, V134, P33, DOI 10.1016/j.jaci.2013.09.050; Ahn BH, 2009, AURIS NASUS LARYNX, V36, P422, DOI 10.1016/j.anl.2008.08.009; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; Chishimba L, 2012, J ASTHMA, V49, P423, DOI 10.3109/02770903.2012.662568; Dales RE, 2003, CHEST, V123, P745, DOI 10.1378/chest.123.3.745; Denning DW, 2009, AM J RESP CRIT CARE, V179, P11, DOI 10.1164/rccm.200805-737OC; Douwes J, 2003, AM J EPIDEMIOL, V158, P203, DOI 10.1093/aje/kwg149; Fokkens WJ, 2009, IMMUNOL ALLERGY CLIN, V29, P677, DOI 10.1016/j.iac.2009.07.002; Hamilos DL, 2011, J ALLERGY CLIN IMMUN, V128, P693, DOI 10.1016/j.jaci.2011.08.004; HOLTER W, 1992, INT ARCH ALLERGY IMM, V98, P273, DOI 10.1159/000236198; Khalid AN, 2008, OTOLARYNG HEAD NECK, V139, P695, DOI 10.1016/j.otohns.2008.07.018; Luong A, 2009, AM J RHINOL ALLERGY, V23, P281, DOI 10.2500/ajra.2009.23.3311; Mak G, 2013, CLIN IMMUNOL, V146, P77, DOI 10.1016/j.clim.2012.11.005; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; Matsuwaki Y, 2009, J IMMUNOL, V183, P6708, DOI 10.4049/jimmunol.0901220; Menzies D, 2011, ALLERGY, V66, P679, DOI 10.1111/j.1398-9995.2010.02542.x; Millien VO, 2013, SCIENCE, V341, P792, DOI 10.1126/science.1240342; Osur SL, 2002, ANN ALLERG ASTHMA IM, V89, P553, DOI 10.1016/S1081-1206(10)62101-1; Pastacaldi C, 2011, ALLERGY, V66, P549, DOI 10.1111/j.1398-9995.2010.02502.x; Paul WE, 1997, CIBA F SYMP, V204, P208; Porter P, 2009, MUCOSAL IMMUNOL, V2, P504, DOI 10.1038/mi.2009.102; Porter PC, 2011, INFECT IMMUN, V79, P4459, DOI 10.1128/IAI.05209-11; Porter PC, 2011, TRENDS IMMUNOL, V32, P43, DOI 10.1016/j.it.2010.11.007; Pulimood TB, 2007, J ALLERGY CLIN IMMUN, V120, P610, DOI 10.1016/j.jaci.2007.04.045; Rath B, 2007, J HEALTH CARE POOR U, V18, P405, DOI 10.1353/hpu.2007.0043; Sacks PL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008263.pub2; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; Staikuniene J, 2008, MEDICINA-LITHUANIA, V44, P257, DOI 10.3390/medicina44040033; Thanasumpun T, 2011, INT FORUM ALLERGY RH, V1, P382, DOI 10.1002/alr.20088; Tieu DD, 2009, J ALLERGY CLIN IMMUN, V124, P37, DOI 10.1016/j.jaci.2009.04.045; Van Crombruggen K, 2011, J ALLERGY CLIN IMMUN, V128, P728, DOI 10.1016/j.jaci.2011.07.049; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Wark PAB, 2003, J ALLERGY CLIN IMMUN, V111, P952, DOI 10.1067/mai.2003.1388; Wood AJ, 2011, INT FORUM ALLERGY RH, V1, P95, DOI 10.1002/alr.20030	35	52	52	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					325	+		10.1016/j.jaci.2014.04.028	http://dx.doi.org/10.1016/j.jaci.2014.04.028			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24928648	Green Accepted			2022-12-18	WOS:000341370800011
J	Sic, H; Kraus, H; Madl, J; Flittner, KA; von Munchow, AL; Pieper, K; Rizzi, M; Kienzler, AK; Ayata, K; Rauer, S; Kleuser, B; Salzer, U; Burger, M; Zirlik, K; Lougaris, V; Plebani, A; Romer, W; Loeffler, C; Scaramuzza, S; Villa, A; Noguchi, E; Grimbacher, B; Eibel, H				Sic, Heiko; Kraus, Helene; Madl, Josef; Flittner, Karl-Andreas; von Muenchow, Audrey Lilly; Pieper, Kathrin; Rizzi, Marta; Kienzler, Anne-Kathrin; Ayata, Korcan; Rauer, Sebastian; Kleuser, Burkhard; Salzer, Ulrich; Burger, Meike; Zirlik, Katja; Lougaris, Vassilios; Plebani, Alessandro; Roemer, Winfried; Loeffler, Christoph; Scaramuzza, Samantha; Villa, Anna; Noguchi, Emiko; Grimbacher, Bodo; Eibel, Hermann			Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sphingosine-1-phosphate; B cells; migration; autoimmunity; circulation; fingolimod; FTY720; primary immunodeficiencies	WISKOTT-ALDRICH-SYNDROME; SYNDROME PROTEIN; DOCK8 MUTATIONS; LYMPHOID ORGANS; BONE-MARROW; T-CELL; DEFICIENCY; WASP; S1P; ACTIVATION	Background: Five different G protein-coupled sphingosine-1-phosphate (S1P) receptors (S1P1-S1P5) regulate a variety of physiologic and pathophysiologic processes, including lymphocyte circulation, multiple sclerosis (MS), and cancer. Although B-lymphocyte circulation plays an important role in these processes and is essential for normal immune responses, little is known about S1P receptors in human B cells. Objective: To explore their function and signaling, we studied B-cell lines and primary B cells from control subjects, patients with leukemia, patients with S1P receptor inhibitor-treated MS, and patients with primary immunodeficiencies. Methods: S1P receptor expression was analyzed by using multicolor immunofluorescence microscopy and quantitative PCR. Transwell assays were used to study cell migration. S1P receptor internalization was visualized by means of time-lapse imaging with fluorescent S1P receptor fusion proteins expressed by using lentiviral gene transfer. B-lymphocyte subsets were characterized by means of flow cytometry and immunofluorescence microscopy. Results: Showing that different B-cell populations express different combinations of S1P receptors, we found that S1P1 promotes migration, whereas S1P4 modulates and S1P2 inhibits S1P1 signals. Expression of CD69 in activated B lymphocytes and B cells from patients with chronic lymphocytic leukemia inhibited S1P-induced migration. Studying B-cell lines, normal B lymphocytes, and B cells from patients with primary immunodeficiencies, we identified Bruton tyrosine kinase, beta-arrestin 2, LPS-responsive beige-like anchor protein, dedicator of cytokinesis 8, and Wiskott-Aldrich syndrome protein as critical signaling components downstream of S1P1. Conclusion: Thus S1P receptor signaling regulates human B-cell circulation and might be a factor contributing to the pathology of MS, chronic lymphocytic leukemia, and primary immunodeficiencies.	[Sic, Heiko; Kraus, Helene; Flittner, Karl-Andreas; von Muenchow, Audrey Lilly; Pieper, Kathrin; Rizzi, Marta; Kienzler, Anne-Kathrin; Ayata, Korcan; Salzer, Ulrich; Grimbacher, Bodo; Eibel, Hermann] Univ Med Ctr, Ctr Chron Immunodeficiency, D-79108 Freiburg, Germany; [Rauer, Sebastian] Univ Med Ctr, Dept Neurol, D-79108 Freiburg, Germany; [Burger, Meike; Zirlik, Katja] Univ Med Ctr, Dept Hematol & Oncol, D-79108 Freiburg, Germany; [Loeffler, Christoph] Univ Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, D-79108 Freiburg, Germany; [Sic, Heiko; Kraus, Helene; Pieper, Kathrin] Univ Freiburg, Fac Biol, D-79106 Freiburg, Germany; [Madl, Josef; Roemer, Winfried] Univ Freiburg, Ctr Biol Signalling Studies, Freiburg, Germany; [Kleuser, Burkhard] Univ Potsdam, Inst Nutr Sci, Dept Nutr Toxicol, Nuthetal, Germany; [Lougaris, Vassilios; Plebani, Alessandro] Spedali Civil Brescia, Pediat Clin, I-25125 Brescia, Italy; [Lougaris, Vassilios; Plebani, Alessandro] Spedali Civil Brescia, A Nocivelli Inst Mol Med, I-25125 Brescia, Italy; [Scaramuzza, Samantha; Villa, Anna] Hosp San Raffaele, Inst Gene Therapy, I-20132 Milan, Italy; [Villa, Anna] CNR, UOS IRGB, Milan Unit, I-20133 Milan, Italy; [Noguchi, Emiko] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Med Genet, Ibaraki, Japan	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Potsdam; Hospital Spedali Civili Brescia; Hospital Spedali Civili Brescia; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); University of Tsukuba	Eibel, H (corresponding author), Univ Med Ctr, Ctr Chron Immunodeficiency, Engesserstr 4, D-79108 Freiburg, Germany.	hermann.eibel@uniklinik-freiburg.de	Scaramuzza, Samantha/AAN-2204-2020; Rizzi, Marta/ABE-7264-2020; Ayata, Korcan/G-8626-2013	Scaramuzza, Samantha/0000-0003-2903-3650; Ayata, Korcan/0000-0001-7043-6692; Kienzler, Anne-Kathrin/0000-0002-3082-9210; Kleuser, Burkhard/0000-0002-1888-9595; Salzer, Ulrich/0000-0002-1769-1157; Villa, Anna/0000-0003-4428-9013; Rizzi, Marta/0000-0002-5153-6089; de la Rosa (nee Pieper), Kathrin/0000-0003-4809-3157	DFG [Ei235/6-2]; Deutsche Krebshilfe grant [109138]; German excellence initiative of the Deutsche Forschungsgemeinschaft [EXC 294]; Ministry of Science, Research and the Arts of Baden-Wurttemberg [Az: 337532.20]; European Research Council [ERC-2011-StG 282105]	DFG(German Research Foundation (DFG)); Deutsche Krebshilfe grant(Deutsche Krebshilfe); German excellence initiative of the Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Ministry of Science, Research and the Arts of Baden-Wurttemberg; European Research Council(European Research Council (ERC)European Commission)	Supported by the Ei235/6-2 DFG Special Program: Sphingolipids-Signaling and Disease and the Deutsche Krebshilfe grant 109138 (to H.E.). W.R. is supported by the German excellence initiative of the Deutsche Forschungsgemeinschaft (EXC 294); by a grant from the Ministry of Science, Research and the Arts of Baden-Wurttemberg (Az: 33-7532.20); and by a starting grant of the European Research Council (Programme "Ideas''-call identifier: ERC-2011-StG 282105).	Alangari A, 2012, J ALLERGY CLIN IMMUN, V130, P481, DOI 10.1016/j.jaci.2012.05.043; Allende ML, 2010, J EXP MED, V207, P1113, DOI 10.1084/jem.20092210; Anton IM, 2002, IMMUNITY, V16, P193, DOI 10.1016/S1074-7613(02)00268-6; Bandhuvula P, 2005, J BIOL CHEM, V280, P33697, DOI 10.1074/jbc.C500294200; Becker-Herman S, 2011, J EXP MED, V208, P2033, DOI 10.1084/jem.20110200; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Chun J, 2011, DISCOV MED, V12, P213; Cinamon G, 2008, NAT IMMUNOL, V9, P54, DOI 10.1038/ni1542; de la Fuente MA, 2007, P NATL ACAD SCI USA, V104, P926, DOI 10.1073/pnas.0610275104; de Rooij MFM, 2012, BLOOD, V119, P2590, DOI 10.1182/blood-2011-11-390989; Donovan EE, 2010, EUR J IMMUNOL, V40, P688, DOI 10.1002/eji.200939858; Dupre L, 2002, IMMUNITY, V17, P157, DOI 10.1016/S1074-7613(02)00360-6; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Fereshteha M, 2012, P NATL ACAD SCI USA, V109, P12532, DOI 10.1073/pnas.1209815109; Fujimoto M, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-42; Girkontaite I, 2004, J EXP MED, V200, P1491, DOI 10.1084/jem.20041483; Green JA, 2011, NAT IMMUNOL, V12, P672, DOI 10.1038/ni.2047; Ha SA, 2006, J EXP MED, V203, P2541, DOI 10.1084/jem.20061041; Harada Y, 2012, BLOOD, V119, P4451, DOI 10.1182/blood-2012-01-407098; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Kabashima K, 2006, J EXP MED, V203, P2683, DOI 10.1084/jem.20061289; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; Lanzi G, 2012, J EXP MED, V209, P29, DOI 10.1084/jem.20110896; Lepley D, 2005, CANCER RES, V65, P3788, DOI 10.1158/0008-5472.CAN-04-2311; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Marangoni F, 2007, J EXP MED, V204, P369, DOI 10.1084/jem.20061334; Massaad MJ, 2013, ANN NY ACAD SCI, V1285, P26, DOI 10.1111/nyas.12049; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Min JA, 2011, MOL PHARMACOL, V80, P760, DOI 10.1124/mol.111.072470; opez-Herrera G, 2012, AM J HUM GENET, V90, P986; Pereira JP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009277; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; Randall KL, 2011, J EXP MED, V208, P2305, DOI 10.1084/jem.20110345; Randall KL, 2009, NAT IMMUNOL, V10, P1283, DOI 10.1038/ni.1820; Ruusala A, 2004, FEBS LETT, V572, P159, DOI 10.1016/j.febslet.2004.06.095; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Schulze T, 2011, FASEB J, V25, P4024, DOI 10.1096/fj.10-179028; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Thrasher AJ, 2010, NAT REV IMMUNOL, V10, P182, DOI 10.1038/nri2724; Vogt DL, 2007, MOL CELL NEUROSCI, V36, P332, DOI 10.1016/j.mcn.2007.07.004; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Xu C, 2011, PROTEIN CELL, V2, P202, DOI 10.1007/s13238-011-1018-1; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	49	52	54	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					420	+		10.1016/j.jaci.2014.01.037	http://dx.doi.org/10.1016/j.jaci.2014.01.037			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24679343	Bronze			2022-12-18	WOS:000341370800023
J	Kim, N; Kim, M; Yun, S; Doh, J; Greenberg, PD; Kim, TD; Choi, I				Kim, Nayoung; Kim, Miju; Yun, Sohyun; Doh, Junsang; Greenberg, Philip D.; Kim, Tae-Don; Choi, Inpyo			MicroRNA-150 regulates the cytotoxicity of natural killers by targeting perforin-1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						miR-150; NK cells; perforin-1; NK cell cytotoxicity; post-transcriptional regulation; immunotherapy; tumor growth and metastasis	NK-CELL CYTOTOXICITY; GRANZYME-B; MIR-150; EXPRESSION; LEUKEMIA; DIFFERENTIATION; RECOGNITION; INVOLVEMENT; RECEPTOR; PATHWAY	Background: Perforin-1 (Prf1) is the predominant cytolytic protein secreted by natural killer (NK) cells. For a rapid immune response, resting NK cells contain high Prf1 mRNA concentrations while exhibiting minimal cytotoxicity caused by a blockage of Prf1 protein synthesis, implying that an unknown posttranscriptional regulatory mechanism exists. Objective: We sought to determine whether microRNA-150 (miR-150) posttranscriptionally regulates Prf1 translation in both mouse and human NK cells at rest and at various time points after activation. Methods: Mouse NK cells with a targeted deletion of miR-150 (miR-150(-/-) NK cells), primary human NK cells, and NK92 MI cells were used to investigate the role of miR-150 in NK cells. NK cell cytotoxicity assays and Western blotting proved that activated miR-150(-/-) NK cells expressed upregulated Prf1, augmenting NK cell cytotoxicity. When immunodeficient mice were injected with miR-150(-/-) NK cells, there was a significant reduction in tumor growth and metastasis of B16F10 melanoma. Results: We report that miR-150 binds to 39 untranslated regions of mouse and human Prf1, posttranscriptionally downregulating its expression. Mouse wild-type NK cells displayed downregulated miR-150 expression in response to IL-15, which led to corresponding repression and induction of Prf1 during rest and after IL-15 activation, respectively. Conclusion: Our results indicate that miR-150 is a common posttranscriptional regulator for Prf1 in mouse and human NK cells that represses NK cell lytic activity. Thus the therapeutic control of miR-150 in NK cells could enhance NK cell-based immunotherapy against cancer, providing a better clinical outcome.	[Kim, Nayoung; Yun, Sohyun; Kim, Tae-Don; Choi, Inpyo] Korea Res Inst Biosci & Biotechnol, Immunotherapy Res Ctr, Taejon 305806, South Korea; [Kim, Tae-Don; Choi, Inpyo] UST, KRIBB, Dept Funct Genom, Taejon, South Korea; [Kim, Miju; Doh, Junsang] POSTECH, Sch Interdisciplinary Biosci & Bioengn I Bio, Pohang, South Korea; [Kim, Miju; Doh, Junsang] POSTECH, Dept Mech Engn, Pohang, South Korea; [Greenberg, Philip D.] Univ Washington, Sch Med, Dept Immunol, Seattle, WA USA; [Greenberg, Philip D.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Greenberg, Philip D.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Science & Technology (UST); Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Choi, I (corresponding author), Korea Res Inst Biosci & Biotechnol, Immunotherapy Res Ctr, 125 Gwahak Ro, Taejon 305806, South Korea.	tdkim@kribb.re.kr; ipchoi@kribb.re.kr		Kim, Tae-Don/0000-0002-5910-4264	GRL project [FGM1401223]; Ministry of Education, Science Technology; Korean Health Technology RD Project [A121934]; Ministry of Health and Welfare; KRIBB Research Initiative Program; Basic Science Research Program through the National Research Foundation of Korea [RBM0261312]; National Institutes of Health [CA33084]; NATIONAL CANCER INSTITUTE [R37CA033084, R01CA033084] Funding Source: NIH RePORTER	GRL project; Ministry of Education, Science Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korean Health Technology RD Project; Ministry of Health and Welfare(Ministry of Health, Labour and Welfare, Japan); KRIBB Research Initiative Program; Basic Science Research Program through the National Research Foundation of Korea(National Research Foundation of Korea); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported in part by grants from the GRL project (FGM1401223); the Ministry of Education, Science & Technology; the Korean Health Technology R&D Project (A121934); the Ministry of Health and Welfare; the KRIBB Research Initiative Program; and the Basic Science Research Program through the National Research Foundation of Korea (RBM0261312). P. D. G. was supported in part by grants from the KRIBB Research Initiative Program and the National Institutes of Health (CA33084).	Agirre X, 2008, MOL CANCER RES, V6, P1830, DOI 10.1158/1541-7786.MCR-08-0167; Andrews DM, 2012, NAT IMMUNOL, V13, P1171, DOI 10.1038/ni.2468; Baltimore D, 2008, NAT IMMUNOL, V9, P839, DOI 10.1038/ni.f.209; Baran K, 2009, IMMUNITY, V30, P684, DOI 10.1016/j.immuni.2009.03.016; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bezman NA, 2011, J EXP MED, V208, P2717, DOI 10.1084/jem.20111386; Colucci F, 1999, J IMMUNOL, V162, P2761; Deniz G, 2013, J ALLERGY CLIN IMMUN, V132, P527, DOI 10.1016/j.jaci.2013.07.030; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Enomoto N, 2012, J IMMUNOL, V188, P1734, DOI 10.4049/jimmunol.1102699; Farhadi N, 2013, J ALLERGY CLIN IMMUN; Fedeli M, 2009, J IMMUNOL, V183, P2506, DOI 10.4049/jimmunol.0901361; Fehniger TA, 2007, IMMUNITY, V26, P798, DOI 10.1016/j.immuni.2007.04.010; Grossman WJ, 2003, CURR OPIN IMMUNOL, V15, P544, DOI 10.1016/S0952-7915(03)00099-2; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523; Jiang X, 2012, CANCER CELL, V22, P524, DOI 10.1016/j.ccr.2012.08.028; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; Kim TD, 2011, BLOOD, V118, P5476, DOI 10.1182/blood-2011-04-347526; Kim TD, 2005, MOL CELL BIOL, V25, P3232, DOI 10.1128/MCB.25.8.3232-3246.2005; Lee SH, 2009, J IMMUNOL, V183, P7931, DOI 10.4049/jimmunol.0902012; Leong JW, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/632329; LICHTENHELD MG, 1989, J IMMUNOL, V143, P4267; Liu X, 2012, IMMUNOL LETT, V143, P208, DOI 10.1016/j.imlet.2012.02.014; Lu J, 2008, DEV CELL, V14, P843, DOI 10.1016/j.devcel.2008.03.012; Luci C, 2012, BRIT J DERMATOL, V166, P789, DOI 10.1111/j.1365-2133.2012.10814.x; Ma YL, 2012, GUT, V61, P1447, DOI 10.1136/gutjnl-2011-301122; Markasz L, 2007, MOL CANCER THER, V6, P644, DOI 10.1158/1535-7163.MCT-06-0358; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Oshimi Y, 1996, J IMMUNOL, V157, P2909; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; Smyth MJ, 1999, J IMMUNOL, V162, P6658; Sullivan RP, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00044; Vanherberghen B, 2013, BLOOD, V121, P1326, DOI 10.1182/blood-2012-06-439851; Vasilescu C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007405; Voskoboinik I, 2005, J BIOL CHEM, V280, P8426, DOI 10.1074/jbc.M413303200; Watanabe A, 2011, LEUKEMIA, V25, P1324, DOI 10.1038/leu.2011.81; Wei HM, 2005, J ALLERGY CLIN IMMUN, V115, P841, DOI 10.1016/j.jaci.2004.11.026; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Zheng QH, 2012, J IMMUNOL, V188, P2118, DOI 10.4049/jimmunol.1103342; Zhou BY, 2007, P NATL ACAD SCI USA, V104, P7080, DOI 10.1073/pnas.0702409104	42	52	55	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					195	+		10.1016/j.jaci.2014.02.018	http://dx.doi.org/10.1016/j.jaci.2014.02.018			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24698324	Green Accepted, hybrid, Green Submitted			2022-12-18	WOS:000338930300025
J	Spertini, F; Perrin, Y; Audran, R; Pellaton, C; Boudousquie, C; Barbier, N; Thierry, AC; Charlon, V; Reymond, C				Spertini, Francois; Perrin, Yannick; Audran, Regine; Pellaton, Celine; Boudousquie, Caroline; Barbier, Nathalie; Thierry, Anne-Christine; Charlon, Vincent; Reymond, Christophe			Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGEN-SPECIFIC IMMUNOTHERAPY; RHINOCONJUNCTIVITIS; INDUCTION		[Spertini, Francois; Perrin, Yannick; Audran, Regine; Pellaton, Celine; Boudousquie, Caroline; Barbier, Nathalie; Thierry, Anne-Christine; Reymond, Christophe] CHU Vaudois, Div Immunol & Allergy, CH-1011 Lausanne, Switzerland; [Charlon, Vincent; Reymond, Christophe] Anergis SA, Epalinges, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Spertini, F (corresponding author), CHU Vaudois, Div Immunol & Allergy, CH-1011 Lausanne, Switzerland.	francois.spertini@chuv.ch		Pellaton, Celine/0000-0003-2090-9572				Deruaz U, 2004, J ALLERGY CLIN IMMUN, V113, P669, DOI 10.1016/j.jaci.2004.01.773; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Juniper EF, 2000, CLIN EXP ALLERGY, V30, P132; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Moldaver D, 2011, ALLERGY, V66, P784, DOI 10.1111/j.1398-9995.2011.02610.x; Patel D, 2013, J ALLERGY CLIN IMMUN, V131, P103, DOI 10.1016/j.jaci.2012.07.028; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pellaton Celine, 2013, Clin Transl Allergy, V3, P17, DOI 10.1186/2045-7022-3-17; Valenta R, 2012, J INTERN MED, V272, P144, DOI 10.1111/j.1365-2796.2012.02556.x	10	52	52	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					239	U801		10.1016/j.jaci.2014.04.001	http://dx.doi.org/10.1016/j.jaci.2014.04.001			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24797422				2022-12-18	WOS:000338930300036
J	Voorend-van Bergen, S; Vaessen-Verberne, AA; Landstra, AM; Brackel, HJ; van den Berg, NJ; Caudri, D; de Jongste, JC; Merkus, PJ; Pijnenburg, MW				Voorend-van Bergen, Sandra; Vaessen-Verberne, Anja A.; Landstra, Anneke M.; Brackel, Hein J.; van den Berg, Norbert J.; Caudri, Daan; de Jongste, Johan C.; Merkus, Peter J.; Pijnenburg, Marielle W.			Monitoring childhood asthma: Web-based diaries and the asthma control test	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; childhood asthma control test; asthma diaries; Internet diaries; asthma-related quality of life; GINA; minimal important difference; pediatrics; validity	QUALITY-OF-LIFE; EXHALED NITRIC-OXIDE; LUNG-FUNCTION; CHILDREN; QUESTIONNAIRE; VALIDATION; VALIDITY; RESPONSIVENESS; OUTCOMES; TRIALS	Background: Data from asthma diaries are frequently used as an end point in asthma studies; however, data on the validity of Web-based diaries are scarce. Objectives: First, we examined the validity of a Web-based diary in assessing asthma control. Second, we determined the cutoff points for well-controlled asthma of the Childhood Asthma Control Test (C-ACT) and the Asthma Control Test (ACT), and calculated the minimal important difference for both tests. Methods: Children with asthma, ages 4-18 years (n = 228) completed a 4-week Web-based diary, C-ACT, ACT, and an asthma-related quality-of-life questionnaire at baseline and after 1-year follow-up. Results: The completion rate of the Web-based diaries was 89%. The diary scores correlated strongly with C-ACT and ACT scores (r = -0.73, P < .01; r = -0.64, P < .01, respectively) and the changes in diary scores correlated well with changes in C-ACT and ACT scores. The best cutoff points for well-controlled asthma were C-ACT >= 22 and ACT >= 23. The minimal important differences were 1.9 (95% CI, 1.3-2.5) for ACT and 1.6 (95% CI, 1.1-2.1) for C-ACT, and 20.7 points/d (95% CI, -1.1 to -0.4) for the Web-based diary. Conclusions: Our Web-based diary was valid for recording asthma symptoms. Cutoff points of >= 22 (C-ACT) and >= 23 (ACT) define well-controlled asthma. We recommend a 2 C-ACT and ACT points difference as minimally important.	[Voorend-van Bergen, Sandra; Caudri, Daan; de Jongste, Johan C.; Pijnenburg, Marielle W.] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Pediat Pulmonol, NL-3000 CB Rotterdam, Netherlands; [Vaessen-Verberne, Anja A.] Amphia Hosp, Dept Pediat, Breda, Netherlands; [Landstra, Anneke M.] Rijnstate Hosp, Dept Pediat, Arnhem, Netherlands; [Brackel, Hein J.] Catharina Hosp, Dept Pediat, Eindhoven, Netherlands; [van den Berg, Norbert J.] Flevo Hosp, De Kinderklin, Dept Pediat, Almere, Netherlands; [Merkus, Peter J.] Radboud Univ Nijmegen, Med Ctr, Dept Pediat Pulmonol, NL-6525 ED Nijmegen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Amphia Hospital; Rijnstate Hospital; Catharina Hospital; Radboud University Nijmegen	Pijnenburg, MW (corresponding author), Erasmus Univ, Med Ctr, Sophia Childrens Hosp, POB 2060, NL-3000 CB Rotterdam, Netherlands.	m.pijnenburg@erasmusmc.nl	Merkus, P.J.F.M./L-4523-2015	Vaessen-Verberne, Anna/0000-0002-2272-8815	ZonMW Netherlands; Dutch Lung Fund; Fund Nuts Ohra	ZonMW Netherlands(Netherlands Organization for Health Research and DevelopmentNetherlands Government); Dutch Lung Fund; Fund Nuts Ohra	This study is part of the BATMAN study (Better Asthma Treatment: Monitoring with ACT and Nitric Oxide), which was funded by ZonMW Netherlands, Dutch Lung Fund, and Fund Nuts Ohra.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Burton C, 2007, J PSYCHOSOM RES, V62, P553, DOI 10.1016/j.jpsychores.2006.12.022; Chan DS, 2007, PEDIATRICS, V119, P569, DOI 10.1542/peds.2006-1884; Global Initiative for Asthma (GINA), 2011, GLOB STRAT ASTHM MAN; HYLAND ME, 1993, BRIT MED J, V306, P487, DOI 10.1136/bmj.306.6876.487; Ireland AM, 2012, J ASTHMA, V49, P952, DOI 10.3109/02770903.2012.724754; Ito Y, 2011, J ASTHMA, V48, P1076, DOI 10.3109/02770903.2011.629356; Jan RL, 2007, TELEMED J E-HEALTH, V13, P257, DOI 10.1089/tmj.2006.0053; Alvarez-Gutierrez FJ, 2010, ARCH BRONCONEUMOL, V46, P370, DOI 10.1016/j.arbres.2010.04.003; Juniper EF, 2010, EUR RESPIR J, V36, P1410, DOI 10.1183/09031936.00117509; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; Koolen BB, 2011, EUR RESPIR J, V38, P561, DOI 10.1183/09031936.00173710; Krishnan JA, 2012, J ALLERGY CLIN IMMUN, V129, pS124, DOI 10.1016/j.jaci.2011.12.981; Lam J, 2010, J DEV BEHAV PEDIATR, V31, P685, DOI 10.1097/DBP.0b013e3181e416ae; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Moloney MF, 2009, HEADACHE, V49, P673, DOI 10.1111/j.1526-4610.2009.01399.x; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Okupa AY, 2013, CHEST, V143, P993, DOI 10.1378/chest.12-1055; Palermo TA, 2004, PAIN, V107, P213, DOI 10.1016/j.pain.2003.10.005; Petsky HL, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006340.pub3; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Raat H, 2005, QUAL LIFE RES, V14, P265, DOI 10.1007/s11136-004-0798-7; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Rosias PPR, 2004, PEDIATR PULM, V38, P107, DOI 10.1002/ppul.20056; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2007, AM J MANAG CARE, V13, P661; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; Senna G, 2007, ALLERGY, V62, P207, DOI 10.1111/j.1398-9995.2006.01250.x; Sorbi MJ, 2007, J MED INTERNET RES, V9, DOI 10.2196/jmir.9.5.e38; Thomas Mike, 2009, Prim Care Respir J, V18, P41, DOI 10.4104/pcrj.2009.00010; Tibosch M, 2012, PEDIATR PULM, V47, P933, DOI 10.1002/ppul.22514; Vaessen-Verberne AAPH, 2010, AM J RESP CRIT CARE, V182, P1221, DOI 10.1164/rccm.201002-0193OC; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	38	52	54	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1599	+		10.1016/j.jaci.2013.10.005	http://dx.doi.org/10.1016/j.jaci.2013.10.005			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	AI2FI	24290276	Bronze			2022-12-18	WOS:000336672500011
J	Ashino, S; Takeda, K; Li, H; Taylor, V; Joetham, A; Pine, PR; Gelfand, EW				Ashino, Shigeru; Takeda, Katsuyuki; Li, Hui; Taylor, Vanessa; Joetham, Anthony; Pine, Polly R.; Gelfand, Erwin W.			Janus kinase 1/3 signaling pathways are key initiators of T(H)2 differentiation and lung allergic responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Janus kinase 1/3; asthma; T(H)2	AIRWAY HYPERRESPONSIVENESS; RHEUMATOID-ARTHRITIS; CELL-DIFFERENTIATION; TH2 DIFFERENTIATION; INTERFERON-GAMMA; DOWN-REGULATION; IN-VITRO; T-BET; ASTHMA; INFLAMMATION	Background: Janus kinases (JAKs) are regulators of signaling through cytokine receptors. The importance of JAK1/3 signaling on T(H)2 differentiation and development of lung allergic responses has not been investigated. Objective: We sought to examine a selective JAK1/3 inhibitor (R256) on differentiation of T-H subsets in vitro and on development of ovalbumin (OVA)-induced airway hyperresponsiveness (AHR) and inflammation in an experimental model of asthma. Methods: A selective JAK1/3 inhibitor was used to assay the importance of this pathway on induction of T(H)1, T(H)2, and T(H)17 differentiation in vitro. In vivo, the effects of inhibiting JAK1/3 signaling were examined by administering the inhibitor during the sensitization or allergen challenge phases in the primary challenge model or just before provocative challenge in the secondary challenge model. Airway inflammation and AHR were examined after the last airway challenge. Results: In vitro, R256 inhibited differentiation of T(H)2 but not T(H)1 or T(H)17 cells, which was associated with downregulation of signal transducer and activator of transcription (STAT) 6 and STAT5 phosphorylation. However, once polarized, T(H)2 cells were unaffected by the inhibitor. In vivo, R256 administered during the OVA sensitization phase prevented the development of AHR, airway eosinophilia, mucus hypersecretion, and T(H)2 cytokine production without changes in T(H)1 and T(H)17 cytokine levels, indicating that selective blockade of T(H)2 differentiation was critical. Inhibitor administration after OVA sensitization but during the challenge phases in the primary or secondary challenge models similarly suppressed AHR, airway eosinophilia, and mucus hypersecretion without any reduction in T(H)2 cytokine production, suggesting the inhibitory effects were downstream of T(H)2 cytokine receptor signaling pathways. Conclusions: Targeting the T(H)2-dependent JAK/STAT activation pathway represents a novel therapeutic approach for the treatment of asthma.	[Ashino, Shigeru; Takeda, Katsuyuki; Joetham, Anthony; Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; [Li, Hui; Taylor, Vanessa; Pine, Polly R.] Rigel Pharmaceut, San Francisco, CA USA	National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Hlth, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njhealth.org			National Institutes of Health [HL-36577, AI-77609]; Rigel Pharmaceuticals; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077609, R56AI077609] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rigel Pharmaceuticals; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants HL-36577 and AI-77609. Funding was received from Rigel Pharmaceuticals in support of this study, and E. W. G. was a consultant to Rigel.	Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Ashino S, 2008, INT IMMUNOL, V20, P259, DOI 10.1093/intimm/dxm138; Ashino S, 2010, INT IMMUNOL, V22, P503, DOI 10.1093/intimm/dxq034; Bosnjak B, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-114; Casanova JL, 2012, IMMUNITY, V36, P515, DOI 10.1016/j.immuni.2012.03.016; Chang YJ, 2002, J BIOL CHEM, V277, P7118, DOI 10.1074/jbc.M109924200; Chiba Y, 2012, PHARMACOL REP, V64, P454; Chiba Y, 2010, J PHARMACOL SCI, V112, P467, DOI 10.1254/jphs.09346SC; Fleischmann R, 2012, NEW ENGL J MED, V367, P495, DOI 10.1056/NEJMoa1109071; Fox DA, 2012, NEW ENGL J MED, V367, P565, DOI 10.1056/NEJMe1206315; Ghoreschi K, 2011, J IMMUNOL, V186, P4234, DOI 10.4049/jimmunol.1003668; Ghoreschi K, 2009, NAT IMMUNOL, V10, P356, DOI 10.1038/ni.1701; Ghoreschi K, 2009, IMMUNOL REV, V228, P273, DOI 10.1111/j.1600-065X.2008.00754.x; Gomez-Valades AG, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.37; Haan C, 2011, CHEM BIOL, V18, P314, DOI 10.1016/j.chembiol.2011.01.012; Heine A, 2013, BLOOD, V122, P1192, DOI 10.1182/blood-2013-03-484642; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Kanehiro A, 2001, AM J RESP CRIT CARE, V163, P173, DOI 10.1164/ajrccm.163.1.2001118; Kobayashi M, 2012, EUR J IMMUNOL, V42, P393, DOI 10.1002/eji.201141845; Kontzias A, 2012, CURR OPIN PHARMACOL, V12, P464, DOI 10.1016/j.coph.2012.06.008; Kudlacz E, 2008, EUR J PHARMACOL, V582, P154, DOI 10.1016/j.ejphar.2007.12.024; Kuperman DA, 2005, J IMMUNOL, V175, P3746, DOI 10.4049/jimmunol.175.6.3746; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liao W, 2011, CURR OPIN IMMUNOL, V23, P598, DOI 10.1016/j.coi.2011.08.003; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; Liu TJ, 2004, J IMMUNOL, V173, P3425, DOI 10.4049/jimmunol.173.5.3425; Mathur AN, 2007, J IMMUNOL, V178, P4901, DOI 10.4049/jimmunol.178.8.4901; Matsunaga Y, 2011, BIOCHEM BIOPH RES CO, V404, P261, DOI 10.1016/j.bbrc.2010.11.104; May RD, 2012, BRIT J PHARMACOL, V166, P177, DOI 10.1111/j.1476-5381.2011.01659.x; Nakano T, 2006, AM J RESP CRIT CARE, V173, P1216, DOI 10.1164/rccm.200410-1420OC; O'Shea JJ, 2008, IMMUNITY, V28, P477, DOI 10.1016/j.immuni.2008.03.002; O'Shea JJ, 2012, IMMUNITY, V36, P542, DOI 10.1016/j.immuni.2012.03.014; Oda A, 1998, BLOOD, V92, P443, DOI 10.1182/blood.V92.2.443.414k25_443_451; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Pesu M, 2008, IMMUNOL REV, V223, P132, DOI 10.1111/j.1600-065X.2008.00644.x; Rossi AB, 2006, J ALLERGY CLIN IMMUN, V118, P749, DOI 10.1016/j.jaci.2006.05.023; Schindler CW, 2002, J CLIN INVEST, V109, P1133, DOI 10.1172/JCI200215644; Scicchitano MS, 2003, EXP HEMATOL, V31, P760, DOI 10.1016/S0301-472X(03)00185-1; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Szefler SJ, 2011, ANN ALLERG ASTHMA IM, V107, P110, DOI 10.1016/j.anai.2011.04.008; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; TAKEDA K, 2005, ALLERGOL INT, V54, P263; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Tong W, 2005, BLOOD, V105, P4604, DOI 10.1182/blood-2004-10-4093; van Vollenhoven RF, 2012, NEW ENGL J MED, V367, P508, DOI 10.1056/NEJMoa1112072; Walsh GM, 2012, EXPERT OPIN EMERG DR, V17, P37, DOI 10.1517/14728214.2012.657625; Wenzel SE, 2002, J IMMUNOL, V169, P4613, DOI 10.4049/jimmunol.169.8.4613; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488; Zhu JF, 2003, IMMUNITY, V19, P739, DOI 10.1016/S1074-7613(03)00292-9; Zhu JF, 2001, J IMMUNOL, V166, P7276, DOI 10.4049/jimmunol.166.12.7276	51	52	54	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1162	+		10.1016/j.jaci.2013.10.036	http://dx.doi.org/10.1016/j.jaci.2013.10.036			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24365136	Green Accepted			2022-12-18	WOS:000333531700028
J	Portnoy, J; Chew, GL; Phipatanakul, W; Williams, PB; Grimes, C; Kennedy, K; Matsui, EC; Miller, JD; Bernstein, D; Blessing-Moore, J; Cox, L; Khan, D; Lang, D; Nicklas, R; Oppenheimer, J; Randolph, C; Schuller, D; Spector, S; Tilles, SA; Wallace, D; Seltzer, J; Sublett, J				Portnoy, Jay; Chew, Ginger L.; Phipatanakul, Wanda; Williams, P. Brock; Grimes, Carl; Kennedy, Kevin; Matsui, Elizabeth C.; Miller, J. David; Bernstein, David; Blessing-Moore, Joann; Cox, Linda; Khan, David; Lang, David; Nicklas, Richard; Oppenheimer, John; Randolph, Christopher; Schuller, Diane; Spector, Sheldon; Tilles, Stephen A.; Wallace, Dana; Seltzer, James; Sublett, James			Environmental assessment and exposure reduction of cockroaches: A practice parameter	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; cockroach; sensitization; disease; morbidity		fThis parameter was developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology. The AAAAI and the ACAAI have jointly accepted responsibility for establishing "Environmental assessment and remediation: a practice parameter.'' This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single person, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention	[Sublett, James] Family Allergy & Asthma, Louisville, KY USA; [Kennedy, Kevin] Childrens Mercy Hosp, Environm Hlth Program, Kansas City, MO 64108 USA; [Portnoy, Jay] Univ Missouri, Childrens Mercy Hosp, Kansas City Sch Med, Sect Allergy Asthma & Immunol, Kansas City, MO 64108 USA; [Bernstein, David] Univ Cincinnati, Coll Med, Dept Clin Med & Environm Hlth, Div Allergy Immunol, Cincinnati, OH USA; [Blessing-Moore, Joann] Stanford Univ, Med Ctr, Dept Med & Pediat, Dept Immunol, Palo Alto, CA 94304 USA; [Khan, David] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Lang, David] Cleveland Clin Fdn, Div Med, Allergy Immunol Sect, Allergy & Immunol Fellowship Training Program, Cleveland, OH 44195 USA; [Nicklas, Richard] George Washington Med Ctr, Dept Med, Washington, DC USA; [Oppenheimer, John] Pulm & Allergy Associates, New Jersey Med Sch, Dept Internal Med, Morristown, NJ USA; [Portnoy, Jay] Univ Missouri, Childrens Mercy Hosp, Kansas City Sch Med, Sect Allergy Asthma & Immunol,Dept Pediat, Kansas City, MO 64108 USA; [Randolph, Christopher] Yale Affiliated Hosp, Ctr Allergy Asthma & Immunol, Dept Pediat, Waterbury, CT USA; [Schuller, Diane] Penn State Univ, Milton S Hershey Med Coll, Dept Pediat, Hershey, PA USA; [Spector, Sheldon] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; [Tilles, Stephen A.] Univ Washington, Sch Med, Dept Med, Redmond, WA USA; [Wallace, Dana] Nova SE Univ, Coll Osteopath Med, Dept Med, Davie, FL USA	Children's Mercy Hospital; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; University System of Ohio; University of Cincinnati; Stanford University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Cleveland Clinic Foundation; George Washington University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Pennsylvania; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Washington; Nova Southeastern University	Portnoy, J (corresponding author), Joint Council Allergy Asthma & Immunol, 50 N Brockway St 3-3, Palatine, IL 60067 USA.	grupes@jcaai.org	Cox, Linda/AAP-1697-2021; Miller, John J/GZG-5663-2022	Cox, Linda/0000-0002-5258-6870; SUBLETT, JAMES L/0000-0003-4696-4609; Matsui, Elizabeth/0000-0001-8134-5593	National Institutes of Health (NIH); Public Health Service; TEVA; Genentech; Pfizer; Merck; Meda; GlaxoSmithKline; Array; Cephalon; MedImmune; Vanberg Family Foundation; NIH/National Institute of Mental Health; Genentech/Novartis; AstraZeneca; Novartis; Boehringer Ingelheim; Amgen; Sanofi; Targacept; Astellas; Amphastar; Sunovion; Boehringer; Ingelheim; Nutricia; Rigel; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073964, K24AI106822] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); TEVA(Teva Pharmaceutical Industries); Genentech(Roche HoldingGenentech); Pfizer(Pfizer); Merck(Merck & Company); Meda; GlaxoSmithKline(GlaxoSmithKline); Array; Cephalon; MedImmune(AstraZenecaMedimmune); Vanberg Family Foundation; NIH/National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Genentech/Novartis(Roche HoldingGenentech); AstraZeneca(AstraZeneca); Novartis(Novartis); Boehringer Ingelheim(Boehringer Ingelheim); Amgen(Amgen); Sanofi; Targacept; Astellas(Astellas Pharmaceuticals); Amphastar; Sunovion; Boehringer(Boehringer Ingelheim); Ingelheim; Nutricia(Danone Nutricia); Rigel; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Disclosure of potential conflict of interest: J. Portnoy is a speaker for Thermo Fisher and Mylan and has consultant arrangements with Thermo Fisher and Sanofi. W. Phipatanakul has received research support from the National Institutes of Health (NIH). C. Grimes is employed by Health Habitats LLC. K. Kennedy has received research support from Public Health Service and is an instructor for Healthy Housing Solutions and the Indoor Air Quality Training Institute. E. C. Matsui has received payment for lectures from Indoor Biotechnologies and has received the Phadia Research Foundation Award. D. Bernstein has received research support from TEVA, Genentech, Pfizer, Merck, Meda, GlaxoSmithKline, Array, Cephalon, and MedImmune and has provided legal consultation or expert witness testimony in cases related to anaphylaxis, contact dermatitis, and occupational asthma. J. Blessing-Moore has received research support and is a speaker for Meda; is a speaker for Alcon, Teva, Sunovion, Genentech/Novartis, Merck, and AstraZeneca; is a committee member of the American College of Chest Physicians, the American College of Allergy, Asthma & Immunology (ACAAI), the American Academy of Allergy, Asthma& Immunology (AAAAI), and the American Thoracic Society. L. Cox has received consulting fees from Stallergenes, has received travel support from the AAAAI, has received fees for participation in review activities from Circassia and Novartis, has received payment for writing or reviewing the manuscript from the Blue Cross Blue Shield Technology Evaluation Center, is a board member for the American Board of Allergy and Immunology, has consultant arrangements with the Food and Drug Administration Allergenic Products Advisory Committee, has provided expert testimony in cases related to chronic cinguteria, and has received payment for lectures from the Southeastern Allergy Asthma Immunology Association and Virginia AAIS. D. Khan is a speaker for Genentech, Merck, Baxter, and Viropharma; has received research support from the Vanberg Family Foundation and the NIH/National Institute of Mental Health; is the Allied Health Chair for the ACAAI; and is a member of the Joint Task Force on Practice Parameters for the Joint Council of Allergy, Asthma & Immunology. D. Lang is a speaker for Genentech/Novartis, GlaxoSmithKline, and Merck; has consultant arrangements with GlaxoSmithKline, Merck, and Aerocrine; and has received research support from Genentech/Novartis and Merck. R. Nicklas is a committee chair, volunteer, and fellow of the ACAAI. J. Oppenheimer has consultant arrangements with GlaxoSmithKline, AstraZeneca, and Mylan; has received research support from AstraZeneca, GlaxoSmithKline, Novartis, Boehringer Ingelheim, and MedImmune; has provided legal consultation/expert witness testimony for a malpractice defense; and is a member of the American Board of Allergy and Immunology. C. Randolph is a speaker for GlaxoSmithKline, TEVA, Viropharma, Merck, and Dey; has received research support from GlaxoSmithKline, Merck, Amgen, and Genentech/Novartis; and is a consultant for AstraZeneca and Meda. S. Spector is employed by the California Allergy & Asthma Medical Group, has consultant arrangements with ISTA Pharmaceutical, is a speaker for Novartis and Merck, and has received research support from AstraZeneca, GlaxoSmithKline, Cephalon, Amgen, Sanofi, and Targacept. S. A.; Tilles has consultant arrangements with SRXA, Sunovion, and Hyrox; has received research support from Astellas, Amphastar, MedImmune, Cephalon, Genentech, Merck, TEVA, Sunovion, Boehringer Ingelheim, Nutricia, Array, Rigel, and AstraZeneca; is Associate Editor of Allergy Watch and the Annals of Allergy; is Assistant Editor of the Joint Task Force on Practice Parameters; and is on the Executive Committee for the Seattle Food Allergy Consortium. D. Wallace has received honoraria for talks from the ACAAI; is a speaker for TEVA and Myland Labs; is an advisor for Sanofi and Sunovion; is on the Executive Committee of the ACAAI; and is on the Board of Directors for the World Allergy Organization. J. Seltzer is on the speaker's bureau and has consultant arrangements with GlaxoSmithKline, is owner of Indoor Hygienic Technologies Corporation, has provided expert witness testimony/legal consultation in cases related to indoor environmental illness, and is on the speaker's bureau for TEVA Pharmaceuticals. J. Sublett has received payment for lectures from GlaxoSmithKline, Merck, Sunovion, and Teva and has stock/stock options with AllergyZone LLC. The rest of the authors declare that they have no relevant conflicts of interest.		0	52	52	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					802	808		10.1016/j.jaci.2013.04.061	http://dx.doi.org/10.1016/j.jaci.2013.04.061			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23938214	Green Accepted			2022-12-18	WOS:000325096500003
J	Scichilone, N; Battaglia, S; Taormina, S; Modica, V; Pozzecco, E; Bellia, V				Scichilone, Nicola; Battaglia, Salvatore; Taormina, Salvatore; Modica, Viviana; Pozzecco, Elena; Bellia, Vincenzo			Alveolar nitric oxide and asthma control in mild untreated asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; biological markers; small airways	SMALL AIRWAYS; REFRACTORY ASTHMA; LUNG-FUNCTION; INFLAMMATION; CHILDREN; ADULTS; SEVERITY; SYMPTOMS; EXCHANGE; FRACTION	Background: The role of the peripheral airways in asthma is increasingly being recognized as a potential target for the achievement of optimal control of the disease. We postulated that the inflammatory changes of the small airways are implicated in the lack of asthma control in mild asthma. Objective: To test this hypothesis, we measured the alveolar fraction of exhaled NO (CalvNO) in patients with mild asthma with different levels of control of symptoms. Methods: Seventy-eight patients with asthma (35 men, age, 37 +/- 15 years; FEV1 percentage of predicted, 100% +/- 9%) were studied. Asthma control was assessed by using the Asthma Control Test (ACT). Measurements of exhaled NO at multiple constant flows were performed. Results: Bronchial NO concentrations were 27.1 +/- 20 ppb, and CalvNO levels were 5.7 +/- 3.4 ppb. The ACT score was 20 +/- 4.2. The level of asthma control was not associated with bronchial NO concentrations (r(s) = 0.16, P = .15). However, a significant correlation was found between the ACT score and CalvNO (r(s) = 0.25, P = .03). Moreover, CalvNO was significantly higher in patients with uncontrolled asthma than in patients with controlled/partially controlled asthma (6.7 +/- 2.6 ppb vs 4.9 +/- 2.6 ppb, respectively, P = .02). In the subgroup of patients with asthma who underwent extrafine inhaled corticosteroid treatment, the magnitude of the inhaled corticosteroid-induced improvement in asthma control positively correlated with baseline CalvNO at 1 month (r(s) = 0.39, P = .003) and at 3 months (r(s) = 0.49, P < .0001). Conclusions: The alveolar component of exhaled NO is associated with the lack of asthma control in patients with mild, untreated asthma. This observation supports the notion that abnormalities of the peripheral airways are implicated in the mildest forms of asthma.	[Scichilone, Nicola; Battaglia, Salvatore; Taormina, Salvatore; Modica, Viviana; Pozzecco, Elena; Bellia, Vincenzo] Univ Palermo, Sez Pneumol, Dipartimento Biomed Med Interna & Specialist DiBi, I-90146 Palermo, Italy	University of Palermo	Scichilone, N (corresponding author), Univ Palermo, Sez Pneumol, Dipartimento Biomed Med Interna & Specialist DiBi, Via Trabucco 180, I-90146 Palermo, Italy.	nicola.scichilone@unipa.it	Battaglia, Salvatore/D-7042-2015	Battaglia, Salvatore/0000-0002-2867-917X; Scichilone, Nicola/0000-0001-6400-6573				American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Barnes PJ, 2010, CHEST, V138, P682, DOI 10.1378/chest.09-2090; Battaglia S, 2005, THORAX, V60, P639, DOI 10.1136/thx.2004.035279; Berry M, 2005, EUR RESPIR J, V25, P986, DOI 10.1183/09031936.05.00132404; Brindicci C, 2007, CHEST, V131, P1353, DOI 10.1378/chest.06-2531; Contoli M, 2010, ALLERGY, V65, P141, DOI 10.1111/j.1398-9995.2009.02242.x; Dolhnikoff M, 2009, J ALLERGY CLIN IMMUN, V123, P1090, DOI 10.1016/j.jaci.2009.02.032; Farah CS, 2012, J ALLERGY CLIN IMMUN, V129, P381, DOI 10.1016/j.jaci.2011.11.017; Gelb AF, 2004, AM J RESP CRIT CARE, V170, P737, DOI 10.1164/rccm.200403-408OC; George SC, 2004, J APPL PHYSIOL, V96, P831, DOI 10.1152/japplphysiol.00950.2003; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Khalili B, 2008, ANN ALLERG ASTHMA IM, V101, P124, DOI 10.1016/S1081-1206(10)60199-8; Lehtimaki L, 2002, EUR RESPIR J, V20, P841, DOI 10.1183/09031936.02.00202002; Lehtimaki L, 2001, EUR RESPIR J, V18, P635, DOI 10.1183/09031936.01.00000201; Mahut B, 2004, CHEST, V125, P1012, DOI 10.1378/chest.125.3.1012; Mahut B, 2004, J ALLERGY CLIN IMMUN, V113, P252, DOI 10.1016/j.jaci.2003.10.038; Mahut B, 2010, ALLERGY, V65, P636, DOI 10.1111/j.1398-9995.2009.02221.x; Michils A, 2008, EUR RESPIR J, V31, P539, DOI 10.1183/09031936.00020407; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Nicolini G, 2010, ALLERGY ASTHMA PROC, V31, pE85, DOI 10.2500/aap.2010.31.3367; Paraskakis E, 2006, AM J RESP CRIT CARE, V174, P260, DOI 10.1164/rccm.200506-962OC; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Puckett JL, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-47; Scichilone N, 2009, ALLERGY, V64, P1563, DOI 10.1111/j.1398-9995.2009.02139.x; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-1427OC; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Stern G, 2011, J ALLERGY CLIN IMMUN, V128, P293, DOI 10.1016/j.jaci.2011.03.010; 't Veen JCCMI, 2000, AM J RESP CRIT CARE, V161, P1902; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653, DOI 10.1152/jappl.1998.85.2.653; van Veen IH, 2006, EUR RESPIR J, V27, P951, DOI 10.1183/09031936.06.00087905	30	52	55	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1513	1517		10.1016/j.jaci.2013.03.009	http://dx.doi.org/10.1016/j.jaci.2013.03.009			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23639306				2022-12-18	WOS:000320532800007
J	Granell, R; Henderson, AJ; Timpson, N; St Pourcain, B; Kemp, JP; Ring, SM; Ho, KR; Montgomery, SB; Dermitzakis, ET; Evans, DM; Sterne, JAC				Granell, Raquel; Henderson, A. John; Timpson, Nicholas; St Pourcain, Beate; Kemp, John P.; Ring, Susan M.; Ho, Karen; Montgomery, Stephen B.; Dermitzakis, Emmanouil T.; Evans, David M.; Sterne, Jonathan A. C.			Examination of the relationship between variation at 17q21 and childhood wheeze phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Avon Longitudinal Study of Parents and Children; wheezing phenotypes; chromosome 17; ORMDL3; gene expression	GENE-ENVIRONMENT INTERACTIONS; GENOME-WIDE ASSOCIATION; LUNG-FUNCTION; ORMDL3 GENE; LARGE-SCALE; ASTHMA; RISK; LOCI; VARIANTS; ONSET	Background: Genome-wide association studies have identified associations of genetic variants at 17q21 near ORMDL3 with childhood asthma. Objectives: We sought to determine whether associations in this region are specific to particular asthma phenotypes and specific to ORMDL3. Methods: We examined associations between 244 independent single nucleotide polymorphisms (SNPs) plus 13 previously identified asthma-related SNPs in the region between 34 and 36 Mb on chromosome 17 and early wheezing phenotypes, doctor-diagnosed asthma and atopy at 71/2 years, and bronchial hyperresponsiveness and lung function at 81/2 years in 7045 children from the Avon Longitudinal Study of Parents and Children birth cohort study. With this, cis expression quantitative trait loci signals for the same SNPs were assessed in 875 samples across genes in the same region. Results: The strongest evidence for phenotypic association was seen for persistent wheezing (rs8076131 near ORMDL3: relative risk ratio [RRR], 1.60 [95% CI, 1.40-1.84], P = 1.4 x 10(-11); rs2305480 near GSDML: RRR, 1.60 [95% CI, 1.39-1.83], P = 1.5 x 10(-11); and rs9303277 near IKZF3: RRR, 1.57 [95% CI, 1.37-1.79], P = 4.4 x 10(-11)). Similar but less precisely estimated effects were seen for intermediate-onset wheeze, but there was little evidence of associations with other wheezing phenotypes. There was some evidence of associations with bronchial hyperresponsiveness. SNPs across the whole region show strong evidence of association with differential levels of expression at GSDML, IKZF3, and MED24, as well as ORMDL3. Conclusions: Associations of SNPs in the 17q21 locus are specific to asthma and specific wheezing phenotypes and are not explained by associations with intermediate phenotypes, such as atopy or lung function. (J Allergy Clin Immunol 2013;131:685-94.)	[Granell, Raquel; Henderson, A. John; Sterne, Jonathan A. C.] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England; [Timpson, Nicholas; St Pourcain, Beate; Kemp, John P.; Ring, Susan M.; Ho, Karen; Evans, David M.] Univ Bristol, MRC Ctr Causal Anal Translat Epidemiol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England; [Montgomery, Stephen B.; Dermitzakis, Emmanouil T.] Univ Geneva, Dept Genet Med & Dev, Sch Med, CH-1211 Geneva 4, Switzerland; [Montgomery, Stephen B.] Wellcome Trust Sanger Inst, Cambridge, England; [Montgomery, Stephen B.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Montgomery, Stephen B.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	University of Bristol; University of Bristol; University of Geneva; Wellcome Trust Sanger Institute; Stanford University; Stanford University	Granell, R (corresponding author), Avon Longitudinal Study Parents & Children, Oakfield House, Bristol BS8 2BN, Avon, England.	raquel.granell@bristol.ac.uk	Evans, David M/H-6325-2013; Fox, Laura J/C-6249-2016; Granell, Raquel/AAB-5256-2022; Timpson, Nicholas John/O-7548-2015; Kemp, John P./R-3091-2018; Granell, Raquel/AAY-4846-2020; Attrill, Lauren/V-1688-2018; Sterne, Jonathan/Z-3106-2019	Evans, David M/0000-0003-0663-4621; Granell, Raquel/0000-0002-4890-4012; Timpson, Nicholas John/0000-0002-7141-9189; Kemp, John P./0000-0002-9105-2249; Sterne, Jonathan/0000-0001-8496-6053; Montgomery, Stephen/0000-0002-5200-3903; Ho, Karen/0000-0003-3478-9751; St Pourcain, Beate/0000-0002-4680-3517; Henderson, Alexander John/0000-0001-9650-231X	UK Medical Research Council [0401540, WT083431MA]; Wellcome Trust [092731]; University of Bristol; MRC [G0401540, G0600705] Funding Source: UKRI; Medical Research Council [G0401540, G0600705, G9815508] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10168] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); University of Bristol; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	The UK Medical Research Council and the Wellcome Trust (grant reference 092731) and the University of Bristol provide core support for Avon Longitudinal Study of Parents and Children. R.G. was supported by the UK Medical Research Council (grant no. 0401540). J.P.K. is funded by a Wellcome Trust 4-year PhD studentship in molecular, genetic, and life course epidemiology (WT083431MA).	Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Barrett JC, 2009, NAT GENET, V41, P703, DOI 10.1038/ng.381; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Boyd A, 2012, INT J EPIDEMIOL; Cantero-Recasens G, 2010, HUM MOL GENET, V19, P111, DOI 10.1093/hmg/ddp471; Flory JH, 2009, J ALLERGY CLIN IMMUN, V124, P605, DOI 10.1016/j.jaci.2009.05.047; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Halapi E, 2010, EUR J HUM GENET, V18, P902, DOI 10.1038/ejhg.2010.38; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Hjelmqvist L, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-6-research0027; Kimura K, 2006, GENOME RES, V16, P55, DOI 10.1101/gr.4039406; Kotecha SJ, 2010, AM J RESP CRIT CARE, V181, P969, DOI 10.1164/rccm.200906-0897OC; Leung TF, 2009, ALLERGY, V64, P621, DOI 10.1111/j.1398-9995.2008.01873.x; Liu XD, 2010, NAT GENET, V42, P658, DOI 10.1038/ng.627; Mahn K, 2009, P NATL ACAD SCI USA, V106, P10775, DOI 10.1073/pnas.0902295106; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Martinez FD, 2003, NEW ENGL J MED, V349, P1473, DOI 10.1056/NEJMe030041; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P26, DOI 10.1513/pats.200607-144JG; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Roberts G, 2005, CLIN EXP ALLERGY, V35, P933, DOI 10.1111/j.1365-2222.2005.02280.x; Rogers AJ, 2009, AM J RESP CRIT CARE, V179, P1084, DOI 10.1164/rccm.200812-1860OC; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Schmitt C, 2002, APOPTOSIS, V7, P277, DOI 10.1023/A:1015372322419; Stahl EA, 2010, NAT GENET, V42, P508, DOI 10.1038/ng.582; Stein Renato T, 2004, Paediatr Respir Rev, V5, P155, DOI 10.1016/j.prrv.2004.01.007; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; von Mutius E, 2004, J ALLERGY CLIN IMMUN, V113, P373, DOI 10.1016/j.jaci.2003.12.040; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; Wjst M, 2008, CLIN EXP ALLERGY, V38, P1579, DOI 10.1111/j.1365-2222.2008.03086.x; Wu H, 2009, ALLERGY, V64, P629, DOI 10.1111/j.1398-9995.2008.01912.x	34	52	52	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					685	694		10.1016/j.jaci.2012.09.021	http://dx.doi.org/10.1016/j.jaci.2012.09.021			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23154084	Green Accepted			2022-12-18	WOS:000315587800008
J	Brauweiler, AM; Bin, LH; Kim, BE; Oyoshi, MK; Geha, RS; Goleva, E; Leung, DYM				Brauweiler, Anne M.; Bin, Lianghua; Kim, Byung Eui; Oyoshi, Michiko K.; Geha, Raif S.; Goleva, Elena; Leung, Donald Y. M.			Filaggrin-dependent secretion of sphingomyelinase protects against staphylococcal alpha-toxin-induced keratinocyte death	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; skin barrier; filaggrin; acid sphingomyelinase; Staphylococcus aureus; alpha-toxin	ATOPIC-DERMATITIS; SKIN; AUREUS; BARRIER; VIRULENCE; DISEASE; PATHOGENESIS; MECHANISMS; EXPRESSION; MUTATIONS	Background: The skin of patients with atopic dermatitis (AD) has defects in keratinocyte differentiation, particularly in expression of the epidermal barrier protein filaggrin. AD skin lesions are often exacerbated by Staphylococcus aureus-mediated secretion of the virulence factor alpha-toxin. It is unknown whether lack of keratinocyte differentiation predisposes to enhanced lethality from staphylococcal toxins. Objective: We investigated whether keratinocyte differentiation and filaggrin expression protect against cell death induced by staphylococcal alpha-toxin. Methods: Filaggrin-deficient primary keratinocytes were generated through small interfering RNA gene knockdown. RNA expression was determined by using real-timePCR. Cell death was determined by using the lactate dehydrogenase assay. Keratinocyte cell survival in filaggrin-deficient (ft/ft) mouse skin biopsies was determined based on Keratin 5 staining. alpha-Toxin heptamer formation and acid sphingomyelinase expression were determined by means of immunoblotting. Results: We found that filaggrin expression, occurring as the result of keratinocyte differentiation, significantly inhibits staphylococcal alpha-toxin-mediated pathogenicity. Furthermore, filaggrin plays a crucial role in protecting cells by mediating the secretion of sphingomyelinase, an enzyme that reduces the number of alpha-toxin binding sites on the keratinocyte surface. Finally, we determined that sphingomyelinase enzymatic activity directly prevents alpha-toxin binding and protects keratinocytes against alpha-toxin-induced cytotoxicity. Conclusions: The current study introduces the novel concept that S aureus alpha-toxin preferentially targets and destroys filaggrin-deficient keratinocytes. It also provides a mechanism to explain the increased propensity for S aureus-mediated exacerbation of AD skin disease. (J Allergy Clin Immunol 2013;131:421-7.)	[Brauweiler, Anne M.; Bin, Lianghua; Kim, Byung Eui; Goleva, Elena; Leung, Donald Y. M.] Natl Jewish Hlth, Div Pediat Allergy & Immunol, Denver, CO 80206 USA; [Oyoshi, Michiko K.; Geha, Raif S.] Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA	National Jewish Health; Harvard University; Boston Children's Hospital; Harvard Medical School	Leung, DYM (corresponding author), Natl Jewish Hlth, 1400 Jackson St,Rm K926I, Denver, CO 80206 USA.	leungd@njhealth.org		Kim, Byung Eui/0000-0003-4923-1814	National Institutes of Health (NIH) [R01 AR41256]; Atopic Dermatitis Research Network (NIH/National Institute of Allergy and Infectious Diseases [NIAID]) [NIH/NIAID HHSN272201000020C]; National Institutes of Health; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Atopic Dermatitis Research Network (NIH/National Institute of Allergy and Infectious Diseases [NIAID]); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health (NIH) grant R01 AR41256 and the Atopic Dermatitis Research Network (NIH/National Institute of Allergy and Infectious Diseases [NIAID] contract NIH/NIAID HHSN272201000020C).; R. S. Geha has received research support from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	ALY R, 1977, ARCH DERMATOL, V113, P780, DOI 10.1001/archderm.113.6.780; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Bhakdi S, 1996, CURR TOP MICROBIOL, V216, P101; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Cai SCS, 2012, BRIT J DERMATOL, V166, P200, DOI 10.1111/j.1365-2133.2011.10541.x; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Chen H, 2011, BRIT J DERMATOL, V165, P106, DOI 10.1111/j.1365-2133.2011.10331.x; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Di Nardo A, 1998, ACTA DERM-VENEREOL, V78, P27; Elias PM, 2011, CLIN REV ALLERG IMMU, V41, P282, DOI 10.1007/s12016-010-8231-1; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; GRAYSON S, 1985, J INVEST DERMATOL, V85, P289, DOI 10.1111/1523-1747.ep12276826; Gruber R, 2011, AM J PATHOL, V178, P2252, DOI 10.1016/j.ajpath.2011.01.053; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Inoshima I, 2011, NAT MED, V17, P1310, DOI 10.1038/nm.2451; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jensen JM, 2004, J INVEST DERMATOL, V122, P1423, DOI 10.1111/j.0022-202X.2004.22621.x; Kennedy AD, 2010, J INFECT DIS, V202, P1050, DOI 10.1086/656043; Kezic S, 2011, ALLERGY, V66, P934, DOI 10.1111/j.1398-9995.2010.02540.x; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kobayashi SD, 2011, J INFECT DIS, V204, P937, DOI 10.1093/infdis/jir441; Mildner M, 2010, J INVEST DERMATOL, V130, P2286, DOI 10.1038/jid.2010.115; Nemoto-Hasebe I, 2009, J INVEST DERMATOL, V129, P682, DOI 10.1038/jid.2008.280; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; PATEL AH, 1987, INFECT IMMUN, V55, P3103, DOI 10.1128/IAI.55.12.3103-3110.1987; Prevost G, 2001, CURR TOP MICROBIOL, V257, P53; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Schlievert PM, 2010, J ALLERGY CLIN IMMUN, V125, P39, DOI 10.1016/j.jaci.2009.10.039; SCHURER NY, 1991, ADV LIPID RES, V24, P27; TAUBLER JH, 1963, J BACTERIOL, V86, P51, DOI 10.1128/JB.86.1.51-57.1963; TOMITA T, 1992, J BIOL CHEM, V267, P13391; Uchida Y, 2002, J LIPID RES, V43, P1293, DOI 10.1194/jlr.M100442-JLR200; Uchida Y, 2000, J LIPID RES, V41, P2071; Wardenburg JB, 2007, INFECT IMMUN, V75, P1040, DOI 10.1128/IAI.01313-06; WATANABE M, 1987, BIOCHIM BIOPHYS ACTA, V898, P257, DOI 10.1016/0005-2736(87)90065-4; Wichmann K, 2009, BRIT J DERMATOL, V161, P300, DOI 10.1111/j.1365-2133.2009.09229.x; Wilke GA, 2010, P NATL ACAD SCI USA, V107, P13473, DOI 10.1073/pnas.1001815107	40	52	53	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					421	+		10.1016/j.jaci.2012.10.030	http://dx.doi.org/10.1016/j.jaci.2012.10.030			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23246020	Green Accepted			2022-12-18	WOS:000314661500020
J	Brunst, KJ; Leung, YK; Ryan, PH; Hershey, GKK; Levin, L; Ji, H; LeMasters, GK; Ho, SM				Brunst, Kelly J.; Leung, Yuet-Kin; Ryan, Patrick H.; Hershey, Gurjit K. Khurana; Levin, Linda; Ji, Hong; LeMasters, Grace K.; Ho, Shuk-Mei			Forkhead box protein 3 (FOXP3) hypermethylation is associated with diesel exhaust exposure and risk for childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DNA METHYLATION; AIR-POLLUTION; CHILDREN		[Brunst, Kelly J.; Ryan, Patrick H.; Levin, Linda; LeMasters, Grace K.] Univ Cincinnati, Coll Med, Div Epidemiol & Biostat, Cincinnati, OH USA; [Brunst, Kelly J.; Leung, Yuet-Kin; Ryan, Patrick H.; Levin, Linda; Ho, Shuk-Mei] Univ Cincinnati, Coll Med, Ctr Environm Genet, Cincinnati, OH USA; [Leung, Yuet-Kin; Ho, Shuk-Mei] Univ Cincinnati, Coll Med, Dept Environm Hlth, Div Environm Genet & Mol Toxicol, Cincinnati, OH 45267 USA; [Ryan, Patrick H.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA; [Hershey, Gurjit K. Khurana; Ji, Hong] Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH USA; [Ho, Shuk-Mei] Cincinnati Veteran Affairs Med Ctr, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Brunst, KJ (corresponding author), Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.	shuk-mei.ho@uc.edu	Ryan, Patrick/HDO-1133-2022; Ryan, Patrick H/L-7062-2015; Leung, Ricky/H-5958-2019	Leung, Ricky/0000-0003-2063-277X; Khurana Hershey, Gurjit/0000-0001-6663-977X; Brunst, Kelly/0000-0001-8201-8631; Ji, Hong/0000-0002-9558-0620	VA [1I01BX000675-01A2] Funding Source: Federal RePORTER; NCATS NIH HHS [UL1 TR000077] Funding Source: Medline; NIEHS NIH HHS [R01ES11170, P30 ES006096, P30ES006096, T32 ES010957, T32ES010957, U01ES020988, U01ES019480, R01 ES011170, R01ES015584, U01 ES019480, R01 ES015584, P50ES015905, U01 ES020988, P50 ES015905] Funding Source: Medline; BLRD VA [I01 BX000675] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096, T32ES010957, P50ES015905, R01ES011170, R01ES015584, U01ES019480, U01ES020988] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000675] Funding Source: NIH RePORTER	VA(US Department of Veterans Affairs); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); BLRD VA; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Veterans Affairs(US Department of Veterans Affairs)		Bacchetta R, 2007, J ALLERGY CLIN IMMUN, V120, P227, DOI 10.1016/j.jaci.2007.06.023; Bateson TF, 2008, J TOXICOL ENV HEAL A, V71, P238, DOI 10.1080/15287390701598234; Breton CV, 2011, AM J RESP CRIT CARE, V184, P191, DOI 10.1164/rccm.201012-2029OC; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Jerrett M, 2008, ENVIRON HEALTH PERSP, V116, P1433, DOI 10.1289/ehp.10968; LeMasters GK, 2006, J PEDIATR-US, V149, P505, DOI 10.1016/j.jpeds.2006.06.035; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Reponen T, 2011, ANN ALLERG ASTHMA IM, V107, P120, DOI 10.1016/j.anai.2011.04.018; Ryan PH, 2008, SCI TOTAL ENVIRON, V404, P139, DOI 10.1016/j.scitotenv.2008.05.051; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715	10	52	55	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					592	594		10.1016/j.jaci.2012.10.042	http://dx.doi.org/10.1016/j.jaci.2012.10.042			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23260754	Green Accepted			2022-12-18	WOS:000314661500044
J	Pennino, D; Bhavsar, PK; Effner, R; Avitabile, S; Venn, P; Quaranta, M; Marzaioli, V; Cifuentes, L; Durham, SR; Cavani, A; Eyerich, K; Chung, KF; Schmidt-Weber, CB; Eyerich, S				Pennino, Davide; Bhavsar, Pankaj K.; Effner, Renate; Avitabile, Simona; Venn, Pascal; Quaranta, Maria; Marzaioli, Viviana; Cifuentes, Liliana; Durham, Stephen R.; Cavani, Andrea; Eyerich, Kilian; Chung, Kian Fan; Schmidt-Weber, Carsten B.; Eyerich, Stefanie			IL-22 suppresses IFN-gamma-mediated lung inflammation in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)22 cells; IL-22; IFN-gamma; asthma; human bronchial epithelial cells; epithelial regulation	NATURAL-KILLER-CELLS; BRONCHIAL EPITHELIAL-CELLS; T-CELLS; AIRWAY HYPERRESPONSIVENESS; VIRUS-INFECTION; INNATE IMMUNITY; INTERLEUKIN 22; POTENTIAL ROLE; KERATINOCYTES; EXPRESSION	Background: IL-22 controls tissue homeostasis by both proinflammatory and anti-inflammatory effects. However, the anti-inflammatory mechanisms of IL-22 remain poorly investigated. Objective: We sought to investigate the anti-inflammatory role for IL-22 in human asthma. Methods: T-cell lines derived from lung biopsy specimens of asthmatic patients were characterized by means of flow cytometry. Human bronchial epithelial cells from healthy and asthmatic subjects were stimulated with IL-22, IFN-gamma, or the combination of both cytokines. Effects of cytokine stimulation were investigated by using whole-genome analysis, ELISA, and flow cytometry. The functional consequence of cytokine stimulation was evaluated in an in vitro wound repair model and T cell-mediated cytotoxicity experiments. In vivo cytokine expression was measured by using immunohistochemistry and Luminex assays in bronchoalveolar lavage fluid of healthy and asthmatic patients. Results: The current study identifies a tissue-restricted antagonistic interplay of IL-22 and the proinflammatory cytokine IFN-gamma. On the one hand, IFN-gamma antagonized IL-22-mediated induction of the antimicrobial peptide S100A7 and epithelial cell migration in bronchial epithelial cells. On the other hand, IL-22 decreased epithelial susceptibility to T cell-mediated cytotoxicity by inhibiting the IFN-gamma-induced expression of MHC-I, MHC-II, and CD54/intercellular adhesion molecule 1 molecules. Likewise, IL-22 inhibited IFN-gamma-induced secretion of the proinflammatory chemokines CCL5/RANTES and CXCL10/interferon-inducible protein 10 in vitro. Consistently, the IL-22 expression in bronchoalveolar lavage fluid of asthmatic patients inversely correlated with the expression of CCL5/RANTES and CXCL10/interferon-inducible protein 10 in vivo. Conclusions: IL-22 might control the extent of IFN-gamma-mediated lung inflammation and therefore play a tissue-restricted regulatory role. (J Allergy Clin Immunol 2013;131:562-70.)	[Pennino, Davide; Effner, Renate; Quaranta, Maria; Marzaioli, Viviana; Cifuentes, Liliana; Schmidt-Weber, Carsten B.; Eyerich, Stefanie] Tech Univ Munich, ZAUM Ctr Allergy & Environm, D-80802 Munich, Germany; [Pennino, Davide; Effner, Renate; Quaranta, Maria; Marzaioli, Viviana; Cifuentes, Liliana; Schmidt-Weber, Carsten B.; Eyerich, Stefanie] Helmholtz Ctr Munich, D-80802 Munich, Germany; [Bhavsar, Pankaj K.; Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, Airways Dis Sect, Natl Heart & Lung Inst, London, England; [Avitabile, Simona; Cavani, Andrea] IDI IRCCS, Expt Immunol Lab, Rome, Italy; [Pennino, Davide; Venn, Pascal; Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Allergy & Clin Immunol, London, England; [Eyerich, Kilian] Tech Univ Munich, Dept Dermatol & Allergy, D-80802 Munich, Germany	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Imperial College London; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Imperial College London; Technical University of Munich	Pennino, D (corresponding author), Tech Univ Munich, ZAUM Ctr Allergy & Environ ZAUM, Biedersteiner Str 29, D-80802 Munich, Germany.	Davide.Pennino@lrz.tu-muenchen.de	Schmidt-Weber, Carsten B./AAU-1621-2021; Quaranta, Maria/AHC-1639-2022; Pennino, Davide/D-7519-2013; Chung, Kian Fan/B-1872-2012; Chung, Kian Fan/I-8456-2019	Schmidt-Weber, Carsten B./0000-0002-3203-8084; Pennino, Davide/0000-0002-5834-1049; Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Marzaioli, Viviana/0000-0001-9410-0835; Quaranta, Maria/0000-0001-7424-0240	German Research Foundation (DFG) [SFB/Tr22]; Hochschulwissenschaftsprogramm (HWP); Kommission Klinische Forschung (KKF) of the Technical University Munich, Bayerische Forschungsstiftung (BFS); CK Care Foundation; GlaxoSmithKline; Wellcome Trust; Asthma UK; Medical Research Council; NIH/NIESH/NIHR; DFG; CK Care; Allergopharma; Helmholtz-Gemeinschaft; Pfizer; Zeller AG; Novartis;  [SFB TR22]; Medical Research Council [G0801056B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0509-10080] Funding Source: researchfish	German Research Foundation (DFG)(German Research Foundation (DFG)); Hochschulwissenschaftsprogramm (HWP); Kommission Klinische Forschung (KKF) of the Technical University Munich, Bayerische Forschungsstiftung (BFS); CK Care Foundation; GlaxoSmithKline(GlaxoSmithKline); Wellcome Trust(Wellcome Trust); Asthma UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIH/NIESH/NIHR; DFG(German Research Foundation (DFG)); CK Care; Allergopharma; Helmholtz-Gemeinschaft(Helmholtz Association); Pfizer(Pfizer); Zeller AG; Novartis(Novartis); ; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the German Research Foundation (DFG) (SFB/Tr22), Hochschulwissenschaftsprogramm (HWP) and Kommission Klinische Forschung (KKF) of the Technical University Munich, Bayerische Forschungsstiftung (BFS), and the CK Care Foundation.; P. K. Bhavsar has received one or more grants from or has one or more grants pending with GlaxoSmithKline. R. Effner is employed by ZAUM (the Center of Allergy and Environment). K. Eyerich has received one or more payments for lecturing from or is on the speakers' bureau for Abbott. K. F. Chung has been supported by one or more grants from the Wellcome Trust and Asthma UK; is an Advisory Board member for GlaxoSmithKline, Gilead, and Boehringer Ingelheim; has received one or more grants from or has one or more grants pending with the Medical Research Council, the Wellcome Trust, Asthma UK, and the NIH/NIESH/NIHR; has received honoraria for lecturing from GlaxoSmithKline, Novartis, and AstraZeneca; and has received one or more payments for attendance at international meetings from Novartis and Boehringer Ingelheim. C. B. Schmidt-Weber has been supported by one or more grants from SFB TR22; has consultancy arrangements with the Patent Law Office, GLB Consultants; has received one or more grants from or has one or more grants pending with DFG, CK Care, Allergopharma, Helmholtz-Gemeinschaft, Pfizer, Zeller AG, and Novartis; and has received one or more payments for lecturing from or is on the speakers' bureau for the University of Coimbra, the European Academy of Allergy and Clinical Immunology, and Allergopharma. The rest of the authors declare that they have no relevant conflicts of interest.	Ahmed ST, 2009, BIOCHEM BIOPH RES CO, V378, P821, DOI 10.1016/j.bbrc.2008.11.147; Allen JM, 2009, J BIOL CHEM, V284, P12020, DOI 10.1074/jbc.M806968200; [Anonymous], 2000, AM J RESP CRIT CARE, V162, P2341; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Besnard AG, 2011, AM J RESP CRIT CARE, V183, P1153, DOI 10.1164/rccm.201008-1383OC; Colonna M, 2009, IMMUNITY, V31, P15, DOI 10.1016/j.immuni.2009.06.008; Crellin NK, 2010, J EXP MED, V207, P281, DOI 10.1084/jem.20091509; Di Meglio P, 2011, IMMUNITY, V35, P857, DOI 10.1016/j.immuni.2011.12.003; Djukanovic R, 2008, NEW ENGL J MED, V359, P2062, DOI 10.1056/NEJMcibr0806978; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Eyerich S, 2011, NEW ENGL J MED, V365, P231, DOI 10.1056/NEJMoa1104200; Eyerich S, 2011, EUR J IMMUNOL, V41, P1894, DOI 10.1002/eji.201041197; Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Fitzgerald J, 2002, FEBS LETT, V517, P61, DOI 10.1016/S0014-5793(02)02579-6; Graham AC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017171; Guo HL, 2010, J VIROL, V84, P7750, DOI 10.1128/JVI.00187-10; Hildenbrand M, 2010, J INVEST DERMATOL, V130, P1922, DOI 10.1038/jid.2010.54; Holgate ST, 2006, J ALLERGY CLIN IMMUN, V117, P496, DOI 10.1016/j.jaci.2006.01.039; Jeong WI, 2008, J GASTROEN HEPATOL, V23, pS112, DOI 10.1111/j.1440-1746.2007.05274.x; Kacena MA, 2005, BONE, V36, P215, DOI 10.1016/j.bone.2004.09.024; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lunardi F, 2011, LAB INVEST, V91, P945, DOI 10.1038/labinvest.2011.1; Miyahara N, 2004, NAT MED, V10, P865, DOI 10.1038/nm1081; Pawliczak R, 2005, PHYSIOL GENOMICS, V23, P28, DOI 10.1152/physiolgenomics.00011.2005; Pennino D, 2010, J IMMUNOL, V184, P4880, DOI 10.4049/jimmunol.0901767; Schwarze J, 1999, J IMMUNOL, V162, P4207; Simonian PL, 2010, J EXP MED, V207, P2239, DOI 10.1084/jem.20100061; Sonnenberg GF, 2010, J EXP MED, V207, P1293, DOI 10.1084/jem.20092054; Traidl C, 2000, J IMMUNOL, V165, P3058, DOI 10.4049/jimmunol.165.6.3058; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; Tudhope SJ, 2007, J IMMUNOL, V179, P6237, DOI 10.4049/jimmunol.179.9.6237; Vijayanand P, 2010, J IMMUNOL, V184, P4568, DOI 10.4049/jimmunol.0901342; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Zenewicz LA, 2007, IMMUNITY, V27, P647, DOI 10.1016/j.immuni.2007.07.023	40	52	55	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					562	570		10.1016/j.jaci.2012.09.036	http://dx.doi.org/10.1016/j.jaci.2012.09.036			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23174657	Bronze, Green Submitted			2022-12-18	WOS:000314661500036
J	Milliken, SVI; Wassall, H; Lewis, BJ; Logie, J; Barker, RN; Macdonald, H; Vickers, MA; Ormerod, AD				Milliken, Sarah V. I.; Wassall, Heather; Lewis, Barry J.; Logie, Judith; Barker, Robert N.; Macdonald, Helen; Vickers, Mark A.; Ormerod, Anthony D.			Effects of ultraviolet light on human serum 25-hydroxyvitamin D and systemic immune function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Narrowband UV-B; vitamin D; regulatory T cells; eczema; psoriasis; FoxP3	REGULATORY T-CELLS; BAND UVB PHOTOTHERAPY; VITAMIN-D STATUS; NARROW-BAND; INDUCED IMMUNOSUPPRESSION; SUN EXPOSURE; RADIATION; PSORIASIS; INDUCTION; SKIN	Background: Many immune-mediated diseases are associated with low levels of vitamin D and sunlight. UV light or supplementation with vitamin D can increase regulatory T-cell activity and prevent animal models of autoimmune disease. Increasing population vitamin D levels may therefore alleviate the burden of human immune-mediated disease. Objective: To determine the responses of circulating 25-hydroxyvitamin D [25(OH)D] levels, regulatory T-cell numbers, and immune function to UV light exposure in patients being treated for skin disease. Methods: Twenty-four subjects with skin disease from the North of Scotland were recruited between December and March. At baseline, and after 2 and 4 weeks of narrowband UV light exposure, we measured peripheral blood 25(OH) D level, numbers of regulatory T cells (CD4(+)CD25(hi)FoxP3(+)), and T-cell proliferative and cytokine responses to anti-CD3/CD28 stimulation. Results: Median (interquartile range) narrowband UV-B received during the study was 39.1 (30.9) as standard erythema dose, comparable to a quarter of the median summer sunlight exposure received locally. This increased the 25(OH)D level from a mean +/- SD of 34 +/- 17 nmol/L to 58 +/- 16 nmol/L after 2 weeks and 78 +/- 19 nmol/L after 4 weeks. The mean proportion of circulating regulatory T cells increased from 0.5% to 1.6% CD3(+) cells, which significantly correlated with the increased 25(OH) D level. UV treatment was also followed by reduced proliferative and IL-10 responses to anti-CD3/CD28 independent of the 25(OH)D level. Conclusion: Narrowband UV light reduces systemic immune responsiveness via the induction of regulatory T cells. Light and 25(OH) D levels may affect particular immune functions independently. The levels of serum 25(OH)D over which these effects are apparent should guide future interventions. (J Allergy Clin Immunol 2012;129:1554-61.)	[Milliken, Sarah V. I.; Wassall, Heather; Lewis, Barry J.; Barker, Robert N.; Macdonald, Helen; Vickers, Mark A.; Ormerod, Anthony D.] Univ Aberdeen, Div Appl Med, Aberdeen AB25 2ZN, Scotland; [Logie, Judith] Aberdeen Royal Infirm, Dept Dermatol, Foresterhill, Scotland	University of Aberdeen	Ormerod, AD (corresponding author), Univ Aberdeen, Div Appl Med, Polwarth Bldg, Aberdeen AB25 2ZN, Scotland.	a.d.ormerod@abdn.ac.uk		Vickers, Mark/0000-0002-3154-1040	UK Food Standards Agency	UK Food Standards Agency	H. MacDonald has received research support from the UK Food Standards Agency and is an advisor for the National Osteoporosis Society. The rest of the authors declare that they have no relevant conflicts of interest.	Alloza I, 2012, GENES IMMUN, V13, P253, DOI 10.1038/gene.2011.81; Artukovic M, 2010, COLLEGIUM ANTROPOL, V34, P175; Barker RN, 2005, PROG INFLAM RES, P39; Barnes MS, 2011, J NUTR, V141, P476, DOI 10.3945/jn.110.131516; Becklund BR, 2010, P NATL ACAD SCI USA, V107, P6418, DOI 10.1073/pnas.1001119107; Cheng JB, 2003, J BIOL CHEM, V278, P38084, DOI 10.1074/jbc.M307028200; Cicarma E, 2010, EXP DERMATOL, V19, pE67, DOI 10.1111/j.1600-0625.2009.00987.x; Correale J, 2011, J NEUROL SCI, V311, P23, DOI 10.1016/j.jns.2011.06.027; Del Bino S, 2006, PIGM CELL RES, V19, P606, DOI 10.1111/j.1600-0749.2006.00338.x; Devereux G, 2000, J IMMUNOL METHODS, V234, P13, DOI 10.1016/S0022-1759(99)00185-4; Devereux G, 2009, AM J RESP CRIT CARE, V179, P739, DOI 10.1164/rccm.200901-0145ED; Diffey BL, 2002, METHODS, V28, P4, DOI 10.1016/S1046-2023(02)00204-9; Dimeloe S, 2010, J STEROID BIOCHEM, V120, P86, DOI 10.1016/j.jsbmb.2010.02.029; Ghoreishi M, 2009, J IMMUNOL, V182, P6071, DOI 10.4049/jimmunol.0804064; Hartmann B, 2012, J INVEST DERMATOL, V132, P330, DOI 10.1038/jid.2011.296; Hewison M, 2010, ENDOCRIN METAB CLIN, V39, P365, DOI 10.1016/j.ecl.2010.02.010; Holick MF, 2004, AM J CLIN NUTR, V80, p1678S, DOI 10.1093/ajcn/80.6.1678S; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Jeffery LE, 2009, J IMMUNOL, V183, P5458, DOI 10.4049/jimmunol.0803217; Johnson-Huang LM, 2010, J INVEST DERMATOL, V130, P2654, DOI 10.1038/jid.2010.166; Kriegel MA, 2011, SEMIN ARTHRITIS RHEU, V40, P512, DOI 10.1016/j.semarthrit.2010.07.009; Krstic G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018492; Lehmann B, 2007, J STEROID BIOCHEM, V103, P682, DOI 10.1016/j.jsbmb.2006.12.033; LEMIRE JM, 1991, J CLIN INVEST, V87, P1103, DOI 10.1172/JCI115072; Lucas RM, 2006, PROG BIOPHYS MOL BIO, V92, P140, DOI 10.1016/j.pbiomolbio.2006.02.019; Macdonald HM, 2011, OSTEOPOROSIS INT, V22, P2461, DOI 10.1007/s00198-010-1467-z; Macdonald HM, 2011, J CLIN ENDOCR METAB, V96, P1677, DOI 10.1210/jc.2010-2032; Majoie IML, 2009, J AM ACAD DERMATOL, V60, P77, DOI 10.1016/j.jaad.2008.08.048; Mittal S, 2008, BLOOD, V111, P5359, DOI 10.1182/blood-2007-08-105395; Miyara M, 2011, AUTOIMMUN REV, V10, P744, DOI 10.1016/j.autrev.2011.05.004; Morales-Tirado V, 2011, CLIN IMMUNOL, V138, P212, DOI 10.1016/j.clim.2010.11.003; Osmancevic A, 2009, PHOTODERMATOL PHOTO, V25, P119, DOI 10.1111/j.1600-0781.2009.00418.x; Prietl B, 2010, ISR MED ASSOC J, V12, P136; Racz E, 2011, J INVEST DERMATOL, V131, P1547, DOI 10.1038/jid.2011.53; Rana S, 2008, AM J PATHOL, V172, P993, DOI 10.2353/ajpath.2008.070517; Ryan C, 2010, ARCH DERMATOL, V146, P836, DOI 10.1001/archdermatol.2010.195; Safety Advisory Committee on Nutrition, 2007, UPD VIT D POS STAT S; Saito C, 2009, J DERMATOL SCI, V53, P231, DOI 10.1016/j.jdermsci.2008.09.011; Schwarz A, 2005, J EXP MED, V201, P173, DOI 10.1084/jem.20041212; Schwarz A, 2004, J IMMUNOL, V172, P1036, DOI 10.4049/jimmunol.172.2.1036; Schwarz T, 2008, PHOTOCHEM PHOTOBIOL, V84, P10, DOI 10.1111/j.1751-1097.2007.00223.x; Schwarz T, 2011, EUR J CELL BIOL, V90, P560, DOI 10.1016/j.ejcb.2010.09.011; Shevach EM, 2011, ADV IMMUNOL, V112, P137, DOI 10.1016/B978-0-12-387827-4.00004-8; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Singh TP, 2010, J IMMUNOL, V184, P7257, DOI 10.4049/jimmunol.0903719; Smolders J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015235; Smolders J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006635; Soyland E, 2011, BRIT J DERMATOL, V164, P344, DOI 10.1111/j.1365-2133.2010.10149.x; Thieden E, 2004, ARCH DERMATOL, V140, P197, DOI 10.1001/archderm.140.2.197; Vahavihu K, 2010, BRIT J DERMATOL, V162, P848, DOI 10.1111/j.1365-2133.2010.09629.x; van der Aar AMG, 2011, J ALLERGY CLIN IMMUN, V127, P1532, DOI 10.1016/j.jaci.2011.01.068; WEATHERALL IL, 1992, J INVEST DERMATOL, V99, P468, DOI 10.1111/1523-1747.ep12616156; Webb AR, 2011, PHOTOCHEM PHOTOBIOL, V87, P483, DOI 10.1111/j.1751-1097.2010.00871.x; Weiland SK, 2004, OCCUP ENVIRON MED, V61, P609, DOI 10.1136/oem.2002.006809; Zold E, 2011, AUTOIMMUN REV, V10, P155, DOI 10.1016/j.autrev.2010.09.018	55	52	53	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1554	1561		10.1016/j.jaci.2012.03.001	http://dx.doi.org/10.1016/j.jaci.2012.03.001			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22502796	Bronze			2022-12-18	WOS:000304764600016
J	Engelhardt, KR; Grimbacher, B				Engelhardt, Karin R.; Grimbacher, Bodo			Mendelian traits causing susceptibility to mucocutaneous fungal infections in human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic mucocutaneous candidiasis; primary immunodeficiency; hyper-IgE syndromes; autoimmune polyendocrinopathy-candidiasis; ectodermal dystrophy; dectin; caspase recruitment domain-containing protein 9; signal transducer and activator of transcription 3; signal transducer and activator of transcription 1; dedicator of cytokinesis 8; T(H)17 cell; IL-17; IL-17 receptor; anti-IL-17 antibody; anti-IL-17 receptor antibody; neutrophil	PATTERN-RECOGNITION RECEPTOR; BETA-GLUCAN RECOGNITION; HYPER-IGE SYNDROME; CANDIDA-ALBICANS; HOST-DEFENSE; TH17 CELLS; T-CELLS; COMBINED IMMUNODEFICIENCY; DECTIN-2 RECOGNITION; ADAPTIVE IMMUNITY	Mucocutaneous candidiasis and dermatophyte infections occur either in isolation or alongside other symptoms in patients with various primary immunodeficiency diseases with diverse genetic defects, which result in impaired IL-17 immunity, IL-22 immunity, or both. In patients with chronic mucocutaneous candidiasis, disease-associated polymorphisms in DECTIN1 act on the level of fungal recognition, whereas mutations in caspase recruitment domain-containing protein 9 (CARD9) disturb the subsequent spleen tyrosine kinase 2-CARD9/BCL10/MALT1-driven signaling cascade, impairing nuclear factor kappa B-mediated maturation of antigen-presenting cells and priming of naive T cells to differentiate into the T(H)17 cell lineage. T(H)17-priming cytokines signal through the transcription factor signal transducer and activator of transcription (STAT) 3, which in turn induces the T(H)17 lineage-determining transcription factor retinoic acid-related orphan receptor gamma t. Dominant-negative mutations in STAT3 result in reduced numbers of T(H)17 cells, causing localized candidiasis in patients with hyper-IgE syndrome. In patients with chronic mucocutaneous candidiasis, gain-of-function STAT1 mutations shift the cellular response toward T(H)17 cell-inhibiting cytokines. T(H)17 cells secrete IL-17 and IL-22, which are cytokines with potent antifungal properties, including production of antimicrobial peptides and activation and recruitment of neutrophils. Neutrophils mediate microbial killing through phagocytosis, degranulation, and neutrophil extracellular traps. Mutations in IL17F and IL17R in patients with chronic mucocutaneous candidiasis, as well as neutralizing autoantibodies against IL-17 and IL-22 in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, directly impair IL-17 and IL-22 immunity. (J Allergy Clin Immunol 2012;129:294-305.)	Royal Free Hosp, Dept Immunol & Mol Pathol, London NW3 2QG, England; UCL, London, England; Univ Med Ctr Freiburg, CCI, Freiburg, Germany; Univ Freiburg, D-79106 Freiburg, Germany	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; University of Freiburg; University of Freiburg	Grimbacher, B (corresponding author), Univ Freiburg Klinikum, Ctr Chron Immunodeficiency, Engesser Str 4, D-79108 Freiburg, Germany.	bodo.grimbacher@uniklinik-freiburg.de			European Commission [MEXT-CT-2006-042316]; European consortium [HEALTH-F2-2008-201549]; Federal Ministry of Education and Research (BMBF) [01 EO0803]	European Commission(European CommissionEuropean Commission Joint Research Centre); European consortium; Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	Supported by grants from the European Commission Marie Curie Excellence program (MEXT-CT-2006-042316), by the European consortium grant EURO-PADnet (HEALTH-F2-2008-201549), and by the Federal Ministry of Education and Research (BMBF 01 EO0803). The authors are responsible for the contents of this publication.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; Al Khatib S, 2009, J ALLERGY CLIN IMMUN, V124, P342, DOI 10.1016/j.jaci.2009.05.004; Antachopoulos C, 2007, EUR J PEDIATR, V166, P1099, DOI 10.1007/s00431-007-0527-7; Barrett NA, 2009, J IMMUNOL, V182, P1119, DOI 10.4049/jimmunol.182.2.1119; Bellocchio S, 2004, J IMMUNOL, V172, P3059, DOI 10.4049/jimmunol.172.5.3059; Brown GD, 2011, ANNU REV IMMUNOL, V29, P1, DOI 10.1146/annurev-immunol-030409-101229; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Cambi A, 2008, J BIOL CHEM, V283, P20590, DOI 10.1074/jbc.M709334200; Chaffin WL, 1998, MICROBIOL MOL BIOL R, V62, P130, DOI 10.1128/MMBR.62.1.130-180.1998; Conti HR, 2011, MUCOSAL IMMUNOL, V4, P448, DOI 10.1038/mi.2011.5; Conti HR, 2010, MICROBES INFECT, V12, P518, DOI 10.1016/j.micinf.2010.03.013; Conti HR, 2009, J EXP MED, V206, P299, DOI 10.1084/jem.20081463; DAVIS SD, 1966, LANCET, V1, P1013; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; de Repentigny L, 2004, CLIN MICROBIOL REV, V17, P729, DOI 10.1128/CMR.17.4.729-759.2004; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Eyerich K, 2008, J INVEST DERMATOL, V128, P2640, DOI 10.1038/jid.2008.139; Eyerich K, 2010, EUR J DERMATOL, V20, P260, DOI 10.1684/ejd.2010.0910; Ferwerda B, 2009, NEW ENGL J MED, V361, P1760, DOI 10.1056/NEJMoa0901053; Gaffen SL, 2011, IMMUNOL RES, V50, P181, DOI 10.1007/s12026-011-8226-x; Gaffen SL, 2008, CYTOKINE, V43, P402, DOI 10.1016/j.cyto.2008.07.017; Glocker E, 2010, CURR OPIN ALLERGY CL, V10, P542, DOI 10.1097/ACI.0b013e32833fd74f; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Goodridge HS, 2011, NATURE, V472, P471, DOI 10.1038/nature10071; Goodridge HS, 2009, IMMUNOL REV, V230, P38, DOI 10.1111/j.1600-065X.2009.00793.x; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Hanna S, 2011, J ALLERGY CLIN IMMUN, V127, P1433, DOI 10.1016/j.jaci.2011.03.026; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hirahara K, 2010, CYTOKINE GROWTH F R, V21, P425, DOI 10.1016/j.cytogfr.2010.10.006; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426; Hubert FX, 2011, BLOOD, V118, P2462, DOI 10.1182/blood-2010-06-286393; Husebye ES, 2009, J INTERN MED, V265, P514, DOI 10.1111/j.1365-2796.2009.02090.x; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jones CE, 2002, AM J RESP CELL MOL, V26, P748, DOI 10.1165/ajrcmb.26.6.4757; Jouault T, 2003, J INFECT DIS, V188, P165, DOI 10.1086/375784; Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002; KAUFFMAN CA, 1981, ARCH INTERN MED, V141, P1076, DOI 10.1001/archinte.141.8.1076; Kerrigan AM, 2010, IMMUNOL REV, V234, P335, DOI 10.1111/j.0105-2896.2009.00882.x; Khader SA, 2009, MUCOSAL IMMUNOL, V2, P403, DOI 10.1038/mi.2009.100; Kirkpatrick CH, 2001, PEDIATR INFECT DIS J, V20, P197, DOI 10.1097/00006454-200102000-00017; KIRKPATRICK CH, 1989, EUR J CLIN MICROBIOL, V8, P448, DOI 10.1007/BF01964059; Kisand K, 2011, EUR J IMMUNOL, V41, P1517, DOI 10.1002/eji.201041253; Kisand K, 2010, J EXP MED, V207, P299, DOI 10.1084/jem.20091669; KLEIN RS, 1984, NEW ENGL J MED, V311, P354, DOI 10.1056/NEJM198408093110602; Klis FM, 2001, MED MYCOL, V39, P1, DOI 10.1080/744118876; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kumar H, 2009, J IMMUNOL, V183, P8061, DOI 10.4049/jimmunol.0902477; Laakso SM, 2010, J AUTOIMMUN, V35, P351, DOI 10.1016/j.jaut.2010.07.008; Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lilic D, 2002, CURR OPIN INFECT DIS, V15, P143, DOI 10.1097/00001432-200204000-00007; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Liu XS, 2007, J ORAL PATHOL MED, V36, P528, DOI 10.1111/j.1600-0714.2007.00572.x; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; McCormick A, 2010, CELL MICROBIOL, V12, P1535, DOI 10.1111/j.1462-5822.2010.01517.x; Mendez-Tovar LJ, 2010, CLIN DERMATOL, V28, P185, DOI 10.1016/j.clindermatol.2009.12.015; Metzger TC, 2011, IMMUNOL REV, V241, P89, DOI 10.1111/j.1600-065X.2011.01008.x; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Milner JD, 2010, CURR OPIN HIV AIDS, V5, P179, DOI 10.1097/COH.0b013e328335ed3e; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; MITCHELL TG, 1995, CLIN MICROBIOL REV, V8, P515, DOI 10.1128/CMR.8.4.515; Moyes DL, 2010, CELL HOST MICROBE, V8, P225, DOI 10.1016/j.chom.2010.08.002; Nauseef WM, 2007, IMMUNOL REV, V219, P88, DOI 10.1111/j.1600-065X.2007.00550.x; Netea MG, 2008, NAT REV MICROBIOL, V6, P67, DOI 10.1038/nrmicro1815; Netea MG, 2006, J CLIN INVEST, V116, P1642, DOI 10.1172/JCI27114; Notarangelo LD, 2006, ADV IMMUNOL, V89, P321, DOI 10.1016/S0065-2776(05)89008-X; Ochs HD, 2009, J ALLERGY CLIN IMMUN, V123, P977, DOI 10.1016/j.jaci.2009.03.030; Onoda T, 2007, INT IMMUNOL, V19, P1191, DOI 10.1093/intimm/dxm090; Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004; Pappas PG, 2009, CLIN INFECT DIS, V48, P503, DOI 10.1086/596757; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pelletier M, 2010, BLOOD, V115, P335, DOI 10.1182/blood-2009-04-216085; Peluso I, 2007, J IMMUNOL, V178, P732, DOI 10.4049/jimmunol.178.2.732; Plantinga TS, 2009, CLIN INFECT DIS, V49, P724, DOI 10.1086/604714; Poeck H, 2010, J CLIN IMMUNOL, V30, P496, DOI 10.1007/s10875-010-9385-6; Poeck H, 2010, J MOL MED, V88, P745, DOI 10.1007/s00109-010-0631-4; Poliani PL, 2009, BLOOD, V114, P105, DOI 10.1182/blood-2009-03-211029; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Puel A, 2010, CURR OPIN IMMUNOL, V22, P467, DOI 10.1016/j.coi.2010.06.009; Puel A, 2010, J EXP MED, V207, P291, DOI 10.1084/jem.20091983; Purvis HA, 2010, BLOOD, V116, P4829, DOI 10.1182/blood-2010-03-272153; Renner ED, 2004, J PEDIATR-US, V144, P93, DOI 10.1016/S0022-3476(03)00449-9; Renner ED, 2008, J ALLERGY CLIN IMMUN, V122, P181, DOI 10.1016/j.jaci.2008.04.037; Rezaei N, 2005, J PEDIAT HEMATOL ONC, V27, P351, DOI 10.1097/01.mph.0000172280.27318.80; Rezaei N, 2007, J CLIN IMMUNOL, V27, P525, DOI 10.1007/s10875-007-9106-y; Robinson MJ, 2009, J EXP MED, V206, P2037, DOI 10.1084/jem.20082818; Romani L, 2011, NAT REV IMMUNOL, V11, P275, DOI 10.1038/nri2939; Ruland J, 2008, ANN NY ACAD SCI, V1143, P35, DOI 10.1196/annals.1443.024; Saijo S, 2007, NAT IMMUNOL, V8, P39, DOI 10.1038/ni1425; Saijo S, 2011, INT IMMUNOL, V23, P467, DOI 10.1093/intimm/dxr046; Saijo S, 2010, IMMUNITY, V32, P681, DOI 10.1016/j.immuni.2010.05.001; Sato K, 2006, J BIOL CHEM, V281, P38854, DOI 10.1074/jbc.M606542200; SCULLY C, 1994, CRIT REV ORAL BIOL M, V5, P125, DOI 10.1177/10454411940050020101; SHAMA SK, 1980, J AM ACAD DERMATOL, V2, P285, DOI 10.1016/S0190-9622(80)80040-5; SOBEL JD, 1984, INFECT IMMUN, V44, P576, DOI 10.1128/IAI.44.3.576-580.1984; Stritesky GL, 2008, J IMMUNOL, V181, P5948, DOI 10.4049/jimmunol.181.9.5948; Taylor PR, 2007, NAT IMMUNOL, V8, P31, DOI 10.1038/ni1408; Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639; van de Veerdonk FL, 2008, CURR OPIN MICROBIOL, V11, P305, DOI 10.1016/j.mib.2008.06.002; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; VANTWOUT JW, 1988, SCAND J INFECT DIS, V20, P193, DOI 10.3109/00365548809032437; Voelz K, 2010, EUKARYOT CELL, V9, P835, DOI 10.1128/EC.00039-10; Woellner C, 2010, J ALLERGY CLIN IMMUN, V125, P424, DOI 10.1016/j.jaci.2009.10.059; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Zhang QA, 2010, DIS MARKERS, V29, P131, DOI 10.3233/DMA-2010-0737; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	112	52	53	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					294	305		10.1016/j.jaci.2011.12.966	http://dx.doi.org/10.1016/j.jaci.2011.12.966			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22284928				2022-12-18	WOS:000299951700002
J	Havstad, S; Wegienka, G; Zoratti, EM; Lynch, SV; Boushey, HA; Nicholas, C; Ownby, DR; Johnson, CC				Havstad, Suzanne; Wegienka, Ganesa; Zoratti, Edward M.; Lynch, Susan V.; Boushey, Homer A.; Nicholas, Charlotte; Ownby, Dennis R.; Johnson, Christine Cole			Effect of prenatal indoor pet exposure on the trajectory of total IgE levels in early childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Total IgE; cohort; longitudinal; multilevel model	TOTAL SERUM IGE; ALLERGIC SENSITIZATION; CESAREAN-SECTION; ASTHMA; CHILDREN; ASSOCIATION; RISK; DELIVERY; ATOPY; AGE	Background: The presence of pets in a home during the prenatal period and during early infancy has been associated with a lower prevalence of allergic sensitization and total IgE levels in middle childhood. No studies have examined the effect of pet exposure in a population-based cohort by using multiple early-life measures of serum total IgE. Objective: We sought to examine within-individual longitudinal trends in total IgE levels during early childhood and assess the effect of indoor prenatal pet exposure on those trends. Also, we sought to use a statistical method that was flexible enough to allow and account for unequally spaced study contacts and missing data. Methods: Using the population-based Wayne County Health, Environment, Allergy and Asthma Longitudinal Study birth cohort (62% African American), we analyzed 1187 infants with 1 to 4 measurements of total IgE collected from birth to 2 years of age. Effects of pet exposure on the shape and trajectory of IgE levels were assessed by using a multilevel longitudinal model, accommodating repeated measures, missing data, and the precise time points of data collection. Results: The best-fit shape to the trajectory of IgE levels was nonlinear, with an accelerated increase before 6 months. Total IgE levels were lower across the entire early-life period when there was prenatal indoor pet exposure (P < .001). This effect was statistically significantly stronger in children delivered by means of cesarean section versus those delivered vaginally (P < .001 and P < .06, respectively) and in those born to non-African American (P < .001) versus African American (P < .3) mothers. Conclusion: Pet exposure and delivery mode might be markers of infant exposure to distinct microbiomes. The effect of exposures might vary by race, suggesting a differential effect by ancestry. (J Allergy Clin Immunol 2011;128:880-5.)	[Havstad, Suzanne; Wegienka, Ganesa; Nicholas, Charlotte; Johnson, Christine Cole] Henry Ford Hosp, Dept Publ Hlth Sci, Detroit, MI 48202 USA; [Zoratti, Edward M.] Henry Ford Hosp, Div Allergy, Dept Internal Med, Detroit, MI 48202 USA; [Lynch, Susan V.; Boushey, Homer A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Ownby, Dennis R.] Georgia Hlth Sci Univ, Dept Pediat, Augusta, GA USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; University of California System; University of California San Francisco; University System of Georgia; Augusta University	Havstad, S (corresponding author), Henry Ford Hosp, Dept Publ Hlth Sci, 1 Ford Pl,3E, Detroit, MI 48202 USA.	shavsta1@hfhs.org		Johnson, Christine Cole/0000-0002-6864-6604	National Institutes of Health [R01AI051598]; Fund for Henry Ford Hospital; National Institute of Allergy and Infectious Diseases; GlaxoSmithKline; Genentech; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051598, R01AI050681] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fund for Henry Ford Hospital; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); GlaxoSmithKline(GlaxoSmithKline); Genentech(Roche HoldingGenentech); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (R01AI051598) and the Fund for Henry Ford Hospital.; G. Wegienka, D. R. Ownby, and C. C. Johnson have received research support from the National Institutes of Health. E. M. Zoratti has received research support from the National Institute of Allergy and Infectious Diseases. H. A. Boushey has provided ad hoc consultation for Kalobios, is on the advisory committee for Pharmaxis, is on the ad hoc advisory committee for Merck and GlaxoSmithKline, has provided consultation for Genentech and Johnson & Johnson, and has received research support from GlaxoSmithKline and Genentech. The rest of the authors have declared they have no conflict of interest.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Bloomfield SF, 2006, CLIN EXP ALLERGY, V36, P402, DOI 10.1111/j.1365-2222.2006.02463.x; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Bufford JD, 2007, CURR ALLERGY ASTHM R, V7, P375, DOI 10.1007/s11882-007-0057-4; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; Kuitunen M, 2009, J ALLERGY CLIN IMMUN, V123, P335, DOI 10.1016/j.jaci.2008.11.019; Maier RM, 2010, APPL ENVIRON MICROB, V76, P2663, DOI 10.1128/AEM.01665-09; Mandhane PJ, 2009, J ALLERGY CLIN IMMUN, V124, P745, DOI 10.1016/j.jaci.2009.06.038; Matricardi PM, 2009, ALLERGY, V64, P1093, DOI 10.1111/j.1398-9995.2009.02055.x; McNeill G, 2009, PAEDIATR PERINAT EP, V23, P506, DOI 10.1111/j.1365-3016.2009.01057.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Pistiner M, 2008, J ALLERGY CLIN IMMUN, V122, P274, DOI 10.1016/j.jaci.2008.05.007; Renz-Polster H, 2005, CLIN EXP ALLERGY, V35, P1466, DOI 10.1111/j.1365-2222.2005.02356.x; Ronmark E, 2009, J ALLERGY CLIN IMMUN, V124, P357, DOI 10.1016/j.jaci.2009.05.011; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Rothers J, 2007, J ALLERGY CLIN IMMUN, V120, P1201, DOI 10.1016/j.jaci.2007.07.036; Rotsides DZ, 2010, RESP MED, V104, P345, DOI 10.1016/j.rmed.2009.10.016; Scirica CV, 2007, J ALLERGY CLIN IMMUN, V119, P81, DOI 10.1016/j.jaci.2006.09.002; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; Smith PH, 2009, CLIN SIGNIFICANCE IM, P845; Thavagnanam S, 2008, CLIN EXP ALLERGY, V38, P629, DOI 10.1111/j.1365-2222.2007.02780.x; Visness CM, 2009, J ALLERGY CLIN IMMUN, V123, P1163, DOI 10.1016/j.jaci.2008.12.1126; Waser M, 2005, ALLERGY, V60, P177, DOI 10.1111/j.1398-9995.2004.00645.x; Wegienka G, 2010, J ALLERGY CLIN IMMUN, V126, P274, DOI 10.1016/j.jaci.2010.05.001; Wright AL, 1999, J ALLERGY CLIN IMMUN, V104, P589, DOI 10.1016/S0091-6749(99)70328-3	31	52	53	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					880	U308		10.1016/j.jaci.2011.06.039	http://dx.doi.org/10.1016/j.jaci.2011.06.039			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21820714	Green Accepted			2022-12-18	WOS:000296538100027
J	Payne, SC; Borish, L; Steinke, JW				Payne, Spencer C.; Borish, Larry; Steinke, John W.			Genetics and phenotyping in chronic sinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fibrosis; chronic sinusitis; aspirin-exacerbated respiratory disease; eosinophils; nasal polyps	LEUKOTRIENE C-4 SYNTHASE; ALLERGIC FUNGAL SINUSITIS; CHRONIC HYPERPLASTIC SINUSITIS; ASPIRIN-SENSITIVE RHINOSINUSITIS; ENDOTHELIAL GROWTH-FACTOR; NASAL POLYP FIBROBLASTS; ASA-INTOLERANT ASTHMA; BACTERIAL BIOFILMS; STAPHYLOCOCCUS-AUREUS; PROMOTER POLYMORPHISM	Chronic sinusitis with nasal polyposis historically has been treated as a single monolithic clinical disorder. Just as asthma is now accepted as numerous heterogeneous diseases, chronic sinusitis should also be viewed as comprising several diseases with varying causes, with each one characterized by distinct histologic and gene and protein expression patterns. This includes recognition of the need to define these diseases based on the presence or absence of an eosinophilic infiltrate but also on additional distinctions based on unique agents that drive their development and perpetuation. As a collection of heterogeneous diseases, proper differential diagnosis is required to delineate appropriate therapeutic intervention. This review will focus on recognized distinct presentations of chronic sinus disease, including distinguishing the clinical presentations, cellular and molecular characteristics, genetic differences, and current treatment options for each. (J Allergy Clin Immunol 2011;128:710-20.)	[Payne, Spencer C.; Borish, Larry; Steinke, John W.] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Carter Immunol Ctr, Dept Med, Charlottesville, VA 22903 USA; [Payne, Spencer C.] Univ Virginia Hlth Syst, Dept Otolaryngol Head & Neck Surg, Charlottesville, VA 22903 USA	University of Virginia; University of Virginia	Borish, L (corresponding author), Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Carter Immunol Ctr, Dept Med, Box 801355, Charlottesville, VA 22903 USA.	lb4m@virginia.edu		Payne, Spencer/0000-0001-9736-4561	Genentech; Merck; National Institutes of Health (NIH); NIH Asthma and Allergic Disease Center; Medtronic	Genentech(Roche HoldingGenentech); Merck(Merck & Company); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Asthma and Allergic Disease Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medtronic(Medtronic)	S. C. Payne has received honoraria from Acclarent and has provided legal consultation or expert witness testimony in cases related to sinus surgery. L. Borish is a consultant for Hoffman LaRoche, Cephalon, Regeneron, and Pfizer; has received honoraria from Merck; has received research support from Genentech and Merck; and is a volunteer for the American Academy of Allergy, Asthma & Immunology and the Charlottesville Free Clinic. J.W. Steinke has received research support from the National Institutes of Health (NIH), the NIH Asthma and Allergic Disease Center, and Medtronic.	Adamjee J, 2006, J PATHOL, V209, P392, DOI 10.1002/path.1979; Adkins TN, 1998, ANN ALLERG ASTHMA IM, V81, P181, DOI 10.1016/S1081-1206(10)62807-4; Artuc M, 1999, EXP DERMATOL, V8, P1, DOI 10.1111/j.1600-0625.1999.tb00342.x; Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Bachert C, 1999, ACI INT, V11, P130; Bachert Claus, 2002, Curr Allergy Asthma Rep, V2, P481, DOI 10.1007/s11882-002-0088-9; Bachert Claus, 2002, Curr Allergy Asthma Rep, V2, P252, DOI 10.1007/s11882-002-0027-9; Baraniuk JN, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-149; Baroody FM, 2008, J ALLERGY CLIN IMMUN, V121, P1126, DOI 10.1016/j.jaci.2008.02.010; Bassichis BA, 2001, OTOLARYNG HEAD NECK, V125, P487, DOI 10.1067/mhn.2001.119585; Batikhan H, 2010, EUR ARCH OTO-RHINO-L, V267, P903, DOI 10.1007/s00405-009-1167-5; Bendouah Z, 2006, OTOLARYNG HEAD NECK, V134, P991, DOI 10.1016/j.otohns.2006.03.001; Benninger MS, 2003, OTOLARYNG HEAD NECK, V129, pS1, DOI 10.1016/S0194-5998(03)01397-4; Berger G, 2002, LARYNGOSCOPE, V112, P738, DOI 10.1097/00005537-200204000-00026; Bernstein JM, 2009, LARYNGOSCOPE, V119, P1258, DOI 10.1002/lary.20239; Borges MS, 2001, ANN ALLERG ASTHMA IM, V87, P201, DOI 10.1016/S1081-1206(10)62226-0; BORISH L, 1994, HUM MOL GENET, V3, P1710, DOI 10.1093/hmg/3.9.1710-a; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919, DOI 10.1164/ajrccm.160.3.9812024; Cady RK, 2002, NEUROLOGY, V58, pS10, DOI 10.1212/WNL.58.9_suppl_6.S10; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Chan KO, 2008, J OTOLARYNGOL-HEAD N, V37, P870, DOI 10.2310/7070.2008.OA0195; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; Chen B, 2006, AM J RHINOL, V20, P325, DOI 10.2500/ajr.2006.20.2870; Chiu AG, 2004, CURR ALLERGY ASTHM R, V4, P486, DOI 10.1007/s11882-004-0016-2; Chiu AG, 2008, AM J RHINOL, V22, P34, DOI 10.2500/ajr.2008.22.3122; Cho SH, 2001, J ALLERGY CLIN IMMUN, V108, P212, DOI 10.1067/mai.2001.117260; Choi JH, 2004, HUM GENET, V114, P337, DOI 10.1007/s00439-004-1082-1; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Cormier C, 2009, J OTOLARYNGOL-HEAD N, V38, P133, DOI 10.2310/7070.2008.OA0220; Corrigan C, 2005, J ALLERGY CLIN IMMUN, V115, P316, DOI 10.1016/j.jaci.2004.10.051; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Cryer J, 2004, ORL-J OTO-RHIN-LARYN, V66, P155, DOI 10.1159/000079994; DAGHISTANI KJ, 1992, J LARYNGOL OTOL, V106, P799, DOI 10.1017/S0022215100120912; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Dahlen B, 2001, NEW ENGL J MED, V344, P142, DOI 10.1056/NEJM200101113440215; de Alarcon A, 2006, AM J RHINOL, V20, P545, DOI 10.2500/ajr.2006.20.2934; Denburg JA, 2008, CHEST, V134, P1037, DOI 10.1378/chest.08-0485; Desrosiers M, 2007, AM J RHINOL, V21, P527, DOI 10.2500/ajr.2007.21.3069; Early SB, 2007, J ALLERGY CLIN IMMUN, V119, pS243, DOI 10.1016/j.jaci.2006.12.320; Early SB, 2007, AM J RESP CELL MOL, V36, P715, DOI 10.1165/rcmb.2006-0252OC; Early SB, 2007, LARYNGOSCOPE, V117, P511, DOI 10.1097/MLG.0b013e31802e927b; Ebbens FA, 2006, J ALLERGY CLIN IMMUN, V118, P1149, DOI 10.1016/j.jaci.2006.07.058; ELOVIC A, 1994, J ALLERGY CLIN IMMUN, V93, P864, DOI 10.1016/0091-6749(94)90379-4; Endam LM, 2010, ARCH OTOLARYNGOL, V136, P187, DOI 10.1001/archoto.2009.219; Erbek SS, 2007, ARCH OTOLARYNGOL, V133, P705, DOI 10.1001/archotol.133.7.705; Fajardo-Dolci G, 2006, OTOLARYNG HEAD NECK, V135, P243, DOI 10.1016/j.otohns.2006.03.034; Feng CL, 2006, BLOOD, V107, P3243, DOI 10.1182/blood-2005-07-2772; Ferguson BJ, 2005, AM J RHINOL, V19, P452, DOI 10.1177/194589240501900506; Folker RJ, 1998, LARYNGOSCOPE, V108, P1623, DOI 10.1097/00005537-199811000-00007; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gwaltney JM, 2000, CLIN INFECT DIS, V30, P387, DOI 10.1086/313661; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; HAMILOS DL, 2001, ACI INT, V13, P27; HARTWIG S, 1988, J LARYNGOL OTOL, V102, P148, DOI 10.1017/S0022215100104372; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Huyett P, 2008, J ALLERGY CLIN IMMUN, V121, pS217, DOI 10.1016/j.jaci.2007.12.815; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; Kaliner MA, 1997, J ALLERGY CLIN IMMUN, V99, pS829, DOI 10.1016/S0091-6749(97)70041-1; Kanda N, 2001, J INVEST DERMATOL, V117, P1635, DOI 10.1046/j.0022-202x.2001.01566.x; Karjalainen J, 2003, ALLERGY, V58, P393, DOI 10.1034/j.1398-9995.2003.00118.x; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, pe1; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kawagishi Y, 2002, J ALLERGY CLIN IMMUN, V109, P936, DOI 10.1067/mai.2002.124466; Kellman RM, 2009, LARYNGOSCOPE, V119, P1682, DOI 10.1002/lary.20583; Kieff DA, 2005, ANN OTO RHINOL LARYN, V114, P941, DOI 10.1177/000348940511401209; Kim JW, 2007, OTOLARYNG HEAD NECK, V137, P925, DOI 10.1016/j.otohns.2007.07.036; Kim SH, 2005, ALLERGY, V60, P760, DOI 10.1111/j.1398-9995.2005.00780.x; Kosugi EM, 2009, RHINOLOGY, V47, P400, DOI 10.4193/Rhin08.226; Lee JY, 2010, AM J RHINOL ALLERGY, V24, pE83, DOI 10.2500/ajra.2010.24.3482; Lin SK, 2008, ARCH OTOLARYNGOL, V134, P522, DOI 10.1001/archotol.134.5.522; Lydiatt W M, 1994, Ear Nose Throat J, V73, P402; Maekawa A, 2008, P NATL ACAD SCI USA, V105, P16695, DOI 10.1073/pnas.0808993105; Marple BF, 1998, AM J RHINOL, V12, P263, DOI 10.2500/105065898781390037; Mascia K, 2005, ANN ALLERG ASTHMA IM, V94, P652, DOI 10.1016/S1081-1206(10)61323-3; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; Matsune S, 2003, ACTA OTO-LARYNGOL, V123, P519, DOI 10.1080/0036554021000028113; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Molnar-Gabor E, 2000, LARYNGOSCOPE, V110, P422, DOI 10.1097/00005537-200003000-00017; Mukherji SK, 1998, RADIOLOGY, V207, P417, DOI 10.1148/radiology.207.2.9577490; NASSER SMS, 1995, AM J RESP CRIT CARE, V151, P1326, DOI 10.1164/ajrccm.151.5.7735581; Nishijima I, 2009, ACTA OTO-LARYNGOL, V129, P110, DOI 10.1080/00016480902936919; Nonaka Y, 2005, BIOCHEM BIOPH RES CO, V337, P281, DOI 10.1016/j.bbrc.2005.09.052; Park SK, 2006, OTOLARYNG HEAD NECK, V135, P928, DOI 10.1016/j.otohns.2006.07.009; Paruchuri S, 2009, J EXP MED, V206, P2543, DOI 10.1084/jem.20091240; Payne SC, 2011, LARYNGOSCOP IN PRESS; Payne SC, 2008, AM J RHINOL, V22, P568, DOI 10.2500/ajr.2008.22.3233; Penn R, 2007, AM J RHINOL, V21, P428, DOI 10.2500/ajr.2007.21.3060; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Perry BF, 2004, OTOLARYNG HEAD NECK, V130, P449, DOI 10.1016/j.otohns.2004.01.005; Platts-Mills TAE, 2004, J ALLERGY CLIN IMMUN, V114, P1359, DOI 10.1016/j.jaci.2004.09.036; Polzehl D, 2006, ALLERGY, V61, P1275, DOI 10.1111/j.1398-9995.2006.01132.x; Ponikau JU, 2005, J ALLERGY CLIN IMMUN, V116, P362, DOI 10.1016/j.jaci.2005.03.049; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; Psaltis AJ, 2008, AM J RHINOL, V22, P1, DOI 10.2500/ajr.2008.22.3119; ROBSON JMB, 1989, AUST NZ J MED, V19, P351, DOI 10.1111/j.1445-5994.1989.tb00278.x; Rosenfeld RM, 2007, OTOLARYNG HEAD NECK, V137, pS1, DOI 10.1016/j.otohns.2007.06.726; Ryan Matthew W, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P18, DOI 10.1097/MOO.0b013e328013dbd9; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sanak M, 2000, AM J RESP CELL MOL, V23, P290, DOI 10.1165/ajrcmb.23.3.4051; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; Sanderson AR, 2006, LARYNGOSCOPE, V116, P1121, DOI 10.1097/01.mlg.0000221954.05467.54; Schmid M, 1999, ACTA OTO-LARYNGOL, V119, P277; Schubert MS, 2004, J ALLERGY CLIN IMMUN, V114, P1376, DOI 10.1016/j.jaci.2004.08.029; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P395, DOI 10.1016/S0091-6749(98)70126-5; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P387, DOI 10.1016/S0091-6749(98)70125-3; Seiberling K, 2009, AM J RHINOL ALLERGY, V23, P303, DOI 10.2500/ajra.2009.23.3315; Sejima T, 2011, AM J RHINOL ALLERGY, V25, P1, DOI 10.2500/ajra.2011.25.3537; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; Shimizu S, 2011, AM J RHINOL ALLERGY, V25, P7, DOI 10.2500/ajra.2011.25.3535; Shun CT, 2011, AM J RHINOL ALLERGY, V25, P15, DOI 10.2500/ajra.2011.25.3557; Singhal D, 2010, LARYNGOSCOPE, V120, P2528, DOI 10.1002/lary.21092; SLADEK K, 1994, AM J RESP CRIT CARE, V149, P940, DOI 10.1164/ajrccm.149.4.8143059; Slavin Raymond G, 2005, J Allergy Clin Immunol, V116, pS13, DOI 10.1016/j.jaci.2005.09.048; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; STAMMBERGER HR, 1995, ANN OTO RHINOL LARYN, V104, P7; Steinke JW, 2008, CURR OPIN ALLERGY CL, V8, P16, DOI 10.1097/ACI.0b013e3282f3f488; Steinke JW, 2006, CURR ALLERGY ASTHM R, V6, P495, DOI 10.1007/s11882-006-0027-2; Steinke JW, 2009, J ALLERGY CLIN IMMUN, V124, P1352, DOI 10.1016/j.jaci.2009.09.018; Steinke JW, 2009, J ALLERGY CLIN IMMUN, V124, P724, DOI 10.1016/j.jaci.2009.07.031; Steinke JW, 2004, IMMUNOL ALLERGY CLIN, V24, P45, DOI 10.1016/S0889-8561(03)00108-5; Steinke JW, 2003, J ALLERGY CLIN IMMUN, V111, P342, DOI 10.1067/mai.2003.67; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stevenson DD, 2003, CLIN REV ALLERG IMMU, V24, P159, DOI 10.1385/CRIAI:24:2:159; Suh JD, 2010, OTOLARYNG CLIN N AM, V43, P521, DOI 10.1016/j.otc.2010.02.010; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; Szczeklik A, 2000, THORAX, V55, pS42, DOI 10.1136/thorax.55.suppl_2.S42; Szczeklik A, 2000, ACI INT, V12, P171; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; Uren B, 2008, LARYNGOSCOPE, V118, P1677, DOI 10.1097/MLG.0b013e31817aec47; Vaidyanathan S, 2011, ANN INTERN MED, V154, P293, DOI 10.7326/0003-4819-154-5-201103010-00003; Vally H, 2002, THORAX, V57, P569, DOI 10.1136/thorax.57.7.569; Van Sambeek R, 2000, J ALLERGY CLIN IMMUN, V106, P72, DOI 10.1067/mai.2000.107603; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Vennera MD, 2010, THORAX; Weschta M, 2004, J ALLERGY CLIN IMMUN, V113, P1122, DOI 10.1016/j.jaci.2004.03.038; Yea SS, 2006, AM J RHINOL, V20, P550, DOI 10.2500/ajr.2006.20.2936; Ying S, 2006, J ALLERGY CLIN IMMUN, V117, P312, DOI 10.1016/j.jaci.2005.10.037; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008; Zhang Z, 2011, J ALLERGY CLIN IMMUN	147	52	55	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					710	722		10.1016/j.jaci.2011.05.022	http://dx.doi.org/10.1016/j.jaci.2011.05.022			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21704364				2022-12-18	WOS:000296538100002
J	Broide, DH; Finkelman, F; Bochner, BS; Rothenberg, ME				Broide, David H.; Finkelman, Fred; Bochner, Bruce S.; Rothenberg, Marc E.			Advances in mechanisms of asthma, allergy, and immunology in 2010	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic conjunctivitis; allergic inflammation; anaphylaxis; asthma; asthma genetics; atopic dermatitis; cytokines; eosinophils; food allergy; immediate hypersensitivity; mast cells; nasal polyposis; polymorphisms	T-CELLS; RECEPTOR; PATHWAY; POLYMORPHISMS; MEPOLIZUMAB; MEDI-563; ANTIBODY; IGE	2010 was marked by rapid progress in our understanding of the cellular and molecular mechanisms involved in the pathogenesis of allergic inflammation and asthma. Studies published in the Journal of Allergy and Clinical Immunology described advances in our knowledge of cells associated with allergic inflammation (mast cells, eosinophils, dendritic cells, and T cells), as well as IgE, cytokines, receptors, signaling molecules, and pathways. Studies used animal models, as well as human cells and tissues, to advance our understanding of mechanisms of asthma, eosinophilic esophagitis, food allergy, anaphylaxis and immediate hypersensitivity, mast cells and their disorders, atopic dermatitis, nasal polyposis, and hypereosinophilic syndromes. Additional studies provided novel information about the induction and regulation of allergic inflammation and the genetic contribution to allergic inflammation. Critical features of these studies and their potential effects on human atopic disorders are summarized here. (J Allergy Clin Immunol 2011;127:689-95.)	[Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Broide, David H.] Univ Calif San Diego, Dept Med, Sect Allergy & Immunol, La Jolla, CA 92093 USA; [Finkelman, Fred] Univ Cincinnati, Coll Med, Cincinnati Vet Affairs Med Ctr, Cincinnati, OH 45221 USA; [Finkelman, Fred] Univ Cincinnati, Coll Med, Div Immunol, Cincinnati, OH 45221 USA; [Finkelman, Fred] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; [Bochner, Bruce S.] Johns Hopkins Univ, Johns Hopkins Asthma & Allergy Ctr, Sch Med, Dept Med,Div Allergy & Clin Immunol, Baltimore, MD 21205 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Johns Hopkins University; Johns Hopkins Medicine	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, MLC 7028,3333 Burnet Ave, Cincinnati, OH 45229 USA.	rothenberg@chmcc.org		Broide, David/0000-0001-8405-9090	National Institutes of Health (NIH); Immune Tolerance Network; Abbott	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Immune Tolerance Network; Abbott(Abbott Laboratories)	D. H. Broide receives research support from the National Institutes of Health (NIH) and has a contract with the Immune Tolerance Network. F. Finkelman receives honoraria from Amgen and Abbott, receives research support from Abbott, and is the treasurer for the Federation of American Societies for Experimental Biology. M. E. Rothenberg has equity interest in a drug manufactured by Cephalon and is the treasurer of the International Eosinophil Society. B. S. Bochner has declared that he has no conflict of interest.	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035; Al-Samri MT, 2010, J ALLERGY CLIN IMMUN, V125, P1161, DOI 10.1016/j.jaci.2010.02.005; Asosingh K, 2010, J ALLERGY CLIN IMMUN, V125, P918, DOI 10.1016/j.jaci.2010.01.017; Basheer M, 2010, J ALLERGY CLIN IMMUN, V126, P1041, DOI 10.1016/j.jaci.2010.07.020; Bonnelykke K, 2010, J ALLERGY CLIN IMMUN, V126, P657, DOI 10.1016/j.jaci.2010.06.027; Bottema RWB, 2010, J ALLERGY CLIN IMMUN, V126, P338, DOI 10.1016/j.jaci.2010.04.024; Bottema RW, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P1237, DOI 10.1016/j.jaci.2010.04.005; Caldwell JM, 2010, J ALLERGY CLIN IMMUN, V125, P879, DOI 10.1016/j.jaci.2010.01.038; Chand HS, 2010, J ALLERGY CLIN IMMUN, V125, P1157, DOI 10.1016/j.jaci.2010.01.020; Conus S, 2010, J ALLERGY CLIN IMMUN, V126, P175, DOI 10.1016/j.jaci.2010.04.029; Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012; Crane MM, 2010, J ALLERGY CLIN IMMUN, V126, P179, DOI 10.1016/j.jaci.2010.03.035; Dua B, 2010, J ALLERGY CLIN IMMUN, V126, P133, DOI 10.1016/j.jaci.2010.04.006; Eckman JA, 2010, J ALLERGY CLIN IMMUN, V125, P889, DOI 10.1016/j.jaci.2009.09.012; Esser J, 2010, J ALLERGY CLIN IMMUN, V126, P1032, DOI 10.1016/j.jaci.2010.06.039; Hasegawa A, 2010, J ALLERGY CLIN IMMUN, V125, P461, DOI 10.1016/j.jaci.2009.09.016; Hassan M, 2010, J ALLERGY CLIN IMMUN, V125, P1037, DOI 10.1016/j.jaci.2010.02.031; Helbig G, 2010, J ALLERGY CLIN IMMUN, V125, P1399, DOI 10.1016/j.jaci.2010.02.024; HONG X, 2010, J ALLERGY CLIN IMMUN, V126, pE1; Hong XM, 2010, J ALLERGY CLIN IMMUN, V126, P1059, DOI 10.1016/j.jaci.2010.08.029; Hulse KE, 2010, J ALLERGY CLIN IMMUN, V125, P247, DOI 10.1016/j.jaci.2009.10.027; Kahn JE, 2010, J ALLERGY CLIN IMMUN, V125, P267, DOI 10.1016/j.jaci.2009.10.014; Kajiwara N, 2010, J ALLERGY CLIN IMMUN, V125, P1137, DOI 10.1016/j.jaci.2010.01.056; Kim S, 2010, J ALLERGY CLIN IMMUN, V125, P1336, DOI 10.1016/j.jaci.2010.03.028; Kirstein F, 2010, J ALLERGY CLIN IMMUN, V126, P347, DOI 10.1016/j.jaci.2010.04.028; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Konya V, 2010, J ALLERGY CLIN IMMUN, V125, P1105, DOI 10.1016/j.jaci.2009.12.002; Massanari M, 2010, J ALLERGY CLIN IMMUN, V125, P383, DOI 10.1016/j.jaci.2009.11.022; McMurchy AN, 2010, J ALLERGY CLIN IMMUN, V126, P1242, DOI 10.1016/j.jaci.2010.09.001; Milovanovic M, 2010, J ALLERGY CLIN IMMUN, V126, P1016, DOI 10.1016/j.jaci.2010.08.020; Munthe-Kaas MC, 2010, J ALLERGY CLIN IMMUN, V125, P1361, DOI 10.1016/j.jaci.2010.02.010; Mutschlechner S, 2010, J ALLERGY CLIN IMMUN, V125, P711, DOI 10.1016/j.jaci.2009.10.052; Nair P, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.032; Neves JS, 2010, J ALLERGY CLIN IMMUN, V125, P477, DOI 10.1016/j.jaci.2009.11.029; Niedoszytko M, 2010, J ALLERGY CLIN IMMUN, V125, P1092, DOI 10.1016/j.jaci.2010.01.021; Ohmatsu H, 2010, J ALLERGY CLIN IMMUN, V126, P1267, DOI 10.1016/j.jaci.2010.08.048; Osterfeld H, 2010, J ALLERGY CLIN IMMUN, V125, P469, DOI 10.1016/j.jaci.2009.09.054; Peters AT, 2010, J ALLERGY CLIN IMMUN, V125, P397, DOI 10.1016/j.jaci.2009.10.072; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Qi YL, 2010, J ALLERGY CLIN IMMUN, V126, P1260, DOI 10.1016/j.jaci.2010.08.040; Reefer AJ, 2010, J ALLERGY CLIN IMMUN, V126, P1049, DOI 10.1016/j.jaci.2010.07.023; Ring S, 2010, J ALLERGY CLIN IMMUN, V125, P237, DOI 10.1016/j.jaci.2009.10.025; Schouten B, 2010, J ALLERGY CLIN IMMUN, V125, P1308, DOI 10.1016/j.jaci.2010.02.039; Schroeder JT, 2010, J ALLERGY CLIN IMMUN, V125, P896, DOI 10.1016/j.jaci.2009.10.021; Semlali A, 2010, J ALLERGY CLIN IMMUN, V125, P844, DOI 10.1016/j.jaci.2010.01.044; Singh M, 2010, J ALLERGY CLIN IMMUN, V125, P1369, DOI 10.1016/j.jaci.2010.02.035; Sonkoly E, 2010, J ALLERGY CLIN IMMUN, V126, P581, DOI 10.1016/j.jaci.2010.05.045; Staevska M, 2010, J ALLERGY CLIN IMMUN, V125, P676, DOI 10.1016/j.jaci.2009.11.047; Suzuki M, 2010, J ALLERGY CLIN IMMUN, V125, P737, DOI 10.1016/j.jaci.2009.11.042; Tachdjian R, 2010, J ALLERGY CLIN IMMUN, V125, P1128, DOI 10.1016/j.jaci.2010.01.054; Wadsworth SJ, 2010, J ALLERGY CLIN IMMUN, V126, P366, DOI 10.1016/j.jaci.2010.05.015; Wang M, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Wang MQ, 2010, J ALLERGY CLIN IMMUN, V126, P306, DOI 10.1016/j.jaci.2010.05.017; Wise EL, 2010, J ALLERGY CLIN IMMUN, V126, P150, DOI 10.1016/j.jaci.2010.04.015; Zaba LC, 2010, J ALLERGY CLIN IMMUN, V125, P1261, DOI 10.1016/j.jaci.2010.03.018; Zaidi AK, 2010, J ALLERGY CLIN IMMUN, V125, P902, DOI 10.1016/j.jaci.2009.12.996	59	52	57	2	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					689	695		10.1016/j.jaci.2011.01.027	http://dx.doi.org/10.1016/j.jaci.2011.01.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21377038				2022-12-18	WOS:000288018400024
J	Burroughs, LM; Torgerson, TR; Storb, R; Carpenter, PA; Rawlings, DJ; Sanders, J; Scharenberg, AM; Skoda-Smith, S; Englund, J; Ochs, HD; Woolfrey, AE				Burroughs, Lauri M.; Torgerson, Troy R.; Storb, Rainer; Carpenter, Paul A.; Rawlings, David J.; Sanders, Jean; Scharenberg, Andrew M.; Skoda-Smith, Suzanne; Englund, Janet; Ochs, Hans D.; Woolfrey, Ann E.			Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hematopoietic cell transplantation; nonmyeloablative conditioning regimen; immunodeficiency; immune dysregulation; autoimmunity; regulatory T cells; immune reconstitution	VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; IPEX SYNDROME; T-CELLS; FOXP3 EXPRESSION; DIARRHEA	Background: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is characterized by severe systemic autoimmunity caused by mutations in the forkhead box protein 3 (FOXP3) gene. Hematopoietic cell transplantation is currently the only viable option for long-term survival, but patients are frequently very ill and may not tolerate traditional myeloablative conditioning regimens. Objective: Here we present the outcome of hematopoietic cell transplantation using a low-intensity, nonmyeloablative conditioning regimen in 2 patients with IPEX syndrome and significant pretransplant risk factors. Methods: Two high-risk patients with IPEX syndrome received HLA-matched related bone marrow or unrelated peripheral blood stem cell grafts following conditioning with 90 mg/m(2) fludarabine and 4 Gy total body irradiation. Postgrafting immunosuppression consisted of mycophenolate mofetil and cyclosporine. Immune reconstitution and immune function was evaluated by measurement of donor chimerism, regulatory T-cell numbers, absolute lymphocyte subsets, and T-cell proliferation assays. Results: Both patients experienced minimal conditioning toxicity and successfully engrafted after hematopoietic cell transplantation. With a follow-up of 4 and 1 years, respectively, patients 1 and 2 have full immune function and normal FOXP3 protein expression. Conclusion: A low-intensity, nonmyeloablative conditioning regimen can establish stable engraftment and correct the life-threatening immune deficiency and enteropathy of IPEX syndrome despite the presence of comorbidities that preclude conventional hematopoietic cell transplantation. (J Allergy Clin Immunol 2010;126:1000-5.)	[Burroughs, Lauri M.; Storb, Rainer; Carpenter, Paul A.; Sanders, Jean; Woolfrey, Ann E.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; [Burroughs, Lauri M.; Torgerson, Troy R.; Storb, Rainer; Carpenter, Paul A.; Rawlings, David J.; Sanders, Jean; Scharenberg, Andrew M.; Skoda-Smith, Suzanne; Englund, Janet; Ochs, Hans D.; Woolfrey, Ann E.] Univ Washington, Sch Med, Seattle, WA 98195 USA; [Torgerson, Troy R.; Rawlings, David J.; Scharenberg, Andrew M.; Skoda-Smith, Suzanne; Ochs, Hans D.] Seattle Childrens Res Inst, Seattle, WA USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Seattle Children's Hospital	Burroughs, LM (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D1-100, Seattle, WA 98109 USA.	lburroug@fhcrc.org	Rawlings, David/CAI-4751-2022		NIH, Bethesda, Md [HL36444, K23 HL085288, CA15704, K08-AI063267, N01-AI30070]; Immunodeficiency Foundation; Jeffrey Modell Foundation; National Institutes of Health; NATIONAL CANCER INSTITUTE [P30CA015704] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL085288, P01HL036444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI030070, K08AI063267] Funding Source: NIH RePORTER	NIH, Bethesda, Md(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Immunodeficiency Foundation; Jeffrey Modell Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by grants HL36444, K23 HL085288, CA15704, K08-AI063267, and N01-AI30070 from the NIH, Bethesda, Md, and grants from the Immunodeficiency Foundation and the Jeffrey Modell Foundation.; H. D. Ochs has received research support from the National Institutes of Health and the Jeffrey Modell Foundation. The rest of the authors have declared that they have no conflict of interest.	Baud O, 2001, NEW ENGL J MED, V344, P1758, DOI 10.1056/NEJM200106073442304; Bennett CL, 2000, AM J HUM GENET, V66, P461, DOI 10.1086/302761; Boeckh M, 1996, BLOOD, V88, P4063, DOI 10.1182/blood.V88.10.4063.bloodjournal88104063; Burroughs LM, 2007, BONE MARROW TRANSPL, V40, P633, DOI 10.1038/sj.bmt.1705778; den Dunnen JT, 2001, HUM GENET, V109, P121, DOI 10.1007/s004390100505; Dorsey MJ, 2009, IMMUNOL RES, V44, P179, DOI 10.1007/s12026-009-8112-y; Filipovich AH, 2005, BIOL BLOOD MARROW TR, V11, P945, DOI 10.1016/j.bbmt.2005.09.004; FLETCHER MA, 1997, CLIN DIAGNOSIS MANAG, P313; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95; Kobayashi I, 2001, J MED GENET, V38, P874, DOI 10.1136/jmg.38.12.874; Mazzolari E, 2005, BONE MARROW TRANSPL, V35, P1033, DOI 10.1038/sj.bmt.1704954; Mielcarek M, 2003, BLOOD, V102, P756, DOI 10.1182/blood-2002-08-2628; Niederwieser D, 2003, BLOOD, V101, P1620, DOI 10.1182/blood-2002-05-1340; POWELL BR, 1982, J PEDIATR-US, V100, P731, DOI 10.1016/S0022-3476(82)80573-8; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Rao A, 2007, BLOOD, V109, P383, DOI 10.1182/blood-2006-05-025072; Rezvani AR, 2008, J CLIN ONCOL, V26, P211, DOI 10.1200/JCO.2007.11.5477; Seidel MG, 2009, BLOOD, V113, P5689, DOI 10.1182/blood-2009-02-206359; Sorror ML, 2005, J CLIN ONCOL, V23, P3819, DOI 10.1200/JCO.2005.04.569; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P250; Taddio A, 2007, EUR J PEDIATR, V166, P1195, DOI 10.1007/s00431-006-0395-6; Wildin RS, 2002, J MED GENET, V39, P537, DOI 10.1136/jmg.39.8.537; Zhan H, 2008, PEDIATRICS, V121, pE998, DOI 10.1542/peds.2007-1863	26	52	54	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					1000	1005		10.1016/j.jaci.2010.05.021	http://dx.doi.org/10.1016/j.jaci.2010.05.021			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20643476	Bronze, Green Accepted			2022-12-18	WOS:000283727100016
J	Magerl, M; Staubach, P; Altrichter, S; Ardelean, E; Krause, K; Metz, M; Weller, K; Maurer, M				Magerl, Markus; Staubach, Petra; Altrichter, Sabine; Ardelean, Elena; Krause, Karoline; Metz, Martin; Weller, Karsten; Maurer, Marcus			Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Magerl, Markus; Altrichter, Sabine; Ardelean, Elena; Krause, Karoline; Metz, Martin; Weller, Karsten; Maurer, Marcus] Charite, Allergie Ctr Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany; [Staubach, Petra] Univ Med Mainz, Dept Dermatol, Mainz, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johannes Gutenberg University of Mainz	Magerl, M (corresponding author), Charite, Allergie Ctr Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany.	marcus.maurer@charite.de	Krause, Karoline/G-5218-2018; Magerl, Markus/ABI-5335-2020; Metz, Martin/B-8799-2009; Maurer, Marcus/ABG-2174-2020; Metz, Martin/M-5237-2013	Krause, Karoline/0000-0001-9711-9654; Magerl, Markus/0000-0001-9218-5468; Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X; Metz, Martin/0000-0002-4070-9976; Altrichter, Sabine/0000-0001-9955-385X; Weller, Karsten/0000-0003-4437-0313				BARLOW RJ, 1993, EUR J DERMATOL, V3, P273; Gaig P, 2004, J INVEST ALLERG CLIN, V14, P214; Kaplan AP, 2008, J ALLERGY CLIN IMMUN, V122, P569, DOI 10.1016/j.jaci.2008.07.006; Kaplan AP, 2004, J ALLERGY CLIN IMMUN, V114, P465, DOI 10.1016/j.jaci.2004.02.049; Maurer M, 2009, BRIT J DERMATOL, V160, P633, DOI 10.1111/j.1365-2133.2008.08920.x; Mlynek A, 2008, ALLERGY, V63, P777, DOI 10.1111/j.1398-9995.2008.01726.x; Scheinfeld Noah, 2005, Dermatol Online J, V11, P2; Sox HC, 2009, ANN INTERN MED, V151, P203, DOI 10.7326/0003-4819-151-3-200908040-00125; Spector SL, 2009, J ALLERGY CLIN IMMUN, V123, P273, DOI 10.1016/j.jaci.2008.07.033; Zuberbier T, 2009, ALLERGY, V64, P1427, DOI 10.1111/j.1398-9995.2009.02178.x; Zuberbier T, 2009, ALLERGY, V64, P1417, DOI 10.1111/j.1398-9995.2009.02179.x	11	52	52	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					665	666		10.1016/j.jaci.2010.05.047	http://dx.doi.org/10.1016/j.jaci.2010.05.047			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20673981				2022-12-18	WOS:000281512500039
J	Chawes, BLK; Edwards, MJ; Shamji, B; Walker, C; Nicholson, GC; Tan, AJ; Folsgaard, NV; Bonnelykke, K; Bisgaard, H; Hansel, TT				Chawes, Bo L. K.; Edwards, Matthew J.; Shamji, Betty; Walker, Christoph; Nicholson, Grant C.; Tan, Andrew J.; Folsgaard, Nilofar V.; Bonnelykke, Klaus; Bisgaard, Hans; Hansel, Trevor T.			A novel method for assessing unchallenged levels of mediators in nasal epithelial lining fluid	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA		[Chawes, Bo L. K.; Folsgaard, Nilofar V.; Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen, Danish Pediat Asthma Ctr, Copenhagen Prospect Studies Asthma Childhood, Copenhagen, Denmark; [Chawes, Bo L. K.; Folsgaard, Nilofar V.; Bonnelykke, Klaus; Bisgaard, Hans] Copenhagen Univ Hosp, Copenhagen, Denmark; [Edwards, Matthew J.; Shamji, Betty; Walker, Christoph] Novartis Horsham Res Ctr, Horsham, W Sussex, England; [Nicholson, Grant C.; Tan, Andrew J.; Hansel, Trevor T.] St Marys Hosp, Imperial Clin Resp Res Unit, London, England	University of Copenhagen; University of Copenhagen; Novartis; Imperial College London	Chawes, BLK (corresponding author), Univ Copenhagen, Danish Pediat Asthma Ctr, Copenhagen Prospect Studies Asthma Childhood, Copenhagen, Denmark.	t.hansel@imperial.ac.uk	Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592; Nicholson, Grant/0000-0001-8724-6115; Bonnelykke, Klaus/0000-0003-2003-1018; Chawes, Bo/0000-0001-6846-6243	Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden)		ALAM R, 1992, J IMMUNOL METHODS, V155, P25, DOI 10.1016/0022-1759(92)90267-W; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; BISGAARD H, 1988, ALLERGY, V43, P219; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Chawes BLK, 2009, ALLERGY, V64, P1547, DOI 10.1111/j.1398-9995.2009.02085.x; DEJONCHEERE CP, 2006, EJHP SCI, V12, P7; Howarth Peter H, 2005, J Allergy Clin Immunol, V115, pS414, DOI 10.1016/j.jaci.2004.12.1134; Ishizaka A, 2001, CRIT CARE MED, V29, P896, DOI 10.1097/00003246-200104000-00043	9	52	53	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1387	1389		10.1016/j.jaci.2010.01.039	http://dx.doi.org/10.1016/j.jaci.2010.01.039			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20304470				2022-12-18	WOS:000278831000029
J	Pavord, ID; Jeffery, PK; Qiu, Y; Zhu, J; Parker, D; Carlsheirner, A; Naya, I; Barnes, NC				Pavord, Ian D.; Jeffery, Peter K.; Qiu, Yusheng; Zhu, Jie; Parker, Debbie; Carlsheirner, Asa; Naya, Ian; Barnes, Neil C.			Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; induced sputum; bronchial biopsy; eosinophils; airway remodeling; inflammation	RELIEVER THERAPY; BASEMENT-MEMBRANE; SINGLE INHALER; LONG-TERM; MAINTENANCE; BUDESONIDE; EXACERBATIONS; EOSINOPHILS; MODERATE; HYPERRESPONSIVENESS	Background: Budesonide/formoterol maintenance and reliever therapy maintains asthma control and reduces exacerbation frequency compared with higher fixed-dose combination regimens. Its effects on eosinophilic airway inflammation and structure are unknown. Objective: We sought to compare the effects of budesonide/formoterol 200/6 mu g twice daily plus as-needed with budesonide/formoterol 800/12 mu g twice daily on airway eosinophils and remodeling. Methods: This 52-week, parallel-group, randomized, double-blind study of 127 asthma patients who were symptomatic despite therapy compared (1) the change between induced sputum percent eosinophils at baseline and the geometric mean of 4 on-treatment values and (2) the change in endobronchial biopsy eosinophil counts pre- and post-treatment. Results: Mean daily doses of budesonide/formoterol were 604/18 mu g in the maintenance and reliever therapy group and 1,600/24 mu g in the high fixed-dose group. In the former, the geometric mean percent sputum eosinophils remained unchanged (1.6% to 1.9%), whereas biopsy specimen subepithelial eosinophils increased (6.2 to 12.3 cells/mm(2)). Sputum and biopsy eosinophil counts decreased with high fixed-dose treatment (2.2% to 1.2% and 7.7 to 4.8 cells/mm(2), respectively), resulting in significant treatment differences of 0.7% (ratio, 1.8; 95% CI, 1.2-2.8; P = .0038) and 7.5 cells/mm(2) (ratio, 2.9; 95% CI, 1.6-5.3; P < .001), respectively. There were no between-treatment differences in reticular basement membrane thickness, exhaled nitric oxide, exacerbation frequency, or FEV1. Conclusion: Compared with fixed-dose combination treatment containing a 4-fold higher maintenance dose of budesonide, budesonide/formoterol maintenance and reliever therapy is associated with higher eosinophil counts, but these remain within the range associated with stable clinical control. (J Allergy Clin Immunol 2009;123:1083-9.)	[Pavord, Ian D.; Parker, Debbie] Univ Hosp Leicester NHS Trust, Dept Resp Med, Glenfield Hosp, Inst Lung Hlth, Leicester LE3 9QP, Leics, England; [Jeffery, Peter K.; Qiu, Yusheng; Zhu, Jie] Univ London Imperial Coll Sci Technol & Med, Dept Gene Therapy, Lung Pathol Unit, Royal Brompton Hosp, London SW7 2AZ, England; [Carlsheirner, Asa] AstraZeneca Res & Dev, Lund, Sweden; [Barnes, Neil C.] London Chest Hosp, Dept Resp Med, London, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Imperial College London; Royal Brompton Hospital; AstraZeneca; University of London; Queen Mary University London	Pavord, ID (corresponding author), Univ Hosp Leicester NHS Trust, Dept Resp Med, Glenfield Hosp, Inst Lung Hlth, Groby Rd, Leicester LE3 9QP, Leics, England.	ian.pavord@uhl-tr.nhs.uk		Pavord, Ian/0000-0002-4288-5973	AstraZeneca, Lund, Sweden; GlaxoSmithKline; Merck Sharpe Dohme; Merck; Boehringer Ingelheim	AstraZeneca, Lund, Sweden(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Merck Sharpe Dohme(Merck & Company); Merck(Merck & Company); Boehringer Ingelheim(Boehringer Ingelheim)	Supported by AstraZeneca, Lund, Sweden.; Disclosure of potential conflict of interest: I. D. Pavord received lecture fees from GlaxoSmithKline and AstraZeneca, received grant support from GlaxoSmithKline, and is a medical advisor for Asthma UK. P. K. Jeffery has received support from GlaxoSmithKline, AstraZeneca. and Merck Sharpe & Dohme to attend conferences: has participated as a paid speaker in scientific meetings and courses organized and financed by various pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, Merck, and Boehringer Ingelheim; hits served as it consultant for GlaxoSmithKline, AstraZeneca, and Novartis; owns shares in GlaxoSmithKline received grant support from GlaxoSmithKline, AstraZeneca. and Merck; and sits on the advisory board on behalf of GlaxoSmithKline. A. Carlsheimer and I. Naya are employed by AstraZeneca with stock ownership in the company. N. C. Barnes has lectured for, or received consulting fees from GlaxoSmithKline, AstraZeneca, Altana, Merck Genetics, Chiesi, and TEVA and has received grant support from GlaxoSmithKline and AstraZeneca. The rest of the authors have declared that they have no conflict of interest.	[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429; Bisgaard H, 2006, CHEST, V130, P1733, DOI 10.1378/chest.130.6.1733; Bousquet J, 2007, RESP MED, V101, P2437, DOI 10.1016/j.rmed.2007.07.014; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; *GINA, 2002, PUBL GINA; Green RH, 2006, EUR RESPIR J, V27, P1144, DOI 10.1183/09031936.06.00102605; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; James AL, 2007, EUR RESPIR J, V30, P134, DOI 10.1183/09031936.00146905; James AL, 2002, AM J RESP CRIT CARE, V166, P1590, DOI 10.1164/rccm.2108069; Jarjour NN, 2006, J ALLERGY CLIN IMMUN, V118, P44, DOI 10.1016/j.jaci.2006.03.043; Jatakanon A, 1999, THORAX, V54, P108, DOI 10.1136/thx.54.2.108; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Kariyawasam HH, 2007, CURR OPIN IMMUNOL, V19, P681, DOI 10.1016/j.coi.2007.07.021; Kips JC, 2000, AM J RESP CRIT CARE, V161, P996, DOI 10.1164/ajrccm.161.3.9812056; Kuna P, 2007, INT J CLIN PRACT, V61, P725, DOI 10.1111/j.1742-1241.2007.01338.x; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406, DOI 10.1164/ajrccm.163.2.9912091; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Pizzichini MMM, 1999, EUR RESPIR J, V13, P15, DOI 10.1183/09031936.99.13101599; Poynter ME, 2004, J IMMUNOL, V173, P7003, DOI 10.4049/jimmunol.173.11.7003; Qiu YS, 2007, THORAX, V62, P475, DOI 10.1136/thx.2006.066670; Rabe KF, 2006, CHEST, V129, P246, DOI 10.1378/chest.129.2.246; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Scicchitano R, 2004, CURR MED RES OPIN, V20, P1403, DOI 10.1185/030079904X2051; Sears MR, 2008, EUR RESPIR J, V31, P982, DOI 10.1183/09031936.00104007; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Tattersfield AE, 1999, THORAX, V54, P753, DOI 10.1136/thx.54.9.753; van Veen IH, 2008, EUR RESPIR J, V32, P344, DOI 10.1183/09031936.00135907; Vogelmeier C, 2005, EUR RESPIR J, V26, P819, DOI 10.1183/09031936.05.00028305	33	52	57	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1083	1089		10.1016/j.jaci.2009.02.034	http://dx.doi.org/10.1016/j.jaci.2009.02.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19368965	Bronze			2022-12-18	WOS:000266309400016
J	Brandt, EB; Munitz, A; Orekov, T; Mingler, MK; McBride, M; Finkelman, FD; Rothenberg, ME				Brandt, Eric B.; Munitz, Ariel; Orekov, Tatyana; Mingler, Melissa K.; McBride, Melissa; Finkelman, Fred D.; Rothenberg, Marc E.			Targeting IL-4/IL-13 signaling to alleviate oral allergen-induced diarrhea	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; anaphylaxis; IL-4; IL-13; IL-13R alpha 1; intestine; mast cell	IL-13 RECEPTOR-ALPHA-1; NEMATODE PARASITES; CELL DEVELOPMENT; FOOD ALLERGY; MICE LACKING; MAST-CELLS; T-CELLS; B-CELLS; INTERLEUKIN-13; IGE	Background: Intestinal anaphylaxis (manifested by acute diarrhea) is dependent on IgE and mast cells. Objective: We aimed to define the respective roles of IL-4 and IL-13 and their receptors in disease pathogenesis. Methods: Wild-type mice and mice deficient in IL-4, IL-43, and IL-13 receptor (IL-13R) alpha 1 (part of the type 2 IL-4 receptor [11,411]) were sensitized with ovalbumin (OVA)/aluminum potassium sulfate and subsequently given repeated intragastric OVA exposures. The IL-4R alpha chain was targeted with anti IL-4R alpha mAb before or after intragastric OVA exposures. Results: IL4(-/-) (and IL4/IL3(-/-)) mice produced almost no IgE and were highly resistant to OVA-induced diarrhea, whereas allergic diarrhea was only partially impaired in IL13(-/-) and IL13R alpha 1(-/-) mice. IL13R alpha 1-deficient mice had decreased IgE levels, despite having normal baseline IL-4 levels. Intestinal mast cell accumulation and activation also depended mainly on IL-4 and, to a lesser extent, on IL-13. Prophylactic anti-IL4R alpha mAb treatment, which blocks all IL-4 and IL-13 signaling, suppressed development of allergic diarrhea. However, treatment with anti-IL-4R alpha mAb for 7 days only partially suppressed IgE and did not prevent intestinal diarrhea. Conclusion: Endogenously produced IL-13 supplements the ability of IL-4 to induce allergic diarrhea by promoting oral allergen sensitization rather than the effector phase of intestinal anaphylaxis. (J Allergy Clin Immunol 2009;123:53-8.)	[Orekov, Tatyana; Finkelman, Fred D.] Cincinnati Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; [Rothenberg, Marc E.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Div Immunol, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org		Brandt, Eric/0000-0003-0617-4100	National Institutes of Health [AI45999-05]; Campaign Urging Research for Eosinophilic Diseases (CURFD); Food Allergy Project; US Department of Veterans Affairs; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI045898, R01AI045898] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Campaign Urging Research for Eosinophilic Diseases (CURFD); Food Allergy Project; US Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by National Institutes of Health grant AI45999-05, the Campaign Urging Research for Eosinophilic Diseases (CURFD), the Food Allergy Project, and the US Department of Veterans Affairs.	Akiho H, 2005, AM J PHYSIOL-GASTR L, V288, pG609, DOI 10.1152/ajpgi.00273.2004; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Chehade M, 2007, CURR OPIN ALLERGY CL, V7, P264, DOI 10.1097/ACI.0b013e32814a5607; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Finkelman FD, 2004, IMMUNOL REV, V201, P139, DOI 10.1111/j.0105-2896.2004.00192.x; Finkelman Fred, 2003, Curr Protoc Immunol, VChapter 6, DOI 10.1002/0471142735.im0628s54; Fish SC, 2005, J IMMUNOL, V174, P7716, DOI 10.4049/jimmunol.174.12.7716; Grunewald SM, 2001, INT ARCH ALLERGY IMM, V125, P322, DOI 10.1159/000053833; Guo LY, 2001, NAT IMMUNOL, V2, P461, DOI 10.1038/87778; Hu ZQ, 2007, CURR MED CHEM, V14, P3044, DOI 10.2174/092986707782793998; Knackmuss S, 2007, BIOL CHEM, V388, P325, DOI 10.1515/BC.2007.036; Knight AK, 2007, AM J PHYSIOL-GASTR L, V293, pG1234, DOI 10.1152/ajpgi.00323.2007; Knippels LMJ, 2004, CURR OPIN ALLERGY CL, V4, P205, DOI 10.1097/01.all.0000129452.96597.c1; Kweon MN, 2000, J CLIN INVEST, V106, P199, DOI 10.1172/JCI8490; Lai YH, 1999, J IMMUNOL, V162, P78; Madden KB, 2002, J IMMUNOL, V169, P4417, DOI 10.4049/jimmunol.169.8.4417; McCoy KD, 2006, IMMUNITY, V24, P329, DOI 10.1016/j.immuni.2006.01.013; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; Munitz A, 2008, P NATL ACAD SCI USA, V105, P7240, DOI 10.1073/pnas.0802465105; Ramalingam TR, 2008, NAT IMMUNOL, V9, P25, DOI 10.1038/ni1544; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Urban JF, 2001, J IMMUNOL, V167, P6078, DOI 10.4049/jimmunol.167.11.6078; Webb DC, 2007, J IMMUNOL, V178, P219, DOI 10.4049/jimmunol.178.1.219; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wood N, 2003, J EXP MED, V197, P703, DOI 10.1084/jem.20020906; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Zdanov A, 2008, CELL, V132, P179, DOI 10.1016/j.cell.2008.01.006; Zhao AP, 2003, J IMMUNOL, V171, P948, DOI 10.4049/jimmunol.171.2.948; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	32	52	53	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					53	58		10.1016/j.jaci.2008.10.001	http://dx.doi.org/10.1016/j.jaci.2008.10.001			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	18996576	Green Accepted			2022-12-18	WOS:000262793900008
J	Nicolaou, NC; Simpson, A; Lowe, LA; Murray, CS; Woodcock, A; Custovic, A				Nicolaou, Nicolaos C.; Simpson, Angela; Lowe, Lesley A.; Murray, Clare S.; Woodcock, Ashley; Custovic, Adnan			Day-care attendance, position in sibship, and early childhood wheezing: A population-based birth cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						day-care; siblings; wheezing; birth cohort	RESPIRATORY-INFECTIONS; RISK-FACTORS; EARLY-LIFE; ASTHMA; SYMPTOMS; AGE; PREVALENCE; ALLERGY; ATOPY; ENDOTOXIN	Background: There are conflicting data on the effect of day-care attendance and position in sibship on the development of wheezing. Objective: To investigate the relationship between day-care attendance and position in sibship with early childhood wheeze. Methods: Prospective population-based birth cohort. At age 5 years, we collected information on parentally reported symptoms (n = 922); lung function was ascertained using plethysmography (n = 745) and allergic sensitization by skin testing (n = 815). Participants were assigned into categories according to the age of entry to day-care (0-6, 6-12, >12 mo) and number of older siblings (0, 1, 2, >2). Results: Current wheeze was reported by 203 participants (22%); 224 (28%) were sensitized. In the multivariate model, sensitization (odds ratio, 2.47; 95% CI, 1.66-3.67), male sex (1.49, 1.01-2.20), maternal asthma (1.72, 1.10-2.68), and maternal smoking during pregnancy (2.15, 1.26-3.66) significantly increased the risk of wheezing. Entering day-care between 6 and 12 or after 12 months of age was significantly and inversely associated with current wheeze (0.25, 0.11-0.60; and 0.65, 0.44-0.98, respectively). Entry into nursery between 6 and 12 months reduced the risk of persistent wheezing (P =.04). We found no association between day-care attendance and lung function. Entering nursery in the first 6 months of life was associated with increased risk of atopy (2.47, 1.23-4.95). Having older siblings was associated only with rhinoconjunctivitis (0.72, 0.54-0.97). Conclusion: Day-care attendance was associated with a reduced risk of current wheezing in 5-year-old children. The protective effect appeared strongest for children who entered day-care between the ages of 6 and 12 months.	[Nicolaou, Nicolaos C.; Simpson, Angela; Lowe, Lesley A.; Murray, Clare S.; Woodcock, Ashley; Custovic, Adnan] Univ Manchester, Univ S Manchester Hosp, Natl Hlth Serv Fdn Trust, Sch Translat Med, Manchester M13 9PL, Lancs, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Nicolaou, NC (corresponding author), Wythenshawe Hosp, N W Lung Ctr, Manchester M23 9LT, Lancs, England.	Nicolaos.Nicolaou@postgrad.manchester.ac.uk	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Simpson, Angela/0000-0003-2733-6666; Woodcock, Ashley/0000-0002-5428-8578; Murray, Clare/0000-0002-8961-8055	Medical Research Council; Moulton Charitable Trust; Asthma UK	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Moulton Charitable Trust; Asthma UK	A. Simpson receives grant support front the Medical Research Council UK, the Moulton Charitable Trust, Asthma UK. and the Grand Charity. C. S. Murray receives grant support from the Medical Research Council UK, the Moulton Charitable Trust. Asthma UK, the Grand Charity, GiaxoSmithKline, and Pharmaxis. A. Woodcock is a consultant for GiaxoSmithKline, Chiesi Pharmaceuticals, and Schering-Plough and receives grant support front the Medical Research Council UK, the Moulton Charitable Trust. Asthma UK, the Grand Charity, Schering-Plough, GlaxoSmith Kline, and Cambridge Antibody. A. Custovic is on the speakers' bureau for GlaxoSmithKline, AstraZeneca, Phadia. and ALK-Abello: is on the advisory board for GlaxoSrnithKline, ALK-Abello, and UCB Institute of Allergy and receives grant support from the Medical Research Council, the Moulton Charitable Trust. and Asthma UK. The rest of the authors have declared that they have no conflict of interest.	ALEXANDER CS, 1990, AM J EPIDEMIOL, V131, P124, DOI 10.1093/oxfordjournals.aje.a115465; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Asher MI, 1998, EUR RESPIR J, V12, P315; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Brady MT, 2005, AM J INFECT CONTROL, V33, P276, DOI 10.1016/j.ajic.2004.11.007; Butland BK, 2006, THORAX, V61, P383, DOI 10.1136/thx.2005.043646; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; CLEMENS S, 2005, CHILDCARE EARLY YEAR; Custovic A, 2004, PEDIATR PULM, P12, DOI 10.1002/ppul.70033; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Custovic A, 2006, PAEDIATR RESPIR REV, V7, pS90, DOI 10.1016/j.prrv.2006.04.164; de Meer G, 2005, ALLERGY, V60, P619, DOI 10.1111/j.1398-9995.2005.00746.x; DENNY FW, 1986, REV INFECT DIS, V8, P527; Devenny A, 2004, BMJ-BRIT MED J, V329, P489, DOI 10.1136/bmj.38139.666447.F7; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Haby MM, 2000, PEDIATR PULM, V30, P377, DOI 10.1002/1099-0496(200011)30:5<377::AID-PPUL3>3.0.CO;2-3; Hagerhed-Engman L, 2006, ALLERGY, V61, P447, DOI 10.1111/j.1398-9995.2006.01031.x; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Infante-Rivard C, 2001, AM J EPIDEMIOL, V153, P653, DOI 10.1093/aje/153.7.653; Instanes C, 2005, INDOOR AIR, V15, P356, DOI 10.1111/j.1600-0668.2005.00381.x; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; Lewis David B, 2006, Curr Probl Pediatr Adolesc Health Care, V36, P189, DOI 10.1016/j.cppeds.2005.11.001; Linehan MF, 2005, ARCH DIS CHILD, V90, P516, DOI 10.1136/adc.2004.061879; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; Lu N, 2004, CHILD CARE HLTH DEV, V30, P361, DOI 10.1111/j.1365-2214.2004.00411.x; Marbury MC, 1997, AM J RESP CRIT CARE, V155, P156, DOI 10.1164/ajrccm.155.1.9001305; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Nafstad P, 2005, PEDIATRICS, V116, pE255, DOI 10.1542/peds.2004-2785; PEARCE N, 1993, EUR RESPIR J, V6, P1455; Rullo VEV, 2002, J ALLERGY CLIN IMMUN, V110, P582, DOI 10.1067/mai.2002.127511; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617, DOI 10.1164/ajrccm.160.5.9811002; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; von Mutius E, 2002, J ALLERGY CLIN IMMUN, V109, pS525, DOI 10.1067/mai.2002.124565; von Mutius E, 2001, EUR RESPIR J, V18, P872, DOI 10.1183/09031936.01.00268401; WALD ER, 1991, J PEDIATR-US, V118, P509, DOI 10.1016/S0022-3476(05)83370-0	39	52	53	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					500	506		10.1016/j.jaci.2008.06.033	http://dx.doi.org/10.1016/j.jaci.2008.06.033			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18774386	Bronze			2022-12-18	WOS:000259234000009
J	Casolaro, V; Fang, X; Tancowny, B; Fan, JS; Wu, F; Srikantan, S; Asaki, SY; De Fani, U; Huang, SK; Gorospe, M; Atasoy, UX; Stellato, C				Casolaro, Vincenzo; Fang, Xi; Tancowny, Brian; Fan, Jinshui; Wu, Fan; Srikantan, Subramanya; Asaki, S. Yukiko; De Fani, Umberto; Huang, Shau-Ku; Gorospe, Myriam; Atasoy, Ulus X.; Stellato, Cristiana			Posttranscriptional regulation of IL-13 in T cells: Role of the RNA-binding protein HuR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inflammation; mRAA turnover; posttranscriptional gene regulation; RNA-binding proteins; IL-13; T(H)2 cytokines; T cells	INTERLEUKIN-2 MESSENGER-RNA; GENE-EXPRESSION; RICH ELEMENT; 3'-UNTRANSLATED REGION; TNF-ALPHA; STABILIZATION; STABILITY; INVOLVEMENT; ACTIVATION; TURNOVER	Background: IL-13, a critical cytokine in allergy, is regulated by as-yet-elusive mechanisms. Objective: We investigated IL-13 posttranscriptional regulation by HuR, a protein associating with adenylate-uridylate-rich elements in the 3' untranslated regions (UTRs) of mRNA, promoting mRNA stability and translation. Methods: IL-13 mRNA decay was monitored in human T(H)2-skewed cells by using the transcriptional inhibitor actinomycin D. The IL-13 3'UTR was subcloned into an inducible beta-globin reporter transiently expressed in H2 cells in the absence or presence of overexpressed HuR. Association of HuR with IL-13 mRNA was detected by means of immunoprecipitation of ribonucleoprotein complexes and a biotin pull-down assay. The effects of HuR transient overexpression and silencing on IL-13 expression were investigated. Results: IL-13 mRNA half-life increased significantly in restimulated T(H)2-skewed cells compared with baseline values. Decay of beta-globin mRNA was significantly faster in H2 cells transfected with the IL-13 3'UTR-containing plasmid than in those carrying a control vector. HuR overexpression increased the beta-globin IL-13 3'-UTR reporter half-life. Significant enrichment of IL-13 mRNA was produced by means of immunoprecipitation of Jurkat cell ribonucleoprotein complexes with anti-HuR. HuR binding to the IL-13 3'UTR was confirmed by means of pull-down assay of biotin-labeled RNA probes spanning the IL-13 3'UTR. Two-dimensional Western blot analysis showed stimulus-induced posttranslational modification of HuR. In Jurkat cells mitogen-induced IL-13 mRNA was significantly affected by HuR overexpression and silencing. Conclusions: Mitogen-induced IL-13 expression involves changes in transcript turnover and a change in phosphorylation of HuR and its association with the mRNA 3'UTR.	[Casolaro, Vincenzo; Fang, Xi; Tancowny, Brian; Fan, Jinshui; Wu, Fan; Asaki, S. Yukiko; De Fani, Umberto; Huang, Shau-Ku; Stellato, Cristiana] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Atasoy, Ulus X.] Univ Missouri, Columbia, MO 65211 USA; [Srikantan, Subramanya; Gorospe, Myriam] NIH, NIA, Baltimore, MD USA	Johns Hopkins University; University of Missouri System; University of Missouri Columbia; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Stellato, C (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	stellato@jhmi.edu	Stellato, Cristiana/P-3001-2015; Casolaro, Vincenzo/E-9144-2010; Huang, Shau-Ku/F-5509-2010	Stellato, Cristiana/0000-0002-1294-8355; Casolaro, Vincenzo/0000-0001-9810-0488; srikantan, subramanya/0000-0003-1810-6519	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060990, R01AI041463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000511] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI041463-07, R01 AI041463-10, R01 AI041463-09, R01 AI060990, R01 AI041463, R01 AI041463-08, R01 AI041463-06A2] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Atasoy U, 2003, J IMMUNOL, V171, P4369, DOI 10.4049/jimmunol.171.8.4369; Atasoy U, 1998, J CELL SCI, V111, P3145; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Butler NS, 2002, J IMMUNOL, V169, P3700, DOI 10.4049/jimmunol.169.7.3700; Cheadle C, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-75; Chen CY, 2000, GENE DEV, V14, P1236; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; De Fanis U, 2007, BLOOD, V109, P4343, DOI 10.1182/blood-2006-05-025940; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Doller A, 2007, MOL BIOL CELL, V18, P2137, DOI 10.1091/mbc.E06-09-0850; Esnault S, 2001, J IMMUNOL, V166, P4658, DOI 10.4049/jimmunol.166.7.4658; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Hamshere M, 2000, GENOMICS, V63, P425, DOI 10.1006/geno.1999.6075; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Katsanou V, 2005, MOL CELL, V19, P777, DOI 10.1016/j.molcel.2005.08.007; Keen JC, 2006, IMMUNOLOGY, V117, P29, DOI 10.1111/j.1365-2567.2005.02260.x; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Kishikawa H, 2001, J IMMUNOL, V167, P4414, DOI 10.4049/jimmunol.167.8.4414; Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Linker K, 2005, NUCLEIC ACIDS RES, V33, P4813, DOI 10.1093/nar/gki797; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, HUM GENET, V99, P32; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Ogilvie RL, 2005, J IMMUNOL, V174, P953, DOI 10.4049/jimmunol.174.2.953; Prechtel AT, 2006, J BIOL CHEM, V281, P10912, DOI 10.1074/jbc.M510306200; Raghavan A, 2002, NUCLEIC ACIDS RES, V30, P5529, DOI 10.1093/nar/gkf682; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Seko Y, 2004, J BIOL CHEM, V279, P33359, DOI 10.1074/jbc.M312306200; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Singh K, 2004, J IMMUNOL, V173, P976, DOI 10.4049/jimmunol.173.2.976; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Wang JG, 2006, J IMMUNOL, V176, P2105, DOI 10.4049/jimmunol.176.4.2105; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Winzen R, 2004, MOL CELL BIOL, V24, P4835, DOI 10.1128/MCB.24.11.4835-4847.2004; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558; Xu YZ, 2005, MOL CELL BIOL, V25, P8139, DOI 10.1128/MCB.25.18.8139-8149.2005; Yarovinsky TO, 2006, J IMMUNOL, V177, P4426, DOI 10.4049/jimmunol.177.7.4426	51	52	55	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					853	859		10.1016/j.jaci.2007.12.1166	http://dx.doi.org/10.1016/j.jaci.2007.12.1166			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18279945	Green Accepted			2022-12-18	WOS:000254884000007
J	Liotta, F; Frosali, F; Querci, V; Mantei, A; Fili, L; Maggi, L; Mazzinghi, B; Angeli, R; Ronconi, E; Santarlasci, V; Biagioli, T; Lasagni, L; Ballerini, C; Parronchi, P; Scheffold, A; Cosmi, L; Maggi, E; Rornagnani, S; Annunziato, F				Liotta, Francesco; Frosali, Francesca; Querci, Valentina; Mantei, Andrej; Fili, Lucia; Maggi, Laura; Mazzinghi, Benedetta; Angeli, Roberta; Ronconi, Elisa; Santarlasci, Veronica; Biagioli, Tiziana; Lasagni, Laura; Ballerini, Clara; Parronchi, Paola; Scheffold, Alexander; Cosmi, Lorenzo; Maggi, Enrico; Rornagnani, Sergio; Annunziato, Francesco			Human immature myeloid dendritic cells trigger a T(H)2-polarizing program via Jagged-1/Notch interaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; T(H)1; T(H)2; Toll-like receptors; notch; Jagged-1; Delta-4; STAT-4; STAT-6; IL-4; IL-12	T-HELPER-CELL; RESPONSES; HYGIENE; ALLERGY; DIFFERENTIATION; DISEASE; IL-12; TH1	Background: The mechanisms by which human dendritic cells (DCs) activate a T(H)1-polarizing or T(H)2-polarizing program are still partially unclear. Objective: Study of the mechanisms responsible for the T(H)1/T(H)2-polarizing activity of human circulating myeloid DCs before and after ligation of their Toll-like receptors (TLRs). Methods: IL-4 and IFN-gamma production by CD4(+) T cells was assessed in cocultures with myeloid DCs before or after TLR triggering. Expression of Jagged-1 and Delta-4 Notch ligands and of GATA-3 and T-box expressed in T cells transcription factors was evaluated by real-time quantitative PCR. Signal transducer and activator of transcription 4 and 6 phosphorylation was assessed by flow cytometry. Knockdown of Jagged-1 or Delta-4 was performed by transfection of DCs with appropriate silencing mRNAs. Results: Myeloid immature DCs constitutively expressed Jagged-1, which induces in CD4(+) T cells a T(H)2 polarization, as shown by Jagged-1 gene silencing. The T(H)2 polarization associated with high GATA-3/T-box expressed in T cells ratio and was at least partially dependent on the early induction of IL-4. Maturation of DCs by TLR ligation resulted in the reduction of Jagged-1 and upregulation of Delta-4, which was at least in part responsible for the polarization of CD4(+) T cells to the T(H)1 phenotype. Conclusion: CD4(+) T-cell responses are usually characterized by a prevalent TH2 phenotype unless TLRs are triggered on DCs by microbial components.	[Liotta, Francesco; Frosali, Francesca; Querci, Valentina; Fili, Lucia; Maggi, Laura; Mazzinghi, Benedetta; Angeli, Roberta; Ronconi, Elisa; Santarlasci, Veronica; Lasagni, Laura; Parronchi, Paola; Cosmi, Lorenzo; Maggi, Enrico; Rornagnani, Sergio; Annunziato, Francesco] Univ Florence, Dipartimento Med Interna, Excellence Ctr Res Transfer & High Educ Novo Ther, I-50134 Florence, Italy; [Biagioli, Tiziana; Ballerini, Clara] Univ Florence, Dept Neurol Sci, I-50134 Florence, Italy; [Mantei, Andrej; Scheffold, Alexander] Deutsch Rheumaforschungszentrum, Berlin, Germany	University of Florence; University of Florence; Deutsches Rheuma-Forschungszentrum (DRFZ)	Rornagnani, S (corresponding author), Univ Florence, Dipartimento Med Interna, Excellence Ctr Res Transfer & High Educ Novo Ther, Viale Morgagni 85, I-50134 Florence, Italy.	s.romagnani@dmi.unifi.it	Maggi, Laura/B-6693-2013; Parronchi, Paola/AAE-5422-2022; Mazzinghi, Benedetta/K-1120-2018; Lasagni, Laura/J-6856-2018; ballerini, clara/I-6460-2012; Scheffold, Alexander/S-2090-2016; Maggi, Enrico/AAA-8045-2019; Annunziato, Francesco/C-1155-2013	Maggi, Laura/0000-0003-2862-9591; Parronchi, Paola/0000-0002-9184-5089; Mazzinghi, Benedetta/0000-0003-2809-5622; Lasagni, Laura/0000-0001-6553-9160; Scheffold, Alexander/0000-0002-0626-343X; Maggi, Enrico/0000-0002-1824-3583; Annunziato, Francesco/0000-0001-8798-7589; ballerini, clara/0000-0002-7812-9029				Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Annunziato F, 2001, J ALLERGY CLIN IMMUN, V108, P815; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Crawford TQ, 2007, DEV DYNAM, V236, P886, DOI 10.1002/dvdy.21083; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Fang TC, 2007, IMMUNITY, V27, P100, DOI 10.1016/j.immuni.2007.04.018; Fili L, 2006, J ALLERGY CLIN IMMUN, V118, P511, DOI 10.1016/j.jaci.2006.05.027; Harrington LE, 2006, CURR OPIN IMMUNOL, V18, P349, DOI 10.1016/j.coi.2006.03.017; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Matricardi PM, 2000, CLIN EXP ALLERGY, V30, P1506, DOI 10.1046/j.1365-2222.2000.00994.x; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Romagnani P, 2005, J ALLERGY CLIN IMMUN, V116, P1372, DOI 10.1016/j.jaci.2005.09.035; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; ROMAGNANI S, 1994, CURR OPIN IMMUNOL, V6, P838, DOI 10.1016/0952-7915(94)90002-7; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Romagnani S, 2007, J ALLERGY CLIN IMMUN, V119, P1511, DOI 10.1016/j.jaci.2007.04.005; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Shortman K, 2007, NAT REV IMMUNOL, V7, P19, DOI 10.1038/nri1996; Skokos D, 2007, J EXP MED, V204, P1525, DOI 10.1084/jem.20062305; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Takeda K, 1997, J MOL MED-JMM, V75, P317, DOI 10.1007/s001090050117; Tanigaki K, 2004, IMMUNITY, V20, P611, DOI 10.1016/S1074-7613(04)00109-8; Tu LL, 2005, J EXP MED, V202, P1037, DOI 10.1084/jem.20050923; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142	34	52	56	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					1000	1005		10.1016/j.jaci.2008.01.004	http://dx.doi.org/10.1016/j.jaci.2008.01.004			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18313135				2022-12-18	WOS:000254884000028
J	Frank, MM				Frank, Michael M.			Hereditary angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hereditary angioedema; bradykinin; C1 inhibitor; C1 esterase inhibitor; complement; androgens; antifibrinolytics; danazol	ANGIONEUROTIC-EDEMA; INHIBITOR; THERAPY; MANAGEMENT; DEFICIENCY	Hereditary angioedema is an episodic swelling disorder with autosomal dominant inheritance. Attacks are characterized by brawny, self-limited, nonpruritic edema of the deep dermal layers of the skin that most often involve the hands and feet. They usually begin in childhood and become more severe after puberty. Patients also have episodic attacks of severe abdominal pain caused by edema of the gastrointestinal mucosa. Swelling attacks are life threatening when they involve the airway. Estrogens exacerbate attacks, and in some patients attacks are precipitated by trauma or psychologic stress. The disease is caused by a mutation in one of the 2 copies of the gene for the plasma protein C1 inhibitor, with the product of 1 gene unable to control generation of bradykinin. Eighty-five percent of patients have low antigenic levels of C1 inhibitor, and 15% have normal levels of poorly functioning protein. Most patients have decreased plasma complement protein C4 levels. Impeded androgens and, less frequently, E-aminocaproic acid are currently the mainstays of chronic treatment. These agents or fresh frozen plasma are also used for prophylaxis. At this time, acute therapy is mostly supportive. There are currently ongoing multiple trials of new therapeutic agents. In half a century, a life-threatening disease has become one that is manageable and rarely causes death.	Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA	Duke University	Frank, MM (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Box 3352, Durham, NC 27710 USA.	frank007@mc.duke.edu						Agostoni A, 1999, IMMUNOPHARMACOLOGY, V44, P21, DOI 10.1016/S0162-3109(99)00107-1; Bowen T, 2004, J ALLERGY CLIN IMMUN, V114, P629, DOI 10.1016/j.jaci.2004.06.043; BRICKMAN CM, 1986, J ALLERGY CLIN IMMUN, V77, P749, DOI 10.1016/0091-6749(86)90424-0; Davis AE, 2006, IMMUNOL ALLERGY CLIN, V26, P633, DOI 10.1016/j.iac.2006.08.003; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; Frank MM, 2006, IMMUNOL ALLERGY CLIN, V26, P653, DOI 10.1016/j.iac.2006.09.005; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; FRANK MM, 1979, ARTHRITIS RHEUM, V22, P1295, DOI 10.1002/art.1780221118; GADEK JE, 1980, NEW ENGL J MED, V302, P542, DOI 10.1056/NEJM198003063021002; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; Gompels MM, 2005, CLIN EXP IMMUNOL, V139, P379, DOI 10.1111/j.1365-2249.2005.02726.x; LANDERMAN NS, 1962, J ALLERGY, V33, P330, DOI 10.1016/0021-8707(62)90032-1; Levi M, 2006, J ALLERGY CLIN IMMUN, V117, P904, DOI 10.1016/j.jaci.2006.01.002; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; SPAULDING WB, 1960, ANN INTERN MED, V53, P739, DOI 10.7326/0003-4819-53-4-739; Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503	17	52	58	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2		2			S398	S401		10.1016/j.jaci.2007.07.057	http://dx.doi.org/10.1016/j.jaci.2007.07.057			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266IB	18241690	Bronze			2022-12-18	WOS:000253426600009
J	Hasdenteufel, F; Luyasu, S; Renaudin, JM; Paquay, JM; Carbutti, G; Beaudounin, E; Moneret-Vautrin, DA; Kanny, G				Hasdenteufel, Frederic; Luyasu, Samuel; Renaudin, Jean-Marie; Paquay, Jean-Marie; Carbutti, Giuseppe; Beaudounin, Etienne; Moneret-Vautrin, Denise Anne; Kanny, Gisele			Anaphylactic shock after first exposure to gadoterate meglumine: Two case reports documented by positive allergy assessment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CONTRAST-MEDIA; DTPA		[Hasdenteufel, Frederic; Renaudin, Jean-Marie; Paquay, Jean-Marie; Beaudounin, Etienne; Moneret-Vautrin, Denise Anne; Kanny, Gisele] Univ Hosp, Dept Internal Med Clin Immunol & Allergol, Diagnos & Therapeut Dept, Nancy, France; [Luyasu, Samuel; Paquay, Jean-Marie; Carbutti, Giuseppe] Clin S Luxemburg, Dept Internal Med & Intens Care, Arlon, Belgium	CHU de Nancy	Hasdenteufel, F (corresponding author), Univ Hosp, Dept Internal Med Clin Immunol & Allergol, Diagnos & Therapeut Dept, Nancy, France.	frederie.hasdenteufel@wanadoo.fr	Kanny, Gisèle/AHA-8910-2022					BAXTER AB, 1993, INVEST RADIOL, V28, P308, DOI 10.1097/00004424-199304000-00009; Beaudouin E, 2003, ALLERG IMMUNOL PARIS, V35, P382; Brockow K, 2002, ALLERGY, V57, P45; Herborn CU, 2007, INVEST RADIOL, V42, P58, DOI 10.1097/01.rli.0000248893.01067.e5; Li A, 2006, BRIT J RADIOL, V79, P368, DOI 10.1259/bjr/88469693; Meuli RA, 1996, AM J ROENTGENOL, V166, P729, DOI 10.2214/ajr.166.3.8623674; MONERETVAUTRIN DA, 1993, CLIN EXP ALLERGY, V23, P629, DOI 10.1111/j.1365-2222.1993.tb01788.x; Rahman SL, 2005, J CARDIOV MAGN RESON, V7, P849, DOI 10.1080/10976640500288206; WEISS KL, 1990, MAGN RESON IMAGING, V8, P817, DOI 10.1016/0730-725X(90)90019-X	9	52	53	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					527	528		10.1016/j.jaci.2007.08.027	http://dx.doi.org/10.1016/j.jaci.2007.08.027			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	17919712				2022-12-18	WOS:000253337800037
J	Savage, JH; Limb, SL; Brereton, NH; Wood, RA				Savage, Jessica H.; Limb, Susan L.; Brereton, Nga H.; Wood, Robert A.			The natural history of peanut allergy: Extending our knowledge beyond childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IGE; POLLEN		Johns Hopkins Univ, Sch Med, Div Allergy & Immunol, Dept Pediat, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Gen Clin Res Ctr, Baltimore, MD USA; US FDA, Ctr Drug Evaluat & Res, Div Pulmonary & Allergy Prod, Rockville, MD 20857 USA	Johns Hopkins University; Johns Hopkins University; US Food & Drug Administration (FDA)	Savage, JH (corresponding author), Johns Hopkins Univ, Sch Med, Div Allergy & Immunol, Dept Pediat, Baltimore, MD 21218 USA.	rwood@jhmi.edu			NCRR NIH HHS [M01RR00052] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMLOT PL, 1987, CLIN ALLERGY, V17, P33, DOI 10.1111/j.1365-2222.1987.tb02317.x; Fleischer DM, 2004, J ALLERGY CLIN IMMUN, V114, P1195, DOI 10.1016/j.jaci.2004.08.035; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Ricci G, 2005, MOL IMMUNOL, V42, P1251, DOI 10.1016/j.molimm.2004.11.011; Vieths S, 2002, ANN NY ACAD SCI, V964, P47	7	52	54	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					717	719		10.1016/j.jaci.2007.07.027	http://dx.doi.org/10.1016/j.jaci.2007.07.027			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17765758				2022-12-18	WOS:000249505400036
J	Zhu, FG; Kandirnalla, ER; Yu, D; Agrawal, S				Zhu, Fu-Gang; Kandirnalla, Ekarnbar R.; Yu, Dong; Agrawal, Sudhir			Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immune modulator; v oligonucleotide; mucosol immune response; oral administration; peanut allergy. T(H)1 immune response; Toll-like receptor 9	2ND-GENERATION IMMUNOMODULATORY OLIGONUCLEOTIDES; AIRWAY HYPERRESPONSIVENESS; IMMUNOSTIMULATORY ACTIVITY; FOOD ALLERGY; MURINE MODEL; DNA; IMMUNOTHERAPY; INDUCTION; RESPONSES; MOTIF	Background: Agonists of Toll-like receptor 9 have been shown to induce potent T(H)1-type immune responses and prevent and reverse ovalbumin-induced T(H)2-dominant allergic asthma in mice. Objective: We examined oral administration of a synthetic agonist of Toll-like receptor 9 (immune modulatory oligonucleotide [IMO]) to modulate peanut-induced allergy in mice. Methods: In the prevention model mice were sensitized 3 times by means of oral administration of peanut in the presence or absence of IMO. In a treatment protocol mice were sensitized orally with peanut on days 0 and 14 and treated 4 times with oral administration of IMO starting on day. 21. Results: In the prevention study mice that received the combination of IMO/peanut showed decreased IgE and increased IgG2a levels in the serum and intestinal tissue compared with mice sensitized with peanut only. In spleen cell recall experiments, production of IL-5 and IL-13 was inhibited and production of IFN-gamma was increased in mice immunized with the peanut/IMO combination compared with those sensitized with peanut only. In the treatment model IMO-treated mice showed decreased IgE, IL-5, and IL-13 levels and increased IgG2a and IFN-gamma levels in the serum, intestines, and spleen cells compared with PBS-treated mice. A reduction in local inflammation and restoration of normal structure in the intestines was found in the mice that received IMO in both models. Conclusion: These results indicate that IMOs can switch peanut-induced T(H)2 immune responses toward T(H)1 responses accompanied by reduced inflammation in the gastrointestinal tract and anaphylaxis in both the prevention and treatment models. Clinical implications: IMOs might be suitable candidates for the management of peanut-induced allergy.	Idec Pharmaceut Inc, Cambridge, MA 02139 USA	Biogen	Agrawal, S (corresponding author), Idec Pharmaceut Inc, 167 Sidney St, Cambridge, MA 02139 USA.	sagrawal@iderapharma.com		Agrawal, Sudhir/0000-0003-4275-2510				Agrawal DK, 2004, INT IMMUNOPHARMACOL, V4, P127, DOI 10.1016/j.intimp.2003.11.005; AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; AGRAWAL S, 1995, BIOCHEM PHARMACOL, V50, P571, DOI 10.1016/0006-2952(95)00160-2; Bashir MEH, 2004, J IMMUNOL, V172, P6978, DOI 10.4049/jimmunol.172.11.6978; Broide D, 1998, J IMMUNOL, V161, P7054; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; Fujieda S, 2000, AM J RESP CRIT CARE, V162, P232, DOI 10.1164/ajrccm.162.1.9906136; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HOMER AA, 2006, CURR ALLERGY ASTHM R, V6, P395; Kandimalla ER, 2005, P NATL ACAD SCI USA, V102, P6925, DOI 10.1073/pnas.0501729102; Kandimalla ER, 2003, P NATL ACAD SCI USA, V100, P14303, DOI 10.1073/pnas.2335947100; Kandimalla ER, 2003, NUCLEIC ACIDS RES, V31, P2393, DOI 10.1093/nar/gkg343; Kandimalla ER, 2002, BIOCONJUGATE CHEM, V13, P966, DOI 10.1021/bc0200374; Lee SY, 2001, CLIN IMMUNOL, V101, P220, DOI 10.1006/clim.2001.5122; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; *NAT I ALL INF DIS, 2003, REP EXP PAN REP FOOD; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Racila DM, 2005, J ALLERGY CLIN IMMUN, V116, P1202, DOI 10.1016/j.jaci.2005.08.050; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Takabayashi K, 2003, J IMMUNOL, V170, P3898, DOI 10.4049/jimmunol.170.7.3898; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Wang DQ, 2005, VACCINE, V23, P2614, DOI 10.1016/j.vaccine.2004.11.028; Yu D, 2000, BIOORG MED CHEM LETT, V10, P2585, DOI 10.1016/S0960-894X(00)00537-0; Yu D, 2002, NUCLEIC ACIDS RES, V30, P4460, DOI 10.1093/nar/gkf582; Yu D, 2002, BIOCHEM BIOPH RES CO, V297, P83, DOI 10.1016/S0006-291X(02)02127-7; Zhu FG, 2004, INT IMMUNOPHARMACOL, V4, P851, DOI 10.1016/j.intimp.2004.03.009	30	52	52	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					631	637		10.1016/j.jaci.2007.05.015	http://dx.doi.org/10.1016/j.jaci.2007.05.015			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17582479				2022-12-18	WOS:000249505400023
J	van Gent, R; van der Ent, CK; Rovers, MM; Kimpen, JLL; van Essen-Zandvliet, LEM; de Meer, G				van Gent, Rene; van der Ent, Cornelis K.; Rovers, Maroeska M.; Kimpen, Jan L. L.; van Essen-Zandvliet, Liesbeth E. M.; de Meer, Gea			Excessive body weight is associated with additional loss of quality of life in children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; children; quality of life; overweight; obesity; body mass index	CHILDHOOD ISAAC; OBESITY; RISK; DETERMINANTS; OVERWEIGHT; RATIONALE; ALLERGIES; PEOPLE	Background: Asthma and excessive body weight frequently coexist, whereas the exact relationship between the 2 diseases is unknown. Objective: To study whether asthma combined with excessive body weight has a greater effect on quality of life in children than the separate effects of asthma or excessive body weight alone. Methods: In a cross-sectional design, 1758 school children (age 7-10 years) participated: 4 study groups were composed of children with asthma and with/without excessive body weight, and healthy controls with/without excessive body weight. Diagnosis of asthma was defined by either a doctor's diagnosis or by core questions of the International Study of Asthma and Allergies in Childhood questionnaire in combination with either reversible airway obstruction or bronchial hyperresponsiveness. Excessive body weight was defined by using international cutoff points for body mass index. Quality of life was evaluated by the Pediatric Asthma Quality of Life Questionnaire. Results: For all domains of quality of life, children with both asthma and excessive body weight had lower scores than children with either asthma alone or excessive body weight alone. Compared with healthy controls, the score was 25% lower in children with asthma and excessive body weight, 14% lower in children with asthma and normal weight, and only 1% lower in overweight controls. Conclusion: Excessive body weight is associated with an additional decrease in quality of life in children with asthma. Clinical implications: Clinicians should be aware of the interaction between asthma and excessive body weight and the effect on quality of life and should give extra attention to children with both conditions.	Maxima Med Ctr, Dept Pediat, NL-5500 MB Veldhoven, Netherlands; Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, NL-3508 TC Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pediat, NL-3508 TC Utrecht, Netherlands; Asthma Ctr Heideheuvel, Dept Pediat, Hilversum, Netherlands; Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; Univ Groningen, Med Ctr, Dept Hlth Sci, NL-9700 AB Groningen, Netherlands	Maxima Medical Center; Utrecht University; Utrecht University; Utrecht University; University of Groningen	van Gent, R (corresponding author), Maxima Med Ctr, Dept Pediat, POB 7777, NL-5500 MB Veldhoven, Netherlands.	R.vanGent@mmc.nl	Rovers, Maroeska/F-2969-2014	Rovers, Maroeska/0000-0002-3095-170X				ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Belamarich PF, 2000, PEDIATRICS, V106, P1436, DOI 10.1542/peds.106.6.1436; Blandon Vijil V, 2004, Allergol Immunopathol (Madr), V32, P259, DOI 10.1157/13066302; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; DALES RE, 1988, AM REV RESPIR DIS, V138, P317, DOI 10.1164/ajrccm/138.2.317; Dixon JB, 1999, OBES SURG, V9, P385, DOI 10.1381/096089299765552981; Ford ES, 2004, J ASTHMA, V41, P327, DOI 10.1081/JAS-120026090; Ford ES, 2003, OBES RES, V11, P81, DOI 10.1038/oby.2003.13; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P1235, DOI 10.1016/j.jaci.2005.09.016; Juniper E F, 1999, Curr Opin Pulm Med, V5, P105, DOI 10.1097/00063198-199903000-00005; Juniper EF, 2004, EUR RESPIR J, V23, P287, DOI 10.1183/09031936.04.00064204; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; Lavoie KL, 2006, RESP MED, V100, P648, DOI 10.1016/j.rmed.2005.08.001; MACGREGOR AMC, 1993, OBES SURG, V3, P15, DOI 10.1381/096089293765559700; OSMAN L, 1996, EUR RESPIR J, V21, P35; Oude Luttikhuis H, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001872.pub2; PEARCE N, 1989, INT J EPIDEMIOL, V18, P976, DOI 10.1093/ije/18.4.976; Peeters A, 2003, ANN INTERN MED, V138, P24, DOI 10.7326/0003-4819-138-1-200301070-00008; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Raat H, 2005, QUAL LIFE RES, V14, P265, DOI 10.1007/s11136-004-0798-7; Sbarbati A, 2006, PEDIATRICS, V117, P220, DOI 10.1542/peds.2004-2854; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P925, DOI 10.1016/j.jaci.2005.01.064; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; Wilson PWF, 2002, ARCH INTERN MED, V162, P1867, DOI 10.1001/archinte.162.16.1867	29	52	55	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					591	596		10.1016/j.jaci.2006.11.007	http://dx.doi.org/10.1016/j.jaci.2006.11.007			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17208288	Green Published			2022-12-18	WOS:000244925000010
J	Lee, KS; Park, SJ; Kim, SR; Min, KH; Jin, SM; Puri, KD; Lee, YC				Lee, Kyung Sun; Park, Seoung Ju; Kim, So Ri; Min, Kyung Hoon; Jin, Sun Mi; Puri, Kamal D.; Lee, Yong Chul			Phosphoinositide 3-kinase-delta inhibitor reduces vascular permeability in a murine model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway; PI3K-delta; vascular permeability; VEGF	ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1; AIRWAY SMOOTH-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN EOSINOPHILS; FACTOR EXPRESSION; BRONCHIAL-ASTHMA; MAST-CELLS; FACTOR-I; INFLAMMATION	Background: Bronchial asthma is characterized by inflammation of the airways, which is usually accompanied by increased vascular permeability, resulting in plasma exudation. Vascular endothelial growth factor (VEGF) has been implicated in contributing to asthmatic tissue edema through its effect on vascular permeability. Many cellular responses of VEGF are regulated by the lipid products of phosphoinositide 3-kinase (PI3K). However, the effect of PI3K catalytic subunit p110 delta on VEGF-mediated signaling is unknown. Recently, an isoform-specific small molecule inhibitor, IC87114, which is selective for p110 delta catalytic activity, has been identified. Objective: We have sought to investigate the role of PI3K-delta, more specifically in the increase of vascular permeability. Methods: Female BALB/c mice were sensitized and challenged with ovalbumin. We have investigated the effect of IC87114 on airway inflammation, T(H)2 cytokines expression, airway hyperresponsiveness, plasma extravasation, hypoxia-inducible factor 1 alpha expression, and VEGF expression in a murine model of asthma. Results: Our current study has revealed that IC87114 reduces antigen-induced airway infiltration of inflammatory cells, secretion of TH2 cytokines in lungs, airway hyperresponsiveness, and vascular permeability. Moreover, we have found that inhibition of p110 delta reduces ovalbumin-induced upregulation of VEGF level. Conclusion: These results suggest that PI3K-delta inhibitor attenuates antigen-induced airway inflammation and hyperresponsiveness by preventing vascular leakage in mice. Clinical implications: These findings provide a crucial molecular mechanism for the potential role of PI3K-delta in asthma and other airway inflammatory disorders.	Chonbuk Natl Univ, Sch Med, Dept Internal Med, Jeonju 561180, Jeonbuk, South Korea; Chonbuk Natl Univ, Sch Med, Airway Remodeling Lab, Jeonju 561180, Jeonbuk, South Korea; Chonbuk Natl Univ, Sch Med, Res Ctr Allerg Immune Dis, Jeonju 561180, Jeonbuk, South Korea; ICOS Corp, Bothell, WA USA	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Icos Corporation	Lee, YC (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Internal Med, San 2-20,Geumamdong, Jeonju 561180, Jeonbuk, South Korea.	leeyc@chonbuk.ac.kr	Kim, So Ri/AAS-1630-2021; Park, Seoungju/D-4444-2014	Kim, So Ri/0000-0002-6074-9158; 				Antony AB, 2002, J ALLERGY CLIN IMMUN, V110, P589, DOI 10.1067/mai.2002.127798; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bracke M, 2000, J LEUKOCYTE BIOL, V68, P655; Charan NB, 1997, EUR RESPIR J, V10, P1173, DOI 10.1183/09031936.97.10051173; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Duan W, 2005, INT IMMUNOPHARMACOL, V5, P495, DOI 10.1016/j.intimp.2004.10.015; Dunzendorfer S, 1998, J LEUKOCYTE BIOL, V64, P828, DOI 10.1002/jlb.64.6.828; DVORAK AM, 1994, BLOOD, V83, P3600; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Eum SY, 2003, AM J RESP CELL MOL, V28, P25, DOI 10.1165/rcmb.4532; Ezeamuzie CI, 2001, AM J RESP CRIT CARE, V164, P1633, DOI 10.1164/ajrccm.164.9.2101104; FOSTER WM, 1982, ANN OCCUP HYG, V26, P227, DOI 10.1093/annhyg/26.2.227; Fruman DA, 2002, SEMIN IMMUNOL, V14, P7, DOI 10.1006/smim.2001.0337; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Fukao T, 2002, NAT IMMUNOL, V3, P875, DOI 10.1038/ni825; Gadina M, 2000, J BIOL CHEM, V275, P26959; Horiuchi T, 1997, AM J RESP CELL MOL, V17, P70, DOI 10.1165/ajrcmb.17.1.2796; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; KIRSCH CM, 1992, EXP LUNG RES, V18, P447, DOI 10.3109/01902149209064339; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V277, pL65; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lazaar AL, 2005, J ALLERGY CLIN IMMUN, V116, P488, DOI 10.1016/j.jaci.2005.06.030; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee KS, 2005, FASEB J, V19, P1033, DOI 10.1096/fj.04-3309fje; Lee KS, 2005, MOL PHARMACOL, V68, P1281, DOI 10.1124/mol.105.016055; Lee KS, 2004, J ALLERGY CLIN IMMUN, V114, P1093, DOI 10.1016/j.jaci.2004.07.039; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; Lee YC, 2001, J ALLERGY CLIN IMMUN, V107, P1106, DOI 10.1067/mai.2001.115628; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Li YM, 2005, CANCER RES, V65, P3257, DOI 10.1158/0008-5472.CAN-04-1284; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Orsida BE, 2001, AM J RESP CRIT CARE, V164, P117, DOI 10.1164/ajrccm.164.1.2006003; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Persson CGA, 1996, AM J RESP CRIT CARE, V153, pS9, DOI 10.1164/ajrccm/153.6_Pt_2.S9; Puri KD, 2004, BLOOD, V103, P3448, DOI 10.1182/blood-2003-05-1667; Sadhu C, 2003, BIOCHEM BIOPH RES CO, V308, P764, DOI 10.1016/S0006-291X(03)01480-3; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; Salvato G, 2001, THORAX, V56, P902, DOI 10.1136/thorax.56.12.902; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Taichman NS, 1997, J LEUKOCYTE BIOL, V62, P397, DOI 10.1002/jlb.62.3.397; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Tamaoki J, 1999, AM J PHYSIOL-LUNG C, V276, pL351, DOI 10.1152/ajplung.1999.276.2.L351; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; VANDEGRAAF EA, 1991, AM REV RESPIR DIS, V143, P362, DOI 10.1164/ajrccm/143.2.362; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Ward SG, 2003, CURR OPIN PHARMACOL, V3, P426, DOI 10.1016/S1471-4892(03)00078-X; Zhong H, 2000, CANCER RES, V60, P1541; Zhu XD, 2000, J IMMUNOL METHODS, V240, P157, DOI 10.1016/S0022-1759(00)00192-7	58	52	56	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					403	409		10.1016/j.jaci.2006.04.041	http://dx.doi.org/10.1016/j.jaci.2006.04.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890765				2022-12-18	WOS:000239877700016
J	Wiertsema, SP; Herpers, BL; Veenhoven, RH; Salimans, MMM; Ruven, HJT; Sanders, EAM; Rijkers, GT				Wiertsema, Selma P.; Herpers, Bjorn L.; Veenhoven, Reinier H.; Salimans, Marcel M. M.; Ruven, Henk J. T.; Sanders, Elisabeth A. M.; Rijkers, Ger T.			Functional polymorphisms in the mannan-binding lectin 2 gene: Effect on MBL levels and otitis media	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mannan-binding lectin; complement; otitis media; functional mannan-binding lectin serum levels; polymorphisms; haplotypes	HAPLOTYPE RECONSTRUCTION; MENINGOCOCCAL DISEASE; FAMILIAL DEFICIENCY; INNATE IMMUNITY; PROTEIN; CHILDREN; SERUM; ASSOCIATION; MUTATIONS; INFECTIONS	Background: Mannan-binding lectin (MBL) can bind to microorganisms, initiating the lectin pathway of complement activation. Aberrant MBL serum levels, caused by MBL2 gene polymorphisms, are a possible risk factor for recurrent infections. Within the 7 common MBL haplotypes, still considerable variation in MBL serum levels exists. Objective: To investigate functional MBL levels and MBL2 polymorphisms in a large cohort of children with recurrent acute otitis media. Methods: Twelve genetic variants in the MBL2 gene and functional MBL serum levels were determined in a cohort of children with recurrent acute otitis media. Haplotypes were constructed and associated with functional MBL serum levels and the number of otitis episodes in the previous year. Results: The 7 common MBL2 haplotypes mainly determine the level of functional MBL in serum. In addition, the 3130G > C single nucleotide polymorphism, located in exon 4, further significantly influenced functional MBL levels within the LXPA haplotype. LXPA carriers with 3130G showed a significantly lower geometric mean functional MBL serum level of 0.19 mu g/mL compared with 0.70 mu g/mL in 3130C carriers (P =.026). Nonwild-type MBL2 carriers between 12 and 24 months had a significantly increased number of otitis episodes (5.1/y) compared with wild-type MBL2 carriers (4.1/y; P =.027). In older children, this association was not found anymore. Conclusion: Additional single nucleotide polymorphisms within the 7 common haplotypes can further explain the observed variation in functional MBL serum levels. MBL seems to be of particular clinical importance during early childhood, when maternally derided antibodies have waned, and protective adaptive immunity is not well developed yet. Clinical implications: Single nucleotide polymorphisms in the promoter region, in exon 1, and in exon 4 of MBL2 contribute to increased risk for otitis media in children younger than 2 years.	Univ Utrecht, Wilhelmina Childrens Hosp, Med Ctr, Dept Pediat Immunol, NL-3584 EA Utrecht, Netherlands; St Antonius Hosp, Dept Med Microbiol & Immunol, Nieuwegein, Netherlands; St Antonius Hosp, Dept Clin Chem, Nieuwegein, Netherlands; Spaame Hosp, Dept Pediat, Hoofddorp, Netherlands; Meander Med Ctr, Dept Med Microbiol, Amersfoort, Netherlands	Utrecht University; Wilhelmina Kinderziekenhuis; St. Antonius Hospital Utrecht; St. Antonius Hospital Utrecht; Spaarne Hospital; Meander Medisch Centrum	Rijkers, GT (corresponding author), Univ Utrecht, Wilhelmina Childrens Hosp, Med Ctr, Dept Pediat Immunol, Lundlaan 6,KC03-063-0, NL-3584 EA Utrecht, Netherlands.	g.rijkers@antonius.net	Rijkers, Ger/R-7236-2019; Rijkers, Ger/AAW-6143-2020	Rijkers, Ger/0000-0001-6948-6123; 				Aittoniemi J, 1998, ARCH DIS CHILD, V78, P245, DOI 10.1136/adc.78.3.245; Bax WA, 1999, LANCET, V354, P1094, DOI 10.1016/S0140-6736(99)02563-5; Bernig T, 2005, HUM GENET, V118, P404, DOI 10.1007/s00439-005-0053-5; Bernig T, 2004, GENES IMMUN, V5, P461, DOI 10.1038/sj.gene.6364116; Block SL, 1997, PEDIATR INFECT DIS J, V16, P449, DOI 10.1097/00006454-199704000-00029; Carlsson M, 2005, CLIN EXP IMMUNOL, V139, P306, DOI 10.1111/j.1365-2249.2004.02690.x; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cedzynski M, 2004, CLIN EXP IMMUNOL, V136, P304, DOI 10.1111/j.1365-2249.2004.02453.x; Crosdale DJ, 2000, EUR J IMMUNOGENET, V27, P111, DOI 10.1046/j.1365-2370.2000.00211.x; den Dunnen JT, 2000, HUM MUTAT, V15, P7; Gabolde M, 1999, HUM MUTAT, V14, P80, DOI 10.1002/(SICI)1098-1004(1999)14:1<80::AID-HUMU10>3.0.CO;2-J; Garred P, 1997, SCAND J IMMUNOL, V46, P204, DOI 10.1046/j.1365-3083.1997.d01-111.x; GARRED P, 1993, CLIN EXP IMMUNOL, V94, P99; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; Hibberd ML, 1999, LANCET, V353, P1049, DOI 10.1016/S0140-6736(98)08350-0; Hoal-van Helden EG, 1999, PEDIATR RES, V45, P459, DOI 10.1203/00006450-199904010-00002; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; Homoe P, 1999, SCAND J INFECT DIS, V31, P363, DOI 10.1080/00365549950163798; IKEDA K, 1987, J BIOL CHEM, V262, P7451; Jack DL, 2003, BIOCHEM SOC T, V31, P753, DOI 10.1042/BST0310753; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kilpatrick DC, 2002, TRANSFUSION MED, V12, P335, DOI 10.1046/j.1365-3148.2002.00408.x; Kilpatrick DC, 2002, BBA-GEN SUBJECTS, V1572, P401, DOI 10.1016/S0304-4165(02)00321-5; Koch A, 2001, JAMA-J AM MED ASSOC, V285, P1316, DOI 10.1001/jama.285.10.1316; Kuipers S, 2002, J IMMUNOL METHODS, V268, P149, DOI 10.1016/S0022-1759(02)00192-8; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; Madsen HO, 1998, J IMMUNOL, V161, P3169; MADSEN HO, 1995, J IMMUNOL, V155, P3013; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Roy S, 2002, LANCET, V359, P1569, DOI 10.1016/S0140-6736(02)08516-1; Salimans MMM, 2004, CLIN DIAGN LAB IMMUN, V11, P806, DOI 10.1128/CDLI.11.4.806-807.2004; Santos IKFD, 2001, INFECT IMMUN, V69, P5212, DOI 10.1128/IAI.69.8.5212-5215.2001; Steffensen R, 2000, J IMMUNOL METHODS, V241, P33, DOI 10.1016/S0022-1759(00)00198-8; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Straetemans M, 2005, J CLIN IMMUNOL, V25, P78, DOI 10.1007/s10875-005-0361-8; Sullivan KE, 1996, ARTHRITIS RHEUM, V39, P2046, DOI 10.1002/art.1780391214; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; SUPER M, 1989, LANCET, V2, P1236; Takahashi K, 2002, MICROBES INFECT, V4, P773, DOI 10.1016/S1286-4579(02)01597-6; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; Tezcan I, 1997, TURKISH J PEDIATR, V39, P453; Thorarinsdottir HK, 2005, SCAND J IMMUNOL, V61, P466, DOI 10.1111/j.1365-3083.2005.01588.x; Townsend R, 2001, CLIN EXP IMMUNOL, V124, P223, DOI 10.1046/j.1365-2249.2001.01549.x; TURNER M W, 1991, Clinical and Experimental Immunology, V86, P53; Turner MW, 2003, MOL IMMUNOL, V40, P423, DOI 10.1016/S0161-5890(03)00155-X; VANEMMERIK LC, 1994, CLIN EXP IMMUNOL, V97, P411; Veenhoven R, 2003, LANCET, V361, P2189, DOI 10.1016/S0140-6736(03)13772-5; Weintraub A, 2003, CARBOHYD RES, V338, P2539, DOI 10.1016/j.carres.2003.07.008	51	52	52	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1344	1350		10.1016/j.jaci.2006.01.031	http://dx.doi.org/10.1016/j.jaci.2006.01.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750996				2022-12-18	WOS:000238332300021
J	Golden, DBK; Breisch, NL; Hamilton, RG; Guralnick, MW; Greene, A; Craig, TJ; Kagey-Sobotka, A				Golden, DBK; Breisch, NL; Hamilton, RG; Guralnick, MW; Greene, A; Craig, TJ; Kagey-Sobotka, A			Clinical and entomological factors influence the outcome of sting challenge studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sting challenge; Hymenoptera; insect sting; anaphylaxis; insect venom	DISCONTINUING VENOM IMMUNOTHERAPY; LARGE LOCAL REACTIONS; NATURAL-HISTORY; HYMENOPTERA VENOM; DIAGNOSTIC METHODS; YELLOW JACKETS; INSECT STINGS; ALLERGY; ANAPHYLAXIS; HYPERSENSITIVITY	Background: The reported frequency of systemic reactions to challenge sting varies greatly. Objective: To evaluate the interaction of clinical and entomological factors that determine the outcome of a challenge sting. Methods: Patients allergic to yellow jacket were stung and monitored for systemic reaction. The frequency and severity of sting reactions were analyzed in relation to the species of insect used and patient characteristics. Results: Objective systemic reactions occurred in 21 of 69 patients (30%) stung with Vespula maculifrons and in 8 of 71 patients (11%) with Vespula germanica (P = .005). Systemic reactions were more frequent in patients with a severe history (9/30; 30%) than in those with a mild or moderate history (21/145; 14%; P = .04). In only 1 of 111 patients (0.9%) was the reaction to sting challenge more severe than previous reactions. The reaction rate was higher when venom skin tests were positive at <1.0 mu g/ml, (17/75 = 23%) than when sensitivity was milder (9/100 = 9%; P = .012). We compared sting outcome and venom-induced histamine release in relation to insects collected in July or in October, and found no difference. Conclusion: Allergic reactions to sting challenge are determined by the species of yellow jacket used, the severity of previous sting reactions, and the degree of skin test sensitivity, but not by the time of year. These factors are important to clinicians when they evaluate the chance of reaction to a future sting and to researchers when they design and report sting challenge studies.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; Univ Maryland, Dept Entomol, College Pk, MD 20742 USA; US Gen Serv Adm, Serv Delivery Support Div, Washington, DC USA; Penn State Univ, Hershey Med Ctr, University Pk, PA 16802 USA	Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland College Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania State University - University Park	Golden, DBK (corresponding author), 5501 Hopkins Bayview Blvd, Baltimore, MD 21224 USA.	dgolden1@jhmi.edu			NCRR NIH HHS [5M01-RR02719] Funding Source: Medline; NIAID NIH HHS [AI08270] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; Clark S, 2005, J ALLERGY CLIN IMMUN, V116, P643, DOI 10.1016/j.jaci.2005.06.026; DVORIN D, 1984, Journal of Allergy and Clinical Immunology, V73, P188; FRANKEN HH, 1994, J ALLERGY CLIN IMMUN, V93, P431, DOI 10.1016/0091-6749(94)90351-4; GALATAS ID, 1994, J ALLERGY CLIN IMMUN, V94, P272, DOI 10.1016/0091-6749(94)90055-8; GOLDEN D, 1984, J ALLERGY CLIN IMMUN, V73, P159; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; GOLDEN DBK, 1981, JAMA-J AM MED ASSOC, V246, P2460, DOI 10.1001/jama.246.21.2460; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, pS159; GRAFT DF, 1984, J PEDIATR-US, V104, P664, DOI 10.1016/S0022-3476(84)80940-3; GREENE A, 1989, J ALLERGY CLIN IMMUN, V83, P229; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1982, ANN ALLERGY, V48, P78; HOFFMAN DR, 1984, ANN ALLERGY, V52, P276; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Landolt PJ, 1998, PHEROMONE COMMUNICAT; LANTNER R, 1989, J ALLERGY CLIN IMMUN, V84, P900, DOI 10.1016/0091-6749(89)90387-4; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; LICHTENSTEIN LM, 1994, J ALLERGY CLIN IMMUN, V94, P137, DOI 10.1016/0091-6749(94)90030-2; MAURIELLO PM, 1984, J ALLERGY CLIN IMMUN, V74, P494, DOI 10.1016/0091-6749(84)90384-1; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1984, TOXICON, V22, P148, DOI 10.1016/0041-0101(84)90148-X; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; SCHUBERTH KC, 1987, J ALLERGY CLIN IMMUN, V79, P126; SETTIPANE GA, 1979, CLIN ALLERGY, V9, P385, DOI 10.1111/j.1365-2222.1979.tb02497.x; SOBOTKA A, 1974, J ALLERGY CLIN IMMUN, V53, P110; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889; WICHER K, 1980, J ALLERGY CLIN IMMUN, V66, P244, DOI 10.1016/0091-6749(80)90047-0; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	35	52	53	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					670	675		10.1016/j.jaci.2005.12.1313	http://dx.doi.org/10.1016/j.jaci.2005.12.1313			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522469	Bronze			2022-12-18	WOS:000236263100025
J	Kelso, JM				Kelso, JM			A second dose of epinephrine for anaphylaxis: How often needed and how to carry	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ABSORPTION		USN, Med Ctr, Div Allergy, San Diego, CA 92152 USA	United States Department of Defense; United States Navy	Kelso, JM (corresponding author), USN, Med Ctr, Div Allergy, San Diego, CA 92152 USA.							Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; Korenblat P, 1999, ALLERGY ASTHMA PROC, V20, P383, DOI 10.2500/108854199778251834; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; Uguz A, 2005, CLIN EXP ALLERGY, V35, P746, DOI 10.1111/j.1365-2222.2005.02257.x	4	52	53	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					464	465		10.1016/j.jaci.2005.11.015	http://dx.doi.org/10.1016/j.jaci.2005.11.015			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461150				2022-12-18	WOS:000235687300031
J	Pearlman, DS; Berger, WE; Kerwin, E; LaForce, C; Kundu, S; Banerji, D				Pearlman, DS; Berger, WE; Kerwin, E; LaForce, C; Kundu, S; Banerji, D			Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; ciclesonide; 24-hour asthma symptom score; daily albuterol use; nighttime awakenings	FLUTICASONE PROPIONATE; INHALED CORTICOSTEROIDS; AXIS; PHARMACOKINETICS; BUDESONIDE; INHALATION; CORTISOL; AIRWAY	Background: Inhaled corticosteroids are recommended as first-line therapy for persistent asthma. Objective: We sought to assess the efficacy and safety of ciclesonide once daily in patients with mild-to-moderate persistent asthma. Methods: An integrated analysis of 2 identical, multicenter, double-blind, randomized, parallel-group, placebo-controlled trials was conducted. Patients (n = 1015; aged >= 12 years) with mild-to-moderate asthma (FEV1 of 60% to 85% of predicted value) were randomized to ciclesonide 80 mu g (CIC80), 160 mu g (CIC160), or 320 mu g (CIC320), once daily (exactuator doses) in the morning or placebo for 12 weeks. Results: All ciclesonide groups showed significant improvements from baseline to week 12 in FEV1 compared with the placebo group (CIC80, 0.12 L [P = .0007]; CIC160, 0.13 L [P = .0004]; and CIC320, 0.14 L [P < .0001]). Likewise, FEV1 percent predicted, morning and evening peak expiratory flow, 24-hour asthma symptom score, daily albuterol use, and nighttime awakenings were significantly improved in all ciclesonide groups compared with the placebo group. Overall ciclesonide safety profile and rates of oropharyngeal adverse events for all groups were low and similar to those of the placebo group. Fewer ciclesonide-treated patients exhibited asthma-aggravated adverse events, and fewer ciclesonide-treated patients discontinued the study for any reason or because of a lack of efficacy compared with those in the placebo group. No suppression of hypothalamic-pituitary-adrenal-axis function (as assessed by means of 24-hour urinary cortisol levels corrected for creatinine and peak serum cortisol levels after stimulation with low-dose [1 mu g] cosyntropin) was observed with any dose of ciclesonide. Conclusions: In this integrated analysis, ciclesonide once daily administered in the morning is effective and well tolerated.	Colorado Allergy & Asthma Ctr, Denver, CO 80230 USA; So Calif Res, Mission Viejo, CA USA; Clin Res Inst So Oregon PC, Medford, MA USA; N Carolina Clin Res, Raleigh, NC USA; Sanofi Aventis, Bridgewater, MA USA	Sanofi-Aventis	Pearlman, DS (corresponding author), Colorado Allergy & Asthma Ctr, 125 Rampart Way, Denver, CO 80230 USA.	ds.pearlman@coloradoallergy.com						Allen David B, 2003, J Allergy Clin Immunol, V112, pS1, DOI 10.1016/S0091-6749(03)01859-1; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; BANERJI D, 2004, ALLERGY ASTHMA PROC, V25, pP206; Casale TB, 2001, ANN ALLERG ASTHMA IM, V87, P379, DOI 10.1016/S1081-1206(10)62918-3; Cave A, 1999, PHARMACOL THERAPEUT, V83, P153, DOI 10.1016/S0163-7258(99)00019-4; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Derom E, 2005, PULM PHARMACOL THER, V18, P328, DOI 10.1016/j.pupt.2005.01.004; Dietzel K, 2001, PROG R RES, V31, P91; DROLLMANN A, 2002, AM J RESP CRIT CARE, V165, pA188; Dubus JC, 2001, ALLERGY, V56, P944, DOI 10.1034/j.1398-9995.2001.00100.x; ENGELSTAETTER R, 2004, AM J RESP CRIT CARE, V169, pA92; Fernandes A L, 2001, Sao Paulo Med J, V119, P169, DOI 10.1590/S1516-31802001000500004; Georgitis JW, 1999, CHEST, V115, P210, DOI 10.1378/chest.115.1.210; Joshi M, 2001, METHOD FIND EXP CLIN, V23, P531, DOI 10.1358/mf.2001.23.10.677118; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Lee DKC, 2005, CHEST, V127, P851, DOI 10.1378/chest.127.3.851; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; Mealy NE, 2001, DRUG FUTURE, V26, P1033, DOI 10.1358/dof.2001.026.11.642072; *NAT ASTHM ED PREV, 2002, J ALLERGY CLIN IMM S, V110, pS142; *NAT I HLTH NAT HE, 2005, GLOB IN ASTHM; Nave R, 2005, PULM PHARMACOL THER, V18, P390, DOI 10.1016/j.pupt.2005.02.012; Nave R, 2004, CLIN PHARMACOKINET, V43, P479, DOI 10.2165/00003088-200443070-00004; NAVE R, 2003, AM J RESP CRIT CARE, V167, pA771; Nave R, 2004, AM J RESP CRIT CARE, V169, pA91; NAVE R, 2003, J ALLERGY CLIN IMMUN, V111, pA606; *NIH, 1997, NIH PUBL; Postma DS, 2001, EUR RESPIR J, V17, P1083, DOI 10.1183/09031936.01.00099701; RAND CS, 1998, EUR RESPIR REV, V8, P270; Richter K, 2005, J CLIN PHARMACOL, V45, P146, DOI 10.1177/0091270004271094; Ringdal N, 2000, RESP MED, V94, P482, DOI 10.1053/rmed.1999.0758; Rohatagi S, 2003, J CLIN PHARMACOL, V43, P365, DOI 10.1177/0091270002250998; Rohatagi Shashank, 2005, Am J Ther, V12, P201; Roland NJ, 2004, CHEST, V126, P213, DOI 10.1378/chest.126.1.213; Szefler S, 2005, CHEST, V128, P1104, DOI 10.1378/chest.128.3.1104; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; Weinbrenner A, 2002, J CLIN ENDOCR METAB, V87, P2160, DOI 10.1210/jc.87.5.2160; *WHO, 2000, BRONCH ASTHM FACT SH	37	52	55	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1206	1212		10.1016/j.jaci.2005.08.037	http://dx.doi.org/10.1016/j.jaci.2005.08.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337447				2022-12-18	WOS:000235687000005
J	Pfab, F; Hammes, M; Backer, M; Huss-Marp, J; Athanasiadis, GI; Tolle, TR; Behrendt, H; Ring, J; Darsow, U				Pfab, F; Hammes, M; Backer, M; Huss-Marp, J; Athanasiadis, GI; Tolle, TR; Behrendt, H; Ring, J; Darsow, U			Preventive effect of acupuncture on histamine-induced itch: A blinded, randomized, placebo-controlled, crossover trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Tech Univ Munich, Dept Dermatol & Allergy, D-80802 Munich, Germany; Tech Univ Munich, Div Environm Dermatol & Allergy GSF, TUM, D-80802 Munich, Germany; Tech Univ Munich, Dept Neurol, D-80802 Munich, Germany; Knappschafts Krankenhaus, Kliniken Essen Mitte, Dept Internal & Integrat Med 5, Essen, Germany	Technical University of Munich; Technical University of Munich; Technical University of Munich; Kliniken Essen-Mitte	Pfab, F (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy, Biedersteiner Str 29, D-80802 Munich, Germany.		Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				Behrendt H, 2001, ACI INT, V13, P122; BELGRADE MJ, 1984, ACTA DERM-VENEREOL, V64, P129; Birch S, 2004, J ALTERN COMPLEM MED, V10, P481, DOI 10.1089/1075553041323911; Darsow U, 2001, INT ARCH ALLERGY IMM, V124, P326, DOI 10.1159/000053748; Darsow U, 1996, ARCH DERMATOL RES, V288, P436, DOI 10.1007/BF02505231; LUNDEBERG T, 1987, BRIT J DERMATOL, V117, P771, DOI 10.1111/j.1365-2133.1987.tb07359.x; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V116, P153, DOI 10.1016/j.jaci.2005.03.017; Yosipovitch G, 2003, LANCET, V361, P690, DOI 10.1016/S0140-6736(03)12570-6; ZHANG E, 1990, CHINESE ACUPUNCTURE, P80; Zijlstra FJ, 2003, MEDIAT INFLAMM, V12, P59, DOI 10.1080/0962935031000114943	10	52	53	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1386	1388		10.1016/j.jaci.2005.08.055	http://dx.doi.org/10.1016/j.jaci.2005.08.055			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337477				2022-12-18	WOS:000235687000036
J	Hatab, AZ; Ballas, ZK				Hatab, AZ; Ballas, ZK			Caseating granulomatous disease in common variable immunodeficiency treated with infliximab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TUMOR-NECROSIS-FACTOR; TUBERCULOSIS; SARCOIDOSIS; MECHANISMS; INFECTION		Univ Iowa, Dept Internal Med, Div Allergy Immunol, Dept Internal Med,Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA; Iowa City VA Med Ctr, Iowa City, IA USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Hatab, AZ (corresponding author), Univ Iowa, Dept Internal Med, Div Allergy Immunol, Dept Internal Med,Univ Iowa Hosp & Clin, C42-E-13,GH,200 Hawkins Dr, Iowa City, IA 52242 USA.			Ballas, Zuhair/0000-0001-5569-1230; Knaack, Aaron/0000-0001-7712-1415				Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Fasano MB, 1996, MEDICINE, V75, P251, DOI 10.1097/00005792-199609000-00002; Gardam MA, 2003, LANCET INFECT DIS, V3, P148, DOI 10.1016/S1473-3099(03)00545-0; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; Moller DR, 2003, J INTERN MED, V253, P31, DOI 10.1046/j.1365-2796.2003.01075.x; PIERSON JC, 1993, CUTIS, V52, P221; TORRELO A, 1995, PEDIATR DERMATOL, V12, P170, DOI 10.1111/j.1525-1470.1995.tb00147.x; Tufariello JM, 2003, LANCET INFECT DIS, V3, P578, DOI 10.1016/S1473-3099(03)00741-2	9	52	54	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1161	1162		10.1016/j.jaci.2005.08.041	http://dx.doi.org/10.1016/j.jaci.2005.08.041			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275393	Bronze			2022-12-18	WOS:000235686700034
J	Presta, LG				Presta, LG			Selection, design, and engineering of therapeutic antibodies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						antibody engineering; target selection; biologic therapeutics	COMPLEMENTARITY-DETERMINING REGIONS; FC-GAMMA-RIII; HUMAN IGG1; MONOCLONAL-ANTIBODIES; HUMANIZED ANTIBODIES; BINDING-SITE; CANCER; GLYCOSYLATION; CYTOTOXICITY; GENERATION	mAbs account for an increasing portion of marketed human biological therapeutics. As a consequence, the importance of optimal selection, design, and engineering of these not only has expanded in the past 2 decades but also is now coming into play as a competitive factor. This review delineates the 4 basic areas for optimal therapeutic antibody selection and provides examples of the increasing number of considerations necessary for, and options available for, antibody design. Though some of the advances in antibody technology (eg, antibodies derived from phage-display libraries) have already made it to market, other more recent advances, such as engineering antibodies for enhanced effector functions, may not be far behind, especially given the increasing competition for therapeutic antibodies to the same target (eg, anti-CD20 and anti-TNF-alpha).	Schering Plough Biopharma, Palo Alto, CA 94304 USA	Merck & Company	Presta, LG (corresponding author), Schering Plough Biopharma, 901 Calif Ave, Palo Alto, CA 94304 USA.	leonard.presta@spcorp.com						Adams GP, 2001, CANCER RES, V61, P4750; ANGAL S, 1993, MOL IMMUNOL, V30, P105, DOI 10.1016/0161-5890(93)90432-B; Cacia J, 1996, BIOCHEMISTRY-US, V35, P1897, DOI 10.1021/bi951526c; Carter P, 2001, J IMMUNOL METHODS, V248, P7, DOI 10.1016/S0022-1759(00)00339-2; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Cichy J, 2003, J CELL BIOL, V161, P839, DOI 10.1083/jcb.200302098; Ewert S, 2004, METHODS, V34, P184, DOI 10.1016/j.ymeth.2004.04.007; Frederick L, 2000, CANCER RES, V60, P1383; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; Hanes J, 2000, NAT BIOTECHNOL, V18, P1287, DOI 10.1038/82407; Helguera G, 2002, CLIN IMMUNOL, V105, P233, DOI 10.1006/clim.2002.5302; Hinton PR, 2004, J BIOL CHEM, V279, P6213, DOI 10.1074/jbc.C300470200; Hoet RM, 2005, NAT BIOTECHNOL, V23, P344, DOI 10.1038/nbt1067; Idusogie EE, 2000, J IMMUNOL, V164, P4178, DOI 10.4049/jimmunol.164.8.4178; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Josephson K, 2002, STRUCTURE, V10, P981, DOI 10.1016/S0969-2126(02)00791-8; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Linenberger ML, 2005, LEUKEMIA, V19, P176, DOI 10.1038/sj.leu.2403598; Mackay F, 2003, CYTOKINE GROWTH F R, V14, P311, DOI 10.1016/S1359-6101(03)00023-6; Magro G, 2003, J PATHOL, V200, P357, DOI 10.1002/path.1360; Marks James D, 2004, Methods Mol Biol, V248, P201; Niv Revital, 2001, Current Pharmaceutical Biotechnology, V2, P19, DOI 10.2174/1389201013378824; Niwa R, 2004, CANCER RES, V64, P2127, DOI 10.1158/0008-5472.CAN-03-2068; Pavlou AK, 2005, EUR J PHARM BIOPHARM, V59, P389, DOI 10.1016/j.ejpb.2004.11.007; PRESS MF, 1990, ONCOGENE, V5, P953; Presta Leonard G., 2002, Current Pharmaceutical Biotechnology, V3, P237, DOI 10.2174/1389201023378256; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Qu ZX, 2005, METHODS, V36, P84, DOI 10.1016/j.ymeth.2005.01.008; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; Rastetter W, 2004, ANNU REV MED, V55, P477, DOI 10.1146/annurev.med.55.091902.104249; Reverter JC, 1996, J CLIN INVEST, V98, P863, DOI 10.1172/JCI118859; Riechmann L, 1999, J IMMUNOL METHODS, V231, P25, DOI 10.1016/S0022-1759(99)00138-6; Ross JS, 2004, AM J CLIN PATHOL, V122, P598, DOI 10.1309/5CWPU41AFR1VYM3F; Scallon B, 2004, MOL IMMUNOL, V41, P73, DOI 10.1016/j.molimm.2004.01.006; Schuurman J, 2001, MOL IMMUNOL, V38, P1, DOI 10.1016/S0161-5890(01)00050-5; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smallshaw JE, 2003, NAT BIOTECHNOL, V21, P387, DOI 10.1038/nbt800; SPIEKERPOLET H, 1995, P NATL ACAD SCI USA, V92, P9348, DOI 10.1073/pnas.92.20.9348; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; TAO MH, 1989, J IMMUNOL, V143, P2595; Tolcher AW, 2003, J CLIN ONCOL, V21, P211, DOI 10.1200/JCO.2003.05.137; Tsurushita N, 2005, METHODS, V36, P69, DOI 10.1016/j.ymeth.2005.01.007; Tsurushita N, 2004, J IMMUNOL METHODS, V295, P9, DOI 10.1016/j.jim.2004.08.018; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; WRIGHT A, 1993, SPRINGER SEMIN IMMUN, V15, P259; Wurzburg BA, 2000, IMMUNITY, V13, P375, DOI 10.1016/S1074-7613(00)00037-6; Yamane-Ohnuki N, 2004, BIOTECHNOL BIOENG, V87, P614, DOI 10.1002/bit.20151	52	52	187	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					731	736		10.1016/j.jaci.2005.08.003	http://dx.doi.org/10.1016/j.jaci.2005.08.003			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210043				2022-12-18	WOS:000235686600002
J	Arbes, SJ; Sever, M; Mehta, J; Collette, N; Thomas, B; Zeldin, DC				Arbes, SJ; Sever, M; Mehta, J; Collette, N; Thomas, B; Zeldin, DC			Exposure to indoor allergens in day-care facilities: Results from 2 North Carolina counties	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alternaria species; Alt a 1; Bla g 1; Can f 1; cat allergen; child day-care centers; cockroach allergen; day care; Der f 1; Der p 1; dog allergen; dust mite allergen; Fel d 1; indoor allergens; mouse allergen; Mus m 1	HOUSE-DUST MITE; INNER-CITY CHILDREN; DER-P-I; FEL D 1; MULTIPLE COMPARISONS; COCKROACH ALLERGENS; DOMESTIC ALLERGENS; EPIDEMIOLOGIC DATA; ATOPIC CHILDREN; NATIONAL-SURVEY	Background: With 63% of US children under 5 years of age in regular child care, day-care facilities could be an important source of exposure to indoor allergens. Objective: This study examined levels of 7 indoor allergens in 89 day-care facilities in 2 North Carolina counties. Methods: At each facility, a questionnaire was administered, observations were made, and vacuumed dust samples were collected from carpeted and noncarpeted areas of one room. Allergen concentrations were measured with antibody-based ELISAs. Results: Each allergen was detected in a majority of facilities (52% to 100%). Geometric mean concentrations were 5.19 mu g/g for Alternaria alternata, 2.06 mu g/g for Can f 1, 1.43 mu g/g for Fel d 1, 0.21 U/g for Bla g 1, 0.20 mu g/g for Der p 1, 0.10 mu g/g for Der f 1, and 0.01 mu g/g for Mus m 1. Concentrations for 5 of the 7 allergens were not statistically different from concentrations found in southern US homes sampled in the National Survey of Lead and Allergens in Housing. In rooms with carpet and hard-surfaced flooring, levels of A alternata, Can f 1, Der f 1, Der p 1, and Fel d 1 were statistically higher on carpet. Conclusions: In this survey of day-care facilities in North Carolina, detectable levels of indoor allergens were commonly found. For many young children and day-care staff, day-care facilities might be a source of clinically relevant exposures to indoor allergens.	NIEHS, NIH, Div Intramural Res, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Zeldin, DC (corresponding author), NIEHS, NIH, Div Intramural Res, POB 12233,MD D2-01, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307; Sever, Michelle/0000-0002-2435-1214	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025041, Z01ES025044, ZIAES025041] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; Burge H, 1993, INDOOR ALLERGENS ASS; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53, DOI 10.1046/j.1365-2222.1998.00183.x; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; DEANDRADE AD, 1995, J ALLERGY CLIN IMMUN, V95, P1158, DOI 10.1016/S0091-6749(95)70071-4; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Engelhart S, 2002, INT J HYG ENVIR HEAL, V205, P453, DOI 10.1078/1438-4639-00192; Fernandez-Caldas E, 2001, ANN ALLERG ASTHMA IM, V87, P196, DOI 10.1016/S1081-1206(10)62225-9; Ferrari E, 2004, J ALLERGY CLIN IMMUN, V114, P341, DOI 10.1016/j.jaci.2004.04.028; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Korsgaard J, 1998, ALLERGY, V53, P77, DOI 10.1111/j.1398-9995.1998.tb05003.x; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995, DOI 10.1164/ajrccm.164.6.2011107; MUNIR AKM, 1995, CLIN EXP ALLERGY, V25, P119, DOI 10.1111/j.1365-2222.1995.tb01016.x; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; PLATTSMILLS TA, 1997, J ALLERGY CLIN IMM S, V100, P2; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339, DOI 10.1159/000235398; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; Rullo VEV, 2002, J ALLERGY CLIN IMMUN, V110, P582, DOI 10.1067/mai.2002.127511; Savitz DA, 1998, AM J EPIDEMIOL, V147, P813, DOI 10.1093/oxfordjournals.aje.a009532; SAVITZ DA, 1995, AM J EPIDEMIOL, V142, P904, DOI 10.1093/oxfordjournals.aje.a117737; SMITH KE, 2002, US BUREAU CENSUS WHO; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Thompson JR, 1998, AM J EPIDEMIOL, V147, P801, DOI 10.1093/oxfordjournals.aje.a009530; *US CENS BUR, 1995, COUNT EST POV; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527, DOI 10.1289/ehp.02110527; Wickman M, 1999, CLIN EXP ALLERGY, V29, P626; Zhang L, 1997, CLIN EXP ALLERGY, V27, P876, DOI 10.1111/j.1365-2222.1997.tb01227.x	31	52	52	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					133	139		10.1016/j.jaci.2005.04.022	http://dx.doi.org/10.1016/j.jaci.2005.04.022			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990786				2022-12-18	WOS:000235686300021
J	Wunschmann, S; Gustchina, A; Chapman, MD; Pomes, A				Wunschmann, S; Gustchina, A; Chapman, MD; Pomes, A			Cockroach allergen Bla g 2: An unusual aspartic proteinase	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	60th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 18-23, 2004	San Francisco, CA	Amer Acad Allergy, Asthma & Immunol		asthma; allergy; allergens; cock-roach; aspartic proteinase	PREGNANCY-ASSOCIATED GLYCOPROTEINS; HOUSE-DUST MITE; ACTIVE-SITE; CATHEPSIN-D; P-I; PROTEASE; IDENTIFICATION; CLONING; PEPSIN; CD23	Background: Enzymatic activity of mite, fungal, and bee venom allergens is thought to potentiate their allergenicity. Bla g 2 is a potent cockroach allergen, but despite sharing sequence homology with aspartic proteinases, it contains critical amino acid substitutions that impair proteolytic activity. The biologic function of Bla g 2 remains unclear. Objective: We sought to investigate the effects of specific amino acid substitutions on enzymatic activity, and the peptide-binding capability of Bla g 2. Methods: Site-directed mutagenesis was used to produce a recombinant Bla g 2 mutant (Mut) with corrected canonical triads and a flap region. Another mutant (MutF(-)) was expressed after additional mutations in the flap region of Mut. Bla g 2 wild-type (Wt), Mut, and MutF(-) were assayed for aspartic proteinase activity, and Bla g 2 Wt was tested for pepstatin binding. Results: Recombinant Bla g 2 Wit and Mut did not show enzymatic activity in a milk-clotting and hemoglobin assay. By using a modified hemoglobin assay, residual activity inhibited by pepstatin was detected for MutF(-) and Wt at 20 mu g/mL, whereas pepsin was active at a 1000-fold lower concentration. Most of Bla g 2 binding to pepstatin-agarose was nonspecific. Conclusion: Residual proteolytic activity was found for Bla g 2 at concentrations of approximately 4 mM. This weak activity suggests that proteolysis is not the primary function of this allergen and that it is unlikely to contribute to the allergenicity of Bla g 2. Bla g 2 has a cleft that might specifically bind ligands other than pepstatin.	INDOOR Biotechnol Inc, Charlottesville, VA 22903 USA; NCI, Frederick, MD 21701 USA	INDOOR Biotechnologies; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wunschmann, S (corresponding author), INDOOR Biotechnol Inc, 1216 Harris St, Charlottesville, VA 22903 USA.	sabina@inbio.com	Pomés, Anna/H-7010-2019	Pomés, Anna/0000-0002-8729-1829; Chapman, Martin/0000-0002-0845-3632	NATIONAL CANCER INSTITUTE [Z01BC010348, ZIABC010348] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; CHO WL, 1992, J BIOL CHEM, V267, P21823; CHO WL, 1991, INSECT BIOCHEM, V21, P165, DOI 10.1016/0020-1790(91)90047-I; COMETTGE R, 2002, INSECT BIOCHEM MOLEC, V32, P1635; COTTRELL TJ, 1995, J BIOL CHEM, V270, P19974, DOI 10.1074/jbc.270.34.19974; DHANARAJ V, 1997, STRUCTURE BASED DRUG, P321; Garbayo JM, 2000, MOL REPROD DEV, V57, P311, DOI 10.1002/1098-2795(200012)57:4&lt;311::AID-MRD2&gt;3.0.CO;2-F; Green JA, 1999, BIOL REPROD, V60, P1069, DOI 10.1095/biolreprod60.5.1069; Guruprasad K, 1996, PROTEIN ENG, V9, P849, DOI 10.1093/protein/9.10.849; Gustchina A, 2005, J MOL BIOL, V348, P433, DOI 10.1016/j.jmb.2005.02.062; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; KAY J, 1976, BIOCHEM J, V157, P499, DOI 10.1042/bj1570499; Markgren PO, 2001, ANAL BIOCHEM, V291, P207, DOI 10.1006/abio.2001.5025; Mathialagan N, 1996, P NATL ACAD SCI USA, V93, P13653, DOI 10.1073/pnas.93.24.13653; Mogensen JE, 2002, J BIOL CHEM, V277, P23684, DOI 10.1074/jbc.M202065200; Park YN, 1997, J BIOCHEM-TOKYO, V121, P118, DOI 10.1093/oxfordjournals.jbchem.a021553; PEARL L, 1984, FEBS LETT, V174, P96, DOI 10.1016/0014-5793(84)81085-6; Peracchi A, 2001, TRENDS BIOCHEM SCI, V26, P497, DOI 10.1016/S0968-0004(01)01911-9; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; Pomes A, 2002, EUR J BIOCHEM, V269, P3086, DOI 10.1046/j.1432-1033.2002.02990.x; Pomes A, 2002, AM J RESP CRIT CARE, V165, P391, DOI 10.1164/ajrccm.165.3.2104027; POMES A, 2001, ALLERGY CLIN IMMUNOL, V13, P162; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1046/j.1365-2222.1997.d01-415.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Shimotohno A, 2001, J BIOCHEM, V129, P943, DOI 10.1093/oxfordjournals.jbchem.a002941; SIELECKI AR, 1989, SCIENCE, V243, P1346, DOI 10.1126/science.2493678; Sorgine MHF, 2000, J BIOL CHEM, V275, P28659, DOI 10.1074/jbc.M005675200; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; Xie S, 1997, P NATL ACAD SCI USA, V94, P12809, DOI 10.1073/pnas.94.24.12809; XIE SC, 1991, P NATL ACAD SCI USA, V88, P10247, DOI 10.1073/pnas.88.22.10247	33	52	54	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					140	145		10.1016/j.jaci.2005.04.024	http://dx.doi.org/10.1016/j.jaci.2005.04.024			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	017IC	15990787				2022-12-18	WOS:000235686300022
J	Lewis, CC; Chu, HW; Westcott, JY; Tucker, A; Langmack, EL; Sutherland, ER; Kraft, M				Lewis, CC; Chu, HW; Westcott, JY; Tucker, A; Langmack, EL; Sutherland, ER; Kraft, M			Airway fibroblasts exhibit a synthetic phenotype in severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PDGF; airway fibroblasts; asthma	GROWTH-FACTOR RECEPTORS; SUBEPITHELIAL FIBROSIS; BETA-RECEPTORS; FIBROGENIC CYTOKINES; PULMONARY FIBROSIS; FLOW OBSTRUCTION; BRONCHIAL-ASTHMA; PDGF-ALPHA; IN-VITRO; B-CHAIN	Background: Platelet-derived growth factor (PDGF) may have a significant role in airway remodeling in asthma, because it is a powerful inductor of many airway fibroblast activities such as collagen synthesis. Objective: To determine whether PDGF is a significant contributor to airway remodeling in patients with asthma by enhancing airway fibroblast procollagen I expression. Methods: Six normal controls without asthma, 10 subjects with mild to moderate asthma, and 5 subjects with severe asthma underwent bronchoscopy with endobronchial biopsy. Biopsies were placed in Dulbecco modified Eagle medium and fibroblasts cultured in the presence and absence of PDGF isoforms -AA, -BB, and -AB (1, 5, 10, 100 ng/mL) and insulin-like growth factor 1 (100 ng/mL). Fibroblast procollagen I and PDGF receptors (PDGFRs) alpha and beta expression were determined by ELISA. Results: Platelet-derived growth factor BB significantly enhanced fibroblast procollagen I expression in patients with severe asthma compared with patients with mild/moderate asthma and normal controls. Furthermore, the baseline fibroblast expression of PDGFR-beta was significantly greater in patients with severe asthma compared with the other groups. Conclusion: This pilot study suggests that airway fibroblasts from patients with severe asthma exhibit a synthetic phenotype, which may be driven by the overexpression of PDGFR-beta.	Natl Jewish Med & Res Ctr, Div Pulm Sci & Crit Care Med, Denver, CO USA; Colorado State Univ, Ft Collins, CO 80523 USA; Duke Univ, Med Ctr, Durham, NC USA	National Jewish Health; Colorado State University; Duke University	Lewis, CC (corresponding author), Univ Calif San Francisco, Lung Biol Ctr, Box 2922, San Francisco, CA 94143 USA.	cclewis@itsa.ucsf.edu	Sutherland, Everett Rand/B-7666-2008	Langmack, Esther/0000-0003-4991-7808	NHLBI NIH HHS [HL03343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM THOR SOC BOARD, 1987, AM REV RESPIR DIS, V136, P328; AUBERT JD, 1994, AM J PHYSIOL, V266, pL655, DOI 10.1152/ajplung.1994.266.6.L655; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035, DOI 10.1164/ajrccm.160.3.9902064; CHANEZ P, 1995, ALLERGY, V50, P878, DOI 10.1111/j.1398-9995.1995.tb02493.x; CHANG LY, 1988, AM J PATHOL, V131, P156; Dube J, 2000, INT J EXP PATHOL, V81, P429, DOI 10.1046/j.1365-2613.2000.00173.x; Dube J, 1998, LAB INVEST, V78, P297; ELIAS JA, 1990, ANN NY ACAD SCI, V580, P233, DOI 10.1111/j.1749-6632.1990.tb17932.x; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELLSTROM B, 1989, KIDNEY INT, V36, P1099, DOI 10.1038/ki.1989.306; Green RJ, 1997, J PERIODONTAL RES, V32, P209, DOI 10.1111/j.1600-0765.1997.tb00526.x; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; Hudon C, 1997, ANN ALLERG ASTHMA IM, V78, P195; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOVACS EJ, 1994, FASEB J, V8, P854, DOI 10.1096/fasebj.8.11.7520879; KOVACS EJ, 1991, IMMUNOL TODAY, V12, P17, DOI 10.1016/0167-5699(91)90107-5; KRAFT M, 1995, EUR RESPIR J, V8, P1966, DOI 10.1183/09031936.95.08111966; Kraft M, 2001, J ALLERGY CLIN IMMUN, V107, P602, DOI 10.1067/mai.2001.113760; MARTINET Y, 1987, NEW ENGL J MED, V317, P202, DOI 10.1056/NEJM198707233170404; Muro S, 2000, CLIN CHEST MED, V21, P225, DOI 10.1016/S0272-5231(05)70263-X; *NATL ASTHM ED PRE, 1997, 974051 NIH; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; OSORNIOVARGAS AR, 1995, AM J RESP CELL MOL, V12, P33, DOI 10.1165/ajrcmb.12.1.7811469; Reif S, 2003, J BIOL CHEM, V278, P8083, DOI 10.1074/jbc.M212927200; REUTERDAHL C, 1993, J CLIN INVEST, V91, P2065, DOI 10.1172/JCI116429; ROCHE WR, 1989, LANCET, V1, P520; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1989, LANCET, V1, P1179; RUBIN K, 1988, LANCET, V1, P1353; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; THORNTON SC, 1990, J LEUKOCYTE BIOL, V47, P312, DOI 10.1002/jlb.47.4.312; WARHEIT DB, 1984, AM REV RESPIR DIS, V129, P301; Zhang K, 1996, BIOL SIGNAL, V5, P232	41	52	53	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					534	540		10.1016/j.jaci.2004.11.051	http://dx.doi.org/10.1016/j.jaci.2004.11.051			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753901				2022-12-18	WOS:000227687000016
J	Rizzo, R; Mapp, CE; Melchiorri, L; Maestrelli, P; Visentin, A; Ferretti, S; Bononi, I; Miotto, D; Baricordi, OR				Rizzo, R; Mapp, CE; Melchiorri, L; Maestrelli, P; Visentin, A; Ferretti, S; Bononi, I; Miotto, D; Baricordi, OR			Defective production of soluble HLA-G molecules by peripheral blood monocytes in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; sHLA-G; IL-10; PBMC	INDUCED AIRWAY HYPERREACTIVITY; ALLERGEN-SPECIFIC TH1; G MESSENGER-RNA; G EXPRESSION; T-CELLS; CLASS-I; IL-10; INTERLEUKIN-10; GENE; MODULATION	Background: HLA-G, a human nonclassic MHC class I molecule, is responsible for complex immunoinhibitory functions. HLA-G is expressed as membrane-bound and is secreted as soluble molecules by the peripheral blood CD14(+) monocytes activated by IL-10. Objective: It has been reported that LPS stimulation induces IL-10 production by PBMCs and that IL-10 levels are reduced L in patients with severe asthma compared with patients with mild asthma and healthy subjects. The study was designed to investigate whether this impaired IL-10 production can affect the expression and the secretion of soluble HLA-G (sHLA-G)-1/HLA-G5 molecules. Methods: We investigated the production of sHLA-G1/HLA-G5 and IL-10 by specific ELISAs in the culture supernatants of LPS-activated PBMCs from 24 healthy subjects and 20 patients with moderate to severe persistent asthma. Results: LPS stimulation induced the secretion of IL-10 and sHLA-G1/HLA-G5 molecules in all healthy subjects. whereas in patients with asthma, the levels of IL-10 were significantly lower (P < .001) and the number of cultures exhibiting detectable sHLA-G1/HLA-G5 was reduced (7/20; P < .001). The addition of exogenous IL-10 to LPS-stimulated PBMCs from patients with asthma restored normal sHLA-G1/HLA-G5 production. Conclusion: Our data suggest that a specific deficit of IL-10 secretion in patients with asthma could prevent the normal production of sHLA-G1/1ILA-G5 molecules. The reduction of immunosuppressive activity mediated by HLA-G could in turn contribute to the persistence of chronic airway inflammation in asthma.	Univ Ferrara, Dept Diagnost & Expt Med, Med Genet Sect, I-44100 Ferrara, Italy; Univ Ferrara, Dept Clin & Expt Med, Sect Hyg & Occupat Med, I-44100 Ferrara, Italy; Univ Padua, Dept Environm Med & Publ Hlth, Sect Occupat Med, Padua, Italy; Univ Ferrara, Dept Diagnost & Expt Med, Sec Pathol, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy	University of Ferrara; University of Ferrara; University of Padua; University of Ferrara; University of Ferrara	Baricordi, OR (corresponding author), Univ Ferrara, Dept Diagnost & Expt Med, Med Genet Sect, Cia L Borsari 46, I-44100 Ferrara, Italy.	bri@unife.it	Ferretti, Stefano/K-8636-2015; Visentin, Andrea/L-7379-2017	Ferretti, Stefano/0000-0001-5241-2101; Visentin, Andrea/0000-0001-6830-6717; Bononi, Ilaria/0000-0002-5286-5845				ABRAMS JS, 1992, IMMUNOL REV, V127, P5, DOI 10.1111/j.1600-065X.1992.tb01406.x; Al-Shammri S, 2004, J NEUROL SCI, V222, P21, DOI 10.1016/j.jns.2004.03.027; Aractingi S, 2001, AM J PATHOL, V159, P71, DOI 10.1016/S0002-9440(10)61675-6; Bainbridge D, 2001, TRENDS IMMUNOL, V22, P548, DOI 10.1016/S1471-4906(01)02031-2; Bainbridge DRJ, 2000, J REPROD IMMUNOL, V48, P17, DOI 10.1016/S0165-0378(00)00070-X; Carosella ED, 2001, TRENDS IMMUNOL, V22, P553, DOI 10.1016/S1471-4906(01)02007-5; *COMM COMM EUR, 1972, COMM REL QUEST CECA; Creput C, 2003, HUM IMMUNOL, V64, P1033, DOI 10.1016/j.humimm.2003.08.356; Crisa L, 1997, J EXP MED, V186, P289, DOI 10.1084/jem.186.2.289; D'Alfonso S, 2000, GENES IMMUN, V1, P231, DOI 10.1038/sj.gene.6363666; DeSmedt T, 1997, EUR J IMMUNOL, V27, P1229, DOI 10.1002/eji.1830270526; Eskdale J, 1998, P NATL ACAD SCI USA, V95, P9465, DOI 10.1073/pnas.95.16.9465; Fainardi E, 2003, J NEUROIMMUNOL, V142, P149, DOI 10.1016/S0165-5728(03)00266-2; Fournel S, 2000, TISSUE ANTIGENS, V55, P510, DOI 10.1034/j.1399-0039.2000.550602.x; Fournel S, 2000, J IMMUNOL, V164, P6100, DOI 10.4049/jimmunol.164.12.6100; FUJII T, 1994, J IMMUNOL, V153, P5516; Gentile DA, 2004, ANN ALLERG ASTHMA IM, V92, P538, DOI 10.1016/S1081-1206(10)61761-9; GERAGHTY DE, 1987, P NATL ACAD SCI USA, V84, P9145, DOI 10.1073/pnas.84.24.9145; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hviid TVF, 2003, IMMUNOGENETICS, V55, P63, DOI 10.1007/s00251-003-0547-z; ISHITANI A, 1992, P NATL ACAD SCI USA, V89, P3947, DOI 10.1073/pnas.89.9.3947; Kapasi K, 2000, IMMUNOLOGY, V101, P191, DOI 10.1046/j.1365-2567.2000.00109.x; Karjalainen J, 2003, CLIN EXP ALLERGY, V33, P78, DOI 10.1046/j.1365-2222.2003.01577.x; Khosrotehrani K, 2001, J INVEST DERMATOL, V117, P750, DOI 10.1046/j.0022-202x.2001.01487.x; KIRSZENBAUM M, 1994, P NATL ACAD SCI USA, V91, P4209, DOI 10.1073/pnas.91.10.4209; Lila N, 2002, CIRCULATION, V105, P1949, DOI 10.1161/01.CIR.0000015075.89984.46; Lim S, 2004, ALLERGY, V59, P505, DOI 10.1111/j.1398-9995.2004.00455.x; Liu LM, 1998, INT IMMUNOL, V10, P1017, DOI 10.1093/intimm/10.8.1017; Lozano JM, 2002, AIDS, V16, P347, DOI 10.1097/00002030-200202150-00005; Maejima M, 1997, AM J REPROD IMMUNOL, V38, P79; Maier S, 1999, TRANSPL P, V31, P1849, DOI 10.1016/S0041-1345(99)00186-4; Makhseed M, 2001, HUM REPROD, V16, P2219, DOI 10.1093/humrep/16.10.2219; Matsumoto K, 2004, INT ARCH ALLERGY IMM, V134, P295, DOI 10.1159/000079167; Moreau P, 1999, INT IMMUNOL, V11, P803, DOI 10.1093/intimm/11.5.803; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Onno M, 2000, J IMMUNOL, V164, P6426, DOI 10.4049/jimmunol.164.12.6426; Park GM, 2004, BIOCHEM BIOPH RES CO, V313, P606, DOI 10.1016/j.bbrc.2003.11.153; Paul P, 1999, CANCER RES, V59, P1954; Paul P, 1998, P NATL ACAD SCI USA, V95, P4510, DOI 10.1073/pnas.95.8.4510; Raghupathy R, 2001, SEMIN IMMUNOL, V13, P219, DOI 10.1006/smim.2001.0316; Randolph DA, 1999, J IMMUNOL, V162, P2375; Rebmann V, 2001, TISSUE ANTIGENS, V57, P15, DOI 10.1034/j.1399-0039.2001.057001015.x; Rebmann V, 2003, HUM IMMUNOL, V64, P1017, DOI 10.1016/j.humimm.2003.08.354; RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P5249, DOI 10.1073/pnas.94.10.5249; SHEFFER AL, 1993, MED CARE, V31, pMS20; Tomita K, 2002, CLIN IMMUNOL, V102, P258, DOI 10.1006/clim.2001.5176; Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x; Vieira PL, 2003, J IMMUNOL, V170, P4483, DOI 10.4049/jimmunol.170.9.4483; Yang YP, 1996, J IMMUNOL, V156, P4224	49	52	58	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					508	513		10.1016/j.jaci.2004.11.031	http://dx.doi.org/10.1016/j.jaci.2004.11.031			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753897				2022-12-18	WOS:000227687000012
J	Cui, JQ; Pazdziorko, S; Miyashiro, JS; Thakker, P; Pelker, JW; DeClercq, C; Jiao, AP; Gunn, J; Mason, L; Leonard, JP; Williams, CMM; Marusic, S				Cui, JQ; Pazdziorko, S; Miyashiro, JS; Thakker, P; Pelker, JW; DeClercq, C; Jiao, AP; Gunn, J; Mason, L; Leonard, JP; Williams, CMM; Marusic, S			T(H)1-mediated airway hyperresponsiveness independent of neutrophilic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway hyperresponsiveness.; T(H)1 cells; T(H)2 cells; cytokines; neutrophils	MUCUS OVERPRODUCTION; CYCLOSPORINE-A; TH2 CELLS; T-CELLS; HYPERREACTIVITY; INTERLEUKIN-4; IL-4; IMMUNOTHERAPY; SUSCEPTIBILITY; DEXAMETHASONE	Background: T(H)2-mediated allergic asthma is characterized by eosinophilia, mucus overproduction, and airway hyperresponsiveness (AHR). Although it is clear that T(H)2 cells and their cytokines; play an important role in AHR, the roles of T(H)1 cells and neutrophils in AHR are controversial. Objective: We sought to determine the roles of T(H)1 cells and neutrophils in AHR. Methods: Ovalbumin-specific CD4(+) T cells were purified from DO11.10 mice, differentiated into TO cells, and injected into naive BALB/c, lL-4RalphaKO, or IL-8RKO mice. After ovalbumin antigen challenge, cytokine mRNA levels in lung samples, as well as inflammatory cell types and numbers in bronchoalveolar lavage fluid (BALF), were determined. AHR was assessed by measuring resistance in tracheostomized mice and enhanced pause in freely moving mice. Results: T(H)1 cells induced AHR as robust as T(H)2 cells. They also induced lung inflammation dominated by neutrophils. Neither AHR nor inflammation were reduced when T(H)1 cells were transferred into IL-4RalphaKO mice. When IL-8RKO mice were used as recipients of T(H)1 cells, neutrophilia was greatly reduced, but the AHR was as strong as that seen in wild-type mice. On the other hand, dexamethasone treatment had no effect on neutrophilia but has significantly reduced AHR. Reduction in AHR was accompanied by a reduction in the numbers of lymphocytes and macrophages in BALF. Conclusions: T(H)1 cells can induce strong AHR independent of IL-4 and IL-13. The AHR is associated with the presence of lymphocytes and macrophages, but not neutrophils, in BALF. Our results point to a pathway whereby T(H)1 cells mediate AHR independent of neutrophilic inflammation.	Wyeth Ayerst Res, Cambridge, MA 02140 USA	Pfizer	Cui, JQ (corresponding author), Wyeth Ayerst Res, 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	jcui@wyeth.com	Leonard, John/M-4379-2014	Leonard, John/0000-0002-5083-1115; Thakker, Paresh/0000-0003-3059-9133				CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Cohn L, 1998, J IMMUNOL, V161, P3813; Cohn L, 1999, J IMMUNOL, V162, P6178; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; ELWOOD W, 1992, AM REV RESPIR DIS, V145, P1289, DOI 10.1164/ajrccm/145.6.1289; Foster PS, 1997, MEM I OSWALDO CRUZ, V92, P55, DOI 10.1590/S0074-02761997000800009; Frendeus B, 2000, J EXP MED, V192, P881, DOI 10.1084/jem.192.6.881; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Jain VV, 2003, CLIN EXP ALLERGY, V33, P1330, DOI 10.1046/j.1365-2222.2003.01763.x; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kibe A, 2003, AM J RESP CRIT CARE, V167, P50, DOI 10.1164/rccm.2110084; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Matsuse H, 2003, INT IMMUNOPHARMACOL, V3, P457, DOI 10.1016/S1567-5769(02)00250-3; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Noben-Trauth N, 1999, J IMMUNOL, V162, P6132; NobenTrauth N, 1997, P NATL ACAD SCI USA, V94, P10838, DOI 10.1073/pnas.94.20.10838; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; ROY R, 1974, COMPUT BIOMED RES, V7, P21, DOI 10.1016/0010-4809(74)90040-8; Sawicka E, 2003, J IMMUNOL, V171, P6206, DOI 10.4049/jimmunol.171.11.6206; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Sugimoto T, 2004, J EXP MED, V199, P535, DOI 10.1084/jem.20031368; Takaoka A, 2001, J IMMUNOL, V167, P2349, DOI 10.4049/jimmunol.167.4.2349; Vargaftig BB, 2003, AM J PHYSIOL-LUNG C, V284, pL260, DOI 10.1152/ajplung.00226.2002; Wada K, 1998, INT ARCH ALLERGY IMM, V117, P24, DOI 10.1159/000053566; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhang XR, 2003, CELL DEATH DIFFER, V10, P203, DOI 10.1038/sj.cdd.4401138; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	30	52	57	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					309	315		10.1016/j.jaci.2004.10.046	http://dx.doi.org/10.1016/j.jaci.2004.10.046			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696086				2022-12-18	WOS:000227043600015
J	de Winter-de Groot, KM; van der Ent, CK; Prins, I; Tersmette, JM; Uiterwaal, CSP				de Winter-de Groot, KM; van der Ent, CK; Prins, I; Tersmette, JM; Uiterwaal, CSP			Exhaled nitric oxide: The missing link between asthma and obesity?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BODY-MASS INDEX; CHILDREN		Univ Utrecht, Ctr Med, Dept Pediat Resp Dis, NL-3508 AB Utrecht, Netherlands; Univ Utrecht, Ctr Med, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Utrecht University; Utrecht University	de Winter-de Groot, KM (corresponding author), Univ Utrecht, Ctr Med, Dept Pediat Resp Dis, KH 01-419-0,POB 85090, NL-3508 AB Utrecht, Netherlands.							Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Shaheen SO, 1999, THORAX, V54, P396, DOI 10.1136/thx.54.5.396; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246	5	52	54	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					419	420		10.1016/j.jaci.2004.11.025	http://dx.doi.org/10.1016/j.jaci.2004.11.025			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696106				2022-12-18	WOS:000227043600034
J	Parameswaran, K; Liang, H; Fanat, A; Watson, R; Snider, DP; O'Byrne, PM				Parameswaran, K; Liang, H; Fanat, A; Watson, R; Snider, DP; O'Byrne, PM			Role for cysteinyl leukotrienes in allergen-induced change in circulating dendritic cell number in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cysteinyl leukotrienes; pranlukast; dendritic cells; allergen inhalation; asthma	AIRWAY INFLAMMATION; BRONCHIAL-MUCOSA; INDUCED SPUTUM; CHEMOKINES; RECRUITMENT; PRANLUKAST; BRONCHOCONSTRICTION; MEDIATORS; MIGRATION; CYTOKINES	Background: Dendritic cells are important antigen-presenting cells. After an allergen inhalation, their numbers rapidly decrease in circulation and increase in the airway mucosa. Objective: number of circulating dendritic cells are mediated by cysteinyl leukotrienes. Methods: In a randomized, double-blind, crossover study, we examined the effects of 2 weeks of treatment with pranlukast (a cysteinyl leukotriene 1 [CysLT(1)] receptor antagonist) 300 mg twice daily and placebo on allergen-induced changes in airway responses and circulating dendritic cells in 15 subjects with mild asthma. We examined by flow cytometry, before and at 3 hours and 24 hours after allergen inhalation, the proportion of myeloid (CD33(+)) and plasmacytoid (CD123(+)) dendritic cells (HLA-DR+, CD14(-), CD16(-)) among all peripheral blood mononuclear cells. The fraction of dendritic cells expressing CysLT(1) receptor was also determined. Results: Compared with placebo, pranlukast significantly attenuated both the maximum early (by 55%) and the late (by 39%) asthma responses, the allergen-induced methacholine airway hyperresponsiveness, and the increase in macrophage inflammatory protein 1alpha and 3alpha in induced sputum. A significantly greater proportion of CD33(+) cells (55%) expressed CysLT(1) receptor compared with CD123(+) cells (11%). Consistent with this, pranlukast prevented the allergen-induced decrease in CD33(+) dendritic cells at 3 hours postallergen (mean Delta from baseline, +4.4%) compared with placebo (mean Delta, -8.4; P < .05), but not CD123(+) cells. Conclusion: Pretreatment with pranlukast attenuated allergen-induced airway responses and the decrease in circulating myeloid dendritic cells, demonstrating a novel role of cysteinyl leukotrienes in dendritic cell trafficking.	McMaster Univ, Hlth Sci Ctr, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada; St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON, Canada	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; McMaster University	O'Byrne, PM (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Med, Room 3W10,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	obyrnep@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bandeira-Melo C, 2002, J EXP MED, V196, P841, DOI 10.1084/jem.20020516; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; Diepgen TL, 2002, PEDIAT ALLERG IMM-UK, V13, P278, DOI 10.1034/j.1399-3038.2002.01047.x; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Espinosa K, 2003, J ALLERGY CLIN IMMUN, V111, P1032, DOI 10.1067/mai.2003.1451; Hamilton A, 1998, J ALLERGY CLIN IMMUN, V102, P177, DOI 10.1016/S0091-6749(98)70083-1; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P421, DOI 10.1067/mai.2000.105010; Hromas R, 1997, BLOOD, V89, P3315; Jahnsen FL, 2000, J IMMUNOL, V165, P4062, DOI 10.4049/jimmunol.165.7.4062; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-509OC; Lukacs NW, 2001, J EXP MED, V194, P551, DOI 10.1084/jem.194.4.551; Menard G, 2000, AM J RESP CELL MOL, V23, P572, DOI 10.1165/ajrcmb.23.4.4152; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1111/j.1365-2222.1996.tb00571.x; O'Byrne PM, 2000, AM J RESP CRIT CARE, V161, pS68, DOI 10.1164/ajrccm.161.supplement_1.ltta-14; Obase Y, 2002, CHEST, V121, P143, DOI 10.1378/chest.121.1.143; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Parameswaran K, 2004, AM J RESP CRIT CARE, V169, P915, DOI 10.1164/rccm.200312-1645OC; Parameswaran K, 2000, Can Respir J, V7, P313; Penna G, 2002, HUM IMMUNOL, V63, P1164, DOI 10.1016/S0198-8859(02)00755-3; Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174; Randolph GJ, 2001, SEMIN IMMUNOL, V13, P267, DOI 10.1006/smim.2001.0322; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-0095OC; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Rossi DL, 1997, J IMMUNOL, V158, P1033; Salvi SS, 2000, CLIN EXP ALLERGY, V30, P1499, DOI 10.1046/j.1365-2222.2000.00990.x; Spanbroek R, 2000, BLOOD, V96, P3857, DOI 10.1182/blood.V96.12.3857.h8003857_3857_3865; Upham JW, 2002, CLIN EXP ALLERGY, V32, P818, DOI 10.1046/j.1365-2222.2002.01375.x; Upham JW, 2000, CYTOMETRY, V40, P50, DOI 10.1002/(SICI)1097-0320(20000501)40:1<50::AID-CYTO7>3.0.CO;2-P; Xu LL, 1996, J LEUKOCYTE BIOL, V60, P365, DOI 10.1002/jlb.60.3.365	35	52	54	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					73	79		10.1016/j.jaci.2004.03.054	http://dx.doi.org/10.1016/j.jaci.2004.03.054			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241347				2022-12-18	WOS:000222534300011
J	Diav-Citrin, O; Shechtman, S; Aharonovich, A; Moerman, L; Arnon, J; Wajnberg, R; Ornoy, A				Diav-Citrin, O; Shechtman, S; Aharonovich, A; Moerman, L; Arnon, J; Wajnberg, R; Ornoy, A			Pregnancy outcome after gestational exposure to loratadine or antihistamines: A prospective controlled cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						loratadine; antihistamines; pregnancy outcome; major anomalies		Background: Loratadine is a second-generation histamine H-1-receptor antagonist, used in the treatment of allergic conditions. No prospective controlled trials on loratadine in human pregnancy have been published to date. Objective: To determine whether the use of loratadine or other antihistamines (OAH) is associated with an increased risk of major anomalies. Methods: Callers who were counseled by the Israeli Teratogen Information Service in regard to loratadine or OAH exposure during pregnancy were prospectively collected and followed up. Pregnancy outcome was compared among three exposure groups: loratadine, OAH, and a control group of patients who were counseled for nonteratogenic exposure, nonteratogenic controls (NTC). The OAH included astemizole, chlorpheniramine, terfenadine, hydroxyzine, promethazine, and dimetindene. Results: We followed up 210 pregnancies exposed to loratadine (77.9% in the first trimester) and 267 pregnancies exposed to OAH (64.6% in the first trimester) and compared pregnancy outcome with that of 929 NTC. The rate of congenital anomalies did not differ among the groups [loratadine: 4/175 (2.3%), OAH: 10/247 (4.0%), NTC: 25/844 (3.0%), P = .553, relative risk (RR), 0.77; 95% confidence interval (CI), 0.27 to 2.19. (loratadine vs NTC); RR, 0.56; 95% CI, 0.18 to 1.77, (loratadine vs OAH)]. The rate did not differ between those exposed to antihistamines in the first trimester and the control patients [loratadine: 1/126 (0.8%), OAH: 7/146 (4.8%), NTC: 25/844 (3.0%), P =.152, RR, 0.27; 95% CI, 0.04 to 1.94, (loratadine vs NTC); RR, 0.17; 95% CI, 0.112 to 1.33, (loratadine vs OAH)]. Conclusions: This study on the use of loratadine in human pregnancy suggests that this agent does not represent a major teratogenic risk. The study was powered to find a 3-fold increase in the overall rate of major anomalies.	Hebrew Univ Jerusalem, Hadassah Med Sch, Israeli Teratogen Informat Serv, Lab Teratol, IL-91120 Jerusalem, Israel; Israel Minist Hlth, Israeli Teratogen Informat Serv, Jerusalem, Israel	Hebrew University of Jerusalem	Ornoy, A (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Israeli Teratogen Informat Serv, Lab Teratol, POB 12272, IL-91120 Jerusalem, Israel.		ornoy, asher/J-8038-2018	ornoy, asher/0000-0002-7268-3512				*CLAR SCHER CORP, 2001, PROD INF; Diav-Citrin O, 2001, TERATOLOGY, V63, P186, DOI 10.1002/tera.1033; Einarson A, 1997, ANN ALLERG ASTHMA IM, V78, P183, DOI 10.1016/S1081-1206(10)63385-6; Erez S, 1971, J Reprod Med, V7, P35; Heinonen OP, 1977, BIRTH DEFECTS DRUGS; Holmes LB, 1999, TERATOLOGY, V59, P1; Kallen B, 2002, J Matern Fetal Neonatal Med, V11, P146, DOI 10.1080/713605486; Kallen B, 2001, INT J RISK SAF MED, V14, P115; Loebstein R, 1999, J ALLERGY CLIN IMMUN, V104, P953, DOI 10.1016/S0091-6749(99)70074-6; Moore KL., 1988, DEV HUMAN CLIN ORIEN, V4th ed.; Ornoy A, 1998, REPROD TOXICOL, V12, P511, DOI 10.1016/S0890-6238(98)00035-5; PARFITT K, 1999, COMPLETE DRUG REFERE; Pastuszak A, 1996, J ALLERGY CLIN IMMUN, V98, P748, DOI 10.1016/S0091-6749(96)70122-7; Sadler T. W., 1996, LANGMANS MED EMBRYOL; Schatz M, 1997, ANN ALLERG ASTHMA IM, V78, P157, DOI 10.1016/S1081-1206(10)63382-0; Wilton LV, 1998, BRIT J OBSTET GYNAEC, V105, P882, DOI 10.1111/j.1471-0528.1998.tb10234.x	16	52	54	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1239	1243		10.1067/mai.2003.1499	http://dx.doi.org/10.1067/mai.2003.1499			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789223				2022-12-18	WOS:000183424700011
J	Wahn, U; Meltzer, EO; Finn, AF; Kowalski, ML; Decosta, P; Hedlin, G; Scheinmann, P; Bachert, C; Pinto, JER; Baena-Cagnani, C; Potter, P; Simons, FER; Ruuth, E				Wahn, U; Meltzer, EO; Finn, AF; Kowalski, ML; Decosta, P; Hedlin, G; Scheinmann, P; Bachert, C; Pinto, JER; Baena-Cagnani, C; Potter, P; Simons, FER; Ruuth, E			Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antihistamine; children; clinical trial; efficacy; fexofenadine; H-1-receptor antagonist; nasal congestion; pediatric; safety; seasonal allergic rhinitis	QUALITY-OF-LIFE; DOUBLE-BLIND; HYDROCHLORIDE 120; CETIRIZINE; PSEUDOEPHEDRINE; MG	Background: This is the first prospective, randomized, double-blind, placebo-controlled study showing statistical improvement of an H-1-antihistamine in children with seasonal allergic rhinitis in all symptoms throughout the entire treatment period. Objective: This randomized, placebo-controlled, parallel-group, double-blind study was performed to assess the efficacy and safety of fexofenadine in children with seasonal allergic rhinitis. Methods: This study was conducted at 148 centers in 15 countries. Nine hundred thirty-five children (aged 6-11 years) were randomized and treated with either fexofenadine HCl 30 mg (n = 464) or placebo (n = 471) tablets twice a day for 14 days. Individual symptoms (sneezing; rhinorrhea; itchy nose, mouth, throat, and/or ears; itchy, watery, and/or red eyes; and nasal congestion) were assessed at baseline and then daily at 7:00 AM and 7:00 PM (+/-1 hour) during the double-blind treatment period. Each total symptom score was the sum of all symptoms, excluding nasal congestion. The primary efficacy variable was the change from baseline in the average of the daily 12-hour evening reflective total symptom scores throughout the double-blind treatment. Safety was evaluated from adverse-event reporting, vital signs, physical examinations, and clinical laboratory data at screening and study end point. Results: Fexofenadine was significantly superior to placebo in the primary efficacy analysis (P less than or equal to .0001). Individual symptom scores showed statistically significant superiority compared with placebo (P < .05), including nasal congestion in the evening reflective assessment (P < .05). There was no significant difference in adverse events between fexofenadine and placebo, either overall or by causality. Conclusion: The efficacy and safety of the H-1-antihistamine fexofenadine has been confirmed in this multicenter, multinational study of children aged 6 to 11 years with seasonal allergic rhinitis.	Univ Childrens Hosp, Dept Pediat & Pneumol & Immunol, DE-13353 Berlin, Germany; Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; Natl Allergy Ctr, Charleston, SC USA; Natl Asthma Ctr, Charleston, SC USA; Natl Urticaria Ctr, Charleston, SC USA; Med Univ Lodz, Dept Allergy & Clin Immunol, Lodz, Poland; Aventis, Paris, France; Karolinska Inst, Dept Pediat, S-10401 Stockholm, Sweden; Grp Hosp Necker Enfants Malad, Paris, France; Univ Ghent, B-9000 Ghent, Belgium; Hosp Dona Estefania, Dept Allergol & Clin Immunol, Lisbon, Portugal; Hosp Infantil Cordoba, Div Immunol & Resp Med, Cordoba, Argentina; Univ Cape Town, Allergol Diagnost & Clin Res Unit, Mowbray, South Africa; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada	University of Hamburg; University Medical Center Hamburg-Eppendorf; Medical University Lodz; Karolinska Institutet; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Ghent University; University of Cape Town; University of Manitoba	Wahn, U (corresponding author), Univ Childrens Hosp, Dept Pediat & Pneumol & Immunol, Augustenburger Pl 1, DE-13353 Berlin, Germany.		Bachert, Claus/J-8825-2012					Abdelaziz MM, 1998, J ALLERGY CLIN IMMUN, V101, P410, DOI 10.1016/S0091-6749(98)70256-8; Aubier M, 2001, ALLERGY, V56, P35, DOI 10.1034/j.1398-9995.2001.00629.x; BAELDE Y, 1992, DRUG INVEST, V4, P466, DOI 10.1007/BF03259210; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Casale TB, 1999, ALLERGY ASTHMA PROC, V20, P193, DOI 10.2500/108854199778553046; Ciprandi G, 1997, CLIN EXP ALLERGY, V27, P1160; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; Craig TJ, 1998, J ALLERGY CLIN IMMUN, V101, P633, DOI 10.1016/S0091-6749(98)70171-X; Finn AF, 1999, J ALLERGY CLIN IMMUN, V104, P1071, DOI 10.1016/S0091-6749(99)70091-6; Graft DF, 2001, ANN ALLERG ASTHMA IM, V87, P22, DOI 10.1016/S1081-1206(10)62317-4; Howarth PH, 1999, J ALLERGY CLIN IMMUN, V104, P927, DOI 10.1016/S0091-6749(99)70070-9; Leynaert Benedicte, 2000, Journal of Allergy and Clinical Immunology, V106, pS201; Malone DC, 1997, J ALLERGY CLIN IMMUN, V99, P22, DOI 10.1016/S0091-6749(97)81040-8; Marone G, 2001, INT ARCH ALLERGY IMM, V124, P249, DOI 10.1159/000053725; Masi M, 1993, Pediatr Allergy Immunol, V4, P47; Mason J, 1999, CLIN EXP ALLERGY, V29, P163, DOI 10.1046/j.1365-2222.1999.0290s3163.x; MELTZER EO, 1995, J ALLERGY CLIN IMMUN, V95, P1097, DOI 10.1016/S0091-6749(95)70213-X; MELTZER EO, 1995, ANN ALLERG ASTHMA IM, V74, P406; Meltzer EO, 2001, J ALLERGY CLIN IMMUN, V108, pS45, DOI 10.1067/mai.2001.115566; MOSGES R, 2000, ALLERGY S, V55, P281; Nathan RA, 1999, CLIN DRUG INVEST, V18, P317, DOI 10.2165/00044011-199918040-00008; Nelson HS, 2001, DM-DIS MON, V47, P5, DOI 10.1016/S0011-5029(01)90014-8; Paolieri F, 1998, ANN ALLERG ASTHMA IM, V81, P601, DOI 10.1016/S1081-1206(10)62712-3; PEARLMAN DS, 1997, CLIN PEDIAT PHILA, P209; Russell T, 1998, CLIN PHARMACOL THER, V64, P612, DOI 10.1016/S0009-9236(98)90052-2; Serra HA, 1998, BRIT J CLIN PHARMACO, V45, P147, DOI 10.1046/j.1365-2125.1998.00657.x; Settipane RA, 1999, ALLERGY ASTHMA PROC, V20, P209, DOI 10.2500/108854199778339053; SHAPIRO GG, 1988, J ALLERGY CLIN IMMUN, V82, P935, DOI 10.1016/0091-6749(88)90036-X; Simons FER, 1996, ALLERGY ASTHMA PROC, V17, P185, DOI 10.2500/108854196778996895; Simons FER, 1996, J ALLERGY CLIN IMMUN, V98, P1062, DOI 10.1016/S0091-6749(96)80192-8; Simons FER, 2001, ANN ALLERG ASTHMA IM, V86, P44, DOI 10.1016/S1081-1206(10)62354-X; SIMONS FER, 2002, HISTAMINE H1 ANTIHIS, P437; Skoner DP, 1997, PEDIATR ASTHMA ALLER, V11, P193, DOI 10.1089/pai.1997.11.193; Tinkelman DG, 1996, PEDIATR ASTHMA ALLER, V10, P9, DOI 10.1089/pai.1996.10.9; Triggiani M, 2001, J IMMUNOL, V166, P4083, DOI 10.4049/jimmunol.166.6.4083; Van Cauwenberge P, 2000, CLIN EXP ALLERGY, V30, P891; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; WATSON WTA, 1995, ANN ALLERG ASTHMA IM, V74, P237; Wober W, 1997, ARZNEIMITTEL-FORSCH, V47, P841	41	52	56	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					763	769		10.1067/mai.2003.1384	http://dx.doi.org/10.1067/mai.2003.1384			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704355	Green Published			2022-12-18	WOS:000182258500015
J	Melo, RE; Sole, D; Naspitz, CK				Melo, RE; Sole, D; Naspitz, CK			Exercise-induced bronchoconstriction in children: Montelukast attenuates the immediate-phase and late-phase responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exercise-induced asthma; late phase; montelukast; leukotrienes; children	LEUKOTRIENE-RECEPTOR ANTAGONIST; LATE ASTHMATIC RESPONSE; 5-LIPOXYGENASE INHIBITOR; ORAL MONTELUKAST; SALMETEROL; ALLERGEN; PROTECTION; REACTIVITY; CHALLENGE	Background: Montelukast, a leukotriene receptor antagonist, attenuates exercise-induced bronchoconstriction. We and others have shown that there is a late-phase response 3 to 8 hours after exercise in a subset of asthmatic patients. Objective: We sought to evaluate the protective effect of montelukast on immediate-phase and late-phase responses after exercise challenges. Methods: Twenty-two atopic asthmatic children aged 7 to 16 years with reproducible exercise-induced bronchoconstriction (minimum of 15% decrease of FEV1 from baseline) were enrolled in this placebo-controlled crossover study. Exercise challenges were performed while breathing cold dry air, and FEV1 measurements were taken up to 480 minutes after exercise. Patients underwent exercise challenges on a screening day and 1 week after placebo treatment. Subsequently, after a week with no treatment, pulmonary function was assessed after breathing dry cold air (control day). Finally, an exercise challenge was carried out after a week of treatment with montelukast. Results: Reproducible late-phase reactions occurred in 5 of 22 patients, which correlated with the extent of the immediate response (P <.05). After 1 week of treatment with montelukast, a significant decrease of immediate responses was observed. Montelukast treatment compared with placebo was associated with a lower mean maximum decrease of FEV1 (mean SEM: 17.3% +/- 2.4% and 35.1% +/- 2.6%, respectively), decrease of the area above the curve (267.8% +/- 42.7%/min and 868.0% +/- 103.8%/min, respectively), and shorter time for recovery (6.9 +/- 1.1 minutes and 30.9 +/- 4.0 minutes, respectively; P < .05). Treatment with montelukast also abolished latephase responses. Conclusion: Once daily treatment with oral montelukast attenuated the immediate-phase response and abolished the latephase response induced by means of exercise challenge in asthmatic children. (J Allergy Clin Immunol 2003;111:301-7.).	Univ Fed Sao Paulo, Escola Paulista Med, Dept Pediat,Div Allergy Clin Immunol & Rheumatol, Disciplina Alergia Imunol Clin & Reumatol, BR-04025002 Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP)	Melo, RE (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Dept Pediat,Div Allergy Clin Immunol & Rheumatol, Disciplina Alergia Imunol Clin & Reumatol, Rua Otonis 725, BR-04025002 Sao Paulo, Brazil.		Solé, Dirceu/D-7789-2013					Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453, DOI 10.1067/mai.2000.109822; Bisgaard H, 2000, AM J RESP CRIT CARE, V162, P187, DOI 10.1164/ajrccm.162.1.9910039; Bronsky EA, 1997, CLIN PHARMACOL THER, V62, P556, DOI 10.1016/S0009-9236(97)90051-5; Carlsen KH, 1998, RESP MED, V92, P308, DOI 10.1016/S0954-6111(98)90114-7; CARLSEN KH, 2001, TXB PEDIAT ASTHMA IN, P211; Chhabra SK, 1998, ANN ALLERG ASTHMA IM, V80, P323, DOI 10.1016/S1081-1206(10)62977-8; Coreno A, 2000, J ALLERGY CLIN IMMUN, V106, P500; Dessanges JF, 1999, J ALLERGY CLIN IMMUN, V104, P1155, DOI 10.1016/S0091-6749(99)70007-2; Diamant Z, 1999, CLIN EXP ALLERGY, V29, P42; Edelman JM, 2000, ANN INTERN MED, V132, P97, DOI 10.7326/0003-4819-132-2-200001180-00002; ENGSTROM I, 1991, ACTA PAEDIATR SCAND, V80, P1058; KARJALAINEN J, 1991, THORAX, V46, P100, DOI 10.1136/thx.46.2.100; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; Koh YY, 1998, ANN ALLERG ASTHMA IM, V81, P366, DOI 10.1016/S1081-1206(10)63130-4; KUNA P, 1997, AM J RESP CRIT CARE, V155, pA975; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Lehnigk B, 1998, EUR RESPIR J, V11, P617; Maspero JF, 2001, CURR MED RES OPIN, V17, P96, DOI 10.1185/0300799039117037; Milgrom H, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.3.e38; NOVISKI N, 1987, AM REV RESPIR DIS, V136, P592, DOI 10.1164/ajrccm/136.3.591; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; Sano F, 1998, PEDIAT ALLERG IMM-UK, V9, P181, DOI 10.1111/j.1399-3038.1998.tb00370.x; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; VATHENEN AS, 1991, THORAX, V46, P811, DOI 10.1136/thx.46.11.811; VENGE P, 1991, J ALLERGY CLIN IMMUN, V88, P699, DOI 10.1016/0091-6749(91)90175-N; VERHOEFF NPLG, 1990, CHEST, V98, P1194, DOI 10.1378/chest.98.5.1194; Villaran C, 1999, J ALLERGY CLIN IMMUN, V104, P547, DOI 10.1016/S0091-6749(99)70322-2; ZAWADSKI DK, 1988, AM REV RESPIR DIS, V137, P837, DOI 10.1164/ajrccm/137.4.837	28	52	57	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					301	307		10.1067/mai.2003.66	http://dx.doi.org/10.1067/mai.2003.66			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589349	Bronze			2022-12-18	WOS:000180942700013
J	Yoshimura, C; Miyamasu, M; Nagase, H; Iikura, M; Yamaguchi, M; Kawanami, O; Morita, Y; Iwata, T; Yamamoto, K; Hirai, K				Yoshimura, C; Miyamasu, M; Nagase, H; Iikura, M; Yamaguchi, M; Kawanami, O; Morita, Y; Iwata, T; Yamamoto, K; Hirai, K			Glucocorticoids induce basophil apoptosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; apoptosis; glucocorticoid; dexamethasone; IL-3; annexin V; allergy; eosinophils	LATE-PHASE RESPONSE; MEDIATOR RELEASE; ALLERGEN; CELLS; IDENTIFICATION; INFLAMMATION; EOSINOPHILS; CYTOKINE; SURVIVAL; ANTIGEN	Background: Induction of apoptosis represents an important mechanism by which glucocorticoids (GCCs) exert their antiinflammatory properties. The effects of GCCs on apoptosis have been determined in various immune cells and found to vary among different cell types. On the other hand, the effects of GCCs on apoptosis of basophils, active participants in allergic inflammation, have remained obscure. Objective: The objective of this study was to investigate the effects of GCCs on basophil apoptosis. Methods: Basophils were highly purified (purity, >97%) by Percoll density gradient centrifugation followed by negative selection. Cell status was determined by their ability to bind annexin V and exclude propidium iodide. DNA fragmentation was determined by Dow cytometry. Results: Dexamethasone (DEX) significantly accelerated the decrease in live cells and increased the number of apoptotic cells in a time-dependent fashion. Light microscopy as well as DNA fragmentation assay confirmed the induction of apoptosis by DEX. A half-maximal effect was observed in a DEX concentration range from 10(-9) to 10(-8) mol/L. Sex steroids did not induce basophil apoptosis at all. DEX also induced basophil apoptosis in the presence of low doses of IL-3. Conclusion: GCCs exert potent apoptogenic effects on basophils. GCC-mediated apoptogenic effects on basophils might have implications with respect to the mechanism of action of this class of drugs in allergic disorders.	Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Resp Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Sch Med, Dept Pediat, Tokyo 113, Japan; Nippon Med Coll, Inst Gerontol, Dept Mol Pathol, Kanagawa, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Nippon Medical School	Hirai, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Yamamoto, Kazuhiko/N-5096-2015; Nagase, Hiroyuki/Y-4367-2019	Nagase, Hiroyuki/0000-0002-0296-5901				BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Brokaw JJ, 1998, AM J RESP CELL MOL, V19, P598, DOI 10.1165/ajrcmb.19.4.2870; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473, DOI 10.1164/ajrccm.161.5.9908090; GUO CB, 1994, AM J RESP CELL MOL, V10, P384, DOI 10.1165/ajrcmb.10.4.7510984; Haslett C, 1999, AM J RESP CRIT CARE, V160, pS5, DOI 10.1164/ajrccm.160.supplement_1.4; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; Iikura M, 1998, J IMMUNOL, V161, P1510; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; KOSHINO T, 1993, CLIN EXP ALLERGY, V23, P919, DOI 10.1111/j.1365-2222.1993.tb00276.x; LAMAS AM, 1991, J IMMUNOL, V147, P254; MARTIN D, 1998, CURRENT PROTOCOLS IM; Meagher LC, 1996, J IMMUNOL, V156, P4422; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NIETO MA, 1992, ANN NY ACAD SCI, V650, P115; SAAVEDRADELGADO AMP, 1980, J ALLERGY CLIN IMMUN, V66, P464, DOI 10.1016/0091-6749(80)90007-X; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SCHLEIMER RP, 1990, AM REV RESPIR DIS S, V141, P59; Schmidt M, 1999, J IMMUNOL, V163, P3484; Schroeder JT, 1997, J IMMUNOL, V158, P5448; SCHROEDER JT, 1995, ALLERGY, V50, P463, DOI 10.1111/j.1398-9995.1995.tb01180.x; WALLEN N, 1991, J IMMUNOL, V147, P3490; YAMAGUCHI M, 1992, INT ARCH ALLERGY IMM, V97, P322, DOI 10.1159/000236140; YAMAGUCHI M, 1994, ALLERGY, V49, P371, DOI 10.1111/j.1398-9995.1994.tb02284.x; Ying S, 1999, J IMMUNOL, V163, P3976	25	52	54	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					215	220		10.1067/mai.2001.116575	http://dx.doi.org/10.1067/mai.2001.116575			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496237				2022-12-18	WOS:000170584600009
J	Nowak-Wegrzyn, AH; Sicherer, SH; Conover-Walker, MK; Wood, RA				Nowak-Wegrzyn, AH; Sicherer, SH; Conover-Walker, MK; Wood, RA			Food allergy after pediatric organ transplantation with tacrolimus immunosuppression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FK506		CUNY Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, New York, NY 10029 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Eudowood Div Allergy & Immunol, Baltimore, MD 21205 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Johns Hopkins University	Nowak-Wegrzyn, AH (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, New York, NY 10029 USA.			Nowak-Wegrzyn, Anna/0000-0002-0960-9854				AsanteKorang A, 1996, J HEART LUNG TRANSPL, V15, P415; Gabe SM, 1998, GASTROENTEROLOGY, V115, P67, DOI 10.1016/S0016-5085(98)70366-X; Inui A, 1999, J PEDIATR GASTR NUTR, V28, P355, DOI 10.1097/00005176-199903000-00036; Lacaille F, 1997, J PEDIATR GASTR NUTR, V25, P228, DOI 10.1097/00005176-199708000-00019; Legendre C, 1997, NEW ENGL J MED, V337, P822, DOI 10.1056/NEJM199709183371204; OROURKE M, 1995, TRANSPLANT P, V27, P1150; Prabhakaran K, 1999, PEDIATRICS, V104, P786	7	52	53	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					146	147						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447402				2022-12-18	WOS:000170171200027
J	Royer, B; Varadaradjalou, S; Saas, P; Gabiot, AC; Kantelip, B; Feger, F; Guillosson, JJ; Kantelip, JP; Arock, M				Royer, B; Varadaradjalou, S; Saas, P; Gabiot, AC; Kantelip, B; Feger, F; Guillosson, JJ; Kantelip, JP; Arock, M			Autocrine regulation of cord blood-derived human mast cell activation by IL-10	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; human; IL-10; leukotriene; C-4, D-4, and E-4; TNF-alpha; IL-5; IL-8	MEDIATOR RELEASE; INTERLEUKIN-10; INDUCTION	Background: Ligation of the high-affinity receptor for IgE on human mast cells (MCs) induces the release of proinflammatory mediators, including vasoactive amines and cytokines (TNF-alpha, IL-5, and IL-8). Moreover, we have recently shown that IL-10 inhibits the release of proinflammatory mediators by activated MCs. Objective: We investigated whether human cord blood-derived MCs (CBMCs) could produce IL-10 and whether this production could inhibit their activation in an autocrine fashion. Methods: IL-10 synthesis by resting or activated human MCs derived from cord blood progenitors was investigated in cell supernatants or by using immunostaining and RT-PCR methods. In addition, the effect of IL-4 on such synthesis was also studied. Anti-IL-10-neutralizing antibodies were used to investigate the validity of the hypothesis of an autocrine regulation of MCs by IL-10. Finally, the presence of specific receptors for IL-10 was searched on human CBMCs by using flow cytometric analysis. Results: Human CBMCs spontaneously synthesize and release IL-10, and this synthesis is increased after IgE/anti-IgE stimulation. In addition, the presence of IL-10 in resting or in activated MCs was proved by immunostaining. Interestingly, the release of IL-10 was also increased after incubation of the cells with IL-4. Besides, the use of neutralizing antibodies against IL-10 confirmed that IL-10 released inhibited MC activation in an autocrine fashion. Finally, the presence of specific receptors for this cytokine was observed on the membranes of our population of human CBMCs. Conclusion: Taken together, our data are in favor of an autocrine regulation pathway through synthesis and release of IL-10 by human MCs. Such an autoregulatory mechanism is, to our knowledge, the first described for these elements.	Fac Pharm, Dept Mol & Cellular Hematol, UPRES EA 2509, F-75006 Paris, France; Fac Med & Pharm, Dept Pharmacol, Besancon, France; Fac Med & Pharm, Pathol Lab, Besancon, France; Ctr Blood Transfus, Besancon, France		Arock, M (corresponding author), Fac Pharm, Dept Mol & Cellular Hematol, UPRES EA 2509, 4 Ave Observ, F-75006 Paris, France.		Saas, Philippe/M-9605-2019; SAAS, Philippe/M-3550-2015	Saas, Philippe/0000-0002-8857-9939; 				Abraham SN, 1998, SEMIN IMMUNOL, V10, P373, DOI 10.1006/smim.1998.0140; Arock M, 1996, EUR J IMMUNOL, V26, P166, DOI 10.1002/eji.1830260126; Arock M, 1998, INFECT IMMUN, V66, P6030, DOI 10.1128/IAI.66.12.6030-6034.1998; Becherel PA, 1997, J IMMUNOL, V159, P5761; Bidri M, 1997, PARASITE IMMUNOL, V19, P475, DOI 10.1046/j.1365-3024.1997.d01-153.x; Bischoff SC, 1999, P NATL ACAD SCI USA, V96, P8080, DOI 10.1073/pnas.96.14.8080; Bradding P, 1996, ANN NY ACAD SCI, V796, P272, DOI 10.1111/j.1749-6632.1996.tb32589.x; Bressler RB, 1997, J ALLERGY CLIN IMMUN, V99, P508, DOI 10.1016/S0091-6749(97)70078-2; Cohen SBA, 1997, J IMMUNOL, V158, P5596; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Hamelmann E, 1999, INT ARCH ALLERGY IMM, V120, P8, DOI 10.1159/000024215; Ishizuka T, 1999, CLIN EXP ALLERGY, V29, P1424; Isler P, 1999, AM J RESP CELL MOL, V20, P270, DOI 10.1165/ajrcmb.20.2.3313; Korholz D, 1997, BLOOD, V90, P4513; Lin TJ, 1997, J IMMUNOL, V159, P4015; Marshall JS, 1996, J CLIN INVEST, V97, P1122, DOI 10.1172/JCI118506; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Miyachi Y, 1998, Australas J Dermatol, V39, P14, DOI 10.1111/j.1440-0960.1998.tb01234.x; Ochi H, 2000, P NATL ACAD SCI USA, V97, P10509, DOI 10.1073/pnas.180318697; OKAYAMA Y, 1994, J IMMUNOL METHODS, V169, P153, DOI 10.1016/0022-1759(94)90259-3; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; Saito H, 1996, J IMMUNOL, V157, P343; SILLABER C, 1991, J IMMUNOL, V147, P4224; Toru H, 1997, BLOOD, V89, P3296, DOI 10.1182/blood.V89.9.3296; Toru H, 1998, J ALLERGY CLIN IMMUN, V102, P491, DOI 10.1016/S0091-6749(98)70140-X; Toru H, 1996, INT IMMUNOL, V8, P1367	26	52	54	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					80	86		10.1067/mai.2001.115753	http://dx.doi.org/10.1067/mai.2001.115753			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447386	Bronze			2022-12-18	WOS:000170171200011
J	Estelle, F; Simons, R				Estelle, F; Simons, R		Early Treatment Atopic Child ETAC	Prevention of acute urticaria in young children with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						urticaria; hives; atopic dermatitis; cetirizine; antihistamine; H-1-receptor antagonist; infant; child; prevention	CETIRIZINE; CHILDHOOD; SKIN; INFANTS	Background: There are no published prospective, randomized, double-blind, placebo-controlled studies of urticaria prevention in children. Objective: Our objective was to study the effect of long-term treatment with the Hi-receptor antagonist cetirizine in the prevention of urticaria in young children with atopic dermatitis, Methods: In the prospective, double-blind, parallel-group Early Treatment of the Atopic Child study, 817 children with atopic dermatitis who were 12 to 24 months of age at study entry were randomized to receive either cetirizine, 0.25 mg/kg, or matching placebo twice daily for 18 months and to be followed up for an additional 6 months, during which time the study medication code remained unbroken, During both these double-blind phases of the study, for a total of 24 months, caregivers prospectively recorded all symptoms and events, including hives, in a diary on a weekly basis when the child was well and on a daily basis when a symptom or event was observed. The diaries were reviewed and validated with the investigators at each regularly scheduled study visit. Results: Acute urticaria occurred in 16.2% of the placebo-treated children and in 5.8% of the children treated with cetirizine (P < .001). The protective effect of cetirizine disappeared when treatment was stopped. In the study population as a whole, urticaria episodes were most commonly associated with intercurrent infection or with food ingestion or direct skin contact. Conclusion: Acute urticaria is common in toddlers with atopic dermatitis and can be prevented with cetirizine in this highrisk population.	Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB R3T 2N2, Canada	University of Manitoba	Simons, R (corresponding author), Childrens Hosp Winnipeg, 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.							Breneman DL, 1996, ANN PHARMACOTHER, V30, P1075, DOI 10.1177/106002809603001001; BUCKLEY RH, 1996, RUDOLPHS PEDIAT, P473; CASALE TB, 1999, OSKIS PEDIAT PRINCIP, P2049; de Longueville M, 1997, PEDIATR ALLERGY IMMU, V8, P177; de Longueville M, 1998, J ALLERGY CLIN IMMUN, V101, pS198; DIEPGEN TL, 1999, J EUR ACAD DERMATOL, V12, pS133; Ehlers I, 1998, ALLERGY, V53, P1074, DOI 10.1111/j.1398-9995.1998.tb03817.x; GHOSH S, 1993, PEDIATR DERMATOL, V10, P107, DOI 10.1111/j.1525-1470.1993.tb00032.x; Greaves MW, 2000, ALLERGY, V55, P309, DOI 10.1034/j.1398-9995.2000.00116.x; Guillet M H, 1993, Allerg Immunol (Paris), V25, P333; HOBBS KF, 1996, ALLERGY ASTHMA IMMUN, P643; Humphreys F, 1998, BRIT J DERMATOL, V138, P635; Jordaan HF, 1997, AM J DERMATOPATH, V19, P119, DOI 10.1097/00000372-199704000-00004; Kwong KY, 1998, PEDIATR ANN, V27, P719, DOI 10.3928/0090-4481-19981101-07; LEGRAIN V, 1990, PEDIATR DERMATOL, V7, P101, DOI 10.1111/j.1525-1470.1990.tb00663.x; Mortureux P, 1998, ARCH DERMATOL, V134, P319, DOI 10.1001/archderm.134.3.319; Orange AP, 1997, PEDIAT ALLERG IMM-UK, V8, P28, DOI 10.1111/j.1399-3038.1997.tb00139.x; Ridout SM, 1997, J ALLERGY CLIN IMMUN, V99, P860, DOI 10.1016/S0091-6749(97)80028-0; Sakurai Michiyo, 2000, Journal of Dermatology (Tokyo), V27, P87; Schmelz M, 1997, J NEUROSCI, V17, P8003; SIMONS FER, 1995, J ALLERGY CLIN IMMUN, V95, P759, DOI 10.1016/S0091-6749(95)70183-4; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P433, DOI 10.1016/S0091-6749(99)70389-1; SLY M, 2000, NELSONS PEDIAT, P684; Spicak V, 1997, CLIN PHARMACOL THER, V61, P325; TUCHINDA M, 1986, ASIAN PAC J ALLERGY, V4, P41; TWAROG FJ, 1983, PEDIATR CLIN N AM, V30, P887; VOLONAKIS M, 1992, ANN ALLERGY, V69, P61; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116	29	52	56	1	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					703	706		10.1067/mai.2001.113866	http://dx.doi.org/10.1067/mai.2001.113866			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295661	Bronze			2022-12-18	WOS:000168190100024
J	Lewis, SA; Weiss, ST; Platts-Mills, TAE; Syring, M; Gold, DR				Lewis, SA; Weiss, ST; Platts-Mills, TAE; Syring, M; Gold, DR			Association of specific allergen sensitization with socioeconomic factors and allergic disease in a population of Boston women	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sensitization; total IgE; socioeconomic status; asthma	SKIN-TEST REACTIVITY; INNER-CITY CHILDREN; RISK-FACTORS; SERUM IGE; COCKROACH ALLERGEN; INDOOR ALLERGENS; MATERNAL SMOKING; CHILDHOOD ASTHMA; EXPOSURE; PREVALENCE	Background: Socioeconomic differences in allergic disease prevalence have been reported; asthma has been associated with poverty in the United States and hay fever and eczema with relative affluence elsewhere. It is not yet established to what degree such differences in disease prevalence reflect patterns of sensitization and specific allergen sensitivities. Objective: We analyzed specific and total IgE measurements in a sample of 458 women, enriched for allergic disease, from the metropolitan Boston area to establish the relation of allergen sensitization to markers of socioeconomic status (SES) and to the prevalence and socioeconomic pattern of allergic disease in this community. Methods: Total and specific IgE antibodies were measured with the UNICAP System; self-reported allergic disease, household income, education, and rate-ethnicity were ascertained with a questionnaire; and a further marker of poverty (percentage living below the poverty level) in the women's area of residence was established on the basis of zip codes. Analysis was performed with SAS statistical software. Results: Markers of low SES were univariately associated with increases in total IgE, number of allergen sensitizations, and levels of specific IgE, Socioeconomic differences in sensitization to cockroach (35% vs 6% in the highest and lowest poverty areas), animal (44% vs 26%) and ragweed (49% vs 23%) allergens were most marked. Sensitization primarily to indoor inhalant allergens (not ragweed or ryegrass) were associated with an increased risk of asthma, even after adjustment for SES, Conclusion: We have demonstrated a socioeconomic gradient in sensitization that concords with increased rates of asthma in less affluent communities in this population.	Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG5 1PB, England; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Univ Virginia, Dept Med, Div Asthma Allergy & Immunol, Charlottesville, VA USA	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; University of Virginia	Lewis, SA (corresponding author), Univ Nottingham, City Hosp, Div Resp Med, Hucknall Rd, Nottingham NG5 1PB, England.			Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [R01AI/EHS35746, AI 20565] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R15AI035746, R37AI020565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Chinn S, 1999, EUR RESPIR J, V14, P876, DOI 10.1034/j.1399-3003.1999.14d25.x; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; HAMMAN RF, 1975, BRIT J PREV SOC MED, V29, P228; JARVIS D, 1995, CLIN EXP ALLERGY, V25, P1083; KANG BC, 1993, J ALLERGY CLIN IMMUN, V92, P802, DOI 10.1016/0091-6749(93)90057-M; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Lewis SA, 1998, RESP MED, V92, P1237, DOI 10.1016/S0954-6111(98)90427-9; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; *MASS STAT DAT CTR, 1992, 1990 CENS POP HOUS; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; PECKHAM C, 1978, J EPIDEMIOL COMMUN H, V32, P79, DOI 10.1136/jech.32.2.79; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Ring J, 1999, INT ARCH ALLERGY IMM, V118, P403, DOI 10.1159/000024148; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1998, ANN ALLERG ASTHMA IM, V80, P303, DOI 10.1016/S1081-1206(10)62973-0; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SHERRILL DL, 1994, J ALLERGY CLIN IMMUN, V94, P954, DOI 10.1016/0091-6749(94)90113-9; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; WEISS ST, 1995, PEDIATR PULM, V19, P153, DOI 10.1002/ppul.1950190302; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	29	52	58	1	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					615	622						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295648				2022-12-18	WOS:000168190100011
J	Gafvelin, G; Johansson, E; Lundin, A; Smith, AM; Chapman, MD; Benjamin, DC; Derewenda, U; van Hage-Hamsten, M				Gafvelin, G; Johansson, E; Lundin, A; Smith, AM; Chapman, MD; Benjamin, DC; Derewenda, U; van Hage-Hamsten, M			Cross-reactivity studies of a new group 2 allergen from the dust mite Glycyphagus domesticus, Gly d 2, and group 2 allergens from Dermatophagoides pteronyssinus, Lepidoglyphus destructor, and Tyrophagus putrescentiae with recombinant allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cross-reactivity; Der p 2; Glycyphagus domesticus; Gly d 2; Lep d 2; mite; recombinant allergen; Tyr p 2	ACID-BINDING PROTEINS; HOUSE-DUST; STORAGE MITES; ACARUS-SIRO; BLOMIA-TROPICALIS; URBAN-POPULATION; SWEDISH FARMERS; CDNA ANALYSIS; IGE; SENSITIZATION	Background: Dust mites are important inducers of allergic disease. Group 2 allergens are recognized as major allergens in several mite species, including Dermatophagoides pteroronyssinus, Lepidoglyphus destructor, and Tyrophagus putrescentiae. No allergens have thus far been characterized on the molecular level from the dust mite Glycyphagus domesticus. Objective: We sought to examine the cross-reactivity among group 2 allergens of G domesticus, L destructor, T putrescentiae, and D pteronyssinus. Methods: A group 2 allergen from G domesticus, Gly d 2, was cloned and expressed as a recombinant protein. Cross-reactivity between Gly d 2 and 3 other group 2 allergens, Lep d 2,Tyr p 2, and Der p 2, was studied by using individual sera and a serum pool RAST-positive to G domesticus, L destructor, T putrescentiae, and D pteronyssinus. Recombinant allergens were used as inhibitors of IgE binding in immunoblotting experiments. Molecular modeling on the basis of the Der p 2 structure was carried out for Gly d 2, Lep d 2, and Tyr p 2. Results: Two cDNAs encoding isoforms of Gly d 2 were isolated, but only the Gly d 2.02 isoform was used in this study Sixteen of 17 subjects had IgE to Gly d 2. The protein sequence of Gly d 2 revealed 79% identity to Lep d 2 and 46% and 41% identity to Tyr p 2 and Der p 2, respectively. Extensive crossreactivity was demonstrated among Gly d 2, Lep d 2, and Tyr p 2, but little cross-reactivity was found between these allergens and Der p 2. According to the tertiary structure of Der p 2 and 3-dimensional models of Gly d 2, Lep d 2, and Tyr p 2, differences reside mainly in surface-exposed residues. Conclusion: Gly d 2 showed high sequence homology to Lep d 2. Cross-reactivity was observed between Gly d 2, Lep d 2, and Tyr p 2, but only limited cross-reactivity was demonstrated between these 3 allergens and Der p 2.	Karolinska Hosp & Inst, Dept Med, Unit Clin Immunol & Allergy, Div Clin Immunol & Allergy, S-17176 Stockholm, Sweden; Univ Virginia, Dept Med, Charlottesville, VA USA; Univ Virginia, Dept Med & Microbiol, Charlottesville, VA USA; Univ Virginia, Dept Microbiol, Charlottesville, VA USA; Univ Virginia, Dept Mol Physiol, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Karolinska Institutet; Karolinska University Hospital; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Gafvelin, G (corresponding author), Karolinska Hosp & Inst, Dept Med, Unit Clin Immunol & Allergy, Div Clin Immunol & Allergy, S-17176 Stockholm, Sweden.		van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Chapman, Martin/0000-0002-0845-3632; Gafvelin, Guro/0000-0003-1618-4011	NIAID NIH HHS [AI-34607] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034607, U19AI034607] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGRISANO A, 1990, ANN ALLERGY, V64, P358; Armentia A, 1997, J ASTHMA, V34, P369, DOI 10.3109/02770909709055378; BLAINEY AD, 1989, J ALLERGY CLIN IMMUN, V84, P296, DOI 10.1016/0091-6749(89)90411-9; BORRIELLO F, 1990, NUCLEIC ACIDS RES, V18, P5481, DOI 10.1093/nar/18.18.5481; Bostrom Sven, 1997, International Journal of Acarology, V23, P127; Caraballo L, 1997, INT ARCH ALLERGY IMM, V112, P341, DOI 10.1159/000237478; Caraballo L, 1998, INT ARCH ALLERGY IMM, V117, P38, DOI 10.1159/000023988; Chew FT, 1999, CLIN EXP ALLERGY, V29, P982, DOI 10.1046/j.1365-2222.1999.00543.x; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CUTHBERT OD, 1979, CLIN ALLERGY, V9, P229, DOI 10.1111/j.1365-2222.1979.tb01547.x; EBNER C, 1994, CLIN EXP ALLERGY, V24, P347, DOI 10.1111/j.1365-2222.1994.tb00245.x; Eriksson TLJ, 1999, INT ARCH ALLERGY IMM, V119, P275, DOI 10.1159/000024204; Eriksson TLJ, 1998, EUR J BIOCHEM, V251, P443, DOI 10.1046/j.1432-1327.1998.2510443.x; Ferrandiz R, 1998, INT ARCH ALLERGY IMM, V116, P206, DOI 10.1159/000023946; Gislason D, 1999, ALLERGY, V54, P878, DOI 10.1034/j.1398-9995.1999.00996.x; Ichikawa S, 1998, J BIOL CHEM, V273, P356, DOI 10.1074/jbc.273.1.356; IVERSEN M, 1990, ALLERGY, V45, P81, DOI 10.1111/j.1398-9995.1990.tb00462.x; Johansson E, 1997, CLIN EXP ALLERGY, V27, P691, DOI 10.1111/j.1365-2222.1997.tb01198.x; JOHANSSON E, 1991, CLIN EXP ALLERGY, V21, P511, DOI 10.1111/j.1365-2222.1991.tb01693.x; JOHANSSON E, 1994, CLIN EXP ALLERGY, V24, P743, DOI 10.1111/j.1365-2222.1994.tb00985.x; Kronqvist M, 1999, ALLERGY, V54, P1142, DOI 10.1034/j.1398-9995.1999.00115.x; LABBE D, 1992, IMMUNOGENETICS, V35, P395; LIN KL, 1994, J ALLERGY CLIN IMMUN, V94, P989, DOI 10.1016/0091-6749(94)90117-1; LUCZYNSKA CM, 1990, CLIN EXP ALLERGY, V20, P403, DOI 10.1111/j.1365-2222.1990.tb02801.x; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; Mueller GA, 1997, J BIOL CHEM, V272, P26893, DOI 10.1074/jbc.272.43.26893; Munhbayarlah S, 1998, YONSEI MED J, V39, P109, DOI 10.3349/ymj.1998.39.2.109; Olsson S, 1998, CLIN EXP ALLERGY, V28, P984, DOI 10.1046/j.1365-2222.1998.00375.x; Park JW, 1999, ANN ALLERG ASTHMA IM, V83, P533, DOI 10.1016/S1081-1206(10)62865-7; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PUERTA L, 1993, J INVEST ALLERG CLIN, V3, P198; REVSBECH P, 1990, ALLERGY, V45, P204, DOI 10.1111/j.1398-9995.1990.tb00484.x; SCHMIDT M, 1995, FEBS LETT, V370, P11, DOI 10.1016/0014-5793(95)98164-E; Smith W, 1999, INT ARCH ALLERGY IMM, V118, P15, DOI 10.1159/000024026; SPIEKSMA FTM, 1991, CLIN EXP ALLERGY, V21, P655, DOI 10.1111/j.1365-2222.1991.tb03192.x; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; TEE RD, 1992, CLIN EXP ALLERGY, V22, P233, DOI 10.1111/j.1365-2222.1992.tb03078.x; Thomas WR, 1998, ALLERGY, V53, P821, DOI 10.1111/j.1398-9995.1998.tb03987.x; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457; van der Heide S, 1998, ALLERGY, V53, P426, DOI 10.1111/j.1398-9995.1998.tb03917.x; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P23; VANHAGEHAMSTEN M, 1985, CLIN ALLERGY, V15, P555; Vidal C, 1997, J ALLERGY CLIN IMMUN, V100, P716, DOI 10.1016/S0091-6749(97)70181-7; *WHO IUS ALL NOM S, 1995, CLIN EXP ALLERGY, V5, P27; WRAITH DG, 1979, CLIN ALLERGY, V9, P545, DOI 10.1111/j.1365-2222.1979.tb00478.x	45	52	60	0	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					511	518		10.1067/mai.2001.112264	http://dx.doi.org/10.1067/mai.2001.112264			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240953				2022-12-18	WOS:000167793300014
J	Kanny, G; Gerbaux, V; Olszewski, A; Fremont, S; Empereur, F; Nabet, F; Cabanis, JC; Moneret-Vautrin, DA				Kanny, G; Gerbaux, V; Olszewski, A; Fremont, S; Empereur, F; Nabet, F; Cabanis, JC; Moneret-Vautrin, DA			No correlation between wine intolerance and histamine content of wine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adverse food reactions; histamine; wine; biogenic amines; double-blind food challenge test	CHRONIC URTICARIA; BIOGENIC-AMINES; ALCOHOL; METHYLHISTAMINE; ASTHMA; URINE	Background: Histamine is thought to be the main clause of adverse reactions to wines. Objective: The purpose of this study was to test the hypothesis that the level of histamine in wine affects the tolerance to wine in 16 subjects with wine intolerance. Methods: We performed a study to examine the effects of wine histamine content in 16 adults with wine intolerance. Each subject underwent 2 double-blind provocation tests with wine: 1 with a wine poor in histamine (0.4 mg/L), and 1 with a wine rich in histamine (13.8 mg/L). Blood was collected for histamine and methylhistamine RIAs at 0, 10, 30, and 45 minutes after ingestion of the wine. Methylhistamine and methylimidazolacetic acid (gas chromatography and mass spectrometry) were measured in urine 5 hours before and 5 hours after ingestion. Results: No significant differences in the occurrence of adverse reactions were noted after ingestion of either of the wines (McNemar test). At 10 minutes, a significant increase was observed in plasma histamine with histamine-poor wine. No significant changes (Wilcoxon test) were observed in the methylhistamine and methylimidazolacetic acid levels after ingestion of either histamine-poor or histamine-rich wine. Conclusion: This study demonstrates that there is no correlation between the histamine content of wine and wine intolerance. The increase of plasma histamine levels at 10 minutes with histamine-poor wine suggested the role of a histamine-releasing substance. The role of acetaldehyde is discussed.	Hop Cent, F-54035 Nancy, France; Hop Cent, ITV France, F-54035 Nancy, France; Fac Med, INSERM, Biochem Unite, Vandoeuvre Les Nancy, France; Hop Marin, Epidemiol Clin, Nancy, France; Hop Marin, Evaluat Clin, Nancy, France; Fac Pharm Montpellier, Ctr Format & Rech Oenol, Inst Super Vigne & Vin, Montpellier, France	CHU de Nancy; CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; CHU de Nancy; CHU de Nancy; Universite de Montpellier	Kanny, G (corresponding author), Hop Cent, 29 Ave De Lattre De Tassigny, F-54035 Nancy, France.		Kanny, Gisèle/AHA-8910-2022; Olszewski, Andrzej J/W-1825-2018	Olszewski, Andrzej J/0000-0003-3368-5475				BAUZA T, 1995, SCI ALIMENT, V15, P367; BAUZA T, 1995, B OFFICE INT VIGNE V, V7678, P42; *BMDP, 1992, STAT SOFTW 7 0; CHAMBERS TL, 1978, J ASSOC OFF ANA CHEM, V61, P1092; HARADA S, 1981, LANCET, V2, P982; HERMANN K, 1993, INT ARCH ALLERGY IMM, V101, P13, DOI 10.1159/000236493; HESTERBERG R, 1984, AGENTS ACTIONS, V14, P324, DOI 10.1007/BF01973821; JARISCH R, 1992, J ALLERGY CLIN IMMUN, V89, P197; KANNY G, 1993, CLIN EXP ALLERGY, V23, P1015, DOI 10.1111/j.1365-2222.1993.tb00293.x; Kanny G, 1999, Allerg Immunol (Paris), V31, P45; Kanny G, 1996, ALLERGY, V51, P935; Kanny G, 1997, REV FR ALLERGOL, V37, P381, DOI 10.1016/S0335-7457(97)80180-3; KHANDELWAL JK, 1982, J BIOL CHEM, V257, P2815; Larmande P., 1993, Medecine et Nutrition, V29, P263; LITTLEWOOD JT, 1988, LANCET, V1, P558, DOI 10.1016/S0140-6736(88)91353-0; LOWENBERG DW, 1981, AM J ENOL VITICULT, V32, P128; MARIA Y, 1989, REV MED INTERNE, V10, P36, DOI 10.1016/S0248-8663(89)80111-0; MIZOI Y, 1979, PHARMACOL BIOCHEM BE, V10, P303, DOI 10.1016/0091-3057(79)90105-9; Moneret-Vautrin DA, 1998, J ALLERGY CLIN IMMUN, V101, pS87; MONERETVAUTRIN DA, 1991, BIBL NUTR DIET, V48, P61; Mordelet-Dambrine M., 1970, MED NUTR, V6, P59; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; MORROW JD, 1991, NEW ENGL J MED, V324, P716, DOI 10.1056/NEJM199103143241102; NEUGEBAUER E, 1981, BEHRING I MITT, V68, P102; Shimoda T, 1996, J ALLERGY CLIN IMMUN, V97, P74, DOI 10.1016/S0091-6749(96)70285-3; SIMON RA, 1982, J ALLERGY CLIN IMMUN, V69, pA103; STEPHAN V, 1990, J ALLERGY CLIN IMMUN, V86, P862, DOI 10.1016/S0091-6749(05)80147-2; Takao A, 1998, J ALLERGY CLIN IMMUN, V101, P576, DOI 10.1016/S0091-6749(98)70162-9; WANTKE F, 1992, ALLERGOLOGIE, V15, P55; ZEE JA, 1983, AM J ENOL VITICULT, V34, P6	30	52	55	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					375	378		10.1067/mai.2001.112122	http://dx.doi.org/10.1067/mai.2001.112122			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174207				2022-12-18	WOS:000167071400027
J	Turner, P; Dear, J; Scadding, G; Foreman, JC				Turner, P; Dear, J; Scadding, G; Foreman, JC			Role of kinins in seasonal allergic rhinitis: Icatibant, a bradykinin B(2) receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; nasal allergen challenge; airway hyperresponsiveness; histamine; kinins; IL-8; icatibant; eosinophils	PLATELET-ACTIVATING-FACTOR; IN-VIVO; AIRWAY HYPERRESPONSIVENESS; INFLAMMATORY CYTOKINES; VASCULAR-PERMEABILITY; CHEMOTACTIC ACTIVITY; RELEASE NEUTROPHIL; EPITHELIAL-CELLS; GUINEA-PIGS; INTERLEUKIN-8	Background: Icatibant, a bradykinin B(2) receptor antagonist, inhibits the reduction in nasal patency after challenge with house dust mite antigen in sensitive subjects and abolishes the nasal hyperresponsiveness induced by platelet-activating factor in nonatopic subjects. Objective: We sought to Investigate the effect of Icatibant on the response to nasal antigen challenge In subjects with seasonal allergic rhinitis. Methods: Patients allergic to grass pollen antigen (n = 9-13) were included in a double-blind, randomized-block, placebo-controlled, crossover study outside the pollen season. Subjects first received an Intranasal spray of icatibant (200 mug per nostril) or a saline control. Subjects were then challenged with antigen or diluent (control), and their responses were monitored by using acoustic rhinometry, Six hours later, nasal lavage fluid was collected and quantified for inflammatory cells and various Inflammatory mediators (kinin, eosinophil cationic protein, IL-5, and IL-8), At 24 hours, the response of the nasal airways to 200 mug of histamine was assessed, and a further nasal lavage was carried out. Results: Antigen challenge caused a significant increase in nasal obstruction and albumin extravasation, which was not affected by icatibant, Nasal hyperresponsiveness to histamine was present 24 hours after antigen and was abolished by pretreatment with icatibant, icatibant also reduced the antigen-induced increase in eosinophils, eosinophil cationic protein, kinin, and IL-8 in nasal lavage fluid. Conclusion: Pretreatment with icatibant dues not affect the acute inflammatory response In seasonal allergic rhinitis. However, our results Imply the involvement of kinins and the bradykinin B(2) receptor in the development of antigen-induced hyperresponsiveness and the associated eosinophilia in the human nasal airway.	UCL, Dept Pharmacol, London WC1E 6BT, England; Royal Natl Throat Nose & Ear Hosp, London WC1X 8DA, England	University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London	Foreman, JC (corresponding author), UCL, Dept Pharmacol, Gower St, London WC1E 6BT, England.			Turner, Paul/0000-0001-9862-5161				ABRAHAM WM, 1991, J ALLERGY CLIN IMMUN, V87, P551; AKBARY AM, 1993, EFFICACY SAFETY HOC; ANDERSSON M, 1988, EUR J CLIN PHARMACOL, V35, P231, DOI 10.1007/BF00558258; AUSTIN CE, 1994, BRIT J CLIN PHARMACO, V37, P33, DOI 10.1111/j.1365-2125.1994.tb04235.x; AUSTIN CE, 1993, BRIT J PHARMACOL, V110, P113, DOI 10.1111/j.1476-5381.1993.tb13779.x; AUSTIN CE, 1994, J PHYSIOL-LONDON, V478, P351, DOI 10.1113/jphysiol.1994.sp020255; AUSTIN CE, 1994, BRIT J PHARMACOL, V111, P969, DOI 10.1111/j.1476-5381.1994.tb14835.x; Bagarozzi DA, 1998, AM J RESP CELL MOL, V18, P363, DOI 10.1165/ajrcmb.18.3.2825; Barnes PJ, 1998, ALLERGY AND ALLERGIC DISEASES, P175; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; Bertrand C, 1996, TRENDS PHARMACOL SCI, V17, P255, DOI 10.1016/S0165-6147(96)10027-4; COYLE AJ, 1995, J CLIN INVEST, V95, P1735, DOI 10.1172/JCI117850; Dear JW, 1996, BRIT J PHARMACOL, V119, P1054, DOI 10.1111/j.1476-5381.1996.tb15777.x; DOUGLASS JA, 1994, AM J RESP CRIT CARE, V150, P1108, DOI 10.1164/ajrccm.150.4.7921444; DRUCE HM, 1985, J ALLERGY CLIN IMMUN, V76, P445, DOI 10.1016/0091-6749(85)90725-0; Evans DM, 1996, IMMUNOPHARMACOLOGY, V32, P117, DOI 10.1016/0162-3109(95)00069-0; FARMER SG, 1992, BRIT J PHARMACOL, V107, P653, DOI 10.1111/j.1476-5381.1992.tb14502.x; Fox AJ, 1996, NAT MED, V2, P814, DOI 10.1038/nm0796-814; Fujimura M, 1997, BRIT J PHARMACOL, V122, P1015, DOI 10.1038/sj.bjp.0701478; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gosset P, 1997, CLIN EXP ALLERGY, V27, P379; KleinJan A, 1999, J ALLERGY CLIN IMMUN, V103, P441, DOI 10.1016/S0091-6749(99)70469-0; KLEMENTSSON H, 1990, J ALLERGY CLIN IMMUN, V86, P466, DOI 10.1016/S0091-6749(05)80201-5; Koyama S, 1998, AM J PATHOL, V153, P1885, DOI 10.1016/S0002-9440(10)65702-1; KUIJPERS TW, 1992, J CELL BIOL, V117, P565, DOI 10.1083/jcb.117.3.565; LEPREVOST C, 1988, INT ARCH ALLER A IMM, V87, P9, DOI 10.1159/000234641; MARUO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P62, DOI 10.1016/0304-4165(91)90040-N; MELTZER EO, 1995, J ALLERGY CLIN IMMUN, V95, P1097, DOI 10.1016/S0091-6749(95)70213-X; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167, DOI 10.1164/ajrccm/142.1.167; Pang LH, 1998, J IMMUNOL, V161, P2509; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; Proud D, 1998, CLIN EXP ALLERGY, V28, P868; PROUD D, 1988, AM REV RESPIR DIS, V137, P613, DOI 10.1164/ajrccm/137.3.613; PROUD D, 1987, J IMMUNOL, V138, P428; Rainger GE, 1998, BLOOD, V92, P4819, DOI 10.1182/blood.V92.12.4819.424k16_4819_4827; Rainger GE, 1997, AM J PHYSIOL-HEART C, V272, pH114, DOI 10.1152/ajpheart.1997.272.1.H114; RAJAKULASINGAM K, 1991, J PHYSIOL-LONDON, V437, P557; Riccio MM, 1996, J ALLERGY CLIN IMMUN, V97, P1252, DOI 10.1016/S0091-6749(96)70193-8; Sato E, 1996, J IMMUNOL, V157, P3122; SHUTE J, 1994, CLIN EXP ALLERGY, V24, P203, DOI 10.1111/j.1365-2222.1994.tb00220.x; SOLER M, 1990, Pulmonary Pharmacology, V3, P9, DOI 10.1016/0952-0600(90)90003-2; TERADA N, 1994, ACTA OTO-LARYNGOL, V114, P203, DOI 10.3109/00016489409126043; TIFFANY CW, 1989, FEBS LETT, V247, P189, DOI 10.1016/0014-5793(89)81331-6; Togias A, 2000, J ALLERGY CLIN IMMUN, V105, pS599, DOI 10.1067/mai.2000.106885; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214, DOI 10.1165/ajrcmb/7.2.214; Turner PJ, 2000, BRIT J PHARMACOL, V129, P525, DOI 10.1038/sj.bjp.0703095; Woessner KM, 1998, J ALLERGY CLIN IMMUN, V101, pS172	50	52	55	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					105	113		10.1067/mai.2001.111145	http://dx.doi.org/10.1067/mai.2001.111145			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11149999				2022-12-18	WOS:000166533300019
J	Bielory, L				Bielory, L			Allergic and immunologic disorders of the eye. Part I: Immunology of the eye	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						ocular immunology; anterior chamber-associated immune deviation; ocular allergy; conjunctiva; seasonal allergic conjunctivitis; perennial allergic conjunctivitis; atopic keratoconjunctivitis; giant papillary conjunctivitis; vernal keratoconjunctivitis	MAST-CELL NUMBERS; EXPERIMENTAL AUTOIMMUNE UVEITIS; CONJUNCTIVAL PROVOCATION TESTS; EPIDERMAL LANGERHANS CELLS; CORNEAL ENDOTHELIAL-CELLS; OCULAR IMMUNE PRIVILEGE; GROWTH-FACTOR-BETA; ANTERIOR-CHAMBER; AQUEOUS-HUMOR; TEAR FLUID	Immuno-ophthalmology evolved during the 20th century as a subspecialty linking ophthalmologists and immunologists. This emerging subspecialty has focused on the use of immunology to better understand and treat ocular disorders. To help the allergist/clinical immunologist better appreciate the growing field of immuno-ophthalmology, this 2-part review series (Part II: Ocular Allergy will appear in the December issue of the Journal) will provide an overview of the impact that immunology has had on our understanding and treatment of allergic and immunologic eye diseases. The current review will focus on mechanisms by which mast cells, T cells, eosinophils, cytokines, and other inflammatory constituents contribute to the unique features of eye disease and their link to allergic responses that occur in other organs of the body.	Univ Med & Dent New Jersey, Asthma & Allergy Res Ctr, New Jersey Med Sch, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Bielory, L (corresponding author), Univ Med & Dent New Jersey, Asthma & Allergy Res Ctr, New Jersey Med Sch, 90 Bergen St,DOC Suite 4700, Newark, NJ 07103 USA.							ABELSON MB, 1995, OPHTHALMOLOGY, V102, P310; Aghayan-Ugurluoglu R, 2000, J ALLERGY CLIN IMMUN, V105, P803, DOI 10.1067/mai.2000.104782; AICHANE A, 1993, J ALLERGY CLIN IMMUN, V92, P49, DOI 10.1016/0091-6749(93)90036-F; AIZUSS DH, 1985, INVEST OPHTH VIS SCI, V26, P1262; ALLANSMITH MR, 1988, CLIN ALLERGY, V18, P1, DOI 10.1111/j.1365-2222.1988.tb02837.x; ALLANSMITH MR, 1990, J AM OPTOM ASSOC, V61, P16; Anderson DF, 1997, CLIN EXP ALLERGY, V27, P1060, DOI 10.1111/j.1365-2222.1997.tb01258.x; Bacon AS, 1998, INVEST OPHTH VIS SCI, V39, P322; BADDELEY SM, 1995, CLIN EXP ALLERGY, V25, P41, DOI 10.1111/j.1365-2222.1995.tb01001.x; BALLOW M, 1980, J ALLERGY CLIN IMMUN, V66, P112, DOI 10.1016/0091-6749(80)90057-3; BAUDOUIN C, 1992, BRIT J OPHTHALMOL, V76, P545, DOI 10.1136/bjo.76.9.545; BENZVI A, 1981, ARCH OPHTHALMOL-CHIC, V99, P1436; BIEBER T, 1989, J INVEST DERMATOL, V93, P215, DOI 10.1111/1523-1747.ep12277574; BIELORY L, 1992, J ALLERGY CLIN IMMUN, V86, P1; BISGAARD H, 1984, PROSTAGLANDINS, V27, P369, DOI 10.1016/0090-6980(84)90196-5; BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579; Bourcier T, 2000, INVEST OPHTH VIS SCI, V41, P120; Brignole F, 1998, EXP EYE RES, V67, P687, DOI 10.1006/exer.1998.0566; BUTRUS SI, 1990, OPHTHALMOLOGY, V97, P1678; CAMPBELL AM, 1993, ANN ALLERGY, V71, P51; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P783, DOI 10.1016/0091-6749(93)90198-O; COOK E, 1996, J ALLERGY CLIN IMMUN, V97, pA318; CRAWFORD KM, 1992, INVEST OPHTH VIS SCI, V33, P3041; Dana MR, 1998, INVEST OPHTH VIS SCI, V39, P70; De Saint Jean M, 2000, INVEST OPHTH VIS SCI, V41, P2531; DEKOZAK Y, 1981, EUR J IMMUNOL, V11, P612, DOI 10.1002/eji.1830110805; DELACROIX DL, 1982, IMMUNOLOGY, V47, P383; DELLADORA F, 1985, CHIBRET ING J OPHTHA, V3, P16; Elner SG, 1996, INVEST OPHTH VIS SCI, V37, P696; FEENEY L, 1961, AM J OPHTHALMOL, V51, P1057; FERGUSON TA, 1992, INVEST OPHTH VIS SCI, V33, P1788; FOSTER CS, 1991, OPHTHALMOLOGY, V98, P1190; FRANKLIN RM, 1984, INVEST OPHTH VIS SCI, V25, P181; FREIDLANDER M, 1987, JAMA-J AM MED ASSOC, V258, P2916; Fujishima H, 1997, CLIN EXP ALLERGY, V27, P372; FUKAGAWA K, 1996, J ALLERGY CLIN IMMUN, V97, pA441; GERMUTH FG, 1959, AM J OPHTHALMOL, V46, P282; GERRITSEN ME, 1989, INVEST OPHTH VIS SCI, V30, P698; Gill KS, 1997, CORNEA, V16, P107; GILLETTE TE, 1982, OPHTHALMOLOGY, V89, P700; Godfrey W A, 1987, Trans Am Ophthalmol Soc, V85, P557; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2; HARA Y, 1992, J IMMUNOL, V148, P1685; HAZLETT LD, 1984, INFECT IMMUN, V43, P783, DOI 10.1128/IAI.43.3.783-790.1984; HEAD JR, 1985, PERSPECT BIOL MED, V29, P115; Hingorani M, 1998, EXP EYE RES, V67, P491, DOI 10.1006/exer.1998.0528; Hingorani M, 1998, J ALLERGY CLIN IMMUN, V102, P821, DOI 10.1016/S0091-6749(98)70023-5; Hogaboam G, 1998, J IMMUNOL, V160, P6166; IRANI AMA, 1990, J ALLERGY CLIN IMMUN, V86, P34, DOI 10.1016/S0091-6749(05)80120-4; Irani AMA, 1997, IMMUNOL ALLERGY CLIN, V17, P1, DOI 10.1016/S0889-8561(05)70287-3; ISAACSON P, 1984, CANCER, V53, P2515, DOI 10.1002/1097-0142(19840601)53:11<2515::AID-CNCR2820531125>3.0.CO;2-C; JAMPEL HD, 1990, CURR EYE RES, V9, P963, DOI 10.3109/02713689009069932; JOHNSON D, 1991, J NEUROPATH EXP NEUR, V50, P227, DOI 10.1097/00005072-199105000-00005; Jorpes E., 1937, Zeitschrift fuer Mikroskopisch-Anatomische Forschung, V42, P279; KAHN M, 1986, INVEST OPHTHALMO S38, V27, P2; Kaiser C J, 1989, Reg Immunol, V2, P42; KAPLAN HJ, 1977, J IMMUNOL, V118, P809; KARI O, 1985, GRAEF ARCH CLIN EXP, V223, P60, DOI 10.1007/BF02150945; Kawashima H, 1997, EUR J IMMUNOL, V27, P2490, DOI 10.1002/eji.1830271005; KNISELY TL, 1994, INVEST OPHTH VIS SCI, V35, P3711; Langford M P, 1995, Ocul Immunol Inflamm, V3, P249, DOI 10.3109/09273949509069119; LEVIN LA, 1993, INVEST OPHTH VIS SCI, V34, P3147; Li Q, 1996, INT ARCH ALLERGY IMM, V109, P277, DOI 10.1159/000237250; MacLeod JDA, 1997, CLIN EXP ALLERGY, V27, P1328; Magone MT, 1998, CLIN IMMUNOL IMMUNOP, V87, P75, DOI 10.1006/clin.1997.4507; MARAK GE, 1979, OPHTHALMIC RES, V11, P97; MCCANNEL CA, 1992, INVEST OPHTH VIS SCI, V33, P160; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Metz DP, 1996, J ALLERGY CLIN IMMUN, V98, P686, DOI 10.1016/S0091-6749(96)70103-3; MICHEL AD, 1984, BRIT J PHARMACOL, V83, P460; Miller S, 1996, OCUL IMMUNOL INFLAMM, V4, P39, DOI 10.3109/09273949609069126; MOCHIZUKI M, 1984, J IMMUNOL, V133, P1699; MONDINO BJ, 1988, OPHTHALMOLOGY, V95, P463; MONDINO BJ, 1990, INVEST OPHTH VIS SCI, V31, P1945; Mondino BJ, 1996, INVEST OPHTH VIS SCI, V37, P1576; MONDINO BJ, 1980, ARCH OPHTHALMOL-CHIC, V98, P2041; MONDINO BJ, 1981, ARCH OPHTHALMOL-CHIC, V99, P1430; MORGAN SJ, 1991, J ALLERGY CLIN IMMUN, V87, P111, DOI 10.1016/0091-6749(91)90221-9; Negro-Alvarez J M, 1996, Allergol Immunopathol (Madr), V24, P177; Niederkorn J Y, 1990, Adv Immunol, V48, P191, DOI 10.1016/S0065-2776(08)60755-5; NOWAK JZ, 1987, OPHTHALMIC RES, V19, P72, DOI 10.1159/000265476; NOWAK JZ, 1985, AGENTS ACTIONS, V16, P80, DOI 10.1007/BF01983106; NOWAK JZ, 1985, POL J PHARMACOL PHAR, V37, P783; Oh JW, 1999, ANN ALLERG ASTHMA IM, V82, P579, DOI 10.1016/S1081-1206(10)63170-5; PLEYER U, 1992, INVEST OPHTH VIS SCI, V33, P2212; PROUD D, 1990, J ALLERGY CLIN IMMUN, V85, P896, DOI 10.1016/0091-6749(90)90075-F; SACKS EH, 1986, OPHTHALMOLOGY, V93, P1276; SALONEN EM, 1988, CLIN EXP IMMUNOL, V73, P146; SCHMIDT ED, 1993, INVEST OPHTH VIS SCI, V34, P2130; SEELDRAYERS PA, 1989, J NEUROIMMUNOL, V25, P221, DOI 10.1016/0165-5728(89)90140-9; SETO SK, 1987, INVEST OPHTH VIS SCI, V28, P1719; SOHOEL P, 1993, J ALLERGY CLIN IMMUN, V92, P73, DOI 10.1016/0091-6749(93)90040-M; SOUKIASIAN SH, 1992, INVEST OPHTH VIS SCI, V33, P453; Steptoe R J, 1994, Ocul Immunol Inflamm, V2, P7, DOI 10.3109/09273949409057797; STOCK EL, 1989, AM J ANAT, V186, P359, DOI 10.1002/aja.1001860405; STREILEIN JW, 1981, J EXP MED, V153, P1058, DOI 10.1084/jem.153.5.1058; Streilein JW, 1997, J IMMUNOL, V158, P3557; STREILEIN JW, 1980, J EXP MED, V152, P1121, DOI 10.1084/jem.152.4.1121; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; Streilein JW, 1996, OCUL IMMUNOL INFLAMM, V4, P57, DOI 10.3109/09273949609069128; STREILEIN JW, 1985, J IMMUNOL, V134, P1381; SUGIURA H, 1990, ARCH DERMATOL RES, V282, P295, DOI 10.1007/BF00375722; Tan M, 1997, AUST NZ J OPHTHALMOL, V25, pS27; TAYLOR AW, 1994, J IMMUNOL, V153, P1080; TAYLOR AW, 1992, CURR EYE RES, V11, P1199, DOI 10.3109/02713689208999545; TUFT SJ, 1989, ACTA OPHTHALMOL, V67, P301, DOI 10.1111/j.1755-3768.1989.tb01875.x; UDELL IJ, 1981, AM J OPHTHALMOL, V91, P226, DOI 10.1016/0002-9394(81)90178-1; VANNAS S., 1959, ACTA OPHTHALMOL, V37, P330; VERHAGEN C, 1994, INVEST OPHTH VIS SCI, V35, P236; VERHAGEN C, 1991, EXP EYE RES, V53, P471, DOI 10.1016/0014-4835(91)90164-A; VERHAGEN C, 1992, INVEST OPHTH VIS SCI, V33, P273; Vesaluoma M, 1999, CLIN EXP ALLERGY, V29, P537; WAHLESTEDT C, 1986, REGUL PEPTIDES, V16, P107, DOI 10.1016/0167-0115(86)90054-6; WANG Y, 1993, INVEST OPHTH VIS SCI, V34, P41; Welge-Lussen U, 1999, INVEST OPHTH VIS SCI, V40, P3209; Wenkel H, 1998, INVEST OPHTH VIS SCI, V39, P1823; WILBANKS GA, 1990, IMMUNOLOGY, V71, P566; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P1031, DOI 10.1002/eji.1830220423; Yoshida A, 1997, BRIT J OPHTHALMOL, V81, P402, DOI 10.1136/bjo.81.5.402	120	52	53	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					805	816		10.1067/mai.2000.111029	http://dx.doi.org/10.1067/mai.2000.111029			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080700				2022-12-18	WOS:000167865200002
J	Fish, JE; Karpel, JP; Craig, TJ; Bensch, GW; Noonan, M; Webb, DR; Silverman, B; Schenkel, EJ; Rooklin, AR; Ramsdell, JW; Nathan, R; Leflein, JG; Grossman, J; Graft, DF; Gower, RG; Garay, SM; Frigas, E; DeGraff, AC; Bronsky, EA; Bernstein, DI; Berger, W; Shneyer, L; Nolop, KB; Harrison, JE				Fish, JE; Karpel, JP; Craig, TJ; Bensch, GW; Noonan, M; Webb, DR; Silverman, B; Schenkel, EJ; Rooklin, AR; Ramsdell, JW; Nathan, R; Leflein, JG; Grossman, J; Graft, DF; Gower, RG; Garay, SM; Frigas, E; DeGraff, AC; Bronsky, EA; Bernstein, DI; Berger, W; Shneyer, L; Nolop, KB; Harrison, JE			Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related duality of life in patients with severe persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mometasone furoate; severe persistent asthma; oral corticosteroid-dependent asthma; prednisone; glucocorticoid; health-related quality of life; steroid sparing	FLUTICASONE PROPIONATE POWDER; QUALITY-OF-LIFE; BECLOMETHASONE DIPROPIONATE; ALLERGIC RHINITIS; PLACEBO; ADULTS; GLUCOCORTICOIDS; BUDESONIDE; TURBUHALER	Background: Inhaled corticosteroid therapy in severe persistent asthma has been shown to reduce or eliminate oral corticosteroid (OCS) use while retaining effective asthma control. Objective: We sought to evaluate the ability of mometasone furoate (MF) delivered by means of dry powder inhaler to reduce daily oral prednisone requirements in OCS-dependent patients with severe persistent asthma. Methods: We performed a 12-week, double-blind, placebo-controlled trial (21 centers, 132 patients) comparing 2 doses of MF (400 and 800 mug administered tu ice daily) with placebo, followed by a 9-month open-label phase in which 128 patients received treatment with MF. Results: At the endpoint of the double-blind trial, MF 400 and 800 mg twice daily reduced daily OCS requirements by 46.0 % and 23.9%, respectively, whereas placebo increased OCS requirements by 164.4% (P <.01). Oral steroids were eliminated in 40%, 37%, and 0% of patients in the MF 400 and 800 mg twice daily and placebo groups, respectively. Pulmonary function and quality of life significantly increased for MF-treated patients. Further reductions in OCS requirements were achieved with long-term MF treatment in the open-label phase. Conclusion: MF inhaled orally as a dry powder is an effective alternative to systemic corticosteroids in patients with severe persistent asthma.	Schering Plough Corp, Res Inst, Kenilworth, NJ USA; So Calif Res Ctr, Mission Viejo, CA USA; Bernstein Clin Res Ctr Inc, Cincinnati, OH USA; Intermt Clin Res, Salt Lake City, UT USA; Hartford Lung Phys Res Ctr, Hartford, CT USA; Mayo Clin, Rochester, MN USA; New York Pulm Associates PC, New York, NY USA; Rockwood Clin, Spokane, WA USA; Pk Nicollet Clin Healthsyst Minnesota, Asthma & Allerg Dis Dept, Minneapolis, MN USA; Allergy Care Consultants Ltd, Tucson, AZ USA; Asthma & Allergy Associate PC, Colorado Springs, CO USA; Univ Calif San Diego, Med Ctr, San Diego Clin Trials Ctr, San Diego, CA 92103 USA; Asthma & Allergy Associates, Crozer Chester Med Ctr, Chester, PA USA; Valley Clin Res Ctr, Easton, PA USA; Long Isl Coll Hosp, Dept Allergy & Immunol, Brooklyn, NY 11201 USA; Allergy & Asthma Associates, Kirkland, WA USA; Allergy Immunol & Asthma Med Grp Inc, Stockton, CA USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Med, Hershey, PA 17033 USA; Montefiore Med Ctr, Bronx, NY 10467 USA; Thomas Jefferson Hosp, Dept Pulm Med, Philadelphia, PA USA	Merck & Company; Schering Plough Corporation; Mayo Clinic; University of California System; University of California San Diego; Long Island College Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Jefferson University	Fish, JE (corresponding author), Jefferson Med Coll, Div Pulm & Crit Care Med, 1025 Walnut St,Room 805, Philadelphia, PA 19107 USA.			Gower, Richard/0000-0002-5042-7059				Aaronson D, 1998, J ALLERGY CLIN IMMUN, V101, P312, DOI 10.1016/S0091-6749(98)70241-6; AFFRIME MB, 2000, IN PRESS CHEST; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Bernstein DI, 1999, RESP MED, V93, P603, DOI 10.1016/S0954-6111(99)90099-9; Busse WW, 1999, J ALLERGY CLIN IMMUN, V104, P1215, DOI 10.1016/S0091-6749(99)70016-3; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Crocker IC, 1998, ANN ALLERG ASTHMA IM, V80, P509, DOI 10.1016/S1081-1206(10)63075-X; Drouin M, 1996, ANN ALLERG ASTHMA IM, V77, P153, DOI 10.1016/S1081-1206(10)63502-8; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; Leone FT, 1999, RESP MED, V93, P788, DOI 10.1016/S0954-6111(99)90263-9; Li JTC, 1999, J ALLERGY CLIN IMMUN, V103, P622, DOI 10.1016/S0091-6749(99)70234-4; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; Medansky R S, 1988, Cutis, V42, P480; *NAT HEART LUNG BL, 1997, 2 NAT HEART LUNG BLO, P1; National Institutes of Health, 1996, CURR CONC BOV MAST, P1; Nayak AS, 2000, ANN ALLERG ASTHMA IM, V84, P417, DOI 10.1016/S1081-1206(10)62275-2; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V103, P267, DOI 10.1016/S0091-6749(99)70501-4; Nelson HS, 1998, CHEST, V113, P1264, DOI 10.1378/chest.113.5.1264; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; Prakash A, 1998, DRUGS, V55, P145, DOI 10.2165/00003495-199855010-00009; Ruhl R, 1993, Allergol Immunopathol (Madr), V21, P53; Smith CL, 1998, ARZNEIMITTEL-FORSCH, V48, P957; Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wasserman SI, 1996, J ASTHMA, V33, P265, DOI 10.3109/02770909609055367	25	52	53	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					852	860		10.1067/mai.2000.110798	http://dx.doi.org/10.1067/mai.2000.110798			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080706				2022-12-18	WOS:000167865200008
J	Moody, A; Fergusson, W; Wells, A; Bartley, J; Kolbe, J				Moody, A; Fergusson, W; Wells, A; Bartley, J; Kolbe, J			Increased nitric oxide production in the respiratory tract in asymptomatic Pacific Islanders: An association with skin prick reactivity to house dust mite	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nitric oxide; house dust mite; atopy; Pacific Islander	BRONCHIAL HYPERRESPONSIVENESS; AIRWAY HYPERRESPONSIVENESS; ASTHMA SYMPTOMS; SPUTUM EOSINOPHILS; POPULATION-SAMPLE; INHALED STEROIDS; GRASS-POLLEN; YOUNG-ADULTS; CHILDREN; PREVALENCE	Background: Exhaled nitric oxide (NO) is increased in asthma and may also be increased in subclinical airway inflammation. The relationship between atopy and subclinical airway inflammation in the pathogenesis of asthma remains unclear. We have evaluated the relationship between exhaled NO levels and skin prick test reactivity to 8 common allergens in 64 asymptomatic adult pacific Islanders. Pacific Islanders were studied as a racial group with major morbidity from asthma. Objective: Our purpose was to determine whether asymptomatic subjects with skin prick test reactivity to common allergens have elevated NO levels. Methods: All subjects underwent full lung function testing and skin prick testing. Exhaled and nasal NO levels were measured by chemiluminescence (Logan LR2000 analyzer) with use of the single-breath and breath-holding techniques, respectively. Results: House dust mite (HDM) reactivity was seen in 38 of 64 (56%). Exhaled NO levels (median 8.9 ppb, range 2.9-47.3 ppb) and nasal NO levels (527.5 +/- 181.5 ppb) lay above the normal European range in 30% and 25% of subjects, respectively HDM reactivity was associated with higher exhaled NO levels (P < .0005) and higher nasal NO levels (P = .01). In HDM-sensitive subjects the wheal size for HDM correlated with exhaled NO levels (r = 0.35, P = .04) and nasal NO levels (r = 0.40, P = .01). On multivariate analysis, exhaled NO levels were independently and positively related to the severity of HDM reactivity (P = .01) and nasal NO levels (P < .02), equation R-2 = 0.27. Conclusion: NO levels are elevated in a significant proportion of asymptomatic Pacific Islanders and are associated with HDM sensitivity. This may denote subclinical airway inflammation in this population and suggests that exposure to HDM in atopic individuals might play an important role in the early pathogenesis of asthma.	Green Lane Hosp, Dept Resp Serv, Auckland 3, New Zealand; Green Lane Hosp, Dept Otolaryngol, Auckland 3, New Zealand; Univ Auckland, Sch Med, Dept Med, Auckland, New Zealand; Royal Brompton Hosp, Interstitial Lund Dis Unit, London SW3 6LY, England	University of Auckland; Royal Brompton Hospital	Kolbe, J (corresponding author), Green Lane Hosp, Dept Resp Serv, Green Lane W, Auckland 3, New Zealand.							[Anonymous], 1976, MED RES COUNC QUEST; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P262, DOI 10.1164/ajrccm.159.1.9804063; BOULET LP, 1998, P WORLD ASTHM M 1998, P58; CRANE J, 1994, NEW ZEAL MED J, V107, P417; Crane P.R., 1990, FIELDIANA GEOLOGY, V20, P1, DOI [10.5962/bhl.title.100826, DOI 10.5962/BHL.TITLE.100826]; D'Souza W, 1999, NEW ZEAL MED J, V112, P198; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; ENDO T, 1995, AM J RESP CRIT CARE, V151, pA177; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69, DOI 10.1164/ajrccm.159.1.9804134; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1773, DOI 10.1164/ajrccm.153.6.8665033; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; Laprise C, 1999, EUR RESPIR J, V14, P63, DOI 10.1034/j.1399-3003.1999.14a12.x; Laprise C, 1997, AM J RESP CRIT CARE, V156, P403, DOI 10.1164/ajrccm.156.2.9606053; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LEUNG RC, 1994, MED J AUSTRALIA, V161, P418, DOI 10.5694/j.1326-5377.1994.tb127522.x; MOODY A, 1999, RESPIROLOGY S, V4, pA18; PATTEMORE PK, 1989, THORAX, V44, P168, DOI 10.1136/thx.44.3.168; PEAT JK, 1992, EUR RESPIR J, V5, P921; PEAT JK, 1994, AUST NZ J MED, V24, P270, DOI 10.1111/j.1445-5994.1994.tb02171.x; Salome CM, 1999, AM J RESP CRIT CARE, V159, P911, DOI 10.1164/ajrccm.159.3.9802108; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Sears MR, 1997, EUR RESPIR J, V10, P51, DOI 10.1183/09031936.97.10010051; SHAW RA, 1991, NEW ZEAL MED J, V104, P175; Simpson A, 1999, AM J RESP CRIT CARE, V160, P45, DOI 10.1164/ajrccm.160.1.9809091; van Rensen ELJ, 1999, THORAX, V54, P403, DOI 10.1136/thx.54.5.403; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; [No title captured]	32	52	54	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					895	899		10.1067/mai.2000.105318	http://dx.doi.org/10.1067/mai.2000.105318			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808168				2022-12-18	WOS:000087185000006
J	Gern, JE				Gern, JE			Viral and bacterial infections in the development and progression of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; viruses; rhinoviruses; allergy; hypersensitivity; cytokines; respiratory syncytial virus	RESPIRATORY SYNCYTIAL VIRUS; T-CELLS; RHINOVIRUS INFECTION; IN-VIVO; AIRWAY HYPERRESPONSIVENESS; NONALLERGIC SUBJECTS; PROSPECTIVE COHORT; ALLERGIC SUBJECTS; TRACT INFECTIONS; RISK-FACTORS	Viral respiratory infections produce wheezing illnesses in patients of all ages, In infancy, infections with respiratory syncytial virus and parainfluenza virus are the major cause of bronchiolitis and croup, whereas infections with common cold viruses such as rhinoviruses are the principal triggers for wheezing in older children and adults with asthma. In addition to causing increased wheezing in asthma, there is mounting evidence that infections early in childhood can affect the development of the immune system and thereby modify the risk for the subsequent development of allergies and asthma, Both of these effects appear to be mediated by virus-induced immune responses, Early during the course of viral infection, resident cells in the airway are activated in an antigen-independent fashion, triggering antiviral responses but also activating and recruiting cells to the airway that could contribute to airway obstruction and respiratory symptoms, Virus-specific T- and B-cell responses may also have dual effects in the presence of preexisting airway inflammation. Finally, there is evidence of synergistic interactions between allergen- and virus-induced airway inflammation. It is Likely that greater definition of mechanisms of virus-induced inflammation will provide therapeutic targets for the treatment and possibly the prevention of allergies and asthma.	Univ Wisconsin, Sch Med, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison	Gern, JE (corresponding author), Univ Wisconsin Hosp & Clin, H4-438 CSC,600 Highland Ave, Madison, WI 53792 USA.				NHLBI NIH HHS [HL/AI 60993] Funding Source: Medline; NIAID NIH HHS [AI 40685, AI 34891] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034891, U19AI034891, R29AI040685] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN W, 1990, J IMMUNOL, V144, P3980; ALWAN WH, 1993, J IMMUNOL, V150, P5211; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Bardin PG, 1996, EUR RESPIR J, V9, P2250, DOI 10.1183/09031936.96.09112250; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; COGSWELL JJ, 1982, BRIT MED J, V284, P1011, DOI 10.1136/bmj.284.6321.1011; DENNY FW, 1986, J PEDIATR-US, V108, P635, DOI 10.1016/S0022-3476(86)81034-4; DOHERTY PC, 1995, J IMMUNOL, V155, P1023; DOHERTY PC, 1994, CURR OPIN IMMUNOL, V6, P545, DOI 10.1016/0952-7915(94)90139-2; DOYLE WJ, 1992, J ALLERGY CLIN IMMUN, V89, P968, DOI 10.1016/0091-6749(92)90219-R; DUFF AL, 1993, PEDIATRICS, V92, P535; Einarsson O, 1996, J CLIN INVEST, V97, P915, DOI 10.1172/JCI118514; EVERARD ML, 1994, ARCH DIS CHILD, V71, P428, DOI 10.1136/adc.71.5.428; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; GAROFALO R, 1992, J PEDIATR-US, V120, P28, DOI 10.1016/S0022-3476(05)80592-X; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1872, DOI 10.1164/ajrccm.155.6.9196088; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Gern JE, 1996, J IMMUNOL, V157, P1605; Gern JE, 1997, J INFECT DIS, V175, P1108, DOI 10.1086/516449; Gern JE, 1996, J IMMUNOL, V156, P621; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; HORN MEC, 1975, J HYG-CAMBRIDGE, V74, P157, DOI 10.1017/S0022172400024220; INGRAM JM, 1995, J PEDIATR-US, V127, P558, DOI 10.1016/S0022-3476(95)70112-5; Jackson M, 1996, J MED VIROL, V49, P161, DOI 10.1002/(SICI)1096-9071(199607)49:3<161::AID-JMV2>3.0.CO;2-2; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1997, J INFECT DIS, V175, P323, DOI 10.1093/infdis/175.2.323; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; KELLNER G, 1989, ACTA PAEDIATR SCAND, V78, P390, DOI 10.1111/j.1651-2227.1989.tb11098.x; Las Heras J, 1983, Pediatr Pathol, V1, P319; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LEVANDOWSKI RA, 1988, J MED VIROL, V25, P423, DOI 10.1002/jmv.1890250406; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MONTO AS, 1971, AM J EPIDEMIOL, V94, P280, DOI 10.1093/oxfordjournals.aje.a121321; Nicholson KG, 1996, BMJ-BRIT MED J, V313, P1119, DOI 10.1136/bmj.313.7065.1119; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; ROBERTS NJ, 1979, J IMMUNOL, V123, P365; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; SHAHEEN SO, 1995, CLIN EXP ALLERGY, V25, P1034; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIGURS N, 1995, PEDIATRICS, V95, P500; Skoner DP, 1996, AM J RESP CRIT CARE, V154, P661, DOI 10.1164/ajrccm.154.3.8810602; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Teran LM, 1997, AM J RESP CRIT CARE, V155, P1362, DOI 10.1164/ajrccm.155.4.9105080; Topham DJ, 1996, J VIROL, V70, P1288, DOI 10.1128/JVI.70.2.1288-1291.1996; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; TURNER RB, 1990, PEDIATR INFECT DIS J, V9, P832, DOI 10.1097/00006454-199011000-00011; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WELLIVER RC, 1995, LANCET, V346, P789, DOI 10.1016/S0140-6736(95)91615-6; WINTHER B, 1984, ACTA OTO-LARYNGOL, P19	58	52	58	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	2	S			S497	S502		10.1016/S0091-6749(00)90050-2	http://dx.doi.org/10.1016/S0091-6749(00)90050-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286JG	10669531				2022-12-18	WOS:000085439600008
J	Vargas, R; Dockhorn, RJ; Findlay, SR; Korenblat, PE; Field, EA; Kral, KM				Vargas, R; Dockhorn, RJ; Findlay, SR; Korenblat, PE; Field, EA; Kral, KM			Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	95th Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics	MAR 30-APR 01, 1994	NEW ORLEANS, LOUISIANA	Amer Soc Clin Pharm & Therapeut		cosyntropin; fluticasone propionate; intranasal	SEASONAL ALLERGIC RHINITIS; ADRENOCORTICAL FUNCTION; INTRANASAL FLUTICASONE; ACTH TEST; STEROIDS; CORTISOL; AGE	Background: Fluticasone propionate is a glucocorticoid with negligible oral bioavailability and very low intranasal bioavailability that is used as an intranasal spray for the treatment of rhinitis. Objective: The purpose of this study was to evaluate the hypothalamic-pituitary-adrenal (HPA)-axis effects of fluticasone propionate aqueous nasal spray (FP ANS) compared with oral prednisone and placebo by using a 6-hour cosyntropin infusion test. Methods: In a 4-week, randomized, double-blind, double-dummy, placebo-controlled parallel-group study, 105 adult patients with allergic rhinitis were randomly assigned to receive FP ANS 200 mu g once daily, FP ANS 400 mu g twice daily, oral prednisone 7.5 mg once daily, oral prednisone 15 mg once daily, or placebo. HPA-axis function was assessed at the screening visit and after 4 weeks of treatment by measuring morning plasma cortisol concentrations and poststimulation concentrations of plasma and urinary cortisol. Results: There was no evidence of altered HPA-axis response to cosyntropin by the end of treatment with FP ANS 200 mu g once daily or FP ANS 400 mu g twice daily when compared with placebo. In contrast, 4 weeks of treatment with oral prednisone 7.5 or 15 mg once daily was associated with significant (p < 0.05 vs placebo) reduction in HPA-axis function, as evidenced by lower plasma cortisol concentrations (area under the plasma concentration-time curve and peak concentrations) after cosyntropin stimulation and reduced mean 24-hour urinary cortisol excretion. FP ANS 400 mu g twice daily and both prednisone regimens were associated with a significant (p < 0.05 vs placebo) reduction in mean morning plasma cortisol concentrations. Conclusion: These results indicate that a 4-week course of FP ANS at four times the recommended dose does not suppress adrenal function in response to a 6-hour cosyntropin stimulation test.	Clin Res Ctr, New Orleans, LA 70112 USA; Immunoallergy Tech Consultants Inc, Prairie Village, KS USA; HealthQuest Therapy & Res Inst, Austin, TX USA; Associated Specialists Med PC, St Louis, MO USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Vargas, R (corresponding author), Clin Res Ctr, 147 S Liberty St, New Orleans, LA 70112 USA.							BAXTER JD, 1987, ENDOCRINOLOGY METABO; BONDY P K, 1985, P816; BROIDE J, 1995, J CLIN ENDOCR METAB, V80, P1243, DOI 10.1210/jc.80.4.1243; DROSZCZ W, 1980, ANN ALLERGY, V44, P174; FEISS G, 1992, J ALLERGY CLIN IMMUN, V89, P1151, DOI 10.1016/0091-6749(92)90299-H; FREY BM, 1984, EUR J CLIN PHARMACOL, V26, P505, DOI 10.1007/BF00542149; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; HICKLIN JA, 1968, ANN RHEUM DIS, V27, P33, DOI 10.1136/ard.27.1.33; HOLT PR, 1990, CLIN EXP ALLERGY, V20, P145, DOI 10.1111/j.1365-2222.1990.tb02659.x; Howland WC, 1996, J ALLERGY CLIN IMMUN, V98, P32, DOI 10.1016/S0091-6749(96)70223-3; LANDON J, 1965, J CLIN ENDOCR METAB, V25, P602, DOI 10.1210/jcem-25-5-602; LINDHOLM J, 1978, J CLIN ENDOCR METAB, V47, P272, DOI 10.1210/jcem-47-2-272; LINDHOLM J, 1987, CLIN ENDOCRINOL, V26, P53, DOI 10.1111/j.1365-2265.1987.tb03638.x; McDowall JE, 1997, CLIN DRUG INVEST, V14, P44, DOI 10.2165/00044011-199714010-00006; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; NATHAN RA, 1991, ANN ALLERGY, V67, P332; NELSON DH, 1980, ADRENAL CORTEX PHYSL, V18, P113; NELSON J, 1978, AM J MED SCI, V27, P165; PADFIELD PL, 1993, EUR RESPIR REV, V3, P493; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; SHERMAN B, 1985, J CLIN ENDOCR METAB, V61, P439, DOI 10.1210/jcem-61-3-439; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371; TORDJMAN K, 1995, J CLIN ENDOCR METAB, V80, P1301, DOI 10.1210/jc.80.4.1301; VANAS A, 1991, ANN ALLERGY, V67, P156; VANBAVEL J, 1994, ARCH INTERN MED, V154, P2699, DOI 10.1001/archinte.1994.00420230086010; WEBB J, 1981, THORAX, V36, P22, DOI 10.1136/thx.36.1.22; WEINER MF, 1987, AM J PSYCHIAT, V144, P646; WILMSMEYER W, 1990, EUR RESPIR J, V3, P786; WOOD JB, 1965, LANCET, V1, P243	29	52	52	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					191	197		10.1016/S0091-6749(98)70085-5	http://dx.doi.org/10.1016/S0091-6749(98)70085-5			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723660				2022-12-18	WOS:000075537100007
J	Pastore, S; Corinti, S; La Placa, M; Didona, B; Girolomoni, G				Pastore, S; Corinti, S; La Placa, M; Didona, B; Girolomoni, G			Interferon-gamma promotes exaggerated cytokine production in keratinocytes cultured from patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; keratinocytes; cytokines; adhesion molecules; interferon-gamma	INTERCELLULAR-ADHESION MOLECULE-1; INTERLEUKIN-1 RECEPTOR ANTAGONIST; IN-SITU; SKIN; EXPRESSION; CELLS; AEROALLERGEN; LYMPHOCYTES; MODULATION; PATTERN	Recent studies suggest that skin keratinocytes from patients with atopic dermatitis (AD) and nonatopic subjects differ in their intrinsic ability to respond to proinflammatory stimuli. In this study keratinocyte cultures established from the normal-looking skin of six adult patients with AD and six healthy, nonatopic control subjects were compared in their response to interferon-gamma, a potent proinflammatory lymphokine whose expression is increased in chronic AD lesions. Basal expression of IFN-gamma receptor as well as IFN-gamma-induced membrane expression of HLA-DR and intercellular adhesion molecule (ICAM)-1 were evaluated by flow cytometry. Keratinocyte release of IL-1 alpha, IL-1 receptor antagonist (IL-1ra), granulocyte-macrophage colony stimulating factor (GM-CSF), and tumor necrosis factor (TNF)-alpha were measured by ELISA on culture supernatants after treatment with IFN-gamma or medium alone. Expression of membrane IFN-gamma receptor was similar in keratinocytes cultured from nonatopic subjects and subjects with AD. IFN-gamma (10 to 500 U/ml) induced comparable levels of membrane HLA-DR and ICAM-1 in both groups of keratinocytes. In contrast, spontaneous release of IL-1 alpha, IL-1ra, GM-CSF, and TNF-alpha were measured by ELISA on culture supernatants after treatment with IFN-gamma or medium alone. Expression of membrane IFN-gamma receptor was similar in keratinocytes cultured from nonatopic subjects and subjects with AD. IFN-gamma (10 to 500 U/ml) induced comparable levels of membrane HLA-DR and ICAM-1 in both groups of keratinocytes. In contrast, spontaneous release of IL-1 alpha, IL-1ra, GM-CSF, and TNF-alpha was increased in the supernatants of unstimulated keratinocytes from control subjects, with IL-1ra and GM-CSF reaching statistically significant difference. Moreover, IFN-gamma-induced release of all the cytokines tested was much higher for keratinocytes from patients with AD, but the IL-1ra/IL-1 alpha ratio for the two groups of keratinocytes was not substantially different, either basally or after IFN-gamma stimulation. The results indicate that keratinocytes from patients with AD are hyperresponsive to IFN-gamma in terms of cytokine release.	IRCCS, Ist Dermopat Immacolata, Immunol Lab, I-00167 Rome, Italy; IRCCS, Ist Dermopat Immacolata, Div Dermatol 1, I-00167 Rome, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Pastore, S (corresponding author), IRCCS, Ist Dermopat Immacolata, Immunol Lab, Via Monti di Creta 104, I-00167 Rome, Italy.		La Placa, Michelangelo/U-7723-2018; CORINTI, SILVIA/B-9984-2016; GIROLOMONI, Giampiero/AAC-3405-2022	La Placa, Michelangelo/0000-0002-6894-3350; CORINTI, SILVIA/0000-0003-4096-4931; Didona, Biagio/0000-0001-6635-0490				ALBANESI C, 1998, IN PRESS J INVEST DE; AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BARKER JNWN, 1987, J AM ACAD DERMATOL, V16, P1175, DOI 10.1016/S0190-9622(87)70153-4; BIGLER CF, 1992, J INVEST DERMATOL, V98, P38, DOI 10.1111/1523-1747.ep12494196; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Calderon MA, 1997, J ALLERGY CLIN IMMUN, V99, P65, DOI 10.1016/S0091-6749(97)70302-6; Carroll JM, 1997, J INVEST DERMATOL, V108, P412, DOI 10.1111/1523-1747.ep12289702; Casolaro V, 1996, CURR OPIN IMMUNOL, V8, P796, DOI 10.1016/S0952-7915(96)80007-0; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; Fujisawa H, 1997, J INTERF CYTOK RES, V17, P347, DOI 10.1089/jir.1997.17.347; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; Gueniche A, 1994, Exp Dermatol, V3, P113, DOI 10.1111/j.1600-0625.1994.tb00268.x; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HORNEFF G, 1994, CLIN INVESTIGATOR, V72, P400; KAGI MK, 1994, INT ARCH ALLERGY IMM, V103, P332, DOI 10.1159/000236651; KAPLAN G, 1987, AM J PATHOL, V128, P345; KUPPER TS, 1995, J INVEST DERMATOL, V105, P62; Leung DYM, 1997, CLIN EXP IMMUNOL, V107, P25; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Nakazawa M, 1997, J ALLERGY CLIN IMMUN, V99, P673, DOI 10.1016/S0091-6749(97)70030-7; NICKOLOFF BJ, 1987, J INVEST DERMATOL, V89, P132, DOI 10.1111/1523-1747.ep12470545; Nishioka Kiyoshi, 1995, Journal of Dermatology (Tokyo), V22, P181; OHMEN JD, 1995, J IMMUNOL, V154, P1953; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; Pastore S, 1996, IMMUNOPHARMACOLOGY, V31, P117, DOI 10.1016/0162-3109(95)00044-5; REINHOLD U, 1993, J AM ACAD DERMATOL, V29, P58, DOI 10.1016/0190-9622(93)70152-J; REINHOLD U, 1991, CLIN EXP IMMUNOL, V86, P444; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; VIRTANEN T, 1995, J ALLERGY CLIN IMMUN, V96, P411, DOI 10.1016/S0091-6749(95)70061-7; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164	39	52	53	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				538	544		10.1016/S0091-6749(98)70361-6	http://dx.doi.org/10.1016/S0091-6749(98)70361-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564808				2022-12-18	WOS:000073113500017
J	Inman, MD; Hamilton, AL; Kerstjens, HAM; Watson, RM; O'Byrne, PM				Inman, MD; Hamilton, AL; Kerstjens, HAM; Watson, RM; O'Byrne, PM			The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway responsiveness; asthma; reproducibility; bronchoprotection; allergen	ALLERGEN-INDUCED INCREASE; INDUCED BRONCHOCONSTRICTION; BRONCHIAL RESPONSIVENESS; SODIUM CROMOGLYCATE; INHALED SALBUTAMOL; MILD ASTHMA; RESPONSES; HISTAMINE; REPRODUCIBILITY; REACTIVITY	Background: Measurements of airway responsiveness are frequently used to evaluate anti-asthma drugs. Objective: This study investigated the utility of methacholine airway responsiveness measurements in evaluating anti-asthma medications, both in terms of a bronchoprotective effect and the ability to attenuate allergen-induced methacholine airway hyperresponsiveness. Methods: Methacholine airway responsiveness was measured as PC20 on two occasions (separated by 35 +/- 17 days, mean +/- SD) in 40 subjects with mild, stable asthma. Additional subjects had PC20 measurements made before and af ter administration of either inhaled salbutamol (200 mu g) (n = 20) or allergen inhalation challenge (n = 31). Results: The reproducibility of the methacholine PC20 with this method was high (intraclass correlation coefficient = 0.94), The average shift in PC20 after salbutamol was 4.11 doubling concentrations (SD = 1.08). On the basis of these results, a sample size of 12 subjects would be required to demonstrate a 1 doubling concentration difference in the bronchoprotective effect of two drugs with a 90% power. The average shift in PC20 after allergen was 1.29 doubling concentrations. On the basis of these results sind an estimated SD of 0.96, a sample size of 24 subjects would be required to demonstrate that a drug is effective in attenuating 50% of allergen-induced airway hyperresponsiveness with a 90% power: Conclusion: These results confirm the high reproducibility of methacholine PC20 measurements in subjects with mild, stable asthma and demonstrate its utility in evaluating the effects of anti-asthma drugs.	McMaster Univ, Fac Hlth Sci, Dept Med, Asthma Res Grp, Hamilton, ON L8N 3Z5, Canada	McMaster University	O'Byrne, PM (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Med, Asthma Res Grp, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		Kerstjens, Huib/N-4754-2017	Kerstjens, Huib/0000-0001-7705-7927; O'Byrne, Paul/0000-0003-0979-281X				ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BRUSASCO V, 1990, J APPL PHYSIOL, V69, P2209, DOI 10.1152/jappl.1990.69.6.2209; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1993, J ALLERGY CLIN IMMUN, V91, P1163, DOI 10.1016/0091-6749(93)90319-B; CRIMI N, 1988, CLIN ALLERGY, V18, P367, DOI 10.1111/j.1365-2222.1988.tb02884.x; DAUTREBANDE L, 1941, PRESSE MED, V49, P942; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; ESAU S, 1984, J ALLERGY CLIN IMMUN, V74, P270, DOI 10.1016/0091-6749(84)90257-4; FREITAG A, 1993, THORAX, V48, P594, DOI 10.1136/thx.48.6.594; Hamilton AL, 1997, THORAX, V52, P348, DOI 10.1136/thx.52.4.348; HARGREAVE FE, 1986, J ALLERGY CLIN IMMUN, V78, P825, DOI 10.1016/0091-6749(86)90226-5; HENDELES L, 1995, J ALLERGY CLIN IMMUN, V95, P505, DOI 10.1016/S0091-6749(95)70312-8; INMAN MD, 1995, J ALLERGY CLIN IMMUN, V95, P1191, DOI 10.1016/S0091-6749(95)70075-7; Juniper E, 1994, HISTAMINE METHACHOLI; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KIRBY JG, 1989, J APPL PHYSIOL, V66, P578, DOI 10.1152/jappl.1989.66.2.578; KUPPER LL, 1989, AM STAT, V43, P101, DOI 10.2307/2684511; MACONOCHIE JG, 1994, INT J CLIN PHARM TH, V32, P329; MANNING PJ, 1991, EUR RESPIR J, V4, P667; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; *NAT HEART LUNG BL, 1991, US DEP HLTH HUM SERV; PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87; RABE KF, 1993, AM REV RESPIR DIS, V147, P1436, DOI 10.1164/ajrccm/147.6_Pt_1.1436; STREINER DL, 1989, HLTH MEASUREMENT SCA, P79; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; TWENTYMAN OP, 1991, AM REV RESPIR DIS, V144, P782, DOI 10.1164/ajrccm/144.4.782; WARD AJM, 1993, AM REV RESPIR DIS, V147, P518, DOI 10.1164/ajrccm/147.3.518; WOOLLEY KL, 1995, AM J RESP CRIT CARE, V151, P1915, DOI 10.1164/ajrccm.151.6.7767540; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	35	52	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					342	348		10.1016/S0091-6749(98)70246-5	http://dx.doi.org/10.1016/S0091-6749(98)70246-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525450				2022-12-18	WOS:000072593900011
J	Juniper, EF				Juniper, EF			Impact of upper respiratory allergic diseases on quality of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	21st Century Management of Upper Respiratory Allergic Diseases - a Focus on Allergy and Asthma	JAN 13-14, 1997	CHICAGO, IL				OF-LIFE; HEALTH-STATUS; CLINICAL-TRIALS; CHILDHOOD ASTHMA; QUESTIONNAIRE; RHINITIS; RHINOCONJUNCTIVITIS; INSTRUMENTS; SALMETEROL; VALIDATION		McMaster Univ, Med Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 325, Canada	McMaster University	Juniper, EF (corresponding author), McMaster Univ, Med Ctr, Dept Clin Epidemiol & Biostat, 1200 Main St W, Hamilton, ON L8N 325, Canada.							BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; CHRISTIE MJ, 1993, PSYCHOSOM MED, V55, P541, DOI 10.1097/00006842-199311000-00010; CREER TL, 1993, J ASTHMA, V30, P467, DOI 10.3109/02770909309056756; deGraafintVeld T, 1996, J ALLERGY CLIN IMMUN, V98, P508, DOI 10.1016/S0091-6749(96)70083-0; FEENY D, 1992, J CLIN ONCOL, V10, P923, DOI 10.1200/JCO.1992.10.6.923; Feinstein AR, 1987, CLINIMETRICS, P141, DOI DOI 10.2307/J.CTT1XP3VBC.13; GAUCI M, 1993, PSYCHOSOM MED, V55, P533, DOI 10.1097/00006842-199311000-00009; GREER TL, 1992, J ASTHMA, V29, P393; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; GUYATT GH, 1992, J CLIN EPIDEMIOL, V45, P1341, DOI 10.1016/0895-4356(92)90194-R; Guyatt GH, 1997, JAMA-J AM MED ASSOC, V277, P1232, DOI 10.1001/jama.277.15.1232; GUYATT GH, IN PRESS PEDIATRICS; HUNT SM, 1980, J EPIDEMIOL COMMUN H, V34, P281, DOI 10.1136/jech.34.4.281; HYLAND ME, 1995, BRIT J CLIN PSYCHOL, V34, P601, DOI 10.1111/j.2044-8260.1995.tb01494.x; HYLAND ME, 1991, J PSYCHOSOM RES, V35, P99, DOI 10.1016/0022-3999(91)90011-C; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; JONES PW, 1994, AM J RESP CRIT CARE, V149, pA211; Juniper EF, 1997, EUR RESPIR J, V10, P2285, DOI 10.1183/09031936.97.10102285; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; JUNIPER EF, 1993, ANN ALLERGY, V70, P225; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, P163, DOI 10.1016/S0091-6749(98)70380-X; JUNIPER EF, 1995, AM J RESP CRIT CARE, V151, P66, DOI 10.1164/ajrccm.151.1.7812574; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; KAPLAN RM, 1989, MED CARE, V27, pS27, DOI 10.1097/00005650-198903001-00003; LYDICK E, 1993, QUAL LIFE RES, V2, P221, DOI 10.1007/BF00435226; Maille A R, 1994, Monaldi Arch Chest Dis, V49, P76; MALO JL, 1993, J ALLERGY CLIN IMMUN, V91, P1121, DOI 10.1016/0091-6749(93)90313-5; MARKS GB, 1993, J CLIN EPIDEMIOL, V46, P1103, DOI 10.1016/0895-4356(93)90109-E; MARSHALL PS, 1993, ANN ALLERGY, V71, P251; NOCON A, 1991, ARCH DIS CHILD, V66, P458, DOI 10.1136/adc.66.4.458; RUTTENVANMOLKEN MPMH, 1995, EUR RESPIR J, V8, P888; SACKETT DL, 1977, AM J PUBLIC HEALTH, V67, P423, DOI 10.2105/AJPH.67.5.423; Schipper H, 1990, QUALITY LIFE ASSESSM, P11; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; TOWNSEND M, 1991, ANN ALLERGY, V67, P403; USHERWOOD TP, 1990, ARCH DIS CHILD, V65, P779, DOI 10.1136/adc.65.7.779; WELLS GA, 1993, J RHEUMATOL, V20, P557; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	46	52	54	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	2	S			S386	S391		10.1016/S0091-6749(98)70227-1	http://dx.doi.org/10.1016/S0091-6749(98)70227-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	ZA245	9500735	Bronze			2022-12-18	WOS:000072343900011
J	Blom, HM; Godthelp, T; Fokkens, WJ; KleinJan, A; Mulder, PGM; Rijntjes, E				Blom, HM; Godthelp, T; Fokkens, WJ; KleinJan, A; Mulder, PGM; Rijntjes, E			The effect of nasal steroid aqueous spray on nasal complaint scores and cellular infiltrates in the nasal mucosa of patients with nonallergic, noninfectious perennial rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nonallergic; noninfections perennial rhinitis; topical steroids; fluticasone propionate; nasal biopsies; immunohistochemistry; nasal symptoms	ALLERGIC RHINITIS; BECLOMETHASONE DIPROPIONATE; FLUTICASONE PROPIONATE; VASOMOTOR RHINITIS; CHALLENGE; SECRETION; CAPSAICIN; DYNAMICS; BIOPSY	Topical corticosteroids are the therapy of choice for nonallergic, noninfectious perennial rhinitis (NANIPER). However, the efficacy of steroid therapy in NANIPER is controversial, as is its mode of action. To our surprise, of 300 patients initially diagnosed as having NANIPER, only 65 reached threshold nasal symptom scores. Patients were randomized into four different treatment regimens: placebo administered twice daily (BD) for 8 weeks, fluticasone propionate aqueous nasal spray (FPANS) (200 mu g) once daily (OD) and placebo OD for 8 weeks, FPANS (200 mu g) OD and placebo OD for 4 weeks followed by FPANS (200 mu g) BD for 4 weeks, and FPANS (200 mu g) BD for 8 weeks. A small decrease in nasal symptoms was found, which only reached significance for sneezing in the FPANS 200 mu g BD group. A significant dose-dependent decrease in immunocompetent cells was found in nasal biopsy specimens obtained before, after 4 weeks, and after 8 weeks of treatment. We conclude that FPANS did not significantly reduce nasal symptoms in this group of selected NANIPER patients, even though a significant effect on cells in the nasal mucosa was seen.	Univ Rotterdam Hosp, Dept Otorhinolaryngol Head & Neck Surg, Rotterdam, Netherlands; Leyenburg Hosp, Dept Otorhinolaryngol Head & Neck Surg, The Hague, Netherlands; Erasmus Univ, Dept Biostat, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam	Blom, HM (corresponding author), Univ Rotterdam Hosp, Dept Otorhinolaryngol, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands.		Fokkens, Wytske WJ/ABF-2185-2020					BARANIUK JN, 1991, PULM PHARMACOL THER, V4, P20, DOI 10.1016/0952-0600(91)90035-2; BENDE M, 1985, ORL J OTO-RHINO-LARY, V47, P303, DOI 10.1159/000275790; BLOM HM, 1995, EUR ARCH OTO-RHINO-L, V1, pS33; BORSON DB, 1991, AM J PHYSIOL, V260, pL212, DOI 10.1152/ajplung.1991.260.4.L212; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; FOKKENS WJ, 1992, CLIN EXP ALLERGY, V22, P701, DOI 10.1111/j.1365-2222.1992.tb00194.x; FOKKENS WJ, 1990, INT ARCH ALLER A IMM, V93, P66, DOI 10.1159/000235281; Godthelp T, 1996, J ALLERGY CLIN IMMUN, V97, P800, DOI 10.1016/S0091-6749(96)80158-8; GODTHELP T, 1995, ALLERGY, V50, P21, DOI 10.1111/j.1398-9995.1995.tb02737.x; JONES AS, 1987, BRIT MED J, V294, P1505, DOI 10.1136/bmj.294.6586.1505; LACROIX JS, 1992, NEW FRONTIERS OTORHI, P59; LUNDBLAD L, 1984, ACTA PHYSIOL SCAND, V121, P277, DOI 10.1111/j.1748-1716.1984.tb07457.x; MALCOMSON K G, 1959, J Laryngol Otol, V73, P73, DOI 10.1017/S0022215100054980; MALM L, 1981, ALLERGY, V36, P209, DOI 10.1111/j.1398-9995.1981.tb01836.x; MONERETVAUTRIN DA, 1990, ANN ALLERGY, V64, P513; MYGIND N, 1973, BRIT MED J, V4, P464, DOI 10.1136/bmj.4.5890.464; MYGIND N, 1995, EUR ARCH OTORHINOL S, V1, pS68; PHILIP G, 1995, EUR ARCH OTO-RHINO-L, V1, pS27; PIEDIMONTE G, 1990, J CLIN INVEST, V86, P1409, DOI 10.1172/JCI114855; PIPKORN U, 1983, ACTA OTO-LARYNGOL, V95, P167, DOI 10.3109/00016488309130931; RAK S, 1994, CLIN EXP ALLERGY, V24, P930, DOI 10.1111/j.1365-2222.1994.tb02724.x; RIECHELMANN H, 1993, HNO, V41, P475; SCADDING GK, 1995, CLIN EXP ALLERGY, V25, P737, DOI 10.1111/j.1365-2222.1995.tb00011.x; SMALL P, 1982, J ALLERGY CLIN IMMUN, V70, P178, DOI 10.1016/0091-6749(82)90039-2; SPECTOR SL, 1992, J ALLERGY CLIN IMMUN, V90, P1042, DOI 10.1016/0091-6749(92)90119-M; WILDE AD, 1995, CLIN OTOLARYNGOL, V20, P345, DOI 10.1111/j.1365-2273.1995.tb00056.x; WOLF G, 1988, LARYNGO RHINO OTOL, V67, P438, DOI 10.1055/s-2007-998536	27	52	56	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				739	747		10.1016/S0091-6749(97)70267-7	http://dx.doi.org/10.1016/S0091-6749(97)70267-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438480	Green Published			2022-12-18	WOS:000071353600004
J	Bernstein, JA; Munson, J; Lummus, ZL; Balakrishnan, K; Leikauf, G				Bernstein, JA; Munson, J; Lummus, ZL; Balakrishnan, K; Leikauf, G			T-cell receptor V beta gene segment expression in diisocyanate-induced occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						diisocyanates; occupational asthma; cell-mediated; T-cell receptor; V beta gene segments; HLA phenotyping	ISOCYANATE-INDUCED ASTHMA; TOLUENE DIISOCYANATE; LYMPHOCYTES; BLOOD; HLA; EOSINOPHILS; SARCOIDOSIS	Background: Diisocyanates are the most common cause of occupational asthma induced by low-molecular-weight chemicals. The disease appears to be immunologically mediated but is independent of IgE antibody synthesis. An underlying genetic susceptibility is suggested by the fact that the disease only develops in approximately 5% to 10% of exposed workers. Objective: The study was designed to determine whether disease susceptibility is influenced by HLA and T-cell receptor V beta gene segment usage. Methods: T-cell receptor V beta gene repertoires were quantitated by using primer pairs specific for V beta gene segments in conjunction with a common C beta region primer. One group of workers with diisocyanate-induced occupational asthma produced diisocyanate-specific IgG and IgE antibodies, whereas the other group did not produce specific antibodies. Occupational asthma was previously confirmed by either workplace challenge or laboratory specific diisocyanate bronchoprovocation. Control groups consisted of diisocyanate-exposed workers who were free of symptoms, patients with nonoccupational asthma, and unexposed subject who were free of symptoms. Results: Lymphocytes from workers with diisocyanate-induced occupational asthma had significantly decreased V beta 1 and V beta 5 gene segment expression before in vitro exposure to diisocyanates, compared with control groups. Percent V beta 1 and V beta 5 gene segment expression was selectively increased when peripheral blood mononuclear cells were stimulated in vitro with diisocyanate-conjugated proteins. Low-resolution HLA class II phenotyping revealed no significant differences in the distribution of HLA-DR or HLA-DQ alleles between diisocyanate-induced occupational asthma and control groups. Conclusions: These findings are consistent with a hypothesis that antigen-specific T-cell subpopulations may be sequestered in the lungs of workers with diisocyanate-induced occupational asthma and clonally expand after further exposure to diisocyanates.	UNIV CINCINNATI,COLL MED,DIV NEPHROL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DIV PULM & CRIT CARE MED,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,HOXWORTH BLOOD CTR,DEPT INTERNAL MED,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT CELLULAR & MOL PHYSIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Bernstein, JA (corresponding author), UNIV CINCINNATI,COLL MED,DIV IMMUNOL,POB 670563,CINCINNATI,OH 45267, USA.			Leikauf, George/0000-0002-4514-7060; Bernstein, Jonathan/0000-0002-3476-1196	NIEHS NIH HHS [ES06096, ES06562, ES06677] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006677, P30ES006096, R01ES006562] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AVERY SB, 1969, CLIN EXP IMMUNOL, V4, P585; BELLOCQ A, 1994, AM J RESP CRIT CARE, V149, P646, DOI 10.1164/ajrccm.149.3.7906994; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; Bernstein David I., 1993, P103; BERNSTEIN JA, 1994, IMMUNOTOXICOLOGY IMM, P617; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71, DOI 10.1164/ajrccm.149.1.8111601; CHARMLEY P, 1992, MANUAL CLIN LAB IMMU, P37; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVEY MP, 1994, J IMMUNOL, V152, P315; DEARMAN RJ, 1992, TOXICOL APPL PHARM, V112, P190, DOI 10.1016/0041-008X(92)90187-W; FINOTTO S, 1991, BRIT J IND MED, V48, P116; FORRESTER JM, 1994, J IMMUNOL, V153, P4291; GALLAGHER JS, 1981, J OCCUP ENVIRON MED, V23, P610, DOI 10.1097/00043764-198109000-00009; HERD ZL, 1994, AM J RESP CRIT CARE, V150, P988, DOI 10.1164/ajrccm.150.4.7522854; Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31; HOPKINS KA, 1991, AM SOC HISTOCOMPATIB, P195; JAMES SP, 1991, CURRENT PROTOCOLS IM; LUYRINK L, 1993, P NATL ACAD SCI USA, V90, P4369, DOI 10.1073/pnas.90.10.4369; MUNSON JL, 1995, HUM IMMUNOL, V42, P43, DOI 10.1016/0198-8859(94)00055-U; NUTMAN TB, 1991, CURRENT PROTOCOLS IM; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; RENZ H, 1992, P NATL ACAD SCI USA, V89, P6438, DOI 10.1073/pnas.89.14.6438; SARLO K, 1990, J ALLERGY CLIN IMMUN, V86, P393, DOI 10.1016/S0091-6749(05)80103-4; SHEA TB, 1994, BIOTECHNIQUES, V16, P1126; TERASAKI PI, 1985, HLA DIS ASS, P18; TSE CST, 1979, TOXICOL APPL PHARM, V51, P39, DOI 10.1016/0041-008X(79)90006-1; WUCHERPFENNIG KW, 1994, J IMMUNOL, V152, P5581	28	52	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					245	250		10.1016/S0091-6749(97)70104-0	http://dx.doi.org/10.1016/S0091-6749(97)70104-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042053	Bronze			2022-12-18	WOS:A1997WH83100016
J	Helm, R; Cockrell, G; Stanley, JS; Brenner, RJ; Burks, W; Bannon, GA				Helm, R; Cockrell, G; Stanley, JS; Brenner, RJ; Burks, W; Bannon, GA			Isolation and characterization of a clone encoding a major allergen (Bla g Bd90K) involved in IgE-mediated cockroach hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroach allergens; cockroach sensitivity; cDNA library; mRNA	AMERICAN PERIPLANETA-AMERICANA; GERMAN BLATTELLA-GERMANICA; MOLECULAR-CLONING; FECAL EXTRACTS; WHOLE-BODY; IDENTIFICATION; ASTHMA; PURIFICATION; CHILDREN; EPIDEMIOLOGY	Previous studies have established that atopic individual living in cockroach-infested housing become sensitized to cockroach aeroallergens and produce IgE antibodies to a variety of proteins. We describe the isolation of a complementary DNA clone from an expression library, constructed with messenger RNA from German (Blattella germanica) cockroaches, which encodes a major allergen involved in mediating cockroach hypersensitivity. Approximately 0.2% of the clones from a lambda ZAP XR cDNA library bound IgE from a patient with cockroach sensitivity A randomly selected subset of these clones revealed that they were either different isolates of the same gene or members of a closely related gene family. One of the largest clones (a 4 kb insert) from this subset, Bla g Bd90k hybridized to a single mRNA of approximately the same size. DNA sequence analysis showed that this gene consisted of seven 576 bp tandem repeats with a short unique region at either end. No significant sequence homologies were found between the cockroach clone and any other gene reported in the GenBank database. Serum from 17 of 22 (77%) patients with cockroach hypersensitivity identified IgE-binding recombinant protein expressed from clone Bla g Bd90K in Escherichia coli XL-Blue cells as determined by sodium dodecylsulfate-polyacrylamide gel electrophoresis/immunoblot analysis. This recombinant protein migrates with a molecular weight (90 kd) apparently similar to one identified in whole body extracts. We have identified and isolated a cDNA that encodes a major cockroach allergen (Bla g Bd90K) present in German cockroaches.	UNIV ARKANSAS MED SCI HOSP, DEPT PEDIAT, LITTLE ROCK, AR USA; UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM & MOL BIOPHYS, LITTLE ROCK, AR USA; USDA, MED & VET ENTOMOL RES LAB, GAINESVILLE, FL USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; United States Department of Agriculture (USDA)								ARRUDA LK, 1993, J ALLERGY CLIN IMMUN, V91, P188; BANNON GA, 1983, NUCLEIC ACIDS RES, V11, P3903, DOI 10.1093/nar/11.12.3903; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; CHAPMAN MD, 1994, J ALLERGY CLIN IMMUN, V93, P205; CHAPMAN MD, 1993, INSIGHTS ALLERGY, V8; HELM R, 1993, MOL IMMUNOL, V30, P1685, DOI 10.1016/0161-5890(93)90443-F; HELM RM, 1990, INT ARCH ALLER A IMM, V92, P154, DOI 10.1159/000235207; HELM RM, 1994, J ALLERGY CLIN IMMUN, V93, P206; HELM RM, 1988, INT ARCH ALLER A IMM, V87, P230, DOI 10.1159/000234678; HELM RM, 1994, INT ARCH ALLERGY IMM, V103, P59, DOI 10.1159/000236606; HULETT AC, 1979, ANN ALLERGY, V42, P160; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG BC, 1989, ANN ALLERGY, V63, P207; KANG BC, 1991, J ALLERGY CLIN IMMUN, V87, P1073, DOI 10.1016/0091-6749(91)92152-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; MENON P, 1991, ANN ALLERGY, V67, P573; MORRIS EC, 1986, J ALLERGY CLIN IMMUN, V77, P206; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1993, ALLERGY PRINCIPLES P, P521; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; RICHMAN PG, 1984, J ALLERGY CLIN IMMUN, V73, P590, DOI 10.1016/0091-6749(84)90516-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEINER O, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P115; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V81, P548, DOI 10.1016/0091-6749(88)90195-9; STANKUS RP, 1990, J ALLERGY CLIN IMMUN, V86, P781, DOI 10.1016/S0091-6749(05)80183-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; WEEKE B, 1983, SCAND J IMMUNOL S10, V17, P265; WU CH, 1988, J ALLERGY CLIN IMMUN, V82, P727, DOI 10.1016/0091-6749(88)90071-1; ZWICK H, 1991, J ALLERGY CLIN IMMUN, V87, P626, DOI 10.1016/0091-6749(91)90380-7	39	52	59	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					172	180		10.1016/S0091-6749(96)70240-3	http://dx.doi.org/10.1016/S0091-6749(96)70240-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765832				2022-12-18	WOS:A1996VA69200021
J	SEDGWICK, JB; QUAN, SF; CALHOUN, WJ; BUSSE, WW				SEDGWICK, JB; QUAN, SF; CALHOUN, WJ; BUSSE, WW			EFFECT OF INTERLEUKIN-5 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR ON IN-VITRO EOSINOPHIL FUNCTION - COMPARISON WITH AIRWAY EOSINOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EOSINOPHIL; CYTOKINE; INTERLEUKIN-5; GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR; ALLERGY; SUPEROXIDE ANION; ADHESION; INTEGRINS; AIRWAY INFLAMMATION	PLATELET-ACTIVATING-FACTOR; 3T3 FIBROBLASTS; ANTIGEN CHALLENGE; CYTO-TOXICITY; ASTHMA; HYPODENSE; IL-5; LYMPHOCYTES; EXPRESSION; CYTOKINES	Eosinophils are hypothesized to be crucial in the development of allergic airway inflammation; however, the actual mechanisms that determine their inflammatory activity are still largely undefined. To investigate the factors that regulate eosinophil function in allergic airway disease, we have previously used segmental bronchoprovocation with allergen to study ex vivo eosinophil function. To determine whether the functional changes associated with airway eosinophils obtained by bronchoalveolar lavage 48 hours after antigen challenge are caused by exposure to airway-generated cytokines, normodense blood eosinophils were cultured in vitro with recombinant human interleukin-5 (IL-5) or granulocyte-macrophage colony stimulating factor (GM-CSF). The effect of cytokine exposure was then evaluated on selected cell functions. In vitro incubation with these cytokines for 24 hours significantly increased eosinophil membrane expression of CD18 and CD11b compared with culture in medium alone ol eosinophils obtained by bronchoalveolar lavage. N-formyl-methionyl-leucyl-phenylalanine-stimulated superoxide anion generation was slightly but significantly enhanced by incubation with IL-5 bur not with GM-CSF. In addition, spontaneous adhesion to human umbilical vein endothelial cell monolayers was increased after exposure to both IL-5 and GM-CSF. However, activated adhesion was enhanced only by culture with IL-5 and stimulation with N-formyl-methionyl-leucyl-phenylalanine. The magnitude of functional changes after in vitro preincubation of eosinophils with these cytokines did not achieve levels of superoxide anion and adhesion noted with airway eosinophils obtained after segmental bronchoprovocation with allergen. These observations raise the possibility that the contribution of IL-5 and GM-CSF to phenotypic changes of airway eosinophils is principally to enhance survival and expression of adhesion proteins. These data also suggest that, in addition to the generation of proinflammatory cytokines, other factors contribute to phenotypic changes in eosinophils as they migrate from the blood to the airway.	UNIV ARIZONA,DEPT MED,PULM & CRIT CARE MED SECT,TUCSON,AZ; UNIV PITTSBURGH,DIV PULM ALLERGY & CRIT CARE MED,PITTSBURGH,PA	University of Arizona; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	SEDGWICK, JB (corresponding author), UNIV WISCONSIN HOSP,CSC H6367,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,ALLERGY UNIT,600 HIGHLAND AVE,MADISON,WI 53792, USA.			Calhoun, William/0000-0001-7075-712X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023181] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL44098] Funding Source: Medline; NIAID NIH HHS [R01-AI23181] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANWAR ARF, 1993, J EXP MED, V177, P839, DOI 10.1084/jem.177.3.839; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; COEFFIER E, 1991, J IMMUNOL, V147, P2595; DRI P, 1991, J IMMUNOL, V147, P613; FRICK WE, 1989, AM REV RESPIR DIS, V139, P1401, DOI 10.1164/ajrccm/139.6.1401; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; JONES DG, 1993, J COMP PATHOL, V108, P317, DOI 10.1016/S0021-9975(08)80204-6; KITA H, 1992, J IMMUNOL, V149, P629; KROEGEL C, 1994, J ALLERGY CLIN IMMUN, V93, P725, DOI 10.1016/0091-6749(94)90252-6; KROEGEL C, 1992, RESP MED, V86, P375, DOI 10.1016/S0954-6111(06)80004-1; KROEGEL C, 1990, LUNG, V168, P5, DOI 10.1007/BF02718107; LEFF AR, 1991, LUNG CELL MOL PHYSL, V4, pL189; NAGATA M, 1994, J ALLERGY CLIN IMMUN, V93, P212; NEELEY SP, 1994, AM J RESPIR CELL MOL, V11, P286; OHASHI Y, 1992, AM REV RESPIR DIS, V145, P1469, DOI 10.1164/ajrccm/145.6.1469; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; OWEN WF, 1991, J CLIN INVEST, V87, P1958, DOI 10.1172/JCI115222; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SEDGWICK JB, 1988, J ALLERGY CLIN IMMUN, V81, P876, DOI 10.1016/0091-6749(88)90945-1; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; TOMIOKA K, 1993, J IMMUNOL, V151, P4989; VANDERBRUGGEN T, 1993, J LEUKOCYTE BIOL, V53, P347, DOI 10.1002/jlb.53.4.347; WALKER C, 1993, J IMMUNOL, V150, P4061; WARDLAW AJ, 1987, ALLERGY, V42, P321, DOI 10.1111/j.1398-9995.1987.tb02218.x	29	52	54	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					375	385		10.1016/S0091-6749(95)70057-9	http://dx.doi.org/10.1016/S0091-6749(95)70057-9			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560640				2022-12-18	WOS:A1995RU66000010
J	KLUCKA, CV; OWNBY, DR; GREEN, J; ZORATTI, E				KLUCKA, CV; OWNBY, DR; GREEN, J; ZORATTI, E			CAT SHEDDING OF FEL-D-I IS NOT REDUCED BY WASHINGS, ALLERPET-C SPRAY, OR ACEPROMAZINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ACEPROMAZINE; ALLERGEN SHEDDING; ALLERPET-C SPRAY; CAT; CAT WASHING; FEL D I	AIRBORNE DUST; IGE ANTIBODY; ALLERGEN; SKIN; POPULATION; EXPOSURE; MITE	Background: No published studies have compared the effectiveness of several treatments proposed to reduce car allergenicity. Car washing studies demonstrating efficacy involved very small sample sizes or infrequent washings. Allerpet-C (Allerpet, Inc, New York, N.Y), a widely advertised topical spray, and acepromazine, a tranquilizer advocated as efficacious in subsedating doses, have never been scientifically studied. Objective: We compared the effects of cat washing, Allerpet-C spray, and acepromazine with that of no treatment on the shedding of the primary cat allergen, Felis domesticus I by cats. Methods: In a blinded, comparative, controlled study, we measured the amounts of Fel d I shed during an 8-week treatment period with a sample of 24 female mongrel cats randomly assigned to four groups; one group received weekly distilled water washings, one received weekly Allerpet-C spray applications, one received daily oral acepromazine, and one had no treatment (control). Thirty-minute, twice-weekly air samples were collected from each cat with a laminated plastic-acrylic chamber and air sampler. Results: One-sample, two-sided t tests comparing baseline to final-week measurements revealed no significant change in Fel d I within each group (mean change +/-SD: washing; 487.6 +/- 1896.4 mU per 30 minutes, p = 0.63; Allerpet-C spray, 429.2 +/- 871.6 mU per 30 minutes, p = 0.46 acepromazine; -620.6 +/- 1031.5 p = 0.52 per 30 minutes). Furthermore, analysis of covariance revealed no significant change in Fel d I levels between groups (p = 0.72). Conclusions: Out data do not show significant reductions in Fel d I shedding as a result of any of these treatments. Therefore we cannot recommend them to patients allergic to cats.	HENRY FORD HLTH SYST,DETROIT,MI	Henry Ford Health System; Henry Ford Hospital								BRYANT DH, 1976, MED J AUSTRALIA, V1, P918, DOI 10.5694/j.1326-5377.1976.tb141170.x; CATHCART RF, 1990, J ALLERGY CLIN IMMUN, V86, P420, DOI 10.1016/S0091-6749(05)80110-1; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHARPIN C, 1991, J ALLERGY CLIN IMMUN, V88, P77, DOI 10.1016/0091-6749(91)90303-6; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V72, P778; ENBERG RN, 1993, ANN ALLERGY, V70, P471; FINDLAY SR, 1983, AM REV RESPIR DIS, V128, P1008; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GLINERT R, 1990, J ALLERGY CLIN IMMUN, V85, P327; KJELLMAN B, 1983, ALLERGY, V38, P65, DOI 10.1111/j.1398-9995.1983.tb00858.x; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; MATA P, 1990, AEROBIOLOGIA, V6, P87; MICKELSEN L, 1984, PEACEFUL SETTLEMENT; OHMAN JL, 1978, J AM VET MED ASSOC, V172, P1403; OHMAN JL, 1983, J ALLERGY CLIN IMMUN, V72, P288, DOI 10.1016/0091-6749(83)90033-7; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; OHMAN JL, 1982, J ALLERGY CLIN IMMUN, V69, P319; SARSFIELD JK, 1976, ARCH DIS CHILD, V51, P186, DOI 10.1136/adc.51.3.186; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; THOMPSON RA, 1983, LANCET, V1, P169; VOORSHORT B, 1975, ALLERGY, V74, P320; WENTZ PE, 1990, J ALLERGY CLIN IMMUN, V85, P94, DOI 10.1016/0091-6749(90)90228-V; WOODFOLK JA, 1992, ANN ALLERGY, V69, P273; ZIELONKA TM, 1993, J ALLERGY CLIN IMMUN, V91, P327; 1988, TESTING ALLERPET C; 1983, J AM VET MED ASSOC, V183, P841	28	52	52	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1995	95	6					1164	1171		10.1016/S0091-6749(95)70072-2	http://dx.doi.org/10.1016/S0091-6749(95)70072-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD309	7797784				2022-12-18	WOS:A1995RD30900003
J	VALENT, P				VALENT, P			THE PHENOTYPE OF HUMAN EOSINOPHILS, BASOPHILS, AND MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							COLONY-STIMULATING FACTOR; HUMAN PERIPHERAL-BLOOD; C-KIT LIGAND; MEDIATOR RELEASE; RECOMBINANT HUMAN; ENDOTHELIAL-CELLS; BINDING-SITES; FORMING CELL; EXPRESSION; INTERLEUKIN-3				VALENT, P (corresponding author), UNIV VIENNA,DEPT INTERNAL MED 1,DIV HEMATOL & HEMOSTASEOL,WAHRINGER GURTEL 18-20,A-1090 VIENNA,AUSTRIA.		Test, PV/U-9451-2019; Test, Test/Y-7921-2019; Gamperl, Susi/V-2715-2019; Valent, Peter/B-8533-2016	Gamperl, Susi/0000-0003-0456-5095; Valent, Peter/0000-0003-0456-5095				AGIS H, 1993, J IMMUNOL, V151, P4221; AGIS H, IN PRESS 5TH P INT W; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; BOCHNER BS, 1990, J IMMUNOL, V145, P1832; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BOCHNER BS, 1988, J CLIN INVEST, V81, P1355, DOI 10.1172/JCI113463; BOCHNER BS, 1991, J IMMUNOL, V146, P2367; COLUMBO M, 1992, J IMMUNOL, V149, P599; CZECH W, 1993, J INVEST DERMATOL, V100, P417, DOI 10.1111/1523-1747.ep12472082; DENBURG JA, 1985, BLOOD, V66, P312; FUREDER W, 1994, IN PRESS SURFACE MEM; FURITSU T, 1989, P NATL ACAD SCI USA, V86, P10039, DOI 10.1073/pnas.86.24.10039; GALLI SJ, 1990, LAB INVEST, V62, P5; GEORAS SN, 1993, BLOOD, V82, P2872; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GUO CB, 1992, BLOOD, V79, P708; HIRAI K, 1988, J IMMUNOL, V141, P3958; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; KITAMURA Y, 1981, NATURE, V291, P159, DOI 10.1038/291159a0; KURIMOTO Y, 1989, J EXP MED, V170, P467, DOI 10.1084/jem.170.2.467; LEARY AG, 1984, BLOOD, V64, P78; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; MAYRHOFER G, 1987, IMMUNOL CELL BIOL, V65, P241, DOI 10.1038/icb.1987.27; MITSUI H, 1993, P NATL ACAD SCI USA, V90, P735, DOI 10.1073/pnas.90.2.735; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SILLABER C, 1991, J IMMUNOL, V147, P4224; SPERR WR, 1992, ANN HEMATOL, V65, P10, DOI 10.1007/BF01715119; SPERR WR, 1993, INT ARCH ALLERGY IMM, V102, P170, DOI 10.1159/000236568; STOCKINGER H, 1990, BLOOD, V75, P1820; VALENT P, 1990, INT ARCH ALLER A IMM, V91, P198, DOI 10.1159/000235115; VALENT P, 1992, ADV IMMUNOL, V52, P333, DOI 10.1016/S0065-2776(08)60879-2; VALENT P, 1989, BLOOD, V73, P1763; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENT P, 1992, BLOOD, V80, P2237; VALENT P, 1991, P NATL ACAD SCI USA, V88, P3339, DOI 10.1073/pnas.88.8.3339; VALENT P, 1990, BLOOD, V76, P1734; VALENT P, 1989, BLOOD, V73, P1778; VALENT P, 1990, J IMMUNOL, V145, P3432	42	52	53	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1177	1183		10.1016/0091-6749(94)90329-8	http://dx.doi.org/10.1016/0091-6749(94)90329-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798557				2022-12-18	WOS:A1994QA02000009
J	LAFFER, S; VRTALA, S; DUCHENE, M; VANREE, R; KRAFT, D; SCHEINER, O; VALENTA, R				LAFFER, S; VRTALA, S; DUCHENE, M; VANREE, R; KRAFT, D; SCHEINER, O; VALENTA, R			IGE-BINDING CAPACITY OF RECOMBINANT TIMOTHY GRASS (PHLEUM-PRATENSE) POLLEN ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						GRASS POLLEN ALLERGY; RECOMBINANT ALLERGENS; PHL P I; PHL P V; PHL P II; PROFILIN; SPECIFIC IGE	CYNODON-DACTYLON POLLEN; MAJOR ALLERGEN; BIRCH-POLLEN; TREE-POLLEN; ELECTROPHORETIC TRANSFER; HAZEL POLLEN; GROUP-I; IDENTIFICATION; PROFILIN; CLONING	A panel of 60 cDNA clones coding for IgE-binding proteins from timothy grass pollen was immunocharacterized with sera from 30 patients allergic to grass pollen and antibodies raised against natural grass pollen allergens. In the cases of five representative patients in whom the IgE reactivity pattern with the recombinant allergens had been determined, IgE immunoadsorption experiments were performed. Recombinant Phl p I, Phl p V and Phl p II and recombinant timothy grass profilin were used for immunoadsorption of the sera, and the percentage of remaining grass pollen-specific IgE was estimated. Although most of the patients showed IgE reactivity to a number of different natural and recombinant timothy grass pollen allergens up to 66% of IgE directed against blotted total natural grass pollen allergens could be immunoadsorbed from the sera with recombinant Phl p V and Phl p I. The data point to the usefulness of recombinant allergens not only to determine IgE specificities of allergic patients but also to estimate the percentage of specific IgE that individuals produce against certain allergens. The fact that only a limited number of recombinant timothy grass pollen allergens account for a high percentage of grass pollen-specific IgE points to the possible usefulness of recombinant allergens not only for in vitro diagnosis but probably also for specific immunotherapy.	UNIV VIENNA,AKH,INST GEN & EXPTL PATHOL,A-1090 VIENNA,AUSTRIA; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,AMSTERDAM,NETHERLANDS	University of Vienna			Duchêne, Michael/G-6659-2019	Duchêne, Michael/0000-0003-1232-3600; Vrtala, Susanne/0000-0003-4250-8243; Valenta, Rudolf/0000-0001-5944-3365				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EBNER C, 1993, J IMMUNOL, V150, P1047; FORD SA, 1987, J ALLERGY CLIN IMMUN, V79, P711, DOI 10.1016/0091-6749(87)90201-6; FORD SA, 1985, INT ARCH ALLER A IMM, V78, P15, DOI 10.1159/000233855; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; OLSEN E, 1991, J IMMUNOL, V147, P205; SCHEINER O, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P153; SCHEINER O, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P115; SHEN HD, 1988, CLIN ALLERGY, V18, P401, DOI 10.1111/j.1365-2222.1988.tb02888.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V87, P677, DOI 10.1016/0091-6749(91)90388-5; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VALENTA R, 1992, INT ARCH ALLERGY IMM, V99, P271, DOI 10.1159/000236263; VALENTA R, 1993, VACCINES93 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P37; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANREE R, 1992, CLIN EXP ALLERGY, V22, P611; VANREE R, 1989, J ALLERGY CLIN IMMUN, V83, P144, DOI 10.1016/0091-6749(89)90489-2; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VRTALA S, 1993, J IMMUNOL, V151, P4773; YMAN L, 1981, DIAGNOSIS TREATMENT, P74	31	52	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					88	94		10.1016/0091-6749(94)90075-2	http://dx.doi.org/10.1016/0091-6749(94)90075-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027502	Bronze			2022-12-18	WOS:A1994NX39300012
J	FERNANDEZ, C; MARTINESTEBAN, M; FIANDOR, A; PASCUAL, C; SERRANO, CL; ALZAMORA, FM; PENA, JMD; CASAS, JAO				FERNANDEZ, C; MARTINESTEBAN, M; FIANDOR, A; PASCUAL, C; SERRANO, CL; ALZAMORA, FM; PENA, JMD; CASAS, JAO			ANALYSIS OF CROSS-REACTIVITY BETWEEN SUNFLOWER POLLEN AND OTHER POLLENS OF THE COMPOSITAE FAMILY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HAY FEVER; POLLEN ALLERGENS; ENTOMOPHILOUS POLLEN; SUNFLOWER ALLERGY; COMPOSITAE POLLEN; CROSS-REACTIVITY	ELECTROPHORETIC TRANSFER; ANAPHYLACTIC REACTION; GRASS-POLLEN; ALLERGENS; INGESTION; NITROCELLULOSE; PROTEINS; BINDING; HONEY	The sera of 20 patients with Compositae pollen allergy were investigated for the presence of IgE antibodies reacting against sunflower pollen by means of RAST and immmunoblotting studies. Thirteen IgE-binding bands were detected with molecular weights ranging from 14.4 to 94 kd. Two of these bands, with molecular weights of 24 and 25 kd, contained major allergens that reacted strongly with 100% (24 kd) and 95% (25 kd) of the sera, respectively. Cross-reactivity between sunflower and other Compositae pollens (mugwort, marguerite, dandelion, golden rod, and short ragweed) was revealed by RAST and immunoblotting inhibition experiments. Mugwort pollen exhibited the greatest degree of allergenic homology (cross-reactivity) with sunflower pollen, whereas at the other end of the spectrum, short ragweed showed less cross-reactive epitopes.	HOSP LA PAZ,MADRID,SPAIN	Hospital Universitario La Paz	FERNANDEZ, C (corresponding author), HOSP GEN GUADALAJARA,UNIDAD ALERGIA,DONANTES SANGRE S-N,E-19002 GUADALAJARA,SPAIN.							ALONSO M, 1988, REV ESP ALERGOL IMMU, V3, P37; BENNER MH, 1973, J ALLERGY CLIN IMMUN, V52, P307, DOI 10.1016/0091-6749(73)90050-X; BIRNBAUM J, 1989, CLIN EXP ALLERGY, V19, P229, DOI 10.1111/j.1365-2222.1989.tb02369.x; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V75, P70, DOI 10.1016/0091-6749(85)90015-6; BOUSQUET J, 1984, ALLERGY, V39, P73, DOI 10.1111/j.1398-9995.1984.tb01936.x; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P419; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; COHEN SH, 1979, J ALLERGY CLIN IMMUN, V64, P270, DOI 10.1016/0091-6749(79)90143-X; CRONQUIST A, 1988, EVOLUTION CLASSIFICA, P261; DELAHOZ F, 1990, MOL IMMUNOL, V27, P651, DOI 10.1016/0161-5890(90)90008-N; FORD SA, 1985, INT ARCH ALLER A IMM, V78, P15, DOI 10.1159/000233855; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; HOLOPAINEN E, 1979, ACTA OTOLARYNGOL S, V360, P16; KING TP, 1986, CLIN REV ALLERG, V4, P425; KRISTIN M, 1976, J ALLERGY CLIN IMMUN, V58, P140; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS WH, 1979, ANN ALLERGY, V42, P309; LOUVEAUX J, 1976, REV FR APIC, V340, P132; LOWENSTEIN H, 1980, ALLERGY, V35, P198, DOI 10.1111/j.1398-9995.1980.tb01743.x; MANSFIELD LE, 1981, ANN ALLERGY, V47, P154; MARTIN ES, 1986, TRATADO ALERGIA INMU, V4, P257; MATTHIESEN F, 1989, J ALLERGY CLIN IMMUN, V83, P1124, DOI 10.1016/0091-6749(89)90456-9; NILSEN BM, 1990, MOL IMMUNOL, V27, P1047, DOI 10.1016/0161-5890(90)90128-M; Ogden EC, 1974, MANUAL SAMPLING AIRB; ORTEGASADA L, 1987, FLORA INTERES APICOL, P41; PAYNE WW, 1964, AM J BOT, V51, P419, DOI 10.2307/2439833; PELTRE G, 1982, IMMUNOL LETT, V5, P127, DOI 10.1016/0165-2478(82)90096-7; RODRIGUEZ CF, 1986, REV ESP ALERGOL INMU, V1, P34; SUBIZA J, 1989, J ALLERGY CLIN IMMUN, V84, P353, DOI 10.1016/0091-6749(89)90420-X; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; WEBER RW, 1985, CLIN REV ALLERG, V3, P291, DOI 10.1007/BF02992997; Wodehouse RP, 1971, HAY FEVER PLANTS, V2nd; Yman L, 1975, Dev Biol Stand, V29, P151; ZAPATA C, 1987, REV ESP ALERGOL IMMU, V2, P189	35	52	55	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					660	667		10.1016/0091-6749(93)90008-4	http://dx.doi.org/10.1016/0091-6749(93)90008-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227856	Bronze			2022-12-18	WOS:A1993MG98200006
J	HAMILTON, RG; WISENAUER, JA; GOLDEN, DBK; VALENTINE, MD; ADKINSON, NF				HAMILTON, RG; WISENAUER, JA; GOLDEN, DBK; VALENTINE, MD; ADKINSON, NF			SELECTION OF HYMENOPTERA VENOMS FOR IMMUNOTHERAPY ON THE BASIS OF PATIENTS IGE ANTIBODY CROSS-REACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HYMENOPTERA VENOM; VENOM IMMUNOTHERAPY; HUMAN IGE ANTIBODY; CROSS-REACTIVITY; RAST INHIBITION	STINGING INSECT ALLERGY; DIAGNOSIS	Background: Positive skin test results to multiple venoms in patients with Hymenoptera venom allergy may result from IgE antibody cross-reactivity among venom proteins. To avoid treatment with unnecessary and costly venoms, we have developed a venom RAST inhibition test that identifies individuals in whom a positive venom IgE RAST result is due to cross-reactive venom-specific IgE antibody. Methods: Serum samples (n = 412) were collected over 5 years from patients with clinically characterized Hymenoptera venom allergy who had positive skin test results to more than one venom. Venom allergosorbent was added to serum containing IgE antivenin and buffer or 100 pg of homologous or heterologous venom. Bound IgE was detected with radiolabeled anti-human IgE. Intraassay variation less than 10% coefficient of variation and homologous venom inhibition greater than 80% were required for acceptance of data. A ''cross-reactivity index'' (CRI) was computed as a ratio of percent inhibition produced by heterologous versus homologous venom. Results: Of the 412 sera-venom combinations analyzed, 41 (10%) were excluded because of incomplete homologous venom inhibition. Of the 371 remaining sera, 82% (n = 305) were studied for IgE anti-Polistes wasp venom (PWV) cross-reactivity with yellow jacket venom (YJV) and the other 66 for other venom specificity cross-inhibitions. Of the serum samples tested, 36.4% (111 of 305) contained IgE anti-PWV venom of which the binding to solid-phase PWV was inhibited with soluble YJV to a level that produced CRIs greater than 95%. We believe that this constitutes complete inhibition and demonstrates exclusively YJV cross-reactive antibodies in these samples. The remaining 63.6% had CRIs from 0% to 95%, indicating IgE specific for a spectrum of unique and cross-reactive PWV allergens. Only 4.3 % (13 of 305) had CRIs less than 5%, which is consistent with IgE restricted to PWV unique allergens. The degree of the IgE anti-PWV inhibition to solid-phase PWV by YJV was independent of the IgE anti-PWV level. Conclusions: This study shows that one third of patients with Hymenoptera venom allergy evaluated with positive YJV- and PWV-reactive IgE in the skin and/or serum were identified as candidates for exclusion of PWV from their immunotherapy regimen because their IgE anti-PWV was more than 95% cross-inhibitable with YJV. Cost analysis of the venom RAST inhibition test and a conventional 5-year Hymenoptera venom immunotherapy program indicates that this serologic evaluation is cost-effective.			HAMILTON, RG (corresponding author), JOHNS HOPKINS UNIV,JOHNS HOPKINS ASTHMA & ALLERGY CTR,DIV CLIN IMMUNOL,BALTIMORE,MD 21224, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI020136] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20136] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GADDE J, 1984, Journal of Allergy and Clinical Immunology, V73, P159; GOLDEN DBK, 1987, CLIN REV ALLERG, V5, P119; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, pA57; GRAFT DF, 1987, CLIN REV ALLERG, V5, P149; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; GURALNICK M W, 1986, Folia Allergologica et Immunologica Clinica, V33, P9; HAMILTON R G, 1986, Folia Allergologica et Immunologica Clinica, V33, P31; HAMILTON RG, 1992, MANUAL CLIN IMMUNOLO, P689; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; HOFFMAN DR, 1987, CLIN REV ALLERG, V5, P75; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KING TP, 1985, J ALLERGY CLIN IMMUN, V75, P621, DOI 10.1016/0091-6749(85)90040-5; KING TP, 1987, CLIN REV ALLERG, V5, P137; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LU G, 1993, J IMMUNOL, V150, P2823; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V89, P1189, DOI 10.1016/0091-6749(92)90304-K; SCHUBERTH KC, 1982, J PEDIATR-US, V100, P546, DOI 10.1016/S0022-3476(82)80750-6; SOBOTKA AK, 1978, J IMMUNOL, V12, P2477	21	52	52	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					651	659		10.1016/0091-6749(93)90007-3	http://dx.doi.org/10.1016/0091-6749(93)90007-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227855				2022-12-18	WOS:A1993MG98200005
J	HOGG, JC				HOGG, JC			PATHOLOGY OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MECHANICS; BRONCHI; AIRWAYS; MODEL; LUNG				HOGG, JC (corresponding author), UNIV BRITISH COLUMBIA,ST PAULS HOSP,DEPT PATHOL,VANCOUVER V67 1Y6,BC,CANADA.							BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/0007-0971(75)90090-X; BULLEN SS, 1952, J ALLERGY, V23, P193, DOI 10.1016/0021-8707(52)90017-8; Curschmann H., 1882, DTSCH ARCH KLIN MED, V32, P1; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; FREEDMAN BJ, 1972, B PHYSIO-PATHOL RESP, V8, P545; GRATZIOU C, 1992, AM REV RESPIR DIS, V145, P1259, DOI 10.1164/ajrccm/145.6.1259; HARLAN JM, 1992, ADHESION ITS ROLE IN; HEARD BE, 1971, J PATHOL, V101, P171; HOUSTON JC, 1953, THORAX, V8, P207, DOI 10.1136/thx.8.3.207; HUBER HL, 1922, ARCH INTERN MED, V30, P687; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JAMES AL, 1988, AM REV RESPIR DIS, V138, P136, DOI 10.1164/ajrccm/138.1.136; JAMES AL, 1988, J APPL PHYSIOL, V64, P913, DOI 10.1152/jappl.1988.64.3.913; JAMES AL, 1987, J APPL PHYSIOL, V63, P1360, DOI 10.1152/jappl.1987.63.4.1360; KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765; KUWANO K, 1990, SMALL AIRWAYS DIMENS; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; MACKLEM PT, 1970, RESP PHYSIOL, V8, P191, DOI 10.1016/0034-5687(70)90015-0; MESSER JW, 1960, DIS CHEST, V38, P616, DOI 10.1378/chest.38.6.616; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; NAYLOR BERNARD, 1962, THORAX, V17, P69, DOI 10.1136/thx.17.1.69; Osler WB, 1892, PRINCIPLES PRACTICE; RICHARDS W, 1965, AM J DIS CHILD, V110, P4, DOI 10.1001/archpedi.1965.02090030010003; SOBONYA RE, 1984, AM REV RESPIR DIS, V130, P289; TAUSSIG MJ, 1984, PROCESSES PATHOLOGY, P3; WIGGS B, 1991, ASTHMA ITS PATHOLOGY, P73; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; WIGGS BR, 1990, J APPL PHYSIOL, V69, P849, DOI 10.1152/jappl.1990.69.3.849	30	52	54	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	1				1	5		10.1016/0091-6749(93)90029-F	http://dx.doi.org/10.1016/0091-6749(93)90029-F			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ353	8335845	Bronze			2022-12-18	WOS:A1993LQ35300001
J	YAMAMOTO, H; NAGATA, M; TABE, K; KIMURA, I; KIUCHI, H; SAKAMOTO, Y; YAMAMOTO, K; DOHI, Y				YAMAMOTO, H; NAGATA, M; TABE, K; KIMURA, I; KIUCHI, H; SAKAMOTO, Y; YAMAMOTO, K; DOHI, Y			THE EVIDENCE OF PLATELET ACTIVATION IN BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BRONCHIAL ASTHMA; PLATELET-ACTIVATING FACTOR; BETA-THROMBOGLOBULIN; PLATELET FACTOR-IV	RABBIT; RESPONSIVENESS; ANAPHYLAXIS	The possible involvement of platelets in bronchial asthma was investigated under three different conditions: (1) chronic asthma, (2) bronchial provocation inhaling house dust mite (HDM), and (3) status asthmaticus. Plasma levels of beta-thromboglobulin (beta-TG), platelet factor 4 (PF4), and in part, platelet-activating factor (PAF) were measured. Approximately one third of the subjects with symptomatic or asymptomatic chronic asthma showed an increased level of beta-TG or PF4. Statistically significant differences occurred in beta-TG and PF4 levels only between healthy controls and symptomatic subjects. Five out of six subjects showed no elevation of beta-TG and PF4 during immediate asthmatic response. In two out of nine subjects with status asthmaticus, beta-TG or PF4 was elevated, and statistically significant correlations occurred between the initial level of PAF and that of beta-TG or PF4. Those results suggest that the platelet activation in the circulation is sometimes provoked in asthma, but plasma level of alpha-granule-derived proteins does not reflect the intensity or severity of asthma, and that PAF is likely to be a mediator responsible for the platelet activation.			YAMAMOTO, H (corresponding author), SAITAMA MED SCH,DEPT INTERNAL MED 2,38 MOROHONGO,MOROYAMA,SAITAMA 35004,JAPAN.							AVERILL FJ, 1992, AM REV RESPIR DIS, V145, P571, DOI 10.1164/ajrccm/145.3.571; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COYLE AJ, 1990, AM REV RESPIR DIS, V142, P587, DOI 10.1164/ajrccm/142.3.587; CUSS FM, 1986, LANCET, V2, P189; DIEZ FL, 1989, J CLIN INVEST, V83, P1733, DOI 10.1172/JCI114074; DURHAM SR, 1985, LANCET, V2, P36; EVANS TW, 1987, J APPL PHYSIOL, V63, P479, DOI 10.1152/jappl.1987.63.2.479; GRESELE P, 1982, NEW ENGL J MED, V306, P549; HEMMENDINGER S, 1989, J ALLERGY CLIN IMMUN, V83, P900; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KLOPROGGE E, 1984, BIOCHEM J, V223, P901, DOI 10.1042/bj2230901; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; MACCIA CA, 1977, J ALLERGY CLIN IMMUN, V59, P101, DOI 10.1016/0091-6749(77)90210-X; MACDERMOT J, 1988, ASTHMA BASIC MECHANI, P97; MCMANUS LM, 1979, J IMMUNOL, V123, P2835; MORRISON JFJ, 1991, THORAX, V46, P197, DOI 10.1136/thx.46.3.197; NAKAMURA T, 1987, INT ARCH ALLER A IMM, V82, P57, DOI 10.1159/000234290; PAGE CP, 1984, INT ARCH ALLER A IMM, V74, P347, DOI 10.1159/000233571; PINCKARD RN, 1977, J IMMUNOL, V119, P2185; SATOUCHI K, 1984, ARCH BIOCHEM BIOPHYS, V234, P318, DOI 10.1016/0003-9861(84)90355-2; VARGAFTIG BB, 1989, MEDIATORS INFLAMMATO, P113; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765	22	52	53	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	1				79	87		10.1016/0091-6749(93)90299-U	http://dx.doi.org/10.1016/0091-6749(93)90299-U			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK044	8423274				2022-12-18	WOS:A1993KK04400006
J	LESER, C; KAUFFMAN, HF; VIRCHOW, C; MENZ, G				LESER, C; KAUFFMAN, HF; VIRCHOW, C; MENZ, G			SPECIFIC SERUM IMMUNOPATTERNS IN CLINICAL-PHASES OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALLERGIC ASTHMA; ASPERGILLUS; IMMUNOBLOTTING; MAJOR ALLERGENS; SPECIFIC IGE; SPECIFIC IGG; SPECIFIC IMMUNOPATTERN	IMMUNOSORBENT-ASSAY ELISA; IMMUNOBLOT ANALYSIS; FUMIGATUS ANTIGENS; MOLECULAR-WEIGHT; DOUBLE-DIFFUSION; DISEASE; ANTIBODIES; DIAGNOSIS; AID	Immunoblotting, radioallergosorbent test (RAST), and enzyme-linked immunosorbent assay (ELISA) were performed to determine specific IgE and IgG responses to Aspergillus fumigatus (Af) allergens (IgE-Af; IgG-Af). Serology results were compared in patients with allergic bronchopulmonary aspergillosis (ABPA) (n = 43), patients with Aspergillus fumigatus-associated asthma (Af-asthma) (n = 26), and healthy individuals (n = 3). In patients with different clinical phases of ABPA, three specific immunopatterns were found by immunoblotting. It is proposed to classify ABPA into the active, intermediate, and remission phase with respect to the specific immunoresponse to Af-allergens and asthma symptoms. First, the active phase of ABPA is characterized by a fully developed specific immunoresponse to Af-allergens and severe asthma. Second, the intermediate phase includes patients with elevated specific immunologic findings without asthma symptoms. Third, the remission phase is characterized by a weak specific immunoresponse to Af-allergens after a long-term asymptomatic period. No correlation occurred between specific immunopatterns and irreversible bronchopulmonary lesions. The IgE-Af RAST and IgG-Af ELISA titers of patients with ABPA in the active and intermediate phase were significantly higher compared with patients with ABPA in remission phase and with patients with Af-asthma. In particular, the demonstration of positive IgG-Af ELISA titer generally allows the serologic discrimination of patients with asthma and ABPA from patients with Af-asthma in clinical practice. The present study revealed that immunoblots of most patients with Af-asthma were negative. Immunoblotting demonstrated an IgG reactivity exclusively to low molecular weight (MW) Af-allergens in 8 out of 26 patients with Af-asthma and in the three healthy individuals, and this IgG response may reflect naturally occurring antibodies.	HOCHGEBIRGSKLIN DAVOS WOLFGANG,ASTHMA & ALLERGY CLIN,CH-7265 DAVOS,SWITZERLAND; UNIV GRONINGEN HOSP,INTERNAL MED CLIN,DEPT ALLERGOL,9700 RB GRONINGEN,NETHERLANDS	University of Groningen								ARBESMAN C E, 1974, Clinical Allergy, V4, P349, DOI 10.1111/j.1365-2222.1974.tb01396.x; BARDANA E, 1980, CRC CRIT REV CLIN LA, V13, P85; BARDANA EJ, 1972, J ALLERGY CLIN IMMUN, V50, P222, DOI 10.1016/0091-6749(72)90016-4; BAUR X, 1989, J ALLERGY CLIN IMMUN, V83, P839, DOI 10.1016/0091-6749(89)90023-7; BENGTSSON A, 1986, INT ARCH ALLER A IMM, V80, P383, DOI 10.1159/000234085; BERNSTEIN JA, 1990, J ALLERGY CLIN IMMUN, V86, P532, DOI 10.1016/S0091-6749(05)80209-X; BROUWER J, 1988, INT ARCH ALLER A IMM, V85, P244, DOI 10.1159/000234510; CURRIE DC, 1987, CLIN RADIOL, V38, P593, DOI 10.1016/S0009-9260(87)80333-1; GLANCY JJ, 1981, THORAX, V36, P345, DOI 10.1136/thx.36.5.345; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; GREENBERGER PA, 1987, CHEST S, V91, P165; HALWIG JM, 1984, J ALLERGY CLIN IMMUN, V74, P738, DOI 10.1016/0091-6749(84)90238-0; HASLAM P, 1976, CLIN ALLERGY, V6, P277, DOI 10.1111/j.1365-2222.1976.tb01908.x; HEARN VM, 1985, J IMMUNOASSAY, V6, P137, DOI 10.1080/01971528508063026; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P91, DOI 10.1016/0091-6749(78)90084-2; JOHANSSON SG, 1970, CLIN EXP IMMUNOL, V6, P43; KAUFFMAN HF, 1983, J ALLERGY CLIN IMMUN, V72, P255, DOI 10.1016/0091-6749(83)90029-5; KAUFFMAN HF, 1989, J ALLERGY CLIN IMMUN, V83, P829, DOI 10.1016/0091-6749(89)90022-5; KAUFFMAN HF, 1980, INT ARCH ALLER A IMM, V62, P252, DOI 10.1159/000232521; KURUP VP, 1989, J CLIN MICROBIOL, V27, P1312, DOI 10.1128/JCM.27.6.1312-1316.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG PSC, 1988, INT ARCH ALLER A IMM, V85, P416, DOI 10.1159/000234544; LONGBOTTOM JL, 1986, J ALLERGY CLIN IMMUN, V78, P9, DOI 10.1016/0091-6749(86)90108-9; LONGBOTTOM JL, 1987, IMMUNOLOGICAL TECHNI, P163; MALO JL, 1981, CLIN ALLERGY, V11, P333, DOI 10.1111/j.1365-2222.1981.tb01603.x; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; MINTZER RA, 1978, RADIOLOGY, V127, P301, DOI 10.1148/127.2.301; PATTERSON R, 1986, ARCH INTERN MED, V146, P916, DOI 10.1001/archinte.146.5.916; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; PATTERSON R, 1983, ANN INTERN MED, V99, P18, DOI 10.7326/0003-4819-99-1-18; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; SCHONHEYDER H, 1987, SCAND J INFECT DI S5, V1, P1; SCHWARTZ HJ, 1978, J ALLERGY CLIN IMMUN, V62, P9, DOI 10.1016/0091-6749(78)90065-9; TOWBIN U, 1979, P NATL ACAD SCI USA, V46, P4350; TURNER KJ, 1974, CLIN ALLERGY, V4, P149, DOI 10.1111/j.1365-2222.1974.tb01372.x; VANSELOW NA, 1960, MANUAL CLIN ALLERGY, P55; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917; ZEASKE R, 1988, J ALLERGY CLIN IMMUN, V82, P73, DOI 10.1016/0091-6749(88)90054-1; ZELLER R, 1983, CELL, V32, P425, DOI 10.1016/0092-8674(83)90462-2	43	52	53	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				589	599		10.1016/0091-6749(92)90131-K	http://dx.doi.org/10.1016/0091-6749(92)90131-K			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1401642	Bronze			2022-12-18	WOS:A1992JT99500004
J	FURUKAWA, CT				FURUKAWA, CT			THE ROLE OF ALLERGY IN SINUSITIS IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		ALLERGY; SINUSITIS	MAXILLARY SINUSITIS	Allergic rhinitis and sinusitis are independently common disorders. Studies document the presence of both disorders in the same patient 25% to 70% of the time. Because this is above the prevalence of allergic rhinitis in the general population, the literature supports that allergy is an important associated factor in sinusitis. Younger children appear to be even more at risk of sinusitis, perhaps because of small anatomic structures, more frequent viral infections, and more exposure to indoor allergens and irritants. Immunodeficiency appears to play an independent role in resistant, severe sinusitis.	NW ASTHMA & ALLERGY CTR,SEATTLE,WA									FURUKAWA CT, 1992, J ALLERGY CLIN IMMUN, V89, P332; KOGUTT MS, 1973, PEDIATRICS, V52, P121; PELIKAN Z, 1990, J ALLERGY CLIN IMMUN, V86, P484, DOI 10.1016/S0091-6749(05)80203-9; RACHELEFSKY G S, 1991, Journal of Allergy and Clinical Immunology, V87, P219, DOI 10.1016/0091-6749(91)91603-Q; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; SAVOLAINEN S, 1989, ALLERGY, V44, P116, DOI 10.1111/j.1398-9995.1989.tb02234.x; SHAPIRO GG, 1991, PEDIATRICS, V87, P311; SHAPIRO GG, 1985, PEDIATR INFECT DIS J, V4, P55; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V81, P284, DOI 10.1016/0091-6749(88)90700-2	9	52	54	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			515	517		10.1016/0091-6749(92)90177-4	http://dx.doi.org/10.1016/0091-6749(92)90177-4			3	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527343				2022-12-18	WOS:A1992JP52100018
J	LOZEWICZ, S; WANG, J; DUDDLE, J; THOMAS, K; CHALSTREY, S; REILLY, G; DEVALIA, JL; DAVIES, RJ				LOZEWICZ, S; WANG, J; DUDDLE, J; THOMAS, K; CHALSTREY, S; REILLY, G; DEVALIA, JL; DAVIES, RJ			TOPICAL GLUCOCORTICOIDS INHIBIT ACTIVATION BY ALLERGEN IN THE UPPER RESPIRATORY-TRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						GLUCOCORTICOIDS; EOSINOPHIL; ALLERGEN; RHINITIS; ECP; ACTIVATION	EOSINOPHIL CATIONIC PROTEIN; MAJOR BASIC-PROTEIN; NASAL-LAVAGE FLUID; ANTIGEN CHALLENGE; MAST-CELLS; INFLAMMATORY CELLS; MEDIATOR RELEASE; RHINITIS; BUDESONIDE; PRETREATMENT	We have studied the effect of a topically administered glucocorticoid, fluticasone propionate (FP), on infiltration and activation of eosinophils in the nasal mucosa after provocation with allergen. Forty-four patients with seasonal allergic rhinitis entered a double-blind, crossover study in which they underwent treatment with either FP (200-mu-g once daily) or identical placebo for 2 weeks. Patients then underwent nasal-allergen provocation followed by nasal lavage and biopsy at one of several time points between 0 and 8 hours. Patients subsequently received the alternate treatment for 2 weeks before repeat allergen provocation, nasal lavage, and biopsy, as before. Biopsy specimens of nasal mucosa obtained during the immediate allergic response demonstrated an influx of eosinophils (stained by monoclonal antibody EG1) of similar magnitude during both FP and placebo treatment. Significantly, fewer esoinophils in these biopsy specimens were activated (stained by monoclonal antibody EG2) after treatment with FP compared with that after placebo treatment (median values, 8.8 and 36.6 cells per square millimeter, respectively; p < 0.02). The concentration of eosinophil cationic protein in nasal lavage fluid was significantly elevated above baseline from 2 to 8 hours after allergen, and this increase was abolished by treatment with FP. These results suggest that topical glucocorticoids inhibit allergen-induced activation of eosinophils in allergic rhinitis.	ST BARTHOLOMEWS HOSP, ST BARTHOLOMEWS CTR CLIN RES, DEPT RESPIRAT MED, LONDON EC1A 7BE, ENGLAND; ST BARTHOLOMEWS HOSP, DEPT EAR NOSE & THROAT, LONDON EC1A 7BE, ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London								ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; AYARS GH, 1989, AM REV RESPIR DIS, V140, P125; BASCOM R, 1989, J ALLERGY CLIN IMMUN, V84, P338, DOI 10.1016/0091-6749(89)90418-1; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BISGAARD H, 1990, J ALLERGY CLIN IMMUN, V85, P891, DOI 10.1016/0091-6749(90)90074-E; BROOKS CD, 1988, ANN ALLERGY, V61, P151; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GOMEZ E, 1988, BRIT MED J, V296, P1572, DOI 10.1136/bmj.296.6636.1572-a; HENRIKSEN JM, 1984, AM REV RESPIR DIS, V130, P1014; HOWARTH PH, 1989, RESP MED, V83, P179, DOI 10.1016/S0954-6111(89)80029-0; LEE TC, 1984, J BIOL CHEM, V259, P5526; LINDER A, 1987, ALLERGY, V42, P583, DOI 10.1111/j.1398-9995.1987.tb00388.x; LOZEWICZ S, 1990, J ALLERGY CLIN IMMUN, V85, P125, DOI 10.1016/0091-6749(90)90233-T; LOZEWICZ S, 1991, INT ARCH ALLER A IMM, V95, P273, DOI 10.1159/000235441; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357, DOI 10.1164/ajrccm/136.2.357; MYGIND N, 1977, CLIN ALLERGY, V7, P69, DOI 10.1111/j.1365-2222.1977.tb01426.x; OLIVER RC, 1982, J CELL SCI, V56, P337; OTSUKA H, 1986, CLIN ALLERGY, V16, P589, DOI 10.1111/j.1365-2222.1986.tb01998.x; PETERS MS, 1986, LAB INVEST, V54, P656; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PIPKORN U, 1982, ALLERGY, V37, P129, DOI 10.1111/j.1398-9995.1982.tb01886.x; PIPKORN U, 1983, ALLERGY, V38, P125, DOI 10.1111/j.1398-9995.1983.tb01596.x; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SHAW RJ, 1985, ALLERGY, V40, P1, DOI 10.1111/j.1398-9995.1985.tb04147.x; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; VILSVIK J S, 1975, Clinical Allergy, V5, P291, DOI 10.1111/j.1365-2222.1975.tb01865.x; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WINQVIST I, 1984, IMMUNOLOGY, V51, P1; YUKAWA T, 1989, THORAX, V44, pP883	31	52	52	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1992	89	5					951	957		10.1016/0091-6749(92)90217-P	http://dx.doi.org/10.1016/0091-6749(92)90217-P			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HU542	1583252				2022-12-18	WOS:A1992HU54200005
J	LYMPANY, P; WELSH, K; MACCOCHRANE, G; KEMENY, DM; LEE, TH				LYMPANY, P; WELSH, K; MACCOCHRANE, G; KEMENY, DM; LEE, TH			GENETIC-ANALYSIS USING DNA POLYMORPHISM OF THE LINKAGE BETWEEN CHROMOSOME-11Q13 AND ATOPY AND BRONCHIAL HYPERRESPONSIVENESS TO METHACHOLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPY; BRONCHIAL HYPERRESPONSIVENESS; GENETICS; DNA; POLYMORPHISM; CHROMOSOME	IMMUNOGLOBULIN-E LEVEL; BEE VENOM; IGE; ANTIBODIES; FRAGMENTS; ANTIGENS; ALLERGY; ASTHMA; RAST	Previous studies have suggested that there is a genetic predisposition for the development of asthma and atopy. A recent study has also demonstrated that there is a striking link between chromosome 11q and the IgE response underlying asthma and rhinitis. To assess the linkage between chromosome 11q (region D11S97) and atopy or bronchial hyperresponsiveness (BH), we have studied nine families of two and, in many instances, three generations with the index case having asthma and/or atopy. With variable number of tandem repeat analysis with the probe, p-lambda-MS.51, we have been unable to confirm a significant link between region D11S97 of chromosome 11q and either atopy or BH to methacholine. We have demonstrated that atopy and BH produce similar log of odds scores with linkage analysis at each recombination fraction from 0.001 to 0.5 with both Hinfl and Taq1 restriction digests and that the use of either a positive skin prick test or positive RAST as a definition of atopy does not significantly alter the log of odds score.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT ALLERGY & APPL RESP DISORDERS,LONDON SE1 9RT,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT TISSUE TYPING,LONDON,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT RESP MED,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059				ANSARI AA, 1991, IMMUNOGENETICS, V33, P24; ARMOUR JA, 1989, NUCLEIC ACIDS RES, V1, P4925; BLUMENTHAL MN, 1986, J ALLERGY CLIN IMMUN, V78, P962, DOI 10.1016/0091-6749(86)90286-1; Cooke RA, 1916, J IMMUNOL, V1, P201; COOKSON WOC, 1989, LANCET, P1292; COOKSON WOCM, 1988, LANCET, V1, P86; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERRARD JW, 1978, AM J HUM GENET, V30, P46; GERRARD JW, 1976, ANN ALLERGY, V36, P10; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KEMENY DM, 1980, CLIN ALLERGY, V10, P413, DOI 10.1111/j.1365-2222.1980.tb02124.x; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V71, P505, DOI 10.1016/0091-6749(83)90469-4; KONIG P, 1973, ARCH DIS CHILD, V48, P513, DOI 10.1136/adc.48.7.513; LONGO G, 1987, AM J DIS CHILD, V141, P331, DOI 10.1001/archpedi.1987.04460030109037; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MARSH DG, 1979, P NATL ACAD SCI USA, V76, P2903, DOI 10.1073/pnas.76.6.2903; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MEYERS DA, 1987, AM J HUM GENET, V41, P51; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NAKAMURA Y, 1987, NUCLEIC ACIDS RES, V15, P10073, DOI 10.1093/nar/15.23.10073; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VAN ARSDEL P P Jr, 1959, Acta Genet Stat Med, V9, P101; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	24	52	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1992	89	2					619	628		10.1016/0091-6749(92)90330-5	http://dx.doi.org/10.1016/0091-6749(92)90330-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD753	1346795				2022-12-18	WOS:A1992HD75300015
J	LEHRER, SB; HORNER, WE; MENON, P; STANKUS, RP				LEHRER, SB; HORNER, WE; MENON, P; STANKUS, RP			COMPARISON OF COCKROACH ALLERGENIC ACTIVITY IN WHOLE-BODY AND FECAL EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BRONCHIAL-ASTHMA; GERMAN; ANTIGENS; CHILDREN; AMERICAN; MITE	Previous studies have established cockroach allergens as important sensitizing agents in the induction/exacerbation of urban asthma. The present investigation compared saline extracts of American cockroach (Periplaneta americana) whole bodies and feces and German cockroach (Blattella germanica) whole bodies and feces as important sources of allergens. All extracts were tested before or after gel filtration on Sephadex G-75 columns (fraction 2) as previously described. Skin test studies of 69 subjects with asthma with extracts of American or German cockroaches demonstrated a significant correlation of reactivity to whole body and fecal extracts for both species. Direct RASTs of 13 sera from cockroach skin test-positive subjects were generally greater to both German whole body extracts (GWBEs) and German fecal extracts (GFEs) as compared to American whole body and fecal extracts. There was a good correlation of RAST reactivity to GWBE with GFE. RAST inhibition demonstrated that GFE contained most of the allergenic activity present in GWBE. These studies demonstrate the allergenic similarities of cockroach whole body and fecal extracts and suggest that cockroach feces are an important sensitizing agent in atopic asthma.			LEHRER, SB (corresponding author), TULANE UNIV, SCH MED, DEPT MED, ALLERGY & CLIN IMMUNOL SECT, 1700 PERDIDO ST, NEW ORLEANS, LA 70112 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022918] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07376] Funding Source: Medline; NIAID NIH HHS [AI 22918] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1970, ANN ALLERGY, V28, P543; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; CHAPMAN MD, 1988, CHEST, V94, P185, DOI 10.1378/chest.94.1.185; CHOOVIVATHANAVANICH P, 1970, LANCET, V2, P1362; CHOOVIVATHANAVANICH P, 1974, J MED ASSOC THAILAND, V57, P237; CORAZEN G, 1973, ANN ALLERGY, V31, P407; FEINBERG AR, 1956, J ALLERGY, V27, P437, DOI 10.1016/0021-8707(56)90103-4; HELM RM, 1988, INT ARCH ALLER A IMM, V87, P230, DOI 10.1159/000234678; HORNER WE, 1988, J ALLERGY CLIN IMMUN, V82, P978, DOI 10.1016/0091-6749(88)90134-0; HORNER WE, IN PRESS INT ARCH AL; HULETT AC, 1979, ANN ALLERGY, V42, P160; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; LIND P, 1988, J ALLERGY CLIN IMMUN, V81, P269, DOI 10.1016/0091-6749(88)90637-9; MENDOZA J, 1970, ANN ALLERGY, V28, P159; MENON V, 1989, J ALLERGY CLIN IMMUN, V83, P265; MORRIS EC, 1986, J ALLERGY CLIN IMMUN, V77, P206; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; RICHMAN PG, 1984, J ALLERGY CLIN IMMUN, V73, P590, DOI 10.1016/0091-6749(84)90516-5; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V81, P548, DOI 10.1016/0091-6749(88)90195-9; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X	24	52	55	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					574	580		10.1016/0091-6749(91)90017-I	http://dx.doi.org/10.1016/0091-6749(91)90017-I			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1993815				2022-12-18	WOS:A1991EX98700016
J	TOWN, GI; HOLGATE, ST				TOWN, GI; HOLGATE, ST			COMPARISON OF THE EFFECT OF LORATADINE ON THE AIRWAY AND SKIN-RESPONSES TO HISTAMINE, METHACHOLINE, AND ALLERGEN IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RECEPTOR ANTAGONIST; BRONCHIAL RESPONSIVENESS; INDUCED IMMEDIATE; TERFENADINE; AZELASTINE; CHALLENGE	Loratadine is a highly selective, long-acting, H-1-receptor agonist. In a randomized double-blind, crossover study, we evaluated the effects of loratadine, 10 and 20 mg, and placebo administered once daily for 3 days on the skin-wheal responses to histamine, the airway responses to inhaled histamine and methacholine, and the skin-wheal and airway responses to allergen in 12 subjects with asthma. There was no evidence of a bronchodilator action 3 hours after a third oral dose. In the airway, the geometric mean of the provocative concentration of histamine causing a 20% fall in FEV, after placebo or loratadine, 10 and 20 mg, was 0.68 mg/ml, 2.71 mg/ml (p, not significant), and 5.96 mg/ml (p < 0.05), respectively. The concentration ratios (value after active treatment/value after placebo) for loratadine, 10 and 20 mg, were 5.1 (p < 0.05) and 13.4 (p < 0.05). Neither dose of loratadine had any significant effect on the methacholine dose-response relationship. In the skin, loratadine also displaced the histamine log-concentration response curves to the right with concentration ratios of 4.7 and 7.6, respectively. Loratadine, 10 and 20 mg, had no protective effect on the early or late-phase bronchoconstrictor responses to inhaled allergen. In the skin, loratadine, 20 mg, significantly inhibited the mean wheal area to allergen. Thus, in the dose regimens studied, although loratadine is a moderately potent and selective H-1 antagonist in the skin and airways, it failed to attenuate the early and late airway responses to inhaled allergen.	UNIV SOUTHAMPTON,IMMUNOPHARMACOL GRP,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND	University of Southampton								BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; BRIK A, 1987, J ALLERGY CLIN IMMUN, V80, P51, DOI 10.1016/S0091-6749(87)80190-2; BURGE PS, 1982, CLIN ALLERGY, V12, P523, DOI 10.1111/j.1365-2222.1982.tb02551.x; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHURCH MK, 1980, BRIT J PHARMACOL, V69, P663, DOI 10.1111/j.1476-5381.1980.tb07919.x; CLISSOLD SP, 1989, DRUGS, V37, P42, DOI 10.2165/00003495-198937010-00003; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; CURZEN N, 1987, THORAX, V42, P946, DOI 10.1136/thx.42.12.946; FINNERTY JP, 1990, EUR RESPIR J, V3, P540; FINNERTY JP, 1988, Q J MED, V249, P5; HAMID M, 1990, CLIN EXP ALLERGY, V20, P261, DOI 10.1111/j.1365-2222.1990.tb02681.x; HOLGATE ST, 1985, J ALLERGY CLIN IMMUN, V76, P375, DOI 10.1016/0091-6749(85)90657-8; KIRKSEN A, 1989, ALLERGY, V44, P566; LEWIS RA, 1984, DRUGS LUNG; RAFFERTY P, 1989, J ALLERGY CLIN IMMUN, V84, P649, DOI 10.1016/0091-6749(89)90292-3; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; RAFFERTY P, 1988, J ALLERGY CLIN IMMUN, V82, P1113, DOI 10.1016/0091-6749(88)90151-0; RAFFERTY P, 1989, J ALLERGY CLIN IMMUN, V84, P141; TWENTYMAN O P, 1990, American Review of Respiratory Disease, V141, pA838	20	52	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				886	893		10.1016/S0091-6749(05)80151-4	http://dx.doi.org/10.1016/S0091-6749(05)80151-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	2148176				2022-12-18	WOS:A1990EQ04500009
J	ATKINS, PC; SCHWARTZ, LB; ADKINSON, NF; VONALLMEN, C; VALENZANO, M; ZWEIMAN, B				ATKINS, PC; SCHWARTZ, LB; ADKINSON, NF; VONALLMEN, C; VALENZANO, M; ZWEIMAN, B			INVIVO ANTIGEN-INDUCED CUTANEOUS MEDIATOR RELEASE - SIMULTANEOUS COMPARISONS OF HISTAMINE, TRYPTASE, AND PROSTAGLANDIN-D2 RELEASE AND THE EFFECT OF ORAL CORTICOSTEROID ADMINISTRATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,CHARLOTTESVILLE,VA; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205	Virginia Commonwealth University; Johns Hopkins University	ATKINS, PC (corresponding author), UNIV PENN,SCH MED,DEPT MED,DIV ALLERGY & IMMUNOL,510 JOHNSON PAVILION,36TH & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.				NIAID NIH HHS [AI-14332, AI-2047] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS PC, 1982, J ALLERGY CLIN IMMUN, V69, P39, DOI 10.1016/0091-6749(82)90085-9; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; COHAN VL, 1989, AM REV RESPIR DIS, V140, P951, DOI 10.1164/ajrccm/140.4.951; DALE DC, 1974, NEW ENGL J MED, V291, P1154, DOI 10.1056/NEJM197411282912203; DUNSKY EH, 1977, J ALLERGY CLIN IMMUN, V59, P142, DOI 10.1016/0091-6749(77)90216-0; MACGLASHAN DW, 1983, FED PROC, V42, P2054; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OELZ O, 1977, PROSTAGLANDINS, V13, P225, DOI 10.1016/0090-6980(77)90004-1; PETERS WP, 1972, NEW ENGL J MED, V286, P342, DOI 10.1056/NEJM197202172860703; PIENKOWSKI MM, 1988, J ALLERGY CLIN IMMUN, V82, P95, DOI 10.1016/0091-6749(88)90057-7; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; RUZICKA T, 1987, J IMMUNOL, V138, P539; SCHLEIMER RP, 1982, J IMMUNOL, V129, P1632; SCHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; SHALIT M, 1989, J ALLERGY CLIN IMMUN, V83, P691, DOI 10.1016/0091-6749(89)90084-5; SHALIT M, 1988, J IMMUNOL, V141, P821; SHALIT M, 1990, J ALLERGY CLIN IMMUN, V86, P117, DOI 10.1016/S0091-6749(05)80131-9; TALBOT S, 1987, ANN ALLERGY, V58, P363; THARP MD, 1987, J ALLERGY CLIN IMMUN, V79, P646, DOI 10.1016/S0091-6749(87)80162-8; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0; ZWEIMAN B, 1976, INT ARCH ALLER A IMM, V52, P48, DOI 10.1159/000231666; ZWEIMAN B, 1976, J ALLERGY CLIN IMMUN, V58, P657, DOI 10.1016/0091-6749(76)90177-9	25	52	54	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				360	370		10.1016/S0091-6749(05)80099-5	http://dx.doi.org/10.1016/S0091-6749(05)80099-5			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	1698845				2022-12-18	WOS:A1990EA85900010
J	KNUTSEN, AP				KNUTSEN, AP			PATIENTS WITH IGG SUBCLASS AND OR SELECTIVE ANTIBODY DEFICIENCY TO POLYSACCHARIDE ANTIGENS - INITIATION OF A CONTROLLED CLINICAL-TRIAL OF INTRAVENOUS IMMUNE GLOBULIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KNUTSEN, AP (corresponding author), ST LOUIS UNIV,MED CTR,PEDIAT RES INST,DEPT PEDIAT,DIV ALLERGY IMMUNOL,1465 S GRAND BLVD,ST LOUIS,MO 63104, USA.							AGOPIAN MS, 1988, 45TH ANN C AM COLL A; AMBROSINO DM, 1987, NEW ENGL J MED, V316, P790, DOI 10.1056/NEJM198703263161306; AMBROSINO DM, 1988, J ALLERGY CLIN IMMUN, V81, P1175, DOI 10.1016/0091-6749(88)90887-1; BJORKANDER J, 1986, J ALLERGY CLIN IMMUN, V77, P124; BJORKANDER J, 1985, NEW ENGL J MED, V313, P720, DOI 10.1056/NEJM198509193131203; BOCTOR FN, 1989, J IMMUNOL METHODS, V120, P167, DOI 10.1016/0022-1759(89)90238-X; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; GRANOFF DM, 1986, NEW ENGL J MED, V315, P1584, DOI 10.1056/NEJM198612183152505; GRANOFF DM, 1985, J PEDIATR, V310, P1561; HAMMARSTROM L, 1985, ACTA PAEDIATR SCAND, V74, P126, DOI 10.1111/j.1651-2227.1985.tb10933.x; HAMMARSTROM L, 1984, CLIN EXP IMMUNOL, V51, P600; INSEL RA, 1986, NEW ENGL J MED, V315, P499, DOI 10.1056/NEJM198608213150807; KNUTSEN AP, 1981, J PEDIATR-US, V98, P420, DOI 10.1016/S0022-3476(81)80709-3; KNUTSEN AP, 1985, CLIN IMMUNOL IMMUNOP, V36, P330, DOI 10.1016/0090-1229(85)90053-4; KRAFT D, 1982, ALLERGY, V37, P481, DOI 10.1111/j.1398-9995.1982.tb02331.x; LAWRENCE EM, 1983, AM J DIS CHILD, V137, P846, DOI 10.1001/archpedi.1983.02140350024007; MORRELL A, 1972, J PEDIATR, V80, P960; OXELIUS VA, 1981, NEW ENGL J MED, V304, P1476, DOI 10.1056/NEJM198106113042408; OXELIUS VA, 1979, CLIN EXP IMMUNOL, V36, P112; OXELIUS VA, 1974, CLIN EXP IMMUNOL, V17, P19; OXELIUS VA, 1979, ACTA PAEDIATR SCAND, V68, P23, DOI 10.1111/j.1651-2227.1979.tb04424.x; OXELIUS VA, 1982, NEW ENGL J MED, V306, P515, DOI 10.1056/NEJM198203043060905; PAGE R, 1988, J PEDIATR-US, V112, P127, DOI 10.1016/S0022-3476(88)80137-9; RIESEN WF, 1976, SCAND J IMMUNOL, V5, P383, DOI 10.1111/j.1365-3083.1976.tb00292.x; SAXON A, 1980, CLIN IMMUNOL IMMUNOP, V17, P235, DOI 10.1016/0090-1229(80)90092-6; SCHIFFMAN G, 1980, J IMMUNOL METHODS, V33, P133, DOI 10.1016/S0022-1759(80)80004-4; SCHUR PH, 1987, ANN ALLERGY, V58, P89; SCHUR PH, 1979, PEDIATR RES, V13, P181, DOI 10.1203/00006450-197903000-00010; SCHUR PH, 1970, NEW ENGL J MED, V283, P631, DOI 10.1056/NEJM197009172831205; SHACKELFORD PG, 1986, J PEDIATR-US, V108, P647, DOI 10.1016/S0022-3476(86)81035-6; SIBER GR, 1980, NEW ENGL J MED, V303, P178, DOI 10.1056/NEJM198007243030402; SILK H, 1987, J ALLERGY CLIN IMMUN, V79, P188; SMITH TF, 1984, J PEDIATR-US, V105, P896, DOI 10.1016/S0022-3476(84)80073-6; Spiegelberg H L, 1974, Adv Immunol, V19, P259, DOI 10.1016/S0065-2776(08)60254-0; STEVENS R, 1983, J CLIN IMMUNOL, V3, P65, DOI 10.1007/BF00919140; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; VANDERGOESSEN M, 1976, CLIN EXP IMMUNOL, V25, P1117; VANLOGHEM E, 1980, J IMMUNOGENET, V7, P285; YOUNT WJ, 1968, J EXP MED, V127, P633, DOI 10.1084/jem.127.3.633; YOUNT WJ, 1970, J CLIN INVEST, V49, P1957, DOI 10.1172/JCI106415	40	52	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	2	S			640	647		10.1016/0091-6749(89)90203-0	http://dx.doi.org/10.1016/0091-6749(89)90203-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZ398	2677097	Bronze			2022-12-18	WOS:A1989AZ39800012
J	KETTELHUT, BV; BERKEBILE, C; BRADLEY, D; METCALFE, DD				KETTELHUT, BV; BERKEBILE, C; BRADLEY, D; METCALFE, DD			A DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER TRIAL OF KETOTIFEN VERSUS HYDROXYZINE IN THE TREATMENT OF PEDIATRIC MASTOCYTOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KETTELHUT, BV (corresponding author), NIAID,MAST CELL PHYSIOL SECT,CLIN INVEST LAB,BLDG 10,ROOM 11C228,BETHESDA,MD 20892, USA.							CZARNETZKI BM, 1983, DERMATOLOGICA, V166, P44, DOI 10.1159/000249832; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; FIOCCHI A, 1985, CURR THER RES CLIN E, V37, P1113; GREENWOOD C, 1982, CHEST S, V1, P455; HUSTON DP, 1986, ANN INTERN MED, V104, P507, DOI 10.7326/0003-4819-104-4-507; KETTELHUT BV, 1987, J PEDIATR-US, V111, P419, DOI 10.1016/S0022-3476(87)80471-7; SHEAR NH, 1983, CLIN INVEST MED, V6, P36; STRATTON D, 1984, BRIT J DIS CHEST, V78, P163, DOI 10.1016/0007-0971(84)90117-7; TINKELMAN DG, 1985, J ALLERGY CLIN IMMUN, V76, P487, DOI 10.1016/0091-6749(85)90732-8; VOLOVITZ B, 1988, J ALLERGY CLIN IMMUN, V1, P526	10	52	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					866	870		10.1016/0091-6749(89)90097-3	http://dx.doi.org/10.1016/0091-6749(89)90097-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2654254	Bronze			2022-12-18	WOS:A1989U716100003
J	BRESSLER, RB; SOWELL, K; HUSTON, DP				BRESSLER, RB; SOWELL, K; HUSTON, DP			THERAPY OF CHRONIC IDIOPATHIC URTICARIA WITH NIFEDIPINE - DEMONSTRATION OF BENEFICIAL EFFECT IN A DOUBLE-BLINDED, PLACEBO-CONTROLLED, CROSSOVER TRIAL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BRESSLER, RB (corresponding author), BAYLOR COLL MED,METHODIST HOSP,6565 FANNIN,MS F-501,HOUSTON,TX 77030, USA.			Huston, David/0000-0002-2332-0010	NCRR NIH HHS [RR-00350] Funding Source: Medline; NIAID NIH HHS [AI-00519] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000350] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARCHER CB, 1984, BRIT J DERMATOL, V110, P45, DOI 10.1111/j.1365-2133.1984.tb07310.x; BERNSTEIN RK, 1985, DIABETES CARE, V8, P197, DOI 10.2337/diacare.8.2.197; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BUTCHERS PR, 1981, BRIT MED J, V282, P1792, DOI 10.1136/bmj.282.6278.1792; CHAND N, 1984, BRIT J PHARMACOL, V83, P899, DOI 10.1111/j.1476-5381.1984.tb16529.x; DIAMANT B, 1974, INT ARCH ALLER A IMM, V47, P412, DOI 10.1159/000231234; ENNIS M, 1983, AGENTS ACTIONS, V13, P144, DOI 10.1007/BF01967319; FAIRLEY JA, 1984, J AM ACAD DERMATOL, V11, P740, DOI 10.1016/S0190-9622(84)70233-7; FERRERI NR, 1986, J IMMUNOL, V136, P4188; FIGUEIREDO A, 1986, DIABETES CARE, V9, P215, DOI 10.2337/diacare.9.2.215; FJELLNER B, 1985, ACTA DERM-VENEREOL, V65, P409; FOREMAN JC, 1972, J PHYSIOL-LONDON, V224, P753, DOI 10.1113/jphysiol.1972.sp009921; FOX CC, 1985, INT ARCH ALLER A IMM, V77, P130, DOI 10.1159/000233767; FOX RW, 1986, J ALLERGY CLIN IMMUN, V78, P1159, DOI 10.1016/0091-6749(86)90266-6; GODFRAIND T, 1986, PHARMACOL REV, V38, P321; GOLDSOBEL AB, 1986, J ALLERGY CLIN IMMUN, V78, P867, DOI 10.1016/0091-6749(86)90232-0; GREEN GR, 1965, ANN ALLERGY, V23, P30; GREENBERG DA, 1987, ANN NEUROL, V21, P317, DOI 10.1002/ana.410210402; HERTZ F, 1988, INT J IMMUNOPHARMACO, V8, P747; ISHIZAKA T, 1980, P NATL ACAD SCI-BIOL, V77, P1903, DOI 10.1073/pnas.77.4.1903; KALINER M, 1973, J EXP MED, V138, P1077, DOI 10.1084/jem.138.5.1077; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KAPLAN AP, 1983, ALLERGY PRINCIPLES P, P1341; KAPLAN AP, 1983, ALLERGY INFLAMMATION, P341; KEMP JP, 1985, ANN ALLERGY, V54, P502; KIM YY, 1985, BRIT J CLIN PHARMACO, V19, P631, DOI 10.1111/j.1365-2125.1985.tb02690.x; KITAMURA Y, 1987, INT J CELL CLONING, V5, P108, DOI 10.1002/stem.5530050203; Kurosawa M, 1987, Agents Actions Suppl, V21, P77; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEE VY, 1983, THORAX, V38, P386, DOI 10.1136/thx.38.5.386; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MONROE EW, 1977, ARCH DERMATOL, V113, P80, DOI 10.1001/archderm.113.1.80; MUELLER HS, 1981, AM J MED, V71, P645, DOI 10.1016/0002-9343(81)90229-1; NINIO E, 1987, J IMMUNOL, V139, P154; OHNMEISS H, 1986, AM J NEPHROL, V6, P81, DOI 10.1159/000167225; OPPENHEIM JJ, 1984, BASIC CLIN IMMUNOL, P86; PETERS SP, 1987, AM REV RESPIR DIS, V135, P1196; RUBIN RP, 1982, CALCIUM CELLULAR SEC, P78; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; SUBRAMANIAN N, 1987, J IMMUNOL, V138, P271; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; TANIZAKI Y, 1983, INT ARCH ALLER A IMM, V72, P102, DOI 10.1159/000234850; THEUSON DO, 1979, J IMMUNOL, V123, P626; VALONE FH, 1987, THROMB RES, V45, P427, DOI 10.1016/0049-3848(87)90306-9; WILLIAMS JD, 1984, J IMMUNOL, V132, P3034	45	52	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					756	763		10.1016/0091-6749(89)90011-0	http://dx.doi.org/10.1016/0091-6749(89)90011-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2651508				2022-12-18	WOS:A1989U342000008
J	KURIHARA, K; WARDLAW, AJ; MOQBEL, R; KAY, AB				KURIHARA, K; WARDLAW, AJ; MOQBEL, R; KAY, AB			INHIBITION OF PLATELET-ACTIVATING FACTOR (PAF)-INDUCED CHEMOTAXIS AND PAF BINDING TO HUMAN EOSINOPHILS AND NEUTROPHILS BY THE SPECIFIC GINKGOLIDE-DERIVED PAF ANTAGONIST, BN-52021	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP, NATL HEART & LUNG INST, DEPT ALLERGY & CLIN IMMUNOL, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND	Imperial College London; Royal Brompton Hospital				Wardlaw, Andrew/0000-0001-6583-0791	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERT DH, 1983, J BIOL CHEM, V258, P97; ALTMAN LC, 1981, J CLIN INVEST, V67, P28, DOI 10.1172/JCI110024; Baroggi N, 1986, Agents Actions Suppl, V20, P87; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BRAQUET P, 1987, Drugs of the Future, V12, P643; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRAQUET P, 1985, LANCET, V1, P1501; Braquet P, 1985, BLOOD VESSELS, V16, P558, DOI DOI 10.2491/JJSTH1970.16.558; CAMUSSI G, 1983, INT ARCH ALLER A IMM, V70, P245, DOI 10.1159/000233331; CAMUSSI G, 1987, 1ST P SAND RES S NEW; CHIGNARD M, 1979, NATURE, V279, P799, DOI 10.1038/279799a0; CHUNG KF, 1987, LANCET, V1, P248; CLARK RAF, 1979, BLOOD, V53, P633; COYLE AJ, 1988, EUR J PHARMACOL, V148, P51, DOI 10.1016/0014-2999(88)90453-0; CUSS FM, 1986, LANCET, V2, P189; DUNSKY EH, 1977, J ALLERGY CLIN IMMUN, V59, P142, DOI 10.1016/0091-6749(77)90216-0; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; HENOCQ E, 1986, LANCET, V1, P1378; HWANG SB, 1988, J BIOL CHEM, V263, P3225; KAY AB, 1970, CLIN EXP IMMUNOL, V6, P75; KAY AB, 1987, J ALLERGY CLIN IMMUN, V80, P1, DOI 10.1016/S0091-6749(87)80183-5; KORTH R, 1987, EUR J PHARMACOL, V142, P331, DOI 10.1016/0014-2999(87)90071-9; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; LELLOUCHTUBIANA A, IN PRESS AM REV RESP; MACDONALD AJ, 1986, J ALLERGY CLIN IMMUN, V77, P227; MAESTRELLI P, 1988, IMMUNOLOGY, V64, P219; MENCIAHUERTA JM, 1983, J IMMUNOL, V131, P2958; MOQBEL R, 1988, ALLERGY, V43, P268, DOI 10.1111/j.1398-9995.1988.tb00899.x; NUNEZ D, 1986, EUR J PHARMACOL, V123, P197, DOI 10.1016/0014-2999(86)90660-6; OFLAHERTY JT, 1986, J CLIN INVEST, V78, P381, DOI 10.1172/JCI112588; OFLAHERTY JT, 1983, CLIN REV ALLERG, V1, P353; SANCHEZCRESPO M, 1985, IMMUNOPHARMACOLOGY, V10, P69, DOI 10.1016/0162-3109(85)90031-1; VADAS MA, 1979, J IMMUNOL, V122, P1228; VALONE FH, 1983, IMMUNOLOGY, V48, P141; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765	36	52	52	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					83	90		10.1016/0091-6749(89)90480-6	http://dx.doi.org/10.1016/0091-6749(89)90480-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2536413				2022-12-18	WOS:A1989T041900011
J	BUSH, RK; SCHROECKENSTEIN, D; MEIERDAVIS, S; BALMES, J; REMPEL, D				BUSH, RK; SCHROECKENSTEIN, D; MEIERDAVIS, S; BALMES, J; REMPEL, D			SOYBEAN FLOUR ASTHMA - DETECTION OF ALLERGENS BY IMMUNOBLOTTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,DEPT MED,MADISON,WI 53706; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,OCCUPAT HLTH CLIN,SAN FRANCISCO,CA 94110	University of Wisconsin System; University of Wisconsin Madison; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	BUSH, RK (corresponding author), WILLIAM S MIDDLETON MEM VET ADM HOSP,ALLERGY SECT,2500 OVERLOOK TERR,MADISON,WI 53705, USA.		Balmes, John/L-6281-2019; Rempel, David/E-8424-2013					BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS SM, 1985, CHEST, V87, pS218, DOI 10.1378/chest.87.5_Supplement.218S; BUSH RK, 1977, CLIN ALLERGY, V7, P369, DOI 10.1111/j.1365-2222.1977.tb01465.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DUKE W. W., 1934, JOUR ALLERGY, V5, P300, DOI 10.1016/S0021-8707(34)90228-8; KROUTIL LA, 1987, J ALLERGY CLIN IMMUN, V80, P170, DOI 10.1016/0091-6749(87)90126-6; MOROZ LA, 1980, NEW ENGL J MED, V302, P1126, DOI 10.1056/NEJM198005153022005; OLSEN A. M., 1936, Proceedings of Staff Meetings of the Mayo Clinic, V11, P465; PETERS GA, 1965, ANN ALLERGY, V23, P270; PETRY RW, 1985, J ALLERGY CLIN IMMUN, V75, P268, DOI 10.1016/0091-6749(85)90056-9; RUBIN SS, 1940, J INDIANA, V33, P406; SHIBASAKI M, 1980, INT ARCH ALLER A IMM, V61, P441, DOI 10.1159/000232472; WIGHTMAN HENRY B., 1938, JOUR ALLERGY, V9, P601, DOI 10.1016/S0021-8707(38)90308-9	13	52	56	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					251	255		10.1016/0091-6749(88)91007-X	http://dx.doi.org/10.1016/0091-6749(88)91007-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	3042839				2022-12-18	WOS:A1988P874100017
J	CHUNG, KF; MINETTE, P; MCCUSKER, M; BARNES, PJ				CHUNG, KF; MINETTE, P; MCCUSKER, M; BARNES, PJ			KETOTIFEN INHIBITS THE CUTANEOUS BUT NOT THE AIRWAY RESPONSES TO PLATELET-ACTIVATING FACTOR IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CHUNG, KF (corresponding author), BROMPTON HOSP,INST CARDIOTHORAC,DEPT CLIN PHARMACOL THORAC MED,LONDON SW3 6HP,ENGLAND.		Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Barnes, Peter/0000-0002-5122-4018				ADACHI M, 1984, PHARMATHERAPEUTICA, V4, P36; ARCHER CB, 1985, BRIT J PHARMACOL, V85, P109, DOI 10.1111/j.1476-5381.1985.tb08836.x; BARNES PJ, 1981, J APPL PHYSIOL, V50, P1193, DOI 10.1152/jappl.1981.50.6.1193; BROBERGER U, 1986, CLIN ALLERGY, V16, P119, DOI 10.1111/j.1365-2222.1986.tb00755.x; CHUNG K F, 1987, American Review of Respiratory Disease, V135, pA181; CHUNG KF, 1986, J PHARMACOL EXP THER, V236, P580; CHUNG KF, 1987, LANCET, V1, P248; CLARKE CW, 1980, BRIT J CLIN PHARMACO, V10, P473, DOI 10.1111/j.1365-2125.1980.tb01791.x; CRAPS L, 1981, PHARMATHERAPEUTICA, V3, P18; CUSHLEY MJ, 1986, BRIT J CLIN PHARMACO, V22, P487, DOI 10.1111/j.1365-2125.1986.tb02923.x; CUSS FM, 1986, LANCET, V2, P189; DYSON AJ, 1980, BRIT MED J, V280, P360, DOI 10.1136/bmj.280.6211.360; ESAU S, 1984, J ALLERGY CLIN IMMUN, V74, P270, DOI 10.1016/0091-6749(84)90257-4; EVANS TW, 1987, J APPL PHYSIOL, V63, P479, DOI 10.1152/jappl.1987.63.2.479; GIRARD JP, 1981, CLIN ALLERGY, V11, P449, DOI 10.1111/j.1365-2222.1981.tb01618.x; GRAFFLONNEVIG V, 1985, J ALLERGY CLIN IMMUN, V76, P59, DOI 10.1016/0091-6749(85)90805-X; HALONEN M, 1985, AM REV RESPIR DIS, V131, P11; Kennedy G.R, 1982, RES CLIN FORUMS, V4, P17; LANE DJ, 1980, CLIN ALLERGY, V10, P519, DOI 10.1111/j.1365-2222.1980.tb02132.x; LEFORT J, 1984, BRIT J PHARMACOL, V82, P565, DOI 10.1111/j.1476-5381.1984.tb10795.x; LEWIS AJ, 1984, AGENTS ACTIONS, V15, P636, DOI 10.1007/BF01966785; LISBOA C, 1985, BRIT J DIS CHEST, V79, P235, DOI 10.1016/S0007-0971(85)80024-3; LOFTUS BG, 1987, J ALLERGY CLIN IMMUN, V79, P350, DOI 10.1016/0091-6749(87)90154-0; LOFTUS BG, 1985, CLIN ALLERGY, V15, P465, DOI 10.1111/j.1365-2222.1985.tb02296.x; MATTSON K, 1979, CLIN ALLERGY, V9, P495, DOI 10.1111/j.1365-2222.1979.tb02514.x; MATTSON K, 1979, CLIN ALLERGY, V9, P411, DOI 10.1111/j.1365-2222.1979.tb02500.x; MAZZONI L, 1985, British Journal of Pharmacology, V86, p571P; MAZZONI L, 1985, J PHYSL, V365, P107; Ney UM, 1982, RES CLIN FORUMS, V4, P9; PAGE CP, 1985, AGENTS ACTIONS, V16, P33, DOI 10.1007/BF01999637; TAMURA G, 1986, CLIN ALLERGY, V10, P535; TINKELMAN DG, 1985, J ALLERGY CLIN IMMUN, V76, P487, DOI 10.1016/0091-6749(85)90732-8; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; Zar JH, 1974, BIOSTATISTICAL ANAL	34	52	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1192	1198		10.1016/0091-6749(88)90890-1	http://dx.doi.org/10.1016/0091-6749(88)90890-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	3288683				2022-12-18	WOS:A1988P002300020
J	DAUL, CB; MORGAN, JE; WARING, NP; MCCANTS, ML; HUGHES, J; LEHRER, SB				DAUL, CB; MORGAN, JE; WARING, NP; MCCANTS, ML; HUGHES, J; LEHRER, SB			IMMUNOLOGICAL EVALUATION OF SHRIMP-ALLERGIC INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,MED CTR,DEPT MED,CLIN IMMUNOL & ALLERGY SECT,NEW ORLEANS,LA 70118; TULANE UNIV,MED CTR,DEPT PEDIAT,NEW ORLEANS,LA 70118	Tulane University; Tulane University					NIAID NIH HHS [AI-19266] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019266] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; AMLOT PL, 1985, INT ARCH ALLER A IMM, V77, P171, DOI 10.1159/000233776; BARNETSON RS, 1981, CLIN EXP IMMUNOL, V46, P54; BJORKSTEN B, 1983, ALLERGY, V38, P119, DOI 10.1111/j.1398-9995.1983.tb01595.x; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BOCK SA, 1983, J ALLERGY CLIN IMMUN, V72, P262, DOI 10.1016/0091-6749(83)90030-1; BOCKMAN DE, 1966, ANAT RECORD, V155, P603, DOI 10.1002/ar.1091550412; BRANDTZAEG P, 1977, NATURE, V266, P262, DOI 10.1038/266262a0; BUCKLEY RH, 1982, JAMA-J AM MED ASSOC, V248, P2627, DOI 10.1001/jama.248.20.2627; CEUPPENS JL, 1982, J IMMUNOL, V128, P2429; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; HALPERN GM, 1987, ANN ALLERGY, V58, P14; HEINER DC, 1962, AM J DIS CHILD, V103, P634, DOI 10.1001/archpedi.1962.02080020649003; MAY CD, 1980, ALLERGY, V35, P301, DOI 10.1111/j.1398-9995.1980.tb01771.x; MAY CD, 1977, CLIN ALLERGY, V7, P583, DOI 10.1111/j.1365-2222.1977.tb01489.x; METCALFE DD, 1984, J ALLERGY CLIN IMMUN, V73, P749, DOI 10.1016/0091-6749(84)90442-1; MINOR JD, 1980, J ALLERGY CLIN IMMUN, V66, P314, DOI 10.1016/0091-6749(80)90027-5; PAGNELLI R, 1983, ARCH DIS CHILD, V58, P201; PARISH WE, 1979, CLIN ALLERGY, V1, P369; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P227, DOI 10.1016/0091-6749(85)90048-X; Siegel S., 1956, NONPARAMETRIC STAT B; WALKER WA, 1984, NER ALLERGY P, V5, P237; WARING NP, 1985, J ALLERGY CLIN IMMUN, V76, P440, DOI 10.1016/0091-6749(85)90724-9; WRAITH DG, 1979, CLIN ALLERGY, V9, P25, DOI 10.1111/j.1365-2222.1979.tb01519.x	25	52	54	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1987	80	5					716	722		10.1016/0091-6749(87)90293-4	http://dx.doi.org/10.1016/0091-6749(87)90293-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K9930	3680815				2022-12-18	WOS:A1987K993000013
J	HEAVEY, DJ; KOBZABLACK, A; BARROW, SE; CHAPPELL, CG; GREAVES, MW; DOLLERY, CT				HEAVEY, DJ; KOBZABLACK, A; BARROW, SE; CHAPPELL, CG; GREAVES, MW; DOLLERY, CT			PROSTAGLANDIN-D2 AND HISTAMINE-RELEASE IN COLD URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL POSTGRAD MED SCH,DEPT CLIN PHARMACOL,LONDON W12 0HS,ENGLAND; INST DERMATOL,LONDON E9 6BX,ENGLAND	Imperial College London								AKIYAMA T, 1981, Journal of Dermatology (Tokyo), V8, P139; AOKI T, 1982, CLIN EXP DERMATOL, V7, P377, DOI 10.1111/j.1365-2230.1982.tb02445.x; BARROW SE, 1984, PROSTAGLANDINS, V28, P743, DOI 10.1016/0090-6980(84)90032-7; BENTLEYPHILLIPS CB, 1976, LANCET, V2, P63; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; FLOWER RJ, 1976, BRIT J PHARMACOL, V56, P229, DOI 10.1111/j.1476-5381.1976.tb07446.x; FULLER RW, 1984, THORAX, V39, P699; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; HEAVEY DJ, 1984, PROSTAGLANDINS, V28, P755, DOI 10.1016/0090-6980(84)90033-9; IND PW, 1982, AGENTS ACTIONS, V12, P12, DOI 10.1007/BF01965099; KAPLAN AP, 1981, NEW ENGL J MED, V305, P1074, DOI 10.1056/NEJM198110293051808; KAPLAN AP, 1979, J INVEST DERMATOL, V67, P327; KELLY FJ, 1953, AM J MED, V15, P431, DOI 10.1016/0002-9343(53)90132-6; LEWIS RA, 1982, J IMMUNOL, V129, P1627; MACDERMOT J, 1984, PROSTAGLANDINS, V27, P163, DOI 10.1016/0090-6980(84)90071-6; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; PETERS SP, 1984, J PHARMACOL EXP THER, V228, P400; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; SCHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; WANDERER AA, 1977, ARCH DERMATOL, V113, P1375, DOI 10.1001/archderm.113.10.1375; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P13, DOI 10.1016/0091-6749(71)90050-9; WASSERMAN SI, 1982, CLIN EXP IMMUNOL, V47, P570; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756	24	52	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1986	78	3	1				458	461		10.1016/0091-6749(86)90033-3	http://dx.doi.org/10.1016/0091-6749(86)90033-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E1148	2428856				2022-12-18	WOS:A1986E114800014
J	OLLIER, S; GOULD, CAL; DAVIES, RJ				OLLIER, S; GOULD, CAL; DAVIES, RJ			THE EFFECT OF SINGLE AND MULTIPLE DOSE THERAPY WITH AZELASTINE ON THE IMMEDIATE ASTHMATIC RESPONSE TO ALLERGEN PROVOCATION TESTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST BARTHOLOMEWS HOSP,ACAD DEPT RESP MED,W SMITHFIELD,LONDON EC1A 7BE,ENGLAND									BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/0007-0971(75)90090-X; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAND N, 1983, J ALLERGY CLIN IMMUN, V71, P149, DOI 10.1016/0091-6749(83)90365-2; CHAND N, 1983, EUR J PHARMACOL, V96, P227, DOI 10.1016/0014-2999(83)90311-4; DIAMANTIS W, 1984, Journal of Allergy and Clinical Immunology, V73, P184; FIELDS DAS, 1984, J ALLERGY CLIN IMMUN, V73, P400, DOI 10.1016/0091-6749(84)90415-9; KATAYAMA S, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1196; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; MOODLEY I, 1981, CLIN SCI, V62, P13; MORGAN DJR, 1985, CLIN SCI, V69, P63, DOI 10.1042/cs0690063; ZECHEL HJ, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1184	11	52	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1986	78	2					358	364		10.1016/S0091-6749(86)80090-2	http://dx.doi.org/10.1016/S0091-6749(86)80090-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D7261	3734289				2022-12-18	WOS:A1986D726100020
J	GREENBERGER, PA; HALWIG, JM; PATTERSON, R; WALLEMARK, CB				GREENBERGER, PA; HALWIG, JM; PATTERSON, R; WALLEMARK, CB			EMERGENCY ADMINISTRATION OF RADIOCONTRAST MEDIA IN HIGH-RISK PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,CTR CANC,BIOMETRY SECT,CHICAGO,IL 60611	Northwestern University	GREENBERGER, PA (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANSELL G, 1970, INVEST RADIOL, V5, P374, DOI 10.1097/00004424-197011000-00002; ELLULMICALLEF R, 1975, THORAX, V30, P312, DOI 10.1136/thx.30.3.312; FISCHER HW, 1972, RADIOLOGY, V103, P497, DOI 10.1148/103.3.497; GREENBERGER PA, 1981, J ALLERGY CLIN IMMUN, V67, P185, DOI 10.1016/0091-6749(81)90059-2; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P540, DOI 10.1016/0091-6749(84)90391-9; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; SAAVEDRADELGADO AMP, 1980, J ALLERGY CLIN IMMUN, V66, P464, DOI 10.1016/0091-6749(80)90007-X; SCHATZ M, 1975, J ALLERGY CLIN IMMUN, V55, P358, DOI 10.1016/0091-6749(75)90007-X; WEINER N, 1980, PHARM BASIS THERAPEU, P157; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832; WITTEN DM, 1975, JAMA-J AM MED ASSOC, V231, P974; WOLFROMM R, 1966, J RADIOL ELEC MED N, V47, P346; ZWEIMAN B, 1975, ANN INTERN MED, V83, P158	13	52	55	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1986	77	4					630	634		10.1016/0091-6749(86)90357-X	http://dx.doi.org/10.1016/0091-6749(86)90357-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A9381	3958391				2022-12-18	WOS:A1986A938100017
J	HOFFMAN, DR				HOFFMAN, DR			ALLERGENS IN HYMENOPTERA VENOM .15. THE IMMUNOLOGICAL BASIS OF VESPID VENOM CROSS-REACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HOFFMAN, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL,GREENVILLE,NC 27834, USA.							GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P57; HOFFMAN DR, 1980, ANN ALLERGY, V45, P276; HOFFMAN DR, 1979, ANN ALLERGY, V43, P211; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P606, DOI 10.1016/0091-6749(85)90037-5; HOFFMAN DR, 1981, ANN ALLERGY, V47, P304; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1	10	52	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	5					611	613		10.1016/0091-6749(85)90038-7	http://dx.doi.org/10.1016/0091-6749(85)90038-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AHV07	2580878				2022-12-18	WOS:A1985AHV0700012
J	PERDUE, MH; GALL, DG				PERDUE, MH; GALL, DG			TRANSPORT ABNORMALITIES DURING INTESTINAL ANAPHYLAXIS IN THE RAT - EFFECT OF ANTIALLERGIC AGENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALGARY,FAC MED,INTESTINAL DIS RES UNIT,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary								AUGUSTIN R, 1972, HDB EXPT IMMUNOLOGY; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; CASTRO GA, 1982, AM J PHYSL G, V243, P321; COOKE HJ, 1984, AM J PHYSIOL, V246, P372; DOBBINS JW, 1981, CLIN GASTROENTEROL, V10, P605; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P313, DOI 10.1111/apm.1966.66.3.313; Enerback L., 1981, MONOGR ALLERGY, V17, P222; FIELD M, 1984, J ALLERGY CLIN IMMUN, V74, P382, DOI 10.1016/0091-6749(84)90135-0; ISHIZAKA T, 1975, PROG ALLERGY, V19, P60, DOI 10.1159/000313384; LINAKER BD, 1981, GUT, V22, P964, DOI 10.1136/gut.22.11.964; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAROM Z, 1983, ANN ALLERGY, V50, P367; PEARCE FL, 1982, J IMMUNOL, V128, P2481; PERDUE MH, 1984, GASTROENTEROLOGY, V86, P391; PERDUE MH, 1984, GASTROENTEST LIV S10, V247, P632; YOUNOSZAI MK, 1978, J CLIN INVEST, V62, P271, DOI 10.1172/JCI109126	16	52	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	3					498	503		10.1016/0091-6749(85)90733-X	http://dx.doi.org/10.1016/0091-6749(85)90733-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ARC09	2863297				2022-12-18	WOS:A1985ARC0900013
J	SHEFFER, AL				SHEFFER, AL			ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ADKINSON NF, 1984, J ALLERGY CLIN IMMUN, V74, P567, DOI 10.1016/0091-6749(84)90108-8; CRADDOCK PR, 1977, NEW ENGL J MED, V296, P769, DOI 10.1056/NEJM197704072961401; DRAZEN JM, 1975, J APPL PHYSIOL, V38, P834, DOI 10.1152/jappl.1975.38.5.834; FEARON DT, 1980, NEW ENGL J MED, V303, P259, DOI 10.1056/NEJM198007313030505; FEINBERG AR, 1956, J ALLERGY, V27, P437, DOI 10.1016/0021-8707(56)90103-4; HALPERN BN, 1967, IMMUNOLOGY, V12, P247; JAMES LP, 1964, NEW ENGL J MED, V270, P597, DOI 10.1056/NEJM196403192701202; JICK H, 1984, J ALLERGY CLIN IMMUN, V74, P555, DOI 10.1016/0091-6749(84)90106-4; KERN RA, 1953, AM J MED SCI, V226, P357, DOI 10.1097/00000441-195310000-00001; KIDD J, 1982, Journal of Allergy and Clinical Immunology, V69, P103; KNAVER KA, 1981, N ENGL J MED, V304, P1414; Lamson R., 1929, JAMA-J AM MED ASSOC, V93, P1775; Lamson R.W., 1924, JAMA-J AM MED ASSOC, V82, P1091; LEVI R, 1984, CIRC RES, V54, P117, DOI 10.1161/01.RES.54.2.117; LEVI R, 1980, DRUG INDUCED HEART D, P337; LEVINE BB, 1973, NEW ENGL J MED, V288, P894, DOI 10.1056/NEJM197304262881707; LEVINE BB, 1966, NEW ENGL J MED, V275, P1115, DOI 10.1056/NEJM196611172752009; LEVINE HD, 1976, AM HEART J, V91, P365, DOI 10.1016/S0002-8703(76)80222-0; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; Lund H, 1941, ARCH PATHOL, V32, P664; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P57; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; MCMANUS LM, 1980, J IMMUNOL, V124, P2919; METCALFE DD, 1984, J ALLERGY CLIN IMMUN, V73, P749, DOI 10.1016/0091-6749(84)90442-1; PARKER CW, 1963, AM J MED, V34, P747, DOI 10.1016/0002-9343(63)90083-4; PARKER CW, 1972, CRITICAL REV TOXICOL, V1, P261; Portier P, 1902, CR SEANC SOC BIOL, V54, P170; RATNOFF OD, 1983, BLOOD, V61, P132; SALE SR, 1981, JAMA-J AM MED ASSOC, V246, P2336, DOI 10.1001/jama.246.20.2336; SHEFFER AL, 1984, J ALLERGY CLIN IMMUN, V73, P699, DOI 10.1016/0091-6749(84)90309-9; SHEFFER AL, 1983, J ALLERGY CLIN IMMUN, V71, P311, DOI 10.1016/0091-6749(83)90085-4; SHEFFER AL, 1979, RHEUMATOLOGY IMMUNOL, V4, P468; SHEFFER AL, 1984, EMERGENCY MED, P163; SULLIVAN TJ, 1984, J ALLERGY CLIN IMMUN, V74, P594, DOI 10.1016/0091-6749(84)90112-X; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; VYAS GN, 1968, LANCET, V2, P312; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P366, DOI 10.1016/0091-6749(71)90083-2; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2	38	52	52	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	2					227	233		10.1016/0091-6749(85)90048-X	http://dx.doi.org/10.1016/0091-6749(85)90048-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABZ05	3968334				2022-12-18	WOS:A1985ABZ0500001
J	SAARINEN, UM				SAARINEN, UM			TRANSFER OF LATENT ATOPY BY BONE-MARROW TRANSPLANTATION - A CASE-REPORT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV HELSINKI,CHILDRENS HOSP,SF-00170 HELSINKI 17,FINLAND	University of Helsinki								GALE RP, 1978, TRANSPLANT P, V10, P223; GEHA RS, 1980, J ALLERGY CLIN IMMUN, V66, P78, DOI 10.1016/0091-6749(80)90142-6; HANSEL FK, 1953, CLIN ALLERGY, P408; LUM LG, 1981, BLOOD, V58, P431; PAHWA SG, 1982, P NATL ACAD SCI-BIOL, V79, P2663, DOI 10.1073/pnas.79.8.2663; RINGDEN O, 1983, BLOOD, V61, P1190; STORB R, 1976, TRANSPLANT P, V8, P637; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; WITHERSPOON RP, 1978, TRANSPLANTATION, V26, P407, DOI 10.1097/00007890-197812000-00008; WITHERSPOON RP, 1981, BLOOD, V58, P360; WITHERSPOON RP, 1982, BLOOD, V59, P844	11	52	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	2					196	200		10.1016/0091-6749(84)90286-0	http://dx.doi.org/10.1016/0091-6749(84)90286-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE226	6379019				2022-12-18	WOS:A1984TE22600014
J	THARP, MD; THIRLBY, R; SULLIVAN, TJ				THARP, MD; THIRLBY, R; SULLIVAN, TJ			GASTRIN INDUCES HISTAMINE-RELEASE FROM HUMAN CUTANEOUS MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,HLTH SCI CTR,DEPT SURG,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas	THARP, MD (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT DERMATOL,DALLAS,TX 75235, USA.							BEFUS AD, 1982, J IMMUNOL, V128, P2475; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; COLLINSW.C, 1965, INT ARCH ALLER A IMM, V27, P110, DOI 10.1159/000229604; Douglas W. W., 1980, PHARMACOL BASIS THER, P609; Edkins JS, 1905, P R SOC LOND B-CONTA, V76, P376, DOI 10.1098/rspb.1905.0029; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; GREGORY RA, 1964, GUT, V5, P107; HAKANSON R, 1970, EUR J PHARMACOL, V12, P94, DOI 10.1016/0014-2999(70)90033-6; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LIPSITZ LA, 1983, NEW ENGL J MED, V309, P81, DOI 10.1056/NEJM198307143090205; MAIN IHM, 1982, BRIT J PHARMACOL, V76, P51, DOI 10.1111/j.1476-5381.1982.tb09190.x; MAN WK, 1981, GUT, V22, P916, DOI 10.1136/gut.22.11.916; MICHAELSSON G, 1973, BRIT J DERMATOL, V88, P525, DOI 10.1111/j.1365-2133.1973.tb08014.x; MORELY JS, 1968, P ROY SOC B, V170, P97; NORMAN PS, 1978, ALLERGY PRINCIPLES P, P256; NOVEY HS, 1983, J ALLERGY CLIN IMMUN, V71, P498, DOI 10.1016/0091-6749(83)90468-2; PARKER CW, 1962, J EXP MED, V115, P821, DOI 10.1084/jem.115.4.821; PEARCE FL, 1982, J IMMUNOL, V128, P2481; RAZIN E, 1982, J BIOL CHEM, V257, P7229; RICHARDSON CT, 1976, J CLIN INVEST, V58, P623, DOI 10.1172/JCI108509; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROSENGREN E, 1969, J PHYSIOL-LONDON, V205, P275, DOI 10.1113/jphysiol.1969.sp008964; ROSENQUIST GL, 1980, GASTROINTESTINAL HOR, P769; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SHAPIRO J, 1964, P WORLD FORUM SYPHIL, P328; SNYDER SH, 1966, J PHARMACOL EXP THER, V153, P544; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P260, DOI 10.1016/S0091-6749(82)80002-X; THARP MD, 1983, J IMMUNOL, V130, P1896; TRACY HJ, 1964, NATURE, V204, P935, DOI 10.1038/204935a0; WALSH JH, 1975, NEW ENGL J MED, V292, P1324, DOI 10.1056/NEJM197506192922505; WALSH JH, 1980, PHYSL GASTROINTESTIN, P59	34	52	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	2					159	165		10.1016/0091-6749(84)90280-X	http://dx.doi.org/10.1016/0091-6749(84)90280-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE226	6205035				2022-12-18	WOS:A1984TE22600008
J	METZGER, WJ; DONNELLY, A; RICHERSON, HB				METZGER, WJ; DONNELLY, A; RICHERSON, HB			MODIFICATION OF LATE ASTHMATIC RESPONSES (LAR) DURING IMMUNOTHERAPY FOR ALTERNARIA-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	52	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					119	119		10.1016/0091-6749(83)90245-2	http://dx.doi.org/10.1016/0091-6749(83)90245-2			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ462		Bronze			2022-12-18	WOS:A1983PZ46200122
J	BURGE, HA; SOLOMON, WR; MUILENBERG, ML				BURGE, HA; SOLOMON, WR; MUILENBERG, ML			EVALUATION OF INDOOR PLANTINGS AS ALLERGEN EXPOSURE SOURCES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BURGE, HA (corresponding author), UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.				NIAID NIH HHS [AI-10181] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSEN AA, 1958, J BACTERIOL, V76, P471, DOI 10.1128/JB.76.5.471-484.1958; BENAIM C, 1973, ANN ALLERGY, V31, P618; BROWN RM, 1964, SCIENCE, V143, P583, DOI 10.1126/science.143.3606.583; CHO JJ, 1975, PHYTOPATHOLOGY, V65, P425, DOI 10.1094/Phyto-65-425; KOZAK PP, 1980, ANN ALLERGY, V45, P167; MCDONALD JL, 1975, J ALLERGY CLIN IMMUN, V55, P89; SOLOMON WR, 1980, J ALLERGY CLIN IMMUN, V65, P305, DOI 10.1016/0091-6749(80)90160-8; SOLOMON WR, 1978, J ALLERGY CLIN IMMUN, V62, P56, DOI 10.1016/0091-6749(78)90073-8; SOLOMON WR, 1975, J ALLERGY CLIN IMMUN, V56, P235, DOI 10.1016/0091-6749(75)90095-0; SOLOMON WR, 1979, US IBP SYNTHESIS SER, V10; STAIB F, 1980, PRAX KLIN PNEUMOL, V34, P732; STAIB F, 1978, MYCOPATHOLOGIA, V66, P27, DOI 10.1007/BF00429589; STAIB F, 1980, HYGIENE MED, V11, P575; STAIB F, 1979, DTSCH MED WOCHENSCHR, V33, P1176; STAIB F, 1978, BUNDESGESUNDHEITSBLA, V26, P471; 1967, ALLERGY ITS MYSTERIO	16	52	53	1	11	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	2					101	108		10.1016/0091-6749(82)90236-6	http://dx.doi.org/10.1016/0091-6749(82)90236-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PB591	7096819	Bronze			2022-12-18	WOS:A1982PB59100005
J	ZEISS, CR; WOLKONSKY, P; PRUZANSKY, JJ; PATTERSON, R				ZEISS, CR; WOLKONSKY, P; PRUZANSKY, JJ; PATTERSON, R			CLINICAL AND IMMUNOLOGICAL EVALUATION OF TRIMELLITIC ANHYDRIDE WORKERS IN MULTIPLE INDUSTRIAL SETTINGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University	ZEISS, CR (corresponding author), VET ADM LAKESIDE MED CTR,CHICAGO,IL 60611, USA.				NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMAD D, 1979, LANCET, V2, P328; BERNSTEIN DI, 1982, J ALLERGY CLIN IMMUN, V69, P311, DOI 10.1016/S0091-6749(82)80009-2; PATTERSON R, 1979, AM REV RESPIR DIS, V120, P1259; PATTERSON R, 1978, J CLIN INVEST, V62, P971, DOI 10.1172/JCI109226; SALE SR, 1981, J ALLERGY CLIN IMMUN, V68, P188, DOI 10.1016/0091-6749(81)90182-2; TURNER ES, 1980, CLIN EXP IMMUNOL, V39, P470; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1980, INT ARCH ALLER A IMM, V61, P380	8	52	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	1					15	18		10.1016/0091-6749(82)90195-6	http://dx.doi.org/10.1016/0091-6749(82)90195-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NY715	7085999	Bronze			2022-12-18	WOS:A1982NY71500006
J	FALLERONI, AE; ZEISS, CR; LEVITZ, D				FALLERONI, AE; ZEISS, CR; LEVITZ, D			OCCUPATIONAL ASTHMA SECONDARY TO INHALATION OF GARLIC DUST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									NORTHWESTERN UNIV, SCH MED, DEPT MED, ALLERGY & IMMUNOL SECT, CHICAGO, IL 60611 USA	Northwestern University					NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLEUMINK E, 1972, BRIT J DERMATOL, V87, P6, DOI 10.1111/j.1365-2133.1972.tb05089.x; BURGESS JF, 1952, CAN MED ASSOC J, V66, P275; BURKS J. W., 1954, ANN ALLERGY, V12, P592; BUSH RK, 1977, CLIN ALLERGY, V7, P369, DOI 10.1111/j.1365-2222.1977.tb01465.x; EDELSTEIN AJ, 1950, ARCH DERMATOL SYPH, V61, P111, DOI 10.1001/archderm.1950.01530080117013; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HENSON G. E., 1940, JOUR FLORIDA MED ASSOC, V27, P86; Hjorth N, 1976, Contact Dermatitis, V2, P28, DOI 10.1111/j.1600-0536.1976.tb02975.x; MAIBACH H, 1976, ARCH DERMATOL, V112, P1289, DOI 10.1001/archderm.112.9.1289; PATTERSON R, 1978, J IMMUNOL, V120, P66; PEPYS J, 1978, ALLERGY PRINCIPLES P, P815; SINHA SM, 1977, ARCH DERMATOL, V113, P776, DOI 10.1001/archderm.113.6.776; VANKETEL WG, 1978, CONTACT DERMATITIS, V4, P167, DOI 10.1111/j.1600-0536.1978.tb03767.x	13	52	52	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	2					156	160		10.1016/0091-6749(81)90173-1	http://dx.doi.org/10.1016/0091-6749(81)90173-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MD162	7252000				2022-12-18	WOS:A1981MD16200011
J	GOLDEN, DBK; KAGEYSOBOTKA, A; VALENTINE, MD; LICHTENSTEIN, LM				GOLDEN, DBK; KAGEYSOBOTKA, A; VALENTINE, MD; LICHTENSTEIN, LM			PROLONGED MAINTENANCE INTERVAL IN HYMENOPTERA VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GOLDEN, DBK (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.				NIAID NIH HHS [AI 08270] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P247, DOI 10.1016/0091-6749(77)90158-0; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; PATTERSON R, 1978, ALLERGY PRINCIPLES P, P887; SOBOTKA AK, 1976, J IMMUNOL, V117, P84	12	52	54	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	6					482	484		10.1016/0091-6749(81)90102-0	http://dx.doi.org/10.1016/0091-6749(81)90102-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LU068	7346532	Bronze			2022-12-18	WOS:A1981LU06800010
J	THOMSON, NC; ROBERTS, R; BANDOUVAKIS, J; NEWBALL, H; HARGREAVE, FE				THOMSON, NC; ROBERTS, R; BANDOUVAKIS, J; NEWBALL, H; HARGREAVE, FE			COMPARISON OF BRONCHIAL RESPONSES TO PROSTAGLANDIN-F2-ALPHA AND METHACHOLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,FIRESTONE REG CHEST & ALLERGY UNIT,HAMILTON L8N 1Y4,ONTARIO,CANADA; MCMASTER UNIV,HAMILTON L8S 4L8,ONTARIO,CANADA; JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21218	McGill University; McMaster University; McMaster University; Johns Hopkins University				Thomson, Neil/0000-0003-1632-6630				BLEECKER ER, 1979, J ALLERGY CLIN IMMUN, V64, P597, DOI 10.1016/0091-6749(79)90020-4; CASTERLINE CL, 1977, J ALLERGY CLIN IMMUN, V59, P420, DOI 10.1016/0091-6749(77)90004-5; CASTERLINE CL, 1976, J ALLERGY CLIN IMMUN, V58, P607, DOI 10.1016/0091-6749(76)90207-4; DANIEL EE, 1980, AIRWAY REACTIVITY, P80; EISER NM, 1980, CLIN SCI, V58, P537, DOI 10.1042/cs0580537; HARGREAVE FE, 1980, AIRWAY REACTIVITY ME, P216; HOLTSMAN ML, 1980, AM REV RESPIR DIS, V112, P17; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; LOPEZVIDRIERO MT, 1977, THORAX, V32, P734, DOI 10.1136/thx.32.6.734; MATHE AA, 1975, AM REV RESPIR DIS, V111, P313; MATHE AA, 1973, BRIT MED J, V1, P193, DOI 10.1136/bmj.1.5847.193; MATHE AA, 1977, NEW ENGL J MED, V296, P850, DOI 10.1056/NEJM197704142961505; NEWBALL HH, 1977, RESP PHYSIOL, V30, P125, DOI 10.1016/0034-5687(77)90026-3; NEWBALL HH, 1980, RESP PHYSIOL, V41, P183, DOI 10.1016/0034-5687(80)90051-1; NOGRADY SG, 1978, THORAX, V33, P700, DOI 10.1136/thx.33.6.700; OREHEK J, 1981, AM REV RESPIR DIS, V123, P269; OREHEK J, 1977, J ALLERGY CLIN IMMUN, V59, P414, DOI 10.1016/0091-6749(77)90003-3; PARANTAINEN J, 1980, CLIN ALLERGY, V10, P181, DOI 10.1111/j.1365-2222.1980.tb02095.x; PATEL KR, 1975, BRIT MED J, V2, P360, DOI 10.1136/bmj.2.5967.360; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; SMITH AP, 1975, CLIN SCI MOL MED, V48, P421, DOI 10.1042/cs0480421; SNAPPER JR, 1979, J APPL PHYSIOL, V47, P13, DOI 10.1152/jappl.1979.47.1.13; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; SZEZKLIK A, 1977, RESPIRATION, V34, P323; TAYLOR P, 1980, PHARMACOL BASIS THER, P92; THOMSON NC, 1979, CLIN SCI, V56, P235, DOI 10.1042/cs0560235; THOMSON NC, 1980, THORAX, V35, P428, DOI 10.1136/thx.35.6.428; WOENNE R, 1978, J ALLERGY CLIN IMMUN, V62, P119, DOI 10.1016/0091-6749(78)90089-1	29	52	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	5					392	398		10.1016/0091-6749(81)90138-X	http://dx.doi.org/10.1016/0091-6749(81)90138-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MQ454	7299003				2022-12-18	WOS:A1981MQ45400008
J	RUFFIN, RE; COCKCROFT, DW; HARGREAVE, FE				RUFFIN, RE; COCKCROFT, DW; HARGREAVE, FE			COMPARISON OF PROTECTIVE EFFECT OF FENOTEROL AND SCH-1000 ON ALLERGEN-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,REG CHEST & ALLERGY UNIT,HAMILTON L8N 1Y4,ONTARIO,CANADA; MCMASTER UNIV,HAMILTON L8S 4L8,ONTARIO,CANADA	McGill University; McMaster University; McMaster University								ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/0007-0971(75)90090-X; BOOIJNOORD H, 1972, INT J CLIN PHARM S4, V6, P69; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FISH JE, 1977, AM REV RESPIR DIS, V115, P371; GOLD WM, 1972, J APPL PHYSIOL, V33, P719, DOI 10.1152/jappl.1972.33.6.719; JORDE W, 1972, INT J CLIN PHARM S4, V6, P73; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; ROSENTHAL RR, 1977, J APPL PHYSIOL, V42, P600, DOI 10.1152/jappl.1977.42.4.600; RUFFIN RJ, UNPUBLISHED; Snedecor G.W., 1980, STAT METHODS, V7; SVEDMYR NLV, 1976, CHEST, V69, P479, DOI 10.1378/chest.69.4.479; TRENDELENBURG U, 1963, PHARMACOL REV, V15, P225; YU DYC, 1972, J APPL PHYSIOL, V32, P823, DOI 10.1152/jappl.1972.32.6.823	17	52	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	1					42	47		10.1016/0091-6749(78)90472-4	http://dx.doi.org/10.1016/0091-6749(78)90472-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH112	145449				2022-12-18	WOS:A1978EH11200007
J	BUTCHER, BT; SALVAGGIO, JE; ONEIL, CE; WEILL, H; GARG, O				BUTCHER, BT; SALVAGGIO, JE; ONEIL, CE; WEILL, H; GARG, O			TOLUENE DIISOCYANATE PULMONARY-DISEASE - IMMUNOPHARMACOLOGIC AND MECHOLYL CHALLENGE STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV, MED CTR, DEPT MED, CLIN IMMUNOL, NEW ORLEANS, LA 70112 USA	Tulane University								AVERY SB, 1969, CLIN EXP IMMUNOL, V4, P585; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P9; BRUGSCH HG, 1963, NEW ENGL J MED, V268, P353, DOI 10.1056/NEJM196302142680705; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; DAVIS TRA, 1967, ARCH ENVIRON HEALTH, V15, P412, DOI 10.1080/00039896.1967.10664942; FUCHS S, 1951, Arch Mal Prof, V12, P191; KONZEN RB, 1966, AM IND HYG ASSOC J, V27, P121, DOI 10.1080/00028896609342803; MALKIEL S, 1967, P SOC EXP BIOL MED, V125, P565; MANN S P, 1971, Histochemical Journal, V3, P319, DOI 10.1007/BF01005014; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MCGEADY S, 1968, J ALLERGY, V41, P108; MURRAY J, 1965, FED PROC, V24, P444; OULLETTE JJ, 1967, J ALLERGY, V39, P160; PARISH WE, 1973, ASTHMA PHYSIOLOGY IM, P297; PETERS J M, 1970, Archives of Environmental Health, V20, P364; SCHAYER RW, 1952, J BIOL CHEM, V199, P245; SCHEEL L D, 1964, Am Ind Hyg Assoc J, V25, P179, DOI 10.1080/00028896409342574; SCHILD HO, 1951, LANCET, V261, P376; SCHWARZ, 1974, PROCEDURES RADIOIMMU; STEVENSON DD, 1975, ARCH INTERN MED, V135, P777, DOI 10.1001/archinte.135.6.777; SZENTIVANYI A, 1963, J INFECT DIS, V113, P86, DOI 10.1093/infdis/113.2.86; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; SZENTIVANYI A, 1965, IMMUNOLOGIC DISEASES; SZENTIVANYI A, 1969, IMMUNOPHARMACOLOGY P; SZENTIVANYI A, 1966, PATHOGENESE THERAPIE; TAYLOR G, 1970, P ROY SOC MED, V63, P379, DOI 10.1177/003591577006300421; TOWNLEY RG, 1967, J ALLERGY, V39, P177, DOI 10.1016/0021-8707(67)90036-6; TOWNLEY RG, 1976, J ALLERGY CLIN IMMUN, V57, P358, DOI 10.1016/0091-6749(76)90093-2; VANERT M, 1975, ANN ALLERGY, V35, P142; Weill H, 1975, Environ Health Perspect, V11, P101	30	52	52	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	3					223	227		10.1016/0091-6749(77)90153-1	http://dx.doi.org/10.1016/0091-6749(77)90153-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	CZ249	65373	Bronze			2022-12-18	WOS:A1977CZ24900006
J	TARLO, SM; COCKCROFT, DW; DOLOVICH, J; HARGREAVE, FE				TARLO, SM; COCKCROFT, DW; DOLOVICH, J; HARGREAVE, FE			BECLOMETHASONE DIPROPIONATE AEROSOL IN PERENNIAL RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,HAMILTON,ONTARIO,CANADA; ST JOSEPHS HOSP,DEPT PEDIAT,HAMILTON,ONTARIO,CANADA; MCMASTER UNIV,MED CTR,HAMILTON 16,ONTARIO,CANADA	McGill University; McMaster University; McGill University; McMaster University; McMaster University				Tarlo, Susan/0000-0002-4746-5310				ARCHER G J, 1975, Clinical Allergy, V5, P285, DOI 10.1111/j.1365-2222.1975.tb01864.x; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHATTERJEE S S, 1974, Clinical Allergy, V4, P343, DOI 10.1111/j.1365-2222.1974.tb01395.x; COCKCROFT DW, 1976, CAN MED ASSOC J, V115, P523; FRANKLAND A W, 1975, Clinical Allergy, V5, P295, DOI 10.1111/j.1365-2222.1975.tb01866.x; GIBSON GJ, 1974, BRIT MED J, V4, P503, DOI 10.1136/bmj.4.5943.503; LAL S, 1975, POSTGRAD MED J, V51, P105; MICHELS MI, 1967, ANN ALLERGY, V25, P569; MORRISONSMITH J, 1975, BRIT MED J, V2, P255; Morrow-Brown HM, 1974, CLIN ALLERGY, V4, P331; MYGIND N, 1973, BRIT MED J, V4, P464, DOI 10.1136/bmj.4.5890.464; NORMAN PS, 1967, J ALLERGY, V40, P57, DOI 10.1016/0021-8707(67)90060-3; NORMAN PS, 1966, J ALLERGY, V38, P93, DOI 10.1016/0021-8707(66)90048-7; TAYLOR G, 1971, Clinical Allergy, V1, P63, DOI 10.1111/j.1365-2222.1971.tb02448.x; 1974, LANCET, V2, P303	15	52	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	3					232	236		10.1016/0091-6749(77)90155-5	http://dx.doi.org/10.1016/0091-6749(77)90155-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CZ249	838992				2022-12-18	WOS:A1977CZ24900008
J	BUCKLE, FG; COHEN, AB				BUCKLE, FG; COHEN, AB			NASAL MUCOSAL HYPERPERMEABILITY TO MACROMOLECULES IN ATOPIC RHINITIS AND EXTRINSIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA; UNIV CALIF,CARDIOVASC RES INST,SAN FRANCISCO,CA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco								BRADLEY JV, 1968, DISTRIBUTION FREE ST, P129; BRADLEY JV, 1968, DISTRIBUTION FREE ST, P195; CALLERAME ML, 1971, J ALLERGY, V47, P187, DOI 10.1016/S0091-6749(71)80464-5; CALLERAME ML, 1971, NEW ENGL J MED, V284, P459, DOI 10.1056/NEJM197103042840902; DITTMER DS, 1961, BLOOD OTHER BODY FLU, P1; GERBER MA, 1971, AM J PATHOL, V62, P339; ISHIZAKA K, 1970, J ALLERGY, V46, P197, DOI 10.1016/0021-8707(70)90023-7; JOHANSSO.SG, 1967, LANCET, V2, P951; LESKOWITZ S, 1972, Clinical Allergy, V2, P237, DOI 10.1111/j.1365-2222.1972.tb01288.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MINDEN P, 1967, HDB EXPT IMMUNOLOGY, P463; SALVAGGIO JE, 1964, J ALLERGY, V35, P62, DOI 10.1016/0021-8707(64)90050-4; SALVAGGIO JE, 1965, INT ARCH ALLER A IMM, V26, P264, DOI 10.1159/000229578	13	52	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	4					213	221		10.1016/0091-6749(75)90139-6	http://dx.doi.org/10.1016/0091-6749(75)90139-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	W1385	1123493				2022-12-18	WOS:A1975W138500001
J	OHMAN, JL; LOWELL, FC; BLOCH, KJ				OHMAN, JL; LOWELL, FC; BLOCH, KJ			ALLERGENS OF MAMMALIAN ORIGIN - CHARACTERIZATION OF ALLERGEN EXTRACTED FROM CAT PELTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,MED SCH,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,MED SERVAALLERGY UNIT,BOSTON,MA 02114; MASSACHUSSETTS GEN HOSP,MED SERV,IMMUNOL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,MED SERV,ARTHRITIS UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital								AAS K, 1967, INT ARCH ALLER A IMM, V31, P239, DOI 10.1159/000229873; AAS K, 1967, INT ARCH ALLER A IMM, V32, P1, DOI 10.1159/000229911; AUGUSTIN R, 1959, IMMUNOLOGY, V2, P230; BELIN L, 1972, INT ARCH ALLER A IMM, V42, P329, DOI 10.1159/000230616; Berrens L, 1970, Rev Allergy, V24, P917; BESCHE DA, 1923, AM J MED SCI, V166, P265; CESKA M, 1972, INT ARCH ALLER A IMM, V43, P427, DOI 10.1159/000230859; CESKA M, 1972, INT ARCH ALLER A IMM, V43, P419, DOI 10.1159/000230858; CESKA M, 1972, INT ARCH ALLER A IMM, V42, P430, DOI 10.1159/000230623; CHRAMBACH A, 1971, SCIENCE, V172, P440, DOI 10.1126/science.172.3982.440; CURRAN WS, 1961, ANN INTERN MED, V55, P777, DOI 10.7326/0003-4819-55-5-777; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FONTANA VJ, 1963, J ALLERGY, V34, P348, DOI 10.1016/0021-8707(63)90052-2; Forster GF, 1928, J EXP MED, V47, P903, DOI 10.1084/jem.47.6.903; GUTMAN AA, 1972, ALLERGIC DISEASES DI; JOHNSON P, 1965, EUR POLYM J, V1, P63; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LAURELL CB, 1965, SCAND J CLIN LAB INV, V17, P271, DOI 10.3109/00365516509075347; Longcope WT, 1925, J IMMUNOL, V10, P599; Longcope WT, 1926, J IMMUNOL, V11, P253; MALLEY A, 1962, J ALLERGY, V33, P84, DOI 10.1016/0021-8707(62)90067-9; O'Brien DP, 1926, J IMMUNOL, V11, P271; OVARY Z, 1963, J EXP MED, V117, P951, DOI 10.1084/jem.117.6.951; RATHER B, 1929, ARCH PATHOL, V8, P635; SALTER HH, 1864, ASTHMA; SQUIRE JR, 1950, CLIN SCI, V9, P127; STANWORTH DR, 1957, BIOCHEM J, V65, P582, DOI 10.1042/bj0650582; TUFT L, 1935, J ALLERGY, V6, P25; VARGA JM, 1972, INT ARCH ALLER A IMM, V42, P438, DOI 10.1159/000230624; WIDE L, 1967, LANCET, V2, P1105	31	52	53	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	4					231	241		10.1016/0091-6749(73)90061-4	http://dx.doi.org/10.1016/0091-6749(73)90061-4			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q9817	4742068	Bronze			2022-12-18	WOS:A1973Q981700005
J	Ozcurumez, MK; Ambrosch, A; Frey, O; Haselmann, V; Holdenrieder, S; Kiehntopf, M; Neumaier, M; Walter, M; Wenzel, F; Wolfel, R; Renz, H				Oezcueruemez, Mustafa K.; Ambrosch, Andreas; Frey, Oliver; Haselmann, Verena; Holdenrieder, Stefan; Kiehntopf, Michael; Neumaier, Michael; Walter, Michael; Wenzel, Folker; Woelfel, Roman; Renz, Harald		COVID-19 Task Force German Soc	SARS-CoV-2 antibody testing-questions to be asked	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antibody response; COVID-19; diagnostic pathway; external quality assurance; immunity; immunoassay; neutralization assay; respiratory tract infections; serologic tests; severe acute respiratory syndrome coronavirus 2	CORONAVIRUSES; COVID-19	Severe acute respiratory syndrome coronavirus 2 infection and development of coronavirus disease 2019 presents a major health care challenge of global dimensions. Laboratory diagnostics of infected patients, and the assessment of immunity against severe acute respiratory syndrome coronavirus 2, presents a major cornerstone in handling the pandemic. Currently, there is an increase in demand for antibody testing and a large number of tests are already marketed or are in the late stage of development. However, the interpretation of test results depends on many variables and factors, including sensitivity, specificity, potential cross-reactivity and cross-protectivity, the diagnostic value of antibodies of different isotypes, and the use of antibody testing in identification of acutely ill patients or in epidemiological settings. In this article, the recently established COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) addresses these issues on the basis of currently available data sets in this rapidly moving field.	[Oezcueruemez, Mustafa K.] Ruhr Univ, Dept Lab Med, Med Clin, Univ Med Ctr Knappschaftskrankenhaus Bochum, Schornau 23-25, D-44892 Bochum, Germany; [Ambrosch, Andreas] Barmherzige Bruder Hosp, Inst Lab Med Microbiol & Hyg, Regensburg, Germany; [Frey, Oliver] Brandenburg Med Sch, Inst Lab Med, Brandenburg, Germany; [Frey, Oliver] Inst Med Diagnost, Berlin, Germany; [Haselmann, Verena; Neumaier, Michael] Heidelberg Univ, Inst Med Diagnost, Univ Med Mannheim, Med Fac Mannheim, Berlin, Germany; [Holdenrieder, Stefan] Tech Univ Munich, Inst Lab Med, German Heart Ctr, Munich, Germany; [Kiehntopf, Michael] Jena Univ Hosp, Dept Clin Chem & Lab Med, Jena, Germany; [Walter, Michael] Rostock Univ, Inst Clin Chem & Lab Med, Med Ctr, Rostock, Germany; [Walter, Michael] Charite Univ Med Ctr, Inst Lab Med Clin Chem & Pathobiochem, Berlin, Germany; [Wenzel, Folker] Hsch Furtwangen, Fac Med & Life Sci, Furtwangen, Germany; [Woelfel, Roman] Bundeswehr Inst Microbiol, Munich, Germany; [Woelfel, Roman] German Ctr Infect Res DZIF, Partner Site Munich, Munich, Germany; [Renz, Harald] Philipps Univ Marburg, German Ctr Lung Res DZL, Univ Giessen & Marburg Lung Ctr, Inst Lab Med, Marburg, Germany	Ruhr University Bochum; Ruprecht Karls University Heidelberg; German Heart Centre Munich; Technical University of Munich; Friedrich Schiller University of Jena; University of Rostock; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Bundeswehr Institute of Microbiology (IMB); German Center for Infection Research; Philipps University Marburg	Ozcurumez, MK (corresponding author), Ruhr Univ, Dept Lab Med, Med Clin, Univ Med Ctr Knappschaftskrankenhaus Bochum, Schornau 23-25, D-44892 Bochum, Germany.	mustafa@ozcurumez.de	Özcürümez, Mustafa K./GRS-4840-2022; Ambrosch, Andreas/GRO-1438-2022; Özcürümez, Mustafa/AAQ-3250-2021; Wölfel, Roman/AAQ-3977-2021	Özcürümez, Mustafa K./0000-0002-4360-5005; Özcürümez, Mustafa/0000-0002-4360-5005; Wölfel, Roman/0000-0002-8756-7821; Haselmann, Verena/0000-0002-8380-6581	Universities Giessen Marburg Lung Center (UGMLC); German Center for Lung Disease (DZL German Lung Center) [82DZL00502]	Universities Giessen Marburg Lung Center (UGMLC); German Center for Lung Disease (DZL German Lung Center)	H.R. is funded by the Universities Giessen Marburg Lung Center (UGMLC) and the German Center for Lung Disease (DZL German Lung Center, no. 82DZL00502) for UGMLC.	AccuPlex, 2020, SARS COV 2 REF MAT K; Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642; an der Heiden M, 2020, MODELLIERUNG BEISPIE, DOI [10.25646/6571.2, DOI 10.25646/6571.2.]; [Anonymous], 2020, LANCET, V395, P755, DOI 10.1016/S0140-6736(20)30522-5; [Anonymous], 2020, SARS COV 2 RECEPTOR, DOI [10.1101/2020.04.10.036418, DOI 10.1101/2020.04.10.036418]; Bendavid E., 2020, MEDRXIV, P1, DOI [10.1101/2020.04.14.20062463, DOI 10.1101/2020.04.14.20062463]; Bioanalytik, 2020, APPL SURV SARS COV 2; College of American Pathologists, 2020, SARS COV 2 MOL PROF; Dimitrov JD, 2013, J IMMUNOL, V191, P993, DOI 10.4049/jimmunol.1300880; European Centre for Disease Prevention and Control, 2020, LAB SUPP COVID 19 EU; Food and Drug Administration, 2020, POL COR DIS 2019 TES; Foundation for Innovative New Diagnostics, 2020, FOUND INNOV NEW DIAG; Fuellen G, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101091; Grzelak L., 2020, SARS COV 2 SEROLOGIC SARS COV 2 SEROLOGIC, DOI [10.1101/2020.04.21.20068858, 10.1126/scitranslmed.abc3103]; Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100; Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310; Haveri A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.11.2000266; Hong KH, 2020, ANN LAB MED, V40, P351, DOI 10.3343/alm.2020.40.5.351; Huang Angkana T, 2020, medRxiv, DOI [10.1038/s41467-020-18450-4, 10.1101/2020.04.14.20065771]; Hussain S, 2005, J VIROL, V79, P5288, DOI 10.1128/JVI.79.9.5288-5295.2005; Iwasaki A, 2020, NAT REV IMMUNOL, V20, P339, DOI 10.1038/s41577-020-0321-6; Jin YJ, 2020, INT J INFECT DIS, V94, P49, DOI 10.1016/j.ijid.2020.03.065; Kabesch M, 2020, PEDIAT ALLERG IMM-UK, V31, P560, DOI 10.1111/pai.13265; Kerkhove MD Van, 2013, INFLUENZA OTHER RESP, V7, P872; Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793; Kucirka L, 2020, VARIATION FALSE NEGA, DOI [04.07.20051474, DOI 10.1101/2020.04.07.20051474, 10.7326/M20-1495]; Laboratory of the Government Chemist Group, 2020, COV SARS COV 2 MOL P; Liu WB, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00461-20; Mandavilli A, 2020, NY TIMES; MCINTOSH K, 1969, J IMMUNOL, V102, P1109; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Meyer B, 2014, VIRUS RES, V194, P175, DOI 10.1016/j.virusres.2014.03.018; Nickbakhsh S, 2020, J INFECT DIS, V222, P17, DOI 10.1093/infdis/jiaa185; Niedrig M, 2005, J CLIN VIROL, V34, P22, DOI 10.1016/j.jcv.2005.01.004; Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841; Randox, 2020, QUAL CONTR MOL DIAGN; Reichhardt H, 2020, GESELLSCHAFT FORDERU; Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783; Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100; Sutton A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17113938; Tan W, 2020, VIRAL KINETICS ANTIB, DOI 10.1101/2020.03.24.20042382; To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1; United Kingdom National External Quality Assessment Service, 2020, NEW COVID 19 UK NEQA; van der Heide V, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0325-2; Vashist SK, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10040202; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Whitman JD, TEST PERFORMANCE EVA, DOI [10.1101/2020.04.25, DOI 10.1101/2020.04.25]; WHO, 2020, LAB TESTING 2019 NOV, P1; Wikramaratna P., 2020, ESTIMATING FALSE NEG, V2020, DOI 10.1101/2020.04.05.20053355; Wolfel R, 2020, NATURE, V588, pE35, DOI 10.1038/s41586-020-2984-3; World Health Organization, 2020, MED PROD AL N 3 2020; World Health Organization, 2004, WHO GUID GLOB SURV S, V2013; Wu F, 2020, SSRN ELECT, DOI [10.1101/2020.03.30.20047365, DOI 10.2139/SSRN.3566211, https://doi.org/10.1101/2020.03.30.20047365]; Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461; Xiao AT, 2020, J INFECTION, V81, P174, DOI 10.1016/j.jinf.2020.03.012; Xiao T., 2020, EARLY VIRAL CLEARANC, DOI [10.1101/2020.04.28.20083139, DOI 10.1101/2020.04.28.20083139]; Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882; Zeng ZK, 2020, J INFECTION, V81, pE80, DOI 10.1016/j.jinf.2020.03.052; Zhang P., 2020, MEDRXIV, P1, DOI [10.1101/ 2020.03.17.20036954, DOI 10.1101/2020.03.17.20036954, 10.1101/2020.03.17.20036954]; Zhang W, 2020, EMERG MICROBES INFEC, V9, DOI 10.1080/22221751.2020.1729071; Zhang YC, 2020, EMERG MICROBES INFEC, V9, P833, DOI 10.1080/22221751.2020.1756699; ZHAO J, 2020, CLIN INFECT DIS, DOI [DOI 10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]; Zhou WM, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-433	63	51	54	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					35	43		10.1016/j.jaci.2020.05.020	http://dx.doi.org/10.1016/j.jaci.2020.05.020			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32479758	Bronze, Green Published			2022-12-18	WOS:000579170500005
J	Nakagawa, H; Nemoto, O; Igarashi, A; Saeki, H; Oda, M; Kabashima, K; Nagata, T				Nakagawa, Hidemi; Nemoto, Osamu; Igarashi, Atsuyuki; Saeki, Hidehisa; Oda, Manabu; Kabashima, Kenji; Nagata, Takeshi			Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; delgocitinib; eczema; pediatric patients; pruritus; Janus kinase; Janus kinase inhibitor; JTE-052; ointment; topical therapy	JANUS KINASE INHIBITOR; BARRIER; SKIN; GUIDELINES; MANAGEMENT; FILAGGRIN; PRURITUS; JTE-052; EXPRESSION; ALLERGY	Background: Topical delgocitinib (JTE-052), a novel Janus kinase inhibitor, had been shown to be clinically effective in adults with atopic dermatitis (AD). However, the efficacy of topical delgocitinib in pediatric patients with AD remained unclear. Objective: We sought to evaluate the efficacy and safety of delgocitinib ointment in pediatric patients with AD. Methods: In this phase 2 clinical study (JapicCTI-173553) Japanese patients aged 2 through 15 years with AD were randomized in a 1:1:1 ratio to receive 0.25% or 0.5% delgocitinib ointment or vehicle ointment twice daily for 4 weeks. The primary efficacy end point was the percentage change from baseline in the modified Eczema Area and Severity Index score at the end of treatment (EOT). Results: At EOT, modified Eczema Area and Severity Index scores in both delgocitinib groups were significantly reduced compared with that in the vehicle group. The least-squares mean percentage change from baseline was -54.2% in the 0.25% group and -61.8% in the 0.5% group versus -4.8% in the vehicle group (P < .001 for both comparisons). Similarly, all other efficacy parameters, including Investigator's Global Assessment and pruritus scores, in both delgocitinib groups were significantly improved compared with those in the vehicle group at EOT. Adverse events in both delgocitinib groups were mild in severity, and no serious adverse events were reported. Conclusions: Delgocitinib ointment improved clinical signs and symptoms in pediatric patients with AD and was well tolerated. These study results indicate that delgocitinib ointment can be a promising therapeutic option for pediatric patients with AD.	[Nakagawa, Hidemi] Jikei Univ, Sch Med, Tokyo, Japan; [Nemoto, Osamu] Kojinkai Sapporo Skin Clin, Sapporo, Hokkaido, Japan; [Igarashi, Atsuyuki] NTT Med Ctr Tokyo, Dept Dermatol, Tokyo, Japan; [Saeki, Hidehisa] Nippon Med Sch, Dept Dermatol, Tokyo, Japan; [Oda, Manabu; Nagata, Takeshi] Japan Tobacco, Pharmaceut Div, Tokyo, Japan; [Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan	Jikei University; Kanto Medical Center NTT EC; Nippon Medical School; Japan Tobacco Inc.; Kyoto University	Nagata, T (corresponding author), Japan Tobacco, Pharmaceut Div, Chuo Ku, 4-1,Nihonbashi Honcho 3 Chome, Tokyo 1030023, Japan.	takeshi.nagata@jt.com			Japan Tobacco	Japan Tobacco	This study was funded by Japan Tobacco. Japan Tobacco contributed to the study design, data collection, analysis, interpretation of the data, and medical writing assistance of this manuscript.	Amano W, 2015, J ALLERGY CLIN IMMUN, V136, P667, DOI 10.1016/j.jaci.2015.03.051; Bao Lei, 2013, JAKSTAT, V2, pe24137, DOI 10.4161/jkst.24137; Bissonnette R, 2016, BRIT J DERMATOL, V175, P902, DOI 10.1111/bjd.14871; Cotter DG, 2018, J AM ACAD DERMATOL, V78, pS53, DOI 10.1016/j.jaad.2017.12.019; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Dainichi T, 2018, NAT IMMUNOL, V19, P1286, DOI 10.1038/s41590-018-0256-2; Egawa G, 2016, J ALLERGY CLIN IMMUN, V138, P350, DOI 10.1016/j.jaci.2016.06.002; Eichenfield LF, 2014, J AM ACAD DERMATOL, V71, P116, DOI 10.1016/j.jaad.2014.03.023; Gooderham MJ, 2018, J AM ACAD DERMATOL, V78, pS28, DOI 10.1016/j.jaad.2017.12.022; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Hengge UR, 2006, J AM ACAD DERMATOL, V54, P1, DOI 10.1016/j.jaad.2005.01.010; Honda T, 2017, J ALLERGY CLIN IMMUN, V140, P369, DOI 10.1016/j.jaci.2017.06.005; Hong J, 2011, SEMIN CUTAN MED SURG, V30, P71, DOI 10.1016/j.sder.2011.05.002; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Kabashima K, 2018, J ALLERGY CLIN IMMUN, V142, P1121, DOI 10.1016/j.jaci.2018.03.018; Kabashima K, 2013, J DERMATOL SCI, V70, P3, DOI 10.1016/j.jdermsci.2013.02.001; Katayama I, 2017, ALLERGOL INT, V66, P230, DOI 10.1016/j.alit.2016.12.003; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Nakagawa H, 2018, BRIT J DERMATOL, V178, P424, DOI 10.1111/bjd.16014; Nakagawa H, 2018, J DERMATOL, V45, P701, DOI 10.1111/1346-8138.14322; Neis MM, 2006, J ALLERGY CLIN IMMUN, V118, P930, DOI 10.1016/j.jaci.2006.07.015; Nomura T, 2018, INT IMMUNOL, V30, P419, DOI 10.1093/intimm/dxy015; O'Shea JJ, 2012, IMMUNITY, V36, P542, DOI 10.1016/j.immuni.2012.03.014; Paller AS, 2019, J ALLERGY CLIN IMMUN, V143, P46, DOI 10.1016/j.jaci.2018.11.006; Paller AS, 2017, J ALLERGY CLIN IMMUN, V140, P633, DOI 10.1016/j.jaci.2017.07.006; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rodrigues MA, 2019, J DERMATOLOG TREAT; Ruzicka T, 2017, NEW ENGL J MED, V376, P826, DOI 10.1056/NEJMoa1606490; Saeki H, 2016, J DERMATOL, V43, P1117, DOI 10.1111/1346-8138.13392; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Tanimoto A, 2018, EXP DERMATOL, V27, P22, DOI 10.1111/exd.13370; Tanimoto A, 2015, INFLAMM RES, V64, P41, DOI 10.1007/s00011-014-0782-9; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Yamamoto Y, 2016, J INVEST DERMATOL, V136, pS92, DOI 10.1016/j.jid.2016.02.556; Zhang YL, 2012, IMMUNOL RES, V52, P211, DOI 10.1007/s12026-012-8264-z	37	51	53	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1575	1583		10.1016/j.jaci.2019.08.004	http://dx.doi.org/10.1016/j.jaci.2019.08.004			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31425780	hybrid			2022-12-18	WOS:000500694900015
J	Steinfeld, J; Bradford, ES; Brown, J; Mallett, S; Yancey, SW; Akuthota, P; Cid, MC; Gleich, GJ; Jayne, D; Khoury, P; Langford, CA; Merkel, PA; Moosig, F; Specks, U; Weller, PF; Wechsler, ME				Steinfeld, Jonathan; Bradford, Eric S.; Brown, Judith; Mallett, Stephen; Yancey, Steven W.; Akuthota, Praveen; Cid, Maria C.; Gleich, Gerald J.; Jayne, David; Khoury, Paneez; Langford, Carol A.; Merkel, Peter A.; Moosig, Frank; Specks, Ulrich; Weller, Peter F.; Wechsler, Michael E.			Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic granulomatosis with polyangiitis; Churg-Strauss syndrome; mepolizumab; eosinophils; IL-5; vasculitis	CHURG-STRAUSS; TARGETING EOSINOPHILS; RECOMMENDATIONS	Background: In a recent phase III trial (NCT02020889) 53% of mepolizumab-treated versus 19% of placebo-treated patients with eosinophilic granulomatosis with polyangiitis (EGPA) achieved protocol-defined remission. Objective: We sought to investigate post hoc the clinical benefit of mepolizumab in patients with EGPA using a comprehensive definition of benefit encompassing remission, oral glucocorticoid (OGC) dose reduction, and EGPA relapses. Methods: The randomized, placebo-controlled, double-blind, parallel-group trial recruited patients with relapsing/refractory EGPA receiving stable OGCs (prednisolone/prednisone, >= 7.5-50 mg/d) for 4 or more weeks. Patients received 300 mg of subcutaneous mepolizumab or placebo every 4 weeks for 52 weeks. Clinical benefit was defined post hoc as follows: remission at any time (2 definitions used), 50% or greater OGC dose reduction during weeks 48 to 52, or no EGPA relapses. The 2 remission definitions were Birmingham Vasculitis Activity Score of 0 plus OGC dose of 4 mg/d or less (remission 1/clinical benefit 1) or 7.5 mg/d or less (remission 2/clinical benefit 2). Clinical benefit was assessed in all patients and among subgroups with a baseline blood eosinophil count of less than 150 cells/mL, baseline OGC dosage of greater than 20 mg/d, or weight of greater than 85 kg. Results: With mepolizumab versus placebo, 78% versus 32% of patients experienced clinical benefit 1, and 87% versus 53% of patients experienced clinical benefit 2 (both P < .001). Significantly more patients experienced clinical benefit 1 with mepolizumab versus placebo in the blood eosinophil count less than 150 cells/mL subgroup (72% vs 43%, P = .033) and weight greater than 85 kg subgroup (68% vs 23%, P = .005); in the OGC greater than 20 mg/d subgroup, results were not significant but favored mepolizumab (60% vs 36%, P = .395). Conclusion: When a comprehensive definition of clinical benefit was applied to data from a randomized controlled trial, 78% to 87% of patients with EGPA experienced benefit with mepolizumab.	[Steinfeld, Jonathan] GlaxoSmithKline, Resp TAU & Flexible Discovery Unit, Philadelphia, PA USA; [Bradford, Eric S.; Yancey, Steven W.] GlaxoSmithKline, Resp Therapeut Area, Res Triangle Pk, NC USA; [Brown, Judith] GlaxoSmithKline, Res & Dev, Immunoinflammat TAU, Stockley Pk West, Uxbridge, Middx, England; [Mallett, Stephen] GlaxoSmithKline, Res & Dev, Stat Programming & Data Stand, Stockley Pk West, Uxbridge, Middx, England; [Akuthota, Praveen] Univ Calif San Diego, Div Pulm Crit Care & Sleep Med, La Jolla, CA 92093 USA; [Cid, Maria C.] Univ Barcelona, Dept Autoimmune Dis, Hosp Clin, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain; [Gleich, Gerald J.] Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT USA; [Gleich, Gerald J.] Univ Utah, Sch Med, Dept Med, Salt Lake City, UT USA; [Jayne, David] Univ Cambridge, Dept Med, Cambridge, England; [Khoury, Paneez] NIAID, Human Eosinophil Sect, Lab Parasit Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Langford, Carol A.] Cleveland Clin, Dept Rheumat & Immunol Dis, Ctr Vasculitis Care & Res, Cleveland, OH 44106 USA; [Merkel, Peter A.] Univ Penn, Div Rheumatol, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA; [Moosig, Frank] Rheumazentrum, Schleswig Holstein Mitte, Neumunster, Germany; [Specks, Ulrich] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA; [Weller, Peter F.] Harvard Med Sch, Dept Med, Beth Israel Deaconess Med Ctr, Div Allergy, Boston, MA 02115 USA; [Weller, Peter F.] Harvard Med Sch, Dept Med, Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02115 USA; [Wechsler, Michael E.] Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80230 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; University of California System; University of California San Diego; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Cambridge; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Cleveland Clinic Foundation; University of Pennsylvania; Mayo Clinic; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Jewish Health	Wechsler, ME (corresponding author), Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80230 USA.	wechslerm@njhealth.org	Khoury, Paneez/ABH-1951-2020; Cid, Maria C./J-4553-2016; Wechsler, Michael/AAC-5506-2019	Khoury, Paneez/0000-0003-1800-0079; Cid, Maria C./0000-0002-4730-0938; Moosig, Frank/0000-0002-7341-9844; Jayne, David/0000-0002-1712-0637	GlaxoSmithKline (GSK) [115921]; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [U01 AI097073]; Division of Intramural Research, NIH/NIAID; GlaxoSmithKline [115921]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020241, U01AI097073] Funding Source: NIH RePORTER	GlaxoSmithKline (GSK)(GlaxoSmithKline); National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Division of Intramural Research, NIH/NIAID; GlaxoSmithKline(GlaxoSmithKline); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was funded by GlaxoSmithKline (GSK ID 115921 ClinicalTrials.gov number NCT02020889), the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID; U01 AI097073) and in part by the Division of Intramural Research, NIH/NIAID. The post hoc analysis of 115921/NCT02020889 presented in this article was funded by GlaxoSmithKline.	Buchman AL, 2001, J CLIN GASTROENTEROL, V33, P289, DOI 10.1097/00004836-200110000-00006; Comarmond C, 2013, ARTHRITIS RHEUM-US, V65, P270, DOI 10.1002/art.37721; Daugherty J, 2018, J ASTHMA, V55, P651, DOI 10.1080/02770903.2017.1353612; Djukanovic R, 2017, NEW ENGL J MED, V376, P1985, DOI 10.1056/NEJMe1704402; Fulkerson PC, 2013, NAT REV DRUG DISCOV, V12, P117, DOI 10.1038/nrd3838; Gioffredi A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00549; GlaxoSmithKline, 2018, CLIN STUD REG 2018; Groh M, 2015, EUR J INTERN MED, V26, P545, DOI 10.1016/j.ejim.2015.04.022; Hellmich B, 2007, ANN RHEUM DIS, V66, P605, DOI 10.1136/ard.2006.062711; Kahn JE, 2010, J ALLERGY CLIN IMMUN, V125, P267, DOI 10.1016/j.jaci.2009.10.014; Khoury P, 2014, NAT REV RHEUMATOL, V10, P474, DOI 10.1038/nrrheum.2014.98; Kim S, 2010, J ALLERGY CLIN IMMUN, V125, P1336, DOI 10.1016/j.jaci.2010.03.028; Moosig F, 2013, ANN RHEUM DIS, V72, P1011, DOI 10.1136/annrheumdis-2012-201531; Moosig F, 2011, ANN INTERN MED, V155, P341, DOI 10.7326/0003-4819-155-5-201109060-00026; Mukherjee M, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-32; Pouliquen IJ, 2015, INT J CLIN PHARM TH, V53, P1015, DOI 10.5414/CP202446; Puechal X, 2017, ARTHRITIS RHEUMATOL, V69, P2175, DOI 10.1002/art.40205; Samson M, 2013, J AUTOIMMUN, V43, P60, DOI 10.1016/j.jaut.2013.03.003; Strehl C, 2016, ANN RHEUM DIS, V75, P952, DOI 10.1136/annrheumdis-2015-208916; Vaglio A, 2013, ALLERGY, V68, P261, DOI 10.1111/all.12088; Wechsler ME, 2017, NEW ENGL J MED, V376, P1921, DOI 10.1056/NEJMoa1702079	21	51	52	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2170	2177		10.1016/j.jaci.2018.11.041	http://dx.doi.org/10.1016/j.jaci.2018.11.041			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30578883	hybrid, Green Published, Green Accepted			2022-12-18	WOS:000470113200021
J	Wood, LG; Li, Q; Scott, HA; Rutting, S; Berthon, BS; Gibson, PG; Hansbro, PM; Williams, E; Horvat, J; Simpson, JL; Young, P; Oliver, BG; Baines, KJ				Wood, Lisa G.; Li, Qian; Scott, Hayley A.; Rutting, Sandra; Berthon, Bronwyn S.; Gibson, Peter G.; Hansbro, Philip M.; Williams, Evan; Horvat, Jay; Simpson, Jodie L.; Young, Paul; Oliver, Brian G.; Baines, Katherine J.			Saturated fatty acids, obesity, and the nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fatty acids; saturated fat; obesity; inflammasome; airway inflammation; IL-1 beta; asthma	BODY-MASS INDEX; NEUTROPHILIC INFLAMMATION; AIRWAY INFLAMMATION; GENE-EXPRESSION; ADIPOSE-TISSUE; MURINE ASTHMA; SPUTUM; ANTIOXIDANT; ENDOTOXIN; RISK	Background: Both obesity and high dietary fat intake activate the nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome. Objective: We aimed to examine NLRP3 inflammasome activity in the airways of obese asthmatic patients after macronutrient overload and in immune cells challenged by inflammasome triggers. Methods: Study 1 was a cross-sectional observational study of nonobese (n = 51) and obese (n = 76) asthmatic adults. Study 2 was a randomized, crossover, acute feeding study in 23 asthmatic adults (n = 12 nonobese and n = 11 obese subjects). Subjects consumed 3 isocaloric meals on 3 separate occasions (ie, saturated fatty acid, n-6 polyunsaturated fatty acid, and carbohydrate) and were assessed at 0 and 4 hours. For Studies 1 and 2, airway inflammation was measured based on sputum differential cell counts, IL-1 beta protein levels (ELISA), and sputum cell gene expression (Nanostring nCounter). In Study 3 peripheral blood neutrophils and monocytes were isolated by using Ficoll density gradient and magnetic bead separation and incubated with or without palmitic acid, LPS, or TNF-alpha for 24 hours, and IL-1 beta release was measured (ELISA). Results: In Study 1 NLRP3 and nucleotide oligomerization domain 1 (NOD1) gene expression was upregulated, and sputum IL-1 beta protein levels were greater in obese versus nonobese asthmatic patients. In Study 2 the saturated fatty acid meal led to increases in sputum neutrophil percentages and sputum cell gene expression of Toll-like receptor 4 (TLR4) and NLRP3 at 4 hours in nonobese asthmatic patients. In Study 3 neutrophils and monocytes released IL-1 beta when challenged with a combination of palmitic acid and LPS or TNF-alpha. Conclusion: The NLRP3 inflammasome is a potential therapeutic target in asthmatic patients. Behavioral interventions that reduce fatty acid exposure, such as weight loss and dietary saturated fat restriction, warrant further exploration.	[Wood, Lisa G.; Li, Qian; Scott, Hayley A.; Rutting, Sandra; Berthon, Bronwyn S.; Gibson, Peter G.; Hansbro, Philip M.; Williams, Evan; Horvat, Jay; Simpson, Jodie L.; Baines, Katherine J.] Univ Newcastle, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia; [Gibson, Peter G.] John Hunter Hosp, Dept Resp & Sleep Med, Newcastle, NSW, Australia; [Rutting, Sandra; Young, Paul; Oliver, Brian G.] Woolcock Inst Med Res, Sydney, NSW, Australia	University of Newcastle; John Hunter Hospital; University of Sydney; Woolcock Institute of Medical Research	Wood, LG (corresponding author), Ctr Hlth Lungs, Level 2,West Wing,HMRI Bldg, New Lambton Height, NSW 2305, Australia.	lisa.wood@newcastle.edu.au	Oliver, Brian/E-7939-2010; Berthon, Bronwyn S/E-7902-2013; Hansbro, Phil/G-7486-2013; SIMPSON, JODIE LOUISE/G-7639-2013; BAINES, KATHERINE JOANNE/G-7654-2013; Scott, Hayley/ABC-5348-2021; Williams, Evan/ABC-2165-2021; Young, Paul/W-4607-2018; gibson, peter/G-6194-2014	Oliver, Brian/0000-0002-7122-9262; Berthon, Bronwyn S/0000-0001-7858-6513; Hansbro, Phil/0000-0002-4741-3035; SIMPSON, JODIE LOUISE/0000-0002-3626-680X; BAINES, KATHERINE JOANNE/0000-0002-4240-6581; Scott, Hayley/0000-0002-3201-8825; Williams, Evan/0000-0003-0532-2060; Young, Paul/0000-0002-4357-7999; Horvat, Jay/0000-0002-8526-0631; gibson, peter/0000-0001-5865-489X	National Health and Medical Research Council (NHMRC) of Australia; NHMRC Practitioner Fellowship; NHMRC Principal Research Fellowship; Brawn Fellowship, Faculty of Health and Medicine, University of Newcastle	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Principal Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Brawn Fellowship, Faculty of Health and Medicine, University of Newcastle	The project was funded by the National Health and Medical Research Council (NHMRC) of Australia. P.G.G. is supported by an NHMRC Practitioner Fellowship, and P.M.H. is supported by an NHMRC Principal Research Fellowship and a Brawn Fellowship, Faculty of Health and Medicine, University of Newcastle.	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Baines KJ, 2010, EUR RESPIR J, V35, P522, DOI 10.1183/09031936.00027409; Baines KJ, 2017, INT J CHRONIC OBSTR, V12, P541, DOI 10.2147/COPD.S119443; Besnard AG, 2011, ALLERGY, V66, P1047, DOI 10.1111/j.1398-9995.2011.02586.x; Boulet LP, 2007, RESP MED, V101, P2240, DOI 10.1016/j.rmed.2007.06.031; Calixto MC, 2010, BRIT J PHARMACOL, V159, P617, DOI 10.1111/j.1476-5381.2009.00560.x; Chi W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097675; Deopurkar R, 2010, DIABETES CARE, V33, P991, DOI 10.2337/dc09-1630; Desai D, 2013, AM J RESP CRIT CARE, V188, P657, DOI 10.1164/rccm.201208-1470OC; Fahy John V, 2009, Proc Am Thorac Soc, V6, P256, DOI 10.1513/pats.200808-087RM; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Glass CK, 2012, CELL METAB, V15, P635, DOI 10.1016/j.cmet.2012.04.001; Global Asthma Network, 2014, GLOB ASTHM REP; Hakala K, 2000, CHEST, V118, P1315, DOI 10.1378/chest.118.5.1315; Hansbro PM, 2017, IMMUNOL REV, V278, P41, DOI 10.1111/imr.12543; Hotamisligil GS, 2008, NAT REV IMMUNOL, V8, P923, DOI 10.1038/nri2449; Huang SL, 2001, CLIN EXP ALLERGY, V31, P1875, DOI 10.1046/j.1365-2222.2001.01222.x; Kim RY, 2017, AM J RESP CRIT CARE, V196, P283, DOI 10.1164/rccm.201609-1830OC; Kim RY, 2015, THORAX, V70, P1199, DOI 10.1136/thoraxjnl-2014-206736; Kurti SP, 2015, BIOMED RES INT, V2015, P10; Lappas M, 2014, J ENDOCRINOL, V222, P99, DOI 10.1530/JOE-14-0179; Marjisse GS, 2014, AM J RESP CRIT CARE, V15, P1284; Mook S, 2004, METABOLISM, V53, P1197, DOI 10.1016/j.metabol.2004.02.023; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8; Nguyen LP, 2008, AM J RESP CELL MOL, V38, P256, DOI 10.1165/rcmb.2007-0279RC; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Ralston JC, 2017, ANNU REV NUTR, V37, P77, DOI 10.1146/annurev-nutr-071816-064836; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; Rheinheimer J, 2017, METABOLISM, V74, P1, DOI 10.1016/j.metabol.2017.06.002; Rodriguez-Rodriguez E, 2010, EUR J CLIN NUTR, V64, P1065, DOI 10.1038/ejcn.2010.127; Scott HA, 2013, CLIN EXP ALLERGY, V43, P36, DOI 10.1111/cea.12004; Scott HA, 2011, EUR RESPIR J, V38, P594, DOI 10.1183/09031936.00139810; Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898; Simpson JL, 2014, EUR RESPIR J, V43, P1067, DOI 10.1183/09031936.00105013; Sin DD, 2002, ARCH INTERN MED, V162, P1477, DOI 10.1001/archinte.162.13.1477; Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Telenga ED, 2012, ALLERGY, V67, P1060, DOI 10.1111/j.1398-9995.2012.02855.x; Todoric K, 2015, ANN ALLERG ASTHMA IM, V114, P251, DOI 10.1016/j.anai.2014.11.010; van Oostrom AJHHM, 2006, ATHEROSCLEROSIS, V185, P331, DOI 10.1016/j.atherosclerosis.2005.06.045; van Oostrom AJHHM, 2003, J LIPID RES, V44, P576, DOI 10.1194/jlr.M200419-JLR200; Vandanmagsar B, 2011, NAT MED, V17, P179, DOI 10.1038/nm.2279; Wood LG, 2003, AM J CLIN NUTR, V77, P150, DOI 10.1093/ajcn/77.1.150; Wood LG, 2012, AM J CLIN NUTR, V96, P534, DOI 10.3945/ajcn.111.032623; Wood LG, 2011, J ALLERGY CLIN IMMUN, V127, P1133, DOI 10.1016/j.jaci.2011.01.036; Zhou YJ, 2015, OBESITY, V23, P1394, DOI 10.1002/oby.21113	47	51	57	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					305	315		10.1016/j.jaci.2018.04.037	http://dx.doi.org/10.1016/j.jaci.2018.04.037			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	29857009	Bronze			2022-12-18	WOS:000454918300034
J	Dolence, JJ; Kobayashi, T; Iijima, K; Krempski, J; Drake, LY; Dent, AL; Kita, H				Dolence, Joseph J.; Kobayashi, Takao; Iijima, Koji; Krempski, James; Drake, Li Y.; Dent, Alexander L.; Kita, Hirohito			Airway exposure initiates peanut allergy by involving the IL-1 pathway and T follicular helper cells in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Follicular T cells; IL-4; IgE; allergy; peanut; IL-1; IL-33	THYMIC STROMAL LYMPHOPOIETIN; DENDRITIC CELLS; FOOD ALLERGY; TH2 RESPONSES; RISK-FACTOR; ANTIGEN; CONSUMPTION; PROMOTES; INDUCE; BCL6	Background: Little is currently known regarding the immunologic mechanism(s) that initiate peanut allergy. Notably, peanut proteins have been detected in house dust, and their levels correlate with peanut allergy prevalence. Objective: This study aimed to develop a new mouse model for peanut allergy and to investigate the immunologic mechanisms involved in peanut allergen sensitization. Methods: To mimic environmental exposure, naive mice were exposed to peanut flour by inhalation for up to 4 weeks. We then analyzed serum levels of IgE antibody and challenged mice with peanut proteins. Immunological mechanisms involved in sensitization were analyzed using cytokine reporter mice, an adoptive cell transfer model, and gene knockout mice. Results: When exposed to peanut flour by inhalation, both BALB/c and C57BL/6 mice developed peanut allergy, as demonstrated by the presence of peanut-specific IgE antibodies and manifestation of acute anaphylaxis on challenge. A large number of follicular helper T (Tfh) cells were also detected in draining lymph nodes of allergic mice. These cells produced IL-4 and IL-21, and they more robustly promoted peanut-specific IgE production than T(H)2 cells did. Genetic depletion of Tfh cells decreased IgE antibody levels and protected mice from anaphylaxis, without affecting T(H)2 cells. Furthermore, peanut flour exposure increased lung levels of IL-1 alpha and IL-1 beta, and mice deficient in the receptor for these cytokines showed a significant decrease in Tfh cells compared with in wild-type mice. Conclusions: Tfh cells play a key role in peanut allergy, and the IL-1 pathway is involved in the Tfh response to peanut allergen exposure.	[Dolence, Joseph J.; Kobayashi, Takao; Iijima, Koji; Krempski, James; Drake, Li Y.; Kita, Hirohito] Mayo Clin Rochester, Dept Med & Immunol, Rochester, MN USA; [Krempski, James] Mayo Grad Sch, Rochester, MN USA; [Dent, Alexander L.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA	Mayo Clinic; Mayo Clinic; Indiana University System; Indiana University Bloomington	Kita, H (corresponding author), Mayo Clin Rochester, Dept Med, Div Allerg Dis, 200 First St SW, Rochester, MN 55905 USA.; Kita, H (corresponding author), Mayo Clin Rochester, Dept Immunol, 200 First St SW, Rochester, MN 55905 USA.	kita.hirohito@mayo.edu		Kita, Hirohito/0000-0002-6854-2936	National Institutes of Health (NIH) [R01 AI71106]; Mayo Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007425, R01AI071106, R37AI071106] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants from the National Institutes of Health (NIH) (R01 AI71106) and the Mayo Foundation.	Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191; Berin MC, 2006, ALLERGY, V61, P64, DOI 10.1111/j.1398-9995.2006.01012.x; Branum Amy M, 2008, NCHS Data Brief, P1; Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P630, DOI 10.1016/j.jaci.2013.02.034; Burton OT, 2017, J ALLERGY CLIN IMMUN, V139, P314, DOI 10.1016/j.jaci.2016.04.034; Burton OT, 2014, IMMUNITY, V41, P141, DOI 10.1016/j.immuni.2014.05.017; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Carpino N, 2004, MOL CELL BIOL, V24, P2584, DOI 10.1128/MCB.24.6.2584-2592.2004; Chevalier N, 2016, ARTHRITIS RHEUMATOL, V68, P1026, DOI 10.1002/art.39481; Chinthrajah RS, 2016, J ALLERGY CLIN IMMUN, V137, P984, DOI 10.1016/j.jaci.2016.02.004; Choi JY, 2015, ARTHRITIS RHEUMATOL, V67, P988, DOI 10.1002/art.39020; Chu DK, 2014, MUCOSAL IMMUNOL, V7, P1395, DOI 10.1038/mi.2014.29; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; de Kleer IM, 2016, IMMUNITY, V45, P1285, DOI 10.1016/j.immuni.2016.10.031; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; du Toit G, 2016, J ALLERGY CLIN IMMUN, V137, P998, DOI 10.1016/j.jaci.2016.02.005; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Flinn A, 2013, CURR ALLERGY ASTHM R, V13, P645, DOI 10.1007/s11882-013-0369-5; Forbes-Blom E, 2012, CLIN EXP ALLERGY, V42, P305, DOI 10.1111/j.1365-2222.2011.03861.x; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; He J, 2013, IMMUNITY, V39, P770, DOI 10.1016/j.immuni.2013.09.007; Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686; Hollister K, 2013, J IMMUNOL, V191, P3705, DOI 10.4049/jimmunol.1300378; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jimenez-Saiz R, 2017, J ALLERGY CLIN IMMUN, V140, P1604, DOI 10.1016/j.jaci.2017.01.018; Karnowski A, 2012, J EXP MED, V209, P2049, DOI 10.1084/jem.20111504; Kenefeck R, 2015, J CLIN INVEST, V125, P292, DOI 10.1172/JCI76238; King C, 2008, ANNU REV IMMUNOL, V26, P741, DOI 10.1146/annurev.immunol.26.021607.090344; King RM, 2009, ALLERGY, V64, P461, DOI 10.1111/j.1398-9995.2008.01843.x; Kobayashi T, 2017, J ALLERGY CLIN IMMUN, V139, P300, DOI 10.1016/j.jaci.2016.04.021; Kuroda E, 2016, IMMUNITY, V45, P1299, DOI 10.1016/j.immuni.2016.11.010; Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; Liang HE, 2012, NAT IMMUNOL, V13, P58, DOI 10.1038/ni.2182; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Mesin L, 2016, IMMUNITY, V45, P471, DOI 10.1016/j.immuni.2016.09.001; Mohrs K, 2005, IMMUNITY, V23, P419, DOI 10.1016/j.immuni.2005.09.006; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; Muehling LM, 2017, J ALLERGY CLIN IMMUN, V140, P1523, DOI 10.1016/j.jaci.2017.02.025; Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Poholek AC, 2010, J IMMUNOL, V185, P313, DOI 10.4049/jimmunol.0904023; Ritvo PGG, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan0368; Shay T, 2013, P NATL ACAD SCI USA, V110, P2946, DOI 10.1073/pnas.1222738110; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Smarr CB, 2011, J IMMUNOL, V187, P5090, DOI 10.4049/jimmunol.1100608; Sun JF, 2007, J IMMUNOL, V179, P6696, DOI 10.4049/jimmunol.179.10.6696; THURLBECK WM, 1982, THORAX, V37, P564, DOI 10.1136/thx.37.8.564; Tordesillas L, 2014, J CLIN INVEST, V124, P4965, DOI 10.1172/JCI75660; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Trendelenburg V, 2013, ALLERGY, V68, P1460, DOI 10.1111/all.12226; Van Dyken SJ, 2016, NAT IMMUNOL, V17, P1381, DOI 10.1038/ni.3582; Zhang YX, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad4322; Zotos D, 2010, J EXP MED, V207, P365, DOI 10.1084/jem.20091777	65	51	52	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1144	+		10.1016/j.jaci.2017.11.020	http://dx.doi.org/10.1016/j.jaci.2017.11.020			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29247716	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000446327300015
J	Zuraw, BL				Zuraw, Bruce L.			Hereditary angioedema with normal C1 inhibitor: Four types and counting	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Hereditary angioedema with normal C1 inhibitor; angiopoietin 1; Factor XII; plasminogen; bradykinin	NORMAL C1-INHIBITOR		[Zuraw, Bruce L.] Univ Calif San Diego, Dept Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA; [Zuraw, Bruce L.] San Diego VA Healthcare, La Jolla, CA USA	University of California System; University of California San Diego	Zuraw, BL (corresponding author), 9500 Gilman Dr,Mailcode 0732, La Jolla, CA 92093 USA.	bzuraw@ucsd.edu			Shire; CSL Behring; Biocryst; Adverum; US Hereditary Angioedema Association	Shire; CSL Behring; Biocryst; Adverum; US Hereditary Angioedema Association	B. L. Zuraw has a patent submitted by both himself and his institution; received royalties from UpToDate; received board membership from US HAEA and MAB; and received consultancy fees from Shire, CSL Behring, Biocryst, and Adverum, and his institution received a grant from the US Hereditary Angioedema Association for other works.	Bafunno V, 2018, J ALLERGY CLIN IMMUN, V141, P1009, DOI 10.1016/j.jaci.2017.05.020; Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Bissler JJ, 1997, P ASSOC AM PHYSICIAN, V109, P164; Bjorkqvist J, 2015, J CLIN INVEST, V125, P3132, DOI 10.1172/JCI77139; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; Bork K, 2018, ALLERGY, V73, P442, DOI 10.1111/all.13270; de Maat S, 2016, J ALLERGY CLIN IMMUN, V138, P1414, DOI 10.1016/j.jaci.2016.02.021; Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092; Zuraw BL, 2016, CLIN REV ALLERG IMMU, V51, P216, DOI 10.1007/s12016-016-8561-8; Zuraw BL, 2012, ALLERGY ASTHMA PROC, V33, pS145, DOI 10.2500/aap.2012.33.3627	10	51	53	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					884	885		10.1016/j.jaci.2018.01.015	http://dx.doi.org/10.1016/j.jaci.2018.01.015			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29410040	Bronze			2022-12-18	WOS:000426974800008
J	Burton, OT; Tamayo, JM; Stranks, AJ; Koleoglou, KJ; Oettgen, HC				Burton, Oliver T.; Tamayo, Jaciel M.; Stranks, Amanda J.; Koleoglou, Kyle J.; Oettgen, Hans C.			Allergen-specific IgG antibody signaling through Fc gamma RIIb promotes food tolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; IgG; regulatory T cell; food allergy; Fc gamma RIIb; oral immunotherapy; tolerance	HUMAN MAST-CELLS; RECEPTOR CROSS-LINKING; ORAL IMMUNOTHERAPY; EPSILON-RI; NEGATIVE REGULATION; SUSTAINED UNRESPONSIVENESS; PEANUT ALLERGY; FUSION PROTEIN; EXPRESSION; INDUCTION	Background: Patients with food allergy produce high-titer IgE antibodies that bind to mast cells through Fc epsilon RI and trigger immediate hypersensitivity reactions on antigen encounter. Food-specific IgG antibodies arise in the setting of naturally resolving food allergy and accompany the acquisition of food allergen unresponsiveness in oral immunotherapy. Objective: In this study we sought to delineate the effects of IgG and its inhibitory Fc receptor, Fc gamma RIIb, on both de novo allergen sensitization in naive animals and on established immune responses in the setting of pre-existing food allergy. Methods: Allergen-specific IgG was administered to mice undergoing sensitization and desensitization to the model food allergen ovalbumin. Cellular and molecular mechanisms were interrogated by using mast cell-and Fc gamma RIIb-deficient mice. The requirement for Fc gamma RII in IgG-mediated inhibition of human mast cells was investigated by using a neutralizing antibody. Results: Administration of specific IgG to food allergy-prone IL4raF709 mice during initial food exposure prevented the development of IgE antibodies, T(H)2 responses, and anaphylactic responses on challenge. When given as an adjunct to oral desensitization in mice with established IgE-mediated hypersensitivity, IgG facilitated tolerance restoration, favoring expansion of forkhead box protein 3-positive regulatory T cells along with suppression of existing T(H)2 and IgE responses. IgG and Fc gamma RIIb suppress adaptive allergic responses through effects on mast cell function. Conclusion: These findings suggest that allergen-specific IgG antibodies can act to induce and sustain immunologic tolerance to foods.	[Burton, Oliver T.; Tamayo, Jaciel M.; Stranks, Amanda J.; Koleoglou, Kyle J.; Oettgen, Hans C.] Boston Childrens Hosp, Dept Med, Boston, MA USA; [Burton, Oliver T.; Tamayo, Jaciel M.; Stranks, Amanda J.; Oettgen, Hans C.] Harvard Med Sch, Dept Pediat, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Burton, OT (corresponding author), 1 Blackfan Circle, Boston, MA 02115 USA.	oliver.burton@childrens.harvard.edu		Burton, Oliver/0000-0003-3884-7373; Oettgen, Hans/0000-0003-1199-1391	National Institutes of Health [1R01AI119918-01, 5T32AI007512-28, 1K01DK106303-01]; Bunning Family Foundation; Nanji Family Fund for Food Allergy Research; Rao Chakravorti Family fund; Christine Olsen and Robert Small Food Allergy Research Fund; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007512, R01AI119918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK106303] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bunning Family Foundation; Nanji Family Fund for Food Allergy Research; Rao Chakravorti Family fund; Christine Olsen and Robert Small Food Allergy Research Fund; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by National Institutes of Health grants 1R01AI119918-01 (to H.C.O.), 5T32AI007512-28 (to O.T.B.), and 1K01DK106303-01 (to O.T.B.). Additional generous support was provided by the Bunning Family Foundation, the Nanji Family Fund for Food Allergy Research, the Rao Chakravorti Family fund, and the Christine Olsen and Robert Small Food Allergy Research Fund.	Bedoret D, 2012, MUCOSAL IMMUNOL, V5, P267, DOI 10.1038/mi.2012.5; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-7; Beutier H, 2017, J ALLERGY CLIN IMMUN, V139, P269, DOI 10.1016/j.jaci.2016.03.028; Bischoff SC, 2001, INT ARCH ALLERGY IMM, V124, P151, DOI 10.1159/000053695; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V79, P947, DOI 10.1016/0091-6749(87)90245-4; BRADDING P, 1995, J IMMUNOL, V155, P297; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; Bruhns P, 2000, J BIOL CHEM, V275, P37357, DOI 10.1074/jbc.M003518200; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, P1240, DOI 10.1016/j.jaci.2014.12.1917; Burton OT, 2013, MUCOSAL IMMUNOL, V6, P740, DOI 10.1038/mi.2012.112; Burton OT, 2017, J ALLERGY CLIN IMMUN, V139, P314, DOI 10.1016/j.jaci.2016.04.034; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Burton OT, 2014, IMMUNITY, V41, P141, DOI 10.1016/j.immuni.2014.05.017; Cassard L, 2012, J IMMUNOL, V189, P2995, DOI 10.4049/jimmunol.1200968; Chen CY, 2015, IMMUNITY, V43, P788, DOI 10.1016/j.immuni.2015.08.020; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Daeron M, 1997, INT ARCH ALLERGY IMM, V113, P138, DOI 10.1159/000237528; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; Fuentes-Aparicio V, 2014, PEDIAT ALLERG IMM-UK, V25, P103, DOI 10.1111/pai.12137; Gibbs BF, 2001, EXP DERMATOL, V10, P312, DOI 10.1034/j.1600-0625.2001.100503.x; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Hoffmann HJ, 2003, CLIN EXP ALLERGY, V33, P930, DOI 10.1046/j.1365-2222.2003.01625.x; Holt PG, 2016, J ALLERGY CLIN IMMUN, V137, P379, DOI 10.1016/j.jaci.2015.08.044; Horton HM, 2011, J IMMUNOL, V186, P4223, DOI 10.4049/jimmunol.1003412; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JAFFE JS, 1995, AM J RESP CELL MOL, V13, P665, DOI 10.1165/ajrcmb.13.6.7576704; JARRETT EEE, 1983, IMMUNOLOGY, V48, P49; Jayapal M, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-210; Jones SM, 2016, J ALLERGY CLIN IMMUN, V137, P1117, DOI 10.1016/j.jaci.2015.12.1316; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kepley CL, 2004, J BIOL CHEM, V279, P35139, DOI 10.1074/jbc.M404318200; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V131, P1555, DOI 10.1016/j.jaci.2013.02.043; Krishnaswamy G, 1997, J INTERF CYTOK RES, V17, P167, DOI 10.1089/jir.1997.17.167; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li B, 2007, INT IMMUNOL, V19, P825, DOI 10.1093/intimm/dxm043; Li FB, 2014, J IMMUNOL, V192, P3021, DOI 10.4049/jimmunol.1302934; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Liu Y, 2013, J ALLERGY CLIN IMMUN, V131, P213, DOI 10.1016/j.jaci.2012.10.018; Lorentz A, 2000, J IMMUNOL, V164, P43, DOI 10.4049/jimmunol.164.1.43; Lorentz A, 2001, IMMUNOL REV, V179, P57, DOI 10.1034/j.1600-065X.2001.790106.x; Madden KB, 2002, J IMMUNOL, V169, P4417, DOI 10.4049/jimmunol.169.8.4417; Malbec O, 1999, J IMMUNOL, V162, P4424; Malbec O, 2007, IMMUNOL REV, V217, P206, DOI 10.1111/j.1600-065X.2007.00510.x; Mathias CB, 2011, J ALLERGY CLIN IMMUN, V127, P795, DOI 10.1016/j.jaci.2010.11.009; Moller A, 1998, IMMUNOLOGY, V93, P289; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Nakae S, 2007, J ALLERGY CLIN IMMUN, V120, P48, DOI 10.1016/j.jaci.2007.02.046; Oettgen HC, 2015, ADV IMMUNOL, V127, P203, DOI 10.1016/bs.ai.2015.03.001; OKAYAMA Y, 1995, J IMMUNOL, V155, P1796; Piconese S, 2009, BLOOD, V114, P2639, DOI 10.1182/blood-2009-05-220004; Rivas MN, 2015, IMMUNITY, V42, P512, DOI 10.1016/j.immuni.2015.02.004; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Saxon A, 2004, CURR OPIN ALLERGY CL, V4, P563, DOI 10.1097/00130832-200412000-00015; Sayama Koichi, 2002, BMC Immunol, V3, P5, DOI 10.1186/1471-2172-3-5; Schwarz A, 2016, J ALLERGY CLIN IMMUN, V138, P1426, DOI 10.1016/j.jaci.2016.01.057; Shan MM, 2013, SCIENCE, V342, P447, DOI 10.1126/science.1237910; Smith M, 2008, J ALLERGY CLIN IMMUN, V121, P1460, DOI 10.1016/j.jaci.2008.03.025; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Sun JB, 2013, J IMMUNOL, V191, P4412, DOI 10.4049/jimmunol.1301324; Suzuki K, 2000, BLOOD, V96, P2172, DOI 10.1182/blood.V96.6.2172.h8002172_2172_2180; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Tachdjian R, 2010, J ALLERGY CLIN IMMUN, V125, P1128, DOI 10.1016/j.jaci.2010.01.054; Toru H, 1998, J ALLERGY CLIN IMMUN, V102, P491, DOI 10.1016/S0091-6749(98)70140-X; van Montfoort N, 2012, J IMMUNOL, V189, P92, DOI 10.4049/jimmunol.1103703; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Wisniewski J, 2013, CLIN EXP ALLERGY, V43, P164, DOI 10.1111/cea.12016; Xing W, 2011, P NATL ACAD SCI USA, V108, P14210, DOI 10.1073/pnas.1111048108; Yamada M, 2001, KIDNEY INT, V59, P1374, DOI 10.1046/j.1523-1755.2001.0590041374.x; Zhao W, 2006, J IMMUNOL, V177, P694, DOI 10.4049/jimmunol.177.1.694; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	76	51	54	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					189	+		10.1016/j.jaci.2017.03.045	http://dx.doi.org/10.1016/j.jaci.2017.03.045			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28479335	Green Accepted, Bronze			2022-12-18	WOS:000419312200025
J	Slack, J; Albert, MH; Balashov, D; Belohradsky, BH; Bertaina, A; Bleesing, J; Booth, C; Buechner, J; Buckley, RH; Ouachee-Chardin, M; Deripapa, E; Drabko, K; Eapen, M; Feuchtinger, T; Finocchi, A; Gaspar, HB; Ghosh, S; Gillio, A; Gonzalez-Granado, LI; Grunebaum, E; Gungor, T; Heilmann, C; Helminen, M; Higuchi, K; Imai, K; Kalwak, K; Kanazawa, N; Karasu, G; Kucuk, ZY; Laberko, A; Lange, A; Mahlaoui, N; Meisel, R; Moshous, D; Muramatsu, H; Parikh, S; Pasic, S; Schmid, I; Schuetz, C; Schulz, A; Schultz, KR; Shaw, PJ; Slatter, MA; Sykora, KW; Tamura, S; Taskinen, M; Wawer, A; Wolska-Kusnierz, B; Cowan, MJ; Fischer, A; Gennery, AR				Slack, James; Albert, Michael H.; Balashov, Dmitry; Belohradsky, Bernd H.; Bertaina, Alice; Bleesing, Jack; Booth, Claire; Buechner, Jochen; Buckley, Rebecca H.; Ouachee-Chardin, Marie; Deripapa, Elena; Drabko, Katarzyna; Eapen, Mary; Feuchtinger, Tobias; Finocchi, Andrea; Gaspar, H. Bobby; Ghosh, Sujal; Gillio, Alfred; Gonzalez-Granado, Luis I.; Grunebaum, Eyal; Gungor, Tayfun; Heilmann, Carsten; Helminen, Merja; Higuchi, Kohei; Imai, Kohsuke; Kalwak, Krzysztof; Kanazawa, Nubuo; Karasu, Gulsun; Kucuk, Zeynep Y.; Laberko, Alexandra; Lange, Andrzej; Mahlaoui, Nizar; Meisel, Roland; Moshous, D.; Muramatsu, Hideki; Parikh, Suhag; Pasic, Srdjan; Schmid, Irene; Schuetz, Catharina; Schulz, Ansgar; Schultz, Kirk R.; Shaw, Peter J.; Slatter, Mary A.; Sykora, Karl-Walter; Tamura, Shinobu; Taskinen, Mervi; Wawer, Angela; Wolska-Kusnierz, Beata; Cowan, Morton J.; Fischer, Alain; Gennery, Andrew R.		European Soc Blood Marrow; European Soc Immunodeficiencies; Stem Cell Transplant; Ctr Int Blood Marrow; Primary Immunodeficiency Treatment	Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ataxia-telangiectasia; Cernunnos-XLF deficiency; DNA repair disorders; DNA ligase IV deficiency; hematopoietic stem cell transplantation; Nijmegen breakage syndrome	SEVERE COMBINED IMMUNODEFICIENCY; CERNUNNOS-XLF DEFICIENCY; LIGASE IV MUTATIONS; FANCONI-ANEMIA; MARROW TRANSPLANTATION; HYPOMORPHIC MUTATIONS; ARTEMIS; PATIENT; BLOOD	Background: Rare DNA breakage repair disorders predispose to infection and lymphoreticular malignancies. Hematopoietic cell transplantation (HCT) is curative, but coadministered chemotherapy or radiotherapy is damaging because of systemic radiosensitivity. We collected HCT outcome data for Nijmegen breakage syndrome, DNA ligase IV deficiency, Cernunnos-XRCC4-like factor (Cernunnos-XLF) deficiency, and ataxia-telangiectasia (AT). Methods: Data from 38 centers worldwide, including indication, donor, conditioning regimen, graft-versus-host disease, and outcome, were analyzed. Conditioning was classified as myeloablative conditioning (MAC) if it contained radiotherapy or alkylators and reduced-intensity conditioning (RIC) if no alkylators and/or 150 mg/m(2) fludarabine or less and 40 mg/kg cyclophosphamide or less were used. Results: Fifty-five new, 14 updated, and 18 previously published patients were analyzed. Median age at HCT was 48 months (range, 1.5-552 months). Twenty-nine patients underwent transplantation for infection, 21 had malignancy, 13 had bone marrow failure, 13 received pre-emptive transplantation, 5 had multiple indications, and 6 had no information. Twenty-two received MAC, 59 received RIC, and 4 were infused; information was unavailable for 2 patients. Seventy-three of 77 patients with DNA ligase IV deficiency, Cernunnos-XLF deficiency, or Nijmegen breakage syndrome received conditioning. Survival was 53 (69%) of 77 and was worse for those receiving MAC than for those receiving RIC (P=.006). Most deaths occurred early after transplantation, suggesting poor tolerance of conditioning. Survival in patients with AT was 25%. Forty-one (49%) of 83 patients experienced acute GvHD, which was less frequent in those receiving RIC compared with those receiving MAC (26/56 [46%] vs 12/21 [57%], P=.45). Median follow-up was 35 months (range, 2-168 months). No secondary malignancies were reported during 15 years of follow-up. Growth and developmental delay remained after HCT; immune-mediated complications resolved. Conclusion: RIC HCT resolves DNA repair disorder associated immunodeficiency. Long-term follow-up is required for secondary malignancy surveillance. Routine HCT for AT is not recommended.	[Slack, James; Slatter, Mary A.; Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Albert, Michael H.; Belohradsky, Bernd H.; Schmid, Irene] Ludwig Maximilians Univ Munchen, Dr von Hauner Univ Childrens Hosp, Munich, Germany; [Balashov, Dmitry; Deripapa, Elena; Laberko, Alexandra] Fed Res Ctr Pediat Hematol Oncol & Immunol, Immunol & Hematopoiet Stem Cell Transplantat Dept, Moscow, Russia; [Bertaina, Alice] Osped Pediat Bambino Gesu, Dept Hematol & Oncol, Stem Cell Transplant Unit, Rome, Italy; [Bleesing, Jack; Kucuk, Zeynep Y.] Univ Cincinnati, Dept Pediat, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Booth, Claire; Gaspar, H. Bobby; Ghosh, Sujal] UCL Great Ormond St Inst Child Hlth, Infect Immun Inflammat Mol & Cellular Immunol Sec, London, England; [Buechner, Jochen] Oslo Univ Hosp, Dept Pediat Hematol & Oncol, Oslo, Norway; [Buckley, Rebecca H.] Duke Univ, Dept Pediat, Med Ctr, Sch Med, Durham, NC 27706 USA; [Buckley, Rebecca H.] Duke Univ, Sch Med, Dept Immunol, Med Ctr, Durham, NC USA; [Ouachee-Chardin, Marie] Robert Debre Hosp, Paediat BMT Unit, Paris, France; [Drabko, Katarzyna] Med Univ Lublin, Dept Pediat Hematol Oncol & Bone Marrow Transplan, Lublin, Poland; [Eapen, Mary] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA; [Feuchtinger, Tobias] Univ Childrens Hosp Tubingen, Dept Haematol & Oncol, Tubingen, Germany; [Ghosh, Sujal; Meisel, Roland] Heinrich Heine Univ, Ctr Child & Adolescent Hlth, Dept Pediat Oncol Hematol & Clin Immunol, Med Fac,Div Pediat Stem Cell Therapy, Dusseldorf, Germany; [Gillio, Alfred] Hackensack Univ, Med Ctr, Joseph M Sanzari Childrens Hosp, Hackensack, NJ USA; [Gonzalez-Granado, Luis I.] Hosp 12 Octubre, Immunodeficiencies Hematol & Oncol Unit, Pediat, Madrid, Spain; [Gonzalez-Granado, Luis I.] Univ Complutense, Inst Invest, Hosp Octubre I 12 12, Madrid, Spain; [Grunebaum, Eyal] Univ Toronto, Hosp Sick Children, Div Immunol & Allergy, Toronto, ON, Canada; [Gungor, Tayfun] Univ Childrens Hosp Zurich, Div Stem Cell Transplantat, Zurich, Switzerland; [Heilmann, Carsten] BorneUngeKlinikken, Copenhagen, Denmark; [Helminen, Merja] Univ Hosp Tampere, Paediat Res Ctr, Tampere, Finland; [Higuchi, Kohei] Osaka Med Ctr & Res Inst forMaternal & Child Hlth, Osaka, Japan; [Imai, Kohsuke] Tokyo Med & Dent Univ, Dept Community Pediat Perinatal & Maternal Med, Tokyo, Japan; [Kalwak, Krzysztof] Wroclaw Med Univ, Dept Pediat Hematol Oncol & BMT, Wroclaw, Poland; [Kanazawa, Nubuo] Wakayama Med Univ, Dept Dermatol, Wakayama, Japan; [Tamura, Shinobu] Wakayama Med Univ, Dept Hematol & Oncol, Wakayama, Japan; [Karasu, Gulsun] Bahcesehir Univ, Fac Med, Goztepe Medicalpark Hosp, Pediat Stem Cell Transplantat Unit, Istanbul, Turkey; [Lange, Andrzej] Polish Acad Sci, Lower Silesian Ctr Cellular Transplantat, Hirszfeld Inst Immunol & Expt Therapy, Wroclaw, Poland; [Mahlaoui, Nizar] Necker Enfants Malad Univ Hosp, AP HP, French Natl Reference Ctr Primary Immune Deficien, Paris, France; [Mahlaoui, Nizar; Moshous, D.; Fischer, Alain] Necker Childrens Hosp, AP HP, Immunohematol Unit, Paris, France; [Muramatsu, Hideki] Nagoya Univ, Grad Sch Med, Dept Pediat, Nagoya, Aichi, Japan; [Pasic, Srdjan] Univ Belgrade, Med Fac, Mother & Child Hlth Inst, Belgrade, Serbia; [Schuetz, Catharina; Schulz, Ansgar] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany; [Schultz, Kirk R.] BC Childrens Hosp, Michael Cuccione Childhood Canc Res Program, Vancouver, BC, Canada; [Schultz, Kirk R.] Child & Family Res Inst, Vancouver, BC, Canada; [Shaw, Peter J.] Childrens Hosp Westmead, Dept Oncol, Westmead, NSW, Australia; [Slatter, Mary A.; Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Primary Immunodeficiency Grp, Newcastle Upon Tyne, Tyne & Wear, England; [Sykora, Karl-Walter] Hannover Med, Dept Pediat Hematol Oncol, Hannover, Germany; [Taskinen, Mervi] Helsinki Univ Hosp, Dept Pediat Hematol Oncol & Stem Cell Transplanta, Helsinki, Finland; [Wawer, Angela] Tech Univ Munich, Paediat Haematol & Oncol, Kinderklin, Krankenhaus Munchen Schwabing, Munich, Germany; [Wolska-Kusnierz, Beata] Childrens Mem Hlth Inst, Dept Immunol, Warsaw, Poland; [Cowan, Morton J.] Univ Calif San Francisco, Benioff Childrens Hosp, Allergy Immunol & Blood & Marrow Transplant Div, San Francisco, CA 94143 USA; [Finocchi, Andrea] Univ Roma Tor Vergata, Dept Syst Med, Unit Immune & Infect Dis, Childrens Hosp Bambino Gesu, Rome, Italy; [Parikh, Suhag] Duke Univ, Med Ctr, Sch Med, Pediat Blood & Marrow Transplant Program, Durham, NC 27710 USA	Newcastle University - UK; University of Munich; Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology & Immunology; IRCCS Bambino Gesu; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of London; University College London; University of Oslo; Duke University; Duke University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Medical University of Lublin; Center for International Blood & Marrow Transplant Research; Medical College of Wisconsin; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; Heinrich Heine University Dusseldorf; Hackensack University Medical Center; Hospital Universitario 12 de Octubre; Complutense University of Madrid; Hospital Universitario 12 de Octubre; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University Children's Hospital Zurich; Tampere University; Tampere University Hospital; Tokyo Medical & Dental University (TMDU); Wroclaw Medical University; Wakayama Medical University; Wakayama Medical University; Bahcesehir University; Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Nagoya University; University of Belgrade; Ulm University; BC Childrens Hospital; University of British Columbia; Child & Family Research Institute; University of Sydney; Newcastle University - UK; Hannover Medical School; University of Helsinki; Helsinki University Central Hospital; Munchen Klinik; Technical University of Munich; Children's Memorial Health Institute; University of California System; University of California San Francisco; IRCCS Bambino Gesu; University of Rome Tor Vergata; Duke University	Gennery, AR (corresponding author), Great North Childrens Hosp, Clin Resource Bldg,Floor 4,Block 2, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	a.r.gennery@ncl.ac.uk	Muramatsu, Hideki/ABA-3376-2021; Mahlaoui, Nizar/J-7928-2017; Tamura, Shinobu/AAZ-7416-2020; Schultz, Kirk R/AAA-3440-2022; Moshous, Despina/B-7507-2017; Karasu, Gulsun/AAR-6689-2020; Lange, Andrzej/AAR-3247-2021; Güngör, Tayfun/ABF-4256-2020; shaw, peter John/D-8255-2011; Imai, Kohsuke/Q-2602-2015; Finocchi, Andrea/K-5926-2016; Gonzalez-Granado, Luis Ignacio/ABG-4515-2020; Kanazawa, Nobuo/AAM-7353-2021; Kalwak, Krzysztof/U-1724-2019; Gonzalez-Granado, Luis Ignacio/B-9257-2009; Balashov, Dmitry/AAW-8132-2020; MAHLAOUI, Nizar/AAH-6103-2020; Buckley, Rebecca/AAB-1578-2019; Muramatsu, Hideki/I-3763-2012; Feuchtinger, Tobias/AAS-3869-2021; Booth, Claire/I-3667-2016	Muramatsu, Hideki/0000-0002-8801-0021; Mahlaoui, Nizar/0000-0002-0030-8094; Moshous, Despina/0000-0001-6719-3693; Lange, Andrzej/0000-0003-3544-1853; Güngör, Tayfun/0000-0002-3261-1186; shaw, peter John/0000-0003-0101-4482; Imai, Kohsuke/0000-0003-2132-8403; Finocchi, Andrea/0000-0003-0958-8536; Gonzalez-Granado, Luis Ignacio/0000-0001-6917-8980; Kanazawa, Nobuo/0000-0003-3000-9711; Kalwak, Krzysztof/0000-0003-1174-5799; Gonzalez-Granado, Luis Ignacio/0000-0001-6917-8980; MAHLAOUI, Nizar/0000-0002-0030-8094; Feuchtinger, Tobias/0000-0002-8517-9681; Drabko, Katarzyna/0000-0002-7094-9129; Wolska-Kusnierz, Beata/0000-0003-4863-4443; Buechner, Jochen/0000-0001-5848-4501; Eapen, Mary/0000-0001-6193-4243; Schultz, Kirk/0000-0002-0001-6438; Booth, Claire/0000-0002-2626-5037; Bertaina, Alice/0000-0002-3729-436X	Division of Allergy, Immunology, and Transplantation; National Institute of Allergy and Infectious Diseases; Intramural Research Program of the National Institute of Allergy and Infectious Diseases; Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health [U54-AI082973]; Public Health Service grant from the National Cancer Institute [U24-CA76518]; National Heart, Lung, and Blood Institute; Fondo de Investigacion Sanitaria [FIS-PI16/2053]; Great Ormond Street Hospital Children's Charity; National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital and University College London; Grants-in-Aid for Scientific Research [15K09640] Funding Source: KAKEN; NATIONAL CANCER INSTITUTE [U24CA076518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI082973] Funding Source: NIH RePORTER	Division of Allergy, Immunology, and Transplantation; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural Research Program of the National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health; Public Health Service grant from the National Cancer Institute; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Fondo de Investigacion Sanitaria(Instituto de Salud Carlos III); Great Ormond Street Hospital Children's Charity; National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital and University College London; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	M.J.C. was supported by the Division of Allergy, Immunology, and Transplantation; the National Institute of Allergy and Infectious Diseases; the Intramural Research Program of the National Institute of Allergy and Infectious Diseases; and the Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health (U54-AI082973). M.E. was funded in part by Public Health Service grant U24-CA76518 from the National Cancer Institute; the National Heart, Lung, and Blood Institute; and the National Institute of Allergy and Infectious Diseases. L.I.G.-G. was supported by a grant from Fondo de Investigacion Sanitaria (FIS-PI16/2053). H.B.G. is supported by the Great Ormond Street Hospital Children's Charity and by the National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital and University College London.	Albert MH, 2010, BONE MARROW TRANSPL, V45, P622, DOI 10.1038/bmt.2009.207; Bacigalupo A, 2009, BIOL BLOOD MARROW TR, V15, P1628, DOI 10.1016/j.bbmt.2009.07.004; Booth C, 2011, BLOOD, V117, P53, DOI 10.1182/blood-2010-06-284935; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Cagdas D, 2012, PEDIATR TRANSPLANT, V16, pE167, DOI 10.1111/j.1399-3046.2011.01491.x; Chao MM, 2015, KLIN PADIATR, V227, P157, DOI 10.1055/s-0035-1548841; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; de la Fuente J, 2003, BONE MARROW TRANSPL, V32, P653, DOI 10.1038/sj.bmt.1704219; de Latour RP, 2013, BLOOD, V122, P4279, DOI 10.1182/blood-2013-01-479733; Deeg HJ, 1996, BLOOD, V87, P386, DOI 10.1182/blood.V87.1.386.bloodjournal871386; Enders A, 2006, J IMMUNOL, V176, P5060, DOI 10.4049/jimmunol.176.8.5060; Faraci M, 2009, PEDIATR TRANSPLANT, V13, P785, DOI 10.1111/j.1399-3046.2008.01028.x; Gadalla SM, 2013, BIOL BLOOD MARROW TR, V19, P1238, DOI 10.1016/j.bbmt.2013.05.021; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V26, pe1; Ghosh S, 2012, J CLIN IMMUNOL, V32, P438, DOI 10.1007/s10875-012-9654-7; Goodarzi AA, 2013, ADV GENET, V82, P1, DOI 10.1016/B978-0-12-407676-1.00001-9; Gruhn B, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-5; Grunebaum E, 2008, J ALLERGY CLIN IMMUN, V122, P1219, DOI 10.1016/j.jaci.2008.08.031; Gungor T, 2014, LANCET, V383, P436, DOI [10.1016/s0140-6736(13)62069-3, 10.1016/S0140-6736(13)62069-3]; Mahlaoui N, 2013, BLOOD, V121, P1510, DOI 10.1182/blood-2012-08-448118; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Ouachee-Chardin M, 2006, PEDIATRICS, V117, pE743, DOI 10.1542/peds.2005-1789; Schuetz C, 2014, BLOOD, V123, P281, DOI 10.1182/blood-2013-01-476432; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Stajner T, 2013, J CLIN MICROBIOL, V51, P2686, DOI 10.1128/JCM.01077-13; Straathof KC, 2009, LANCET, V374, P912, DOI 10.1016/S0140-6736(09)60945-4; Tamura S, 2015, CLIN IMMUNOL, V160, P255, DOI 10.1016/j.clim.2015.07.004; Ussowicz M, 2013, BONE MARROW TRANSPL, V48, P740, DOI 10.1038/bmt.2012.207; van der Burg M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121; van der Burg M, 2009, J CLIN INVEST, V119, P91, DOI 10.1172/JCI37141; Wang C, 2013, INT J RADIAT ONCOL, V86, P440, DOI 10.1016/j.ijrobp.2013.01.011; Waters CA, 2014, DNA REPAIR, V17, P39, DOI 10.1016/j.dnarep.2014.02.008; Wolska-Kusnierz B, 2015, J CLIN IMMUNOL, V35, P538, DOI 10.1007/s10875-015-0186-9; Woodbine L, 2014, DNA REPAIR, V17, P9, DOI 10.1016/j.dnarep.2014.04.002; Woodbine L, 2013, J CLIN INVEST, V123, P2969, DOI 10.1172/JCI67349; Wozniak M, 2015, PEDIATR TRANSPLANT, V19, pE51, DOI 10.1111/petr.12420	40	51	51	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					322	+		10.1016/j.jaci.2017.02.036	http://dx.doi.org/10.1016/j.jaci.2017.02.036			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28392333	Green Accepted, Green Published, Green Submitted			2022-12-18	WOS:000419312200037
J	Achour, A; Simon, Q; Mohr, A; Seite, JF; Youinou, P; Bendaoud, B; Ghedira, I; Pers, JO; Jamin, C				Achour, Achouak; Simon, Quentin; Mohr, Audrey; Seite, Jean-Francois; Youinou, Pierre; Bendaoud, Boutahar; Ghedira, Ibtissem; Pers, Jacques-Olivier; Jamin, Christophe			Human regulatory B cells control the T-FH cell response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory B cells; follicular T helper cells; IL-12; IL-21; antibody production; humoral immune response	HUMAN DENDRITIC CELLS; CUTTING EDGE; DIFFERENTIATION; IL-21; AUTOIMMUNITY; INDUCTION; SUBSET; SUPPRESSION; PHENOTYPE; FOLLICLES	Background: Follicular helper T (T-FH) cells support terminal B-cell differentiation. Human regulatory B (Breg) cells modulate cellular responses, but their control of T-FH cell-dependent humoral immune responses is unknown. Objective: We sought to assess the role of Breg cells on T-FH cell development and function. Methods: Human T cells were polyclonally stimulated in the presence of IL-12 and IL-21 to generate T-FH cells. They were cocultured with B cells to induce their terminal differentiation. Breg cells were included in these cultures, and their effects were evaluated by using flow cytometry and ELISA. Results: B-cell lymphoma 6, IL-21, inducible costimulator, CXCR5, and programmed cell death protein 1 (PD-1) expressions increased on stimulated human T cells, characterizing T-FH cell maturation. In cocultures they differentiated B cells into CD138(+) plasma and IgD(-) CD27(+) memory cells and triggered immunoglobulin secretions. Breg cells obtained by Toll-like receptor 9 and CD40 activation of B cells prevented T-FH cell development. Added to T-FH cell and B-cell cocultures, they inhibited B-cell differentiation, impeded immunoglobulin secretions, and expanded Foxp(3+) CXCR5(+) PD-1(+) follicular regulatory T cells. Breg cells modulated IL-21 receptor expressions on T-FH cells and B cells, and their suppressive activities involved CD40, CD80, CD86, and intercellular adhesion molecule interactions and required production of IL-10 and TGF-beta. C Conclusion: HumanBreg cells control T-FH cell maturation, expand follicular regulatory T cells, and inhibit the T-FH cell-mediated antibody secretion. These novel observations demonstrate a role for the Breg cell in germinal center reactions and suggest that deficient activities might impair the T-FH cell-dependent control of humoral immunity and might lead to the development of aberrant autoimmune responses.	[Achour, Achouak; Simon, Quentin; Mohr, Audrey; Seite, Jean-Francois; Youinou, Pierre; Pers, Jacques-Olivier; Jamin, Christophe] Univ Brest, INSERM, U1227, Lymphocytes & Autoimmunite B, Brest, France; [Achour, Achouak; Simon, Quentin; Mohr, Audrey; Seite, Jean-Francois; Youinou, Pierre; Pers, Jacques-Olivier; Jamin, Christophe] LabEx IGO, Brest, France; [Seite, Jean-Francois; Youinou, Pierre; Bendaoud, Boutahar; Pers, Jacques-Olivier; Jamin, Christophe] CHRU Morvan, Lab Immunol, BP 824, F-29609 Brest, France; [Ghedira, Ibtissem] Fac Pharm, Dept Immunol, Res Unit UR 03 07 02, Monastir, Tunisia	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bretagne Occidentale; CHU Brest; Universite de Monastir	Jamin, C (corresponding author), CHRU Morvan, Lab Immunol, BP 824, F-29609 Brest, France.	christophe.jamin@univ-brest.fr	Simon, Quentin/AAW-8810-2020; Pers, Jacques-Olivier/AGG-7221-2022; Mohr, Audrey/AAB-4999-2019; Mohr, Audrey/P-2999-2017	Simon, Quentin/0000-0002-2383-2809; Mohr, Audrey/0000-0001-7031-8602; Mohr, Audrey/0000-0001-7031-8602	Labex IGO project - "Investissements d'Avenir'' French Government program [ANR-11-LABX-0016-01]	Labex IGO project - "Investissements d'Avenir'' French Government program(French National Research Agency (ANR))	This work has been carried out thanks to the support of the Labex IGO project (no. ANR-11-LABX-0016-01) funded by the "Investissements d'Avenir'' French Government program, managed by the French National Research Agency (ANR).	Batten M, 2010, J EXP MED, V207, P2895, DOI 10.1084/jem.20100064; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Bryant VL, 2007, J IMMUNOL, V179, P8180, DOI 10.4049/jimmunol.179.12.8180; Carter NA, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3736; Choi YS, 2011, IMMUNITY, V34, P932, DOI 10.1016/j.immuni.2011.03.023; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Cyster JG, 2010, NAT IMMUNOL, V11, P989, DOI 10.1038/ni.1946; Dienz O, 2009, J EXP MED, V206, P69, DOI 10.1084/jem.20081571; DiLillo DJ, 2010, ANN NY ACAD SCI, V1183, P38, DOI 10.1111/j.1749-6632.2009.05137.x; Eto D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017739; Ettinger R, 2005, J IMMUNOL, V175, P7867, DOI 10.4049/jimmunol.175.12.7867; Ettinger R, 2008, IMMUNOL REV, V223, P60, DOI 10.1111/j.1600-065X.2008.00631.x; Evans JG, 2007, J IMMUNOL, V178, P7868, DOI 10.4049/jimmunol.178.12.7868; Good KL, 2006, J IMMUNOL, V177, P5236, DOI 10.4049/jimmunol.177.8.5236; Goodnow CC, 2010, NAT IMMUNOL, V11, P681, DOI 10.1038/ni.1900; Iikuni N, 2009, J IMMUNOL, V183, P1518, DOI 10.4049/jimmunol.0901163; Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249; Jamin C, 2008, ARTHRITIS RHEUM-US, V58, P1900, DOI 10.1002/art.23487; Lemoine S, 2011, J AUTOIMMUN, V36, P228, DOI 10.1016/j.jaut.2011.01.005; Li HS, 2015, EUR J IMMUNOL, V45, P298, DOI 10.1002/eji.201444911; Lim HW, 2005, J IMMUNOL, V175, P4180, DOI 10.4049/jimmunol.175.7.4180; Lim HW, 2004, J CLIN INVEST, V114, P1640, DOI 10.1172/JCI22325; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Linterman MA, 2009, J EXP MED, V206, P561, DOI 10.1084/jem.20081886; Ma CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994; Ma CS, 2009, IMMUNOL CELL BIOL, V87, P590, DOI 10.1038/icb.2009.64; Matsushita T, 2008, J CLIN INVEST, V118, P3420, DOI 10.1172/JCI36030; Mauri C, 2012, ANNU REV IMMUNOL, V30, P221, DOI 10.1146/annurev-immunol-020711-074934; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Morva A, 2012, BLOOD, V119, P106, DOI 10.1182/blood-2011-06-360768; Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676; Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297; Rasheed AU, 2006, EUR J IMMUNOL, V36, P1892, DOI 10.1002/eji.200636136; Schmitt N, 2009, IMMUNITY, V31, P158, DOI 10.1016/j.immuni.2009.04.016; Simpson N, 2010, ARTHRITIS RHEUM-US, V62, P234, DOI 10.1002/art.25032; Subramanian S, 2006, P NATL ACAD SCI USA, V103, P9970, DOI 10.1073/pnas.0603912103; Suto A, 2008, J EXP MED, V205, P1369, DOI 10.1084/jem.20072057; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Victora GD, 2012, BLOOD, V120, P2240, DOI 10.1182/blood-2012-03-415380; Vinuesa CG, 2011, IMMUNITY, V35, P671, DOI 10.1016/j.immuni.2011.11.001; Vinuesa CG, 2010, IMMUNOL REV, V237, P72, DOI 10.1111/j.1600-065X.2010.00937.x; Vinuesa CG, 2005, NAT REV IMMUNOL, V5, P853, DOI 10.1038/nri1714; Vinuesa CG, 2005, NATURE, V435, P452, DOI 10.1038/nature03555; Wollenberg I, 2011, J IMMUNOL, V187, P4553, DOI 10.4049/jimmunol.1101328; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017; Yang X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062855; Yoshizaki A, 2012, NATURE, V491, P264, DOI 10.1038/nature11501; Yu D, 2009, IMMUNITY, V31, P457, DOI 10.1016/j.immuni.2009.07.002	49	51	54	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					215	222		10.1016/j.jaci.2016.09.042	http://dx.doi.org/10.1016/j.jaci.2016.09.042			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	27865860	Bronze			2022-12-18	WOS:000404542000021
J	Engebretsen, KA; Bager, P; Wohlfahrt, J; Skov, L; Zachariae, C; Andersen, AMN; Melbye, M; Thyssen, JP				Engebretsen, Kristiane A.; Bager, Peter; Wohlfahrt, Jan; Skov, Lone; Zachariae, Claus; Andersen, Anne-Marie Nybo; Melbye, Mads; Thyssen, Jacob P.			Prevalence of atopic dermatitis in infants by domestic water hardness and season of birth: Cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; birth cohort; climate; risk factors; season of birth; water hardness	SKIN BARRIER FUNCTION; AMINO-ACID CONTENT; STRATUM-CORNEUM; ENVIRONMENTAL HUMIDITY; FILAGGRIN MUTATIONS; CHILDHOOD ECZEMA; HAIRLESS MICE; DISEASE; ASSOCIATION; TEMPERATURE	Background: Atopic dermatitis (AD) appears to be more common in regions with hard domestic water and in children with a fall/winter birth. However, it is unknown whether a synergistic effect exists. Objective: We sought to evaluate the association between domestic water hardness and season of birth, respectively, with onset of AD within the first 18 months of life in a large Danish birth cohort. Methods: Of children from the Danish National Birth Cohort, 52,950 were included. History of physician-diagnosed AD and population characteristics were obtained from interviews. Birth data were obtained from the Civil Registration System, and domestic water hardness data were obtained from the Geological Survey of Denmark and Greenland. The relative prevalence (RP) of AD was calculated by using log-linear binomial regression. Results: The prevalence of AD was 15.0% (7,942/52,950). The RP of AD was 5% (RPtrend, 1.05; 95% CI, 1.03-1.07) higher for each 58 increase in domestic water hardness (range, 6.60-35.90 German degrees of hardness [118-641 mg/L]). Although the RP of AD was higher in children with a fall (RP, 1.24; 95% CI, 1.17-1.31) or winter (RP, 1.18; 95% CI, 1.11-1.25) birth, no significant interaction was observed with domestic water hardness. The population attributable risk of hard domestic water on AD was 2%. Conclusion: We observed that early exposure to hard domestic water and a fall/winter birth was associated with an increase in the relative prevalence of AD within the first 18 months of life. Although the 2 exposures did not interact synergistically, a doseresponse relationship was observed between domestic water hardness and AD.	[Engebretsen, Kristiane A.; Thyssen, Jacob P.] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Natl Allergy Res Ctr, Hellerup, Denmark; [Engebretsen, Kristiane A.; Skov, Lone; Zachariae, Claus; Thyssen, Jacob P.] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Hellerup, Denmark; [Bager, Peter; Wohlfahrt, Jan; Melbye, Mads] Statens Serum Inst, Dept Epidemiol Res, Copenhagen, Denmark; [Andersen, Anne-Marie Nybo] Univ Copenhagen, Sect Social Med, Dept Publ Hlth, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; Statens Serum Institut; University of Copenhagen	Thyssen, JP (corresponding author), Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Natl Allergy Res Ctr, Kildegardsvej 28, DK-2900 Hellerup, Denmark.	jacob.pontoppidan.thyssen@regionh.dk	Thyssen, Jacob/ABD-8517-2020; Bager, Peter/R-3310-2019; Skov, Lone/W-3575-2018; Zachariae, Claus Otto Carl/G-6144-2018; Nybo Andersen, Anne-Marie/AAA-1997-2022	Bager, Peter/0000-0002-3577-8459; Zachariae, Claus Otto Carl/0000-0001-5506-1319; Nybo Andersen, Anne-Marie/0000-0002-4296-8488; melbye, mads/0000-0001-8264-6785; Skov, Lone/0000-0002-4784-9680; Thyssen, Jacob Pontoppidan/0000-0003-3770-1743	Lundbeck Foundation; Oak Foundation fellowship; Danish National Research Foundation; Pharmacy Foundation; Egmont Foundation; March Dimes Birth Defects Foundation; Augustinus Foundation; Health Foundation; Lundbeck Foundation [R139-2012-12679] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden); Oak Foundation fellowship; Danish National Research Foundation(Danmarks Grundforskningsfond); Pharmacy Foundation; Egmont Foundation; March Dimes Birth Defects Foundation; Augustinus Foundation; Health Foundation; Lundbeck Foundation(Lundbeckfonden)	J.P.T. and K.A.E. are financially supported by an unrestricted grant from the Lundbeck Foundation. P.B. is supported by an Oak Foundation fellowship. The Danish National Research Foundation has established the Danish Epidemiology Science Centre, which initiated and created the Danish National Birth Cohort (DNBC); furthermore, the cohort is a result of a major grant from this foundation. Additional support for the DNBC is obtained from the Pharmacy Foundation, the Egmont Foundation, the March Dimes Birth Defects Foundation, the Augustinus Foundation, and the Health Foundation.	Andersen AMN, 2011, SCAND J PUBLIC HEALT, V39, P115, DOI 10.1177/1403494811407674; Aoki Toshiyuki, 1998, Allergology International, V47, P137, DOI 10.2332/allergolint.47.137; Arnedo-Pena A, 2007, SALUD PUBLICA MEXICO, V49, P295, DOI 10.1590/S0036-36342007000400009; Ashida Y, 2003, BRIT J DERMATOL, V149, P240, DOI 10.1046/j.1365-2133.2003.05408.x; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Chaumont A, 2012, ENVIRON RES, V116, P52, DOI 10.1016/j.envres.2012.04.013; Conti A., 1996, International Journal of Cosmetic Science, V18, P1, DOI 10.1111/j.1467-2494.1996.tb00131.x; Engebretsen KA, 2016, J EUR ACAD DERMATOL, V30, P223, DOI 10.1111/jdv.13301; Font-Ribera L, 2015, ENVIRON RES, V142, P579, DOI 10.1016/j.envres.2015.07.013; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Katagiri C, 2003, J DERMATOL SCI, V31, P29, DOI 10.1016/S0923-1811(02)00137-8; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kristensen I. T., 2006, LANDDISTRIKTSKOMMUNE; Kusunoki T, 1999, J ALLERGY CLIN IMMUN, V103, P1148, DOI 10.1016/S0091-6749(99)70191-0; Kuzume K, 2007, PEDIATR ALLERGY IMMU, V18, P281, DOI 10.1111/j.1399-3038.2006.00526.x; Lockett GA, 2016, ALLERGY, V71, P1314, DOI 10.1111/all.12882; Marcussen H, 2013, FOOD RES INT, V54, P389, DOI 10.1016/j.foodres.2013.07.017; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; McNally NJ, 1998, LANCET, V352, P527, DOI 10.1016/S0140-6736(98)01402-0; MIDDLETO.JD, 1969, BRIT J DERMATOL, V81, P717, DOI 10.1111/j.1365-2133.1969.tb15930.x; MIDDLETON JD, 1973, J SOC COSMET CHEM, V24, P239; Miyake Y, 2004, ENVIRON RES, V94, P33, DOI 10.1016/S0013-9351(03)00068-9; Nikolovski J, 2008, J INVEST DERMATOL, V128, P1728, DOI 10.1038/sj.jid.5701239; Olsen J, 2001, SCAND J PUBLIC HEALT, V29, P300, DOI 10.1177/14034948010290040201; Pedersen CB, 2006, DAN MED BULL, V53, P441; Perkin MR, 2016, J ALLERGY CLIN IMMUN, V138, P509, DOI 10.1016/j.jaci.2016.03.031; Sato J, 2001, ARCH DERMATOL RES, V293, P477, DOI 10.1007/s004030100262; Silverberg JI, 2015, BRIT J DERMATOL, V173, P1400, DOI 10.1111/bjd.14031; Silverberg JI, 2013, J INVEST DERMATOL, V133, P1752, DOI 10.1038/jid.2013.19; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Simpson EL, 2010, J AM ACAD DERMATOL, V63, P587, DOI 10.1016/j.jaad.2009.11.011; Tanaka A, 2009, ALLERGY, V64, P556; Tanaka A, 2015, ACTA DERM-VENEREOL, V95, P787, DOI 10.2340/00015555-2083; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Thomas KS, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15080; Thomas KS, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000395; Thysen AH, 2015, J ALLERGY CLIN IMMUN, V137, pe1; Thysen AH, 2015, J ALLERGY CLIN IMMUN, V136, P1123, DOI 10.1016/j.jaci.2015.04.044; Thyssen JP, 2015, J ALLERGY CLIN IMMUN, V136, P1163, DOI 10.1016/j.jaci.2015.06.042; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Togawa Y, 2014, J DERMATOL SCI, V76, P269, DOI 10.1016/j.jdermsci.2014.10.009; Wang Ting-Shun, 2014, Reviews on Environmental Health, V29, P217, DOI 10.1515/reveh-2014-0047; Warren R, 1996, CONTACT DERMATITIS, V35, P337, DOI 10.1111/j.1600-0536.1996.tb02414.x; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; WILDNAUER RH, 1971, J INVEST DERMATOL, V56, P72, DOI 10.1111/1523-1747.ep12292018; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; World Health Organization, 2009, CALC MAGN DRINK WAT; Xu F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036174; Yemaneberhan H, 2004, CLIN EXP ALLERGY, V34, P779, DOI 10.1111/j.1365-2222.2004.1946.x	52	51	52	3	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1568	+		10.1016/j.jaci.2016.11.021	http://dx.doi.org/10.1016/j.jaci.2016.11.021			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	28017882	Bronze			2022-12-18	WOS:000400465300017
J	Jusot, JF; Neill, DR; Waters, EM; Bangert, M; Collins, M; Moreno, LB; Lawan, KG; Moussa, M; Dearing, E; Everett, DB; Collard, JM; Kadioglu, A				Jusot, Jean-Francois; Neill, Daniel R.; Waters, Elaine M.; Bangert, Mathieu; Collins, Marisol; Moreno, Laura Bricio; Lawan, Katiellou G.; Moussa, Mouhaiminou Moussa; Dearing, Emma; Everett, Dean B.; Collard, Jean-Marc; Kadioglu, Aras			Airborne dust and high temperatures are risk factors for invasive bacterial disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Meningitis; climate; Neisseria meningitidis; Streptococcus pneumoniae; pollution; dust	STREPTOCOCCUS-PNEUMONIAE; MENINGITIS EPIDEMICS; COARSE PARTICLES; AIR-POLLUTION; SAHARAN DUST; PNEUMOLYSIN; COLONIZATION; VIRULENCE; OUTDOOR	Background: The Sahel region of West Africa has the highest bacterial meningitis attack and case fatality rate in the world. The effect of climatic factors on patterns of invasive respiratory bacterial disease is not well documented. Objective: We aimed to assess the link between climatic factors and occurrence of invasive respiratory bacterial disease in a Sahel region of Niger. Methods: We conducted daily disease surveillance and climatic monitoring over an 8-year period between January 1, 2003, and December 31, 2010, in Niamey, Niger, to determine risk factors for bacterial meningitis and invasive bacterial disease. We investigated the mechanistic effects of these factors on Streptococcus pneumoniae infection in mice. Results: High temperatures and low visibility (resulting from high concentrations of airborne dust) were identified as significant risk factors for bacterial meningitis. Dust inhalation or exposure to high temperatures promoted progression of stable asymptomatic pneumococcal nasopharyngeal carriage to pneumonia and invasive disease. Dust exposure significantly reduced phagocyte-mediated bacterial killing, and exposure to high temperatures increased release of the key pneumococcal toxin pneumolysin through increased bacterial autolysis. Conclusion: Our findings show that climatic factors can have a substantial influence on infectious disease patterns, altering density of pneumococcal nasopharyngeal carriage, reducing phagocytic killing, and resulting in increased inflammation and tissue damage and consequent invasiveness. Climatic surveillance should be used to forecast invasive bacterial disease epidemics, and simple control measures to reduce particulate inhalation might reduce the incidence of invasive bacterial disease in regions of the world exposed to high temperatures and increased airborne dust.	[Jusot, Jean-Francois; Collard, Jean-Marc] Ctr Rech Med & Sanit, Niamey, Niger; [Neill, Daniel R.; Waters, Elaine M.; Bangert, Mathieu; Collins, Marisol; Moreno, Laura Bricio; Dearing, Emma; Everett, Dean B.; Kadioglu, Aras] Univ Liverpool, Dept Clin Infect Microbiol & Immunol, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England; [Bangert, Mathieu] European Ctr Dis Prevent & Control ECDC, European Publ Hlth Microbiol Training Programme E, Stockholm, Sweden; [Lawan, Katiellou G.; Moussa, Mouhaiminou Moussa] Direct Meteorol Natl, Niamey, Niger; [Everett, Dean B.] Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi	University of Liverpool; European Centre for Disease Prevention & Control; University of Malawi	Kadioglu, A (corresponding author), Univ Liverpool, Dept Clin Infect Microbiol & Immunol, Inst Infect & Global Hlth, Ronald Ross Bldg,8 West Derby St, Liverpool L697BEA, Merseyside, England.	kadioglu@liverpool.ac.uk	Collard, Jean-Marc/Q-2342-2019; Bangert, Mathieu/K-7233-2019; Neill, Daniel/Q-6290-2019; Bricio-Moreno, Laura/AAD-2781-2019; Waters, Elaine/C-8460-2018	Collard, Jean-Marc/0000-0002-1490-3978; Neill, Daniel/0000-0002-7911-8153; Waters, Elaine/0000-0002-6573-3462; Everett, Dean/0000-0002-8458-6779; kadioglu, aras/0000-0003-1137-6321; Bangert, Mathieu/0000-0003-1320-8145; Bricio Moreno, Laura/0000-0002-4956-7142	Sanofi Pasteur [Men07]; Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom; Biotechnology and Biological Sciences Research Council [1510651] Funding Source: researchfish	Sanofi Pasteur; Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	French Ministry of Foreign Affairs (FSP No. 2005-174) and Sanofi Pasteur (contract Men07) supported the climatic surveillance. Infection modeling was funded by the Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.	Akaike H., 1973, 2 INT S INF THEOR; Bangert M, 2012, J INFECT DIS, V205, P1399, DOI 10.1093/infdis/jis223; Boisier P, 2007, CLIN INFECT DIS, V44, P657, DOI 10.1086/511646; Cemerski S, 2003, EUR J IMMUNOL, V33, P2178, DOI 10.1002/eji.200323898; Claus H, 2007, FEMS MICROBIOL REV, V31, P43, DOI 10.1111/j.1574-6976.2006.00047.x; Collard JM, 2011, EPIDEMIOL INFECT, V139, P1656, DOI 10.1017/S0950268810003092; Djibo S, 2003, TROP MED INT HEALTH, V8, P1118, DOI 10.1046/j.1360-2276.2003.01126.x; FOSTER SJ, 1995, J BACTERIOL, V177, P5723, DOI 10.1128/jb.177.19.5723-5725.1995; Garcia-Pando CP, 2014, ENVIRON HEALTH PERSP, V122, P679, DOI 10.1289/ehp.1306640; GREENWOOD BM, 1984, LANCET, V1, P1339; Gyan K, 2005, INT J BIOMETEOROL, V49, P371, DOI 10.1007/s00484-005-0257-3; Houston P, 2011, INFECT IMMUN, V79, P1153, DOI 10.1128/IAI.00364-10; Jackou-Boulama M, 2005, Med Trop (Mars), V65, P329; Kadioglu A, 2008, NAT REV MICROBIOL, V6, P288, DOI 10.1038/nrmicro1871; Kim SH, 2015, ANN OCCUP ENVIRON ME, V27, DOI 10.1186/s40557-014-0048-6; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; Lelieveld J, 2015, NATURE, V525, P367, DOI 10.1038/nature15371; Lundborg M, 2001, ENVIRON RES, V86, P244, DOI 10.1006/enrs.2001.4269; Martuzzi M, 2003, EUR RESPIR J, V21, p86S, DOI 10.1183/09031936.03.00403303; Molesworth AM, 2003, EMERG INFECT DIS, V9, P1287; MORTON DB, 1985, VET REC, V116, P431, DOI 10.1136/vr.116.16.431; Neill DR, 2014, AM J RESP CRIT CARE, V189, P1250, DOI 10.1164/rccm.201401-0128OC; OZER P, 2005, ENVIRON RISQUE SANTE, V4, P43; PATON JC, 1983, INFECT IMMUN, V40, P548, DOI 10.1128/IAI.40.2.548-552.1983; Perez L, 2008, EPIDEMIOLOGY, V19, P800, DOI 10.1097/EDE.0b013e31818131cf; Richards L, 2010, IMMUNOBIOLOGY, V215, P251, DOI 10.1016/j.imbio.2009.12.004; Sajani SZ, 2012, EPIDEMIOLOGY, V23, P642, DOI 10.1097/EDE.0b013e318258c23f; SAXTON C, 1975, AVIAT SPACE ENVIR MD, V46, P41; Sultan B, 2005, PLOS MED, V2, P43, DOI 10.1371/journal.pmed.0020006; Tikhomirov Eugene, 1997, World Health Statistics Quarterly, V50, P170; Tobias A, 2011, INT J INFECT DIS, V15, pE503, DOI 10.1016/j.ijid.2011.03.008; Uberos J, 2007, EPIDEMIOL INFECT, V135, P857, DOI 10.1017/S0950268806007539; Vajanapoom N, 2001, J EXPO ANAL ENV EPID, V11, P97, DOI 10.1038/sj.jea.7500148; Wall EC, 2012, CLIN INFECT DIS, V54, P701, DOI 10.1093/cid/cir926; Wellmer A, 2002, INFECT IMMUN, V70, P6504, DOI 10.1128/IAI.70.11.6504-6508.2002; World Health Organization Geneva, 2005, Wkly Epidemiol Rec, V80, P313	36	51	52	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					977	+		10.1016/j.jaci.2016.04.062	http://dx.doi.org/10.1016/j.jaci.2016.04.062			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27523432	Green Published, hybrid			2022-12-18	WOS:000397295800029
J	Hansen, S; Strom, M; Maslova, E; Dahl, R; Hoffmann, HJ; Rytter, D; Bech, BH; Henriksen, TB; Granstrom, C; Halldorsson, TI; Chavarro, JE; Linneberg, A; Olsen, SF				Hansen, Susanne; Strom, Marin; Maslova, Ekaterina; Dahl, Ronald; Hoffmann, Hans Juergen; Rytter, Dorte; Bech, Bodil Hammer; Henriksen, Tine Brink; Granstrom, Charlotta; Halldorsson, Thorhallur I.; Chavarro, Jorge E.; Linneberg, Allan; Olsen, Sjurdur F.			Fish oil supplementation during pregnancy and allergic respiratory disease in the adult offspring	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Randomized controlled trial; fetal programming; asthma; allergies; long-chain n-3 polyunsaturated fatty acids	RANDOMIZED CONTROLLED-TRIAL; FATTY-ACID STATUS; MEDITERRANEAN DIET; CORD BLOOD; HIGH-RISK; ASTHMA; INFANTS; LACTATION; CHILDREN; ATOPY	Background: Maternal supplementation with long-chain n-3 polyunsaturated fatty acids can have immunologic effects on the developing fetus through several anti-inflammatory pathways. However, there is limited knowledge of the long-term programming effects. Objective: In a randomized controlled trial from 1990 with 24 years of follow-up, our aim was to determine whether supplementation with 2.7 g of long-chain n-3 polyunsaturated fatty acids in pregnancy can reduce the risk of asthma in offspring and allergic respiratory disease. Methods: The randomized controlled trial included 533 women who were randomly assigned to receive fish oil during the third trimester of pregnancy, olive oil, or no oil in the ratio 2: 1: 1. The offspring were followed in a mandatory national prescription register, with complete follow-up for prescriptions related to the treatment of asthma and allergic rhinitis as primary outcomes. Furthermore, the offspring were invited to complete a questionnaire (74% participated) and attend a clinical examination (47% participated) at age 18 to 19 years. Results: In intention-to-treat analyses the probability of having had asthma medication prescribed was significantly reduced in the fish oil group compared with the olive oil group (hazard ratio, 0.54, 95% CI, 0.32-0.90; P = .02). The probability of having had allergic rhinitis medication prescribed was also reduced in the fish oil group compared with the olive oil group (hazard ratio, 0.70, 95% CI, 0.47-1.05; P = .09), but the difference was not statistically significant. Self-reported information collected at age 18 to 19 years supported these findings. No associations were detected with respect to lung function outcomes or allergic sensitization at 18 to 19 years of age. Conclusion: Maternal supplementation with fish oil might have prophylactic potential for long-term prevention of asthma in offspring.	[Hansen, Susanne; Strom, Marin; Maslova, Ekaterina; Granstrom, Charlotta; Halldorsson, Thorhallur I.; Olsen, Sjurdur F.] Statens Serum Inst, Dept Epidemiol Res, Ctr Fetal Programming, Copenhagen, Denmark; [Strom, Marin] Univ Faroe Islands, Fac Nat & Hlth Sci, Torshavn, Denmark; [Dahl, Ronald; Hoffmann, Hans Juergen] Aarhus Univ Hosp, Dept Pulm Med & Allergy, Aarhus, Denmark; [Dahl, Ronald] Odense Univ Hosp, Allergy Ctr, Odense, Denmark; [Rytter, Dorte; Bech, Bodil Hammer] Aarhus Univ, Epidemiol Sect, Dept Publ Hlth, DK-8000 Aarhus C, Denmark; [Henriksen, Tine Brink] Aarhus Univ Hosp, Dept Pediat, Skejby, Denmark; [Halldorsson, Thorhallur I.] Univ Iceland, Fac Food Sci & Nutr, Reykjavik, Iceland; [Halldorsson, Thorhallur I.] Landspitali Univ Hosp, Unit Nutr Res, Reykjavik, Iceland; [Chavarro, Jorge E.; Olsen, Sjurdur F.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA; [Chavarro, Jorge E.; Olsen, Sjurdur F.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Chavarro, Jorge E.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Chavarro, Jorge E.] Harvard Med Sch, Boston, MA USA; [Linneberg, Allan] Capital Reg Denmark, Res Ctr Prevent & Hlth, Copenhagen, Denmark; [Linneberg, Allan] Glostrup Univ Hosp, Dept Clin Expt Res, Glostrup, Denmark; [Linneberg, Allan] Univ Copenhagen, Dept Clin Med, Fac Hlth & Med Sci, DK-1168 Copenhagen, Denmark	Statens Serum Institut; University of the Faroe Islands; Aarhus University; University of Southern Denmark; Odense University Hospital; Aarhus University; Aarhus University; University of Iceland; Landspitali National University Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Copenhagen; University of Copenhagen	Hansen, S (corresponding author), Statens Serum Inst, Artillerivej 5, DK-2300 Copenhagen S, Denmark.	suu@ssi.dk	Chavarro, Jorge E/AAE-5665-2021; Hoffman, Hans Jurgen/I-6969-2018; Bech, Bodil Hammer/B-9646-2016; Hansen, Susanne/AAE-7275-2021; Hansen, Susanne/F-1657-2017	Chavarro, Jorge E/0000-0002-4436-9630; Hoffman, Hans Jurgen/0000-0002-6743-7931; Bech, Bodil Hammer/0000-0002-0287-3687; Hansen, Susanne/0000-0002-9550-6703; Strom, Marin/0000-0003-1926-6610; Linneberg, Allan/0000-0002-0994-0184; Olsen, Sjurdur/0000-0003-3017-7096; Rytter, Dorte/0000-0003-1518-0975; Henriksen, Tine Brink/0000-0001-6933-8294; Halldorsson, Thorhallur/0000-0002-3488-0777	National Center for Complementary and Integrative Health (NCCIH) [R21AT004603]; Danish Agency for Science, Technology and Innovation [DSF: 09-067124, DSF: 09-063072, DFS: 2101-06-0005, FSS: 09-065631]; Lundbeck Foundation [R13-A907]; Danish Lung Association [2-2010]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT004603] Funding Source: NIH RePORTER	National Center for Complementary and Integrative Health (NCCIH); Danish Agency for Science, Technology and Innovation; Lundbeck Foundation(Lundbeckfonden); Danish Lung Association; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	Supported by grant no. R21AT004603 from the National Center for Complementary and Integrative Health (NCCIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCCIH or the National Institutes of Health. This study was further supported by the Danish Agency for Science, Technology and Innovation (DSF: 09-067124 [Centre for Fetal Programming], DSF: 09-063072 [Danish Obesity Research Centre], DFS: 2101-06-0005, and FSS: 09-065631), the Lundbeck Foundation (R13-A907), and the Danish Lung Association (2-2010).	ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Boris J, 2004, LIPIDS, V39, P1191, DOI 10.1007/s11745-004-1347-7; Calder PC, 2015, BBA-MOL CELL BIOL L, V1851, P469, DOI 10.1016/j.bbalip.2014.08.010; Calder PC, 2010, P NUTR SOC, V69, P373, DOI 10.1017/S0029665110001552; Chatzi L, 2008, THORAX, V63, P507, DOI 10.1136/thx.2007.081745; de Batlle J, 2008, ALLERGY, V63, P1310, DOI 10.1111/j.1398-9995.2008.01722.x; Duijts L, 2012, EUR J EPIDEMIOL, V27, P5, DOI 10.1007/s10654-012-9657-y; Dunstan JA, 2003, CLIN EXP ALLERGY, V33, P442, DOI 10.1046/j.1365-2222.2003.01590.x; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Furuhjelm C, 2011, PEDIAT ALLERG IMM-UK, V22, P505, DOI 10.1111/j.1399-3038.2010.01096.x; Furuhjelm C, 2009, ACTA PAEDIATR, V98, P1461, DOI 10.1111/j.1651-2227.2009.01355.x; Grigoropoulou D, 2011, ALLERGY ASTHMA PROC, V32, P351, DOI 10.2500/aap.2011.32.3463; Haggarty P, 2002, PLACENTA, V23, pS28, DOI 10.1053/plac.2002.0791; Hansen S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036328; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Krauss-Etschmann S, 2008, J ALLERGY CLIN IMMUN, V121, P464, DOI 10.1016/j.jaci.2007.09.018; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Moth G, 2007, EUR J CLIN PHARMACOL, V63, P605, DOI 10.1007/s00228-007-0286-4; OLSEN SF, 1992, LANCET, V339, P1003, DOI 10.1016/0140-6736(92)90533-9; Olsen SF, 2008, AM J CLIN NUTR, V88, P167, DOI 10.1093/ajcn/88.1.167; Palmer DJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e184; Prescott SL, 2007, LIPIDS, V42, P801, DOI 10.1007/s11745-007-3030-z; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Serhan CN, 2004, LIPIDS, V39, P1125, DOI 10.1007/s11745-004-1339-7; SORENSEN JD, 1993, AM J OBSTET GYNECOL, V168, P915, DOI 10.1016/S0002-9378(12)90845-5; VANHOUWELINGEN AC, 1995, BRIT J NUTR, V74, P723, DOI 10.1079/BJN19950175	26	51	55	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					104	+		10.1016/j.jaci.2016.02.042	http://dx.doi.org/10.1016/j.jaci.2016.02.042			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27246522	Green Submitted, Bronze			2022-12-18	WOS:000393996800012
J	Robinette, ML; Colonna, M				Robinette, Michelle L.; Colonna, Marco			Immune modules shared by innate lymphoid cells and T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Innate lymphoid cell; T cell; innate; adaptive; lymphocyte	TRANSCRIPTION FACTOR GATA3; IFN-GAMMA PRODUCTION; TYPE-2 IMMUNITY; CYTOKINE PRODUCTION; LINEAGE COMMITMENT; INTESTINAL INFLAMMATION; COMMENSAL BACTERIA; TISSUE HOMEOSTASIS; LUNG INFLAMMATION; GENE-EXPRESSION	In recent years, innate lymphoid cells (ILCs) have emerged as innate correlates to T cells. The similarities between ILCs and T cells indicate that lymphocytes of fundamentally distinct lineages can share core "immune modules'' that encompass transcriptional circuitry and effector functions while using nonredundant complementary mechanisms of pattern recognition to enact these functions. We review modules currently recognized to be shared between ILCs and T cells.	[Robinette, Michelle L.; Colonna, Marco] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL)	Colonna, M (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.	mcolonna@pathology.wustl.edu			US National Institutes of Health [R01DE021255, R21CA16719, 1F30DK107053-01]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE021255] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK103039, F30DK107053] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the US National Institutes of Health (R01DE021255 and R21CA16719 to the Colonna laboratory and 1F30DK107053-01 to M.L.R.).	Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Bando JK, 2015, NAT IMMUNOL, V16, P153, DOI 10.1038/ni.3057; Basu R, 2012, IMMUNITY, V37, P1061, DOI 10.1016/j.immuni.2012.08.024; Bedoui S, 2016, NAT IMMUNOL, V17, P490, DOI 10.1038/ni.3432; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Bjorklund AK, 2016, NAT IMMUNOL, V17, P451, DOI 10.1038/ni.3368; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Cella M, 2015, SEMIN IMMUNOL, V27, P310, DOI 10.1016/j.smim.2015.10.002; Cella M, 2010, P NATL ACAD SCI USA, V107, P10961, DOI 10.1073/pnas.1005641107; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Cheroutre H, 2011, NAT REV IMMUNOL, V11, P445, DOI 10.1038/nri3007; Chung Y, 2009, IMMUNITY, V30, P576, DOI 10.1016/j.immuni.2009.02.007; Ciccia F, 2015, ANN RHEUM DIS, V74, P1739, DOI 10.1136/annrheumdis-2014-206323; Ciofani M, 2012, CELL, V151, P289, DOI 10.1016/j.cell.2012.09.016; Cols M, 2016, J ALLERGY CLIN IMMUN, V137, P1206, DOI 10.1016/j.jaci.2015.09.013; Constantinides MG, 2015, P NATL ACAD SCI USA, V112, P5123, DOI 10.1073/pnas.1423244112; Constantinides MG, 2014, NATURE, V508, P397, DOI 10.1038/nature13047; Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; Cording S, 2016, NAT IMMUNOL, V17, P755, DOI 10.1038/ni.3448; Cortez VS, 2016, IMMUNITY, V44, P1127, DOI 10.1016/j.immuni.2016.03.007; Cortez VS, 2015, CURR OPIN IMMUNOL, V32, P71, DOI 10.1016/j.coi.2015.01.004; Crellin NK, 2010, J EXP MED, V207, P281, DOI 10.1084/jem.20091509; Cruz-Guilloty F, 2009, J EXP MED, V206, P51, DOI 10.1084/jem.20081242; Daussy C, 2014, J EXP MED, V211, P563, DOI 10.1084/jem.20131560; Diefenbach A, 2014, IMMUNITY, V41, P354, DOI 10.1016/j.immuni.2014.09.005; Djuretic IM, 2007, NAT IMMUNOL, V8, P145, DOI 10.1038/ni1424; Dyring-Andersen B, 2014, BRIT J DERMATOL, V170, P609, DOI 10.1111/bjd.12658; Eberl G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa6566; Ebihara T, 2015, NAT IMMUNOL, V16, P1124, DOI 10.1038/ni.3272; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Fuchs A, 2013, IMMUNITY, V38, P769, DOI 10.1016/j.immuni.2013.02.010; Gerbe F, 2016, NATURE, V529, P226, DOI 10.1038/nature16527; Gold MJ, 2014, J ALLERGY CLIN IMMUN, V133, P1142, DOI 10.1016/j.jaci.2014.02.033; Gordon SM, 2012, IMMUNITY, V36, P55, DOI 10.1016/j.immuni.2011.11.016; Guo LY, 2015, NAT IMMUNOL, V16, P1051, DOI 10.1038/ni.3244; Guo LY, 2009, P NATL ACAD SCI USA, V106, P13463, DOI 10.1073/pnas.0906988106; Guo XH, 2014, IMMUNITY, V40, P25, DOI 10.1016/j.immuni.2013.10.021; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hegazy AN, 2010, IMMUNITY, V32, P116, DOI 10.1016/j.immuni.2009.12.004; Hepworth MR, 2015, SCIENCE, V348, P1031, DOI 10.1126/science.aaa4812; Hepworth MR, 2013, NATURE, V498, P113, DOI 10.1038/nature12240; Howitt MR, 2016, SCIENCE, V351, P1329, DOI 10.1126/science.aaf1648; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Hwang ES, 2005, SCIENCE, V307, P430, DOI 10.1126/science.1103336; Intlekofer AM, 2005, NAT IMMUNOL, V6, P1236, DOI 10.1038/ni1268; Ishizuka IE, 2016, NAT IMMUNOL, V17, P269, DOI 10.1038/ni.3344; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Juelke K, 2016, CURR OPIN IMMUNOL, V38, P75, DOI 10.1016/j.coi.2015.11.005; Kaech SM, 2012, NAT REV IMMUNOL, V12, P749, DOI 10.1038/nri3307; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kiss EA, 2011, SCIENCE, V334, P1561, DOI 10.1126/science.1214914; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Klose CSN, 2014, CELL, V157, P340, DOI 10.1016/j.cell.2014.03.030; Klose CSN, 2013, NATURE, V494, P261, DOI 10.1038/nature11813; Knox JJ, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00217; Koues OI, 2016, CELL, V165, P1134, DOI 10.1016/j.cell.2016.04.014; Lee DU, 2004, P NATL ACAD SCI USA, V101, P16010, DOI 10.1073/pnas.0407031101; Lee JS, 2012, NAT IMMUNOL, V13, P144, DOI 10.1038/ni.2187; Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005; Li J, 2016, CELL IMMUNOL, V304, P63, DOI 10.1016/j.cellimm.2016.05.001; Li-Weber M, 2003, NAT REV IMMUNOL, V3, P534, DOI 10.1038/nri1128; Lupar E, 2015, J IMMUNOL, V195, P4742, DOI 10.4049/jimmunol.1501159; McLane LM, 2013, J IMMUNOL, V190, P3207, DOI 10.4049/jimmunol.1201556; Meisel C, 2001, J IMMUNOL, V166, P3143, DOI 10.4049/jimmunol.166.5.3143; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Molofsky AB, 2013, J EXP MED, V210, P535, DOI 10.1084/jem.20121964; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Mortha A, 2014, SCIENCE, V343, P1477, DOI 10.1126/science.1249288; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nussbaum JC, 2013, NATURE, V502, P245, DOI 10.1038/nature12526; O'Sullivan TE, 2016, IMMUNITY, V45, P428, DOI 10.1016/j.immuni.2016.06.016; Ohne Y, 2016, NAT IMMUNOL, V17, P646, DOI 10.1038/ni.3447; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Paul WE, 2010, IMMUNOL CELL BIOL, V88, P236, DOI 10.1038/icb.2010.2; Pearce EL, 2003, SCIENCE, V302, P1041, DOI 10.1126/science.1090148; Peng H, 2013, J CLIN INVEST, V123, P1444, DOI 10.1172/JCI66381; Pikovskaya O, 2016, J IMMUNOL, V196, P1449, DOI 10.4049/jimmunol.1502396; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Qiu J, 2012, IMMUNITY, V36, P92, DOI 10.1016/j.immuni.2011.11.011; Rankin LC, 2016, NAT IMMUNOL, V17, P179, DOI 10.1038/ni.3332; Rankin LC, 2013, NAT IMMUNOL, V14, P389, DOI 10.1038/ni.2545; Robinette ML, 2015, NAT IMMUNOL, V16, P306, DOI 10.1038/ni.3094; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Satoh-Takayama N, 2008, IMMUNITY, V29, P958, DOI 10.1016/j.immuni.2008.11.001; Sawa S, 2010, SCIENCE, V330, P665, DOI 10.1126/science.1194597; Sciume G, 2012, J EXP MED, V209, P2331, DOI 10.1084/jem.20122097; Seillet C, 2014, J EXP MED, V211, P1733, DOI 10.1084/jem.20140145; Serafini N, 2015, NAT REV IMMUNOL, V15, P415, DOI 10.1038/nri3855; Shih HY, 2016, CELL, V165, P1120, DOI 10.1016/j.cell.2016.04.029; Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443; SMIRNOV DV, 1995, GENE, V155, P277, DOI 10.1016/0378-1119(94)00720-D; Sojka DK, 2014, ELIFE, V3, DOI 10.7554/eLife.01659; Song C, 2015, J EXP MED, V212, P1869, DOI 10.1084/jem.20151403; Spits H, 2016, NAT IMMUNOL, V17, P758, DOI 10.1038/ni.3482; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Sun JC, 2011, NAT REV IMMUNOL, V11, P645, DOI 10.1038/nri3044; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2351, DOI 10.1038/jid.2014.146; Townsend MJ, 2004, IMMUNITY, V20, P477, DOI 10.1016/S1074-7613(04)00076-7; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; von Moltke J, 2016, NATURE, V529, P221, DOI 10.1038/nature16161; Vonarbourg C, 2010, IMMUNITY, V33, P736, DOI 10.1016/j.immuni.2010.10.017; Voskoboinik I, 2015, NAT REV IMMUNOL, V15, P388, DOI 10.1038/nri3839; Walker JA, 2013, NAT REV IMMUNOL, V13, P75, DOI 10.1038/nri3349; Withers DR, 2016, NAT MED, V22, P319, DOI 10.1038/nm.4046; Yagi RJ, 2014, IMMUNITY, V40, P378, DOI 10.1016/j.immuni.2014.01.012; Yagi R, 2011, INT IMMUNOL, V23, P415, DOI 10.1093/intimm/dxr029; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhou MX, 2001, J EXP MED, V194, P1461, DOI 10.1084/jem.194.10.1461; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128; Zhu JF, 2006, CELL RES, V16, P3, DOI 10.1038/sj.cr.7310002; Zhu JF, 2015, CYTOKINE, V75, P14, DOI 10.1016/j.cyto.2015.05.010; Zhu JF, 2012, IMMUNITY, V37, P660, DOI 10.1016/j.immuni.2012.09.007; Zook EC, 2016, NAT IMMUNOL, V17, P775, DOI 10.1038/ni.3481	124	51	51	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1243	1252		10.1016/j.jaci.2016.09.006	http://dx.doi.org/10.1016/j.jaci.2016.09.006			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27817796	Green Accepted, Bronze			2022-12-18	WOS:000389542700001
J	Kim, JH; Choi, YJ; Lee, BH; Song, MY; Ban, CY; Kim, J; Park, J; Kim, SE; Kim, TG; Park, SH; Kim, HP; Sung, YC; Kim, SC; Shin, EC				Kim, Jong Hoon; Choi, Young Joon; Lee, Byung Ha; Song, Mi-Young; Ban, Chae Yeon; Kim, Jihye; Park, Junsik; Kim, Song-Ee; Kim, Tae-Gyun; Park, Su-Hyung; Kim, Hyoung-Pyo; Sung, Young-Chul; Kim, Soo-Chan; Shin, Eui-Cheol			Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psoriasis; programmed cell death 1; programmed cell death ligand 1; IL-17A; T cell	SKIN INFLAMMATION; PD-1 PATHWAY; MICE; RESPONSES; USTEKINUMAB; IMMUNOLOGY; TOLERANCE; ARTHRITIS; BLOCKADE	Background: Psoriasis is one of the most common chronic inflammatory diseases of the skin. Recently, IL-17-producing T cells have been shown to play a critical role in psoriatic inflammation. Programmed cell death 1 (PD-1) is a coinhibitory receptor expressed on T cells in various chronic inflammatory diseases; however, the expression and function of PD-1 during psoriatic inflammation have not previously been characterized. Objective: We examined PD-1 expression on IL-17A-producing T cells from imiquimod-treated mice and patients with psoriasis. Additionally, we investigated the therapeutic effect of recombinant programmed cell death ligand 1 (PD-L1) protein on imiquimod-induced psoriatic inflammation. Methods: PD-1 expression on IL-17A-producing gamma delta T cells from imiquimod-treated mice was examined by means of multicolor flow cytometric analysis. In the psoriatic skin of patients, PD-1 and IL-17A expression was analyzed by using immunofluorescence. The therapeutic effect of PD-L1-Fc fusion protein (PD-L1-Fc) was assessed in imiquimod-treated mice ex vivo and in vivo. Results: During imiquimod-induced psoriatic inflammation, PD-1 is overexpressed on CD27(-)V gamma 1(-) gamma delta T cells. Furthermore, PD-1 expression on IL-17A(+) T cells was confirmed in psoriatic skin tissues from patients and imiquimod-treated mice. In the CD27(-)V gamma 1(-) gamma delta T-cell population, V gamma 4(-) gamma delta T cells with V gamma 6 mRNA expression showed a high level of PD-1 expression. Furthermore, these PD-1(hi)V gamma 4(-)(V gamma 6(+)) gamma delta Tcells were specialized for anti-CD3-induced IL-17A production, which was inhibited by PD-L1-Fc treatment. In imiquimod-treated mice PD-L1-Fc reduced psoriatic inflammation when given alone and enhanced the therapeutic effect of anti-p40 when given in combination. Conclusion: PD-1 is overexpressed in IL-17A-producing T cells in both imiquimod-treated mice and patients with psoriasis. Moreover, recombinant PD-L1-Fc alleviates psoriatic inflammation in imiquimod-treated mice.	[Kim, Jong Hoon; Choi, Young Joon; Ban, Chae Yeon; Kim, Jihye; Park, Junsik; Shin, Eui-Cheol] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Lab Immunol & Infect Dis, 291 Daehak Ro, Taejon 305701, South Korea; [Park, Su-Hyung] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Lab Translat Immunol & Vaccinol, Taejon 305701, South Korea; [Kim, Jong Hoon; Kim, Song-Ee; Kim, Soo-Chan] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Dermatol, 211 Eonjuro, Seoul 135720, South Korea; [Kim, Jong Hoon; Kim, Song-Ee; Kim, Soo-Chan] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Cutaneous Biol Res Inst, Seoul 135720, South Korea; [Kim, Tae-Gyun; Kim, Hyoung-Pyo] Yonsei Univ, Coll Med, Inst Trop Med, Dept Environm Med Biol, Seoul 135720, South Korea; [Lee, Byung Ha; Sung, Young-Chul] Genexine, Songnam, South Korea; [Song, Mi-Young] Pohang Univ Sci & Technol, Div Integrat Biosci & Biotechnol, Pohang, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Pohang University of Science & Technology (POSTECH)	Shin, EC (corresponding author), Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Lab Immunol & Infect Dis, 291 Daehak Ro, Taejon 305701, South Korea.; Kim, SC (corresponding author), Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Dermatol, 211 Eonjuro, Seoul 135720, South Korea.	kimsc@yuhs.ac; ecshin@kaist.ac.kr	Shin, Eui-Cheol/C-1690-2011; Kim, Jong Hoon/I-3135-2019; Park, Su-Hyung/N-3514-2014	Shin, Eui-Cheol/0000-0002-6308-9503; Kim, Jong Hoon/0000-0002-3385-8180; Park, Su-Hyung/0000-0001-6363-7736; Kim, Hyoung-Pyo/0000-0003-1441-8822; Kim, Jihye/0000-0001-6297-4562; KIM, SOO-CHAN/0000-0002-2327-4755; Kim, Tae-Gyun/0000-0002-2116-4579				Ansari MJI, 2003, J EXP MED, V198, P63, DOI 10.1084/jem.20022125; Cai YH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4986; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Ganguly D, 2009, J EXP MED, V206, P1983, DOI 10.1084/jem.20090480; Gianchecchi E, 2013, AUTOIMMUN REV, V12, P1091, DOI 10.1016/j.autrev.2013.05.003; Griffiths CEM, 2010, NEW ENGL J MED, V362, P118, DOI 10.1056/NEJMoa0810652; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Haas JD, 2012, IMMUNITY, V37, P48, DOI 10.1016/j.immuni.2012.06.003; Jin L, 2014, MED RES REV, V34, P438, DOI 10.1002/med.21291; Johnston A, 2004, CLIN EXP IMMUNOL, V138, P83, DOI 10.1111/j.1365-2249.2004.00600.x; Koenen P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2719; Lande R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6621; Lebwohl M, 2015, NEW ENGL J MED, V373, P1318, DOI 10.1056/NEJMoa1503824; Lee E, 2004, J EXP MED, V199, P125, DOI 10.1084/jem.20030451; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Michel ML, 2012, P NATL ACAD SCI USA, V109, P17549, DOI 10.1073/pnas.1204327109; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Pantelyushin S, 2012, J CLIN INVEST, V122, P2252, DOI 10.1172/JCI61862; Peled M, 2015, INFLAMMATION, V38, P1573, DOI 10.1007/s10753-015-0132-2; Raptopoulou AP, 2010, ARTHRITIS RHEUM-US, V62, P1870, DOI 10.1002/art.27500; Reynoso ED, 2009, J IMMUNOL, V182, P2102, DOI 10.4049/jimmunol.0802769; Ribot JC, 2009, NAT IMMUNOL, V10, P427, DOI 10.1038/ni.1717; Roller A, 2012, J IMMUNOL, V189, P4612, DOI 10.4049/jimmunol.1103173; Rustin MHA, 2012, BRIT J DERMATOL, V167, P3, DOI 10.1111/j.1365-2133.2012.11208.x; Salama AD, 2003, J EXP MED, V198, P71, DOI 10.1084/jem.20022119; Song MY, 2015, GUT, V64, P260, DOI 10.1136/gutjnl-2014-307311; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Valdimarsson H, 2009, TRENDS IMMUNOL, V30, P494, DOI 10.1016/j.it.2009.07.008; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384; Wencker M, 2014, NAT IMMUNOL, V15, P80, DOI 10.1038/ni.2773	33	51	55	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1466	U265		10.1016/j.jaci.2015.11.021	http://dx.doi.org/10.1016/j.jaci.2015.11.021			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26824999	Bronze			2022-12-18	WOS:000376180200023
J	Machado, Y; Freier, R; Scheiblhofer, S; Thalhamer, T; Mayr, M; Briza, P; Grutsch, S; Ahammer, L; Fuchs, JE; Wallnoefer, HG; Isakovic, A; Kohlbauer, V; Hinterholzer, A; Steiner, M; Danzer, M; Horejs-Hoeck, J; Ferreira, F; Liedl, KR; Tollinger, M; Lackner, P; Johnson, CM; Brandstetter, H; Thalhamer, J; Weiss, R				Machado, Yoan; Freier, Regina; Scheiblhofer, Sandra; Thalhamer, Theresa; Mayr, Melissa; Briza, Peter; Grutsch, Sarina; Ahammer, Linda; Fuchs, Julian E.; Wallnoefer, Hannes G.; Isakovic, Almedina; Kohlbauer, Vera; Hinterholzer, Arthur; Steiner, Markus; Danzer, Martin; Horejs-Hoeck, Jutta; Ferreira, Fatima; Liedl, Klaus R.; Tollinger, Martin; Lackner, Peter; Johnson, Christopher M.; Brandstetter, Hans; Thalhamer, Josef; Weiss, Richard			Fold stability during endolysosomal acidification is a key factor for allergenicity and immunogenicity of the major birch pollen allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic sensitization; Bet v 1; structural stability; endolysosomal degradation; antigen processing and presentation; molecular allergology	BET V 1; T-CELL EPITOPE; CONFORMATIONAL STABILITY; 3-DIMENSIONAL STRUCTURE; CROSS-REACTIVITY; GENERATION; DYNAMICS	Background: The search for intrinsic factors, which account for a protein's capability to act as an allergen, is ongoing. Fold stability has been identified as a molecular feature that affects processing and presentation, thereby influencing an antigen's immunologic properties. Objective: We assessed how changes in fold stability modulate the immunogenicity and sensitization capacity of the major birch pollen allergen Bet v 1. Methods: By exploiting an exhaustive virtual mutation screening, we generated mutants of the prototype allergen Bet v 1 with enhanced thermal and chemical stability and rigidity. Structural changes were analyzed by means of x-ray crystallography, nuclear magnetic resonance, and molecular dynamics simulations. Stability was monitored by using differential scanning calorimetry, circular dichroism, and Fourier transform infrared spectroscopy. Endolysosomal degradation was simulated in vitro by using the microsomal fraction of JAWS II cells, followed by liquid chromatography coupled to mass spectrometry. Immunologic properties were characterized in vitro by using a human T-cell line specific for the immunodominant epitope of Bet v 1 and in vivo in an adjuvant-free BALB/c mouse model. Results: Fold stabilization of Bet v 1 was pH dependent and resulted in resistance to endosomal degradation at a pH of 5 or greater, affecting presentation of the immunodominant T-cell epitope in vitro. These properties translated in vivo into a strong allergy-promoting T(H)2-type immune response. Efficient T(H)2 cell activation required both an increased stability at the pH of the early endosome and efficient degradation at lower pH in the late endosomal/lysosomal compartment. Conclusions: Our data indicate that differential pH-dependent fold stability along endosomal maturation is an essential protein-inherent determinant of allergenicity.	[Machado, Yoan; Freier, Regina; Scheiblhofer, Sandra; Thalhamer, Theresa; Mayr, Melissa; Briza, Peter; Isakovic, Almedina; Kohlbauer, Vera; Hinterholzer, Arthur; Steiner, Markus; Horejs-Hoeck, Jutta; Ferreira, Fatima; Lackner, Peter; Brandstetter, Hans; Thalhamer, Josef; Weiss, Richard] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Grutsch, Sarina; Ahammer, Linda; Fuchs, Julian E.; Wallnoefer, Hannes G.; Liedl, Klaus R.; Tollinger, Martin] Univ Innsbruck, Ctr Mol Biosci, A-6020 Innsbruck, Austria; [Grutsch, Sarina; Ahammer, Linda; Tollinger, Martin] Univ Innsbruck, Inst Organ Chem, A-6020 Innsbruck, Austria; [Fuchs, Julian E.; Wallnoefer, Hannes G.; Liedl, Klaus R.] Univ Innsbruck, Inst Gen Inorgan & Theoret Chem, A-6020 Innsbruck, Austria; [Danzer, Martin] Austrian Red Cross, Blood Transfus Serv Upper Austria, Linz, Austria; [Johnson, Christopher M.] MRC Lab Mol Biol, Cambridge, England	Salzburg University; University of Innsbruck; University of Innsbruck; University of Innsbruck; MRC Laboratory Molecular Biology	Weiss, R (corresponding author), Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria.	Richard.Weiss@sbg.ac.at	Machado, Yoan/AAC-4976-2020; Horejs-Hoeck, Jutta/E-5010-2011; Machado, Yoan/D-9429-2016; Ferreira, Fatima/AAB-4321-2019; Tollinger, Martin/E-5896-2011; Brandstetter, Hans/E-6754-2011; Lackner, Peter/L-2900-2015; Horejs-Hoeck, Jutta/AAF-1735-2019; Ferreira, Fatima/E-4889-2011; Liedl, Klaus/ABB-4725-2021; Briza, Peter/D-7309-2012; Liedl, Klaus R/F-3099-2015; Thalhamer, Josef/E-5787-2011; Weiss, Richard/N-7279-2013	Horejs-Hoeck, Jutta/0000-0002-0984-204X; Machado, Yoan/0000-0002-8251-3744; Ferreira, Fatima/0000-0003-0989-2335; Tollinger, Martin/0000-0002-2177-983X; Brandstetter, Hans/0000-0002-6089-3045; Lackner, Peter/0000-0003-4681-6307; Horejs-Hoeck, Jutta/0000-0002-0984-204X; Ferreira, Fatima/0000-0003-0989-2335; Liedl, Klaus/0000-0002-0985-2299; Briza, Peter/0000-0002-4941-6782; Liedl, Klaus R/0000-0002-0985-2299; Thalhamer, Josef/0000-0003-2285-6400; Hinterholzer, Arthur/0000-0003-0006-6547; Steiner, Markus/0000-0003-4424-6347; Weiss, Richard/0000-0003-3185-7253; Scheiblhofer, Sandra/0000-0003-2867-9054; Freier, Regina/0000-0002-8202-5599	Austrian Science Fund (FWF) [P26997, W01213]; MRC [MC_U105178788] Funding Source: UKRI; Medical Research Council [MC_U105178788] Funding Source: researchfish	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by the Austrian Science Fund (FWF), projects #P26997 and #W01213.	Arancibia S, 2012, EUR J IMMUNOL, V42, P688, DOI 10.1002/eji.201142011; Asam C, 2014, CLIN EXP ALLERGY, V44, P1083, DOI 10.1111/cea.12361; Bauer L, 1997, CLIN EXP IMMUNOL, V107, P536, DOI 10.1046/j.1365-2249.1997.d01-953.x; Carmicle S, 2007, MOL IMMUNOL, V44, P1159, DOI 10.1016/j.molimm.2006.06.014; Case D. A., 2012, AMBER VERSION 12; Dai GX, 2001, J BIOL CHEM, V276, P41913, DOI 10.1074/jbc.M106018200; Delamarre L, 2005, SCIENCE, V307, P1630, DOI 10.1126/science.1108003; Delamarre L, 2006, J EXP MED, V203, P2049, DOI 10.1084/jem.20052442; Egger M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017278; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Gepp B, 2014, J ALLERGY CLIN IMMUN, V134, P188, DOI 10.1016/j.jaci.2013.12.1073; Grutsch S, 2014, BIOPHYS J, V107, P2963, DOI 10.1016/j.bpj.2014.10.062; Hartl A, 2004, METHODS, V32, P328, DOI 10.1016/j.ymeth.2003.08.014; Huber RG, 2015, PROTEIN SCI, V24, P174, DOI 10.1002/pro.2601; Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Kim A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6369; Kitzmuller C, 2015, J ALLERGY CLIN IMMUN, V136, P151, DOI 10.1016/j.jaci.2014.12.1928; Klinglmayr E, 2009, ALLERGY, V64, P647, DOI 10.1111/j.1398-9995.2008.01844.x; Lecoq A, 2008, VACCINE, V26, P2615, DOI 10.1016/j.vaccine.2008.02.057; Lemmon SK, 2000, CURR OPIN CELL BIOL, V12, P457, DOI 10.1016/S0955-0674(00)00117-4; Liu WH, 2012, PROTEIN ENG DES SEL, V25, P1, DOI 10.1093/protein/gzr053; Mittermaier A, 2006, SCIENCE, V312, P224, DOI 10.1126/science.1124964; Mutschlechner S, 2010, J ALLERGY CLIN IMMUN, V125, P711, DOI 10.1016/j.jaci.2009.10.052; Neunkirchner A, 2011, J IMMUNOL, V187, P4077, DOI 10.4049/jimmunol.1003220; Ohkuri T, 2010, J IMMUNOL, V185, P4199, DOI 10.4049/jimmunol.0902249; Qi H, 2006, SCIENCE, V312, P1672, DOI 10.1126/science.1125703; Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, P847, DOI 10.1016/j.jaci.2008.01.025; Roth-Walter F, 2014, J BIOL CHEM, V289, P17416, DOI 10.1074/jbc.M114.567875; Seutter von Loetzen C, 2014, BIOCHEM J, V457, P379, DOI 10.1042/BJ20130413; So T, 1997, J BIOL CHEM, V272, P32136, DOI 10.1074/jbc.272.51.32136; So T, 2001, IMMUNOLOGY, V104, P259, DOI 10.1046/j.1365-2567.2001.01314.x; Thai R, 2004, J BIOL CHEM, V279, P50257, DOI 10.1074/jbc.M405738200; Thalhamer T, 2010, J ALLERGY CLIN IMMUN, V125, P926, DOI 10.1016/j.jaci.2010.01.031; Traidl-Hoffmann C, 2009, J ALLERGY CLIN IMMUN, V123, P558, DOI 10.1016/j.jaci.2008.12.003; Turbant S, 2009, VACCINE, V27, P5349, DOI 10.1016/j.vaccine.2009.06.083; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; van Niel G, 2008, CURR OPIN CELL BIOL, V20, P437, DOI 10.1016/j.ceb.2008.05.011; Weinberger EE, 2013, J CONTROL RELEASE, V165, P101, DOI 10.1016/j.jconrel.2012.11.002; Wiederstein M, 2005, J MOL BIOL, V345, P1199, DOI 10.1016/j.jmb.2004.11.012; Wills-Karp M, 2010, MUCOSAL IMMUNOL, V3, P104, DOI 10.1038/mi.2009.138; Zaborsky N, 2010, J IMMUNOL, V184, P725, DOI 10.4049/jimmunol.0902080	43	51	51	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1525	1534		10.1016/j.jaci.2015.09.026	http://dx.doi.org/10.1016/j.jaci.2015.09.026			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26559323	Green Published, hybrid			2022-12-18	WOS:000376180200029
J	Broekman, H; Verhoeckx, KC; Jager, CFD; Kruizinga, AG; Pronk-Kleinjan, M; Remington, BC; Bruijnzeel-Koomen, CA; Houben, GF; Knulst, AC				Broekman, Henrike; Verhoeckx, Kitty C.; Jager, Constance F. den Hartog; Kruizinga, Astrid G.; Pronk-Kleinjan, Marieke; Remington, Benjamin C.; Bruijnzeel-Koomen, Carla A.; Houben, Geert F.; Knulst, Andre C.			Majority of shrimp-allergic patients are allergic to mealworm	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD ALLERGENS; INSECTS		[Broekman, Henrike; Verhoeckx, Kitty C.; Jager, Constance F. den Hartog; Pronk-Kleinjan, Marieke; Bruijnzeel-Koomen, Carla A.; Houben, Geert F.] Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands; [Verhoeckx, Kitty C.; Kruizinga, Astrid G.; Remington, Benjamin C.; Houben, Geert F.; Knulst, Andre C.] TNO, NL-3700 AJ Zeist, Netherlands	Utrecht University; Utrecht University Medical Center; Netherlands Organization Applied Science Research	Broekman, H (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands.	h.c.h.broekman-4@umcutrecht.nl		Verhoeckx, Kitty/0000-0002-6557-3198; Knulst, Andre/0000-0002-1056-3179; Remington, Benjamin/0000-0001-5450-8334; Houben, Geert/0000-0001-7261-3912				Ballmer-Weber BK, 2015, J ALLERGY CLIN IMMUN, V135, P964, DOI 10.1016/j.jaci.2014.10.047; Finke MD, 2007, ZOO BIOL, V26, P105, DOI 10.1002/zoo.20123; Jirapongsananuruk O, 2008, CLIN EXP ALLERGY, V38, P1038, DOI 10.1111/j.1365-2222.2008.02979.x; Klunder HC, 2012, FOOD CONTROL, V26, P628, DOI 10.1016/j.foodcont.2012.02.013; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; Taylor SL, 2014, FOOD CHEM TOXICOL, V63, P9, DOI 10.1016/j.fct.2013.10.032; Thalayasingam M, 2015, CLIN EXP ALLERGY, V45, P687, DOI 10.1111/cea.12416; Verhoeckx KCM, 2014, FOOD CHEM TOXICOL, V65, P364, DOI 10.1016/j.fct.2013.12.049	8	51	51	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1261	+		10.1016/j.jaci.2016.01.005	http://dx.doi.org/10.1016/j.jaci.2016.01.005			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26944404	Bronze			2022-12-18	WOS:000373351200039
J	Gavino, C; Hamel, N; Zeng, JB; Legault, C; Guiot, MC; Chankowsky, J; Lejtenyi, D; Lemire, M; Alarie, I; Dufresne, S; Boursiquot, JN; McIntosh, F; Langelier, M; Behr, MA; Sheppard, DC; Foulkes, WD; Vinh, DC				Gavino, Christina; Hamel, Nancy; Zeng, Ji Bin; Legault, Catherine; Guiot, Marie-Christine; Chankowsky, Jeffrey; Lejtenyi, Duncan; Lemire, Martine; Alarie, Isabelle; Dufresne, Simon; Boursiquot, Jean-Nicolas; McIntosh, Fiona; Langelier, Melanie; Behr, Marcel A.; Sheppard, Donald C.; Foulkes, William D.; Vinh, Donald C.			Impaired RASGRF1/ERK-mediated GM-CSF response characterizes CARD9 deficiency in French-Canadians	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Caspase recruitment domain-containing protein 9; spontaneous central nervous system candidiasis; candidiasis; Ras protein-specific guanine nucleotide-releasing factor 1; extracellular signal-regulated kinase; GM-CSF; CSF2	COLONY-STIMULATING FACTOR; CANDIDA-ALBICANS; COMBINED IMMUNODEFICIENCY; MUTATIONS; RAS; ACTIVATION; PATHWAY; KINASE; FAMILY; GRF	Background: Caspase recruitment domain-containing protein 9 (CARD9) deficiency is an autosomal recessive primary immunodeficiency conferring human susceptibility to invasive fungal disease, including spontaneous central nervous system candidiasis (sCNSc). However, clinical characterization of sCNSc is variable, hindering its recognition. Furthermore, an in-depth understanding of the bases for this susceptibility has remained elusive. Objectives: We sought to comprehensively characterize sCNSc and to dissect the mechanisms by which a hypomorphic CARD9 mutation causes susceptibility to Candida species. Methods: We describe the clinical and radiologic findings of sCNSc caused by CARD9 deficiency in a French-Canadian cohort. We performed genetic, cellular, and molecular analyses to further decipher its pathophysiology. Results: In our French-Canadian series (n 5 4) sCNSc had onset in adulthood (median, 38 years) and was often misinterpreted radiologically as brain malignancies; 1 patient had additional novel features (eg, endophthalmitis and osteomyelitis). CARD9 deficiency resulted from a hypomorphic p.Y91H mutation and allelic imbalance established in this population through founder effects. We demonstrate a consistent cellular phenotype of impaired GM-CSF responses. The ability of CARD9 to complex with B-cell CLL/lymphoma 10 (BCL10) and mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is intact in our series, arguing against its involvement in susceptibility to fungi. Instead, we show that the p.Y91H mutation impairs the ability of CARD9 to complex with Ras protein-specific guanine nucleotide-releasing factor 1 (RASGRF1), leading to impaired activation of nuclear factor kappa B and extracellular signal-regulated kinase (ERK) in monocytes and subsequent GM-CSF responses. Successful treatment of a second patient with adjunctive GM-CSF bolsters the clinical relevance of these findings. Conclusions: Hypomorphic CARD9 deficiency caused by p.Y91H results in adult-onset disease with variable penetrance and expressivity. Our findings establish the CARD9/RASGRF1/ERK/GM-CSF axis as critical to the pathophysiology of sCNSc.	[Gavino, Christina; Zeng, Ji Bin; Langelier, Melanie; Vinh, Donald C.] McGill Univ, Hlth Ctr MUHC, Infect Dis Susceptibil Program, 1001 Decarie Blvd,Glen Site,Block E,Rm EM3-3230, Montreal, PQ H4A 3J1, Canada; [Gavino, Christina; Zeng, Ji Bin; Langelier, Melanie; Vinh, Donald C.] Res Inst MUHC RI MUHC, Montreal, PQ, Canada; [Hamel, Nancy; Foulkes, William D.] RI MUHC, Dept Med Genet, Montreal, PQ, Canada; [McIntosh, Fiona; Behr, Marcel A.] RI MUHC, McGill Int TB Ctr, Montreal, PQ, Canada; [Hamel, Nancy; Foulkes, William D.; Vinh, Donald C.] McGill Univ, Dept Human Genet, 1001 Decarie Blvd,Glen Site,Block E,Rm EM3-3230, Montreal, PQ H4A 3J1, Canada; [Legault, Catherine] MUHC, Dept Neurol, Montreal, PQ, Canada; [Guiot, Marie-Christine] MUHC, Dept Pathol, Montreal, PQ, Canada; [Chankowsky, Jeffrey] MUHC, Dept Radiol, Montreal, PQ, Canada; [Lejtenyi, Duncan] MUHC, Dept Pediat, Montreal, PQ, Canada; [Lemire, Martine] MUHC, Div Allergy & Clin Immunol, Montreal, PQ, Canada; [Alarie, Isabelle] CHU Sherbrooke, Dept Microbiol & Infect Dis, Sherbrooke, PQ J1H 5N4, Canada; [Dufresne, Simon] Hop Maison Neuve Rosemont, Dept Microbiol & Infect Dis, Montreal, PQ H1T 2M4, Canada; [Boursiquot, Jean-Nicolas] Ctr Hosp Univ Quebec, Dept Clin Immunol & Allergy, Quebec City, PQ, Canada; [Behr, Marcel A.; Sheppard, Donald C.] McGill Univ, Dept Microbiol & Immunol, 1001 Decarie Blvd,Glen Site,Block E,Rm EM3-3230, Montreal, PQ H4A 3J1, Canada; [Behr, Marcel A.; Sheppard, Donald C.] McGill Univ, Dept Med, 1001 Decarie Blvd,Glen Site,Block E,Rm EM3-3230, Montreal, PQ H4A 3J1, Canada	McGill University; McGill University; University of Sherbrooke; Universite de Montreal; Laval University; McGill University; McGill University	Vinh, DC (corresponding author), McGill Univ, Ctr Hlth, 1001 Decarie Blvd,Glen Site,Block E,Rm EM3-3230, Montreal, PQ H4A 3J1, Canada.	donald.vinh@mcgill.ca	Foulkes, William D./AAR-9586-2021; Hamel, Nancy/L-5122-2016; Sheppard, Donald/B-4637-2008	Foulkes, William D./0000-0001-7427-4651; Hamel, Nancy/0000-0001-8971-0428; Sheppard, Donald/0000-0001-8877-880X; VINH, DONALD/0000-0003-1347-7767	McGill University Health Centre (Department of Medicine/Research Institute); CSL Behring Canada; Astellas Canada [SG183]; La Fondation du Grand Defi Pierre Lavoie; Fonds de recherche du Quebec-Sante (FRQS); FRQS	McGill University Health Centre (Department of Medicine/Research Institute); CSL Behring Canada; Astellas Canada(Astellas Pharmaceuticals); La Fondation du Grand Defi Pierre Lavoie; Fonds de recherche du Quebec-Sante (FRQS); FRQS	Supported by start-up funds from McGill University Health Centre (Department of Medicine/Research Institute), CSL Behring Canada, Astellas Canada (grant SG183), and La Fondation du Grand Defi Pierre Lavoie, as well as salary support to DCV from the Fonds de recherche du Quebec-Sante (FRQS). D.C.V. is supported by a FRQS chercheur-boursier junior 1 award.	Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Belisle G, 1968, Union Med Can, V97, P710; BLACK JT, 1970, J NEUROL NEUROSUR PS, V33, P864, DOI 10.1136/jnnp.33.6.864; Borha A, 2009, NEUROCHIRURGIE, V55, P57, DOI 10.1016/j.neuchi.2008.06.001; Dalliere CC, 2010, REV NEUROL-FRANCE, V166, P741, DOI 10.1016/j.neurol.2010.01.006; Drewniak A, 2013, BLOOD, V121, P2385, DOI 10.1182/blood-2012-08-450551; Duffy D, 2014, IMMUNITY, V40, P436, DOI 10.1016/j.immuni.2014.03.002; Esnault S, 2002, BLOOD, V99, P4048, DOI 10.1182/blood.V99.11.4048; Francisco-Cruz A, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0774-6; Gavino C, 2014, CLIN INFECT DIS, V59, P81, DOI 10.1093/cid/ciu215; GERMAIN M, 1994, AM J MED SCI, V307, P282, DOI 10.1097/00000441-199404000-00008; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Goodridge HS, 2009, J IMMUNOL, V182, P1146, DOI 10.4049/jimmunol.182.2.1146; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Grumach AS, 2015, J CLIN IMMUNOL, V35, P486, DOI 10.1007/s10875-015-0170-4; Guerrero C, 1996, ONCOGENE, V12, P1097; Hamel N, 2011, EUR J HUM GENET, V19, P300, DOI 10.1038/ejhg.2010.203; Herbst M, 2015, PEDIATR INFECT DIS J, V34, P999, DOI 10.1097/INF.0000000000000736; Hoarau G, 2013, J INFECTION, V67, P622, DOI 10.1016/j.jinf.2013.08.002; Jabara HH, 2013, J ALLERGY CLIN IMMUN, V132, P151, DOI 10.1016/j.jaci.2013.04.047; Jia XM, 2014, J EXP MED, V211, P2307, DOI 10.1084/jem.20132349; Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181; Lanternier F, 2015, J ALLERGY CLIN IMMUN, V135, P1558, DOI 10.1016/j.jaci.2014.12.1930; Lanternier F, 2015, J INFECT DIS, V211, P1241, DOI 10.1093/infdis/jiu412; Lanternier F, 2013, CURR OPIN PEDIATR, V25, P736, DOI 10.1097/MOP.0000000000000031; Lanternier F, 2013, NEW ENGL J MED, V369, P1704, DOI 10.1056/NEJMoa1208487; Liang P, 2015, MYCOPATHOLOGIA, V179, P347, DOI 10.1007/s11046-015-9877-2; Torres JM, 2014, J CLIN INVEST, V124, P5239, DOI 10.1172/JCI77493; McGeachy MJ, 2011, NAT IMMUNOL, V12, P521, DOI 10.1038/ni.2044; McKinnon ML, 2014, J ALLERGY CLIN IMMUN, V133, P1458, DOI 10.1016/j.jaci.2013.10.045; Meja KK, 2000, BRIT J PHARMACOL, V131, P1143, DOI 10.1038/sj.bjp.0703684; MORRIS AA, 1945, ARCH NEURO PSYCHIATR, V54, P361, DOI 10.1001/archneurpsyc.1945.02300110045006; Punwani D, 2015, J CLIN IMMUNOL, V35, P135, DOI 10.1007/s10875-014-0125-1; Renner ED, 2008, J ALLERGY CLIN IMMUN, V122, P181, DOI 10.1016/j.jaci.2008.04.037; Ruping MJGT, 2011, MYCOSES, V54, pE557, DOI 10.1111/j.1439-0507.2010.01989.x; Scriver CR, 2001, ANNU REV GENOM HUM G, V2, P69, DOI 10.1146/annurev.genom.2.1.69; Segal BH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009631; Smeekens SP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2343; Vinh DC, 2011, CLIN INFECT DIS, V52, pE99, DOI 10.1093/cid/ciq215; Wang XW, 2014, J ALLERGY CLIN IMMUN, V133, P905, DOI 10.1016/j.jaci.2013.09.033; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Yang JC, 2008, BLOOD, V112, P805, DOI 10.1182/blood-2007-11-126326	42	51	53	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1178	+		10.1016/j.jaci.2015.09.016	http://dx.doi.org/10.1016/j.jaci.2015.09.016			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26521038	Bronze			2022-12-18	WOS:000373351200025
J	Jackson, DJ; Gern, JE; Lemanske, RF				Jackson, Daniel J.; Gern, James E.; Lemanske, Robert F., Jr.			The contributions of allergic sensitization and respiratory pathogens to asthma inception	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; viruses; bacteria; childhood; rhinovirus; respiratory syncytial virus; allergic sensitization; inflammation	INNATE IMMUNE-RESPONSES; HUMAN RHINOVIRUS-C; SYNCYTIAL VIRUS; EARLY-LIFE; VIRAL-INFECTIONS; EARLY-CHILDHOOD; YOUNG-CHILDREN; INFANT BRONCHIOLITIS; BRONCHIAL EPITHELIUM; RECURRENT WHEEZE	Of the chronic diseases affecting grade-school children, asthma is the most common and accounts for the greatest number of school days missed. Moreover, it can influence family dynamics and function in other ways, and unfortunately, it can also be associated with mortality, particularly in the inner-city environments of the United States. Thus understanding factors that lead to its development in early life is essential in developing strategies aimed at primary prevention. Two risk factors that have been identified by a number of investigators include the development of allergic sensitization and wheezing respiratory tract illnesses caused by viruses and bacteria, either !alone or in combination. Both of these factors appear to exert their influences within the first few years of life, such that asthma becomes established before the child enters grade school at age 5 to 6 years. Therefore, because both allergic sensitization and viral and bacterial illnesses can occur in children who do not have asthma, it is paramount to identify genetic and environmental factors that activate, interact with, and/or direct the immune system and components of the respiratory tract along pathways that allow asthma to become established and expressed clinically.	[Jackson, Daniel J.; Gern, James E.; Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53706 USA; [Gern, James E.; Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jackson, DJ (corresponding author), 600 Highland Ave K4-936, Madison, WI 53792 USA.	djj@medicine.wisc.edu			National Institutes of Health [PO1HL070831, UM1AI114271, U19AI104317]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI114271, U19AI104317] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants PO1HL070831, UM1AI114271, and U19AI104317.	Allander T, 2007, CLIN INFECT DIS, V44, P904, DOI 10.1086/512196; Annamalay AA, 2012, PEDIATR INFECT DIS J, V31, P673, DOI 10.1097/INF.0b013e318256ffc6; Ashraf S, 2013, VIROLOGY, V436, P143, DOI 10.1016/j.virol.2012.11.002; Bacharier LB, 2015, JAMA-J AM MED ASSOC, V314, P2034, DOI 10.1001/jama.2015.13896; Beale J, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009124; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917; Bochkov YA, 2015, P NATL ACAD SCI USA, V112, P5485, DOI 10.1073/pnas.1421178112; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Contoli M, 2015, ALLERGY, V70, P910, DOI 10.1111/all.12627; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Cox DW, 2013, AM J RESP CRIT CARE, V188, P1358, DOI 10.1164/rccm.201303-0498OC; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Esposito S, 2013, PEDIATR INFECT DIS J, V32, P1199, DOI 10.1097/INF.0b013e31829ec274; Farley R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005189.pub4; Franz A, 2010, J CLIN VIROL, V48, P239, DOI 10.1016/j.jcv.2010.05.007; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Geevarghese B, 2012, ANTIVIR THER, V17, P201, DOI 10.3851/IMP2061; Gern JE, 2010, J VIROL, V84, P7418, DOI 10.1128/JVI.02290-09; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1872, DOI 10.1164/ajrccm.155.6.9196088; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Gern JE, 2013, FIELDS VIROLOGY, V6th, P531; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Habibi MS, 2012, CURR OPIN INFECT DIS, V25, P687, DOI 10.1097/QCO.0b013e32835a1d92; Hasegawa K, 2014, EXPERT REV ANTI-INFE, V12, P817, DOI 10.1586/14787210.2014.906901; Havstad S, 2014, J ALLERGY CLIN IMMUN, V134, P722, DOI 10.1016/j.jaci.2014.01.022; Henderson J, 2005, PEDIAT ALLERG IMM-UK, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Holt PG, 2012, CURR OPIN ALLERGY CL, V12, P151, DOI 10.1097/ACI.0b013e3283520166; Hyvarinen MK, 2005, PEDIATR PULM, V40, P316, DOI 10.1002/ppul.20273; Iwane MK, 2011, J INFECT DIS, V204, P1702, DOI 10.1093/infdis/jir634; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2014, CURR OPIN ALLERGY CL, V14, P131, DOI 10.1097/ACI.0000000000000047; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Jackson DJ, 2010, CURR OPIN ALLERGY CL, V10, P133, DOI 10.1097/ACI.0b013e3283352f7c; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Jakiela B, 2008, AM J RESP CELL MOL, V38, P517, DOI 10.1165/rcmb.2007-0050OC; James KM, 2013, J ALLERGY CLIN IMMUN, V132, P227, DOI 10.1016/j.jaci.2013.01.009; Jartti T, 2008, EUR RESPIR J, V32, P314, DOI 10.1183/09031936.00161907; Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629; Kalu SU, 2010, PEDIATR INFECT DIS J, V29, P746, DOI 10.1097/INF.0b013e3181d743c8; Kloepfer KM, 2010, IMMUNOL ALLERGY CLIN, V30, P553, DOI 10.1016/j.iac.2010.08.002; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Krishnamoorthy N, 2012, NAT MED, V18, P1525, DOI 10.1038/nm.2896; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Lachowicz-Scroggins ME, 2010, AM J RESP CELL MOL, V43, P652, DOI 10.1165/rcmb.2009-0244OC; Lee WM, 2012, AM J RESP CRIT CARE, V186, P886, DOI 10.1164/rccm.201202-0330OC; Lehtinen P, 2006, EUR J CLIN MICROBIOL, V25, P463, DOI 10.1007/s10096-006-0166-3; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Librizzi Jamie, 2014, Hosp Pediatr, V4, P33, DOI 10.1542/hpeds.2013-0073; Loss GJ, 2015, AM J RESP CRIT CARE; Lynch JP, 2014, EUR RESPIR J, V43, P264, DOI 10.1183/09031936.00203412; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Malmstrom K, 2006, J ALLERGY CLIN IMMUN, V118, P591, DOI 10.1016/j.jaci.2006.04.032; MCFADDEN ER, 1985, J APPL PHYSIOL, V58, P564, DOI 10.1152/jappl.1985.58.2.564; Miller EK, 2013, PEDIATR INFECT DIS J, V32, P950, DOI 10.1097/INF.0b013e31829b7e43; Miller EK, 2011, J ALLERGY CLIN IMMUN, V127, P883, DOI 10.1016/j.jaci.2010.11.041; Mills KHG, 2014, AM J RESP CRIT CARE, V189, P126, DOI 10.1164/rccm.201312-2158ED; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; O'Brien KL, 2015, LANCET INFECT DIS, V15, P1398, DOI 10.1016/S1473-3099(15)00247-9; Papadopoulos NG, 1999, J MED VIROL, V58, P100, DOI 10.1002/(SICI)1096-9071(199905)58:1&lt;100::AID-JMV16&gt;3.0.CO;2-D; Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-118BC; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Peltola V, 2009, J MED VIROL, V81, P1831, DOI 10.1002/jmv.21590; Pritchard AL, 2012, J IMMUNOL, V188, P5898, DOI 10.4049/jimmunol.1103507; Rockett RJ, 2015, EMERG INFECT DIS, V21, P365, DOI 10.3201/eid2102.141429; Ruuskanen O, 1993, Curr Probl Pediatr, V23, P50, DOI 10.1016/0045-9380(93)90003-U; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Savenije OE, 2014, J ALLERGY CLIN IMMUN, V134, P170, DOI 10.1016/j.jaci.2013.12.1080; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Simoes EAF, 2010, J ALLERGY CLIN IMMUN, V126, P256, DOI 10.1016/j.jaci.2010.05.026; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Soto-Quiros M, 2012, J ALLERGY CLIN IMMUN, V129, P1499, DOI 10.1016/j.jaci.2012.03.040; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stoltz DJ, 2013, CLIN EXP ALLERGY, V43, P233, DOI 10.1111/cea.12050; STOTT EJ, 1972, ANNU REV MICROBIOL, V26, P503, DOI 10.1146/annurev.mi.26.100172.002443; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Turunen R, 2014, PEDIAT ALLERG IMM-UK, V25, P796, DOI 10.1111/pai.12318; van der Gugten AC, 2013, PEDIATR INFECT DIS J, V32, P827, DOI 10.1097/INF.0b013e318290620e; Voraphani N, 2014, AM J RESP CRIT CARE, V190, P392, DOI 10.1164/rccm.201311-2095OC; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Yoshihara S, 2013, PEDIATRICS, V132, P811, DOI 10.1542/peds.2013-0982	92	51	52	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					659	666		10.1016/j.jaci.2016.01.002	http://dx.doi.org/10.1016/j.jaci.2016.01.002			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26947979	Bronze, Green Accepted, Green Published			2022-12-18	WOS:000371897500001
J	Schnaar, RL				Schnaar, Ronald L.			Glycans and glycan-binding proteins in immune regulation: A concise introduction to glycobiology for the allergist	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Glycome; lectin; selectin; galectin; siglec; sialic acid; inflammation	SIALYLATED PATHOGEN; CELL-FUNCTION; SIALOADHESIN; MACROPHAGES; INFLUENZA; RECOGNITION; RECEPTORS; GLYCOSYLATION; AUTOIMMUNITY; ACTIVATION	Cells are endowed with a rich surface coat of glycans that are carried as glycoproteins and glycolipids on the outer leaflets of their plasma membranes and constitute a major molecular interface between cells and their environment. Each cell's glycome, the sum of its diverse glycan structures, comprises a distinct cellular signature defined by expression levels of the enzymes responsible for glycan biosynthesis. This signature can be read by complementary glycan-binding proteins (GBPs) that translate glycan recognition into function. Nowhere is this more evident than in the immune system, where glycans and GBPs are integral to pathogen recognition and control of inflammatory responses. Glycobiology, the study of glycan structures and their functions, increasingly provides insight into immunoregulatory mechanisms and thereby provides opportunities for therapeutic intervention. This review briefly examines the makeup of the human glycome and the GBPs that translate glycan recognition into function and provides examples of glycan recognition events that are responsible for immune system regulation to promote wider appreciation of this rapidly expanding area of research.	[Schnaar, Ronald L.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Schnaar, Ronald L.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Schnaar, RL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol, 318 Wood Basic Sci Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	schnaar@jhu.edu	Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484	National Institutes of Health/National Heart, Lung, and Blood Institute [P01HL-107151]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL107151] Funding Source: NIH RePORTER	National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by a program project grant from the National Institutes of Health/National Heart, Lung, and Blood Institute (P01HL-107151).	Barral P, 2010, NAT IMMUNOL, V11, P303, DOI 10.1038/ni.1853; Bernardi A, 2013, CHEM SOC REV, V42, P4709, DOI 10.1039/c2cs35408j; Bochner BS, 2015, J ALLERGY CLIN IMMUN, V135, P598, DOI 10.1016/j.jaci.2014.11.031; Chang JS, 2010, BLOOD, V116, P1779, DOI 10.1182/blood-2009-12-260513; Chang YC, 2014, J MOL MED, V92, P951, DOI 10.1007/s00109-014-1157-y; Chang YC, 2014, GLYCOBIOLOGY, V24, P818, DOI 10.1093/glycob/cwu067; Chen HL, 2009, J BIOL CHEM, V284, P32454, DOI 10.1074/jbc.M109.023630; Cohen M, 2010, OMICS, V14, P455, DOI 10.1089/omi.2009.0148; Cummings RD, 2009, MOL BIOSYST, V5, P1087, DOI 10.1039/b907931a; Delputte PL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016827; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; Dennis JW, 2009, TRAFFIC, V10, P1569, DOI 10.1111/j.1600-0854.2009.00981.x; Ernst B, 2009, NAT REV DRUG DISCOV, V8, P661, DOI 10.1038/nrd2852; Frey H, 2013, FEBS J, V280, P2165, DOI 10.1111/febs.12145; Garner OB, 2008, BIOCHEM SOC T, V36, P1472, DOI 10.1042/BST0361472; GOTTSCHALK A, 1958, NATURE, V181, P377, DOI 10.1038/181377a0; Grigorian A, 2007, J BIOL CHEM, V282, P20027, DOI 10.1074/jbc.M701890200; Hellbusch CC, 2007, J BIOL CHEM, V282, P10762, DOI 10.1074/jbc.M700314200; Hirst GK, 1942, J EXP MED, V76, P195, DOI 10.1084/jem.76.2.195; Hoving JC, 2014, CELL MICROBIOL, V16, P185, DOI 10.1111/cmi.12249; Izquierdo-Useros N, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004146; Johnson JL, 2013, TRENDS IMMUNOL, V34, P290, DOI 10.1016/j.it.2013.01.006; Junt T, 2007, NATURE, V450, P110, DOI 10.1038/nature06287; Kawasaki N, 2013, P NATL ACAD SCI USA, V110, P7826, DOI 10.1073/pnas.1219888110; Klaas M, 2012, J IMMUNOL, V189, P2414, DOI 10.4049/jimmunol.1200776; Klaas M, 2012, SEMIN IMMUNOPATHOL, V34, P353, DOI 10.1007/s00281-012-0310-3; Li CF, 2013, J NEUROIMMUNOL, V256, P71, DOI 10.1016/j.jneuroim.2012.12.008; Liu FT, 2010, ANN NY ACAD SCI, V1183, P158, DOI 10.1111/j.1749-6632.2009.05131.x; Luhn K, 2001, BLOOD, V97, P330, DOI 10.1182/blood.V97.1.330; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/88289; Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737; Marquardt T, 1999, BLOOD, V94, P3976, DOI 10.1182/blood.V94.12.3976.424k06_3976_3985; Marth JD, 2008, NAT REV IMMUNOL, V8, P874, DOI 10.1038/nri2417; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; Nairn AV, 2008, J BIOL CHEM, V283, P17298, DOI 10.1074/jbc.M801964200; Nimrichter L, 2008, BLOOD, V112, P3744, DOI 10.1182/blood-2008-04-149641; O'Neill ASG, 2013, IMMUNOLOGY, V138, P198, DOI 10.1111/imm.12042; Padler-Karavani V, 2014, FASEB J, V28, P1280, DOI 10.1096/fj.13-241497; Paulson JC, 2006, NAT CHEM BIOL, V2, P238, DOI 10.1038/nchembio785; Rabinovich GA, 2012, ANN NY ACAD SCI, V1253, P1, DOI 10.1111/j.1749-6632.2012.06492.x; Rabinovich GA, 2009, NAT REV IMMUNOL, V9, P338, DOI 10.1038/nri2536; Severi E, 2007, MICROBIOL-SGM, V153, P2817, DOI 10.1099/mic.0.2007/009480-0; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Stevens J, 2008, J MOL BIOL, V381, P1382, DOI 10.1016/j.jmb.2008.04.016; Stevens J, 2006, NAT REV MICROBIOL, V4, P857, DOI 10.1038/nrmicro1530; Taylor ME, 2014, CURR OPIN STRUC BIOL, V28, P14, DOI 10.1016/j.sbi.2014.07.003; van Kooyk Y, 2008, NAT IMMUNOL, V9, P593, DOI 10.1038/ni.f.203; Varki A, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005462; Varki A, 2009, PROTEOMICS, V9, P5398, DOI 10.1002/pmic.200900708; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; von Itzstein M, 2007, NAT REV DRUG DISCOV, V6, P967, DOI 10.1038/nrd2400; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; Wu C, 2009, J IMMUNOL, V182, P6508, DOI 10.4049/jimmunol.0804247; Wun T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101301; Zarbock A, 2011, BLOOD, V118, P6743, DOI 10.1182/blood-2011-07-343566	55	51	51	1	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					609	615		10.1016/j.jaci.2014.10.057	http://dx.doi.org/10.1016/j.jaci.2014.10.057			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25649080	Green Accepted			2022-12-18	WOS:000351065000003
J	Amison, RT; Momi, S; Morris, A; Manni, G; Keir, S; Gresele, P; Page, CP; Pitchford, SC				Amison, Richard T.; Momi, Stefania; Morris, Abigail; Manni, Giorgia; Keir, Sandra; Gresele, Paolo; Page, Clive P.; Pitchford, Simon C.			RhoA signaling through platelet P2Y(1) receptor controls leukocyte recruitment in allergic mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Platelets; P2Y(1); P2Y(12); P2X(1); allergic inflammation; RhoA	P-SELECTIN; DIFFERENTIAL INVOLVEMENT; ANTIGEN-CHALLENGE; P(2T) RECEPTOR; MURINE MODEL; PAF-ACETHER; CROSS-TALK; ACTIVATION; ANTAGONIST; EOSINOPHIL	Background: Clinical studies reveal platelet activation in patients with asthma, allergic rhinitis, and eczema. This is distinct from platelet aggregation, which is critical for the maintenance of hemostasis and in which a role for platelet purinergic receptors is well documented. However, purines are also essential for inflammatory cell trafficking in animal models of allergic lung inflammation, which are known to be platelet dependent, yet the role of purines in the platelet activation accompanying inflammation is unknown. Objectives: We investigated whether the involvement of purine activation of platelets during allergic inflammation is distinct from purine involvement in platelet aggregation. Methods: BALB/c mice were sensitized to ovalbumin and subsequent airway ovalbumin challenge. Bronchoalveolar lavage fluid was analyzed for inflammatory cells, and blood samples were assessed for platelet activation. The role of platelet purinergic receptors and associated signaling mechanisms (RhoA) were assessed. Results: P2Y(1), but not P2Y(12) or P2X(1), antagonism inhibited pulmonary leukocyte recruitment. The formation of platelet-leukocyte complexes in vivo and platelet/P-selectin-dependent polymorphonuclear cell migration in vitro were exclusively platelet P2Y(1) receptor dependent. Furthermore, platelet P2Y(1) activation resulted in RhoA activity in vivo after allergen challenge, and RhoA signaling in platelets through P2Y(1) stimulation was required for platelet-dependent leukocyte chemotaxis in vitro. Leukocyte recruitment in thrombocytopenic mice remained suppressed after reinfusion of platelets pretreated with a P2Y(1) antagonist or a Rho-associated kinase 1 inhibitor, confirming the crucial role of platelet P2Y(1) receptor and subsequent activation of RhoA. Conclusion: RhoA signaling downstream of platelet P2Y(1), but not P2Y(12), represents a clear dichotomy in platelet activation during allergic inflammation versus hemostasis.	[Amison, Richard T.; Morris, Abigail; Keir, Sandra; Page, Clive P.; Pitchford, Simon C.] Kings Coll London, Inst Pharmaceut Sci, Sackler Inst Pulm Pharmacol, London SE9 1NH, England; [Momi, Stefania; Manni, Giorgia; Gresele, Paolo] Univ Perugia, Sect Internal & Cardiovasc Med, Dept Med, I-06100 Perugia, Italy	University of London; King's College London; University of Perugia	Pitchford, SC (corresponding author), Kings Coll London, Inst Pharmaceut Sci, Sackler Inst Pulm Pharmacol, Rm 5-91,Franklin Wilkins Bldg,Waterloo Campus, London SE9 1NH, England.	simon.pitchford@kcl.ac.uk	gresele, paolo/AAG-8019-2019; Manni, Giorgia/AAC-2412-2019	Amison, Richard/0000-0002-6616-4599; Pitchford, Simon/0000-0003-3961-0407; Manni, Giorgia/0000-0002-5697-2648	BBSRC [BB/H015728/1]; Sackler Foundation; Italian Ministry of University and Research (MIUR) [2012773NE3]; Biotechnology and Biological Sciences Research Council [984648] Funding Source: researchfish	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Sackler Foundation; Italian Ministry of University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	Supported by the BBSRC (grant no. BB/H015728/1) and the Sackler Foundation and a grant from the Italian Ministry of University and Research (MIUR prot. 2012773NE3; to P.G.).	Aslan JE, 2013, J THROMB HAEMOST, V11, P35, DOI 10.1111/jth.12051; AVERILL FJ, 1992, AM REV RESPIR DIS, V145, P571, DOI 10.1164/ajrccm/145.3.571; Baurand A, 2001, EUR J PHARMACOL, V412, P213, DOI 10.1016/S0014-2999(01)00733-6; Bird JE, 2012, J THROMB THROMBOLYS, V34, P199, DOI 10.1007/s11239-012-0745-3; Boyer JL, 1998, BRIT J PHARMACOL, V124, P1, DOI 10.1038/sj.bjp.0701837; Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018-007-6497-0; CARDOT E, 1992, INT ARCH ALLERGY IMM, V98, P127, DOI 10.1159/000236175; Cattaneo M, 2004, BIOCHEM PHARMACOL, V68, P1995, DOI 10.1016/j.bcp.2004.06.026; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; Corriden R, 2012, PURINERG SIGNAL, V8, P587, DOI 10.1007/s11302-012-9311-x; COYLE AJ, 1990, AM REV RESPIR DIS, V142, P587, DOI 10.1164/ajrccm/142.3.587; Damer S, 1998, EUR J PHARMACOL, V350, pR5, DOI 10.1016/S0014-2999(98)00316-1; DeSanctis GT, 1997, J APPL PHYSIOL, V83, P681, DOI 10.1152/jappl.1997.83.3.681; Duarte D, 2013, ALLERGY, V68, P1073, DOI 10.1111/all.12190; Durk T, 2013, AM J RESP CRIT CARE, V187, P476, DOI 10.1164/rccm.201208-1440OC; Eckly A, 2001, THROMB HAEMOSTASIS, V85, P694, DOI 10.1055/s-0037-1615655; Gachet C, 2006, ANNU REV PHARMACOL, V46, P277, DOI 10.1146/annurev.pharmtox.46.120604.141207; GALLAGHER JS, 1978, J ALLERGY CLIN IMMUN, V62, P229, DOI 10.1016/0091-6749(78)90212-9; Gear ARL, 2001, BLOOD, V97, P937, DOI 10.1182/blood.V97.4.937; GRESELE P, 1982, NEW ENGL J MED, V306, P549; GRESELE P, 1993, J ALLERGY CLIN IMMUN, V91, P894, DOI 10.1016/0091-6749(93)90347-I; Hardy AR, 2004, BLOOD, V104, P1745, DOI 10.1182/blood-2004-02-0534; Hechler B, 2006, J PHARMACOL EXP THER, V316, P556, DOI 10.1124/jpet.105.094037; Hechler B, 1998, BRIT J HAEMATOL, V103, P858, DOI 10.1046/j.1365-2141.1998.01056.x; Hirata H, 2003, J CLIN IMMUNOL, V23, P34, DOI 10.1023/A:1021948214742; Holm ACBS, 2011, PLATELETS, V22, P45, DOI 10.3109/09537104.2010.515696; Housten D., 1998, COMB CHEM HIGH T SCR, V11, P410; HUMPHRIES RG, 1994, BRIT J PHARMACOL, V113, P1057, DOI 10.1111/j.1476-5381.1994.tb17100.x; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; IND PW, 1991, CLIN EXP ALLERGY, V21, P395, DOI 10.1111/j.1365-2222.1991.tb01677.x; Ingall AH, 1999, J MED CHEM, V42, P213, DOI 10.1021/jm981072s; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Johansson MW, 2012, AM J RESP CRIT CARE, V185, P498, DOI 10.1164/rccm.201109-1712OC; Kasperska-Zajac A, 2005, CLIN EXP ALLERGY, V35, P1462, DOI 10.1111/j.1365-2222.2005.02357.x; Kim HS, 2003, J MED CHEM, V46, P4974, DOI 10.1021/jm030127+; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; Kornerup KN, 2010, J APPL PHYSIOL, V109, P758, DOI 10.1152/japplphysiol.01086.2009; Kowal K, 2006, CLIN EXP ALLERGY, V36, P426, DOI 10.1111/j.1365-2222.2006.02446.x; Kuehn HS, 2007, IMMUNOL LETT, V113, P59, DOI 10.1016/j.imlet.2007.08.007; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LELLOUCHTUBIANA A, 1988, AM REV RESPIR DIS, V137, P948, DOI 10.1164/ajrccm/137.4.948; Leon C, 2003, ARTERIOSCL THROM VAS, V23, P1941, DOI 10.1161/01.ATV.0000092127.16125.E6; Lukacs NW, 2002, J IMMUNOL, V169, P2120, DOI 10.4049/jimmunol.169.4.2120; Metzger W J, 1987, Agents Actions Suppl, V21, P151; Momi S, 2005, THROMB HAEMOSTASIS, V93, P535, DOI 10.1160/TH04-07-0464; Momi S, 2009, J EXP MED, V206, P2365, DOI 10.1084/jem.20090687; MORLEY J, 1985, LANCET, V2, P726; Offermanns S, 2006, CIRC RES, V99, P1293, DOI 10.1161/01.RES.0000251742.71301.16; PAGE CP, 1988, TRENDS PHARMACOL SCI, V9, P66, DOI 10.1016/0165-6147(88)90120-4; Paruchuri S, 2009, J EXP MED, V206, P2543, DOI 10.1084/jem.20091240; Pitchford SC, 2005, BLOOD, V105, P2074, DOI 10.1182/blood-2004-06-2282; Pitchford SC, 2004, BLOOD, V103, P639, DOI 10.1182/blood-2003-05-1707; Pitchford SC, 2003, J ALLERGY CLIN IMMUN, V112, P109, DOI 10.1067/mai.2003.1514; Pitchford SC, 2008, AM J RESP CRIT CARE, V177, P604, DOI 10.1164/rccm.200702-214OC; Pleines I, 2012, BLOOD, V119, P1054, DOI 10.1182/blood-2011-08-372193; ROBERTSON DN, 1987, BRIT J PHARMACOL, V92, P105, DOI 10.1111/j.1476-5381.1987.tb11301.x; Sakumura Y, 2005, BIOPHYS J, V89, P812, DOI 10.1529/biophysj.104.055624; Savi P, 2001, BIOCHEM BIOPH RES CO, V283, P379, DOI 10.1006/bbrc.2001.4816; Storey RF, 2000, BRIT J HAEMATOL, V110, P925, DOI 10.1046/j.1365-2141.2000.02208.x; Storey RF, 2002, THROMB HAEMOSTASIS, V88, P488; Sullivan PJ, 2000, RESPIRATION, V67, P514, DOI 10.1159/000067466; Sun B, 1998, J BIOL CHEM, V273, P11544, DOI 10.1074/jbc.273.19.11544; SZCZEKLIK A, 1986, THROMB HAEMOSTASIS, V56, P283; Xu B, 2002, J MED CHEM, V45, P5694, DOI 10.1021/jm020173u; YAMAMOTO H, 1993, J ALLERGY CLIN IMMUN, V91, P79, DOI 10.1016/0091-6749(93)90299-U; YASUBA H, 1991, J LIPID MEDIATOR, V4, P5; Yoshida A, 2002, BRIT J PHARMACOL, V137, P146, DOI 10.1038/sj.bjp.0704852	67	51	54	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					528	U338		10.1016/j.jaci.2014.09.032	http://dx.doi.org/10.1016/j.jaci.2014.09.032			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25445826				2022-12-18	WOS:000349372300027
J	Gruzieva, O; Gehring, U; Aalberse, R; Agius, R; Beelen, R; Behrendt, H; Bellander, T; Birk, M; de Jongste, JC; Fuertes, E; Heinrich, J; Hoek, G; Klumper, C; Koppelman, G; Korek, M; Kramer, U; Lindley, S; Molter, A; Simpson, A; Standl, M; van Hage, M; von Berg, A; Wijga, A; Brunekreef, B; Pershagen, G				Gruzieva, Olena; Gehring, Ulrike; Aalberse, Rob; Agius, Raymond; Beelen, Rob; Behrendt, Heidrun; Bellander, Tom; Birk, Matthias; de Jongste, Johan C.; Fuertes, Elaine; Heinrich, Joachim; Hoek, Gerard; Kluemper, Claudia; Koppelman, Gerard; Korek, Michal; Kraemer, Ursula; Lindley, Sarah; Moelter, Anna; Simpson, Angela; Standl, Marie; van Hage, Marianne; von Berg, Andrea; Wijga, Alet; Brunekreef, Bert; Pershagen, Goeran			Meta-analysis of air pollution exposure association with allergic sensitization in European birth cohorts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air pollution; children; cohort; IgE; sensitization; meta-analysis; European Study of Cohorts for Air Pollution Effects	USE REGRESSION-MODELS; PM2.5 ABSORBENCY; ASTHMA; AREAS; NO2; STABILITY; CONTRASTS; PMCOARSE; PM10; OSLO	Background: Evidence on the long-term effects of air pollution exposure on childhood allergy is limited. Objective: We investigated the association between air pollution exposure and allergic sensitization to common allergens in children followed prospectively during the first 10 years of life. Methods: Five European birth cohorts participating in the European Study of Cohorts for Air Pollution Effects project were included: BAMSE (Sweden), LISAplus and GINIplus (Germany), MAAS (Great Britain), and PIAMA (The Netherlands). Land-use regression models were applied to assess the individual residential outdoor levels of particulate matter with an aerodynamic diameter of less than 2.5 mm (PM2.5), the mass concentration of particles between 2.5 and 10 mm in size, and levels of particulate matter with an aerodynamic diameter of less than 10 mm (PM10), as well as measurement of the blackness of PM2.5 filters and nitrogendioxide and nitrogen oxide levels. Blood samples drawn at 4 to 6 years of age, 8 to 10 years of age, or both from more than 6500 children were analyzed for allergen-specific serum IgE against common allergens. Associations were assessed by using multiple logistic regression and subsequent meta-analysis. Results: The prevalence of sensitization to any common allergen within the 5 cohorts ranged between 24.1% and 40.4% at the age of 4 to 6 years and between 34.8% and 47.9% at the age of 8 to 10 years. Overall, air pollution exposure was not associated with sensitization to any common allergen, with odds ratios ranging from 0.94 (95% CI, 0.63-1.40) for a 1 x 10(-5) . m(-1) increase in measurement of the blackness of PM2.5 filters to 1.26 (95% CI, 0.90-1.77) for a 5 mu g/m(3) increase in PM2.5 exposure at birth address. Further analyses did not provide consistent evidence for a modification of the air pollution effects by sex, family history of atopy, or moving status. Conclusion: No clear associations between air pollution exposure and development of allergic sensitization in children up to 10 years of age were revealed.	[Gruzieva, Olena; Bellander, Tom; Korek, Michal; Pershagen, Goeran] Karolinska Inst, Inst Environm Med, SE-17177 Stockholm, Sweden; [Gehring, Ulrike; Beelen, Rob; Hoek, Gerard; Brunekreef, Bert] Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; [Aalberse, Rob] Sanquin Res, Amsterdam, Netherlands; [Agius, Raymond; Moelter, Anna] Univ Manchester, Ctr Epidemiol, Inst Populat Hlth, Manchester M13 9PL, Lancs, England; [Agius, Raymond; Moelter, Anna] Univ Manchester, Inst Inflammat & Repair, Manchester Acad Hlth Sci Ctr, Manchester M13 9PL, Lancs, England; [Behrendt, Heidrun] Tech Univ TUM, Helmholtz Ctr Munich, ZAUM Ctr Allergy & Environm, Munich, Germany; [Bellander, Tom; Pershagen, Goeran] Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden; [Birk, Matthias; Fuertes, Elaine; Heinrich, Joachim; Standl, Marie] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol 1, Neuherberg, Germany; [de Jongste, Johan C.] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Pediat, Rotterdam, Netherlands; [Kluemper, Claudia; Kraemer, Ursula] Univ Dusseldorf, IUF Leibniz Res Inst Environm Med, Dusseldorf, Germany; [Koppelman, Gerard] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergol, Beatrix Childrens Hosp, NL-9700 AB Groningen, Netherlands; [Lindley, Sarah] Univ Manchester, Sch Environm & Dev Geog, Manchester M13 9PL, Lancs, England; [van Hage, Marianne] Karolinska Inst, Clin Immunol & Allergy Unit, Dept Med, SE-17177 Stockholm, Sweden; [van Hage, Marianne] Univ Hosp, Stockholm, Sweden; [von Berg, Andrea] Marien Hosp Wesel, Res Inst, Dept Pediat, Wesel, Germany; [Wijga, Alet] Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; [Brunekreef, Bert] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 TC Utrecht, Netherlands	Karolinska Institutet; Utrecht University; University of Manchester; University of Manchester; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Stockholm County Council; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Heinrich Heine University Dusseldorf; Leibniz Institut fur Umweltmedizinische Forschung (IUF); University of Groningen; University of Manchester; Karolinska Institutet; St. Marien Hospital; Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University Medical Center	Gruzieva, O (corresponding author), Karolinska Inst, Inst Environm Med, Nobels Vag 13,Box 210, SE-17177 Stockholm, Sweden.	olena.gruzieva@ki.se	Lindley, Sarah/O-4284-2014; Koppelman, Gerard/AAG-9187-2020; Heinrich, Joachim/N-1720-2013; Mölter, Anna/N-6003-2014; van Hage, Marianne/A-9678-2017	Lindley, Sarah/0000-0003-0581-4284; Heinrich, Joachim/0000-0002-9620-1629; Mölter, Anna/0000-0002-0824-4478; van Hage, Marianne/0000-0003-3091-1596; Fuertes, Elaine/0000-0003-0205-9025; Korek, Michal/0000-0001-9326-3675; brunekreef, bert/0000-0001-9908-0060; Simpson, Angela/0000-0003-2733-6666; Pershagen, Goran/0000-0002-9701-1130; Standl, Marie/0000-0002-5345-2049; Gehring, Ulrike/0000-0003-3612-5780; Koppelman, Gerard/0000-0001-8567-3252; Gruzieva, Olena/0000-0003-4147-5654	European Community [211250]; Swedish Heart-Lung Foundation; Konsul ThC Bergh Foundation; Stockholm County Council; Swedish Asthma and Allergy Association Research Foundation; Swedish Foundation for Health Care Sciences and Allergy Research; Swedish Environmental Protection Agency; Netherlands Organization for Health Research and Development; Netherlands Organization for Scientific Research; Netherlands Asthma Fund; Netherlands Ministry of Spatial Planning, Housing, and the Environment; Netherlands Ministry of Health, Welfare, and Sport; Federal Ministry for Environment; Federal Ministry for Education, Science, Research and Technology; Helmholtz Zentrum Munich; Helmholtz Centre for Environmental Research-UFZ; Leipzig; Department of Pediatrics; MarienHospital Wesel; Pediatric Practice; Asthma UK; Moulton Charitable Trust; MRC [G0601361] Funding Source: UKRI; Medical Research Council [G0601361] Funding Source: researchfish	European Community(European Commission); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Konsul ThC Bergh Foundation; Stockholm County Council(Stockholm County Council); Swedish Asthma and Allergy Association Research Foundation; Swedish Foundation for Health Care Sciences and Allergy Research; Swedish Environmental Protection Agency; Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Netherlands Asthma Fund; Netherlands Ministry of Spatial Planning, Housing, and the Environment; Netherlands Ministry of Health, Welfare, and Sport; Federal Ministry for Environment; Federal Ministry for Education, Science, Research and Technology; Helmholtz Zentrum Munich; Helmholtz Centre for Environmental Research-UFZ(Helmholtz Association); Leipzig; Department of Pediatrics; MarienHospital Wesel; Pediatric Practice; Asthma UK; Moulton Charitable Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The research leading to these results has received funding from the European Community's Seventh Framework Program (FP7/2007-2011) under grant agreement no. 211250. The BAMSE study was supported by the Swedish Heart-Lung Foundation, the Konsul ThC Bergh Foundation, the Stockholm County Council, the Swedish Asthma and Allergy Association Research Foundation, the Swedish Foundation for Health Care Sciences and Allergy Research, the Swedish Environmental Protection Agency. The PIAMA study is supported by the Netherlands Organization for Health Research and Development; the Netherlands Organization for Scientific Research; the Netherlands Asthma Fund; the Netherlands Ministry of Spatial Planning, Housing, and the Environment; and the Netherlands Ministry of Health, Welfare, and Sport. The GINIplus study was mainly supported for the first 3 years of the Federal Ministry for Education, Science, Research and Technology (interventional arm) and Helmholtz Zentrum Munich (formerly GSF; observational arm). The 4-year, 6-year, and 10-year follow-up examinations of the GINIplus study were covered from the respective budgets of the 5 study centres (Helmholtz Zentrum Munich [formerly GSF], Research Institute, Department of Pediatrics, Marien-Hospital Wesel, LMU Munich, TU Munich, and from 6 years onward also from IUF-Leibniz Research Institute for Environmental Medicine) and a grant from the Federal Ministry for Environment. The LISAplus study was mainly supported by grants from the Federal Ministry for Education, Science, Research and Technology and in addition from Helmholtz Zentrum Munich (formerly GSF), Helmholtz Centre for Environmental Research-UFZ, Leipzig, Research Institute, Department of Pediatrics, MarienHospital Wesel, Pediatric Practice, Bad Honnef for the first 2 years. The 4-year, 6-year, and 10-year follow-up examinations of the LISAplus study were covered from the respective budgets of the involved partners (Helmholtz Zentrum Munich [formerly GSF], Helmholtz Centre for Environmental Research-UFZ, Leipzig, Research Institute, Department of Pediatrics, Marien-Hospital Wesel, Pediatric Practice, Bad Honnef, IUF-Leibniz-Research Institute for Environmental Medicine) and in addition by a grant from the Federal Ministry for Environment. The MAAS study was supported by Asthma UK grant and the Moulton Charitable Trust.	[Anonymous], 2010, HLTH EFFECTS I SPECI, P1; Beelen R, 2007, ATMOS ENVIRON, V41, P1343, DOI 10.1016/j.atmosenv.2006.10.020; Braback L, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-17; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Carlsten C, 2012, CURR OPIN ALLERGY CL, V12, P455, DOI 10.1097/ACI.0b013e328357cc55; Cesaroni G, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-48; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Cyrys J, 2012, ATMOS ENVIRON, V62, P374, DOI 10.1016/j.atmosenv.2012.07.080; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Eeftens M, 2012, ATMOS ENVIRON, V62, P303, DOI 10.1016/j.atmosenv.2012.08.038; Eeftens M, 2012, ENVIRON SCI TECHNOL, V46, P11195, DOI 10.1021/es301948k; Eeftens M, 2011, OCCUP ENVIRON MED, V68, P765, DOI 10.1136/oem.2010.061135; Gehring U, 2010, AM J RESP CRIT CARE, V181, P596, DOI 10.1164/rccm.200906-0858OC; Gruzieva O, 2012, J ALLERGY CLIN IMMUN, V129, P240, DOI 10.1016/j.jaci.2011.11.001; Heinrich J, 2002, EUR RESPIR J, V20, P617, DOI 10.1183/09031936.02.02322001; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hochadel M, 2006, ATMOS ENVIRON, V40, P542, DOI 10.1016/j.atmosenv.2005.09.067; Kramer U, 2009, J DERMATOL SCI, V56, P99, DOI 10.1016/j.jdermsci.2009.07.014; Madsen C, 2011, ATMOS ENVIRON, V45, P3576, DOI 10.1016/j.atmosenv.2011.03.069; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Nordling E, 2008, EPIDEMIOLOGY, V19, P401, DOI 10.1097/EDE.0b013e31816a1ce3; Oftedal B, 2007, CLIN EXP ALLERGY, V37, P1632, DOI 10.1111/j.1365-2222.2007.02823.x; Ryan PH, 2008, SCI TOTAL ENVIRON, V404, P139, DOI 10.1016/j.scitotenv.2008.05.051; Wang RR, 2013, ATMOS ENVIRON, V64, P312, DOI 10.1016/j.atmosenv.2012.09.056; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x	27	51	52	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					767	+		10.1016/j.jaci.2013.07.048	http://dx.doi.org/10.1016/j.jaci.2013.07.048			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24094547	Bronze			2022-12-18	WOS:000332397600019
J	Nakamura, Y; Nakano, N; Ishimaru, K; Hara, M; Ikegami, T; Tahara, Y; Katoh, R; Ogawa, H; Okumura, K; Shibata, S; Nishiyama, C; Nakao, A				Nakamura, Yuki; Nakano, Nobuhiro; Ishimaru, Kayoko; Hara, Mutsuko; Ikegami, Takako; Tahara, Yu; Katoh, Ryohei; Ogawa, Hideoki; Okumura, Ko; Shibata, Shigenobu; Nishiyama, Chiharu; Nakao, Atsuhito			Circadian regulation of allergic reactions by the mast cell clock in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						The circadian clock; mast cells; IgE; allergy; mouse	RI BETA-CHAIN; REVEALS PERSISTENT; GENE-EXPRESSION; HOUSE-DUST; DEGRANULATION; ACTIVATION; IGE; TRANSCRIPTION; OSCILLATIONS; ASTHMA	Background: It remains elusive how allergic symptoms exhibit prominent 24-hour variations. In mammals the circadian clocks present in nearly all cells, including mast cells, drive the daily rhythms of physiology. Recently, we have shown that the circadian clocks drive the daily rhythms in IgE/mast cell-mediated allergic reactions. However, the precise mechanisms, particularly the specific roles of the mast cell-intrinsic clockwork in temporal regulation, remain unclear. Objective: We determined whether the mast cell clockwork contributes to the temporal regulation of IgE/mast cell-mediated allergic reaction. Methods: The kinetics of a time of day-dependent variation in passive cutaneous anaphylactic reactions were compared between mast cell-deficient mice reconstituted with bone marrow-derived cultured mast cells generated from mice with a wild-type allele and a dominant negative type mutation of the key clock gene Clock. We also examined the temporal responses of wild-type and Clock-mutated bone marrow-derived cultured mast cells to IgE stimulation in vitro. Furthermore, factors influencing the mast cell clockwork were determined by using in vivo imaging. Results: The Clock mutation in mast cells resulted in the absence of temporal variations in IgE-mediated degranulation in mast cells both in vivo and in vitro associated with the loss of temporal regulation of Fc epsilon RI expression and signaling. Additionally, adrenalectomy abolished the mast cell clockwork in vivo. Conclusion: The mast cell-intrinsic clockwork, entrained by humoral factors from the adrenal gland, primarily contributes to the temporal regulation of IgE/mast cell-mediated allergic reactions. Our results reveal a novel regulatory mechanism for IgE-mediated mast cell responses that might underlie the circadian pathophysiology in patients with allergic diseases.	[Nakamura, Yuki; Ishimaru, Kayoko; Nakao, Atsuhito] Univ Yamanashi, Dept Immunol, Fac Med, Yamanashi 4093898, Japan; [Katoh, Ryohei] Univ Yamanashi, Dept Pathol, Fac Med, Yamanashi 4093898, Japan; [Nakano, Nobuhiro; Hara, Mutsuko; Ogawa, Hideoki; Okumura, Ko; Nishiyama, Chiharu; Nakao, Atsuhito] Juntendo Univ, Sch Med, Atopy Res Ctr, Tokyo 113, Japan; [Ikegami, Takako] Juntendo Univ, Grad Sch Med, Lab Mol & Biochem Res, Res Support Ctr, Tokyo, Japan; [Tahara, Yu; Shibata, Shigenobu] Waseda Univ, Dept Physiol & Pharmacol, Sch Adv Sci & Engn, Tokyo, Japan	University of Yamanashi; University of Yamanashi; Juntendo University; Juntendo University; Waseda University	Nakao, A (corresponding author), Univ Yamanashi, Dept Immunol, Fac Med, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.	anakao@yamanashi.ac.jp	Nishiyama, Chiharu/GPW-9372-2022; Tahara, Yu/Q-4324-2018	Tahara, Yu/0000-0002-3015-8883; Nakano, Nobuhiro/0000-0002-5317-5950	Ministry of Education, Culture, Sports, Science, and Technology, Japan	Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Supported in part by grants from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.	Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; DeBruyne JP, 2006, NEURON, V50, P465, DOI 10.1016/j.neuron.2006.03.041; Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev-physiol-021909-135821; Dickmeis T, 2009, J ENDOCRINOL, V200, P3, DOI 10.1677/JOE-08-0415; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gelfand EW, 2004, J ALLERGY CLIN IMMUN, V114, pS135, DOI 10.1016/j.jaci.2004.08.043; Hardin PE, 2004, J BIOL RHYTHM, V19, P348, DOI 10.1177/0748730404268052; Holgate ST, 2011, EUR J CLIN INVEST, V41, P1339, DOI 10.1111/j.1365-2362.2011.02534.x; KIMURA Y, 1974, IMMUNOLOGY, V26, P983; Kitahata Y, 2010, INT ARCH ALLERGY IMM, V152, P22, DOI 10.1159/000312122; Kowalska E, 2007, COLD SPRING HARB SYM, V72, P301, DOI 10.1101/sqb.2007.72.014; Kraft S, 2004, INT ARCH ALLERGY IMM, V135, P62, DOI 10.1159/000080231; Maeda K, 2003, J IMMUNOL, V170, P334, DOI 10.4049/jimmunol.170.1.334; Maeda K, 2006, BLOOD, V108, P262, DOI 10.1182/blood-2005-07-2878; Maurer M, 2009, BRIT J DERMATOL, V160, P633, DOI 10.1111/j.1365-2133.2008.08920.x; Metcalfe DD, 2009, J ALLERGY CLIN IMMUN, V124, P639, DOI 10.1016/j.jaci.2009.08.035; Nakamura Y, 2011, J ALLERGY CLIN IMMUN, V127, P1038, DOI 10.1016/j.jaci.2011.02.006; Nakamura Y, 2009, FEBS LETT, V583, P2088, DOI 10.1016/j.febslet.2009.05.030; Ra C, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00112; REINBERG A, 1969, J ALLERGY, V44, P292, DOI 10.1016/0021-8707(69)90034-3; REINBERG A, 1963, J ALLERGY, V34, P323, DOI 10.1016/0021-8707(63)90049-2; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Ripperger JA, 2011, FEBS LETT, V585, P1406, DOI 10.1016/j.febslet.2011.04.047; Ripperger JA, 2011, FEBS LETT, V585, P1384, DOI 10.1016/j.febslet.2011.02.027; Rivera J, 2008, ADV IMMUNOL, V98, P85, DOI 10.1016/S0065-2776(08)00403-3; Sei H, 2008, ENDOCRINOLOGY, V149, P3576, DOI 10.1210/en.2007-1714; Smolensky MH, 2007, ADV DRUG DELIVER REV, V59, P852, DOI 10.1016/j.addr.2007.08.016; Takahashi JS, 2008, NAT REV GENET, V9, P764, DOI 10.1038/nrg2430; Tokura T, 2005, BIOSCI BIOTECH BIOCH, V69, P1974, DOI 10.1271/bbb.69.1974; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Wang XJ, 2011, BRAIN BEHAV IMMUN, V25, P127, DOI 10.1016/j.bbi.2010.09.007; Welsh DK, 2004, CURR BIOL, V14, P2289, DOI 10.1016/j.cub.2004.11.057; Yamaguchi M, 2001, INT IMMUNOL, V13, P843, DOI 10.1093/intimm/13.7.843; Yoo SH, 2005, P NATL ACAD SCI USA, V102, P2608, DOI 10.1073/pnas.0409763102; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101	35	51	53	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					568	+		10.1016/j.jaci.2013.07.040	http://dx.doi.org/10.1016/j.jaci.2013.07.040			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24060274				2022-12-18	WOS:000332397100034
J	Coogan, PF; Wise, LA; O'Connor, GT; Brown, TA; Palmer, JR; Rosenberg, L				Coogan, Patricia F.; Wise, Lauren A.; O'Connor, George T.; Brown, Timothy A.; Palmer, Julie R.; Rosenberg, Lynn			Abuse during childhood and adolescence and risk of adult-onset asthma in African American women	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; child abuse; adolescent abuse; incidence; longitudinal studies; cohort studies; African Americans; women	BODY-MASS INDEX; INTIMATE PARTNER VIOLENCE; COMMUNITY VIOLENCE; DOMESTIC VIOLENCE; DISORDERS; MORBIDITY; STRESS	Background: Experiences of violence contribute to the occurrence of childhood asthma, but there is little information on the effect of early-life abuse on adult-onset asthma. Objective: We prospectively assessed the relation between physical and sexual abuse during childhood and adolescence and the incidence of adult-onset asthma in the Black Women's Health Study. Methods: We followed 28,456 women from 1995 through 2011 with biennial mailed questionnaires. Experiences of physical and sexual abuse that occurred during childhood and adolescence were obtained in 2005. Cox regression models were used to estimate incidence rate ratios (IRRs) and 95% CIs. Results: During 417,931 person-years of follow-up, 1,160 participants reported physician-diagnosed asthma and concurrent use of asthma medication. Compared with women who experienced no abuse during childhood or adolescence, the multivariable IRR for any childhood abuse was 1.24 (95% CI, 1.06-1.45), and for any adolescent abuse, it was 1.10 (95% CI, 0.88-1.36). The IRR was higher for childhood physical abuse (IRR, 1.29; 95% CI, 1.07-1.49) than for childhood sexual abuse (IRR, 1.15; 95% CI, 0.88-1.49). IRRs for physical and sexual abuse during adolescence were compatible with 1.0. The association between childhood abuse and asthma incidence was stronger in older compared with younger women. Conclusion: In this large cohort of African American women, there was a positive association between adult-onset asthma and childhood physical abuse and weaker associations for childhood sexual abuse and any abuse during adolescence. Given the high prevalence of asthma and childhood abuse, this association is of public health importance. (J Allergy Clin Immunol 2013; 131:1058-63.)	[Coogan, Patricia F.; Wise, Lauren A.; Palmer, Julie R.; Rosenberg, Lynn] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA; [O'Connor, George T.] Boston Univ, Sch Med, Dept Med, Ctr Pulm, Boston, MA 02215 USA; [Brown, Timothy A.] Boston Univ, Dept Psychol, Ctr Anxiety & Related Disorders, Boston, MA 02215 USA	Boston University; Boston University; Boston University	Coogan, PF (corresponding author), Boston Univ, Slone Epidemiol Ctr, 1010 Commonwealth Ave, Boston, MA 02215 USA.	pcoogan@bu.edu		Wise, Lauren/0000-0003-2138-3752; Rosenberg, Lynn/0000-0003-2760-2987; Coogan, Patricia/0000-0003-3671-7663; Palmer, Julie/0000-0002-6534-335X; O'Connor, George/0000-0002-6476-3926	National Heart, Lung, and Blood Institute of the National Institutes of Health [HL107314]; National Institutes of Health/National Heart, Lung, and Blood Institute; NATIONAL CANCER INSTITUTE [R01CA058420, UM1CA164974] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL107314] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by a grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (HL107314).; Disclosure of potential conflict of interest: All authors received grants from the National Institutes of Health/National Heart, Lung, and Blood Institute.	Beckett WS, 2001, AM J RESP CRIT CARE, V164, P2045, DOI 10.1164/ajrccm.164.11.2004235; BURR ML, 1992, CLIN EXP ALLERGY, V22, P509, DOI 10.1111/j.1365-2222.1992.tb00158.x; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; Cisternas MG, 2003, J ALLERGY CLIN IMMUN, V111, P1212, DOI 10.1067/mai.2003.1449; Cohen RT, 2008, AM J RESP CRIT CARE, V178, P453, DOI 10.1164/rccm.200711-1629OC; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Coker AL, 2005, J WOMENS HEALTH, V14, P829, DOI 10.1089/jwh.2005.14.829; Degens H, 2012, AGE DORDR; Deshmukh A, 2010, J NEUROIMMUNOL, V225, P13, DOI 10.1016/j.jneuroim.2010.03.010; Flaherty EG, 2008, PEDIATRICS, V122, P611, DOI 10.1542/peds.2007-2311; Heim C, 2000, JAMA-J AM MED ASSOC, V284, P592, DOI 10.1001/jama.284.5.592; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; Liu LY, 2002, AM J RESP CRIT CARE, V165, P1062, DOI 10.1164/ajrccm.165.8.2109065; Loxton D, 2006, VIOLENCE AGAINST WOM, V12, P715, DOI 10.1177/1077801206291483; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Nystad W, 2004, AM J EPIDEMIOL, V160, P969, DOI 10.1093/aje/kwh303; Peat JK, 2001, THORAX, V56, P406, DOI 10.1136/thorax.56.5.406; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Raphael KG, 2001, PAIN, V92, P283, DOI 10.1016/S0304-3959(01)00270-6; Romans S, 2002, PSYCHOTHER PSYCHOSOM, V71, P141, DOI 10.1159/000056281; Romieu I, 2003, AM J EPIDEMIOL, V158, P165, DOI 10.1093/aje/kwg131; Rosenberg L, 1995, J Am Med Womens Assoc (1972), V50, P56; Scott KM, 2008, PSYCHOSOM MED, V70, P1035, DOI 10.1097/PSY.0b013e318187a2fb; Spitzer C, 2009, PSYCHOSOM MED, V71, P1012, DOI 10.1097/PSY.0b013e3181bc76b5; Sternthal MJ, 2010, EUR RESPIR J, V36, P1400, DOI 10.1183/09031936.00003010; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; Subramanian SV, 2007, INT J EPIDEMIOL, V36, P569, DOI 10.1093/ije/dym007; Suglia SF, 2009, ARCH PEDIAT ADOL MED, V163, P244, DOI 10.1001/archpediatrics.2008.555; US Department of Health and Human Services. Administration on Children Youth and Families. Children's Bureau, 2011, CHILD MALTR 2010; Wegman HL, 2009, PSYCHOSOM MED, V71, P805, DOI 10.1097/PSY.0b013e3181bb2b46; Wise LA, 2009, AM J PUBLIC HEALTH, V99, pS460, DOI 10.2105/AJPH.2008.149005; Wright RJ, 2010, J EPIDEMIOL COMMUN H, V64, P630, DOI 10.1136/jech.2009.090795; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2001, ENVIRON HEALTH PERSP, V109, P1085, DOI 10.2307/3454965; Wu ZX, 2009, ENVIRON HEALTH PERSP, V117, P1434, DOI 10.1289/ehp.0800511	39	51	51	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1058	1063		10.1016/j.jaci.2012.10.023	http://dx.doi.org/10.1016/j.jaci.2012.10.023			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	120QT	23219171	Green Accepted			2022-12-18	WOS:000317187200013
J	Arshad, SH; Karmaus, W; Raza, A; Kurukulaaratchy, RJ; Matthews, SM; Holloway, JW; Sadeghnejad, A; Zhang, HM; Roberts, G; Ewart, SL				Arshad, S. Hasan; Karmaus, Wilfried; Raza, Abid; Kurukulaaratchy, Ramesh J.; Matthews, Sharon M.; Holloway, John W.; Sadeghnejad, Alireza; Zhang, Hongmei; Roberts, Graham; Ewart, Susan L.			The effect of parental allergy on childhood allergic diseases depends on the sex of the child	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Maternal; paternal; sex; cohort; parent of origin; atopy; asthma; eczema; rhinitis; allergy; IgE	ATOPIC-DERMATITIS; FAMILY-HISTORY; RISK-FACTORS; BIRTH COHORT; ENVIRONMENTAL-FACTORS; ODDS RATIO; EARLY-LIFE; ASTHMA; PREVALENCE; INFANCY	Background: The parent-of-origin effect is important in understanding the genetic basis of childhood allergic diseases and improving our ability to identify high-risk children. Objective: We sought to investigate the parent-of-origin effect in childhood allergic diseases. Methods: The Isle of Wight Birth Cohort (n = 1456) has been examined at 1, 2, 4, 10, and 18 years of age. Information on the prevalence of asthma, eczema, rhinitis, and environmental factors was obtained by using validated questionnaires. Skin prick tests were carried out at ages 4, 10, and 18 years, and total IgE measurement was carried out at 10 and 18 years. Parental history of allergic disease was assessed soon after the birth of the child, when maternal IgE levels were also measured. Prevalence ratios (PRs) and their 95% CIs were estimated, applying log-linear models adjusted for confounding variables. Results: When stratified for sex of the child, maternal asthma was associated with asthma in girls (PR, 1.91; 95% CI, 1.34-2.72; P = .0003) but not in boys (PR, 1.29; 95% CI, 0.85-1.96; P = .23),whereas paternal asthma was associated with asthma in boys (PR, 1.99; 95% CI, 1.42-2.79; P < .0001) but not in girls (PR, 1.03; 95% CI, 0.59-1.80; P = .92). Maternal eczema increased the risk of eczema in girls (PR, 1.92; 95% CI, 1.37-2.68; P = .0001) only, whereas paternal eczema did the same for boys (PR, 2.07; 95% CI, 1.32-3.25; P = .002). Similar trends were observed when the effect of maternal and paternal allergic disease was assessed for childhood atopy and when maternal total IgE levels were related to total IgE levels in children at ages 10 and 18 years. Conclusions: The current study indicates a sex-dependent association of parental allergic conditions with childhood allergies, with maternal allergy increasing the risk in girls and paternal allergy increasing the risk in boys. This has implications for childhood allergy prediction and prevention. (J Allergy Clin Immunol 2012;130:427-34.)	[Holloway, John W.] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England; [Karmaus, Wilfried; Zhang, Hongmei] Univ S Carolina, Dept Epidemiol & Biostat, Arnold Sch Publ Hlth, Columbia, SC 29208 USA; [Sadeghnejad, Alireza] Capital Hlth Syst, Dept Med, Trenton, NJ USA; [Ewart, Susan L.] Michigan State Univ, Dept Large Anim Clin Sci, E Lansing, MI 48824 USA	University of Southampton; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Michigan State University	Arshad, SH (corresponding author), Southampton Gen Hosp, MP 810,South Block,Tremona Rd, Southampton SO9 4XY, Hants, England.	sha@soton.ac.uk	Holloway, John W/B-5424-2009	Holloway, John W/0000-0001-9998-0464; Roberts, Graham/0000-0003-2252-1248; Kurukulaaratchy, Ramesh/0000-0002-1588-2400	National Institutes of Health [R01 HL082925, R01AI091905-01]; Asthma UK [364]; National Institute of Allergy and Infectious Diseases; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI091905] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Asthma UK; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The Isle of Wight birth cohort assessments have been supported by the National Institutes of Health (grant nos. R01 HL082925 and R01AI091905-01) and Asthma UK (grant no. 364).; W. Karmaus, R. J. Kurukulaaratchy, H. Zhang, and S. L. Ewart have received research support from the National Institutes of Health. J. W. Holloway has received research support from the National Institute of Allergy and Infectious Diseases. The rest of the authors declare that they have no relevant conflicts of interest.	ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bisgaard H, 2009, J ALLERGY CLIN IMMUN, V123, P1355, DOI 10.1016/j.jaci.2009.03.046; Bjerg A, 2007, PEDIATRICS, V120, P741, DOI 10.1542/peds.2006-3742; Bohme M, 2003, CLIN EXP ALLERGY, V33, P1226, DOI 10.1046/j.1365-2222.2003.01749.x; Bradley M, 2000, ACTA DERM-VENEREOL, V80, P106; Burke W, 2003, AM J PREV MED, V24, P160, DOI 10.1016/S0749-3797(02)00589-5; Diepgen TL, 1996, J INVEST DERMATOL, V106, P977, DOI 10.1111/1523-1747.ep12338475; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; DOTTERUD LK, 1995, ACTA DERM-VENEREOL, V75, P50; Eichler EE, 2010, NAT REV GENET, V11, P446, DOI 10.1038/nrg2809; Guilmatre A, 2012, CLIN GENET, V81, P201, DOI 10.1111/j.1399-0004.2011.01790.x; Hager R, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-303; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Kuiper S, 2007, J ALLERGY CLIN IMMUN, V120, P388, DOI 10.1016/j.jaci.2007.03.038; Kurukulaaratchy RJ, 2002, RESP MED, V96, P163, DOI 10.1053/rmed.2001.1236; Lee JT, 2004, ANN ACAD MED SINGAP, V33, P71; Li YF, 2011, CELL RES, V21, P466, DOI 10.1038/cr.2011.15; Lim RH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010134; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; Ly NP, 2007, J ALLERGY CLIN IMMUN, V120, P271, DOI 10.1016/j.jaci.2007.05.045; Mandhane PJ, 2005, AM J RESP CRIT CARE, V172, P45, DOI 10.1164/rccm.200412-1738OC; Matson AP, 2007, J IMMUNOL, V179, P1282, DOI 10.4049/jimmunol.179.2.1282; Melen E, 2004, CLIN EXP ALLERGY, V34, P839, DOI 10.1111/j.1365-2222.2004.01957.x; Moffatt MF, 1998, CLIN EXP ALLERGY, V28, P56; Pike KC, 2010, THORAX, V65, P1099, DOI 10.1136/thx.2010.134742; Prabhu N, 2010, THORAX, V65, P235, DOI 10.1136/thx.2009.123232; Purvis DJ, 2005, BRIT J DERMATOL, V152, P742, DOI 10.1111/j.1365-2133.2005.06540.x; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; RUIZ RGG, 1992, CLIN EXP ALLERGY, V22, P762, DOI 10.1111/j.1365-2222.1992.tb02816.x; Scott M, 2010, THORAX, V65, P258, DOI 10.1136/thx.2009.125443; Shaheen SO, 2010, J ALLERGY CLIN IMMUN, V126, P1141, DOI 10.1016/j.jaci.2010.08.047; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Wadonda-Kabondo N, 2004, ARCH DIS CHILD, V89, P917, DOI 10.1136/adc.2003.034033; Withers NJ, 1998, AM J RESP CRIT CARE, V158, P352, DOI 10.1164/ajrccm.158.2.9705079; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zutavern A, 2005, CLIN EXP ALLERGY, V35, P1301, DOI 10.1111/j.1365-2222.2005.02350.x	42	51	53	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					427	+		10.1016/j.jaci.2012.03.042	http://dx.doi.org/10.1016/j.jaci.2012.03.042			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22607991	Green Accepted			2022-12-18	WOS:000307002200024
J	Janssen, CEI; Rose, CD; De Hertogh, G; Martin, TM; Meunier, BB; Cimaz, R; Harjacek, M; Quartier, P; Ten Cate, R; Thomee, C; Desmet, VJ; Fischer, A; Roskams, T; Wouters, CH				Janssen, Carl E. I.; Rose, Carlos D.; De Hertogh, Gert; Martin, Tammy M.; Meunier, Brigitte Bader; Cimaz, Rolando; Harjacek, Miroslav; Quartier, Pierre; Ten Cate, Rebecca; Thomee, Caroline; Desmet, Valeer J.; Fischer, Alain; Roskams, Tania; Wouters, Carine H.			Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2-related disorders Blau syndrome and Crohn disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nucleotide oligomerization domain 2; Blau syndrome; Crohn disease; granuloma; T(H)17 cell; monocyte macrophage lineage; multinucleated giant cell	INFLAMMATORY-BOWEL-DISEASE; PULMONARY SARCOIDOSIS; CARD15 MUTATIONS; INTERFERON-GAMMA; MEDICAL PROGRESS; TGF-BETA; T-CELLS; ARTHRITIS; ONSET; NOD2	Background: Blau syndrome (BS) and Crohn disease (CD) are both characterized by granulomatous inflammation and related to nucleotide oligomerization domain 2 (NOD2) mutations. Objective: This study aimed to define the morphologic and immunohistochemical characteristics of granulomas in patients with NOD2-related BS and CD. Methods: Granuloma-containing biopsy specimens from 6 patients with BS and 7 pediatric patients with CD carrying NOD2 mutations or single nucleotide polymorphisms were studied for morphology, cellular composition, and cytokine expression by using hematoxylin and eosin staining and immunohistochemistry. Results: Biopsy specimens from patients with BS typically showed polycyclic granulomas with large lymphocytic coronas, extensive emperipolesis of lymphocytes within multinucleated giant cells (MGCs), MGC death, and fibrinoid necrosis and fibrosis. In contrast, biopsy specimens from patients with CD showed simple granulomas with subtle/absent lymphocytic coronas, sclerosis of the surrounding tissue, and polymorphonuclear cells. Findings found to be similar in all granulomas were as follows: CD68 and HLA-DR expression by epithelioid cells, monocyte-macrophage lineage cells and MGCs, increased lymphocytic HLA-DR expression, increased CD4(+)/CD8(+) T-cell ratio, and CD20(+) B lymphocytes evenly distributed within and around granulomas. In both patient groups prominent IFN-gamma expression was found in and around granulomas, and TNF-alpha and IL-23 receptor expression was moderate. IL-6, IL-17, and TGF-beta expression was prominent in granulomas from patients with BS but sporadic in granulomas from patients with CD. IL-10 expression was absent. Conclusion: Granulomas from patients with BS and granulomas from patients with NOD2-associated CD show distinct morphologic features and cytokine expression patterns, suggesting that the T(H)17 axis might be involved in the pathogenesis of BS, whereas T(H)1 is important in both patients with BS and patients with CD. (J Allergy Clin Immunol 2012;129:1076-84.)	[Janssen, Carl E. I.; De Hertogh, Gert; Wouters, Carine H.] Univ Hosp Leuven, Dept Pediat Rheumatol, B-3000 Louvain, Belgium; [Janssen, Carl E. I.; Desmet, Valeer J.; Roskams, Tania] Univ Hosp Leuven, Dept Pathol, B-3000 Louvain, Belgium; [Rose, Carlos D.] Thomas Jefferson Univ, Dept Pediat Rheumatol, Wilmington, DE USA; [Martin, Tammy M.] Casey Eye Inst, Portland, OR USA; [Martin, Tammy M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Meunier, Brigitte Bader; Quartier, Pierre; Fischer, Alain] Hop Necker Enfants Malad, Dept Pediat Immunol Hematol & Rheumatol, Paris, France; [Meunier, Brigitte Bader; Quartier, Pierre; Fischer, Alain] Univ Paris 05, Inst Hosp Univ IMAGINE, Paris, France; [Meunier, Brigitte Bader; Quartier, Pierre; Fischer, Alain] INSERM U768, Inst Natl Sante & Rech Med, Paris, France; [Cimaz, Rolando] Univ Florence, I-50121 Florence, Italy; [Harjacek, Miroslav] Univ Hosp Zagreb, Dept Pediat Rheumatol, Zagreb, Croatia; [Ten Cate, Rebecca] Leiden Univ, Med Ctr, Dept Pediat Rheumatol, NL-2300 RA Leiden, Netherlands; [Thomee, Caroline] Ctr Hosp Luxembourg, Dept Pediat Rheumatol, Luxembourg, Luxembourg	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; Jefferson University; Oregon Health & Science University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Florence; University of Zagreb; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Luxembourg Hospital Center	Wouters, CH (corresponding author), Univ Hosp Leuven, Dept Pediat Rheumatol, Herestr 49, B-3000 Louvain, Belgium.	carine.wouters@uzleuven.be	CIMAZ, Rolando/AAA-9058-2019	CIMAZ, Rolando/0000-0002-3260-4226; Wouters, Carine/0000-0002-6426-8845; Harjacek, Miroslav/0000-0002-8322-9702; bader-meunier, brigitte/0000-0001-8476-8196; Roskams, Tania/0000-0002-2816-1530; Quartier, Pierre/0000-0002-1769-549X	GlaxoSmithKline; National Institutes of Health and the Research to Prevent Blindness	GlaxoSmithKline(GlaxoSmithKline); National Institutes of Health and the Research to Prevent Blindness	C.H.W. was awarded an unrestricted grant from GlaxoSmithKline to study Blau syndrome, and C.D.R. is a coinvestigator on that grant. T.M. is supported by the National Institutes of Health and the Research to Prevent Blindness.	Abreu MT, 2002, GASTROENTEROLOGY, V123, P679, DOI 10.1053/gast.2002.35393; Arostegui JI, 2007, ARTHRITIS RHEUM-US, V56, P3805, DOI 10.1002/art.22966; Baumer I, 1997, AM J RESP CELL MOL, V16, P171; Benchimol EI, 2011, INFLAMM BOWEL DIS, V17, P423, DOI 10.1002/ibd.21349; Benwell RK, 2010, CLIN IMMUNOL, V134, P178, DOI 10.1016/j.clim.2009.09.013; Biank V, 2007, INFLAMM BOWEL DIS, V13, P1430, DOI 10.1002/ibd.20213; Biswas A, 2010, P NATL ACAD SCI USA, V107, P14739, DOI 10.1073/pnas.1003363107; BLAU EB, 1985, J PEDIATR-US, V107, P689, DOI 10.1016/S0022-3476(85)80394-2; Bousvaros A, 2010, EXPERT REV CLIN IMMU, V6, P659, DOI [10.1586/eci.10.46, 10.1586/ECI.10.46]; Chamaillard M, 2003, P NATL ACAD SCI USA, V100, P3455, DOI 10.1073/pnas.0530276100; DECHADAREVIAN JP, 1993, ARCH PATHOL LAB MED, V117, P1050; Ephgrave K, 2007, SURG CLIN N AM, V87, P673, DOI 10.1016/j.suc.2007.03.003; Ewida AS, 2002, APPL IMMUNOHISTO M M, V10, P171, DOI 10.1097/00022744-200206000-00013; GALLWITZ B, 1994, Z GASTROENTEROL, V32, P252; Gazouli M, 2010, WORLD J GASTROENTERO, V16, P1753, DOI 10.3748/wjg.v16.i14.1753; GEBOES K, 1986, VIRCHOWS ARCH A, V409, P679, DOI 10.1007/BF00713433; Hansen R, 2010, J GASTROENTEROL, V45, P266, DOI 10.1007/s00535-009-0191-y; Hernandez-Pando R, 2000, IMMUNOLOGY, V100, P352, DOI 10.1046/j.1365-2567.2000.00025.x; HUMBLE JG, 1956, BRIT J HAEMATOL, V2, P283, DOI 10.1111/j.1365-2141.1956.tb06700.x; HUNNINGHAKE GW, 1981, NEW ENGL J MED, V305, P429, DOI 10.1056/NEJM198108203050804; Iannuzzi MC, 2007, NEW ENGL J MED, V357, P2153, DOI 10.1056/NEJMra071714; Kakazu T, 1999, AM J GASTROENTEROL, V94, P2149; Kanazawa N, 2005, BLOOD, V105, P1195, DOI 10.1182/blood-2004-07-2972; Kumar B, 2008, DIAGN CYTOPATHOL, V36, P691, DOI 10.1002/dc.20904; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Magalhaes JG, 2011, CURR OPIN IMMUNOL, V23, P29, DOI 10.1016/j.coi.2010.12.003; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Milman Nils, 2006, Ugeskr Laeger, V168, P3612; Morishima N, 2009, BIOCHEM BIOPH RES CO, V386, P105, DOI 10.1016/j.bbrc.2009.05.140; Newman LS, 1997, NEW ENGL J MED, V336, P1224, DOI 10.1056/NEJM199704243361706; Oki M, 2005, LAB INVEST, V85, P137, DOI 10.1038/labinvest.3700189; Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x; Pierik M, 2005, GUT, V54, P223, DOI 10.1136/gut.2004.042572; PRIOR C, 1991, AM REV RESPIR DIS, V143, P53, DOI 10.1164/ajrccm/143.1.53; Rose CD, 2006, ARTHRITIS RHEUM, V54, P3337, DOI 10.1002/art.22122; Rose CD, 2005, J RHEUMATOL, V32, P373; Seiderer J, 2008, INFLAMM BOWEL DIS, V14, P437, DOI 10.1002/ibd.20339; Singhal N, 2011, DIAGN CYTOPATHOL, V39, P553, DOI 10.1002/dc.21421; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Strober W, 2011, GASTROENTEROLOGY, V140, P1756, DOI 10.1053/j.gastro.2011.02.016; SWIDER C, 1995, CLIN EXP IMMUNOL, V100, P401; THOMAS PD, 1987, AM REV RESPIR DIS, V135, P747; van Beelen AJ, 2007, IMMUNITY, V27, P660, DOI 10.1016/j.immuni.2007.08.013; Venkataraman G, 2010, AM J SURG PATHOL, V34, P589, DOI 10.1097/PAS.0b013e3181d5ddf8; WATANABE M, 1995, J GASTROENTEROL, V30, P73; Weaver CT, 2007, SEMIN IMMUNOL, V19, P351, DOI 10.1016/j.smim.2008.01.001; Xia P, 2008, CELL RES, V18, P705, DOI 10.1038/cr.2008.64; Yazdanyar S, 2010, J INTERN MED, V267, P228, DOI 10.1111/j.1365-2796.2009.02137.x; Yoshida YO, 2010, J IMMUNOL, V184, P4414, DOI 10.4049/jimmunol.0903332; Zheng SG, 2008, J IMMUNOL, V180, P7112, DOI 10.4049/jimmunol.180.11.7112	50	51	56	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1076	1084		10.1016/j.jaci.2012.02.004	http://dx.doi.org/10.1016/j.jaci.2012.02.004			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22464675				2022-12-18	WOS:000302144600024
J	Rand, CS; Wright, RJ; Cabana, MD; Foggs, MB; Halterman, JS; Olson, L; Vollmer, WM; Wilson, SR; Taggart, V				Rand, Cynthia S.; Wright, Rosalind J.; Cabana, Michael D.; Foggs, Michael B.; Halterman, Jill S.; Olson, Lynn; Vollmer, William M.; Wilson, Sandra R.; Taggart, Virginia			Mediators of asthma outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adherence; self-management skills; asthma patient education; stress	SELF-MANAGEMENT PROGRAM; STRESSFUL LIFE EVENTS; MEDICATION ADHERENCE; INHALED CORTICOSTEROIDS; POSTNATAL DEPRESSION; PREDICTIVE-VALIDITY; CHRONIC DISEASE; CHILDREN; VALIDATION; KNOWLEDGE	Background: Patient adherence, the level of asthma self-management skills, exposure to stress, and depression can have considerable influence on a wide range of asthma outcomes and thus are considered asthma outcome mediators. Objective: National Institutes of Health institutes and other federal agencies convened an expert group to recommend standardized measures for 7 domains of asthma clinical research outcomes measures. Although the review of mediators of these outcomes was not within the scope of any specific outcome topic, a brief summary is presented so that researchers might consider potential mediators. Methods: We prepared a summary of key mediators of asthma outcomes based on expertise and knowledge of the literature. Results: The rationale for including measures of adherence, self-management skills, and exposures to stress in asthma clinical research is presented, along with a brief review of instruments for collecting this information from clinical research participants. Conclusions: Appropriate measurement of adherence, self-management skills, and exposures to stress will enhance characterization of study participants and provide information about the potential impact these factors can have on mediating the effects of treatment interventions. (J Allergy Clin Immunol 2012; 129: S136-41.)	[Taggart, Virginia] NHLBI, DLD, NIH, Bethesda, MD 20892 USA; [Rand, Cynthia S.] Johns Hopkins Univ, Baltimore, MD USA; [Wright, Rosalind J.] Harvard Univ, Sch Med, Boston, MA USA; [Cabana, Michael D.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Foggs, Michael B.] Advocate Hlth Care, Oak Brook, IL USA; [Halterman, Jill S.] Univ Rochester, Rochester, NY 14627 USA; [Olson, Lynn] Amer Acad Pediat, Elk Grove Village, IL USA; [Vollmer, William M.] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA; [Wilson, Sandra R.] Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; University of Rochester; American Academy of Pediatrics; Kaiser Permanente; Palo Alto Medical Foundation Research Institute	Taggart, V (corresponding author), NHLBI, DLD, NIH, 6701 Rockledge Dr, Bethesda, MD 20892 USA.	taggartv@nih.gov			National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Environmental Health Sciences; Agency for Healthcare Research and Quality; Merck Childhood Asthma Network; Robert Wood Johnson Foundation; US Environmental Protection Agency; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL095606] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Merck Childhood Asthma Network; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); US Environmental Protection Agency(United States Environmental Protection Agency); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The Asthma Outcomes workshop was funded by contributions from the National Institute of Allergy and Infectious Diseases; the National Heart, Lung, and Blood Institute; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; the Agency for Healthcare Research and Quality; and the Merck Childhood Asthma Network, as well as by a grant from the Robert Wood Johnson Foundation. Contributions from the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; and the US Environmental Protection Agency funded the publication of this article and for all other articles in this supplement.	Allen RM, 1998, J ASTHMA, V35, P537, DOI 10.3109/02770909809048956; [Anonymous], 1997, MEASURING STRESS GUI; Bartlett SJ, 2004, PEDIATRICS, V113, P229, DOI 10.1542/peds.113.2.229; Beck A.T., 1996, BDI 2 BECK DEPRESSIO, DOI [10.1037/t00742-000, DOI 10.1037/T00742-000]; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Bergink V, 2011, J PSYCHOSOM RES, V70, P385, DOI 10.1016/j.jpsychores.2010.07.008; Berry C, 2001, PSYCHOL REP, V88, P713, DOI 10.2466/PR0.88.3.713-724; Berry CA, 2006, PSYCHOL REP, V98, P123, DOI 10.2466/PRO.98.1.123-132; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Carlson MC, 2005, J GERONTOL A-BIOL, V60, P217, DOI 10.1093/gerona/60.2.217; Chen E, 2008, ENVIRON HEALTH PERSP, V116, P970, DOI 10.1289/ehp.11076; Chen E, 2007, AM J RESP CRIT CARE, V176, P644, DOI 10.1164/rccm.200610-1473OC; Chida Y, 2008, PSYCHOSOM MED, V70, P102, DOI 10.1097/PSY.0b013e31815c1b71; CLARK NM, 1986, PATIENT EDUC COUNS, V8, P27, DOI 10.1016/0738-3991(86)90024-8; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COHEN S, 1990, HEALTH PSYCHOL, V9, P466, DOI 10.1037/0278-6133.9.4.466; COHEN S, 1988, CLAR SYMP, P31; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Cox JL, 1996, J AFFECT DISORDERS, V39, P185, DOI 10.1016/0165-0327(96)00008-0; Dale O, 2007, J CLIN EPIDEMIOL, V60, P8, DOI 10.1016/j.jclinepi.2006.04.005; Helena ETD, 2008, REV SAUDE PUBL, V42, P764, DOI 10.1590/S0034-89102008000400025; Erickson SR, 2001, ANN PHARMACOTHER, V35, P997, DOI 10.1345/aph.10379; Farris KB, 2008, ANN PHARMACOTHER, V42, P1026, DOI 10.1345/aph.1G502; Fialko L, 2008, SCHIZOPHR RES, V100, P53, DOI 10.1016/j.schres.2007.10.029; Gamble J, 2009, AM J RESP CRIT CARE, V180, P817, DOI 10.1164/rccm.200902-0166OC; Gibson PG, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001117], 10.1002/14651858.CD001117]; Guevara JP, 2003, BMJ-BRIT MED J, V326, P1308, DOI 10.1136/bmj.326.7402.1308; Hansen RA, 2009, ANN PHARMACOTHER, V43, P413, DOI 10.1345/aph.1L496; Ho J, 2003, J ALLERGY CLIN IMMUN, V111, P498, DOI 10.1067/mai.2003.160; Hufford MR, 2001, DRUG INF J, V35, P755, DOI 10.1177/009286150103500314; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Koop A, 2002, CONTROL CLIN TRIALS, V23, P469, DOI 10.1016/S0197-2456(02)00224-6; Kopp MS, 2010, J PSYCHOSOM RES, V69, P211, DOI 10.1016/j.jpsychores.2009.09.006; Krousel-Wood M, 2009, AM J MANAG CARE, V15, P59; Kub J, 2009, PUBLIC HEALTH NURS, V26, P297, DOI 10.1111/j.1525-1446.2009.00784.x; Lazarus R.S., 1984, STRESS APPRAISAL; Mancuso CA, 2009, ANN ALLERG ASTHMA IM, V102, P294, DOI 10.1016/S1081-1206(10)60334-1; Mattke S, 2009, PEDIATRICS, V123, pS199, DOI 10.1542/peds.2008-2233K; Matza LS, 2009, ANN PHARMACOTHER, V43, P1621, DOI 10.1345/aph.1M174; McQuaid EL, 2001, CHILD HEALTH CARE, V30, P183, DOI 10.1207/S15326888CHC3003_2; Miller GE, 2006, P NATL ACAD SCI USA, V103, P5496, DOI 10.1073/pnas.0506312103; Miller GE, 2009, J ALLERGY CLIN IMMUN, V123, P824, DOI 10.1016/j.jaci.2008.12.019; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x; National Asthma Education and Prevention Program NH Lung and Blood Institute National Institutes of Health US Department of Health and Human Services., 2007, 3 US DEP HLTH HUM SE; Peters TE, 2010, CHILD ADOLESC PSYCHI, V19, pix; Peters TE, 2010, CHILD ADOL PSYCH CL, V19, P319, DOI 10.1016/j.chc.2010.01.006; Price MR, 2002, ANN ALLERG ASTHMA IM, V89, P572, DOI 10.1016/S1081-1206(10)62104-7; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RAND CS, 1994, AM J RESP CRIT CARE, V149, pS69, DOI 10.1164/ajrccm/149.2_Pt_2.S69; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Riekert KA, 2002, J CLIN PSYCHOL MED S, V9, P25, DOI 10.1023/A:1014131928789; Ritz T, 2000, PSYCHOSOM MED, V62, P808, DOI 10.1097/00006842-200011000-00011; Sandberg S, 2004, THORAX, V59, P1046, DOI 10.1136/thx.2004.024604; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Schaffer SD, 2007, J AM ACAD NURSE PRAC, V19, P530, DOI 10.1111/j.1745-7599.2007.00253.x; Schmittdiel J, 2008, J GEN INTERN MED, V23, P77, DOI 10.1007/s11606-007-0452-5; Schreier HMC, 2011, IMMUNOL ALLERGY CLIN, V31, P41, DOI 10.1016/j.iac.2010.09.003; Shalowitz MU, 2006, PEDIATRICS, V117, pE940, DOI 10.1542/peds.2005-2446; Shalowitz MU, 1998, HEALTH SERV RES, V33, P1381; Shalowitz MU, 2001, AMBUL PEDIATR, V1, P185, DOI 10.1367/1539-4409(2001)001<0185:TROLSA>2.0.CO;2; Shames RS, 2004, ANN ALLERG ASTHMA IM, V92, P611, DOI 10.1016/S1081-1206(10)61426-3; SNYDER SE, 1987, J ASTHMA, V24, P153, DOI 10.3109/02770908709070931; STEINER JF, 1988, MED CARE, V26, P814, DOI 10.1097/00005650-198808000-00007; Turyk ME, 2008, PEDIAT ALLERG IMM-UK, V19, P255, DOI 10.1111/j.1399-3038.2007.00603.x; WIGAL JK, 1993, CHEST, V104, P1144, DOI 10.1378/chest.104.4.1144; Willey C, 2000, CLIN THER, V22, P858, DOI 10.1016/S0149-2918(00)80058-2; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; Williams LK, 2007, J ALLERGY CLIN IMMUN, V120, P1153, DOI 10.1016/j.jaci.2007.08.020; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; Wolf FM, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000326; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Wright RJ, 2007, PAEDIATR PERINAT EP, V21, P8, DOI 10.1111/j.1365-3016.2007.00879.x; Wright RJ, 2009, J ALLERGY CLIN IMMUN, V123, P831, DOI 10.1016/j.jaci.2009.02.017; Zelikovsky N, 2005, NAT KIDN FDN 2005 SP	78	51	51	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3		S			S136	S141		10.1016/j.jaci.2011.12.987	http://dx.doi.org/10.1016/j.jaci.2011.12.987			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	901OL	22386506	Green Accepted			2022-12-18	WOS:000300976600009
J	Guilbert, TW; Mauger, DT; Allen, DB; Zeiger, RS; Lemanske, RF; Szefler, SJ; Strunk, RC; Bacharier, LB; Covar, R; Sorkness, CA; Taussig, LM; Martinez, FD				Guilbert, Theresa W.; Mauger, David T.; Allen, David B.; Zeiger, Robert S.; Lemanske, Robert F., Jr.; Szefler, Stanley J.; Strunk, Robert C.; Bacharier, Leonard B.; Covar, Ronina; Sorkness, Christine A.; Taussig, Lynn M.; Martinez, Fernando D.		Natl Heart Lung Blood Inst	Growth of preschool children at high risk for asthma 2 years after discontinuation of fluticasone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma Predictive Index; atopy; clinical trials; early childhood asthma; fluticasone; inhaled corticosteroids; intermittent wheezing; linear growth; research network	CHILDHOOD ASTHMA; YOUNG-CHILDREN; BUDESONIDE; PREVENTION; PROPIONATE; NEDOCROMIL; STANDARDS; INFANTS	Background: The effect on linear growth of daily long-term inhaled corticosteroid therapy in preschool-aged children with recurrent wheezing is controversial. Objective: We sought to determine the effect of daily inhaled corticosteroid given for 2 years on linear growth in preschool children with recurrent wheezing. Methods: Children aged 2 and 3 years with recurrent wheezing and positive modified Asthma Predictive Index scores were randomized to a 2-year treatment period of chlorofluorocarbon-delivered fluticasone propionate (176 mu g/d) or masked placebo delivered through a valved chamber with a mask and then followed for 2 years off study medication. Height growth determined by means of stadiometry was compared between treatment groups. Results: In the study cohort as a whole, the fluticasone group did not have significantly less linear growth than the placebo group (change in height from baseline difference, -0.2 cm; 95% CI, -1.1 to 0.6) 2 years after discontinuation of study treatment. In post hoc analyses children 2 years old who weighed less than 15 kg at enrollment and were treated with fluticasone had less linear growth compared with those treated with placebo (change in height from baseline difference, -1.6 cm; 95% CI, -2.8 to -0.4; P = .009). Conclusion: Linear growth was not significantly different in high-risk preschool-aged children with recurrent wheezing treated with 176 mu g/d chlorofluorocarbon-delivered fluticasone compared with placebo 2 years after fluticasone is discontinued. However, post hoc subgroup analyses revealed that children who are younger in age and of lesser weight relative to the entire study cohort had significantly less linear growth, possibly because of a higher relative fluticasone exposure. (J Allergy Clin Immunol 2011;128: 956-63.)	[Guilbert, Theresa W.; Allen, David B.] Univ Wisconsin Madison, Dept Pediat, Madison, WI 53716 USA; [Lemanske, Robert F., Jr.] Univ Wisconsin Madison, Dept Med, Madison, WI 53716 USA; [Sorkness, Christine A.] Univ Wisconsin Madison, Sch Pharm, Madison, WI 53716 USA; [Mauger, David T.] Penn State Univ, Dept Publ Hlth Serv, Hershey, PA USA; [Zeiger, Robert S.] Univ Calif San Diego, Dept Allergy, La Jolla, CA 92093 USA; [Zeiger, Robert S.] Kaiser Permanente San Diego, San Diego, CA USA; [Szefler, Stanley J.; Covar, Ronina; Taussig, Lynn M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Strunk, Robert C.; Bacharier, Leonard B.] Washington Univ, Dept Pediat, St Louis, MO 63130 USA; [Martinez, Fernando D.] Univ Arizona, Dept Pediat, Arizona Resp Ctr, Tucson, AZ 85721 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of California System; University of California San Diego; Kaiser Permanente; National Jewish Health; Washington University (WUSTL); University of Arizona	Guilbert, TW (corresponding author), Univ Wisconsin Madison, Dept Pediat, 600 Highland Ave,K4-944,CSC 4108, Madison, WI 53716 USA.	tguilbert@wisc.edu		Zeiger, Robert/0000-0001-5788-5063; Bacharier, Leonard/0000-0003-0432-2704; Szefler, Stanley/0000-0002-6911-3199; Paul, Ian/0000-0002-6344-8609; Guilbert, Theresa/0000-0002-6932-712X	National Heart, Lung, and Blood Institute [HL071742, HL004519-04, 5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, 5U10HL064313]; National Institutes of Health (NIH) [1 UL1 RR025780]; National Center for Research Resources (NCRR); Altus Pharmaceuticals; Inspire Pharmaceuticals; National Institutes of Health (NIH); Aerocrine; Genentech; GlaxoSmithKline; Merck and Co; AstraZeneca; TEVA Pharmaceuticals; Medical Research and Education (Detroit); Children's Hospital of Minnesota; Toronto Allergy Society; Beaumont Hospital (Detroit); University of Illinois; Canadian Society of Allergy and Clinical Immunology, New York Presbyterian; American College of Allergy, Asthma Immunology; American Academy of Allergy, Asthma Immunology; National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Environmental Health Sciences/Environmental Protection Agency; NIH/National Heart, Lung, and Blood Institute (NHLBI); NIH/NHLBI; Schering-Plough; Compleware/Sandoz; MedImmune; Pfizer; NIH; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780, M01RR000036] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K30HL004519, K08HL071742, U10HL064287, U10HL064313, U10HL064307, U10HL064288, U10HL064305, U10HL064295] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Altus Pharmaceuticals; Inspire Pharmaceuticals; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Aerocrine; Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Merck and Co(Merck & Company); AstraZeneca(AstraZeneca); TEVA Pharmaceuticals(Teva Pharmaceutical Industries); Medical Research and Education (Detroit); Children's Hospital of Minnesota; Toronto Allergy Society; Beaumont Hospital (Detroit); University of Illinois; Canadian Society of Allergy and Clinical Immunology, New York Presbyterian; American College of Allergy, Asthma Immunology; American Academy of Allergy, Asthma Immunology; National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Environmental Health Sciences/Environmental Protection Agency(United States Environmental Protection AgencyUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIH/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Schering-Plough(Merck & CompanySchering Plough Corporation); Compleware/Sandoz; MedImmune(AstraZenecaMedimmune); Pfizer(Pfizer); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants HL071742, HL004519-04, 5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, and 5U10HL064313 from the National Heart, Lung, and Blood Institute. This study was carried out in part in the General Clinical Research Centers at Washington University School of Medicine (M01 RR00036) and under Colorado CTSA grant 1 UL1 RR025780 from the National Institutes of Health (NIH) and National Center for Research Resources (NCRR).; Disclosure of potential conflict of interest: T. W. Guilbert has consulted for GlaxoSmithKline, AstraZeneca, MAP Pharmaceutical, Merck/Schering-Plough, and Genentech/Novartis; has designed and presented a CME-accredited series on respiratory syncytial virus disease for Peerpoint Medical Education Institute; and has received research support from Altus Pharmaceuticals, Inspire Pharmaceuticals, and the National Institutes of Health (NIH). R. S. Zeiger has consulted for AstraZeneca, Aerocrine, Genentech, Novartis, Merck and Co, Schering-Plough, and Med-Immune and has received research support through Kaiser Permanente or the Childhood Asthma Research and Education Network Clinical Trial from Aerocrine, Genentech, GlaxoSmithKline, Merck and Co, AstraZeneca, and TEVA Pharmaceuticals. R. F. Lemanske, Jr has given lectures for Merck, AstraZeneca, Doembecher Children's Hospital, Washington University, Medicus Group, Park Nicolet Institute, the LA Allergy Society, the Michigan Allergy/Asthma Society, the Medical College of Wisconsin, the Fund for Medical Research and Education (Detroit), Children's Hospital of Minnesota, the Toronto Allergy Society, Beaumont Hospital (Detroit), the University of Illinois, the Canadian Society of Allergy and Clinical Immunology, New York Presbyterian, the American College of Allergy, Asthma & Immunology, and the American Academy of Allergy, Asthma & Immunology; has consulted for AstraZeneca, Map Pharmaceuticals, Gray Consulting, Smith Research, Quintiles/ Innovax, RC Horowitz & Co, International Meetings and Science, and Scienomics; has written for Up-to-Date; and has edited a textbook for Elsevier. S. J. Szefler has consulted for GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and has received research support from the National Institute of Allergy and Infectious Diseases (NIAID), GlaxoSmithKline, the National Institute of Environmental Health Sciences/Environmental Protection Agency, and the NIH/National Heart, Lung, and Blood Institute (NHLBI). L. B. Bacharier has received honoraria from AstraZeneca; received honoraria and served on an advisory board for Genentech, GlaxoSmithKline, Merck, Schering-Plough, and Aerocrine; and received research support from the NIH/NHLBI. R. Covar has received research support from the NIH/NHLBI. C. A. Sorkness has served on advisory boards for GlaxoSmithKline, Schering-Plough, AstraZeneca, and Novartis and received research support from Schering-Plough and Compleware/Sandoz. F. D. Martinez has served on an advisory board for and received lecture fees from Merck; has consulted for GlaxoSmithKline and MedImmune; has received lecture fees from Pfizer; and has received research support from the NIH. The rest of the authors have declared that they have no conflict of interest.	Agertoft L, 2000, NEW ENGL J MED, V343, P1064, DOI 10.1056/NEJM200010123431502; Allen DB, 2002, PEDIATRICS, V109, P373; Bacharier LB, 2009, J ALLERGY CLIN IMMUN, V123, P1077, DOI 10.1016/j.jaci.2008.12.1120; Bisgaard H, 2004, PEDIATRICS, V113, P87; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Childhood Asthma Management Program, 1994, CHILDH ASTHM MAN PRO; Chu YT, 2009, PEDIATR PULM, V44, P472, DOI 10.1002/ppul.21023; Cottrell L, 2011, AM J RESP CRIT CARE, V183, P441, DOI 10.1164/rccm.201004-0603OC; de Onis M, 2007, J NUTR, V137, P144, DOI 10.1093/jn/137.1.144; Dolovich M, 1997, ASTHMA, P1359; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Jeong Yoolwon, 2010, J Prev Med Public Health, V43, P369, DOI 10.3961/jpmph.2010.43.5.369; Kuczmarski R J, 2000, Adv Data, P1; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Ross KR, 2009, PEDIATR PULM, V44, P877, DOI 10.1002/ppul.21065; Scholtens S, 2009, J ALLERGY CLIN IMMUN, V123, P1312, DOI 10.1016/j.jaci.2009.02.029; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; Skoner DP, 2000, J ALLERGY CLIN IMMUN, V105, P259, DOI 10.1016/S0091-6749(00)90074-5; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Strunk RC, 2009, J PEDIATR-US, V154, P682, DOI 10.1016/j.jpeds.2008.11.036; Szefler S, 2000, NEW ENGL J MED, V343, P1054; van Dijk CE, 2009, PEDIATRICS, V123, P102, DOI 10.1542/peds.2007-3382	25	51	54	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					956	U386		10.1016/j.jaci.2011.06.027	http://dx.doi.org/10.1016/j.jaci.2011.06.027			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21820163	Green Accepted			2022-12-18	WOS:000296578200006
J	Wang, JL; Calatroni, A; Visness, CM; Sampson, HA				Wang, Julie; Calatroni, Agustin; Visness, Cynthia M.; Sampson, Hugh A.			Correlation of specific IgE to shrimp with cockroach and dust mite exposure and sensitization in an inner-city population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cockroach; dust mite; shrimp; tropomyosin; cross-reactivity	FOOD ALLERGY; BIRCH POLLEN; CHILDREN; ASTHMA; REACTIVITY; MORBIDITY; RISK	Background: Studies have demonstrated that IgE-binding cross-reactive epitopes between shrimp, cockroach, and house dust mite tropomyosins can account for the presence of detectable IgE to shrimp in patients with cockroach and dust mite allergies. Objective: We investigated the correlation between IgE-mediated sensitization to shrimp, cockroach, and dust mite in relation to allergen exposure in inner-city children. Methods: Five hundred four serum samples from the National Cooperative Inner-City Asthma Study were evaluated for specific IgE to shrimp, and the results were compared with specific IgE to cockroach (Blattella germanica) and dust mite (Dermatophagoides farinae). Associations between IgE sensitization to these allergens and environmental exposures were determined. Results: There was a strong positive correlation between shrimp, cockroach, and dust mite IgE levels. High exposure to cockroach (B germanica) in the home, particularly in the bedroom and television room, was significantly correlated with higher shrimp and cockroach IgE levels. In contrast, high exposure to dust mite in the home was highly correlated with IgE levels to D farinae but not with shrimp IgE levels. There is a synergistic relationship between cockroach IgE levels and exposure in predicting shrimp IgE levels. Conclusions: For children with evidence of IgE-mediated sensitization to cockroach and shrimp, having high exposure to cockroach in the home can contribute to higher shrimp IgE levels, which might not correlate with clinical reactivity. Further patient evaluations with clinical histories of shrimp exposure and reactions, as well as oral food challenges, would have to be performed to confirm these findings. (J Allergy Clin Immunol 2011;128:834-7.)	[Wang, Julie] Mt Sinai Hosp, Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA; [Calatroni, Agustin; Visness, Cynthia M.] Rho Fed Syst Div Inc, Chapel Hill, NC USA	Icahn School of Medicine at Mount Sinai	Wang, JL (corresponding author), Mt Sinai Hosp, Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	Julie.wang@mssm.edu			National Institutes of Allergy and Infectious Disease (National Institutes of Health [NIH], Bethesda, Md) [UOI A1-30751, A1-30752, A1-30756, A1-30772, A1-30773-01, A1-30777, A1-30779, A1-30780, N01-A1-15105]; National Center for Research Resources (NCRR), a component of the NIH [M01-RR-00071]; NIH/National Institute of Allergy and Infectious Diseases [K23 AI083883]; NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI083883] Funding Source: NIH RePORTER	National Institutes of Allergy and Infectious Disease (National Institutes of Health [NIH], Bethesda, Md)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources (NCRR), a component of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The National Cooperative Inner-City Asthma Study was supported by grants UOI A1-30751, A1-30752, A1-30756, A1-30772, A1-30773-01, A1-30777, A1-30779, A1-30780, and N01-A1-15105 from the National Institutes of Allergy and Infectious Disease (National Institutes of Health [NIH], Bethesda, Md). The project described was supported in part by grant no. M01-RR-00071 from the National Center for Research Resources (NCRR), a component of the NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or NIH. J.W. is supported in part by a grant from the NIH/National Institute of Allergy and Infectious Diseases (K23 AI083883).; C. M. Visness has received research support from the NIH/National Institute of Allergy and Infectious Diseases. H. A. Sampson has received research support from the NIH. The rest of the authors have declared that they have no conflict of interest.	Ayuso R, 2002, INT ARCH ALLERGY IMM, V129, P38, DOI 10.1159/000065172; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Fernandes J, 2003, CLIN EXP ALLERGY, V33, P956, DOI 10.1046/j.1365-2222.2003.01722.x; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P435, DOI 10.1111/j.1399-3038.2004.00188.x; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; Mitchell H, 1997, PEDIATR PULM, V24, P237; Mittag D, 2004, J ALLERGY CLIN IMMUN, V114, P1410, DOI 10.1016/j.jaci.2004.09.014; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Schroeder A, 2009, CLIN EXP ALLERGY, V39, P261, DOI 10.1111/j.1365-2222.2008.03160.x; Simpson AB, 2007, PEDIATR PULM, V42, P489, DOI 10.1002/ppul.20605; Wang JL, 2005, J ALLERGY CLIN IMMUN, V115, P1076, DOI 10.1016/j.jaci.2005.02.014	17	51	53	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					834	837		10.1016/j.jaci.2011.07.045	http://dx.doi.org/10.1016/j.jaci.2011.07.045			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21872304	Green Accepted			2022-12-18	WOS:000296538100021
J	Audry, M; Ciancanelli, M; Yang, K; Cobat, A; Chang, HH; Sancho-Shimizu, V; Lorenzo, L; Niehues, T; Reichenbach, J; Li, XX; Israel, A; Abel, L; Casanova, JL; Zhang, SY; Jouanguy, E; Puel, A				Audry, Magali; Ciancanelli, Michael; Yang, Kun; Cobat, Aurelie; Chang, Huey-Hsuan; Sancho-Shimizu, Vanessa; Lorenzo, Lazaro; Niehues, Tim; Reichenbach, Janine; Li, Xiao-Xia; Israel, Alain; Abel, Laurent; Casanova, Jean-Laurent; Zhang, Shen-Ying; Jouanguy, Emmanuelle; Puel, Anne			NEMO is a key component of NF-kappa B- and IRF-3-dependent TLR3-mediated immunity to herpes simplex virus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NEMO; immunodeficiency; Toll-like receptor 3; herpes simplex encephalitis	ANHIDROTIC ECTODERMAL DYSPLASIA; ESSENTIAL MODULATOR MUTATION; NONTUBERCULOUS MYCOBACTERIAL INFECTION; PYOGENIC BACTERIAL-INFECTIONS; INCONTINENTIA PIGMENTI; IFN-GAMMA; PROTECTIVE IMMUNITY; INHERITED DISORDERS; MOLECULAR ANALYSIS; MEDIATED IMMUNITY	Background: Children with germline mutations in Toll-like receptor 3 (TLR3), UNC93B1, TNF receptor-associated factor 3, and signal transducer and activator of transcription 1 are prone to herpes simplex virus-1 encephalitis, owing to impaired TLR3-triggered, UNC-93B-dependent, IFN-alpha/beta, and/or IFN-lambda-mediated signal transducer and activator of transcription 1-dependent immunity. Objective: We explore here the molecular basis of the pathogenesis of herpes simplex encephalitis in a child with a hypomorphic mutation in nuclear factor-kappa B (NF-kappa B) essential modulator, which encodes the regulatory subunit of the inhibitor of the I kappa b kinase complex. Methods: The TLR3 signaling pathway was investigated in the patient's fibroblasts by analyses of IFN-beta, IFN-lambda, and IL-6 mRNA and protein levels, by quantitative PCR and ELISA, respectively, upon TLR3 stimulation (TLR3 agonists or TLR3-dependent viruses). NF-kappa B activation was assessed by electrophoretic mobility shift assay and interferon regulatory factor 3 dimerization on native gels after stimulation with a TLR3 agonist. Results: The patient's fibroblasts displayed impaired responses to TLR3 stimulation in terms of IFN-beta, IFN-lambda, and IL-6 production, owing to impaired activation of both NF-kappa B and IRF-3. Moreover, vesicular stomatitis virus, a potent IFN-inducer in human fibroblasts, and herpes simplex virus-1, induced only low levels of IFN-beta and IFN-lambda in the patient's fibroblasts, resulting in enhanced viral replication and cell death, as reported for UNC-93B-deficient fibroblasts. Conclusion: Herpes simplex encephalitis may occur in patients carrying NF-kappa B essential modulator mutations, due to the impairment of NF-kappa B- and interferon regulatory factor 3-dependent-TLR3-mediated antiviral IFN production. (J Allergy Clin Immunol 2011;128:610-7.)	[Audry, Magali; Ciancanelli, Michael; Abel, Laurent; Casanova, Jean-Laurent; Zhang, Shen-Ying; Jouanguy, Emmanuelle] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, New York, NY 10065 USA; [Yang, Kun; Cobat, Aurelie; Chang, Huey-Hsuan; Sancho-Shimizu, Vanessa; Lorenzo, Lazaro; Abel, Laurent; Casanova, Jean-Laurent; Zhang, Shen-Ying; Jouanguy, Emmanuelle; Puel, Anne] Univ Paris 05, Necker Med Sch, INSERM U980, Lab Human Genet Infect Dis,Inst Natl Sante & Rech, Paris, France; [Yang, Kun; Casanova, Jean-Laurent; Zhang, Shen-Ying; Jouanguy, Emmanuelle] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, French Chinese Lab Genom & Life Sci, Shanghai 200030, Peoples R China; [Niehues, Tim] Univ Dusseldorf, Immunodeficiency & Pediat Rheumatol Ctr, HELIOS Klinikum Krefeld, Ctr Child Hlth & Adolescence, Dusseldorf, Germany; [Reichenbach, Janine] Univ Childrens Hosp, Div Immunol Hematol & Bone Marrow Transplantat, Zurich, Switzerland; [Li, Xiao-Xia] Cleveland Clin Fdn, Dept Immunol, Cleveland, OH USA; [Israel, Alain] Inst Pasteur, CNRS, URA 2582, Mol Signaling & Cellular Activat Unit, Paris, France; [Casanova, Jean-Laurent] Necker Hosp Sick Children, Pediat Immunol Hematol Unit, Paris, France	Rockefeller University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Shanghai Jiao Tong University; Heinrich Heine University Dusseldorf; Helios Kliniken; University Children's Hospital Zurich; Cleveland Clinic Foundation; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Casanova, JL (corresponding author), Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, New York, NY 10065 USA.	jean-laurent.casanova@rockefeller.edu; shzh289@rockefeller.edu	Cobat, Aurélie/H-4722-2017; Puel, Anne/H-7305-2017; Zhang, Shen-Ying/I-2685-2017; Jouanguy, Emmanuelle/H-7901-2017; Casanova, Jean-Laurent/I-3418-2017; Lorenzo, Lazaro/H-7902-2017; Reichenbach, Janine/U-2171-2018; Abel, Laurent/H-8888-2017	Cobat, Aurélie/0000-0001-7209-6257; Puel, Anne/0000-0003-2603-0323; Zhang, Shen-Ying/0000-0002-9449-3672; Jouanguy, Emmanuelle/0000-0002-7358-9157; Lorenzo, Lazaro/0000-0001-6648-8684; Reichenbach, Janine/0000-0002-9008-1312; Abel, Laurent/0000-0001-7016-6493; Ciancanelli, Michael/0000-0002-4623-852X; Casanova, Jean-Laurent/0000-0002-7782-4169	Rockefeller University Center for Clinical and Translational Science [5UL1RR024143-04]; Rockefeller University; INSERM; Paris Descartes University; National Institute of Allergy and Infectious Diseases [1R01AI088364-01]; St Giles Foundation; Eppley Foundation; Thrasher Research Fund; Jeffrey Modell Foundation; Talecris Biother-apeutics ANR; FSER; BNP-Paribas Foundation; GIS Maladies Rares; March of Dimes; Bettencourt Foundation; Howard Hughes Medical Institute; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI088364] Funding Source: NIH RePORTER	Rockefeller University Center for Clinical and Translational Science; Rockefeller University; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Paris Descartes University; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); St Giles Foundation; Eppley Foundation; Thrasher Research Fund; Jeffrey Modell Foundation; Talecris Biother-apeutics ANR(French National Research Agency (ANR)); FSER; BNP-Paribas Foundation; GIS Maladies Rares; March of Dimes(March of Dimes); Bettencourt Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was conducted in the 2 branches of the Laboratory of Human Genetics of Infectious Diseases and was funded by The Rockefeller University Center for Clinical and Translational Science, grant no. 5UL1RR024143-04; The Rockefeller University; INSERM; Paris Descartes University; the National Institute of Allergy and Infectious Diseases, grant no. 1R01AI088364-01; the St Giles Foundation; the Eppley Foundation; the Thrasher Research Fund; the Jeffrey Modell Foundation and Talecris Biother-apeutics ANR; FSER; the BNP-Paribas Foundation; the GIS Maladies Rares; and the March of Dimes. M. Audry has been supported by the Bettencourt Foundation since January 2010. J.-L. Casanova was an International Scholar of the Howard Hughes Medical Institute from 2005 to 2008.	Abel L, J PEDIAT, V157, p[623, 9e1]; Abinun M, 1996, EUR J PEDIATR, V155, P146, DOI 10.1007/s004310050395; Alcais A, 2010, ANN NY ACAD SCI, V1214, P18, DOI 10.1111/j.1749-6632.2010.05834.x; Alcais A, 2009, J CLIN INVEST, V119, P2506, DOI 10.1172/JCI38111; Aradhya S, 2001, AM J HUM GENET, V68, P765, DOI 10.1086/318806; Carrol ED, 2003, ARCH DIS CHILD, V88, P340, DOI 10.1136/adc.88.4.340; Casanova JL, 2007, SCIENCE, V317, P617, DOI 10.1126/science.1142963; Casrouge A, 2006, SCIENCE, V314, P308, DOI 10.1126/science.1128346; Chang TT, 2008, J AM ACAD DERMATOL, V58, P316, DOI 10.1016/j.jaad.2007.02.024; Chapgier A, 2009, J CLIN INVEST, V119, P1502, DOI 10.1172/JCI37083; Chariot A, 2002, J BIOL CHEM, V277, P37029, DOI 10.1074/jbc.M205069200; Dai YS, 2004, J AM ACAD DERMATOL, V51, P718, DOI 10.1016/j.jaad.2004.05.032; de Diego RP, 2010, IMMUNITY, V33, P400, DOI 10.1016/j.immuni.2010.08.014; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Dupuis-Girod S, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e97; Feinberg J, 2004, EUR J IMMUNOL, V34, P3276, DOI 10.1002/eji.200425221; Filipe-Santos O, 2006, SEMIN IMMUNOL, V18, P347, DOI 10.1016/j.smim.2006.07.010; Filipe-Santos O, 2006, J EXP MED, V203, P1745, DOI 10.1084/jem.20060085; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Frucht DM, 1999, CLIN IMMUNOL, V91, P234, DOI 10.1006/clim.1999.4688; Frucht DM, 1996, J IMMUNOL, V157, P411; Fusco F, 2004, HUM MOL GENET, V13, P1763, DOI 10.1093/hmg/ddh192; Hanson EP, 2008, J ALLERGY CLIN IMMUN, V122, P1169, DOI 10.1016/j.jaci.2008.08.018; Haverkamp MH, 2004, CLIN INFECT DIS, V39, P450, DOI 10.1086/422319; HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Jain A, 2004, J CLIN INVEST, V114, P1593, DOI 10.1172/JCI200421345; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Kosaki K, 2001, AM J HUM GENET, V69, P664, DOI 10.1086/323003; Ku CL, 2007, J EXP MED, V204, P2407, DOI 10.1084/jem.20070628; Ku CL, 2007, J MED GENET, V44, P16, DOI 10.1136/jmg.2006.044446; Ku CL, 2005, PEDIATRICS, V115, pE615, DOI 10.1542/peds.2004-1754; Ku CL, 2005, IMMUNOL REV, V203, P10, DOI 10.1111/j.0105-2896.2005.00235.x; Lee WI, 2005, BLOOD, V105, P1881, DOI 10.1182/blood-2003-12-4420; Lie S O, 1978, J Inherit Metab Dis, V1, P137, DOI 10.1007/BF01805582; Mancini AJ, 2008, ARCH DERMATOL, V144, P342, DOI 10.1001/archderm.144.3.342; Mansour S, 2001, AM J MED GENET, V99, P172, DOI 10.1002/1096-8628(2001)9999:9999<::AID-AJMG1155>3.0.CO;2-Y; Martinez-Pomar N, 2005, HUM GENET, V118, P458, DOI 10.1007/s00439-005-0068-y; McDonald DR, 2006, J ALLERGY CLIN IMMUN, V118, P1357, DOI 10.1016/j.jaci.2006.08.006; Medvedev AE, 2003, J EXP MED, V198, P521, DOI 10.1084/jem.20030701; Mooster JL, 2010, J ALLERGY CLIN IMMUN, V126, P127, DOI 10.1016/j.jaci.2010.04.026; Niehues T, 2004, J ALLERGY CLIN IMMUN, V114, P1456, DOI 10.1016/j.jaci.2004.08.047; Nishikomori R, 2004, BLOOD, V103, P4565, DOI 10.1182/blood-2003-10-3655; Orange JS, 2005, IMMUNOL REV, V203, P21, DOI 10.1111/j.0105-2896.2005.00221.x; Orange JS, 2004, J ALLERGY CLIN IMMUN, V114, P650, DOI 10.1016/j.jaci.2004.06.052; Orange JS, 2004, J ALLERGY CLIN IMMUN, V113, P725, DOI 10.1016/j.jaci.2004.01.762; Orange JS, 2002, J CLIN INVEST, V109, P1501, DOI 10.1172/JCI200214858; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Picard C, 2010, MEDICINE, V89, P403, DOI 10.1097/MD.0b013e3181fd8ec3; Puel A, 2006, AM J HUM GENET, V78, P691, DOI 10.1086/501532; Puel A, 2004, CURR OPIN IMMUNOL, V16, P34, DOI 10.1016/j.coi.2003.11.013; Salt BH, 2008, J ALLERGY CLIN IMMUN, V121, P976, DOI 10.1016/j.jaci.2007.11.014; Sancho-Shimizu V, 2007, CURR OPIN ALLERGY CL, V7, P495, DOI 10.1097/ACI.0b013e3282f151d2; Schmid JMP, 2006, PEDIATRICS, V117, pE1049, DOI 10.1542/peds.2005-2062; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Smahi A, 2000, NATURE, V405, P466; Sweeney SE, 2010, J IMMUNOL, V184, P7162, DOI 10.4049/jimmunol.0903944; von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298; Whitley RJ, 2006, ANTIVIR RES, V71, P141, DOI 10.1016/j.antiviral.2006.04.002; Yang K, 2005, IMMUNITY, V23, P465, DOI 10.1016/j.immuni.2005.09.016; Zhang SY, 2008, IMMUNOL REV, V226, P29, DOI 10.1111/j.1600-065X.2008.00698.x; Zhang SY, 2007, IMMUNOL REV, V220, P225, DOI 10.1111/j.1600-065X.2007.00564.x; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522; Zhao TJ, 2007, NAT IMMUNOL, V8, P592, DOI 10.1038/ni1465; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	67	51	52	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					610	U264		10.1016/j.jaci.2011.04.059	http://dx.doi.org/10.1016/j.jaci.2011.04.059			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21722947	Green Accepted			2022-12-18	WOS:000294283400021
J	Jin, SLC; Goya, S; Nakae, S; Wang, D; Bruss, M; Hou, CY; Umetsu, D; Conti, M				Jin, S. -L. Catherine; Goya, Sho; Nakae, Susumu; Wang, Dan; Bruss, Matthew; Hou, Chiaoyin; Umetsu, Dale; Conti, Marco			Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; PDE4B; T(H)2 cytokines; airway hyperresponsiveness; airway inflammation; cAMP signaling	OBSTRUCTIVE PULMONARY-DISEASE; T-CELL-ACTIVATION; CYCLIC-AMP; ADENOSINE-MONOPHOSPHATE; SELECTIVE-INHIBITION; CYTOKINE PRODUCTION; PDE4 INHIBITOR; PROTEIN-KINASE; 207499 ARIFLO; GUINEA-PIG	Background: Cyclic AMP (cAMP) signaling modulates functions of inflammatory cells involved in the pathogenesis of asthma, and type 4 cAMP-specific phosphodiesterases (PDE4s) are essential components of this pathway. Induction of the PDE4 isoform PDE4B is necessary for Toll-like receptor signaling in monocytes and macrophages and is associated with T cell receptor/CD3 in T cells; however, its exact physiological function in the development of allergic asthma remains undefined. Objectives: We investigated the role of PDE4B in the development of allergen-induced airway hyperresponsiveness (AHR) and T(H)2-driven inflammatory responses. Methods: Wild-type and PDE4B(-/-) mice were sensitized and challenged with ovalbumin and AHR measured in response to inhaled methacholine. Airway inflammation was characterized by analyzing leukocyte infiltration and cytokine accumulation in the airways. Ovalbumin-stimulated cell proliferation and T(H)2 cytokine production were determined in cultured bronchial lymph node cells. Results: Mice deficient in PDE4B do not develop AHR. This protective effect was associated with a significant decrease in eosinophils recruitment to the lungs and decreased T(H)2 cytokine levels in the bronchoalveolar lavage fluid. Defects in T-cell replication, T(H)2 cytokine production, and dendritic cell migration were evident in cells from the airway-draining lymph nodes. Conversely, accumulation of the T(H)1 cytokine IFN-gamma was not affected in PDE4B 2/2 mice. Ablation of the orthologous PDE4 gene PDE4A has no impact on airway inflammation. Conclusion: By relieving a cAMP-negative constraint, PDE4B plays an essential role in T(H)2-cell activation and dendritic cell recruitment during airway inflammation. These findings provide proof of concept that PDE4 inhibitors with PDE4B selectivity may have efficacy in asthma treatment. (J Allergy Clin Immunol 2010;126:1252-9.)	[Wang, Dan; Conti, Marco] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; [Jin, S. -L. Catherine; Hou, Chiaoyin] Natl Cent Univ, Dept Life Sci, Jhongli, Taiwan; [Goya, Sho; Umetsu, Dale] Harvard Univ, Sch Med, Childrens Hosp Boston, Cambridge, MA 02138 USA; [Nakae, Susumu] Univ Tokyo, Inst Med Sci, Frontier Res Initiat, Tokyo, Japan; [Jin, S. -L. Catherine; Bruss, Matthew] Stanford Univ, Div Reprod Biol, Dept Obstet & Gynecol, Sch Med, Stanford, CA 94305 USA	University of California System; University of California San Francisco; National Central University; Harvard University; Boston Children's Hospital; University of Tokyo; Stanford University	Conti, M (corresponding author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, 513 Parnassus Ave,HSW 1656,Box 0556, San Francisco, CA 94143 USA.	contim@obgyn.ucsf.edu			NIH-SCOR center [NIH-HL67674]; NIH [1R56AI073705-01]; Sandler Foundation for Asthma Research; National Science Council, Taiwan [NSC98-2320-B-008-001]; National Science Council (Taiwan); National Institutes of Health; Sandler Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD052909] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL067674, P01HL067674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI073705] Funding Source: NIH RePORTER	NIH-SCOR center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sandler Foundation for Asthma Research; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); National Science Council (Taiwan)(Ministry of Science and Technology, Taiwan); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sandler Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the NIH-SCOR center (NIH-HL67674), NIH 1R56AI073705-01, and the Sandler Foundation for Asthma Research grants (to M.C.) and a National Science Council grant (NSC98-2320-B-008-001, Taiwan) to S.-L.C. Jin.; Disclosure of potential conflict of interest: S.-L.C. Jin has received research support from the National Science Council (Taiwan). D. Umetsu has received research support from the National Institutes of Health. M. Conti is a consultant for Pfizer, has received an honorarium from Nycomed, and has received research support from the NIH and the Sandler Foundation. The rest of the authors have declared that they have no conflict of interest.	Abrahamsen H, 2004, J IMMUNOL, V173, P4847, DOI 10.4049/jimmunol.173.8.4847; Alves AC, 1996, EUR J PHARMACOL, V312, P89, DOI 10.1016/0014-2999(96)00357-3; Aoki M, 2001, J PHARMACOL EXP THER, V297, P165; Ariga M, 2004, J IMMUNOL, V173, P7531, DOI 10.4049/jimmunol.173.12.7531; Arp J, 2003, MOL CELL BIOL, V23, P8042, DOI 10.1128/MCB.23.22.8042-8057.2003; BAILLY S, 1990, Cytokine, V2, P205, DOI 10.1016/1043-4666(90)90017-N; Barnette MS, 1998, J PHARMACOL EXP THER, V284, P420; Baroja ML, 1999, J IMMUNOL, V162, P2016; Clayton RA, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-4; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Dizier MH, 2007, HUM HERED, V63, P162, DOI 10.1159/000099828; Fabbri LM, 2009, LANCET, V374, P695, DOI 10.1016/S0140-6736(09)61252-6; Fedyk ER, 1996, CLIN IMMUNOL IMMUNOP, V81, P101, DOI 10.1006/clin.1996.0165; Foster PS, 2002, PHARMACOL THERAPEUT, V94, P253, DOI 10.1016/S0163-7258(02)00220-6; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 2000, AM J RESP CELL MOL, V23, P327, DOI 10.1165/ajrcmb.23.3.3796; Hansen G, 2000, P NATL ACAD SCI USA, V97, P6751, DOI 10.1073/pnas.97.12.6751; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; HUANG SK, 1995, J IMMUNOL, V155, P2688; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998; Jin SLC, 2005, J IMMUNOL, V175, P1523, DOI 10.4049/jimmunol.175.3.1523; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Kanehiro A, 2001, AM J RESP CRIT CARE, V164, P2229, DOI 10.1164/ajrccm.164.12.2012059; KANEKO T, 1995, CELL SIGNAL, V7, P527, DOI 10.1016/0898-6568(95)00023-I; KRAUSE DS, 1991, J IMMUNOL, V146, P2285; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; Lehnart SE, 2005, CELL, V123, P25, DOI 10.1016/j.cell.2005.07.030; Lipworth BJ, 2005, LANCET, V365, P167, DOI 10.1016/S0140-6736(05)17708-3; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; MARY D, 1987, J IMMUNOL, V139, P1179; Mehats C, 2003, FASEB J, V17, P1831, DOI 10.1096/fj.03-0274com; Mustelin T, 2003, BIOCHEM J, V371, P15, DOI 10.1042/BJ20021637; Naganuma K, 2009, BIOORG MED CHEM LETT, V19, P3174, DOI 10.1016/j.bmcl.2009.04.121; Nakae S, 2007, J ALLERGY CLIN IMMUN, V120, P48, DOI 10.1016/j.jaci.2007.02.046; PAULEUGENE N, 1995, CYTOKINE, V7, P64, DOI 10.1006/cyto.1995.1008; Peter D, 2007, J IMMUNOL, V178, P4820, DOI 10.4049/jimmunol.178.8.4820; Procopio DO, 1999, BRIT J PHARMACOL, V127, P1195, DOI 10.1038/sj.bjp.0702624; Robichaud A, 2002, J CLIN INVEST, V110, P1045, DOI 10.1172/JCI200215506; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Santamaria LF, 1997, BRIT J PHARMACOL, V121, P1150, DOI 10.1038/sj.bjp.0701243; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; SOUNESS JE, 1991, BIOCHEM PHARMACOL, V42, P937, DOI 10.1016/0006-2952(91)90056-B; Spina D, 2008, BRIT J PHARMACOL, V155, P308, DOI 10.1038/bjp.2008.307; Suto H, 2006, J IMMUNOL, V176, P4102, DOI 10.4049/jimmunol.176.7.4102; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; TORPHY TJ, 1994, TRENDS PHARMACOL SCI, V15, P370, DOI 10.1016/0165-6147(94)90157-0; Underwood DC, 1998, J PHARMACOL EXP THER, V287, P988; Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258	53	51	53	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1252	U283		10.1016/j.jaci.2010.08.014	http://dx.doi.org/10.1016/j.jaci.2010.08.014			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21047676	Bronze, Green Accepted			2022-12-18	WOS:000284947800025
J	Katial, RK; Strand, M; Prasertsuntarasai, T; Leung, R; Zheng, WH; Alam, R				Katial, Rohit K.; Strand, Matthew; Prasertsuntarasai, Theerapol; Leung, Roxanne; Zheng, Weihong; Alam, Rafeul			The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; biomarkers; IL-4; MMP-9; FLT3 ligand	EXHALED NITRIC-OXIDE; ASTHMATIC-PATIENTS; URINARY LEUKOTRIENE-E4; RHINOSINUSITIS-ASTHMA; AIRWAY INFLAMMATION; MATRIX-METALLOPROTEINASE-9; CHALLENGE; SPUTUM; CELLS; HYPERRESPONSIVENESS	Background: Patients with aspirin-exacerbated respiratory disease have been shown to benefit clinically from aspirin desensitization followed by chronic high-dose aspirin therapy. However, the mechanism of this phenomenon is still unclear. Objective: The aim of this study was to characterize the airway inflammatory response to aspirin desensitization and after treatment with high-dose aspirin for 6 months. Methods: Twenty-one adult patients with asthma, chronic polypoid sinusitis, and a convincing history of acute respiratory reaction to the ingestion of aspirin or nonsteroidal anti-inflammatory drugs were selected. These patients underwent an oral desensitization to aspirin over a 2-day period, followed by daily ingestion of aspirin 650 mg twice daily. Induced sputum samples and exhaled nitric oxide measurements were taken before the procedure, during the second day of the procedure, and after 6 months of treatment. Results: There was a significant elevation in both the exhaled nitric oxide level (P = .03) and sputum tryptase level (P = .05 ) during the desensitization process. After 6 months of aspirin treatment, sputum IL-4 (P = .0007) and matrix metalloproteinase 9 (MMP-9; P = .05 ) decreased significantly compared with baseline. Predesensitization to postdesensitization changes in MMP-9 and tissue inhibitors of metalloproteinases 1 were highly correlated (r = 0.79; P = .0003). Immediately after the desensitization, MMP-9 and tryptase were correlated (r = 0.82; P = .001), whereas IL-4 was inversely related with FMS-like tyrosine kinase 3 ligand (FLT3-L) (r = -0.79; P = .0008). There was a significant decrease in the average symptom score at 6 months. Conclusion: Consistent with previous reports, acute aspirin desensitization in patients with aspirin-exacerbated respiratory disease involves mast cell degranulation. In contrast, long-term treatment with aspirin involves suppression of IL-4 as well as downregulation of proinflammatory MMP-9 while T H 1 marker FLT3-L increases. (J Allergy Clin Immunol 2010;126:738-44.)	[Katial, Rohit K.; Prasertsuntarasai, Theerapol; Leung, Roxanne; Zheng, Weihong; Alam, Rafeul] Natl Jewish Hlth, Div Allergy & Immunol, Denver, CO 80206 USA; [Strand, Matthew] Natl Jewish Hlth, Div Biostat & Bioinformat, Denver, CO 80206 USA	National Jewish Health; National Jewish Health	Katial, RK (corresponding author), Natl Jewish Hlth, Div Allergy & Immunol, 1400 Jackson St, Denver, CO 80206 USA.	katialr@njhealth.org	Strand, Matt/AAU-3762-2021	Strand, Matt/0000-0002-9083-5989	divisional funds	divisional funds	Supported by divisional funds.	Berges-Gimeno MP, 2003, ANN ALLERG ASTHMA IM, V90, P338, DOI 10.1016/S1081-1206(10)61803-0; Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; Cataldo DD, 2002, AM J PATHOL, V161, P491, DOI 10.1016/S0002-9440(10)64205-8; Cataldo DD, 2002, CHEST, V122, P1553, DOI 10.1378/chest.122.5.1553; CHIU JT, 1983, J ALLERGY CLIN IMMUN, V71, P560, DOI 10.1016/0091-6749(83)90437-2; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Cianferoni A, 2001, BLOOD, V97, P1742, DOI 10.1182/blood.V97.6.1742; Cundall M, 2003, J ALLERGY CLIN IMMUN, V112, P1064, DOI 10.1016/j.jaci.2003.08.013; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; Early SB, 2007, AM J RESP CELL MOL, V36, P715, DOI 10.1165/rcmb.2006-0252OC; Edwan JH, 2005, INT IMMUNOPHARMACOL, V5, P345, DOI 10.1016/j.intimp.2004.10.002; Edwan JH, 2004, J IMMUNOL, V172, P5016, DOI 10.4049/jimmunol.172.8.5016; Erekosima NU, 2009, CURR ALLERGY ASTHM R, V9, P134, DOI 10.1007/s11882-009-0020-7; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; GLIKLICH RE, 1995, LARYNGOSCOPE, V105, P387, DOI 10.1288/00005537-199504000-00010; Gueders MM, 2006, EUR J PHARMACOL, V533, P133, DOI 10.1016/j.ejphar.2005.12.082; He YK, 2000, HUM GENE THER, V11, P547, DOI 10.1089/10430340050015734; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; JUERGENS UR, 1995, J ALLERGY CLIN IMMUN, V96, P148, DOI 10.1016/S0091-6749(95)70002-1; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P1157; Littell R.C., 2006, SAS MIXED MODELS; Macy E, 2007, ANN ALLERG ASTHMA IM, V98, P172, DOI 10.1016/S1081-1206(10)60692-8; Nasser S, 1996, THORAX, V51, P64, DOI 10.1136/thx.51.1.64; Ohno I, 1997, AM J RESP CELL MOL, V16, P212, DOI 10.1165/ajrcmb.16.3.9070604; Piccirillo JF, 2002, OTOLARYNG HEAD NECK, V126, P41, DOI 10.1067/mhn.2002.121022; Rolla G, 2004, ALLERGY, V59, P827, DOI 10.1111/j.1398-9995.2004.00502.x; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sanak M, 2004, CLIN EXP ALLERGY, V34, P1899, DOI 10.1111/j.1365-2222.2004.02123.x; Shao ZF, 2009, J IMMUNOL, V183, P7531, DOI 10.4049/jimmunol.0901341; SLADEK K, 1993, EUR RESPIR J, V6, P391; SLADEK K, 1994, AM J RESP CRIT CARE, V149, P940, DOI 10.1164/ajrccm.149.4.8143059; SMITH CM, 1992, EUR RESPIR J, V5, P693; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Steinke JW, 2009, J ALLERGY CLIN IMMUN, V124, P724, DOI 10.1016/j.jaci.2009.07.031; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stevenson DD, 2003, CLIN REV ALLERG IMMU, V24, P159, DOI 10.1385/CRIAI:24:2:159; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; Szczeklik A, 1996, AM J RESP CRIT CARE, V154, P1608, DOI 10.1164/ajrccm.154.6.8970343; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058	44	51	52	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					738	744		10.1016/j.jaci.2010.06.036	http://dx.doi.org/10.1016/j.jaci.2010.06.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20728206				2022-12-18	WOS:000282510000008
J	Rabinovitch, N; Graber, NJ; Chinchilli, VM; Sorkness, CA; Zeiger, RS; Strunk, RC; Bacharier, LB; Martinez, FD; Szefler, SJ				Rabinovitch, Nathan; Graber, Nora J.; Chinchilli, Vernon M.; Sorkness, Christine A.; Zeiger, Robert S.; Strunk, Robert C.; Bacharier, Leonard B.; Martinez, Fernando D.; Szefler, Stanley J.		Natl Heart Lung Blood Inst	Urinary leukotriene E-4/exhaled nitric oxide ratio and montelukast response in childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; biomarkers; fluticasone propionate; inhaled corticosteroids; leukotriene E-4; montelukast	CHILDREN; FLUTICASONE; SMOKING; TRIAL; E-4	Background: A subset of children with asthma respond better to leukotriene receptor antagonists than to inhaled corticosteroids. Information is needed to identify children with these preferential responses. Objective: We sought to determine whether the ratio of urinary leukotriene E-4 (LTE4) to fractional exhaled nitric oxide (FENO) delineates children with preferential responsiveness to montelukast compared with fluticasone propionate (FP) therapy. Methods: Data from 318 children with mild-to-moderate asthma enrolled in 2 National Heart, Lung, and Blood Institute Childhood Asthma Research and Education Network studies (Characterizing the Response to a Leukotriene Receptor Antagonist and an Inhaled Corticosteroid [CLIC] and the Pediatric Asthma Controller Trial [PACT]) were analyzed. The association between LTE4/FENO ratios at baseline and improved lung function or asthma control days (ACDs) with montelukast and FP therapy was determined, and phenotypic characteristics related to high ratios were assessed. Results: LTE4/FENO ratios were associated with a greater response to montelukast than FP therapy for FEV1 measurements (2.1% increase per doubling of ratio, P = .001) and for ACDs per week (0.3-ACD increase, P = .009) in the CLIC study. In PACT the ratio was associated with greater FEV1 responsiveness to montelukast than FP therapy (0.6% increase, P = .03). In a combined study analysis, LTE4/FENO ratios were associated with greater response to montelukast than FP therapy for FEV1 (0.8% increase, P = .0005) and ACDs (0.3-ACD increase, P = .008). Children with LTE4/FENO ratios at or above the 75th percentile were likely (P <.05) to be younger and female and exhibit lower levels of atopic markers and methacholine reactivity. Conclusion: LTE4/FENO ratios predict a better response to montelukast than FP therapy in children with mild-to-moderate asthma. (J Allergy Clin Immunol 2010;126:545-51.)	[Rabinovitch, Nathan; Szefler, Stanley J.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Rabinovitch, Nathan; Szefler, Stanley J.] Univ Colorado, Denver Sch Med, Denver, CO 80202 USA; [Graber, Nora J.; Chinchilli, Vernon M.] Penn State Univ, Dept Publ Hlth Sci, Hershey, PA USA; [Sorkness, Christine A.] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; [Sorkness, Christine A.] Univ Wisconsin, Sch Med, Madison, WI USA; [Sorkness, Christine A.] Univ Wisconsin, Sch Publ Hlth, Madison, WI USA; [Zeiger, Robert S.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Zeiger, Robert S.] Kaiser Permanente, Dept Allergy, San Diego, CA USA; [Strunk, Robert C.; Bacharier, Leonard B.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Martinez, Fernando D.] Univ Arizona, Dept Pediat, Phoenix, AZ USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Diego; Kaiser Permanente; Washington University (WUSTL); University of Arizona	Szefler, SJ (corresponding author), Natl Jewish Hlth, Dept Pediat, 1400 Jackson St,Rm J304, Denver, CO 80206 USA.	Szeflers@njhealth.org		Zeiger, Robert/0000-0001-5788-5063; Paul, Ian/0000-0002-6344-8609; Bacharier, Leonard/0000-0003-0432-2704	NIH/NIEHS [ES015510-01]; National Heart, Lung, and Blood Institute [HL064307, HL64288, HL064295, HL64287, HL064305]; Schering-Plough; Sandoz; Aerocrine; Genentech; Merck and Co; GlaxoSmithKline; AstraZeneca; TEVA Pharm; National Institutes of Health (NIH); NIH/NHLBI; NIH/National Institute of Allergy and Infectious Disease; NIEHS/US Environmental Protection Agency; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, M01RR000069, M01RR003186, M01RR000036] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064307, U10HL064305, U10HL064295, U10HL064288, U10HL064287, U10HL064313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K23ES015510] Funding Source: NIH RePORTER	NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Schering-Plough(Merck & CompanySchering Plough Corporation); Sandoz(Novartis); Aerocrine; Genentech(Roche HoldingGenentech); Merck and Co(Merck & Company); GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); TEVA Pharm(Teva Pharmaceutical Industries); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS/US Environmental Protection Agency(United States Environmental Protection AgencyUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by NIH/NIEHS K23 grant no. ES015510-01 and grants HL064307, HL64288, HL064295, HL64287, and HL064305 from the National Heart, Lung, and Blood Institute. This study was carried out in part by the General Clinical Research Centers at Washington University School of Medicine (M01 RR00036), National Jewish Health (M01 RR00051), and the University of Wisconsin (M01 RR03186).; Disclosure of potential conflict of interest: N. Rabinovitch has a patent application pending for LTE<INF>4</INF>/FE<INF>NO</INF> ratio from National Jewish Health. V. M. Chinchilli receives research support from the National Heart, Lung, and Blood Institute (NHLBI). C. A. Sorkness is on advisory boards for GlaxoSmithKline, Schering-Plough, AstraZeneca, and Novartis and receives research support from Schering-Plough and Sandoz. R. S. Zeiger has consultant arrangements with AstraZeneca, Aerocrine, Genentech, GlaxoSmithKline, Merck and Co, Schering-Plough, and MedImmune and receives research support from Aerocrine, Genentech, Merck and Co, GlaxoSmithKline, AstraZeneca, and TEVA Pharm. L. B. Bacharier receives honoraria from AstraZeneca, Genentech, GlaxoSmithKline, Merck, Schering-Plough, and Aerocrine. F. D. Martinez receives honoraria from MedImmune and Merck and receives research support from the National Institutes of Health (NIH). S. J. Szefler is a consultant for GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and receives research support from the NIH/NHLBI, the NIH/National Institute of Allergy and Infectious Disease, GlaxoSmithKline, and the NIEHS/US Environmental Protection Agency. The rest of the authors have declared that they have no conflict of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Armstrong M, 2009, J CHROMATOGR B, V877, P3169, DOI 10.1016/j.jchromb.2009.08.011; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Bisgaard H, 2003, AM J RESP CRIT CARE, V167, P379, DOI 10.1164/rccm.200207-747OC; Covar RA, 2003, J PEDIATR-US, V142, P469, DOI 10.1067/mpd.2003.187; Fauler J, 1997, EUR J CLIN INVEST, V27, P43, DOI 10.1046/j.1365-2362.1997.650619.x; Johnston NW, 2007, PEDIATRICS, V120, pE702, DOI 10.1542/peds.2006-3317; Kelly JT, 2008, J ALLERGY CLIN IMMUN, V122, P671, DOI 10.1016/j.jaci.2008.08.013; Kishi N, 2001, ANAL SCI, V17, P709, DOI 10.2116/analsci.17.709; Knuffman JE, 2009, J ALLERGY CLIN IMMUN, V123, P411, DOI 10.1016/j.jaci.2008.11.016; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Linn WS, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-28; Maspero JF, 2001, CURR MED RES OPIN, V17, P96, DOI 10.1185/0300799039117037; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Pao CS, 2002, AM J RESP CRIT CARE, V166, P945, DOI 10.1164/rccm.200203-265OC; Rabinovitch N, 2008, J ALLERGY CLIN IMMUN, V121, P1365, DOI 10.1016/j.jaci.2008.03.016; Rabinovitch N, 2006, J ALLERGY CLIN IMMUN, V118, P635, DOI 10.1016/j.jaci.2006.05.011; Rabinovitch N, 2006, AM J RESP CRIT CARE, V173, P1098, DOI 10.1164/rccm.200509-1393OC; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Warke TJ, 2003, ARCH ENVIRON HEALTH, V58, P613, DOI 10.3200/AEOH.58.10.613-616; Westcott JY, 1998, PROSTAG OTH LIPID M, V55, P301, DOI 10.1016/S0090-6980(98)00027-6; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	24	51	53	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					545	U239		10.1016/j.jaci.2010.07.008	http://dx.doi.org/10.1016/j.jaci.2010.07.008			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816189	Green Accepted			2022-12-18	WOS:000281512500021
J	Martin, P; Gomez, M; Lamana, A; Marin, AM; Cortes, JR; Ramirez-Huesca, M; Barreiro, O; Lopez-Romero, P; Gutierrez-Vazquez, C; de la Fuente, H; Cruz-Adalia, A; Sanchez-Madrid, F				Martin, Pilar; Gomez, Manuel; Lamana, Amalia; Matesanz Marin, Adela; Cortes, Jose R.; Ramirez-Huesca, Marta; Barreiro, Olga; Lopez-Romero, Pedro; Gutierrez-Vazquez, Cristina; de la Fuente, Hortensia; Cruz-Adalia, Aranzazu; Sanchez-Madrid, Francisco			The leukocyte activation antigen CD69 limits allergic asthma and skin contact hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic airway inflammation; contact hypersensitivity; inflammation; CD69; T helper responses	IL-17-PRODUCING T-CELLS; COLLAGEN-INDUCED ARTHRITIS; DENDRITIC CELLS; TRANSGENIC MICE; INFLAMMATION; EXPRESSION; RESPONSES; MECHANISMS; IL-17; INDUCTION	Background: Allergic diseases have a major health care impact in industrialized countries. The development of these diseases is influenced by exposure to allergen and to immunological and genetic factors. However, the molecular mechanisms underlying the inflammatory response that triggers allergy are not well defined. Objective: We have investigated the role of the leukocyte activation antigen CD69 in the regulation of two allergic diseases, asthma and contact dermatitis. Methods: Analysis of two models of allergic diseases in CD69 knockout and wild-type mice: ovalbumin-induced allergic airway inflammation (BALB/c genetic background) and contact hypersensitivity to oxazolone (C57BL/6J genetic background). Results: CD69 deficiency dramatically enhanced the inflammatory response in the ovalbumin-induced asthma model of antigen-induced airway allergy. CD69 knockout mice showed exacerbated pulmonary eosinophil recruitment, high vascular cell adhesion molecule 1 expression levels in lung vasculature, and enhanced T(H)2 and T(H)17 cytokines in the bronchoalveolar space and lung tissue. In the hapten-induced cutaneous contact hypersensitivity model, both CD69 deficiency and treatment with anti-CD69 mAb increased inflammation. Treatment with contact allergens induced enhanced T(H)1 and T(H)17 responses in CD69 deficient mice, and neutralizing anti-IL-17 antibodies reduced skin inflammation. In both experimental systems, adoptive transfer of lymph node cells from CD69 knockout mice increased the inflammatory response in recipient mice. Conclusion: These results demonstrate that the early activation receptor CD69 is an intrinsic modulator of immune allergic processes through the negative regulation of allergen-induced T-cell effector responses. (J Allergy Clin Immunol 2010;126:355-65.)	[Gomez, Manuel; Lamana, Amalia; de la Fuente, Hortensia; Sanchez-Madrid, Francisco] Univ Autonoma Madrid, Serv Inmunol, Hosp La Princesa, Madrid 28006, Spain; [Martin, Pilar; Matesanz Marin, Adela; Cortes, Jose R.; Ramirez-Huesca, Marta; Barreiro, Olga; Lopez-Romero, Pedro; Gutierrez-Vazquez, Cristina; Cruz-Adalia, Aranzazu; Sanchez-Madrid, Francisco] Fdn Ctr Nacl Invest Cardiovasc Carlos 3, Dept Vasc Biol & Inflammat, Madrid, Spain	Autonomous University of Madrid; Hospital de La Princesa; Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Sanchez-Madrid, F (corresponding author), Univ Autonoma Madrid, Serv Inmunol, Hosp La Princesa, C Diego Leon 62, Madrid 28006, Spain.	fsanchez.hlpr@salud.madrid.org	Sanchez-Madrid, Francisco/M-7889-2016; LAMANA, AMALIA/I-6971-2017; Martin, Pilar/F-8193-2014; Cruz Adalia, Aranzazu/AAX-8559-2021; de la Fuente, Hortensia/J-9890-2014; Adalia, Aranzazu Cruz/K-2273-2014; CRUZ ADALIA, ARANZAZU/AAX-8267-2021	Sanchez-Madrid, Francisco/0000-0001-5303-0762; LAMANA, AMALIA/0000-0001-8779-5034; Martin, Pilar/0000-0002-2392-1764; Cruz Adalia, Aranzazu/0000-0001-7029-9472; de la Fuente, Hortensia/0000-0001-8708-753X; Adalia, Aranzazu Cruz/0000-0001-7029-9472; Gutierrez-Vazquez, Cristina/0000-0002-3846-4631	Spanish Ministry of Science and Innovation [SAF2008-06235, SAF2008-02719]; Instituto de Salud Carlos III-Spanish Ministry of Science and Innovation [PI06/0937]; MEICA from Genoma Espana Foundation; INSINET from Comunidad Autonoma de Madrid; Ministry of Science and Innovation; Pro Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III Foundation;  [FONCICYT-C002-2009-1ALA/127249]	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Instituto de Salud Carlos III-Spanish Ministry of Science and Innovation(Instituto de Salud Carlos IIIMinistry of Science and Innovation, Spain (MICINN)Spanish Government); MEICA from Genoma Espana Foundation; INSINET from Comunidad Autonoma de Madrid; Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Pro Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III Foundation; 	Supported by the Spanish Ministry of Science and Innovation (SAF2008-06235 to F.S.-M.; SAF2008-02719 to P. M.), Instituto de Salud Carlos III-Spanish Ministry of Science and Innovation (grant PI06/0937 to M. G.), and MEICA from Genoma Espana Foundation, INSINET from Comunidad Autonoma de Madrid, and FONCICYT-C002-2009-1ALA/127249 to F. S.-M. P. M. is an investigator from Spanish Ministry of Science and Innovation "Ramon y Cajal Program'' (RYC-2006). Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III is supported by the Ministry of Science and Innovation and the Pro Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III Foundation.	Akdis CA, 2008, J ALLERGY CLIN IMMUN, V122, P700, DOI 10.1016/j.jaci.2008.07.048; Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Broide D, 2008, J ALLERGY CLIN IMMUN, V122, P475, DOI 10.1016/j.jaci.2008.06.025; CEBRIAN M, 1988, J EXP MED, V168, P1621, DOI 10.1084/jem.168.5.1621; COSULICH ME, 1987, P NATL ACAD SCI USA, V84, P4205, DOI 10.1073/pnas.84.12.4205; Crispin JC, 1998, SCAND J IMMUNOL, V48, P196; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Esplugues E, 2003, J EXP MED, V197, P1093, DOI 10.1084/jem.20021337; GARCIAMONZON C, 1990, GASTROENTEROLOGY, V98, P1029, DOI 10.1016/0016-5085(90)90030-5; Gessl A, 1998, CLIN IMMUNOL IMMUNOP, V87, P168, DOI 10.1006/clin.1998.4524; Gomez M, 2009, CARDIOVASC RES, V81, P197, DOI 10.1093/cvr/cvn227; Gorbachev AV, 2001, CRIT REV IMMUNOL, V21, P451; Haberberger RV, 2009, J ALLERGY CLIN IMMUN, V124, P933, DOI 10.1016/j.jaci.2009.06.034; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; He DG, 2006, J IMMUNOL, V177, P6852, DOI 10.4049/jimmunol.177.10.6852; He DG, 2009, J IMMUNOL, V183, P1463, DOI 10.4049/jimmunol.0804108; Honda T, 2009, J ALLERGY CLIN IMMUN, V124, P809, DOI 10.1016/j.jaci.2009.04.029; Huang MC, 2007, J IMMUNOL, V178, P6806, DOI 10.4049/jimmunol.178.11.6806; Hung LY, 2008, CRIT REV IMMUNOL, V28, P269, DOI 10.1615/CritRevImmunol.v28.i4.10; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Jolly PS, 2002, MOL IMMUNOL, V38, P1239, DOI 10.1016/S0161-5890(02)00070-6; Kalish RS, 1999, J ALLERGY CLIN IMMUN, V103, P192, DOI 10.1016/S0091-6749(99)70489-6; Kawaguchi M, 2001, J IMMUNOL, V167, P4430, DOI 10.4049/jimmunol.167.8.4430; Kish DD, 2009, J IMMUNOL, V182, P5949, DOI 10.4049/jimmunol.0802830; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; Lamana A, 2006, EUR J IMMUNOL, V36, P2632, DOI 10.1002/eji.200636355; Lauzurica P, 2000, BLOOD, V95, P2312, DOI 10.1182/blood.V95.7.2312.007k16_2312_2320; Martin P, 2002, BLOOD, V100, P383, DOI 10.1182/blood.V100.2.383; Martin P, 2005, P NATL ACAD SCI USA, V102, P9866, DOI 10.1073/pnas.0501202102; McDuffie Eric, 2006, J Inflamm (Lond), V3, P15, DOI 10.1186/1476-9255-3-15; Miki-Hosokawa T, 2009, J IMMUNOL, V183, P8203, DOI 10.4049/jimmunol.0900646; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nembrini C, 2009, J ALLERGY CLIN IMMUN, V123, P986, DOI 10.1016/j.jaci.2009.03.033; Peroni DG, 1996, EUR RESPIR J, V9, P2236, DOI 10.1183/09031936.96.09112236; Rivera J, 2008, NAT REV IMMUNOL, V8, P753, DOI 10.1038/nri2400; SANCHEZMATEOS P, 1989, IMMUNOLOGY, V68, P72; Sancho D, 2003, J CLIN INVEST, V112, P872, DOI 10.1172/JCI200319112; Sancho D, 2005, TRENDS IMMUNOL, V26, P136, DOI 10.1016/j.it.2004.12.006; Sancho D, 2006, J LEUKOCYTE BIOL, V80, P1233, DOI 10.1189/jlb.1205749; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Skeritzian CA, 2007, PHARMACOL THERAPEUT, V115, P390, DOI 10.1016/j.pharmthera.2007.05.011; Song CW, 2008, J IMMUNOL, V181, P6117, DOI 10.4049/jimmunol.181.9.6117; Suzuki S, 2007, INT ARCH ALLERGY IMM, V143, P89, DOI 10.1159/000101413; Swaidani S, 2009, J IMMUNOL, V182, P1631, DOI 10.4049/jimmunol.182.3.1631; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; Wang WG, 2007, J IMMUNOL, V178, P4885, DOI 10.4049/jimmunol.178.8.4885; Xu H, 1996, J EXP MED, V183, P1001, DOI 10.1084/jem.183.3.1001; Zhang J, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-4; Zhao Y, 2010, INT ARCH ALLERGY IMM, V151, P297, DOI 10.1159/000250438	54	51	55	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					355	U65		10.1016/j.jaci.2010.05.010	http://dx.doi.org/10.1016/j.jaci.2010.05.010			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20621339				2022-12-18	WOS:000281203800022
J	Kumar, R; Ouyang, FX; Story, RE; Pongracic, JA; Hong, XM; Wang, GY; Pearson, C; Ortiz, K; Bauchner, H; Wang, XB				Kumar, Rajesh; Ouyang, Fengxiu; Story, Rachel E.; Pongracic, Jacqueline A.; Hong, Xiumei; Wang, Guoying; Pearson, Colleen; Ortiz, Kathryn; Bauchner, Howard; Wang, Xiaobin			Gestational diabetes, atopic dermatitis, and allergen sensitization in early childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; eczema; food allergen sensitization; gestational diabetes	FETAL-GROWTH; RISK-FACTORS; FOLLOW-UP; PRENATAL EXPOSURE; UNITED-STATES; ASTHMA; BIRTH; CHILDREN; OBESITY; ASSOCIATION	Background: The relationship between the prenatal environment, maternal-fetal interaction, and allergic disease in the offspring remains understudied. Objective: We sought to determine whether gestational diabetes (GDM) modifies the risk of early childhood atopic manifestations, including atopic dermatitis and allergen sensitization. Methods: This study includes 680 children from the Boston Birth Cohort. Mother-child dyads were recruited at birth and followed prospectively to a mean age of 3.2 +/- 2.3 years, with study visits aligned with the pediatric primary care schedule. The primary outcomes were physician-diagnosed atopic dermatitis on standardized medical record abstraction and allergen sensitization based on ImmunoCAP to 7 common foods and 5 common aeroallergens (specific IgE, >= 0.10 kUA/L; Phadia, Uppsala, Sweden). GDM was determined by means of standardized medical record review. Logistic regression analysis, stratified by term/preterm status, evaluated the association of GDM with atopic dermatitis and allergen sensitization, respectively, controlling for maternal prepregnancy body mass index, fetal growth, and pertinent covariates. Results: Of the 680 children, 488 were term, and 192 were preterm (<37 weeks' gestation). Overall, 4.9% of the mothers had GDM. Among the 680 children, 34.4% had atopic dermatitis, and 51% had allergen sensitization. In term births GDM was significantly associated with atopic dermatitis (odds ratio [OR], 7.2; 95% CI, 1.5-34.5) and allergen sensitization (OR, 5.7; 95% CI, 1.2-28.0). Adjusting for fetal growth had little effect. The association with sensitization was driven primarily by food sensitization (OR, 8.3; 95% CI, 1.6-43.3). The above associations were not observed in preterm births. Conclusions: In term births GDM increased the risk of atopic dermatitis and early childhood allergen sensitization independently of maternal prepregnancy body mass index and fetal growth. (J Allergy Clin Immunol 2009;124:1031-8.)	[Kumar, Rajesh; Story, Rachel E.; Pongracic, Jacqueline A.] Childrens Mem Hosp, Div Allergy & Immunol, Chicago, IL 60614 USA; [Ouyang, Fengxiu; Hong, Xiumei; Wang, Xiaobin] Childrens Mem Hosp, Mary Ann & J Milburn Smith Child Hlth Res Program, Chicago, IL 60614 USA; [Ouyang, Fengxiu; Hong, Xiumei; Wang, Xiaobin] Childrens Mem Res Ctr, Chicago, IL USA; [Pearson, Colleen; Ortiz, Kathryn; Bauchner, Howard] Boston Univ, Dept Pediat, Sch Med, Boston, MA 02215 USA; [Pearson, Colleen; Ortiz, Kathryn; Bauchner, Howard] Boston Med Ctr, Boston, MA USA; [Wang, Guoying] Univ Illinois, Sch Publ Hlth, Ctr Populat Genet, Chicago, IL USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; Boston University; Boston Medical Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kumar, R (corresponding author), Childrens Mem Hosp, Div Allergy & Immunol, 2300 Childrens Plaza 60, Chicago, IL 60614 USA.	rkumar@childrensmemorial.org	Wang, Guoying/F-8908-2011	Kumar, Rajesh/0000-0002-1962-7108; Bauchner, Howard/0000-0002-8368-9805	March of Dimes PERI [20-FY02-56]; National Institute of Environmental Health Sciences [R21 ES011666]; National Institute of Child Health and Human Development [R01 HD041702]; Food Allergy; National Institute for Allergy and Infectious Disease [R21A1079872]; National Heart, Lung, and Blood Institute [K23HL093023]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD041702] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL093023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI079872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES011666] Funding Source: NIH RePORTER	March of Dimes PERI(March of Dimes); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Food Allergy; National Institute for Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by the March of Dimes PERI grants (PI: Wang, 20-FY02-56). the National Institute of Environmental Health Sciences (PI: Wang. R21 ES011666), and the National Institute of Child Health and Human Development (PI: Wang, R01 HD041702). The follow-up study is in part supported by Food Allergy Project and National Institute for Allergy and Infectious Disease (PI Wang, R21A1079872). R. K. is also supported by the National Heart, Lung, and Blood Institute (PI: Kumar. K23HL093023).	Abenhaim Haim A., 2007, Archives of Gynecology and Obstetrics, V275, P39, DOI 10.1007/s00404-006-0219-y; Barker DJP, 1994, MOTHERS BABIES DIS L; Bolte G, 2004, CLIN EXP ALLERGY, V34, P381, DOI 10.1111/j.1365-2222.2004.01890.x; Chu SY, 2009, MATERN CHILD HLTH J, V13, P614, DOI 10.1007/s10995-008-0388-3; de Benedictis FM, 2009, ALLERGY, V64, P295, DOI 10.1111/j.1398-9995.2008.01779.x; Dekkers JC, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-69; Drougia A, 2009, NEPHROL DIAL TRANSPL, V24, P142, DOI 10.1093/ndt/gfn431; Ege MJ, 2008, J ALLERGY CLIN IMMUN, V122, P407, DOI 10.1016/j.jaci.2008.06.011; Gao XL, 2008, CHINESE MED J-PEKING, V121, P701, DOI 10.1097/00029330-200804020-00008; Husemoen LLN, 2008, ALLERGY, V63, P575, DOI 10.1111/j.1398-9995.2007.01613.x; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Johnson CC, 1998, AM J EPIDEMIOL, V147, P1145; Kerkhof M, 2003, CLIN EXP ALLERGY, V33, P1336, DOI 10.1046/j.1365-2222.2003.01751.x; Krzyzanowska K, 2006, CLIN SCI, V110, P605, DOI 10.1042/CS20050363; Kumar R, 2008, J ALLERGY CLIN IMMUN, V121, P878, DOI 10.1016/j.jaci.2008.01.030; Kumar R, 2008, CURR OPIN PEDIATR, V20, P682, DOI 10.1097/MOP.0b013e3283154f26; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Leadbitter P, 1999, THORAX, V54, P905, DOI 10.1136/thx.54.10.905; Lewandowski KC, 2007, DIABETOLOGIA, V50, P1033, DOI 10.1007/s00125-007-0610-7; Moore MM, 2004, PEDIATRICS, V113, P468, DOI 10.1542/peds.113.3.468; Mortimer K, 2008, EPIDEMIOLOGY, V19, P61; Mortimer K, 2008, EPIDEMIOLOGY, V19, P550, DOI 10.1097/EDE.0b013e31816a9dcb; Olesen AB, 1997, BRIT MED J, V314, P1003, DOI 10.1136/bmj.314.7086.1003; Peters JL, 2009, J ALLERGY CLIN IMMUN, V123, P1041, DOI 10.1016/j.jaci.2009.02.027; Prescott SL, 2008, ALLERGY, V63, P1481, DOI 10.1111/j.1398-9995.2008.01778.x; Purvis DJ, 2005, BRIT J DERMATOL, V152, P742, DOI 10.1111/j.1365-2133.2005.06540.x; Radon K, 2008, ALLERGY, V63, P1448, DOI 10.1111/j.1398-9995.2008.01714.x; Rasanen M, 2001, Twin Res, V4, P392; Rasanen M, 2000, THORAX, V55, P25, DOI 10.1136/thorax.55.1.25; Rebordosa C, 2008, INT J EPIDEMIOL, V37, P583, DOI 10.1093/ije/dyn070; Rona RJ, 2005, THORAX, V60, P549, DOI 10.1136/thx.2004.032359; Rotteveel J, 2008, PEDIATRICS, V122, P313, DOI 10.1542/peds.2007-2012; Rusconi F, 2007, AM J RESP CRIT CARE, V175, P16, DOI 10.1164/rccm.200512-1978OC; Schaefer-Graf UM, 2003, DIABETES CARE, V26, P193, DOI 10.2337/diacare.26.1.193; Schaefer-Graf UM, 2002, J PERINAT MED, V30, P313, DOI 10.1515/JPM.2002.046; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; Seidell JC, 1997, BRIT MED BULL, V53, P238, DOI 10.1093/oxfordjournals.bmb.a011611; Shields Margot, 2008, Health Rep, V19, P61; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Sin DD, 2004, ARCH PEDIAT ADOL MED, V158, P60, DOI 10.1001/archpedi.158.1.60; VONMUTIUS E, 1993, J PEDIATR-US, V123, P223, DOI 10.1016/S0022-3476(05)81692-0; Wang CW, 2008, PEDIATRICS, V122, pE107, DOI 10.1542/peds.2007-3370; Wang L, 2006, AM J HUM GENET, V78, P770, DOI 10.1086/503712; Wang XB, 2002, JAMA-J AM MED ASSOC, V287, P195, DOI 10.1001/jama.287.2.195; Xu BZ, 2002, EUR J PUBLIC HEALTH, V12, P166, DOI 10.1093/eurpub/12.3.166; Yuan W, 2003, EUR J EPIDEMIOL, V18, P763, DOI 10.1023/A:1025390420122; Yuan W, 2002, INT J EPIDEMIOL, V31, P1240, DOI 10.1093/ije/31.6.1240	48	51	54	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1031	1038		10.1016/j.jaci.2009.06.052	http://dx.doi.org/10.1016/j.jaci.2009.06.052			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19733904	Green Accepted			2022-12-18	WOS:000272108000024
J	Hare, ND; Smith, BJ; Ballas, ZK				Hare, Nathaniel D.; Smith, Brian J.; Ballas, Zuhair K.			Antibody response to pneumococcal vaccination as a function of preimmunization titer	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pneumococcal vaccine; antibody; high preimmunization titer; fold response; age; sex; IgG; IgG subclass	CAPSULAR POLYSACCHARIDES; STREPTOCOCCUS-PNEUMONIAE; PRIMARY IMMUNODEFICIENCY; DEFICIENCY; POPULATION; ADULTS; AGE	Background: The interpretation of an adequate response to the unconjugated 23-valent pneumococcal vaccine for serotypes having high preimmunization titers remains challenging. Objectives: We sought to determine whether high preimmunization titers preclude a 4-fold or greater response to vaccination. Moreover, we sought to determine the effect of the following covariates on this response: absolute preimmunization titer value, age, sex, serum IgG level, and serum IgG subclasses. Methods: We conducted a retrospective analysis of patients who were seen in our immune disorders clinic between 2001 and 2007 who had received the unconjugated 23-valent pneumococcal vaccine. Logistic regression was used to estimate the effect of different covariates, including preimmunization titer values, age, sex, IgG levels, and IgG subclass values, on the odds of a 4-fold or greater antibody response. Results: Per serotype, 10% to 40% of subjects with a high preimmunization titer attained at least a 4-fold response to vaccination. However, the odds of a 4-fold or greater response were found to decrease as a function of the absolute preimmunization titer value with an absolute value for each serotype beyond which the odds ratio approached zero. Conclusion: High pneumococcal preimmunization titers do not necessarily preclude a 4-fold or greater response to vaccination. However, there appear to be serotype-specific preimmunization titer values, ranging from 4.4 to 10.3 mu g/mL, above which a 4-fold or greater response would not be expected. This response does not seem to be significantly affected by age, sex, IgG level, or IgG subclass value. (J Allergy Clin Immunol 2009;1.23:195-200.)	[Hare, Nathaniel D.; Ballas, Zuhair K.] Univ Iowa Hosp & Clin, Div Allergy Immunol, Dept Internal Med, Iowa City, IA 52242 USA; [Smith, Brian J.] Univ Iowa, Dept Biostat, Iowa City, IA USA; [Hare, Nathaniel D.; Ballas, Zuhair K.] Iowa City VA Med Ctr, Iowa City, IA USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Ballas, ZK (corresponding author), Univ Iowa Hosp & Clin, Div Allergy Immunol, Dept Internal Med, C42-E-13,GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	Ballasz@uiowa.edu		Ballas, Zuhair/0000-0001-5569-1230; Knaack, Aaron/0000-0001-7712-1415	National Cancer Institute [P30 CA086862-09]; National Institutes of Health [AA014418-06]; NATIONAL CANCER INSTITUTE [P30CA086862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA014418] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	Dr Smith is supported by National Cancer Institute grant P30 CA086862-09. Dr Ballas is supported by VA Merit and National Institutes of Health grant AA014418-06.	AMBROSINO DM, 1985, J CLIN INVEST, V75, P1935, DOI 10.1172/JCI111909; AMMANN AJ, 1984, JAMA-J AM MED ASSOC, V251, P1447, DOI 10.1001/jama.251.11.1447; Artz AS, 2003, CLIN MICROBIOL REV, V16, P308, DOI 10.1128/CMR.16.2.308-318.2003; Ballow M, 2002, J ALLERGY CLIN IMMUN, V109, P581, DOI 10.1067/mai.2002.122466; Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8; Brandao AP, 2004, VACCINE, V23, P762, DOI 10.1016/j.vaccine.2004.07.024; Edwards E, 2004, CLIN IMMUNOL, V111, P93, DOI 10.1016/j.clim.2003.12.005; Gleeson M, 1996, CLIN EXP IMMUNOL, V105, P238, DOI 10.1046/j.1365-2249.1996.d01-752.x; Go ES, 1996, J ALLERGY CLIN IMMUN, V98, P205, DOI 10.1016/S0091-6749(96)70244-0; JANOFF EN, 1993, J INFECT DIS, V167, P49, DOI 10.1093/infdis/167.1.49; Kamchaisatian W, 2006, J ALLERGY CLIN IMMUN, V118, P1336, DOI 10.1016/j.jaci.2006.09.036; Ko J, 2005, CLIN IMMUNOL, V116, P37, DOI 10.1016/j.clim.2005.03.019; LANDESMAN SH, 1981, REV INFECT DIS, V3, pS184; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Pickering JW, 2002, AM J CLIN PATHOL, V117, P589; RODRIGUEZBARRADAS MC, 1992, J INFECT DIS, V165, P553, DOI 10.1093/infdis/165.3.553; Rubins JB, 1998, J INFECT DIS, V178, P431, DOI 10.1086/515644; Sankilampi U, 1997, INT J EPIDEMIOL, V26, P420, DOI 10.1093/ije/26.2.420; SIBER GR, 1980, NEW ENGL J MED, V303, P178, DOI 10.1056/NEJM198007243030402; SIBER GR, 1980, INFECT IMMUN, V28, P641; Sorensen RU, 1998, J ALLERGY CLIN IMMUN, V102, P215, DOI 10.1016/S0091-6749(98)70089-2	21	51	51	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					195	200		10.1016/j.jaci.2008.09.021	http://dx.doi.org/10.1016/j.jaci.2008.09.021			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	18951616	Bronze, Green Accepted			2022-12-18	WOS:000262793900032
J	Ciprandi, G; Fenoglio, D; De Amici, M; Quaglini, S; Negrini, S; Filaci, G				Ciprandi, Giorgio; Fenoglio, Daniela; De Amici, Mara; Quaglini, Silvana; Negrini, Simone; Filaci, Gilberto			Serum IL-17 levels in patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTERLEUKIN-17		[Ciprandi, Giorgio; Fenoglio, Daniela; Negrini, Simone; Filaci, Gilberto] Univ Genoa, Dept Internal Med, Azienda Osped Univ San Martino, I-16126 Genoa, Italy; [De Amici, Mara] Univ Pavia, Fdn IRCCS San Matteo, Pediat Clin, Dept Pediat Sci, I-27100 Pavia, Italy; [Quaglini, Silvana] Univ Pavia, Dept Informat & Comp Sci, I-27100 Pavia, Italy	University of Genoa; IRCCS AOU San Martino IST; IRCCS Fondazione San Matteo; University of Pavia; University of Pavia	Ciprandi, G (corresponding author), Univ Genoa, Dept Internal Med, Azienda Osped Univ San Martino, I-16126 Genoa, Italy.	gio.cip@libero.it	Ciprandi, Giorgio/G-7462-2012; NEGRINI, Simone/AAC-6823-2021; quaglini, silvana/AAC-2687-2022; De Amici, Mara/AAC-2746-2020; Fenoglio, Daniela/I-7220-2018; Filaci, Gilberto/K-5062-2016	Ciprandi, Giorgio/0000-0001-7016-8421; NEGRINI, Simone/0000-0003-1267-4320; quaglini, silvana/0000-0002-4288-2561; De Amici, Mara/0000-0003-1055-8123; Fenoglio, Daniela/0000-0001-9532-6473; Filaci, Gilberto/0000-0001-6445-8414				[Anonymous], 1989, ALLERGY S10, V10, P1; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; HUSSEIN MR, 2008, PATHOL ONCOL RE 0408; Klemens C, 2007, ALLERGY ASTHMA PROC, V28, P434, DOI 10.2500/aap.2007.28.3017; Lei Z, 2008, ALLERGY, V63, P327, DOI 10.1111/j.1398-9995.2007.01566.x; Lucia A, 2008, NEUROSCI LETT, V431, P106, DOI 10.1016/j.neulet.2007.11.028; Romagnani S, 2006, CLIN EXP ALLERGY, V36, P1357, DOI 10.1111/j.1365-2222.2006.02606.x; Schmidt-Weber CB, 2007, J ALLERGY CLIN IMMUN, V120, P247, DOI 10.1016/j.jaci.2007.06.039; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Sergejeva S, 2005, AM J RESP CELL MOL, V33, P248, DOI 10.1165/rcmb.2004-0213OC; TROISE C, 1992, J INVEST ALLERG CLIN, V2, P313; Yasumi Y, 2007, HEPATOL RES, V37, P248, DOI 10.1111/j.1872-034X.2007.00040.x	13	51	57	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					650	651		10.1016/j.jaci.2008.06.005	http://dx.doi.org/10.1016/j.jaci.2008.06.005			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18602680				2022-12-18	WOS:000259234000032
J	Basagana, M; Bartolome, B; Pastor, C; Torres, F; Alonso, R; Vivanco, F; Cistero-Bahima, A				Basagana, Maria; Bartolome, Borja; Pastor, Carlos; Torres, Ferran; Alonso, Rosario; Vivanco, Fernando; Cistero-Bahima, Anna			Allergy to human seminal fluid: Cross-reactivity with dog dander	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen characterization; cross-reactivity; dog epithelium allergy; human seminal plasma allergy; prostate-specific antigen	PROSTATE-SPECIFIC ANTIGEN; PLASMA ALLERGY; PROTEINS; ALBUMIN; PURIFICATION; PEPTIDE; CAT	Background: Human seminal plasma (HSP) allergy is uncommon, with symptoms ranging from vulvovaginal pruritus to life-threatening anaphylaxis. Although several seminal plasma allergens have been reported and their molecular masses have been estimated to range between 12 and 75 kd, the prostate-specific antigen (PSA) has recently been identified as a causative allergen. Given that in a large number of cases symptoms appeared during or after the first intercourse, a cross- reactivity phenomenon might be implicated. Objective: We sought to assess the presence of IgE cross-reactivity among proteins from dog epithelium and HSP and to attempt to identify the allergens involved. Methods: Forty-one patients with dog epithelium allergy were selected. One of them experienced anaphylaxis in contact with her husband's seminal plasma. Skin prick tests, serum specific IgE measurements, SDS-PAGE immunoblotting, and inhibition tests were performed to study the pattern of IgE-binding proteins and the potential cross-reactivity between HSP and dog epithelium. Mass spectrometry was carried out to identify the protein involved in allergy reactions. Results: Twenty-four percent of the sera from patients with dog epithelium allergy recognized an IgE-binding band of 28 kd in HSP immunoblotting. Mass spectrometry identified this band as the PSA. SDS-PAGE immunoblotting-inhibition showed a complete IgE-binding inhibition when sera from these patients were preincubated with dog dander extract. Conclusions: IgE cross- reactivity among proteins from dog dander and human PSA is demonstrated.	[Basagana, Maria; Cistero-Bahima, Anna] Inst Univ Dexeus, Dept Allergy, E-08017 Barcelona, Spain; [Bartolome, Borja] Lab Bial Aristegui, Bilbao, Spain; [Pastor, Carlos] SIC Ingen SLL, Madrid, Spain; [Torres, Ferran] Univ Autonoma Barcelona, Dept Biostat & Epidemiol, Barcelona, Spain; [Torres, Ferran] Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain; [Vivanco, Fernando] Fdn Jimenez Diaz, Dept Immunol, E-28040 Madrid, Spain; [Vivanco, Fernando] Univ Complutense, Dept Biochem & Mol Biol, E-28040 Madrid, Spain	Autonomous University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; Complutense University of Madrid	Basagana, M (corresponding author), Inst Univ Dexeus, Dept Allergy, Passeig Bonanova 67-69, E-08017 Barcelona, Spain.	34917mbt@comb.es	Vivanco, Fernando/Q-6866-2016; Pastor Vargas, Carlos/B-4112-2010; Torres, Ferran/D-1296-2011	Pastor Vargas, Carlos/0000-0002-4678-7967; Torres, Ferran/0000-0002-7355-7913				BERNSTEIN IL, 1981, ANN INTERN MED, V116, P209; Bernstein JA, 1997, ANN ALLERG ASTHMA IM, V78, P54, DOI 10.1016/S1081-1206(10)63372-8; Bosse D, 2005, J CLIN PHARMACOL, V45, P57, DOI 10.1177/0091270004269646; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; Ferre-Ybarz L, 2006, J INVEST ALLERG CLIN, V16, P314; Fung KYC, 2004, PROSTATE, V61, P171, DOI 10.1002/pros.20089; Gobom J, 2002, ANAL CHEM, V74, P3915, DOI 10.1021/ac011203o; HALPERN BN, 1967, IMMUNOLOGY, V12, P247; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE BB, 1973, NEW ENGL J MED, V288, P894, DOI 10.1056/NEJM197304262881707; LILJA G, 1989, J ALLERGY CLIN IMMUN, V83, P37, DOI 10.1016/0091-6749(89)90475-2; MALLING HJ, 1993, ALLERGY, V48, P9; Mari A, 2005, INT ARCH ALLERGY IMM, V138, P88, DOI 10.1159/000087848; Pandjaitan B, 2000, J ALLERGY CLIN IMMUN, V105, P279, DOI 10.1016/S0091-6749(00)90077-0; Polascik TJ, 1999, J UROLOGY, V162, P293, DOI 10.1016/S0022-5347(05)68543-6; Reininger R, 2007, CLIN EXP ALLERGY, V37, P116, DOI 10.1111/j.1365-2222.2006.02611.x; Saarelainen S, 2004, CLIN EXP ALLERGY, V34, P1576, DOI 10.1111/j.1365-2222.2004.02071.x; *SEAIC, 2005, AL 2005 FACT EP EL S; Shah A, 2004, CLIN EXP ALLERGY, V34, P827, DOI 10.1111/j.1365-2222.2004.01962.x; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Spitzauer S, 1999, INT ARCH ALLERGY IMM, V120, P259, DOI 10.1159/000024278; Spitzauer S, 1997, J ALLERGY CLIN IMMUN, V99, P100, DOI 10.1016/S0091-6749(97)70306-3; SPITZAUER S, 1994, J ALLERGY CLIN IMMUN, V93, P614, DOI 10.1016/S0091-6749(94)70073-7; SPITZAUER S, 1991, INT ARCH ALLER A IMM, V94, P346, DOI 10.1159/000235399; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Virtanen T, 1999, INT ARCH ALLERGY IMM, V120, P247, DOI 10.1159/000024277; Virtanen T, 1999, IMMUNOL TODAY, V20, P398, DOI 10.1016/S0167-5699(99)01515-7; Weidinger S, 2005, CHEM IMMUNOL ALLERGY, V88, P128, DOI 10.1159/000087830; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V117, P213, DOI 10.1016/j.jaci.2005.09.040; Yman L, 1975, Dev Biol Stand, V29, P151	32	51	51	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					233	239		10.1016/j.jaci.2007.10.008	http://dx.doi.org/10.1016/j.jaci.2007.10.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18061650	Bronze			2022-12-18	WOS:000252372000036
J	Dhiman, N; Poland, GA; Cunningham, JM; Jacobson, RM; Ovsyannikova, IG; Vierkant, RA; Wu, Y; Pankratz, VS				Dhiman, Neelam; Poland, Gregory A.; Cunningham, Julie M.; Jacobson, Robert M.; Ovsyannikova, Inna G.; Vierkant, Robert A.; Wu, Yanhong; Pankratz, V. Shane			Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	5th World Congress on Vaccines, Immunisation and Immunotherapy	NOV 06-09, 2006	Montreal, CANADA	Infect Control World Org		measles vaccine; single nucleotide polymorphisms; signaling lymphocyte activation molecule; CD46; measles virus receptors	CLASS-II ALLELES; SINGLE-NUCLEOTIDE POLYMORPHISMS; CELL-MEDIATED-IMMUNITY; COFACTOR PROTEIN CD46; ACTIVATION MOLECULE; DOWN-REGULATION; RESTRICTED PRESENTATION; TYPE-1 INFECTION; BINDING-SITES; HLA	Background: Measles infection requires 2 cellular receptors, signaling lymphocyte activation molecule (SLAM) and CD46. Known and novel single nucleotide polymorphisms (SNPs) in SLAM and CD46 genes might influence the immune response to measles vaccine. Objective: We sought to identify SNP associations in SLAM and CD46 genes with variations in measles antibody response. Methods: We genotyped known SNPs in SLAM and CD46 genes in 339 subjects vaccinated with 2 doses of measles-mumps-rubella vaccine. We also sequenced the measles virus-binding domains of SLAM and CD46 to identify novel SNPs. Results: Increased representation of minor alleles for rs3796504 and rs164288 in the SLAM gene was associated with an allele dose-related decrease (4-fold) in measles-specific antibodies. Heterozygous genotype TC for rs12076998 located in the untranslated region 33 bp upstream of the measles virus-binding domain of the SLAM gene was associated with higher median antibody levels (1991 vs 1467 IU/L, P =.01) compared with wild-type TT. Within the CD46 gene, the minor allele C for intronic SNP (rs11118580) was associated with an allele dose-related decrease in measles antibodies (1072 vs 1795 IU/L, P <.01). Decreases in minor allele counts for rs3796504, rs164288, and rs1118580 demonstrated a significant (P <.001) additive effect on measles-specific antibodies. Conclusion: Our data suggest that specific SNPs present in both the SLAM and CD46 genes are associated with measurable and significant variations in antibody response after measles vaccination. Clinical implications: Understanding the immunogenetics of measles vaccine receptors is important to better understand variations in immune responses to vaccines and to design better vaccines.	Mayo Clin, Mayo Vaccine Res Grp, Rochester, MN 55905 USA; Mayo Clin, Program Translat Immunovirol & Biodefense, Rochester, MN 55905 USA; Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Mayo Clin, Div Biostat, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Poland, GA (corresponding author), Mayo Clin, Mayo Vaccine Res Grp, Guggenheim 611C,200 1st St SW, Rochester, MN 55905 USA.	poland.gregory@mayo.edu	Vierkant, Robert/AAP-4927-2020	Vierkant, Robert/0000-0001-6242-5221; Jacobson, Robert/0000-0002-6355-8752	NCRR NIH HHS [M01-RR00585] Funding Source: Medline; NIAID NIH HHS [AI 33144, AI 48793] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI048793, R01AI048793] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aversa G, 1997, IMMUNOL CELL BIOL, V75, P202, DOI 10.1038/icb.1997.30; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Caillat-Zucman S, 1998, KIDNEY INT, V53, P1626, DOI 10.1046/j.1523-1755.1998.00909.x; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; den Dunnen JT, 2001, HUM GENET, V109, P121, DOI 10.1007/s004390100505; Desombere I, 1998, TISSUE ANTIGENS, V51, P593, DOI 10.1111/j.1399-0039.1998.tb03001.x; Dhiman N, 2005, CLIN IMMUNOL, V115, P154, DOI 10.1016/j.clim.2004.12.010; Dhiman N, 2004, REV MED VIROL, V14, P217, DOI 10.1002/rmv.430; Dhiman N, 2007, J INFECT DIS, V195, P21, DOI 10.1086/510596; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; EMIGH TH, 1980, BIOMETRICS, V36, P627, DOI 10.2307/2556115; Erlenhoefer C, 2001, J VIROL, V75, P4499, DOI 10.1128/JVI.75.10.4499-4505.2001; Erlenhofer C, 2002, J GEN VIROL, V83, P1431, DOI 10.1099/0022-1317-83-6-1431; Evlashev A, 2001, J GEN VIROL, V82, P2125, DOI 10.1099/0022-1317-82-9-2125; Ferrand V, 2003, J MED VIROL, V70, P131, DOI 10.1002/jmv.10373; Galbraith SE, 1998, J VIROL, V72, P10292, DOI 10.1128/JVI.72.12.10292-10297.1998; GERLIER D, 1994, J EXP MED, V179, P353, DOI 10.1084/jem.179.1.353; Helminen ME, 2001, J INFECT DIS, V184, P777, DOI 10.1086/322987; Henning G, 2001, EUR J IMMUNOL, V31, P2741, DOI 10.1002/1521-4141(200109)31:9<2741::AID-IMMU2741>3.0.CO;2-6; Hsu EC, 2001, VIROLOGY, V279, P9, DOI 10.1006/viro.2000.0711; Hu CL, 2004, BIOCHEM BIOPH RES CO, V316, P698, DOI 10.1016/j.bbrc.2004.02.106; HURME M, 2003, J MED VIROL, V70, pS458; Karp CL, 1999, IMMUNOL REV, V168, P91, DOI 10.1111/j.1600-065X.1999.tb01285.x; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Kaslow RA, 2005, J INFECT DIS, V191, pS68, DOI 10.1086/425269; Kurita-Taniguchi M, 2000, J IMMUNOL, V165, P5143, DOI 10.4049/jimmunol.165.9.5143; Kusuhara K, 2000, J INFECT DIS, V181, P1447, DOI 10.1086/315386; Lecouturier V, 1999, BIOCHEM BIOPH RES CO, V264, P268, DOI 10.1006/bbrc.1999.1517; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; Liu CL, 2003, J INFECT DIS, V187, P1404, DOI 10.1086/374394; Ma CS, 2007, ANNU REV IMMUNOL, V25, P337, DOI 10.1146/annurev.immunol.25.022106.141651; MANCHESTER M, 1995, P NATL ACAD SCI USA, V92, P2303, DOI 10.1073/pnas.92.6.2303; Manly B.F.J., 1997, RANDOMIZATION BOOTST, V2; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; Ono N, 2001, J VIROL, V75, P4399, DOI 10.1128/JVI.75.9.4399-4401.2001; Ono N, 2001, J VIROL, V75, P1594, DOI 10.1128/JVI.75.4.1594-1600.2001; Ovsyannikova IG, 2005, J INFECT DIS, V191, P515, DOI 10.1086/427558; Ovsyannikova IG, 2005, IMMUNOGENETICS, V56, P798, DOI 10.1007/s00251-004-0756-0; Ovsyannikova IG, 2004, HUM IMMUNOL, V65, P1506, DOI 10.1016/j.humimm.2004.07.001; POLAND GA, 2007, IN PRESS GENETIC SUS; Punnonen J, 1997, J EXP MED, V185, P993, DOI 10.1084/jem.185.6.993; RISK JM, 1991, HUM IMMUNOL, V30, P162, DOI 10.1016/0198-8859(91)90030-D; Rivailler P, 1998, EUR J IMMUNOL, V28, P1301, DOI 10.1002/(SICI)1521-4141(199804)28:04<1301::AID-IMMU1301>3.0.CO;2-S; Schneider U, 2002, J VIROL, V76, P7460, DOI 10.1128/JVI.76.15.7460-7467.2002; SCHNEIDERSCHAULIES J, 1995, P NATL ACAD SCI USA, V92, P3943, DOI 10.1073/pnas.92.9.3943; Schnorr JJ, 1997, J GEN VIROL, V78, P3217, DOI 10.1099/0022-1317-78-12-3217; SCHNORR JJ, 1995, EUR J IMMUNOL, V25, P976, DOI 10.1002/eji.1830250418; SILVERMAN TA, 1992, J BIOL CHEM, V267, P9738; Tang JM, 1999, AIDS RES HUM RETROV, V15, P317, DOI 10.1089/088922299311277; Tang JM, 2002, AIDS, V16, P2275, DOI 10.1097/00002030-200211220-00007; Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579; Thio CL, 2004, J VIROL, V78, P11258, DOI 10.1128/JVI.78.20.11258-11262.2004; Wang CB, 2004, HEPATOLOGY, V39, P978, DOI 10.1002/hep.20142; WILTON AN, 1992, IMMUNOGENETICS, V36, P79, DOI 10.1007/BF00215283; Xu Q, 2006, J BIOCHEM MOL BIOL, V39, P406; Yakub I, 2005, J INFECT DIS, V192, P1741, DOI 10.1086/497340; Yanagi Y, 2006, JPN J INFECT DIS, V59, P1	57	51	53	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					666	672		10.1016/j.jaci.2007.04.036	http://dx.doi.org/10.1016/j.jaci.2007.04.036			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17560639				2022-12-18	WOS:000249505400028
J	Sloane, DE; Lee, CW; Sheffer, AL				Sloane, David E.; Lee, Chyh Woei; Sheffer, Albert L.			Hereditary angioedema: Safety of long-term stanozolol therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hereditary angioedema; attenuated androgens; stanozolol; side effects	DANAZOL; MANAGEMENT	Background: Attenuated androgens control attacks of hereditary angioedema. Short-term studies of such patients treated at our institution with attenuated androgens demonstrated no adverse effects. However, the side-effect frequencies in patients receiving long-term treatment are relatively less well characterized. Objective: To assess the frequencies of various side effects of the attenuated androgen stanozolol in a population of patients with hereditary angioedema treated for 20 to 40 years. Methods: Data on side effects in patients who continued stanozolol therapy since 1987 were obtained by means of questionnaire. Patients were evaluated by physical examination; biochemical assays of hepatic function, serum lipids, and prostate specific antigen; and liver ultrasound. Results: The minimal initial effective dosage of stanozolol was 0.5 to 2.0 mg daily, although most patients achieved symptomatic control and decreased the dose and frequency as the frequency of attacks decreased. Treatment-related symptoms developed in 10 of 21 patients. No interruption in stanozolol therapy was required because symptoms subsided with a reduction in the stanozolol dosage. Adverse side effects included hirsutism, weight gain, menstrual irregularities or postmenopausal bleeding, acne, and mood changes. Liver enzyme assays revealed no persistent abnormalities. Liver ultrasounds in 8 patients revealed 3 abnormalities deemed unrelated to therapy. Five patients had a reduced high-density lipoprotein, and 2 patients had elevated triglycerides. Conclusion: Stanozolol is a safe and effective drug for the long-term management of hereditary angioedema. Clinical implications: Stanozolol may be used in the long-term treatment of patients with hereditary angioedema provided such patients are closely supervised with routine clinical, biochemical, and radiologic assessments.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Chestnut Hill, MA 02467 USA	Harvard University; Brigham & Women's Hospital	Sheffer, AL (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, 850 Boylston St,Suite 540, Chestnut Hill, MA 02467 USA.	asheffev@parrtners.org						AGOSTONI A, 1980, J ALLERGY CLIN IMMUN, V65, P75, DOI 10.1016/0091-6749(80)90181-5; Bork K, 1999, LANCET, V353, P1066, DOI 10.1016/S0140-6736(99)00110-5; Bowen T, 2004, J ALLERGY CLIN IMMUN, V114, P629, DOI 10.1016/j.jaci.2004.06.043; Cicardi M, 1997, J ALLERGY CLIN IMMUN, V99, P194, DOI 10.1016/S0091-6749(97)70095-2; CICARDI M, 1983, J ALLERGY CLIN IMMUN, V72, P294, DOI 10.1016/0091-6749(83)90034-9; FARRELL GC, 1975, LANCET, V1, P430; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; JOHNSON FL, 1972, LANCET, V2, P1273; Prematta M, 2007, ANN ALLERG ASTHMA IM, V98, P383, DOI 10.1016/S1081-1206(10)60886-1; SHEFFER AL, 1987, J ALLERGY CLIN IMMUN, V80, P855, DOI 10.1016/S0091-6749(87)80277-4; SHEFFER AL, 1981, J ALLERGY CLIN IMMUN, V68, P181, DOI 10.1016/0091-6749(81)90181-0; SHEFFER AL, 1977, ANN INTERN MED, V86, P306, DOI 10.7326/0003-4819-86-3-306; SHEFFER AL, 1979, J ALLERGY CLIN IMMUN, V64, P275, DOI 10.1016/0091-6749(79)90144-1; SPAULDING W, 1960, ANN INTERN MED, V53, P139; ZURLO JJ, 1990, FERTIL STERIL, V54, P64	15	51	51	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					654	658		10.1016/j.jaci.2007.06.037	http://dx.doi.org/10.1016/j.jaci.2007.06.037			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17765757				2022-12-18	WOS:000249505400026
J	Liem, JJ; Kozyrskyj, AL; Huq, SI; Becker, AB				Liem, Joel J.; Kozyrskyj, Anita L.; Huq, Shamima I.; Becker, Allan B.			The risk of developing food allergy in premature or low-birth-weight children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epinephrine; food allergy; gestational age; low birth weight; prematurity	PRETERM INFANTS; INTESTINAL PERMEABILITY; PRIMARY PREVENTION; IMMUNE-RESPONSES; PEANUT ALLERGENS; COWS MILK; ASTHMA; ABSORPTION; CHILDHOOD; ANTIGEN	Background: Premature or low-birth-weight children have increased gut permeability compared with term or normal-birth-weight children. Objective: To determine whether premature or low-birthweight children have an increased risk of developing food allergy compared with term or normal-birth-weight children. Methods: The 1995 Manitoba Birth Cohort was studied using the Manitoba Health Services Insurance Plan (MHSIP) database. This database is a population-based, health care administrative and prescription database. It has records of every child born and subsequent utilization of the provincial health care system. The diagnosis of food allergy (ICD-9-CM code of 693 in hospital/medical claims or a prescription of injectable epinephrine excluding a sole diagnosis of venom allergy) was obtained up until the year 2002. The relative risks of food allergy in premature or low-birth-weight children compared with term or normal-birth-weight children were determined. Results: A total of 13,980 children were born in 1995 and continue to live in the province of Manitoba. Of these, 592 children (4.23%) were found to have food allergy and epinephrine was prescribed in 316 (2.26%) children. No gestational age or birth weight group had a statistically significant increased risk for food allergy. Conclusion: Prematurity and low birth weight are not associated with a change in risk for development of food allergy in childhood. Clinical implications: Immaturity of the gastrointestinal tract or immune response does not seem to change the risk for development of food allergies. We ask whether early exposure to food antigens may protect premature children by increasing immune tolerance to those antigens.	Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB R3A 1R9, Canada; Univ Manitoba, Fac Pharm, Dept Community Hlth Sci, Winnipeg, MB R3A 1R9, Canada; Univ Manitoba, Fac Med, Dept Community Hlth Sci, Winnipeg, MB R3A 1R9, Canada; Manitoba Inst Child Hlth, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba; University of Manitoba	Becker, AB (corresponding author), Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Room AE101,820 Sherbrook St,101-671 William Ave, Winnipeg, MB R3A 1R9, Canada.	becker@cc.umanitoba.ca						Alpan O, 2001, Curr Allergy Asthma Rep, V1, P572, DOI 10.1007/s11882-001-0067-6; AXELSSON I, 1989, ACTA PAEDIATR SCAND, V78, P532, DOI 10.1111/j.1651-2227.1989.tb17932.x; Baker SS, 2000, PEDIATRICS, V106, P346; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; BERNBAUM J, 1984, CLIN PERINATOL, V11, P73, DOI 10.1016/S0095-5108(18)30937-0; BOCK SA, 1987, PEDIATRICS, V79, P683; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; CONWAY S, 1993, J INFECTION, V27, P143, DOI 10.1016/0163-4453(93)94674-Z; DEMARTINO M, 1989, BIOL NEONATE, V56, P301, DOI 10.1159/000243138; Eigenmann PA, 2001, ALLERGY, V56, P1112, DOI 10.1034/j.1398-9995.2001.00080.x; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; FERGUSSON DM, 1983, ARCH DIS CHILD, V58, P48, DOI 10.1136/adc.58.1.48; Franco L, 1998, CELL IMMUNOL, V190, P1, DOI 10.1006/cimm.1998.1356; Hikino S, 2001, ACTA PAEDIATR, V90, P850, DOI 10.1080/08035250152509537; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Kozyrskyj AL, 1998, ANN PHARMACOTHER, V32, P1152, DOI 10.1345/aph.18117; KUITUNEN OOM, 1994, PEDIATR RES, V35, P344, DOI 10.1203/00006450-199403000-00014; LUCAS A, 1984, BRIT MED J, V289, P1254, DOI 10.1136/bmj.289.6454.1254; LUCAS A, 1990, ARCH DIS CHILD, V65, P411, DOI 10.1136/adc.65.4.411; LUCAS A, 1990, BRIT MED J, V300, P837, DOI 10.1136/bmj.300.6728.837; MCNEISH AS, 1984, ANN ALLERGY, V53, P643; MILLER A, 1994, EUR J IMMUNOL, V24, P1026, DOI 10.1002/eji.1830240503; Penard-Morand C, 2005, ALLERGY, V60, P1165, DOI 10.1111/j.1398-9995.2005.00860.x; Pomes A, 2003, J ALLERGY CLIN IMMUN, V111, P640, DOI 10.1067/mai.2003.118; Rance F, 2005, CLIN EXP ALLERGY, V35, P167, DOI 10.1111/j.1365-2222.2005.02162.x; ROBERTON DM, 1982, ARCH DIS CHILD, V57, P369, DOI 10.1136/adc.57.5.369; Robinson JR, 1997, MED CARE, V35, P932, DOI 10.1097/00005650-199709000-00006; Schappi GF, 2001, ALLERGY, V56, P1216, DOI 10.1034/j.1398-9995.2001.00280.x; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; Siltanen M, 2002, J ALLERGY CLIN IMMUN, V110, P658, DOI 10.1067/mai.2002.128077; Siltanen M, 2001, J ALLERGY CLIN IMMUN, V107, P229, DOI 10.1067/mai.2001.112128; Simons FER, 2002, J ALLERGY CLIN IMMUN, V110, P647, DOI 10.1067/mai.2002.127860; SOOTHILL JF, 1976, CLIN ALLERGY, V6, P305, DOI 10.1111/j.1365-2222.1976.tb01911.x; Strid J, 2004, IMMUNOLOGY, V113, P293, DOI 10.1111/j.1365-2567.2004.01989.x; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; TAYLOR B, 1973, LANCET, V2, P111; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; UDALL JN, 1981, PEDIATR RES, V15, P245, DOI 10.1203/00006450-198103000-00009; Vadas P, 2001, JAMA-J AM MED ASSOC, V285, P1746, DOI 10.1001/jama.285.13.1746; WALKER WA, 1987, ANN ALLERGY, V59, P7; WEAVER LT, 1984, ARCH DIS CHILD, V59, P236, DOI 10.1136/adc.59.3.236; Zeiger RS, 2003, PEDIATRICS, V111, P1662	42	51	52	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1203	1209		10.1016/j.jaci.2006.12.671	http://dx.doi.org/10.1016/j.jaci.2006.12.671			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17379288				2022-12-18	WOS:000246427200022
J	Oh, SY; Zheng, T; Bailey, ML; Barber, DL; Schroeder, JT; Kim, YK; Zhu, Z				Oh, Sun-Young; Zheng, Tao; Bailey, Monica L.; Barber, Dwayne L.; Schroeder, John T.; Kim, Yoon-Keun; Zhu, Zhou			Src homology 2 domain-containing inositol 5-phosphatase 1 deficiency leads to a spontaneous allergic inflammation in the murine lung	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						phosphatase; phosphoinositide 3-kinase; signaling; T(H)2 inflammation; asthma; allergy	INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; NEGATIVE REGULATOR; AIRWAY HYPERRESPONSIVENESS; EXPERIMENTAL ASTHMA; CELL-SURVIVAL; B-LYMPHOCYTES; MAST-CELLS; SHIP; IL-13; MICE	Background: Src homology 2 domain-containing inositol 5-phosphatase 1 (SHIP-1) controls the intracellular level of the phosphoinositide 3-kinase product phosphotidylinositol-3,4,5-trisphosphate and functions as a negative regulator of cytokine and immune receptor signaling. Emerging evidence suggests that the phosphoinositide 3-kinase pathway might be involved in allergic inflammation in the lung. However, the functional relevance of SHIP-1 in the T(H)2 activation pathway has not been established. SHIP-1(-/-) mice have spontaneous myeloproliferative inflammation in the lung, the nature of which has not been elucidated. We hypothesized that SHIP-1 plays an important role as a regulator in pulmonary allergic inflammation and in maintaining lung homeostasis. Objective: To test our hypothesis, we characterized the pulmonary phenotype of SHIP-1(-/-) mice. Results: Analyses of lung histopathology and bronchoalveolar lavage cellularity revealed that the majority of SHIP-1(-/-) mice had progressive and severe pulmonary inflammation of macrophages, lymphocytes, neutrophils, and eosinophils-1 mucous hyperplasia; airway epithelial hypertrophy; and subepithelial fibrosis. These pathologic changes were accompanied by exaggerated production of T(H)2 cytokines and chemokines, including IL-4, IL-13, eotaxin, and monocyte chemoattractant protein 1, in the lung. Furthermore, the number of mast cells significantly increased, and many of these cells were undergoing degranulation, which was correlated with increased content and spontaneous release of histamine in the lung tissue of SHIP-1(-/-) mice. Conclusion: These findings provide strong evidence that mice lacking SHIP-1 have an allergic inflammation in the lung, suggesting that SHIP-1 plays an important role in regulating the T(H)2 signaling pathway and in maintaining lung homeostasis. Clinical implications: SHIP-1 as a regulator might be a potential therapeutic target for controlling allergic inflammation in diseases such as asthma.	Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M4X 1K9, Canada; Seoul Natl Univ, Coll Med, Dept Internal Med, Inst Allergy & Clin Immunol, Seoul 151, South Korea	Johns Hopkins University; Johns Hopkins Medicine; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Seoul National University (SNU)	Zhu, Z (corresponding author), Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	zzhu@jhmi.edu		Barber, Dwayne/0000-0001-5528-8150	NHLBI NIH HHS [R01HL074095, R01 HL074095] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074095] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beavitt SJE, 2005, J IMMUNOL, V175, P1867, DOI 10.4049/jimmunol.175.3.1867; Chacko GW, 1996, J IMMUNOL, V157, P2234; Daigle I, 2002, NAT MED, V8, P61, DOI 10.1038/nm0102-61; Duan W, 2005, INT IMMUNOPHARMACOL, V5, P495, DOI 10.1016/j.intimp.2004.10.015; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Gessner A, 2005, J IMMUNOL, V174, P1063, DOI 10.4049/jimmunol.174.2.1063; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guo L, 2000, J BIOL CHEM, V275, P8032, DOI 10.1074/jbc.275.11.8032; Helgason CD, 2000, J EXP MED, V191, P781, DOI 10.1084/jem.191.5.781; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Huber M, 2002, IMMUNOL LETT, V82, P17, DOI 10.1016/S0165-2478(02)00012-3; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; MacDonald SM, 2002, MOL IMMUNOL, V38, P1323, DOI 10.1016/S0161-5890(02)00082-2; Min B, 2004, J EXP MED, V200, P507, DOI 10.1084/jem.20040590; Myou S, 2003, J EXP MED, V198, P1573, DOI 10.1084/jem.20030298; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Rauh MJ, 2005, IMMUNITY, V23, P361, DOI 10.1016/j.immuni.2005.09.003; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Schroeder JT, 2006, MANUAL OF MOLECULAR AND CLINICAL LABORATORY IMMUNOLOGY, 7TH EDITION, P964; Vonakis BM, 2001, J ALLERGY CLIN IMMUN, V108, P822, DOI 10.1067/mai.2001.119159; Webb DC, 2001, J BIOL CHEM, V276, P41969, DOI 10.1074/jbc.M106223200; Weiss DL, 2001, IMMUNOL REV, V179, P35, DOI 10.1034/j.1600-065X.2001.790104.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zamorano J, 1998, J IMMUNOL, V161, P859; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	31	51	52	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					123	131		10.1016/j.jaci.2006.08.029	http://dx.doi.org/10.1016/j.jaci.2006.08.029			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208593	Green Accepted			2022-12-18	WOS:000243622200018
J	Joseph, CLM; Williams, LK; Ownby, DR; Saltzgaber, J; Johnson, CC				Joseph, CLM; Williams, LK; Ownby, DR; Saltzgaber, J; Johnson, CC			Applying epidemiologic concepts of primary, secondary, and tertiary prevention to the elimination of racial disparities in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; racial disparities; disease prevention	INNER-CITY CHILDREN; LOW-BIRTH-WEIGHT; EARLY-CHILDHOOD ASTHMA; PUERTO-RICAN CHILDREN; SOCIOECONOMIC-STATUS; AFRICAN-AMERICANS; UNITED-STATES; MANAGEMENT-PRACTICES; COCKROACH ALLERGEN; PHYSICAL-ACTIVITY	.Despite medical and scientific advances, racial and ethnic disparities persist in US asthma morbidity and mortality rates. Progress in the elimination of these disparities will involve disentangling the contribution of social constructs, such as race, socioeconomic status, and culture, from that of the physical environment and genetic susceptibility. One approach to reducing asthma disparities is through the traditional disease prevention stages of intervention. As such, primary prevention targets reductions in asthma incidence; secondary prevention is the mitigation of established disease and involves disease detection, management, and control; and tertiary prevention is the reduction of complications caused by severe disease. Once causative factors at each level of disease prevention are understood, this knowledge can be translated into clinical practice and public health policy.	Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; Med Coll Georgia, Augusta, GA 30912 USA	Henry Ford Health System; Henry Ford Hospital; University System of Georgia; Augusta University	Joseph, CLM (corresponding author), Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, 1 Ford Pl,3E, Detroit, MI 48202 USA.	cjosephl@hfhs.org		Johnson, Christine Cole/0000-0002-6864-6604	NHLBI NIH HHS [R01 HL079055, R01 HL068971] Funding Source: Medline; NIAID NIH HHS [R01 AI061774] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079055, R01HL068971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061774] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akinbami LJ, 2005, PEDIATRICS, V115, P1254, DOI 10.1542/peds.2004-0897; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Bamshad M, 2005, JAMA-J AM MED ASSOC, V294, P937, DOI 10.1001/jama.294.8.937; Beckett WS, 2001, AM J RESP CRIT CARE, V164, P2045, DOI 10.1164/ajrccm.164.11.2004235; Belamarich PF, 2000, PEDIATRICS, V106, P1436, DOI 10.1542/peds.106.6.1436; Boudreaux ED, 2003, CHEST, V124, P803, DOI 10.1378/chest.124.3.803; Braganza S, 2003, J ASTHMA, V40, P823, DOI 10.1081/JAS-120023574; Brandon DT, 2005, J NATL MED ASSOC, V97, P951; Brisbon N, 2005, J ALLERGY CLIN IMMUN, V115, P1024, DOI 10.1016/j.jaci.2005.02.020; Brooks AM, 2001, ARCH PEDIAT ADOL MED, V155, P401, DOI 10.1001/archpedi.155.3.401; Brown P, 2003, SOC SCI MED, V57, P453, DOI 10.1016/S0277-9536(02)00375-1; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919, DOI 10.1164/ajrccm.160.3.9812024; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; *CDCP, 2004, MMWR-MORBID MORTAL W, V53, P145; Celedon JC, 2004, CHEST, V125, P85, DOI 10.1378/chest.125.1.85; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P143; Chan KS, 2005, ARCH PEDIAT ADOL MED, V159, P283, DOI 10.1001/archpedi.159.3.283; Chen M, 2002, NANO LETT, V2, P211, DOI 10.1021/nl015649w; Choudhry S, 2005, AM J RESP CRIT CARE, V172, P173, DOI 10.1164/rccm.200409-1232OC; Choudhry S, 2005, AM J RESP CRIT CARE, V171, P563, DOI 10.1164/rccm.200409-1286OC; Clark NM, 2002, J CLIN EPIDEMIOL, V55, P870, DOI 10.1016/S0895-4356(02)00451-1; Cooper RS, 2003, NEW ENGL J MED, V348, P1166, DOI 10.1056/NEJMsb022863; CRAIN EF, 1994, PEDIATRICS, V94, P356; Crater DD, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.6.e97; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Federico MJ, 2005, CHEST, V127, P571, DOI 10.1378/chest.127.2.571; Findley S, 2003, J ASTHMA, V40, P557, DOI 10.1081/JAS-120019028; Flint A J, 1997, Tob Control, V6, P14, DOI 10.1136/tc.6.1.14; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Ford M E, 1997, Ethn Health, V2, P329; Freeman NCG, 2003, AM J PUBLIC HEALTH, V93, P1316, DOI 10.2105/AJPH.93.8.1316; Freeman NCG, 2003, J EXPO ANAL ENV EPID, V13, P169, DOI 10.1038/sj.jea.7500266; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; George M, 2003, J ALLERGY CLIN IMMUN, V111, P967, DOI 10.1067/mai.2003.1459; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; Grant EN, 2000, AM J PUBLIC HEALTH, V90, P1923, DOI 10.2105/AJPH.90.12.1923; HALONEN M, 1991, CLIN EXP ALLERGY, V21, P235, DOI 10.1111/j.1365-2222.1991.tb00836.x; Hartert T V, 2000, Curr Opin Pulm Med, V6, P4, DOI 10.1097/00063198-200001000-00002; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Hudson CG, 2005, AM J ORTHOPSYCHIAT, V75, P3, DOI 10.1037/0002-9432.75.1.3; HUSS K, 1994, ANN ALLERGY, V72, P173; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Johnson ML, 2005, CRIT REV EUKAR GENE, V15, P229, DOI 10.1615/CritRevEukarGeneExpr.v15.i3.50; Joseph CLM, 2005, ENVIRON HEALTH PERSP, V113, P900, DOI 10.1289/ehp.7453; Joseph CLM, 2005, J PEDIATR-US, V146, P96, DOI 10.1016/j.jpeds.2004.09.001; Joseph CLM, 2002, ANN ALLERG ASTHMA IM, V88, P507, DOI 10.1016/S1081-1206(10)62390-3; Joseph CLM, 2000, CHEST, V117, P1336, DOI 10.1378/chest.117.5.1336; Lara M, 1999, WESTERN J MED, V170, P75; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419, DOI 10.1289/ehp.02110419; Lieu TA, 2002, PEDIATRICS, V109, P857, DOI 10.1542/peds.109.5.857; Lim S, 1998, LANCET, V352, P113, DOI 10.1016/S0140-6736(98)85018-6; Litonjua AA, 2002, THORAX, V57, P581, DOI 10.1136/thorax.57.7.581; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; Lucas SR, 2005, J ALLERGY CLIN IMMUN, V115, P928, DOI 10.1016/j.jaci.2005.01.033; Lwebuga-Mukasa JS, 2002, J HEALTH CARE POOR U, V13, P214; McConnochie KM, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.6.e75; Miller JE, 2000, AM J PUBLIC HEALTH, V90, P428, DOI 10.2105/AJPH.90.3.428; Milner JD, 2004, PEDIATRICS, V114, P27, DOI 10.1542/peds.114.1.27; Mustillo S, 2004, AM J PUBLIC HEALTH, V94, P2125, DOI 10.2105/AJPH.94.12.2125; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Ness RB, 2004, AM J EPIDEMIOL, V160, P1033, DOI 10.1093/aje/kwh325; Nieman DC, 1999, J AM DIET ASSOC, V99, P294, DOI 10.1016/S0002-8223(99)00077-2; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; OSBORNE NG, 1992, JAMA-J AM MED ASSOC, V267, P275, DOI 10.1001/jama.267.2.275; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; PACHTER LM, 1995, ARCH PEDIAT ADOL MED, V149, P982, DOI 10.1001/archpedi.1995.02170220048007; Ponsonby AL, 2002, CHEST, V121, P135, DOI 10.1378/chest.121.1.135; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Silverman ES, 2004, AM J RESP CRIT CARE, V169, P214, DOI 10.1164/rccm.200307-973OC; Sood A, 2005, J ALLERGY CLIN IMMUN, V115, P921, DOI 10.1016/j.jaci.2005.02.033; Warman KL, 2002, ARCH PEDIAT ADOL MED, V156, P673, DOI 10.1001/archpedi.156.7.673; Williams DR, 1996, INT J HEALTH SERV, V26, P483, DOI 10.2190/U9QT-7B7Y-HQ15-JT14; Williams DR, 2001, PUBLIC HEALTH REP, V116, P404, DOI 10.1016/S0033-3549(04)50068-7; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Wright RJ, 2001, ENVIRON HEALTH PERSP, V109, P1085, DOI 10.2307/3454965; Yawn BP, 2003, ANN ALLERG ASTHMA IM, V90, P508, DOI 10.1016/S1081-1206(10)61844-3; Yeatts K, 2003, PEDIATRICS, V111, P1046, DOI 10.1542/peds.111.5.1046; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001; Zoratti EM, 1998, AM J RESP CRIT CARE, V158, P371, DOI 10.1164/ajrccm.158.2.9608039	87	51	51	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					233	240		10.1016/j.jaci.2005.11.004	http://dx.doi.org/10.1016/j.jaci.2005.11.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	017IM	16461121	Green Accepted			2022-12-18	WOS:000235687300001
J	Kleine-Tebbe, J; Heinatz, A; Graser, I; Dautel, H; Hansen, GN; Kespohl, S; Rihs, HP; Raulf-Heimsoth, M; Vater, G; Rytter, M; Haustein, UF				Kleine-Tebbe, J; Heinatz, A; Graser, I; Dautel, H; Hansen, GN; Kespohl, S; Rihs, HP; Raulf-Heimsoth, M; Vater, G; Rytter, M; Haustein, UF			Bites of the European pigeon tick (Argas reftexus): Risk of IgE-mediated sensitizations and anaphylactic reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						arthropod allergy; pigeon tick; Argas reflexus; tick bite; IgE-mediated reaction; anaphylaxis; whole-body extract; skin prick test; allergen specific IgE	REFLEXUS ACARI; VENOM ALLERGY; STING ALLERGY; SOFT TICK; SENSITIVITY; POPULATION; BINDING; INSECT; BERLIN; TESTS	Background: Local and systemic reactions can occur after bites of Argas reflexus (Argas), a soft tick parasitizing pigeons. Objective: Risk assessment of IgE-mediated sensitizations and systemic reactions after Argas bites. Methods: Case histories, skin prick tests (SPTs) with a whole-body extract of Argas containing major allergen Arg r 1, and common inhalants and specific IgE measurements were obtained from 148 subjects who had had Argas bites and 20 volunteers as a control group. Results: Systemic reactions (urticaria, angioedema, dyspnea, cardiovascular dysregulation, unconsciousness) were reported in 12 of 148 (8%); 146 of 148 (99%) had local reactions. Atopy was found in 37 of 146 (25%) with local reactions and 3 of 12 (25%) with systemic reactions. SPT to Argas was positive in 24 of 148 (16%) with a high proportion of atopics 10 of 24 (42%); specific IgE to Argas was detectable in 12 of 135 (8% of 148) with moderate concordance to systemic reactions. No positive SPT or specific IgE results to Argas were obtained in the control group. Immunoblotting of 23 sera revealed an IgE-binding protein in 19 of 23 sera (82%) at 22 kd, indicating a major allergen of Argas. Conclusion: Severe anaphylactic reactions were infrequently (approximately 8%) found after bites of the soft tick Argas reflexus. Atopy is a risk factor for skin sensitizations to Argas, but not for systemic reactions after bites by Argas. Using a whole-body extract of Argas, diagnosis through SPT and specific IgE is hampered by false-negative and irrelevant positive results, particularly in atopy.	Univ Leipzig, Div Allergy Occupat Dermatol & Environm Med, Clin & Outpatient, Dept Deramatol Venerol & Allergol, Leipzig, Germany; Free Univ Berlin, Inst Biol Anim Ecol, Berlin, Germany; ALK Abello AS, Horsholm, Denmark; Ruhr Univ Bochum, Res Int Occupat Med Berufsgenossensch, Bochum, Germany; Landesuntersuchungsanstalt Gesundheits & Vet Sach, Leipzig, Germany	Leipzig University; Free University of Berlin; ALK-Abello AS; Ruhr University Bochum	Kleine-Tebbe, J (corresponding author), Ctr Asthma & Allergy, Spandauer Damm 130,Haus 9, D-14050 Berlin, Germany.	kleine-tebbe@allergie-experten.de		Kespohl, Sabine/0000-0001-7571-1323; Kleine-Tebbe, Joerg/0000-0002-2862-7353				ALT K, 1892, WOCHENSCHRIFT, V30, P531; Bessot JC, 1997, REV FR ALLERGOL, V37, P431, DOI 10.1016/S0335-7457(97)80070-6; BJORNSSON E, 1995, ALLERGY, V50, P800, DOI 10.1111/j.1398-9995.1995.tb05052.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caplan EL, 2003, J ALLERGY CLIN IMMUN, V111, P1274, DOI 10.1067/mai.2003.1453; Chappard Colette, 1996, Biomedical Research (Aligarh), V7, P11; Chen ZP, 1998, J ALLERGY CLIN IMMUN, V102, P476, DOI 10.1016/S0091-6749(98)70138-1; CLARKE PS, 1986, MED J AUSTRALIA, V145, P564, DOI 10.5694/j.1326-5377.1986.tb139498.x; DAUTEL H, 1991, J APPL ENTOMOL, V111, P380, DOI 10.1111/j.1439-0418.1991.tb00338.x; Dautel H, 1997, EXP APPL ACAROL, V21, P697, DOI 10.1023/A:1018464820252; Dautel H, 1997, J INSECT PHYSIOL, V43, P843, DOI 10.1016/S0022-1910(97)00025-5; DAUTEL H, 1994, FOLIA PARASIT, V41, P155; Dautel H, 1998, J MED ENTOMOL, V35, P26, DOI 10.1093/jmedent/35.1.26; Dautel H, 1999, J INSECT PHYSIOL, V45, P55, DOI 10.1016/S0022-1910(98)00099-7; DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Hilger C, 2005, J ALLERGY CLIN IMMUN, V115, P617, DOI 10.1016/j.jaci.2004.11.052; KLEINETEBBE J, 1992, ANN ALLERGY, V69, P497; LIGHTON JRB, 1993, J EXP BIOL, V180, P229; MIADONNA A, 1982, ANN ALLERGY, V49, P293; PATRIZZI R, 1979, ALLERGY, V34, P249, DOI 10.1111/j.1398-9995.1979.tb01705.x; PRZYBILLA B, 1991, ALLERGY, V46, P570, DOI 10.1111/j.1398-9995.1991.tb00625.x; Rolla G, 2004, INT ARCH ALLERGY IMM, V135, P293, DOI 10.1159/000082322; SANTRACH PJ, 1980, ANN ALLERGY, V45, P130; Schafer T, 1996, ALLERGY, V51, P372; SCHWARTZ HJ, 1981, J ALLERGY CLIN IMMUN, V67, P81, DOI 10.1016/0091-6749(81)90051-8; Sirianni MC, 2000, ALLERGY, V55, P303, DOI 10.1034/j.1398-9995.2000.00525.x; STORCK H, 1973, ALLERGIE; TRAUTMANN A, 1995, DERMATOSEN, V42, P215; Vater G, 1992, PRAKT SCHADLINGSBEKA, V44, P152; Veraldi S, 1996, INT J DERMATOL, V35, P34, DOI 10.1111/j.1365-4362.1996.tb01612.x	31	51	55	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					190	195		10.1016/j.jaci.2005.08.056	http://dx.doi.org/10.1016/j.jaci.2005.08.056			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387605				2022-12-18	WOS:000235687100031
J	Encinas, JA; Janssen, EM; Weiner, DB; Calarota, SA; Nieto, D; Moll, T; Carlo, DJ; Moss, RB				Encinas, JA; Janssen, EM; Weiner, DB; Calarota, SA; Nieto, D; Moll, T; Carlo, DJ; Moss, RB			Anti-T-cell 19 and mucin domain-containing protein 1 antibody decreases T(H)2 airway inflammation in a mouse model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; T-cell Ig and mucin domain-containing protein; T(H)2; cytokines	HEPATITIS-A VIRUS; TIM GENE FAMILY; ALLERGIC DISEASES; T-CELLS; HYPERREACTIVITY; INTERLEUKIN-13; ACTIVATION; EXPRESSION; OVEREXPRESSION; IDENTIFICATION	Background: The T-cell Ig and mucin domain-containing (TIM) gene locus has been linked to differences in T(H)2 responsiveness and asthma susceptibility in mice. The homologous locus in human subjects harbors the gene for TIM-1, which encodes a receptor for hepatitis A virus and has been linked with decreased susceptibility to atopic disease in hepatitis A virus-seropositive individuals. Objective: We investigated the effects of administering antibodies against TIM-1 in a mouse model of allergic asthma to determine whether the treatment could downregulate T(H)2 cytokines and reduce pulmonary inflammation. Methods: BALB/c mice were sensitized and challenged with ovalbumin to induce airway inflammation. Before the ovalbumin challenge, mice were treated with anti-TIM-1 mAb or a control antibody. Results: Administration of anti-TIM-1 antibody to mice after ovalbumin sensitization and before ovalbumin challenge results in a significant decrease in inflammatory cells in bronchoalveolar lavage fluid compared with administration of a control antibody. The decrease is accompanied by significantly lower antigen-specific production of the TH2 cytokines IL-10 and IL-13 by cells from the draining lymph nodes. The TO cytokine IFN-gamma appears to be unaffected. Analysis of the lungs shows that goblet cell hyperplasia and mucus production and the expression of IL-10 are markedly decreased in anti-TIM-1-treated mice. Conclusion: The results indicate that anti-TIM-1 might offer a novel approach to treating asthma.	Telos Pharmaceut LLC, San Diego, CA 92131 USA; La Jolla Inst Allergy & Immunol, Dept Dev Immunol, San Diego, CA USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	La Jolla Institute for Immunology; University of Pennsylvania	Encinas, JA (corresponding author), Telos Pharmaceut LLC, 10150 Meanley Dr, San Diego, CA 92131 USA.	jencinas@forestlifesciences.com	Weiner, David B/H-8579-2014; Moss, Richard B./S-9218-2019	Moss, Richard B./0000-0003-3611-4221				BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257, DOI 10.1165/ajrcmb.13.3.7544594; Chae SC, 2003, BIOCHEM BIOPH RES CO, V312, P346, DOI 10.1016/j.bbrc.2003.10.125; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Ichimura T, 1998, J BIOL CHEM, V273, P4135, DOI 10.1074/jbc.273.7.4135; Kaplan G, 1996, EMBO J, V15, P4282, DOI 10.1002/j.1460-2075.1996.tb00803.x; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kuchroo VK, 2003, NAT REV IMMUNOL, V3, P454, DOI 10.1038/nri1111; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lee CG, 2002, J BIOL CHEM, V277, P35466, DOI 10.1074/jbc.M206395200; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; McIntire JJ, 2003, NATURE, V425, P576, DOI 10.1038/425576a; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; Meyers JH, 2005, NAT IMMUNOL, V6, P455, DOI 10.1038/ni1185; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Moss RB, 2004, EXPERT OPIN BIOL TH, V4, P1887, DOI 10.1517/14712598.4.12.1887; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Salvi S, 1999, CLIN EXP ALLERGY, V29, P1597, DOI 10.1046/j.1365-2222.1999.00644.x; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; Umetsu SE, 2005, NAT IMMUNOL, V6, P447, DOI 10.1038/ni1186; Whittaker L, 2002, AM J RESP CELL MOL, V27, P593, DOI 10.1165/rcmb.4838; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Yang X, 2000, EUR J IMMUNOL, V30, P382, DOI 10.1002/1521-4141(200002)30:2<382::AID-IMMU382>3.0.CO;2-L; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	29	51	58	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1343	1349		10.1016/j.jaci.2005.08.031	http://dx.doi.org/10.1016/j.jaci.2005.08.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337469				2022-12-18	WOS:000235687000028
J	De Swerdt, A; Van den Keybus, C; Kasran, A; Cadot, P; Neyens, K; Coorevits, L; Kochuyt, AM; Degreef, H; Ceuppens, JL				De Swerdt, A; Van den Keybus, C; Kasran, A; Cadot, P; Neyens, K; Coorevits, L; Kochuyt, AM; Degreef, H; Ceuppens, JL			Detection of basophil-activating IgG autoantibodies in chronic idiopathic urticaria by induction of CD63	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						autoantibodies; autoimmunity; autologous serum skin test; basophil; basotest; CD63; chronic idiopathic urticaria	FC-EPSILON-RI; HISTAMINE-RELEASE; SERUM; EXPRESSION; CYTOKINES; RECEPTOR; CELL	Background: Approximately 40% to 50% of patients with chronic idiopathic urticaria (CIU) have functional IgG autuantibodies against Fc epsilon RI alpha or IgE, which induce histamine release from basophils and cutaneous mast cells. A positive autologous; serum skin test response is believed to reflect the presence of these autoantibodies. Objective: We sought to further define the functional properties of and develop a sensitive functional assay for detection of autoantibodies in patients with CIU. Methods: Sera from patients with CIU (n = 61) and sera from healthy control subjects (n = 23) were incubated with donor basophils. Activation of basophils was determined on the basis of CD63 surface expression, as analyzed on a FACS can flow cytometer. Results: A positive basophil activation test result was found in 51% of patients with CIU, and basophil-activating properties were present in the IgG fractions of sera. When both the in vitro test and the autologous; serum skin test were considered, basophil/mast cell-activating autoantibodies were present in 62% of the patients. Patients with a positive basophil activation test result had a significantly higher prevalence of other autoantibodies, had more severe urticaria, and were more likely to have angioedema. Conclusion: The results demonstrate the presence of basophil-activating autoantibodies; in about 50% of patients with CIU. The data support the autoimmune cause of the disease and provide a simple test for detection of these autoantibodies.	Univ Hosp Gasthuisberg, Dept Internal Med, Div Allergy & Clin Immunol, B-3000 Louvain, Belgium; Univ Hosp Gasthuisberg, Dept Clin Immunol, B-3000 Louvain, Belgium; Univ Hosp Gasthuisberg, Dept Dermatol, B-3000 Louvain, Belgium	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven	Ceuppens, JL (corresponding author), Univ Hosp Gasthuisberg, Dept Internal Med, Div Allergy & Clin Immunol, Herestr 49, B-3000 Louvain, Belgium.	Ceuppens@uz.kuleuven.ac.be		Ceuppens, Jan/0000-0003-4502-2679				Budde IK, 2001, INT ARCH ALLERGY IMM, V126, P277, DOI 10.1159/000049524; Ebo DG, 2004, CLIN EXP ALLERGY, V34, P332, DOI 10.1111/j.1365-2222.2004.01891.x; Ferrer M, 2003, ALLERGY, V58, P802, DOI 10.1034/j.1398-9995.2003.00195.x; Ferrer M, 2002, INT ARCH ALLERGY IMM, V129, P254, DOI 10.1159/000066772; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; Greaves MW, 2003, CURR OPIN ALLERGY CL, V3, P363, DOI 10.1097/01.all.0000092607.76804.f1; Gyimesi E, 2004, BRIT J DERMATOL, V151, P388, DOI 10.1111/j.1365-2133.2004.06042.x; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Hidvegi B, 2003, INT ARCH ALLERGY IMM, V132, P177, DOI 10.1159/000073719; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; Kikuchi Y, 2002, J ALLERGY CLIN IMMUN, V109, P114, DOI 10.1067/mai.2002.120954; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; Sabroe RA, 2002, J ALLERGY CLIN IMMUN, V110, P492, DOI 10.1067/mai.2002.126782; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446; Sabroe RA, 1999, J AM ACAD DERMATOL, V40, P443, DOI 10.1016/S0190-9622(99)70495-0; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Wedi B, 2000, J ALLERGY CLIN IMMUN, V105, P552, DOI 10.1067/mai.2000.104939; Ying S, 2002, J ALLERGY CLIN IMMUN, V109, P694, DOI 10.1067/mai.2002.123236	19	51	53	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					662	667		10.1016/j.jaci.2005.04.042	http://dx.doi.org/10.1016/j.jaci.2005.04.042			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159640				2022-12-18	WOS:000235686500030
J	Joubert, P; Hamid, Q				Joubert, P; Hamid, Q			Role of airway smooth muscle in air-way remodeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							ASTHMA; CELLS		McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada	McGill University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain, Montreal, PQ H2X 2P2, Canada.			Joubert, Philippe/0000-0001-7784-6387				Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Black JL, 2001, AM J RESP CRIT CARE, V164, pS63, DOI 10.1164/ajrccm.164.supplement_2.2106059; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Hakonarson H, 1999, J CLIN INVEST, V104, P657, DOI 10.1172/JCI7137; Hamid Q, 2004, J ALLERGY CLIN IMMUN, V114, P1479, DOI 10.1016/j.jaci.2004.10.016; Howarth Peter H, 2004, J Allergy Clin Immunol, V114, pS32, DOI 10.1016/j.jaci.2004.04.041; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141, DOI 10.1164/ajrccm.164.1.2008060; Madison JM, 2003, AM J RESP CELL MOL, V29, P8, DOI 10.1165/rcmb.F272; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC	9	51	52	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					713	716		10.1016/j.jaci.2005.05.042	http://dx.doi.org/10.1016/j.jaci.2005.05.042			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159653				2022-12-18	WOS:000235686500043
J	Asturias, JA; Ibarrola, I; Ferrer, A; Andreu, C; Lopez-Pascual, E; Quiralte, J; Florido, F; Martinez, A				Asturias, JA; Ibarrola, I; Ferrer, A; Andreu, C; Lopez-Pascual, E; Quiralte, J; Florido, F; Martinez, A			Diagnosis of Alternaria alternata sensitization with natural and recombinant Alt a 1 allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Alt a 1; diagmpsis; IgE; mold allergy; recombinant allergen; skin prick test	COMPONENT-RESOLVED DIAGNOSIS; MOLECULAR-CLONING; POLLEN EXTRACT; IGE; REACTIVITY; ALT; IMMUNOTHERAPY; EXPRESSION	Background: Diagnosis of Alternaria alternata sensitization is hampered by the variability and complexity of fungal extracts, and thus simplification of the diagnostic procedures with purified allergens should be pursued. Objective: We sought to compare A alternata extract and purified natural Alt a 1 (nAlt a 1) and recombinant Alt a 1 (rAlt a 1) allergens for their diagnostic value. Methods: Forty-two patients allergic to A alternata, 10 atopic patients with negative skin prick test responses to A alternata extract, and 10 healthy subjects were investigated. Skin prick tests and determination of specific IgE levels were performed with nAlt a 1 and 2 different types of rAlt a 1: rbAlt a 1, expressed in Escherichia coli, and ryAlt a 1, expressed in the yeast Yarrowia lipolytica. Results: Prevalence for Alt a 1, Alt a 2, and Alt a 11 by IgE dot-blot testing was 98%, 0%, and 15%, respectively, and therefore Alt a I was used as a marker for A alternata sensitization. Immunoblotting and inhibition analysis showed no IgE-binding differences between nAlt a I and rAlt a 1. The whole group of patients with allergy to A alternata had positive skin test reactions to purified allergens at 100 mu g/mL, whereas no false-positive reactions were detected. Natural or ryAlt a I elicited a similar response in skin tests compared with A alternata extract, although a reduced reactivity was observed with rbAlt a 1. Specific IgE levels to nAlt a I or rAlt a I showed significant correlation and similar sensitivity and specificity. Conclusions: Alt a 1, either in its natural or recombinant form, is sufficient for a reliable diagnosis of A alternata sensitization and induces skin prick reactivity comparable with that produced by A alternata extract.	R&D, Bilbao 48008, Spain; Hosp Vega Baja, Serv Alergia, Alicante, Spain; Hosp Gen Jaen, Serv Alergia, Jaen, Spain		Asturias, JA (corresponding author), R&D, Alameda Urquijo 27, Bilbao 48008, Spain.	juan.asturias@bial.com	IBIS, ALERGICAS/C-1733-2016; Ferrer, Marta/C-4319-2016	Ferrer, Marta/0000-0001-8495-1302; Quiralte, Joaquin/0000-0002-6020-1707; Ferrer, Angel/0000-0001-6567-053X; Asturias, Juan/0000-0001-9570-522X				ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; Asturias JA, 2003, ANN ALLERG ASTHMA IM, V90, P529, DOI 10.1016/S1081-1206(10)61846-7; Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Bush RK, 1999, J ALLERGY CLIN IMMUN, V104, P665, DOI 10.1016/S0091-6749(99)70340-4; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385, DOI 10.1159/000237397; Dominguez A, 1998, Int Microbiol, V1, P131; Esch RE, 2004, J ALLERGY CLIN IMMUN, V113, P210, DOI 10.1016/j.jaci.2003.11.024; Harwanegg C, 2003, CLIN EXP ALLERGY, V33, P7, DOI 10.1046/j.1365-2222.2003.01550.x; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161, DOI 10.1128/CMR.8.2.161; Kuo IC, 2003, J ALLERGY CLIN IMMUN, V111, P603, DOI 10.1067/mai.2003.167; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mari A, 2003, CLIN EXP ALLERGY, V33, P1429, DOI 10.1046/j.1365-2222.2003.01783.x; Mari A, 2003, CLIN EXP ALLERGY, V33, P43, DOI 10.1046/j.1365-2222.2003.01569.x; MARTINEZ J, 1985, SABOURAUDIA, V23, P317; MORIN M, 2003, THESIS SALAMANCA U; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PARIS S, 1990, J ALLERGY CLIN IMMUN, V85, P941, DOI 10.1016/0091-6749(90)90081-E; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; Rossi RE, 2004, INT ARCH ALLERGY IMM, V135, P44, DOI 10.1159/000080042; Schmid-Grendelmeier P, 2001, INT ARCH ALLERGY IMM, V125, P96, DOI 10.1159/000053803; Schmidt M, 2002, INT ARCH ALLERGY IMM, V128, P264, DOI 10.1159/000063865; Simon-Nobbe B, 2000, J ALLERGY CLIN IMMUN, V106, P887, DOI 10.1067/mai.2000.110799; Tresch S, 2003, CLIN EXP ALLERGY, V33, P1153, DOI 10.1046/j.1365-2222.2003.01717.x; Unger A, 1999, INT ARCH ALLERGY IMM, V118, P220, DOI 10.1159/000024076; Vailes LD, 2001, CLIN EXP ALLERGY, V31, P1891, DOI 10.1046/j.1365-2222.2001.00745.x; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Weichel M, 2003, ALLERGY, V58, P198, DOI 10.1034/j.1398-9995.2003.23822.x; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5	31	51	54	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1210	1217		10.1016/j.jaci.2005.02.012	http://dx.doi.org/10.1016/j.jaci.2005.02.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940136				2022-12-18	WOS:000229815400016
J	Hartl, D; Griese, M; Nicolai, T; Zissel, G; Prell, C; Konstantopoulos, N; Gruber, R; Reinhardt, D; Schendel, DJ; Krauss-Etschmann, S				Hartl, D; Griese, M; Nicolai, T; Zissel, G; Prell, C; Konstantopoulos, N; Gruber, R; Reinhardt, D; Schendel, DJ; Krauss-Etschmann, S			Pulmonary chemokines and their receptors differentiate children with asthma and chronic cough	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chemokine; chemokine receptor; bronchoalveolar lavage; children; chronic cough; asthma; CXCR3; CCR4; TARC; MDC	ACTIVATION-REGULATED CHEMOKINE; BRONCHOALVEOLAR LAVAGE FLUID; CELLS IN-VITRO; T-CELLS; EXPRESSION; THYMUS; CCR4; TARC; PROFILES; TYPE-1	Background: Cough is a frequent symptom in children, but the differentiation of asthmatic cough from cough of other origins can be difficult. Chemokines recruit T lymphocytes to inflamed tissues, and the corresponding chemokine receptors are differentially expressed on T(H)1 and T(H)2 cells. Objective: We sought to determine whether levels of T(H)1/T(H)2-related chemokines and their receptors differ in bronchoalveolar lavage fluid (BALF) from 12 children with allergic asthma, 15 nonatopic children with chronic cough, and 10 children without airway disease. Methods: The T(H)1-related (IFN-gamma-inducible protein of 10 kd [IP-10], IFN-gamma-inducible T cell a chemoattractant [ITAC], monokine induced by IFN-gamma [Mig], and IFN-gamma) and T(H)2-related (thymus- and activation-regulated chemokine [TARC], macrophage-derived chemokine [MDC], IL-5, and IL-4) chemokines and cytokines were quantified in BALF by ELISA and a particle-based multiplex array. Percentages of pulmonary lymphocytes expressing CXCR3(+) and CCR5(+) (T(H)1) and CCR4(+) and CCR3(+) (T(H)2) chemokine receptors were determined in BALF by flow cytometry. Results: Pulmonary CCR4(+)CD4(+) cells and levels of TARC and MDC were significantly increased in asthmatic children versus children with chronic cough or without airway disease. In asthmatic children CCR4+CD4+ cells correlated positively with levels of TARC, MDC, and serum IgE levels and negatively with FEV1. In contrast, CXCR3(+)CD8(+) cells and levels of ITAC were significantly increased in children with non-atopic chronic cough compared with the other groups. In children with chronic cough, CXCR3(+)CD8(+) cells correlated with levels of ITAC and IFN-gamma. Conclusion: Pulmonary CCR4(+)CD4(+) and CXCR3(+)CD8(+) cells and their ligands TARC, MDC, and ITAC clearly differentiate asthmatic children from nonatopic children with chronic cough. The analysis of these markers could facilitate the diagnostic discrimination of asthma versus other reasons for chronic cough in children.	Childrens Hosp Ludwig Maximilians Univ, D-80337 Munich, Germany; GSF Natl Res Ctr Environm & Hlth Univ, Clin Operat Grp Pediat Immuneregulat, D-80337 Munich, Germany; Univ Hosp, Ctr Med, Dept Pneumol, Freiburg, Germany; Univ Munich, Med Policlin, Munich, Germany; GSF Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Munich, Germany	University of Munich; University of Freiburg; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Krauss-Etschmann, S (corresponding author), Childrens Hosp Ludwig Maximilians Univ, Lindwurmstr 2A, D-80337 Munich, Germany.	susanne.krauss-etschmann@med.uni-muenchen.de	Zissel, Gernot/B-1208-2010; Krauss-Etschmann, Susanne/H-5198-2018	Zissel, Gernot/0000-0001-8021-9798; Krauss-Etschmann, Susanne/0000-0001-5945-5702				Annunziato F, 1999, J LEUKOCYTE BIOL, V65, P691, DOI 10.1002/jlb.65.5.691; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Berin MC, 2001, AM J RESP CELL MOL, V24, P382, DOI 10.1165/ajrcmb.24.4.4360; Bochner BS, 2003, J ALLERGY CLIN IMMUN, V112, P930, DOI 10.1016/j.jaci.2003.08.012; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Campbell JJ, 2001, J IMMUNOL, V166, P2842, DOI 10.4049/jimmunol.166.4.2842; Clark TJH, 2002, NIH PUBLICATION, P1; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Griese M, 2004, PEDIATR PULM, V37, P356, DOI 10.1002/ppul.10432; HANNAWAY PJ, 1982, JAMA-J AM MED ASSOC, V247, P206, DOI 10.1001/jama.247.2.206; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; KAMEI RK, 1991, PEDIATR CLIN N AM, V38, P593; Kim CH, 2001, J CLIN INVEST, V108, P1331, DOI 10.1172/JCI200113543; Kim CK, 2003, J ALLERGY CLIN IMMUN, V112, P64, DOI 10.1067/mai.2003.1618; Kunkel EJ, 2002, AM J PATHOL, V160, P347, DOI 10.1016/S0002-9440(10)64378-7; Leung TF, 2002, J ALLERGY CLIN IMMUN, V110, P404, DOI 10.1067/mai.2002.126378; Lezcano-Meza D, 2003, ALLERGY, V58, P1125, DOI 10.1034/j.1398-9995.2003.00273.x; Liu LY, 2004, AM J RESP CRIT CARE, V169, P1118, DOI 10.1164/rccm.200312-1659OC; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Marguet C, 2000, AM J RESP CRIT CARE, V162, P1016, DOI 10.1164/ajrccm.162.3.9902101; Marguet C, 1999, AM J RESP CRIT CARE, V159, P1533, DOI 10.1164/ajrccm.159.5.9805028; Misu T, 2001, J NEUROIMMUNOL, V114, P207, DOI 10.1016/S0165-5728(00)00456-2; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; RATJEN F, 1995, AM J RESP CRIT CARE, V152, P174, DOI 10.1164/ajrccm.152.1.7599820; RIEDLER J, 1995, AM J RESP CRIT CARE, V152, P163, DOI 10.1164/ajrccm.152.1.7599817; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Saetta M, 2002, AM J RESP CRIT CARE, V165, P1404, DOI 10.1164/rccm.2107139; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sekiya T, 2000, J IMMUNOL, V165, P2205, DOI 10.4049/jimmunol.165.4.2205; Sekiya T, 2002, ALLERGY, V57, P173, DOI 10.1034/j.1398-9995.2002.1s3256.x	33	51	55	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					728	736		10.1016/j.jaci.2004.11.049	http://dx.doi.org/10.1016/j.jaci.2004.11.049			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15805991				2022-12-18	WOS:000228373400010
J	Barderas, R; Purohit, A; Papanikolaou, I; Rodriguez, R; Pauli, G; Villalba, M				Barderas, R; Purohit, A; Papanikolaou, I; Rodriguez, R; Pauli, G; Villalba, M			Cloning, expression, and clinical significance of the major allergen from ash pollen, Fra e 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fra e 1; histamine release; Ole e 1-like family; Pichia pastoris; recombinant allergen; skin prick test	OLE-E-I; OLIVE TREE POLLEN; CROSS-REACTIVITY; OLEACEAE POLLENS; PICHIA-PASTORIS; MAIN ALLERGEN; PROTEINS; FAMILY; IDENTIFICATION; POLLINOSIS	Background: Ash tree, an Oleaceae member, is considered an important source of pollen allergy in Central Europe. Fra e 1 is a protein of the Ole e 1-like family, which regulates pollen tube growth. It has been suggested to be a relevant allergen from ash pollen. Objective: Cloning Fra e 1-cDNA and overproducing a properly folded recombinant allergen to analyze its clinical significance. Methods: Fra e 1-encoding cDNA was amplified by PCR, cloned in Escherichia coli, and sequenced. The recombinant allergen was produced in Pichia pastoris and used in immunoblotting, ELISA, histamine release, and skin prick tests. Sera and blood cells from patients sensitized to ash pollen as well as anti-Ole e 1 monoclonal and polyclonal antisera were used. Results: Recombinant Fra e 1 (rFra e 1) is a glycoprotein of 145 amino acids exhibiting 82%, 88%, and 91% identity with Syr v 1, Ole e 1, and Lig v 1, allergens of the Oleaceae family. It was secreted to the extracellular medium of the yeast cultures and purified by means of 3 chromatographic steps. IgG from Ole e I-specific antibodies recognized rFra e 1. IgE antibodies from ash-sensitized patients bound to rFra e 1 with a prevalence or 75%. The recombinant allergen induced histamine release. Twenty-nine of 30 ash-sensitized patients were positive to rFra e 1 by skin prick tests. Conclusion: Fra e 1 is a relevant allergen in ash pollen sensitization. It has been efficiently produced in P pastoris and could be used in diagnosis.	Univ Complutense, Fac Ciencias Quim, Dpto Bioquim & Biol Mol, E-28040 Madrid, Spain; Hop Univ Strasbourg, Hop Lyautey, Serv Pneumol, Strasbourg, France	Complutense University of Madrid; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Villalba, M (corresponding author), Univ Complutense, Fac Ciencias Quim, Dpto Bioquim & Biol Mol, E-28040 Madrid, Spain.	mayte@bbm1.ucm.es	RODRIGUEZ, ROSALIA/K-4993-2014; Villalba, Mayte/K-5365-2014; Barderas, Rodrigo/K-3560-2014; Villalba, María Teresa/AAW-1067-2020	RODRIGUEZ, ROSALIA/0000-0002-4280-3691; Barderas, Rodrigo/0000-0003-3539-7469; Villalba, María Teresa/0000-0002-0042-9953				Alche JDD, 1999, J CELL SCI, V112, P2501; BALDO BA, 1992, MOL IMMUNOL, V29, P1209, DOI 10.1016/0161-5890(92)90057-5; Barderas R, 2002, INT ARCH ALLERGY IMM, V127, P47, DOI 10.1159/000048168; BATANERO E, 1994, MOL IMMUNOL, V31, P31, DOI 10.1016/0161-5890(94)90135-X; BATANERO E, 1994, EUR J BIOCHEM, V221, P187, DOI 10.1111/j.1432-1033.1994.tb18728.x; Batanero E, 1996, CLIN EXP ALLERGY, V26, P1401, DOI 10.1046/j.1365-2222.1996.d01-298.x; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; Calabozo B, 2001, CLIN EXP ALLERGY, V31, P322, DOI 10.1046/j.1365-2222.2001.00985.x; DAMATO G, 1988, CLIN ALLERGY, V18, P541, DOI 10.1111/j.1365-2222.1988.tb02905.x; De Blay F., 1996, Revue de Pneumologie Clinique, V52, P79; Gonzalez E, 2001, CLIN EXP ALLERGY, V31, P313, DOI 10.1046/j.1365-2222.2001.00980.x; Gonzalez EM, 2002, MOL IMMUNOL, V39, P93, DOI 10.1016/S0161-5890(02)00044-5; Hemmer W, 2000, ALLERGY, V55, P923, DOI 10.1034/j.1398-9995.2000.00671.x; Huecas S, 1999, EUR J BIOCHEM, V261, P539, DOI 10.1046/j.1432-1327.1999.00307.x; Johnson MA, 2003, TRENDS PLANT SCI, V8, P97, DOI 10.1016/S1360-1385(03)00009-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liccardi G, 1996, INT ARCH ALLERGY IMM, V111, P210, DOI 10.1159/000237370; Liccardi G, 1995, Allergol Immunopathol (Madr), V23, P41; MARTINOROZCO E, 1994, INT ARCH ALLERGY IMM, V104, P160, DOI 10.1159/000236725; Niederberger V, 2002, CLIN EXP ALLERGY, V32, P933, DOI 10.1046/j.1365-2222.2002.01369.x; OBISPO TM, 1993, CLIN EXP ALLERGY, V23, P311, DOI 10.1111/j.1365-2222.1993.tb00328.x; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; Quiralte J, 2002, ALLERGY, V57, P47, DOI 10.1034/j.1398-9995.2002.057s71047.x; Rodriguez R, 2002, ALLERGY, V57, P6, DOI 10.1034/j.1398-9995.2002.057s71006.x; Sambrook J, 1989, MOL CLONING LAB MANU, V1, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANIZAKI Y, 1984, INT ARCH ALLER A IMM, V73, P141, DOI 10.1159/000233454; VALENTA R, 1999, ALLERGENS ALLERGEN I, P85; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P970, DOI 10.1016/S0091-6749(95)70097-8; VILLALBA M, 1994, J BIOL CHEM, V269, P15217; VILLALBA M, 1993, EUR J BIOCHEM, V216, P863, DOI 10.1111/j.1432-1033.1993.tb18208.x; Wahl R, 1996, J ALLERGY CLIN IMMUN, V98, P99, DOI 10.1016/S0091-6749(96)70231-2	33	51	52	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					351	357		10.1016/j.jaci.2004.10.001	http://dx.doi.org/10.1016/j.jaci.2004.10.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696094	Bronze			2022-12-18	WOS:000227043600023
J	Pujols, L; Mullol, J; Alobid, I; Roca-Ferrer, J; Xaubet, A; Picado, C				Pujols, L; Mullol, J; Alobid, I; Roca-Ferrer, J; Xaubet, A; Picado, C			Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin-induced asthma; aspirin-intolerant asthma/rhinitis; aspirin -tolerant asthma/rhinitis; rhinosinusitis; nasal polyps; COX; real-time PCR	PERIPHERAL-BLOOD CELLS; ARACHIDONIC-ACID; EXPRESSION; SYNTHASE; CYCLOOXYGENASE-1; METABOLISM; CLONING	Background: Only dynamic studies can elucidate the discrepancies concerning the expression of the inducible COX-2 gene in inflammatory airway diseases. Objectives: To quantify the expression and spontaneous regulation of COX-1 and COX-2 mRNAs in nasal polyps and nasal mucosa by real-time PCR. Methods: Nasal polyps were obtained from 16 aspirin-tolerant patients with asthma/rhinitis (ATAR) and 18 aspirin-intolerant patients with asthma/rhinitis (AIAR) undergoing nasal polypectomy. Nasal mucosa was obtained from 12 subjects undergoing nasal corrective surgery. All specimens were cut into 3 pieces. One was immediately snap-frozen in liquid nitrogen, and the remaining 2 were left at room temperature for 30 or 60 minutes before freezing. Data are presented as medians and 25th to 75th percentiles of 10(6) cDNA molecules/mug total RNA. Results: Baseline COX-2 mRNA levels were significantly lower in both ATAR (0.45; 0.13-1.20; P < .05) and AIAR (0.24; 0.12-0.41; P < .001) nasal polyps than in nasal mucosa (1.35; 0.52-3.90). COX-2 mRNA expression did not change over time in nasal mucosa but increased significantly in ATAR nasal polyps (P < .05), reaching similar levels to nasal mucosa after 60 minutes. In contrast, COX-2 mRNA showed no significant change over time in AIAR nasal polyps. COX-1 mRNA was higher in nasal polyps than in nasal mucosa, and its expression was not modified over time in any group of patients. Conclusion: These results suggest differential kinetics of COX-2 mRNA between nasal mucosa and nasal polyps. AIAR nasal polyps appear to have a greater abnormality of the COX-2 pathway than ATAR.	Univ Barcelona, Dept Med, Hosp Clin Barcelona,Inst Clin Pneumol & Cirugia T, Inst Invest Biomed August Pi Sunyer, Barcelona, Spain; Univ Barcelona, Dept Med, Hosp Clin Barcelona,Inst Clin Penumol & Cirugia T, Serv Otorinolaringol, Barcelona, Spain; Univ Barcelona, Dept Med, Hosp Clin Barcelona,Serv Pneumol Allergia Resp, Inst Clin Pneumol & Chirugia Toracica, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona	Picado, C (corresponding author), Hosp Clin Barcelona, Serv Pneumol, Villarroel 170, E-08036 Barcelona, Spain.	cpicado@ub.edu	Pujols, Laura/G-8920-2015; /AFX-9519-2022; /AAL-7347-2021; Roca-Ferrer, Jordi/AFQ-4652-2022	Pujols, Laura/0000-0003-3708-5098; Roca-Ferrer, Jordi/0000-0002-9527-2273				Antczak A, 2002, AM J RESP CRIT CARE, V166, P301, DOI 10.1164/rccm.2101021; Casadevall J, 2000, THORAX, V55, P921, DOI 10.1136/thorax.55.11.921; Chambers LS, 2003, AM J PHYSIOL-LUNG C, V285, pL619, DOI 10.1152/ajplung.00416.2002; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Demoly P, 1997, AM J RESP CRIT CARE, V155, P670, DOI 10.1164/ajrccm.155.2.9032211; Demoly P, 1998, CLIN EXP ALLERGY, V28, P278; Fernandez-Morata JC, 2000, CLIN EXP ALLERGY, V30, P1275; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391, DOI 10.1164/ajrccm.161.2.9902034; Mullol J, 2002, J ALLERGY CLIN IMMUN, V109, P824, DOI 10.1067/mai.2002.123534; Picado C, 1999, AM J RESP CRIT CARE, V160, P291, DOI 10.1164/ajrccm.160.1.9808048; Picado C, 2003, ALLERGY, V58, P122, DOI 10.1034/j.1398-9995.2003.23792.x; Picado Cesar, 2002, Curr Allergy Asthma Rep, V2, P488, DOI 10.1007/s11882-002-0089-8; Pierzchalska M, 2003, J ALLERGY CLIN IMMUN, V111, P1041, DOI 10.1067/mai.2003.1491; Redington AE, 2001, THORAX, V56, P351, DOI 10.1136/thorax.56.5.351; Schafer D, 1999, EUR RESPIR J, V13, P638, DOI 10.1183/09031936.99.13363899; Schmid M, 1999, ACTA OTO-LARYNGOL, V119, P277; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sousa AR, 1997, THORAX, V52, P940, DOI 10.1136/thx.52.11.940; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Taha R, 2000, AM J RESP CRIT CARE, V161, P636, DOI 10.1164/ajrccm.161.2.9811063; Vancheri C, 2004, TRENDS IMMUNOL, V25, P40, DOI 10.1016/j.it.2003.11.001; Wu KKY, 1998, LUNG BIOL HEALTH DIS, V114, P129; Yamashita T, 1989, Rhinol Suppl, V8, P15	27	51	54	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					814	819		10.1016/j.jaci.2004.07.050	http://dx.doi.org/10.1016/j.jaci.2004.07.050			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480320				2022-12-18	WOS:000224439100014
J	Benson, M; Carlsson, L; Adner, M; Jernas, M; Rudemo, M; Sjogren, A; Svensson, PA; Uddman, R; Cardell, LO				Benson, M; Carlsson, L; Adner, M; Jernas, M; Rudemo, M; Sjogren, A; Svensson, PA; Uddman, R; Cardell, LO			Gene profiling reveals increased expression of uteroglobin and other anti-inflammatory genes in glucocorticoid-treated nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						polyp; microarray; uteroglobin	NECROSIS-FACTOR-ALPHA; ALLERGIC RHINITIS; SCHOOL-CHILDREN; MESSENGER-RNA; INFLAMMATION; APOPTOSIS; CYTOKINES; RESPONSES; CELLS; DEXAMETHASONE	Background: Treatment with local glucocorticoids (GCs) decreases symptoms and the size of nasal polyps. This might depend on the downregulation of proinflammatory genes, as well as the upregulation of anti-inflammatory genes. Objective: We sought to identify GC-regulated anti-inflammatory genes in nasal polyps. Methods: Affymetrix DNA microarrays were used to analyze the expression of 22,283 genes in 4 nasal polyps before and after local treatment with fluticasone (400 mug/d). Expression of uteroglobin and mammaglobin B was analyzed with real-time PCR in 6 nasal polyps and in nasal biopsy specimens from 6 healthy control subjects. Results: Two hundred three genes had changed in expression in treated polyps, and 139 had known functions: 54 genes were downregulated, and 85 were upregulated. Genes associated with inflammation constituted the largest single functional group. These genes affected key steps in inflammation (eg, immunoglobulin production; antigen processing and presentation; and the chemoattraction and activation of granulocytes, T cells, and B cells). Several proinflammatory genes were downregulated. In contrast, some anti-inflammatory genes were upregulated. The gene that increased most in terms of expression was uteroglobin. This was confirmed with real-time PCR. By contrast, expression of uteroglobin was lower in untreated polyps than in healthy nasal mucosa. Immunohistochemical investigation showed staining of uteroglobin in the epithelium and in seromucous glands in control subjects and in nasal polyps. Conclusion: Upregulation of anti-inflammatory genes, such as uteroglobin, might contribute to the effects of local treatment with GCs in nasal polyps.	Queen Silvia Childrens HOsp, Pediat Allergy Res Grp, SE-41685 Gothenburg, Sweden; Malmo Univ Hosp, Dept Otorhinolaryngol, Lab Clin & Expt Allergy Res, Malmo, Sweden; Sahlgrens Univ Hosp, Res Ctr Endocrinol & Metab, S-41345 Gothenburg, Sweden; Chalmers Univ Technol, Dept Math Stat, S-41296 Gothenburg, Sweden	Queen Silvia Children's Hospital; Lund University; Skane University Hospital; Sahlgrenska University Hospital; Chalmers University of Technology	Benson, M (corresponding author), Queen Silvia Childrens HOsp, Pediat Allergy Res Grp, SE-41685 Gothenburg, Sweden.		Svensson, Per-Arne/R-4626-2019; Carlsson, Lena/F-7570-2018	Carlsson, Lena/0000-0003-4145-6242; Svensson, Per-Arne/0000-0002-6731-806X				Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Benson M, 1997, PEDIATR ALLERGY IMMU, V8, P143, DOI 10.1111/j.1399-3038.1997.tb00168.x; Benson M, 1999, PEDIATR ALLERGY IMMU, V10, P178; Benson M, 2002, CLIN EXP ALLERGY, V32, P301, DOI 10.1046/j.1365-2222.2002.01300.x; Benson M, 2000, J ALLERGY CLIN IMMUN, V106, P307, DOI 10.1067/mai.2000.108111; Berg T, 2002, BIOCHEM BIOPH RES CO, V293, P907, DOI 10.1016/S0006-291X(02)00319-4; Cancedda C, 2002, ANN NY ACAD SCI, V966, P49, DOI 10.1111/j.1749-6632.2002.tb04201.x; Daun JM, 2000, AM J PHYSIOL-REG I, V278, pR855, DOI 10.1152/ajpregu.2000.278.4.R855; Delgado M, 2002, ARCH DERMATOL RES, V294, P190, DOI 10.1007/s00403-002-0313-3; Efron B, 2001, J AM STAT ASSOC, V96, P1151, DOI 10.1198/016214501753382129; Fritz SB, 2003, J ALLERGY CLIN IMMUN, V112, P1057, DOI 10.1016/j.jaci.2003.09.042; Gabrielsson BG, 2002, OBES RES, V10, P608, DOI 10.1038/oby.2002.83; GAMBLE E, 2003, AM J RESP CRIT CARE; Hale G, 2002, MED ONCOL, V19, pS33, DOI 10.1385/MO:19:2S:S33; Hamilos DL, 1999, J ALLERGY CLIN IMMUN, V103, P79, DOI 10.1016/S0091-6749(99)70529-4; Heaney ML, 1998, J LEUKOCYTE BIOL, V64, P135, DOI 10.1002/jlb.64.2.135; Henriksson G, 2001, AM J RHINOL, V15, P1, DOI 10.2500/105065801781329446; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Lohr J, 2003, NAT IMMUNOL, V4, P664, DOI 10.1038/ni939; Mastruzzo C, 2003, J ALLERGY CLIN IMMUN, V112, P37, DOI 10.1067/mai.2003.1586; Maurer M, 2001, HORM METAB RES, V33, P691, DOI 10.1055/s-2001-19142; Meagher LC, 1996, J IMMUNOL, V156, P4422; Miele L, 2003, J CLIN INVEST, V111, P19, DOI 10.1172/JCI200317506; Mygind N, 2000, THORAX, V55, pS79, DOI 10.1136/thorax.55.suppl_2.S79; Obexer P, 2001, ONCOGENE, V20, P4324, DOI 10.1038/sj.onc.1204573; Ohlsson BG, 1996, J CLIN INVEST, V98, P78, DOI 10.1172/JCI118780; Ramirez F, 1996, J IMMUNOL, V156, P2406; RE F, 1994, J EXP MED, V179, P739, DOI 10.1084/jem.179.2.739; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; Schwiebert LA, 1996, J ALLERGY CLIN IMMUN, V97, P143, DOI 10.1016/S0091-6749(96)80214-4; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927, DOI 10.1164/ajrccm.152.3.7545059; Singh G, 2000, ANN NY ACAD SCI, V923, P43; Sohn J, 2003, J CLIN INVEST, V111, P121, DOI 10.1172/JCI200315937; Speed T., 2003, STAT ANAL GENE EXPRE; Suzuki T, 2001, J IMMUNOL, V166, P5567, DOI 10.4049/jimmunol.166.9.5567; Tonko M, 2001, FASEB J, V15, P693, DOI 10.1096/fj.00-0327com; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Webster JC, 2002, ENDOCRINOLOGY, V143, P3866, DOI 10.1210/en.2002-220188; Webster JI, 2002, ANNU REV IMMUNOL, V20, P125, DOI 10.1146/annurev.immunol.20.082401.104914; Yoshida NL, 2002, BIOCHEM BIOPH RES CO, V293, P1254	40	51	53	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1137	1143		10.1016/j.jaci.2004.02.028	http://dx.doi.org/10.1016/j.jaci.2004.02.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208596				2022-12-18	WOS:000222091000020
J	Lee, KS; Jin, SM; Kim, SS; Lee, YC				Lee, KS; Jin, SM; Kim, SS; Lee, YC			Doxycycline reduces airway inflammation and hyperresponsiveness in a murine model of toluene diisocyanate-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						toluene di-isocyanate; matrix metalloproteinase; asthma; doxycycline	CHEMICALLY-MODIFIED TETRACYCLINES; NEUTROPHIL COLLAGENASE MMP-8; ABDOMINAL AORTIC-ANEURYSMS; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; IN-VITRO; BASEMENT-MEMBRANE; PHOSPHATIDYLINOSITOL 3-KINASE; POLYMORPHONUCLEAR NEUTROPHILS; HUMAN EOSINOPHILS	Background: Toluene diisocyanate (TDI) is a leading cause of occupational asthma. Although considerable controversy remains regarding its pathogenesis, TDI-induced asthma is an inflammatory disease of the airways characterized by airway remodeling caused, at least in part, by an excess of extracellular matrix deposition in the airway wall. Matrix metalloproteinases (MMPs) are major proteolytic enzymes that are involved in extracellular matrix turnover because of their ability to cleave all proteins constituting extracellular matrix. Previous studies have reported that MMP-9 might play a role in chronic airway inflammation and remodeling in asthma. Objective: An aim of the current study was to evaluate the effects of MMP-inhibiting antibiotic, doxycycline, and MMP inhibitors on hyperresponsiveness and inflammation of the airways in TDI-induced asthma. Methods: We used a murine model for TDI-induced asthma to examine the effect of doxycycline or MMP inhibitors on bronchial inflammation and airway hyperresponsiveness. Results: The following typical pathophysiologic features are observed in the lungs of the mice: airway inflammation, airway hyperresponsiveness, and increased expression of MMP-9 mRNA and protein. Administration of doxycycline and MMP inhibitors reduced all of these pathophysiologic findings. In addition, the increased phosphorylated Akt but not Akt protein levels in lung tissues after TDI inhalation were significantly reduced by the administration of doxycycline and MMP inhibitors. Conclusion: These findings suggest that doxycycline may reduce airway inflammation and hyperresponsiveness through phosphatidylinositol 3-kinase pathway in a murine model of TDI-induced asthma.	Chonbuk Natl Univ, Sch Med, Dept Internal Med, Res Ctr Allerg Immune Dis, Jeonju 561712, South Korea	Jeonbuk National University	Lee, KS (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Internal Med, Res Ctr Allerg Immune Dis, 634-18 Keumamdong, Jeonju 561712, South Korea.	leeyc@moak.chonbuk.ac.kr						Bendeck MP, 2002, AM J PATHOL, V160, P1089, DOI 10.1016/S0002-9440(10)64929-2; BOSCHETTO P, 1987, J ALLERGY CLIN IMMUN, V80, P261, DOI 10.1016/0091-6749(87)90028-5; Boyle JR, 1998, J VASC SURG, V27, P354, DOI 10.1016/S0741-5214(98)70367-2; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; CHANYEUNG M, 1990, CHEST, V98, pS148, DOI 10.1378/chest.98.5.148S; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Curci JA, 2000, J VASC SURG, V31, P325, DOI 10.1016/S0741-5214(00)90163-0; Curci JA, 1998, J VASC SURG, V28, P1082, DOI 10.1016/S0741-5214(98)70035-7; DELACOURT C, 1995, AM J RESP CRIT CARE, V152, P765, DOI 10.1164/ajrccm.152.2.7633740; Delclaux C, 1996, AM J RESP CELL MOL, V14, P288, DOI 10.1165/ajrcmb.14.3.8845180; Dunzendorfer S, 1998, J LEUKOCYTE BIOL, V64, P828, DOI 10.1002/jlb.64.6.828; Esteve PO, 2002, BIOCHEM BIOPH RES CO, V296, P864, DOI 10.1016/S0006-291X(02)02008-9; Ezeamuzie CI, 2001, AM J RESP CRIT CARE, V164, P1633, DOI 10.1164/ajrccm.164.9.2101104; FIFE RS, 1995, J LAB CLIN MED, V125, P407; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; Golub L M, 1998, Adv Dent Res, V12, P12; GOLUB LM, 1995, J CLIN PERIODONTOL, V22, P100; GOLUB LM, 1991, CRIT REV ORAL BIOL M, V2, P297, DOI 10.1177/10454411910020030201; GREENWALD RA, 1992, J RHEUMATOL, V19, P927; GREENWALD RA, 1988, J ORTHOPAED RES, V6, P695, DOI 10.1002/jor.1100060512; GREENWALD RA, 1987, J RHEUMATOL, V14, P28; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hayashi T, 1996, AM J PATHOL, V149, P1241; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Kumagai K, 1999, J IMMUNOL, V162, P4212; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; LAUHIO A, 1994, CLIN EXP IMMUNOL, V98, P21; Lee YC, 2001, J ALLERGY CLIN IMMUN, V108, P1021, DOI 10.1067/mai.2001.120132; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; LEPPERT D, 1995, J IMMUNOL, V154, P4379; MAPP CE, 1987, B EUR PHYSIOPATH RES, V23, P583; MELTZER S, 1989, J ALLERGY CLIN IMMUN, V83, P960, DOI 10.1016/0091-6749(89)90112-7; Nagase H, 1997, BIOL CHEM, V378, P151; *NCR I LAB AN RES, 1996, GUID CAR US LAB AN; Okada S, 1997, AM J RESP CELL MOL, V17, P519, DOI 10.1165/ajrcmb.17.4.2877; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Park Hae-Sim, 1996, Journal of Korean Medical Science, V11, P314; Petrinec D, 1996, J VASC SURG, V23, P336, DOI 10.1016/S0741-5214(96)70279-3; Ricou B, 1996, AM J RESP CRIT CARE, V154, P346, DOI 10.1164/ajrccm.154.2.8756805; ROCHE WR, 1989, LANCET, V1, P520; Sato T, 2002, CANCER RES, V62, P1025; Seftor REB, 1998, CLIN EXP METASTAS, V16, P217, DOI 10.1023/A:1006588708131; SEPPER R, 1995, CHEST, V107, P1641, DOI 10.1378/chest.107.6.1641; SIBILLE Y, 1993, EUR RESPIR J, V6, P1529; Smith GN, 1996, ARTHRITIS RHEUM, V39, P235, DOI 10.1002/art.1780390209; TAMARGO RJ, 1991, CANCER RES, V51, P672; Tigani B, 2001, EUR J PHARMACOL, V433, P217, DOI 10.1016/S0014-2999(01)01515-1; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; YU LP, 1992, ARTHRITIS RHEUM, V35, P1150, DOI 10.1002/art.1780351007; Zhu XD, 2000, J IMMUNOL METHODS, V240, P157, DOI 10.1016/S0022-1759(00)00192-7	53	51	57	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					902	909		10.1016/j.jaci.2004.03.008	http://dx.doi.org/10.1016/j.jaci.2004.03.008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131573	Bronze			2022-12-18	WOS:000221269000013
J	Camara, AA; Silva, JM; Ferriani, VPL; Tobias, KRC; Macedo, LS; Padovani, MA; Harsi, CM; Cardoso, MRA; Chapman, MD; Arruda, E; Platts-Mills, TAE; Arruda, LK				Camara, AA; Silva, JM; Ferriani, VPL; Tobias, KRC; Macedo, LS; Padovani, MA; Harsi, CM; Cardoso, MRA; Chapman, MD; Arruda, E; Platts-Mills, TAE; Arruda, LK			Risk factors for wheezing in a subtropical environment: Role of respiratory viruses and allergen sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						wheezing; asthma; allergy; mites; cockroach; respiratory viruses; respiratory syncytial virus; rhinovirus; allergens	URBAN NORTHEAST BRAZIL; SYNCYTIAL VIRUS; VIRAL-INFECTIONS; ASCARIS-LUMBRICOIDES; INHALANT ALLERGENS; PRESCHOOL-CHILDREN; YOUNG-CHILDREN; ASTHMA; RHINOVIRUS; IGE	Background: Risk factors for acute wheezing among children in subtropical areas are largely unknown. Objective: To investigate the role of viral infections, allergen sensitization, and exposure to indoor allergens as risk factors for acute wheezing in children 0 to 12 years old. Methods: One hundred thirty-two children 0 to 12 years of age who sought emergency department care for wheezing and 65 children with no history of wheezing were enrolled in this case-control study. Detection of respiratory syncytial virus antigen, rhinovirus and coronavirus RNA, adenovirus, influenza, and parainfluenza antigens was performed in nasal washes. Total IgE and specific IgE to mites, cockroach, cat, and dog were measured with the CAP system. Major allergens from mites, cockroach, cat, and dog were quantified in dust samples by ELISA. Univariate and multivariate analyses were performed by logistic regression. Results: In children under 2 years of age, infection with respiratory viruses and family history of allergy were independently associated with wheezing (odds ratio, 15.5 and 4.2; P=.0001 and P=.008, respectively). Among children 2 to 12 years old, sensitization to inhalant allergens was the major risk factor for wheezing (odds ratio, 2.7; P=.03). High-level allergen exposure, exposure to tobacco smoke, and lack of breast-feeding showed no association with wheezing. Conclusions: Some risk factors for wheezing previously identified in temperate climates were present in a subtropical area, including respiratory syncytial virus infection in infants and allergy in children older than 2 years. Rhinovirus was not associated with wheezing and did not appear to be a trigger for asthma exacerbations.	Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pediat, BR-14049900 Ribeirao Preto, SP, Brazil; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; Indoor Biotechnol Inc, Charlottesville, VA USA; Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil; Univ Sao Paulo, Inst Biomed Sci, Sao Paulo, Brazil; Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Cell & Mol Biol, Sao Paulo, Brazil; Santa Lydia Hosp, Ribeirao Preto, Brazil	Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); University of Virginia; INDOOR Biotechnologies; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Arruda, LK (corresponding author), Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pediat, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.		Ferriani, Virginia PL/E-2209-2012; Arruda, Eurico/E-4101-2012; Cardoso, Maria Regina A/J-7280-2012; Arruda, L. Karla/D-5845-2013	Arruda, L. Karla/0000-0002-7505-210X; Chapman, Martin/0000-0002-0845-3632; Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [R01 AI020565, AI-20565, R37 AI020565] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R37AI020565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALARCON A, 2001, J PEDIATR, V138, P311; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Camelo-Nunes IC, 2001, J ALLERGY CLIN IMMUN, V107, pS230; Carballal Guadalupe, 2002, BMC Pediatr, V2, P6, DOI 10.1186/1471-2431-2-6; Cintra OAL, 2001, J MED VIROL, V65, P408, DOI 10.1002/jmv.2049; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Costa SRR, 2002, J ALLERGY CLIN IMMUN, V109, pS55, DOI 10.1016/S0091-6749(02)81256-8; DEARRUDA E, 1991, J INFECT DIS, V164, P252, DOI 10.1093/infdis/164.2.252; DUFF AL, 1993, PEDIATRICS, V92, P535; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gern JE, 2000, J ALLERGY CLIN IMMUN, V106, P201, DOI 10.1067/mai.2000.108604; GREEN RM, 2002, BRIT MED J, V324, P1; Gwaltney JM, 1997, VIRAL INFECT HUMANS, P815; Hogg JC, 2001, AM J RESP CRIT CARE, V164, pS71, DOI 10.1164/ajrccm.164.supplement_2.2106063; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kidd AH, 1996, J CLIN MICROBIOL, V34, P622, DOI 10.1128/JCM.34.3.622-627.1996; Krawiec ME, 2001, AM J RESP CRIT CARE, V163, P1338, DOI 10.1164/ajrccm.163.6.2005116; Larranaga C, 2000, J MED VIROL, V60, P342, DOI 10.1002/(SICI)1096-9071(200003)60:3&lt;342::AID-JMV14&gt;3.0.CO;2-0; Martinez FD, 2002, PEDIATRICS, V109, P362; MCFADDEN ER, 1985, J APPL PHYSIOL, V58, P564, DOI 10.1152/jappl.1985.58.2.564; Medeiros M, 2003, J ALLERGY CLIN IMMUN, V111, P947, DOI 10.1067/mai.2003.1381; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; Pitkaranta A, 1998, PEDIATRICS, V102, P291, DOI 10.1542/peds.102.2.291; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Ruuskanen Olli, 2002, P515; Sales VS, 2002, J ALLERGY CLIN IMMUN, V109, pS27, DOI 10.1016/S0091-6749(02)81160-5; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Souza LSD, 2003, PEDIATR PULM, V35, P184, DOI 10.1002/ppul.10194; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Strunk RC, 2002, PEDIATRICS, V109, P357; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; WANER JL, 1999, MANUAL CLIN MICROBIO, P936; Weber MW, 1998, TROP MED INT HEALTH, V3, P268, DOI 10.1046/j.1365-3156.1998.00213.x; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396; ZIEGLER T, 1999, MANUAL CLIN MICROBIO, P928	42	51	54	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					551	557		10.1016/j.jaci.2003.11.027	http://dx.doi.org/10.1016/j.jaci.2003.11.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007360	Bronze, Green Published			2022-12-18	WOS:000220144200030
J	Asero, R; Mistrello, G; Roncarolo, D; Amato, S; Falagiani, P				Asero, R; Mistrello, G; Roncarolo, D; Amato, S; Falagiani, P			Analysis of the heat stability of lipid transfer protein from apple	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ORAL ALLERGY SYNDROME; PLANT-DERIVED FOODS; CROSS-REACTIVITY; MAJOR ALLERGEN; PEACH; ROSACEAE		Clin San Carlo, Paderno Dugnano, Rio Negro, Argentina; Lofarma SpA, Milan, Italy		Asero, R (corresponding author), Clin San Carlo, Paderno Dugnano, Rio Negro, Argentina.		Amato, Sandra/AAH-4430-2021	Amato, Sandra/0000-0002-3277-0662				Asero R, 2002, ALLERGY, V57, P900, DOI 10.1034/j.1398-9995.2002.t01-1-23541.x; Asero R, 2001, ANN ALLERG ASTHMA IM, V87, P65, DOI 10.1016/S1081-1206(10)62325-3; Asero R, 1999, ANN ALLERG ASTHMA IM, V83, P377, DOI 10.1016/S1081-1206(10)62834-7; Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; Brenna O, 2000, J AGR FOOD CHEM, V48, P493, DOI 10.1021/jf9906681; Fernandez-Rivas M, 1997, J ALLERGY CLIN IMMUN, V100, P728, DOI 10.1016/S0091-6749(97)70265-3; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; Lindorff-Larsen K, 2001, FEBS LETT, V488, P145, DOI 10.1016/S0014-5793(00)02424-8; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V106, P744, DOI 10.1067/mai.2000.108712	11	51	52	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					1009	1011		10.1016/S0091-6749(03)02006-2	http://dx.doi.org/10.1016/S0091-6749(03)02006-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610497	Bronze			2022-12-18	WOS:000186553300028
J	Ronmark, E; Perzanowski, M; Platts-Mills, T; Lundback, B				Ronmark, E; Perzanowski, M; Platts-Mills, T; Lundback, B			Four-year incidence of allergic sensitization among schoolchildren in a community where allergy to cat and dog dominates sensitization: Report from the Obstructive Lung Disease in Northern Sweden Study Group	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic sensitization; prevalence; incidence; risk factors; schoolchildren	SKIN PRICK TESTS; RESPIRATORY SYMPTOMS; POPULATION-SAMPLE; TEST REACTIVITY; ASTHMA; EXPOSURE; CHILDREN; PREVALENCE; SCHOOL; ATOPY	Background: Exposure to high levels of cat allergen might prevent sensitization. Objective: We sought to measure the incidence of allergic sensitization among schoolchildren living in a dust mite- and cockroach-free environment and the associated risk factors. Methods: In 1996, a longitudinal cohort was established in northern Sweden, including 2454 children aged 7 to 8 years. Children were skin tested, and the testing was repeated 4 years later. Questionnaires were completed yearly. Participation was 88% both in 1996 and 2000. Results: The prevalence of positive skin test results increased from 20.6% at age 7 and 8 years to 30.4% at age 11 and 12 years, a cumulative incidence of 13.8%, and was significantly higher among boys. The incidence was highest for cat (6.0%), timothy grass (5.9%), dog (4.9%), and birch (3.6%). A family history of allergy was the major risk factor for both a positive skin test response at age 7 and 8 years (odds ratio [OR], 1.69; 95% Cl, 1.36-2.10) and for development of a positive skin test response over the next 4 years (OR, 1.67; 95% CI, 1.23-2.28). A significant inverse association between cat and dog ownership and the prevalence of type 1 allergy was found, particularly for those children who had lived with a cat both before age 7 and 8 years and during the next 4 years (OR, 0.44; 95% CI, 0.31-0.61). A similar pattern, although not significant, was found for incident cases. Conclusion: The high incidence of type 1 allergy at this age was similar to reports from communities with mite and cockroach allergen. Despite cat and dog being the most common allergens of sensitization, keeping these animals at home was not associated with an increased risk for sensitization.	Sunderby Cent Hosp Norrbotten, Lulea Hlth Care Ctr, Dept Med, OLIN Study Grp, SE-97239 Lulea, Sweden; Karolinska Inst, Natl Inst Environm Med, Stockholm, Sweden; Umea Univ, Dept Resp Med & Allergy, Umea, Sweden; Univ Virginia, Asthma & Allergy Dis Ctr, Charlottesville, VA USA	Karolinska Institutet; Umea University; University of Virginia	Ronmark, E (corresponding author), Sunderby Cent Hosp Norrbotten, Lulea Hlth Care Ctr, Dept Med, OLIN Study Grp, Repslagaregatan 4-6, SE-97239 Lulea, Sweden.			Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [AI-20565, AI-34607] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, U19AI034607, U01AI034607, R37AI020565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Baldacci S, 1996, ALLERGY, V51, P149, DOI 10.1111/j.1398-9995.1996.tb00055.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; CANONICA GW, 1989, ALLERGY, V44, P1, DOI 10.1111/j.1398-9995.1989.tb00438.x; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Kihlstrom A, 2002, J ALLERGY CLIN IMMUN, V110, P78, DOI 10.1067/mai.2002.125829; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Nilsson L, 1999, ALLERGY, V54, P716, DOI 10.1034/j.1398-9995.1999.00896.x; NORRMAN E, 1994, ALLERGY, V49, P808, DOI 10.1111/j.1398-9995.1994.tb00779.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Patchett K, 1997, J ALLERGY CLIN IMMUN, V100, P755, DOI 10.1016/S0091-6749(97)70269-0; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Plaschke P, 1996, ALLERGY, V51, P461, DOI 10.1111/j.1398-9995.1996.tb00163.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; SIBBALD B, 1990, BRIT J GEN PRACT, V40, P338; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TURNER KJ, 1986, J ALLERGY CLIN IMMUN, V77, P558, DOI 10.1016/0091-6749(86)90345-3; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692	31	51	52	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					747	754		10.1016/S0091-6749(03)01866-9	http://dx.doi.org/10.1016/S0091-6749(03)01866-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564356				2022-12-18	WOS:000185831200015
J	Sutherland, ER; Ellison, MC; Kraft, M; Martin, RJ				Sutherland, ER; Ellison, MC; Kraft, M; Martin, RJ			Elevated serum melatonin is associated with the nocturnal worsening of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						melatonin; circadian rhythm; inflammation	RECEPTOR; LYMPHOCYTES	Background: Increased airway inflammation at night contributes to the nocturnal worsening of asthma. In vitro studies have shown exogenous melatonin to be pro-inflammatory in asthma, but it is unknown whether endogenous melatonin levels are a controller of airway inflammation in nocturnal asthma. Objective: Our aim was to determine 24-hour patterns of serum melatonin and their relationship to overnight decline in physiology in subjects with nocturnal asthma, non-nocturnal asthma, and in healthy controls. Methods: Observational study of pulmonary physiology and melatonin levels in patients with nocturnal asthma (n = 7), non-nocturnal asthma (n = 13), and healthy controls (n = 11). Subjects maintained a constant sleep-wake regimen for 7 days. On day 8, serum melatonin was measured every 2 hours by radioimmunoassay and analyzed by cosinor modeling. The correlation between serum melatonin levels and overnight change in spirometry was evaluated by Spearman's rank correlation analysis. Results: In subjects with nocturnal asthma, peak melatonin levels were significantly elevated compared with healthy controls (67.6 +/- 5.0 pg/mL versus 53.5 +/- 4.0 pg/mL, P = .03). Melatonin acrophase was delayed in nocturnal asthma (02:54 versus 01:58 in healthy controls, P = .003, and 02:15 in non-nocturnal asthma, P = .01). In subjects with nocturnal asthma, increasing melatonin levels were significantly and inversely correlated with overnight change in FEV1 (r = -.79, P = .04), a relationship that was not observed in non-nocturnal asthma or healthy controls. Conclusions: Nocturnal asthma is associated with elevation and phase delay of peak serum melatonin levels. Elevated melatonin levels might contribute to the pathogenesis of nocturnal asthma.	Natl Jewish Med & Res Ctre, Dept Med, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Martin, RJ (corresponding author), 1400 Jackson St,B-116, Denver, CO 80206 USA.		Sutherland, Everett Rand/B-7666-2008		NHLBI NIH HHS [R01 HL 64804, K23 HL 04385] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064804, K23HL004385] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arendt J, 1996, BRIT MED J, V312, P1242, DOI 10.1136/bmj.312.7041.1242; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P577, DOI 10.1164/ajrccm/145.3.577; Cunningham S.J., 1997, EMERG PEDIAT, V10, P33; CZEISLER CA, 1986, SCIENCE, V233, P667, DOI 10.1126/science.3726555; Garcia-Maurino S, 1999, LIFE SCI, V65, P2143, DOI 10.1016/S0024-3205(99)00479-8; GarciaMaurino S, 1997, J IMMUNOL, V159, P574; Halberg F., 1967, CELLULAR ASPECTS BIO, P20, DOI DOI 10.1007/978-3-642-88394-1; Kos-Kudla, 1997, Endocr Regul, V31, P47; Kraft M, 1999, J ALLERGY CLIN IMMUN, V103, P66, DOI 10.1016/S0091-6749(99)70527-0; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Landstra AM, 2002, AM J RESP CRIT CARE, V165, P708, DOI 10.1164/ajrccm.165.5.2102115; MARTIN RJ, 1990, AM REV RESPIR DIS, V141, P33, DOI 10.1164/ajrccm/141.1.33; Martin RJ, 1999, CHRONOBIOL INT, V16, P623, DOI 10.3109/07420529908998731; Martins E, 2001, J PINEAL RES, V31, P363, DOI 10.1034/j.1600-079X.2001.310412.x; PINCUS DJ, 1995, J ALLERGY CLIN IMMUN, V95, P1172, DOI 10.1016/S0091-6749(95)70073-0; RAHAMIMOFF R., 1965, LIFE SCI, V4, P1383, DOI 10.1016/0024-3205(65)90016-0; *SAS I INC, 1999, SAS STAT US GUID VER, P2419; Shaji AV, 1998, CLIN EXP IMMUNOL, V111, P181; Sutherland ER, 2002, AM J RESP CRIT CARE, V166, P1055, DOI 10.1164/rccm.200204-356OC; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; VanKeimpema ARJ, 1997, RESPIRATION, V64, P29; Weekley L B, 1995, Clin Auton Res, V5, P53, DOI 10.1007/BF01845499	23	51	57	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					513	517		10.1067/mai.2003.1679	http://dx.doi.org/10.1067/mai.2003.1679			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679809				2022-12-18	WOS:000185231200009
J	Logan, MR; Lacy, P; Bablitz, B; Moqbel, R				Logan, MR; Lacy, P; Bablitz, B; Moqbel, R			Expression of eosinophil target SNAREs as potential cognate receptors for vesicle-associated membrane protein-2 in exocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil exocytosis; SNARES; SNAP-23; syntaxin-4; confocal microscopy; subcellular fractionation	PLATELET EXOCYTOSIS; NONNEURONAL TISSUES; 3T3-L1 ADIPOCYTES; INTERFERON-GAMMA; MAST-CELLS; SNAP-23; SYNTAXIN-4; IDENTIFICATION; SECRETION; RELEASE	Background: Exocytosis of eosinophil granule-derived mediators is thought to be an important effector response contributing to allergic inflammation. Secretion from many cell types has been shown to be dependent on the formation of a docking complex composed of soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP) receptors (SNAREs) located on the vesicle (v-SNAREs) and the target membrane (t-SNAREs). The SNARE isoforms VAMP-2, SNAP-23, and syntaxin-4 have been described in secretory processes in myeloid cells. Previously, we have demonstrated that the v-SNARE VAMP-2 is a candidate v-SNARE involved in eosinophil exocytosis and is localized to a pool of RANTES-positive vesicles that translocate to the cell periphery after IFN-gamma-induced degranulation. Objective: We sought to determine whether eosinophils express the t-SNARE isoforms SNAP-23 and syntaxin-4 as potential binding targets for VAMP-2 during exocytosis. Methods: Human peripheral blood eosinophils (>97%) from atopic subjects were subjected to RT-PCR and sequence analysis by using specific primers for SNAP-23 and syntaxin-4. Protein expression and localization was determined by means of Western blot analysis of eosinophil subcellular fractions and confirmed with confocal laser scanning microscopy. Results: Nucleotide sequences obtained from PCR products exhibited nearly identical (>95%) homology with reported sequences for human SNAP-23 and syntaxin-4. Both SNAP-23 and syntaxin-4 were present in plasma membranes, with some staining in endoplasmic reticulum and Golgi membranes. Negligible expression was detected in crystalloid and small secretory granules. Conclusions: The plasma membrane-associated t-SNAREs SNAP-23 and syntaxin-4 are expressed in human eosinophils and are likely candidates for association with VAMP-2 during docking, which is followed by exocytosis. These findings support a role for SNARE molecules in eosinophil mediator release.	Univ Alberta, Heritage Med Res Ctr 550A, Pulm Res Grp, Dept Med, Edmonton, AB T6G 2S2, Canada	University of Alberta	Moqbel, R (corresponding author), Univ Alberta, Heritage Med Res Ctr 550A, Pulm Res Grp, Dept Med, Edmonton, AB T6G 2S2, Canada.		Lacy, Paige/A-6021-2010	Lacy, Paige/0000-0001-8885-6011				BACH MK, 1992, AGENTS ACTIONS, V35, P1, DOI 10.1007/BF01990944; BRUMELL JH, 1995, J IMMUNOL, V155, P5750; CAPRON M, 1989, INT ARCH ALLER A IMM, V88, P54, DOI 10.1159/000234748; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; DVORAK AM, 1991, AM J PATHOL, V138, P69; Erjefalt JS, 1999, AM J RESP CRIT CARE, V160, P304, DOI 10.1164/ajrccm.160.1.9809048; Feng D, 2001, J HISTOCHEM CYTOCHEM, V49, P293, DOI 10.1177/002215540104900303; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; Hackam DJ, 1996, J IMMUNOL, V156, P4377; Hoffmann HJ, 2001, BIOCHEM BIOPH RES CO, V282, P194, DOI 10.1006/bbrc.2001.4499; Jagadish MN, 1996, BIOCHEM J, V317, P945, DOI 10.1042/bj3170945; Kawanishi M, 2000, J BIOL CHEM, V275, P8240, DOI 10.1074/jbc.275.11.8240; LACY P, 1995, J CELL SCI, V108, P3547; Lacy P, 1999, IMMUNOLOGY, V98, P244; Lacy P, 1999, BLOOD, V94, P23, DOI 10.1182/blood.V94.1.23.413k13_23_32; Lacy P, 1998, BLOOD, V91, P2508, DOI 10.1182/blood.V91.7.2508.2508_2508_2516; Lacy P, 2001, J ALLERGY CLIN IMMUN, V107, P671, DOI 10.1067/mai.2001.113562; Lemons PP, 1997, BLOOD, V90, P1490, DOI 10.1182/blood.V90.4.1490.1490_1490_1500; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Martin-Martin B, 2000, BLOOD, V96, P2574; Mollinedo F, 1997, BIOCHEM BIOPH RES CO, V231, P808, DOI 10.1006/bbrc.1997.6196; Paumet F, 2000, J IMMUNOL, V164, P5850, DOI 10.4049/jimmunol.164.11.5850; RALSTON E, 1994, J BIOL CHEM, V269, P15403; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rossetto O, 1996, J CELL BIOL, V132, P167, DOI 10.1083/jcb.132.1.167; SEELIG HP, 1994, MOL CELL BIOL, V14, P2564, DOI 10.1128/MCB.14.4.2564; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TOMASSINI M, 1991, J ALLERGY CLIN IMMUN, V88, P365, DOI 10.1016/0091-6749(91)90099-A; Valdez AC, 1999, J CELL SCI, V112, P845; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6	34	51	52	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					299	306		10.1067/mai.2002.121453	http://dx.doi.org/10.1067/mai.2002.121453			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842301				2022-12-18	WOS:000174232600016
J	Crespo, JF; Rodriguez, J; Vives, R; James, JM; Reano, M; Daroca, P; Burbano, C; Muzquiz, M				Crespo, JF; Rodriguez, J; Vives, R; James, JM; Reano, M; Daroca, P; Burbano, C; Muzquiz, M			Occupational IgE-mediated allergy after exposure to lupine seed flour	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lupine; hypersensitivity; legume; occupational; asthma; bronchial provocation test	ASTHMA; INHALATION	The ingestion of lupine seed flour (LSF) has been reported as a cause of allergic reactions, particularly in patients sensitized to peanut, but there is little evidence of its allergenic potential after inhalation. We sought to evaluate the clinical and immunologic reactivity to lupine in employees working with this seed flour. An occupational history was obtained in 7 subjects (median age, 35 years) working with LSF at an agricultural research center. Three subjects (1, 6, and 7) reported work-related allergy symptoms immediately after being exposed to lupine. Skin prick test results with LSF extract were positive in these 3 patients with work-related symptoms. Moreover, lupine-specific IgE antibodies were detected in subjects 6 and 7. In subject 6, the controlled exposure to LSF elicited immediate naso-ocular symptoms without changes in FEV1. In subject 7, a bronchial provocation with LSF extract elicited an immediate fall (25%) in FEV1. Double-blinded, placebo-controIled LSF oral challenge results were positive in subjects 6 and 7. Immunologic reactivity to other legumes was detected in subjects 6 and 7, but specific inhalation testing and oral challenge results were negative. Thus, the inhalation of lupine flour could be an important cause of allergic sensitization in exposed workers and might give rise to occupational asthma and food allergy.	Hosp Univ Doce de Octubre, Serv Alergia, Madrid, Spain; Colorado Allergy & Asthma Ctr, Ft Collins, CO USA; Inst Nacl Invest & Tecnol Agr & Alimentaria, Madrid, Spain	Hospital Universitario 12 de Octubre; Instituto Nacional Investigacion Tecnologia Agraria Alimentaria (INIA)	Crespo, JF (corresponding author), Hosp Univ Doce de Octubre, Serv Alergia, Ctra Andalucia Km 5400, Madrid, Spain.							BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Gutierrez D, 1997, CONTACT DERMATITIS, V36, P311, DOI 10.1111/j.1600-0536.1997.tb00012.x; HEFLE SL, 1994, J ALLERGY CLIN IMMUN, V94, P167, DOI 10.1016/0091-6749(94)90036-1; LYBARGER JA, 1982, J ALLERGY CLIN IMMUN, V69, P448, DOI 10.1016/0091-6749(82)90120-8; Matheu V, 1999, ANN ALLERG ASTHMA IM, V83, P406, DOI 10.1016/S1081-1206(10)62838-4; Moneret-Vautrin DA, 1999, J ALLERGY CLIN IMMUN, V104, P883, DOI 10.1016/S0091-6749(99)70303-9; MoneretVautrin DA, 1996, REV MED INTERNE, V17, P551, DOI 10.1016/0248-8663(96)83091-8; Novembre E, 1999, J ALLERGY CLIN IMMUN, V103, P1214, DOI 10.1016/S0091-6749(99)70203-4; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; Rodriguez J, 1997, ALLERGY, V52, P866, DOI 10.1111/j.1398-9995.1997.tb02159.x	10	51	53	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					295	297		10.1067/mai.2001.116860	http://dx.doi.org/10.1067/mai.2001.116860			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496250				2022-12-18	WOS:000170584600022
J	Lonnkvist, K; Hellman, C; Lundahl, J; Hallden, G; Hedlin, G				Lonnkvist, K; Hellman, C; Lundahl, J; Hallden, G; Hedlin, G			Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: Impact of budesonide treatment and withdrawal	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						budesonide; withdrawal; cessation; eosinophil cationic protein; eosinophil peroxidase; eosinophil protein X; eosinophils; children; asthma; animal dander allergy; bronchial hyperresponsiveness	CATIONIC PROTEIN; PERIPHERAL-BLOOD; MILD ASTHMA; INFLAMMATION; CHILDREN; PURIFICATION; EXACERBATION; PEROXIDASE	Background: Markers of airway inflammation are needed for prediction of asthma deterioration and evaluation of disease severity. Few studies have focused on the dynamics of airway inflammation as reflected by the activity of the eosinophils and their proteins after withdrawal of inhaled corticosteroids, Objective: Our goal was to investigate the effect of withdrawal of inhaled budesonide on eosinophil count in blood and eosinophil proteins in serum and urine and to relate the levels of these markers to the risk of symptoms of asthma, increased bronchial hyperresponsiveness, and deterioration of lung function. Methods: Thirty-three children were randomly selected to continue or discontinue use of inhaled budesonide in a double-blind, placebo-controlled study They H ere followed up for 4 months with regular analysis of blood, serum, and urine samples; lung function; and methacholine challenges. Eosinophil activity markers were analyzed. Age-matched healthy children provided reference data for all parameters measured. Results: The eosinophil number in blood and eosinophil protein Levels in serum (serum eosinophil cationic protein [ECP] and serum eosinophil peroxidase [EPO]) increased significantly in the withdrawal group, and the difference between the groups was significant (P = .02 for all). Twenty-nine percent of the children in the withdrawal group remained symptom free. This subgroup had eosinophil counts at baseline below 350/muL, a serum ECP level below 15 mug/L, and a serum EPO le, el below 25 mug/L, each of which was related to a low risk of exacerbation (relative risk = 0.37, 0.48, and 0.37 respectively; P < .05 for all). All eosinophil markers were lower in the healthy children than in the symptom-free children with asthma, Conclusion: Our data indicate that eosinophil count and/or ECP and EPO levels can be used to estimate the short-term risk of deterioration and the need for corticosteroid treatment in cases of mild and moderate allergic asthma.	Astrid Lindgren Childrens Hosp, Karolinska Hosp, S-17176 Stockholm, Sweden; Karolinska Hosp, Div Clin Immunol, Dept Lab Med, S-10401 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Lonnkvist, K (corresponding author), Astrid Lindgren Childrens Hosp, Karolinska Hosp, Q2-05, S-17176 Stockholm, Sweden.							BJORNSSON E, 1994, ALLERGY, V49, P730, DOI 10.1111/j.1398-9995.1994.tb02095.x; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Fernvik E, 1996, ALLERGY, V51, P697; Fujisawa T, 1998, CLIN EXP ALLERGY, V28, P19; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Hallden G, 1999, CLIN EXP ALLERGY, V29, P595; Hallden G, 1999, ANN ALLERG ASTHMA IM, V83, P413, DOI 10.1016/S1081-1206(10)62839-6; HALLDEN G, 1993, ACI NEWS, V5, P139; HEDLIN G, 1992, PEDIAT ALLERG IMM-UK, V3, P144; Hoekstra MO, 1998, PEDIATR ALLERGY IMMU, V9, P143, DOI 10.1111/j.1399-3038.1998.tb00361.x; in't Veen JCCM, 1999, AM J RESP CRIT CARE, V160, P93; JANSON C, 1992, RESP MED, V86, P101, DOI 10.1016/S0954-6111(06)80223-4; Jatakanon A, 1998, EUR RESPIR J, V12, P1084, DOI 10.1183/09031936.98.12051084; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; Kuwasaki T, 1998, INT ARCH ALLERGY IMM, V117, P77, DOI 10.1159/000053578; Lonnkvist K, 1999, PEDIAT ALLERG IMM-UK, V10, P45, DOI 10.1034/j.1399-3038.1999.101001.x; Martinez FD, 1998, J ALLERGY CLIN IMMUN, V102, P915, DOI 10.1016/S0091-6749(98)70328-8; OLSEN RL, 1983, BIOCHEM J, V209, P781, DOI 10.1042/bj2090781; Rubira N, 1997, ANN ALLERG ASTHMA IM, V78, P394; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; WILSON JW, 1994, AM J RESP CRIT CARE, V149, P86, DOI 10.1164/ajrccm.149.1.8111605; Wood JJ, 1998, AM J RESP CRIT CARE, V157, P99, DOI 10.1164/ajrccm.157.1.9704125; ZIMMERMAN B, 1993, CLIN EXP ALLERGY, V23, P564, DOI 10.1111/j.1365-2222.1993.tb00895.x	27	51	55	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					812	817		10.1067/mai.2001.114246	http://dx.doi.org/10.1067/mai.2001.114246			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344347				2022-12-18	WOS:000168812300008
J	Htut, T; Higenbottam, TW; Gill, GW; Darwin, R; Anderson, PB; Syed, N				Htut, T; Higenbottam, TW; Gill, GW; Darwin, R; Anderson, PB; Syed, N			Eradication of house dust mite from homes of atopic asthmatic subjects: A double-blind trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic asthma; indoor allergens; house dust mites; Der p 1; Der p 2; histamine challenge; combined steam-heat cleaning; environmental control	PEAK EXPIRATORY FLOW; ALLERGEN AVOIDANCE; MECHANICAL VENTILATION; CHILDREN; ENCASEMENT; DWELLINGS	Background: House dust mite (HDM) allergens can accumulate to very high levels in homes. From the observed sensitivity of HDMs to heat and their allergens to steam, a novel treatment of furnishings has been developed. Objective: We sought to determine whether combined steam and heat treatment of home furnishings reduced asthmatic patients' bronchial hyperreactivity (BHR) and lowered HDR-I antigen loads. Methods: The homes of 30 asthmatic subjects aged 18 to 45 years were randomly allocated into 3 groups. In groups 1 and 2 mattresses and duvets were treated with hut sir (110 degreesC), followed by steam and then heat again. All their carpets were steam cleaned. Group 2 also had a special ventilation system installed above each patient's bedroom. The homes of subjects in group 3 were sham treated. Neither patient nor laboratory staff was aware of the types of treatment. Der p 1 and 2 levels in the household dust from the lounge, bedroom carpet, and beds were determined before and after treatment and thm at 6 and 12 months. BHR, measured by using: histamine PD20 values, was recorded during the l-Reek run-in period and at 3, 6, 9, 12 months after treatment Results: Active heat-steam treatment of homes caused a sustained reduction of Der p 1 (P =.003) and Her p 2 (P =.001) compared with no change in sham-treated group 3 homes, Patients whose homes were treated showed a 4-fold reduction in BHR at 9 months in group 1 and throughout the posttreatment period in group 2. No change was observed in the asthmatic subjects whose homes were not treated. These improvements were sustained for 12 months in the homes with bedroom ventilation units. Conclusions: A single treatment of home furnishings reduced mite allergen load to below the risk level for sensitization and improved the asthmatic patients' BHR by 4-fold.	Univ Sheffield, Sch Med, Div Clin Sci CSUHT, Sheffield S10 2RX, S Yorkshire, England; No Gen Hosp, Chest Clin, Sheffield S5 7AU, S Yorkshire, England	University of Sheffield; Northern General Hospital	Higenbottam, TW (corresponding author), Univ Sheffield, Sch Med, Div Clin Sci CSUHT, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.							BARNES N, 1996, EUR RESPIR REV, V6, P31; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COLLOFF MJ, 1995, CLIN EXP ALLERGY, V25, P1061, DOI 10.1111/j.1365-2222.1995.tb03252.x; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; DIETEMANN A, 1993, J ALLERGY CLIN IMMUN, V91, P738, DOI 10.1016/0091-6749(93)90193-J; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Fletcher AM, 1996, CLIN EXP ALLERGY, V26, P1051, DOI 10.1111/j.1365-2222.1996.tb00643.x; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; GARDNER SB, 1991, CIA CONFIDENCE INTER; GREGG I, 1989, BMJ-BRIT MED J, V298, P1071, DOI 10.1136/bmj.298.6680.1071; HTUT T, 1997, THORAX S6, V53, pP34; Htut Tin, 1996, International Journal of Environmental Health Research, V6, P233, DOI 10.1080/09603129609356894; HYLAND ME, 1995, THORAX, V50, P724, DOI 10.1136/thx.50.7.724; JOOMA OF, 1995, S AFR MED J, V85, P1002; KALRA S, 1993, THORAX, V48, P10, DOI 10.1136/thx.48.1.10; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; Niven RM, 1999, J ALLERGY CLIN IMMUN, V103, P756, DOI 10.1016/S0091-6749(99)70416-1; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; RODRIGUEZROISIN R, 1996, EUR RESPIR REV, V6, P19; SIEBERS R, 1997, LANCET S, P350; vanderHeide S, 1997, ALLERGY, V52, P921, DOI 10.1111/j.1398-9995.1997.tb01252.x; WALSHAW MJ, 1986, Q J MED, V58, P199; WARNER JA, 1993, CLIN EXP ALLERGY, V23, P279, DOI 10.1111/j.1365-2222.1993.tb00323.x; Weeks J, 1995, CLIN EXP ALLERGY, V25, P1179, DOI 10.1111/j.1365-2222.1995.tb03041.x	30	51	56	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					55	60		10.1067/mai.2001.111240	http://dx.doi.org/10.1067/mai.2001.111240			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11149991				2022-12-18	WOS:000166533300010
J	Yoshida, S; Ishizaki, Y; Onuma, K; Shoji, T; Nakagawa, H; Amayasu, H				Yoshida, S; Ishizaki, Y; Onuma, K; Shoji, T; Nakagawa, H; Amayasu, H			Selective cyclo-oxygenase 2 inhibitor in patients with aspirin-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; AOKI Int Med Ctr, Hirosaki, Aomori, Japan; Hirosaki Univ, Sch Med, Hirosaki, Aomori 036, Japan	Harvard University; Harvard Medical School; Hirosaki University	Yoshida, S (corresponding author), Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9	2	51	53	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1201	1202		10.1067/mai.2000.110926	http://dx.doi.org/10.1067/mai.2000.110926			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112909	Bronze			2022-12-18	WOS:000165930300028
J	Gruchalla, R				Gruchalla, R			Understanding drug allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Advances in Allergic Diseases - An Update for the New Millennium	FEB 11, 1999	WASHINGTON, D.C.			adverse drug reactions; allergic drug reactions; drug allergy; drug desensitization; haptens; hypersensitivity reactions; toxicity	SULFAMETHOXAZOLE; DESENSITIZATION; HYPERSENSITIVITY; DIAGNOSIS	At this time, the incidence of adverse drug reactions can only be estimated because the intensive monitoring and documenting that is required to make this determination does not exist at most hospitals and clinics, Despite these limitations, a metaanalysis of prospective studies has estimated the incidence of serious adverse drug reactions in hospitalized patients to be 6.7% and the incidence of fatal adverse drug reactions to be 0.32%, When evaluating and managing the condition of a patient who has experienced an adverse drug reaction, the physician first obtains an accurate history and performs a careful physical examination to determine whether the reaction was immunologic in nature. Drug reactions that are immunologically mediated (1) require a period of sensitization, (2) occur in a small proportion of the population, (3) are elicited at drug doses far below the therapeutic range, and (4) subside after drug discontinuation in most instances. All possible culprit drugs should be identified, with dosages and dates of administration and discontinuation, and the patient should be asked about any previous drug exposure history. Although immunodiagnostic tests for allergic drug reactions are limited, several tests do exist and may be useful in the identification of drug-specific antibodies, drug-specific T lymphocytes, or mediators from activated cells. If the reaction was not consistent with an IgE-mediated event and if it did not involve serious organ damage, cautious rechallenge may be considered. Far those reactions that appear to be IgE-mediated and for which there is no reliable skin test reagent, drug desensitization may be performed by allergists who are trained in this procedure.	Univ Texas, SW Med Ctr, Div Allergy & Immunol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gruchalla, R (corresponding author), Univ Texas, SW Med Ctr, Div Allergy & Immunol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							ABSAR N, 1994, J ALLERGY CLIN IMMUN, V93, P1001, DOI 10.1016/S0091-6749(94)70048-6; ANNE S, 1994, ANN ALLERGY, V73, P402; BERNSTEIN IL, 1999, ANN ALLERGY ASTHMA 3, P83; BIGBY M, 1986, JAMA-J AM MED ASSOC, V256, P3358; BRANDT MA, 1993, J ALLERGY CLIN IMMUN, V91, P263; deShazo RD, 1997, JAMA-J AM MED ASSOC, V278, P1895, DOI 10.1001/jama.278.22.1895; EMPEDRAD RB, 1922, J ALLERGY CLIN IMMUN, V105, pS272; Gell PGH., 1975, CLIN ASPECTS IMMUNOL, V3; Gruchalla R. S., 1998, Clinical and Experimental Allergy, V28, P63; Gruchalla RS, 1998, J ALLERGY CLIN IMMUN, V101, P371, DOI 10.1016/S0091-6749(98)70250-7; Hunziker T, 1997, ALLERGY, V52, P388, DOI 10.1111/j.1398-9995.1997.tb01017.x; KEARNS GL, 1994, J PEDIATR-US, V125, P805, DOI 10.1016/S0022-3476(94)70112-1; KENNA JG, 1991, BIOCHEM SOC T, V19, P191, DOI 10.1042/bst0190191; Khoury L, 1996, J ALLERGY CLIN IMMUN, V98, P462, DOI 10.1016/S0091-6749(96)70172-0; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LITT J, 1995, DRUG ERUPTION REFERE; MARTIN JL, 1993, HEPATOLOGY, V18, P858, DOI 10.1002/hep.1840180417; MEEKINS CV, 1994, J ALLERGY CLIN IMMUN, V94, P1017, DOI 10.1016/0091-6749(94)90120-1; NARANJO CA, 1992, J CLIN PHARMACOL, V32, P897, DOI 10.1002/j.1552-4604.1992.tb04635.x; Nyfeler B, 1997, CLIN EXP ALLERGY, V27, P175, DOI 10.1111/j.1365-2222.1997.tb00690.x; PARK BK, 1987, BIOCHEM PHARMACOL, V36, P581; RIEDER MJ, 1988, J PHARMACOL EXP THER, V244, P724; RIEDER MJ, 1995, J ACQ IMMUN DEF SYND, V8, P134, DOI 10.1097/00042560-199502000-00004; SHEAR NH, 1990, ARCH DERMATOL, V126, P94, DOI 10.1001/archderm.126.1.94; Solensky R, 1999, J ALLERGY CLIN IMMUN, V103, pS33; SPIELBERG SP, 1984, FED PROC, V43, P2308; SULLIVAN TJ, 1989, J ALLERGY CLIN IMMUN, V83, P270; SULLIVAN TJ, 1994, ANN ALLERGY, V73, P375; Sullivan TJ, 1993, ALLERGY PRINCIPLES P, P1726; Weiss ME, 1998, IMMUNOL ALLERGY CLIN, V18, P731, DOI 10.1016/S0889-8561(05)70035-7	31	51	54	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	2	S			S637	S644		10.1067/mai.2000.106156	http://dx.doi.org/10.1067/mai.2000.106156			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	328QU	10856171				2022-12-18	WOS:000087862200009
J	Cadot, P; Diaz, JF; Proost, P; Van Damme, J; Engelborghs, Y; Stevens, EAM; Ceuppens, JL				Cadot, P; Diaz, JF; Proost, P; Van Damme, J; Engelborghs, Y; Stevens, EAM; Ceuppens, JL			Purification and characterization of an 18-kd allergen of birch (Betula verrucosa) pollen: Identification as a cyclophilin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; birch pollen; chromatography; cyclophilin; peptidyl-prolyl isomerase	CIS-TRANS ISOMERASE; ARABIDOPSIS-THALIANA; MAJOR ALLERGEN; PEPTIDYLPROLYL CIS; PLANT ORGANELLES; BINDING-PROTEIN; CYCLOSPORIN-A; GENE FAMILY; IGE-BINDING; BET-V-1	Background: Five birch pollen allergens have been identified so far. In a previous study we detected new birch pollen allergens with an isoelectric point in the range 9.0 to 9.3, present only in extracts prepared at controlled basic pH. Objective: The purpose of the current study was to purify and characterize those allergens. Methods: The target allergens were purified by ion exchange and hydrophobic interaction chromatography. Analyses were carried out by SDS-PAGE, isoelectric focusing, immunoblotting, and amino acid sequencing. The in vivo reactivity of the allergens was evaluated by skin testing. Results: An 18-kd protein, which we named Bet v 7, was purified. This 18-kd protein corresponded to 3 bands on isoelectric-focusing immunoblots that probably represent isoforms. On immunoblots up to 20.8 % of birch pollen-allergic patients recognized those allergens. The clinical relevance of Bet v 7 was demonstrated by positive immediate-type skin testing on a patient allergic to birch pollen. Sequencing of an internal peptide yielded an amino acid sequence showing high homology with various plant cyclophilins. The rotamase activity of the protein, inhibited by cyclosporin A, further confirmed that Bet v 7 belongs to the group of cyclophilins. Conclusion: We have purified a novel allergen of birch pollen, Bet v 7, belonging to the cyclophilin family. Because cyclophilins are highly conserved proteins over the phylogeny, we may postulate that Bet v 7 is a member of a new family of panallergens.	Katholieke Univ Leuven, Expt Immunol Lab, Fac Med, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Biomol Dynam, Fac Sci, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium	KU Leuven; KU Leuven; KU Leuven	Cadot, P (corresponding author), Katholieke Univ Leuven, Expt Immunol Lab, Fac Med, Gasthuisberg O&N,Herestr 49, B-3000 Louvain, Belgium.		Díaz, J. Fernando/U-3532-2017; Proost, Paul/V-3052-2017; Díaz, J. Fernando/M-6853-2019	Díaz, J. Fernando/0000-0003-2743-3319; Proost, Paul/0000-0002-0133-5545; Díaz, J. Fernando/0000-0003-2743-3319; Ceuppens, Jan/0000-0003-4502-2679				Appenzeller U, 1999, INT ARCH ALLERGY IMM, V118, P193, DOI 10.1159/000024064; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BREIMAN A, 1992, J BIOL CHEM, V267, P21293; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CADOT P, 1995, ALLERGY, V50, P431, DOI 10.1111/j.1398-9995.1995.tb01173.x; Chou IT, 1997, PLANT MOL BIOL, V35, P873, DOI 10.1023/A:1005930024796; Crameri R, 1999, Contrib Microbiol, V2, P44; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Engel E, 1997, J BIOL CHEM, V272, P28630, DOI 10.1074/jbc.272.45.28630; FAHLBUSCH B, 1995, INT ARCH ALLERGY IMM, V108, P119, DOI 10.1159/000237128; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; GASSER CS, 1990, P NATL ACAD SCI USA, V87, P9519, DOI 10.1073/pnas.87.24.9519; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HAYMAN GT, 1994, BBA-GENE STRUCT EXPR, V1219, P536, DOI 10.1016/0167-4781(94)90083-3; HORNER WE, 1995, INT ARCH ALLERGY IMM, V107, P298, DOI 10.1159/000237007; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; Kullertz G, 1999, PLANTA, V208, P599, DOI 10.1007/s004250050598; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindborg M, 1999, J INVEST DERMATOL, V113, P156, DOI 10.1046/j.1523-1747.1999.00661.x; LIPPUNER V, 1994, J BIOL CHEM, V269, P7863; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LUAN S, 1994, P NATL ACAD SCI USA, V91, P984, DOI 10.1073/pnas.91.3.984; MARIVET J, 1994, PLANT MOL BIOL, V26, P1181, DOI 10.1007/BF00040698; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; Mattoo AK, 1998, METHOD ENZYMOL, V290, P84, DOI 10.1016/S0076-6879(98)90009-X; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; Sheldon PS, 1996, BIOCHEM J, V315, P965, DOI 10.1042/bj3150965; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; SWOBODA I, 1994, BBA-GENE STRUCT EXPR, V1219, P457, DOI 10.1016/0167-4781(94)90072-8; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1999, ALLERGENS ALLERGEN I, P85; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Vieths S, 1998, SCAND J IMMUNOL, V47, P263; VIETHS S, 1995, ALLERGY, V50, P421, DOI 10.1111/j.1398-9995.1995.tb01172.x	38	51	55	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				286	291		10.1016/S0091-6749(00)90078-2	http://dx.doi.org/10.1016/S0091-6749(00)90078-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669849				2022-12-18	WOS:000085402200013
J	Molet, S; Furukawa, K; Maghazechi, A; Hamid, Q; Giaid, A				Molet, S; Furukawa, K; Maghazechi, A; Hamid, Q; Giaid, A			Chemokine- and cytokine-induced expression of endothelin 1 and endothelin-converting enzyme 1 in endothelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endothelin; endothelin-converting enzyme 1; endothelial cells; Northern blot; messenger RNA; chemokines; cytokines; radioimmunoassay; human	MONOCYTE CHEMOATTRACTANT; BIG ENDOTHELIN-1; TNF-ALPHA; FAMILY; ACTIVATION; PROTEIN-1; INDUCTION; RELEASE; RANTES	Background: Endothelin 1 (ET-1) is a product of endothelial and many other cell types that possesses a wide range of actions, including vasoconstriction, bronchoconstriction, and mitogenic activity on smooth muscle cells and fibroblasts. ET-1 release and expression is induced in several disease conditions associated with inflammation and cellular injury. Objective: The purpose of this study is to determine the effects of alpha-chemokines (IL-8 and melanoma growth-stimulating activator), beta-chemokines (monocyte chemotactic protein 1, macrophage inflammatory protein 1 alpha [MIP-1 alpha], MIP-1 beta, and RANTES), and proinflammatory cytokines (IL-1 beta, TNF-alpha, and IFN-gamma) on the expression of both ET-1 and endothelin-converting enzyme 1 (ECE-1) by human umbilical vein endothelial cells. Methods: Subconfluent monolayers of human umbilical vein endothelial cells were incubated with each chemokine individually for 24 hours or with a mixture (cytomix) of TNP-alpha, IL-1 beta, and IFN-gamma for 6 and 24 hours. Results: Incubation with the alpha-chemokines melanoma growth-stimulating activity and IL-8 did not significantly increase ET-1 and ECE-1 messenger (m)RNA expression and had no effect on ET-1 release. Monocyte chemotactic protein 1 exerted the most potent increase in ET-1 and ECE-1 mRNA and ET-1 release among all chemokines studied (P < .05), MTP-1 alpha and RANTES exerted a moderate, but significant, increase on the ET system (P < .05). The cytomix resulted in a significant increase in ET-1 and ECE-1 mRNA expression (P < .05). Conclusion: These data demonstrate that, like cytokines, chemokines can induce endothelial ET-1 and ECE-1 in vitro and suggest a possible role for these inflammatory mediators in the induction of the ET system in inflammatory and vascular diseases.	Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; Univ Oslo, Dept Anat, N-0316 Oslo, Norway	McGill University; McGill University; University of Oslo	Giaid, A (corresponding author), Montreal Gen Hosp, Suite L3-314,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.							Bacon KB, 1996, INT ARCH ALLERGY IMM, V109, P97, DOI 10.1159/000237207; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORDER R, 1995, J CARDIOVASC PHARM, V26, pS56; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; FILEP JG, 1993, LIFE SCI, V52, P119, DOI 10.1016/0024-3205(93)90131-L; Furukawa K, 1996, AM J RESP CELL MOL, V14, P248, DOI 10.1165/ajrcmb.14.3.8845175; HELSET E, 1994, MEDIAT INFLAMM, V3, P155, DOI 10.1155/S0962935194000207; HELSET E, 1994, CIRC SHOCK, V44, P201; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; JIANG YL, 1992, J IMMUNOL, V148, P2423; KOWALA MC, 1991, ADV PHARMACOL, V7, P299; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; Lusher T.F., 1993, HYPERTENSION, V11, P121; Maghazachi AA, 1996, EUR J IMMUNOL, V26, P315, DOI 10.1002/eji.1830260207; MAGHAZACHI AA, 1994, J IMMUNOL, V153, P4969; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; MCCARRON RM, 1993, NEUROSCI LETT, V156, P31, DOI 10.1016/0304-3940(93)90432-K; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; NOVERAL JP, 1992, AM J PHYSIOL, V263, pL317, DOI 10.1152/ajplung.1992.263.3.L317; OKADA K, 1990, BIOCHEM BIOPH RES CO, V171, P1192, DOI 10.1016/0006-291X(90)90811-Z; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; Saleh D, 1997, AM J RESP CELL MOL, V16, P187, DOI 10.1165/ajrcmb.16.2.9032126; SELDAH NG, 1993, ANN NY ACAD SCI, V880, P135; Strieter RM, 1996, J IMMUNOL, V156, P3583; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; SUZUKI N, 1990, J IMMUNOL METHODS, V127, P165, DOI 10.1016/0022-1759(90)90065-4; VADDI K, 1994, J LEUKOCYTE BIOL, V55, P756, DOI 10.1002/jlb.55.6.756; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252	33	51	56	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				333	338		10.1016/S0091-6749(00)90084-8	http://dx.doi.org/10.1016/S0091-6749(00)90084-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669855				2022-12-18	WOS:000085402200019
J	Hanazawa, T; Antuni, JD; Kharitonov, SA; Barnes, PJ				Hanazawa, T; Antuni, JD; Kharitonov, SA; Barnes, PJ			Intranasal administration of eotaxin increases nasal eosinophils and nitric oxide in patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal nitric oxide; inducible nitric oxide synthase; nitrotyrosine; eotaxin; eosinophil; epithelial cell; oxidative stress; allergic rhinitis	EPITHELIAL-CELLS; MESSENGER-RNA; RECEPTOR CCR3; IN-VIVO; EXPRESSION; ASTHMA; LUNG; CHEMOKINE; SYNTHASE; BINDING	Background: Nitric oxide (NO) plays an important role as an inflammatory mediator in the airways. Inducible NO synthase in the nasal mucosa is upregulated in perennial allergic rhinitis, and nasal NO is reduced after treatment with topical corticosteroids. A previous study has suggested that there is a significant correlation between exhaled NO and sputum eosinophils in patients with asthma. Objective: We investigated the ability of intranasal administration of eotaxin, a potent chemoattractant for eosinophils, to induce eosinophil accumulation and the relationship between eosinophil recruitment in the nasal mucosa and nasal NO production in patients with allergic rhinitis. Methods: Nine patients with allergic rhinitis were studied, Eotaxin or diluent was delivered intranasally in patients by using a metered spray pump. Nasal NO, symptom scores, and the influx of inflammatory cells in nasal lavage fluid were assessed before and after the challenge, Immunoreactivity for inducible NO synthase and nitrotyrosine was evaluated in nasal lavage cells. Results: Eotaxin induced a significant influx of eosinophils (P < .05) with mild symptoms of rhinitis. There was neither significant migration of lymphocytes, basophils, and macrophages into nasal lavage fluid nor a shedding of nasal epithelial cells after eotaxin challenge. Nasal NO was increased significantly (P < .05) 8 hours after eotaxin challenge compared with diluent challenge. Nitrotyrosine immunoreactivity was moderately elevated in nasal epithelial cells after the challenge. Conclusion: We have shown that eotaxin causes chemotaxis of eosinophils with a clinically symptomatic inflammatory response in the nasal mucosa and that eosinophil recruitment accompanies an increase in nasal NO, contributing to oxidative stress.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England	Imperial College London	Barnes, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.			Antuni, Julio Daniel/0000-0002-9069-0855; Barnes, Peter/0000-0002-5122-4018				ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; BARNES PJ, 1993, THORAX, V48, P1034, DOI 10.1136/thx.48.10.1034; BELVISI MG, 1992, J APPL PHYSIOL, V73, P2505, DOI 10.1152/jappl.1992.73.6.2505; delPozo V, 1997, J IMMUNOL, V158, P859; DuBois AB, 1998, J APPL PHYSIOL, V84, P1217, DOI 10.1152/jappl.1998.84.4.1217; Fokkens WJ, 1997, ALLERGY, V52, P29, DOI 10.1111/j.1398-9995.1997.tb04819.x; Furukawa K, 1996, AM J RESP CRIT CARE, V153, P847, DOI 10.1164/ajrccm.153.2.8564142; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GERLACH H, 1994, LANCET, V343, P518, DOI 10.1016/S0140-6736(94)91465-6; Greiff L, 1990, CLIN EXP ALLERGY, V86, P599; GRIFFITHSJOHNSON DA, 1993, BIOCHEM BIOPH RES CO, V197, P1167, DOI 10.1006/bbrc.1993.2599; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Kanazawa H, 1997, J ALLERGY CLIN IMMUN, V99, P624, DOI 10.1016/S0091-6749(97)70024-1; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1773, DOI 10.1164/ajrccm.153.6.8665033; Kharitonov SA, 1997, J ALLERGY CLIN IMMUN, V99, P58; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; Kuna P, 1998, AM J RESP CRIT CARE, V157, P873, DOI 10.1164/ajrccm.157.3.9610052; LIEW FY, 1994, IMMUNOL LETT, V43, P95, DOI 10.1016/0165-2478(94)00157-X; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; RIJN MVD, 1998, J ALLERGY CLIN IMMUN, V102, P65; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V203, P209, DOI 10.1006/bbrc.1994.2169; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Tenscher K, 1996, BLOOD, V88, P3195, DOI 10.1182/blood.V88.8.3195.bloodjournal8883195; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170	29	51	57	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				58	64		10.1016/S0091-6749(00)90178-7	http://dx.doi.org/10.1016/S0091-6749(00)90178-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629453				2022-12-18	WOS:000084992100008
J	Huang, SW				Huang, SW			A survey of Epi-PEN use in patients with a history of anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Univ Florida, Coll Med, Dept Pediat, Div Infect Dis & Immunol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Huang, SW (corresponding author), Univ Florida, Coll Med, Dept Pediat, Div Infect Dis & Immunol, Box 100296, Gainesville, FL 32610 USA.							CHIANG AA, 1994, NEW ENGL J MED, V330, P1690, DOI 10.1056/NEJM199406093302320; HUTCHESON PS, 1990, ANN ALLERGY, V64, P306; McDougle Leon, 1995, Journal of Emergency Medicine, V13, P9, DOI 10.1016/0736-4679(94)00105-7	3	51	52	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					525	526		10.1016/S0091-6749(98)70145-9	http://dx.doi.org/10.1016/S0091-6749(98)70145-9			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768598	Bronze			2022-12-18	WOS:000076212800032
J	Reed, CE; Offord, KP; Nelson, HS; Li, JT; Tinkelman, DG				Reed, CE; Offord, KP; Nelson, HS; Li, JT; Tinkelman, DG		Amer Acad Allergy Asthma Immunology Beclometha	Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; beclomethasone; theophylline	ORAL THEOPHYLLINE; CHILDREN	Background: Inhaled corticosteroids and oral theophylline are effective treatments for moderate asthma. Objective: We sought to compare the benefits and adverse reactions of theophylline and aerosol beclomethasone spray. Methods: A multicenter, double-blind, double-placebo, randomized, controlled trial of 1-year duration was performed. Seven hundred forty-seven patients with asthma received either beclomethasone dipropionate aerosol spray (84 mu g four times per day) or sustained-release theophylline twice per day in doses adjusted for optimum control of the disease. The main outcome measures were daily diary of symptoms and peak flow rates (recorded on a mark-sense computer-readable form); supplemental bronchodilator use; doctor's office or hospital visits and absence from work or school; spirometry; methacholine testing; adverse experiences; and cortisol blood measurements. Results: Both treatment strategies reduced symptoms promptly and achieved low absenteeism from work or school and low rates of emergency treatment for asthma. Both maintained nearly normal pulmonary function. Beclomethasone was statistically significantly more effective in reducing symptoms, supplemental bronchodilator and systemic glucocorticoid doses, bronchial hyperresponsiveness, and eosinophilia. However, the magnitude of these differences was small. Theophylline caused more headache, nervousness, insomnia, and gastrointestinal distress, and more patients discontinued treatment because of side effects. Beclomethasone caused more oropharyngeal candidiases and hoarseness and reduced morning plasma cortisol levels before and after cosyntropin. It reduced the rate of growth in children, No new cataracts or glaucoma developed. Conclusion: Theophylline effectively controlled symptoms at lower than the customarily recommended blood level. The risk/benefit profiles of these agents suggest that inhaled corticosteroids may be the preferred agent for most adult patients and for some children.	Mayo Clin & Mayo Fdn, Dept Allergy Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biostat, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Allergy, Rochester, MN 55905 USA; Natl Jewish Ctr Immunol & Resp Med, Denver, CO 80206 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; National Jewish Health	Li, JT (corresponding author), Mayo Clin & Mayo Fdn, Dept Allergy Res, 200 1st St SW, Rochester, MN 55905 USA.							*ATS STAT, 1987, AM REV RESPIR DIS, V136, P1283; BARNES PJ, 1995, EUR RESPIR J, V8, P457, DOI 10.1183/09031936.95.08030457; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; CRESCIOLI S, 1991, ANN ALLERGY, V66, P245; DJUKANOVIC R, 1995, EUR RESPIR J, V8, P831; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; Galant SP, 1996, ANN ALLERG ASTHMA IM, V77, P112, DOI 10.1016/S1081-1206(10)63496-5; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; Kay AB, 1996, AM J RESP CRIT CARE, V154, pS66, DOI 10.1164/ajrccm/154.2_Pt_2.S66; KIDNEY J, 1995, AM J RESP CRIT CARE, V151, P1907, DOI 10.1164/ajrccm.151.6.7767539; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; MANTEL N, 1959, J NATL CANCER I, V22, P719; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; *NAT HEART BLOOD I, 1997, EXP PAN REP GUID DIA, V2; Polgar G, 1971, PULMONARY FUNCTION T; REED CE, 1986, J ALLERGY CLIN IMMUN, V77, P537, DOI 10.1016/0091-6749(86)90342-8; SALZMAN GA, 1988, J ALLERGY CLIN IMMUN, V81, P424, DOI 10.1016/0091-6749(88)90911-6; SCHUDT C, 1995, EUR RESPIR J, V8, P1179, DOI 10.1183/09031936.95.08071179; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; TOOGOOD J, 1981, American Review of Respiratory Disease, V123, P113; TOOGOOD JH, 1980, J ALLERGY CLIN IMMUN, V65, P145, DOI 10.1016/0091-6749(80)90200-6; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; WARD AJM, 1993, AM REV RESPIR DIS, V147, P518, DOI 10.1164/ajrccm/147.3.518	27	51	52	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				14	23		10.1016/S0091-6749(98)70187-3	http://dx.doi.org/10.1016/S0091-6749(98)70187-3			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449495				2022-12-18	WOS:000071539800003
J	Lebecque, S; Dolecek, C; Laffer, S; Visco, V; Denepoux, S; Pin, JJ; Guret, C; BoltzNitulescu, G; Weyer, A; Valenta, R				Lebecque, S; Dolecek, C; Laffer, S; Visco, V; Denepoux, S; Pin, JJ; Guret, C; BoltzNitulescu, G; Weyer, A; Valenta, R			Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						monoclonal antibodies; major birch pollen allergen; Bet v 1; modulation of IgE binding	TREE-POLLEN; CONFORMATIONAL-CHANGES; ESCHERICHIA-COLI; HAZEL POLLEN; IDENTIFICATION; PURIFICATION; EXPRESSION; EPITOPES; HISTAMINE; PROFILIN	Background: Bet v 1 and homologous proteins represent major allergens for almost 95% of patients allergic to tree pollen and approximately 70% of those allergic to fruits and vegetables. As yet, no continuous (sequential) IgE epitopes have been determined for Bet v 1, and evidence has accumulated that Bet vl IgE epitopes belong to the conformational (discontinuous) type, Objective: A panel of 85 mouse monoclonal anti-Bet v 1 antibodies was raised as a tool with which to study the interaction of human IgE antibodies with Bet v 1. Methods: The epitopes of selected monoclonal antibodies (mAbs) were characterized by mapping with synthetic overlapping peptides and by cross-competition experiments, Cross-reactivity of Bet v I-specific mAbs with tree and plant food allergens was investigated by Western blotting. The influence of Bet v 1-specific mAbs on the IgE-Bet v I interaction was studied by competition assays with immobilized purified recombinant Bet v 1 and by basophil histamine release experiments. Results: Antibodies that increased the IgE binding to Bet v I up to fivefold could be defined, whereas others inhibited IgE binding to Bet v 1 up to 99% and competed with the Bet v 1-induced histamine release from patients' basophils. Conclusion: The activity of the enhancing antibodies is interpreted as a stabilization of Bet v 1 states/IgE epitopes, which are either more accessible for certain IgE antibodies or are recognized with higher affinity. Those mAbs that competed with the Bet v 1-IgE interaction, if humanized or produced as recombinant antibody fragments, might be considered as potential tools for local allergy therapy.	UNIV VIENNA,AKH,INST GEN & EXPT PATHOL,VIENNA,AUSTRIA; INST PASTEUR,UNITE IMMUNOALLERGIE,F-75724 PARIS,FRANCE	University of Vienna; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Lebecque, S (corresponding author), SCHERING PLOUGH CORP,LAB IMMUNOL RES,27 CHEMIN PEUPLIERS,BP11,F-69571 DARDILLY,FRANCE.			lebecque, serge/0000-0003-4006-8061; Valenta, Rudolf/0000-0001-5944-3365				BALL T, 1994, J BIOL CHEM, V269, P28323; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BUFE A, 1996, IN PRESS PLANTA; CHRETIEN I, 1990, EUR J IMMUNOL, V20, P243, DOI 10.1002/eji.1830200203; COLEMAN JW, 1985, EUR J IMMUNOL, V15, P966, DOI 10.1002/eji.1830150920; COLLAWN JF, 1988, J BIOL CHEM, V263, P8625; DEAN J, 1979, J BIOL CHEM, V254, P9185; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; LEBEL B, 1983, ANAL BIOCHEM, V133, P16, DOI 10.1016/0003-2697(83)90217-8; LUBECK M, 1982, VIROLOGY, V118, P1, DOI 10.1016/0042-6822(82)90313-0; MARCSERIES I, 1990, INT ARCH ALLER A IMM, V92, P226, DOI 10.1159/000235182; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; Noon L, 1911, LANCET, V1, P1572; ROHAC M, 1991, MOL IMMUNOL, V28, P897, DOI 10.1016/0161-5890(91)90054-N; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; THOMPSON RA, 1989, ALLERGY, V44, P369; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V87, P677, DOI 10.1016/0091-6749(91)90388-5; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; Visco V, 1996, J IMMUNOL, V157, P956; WILSON MB, 1978, IMMUNOFLUORESCENCE R	33	51	59	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					374	384		10.1016/S0091-6749(97)70056-3	http://dx.doi.org/10.1016/S0091-6749(97)70056-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058694				2022-12-18	WOS:A1997WM42200015
J	Kapsali, T; Horowitz, E; Diemer, F; Togias, A				Kapsali, T; Horowitz, E; Diemer, F; Togias, A			Rhinitis is ubiquitous in allergic asthmatics.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	51	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	2	S			556	556						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH142					2022-12-18	WOS:A1997WH14200554
J	Simons, FER; Bergman, JN; Watson, WTA; Simons, KJ				Simons, FER; Bergman, JN; Watson, WTA; Simons, KJ			The clinical pharmacology of fexofenadine in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT PEDIAT & CHILD HLTH,WINNIPEG,MB,CANADA; UNIV MANITOBA,FAC PHARM,WINNIPEG,MB R3T 2N2,CANADA; UNIV MANITOBA,FAC SCI,WINNIPEG,MB,CANADA	University of Manitoba; University of Manitoba; University of Manitoba								Lippert Christina, 1995, Pharmaceutical Research (New York), V12, pS390; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; SIMONS FER, 1993, J PEDIATR-US, V122, P641; Woosley RL, 1996, ANNU REV PHARMACOL, V36, P233, DOI 10.1146/annurev.pa.36.040196.001313; 1995, FEXOFENADINE HYDROCH	5	51	51	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1062	1064		10.1016/S0091-6749(96)80192-8	http://dx.doi.org/10.1016/S0091-6749(96)80192-8			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977506				2022-12-18	WOS:A1996WB37800010
J	Andri, L; Senna, G; Betteli, C; Givanni, S; Andri, G; Dimitri, G; Falagiani, P; Mezzelani, P				Andri, L; Senna, G; Betteli, C; Givanni, S; Andri, G; Dimitri, G; Falagiani, P; Mezzelani, P			Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: A double-blind study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hay fever; local nasal immunotherapy; allergic rhinitis; grass pollens pollenosis	INTRANASAL IMMUNOTHERAPY; HAY-FEVER; ALLERGIC RHINITIS; RAGWEED EXTRACT; EFFICACY	Background: Local nasal immunotherapy has been studied, by means of an extract Methods: Thirty-two patients allergic to grass were studied for 37 weeks in a double-blind controlled trial. Subjects were selected on the basis of a positive history, skin test result, RAST finding, and result of intranasal challenge to grass pollen. Two 16-patient groups were randomly assigned to active or placebo treatment. The treatment lasted 26 weeks (14 for the build-up phase, 12 for the maintenance period). Results: No significant differences were observed in nasal symptoms during the treatment. During the pollen season the mean weekly symptom and medication scores were significantly lower in the treated group, compared with the control group, even considering each allergic symptom separately. Moreover, only in the treated group was a significant increase of specific nasal threshold to grass pollen observed after treatment. Conclusions: This study indicates that local nasal immunotherapy with allergen in powder form can be a suitable alternative to the traditional subcutaneous immunotherapy in terms of clinical efficacy and safety in grass-allergic rhinitis.	VERONA GEN HOSP, CLIN ALLERGOL UNIT, VERONA, ITALY; VERONA GEN HOSP, LAB CLIN CHEM & HEMATOL, VERONA, ITALY; PHARMACEUT LAB LOFARMA, MILAN, ITALY; UNIV VERONA, INST CLIN MED, I-37100 VERONA, ITALY	University of Verona			Senna, Gianenrico/AAC-5201-2022	Senna, Gianenrico/0000-0003-4172-3216				ALBANO M, 1994, ACI NEWS S2, V6, P126; ANDERSON MC, 1983, RAST INHIBITION PROC; ANDRI L, 1992, ALLERGY, V47, P318, DOI 10.1111/j.1398-9995.1992.tb02061.x; ANDRI L, 1993, J ALLERGY CLIN IMMUN, V91, P987, DOI 10.1016/0091-6749(93)90211-W; ARMITAGE P, 1971, STATISTICAL METHODS, P456; BACHERT C, 1988, LARYNGO RHINO OTOL, V67, P57, DOI 10.1055/s-2007-998449; BERTONI M, 1993, ALLERGY S, V48, P16; BJORKSTEN B, 1987, CLIN ALLERGY, V17, P91, DOI 10.1111/j.1365-2222.1987.tb02325.x; BJORKSTEN B, 1994, ALLERGY, V49, P299, DOI 10.1111/j.1398-9995.1994.tb02271.x; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; DEUSCHL H, 1977, ACTA ALLERGOL, V32, P248, DOI 10.1111/j.1398-9995.1977.tb01357.x; DREBORG S, 1989, ALLERGY S10, V44, P26; FOUCARD T, 1973, Clinical Allergy, V3, P91, DOI 10.1111/j.1365-2222.1973.tb01313.x; GEORGITIS JW, 1986, INT ARCH ALLER A IMM, V81, P170, DOI 10.1159/000234127; GEORGITIS JW, 1983, J ALLERGY CLIN IMMUN, V71, P71, DOI 10.1016/0091-6749(83)90549-3; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V75, P496, DOI 10.1016/S0091-6749(85)80023-3; HEDLIN G, 1989, J ALLERGY CLIN IMMUN, V84, P390, DOI 10.1016/0091-6749(89)90426-0; JUNIPER EF, 1978, THORAX, V33, P710; MISTRELLO G, 1991, ALLERGY, V46, P52, DOI 10.1111/j.1398-9995.1991.tb00543.x; NEGRINI AC, 1992, ALLERGY, V47, P371, DOI 10.1111/j.1398-9995.1992.tb02074.x; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P41, DOI 10.1016/0091-6749(81)90121-4; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; PASTORELLO EA, 1992, ALLERGY, V47, P281, DOI 10.1111/j.1398-9995.1992.tb02054.x; SCHUMACHER MJ, 1989, J ALLERGY CLIN IMMUN, V83, P711, DOI 10.1016/0091-6749(89)90001-8; SCHUMACHER MJ, 1981, ALLERGY, V37, P241; SEDGWICK JD, 1983, IMMUNOLOGY, V50, P625; STEWART GA, 1989, LANCET, V2, P154, DOI 10.1016/S0140-6736(89)90203-1; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; WELSH PW, 1983, J ALLERGY CLIN IMMUN, V71, P454, DOI 10.1016/0091-6749(83)90461-X; WIDE L, 1967, LANCET, V2, P1105	30	51	52	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	1				34	41		10.1016/S0091-6749(96)70280-4	http://dx.doi.org/10.1016/S0091-6749(96)70280-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TR947	8568135				2022-12-18	WOS:A1996TR94700005
J	TOMAZIC, VJ; WITHROW, TJ; HAMILTON, RG				TOMAZIC, VJ; WITHROW, TJ; HAMILTON, RG			CHARACTERIZATION OF THE ALLERGEN(S) IN LATEX PROTEIN EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX; ALLERGEN; ANAPHYLAXIS; TYPE I ALLERGIC REACTION; IGE ANTIBODIES; GEL ELECTROPHORESIS; IMMUNOBLOTTING	CONTACT URTICARIA; SPINA-BIFIDA; RUBBER; ANAPHYLAXIS; REACTIVITY; ANTIGENS; HYPERSENSITIVITY; IDENTIFICATION; CHILDREN; GLOVES	Background: Immediate hypersensitivity to latex, induced by natural latex proteins remaining on the finished products, may lead to severe anaphylactic reactions. Methods: We investigated the distribution of later proteins by molecular weight and identified the specific allergenic molecules. Proteins extracted from various latex products were compared with those extracted from raw latex sap, both ammoniated and nonammoniated. Results: Variations in the levels of extractable protein, as well as in the number of molecules and the molecular weight distribution, were observed especially among finished latex products. To identify allergenic (i.e., IgE-binding) molecules, we performed immunoblots with the sera from Inter-sensitive persons. The results indicated that antigenic molecule profiles differed among the products and also between the finished products and the raw material. In addition, specificities of the anti-latex IgE antibodies varied among the sensitized persons. Conclusions: It appeared that persons with the same history of sensitization had similar patterns of antigenic specificities. If the history of exposure, as well as genetic predisposition and medical history of the patient, plays a significant role in the specific IgE response, it may be difficult to select a ''standard'' antigen and a ''standard'' antiserum for the evaluation of the latex sensitivity and allergenicity.	JOHNS HOPKINS UNIV,CTR ASTHMA & ALLERGY,BALTIMORE,MD 21224	Johns Hopkins University	TOMAZIC, VJ (corresponding author), US FDA,HLTH SCI CTR,DIV LIFE SCI,OFF SCI & TECHNOL,CTR DEVICES & RADIOL HLTH,HFZ-112,ROCKVILLE,MD 20852, USA.							ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; ALENIUS H, 1992, P INT C BALTIMORE, P40; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; CEUPPENS JL, 1992, LANCET, V339, P493, DOI 10.1016/0140-6736(92)91101-D; CHAMBEYRON C, 1992, ALLERGY, V47, P92, DOI 10.1111/j.1398-9995.1992.tb05094.x; DECORRES LF, 1993, ANN ALLERGY, V70, P35; DENNIS MS, 1989, J BIOL CHEM, V264, P18608; Fisher Benjamin R., 1993, Clinical Materials, V14, P199, DOI 10.1016/0267-6605(93)90003-P; HAMILTON RG, 1994, J LAB CLIN MED, V123, P594; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; KALRYMPLE SJ, 1992, RUBBER DEV, V45, P51; KURUP VP, 1993, J ALLERGY CLIN IMMUN, V91, P1128, DOI 10.1016/0091-6749(93)90314-6; KURUP VP, 1993, J ALLERGY CLIN IMMUN, V92, P638, DOI 10.1016/0091-6749(93)90005-Z; LACHAPELLE JM, 1979, CONTACT DERMATITIS, V5, P244, DOI 10.1111/j.1600-0536.1979.tb04859.x; LAVAUD F, 1992, LANCET, V339, P492, DOI 10.1016/0140-6736(92)91100-M; MONERETVAUTRIN DA, 1990, LANCET, V335, P865, DOI 10.1016/0140-6736(90)90989-I; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; RODRIGUEZ M, 1993, ANN ALLERGY, V70, P31; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1990, ANN ALLERGY, V65, P411; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; STCYR DR, 1988, ENCY POLYM SCI ENG, P687; SUSSMAN GL, 1992, ALLERGY PROC, V13, P67, DOI 10.2500/108854192778878890; TOMAZIC VJ, 1992, CLIN IMMUNOL IMMUNOP, V64, P89, DOI 10.1016/0090-1229(92)90185-Q; TOMAZIC VJ, 1994, J ALLERGY CLIN IMMUN, V93, P751, DOI 10.1016/0091-6749(94)90255-0; TOMAZIC VJ, 1992, P INT LAT C BALT, P50; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; WARPINSKI JR, 1991, ALLERGY PROC, V12, P95, DOI 10.2500/108854191779011846; WILSON HTH, 1969, BRIT J DERMATOL, V81, P175, DOI 10.1111/j.1365-2133.1969.tb16002.x; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3	34	51	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	1				635	642		10.1016/S0091-6749(95)70262-8	http://dx.doi.org/10.1016/S0091-6749(95)70262-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TG528	7499680				2022-12-18	WOS:A1995TG52800009
J	WARDLAW, AJ; SYMON, FS; WALSH, GM				WARDLAW, AJ; SYMON, FS; WALSH, GM			EOSINOPHIL ADHESION IN ALLERGIC INFLAMMATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							VASCULAR ENDOTHELIAL-CELLS; BRONCHIAL EPITHELIAL-CELLS; P-SELECTIN; HLA-DR; EXPRESSION; MOLECULE-1; ADHERENCE; INVITRO; ASTHMA; IL-4				WARDLAW, AJ (corresponding author), UNIV LEICESTER,GLENFIELD GEN HOSP,SCH MED,DEPT RESP MED,GROBY RD,LEICESTER LE3 9QP,LEICS,ENGLAND.		Walsh, Garry/D-4869-2013	Walsh, Garry/0000-0002-7138-4078; Wardlaw, Andrew/0000-0001-6583-0791				ALTMAN LC, 1993, J ALLERGY CLIN IMMUN, V92, P527, DOI 10.1016/0091-6749(93)90077-S; ANWAR ARE, 1994, IMMUNOLOGY, V82, P222; ANWAR ARF, 1993, J EXP MED, V177, P839, DOI 10.1084/jem.177.3.839; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BENTLEY AM, 1993, J ALLERGY CLIN IMMUN, V92, P857, DOI 10.1016/0091-6749(93)90064-M; BLOEMEN PGM, 1993, AM J RESP CELL MOL, V9, P586, DOI 10.1165/ajrcmb/9.6.586; BOCHNER BS, 1994, J IMMUNOL, V152, P774; BOCHNER BS, 1991, J EXP MED, V173, P1552; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; DESREUMAUX P, J EXP MED, V175, P293; DEVALIA JL, 1992, AM J RESP CELL MOL, V7, P270, DOI 10.1165/ajrcmb/7.3.270; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; DRI P, 1991, J IMMUNOL, V147, P613; EBEISAWA M, 1992, J IMMUNOL, V149, P4021; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261, DOI 10.1165/ajrcmb/7.3.261; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; GUNDEL RH, 1993, ASTHMA, P173; HANSEL TT, 1992, J IMMUNOL, V149, P2130; HARTNELL A, 1992, IMMUNOLOGY, V77, P488; HARTNELL A, 1993, IMMUNOLOGY, V80, P281; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIMANI G, 1988, J IMMUNOL, V140, P3161; KNOL EF, 1993, J ALLERGY CLIN IMMUN, V91, P334; KUIJPERS TW, J EXP MED, V178, P279; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LAMAS AM, 1988, J IMMUNOL, V140, P1500; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; MARTIN SD, 1987, CELL, V51, P813; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393, DOI 10.1165/ajrcmb/7.4.393; MONTEFORT S, 1992, EUR RESPIR J, V5, P815; MONTEFORT S, 1993, J ALLERGY CLIN IMMUN, V91, P822; MOSER R, 1992, J IMMUNOL, V149, P1432; MOSER R, 1992, BLOOD, V79, P2937; MOULD AP, 1990, J BIOL CHEM, V265, P4020; NEELEY SP, 1993, AM J RESP CELL MOL, V8, P633, DOI 10.1165/ajrcmb/8.6.633; ROBBINS RA, 1992, AM J RESP CELL MOL, V7, P19, DOI 10.1165/ajrcmb/7.1.19; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SMITH CH, 1993, J IMMUNOL, V151, P3274; SPRINGER TA, 1991, NATURE, V349, P425; STAMPER HB, 1976, J EXP MED, V144, P828, DOI 10.1084/jem.144.3.828; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; THORNHILL MH, 1991, J IMMUNOL, V146, P592; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214, DOI 10.1165/ajrcmb/7.2.214; VADAS MA, 1993, EOSINOPHILS ALLERGY, P69; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689, DOI 10.1164/ajrccm/148.3.689; WALKER C, 1993, J IMMUNOL, V150, P4061; WALSH GM, 1991, J IMMUNOL, V146, P3419; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WARDLAW AJ, 1994, IMMUNOPHARMACOLOGY N, P133; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561; WEGNER CD, 1993, ASTHMA, P227; WEGNER CD, 1990, SCIENCE, V247, P416; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430	61	51	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1163	1171		10.1016/0091-6749(94)90327-1	http://dx.doi.org/10.1016/0091-6749(94)90327-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798555				2022-12-18	WOS:A1994QA02000007
J	KAULBACH, HC; WHITE, MV; IGARASHI, Y; HAHN, BK; KALINER, MA				KAULBACH, HC; WHITE, MV; IGARASHI, Y; HAHN, BK; KALINER, MA			ESTIMATION OF NASAL EPITHELIAL LINING FLUID USING UREA AS A MARKER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EPITHELIAL LINING FLUID; GLANDULAR SECRETION; VASCULAR PERMEABILITY; UREA	BRONCHOALVEOLAR LAVAGE FLUID; PATHO-PHYSIOLOGY; ELECTROLYTE TRANSPORT; RHINITIS; SECRETIONS; LUNG; PERMEABILITY; ALLERGEN; PROTEIN; DISEASE	Background: The luminal surface of respiratory mucous membranes is lined with an epithelial lining fluid (ELF) layer. Previous attempts to determine ELF volumes in airways have used dyes or freely diffusible molecules such as urea, yet have not led to a universally accepted method. The nasal mucous membrane provides an accessible area to examine whether urea is an appropriate marker of respiratory ELF volume. Methods and Results: Collection of undiluted nasal secretions after either glandular stimulation or induction of vascular permeability confirmed that plasma urea and nasal urea concentrations are equivalent. Baseline ELF volume was calculated as 800 mul/nostril. The calculated molar concentrations of urea in ELF did not vary with either methacholine or histamine challenge. Conclusions: These data indicate the plasma, interstitial, glandular and ELF urea concentrations are equivalent and, therefore, that urea is a useful marker of ELF volume in the nasal mucosa.	NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BLDG 10,ROOM 11C205,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BAUGHMAN RP, 1983, AM REV RESPIR DIS, V128, P266; BERGER HA, 1991, HOSP PRACT, V26, P53, DOI 10.1080/21548331.1991.11707712; CROSS CE, 1960, AM J PHYSIOL, V198, P1029, DOI 10.1152/ajplegacy.1960.198.5.1029; DULFANO MJ, 1973, SPUTUM FUNDAMENTALS, P113; EFFROS RM, 1990, J APPL PHYSIOL, V68, P275, DOI 10.1152/jappl.1990.68.1.275; ENNA SJ, 1972, AM J PHYSIOL, V222, P409, DOI 10.1152/ajplegacy.1972.222.2.409; GALLUCCI E, 1971, ARCH INT PHYS BIOCH, V79, P881, DOI 10.3109/13813457109104847; GARRICK RA, 1980, MICROVASC RES, V20, P88, DOI 10.1016/0026-2862(80)90022-9; GORIN AB, 1979, J APPL PHYSIOL, V47, P1315, DOI 10.1152/jappl.1979.47.6.1315; HUNNINGHAKE GW, 1979, AM J PATHOL, V97, P149; JONES KP, 1990, EUR RESPIR J, V3, P152; JUETTNER FM, 1988, RESPIRATION, V54, P226, DOI 10.1159/000195529; KAULBACH HC, 1992, J ALLERGY CLIN IMMUN, V89, P599, DOI 10.1016/0091-6749(92)90328-Y; KEIMOWITZ RI, 1964, J LAB CLIN MED, V63, P54; KELLY CA, 1987, THORAX, V42, P624, DOI 10.1136/thx.42.8.624; KELLY CA, 1988, AM REV RESPIR DIS, V138, P81, DOI 10.1164/ajrccm/138.1.81; KNEPPER MA, 1990, AM J PHYSIOL, V259, pF393, DOI 10.1152/ajprenal.1990.259.3.F393; Lucas AM, 1934, ARCHIV OTOLARYNGOL, V20, P518; MARCY TW, 1987, AM REV RESPIR DIS, V135, P1276; MEREDITH SD, 1989, J ALLERGY CLIN IMMUN, V84, P920, DOI 10.1016/0091-6749(89)90390-4; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; PERSSON CGA, 1990, EUROPEAN RESPIRA S12, V3, pS625; PERSSON CGA, 1987, AM REV RESPIR DIS, V135, P571; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V88, P33, DOI 10.1016/0091-6749(91)90298-3; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; REYNOLDS HY, 1974, J LAB CLIN MED, V84, P559; SEITSEMA K, 1986, AM REV RESPIR DIS, V133, pA20; TAYLOR AE, 1965, CIRC RES, V16, P353, DOI 10.1161/01.RES.16.4.353; THEODORE J, 1975, AM J PHYSIOL, V229, P989, DOI 10.1152/ajplegacy.1975.229.4.989; VANDEGRAAF EA, 1991, CLIN CHIM ACTA, V196, P27, DOI 10.1016/0009-8981(91)90205-Q; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; WHITE MV, 1987, J IMMUNOL, V139, P1624	35	51	51	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1993	92	3					457	465		10.1016/0091-6749(93)90125-Y	http://dx.doi.org/10.1016/0091-6749(93)90125-Y			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LX309	8360397				2022-12-18	WOS:A1993LX30900012
J	FISCHER, MB; HAUBER, I; VOGEL, E; WOLF, HM; MANNHALTER, JW; EIBL, MM				FISCHER, MB; HAUBER, I; VOGEL, E; WOLF, HM; MANNHALTER, JW; EIBL, MM			DEFECTIVE INTERLEUKIN-2 AND INTERFERON-GAMMA GENE-EXPRESSION IN RESPONSE TO ANTIGEN IN A SUBGROUP OF PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COMMON VARIABLE IMMUNODEFICIENCY; ANTIBODY DEFICIENCY; CYTOKINE GENE EXPRESSION; DEFECT IN T-CELL ACTIVATION	PERIPHERAL-BLOOD LYMPHOCYTES; T-CELL ACTIVATION; VARIED IMMUNODEFICIENCY; PROLIFERATIVE RESPONSE; HYPOGAMMAGLOBULINEMIA; INVITRO; IL-2; DIFFERENTIATION; ABNORMALITIES; LYMPHOKINES	Patients with common variable immunodeficiency (CVID) are heterogeneous in the clinical manifestations of the disease and in the underlying mechanisms leading to the immunodeficiency The impairment of B-cell function can be due to an intrinsic defect of the B cells, a deficiency in the function of the antigen-presenting cell, or a dysfunction in the course of T-cell activation. In the present report we have focused our attention on T-lymphocyte activation in three patients with CVID. Numbers of T and B cells, as well as CD4 and CD8 T cell subsets, were within the normal range. The patients' B cells secreted IgM but did not secrete IgG and IgA in response to B-cell stimuli in vitro. Addition of allogeneic T cells was followed by an increase in IgM production but had no effect on the other immunoglobulin isotypes. Examination of T-cell function revealed impaired proliferative response, interleukin-2 (IL-2) and interferon-gamma gene expression and IL-2 release after antigenic stimulation, whereas T-cell proliferation, as well as IL-2 gene expression and release in response to stimulation Wa anti-CD3, were comparable to those of healthy control subjects. Anti-CD3-induced IFN-gamma gene activation in T cells from two patients was comparable to that of control subjects, whereas T cells from the third patient showed reduced expression of IFN-gamma mRNA. In contrast to the decreased IL-2 and IFN-gamma mRNA levels, IL-2R transcripts examined in parallel were normal in CVID T cells on stimulation with antigen. The defect in IL-2 and IFN-gamma mRNA expression after stimulation with antigen, but not with anti-CD3, suggests an abnormality confined to T-cell activation by the T-cell receptor.	UNIV VIENNA,INST IMMUNOL,BORSCHKEGASSE 8A,A-1090 VIENNA,AUSTRIA; IMMUNO AG WIEN,DEPT IMMUNOL RES,VIENNA,AUSTRIA	University of Vienna			Fischer, Michael/AAU-5579-2020	Fischer, Michael/0000-0002-5876-0243				BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRYANT A, 1990, CLIN IMMUNOL IMMUNOP, V56, P239, DOI 10.1016/0090-1229(90)90145-G; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNINGHAMRUNDLES S, 1982, SCAND J IMMUNOL, V15, P279, DOI 10.1111/j.1365-3083.1982.tb00650.x; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; DISANTO JP, 1990, J EXP MED, V171, P1697, DOI 10.1084/jem.171.5.1697; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; EIBL M, 1982, CLIN EXP IMMUNOL, V47, P260; EIBL MM, 1982, CLIN IMMUNOL IMMUNOP, V22, P316, DOI 10.1016/0090-1229(82)90048-4; EIBL MM, 1982, NEW ENGL J MED, V307, P803, DOI 10.1056/NEJM198209233071307; FARRANT J, 1989, CLIN IMMUNOL IMMUNOP, V51, P196, DOI 10.1016/0090-1229(89)90019-6; FISCHER MB, 1991, PROGR IMMUNE DEFICIE, V3, P67; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GRABSTEIN K, 1986, J IMMUNOL, V136, P4503; GRAY PW, 1982, NATURE, V295, P503, DOI 10.1038/295503a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HADDEN JW, 1988, IMMUNOL TODAY, V9, P235, DOI 10.1016/0167-5699(88)91222-4; JUNE CH, 1989, J IMMUNOL, V143, P153; KRUGER G, 1984, J CLIN IMMUNOL, V4, P295, DOI 10.1007/BF00915297; KUMAGAI N, 1988, J IMMUNOL, V140, P37; LEBRANCHU Y, 1990, NEW ENGL J MED, V323, P276; LEWIS DB, 1986, J EXP MED, V163, P1018, DOI 10.1084/jem.163.4.1018; LOPEZBOTET M, 1982, J IMMUNOL, V128, P679; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKAGAWA T, 1985, J IMMUNOL, V134, P959; NIKAIDO T, 1984, NATURE, V311, P626; NOELLE RJ, 1991, FASEB J, V5, P2770, DOI 10.1096/fasebj.5.13.1833257; NORTH ME, 1990, CLIN EXP IMMUNOL, V81, P412; NORTH ME, 1989, CLIN EXP IMMUNOL, V76, P19; PASTORELLI G, 1989, CLIN EXP IMMUNOL, V78, P334; PELLEGRINO MA, 1976, J IMMUNOL METHODS, V11, P273, DOI 10.1016/0022-1759(76)90120-4; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; REINHERZ EL, 1979, NEW ENGL J MED, V301, P1018, DOI 10.1056/NEJM197911083011902; ROZYNSKA KE, 1989, CLIN EXP IMMUNOL, V79, P1; SAIKI O, 1982, P NATL ACAD SCI-BIOL, V79, P6008, DOI 10.1073/pnas.79.19.6008; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SNELLER MC, 1990, J IMMUNOL, V144, P3762; SPICKETT G P, 1990, Immunodeficiency Reviews, V2, P199; SPICKETT GP, 1989, IMMUNOL TODAY, V10, P192, DOI 10.1016/0167-5699(89)90323-X; WALDMANN TA, 1974, LANCET, V2, P609; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406; 1989, IMMUNODEF REV, V1, P173	43	51	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					340	352		10.1016/0091-6749(93)90178-I	http://dx.doi.org/10.1016/0091-6749(93)90178-I			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	8349943				2022-12-18	WOS:A1993LT46900015
J	BUSINCO, L; IOPPI, M; MORSE, NL; NISINI, R; WRIGHT, S				BUSINCO, L; IOPPI, M; MORSE, NL; NISINI, R; WRIGHT, S			BREAST-MILK FROM MOTHERS OF CHILDREN WITH NEWLY DEVELOPED ATOPIC ECZEMA HAS LOW-LEVELS OF LONG-CHAIN POLYUNSATURATED FATTY-ACIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BREAST MILK; ATOPIC ECZEMA; ESSENTIAL FATTY ACIDS; GAMMA-LINOLENIC ACID; DIHOMO-GAMMA-LINOLENIC ACID; ARACHIDONIC ACID; PROSTAGLANDINS	INFANTS; DERMATITIS; GAMMA; LYMPHOCYTES; RESPONSES; DISEASE	Background: Infants at risk of atopic dermatitis have lower than normal levels of long chain polyunsaturated fatty acids. These fatty acids are normally present in substantial quantities in human breast milk. Methods: Because of the equivocal evidence concerning the ability of breastfeeting to delay the onset or reduce the severity of atopic dermatitis, we have analyzed the fatty acid composition of breast milk from the mothers of children with newly developed disease with the use of gas chromatography. Results: Breast milk lipids from mothers of children with newly developed atopic dermatitis had increased proportions of linoleic acid and significantly decreased proportions of its long chain polyunsaturated derivatives compared with a control group. The ratio of linoleic acid to the sum of its metabolites, gamma-linolenic acid, dihomo-gamma-linolenic acid, and arachidonic acid was 11.78 in the atopic group and 9.02 in the control group (p < 0.01). Conclusions: These results are consistent with previous findings of an abnormal fatty acid status in atopic subjects and may account for some of the inconsistent results from studies of the effect of breastfeeding on the subsequent development of atopic dermatitis. We conclude that further studies to examine the effects of supplementation of the diet of breastfeeding mothers with long chain polyunsaturates should be done.	F HOSP, DEPT PAEDIAT, ROME, ITALY; ROYAL FREE HOSP, DEPT DERMATOL, LONDON, ENGLAND; EFAMOL RES INST, KENTVILLE, NS, CANADA	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	BUSINCO, L (corresponding author), UNIV ROMA LA SAPIENZA, DEPT PAEDIAT, DIV ALLERGY & IMMUNOL, VIA REGINA ELENA 324, I-00185 ROME, ITALY.							ATHERTON DJ, 1983, BRIT MED J, V287, P775, DOI 10.1136/bmj.287.6395.775; BACH MA, 1974, PROSTAGLANDIN SYNTHE, P241; BAMFORD JTM, 1985, J AM ACAD DERMATOL, V13, P959, DOI 10.1016/S0190-9622(85)70245-9; BORDONI A, 1988, DRUG EXP CLIN RES, V14, P291; BUSINCO L, 1987, ANN ALLERGY, V59, P183; CANT A, 1991, J NUTR SCI VITAMINOL, V37, P573, DOI 10.3177/jnsv.37.573; CHRISTOP.SW, 1969, J DAIRY SCI, V52, P1289, DOI 10.3168/jds.S0022-0302(69)86739-1; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; GALLI E, 1989, PEDIATR RES, V26, P519, DOI 10.1203/00006450-198911000-00122; GIBSON RA, 1981, AM J CLIN NUTR, V34, P252, DOI 10.1093/ajcn/34.2.252; Grulee CG, 1936, J PEDIATR-US, V9, P223, DOI 10.1016/S0022-3476(36)80058-4; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; HEDDLE RJ, 1991, IN PRESS MED J AUST; IOPPI M, IN PRESS J INVEST CL; LINDFORS A, 1988, ALLERGY, V43, P11, DOI 10.1111/j.1398-9995.1988.tb02038.x; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; MELNIK BC, 1991, PROSTAG LEUKOTR ESS, V42, P125, DOI 10.1016/0952-3278(91)90079-K; MILLER CC, 1988, BIOCHEM BIOPH RES CO, V154, P967, DOI 10.1016/0006-291X(88)90234-3; MORSE PF, 1989, BRIT J DERMATOL, V121, P75, DOI 10.1111/j.1365-2133.1989.tb01403.x; PARKER CW, 1977, J INVEST DERMATOL, V68, P302, DOI 10.1111/1523-1747.ep12494569; PENE J, 1988, J IMMUNOL, V141, P1218; SANDERS TAB, 1979, BRIT J NUTR, V41, P619, DOI 10.1079/BJN19790077; SANTOLI D, 1989, J IMMUNOL, V143, P1303; SAVILAHTI E, 1987, ARCH DIS CHILD, V62, P269, DOI 10.1136/adc.62.3.269; STRANNEGARD IL, 1987, INT ARCH ALLER A IMM, V82, P422, DOI 10.1159/000234245; SUSTIEL A, 1989, CLIN EXP ALLERGY, V19, P11, DOI 10.1111/j.1365-2222.1989.tb02337.x; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; WRIGHT S, 1982, LANCET, V2, P1120; WRIGHT S, 1989, BRIT J NUTR, V62, P693, DOI 10.1079/BJN19890069; WRIGHT S, 1985, ACTA DERM-VENEREOL, P143; ZURIER RB, 1990, OMEGA 6 ESSENTIAL FA, P203	31	51	53	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1134	1139		10.1016/0091-6749(93)90315-7	http://dx.doi.org/10.1016/0091-6749(93)90315-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	8509576				2022-12-18	WOS:A1993LG74000004
J	BOULET, LP; TURCOTTE, H; BOUTET, M; MONTMINY, L; LAVIOLETTE, M				BOULET, LP; TURCOTTE, H; BOUTET, M; MONTMINY, L; LAVIOLETTE, M			INFLUENCE OF NATURAL ANTIGENIC EXPOSURE ON EXPIRATORY FLOWS, METHACHOLINE RESPONSIVENESS, AND AIRWAY INFLAMMATION IN MILD ALLERGIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SEASONAL ASTHMA; POLLEN-INDUCED ASTHMA; ALLERGIC ASTHMA; AIRWAY HYPERRESPONSIVENESS; AIRWAY INFLAMMATION; BRONCHOALVEOLAR LAVAGE; BRONCHIAL BIOPSIES	BRONCHIAL RESPONSIVENESS; BRONCHOALVEOLAR LAVAGE; POLLEN SEASON; GRASS-POLLEN; HYPERREACTIVITY; HISTAMINE; INCREASES; CLEARANCE; BIOPSIES; SODIUM	Background: This study looked at respiratory symptoms, peak expiratory flow rates (PEFRs), airway responsiveness to methacholine and inflammatory changes on bronchial biopsies, bronchial lavage (BL), and bronchoalveolar lavage (BAL) during natural antigenic exposure in nine subjects with pollen-sensitized seasonal asthma. Methods: The subjects recorded daily symptoms of asthma,cough and rhinitis, and morning and evening PEFRs between January and September, during and out of the pollen exposure. Baseline forced expiratory volume in 1 second, forced vital capacity, and methacholine responsiveness were measured every 3 to 4 weeks. BAL, BL, and bronchial biopsies were performed in the pollen season at the initial increase of asthma symptoms and out of pollen exposure. Results: At the time of bronchoscopy during the pollen season compared with out of season, asthmatic subjects had an increase in asthma symptom score (1.18 +/- 0.24/0.44 +/- 0.18, p < 0.05), a reduction of PEFR (407 +/- 23/442 +/- 20 L/min, p = 0.02), and a decrease in PC20 (1.15/1.48 mg/ml, p = 0.05). In asthmatic subjects, median BAL and BL cell counts and cell differentials during or out of antigenic exposure were similar, but BAL and BL eosinophils and metachromatic cells counts were always higher than in healthy subjects. In comparison with controls, biopsies obtained in asthmatic subjects showed airway lesions such as epithelial desquamation, squamous cell metaplasia, thickening of basal membrane, inflammatory cells (p < 0.05 for neutrophils), edema, and ciliary abnormalities. During pollen exposure, inflammatory signs increased, but this change was only significant for the extent of epithelial desquamation and neutrophil counts. No significant correlation was found between the intensity of airway inflammation and changes in airway responsiveness. Conclusions: In subjects with mild allergic asthma and pollen-induced asthma, seasonal antigenic exposure was associated with an increase in epithelial shedding and in the number of neutrophils on bronchial biopsies, suggesting a mild increase in baseline airway inflammation. However, these changes were not correlated with increases in airway responsiveness.			BOULET, LP (corresponding author), UNIV LAVAL, HOP LAVAL, CTR PNEUMOL, UNITE RECH, 2725 CHEMIN ST FOY, Ste Foy G1V 4G5, PQ, CANADA.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BATEMAN JRM, 1983, THORAX, V38, P463, DOI 10.1136/thx.38.6.463; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADLEY B, 1990, Clinical and Experimental Allergy, V20, P121; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; CHANG EY, 1990, COMSAT TECH REV, V20, P1; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1987, IMMUNOL ALLERGY PRAC, V9, P17; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DORWARD AJ, 1986, CLIN ALLERGY, V16, P309, DOI 10.1111/j.1365-2222.1986.tb01962.x; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FOX B, 1981, CHEST, V80, P796, DOI 10.1378/chest.80.6.796; GOLDSTEIN RA, 1990, AM REV RESPIR DIS, V142, P481; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HOLGATE ST, 1991, CLIN EXP ALLERGY, V21, P11, DOI 10.1111/j.1365-2222.1991.tb01758.x; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JUNIPER EF, 1982, THORAX, V37, P288, DOI 10.1136/thx.37.4.288; KAY AB, 1986, J ALLERGY CLIN IMMUN, V77, P236; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAVIOLETTE M, 1988, AM REV RESPIR DIS, V138, P451, DOI 10.1164/ajrccm/138.2.451; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; LOZEWICZ S, 1988, BRIT MED J, V297, P1515, DOI 10.1136/bmj.297.6662.1515; MESSINA MS, 1991, AM REV RESPIR DIS, V143, P993, DOI 10.1164/ajrccm/143.5_Pt_1.993; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, pS35, DOI 10.1164/ajrccm/136.4_Pt_2.S35; SATIR P, 1974, SCI AM, V231, P44; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56	32	51	52	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1993	91	4					883	893		10.1016/0091-6749(93)90346-H	http://dx.doi.org/10.1016/0091-6749(93)90346-H			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KY251	8473677				2022-12-18	WOS:A1993KY25100009
J	AGATA, H; KONDO, N; FUKUTOMI, O; SHINODA, S; ORII, T				AGATA, H; KONDO, N; FUKUTOMI, O; SHINODA, S; ORII, T			EFFECT OF ELIMINATION DIETS ON FOOD-SPECIFIC IGE ANTIBODIES AND LYMPHOCYTE PROLIFERATIVE RESPONSES TO FOOD ANTIGENS IN ATOPIC-DERMATITIS PATIENTS EXHIBITING SENSITIVITY TO FOOD ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPIC DERMATITIS; ELIMINATION DIETS; FOOD ALLERGY; LYMPHOCYTE PROLIFERATIVE RESPONSES; SPECIFIC IGE ANTIBODIES	T-LYMPHOCYTES; MILK-PROTEINS; DOUBLE-BLIND; HYPERSENSITIVITY; CHILDREN; INVITRO; IMMUNOTHERAPY; RHINITIS; RELEASE; ASTHMA	Peripheral blood mononuclear cells (PBMCs) from patients with atopic dermatitis (AD) selected as being sensitive to hen's egg or cow's milk responded to food antigens, ovalbumin, or bovine serum albumin, with significantly enhanced DNA synthesis compared with the DNA synthesis in PBMCs from nonatopic control subjects and food-sensitive patients with immediate symptoms. Patients were treated with elimination diets. Symptoms of AD had been in remission during elimination diets. The levels of specific IgE antibodies to hen's egg or cow's milk decreased during elimination diets in patients with positive radioallergosorbent test (RAST). In patients with negative RAST, specific IgE antibodies remained negative during elimination diets. The proliferative responses of PBMCs to food antigens also decreased during elimination diets in patients with proliferative responses before elimination diets. Taken together, specific IgE antibodies to food antigens are useful indexes of the effect of elimination diets in food-sensitive patients with AD and positive RAST, and proliferative responses of PBMCs to food antigens are useful indexes of the effect of elimination diets in food-sensitive patients with AD and proliferative responses of PBMCs.			AGATA, H (corresponding author), GIFU UNIV,SCH MED,DEPT PEDIAT,TSUKASA MACHI 40,GIFU 500,JAPAN.							ALAM R, 1984, ANN ALLERGY, V53, P66; BLACK PL, 1980, J ALLERGY CLIN IMMUN, V66, P394, DOI 10.1016/0091-6749(80)90119-0; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BRUYNZEELKOOMEN CAFM, 1988, ALLERGY, V43, P15, DOI 10.1111/j.1398-9995.1988.tb05043.x; BUCKLEY RH, 1977, J ALLERGY CLIN IMMUN, V59, P70, DOI 10.1016/0091-6749(77)90180-4; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; BUSINCO L, 1984, ANN ALLERGY, V53, P615; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P477, DOI 10.1016/0091-6749(76)90191-3; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; GIRARD JP, 1967, J ALLERGY, V39, P65, DOI 10.1016/0021-8707(67)90113-X; GOLDMAN AS, 1963, PEDIATRICS, V32, P425; GOLDMAN AS, 1963, PEDIATRICS, V32, P572; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; HIRATANI M, 1981, J ALLERGY CLIN IMMUN, V68, P205, DOI 10.1016/0091-6749(81)90185-8; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P256, DOI 10.1016/0091-6749(75)90145-1; HORSMANHEIMO M, 1979, ARCH DERMATOL, V115, P161, DOI 10.1001/archderm.115.2.161; HSIEH KH, 1984, J ALLERGY CLIN IMMUN, V74, P34, DOI 10.1016/0091-6749(84)90084-8; HWANG KC, 1983, ALLERGY, V38, P113, DOI 10.1111/j.1398-9995.1983.tb01594.x; KONDO N, 1990, J ALLERGY CLIN IMMUN, V86, P253, DOI 10.1016/S0091-6749(05)80073-9; MATLOFF SM, 1983, J ALLERGY CLIN IMMUN, V72, P359, DOI 10.1016/0091-6749(83)90500-6; MAY CD, 1977, CLIN ALLERGY, V7, P583, DOI 10.1111/j.1365-2222.1977.tb01489.x; METCALFE DD, 1990, J ALLERGY CLIN IMMUN, V86, P421, DOI 10.1016/S0091-6749(05)80252-0; PEARSON JR, 1983, PEDIATR RES, V17, P406, DOI 10.1203/00006450-198305000-00017; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROCKLIN RE, 1974, J CLIN INVEST, V53, P735, DOI 10.1172/JCI107612; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; STRANNEGARD IL, 1976, INT ARCH ALLER A IMM, V50, P684, DOI 10.1159/000231547; VANSICKLE GJ, 1985, GASTROENTEROLOGY, V88, P1915, DOI 10.1016/0016-5085(85)90019-8; WRAITH DG, 1979, CLIN ALLERGY, V9, P25, DOI 10.1111/j.1365-2222.1979.tb01519.x	36	51	51	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1993	91	2					668	679		10.1016/0091-6749(93)90273-I	http://dx.doi.org/10.1016/0091-6749(93)90273-I			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KN548	8436780	Bronze			2022-12-18	WOS:A1993KN54800015
J	WAGENMANN, M; NACLERIO, RM				WAGENMANN, M; NACLERIO, RM			ANATOMIC AND PHYSIOLOGICAL CONSIDERATIONS IN SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		NOSE; MUCOCILIARY TRANSPORT; NASAL CYCLE; SINUSES; ETHMOID; FRONTAL; MAXILLARY; SPHENOID	SURGERY	The anatomy and physiology of the nose, the paranasal sinuses, and related structures are of major importance in understanding sinusitis. A brief description of the airflow, blood flow, nasal cycle, histology and the developmental anatomy are given. These elements combine to condition inhaled air by warming, humidifying, and filtering it. An important mechanism for understanding sinusitis is mucociliary clearance. The nasal cavity and the paranasal sinuses are covered by a pseudostratified, columnar, ciliated epithelium with a thin mucous layer on top of it. In the sinuses the beat of the cilia is directed toward their natural ostia. The ostia of most of the paranasal sinuses lead into the region of the middle meatus and the anterior ethmoid, the osteomeatal complex. Obstruction in this area reduces clearance and plays a major role in the pathophysiology of sinusitis.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University			Wagenman, Martin/B-2524-2012	Wagenman, Martin/0000-0002-9734-0241	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031335] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31335] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOLGER WE, 1991, LARYNGOSCOPE, V101, P56; GRANEY DO, 1986, OTOLARYNGOLOGY HEAD, V1, P845; Hadfield E H, 1970, Ann R Coll Surg Engl, V46, P301; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; MESSERKLINGER W, 1967, OHRENHEILKD, V101, P313; NAUMANN H, 1965, 8 P INT C OT AMST, P80; PROCTOR DF, 1966, BACTERIOL REV, V30, P498, DOI 10.1128/MMBR.30.3.498-513.1966; STAMMBERGER H, 1986, OTOLARYNG HEAD NECK, V94, P143, DOI 10.1177/019459988609400202; STOKSTED P, 1952, Acta Otolaryngol, V42, P175, DOI 10.3109/00016485209120341; TORJUSSEN W, 1979, CANCER, V44, P963, DOI 10.1002/1097-0142(197909)44:3<963::AID-CNCR2820440326>3.0.CO;2-H; WILSON WR, 1976, ANN OTO RHINOL LARYN, V85, P391, DOI 10.1177/000348947608500311	11	51	53	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			419	423		10.1016/0091-6749(92)90161-T	http://dx.doi.org/10.1016/0091-6749(92)90161-T			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527330				2022-12-18	WOS:A1992JP52100002
J	ZEIGER, RS				ZEIGER, RS			PROSPECTS FOR ANCILLARY TREATMENT OF SINUSITIS IN THE 1990S	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		SINUSITIS; HYPERTHERMIA; ALPHA-AGONISTS; MUCOREGULATORS; MUCOCILIARY CLEARANCE; N-ACETYLCYSTEINE; IODINATED GLYCEROL; ADENOSINE TRIPHOSPHATE; TOPICAL CORTICOSTEROIDS; MEDIATOR ANTAGONISTS	ASPIRIN-SENSITIVE RHINOSINUSITIS; CHRONIC MAXILLARY SINUSITIS; CHRONIC OBSTRUCTIVE BRONCHITIS; PRIMARY CILIARY DYSKINESIA; MAJOR BASIC-PROTEIN; MUCOCILIARY FUNCTION; DOUBLE-BLIND; IPRATROPIUM BROMIDE; RESPIRATORY-TRACT; NASAL PROVOCATION	The basis for ancillary therapy of sinusitis derives from anecdotal accounts and personal beliefs rather than definitive data. The recent appreciation that noninfectious inflammatory causes predispose to infectious sinusitis has stimulated renewed interest in developing and documenting efficacious ancillary therapies that could supplement or abrogate antibiotic use. Ancillary therapies of sinusitis could be directed toward (1) preventing viral upper respiratory tract infections (immunizations, virucidal-impregnated tissues, and proper hand-washing techniques); (2) blocking rhinoviral replication and suppressing mediator release with supraphysiologic nasal hyperthermia, although contradictory studies exist with regard to efficacy; (3) promoting sinus and nasal ventilation with both topical and oral alpha-agonists and exercise; (4) improving mucociliary clearance by reducing mucus viscosity and elasticity with saline solution irrigation, mucoregulators (N-acetylcysteine, S-carboxymethylcysteine, and iodinated glycerol), and ciliary stimulants (adenosine triphosphate); and (5) suppressing/modulating cellular inflammation (eosinophilic, basophilic, and neutrophilic) with topical nasal corticosteroid sprays and mediator antagonists. Recommendations are forwarded for future investigations of promising nonantibiotic ancillary therapies of chronic sinusitis.			ZEIGER, RS (corresponding author), KAISER PERMANENTE MED CTR,DEPT ALLERGY,7060 CLAIREMONT MESA BLVD,SAN DIEGO,CA 92111, USA.			Zeiger, Robert/0000-0001-5788-5063				Akerlund A., 1991, AM J RHINOL, V5, P157; ASCHAN G, 1974, ACTA OTO-LARYNGOL, V77, P433, DOI 10.3109/00016487409124646; AUST R, 1974, ACTA OTO-LARYNGOL, V78, P264, DOI 10.3109/00016487409126354; AUST R, 1979, ACTA OTO-LARYNGOL, V88, P455, DOI 10.3109/00016487909137193; AXELSSON A, 1981, ACTA OTO-LARYNGOL, V91, P313, DOI 10.3109/00016488109138513; AYLWARD M, 1980, EUR J RESPIR DIS, V61, P81; BAND BC, 1967, J HOPKINS MED J, V121, P38; BANG BG, 1967, JOHNS HOPKINS MED J, V121, P38; BENDE M, 1983, ACTA OTO-LARYNGOL, V96, P523, DOI 10.3109/00016488309132740; BOMAN G, 1983, EUR J RESPIR DIS, V64, P405; BORUM P, 1980, J ALLERGY CLIN IMMUN, V66, P25, DOI 10.1016/0091-6749(80)90134-7; BORUM P, 1979, CLIN OTOLARYNGOL, V4, P407, DOI 10.1111/j.1365-2273.1979.tb01773.x; BROOKS CD, 1985, ANN ALLERGY, V55, P557; BROWN EARL, 1960, ANN ALLERGY, V18, P1321; CHODOSH S, B EUR PHYSIOPATHOL R, V9, P452; COLE P, 1984, AM REV RESPIR DIS, V129, P351; COLE P, 1982, NOSE; CONNELL JT, 1987, AM J RHINOL, V1, P87; CUENANT G, 1986, ORL J OTO-RHINO-LARY, V48, P226, DOI 10.1159/000275873; DALY K, 1991, PEDIATR INFECT DIS J, V10, P500, DOI 10.1097/00006454-199107000-00004; DECHATEAU GSM, 1986, ALLERGY, V41, P260; DEITMER T, 1991, AM J RHINOL, V5, P39; DULFANO MJ, 1973, AM REV RESPIR DIS, V107, P130; EDWARDS GF, 1976, CHEST, V70, P506, DOI 10.1378/chest.70.4.506; ERICSSON CH, 1986, EUR J RESPIR DIS, V69, P248; FALLIERS CJ, 1980, ANN ALLERGY, V45, P75; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; FORREST JB, 1979, AM REV RESPIR DIS, V120, P511; FOSTER WM, 1983, EUR J RESPIR DIS, V64, P554; FRANCIS RA, 1977, BRIT J DIS CHEST, V71, P173, DOI 10.1016/0007-0971(77)90107-3; GAFFEY MJ, 1988, PEDIATR INFECT DIS J, V7, P223, DOI 10.1097/00006454-198803000-00032; GERRITY TR, 1983, NEW ENGL J MED, P139; GRASSI C, 1980, EUR J RESP DIS S111, V61, P93; GROSSAN M, 1976, ANL, V3, P65; GROTH ML, 1991, AM REV RESPIR DIS, V144, P1042, DOI 10.1164/ajrccm/144.5.1042; HENDERSON WR, 1984, IMMUNOLOGY, V51, P679; HIRATA K, 1985, Mie Medical Journal, V34, P205; HIRSCH SR, 1967, J ALLERGY, V39, P265, DOI 10.1016/0021-8707(67)90090-1; HIRSCH SR, 1973, CHEST, V63, P9, DOI 10.1378/chest.63.1.9; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; HOLMBERG K, 1986, EUR J CLIN PHARMACOL, V30, P625, DOI 10.1007/BF00542425; INGELS K J A O, 1991, Rhinology (Utrecht), V29, P17; IRAVANI J, 1976, PHARMACOL THER PT B, V2, P471, DOI 10.1016/0306-039X(76)90003-9; IRAVANI J, 1974, RESPIRATION, V31, P350, DOI 10.1159/000193595; JANNERT M, 1984, ACTA OTO-LARYNGOL, V97, P325, DOI 10.3109/00016488409130996; JOHNSON NT, 1991, AM REV RESPIR DIS, V144, P1091, DOI 10.1164/ajrccm/144.5.1091; JONES AS, 1985, BRIT MED J, V290, P1171, DOI 10.1136/bmj.290.6476.1171; JUTO JE, 1984, ACTA OTO-LARYNGOL, V98, P533, DOI 10.3109/00016488409107594; KARJA J, 1983, INT J PEDIATR OTORHI, V5, P275, DOI 10.1016/S0165-5876(83)80040-8; KIRKEGAARD J, 1987, J ALLERGY CLIN IMMUN, V79, P585, DOI 10.1016/S0091-6749(87)80153-7; KUHN JJ, 1982, CHEST, V82, P713, DOI 10.1378/chest.82.6.713; LAKE CR, 1988, AM J MED, V85, P339, DOI 10.1016/0002-9343(88)90583-9; LEE TC, 1984, J BIOL CHEM, V259, P5526; LILDHOLDT T, 1988, ACTA OTO-LARYNGOL, V105, P140, DOI 10.3109/00016488809119457; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; LUNDGREN JD, 1991, J ALLERGY CLIN IMMUN, V87, P689, DOI 10.1016/0091-6749(91)90390-A; LWOFF A, 1969, BACTERIOL REV, V33, P390, DOI 10.1128/MMBR.33.3.390-403.1969; MACKNIN ML, 1990, JAMA-J AM MED ASSOC, V264, P989; MAJIMA Y, 1983, BIORHEOLOGY, V20, P251; MAJIMA Y, 1990, AM REV RESPIR DIS, V141, P79, DOI 10.1164/ajrccm/141.1.79; MARRIOTT C, 1982, ADV EXP MED BIOL, V144, P75; MATTHYS H, 1985, RESPIRATION, V48, P329, DOI 10.1159/000194847; MATTHYS H, 1974, SCAND J RESPIR D S85, V55, P33; MCLEAN JA, 1983, J ALLERGY CLIN IMMUN, V72, P187, DOI 10.1016/0091-6749(83)90528-6; MELEN I, 1986, ACTA OTO-LARYNGOL, V102, P99, DOI 10.3109/00016488609108652; MELEN I, 1986, ACTA OTO-LARYNGOL, V101, P494, DOI 10.3109/00016488609108636; MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V89, P301; MELTZER EO, 1988, ALLERGY PRINCIPLES P, P1273; MYGIND N, 1991, RHINITIS, P247; NACLERIO RM, 1988, PEDIATR INFECT DIS J, V7, P218, DOI 10.1097/00006454-198803000-00031; NELSON BL, 1982, J ALLERGY CLIN IMMUN, V70, P125, DOI 10.1016/0091-6749(82)90240-8; NUUTINEN J, 1985, ACTA OTO-LARYNGOL, V99, P605, DOI 10.3109/00016488509182267; NUUTINEN J, 1985, Rhinology (Utrecht), V23, P3; NUUTINEN J, 1985, INT J PEDIATR OTORHI, V10, P47, DOI 10.1016/S0165-5876(85)80056-2; NUUTINEN J, 1988, ARCH OTO-RHINO-LARYN, V245, P284, DOI 10.1007/BF00464631; OHKI M, 1987, ACTA OTO-LARYNGOL, V104, P328, DOI 10.3109/00016488709107336; OHKI M, 1989, AM J RHINOL, V3, P1, DOI DOI 10.2500/105065889782024393; OPHIR D, 1988, ANN OTO RHINOL LARYN, V97, P259, DOI 10.1177/000348948809700309; OPHIR D, 1987, AM J OTOLARYNG, V3, P149; PANOSETTI E, 1980, EUR J RESPIR DIS, V61, P159; PATRIARCA G, 1991, ANN ALLERGY, V67, P60; PAVIA D, 1978, AM REV RESPIR DIS, V117, P199; PAVIA D, 1985, EUR J RESPIR DIS, V67, P177; PETRUSON B, 1982, ACTA OTO-LARYNGOL, V94, P563, DOI 10.3109/00016488209128948; PETTY TL, 1990, CHEST, V97, P75, DOI 10.1378/chest.97.1.75; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; POLAKOW ES, 1973, S AFR MED J, V47, P985; PORTA M, 1986, ANN ALLERGY, V57, P340; PROUD D, 1988, AM REV RESPIR DIS, V137, P613, DOI 10.1164/ajrccm/137.3.613; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V87, P457, DOI 10.1016/0091-6749(91)90001-5; ROSSMAN CM, 1984, AM REV RESPIR DIS, V129, P161; ROSSMAN CM, 1988, PEDIATR PULM, V5, P36, DOI 10.1002/ppul.1950050109; SAANO V, 1991, ACTA OTO-LARYNGOL, V111, P130; SAKAKURA Y, 1985, CLIN OTOLARYNGOL, V10, P79, DOI 10.1111/j.1365-2273.1985.tb01171.x; SAKETKHOO D, 1978, CHEST, V74, P408; SAKETKHOO K, 1978, AM REV RESPIR DIS, V118, P251; SALVIN RG, 1988, J ALLERGY CLIN IMMUN, V81, P284; SANTACRUZ R, 1974, AM REV RESPIR DIS, V109, P458; Schleimer RP, 1989, ANTIINFLAMMATORY STE; SEDERBERG-OLSEN J F, 1989, Rhinology (Utrecht), V27, P251; Siegel SC, 1991, RHINITIS, P231; SPECTOR SL, 1982, CLIN ALLERGY, V12, P187, DOI 10.1111/j.1365-2222.1982.tb01638.x; STEEN SN, 1974, CLIN PHARMACOL THER, V16, P58; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; STEVENSON DD, 1987, J ALLERGY CLIN IMMUN, V80, P788, DOI 10.1016/S0091-6749(87)80266-X; STIERNA P, 1991, ACTA OTO-LARYNGOL, V111, P135, DOI 10.3109/00016489109137364; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; SYKES DA, 1986, LANCET, V2, P159; TOS M, 1984, ACTA OTO-LARYNGOL, V97, P151, DOI 10.3109/00016488409130975; TYRRELL D, 1989, BRIT MED J, V298, P1280, DOI 10.1136/bmj.298.6683.1280; TYRRELL DAJ, 1988, ANNU REV MICROBIOL, V42, P35; WEISSBERGER D, 1981, J ALLERGY CLIN IMMUN, V67, P357, DOI 10.1016/0091-6749(81)90080-4; YERUSHALMI A, 1980, CR ACAD SCI D NAT, V291, P957; ZEIGER RS, 1989, AM J RHINOL, V3, P113; ZEIGER RS, 1983, IMMUNOL ALLERGY PRAC, V5, P51; ZIMENT I, 1988, BIOMED PHARMACOTHER, V42, P513; ZIMENT I, 1986, RESPIRATION, V50, P26, DOI 10.1159/000195085; ZIMENT I, 1989, DRUGS BRONCHIAL MUCO; ZIMENT I, 1988, PROBLEMS RESP CARE, V1, P15; 1985, THORAX, V40, P832	120	51	56	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			478	495		10.1016/0091-6749(92)90173-Y	http://dx.doi.org/10.1016/0091-6749(92)90173-Y			18	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1382084				2022-12-18	WOS:A1992JP52100014
J	MAKINENKILJUNEN, S; TURJANMAA, K; PALOSUO, T; REUNALA, T				MAKINENKILJUNEN, S; TURJANMAA, K; PALOSUO, T; REUNALA, T			CHARACTERIZATION OF LATEX ANTIGENS AND ALLERGENS IN SURGICAL GLOVES AND NATURAL-RUBBER BY IMMUNOELECTROPHORETIC METHODS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX ALLERGENS; IMMUNOELECTROPHORESIS; CROSS-REACTION; LATEX GLOVES; RUBBER; IMMEDIATE HYPERSENSITIVITY	CONTACT URTICARIA	Allergy to natural rubber (latex) products is increasingly frequent among both medical personnel and lay subjects. Although individual antigens and allergens in latex products have not been fully characterized, they are believed to derive from the sap of the rubber tree. Rabbit IgG and human IgE antibodies against rubber proteins were used to characterize antigens and allergens in surgical latex gloves and natural rubber by crossed immunoelectrophoresis and its modifications. The results from crossed-line immunoelectrophoresis demonstrated that the surgical latex gloves had at least 10 antigens in common with natural rubber sap and ammoniated latex. In crossed radioimmunoelectrophoresis, at least six of the 10 protein antigens in the surgical glove extract and natural rubber were allergens since they bound IgE antibodies from the latex-allergic patients' sera. The surgical glove extract also demonstrated one allergen not found in natural rubber, suggesting that rubber proteins may be altered during glove manufacture.	UNIV HOSP TAMPERE, DEPT DERMATOL, TAMPERE, FINLAND; NATL PUBL HLTH INST, SF-00280 HELSINKI 28, FINLAND	Tampere University; Tampere University Hospital; Finland National Institute for Health & Welfare	MAKINENKILJUNEN, S (corresponding author), UNIV HELSINKI CENT HOSP, DEPT DERMATOL & ALLERGOL, MEILAHDENTIE 2, SF-00250 HELSINKI, FINLAND.							ALENIUS H, 1991, INT ARCH ALLER A IMM, V96, P376, DOI 10.1159/000235525; ARCHER BL, 1960, BIOCHEM J, V75, P236, DOI 10.1042/bj0750236; AXELSEN NH, 1983, SCAND J IMMUNOL S10, V17, P141; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; Cronin E., 1980, RUBBER CONTACT DERMA, P714; Gelfanf D. W., 1990, AM J RADIOL, V156, P1; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; MAKINEN-KILJUNEN S, 1991, Journal of Allergy and Clinical Immunology, V87, P270, DOI 10.1016/0091-6749(91)91807-6; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; SLATER J E, 1991, Journal of Allergy and Clinical Immunology, V87, P268, DOI 10.1016/0091-6749(91)91799-Y; SLATER JE, 1990, ANN ALLERGY, V65, P411; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1988, BRIT MED J, V297, P1029, DOI 10.1136/bmj.297.6655.1029; TURJANMAA K, 1990, LANCET, V336, P1588, DOI 10.1016/0140-6736(90)93372-V	19	51	51	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					230	235		10.1016/0091-6749(92)90076-E	http://dx.doi.org/10.1016/0091-6749(92)90076-E			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1500627				2022-12-18	WOS:A1992JJ42300013
J	BOUSQUET, J; HEJJAOUI, A; BECKER, WM; COUR, P; CHANAL, I; LEBEL, B; DHIVERT, H; MICHEL, FB				BOUSQUET, J; HEJJAOUI, A; BECKER, WM; COUR, P; CHANAL, I; LEBEL, B; DHIVERT, H; MICHEL, FB			CLINICAL AND IMMUNOLOGICAL REACTIVITY OF PATIENTS ALLERGIC TO GRASS POLLENS AND TO MULTIPLE POLLEN SPECIES .1. CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PLACEBO-CONTROLLED IMMUNOTHERAPY; EOSINOPHIL CATIONIC PROTEIN; HLA ANTIGEN FREQUENCIES; SERUM IGE LEVELS; DOUBLE-BLIND; MEDITERRANEAN AREA; RUSH IMMUNOTHERAPY; NASAL CHALLENGE; NITROCELLULOSE; EXTRACT	The heterogeneity of pollen-allergic individuals is well-known but poorly characterized. Twenty-six patients were studied to characterize their immunologic and clinical patterns. Thirteen patients were allergic only to grass pollens, and 13 other patients were allergic to grass-pollen and other pollen species, including Cupressaceae, plane tree, olive, and Parietaria. The IgE response was assessed by the titration of serum total IgE and orchard grass-specific IgE, as well as by IgE immunoblots to orchard-grass pollens. Clinical reactivity was assessed by nasal challenge with orchard-grass pollens before the pollen season and nasal and bronchial symptom-medication scores between April 1 and June 15. Pollen counts were obtained during this period of survey. Polysensitized patients had significantly increased levels of serum total and specific IgE and a greater heterogeneity of IgE immunoblots, suggesting an enhanced qualitative and quantitative IgE immune response. Polysensitized patients had nasal and bronchial symptoms occurring earlier than grass pollen-allergic individuals, confirming the priming effect caused by other plans flowering with an earlier season for both nasal and bronchial mucosa. Alternatively, the early symptoms may be attributable to the tree pollens or might reflect the higher grass-pollen IgE level in the polysensitized group. Bronchial symptoms appeared a few weeks after nasal symptoms. Nasal challenges were similar in both groups, and the severity of nasal symptoms during the season was not significantly different in both groups, suggesting that the intensity of symptoms is not related to the sensitization nor to the IgE immune response of the subjects.	CHU MONTPELLIER, MALAD RESP CLIN, F-34059 MONTPELLIER, FRANCE; FORSCHUNGSINST BORSTEL, W-2061 BORSTEL, GERMANY; CNRS, PALYNOL LAB, F-34033 MONTPELLIER, FRANCE; INSERM, U58, F-34100 MONTPELLIER, FRANCE	Universite de Montpellier; CHU de Montpellier; Forschungszentrum Borstel; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			Bousquet, Jean/O-4221-2019					ANDERSSON M, 1989, ALLERGY, V44, P342, DOI 10.1111/j.1398-9995.1989.tb00456.x; BACON JR, 1981, J ALLERGY CLIN IMMUN, V67, P111, DOI 10.1016/0091-6749(81)90005-1; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BATTEIGER B, 1982, J IMMUNOL METHODS, V55, P297, DOI 10.1016/0022-1759(82)90089-8; BORUM P, 1983, EUR J RESPIR DIS, V64, P65; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1987, INT ARCH ALLER A IMM, V82, P550, DOI 10.1159/000234277; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; BOUSQUET J, IN PRESS ANN ALLERGY; BROSTROM G, 1989, GRANA, V28, P123, DOI 10.1080/00173138909429963; CHARPIN J, 1960, PRESSE MED, V68, P2175; CONNELL JT, 1968, J ALLERGY, V41, P101; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CONROY MC, 1977, J IMMUNOL, V118, P1317; COUR P, 1974, Pollen et Spores, V16, P103; DEWECK AL, 1989, ALLERGOLOGIE, V12, pS85; DREBORG S, 1986, HDB XPT IMMUNOLOGY, V1; FORD SA, 1985, INT ARCH ALLER A IMM, V78, P15, DOI 10.1159/000233855; HAAS H, 1986, INT ARCH ALLER A IMM, V79, P434, DOI 10.1159/000234014; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; HEJJAOUI A, 1985, J ALLERGY CLIN IMMUN, V75, P164, DOI 10.1016/0091-6749(85)90372-0; JULIUSSON S, 1988, CLIN ALLERGY, V18, P615, DOI 10.1111/j.1365-2222.1988.tb02913.x; KONNO A, 1983, EUR J RESPIR DIS, V64, P155; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; MACLOUF J, 1986, PROSTAGLANDINS, V31, P123, DOI 10.1016/0090-6980(86)90230-3; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1977, IMMUNOGENETICS, V5, P235, DOI 10.1007/BF01570479; MARSH DG, 1977, IMMUNOGENETICS, V5, P217, DOI 10.1007/BF01570478; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; PELTRE G, 1987, GRANA, V26, P158, DOI 10.1080/00173138709429945; PELTRE G, 1982, IMMUNOL LETT, V5, P127, DOI 10.1016/0165-2478(82)90096-7; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; RAFFERTY P, 1989, PROGRESS IN ALLERGY AND CLINICAL IMMUNOLOGY, P218; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; Righetti P.G., 1983, ISOELECTRIC FOCUSING; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; SINGH MB, 1985, INT ARCH ALLER A IMM, V78, P300, DOI 10.1159/000233901; TAUDORF E, 1988, INT ARCH ALLER A IMM, V86, P225, DOI 10.1159/000234576; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VIEGAS M, 1987, BRIT MED J, V294, P414, DOI 10.1136/bmj.294.6569.414; WACHS M, 1989, J ALLERGY CLIN IMMUN, V84, P492, DOI 10.1016/0091-6749(89)90362-X; 1989, GUIDELINES REGISTRAT	53	51	52	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					737	746		10.1016/0091-6749(91)90397-7	http://dx.doi.org/10.1016/0091-6749(91)90397-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005328				2022-12-18	WOS:A1991FB80100021
J	LANTNER, R; REISMAN, RE				LANTNER, R; REISMAN, RE			CLINICAL AND IMMUNOLOGICAL FEATURES AND SUBSEQUENT COURSE OF PATIENTS WITH SEVERE INSECT-STING ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO, BUFFALO GEN HOSP,DEPT MED,DIV ALLERGY, ALLERGY RES LAB, BUFFALO, NY 14260 USA	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BROWN H, 1970, ARCH INTERN MED, V125, P665, DOI 10.1001/archinte.125.4.665; ENICK F, 1980, W J MED, V133, P463; FRAZIER CLAUDE A., 1964, SOUTHERN MED J, V57, P1028, DOI 10.1097/00007611-196409000-00006; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V83, P273; HARVEY P, 1984, MED J AUSTRALIA, V140, P209, DOI 10.5694/j.1326-5377.1984.tb103996.x; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JENSEN OM, 1962, ACTA PATHOL MIC SC, V54, P9; LIGHT WC, 1976, CLIN ALLERGY, V6, P293, DOI 10.1111/j.1365-2222.1976.tb01909.x; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; MAURIELLO PM, 1984, J ALLERGY CLIN IMMUN, V74, P494, DOI 10.1016/0091-6749(84)90384-1; MOSBECH H, 1983, ALLERGY, V38, P195, DOI 10.1111/j.1398-9995.1983.tb01606.x; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; RANDOLPH CC, 1986, J ALLERGY CLIN IMMUN, V77, P823, DOI 10.1016/0091-6749(86)90379-9; REISMAN RE, 1989, INT ARCH ALLER A IMM, V89, P67, DOI 10.1159/000234925; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; SAVLIWALA MN, 1987, J ALLERGY CLIN IMMUN, V80, P741, DOI 10.1016/0091-6749(87)90296-X; SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0	20	51	51	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				900	906		10.1016/0091-6749(89)90387-4	http://dx.doi.org/10.1016/0091-6749(89)90387-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2600324				2022-12-18	WOS:A1989CG29300008
J	BUIST, AS				BUIST, AS			ASTHMA MORTALITY - WHAT HAVE WE LEARNED	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									OREGON HLTH SCI UNIV, DEPT PHYSIOL, PORTLAND, OR 97201 USA	Oregon Health & Science University	BUIST, AS (corresponding author), OREGON HLTH SCI UNIV, DEPT MED, MAIL CODE L334A, PORTLAND, OR 97201 USA.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BARGER LW, 1988, ANN ALLERGY, V60, P31; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; BOSCO LA, 1987, J ALLERGY CLIN IMMUN, V80, P398, DOI 10.1016/0091-6749(87)90058-3; BUIST AS, 1988, CHEST, V93, P449, DOI 10.1378/chest.93.3.449; BURNEY P, 1987, CHEST, V91, pS79, DOI 10.1378/chest.91.6.79S; BURR ML, 1974, J EPIDEMIOL COMMUNIT, V41, P185; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; DOLL R, 1967, BRIT MED J, V1, P756, DOI 10.1136/bmj.1.5542.756-a; ESDAILE JM, 1987, ARCH INTERN MED, V147, P543, DOI 10.1001/archinte.147.3.543; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GROSS NJ, 1980, AM REV RESPIR DIS, V121, P203; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; JACKSON R, 1988, CHEST, V94, P914, DOI 10.1378/chest.94.5.914; JOSEPH X, 1981, FUNDAM APPL TOXICOL, V2, P147; KIRCHER T, 1987, JAMA-J AM MED ASSOC, V258, P349, DOI 10.1001/jama.258.3.349; KLEBBA AJ, 1980, MON VITAL STAT REP, V28, pS1; MAO Y, 1987, CAN MED ASSOC J, V137, P620; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; PAULOZZI LJ, 1986, ANN ALLERGY, V56, P392; ROBIN ED, 1988, CHEST, V93, P614, DOI 10.1378/chest.93.3.614; SAMET JM, 1987, CHEST, V91, pS74, DOI 10.1378/chest.91.6.74S; SEARS MR, 1987, J ALLERGY CLIN IMM 2, V80, P373; SEARS MR, 1987, J RESPIR DIS, V8, P39; SHEFFER AL, 1987, J ALLERGY CLIN IMMUN, V80, P361, DOI 10.1016/0091-6749(87)90047-9; SLY RM, 1984, ANN ALLERGY, V53, P20; SLY RM, 1987, J ALLERGY CLIN IMMUN, V80, P438, DOI 10.1016/0091-6749(87)90070-4; SPEIZER FE, 1987, J ALLERGY CLIN IMMUN, V80, P368, DOI 10.1016/0091-6749(87)90051-0; STEWART CJ, 1985, BRIT J DIS CHEST, V79, P229, DOI 10.1016/S0007-0971(85)80023-1; STOLLEY PD, 1978, PREV MED, V7, P519, DOI 10.1016/0091-7435(78)90265-7; WOOLCOCK AJ, 1985, CHEST, V87, pS209, DOI 10.1378/chest.87.5_Supplement.209S; WOOLCOCK AJ, 1987, CHEST, V91, pS89, DOI 10.1378/chest.91.6.89S; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; 1984, MONTHLY VITAL STA S2, V32; 1970, CAUSES DEATH; 1972, NATIONAL PRESCRIPTIO	38	51	52	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					275	283		10.1016/0091-6749(89)90408-9	http://dx.doi.org/10.1016/0091-6749(89)90408-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2674261	Bronze			2022-12-18	WOS:A1989AR19900001
J	GOLDEN, DBK; ADDISON, BI; GADDE, J; KAGEYSOBOTKA, A; VALENTINE, MD; LICHTENSTEIN, LM				GOLDEN, DBK; ADDISON, BI; GADDE, J; KAGEYSOBOTKA, A; VALENTINE, MD; LICHTENSTEIN, LM			PROSPECTIVE OBSERVATIONS ON STOPPING PROLONGED VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GOLDEN, DBK (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,DEPT MED,DIV CLIN IMMUNOL,GOOD SAMARITAN PROFESS BLDG,BALTIMORE,MD 21239, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08270] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DAY JH, 1985, J ALLERGY CLIN IMMUN, V75, P209, DOI 10.1016/0091-6749(85)90553-6; GADDE J, 1985, ANN ALLERGY, V54, P348; GADDE J, 1984, Journal of Allergy and Clinical Immunology, V73, P159; GOLDEN D B K, 1984, Journal of Allergy and Clinical Immunology, V73, P189; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P435, DOI 10.1016/0091-6749(86)90177-6; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; GOLDEN DBK, 1983, J ALLERGY CLIN IMMUN, V71, P140, DOI 10.1016/0091-6749(83)90330-5; GOLDEN DBK, 1985, ALLERGY, P507; GOLDEN DBK, 1983, J CLIN IMMUNOASSAY, V6, P172; GRAFT DF, 1987, J ALLERGY CLIN IMMUN, V80, P162, DOI 10.1016/0091-6749(87)90125-4; HAMILTON RG, 1981, J ALLERGY CLIN IMMUN, V67, P14, DOI 10.1016/0091-6749(81)90039-7; HOFFMAN DR, 1981, ANN ALLERGY, V46, P17; LAWRENCE ID, 1986, J ALLERGY CLIN IMMUN, V77, P178; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P791; RANDOLPH CC, 1986, J ALLERGY CLIN IMMUN, V77, P823, DOI 10.1016/0091-6749(86)90379-9; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P735; SETTIPANE GA, 1979, CLIN ALLERGY, V9, P385, DOI 10.1111/j.1365-2222.1979.tb02497.x; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; URBANEK R, 1985, J PEDIATR-US, V107, P367, DOI 10.1016/S0022-3476(85)80508-4	20	51	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1989	84	2					162	167		10.1016/0091-6749(89)90320-5	http://dx.doi.org/10.1016/0091-6749(89)90320-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL836	2760358				2022-12-18	WOS:A1989AL83600005
J	AYARS, GH; ALTMAN, LC; FRAZIER, CE; CHI, EY				AYARS, GH; ALTMAN, LC; FRAZIER, CE; CHI, EY			THE TOXICITY OF CONSTITUENTS OF CEDAR AND PINE WOODS TO PULMONARY EPITHELIUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON, DEPT MED, DIV ALLERGY & INFECT DIS, RM-13, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT INTERNAL MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, COLL FOREST RESOURCES, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002366] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 0 8229] Funding Source: Medline; NIEHS NIH HHS [R01 ES0 2366] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AYARS GH, 1984, AM REV RESPIR DIS, V129, P964; AYARS GH, 1986, J CLIN INVEST, V78, P1579, DOI 10.1172/JCI112750; BARDANA EJ, 1983, EUR J RESPIR DIS, V64, P241; Black T. H, 1983, ALDRICHIM ACTA, V16, P3; BURGE PS, 1980, CLIN ALLERGY, V10, P137, DOI 10.1111/j.1365-2222.1980.tb02091.x; BURGE PS, 1981, THORAX, V36, P828, DOI 10.1136/thx.36.11.828; BURGE PS, 1979, LANCET, V2, P591; BURGE PS, 1978, CLIN ALLERGY, V8, P1, DOI 10.1111/j.1365-2222.1978.tb00441.x; BURGE PS, 1982, THORAX, V37, P348, DOI 10.1136/thx.37.5.348; BUTCHER BT, 1986, J ALLERGY CLIN IMMUN, V78, P547, DOI 10.1016/0091-6749(86)90068-0; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1987, J ALLERGY CLIN IMMUN, V79, P792, DOI 10.1016/0091-6749(87)90212-0; CHANYEUNG M, 1980, J ALLERGY CLIN IMMUN, V65, P333, DOI 10.1016/0091-6749(80)90209-2; CHANYEUNG M, 1977, AM REV RESPIR DIS, V116, P1023; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; DIEM K, 1975, SCI TABLES; DOBBS LG, 1980, BIOCHIM BIOPHYS ACTA, V618, P510, DOI 10.1016/0005-2760(80)90270-2; FISHER AA, 1981, CUTIS, V27, P466; FISHER AB, 1980, J APPL PHYSIOL, V49, P743, DOI 10.1152/jappl.1980.49.4.743; GANDEVIA B, 1970, BRIT J IND MED, V27, P235; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; KIKKAWA Y, 1974, LAB INVEST, V30, P76; LANE BP, 1976, ENVIRON HEALTH PERSP, V16, P89, DOI 10.2307/3428589; MACDONAL.BF, 1970, J CHROMATOGR, V51, P553, DOI 10.1016/S0021-9673(01)96907-9; MASON RJ, 1977, AM REV RESPIR DIS, V115, P1015; MILNE J, 1969, MED J AUSTRALIA, V2, P741, DOI 10.5694/j.1326-5377.1969.tb107378.x; MOIRA CY, 1984, AM REV RESPIR DIS, V130, P1038; NADEL JA, 1985, CHEST, V87, pS171, DOI 10.1378/chest.87.5_Supplement.171S; ROONEY JC, 1971, J PEDIATR-US, V79, P744, DOI 10.1016/S0022-3476(71)80385-2; TSE KS, 1982, CLIN ALLERGY, V12, P249, DOI 10.1111/j.1365-2222.1982.tb02525.x; WARD PA, 1986, J ALLERGY CLIN IMMUN, V78, P373, DOI 10.1016/0091-6749(86)90020-5; WHITEHEAD LW, 1981, AM IND HYG ASSOC J, V42, P178, DOI 10.1080/15298668191419541; YEUNG MC, 1973, AM REV RESPIR DIS, V108, P1103	34	51	53	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1989	83	3					610	618		10.1016/0091-6749(89)90073-0	http://dx.doi.org/10.1016/0091-6749(89)90073-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T8596	2926083				2022-12-18	WOS:A1989T859600007
J	PELIKAN, Z; PELIKANFILIPEK, M				PELIKAN, Z; PELIKANFILIPEK, M			CYTOLOGIC CHANGES IN THE NASAL SECRETIONS DURING THE IMMEDIATE NASAL RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PELIKAN, Z (corresponding author), INST MED SCI DE KLOKKENBERG,DEPT ALLERGOL & IMMUNOL,GALDERSEWEG 81,4836 AE BREDA,NETHERLANDS.							BEESON PB, 1980, EOSINOPHIL HLTH DISE, P313; BHANDARI CM, 1976, ANN ALLERGY, V37, P280; BICKMORE JT, 1976, LARYNGOSCOPE, V86, P516, DOI 10.1288/00005537-197604000-00007; BRYAN W T, 1959, Trans Am Acad Ophthalmol Otolaryngol, V63, P613; BRYAN WTK, 1964, ANN OTO RHINOL LARYN, V73, P474, DOI 10.1177/000348946407300217; BRYAN WTK, 1958, T AM ACAD OPHTHALMOL, V63, P597; CAUNA N, 1969, ANN OTO RHINOL LARYN, V78, P865, DOI 10.1177/000348946907800418; Cohen SG, 1983, ALLERGY PRINCIPLES P, P701; CONNELL JT, 1984, CLIN REV ALLERG, V2, P213; CONNELL JT, 1976, BRONCHIAL ASTHMA MEC, P481; GILLESPIE E, 1977, COMPREHENSIVE IMMU 3, P101; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P73, DOI 10.1016/0091-6749(77)90086-0; GOETZL EJ, 1975, ARCH PATHOL, V99, P1; GOETZL EJ, 1977, COMPREHENSIVE IMMU 3, P113; HANSEL FK, 1953, CLIN ALLERGY, P408; HANSEL FRENCH K., 1934, JOUR ALLERGY, V5, P357, DOI 10.1016/S0021-8707(34)90159-3; HASTIE R, 1979, LAB INVEST, V40, P554; HENSON PM, 1977, IMMUNOLOGY RECEPTORS, P131; HENSON PM, 1981, BIOCH ACUTE ALLERGIC, P51; HOLOPAINEN E, 1974, MSCHR OHR HK WIEN, V108, P361; HOURI M, 1972, Clinical Allergy, V2, P285, DOI 10.1111/j.1365-2222.1972.tb01292.x; HUBSCHER TT, 1977, ANN ALLERGY, V38, P83; IGNARRO LJ, 1975, J CYCLIC NUCL PROT, V1, P283; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; JALOWAYSKI AA, 1983, J ALLERGY CLIN IMMUN, V71, P89, DOI 10.1016/0091-6749(83)90125-2; KAJOSAARI M, 1981, ALLERGY, V36, P329, DOI 10.1111/j.1398-9995.1981.tb01584.x; KAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P90, DOI 10.1016/0091-6749(79)90042-3; MALMBERG H, 1979, ALLERGY, V34, P331; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; MURRAY AB, 1969, J ALLERGY, V43, P1, DOI 10.1016/0021-8707(69)90014-8; MURRAY AB, 1970, ANN ALLERGY, V28, P142; MURRAY AB, 1971, CAN MED ASSOC J, V104, P599; MYGIND N, 1973, ARCH KLIN EXP OHR, V204, P123, DOI 10.1007/BF00302160; Mygind N, 1979, NASAL ALLERGY, P170; MYGIND N, 1979, ALLERGY, V34, P194; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P283, DOI 10.1007/BF00457469; OKUDA M, 1982, RHINOLOGY S, V19, P115; OLSSON I, 1979, ALLERGY, V34, P353, DOI 10.1111/j.1398-9995.1979.tb02005.x; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PELIKAN Z, 1983, J ALLERGY CLIN IMMUN, V72, P657, DOI 10.1016/0091-6749(83)90625-5; PELIKAN Z, 1977, ANN ALLERGY, V38, P263; PELIKAN Z, 1985, J ALLERGY CLIN IMMUN, V75, P112, DOI 10.1016/0091-6749(85)90167-8; PELIKAN Z, 1981, 12TH P ANN M EUR AC, P634; PELIKAN Z, 1979, 1979 P INT S DAV SWI, P772; PLAUT M, 1983, ALLERGY PRINCIPLES P, P119; SASAKI Y, 1977, ANN ALLERGY, V39, P106; SCHIEIMER RP, 1983, CLIN REV ALLERGY MAS, V1, P327; SCHLEIMER RP, 1984, J ALLERGY CLIN IMMUN, V74, P473, DOI 10.1016/0091-6749(84)90381-6; SHIODA H, 1979, MAST CELL, P422; SMITH JA, 1980, CELL BIOL INFLAMMATI, P189; VAHERI EINO, 1956, ACTA ALLERGOL, V10, P203, DOI 10.1111/j.1398-9995.1956.tb02997.x; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2; WASSERMAN SI, 1983, 11 P INV S INT C ALL, P29; WILLIAMS RB, 1972, ANN ALLERGY, V30, P189; Zucker-Franklin D, 1974, Adv Intern Med, V19, P1; 1972, HAMATOLOGISCHE TAFEL, P32	56	51	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					1103	1112		10.1016/0091-6749(88)90150-9	http://dx.doi.org/10.1016/0091-6749(88)90150-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	3204254				2022-12-18	WOS:A1988R631100021
J	NORMAN, PS				NORMAN, PS			IMMUNOTHERAPY FOR NASAL ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI020136, R01AI004866, R37AI004866] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20136, AI 04866] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUKRUST L, 1979, INT ARCH ALLER A IMM, V60, P68, DOI 10.1159/000232324; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; FONTANA VJ, 1966, J AMER MED ASSOC, V195, P985, DOI 10.1001/jama.195.12.985; FRANKLAND AW, 1954, LANCET, V1, P1055; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; METZGER WJ, 1983, J ALLERGY CLIN IMMUN, V71, P119, DOI 10.1016/0091-6749(83)90245-2; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; PELIKAN Z, 1982, ANN ALLERGY, V49, P200; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SHAMPAIN MP, 1982, AM REV RESPIR DIS, V126, P493; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; VIANDER M, 1976, CLIN ALLERGY, V8, P387; WARNER JO, 1978, LANCET, V2, P912; WEYER A, 1981, ALLERGY, V36, P309, DOI 10.1111/j.1398-9995.1981.tb01582.x; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5	29	51	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	2	S			992	996		10.1016/0091-6749(88)90167-4	http://dx.doi.org/10.1016/0091-6749(88)90167-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7037	3372917				2022-12-18	WOS:A1988N703700012
J	TAKIZAWA, H; SUKO, M; KOBAYASHI, N; SHOJI, S; OHTA, K; NOGAMI, M; OKUDAIRA, H; MIYAMOTO, T; SHIGA, J				TAKIZAWA, H; SUKO, M; KOBAYASHI, N; SHOJI, S; OHTA, K; NOGAMI, M; OKUDAIRA, H; MIYAMOTO, T; SHIGA, J			EXPERIMENTAL HYPERSENSITIVITY PNEUMONITIS IN THE MOUSE - HISTOLOGIC AND IMMUNOLOGICAL FEATURES AND THEIR MODULATION WITH CYCLOSPORIN-A	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TOKYO,SCH MED,FAC MED,DEPT PATHOL,TOKYO 113,JAPAN	University of Tokyo	TAKIZAWA, H (corresponding author), UNIV TOKYO,SCH MED,FAC MED,DEPT MED & PHYS THERAPY,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.							BLYTH W, 1978, CLIN EXP IMMUNOL, V32, P272; CAMPBELL DA, 1985, AM REV RESPIR DIS, V132, P1300; GODORD P, 1981, CHEST, V80, P447; HIRATA T, 1982, CHEST, V82, P232; HOLT PG, 1981, IMMUNOLOGY, V42, P409; HUNNINGHAKE GW, 1981, AM REV RESPIR DIS, V123, P407; KAIBARA N, 1983, J EXP MED, V158, P2007, DOI 10.1084/jem.158.6.2007; KAWATA H, 1964, J IMMUNOL, V93, P433; KELLER RH, 1984, AM REV RESPIR DIS, V130, P766; KOPP WC, 1985, AM REV RESPIR DIS, V132, P1027; KUZE F, 1985, JPN J THORACIC DIS, V23, P1105; LEDBETTER JA, 1981, J EXP MED, V153, P310, DOI 10.1084/jem.153.2.310; LOPEZ M, 1976, ANNU REV MED, V27, P453, DOI 10.1146/annurev.me.27.020176.002321; REYNOLDS HY, 1973, J IMMUNOL, V111, P358; REYNOLDS HY, 1980, J CLIN INVEST, V80, P447; ROBERTS RC, 1977, AM REV RESPIR DIS, V116, P1075; ROSSI GA, 1985, AM REV RESPIR DIS, V131, P150; SCHATZ M, 1977, J ALLERGY CLIN IMMUN, V60, P27, DOI 10.1016/0091-6749(77)90079-3; SCHUYLER M, 1982, INT ARCH ALLER A IMM, V68, P108, DOI 10.1159/000233077; SCHUYLER M, 1982, INT ARCH ALLER A IMM, V68, P112, DOI 10.1159/000233078; SEPPA A, 1984, ACTA PATH MICRO IM A, V92, P125; TAKIZAWA H, 1986, AM REV RESPIR DIS, V134, P296; THRALL RS, 1984, AM REV RESPIR DIS, V129, P279; Voller A., 1976, AM SOC MICROBIOL, V17, P506; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WILSON BD, 1982, J IMMUNOL, V129, P2160	26	51	51	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					391	400		10.1016/0091-6749(88)90907-4	http://dx.doi.org/10.1016/0091-6749(88)90907-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	3339196	Bronze			2022-12-18	WOS:A1988M099300005
J	EIGEN, H; REID, JJ; DAHL, R; DELBUFALO, C; FASANO, L; GUNELLA, G; SAHLSTROM, KK; ALANKO, KLJ; GREENBAUM, J; HAGELUND, CH; SHAPIRO, GG; MARQUES, RA; BELLIA, V; BONSIGNORE, G; RESTA, O; FOSCHINO, MP; CARNIMEO, N; GRANSTROM, SA; HERRMAN, F; KJAERULFF, J; NUCHELPEDERSEN, B; MCDONALD, GF; SHER, N; SHEFFER, AL				EIGEN, H; REID, JJ; DAHL, R; DELBUFALO, C; FASANO, L; GUNELLA, G; SAHLSTROM, KK; ALANKO, KLJ; GREENBAUM, J; HAGELUND, CH; SHAPIRO, GG; MARQUES, RA; BELLIA, V; BONSIGNORE, G; RESTA, O; FOSCHINO, MP; CARNIMEO, N; GRANSTROM, SA; HERRMAN, F; KJAERULFF, J; NUCHELPEDERSEN, B; MCDONALD, GF; SHER, N; SHEFFER, AL			EVALUATION OF THE ADDITION OF CROMOLYN SODIUM TO BRONCHODILATOR MAINTENANCE THERAPY IN THE LONG-TERM MANAGEMENT OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,110 FRANCIS ST,BOSTON,MA 02115; INDIANA UNIV,MED CTR,PULM SECT,INDIANAPOLIS,IN 46204; UNIV OTAGO,DEPT GEN PRACTICE,DUNEDIN,NEW ZEALAND; AARHUS KOMMUNE HOSP,DEPT LUNG,DK-8000 AARHUS C,DENMARK; UNIV BOLOGNA,I-40126 BOLOGNA,ITALY; UNIV NOVA LISBOA,P-1200 LISBON,PORTUGAL; COPENHAGEN CTY HOSP,DEPT LUNG,COPENHAGEN,DENMARK; EDMONTON GEN HOSP,EDMONTON,ALBERTA,CANADA; N YORK GEN HOSP,MARHAM,ONTARIO,CANADA; POLICLIN BARI,IST FISIPATOL RESP,BARI,ITALY; UNIV UPPSALA,S-75105 UPPSALA,SWEDEN; HJORRING SYGEHUS,DEPT LUNG,HJORRING,DENMARK; VEJLE SYGEHUS,DEPT LUNG,VEJLE,DENMARK; OSPED CERVELLO,PALERMO,ITALY; NW ASTHMA & ALLERGY CTR,SEATTLE,WA; CENT HOSP,PAEIJAET HAEME,FINLAND; MCMASTER UNIV,HAMILTON L8S 4L8,ONTARIO,CANADA; SANDEFJORD SYKEHUS,DEPT LUNG,SANDEJORD,DENMARK	Harvard University; Harvard Medical School; Indiana University System; Indiana University-Purdue University Indianapolis; University of Otago; Aarhus University; University of Bologna; Universidade Nova de Lisboa; University of Toronto; University Toronto Affiliates; North York General Hospital; Universita degli Studi di Bari Aldo Moro; Uppsala University; University of Southern Denmark; Lillebaelt Hospital; McMaster University			Dahl, Ronahl/F-8170-2013	FOSCHINO BARBARO, MARIA PIA/0000-0001-9939-2697				ALTOUNYAN RE, 1967, ACTA ALLERGOL, V22, P487; BASRAN GS, 1984, BR J DIS CHEST, V78, P254; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BURNS RBP, 1983, J ASTHMA, V20, P105, DOI 10.3109/02770908309077073; COCKCROFT DW, 1985, ANN ALLERGY, V55, P857; CORDIER R, 1984, CLIN TRIALS J, V21, P483; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; DIAZ P, 1984, J ALLERGY CLIN IMMUN, V74, P41, DOI 10.1016/0091-6749(84)90085-X; HAMBLETON G, 1977, LANCET, V1, P381; HEGARDT B, 1981, ALLERGY, V36, P115, DOI 10.1111/j.1398-9995.1981.tb04105.x; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; MUNROFORD R, 1971, ANN ALLERGY, V29, P3; NEWTH C J L, 1980, American Review of Respiratory Disease, V121, P297; REED CE, 1986, J ALLERGY CLIN IMMUN, V77, P537, DOI 10.1016/0091-6749(86)90342-8; RUBIN AE, 1983, CURR MED RES OPIN, V8, P553, DOI 10.1185/03007998309109797; SHAPIRO G, 1986, J ALLERGY CLIN IMMUN, V77, P184; SHAPIRO GG, 1985, PHARMACOTHERAPY, V156, P5; TURNERWARWICK M, 1972, BRIT MED J, V4, P383	18	51	53	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1987	80	4					612	621		10.1016/0091-6749(87)90016-9	http://dx.doi.org/10.1016/0091-6749(87)90016-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5224	3117864				2022-12-18	WOS:A1987K522400016
J	TOGIAS, A; PROUD, D; KAGEYSOBOTKA, A; NORMAN, P; LICHTENSTEIN, L; NACLERIO, R				TOGIAS, A; PROUD, D; KAGEYSOBOTKA, A; NORMAN, P; LICHTENSTEIN, L; NACLERIO, R			THE EFFECT OF A TOPICAL TRICYCLIC ANTIHISTAMINE ON THE RESPONSE OF THE NASAL-MUCOSA TO CHALLENGE WITH COLD, DRY AIR AND HISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022488] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32272] Funding Source: Medline; NIAID NIH HHS [AI08270] Funding Source: Medline; NINDS NIH HHS [NS22488] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; DOUGLAS WW, 1970, PHARMACOL BASIS, P621; EGGLESTON PA, 1983, J ALLERGY CLIN IMMUN, V71, P93, DOI 10.1016/0091-6749(83)90143-4; EGGLESTON PA, 1983, AM REV RESPIR DIS, V130, P89; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1984, ARCH OTOLARYNGOL, V110, P25; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6; SEPHARD D, 1982, J APPL PHYSL, V53, P169; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; TOGIAS AG, 1986, AM REV RESPIR DIS, V133, P1133; TOGIAS AG, 1986, JAMA-J AM MED ASSOC, V255, P225, DOI 10.1001/jama.255.2.225	12	51	55	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1987	79	4					599	604		10.1016/S0091-6749(87)80155-0	http://dx.doi.org/10.1016/S0091-6749(87)80155-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G9720	3558996				2022-12-18	WOS:A1987G972000008
J	WEINMANN, GG; ZACUR, H; FISH, JE				WEINMANN, GG; ZACUR, H; FISH, JE			ABSENCE OF CHANGES IN AIRWAY RESPONSIVENESS DURING THE MENSTRUAL-CYCLE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS MED INST,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT ENVIRONM HLTH SCI,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT GYNECOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					PHS HHS [30787, 10342] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEDWANI JR, 1975, BR J PHARM, V33, P547; BODEL P, 1972, J LAB CLIN MED, V80, P373; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHALLIS JRG, 1981, SEMIN PERINATOL, V5, P192; CHALON J, 1971, J AMER MED ASSOC, V218, P1928, DOI 10.1001/jama.218.13.1928; CLAUDE F, 1938, PRESSE MED, V46, P755; COHEN BH, 1977, AM J EPIDEMIOL, V105, P223, DOI 10.1093/oxfordjournals.aje.a112378; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; ENJETI S, 1978, AM REV RESPIR DIS, V118, P667, DOI 10.1164/arrd.1978.118.4.667; FOSTER PS, 1983, BRIT J PHARMACOL, V78, P441, DOI 10.1111/j.1476-5381.1983.tb09409.x; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; GENAZZANI AR, 1975, J CLIN ENDOCR METAB, V41, P431, DOI 10.1210/jcem-41-3-431; GERTNER A, 1982, AM REV RESPIR DIS, V126, P1020; GIBBS CJ, 1984, THORAX, V39, P833, DOI 10.1136/thx.39.11.833; HACKNEY JF, 1981, J STEROID BIOCHEM, V14, P971, DOI 10.1016/0022-4731(81)90204-1; HANLEY SP, 1981, BRIT J DIS CHEST, V75, P306, DOI 10.1016/0007-0971(81)90010-3; Hansen-Pruss OC, 1943, J CLIN ENDOCRINOL, V3, P81, DOI 10.1210/jcem-3-2-81; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MCGOVERN JP, 1977, CHRONOBIOLOGY ALLERG, P79; NAKAGAWA H, 1979, JPN J PHARMACOL, V29, P509, DOI 10.1254/jjp.29.509; PADBURY JF, 1981, AM J OBSTET GYNECOL, V141, P199, DOI 10.1016/S0002-9378(16)32593-5; Reinberg A, 1974, BIORHYTHMS HUMAN REP, P241; SVEC F, 1980, ENDOCRINOLOGY, V107, P566, DOI 10.1210/endo-107-2-566; WULFSOHN N. L., 1964, S AFRICAN MED JOUR, V38, P173; ZAMEL N, 1984, J APPL PHYSIOL, V56, P129, DOI 10.1152/jappl.1984.56.1.129	25	51	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1987	79	4					634	638		10.1016/S0091-6749(87)80160-4	http://dx.doi.org/10.1016/S0091-6749(87)80160-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G9720	3559000				2022-12-18	WOS:A1987G972000013
J	PATEL, KR				PATEL, KR			EFFECT OF TERFENADINE ON METHACHOLINE-INDUCED BRONCHOCONSTRICTION IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PATEL, KR (corresponding author), WESTERN INFIRM,DEPT RESP MED,GLASGOW G11 6NT,SCOTLAND.							BARNES PJ, 1980, THORAX, V35, P675; BRUCE C, 1976, THORAX, V31, P724, DOI 10.1136/thx.31.6.724; CATERLINE CL, 1976, J ALLERGY CLIN IMMUN, V58, P607; DORWARD AJ, 1982, CLIN ALLERGY, V12, P355, DOI 10.1111/j.1365-2222.1982.tb02539.x; DRAZEN JM, 1975, J APPL PHYSIOL, V38, P834, DOI 10.1152/jappl.1975.38.5.834; DUNLOP LS, 1977, BRIT J PHARMACOL, V59, P475; HARTLEY JPR, 1980, THORAX, V35, P675, DOI 10.1136/thx.35.9.675; HAWKINS DF, 1955, BRIT J PHARM CHEMOTH, V10, P230, DOI 10.1111/j.1476-5381.1955.tb00088.x; HODGES IGC, 1983, BRIT J DIS CHEST, V77, P270; ITKIN IH, 1970, J ALLERGY, V45, P178, DOI 10.1016/0021-8707(70)90126-7; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; MILLS JE, 1969, J PHYSIOL-LONDON, V203, P337, DOI 10.1113/jphysiol.1969.sp008867; NATHAN RA, 1981, J ALLERGY CLIN IMMUN, V67, P171, DOI 10.1016/0091-6749(81)90057-9; NOGRADY SG, 1978, THORAX, V33, P700, DOI 10.1136/thx.33.6.700; NOGRADY SG, 1978, THORAX, V33, P479, DOI 10.1136/thx.33.4.479; PARTRIDGE MR, 1979, THORAX, V34, P771, DOI 10.1136/thx.34.6.771; PATEL KR, 1984, BRIT MED J, V288, P1496, DOI 10.1136/bmj.288.6429.1496; POPA VT, 1980, CHEST, V78, P442, DOI 10.1378/chest.78.3.442; POPA VT, 1977, J ALLERGY CLIN IMMUN, V59, P54, DOI 10.1016/0091-6749(77)90177-4; WOODWARD JK, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1154	20	51	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1987	79	2					355	358		10.1016/0091-6749(87)90155-2	http://dx.doi.org/10.1016/0091-6749(87)90155-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G1791	2880885				2022-12-18	WOS:A1987G179100010
J	LORUSSO, JR; MOFFAT, S; OHMAN, JL				LORUSSO, JR; MOFFAT, S; OHMAN, JL			IMMUNOLOGICAL AND BIOCHEMICAL-PROPERTIES OF THE MAJOR MOUSE URINARY ALLERGEN (MUS M-1)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM OUTPATIENT CLIN,ALLERGY RES LAB,17 COURT ST,BOSTON,MA 02108; TUFTS UNIV,SCH MED,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111	Tufts University; Tufts University								DERMAN E, 1981, P NATL ACAD SCI-BIOL, V78, P5425, DOI 10.1073/pnas.78.9.5425; FAHEY JL, 1978, HDB EXPT IMMUNOLOGY, V1; FINLAYSON JS, 1974, BIOCHEM GENET, V11, P325, DOI 10.1007/BF00486000; FINLAYSON JS, 1958, AM J PHYSL, V192, P62; FINLAYSON JS, 1965, SCIENCE, V149, P481; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; HASTIE ND, 1979, CELL, V17, P449, DOI 10.1016/0092-8674(79)90171-5; HOOK WA, 1984, J ALLERGY CLIN IMMUN, V73, P457, DOI 10.1016/0091-6749(84)90355-5; KRAUTER K, 1982, J CELL BIOL, V94, P414, DOI 10.1083/jcb.94.2.414; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LEVY DA, 1975, INT ARCH ALLER A IMM, V49, P219, DOI 10.1159/000231399; LINCOLN TA, 1974, J OCCUP ENVIRON MED, V16, P465; NEWMANTAYLOR A, 1977, LANCET, V2, P847; OHMAN J L JR, 1984, Journal of Allergy and Clinical Immunology, V73, P191; OHMAN JL, 1973, J ALLERGY CLIN IMMUN, V52, P231, DOI 10.1016/0091-6749(73)90061-4; OHMAN JL, 1975, J ALLERGY CLIN IMMUN, V55, P16, DOI 10.1016/S0091-6749(75)80004-2; RAO PVS, 1983, J IMMUNOL METHODS, V57, P71, DOI 10.1016/0022-1759(83)90066-2; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; SCHUMACHER MJ, 1980, MOL IMMUNOL, V17, P1087, DOI 10.1016/0161-5890(80)90105-4; SHAW PH, 1983, CELL, V32, P755, DOI 10.1016/0092-8674(83)90061-2; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V63, P435, DOI 10.1016/0091-6749(79)90219-7; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P522, DOI 10.1016/0091-6749(82)90177-4; WILLIAMS CA, 1968, METHODS IMMUNOLOGY I, V2, P344	25	51	53	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	1				928	937		10.1016/0091-6749(86)90242-3	http://dx.doi.org/10.1016/0091-6749(86)90242-3			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9713	3097107				2022-12-18	WOS:A1986E971300017
J	YANG, WH; PURCHASE, ECR; RIVINGTON, RN				YANG, WH; PURCHASE, ECR; RIVINGTON, RN			POSITIVE SKIN-TESTS AND PRAUSNITZ-KUSTNER REACTIONS IN METABISULFITE-SENSITIVE SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV OTTAWA,SCH MED,OTTAWA CIVIC & OTTAWA GEN HOSP,DEPT MED,OTTAWA K1N 6N5,ONTARIO,CANADA; UNIV OTTAWA,SCH MED,DIV RESP,OTTAWA K1N 6N5,ONTARIO,CANADA	University of Ottawa; University of Ottawa								ANDRES C, 1984, FOOD PROCESSING, V45, P34; [Anonymous], 1984, OFFICIAL METHODS ANA; BELLANTI JA, 1985, ANN ALLERGY, V54, P375; DELOHERY J, 1984, Journal of Allergy and Clinical Immunology, V73, P136; Habenicht H, 1983, IMMUNOL ALLERGY PRAC, V5, P243; HECHT A, 1983, FDA CONSUMER, V17, P11; HUANG AS, 1984, NEW ENGL J MED, V311, P542; JACOBSEN D W, 1984, Journal of Allergy and Clinical Immunology, V73, P135; KOEPKE JW, 1984, JAMA-J AM MED ASSOC, V251, P2982, DOI 10.1001/jama.251.22.2982; KOEPKE JW, 1983, J ALLERGY CLIN IMMUN, V72, P504, DOI 10.1016/0091-6749(83)90588-2; LECOS C, 1984, FDA CONSUM, P23; LEVINE AS, 1985, NEW ENGL J MED, V312, P628, DOI 10.1056/NEJM198503073121006; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P295; PRENNER BM, 1976, ANN ALLERGY, V37, P180; SCHWARTZ HJ, 1984, J ALLERGY CLIN IMMUN, V74, P511, DOI 10.1016/0091-6749(84)90387-7; SCHWARTZ HJ, 1983, J ALLERGY CLIN IMMUN, V71, P487, DOI 10.1016/0091-6749(83)90466-9; SIMON RA, 1984, J ALLERGY CLIN IMMUN, V74, P623, DOI 10.1016/0091-6749(84)90116-7; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P469, DOI 10.1016/0091-6749(84)90380-4; SULLIVAN DM, 1985, FOOD TECHNOL-CHICAGO, V39, P45; TWAROG FJ, 1982, JAMA-J AM MED ASSOC, V248, P2030, DOI 10.1001/jama.248.16.2030; TWAROG FJ, 1983, N ENGL REG ALLERGY P, V4, P100; WOLF SI, 1985, ANN ALLERGY, V54, P420; YANG WH, 1985, CAN MED ASSOC J, V133, P865; 1981, J ALLERGY CLIN IMMUN, V67, P1; 1976, NUTR REV, V34, P58; 1984, FDA DRUG B, V14, P24; 1983, CHEM WEEK, V133, P16	28	51	52	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1986	78	3	1				443	449		10.1016/0091-6749(86)90031-X	http://dx.doi.org/10.1016/0091-6749(86)90031-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E1148	3760403				2022-12-18	WOS:A1986E114800012
J	FALLOON, J; GALLIN, JI				FALLOON, J; GALLIN, JI			NEUTROPHIL GRANULES IN HEALTH AND DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											FALLOON, J (corresponding author), NIAID,CLIN INVEST LAB,BACTERIAL DIS SECT,BLDG 10,RM 11N112,BETHESDA,MD 20892, USA.							AMBRUSO DR, 1984, PEDIATR RES, V18, P1148, DOI 10.1203/00006450-198411000-00019; AMBRUSO DR, 1981, J CLIN INVEST, V67, P352, DOI 10.1172/JCI110042; ANDERSON DC, 1981, J CLIN INVEST, V68, P863, DOI 10.1172/JCI110341; ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; ARNOLD RR, 1982, INFECT IMMUN, V35, P792, DOI 10.1128/IAI.35.3.792-799.1982; BABIOR BM, 1984, J CLIN INVEST, V73, P599, DOI 10.1172/JCI111249; BABIOR BM, 1984, BLOOD, V64, P959; Baggiolini M, 1984, Contemp Top Immunobiol, V14, P221; BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; BERGER M, 1984, J CLIN INVEST, V74, P1566, DOI 10.1172/JCI111572; BLUME RS, 1972, MEDICINE, V51, P247, DOI 10.1097/00005792-197207000-00001; BORREGAARD N, 1985, AM J HEMATOL, V18, P255, DOI 10.1002/ajh.2830180306; BORREGAARD N, 1984, J BIOL CHEM, V259, P47; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BRETZ U, 1974, J CELL BIOL, V63, P251, DOI 10.1083/jcb.63.1.251; BROXMEYER HE, 1980, BLOOD, V55, P324; BUESCHER ES, 1985, BLOOD, V65, P1382, DOI 10.1182/blood.V65.6.1382.bloodjournal6561382; CLARK RA, 1982, J IMMUNOL, V128, P1507; CLARK RA, 1985, BLOOD, V65, P375; CLARK RA, 1983, ADV INFLAMMAT RES, V5, P107; CLAWSON CC, 1979, AM J PATHOL, V94, P539; Cochrane C G, 1977, Inflammation, V2, P319, DOI 10.1007/BF00921011; CRAMER E, 1985, BLOOD, V65, P423; CROSS AS, 1985, CLIN RES, V33, pA398; DAVIS JM, 1980, J IMMUNOL, V124, P1467; DEWALD B, 1982, J CLIN INVEST, V70, P518, DOI 10.1172/JCI110643; DEWALD B, 1975, J EXP MED, V141, P709; DUQUE RE, 1985, AM J PATHOL, V118, P116; Ehrlich P., 1900, 13 C INT MED PAR; ELSBACH P, 1983, REV INFECT DIS, V5, P843; FLETCHER MP, 1982, J IMMUNOL, V128, P941; FLETCHER MP, 1983, BLOOD, V62, P792; FOX RB, 1984, J CLIN INVEST, V74, P1456, DOI 10.1172/JCI111558; GABIG TG, 1984, J CLIN INVEST, V73, P701, DOI 10.1172/JCI111262; GALLIN JI, 1982, BLOOD, V59, P1317; GALLIN JI, 1985, ANNU REV MED, V36, P263; GALLIN JI, 1984, CLIN RES, V32, P320; GALLIN JI, 1983, ANN INTERN MED, V99, P657, DOI 10.7326/0003-4819-99-5-657; GALLIN JI, 1984, J IMMUNOL, V133, P415; GALLIN JI, 1985, J INFECT DIS, V152, P661, DOI 10.1093/infdis/152.4.661; GOLDSTEIN IM, 1984, CONT TOP IMMUNOBIOL, V14, P221; GORDON LI, 1979, J CLIN INVEST, V64, P226, DOI 10.1172/JCI109443; HAAK RA, 1979, J CLIN INVEST, V64, P138, DOI 10.1172/JCI109432; HARLAN JM, 1985, BLOOD, V65, P513; HARLAN JM, 1985, BLOOD, V66, P167; HARRIS MC, 1985, J CLIN MICROBIOL, V21, P243, DOI 10.1128/JCM.21.2.243-246.1985; HIGSON FK, 1985, J IMMUNOL, V135, P519; HOFFSTEIN ST, 1982, J CELL BIOL, V95, P234, DOI 10.1083/jcb.95.1.234; JACOB HS, 1980, NEW ENGL J MED, V302, P789; JANOFF A, 1983, J APPL PHYSIOL, V55, P285, DOI 10.1152/jappl.1983.55.2.285; KLEMPNER MS, 1985, J CLIN INVEST, V76, P303, DOI 10.1172/JCI111961; MALECH HL, 1977, J CELL BIOL, V75, P666, DOI 10.1083/jcb.75.3.666; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; Metchnikoff E., 1905, IMMUNITY INFECTIVE D; MILLER ME, 1979, PEDIATRICS, V64, P709; MULLANE K, 1984, CLIN RES, V32, pA475; NAMERE I, 1985, CELL MOTIL, V5, P17; NATH J, 1982, J CELL BIOL, V95, P519, DOI 10.1083/jcb.95.2.519; NAUSEEF WM, 1983, BLOOD, V61, P483; NUNOI H, 1985, BLOOD, V66, P106; O'SHEA JJ, 1985, J IMMUNOL, V134, P2580; OHNO Y, 1985, J BIOL CHEM, V260, P2409; OHNO Y, BLOOD; OLIVER JM, 1978, AM J PATHOL, V93, P221; OLSON TA, 1983, PEDIATR RES, V17, P993, DOI 10.1203/00006450-198312000-00013; OSEAS R, 1981, BLOOD, V57, P939; PARMLEY RT, 1983, BLOOD, V62, P538; PARRY MF, 1981, ANN INTERN MED, V95, P293, DOI 10.7326/0003-4819-95-3-293; PRENTKI M, 1984, J BIOL CHEM, V259, P3777; RINALDO JE, 1982, NEW ENGL J MED, V306, P900, DOI 10.1056/NEJM198204153061504; RINGEL EW, 1984, IMMUNOLOGY, V52, P649; ROOS D, 1983, J CELL BIOL, V97, P368, DOI 10.1083/jcb.97.2.368; ROOT RK, 1981, REV INFECT DIS, V3, P565; SACCHI F, 1984, J EXP MED, V160, P1247, DOI 10.1084/jem.160.4.1247; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SCHIFFER CA, 1984, CURRENT CLIN TOPICS, V5, P189; SCHWARTZ BR, 1985, BLOOD, V65, P1553, DOI 10.1182/blood.V65.6.1553.bloodjournal6561553; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; SEGAL AW, 1983, NEW ENGL J MED, V308, P245, DOI 10.1056/NEJM198302033080503; SEGAL AW, 1985, LANCET, V1, P1378; SNYDERMAN R, 1982, CECIL TXB MED, P1832; SPITZNAGEL JK, 1985, REV INFECT DIS, V7, P398; SPITZNAGEL JK, 1974, LAB INVEST, V30, P774; SPITZNAGEL JK, 1984, CONT TOP IMMUNOBIOL, V14, P221; SPITZNAGEL JK, 1983, REV INFECT DIS, V5, P806; STROMINGER JL, 1967, SCIENCE, V156, P213, DOI 10.1126/science.156.3772.213; SULLIVAN SJ, 1984, J CELL BIOL, V99, P1461, DOI 10.1083/jcb.99.4.1461; TATE RM, 1983, AM REV RESPIR DIS, V128, P552, DOI 10.1164/arrd.1983.128.3.552; TAUBER AI, 1983, MEDICINE, V62, P286, DOI 10.1097/00005792-198309000-00003; TILL GO, 1985, AM J PATHOL, V119, P376; WARD PA, 1968, J EXP MED, V128, P1201, DOI 10.1084/jem.128.5.1201; WARDEN GD, 1974, J CLIN INVEST, V54, P1001, DOI 10.1172/JCI107815; WEISS SJ, 1984, J CLIN INVEST, V73, P1297, DOI 10.1172/JCI111332; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27; WEITZMAN SA, 1985, SCIENCE, V227, P1231, DOI 10.1126/science.3975611; WEST BC, 1974, AM J PATHOL, V77, P41; WHITE JG, 1980, AM J PATHOL, V98, P151; WILKINSON PC, 1982, CHEMOTAXIS INFLAMMAT; WOLACH B, 1984, J LAB CLIN MED, V103, P284; WOLFF SM, 1972, ANN INTERN MED, V76, P293, DOI 10.7326/0003-4819-76-2-293; WRIGHT DG, 1977, J IMMUNOL, V119, P1068; WRIGHT DG, 1979, EXP HEMATOL, V7, P11; WRIGHT DG, 1979, J IMMUNOL, V123, P285	104	51	52	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					653	662		10.1016/0091-6749(86)90404-5	http://dx.doi.org/10.1016/0091-6749(86)90404-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	3009589				2022-12-18	WOS:A1986C390300002
J	CARTIER, A; MALO, JL; PINEAU, L; DOLOVICH, J				CARTIER, A; MALO, JL; PINEAU, L; DOLOVICH, J			OCCUPATIONAL ASTHMA DUE TO PEPSIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP SACRE COEUR, DEPT CHEST MED, MONTREAL H4J 1C5, QUEBEC, CANADA; MCMASTER UNIV, DEPT PEDIAT, HAMILTON L8S 4L8, ONTARIO, CANADA	Universite de Montreal; McMaster University								BERNSTEIN IL, 1981, CLIN CHEST MED, V2, P255; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COLTEN HR, 1975, NEW ENGL J MED, V292, P1050, DOI 10.1056/NEJM197505152922003; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; DOLAN TF, 1974, AM REV RESPIR DIS, V110, P812; FLINDT MLH, 1979, LANCET, V1, P1407; FLINDT MLH, 1969, LANCET, V1, P1177; FLINDT MLH, 1978, LANCET, V1, P430; GALLEGUILLOS F, 1978, CLIN ALLERGY, V8, P21, DOI 10.1111/j.1365-2222.1978.tb00443.x; GREENBERG M, 1970, BMJ-BRIT MED J, V2, P629, DOI 10.1136/bmj.2.5710.629; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MILNE J, 1975, BRIT J IND MED, V32, P302; MITCHELL CA, 1971, AM REV RESPIR DIS, V104, P1; NEWHOUSE ML, 1970, LANCET, V1, P689; PARKES WR, 1982, OCCUPATIONAL LUNG DI, P415; PAUWELS R, 1978, LANCET, V1, P669; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEPYS J, 1973, Clinical Allergy, V3, P143, DOI 10.1111/j.1365-2222.1973.tb01318.x; Pilat L, 1967, Rev Fr Allergol, V7, P153, DOI 10.1016/S0370-4688(67)80115-7; TARLO SM, 1978, CLIN ALLERGY, V8, P207, DOI 10.1111/j.1365-2222.1978.tb03216.x; ZWEIMAN B, 1967, J ALLERGY, V39, P11, DOI 10.1016/0021-8707(67)90121-9	21	51	51	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					574	577		10.1016/0091-6749(84)90513-X	http://dx.doi.org/10.1016/0091-6749(84)90513-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS045	6425388				2022-12-18	WOS:A1984SS04500006
J	BERNSTEIN, DI; GALLAGHER, JS; BERNSTEIN, IL				BERNSTEIN, DI; GALLAGHER, JS; BERNSTEIN, IL			MEALWORM ASTHMA - CLINICAL AND IMMUNOLOGICAL STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BERNSTEIN, DI (corresponding author), UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267, USA.				NIAID NIH HHS [AI13702-57] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNSTEIN IL, 1975, J ALLERGY CLIN IMMUN, V56, P323; BURGE PS, 1980, CLIN ALLERGY, V10, P355, DOI 10.1111/j.1365-2222.1980.tb02119.x; FEINBERG AR, 1956, J ALLERGY, V27, P437, DOI 10.1016/0021-8707(56)90103-4; FIGLEY KD, 1929, AM J MED SCI, V178, P388; FRANKLAND AW, 1965, BRIT J IND MED, V22, P157; HOFFMAN DR, 1975, IMMUNOCHEMISTRY, V12, P535, DOI 10.1016/0019-2791(75)90080-4; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; LANGLOIS C, 1963, J ALLERGY, V34, P385, DOI 10.1016/0021-8707(63)90001-7; PARLATO SJ, 1920, J ALLERGY, V1, P307; PERLMAN F, 1961, J ALLERGY, V32, P2; POPA V, 1970, ACTA ALLERGOL, V25, P159, DOI 10.1111/j.1398-9995.1970.tb01389.x; SHELDON J. M., 1941, JOUR ALLERGY, V12, P493, DOI 10.1016/S0021-8707(41)90228-9; STEVENSON DD, 1967, J ALLERGY, V39, P274, DOI 10.1016/0021-8707(67)90091-3; STOCKLEY RA, 1982, CLIN ALLERGY, V12, P15; WIDE L, 1967, LANCET, V2, P1105; WISEMAN RD, 1959, J ALLERGY, V30, P191, DOI 10.1016/0021-8707(59)90067-X	16	51	52	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					475	480		10.1016/0091-6749(83)90584-5	http://dx.doi.org/10.1016/0091-6749(83)90584-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RR916	6630798				2022-12-18	WOS:A1983RR91600008
J	MEKORI, YA; GIORNO, RC; ANDERSON, P; KOHLER, PF				MEKORI, YA; GIORNO, RC; ANDERSON, P; KOHLER, PF			LYMPHOCYTE SUBPOPULATIONS IN THE SKIN OF PATIENTS WITH CHRONIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MEKORI, YA (corresponding author), UNIV COLORADO,HLTH SCI CTR,DIV CLIN IMMUNOL B-164,DENVER,CO 80262, USA.				NCRR NIH HHS [RR-00051] Funding Source: Medline; NIAID NIH HHS [AI-07166] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHAN AK, 1981, J EXP MED, V154, P737, DOI 10.1084/jem.154.3.737; CENTER DM, 1983, J ALLERGY CLIN IMMUN, V71, P29, DOI 10.1016/0091-6749(83)90543-2; GIORNO R, 1983, Diagnostic Immunology, V1, P17; GIORNO R, 1982, LAB MED, V13, P554; IDA S, 1980, CLIN EXP IMMUNOL, V41, P380; KAPLAN AP, 1981, AM J MED, V70, P755, DOI 10.1016/0002-9343(81)90528-3; KOHLER PF, 1981, P N ENGL ALLERGY SOC, V2, P136; KUNG PC, 1980, VOX SANG, V39, P121, DOI 10.1111/j.1423-0410.1980.tb01846.x; LAMPERT IA, 1982, CLIN EXP IMMUNOL, V50, P123; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; MATHEWS KP, 1980, J ALLERGY CLIN IMMUN, V66, P347, DOI 10.1016/0091-6749(80)90113-X; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NADLER LM, 1981, HUM IMMUNOL, V1, P77; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P436, DOI 10.1016/0091-6749(80)90237-7; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P371, DOI 10.1016/0091-6749(80)90215-8; REINHERZ EL, 1979, J EXP MED, V150, P1472, DOI 10.1084/jem.150.6.1472; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; ROYSTON I, 1979, BLOOD S1, V54, P106; SCHEYNIUS A, 1982, CLIN EXP IMMUNOL, V49, P325; SUSSMAN GL, 1982, J ALLERGY CLIN IMMUN, V70, P337, DOI 10.1016/0091-6749(82)90022-7; TANNENBAUM S, 1980, J IMMUNOL, V125, P325; THUESON DO, 1979, J IMMUNOL, V123, P626; TODD RF, 1982, BLOOD, V59, P775; VANVOORHIS WC, 1982, NEW ENGL J MED, V307, P1593, DOI 10.1056/NEJM198212233072601; WARNKE R, 1980, J HISTOCHEM CYTOCHEM, V28, P771, DOI 10.1177/28.8.7003003; YECIES LD, 1980, CLIN IMMUNOLOGY, P1283	28	51	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	6					681	684		10.1016/0091-6749(83)90629-2	http://dx.doi.org/10.1016/0091-6749(83)90629-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RW048	6227650				2022-12-18	WOS:A1983RW04800008
J	AGARWAL, MK; JONES, RT; YUNGINGER, JW				AGARWAL, MK; JONES, RT; YUNGINGER, JW			SHARED ALLERGENIC AND ANTIGENIC DETERMINANTS IN ALTERNARIA AND STEMPHYLIUM EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905; MAYO MED SCH,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO MED SCH,DEPT INTERNAL MED ALLERGY,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic					NIAID NIH HHS [AI-16791] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016791] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DIXON WJ, 1969, INTRO STATISTICAL AN, P189; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HARBOE N, 1973, Scandinavian Journal of Immunology, V2, P161; HOFFMAN DR, 1979, J ALLERGY CLIN IMMUN, V63, P213; KROLL J, 1973, SCAND J IMMUNOL, V2, P79, DOI 10.1111/j.1365-3083.1973.tb03783.x; MACY NE, 1968, P SOC EXP BIOL MED, V128, P1098; RODBARD D, 1974, CLIN CHEM, V20, P1255; WEEKE B, 1973, SCAND J IMMUNOL, V2, P47, DOI 10.1111/j.1365-3083.1973.tb03778.x; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; ZAR JH, 1974, BIOSTAT ANAL, P252	12	51	52	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	6					437	444		10.1016/0091-6749(82)90006-9	http://dx.doi.org/10.1016/0091-6749(82)90006-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PT744	6183306				2022-12-18	WOS:A1982PT74400006
J	SZEFLER, SJ; ELLIS, EF; BRENNER, M; ROSE, JQ; SPECTOR, SL; YURCHAK, AM; ANDREWS, F; JUSKO, WJ				SZEFLER, SJ; ELLIS, EF; BRENNER, M; ROSE, JQ; SPECTOR, SL; YURCHAK, AM; ANDREWS, F; JUSKO, WJ			STEROID-SPECIFIC AND ANTICONVULSANT INTERACTION ASPECTS OF TROLEANDOMYCIN-STEROID THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,SCH MED,DEPT PEDIAT,BUFFALO,NY 14260; SUNY BUFFALO,SCH MED,DEPT FAMILY & COMMUNITY MED,BUFFALO,NY 14260; SUNY BUFFALO,SCH MED,DEPT PHARMACOL & THERAPEUT,BUFFALO,NY 14260; SUNY BUFFALO,SCH PHARM,BUFFALO,NY 14260; NATL JEWISH HOSP & RES CTR,DEPT PEDIAT,DENVER,CO 80206; NATL JEWISH HOSP & RES CTR,DEPT MED,DENVER,CO 80206	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Jewish Health; National Jewish Health			Jusko, William J/G-4885-2015		NHLBI NIH HHS [HL-26975] Funding Source: Medline; NIAID NIH HHS [AI-14198] Funding Source: Medline; PHS HHS [24211] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BROOKS SM, 1972, NEW ENGL J MED, V286, P1125, DOI 10.1056/NEJM197205252862103; BURSTEIN S, 1965, J CLIN ENDOCR METAB, V25, P293, DOI 10.1210/jcem-25-2-293; CHOI Y, 1971, J PHARMACOL EXP THER, V176, P27; CONNEY A. H., 1965, LIFE SCI, V4, P1091, DOI 10.1016/0024-3205(65)90229-8; FOX JL, 1961, PENN MED J, V64, P634; HAQUE N, 1972, J CLIN ENDOCR METAB, V34, P44, DOI 10.1210/jcem-34-1-44; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; KAPLAN MA, 1959, ANTIBIOTICS ANN 1958, P273; LASSEN NA, 1979, TRACER KINETIC METHO, P76; MESDJIAN E, 1980, EPILEPSIA, V21, P489, DOI 10.1111/j.1528-1157.1980.tb04300.x; PESSAYRE D, 1981, BIOCHEM PHARMACOL, V30, P559, DOI 10.1016/0006-2952(81)90126-X; ROSE JQ, 1979, J CHROMATOGR, V162, P273, DOI 10.1016/S0378-4347(00)81514-5; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; STJERNHOLM MR, 1975, J CLIN ENDOCR METAB, V41, P887, DOI 10.1210/jcem-41-5-887; SZEFLER SJ, 1980, J ALLERGY CLIN IMMUN, V66, P447, DOI 10.1016/0091-6749(80)90004-4; TICKTIN HE, 1962, NEW ENGL J MED, V267, P964, DOI 10.1056/NEJM196211082671905; WEINBERGER M, 1977, J ALLERGY CLIN IMMUN, V59, P228, DOI 10.1016/0091-6749(77)90154-3; WERK EE, 1964, J CLIN INVEST, V43, P1824, DOI 10.1172/JCI105056; YEH KC, 1978, J PHARMACOKINET BIOP, V6, P79, DOI 10.1007/BF01066064; ZEIGER RS, 1980, J ALLERGY CLIN IMMUN, V66, P438, DOI 10.1016/0091-6749(80)90003-2	20	51	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	5					455	460		10.1016/0091-6749(82)90121-X	http://dx.doi.org/10.1016/0091-6749(82)90121-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NP934	6978898				2022-12-18	WOS:A1982NP93400008
J	EASTON, JG				EASTON, JG			EFFECT OF AN INHALED CORTICOSTEROID ON METHACHOLINE AIRWAY REACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SO CALIF KAISER PERMANENTE MED CTR,DEPT ALLERGY & CLIN IMMUNOL,LOS ANGELES,CA	Kaiser Permanente								ARKINS JA, 1968, J ALLERGY, V41, P209, DOI 10.1016/0021-8707(68)90043-9; AVIADO DM, 1970, J CLIN PHARMACOL N D, V10, P3; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; FALLIERS CJ, 1972, J ALLERGY CLIN IMMUN, V49, P156, DOI 10.1016/0091-6749(72)90109-1; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; HARTER JG, 1963, NEW ENGL J MED, V269, P591, DOI 10.1056/NEJM196309192691201; KOELLE GB, 1966, PHARM BASIS THERAPEU, P494; MORRIS HG, 1980, ALLERGIC DISEASES IN, P666; TIFFENEAU R, 1956, PRESSE MED, V64, P719; WOLFE JD, 1979, J ALLERGY CLIN IMMUN, V63, P162; 1974, LANCET, V2, P303; 1962, AM REV RESPIR DIS, V85, P762	13	51	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	5					388	390		10.1016/0091-6749(81)90084-1	http://dx.doi.org/10.1016/0091-6749(81)90084-1			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ563	7229227				2022-12-18	WOS:A1981LQ56300009
J	HENDRIX, SG; PATTERSON, R; ZEISS, CR; PRUZANSKY, JJ; SUSZKO, IM; MCQUEEN, RC; SLAVIN, RG; MILLER, MP; LIEBERMAN, PL; SHEFFER, AL				HENDRIX, SG; PATTERSON, R; ZEISS, CR; PRUZANSKY, JJ; SUSZKO, IM; MCQUEEN, RC; SLAVIN, RG; MILLER, MP; LIEBERMAN, PL; SHEFFER, AL			A MULTI-INSTITUTIONAL TRIAL OF POLYMERIZED WHOLE RAGWEED FOR IMMUNOTHERAPY OF RAGWEED ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LOUIS MED CTR,DEPT INTERNAL MED,ST LOUIS,MO; UNIV TENNESSEE,CTR HLTH SCI,DEPT INTERNAL MED,MEMPHIS,TN 38163; NORTHWESTERN UNIV,DEPT INTERNAL MED,CHICAGO,IL 60611	University of Tennessee System; University of Tennessee Health Science Center; Northwestern University					NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACAL E, 1978, J ALLERGY CLIN IMMUN, V62, P289, DOI 10.1016/0091-6749(78)90160-4; HENDRIX S, 1980, J ALLERGY CLIN IMMUN, V65, P57, DOI 10.1016/0091-6749(80)90177-3; IRONS JS, 1977, J ALLERGY CLIN IMMUN, V59, P190, DOI 10.1016/0091-6749(77)90149-X; JOHANSSON SG, 1974, CLIN ALLERGY, V4, P255, DOI 10.1111/j.1365-2222.1974.tb01383.x; KATZ DH, 1978, J ALLERGY CLIN IMMUN, V62, P44, DOI 10.1016/0091-6749(78)90072-6; KELLY JF, 1980, J ALLERGY CLIN IMMUN, V65, P50, DOI 10.1016/0091-6749(80)90176-1; LEVINE MI, 1979, J ALLERGY CLIN IMMUN, V63, P209; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; Lieberman P, 1974, Adv Intern Med, V19, P391; MARSH DG, 1970, IMMUNOLOGY, V18, P705; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V65, P87, DOI 10.1016/0091-6749(80)90191-8; NORMAN PS, 1971, IMMUNOLOGIC DISEASES, V2, P840; PATTERSON R, 1977, J ALLERGY CLIN IMMUN, V59, P314, DOI 10.1016/0091-6749(77)90053-7; PATTERSON R, 1973, J IMMUNOL, V110, P1402; PATTERSON R, 1973, J IMMUNOL, V110, P1413; PATTERSON R, 1978, ALLERGY PRINCIPLES P, P1100; PATTERSON R, 1976, 9TH P INT C ALL BUEN; PATTERSON R, 1979, J ALLERGY CLIN IMMUN, V64, P135; SEHON AH, 1978, J ALLERGY CLIN IMMUN, V62, P257, DOI 10.1016/0091-6749(78)90155-0; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; SOLOMON WR, 1978, ALLERGY PRINCIPLES P, P899; WISE PJ, 1979, J ALLERGY CLIN IMMUN, V63, P216; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; ZEISS CR, 1978, J ALLERGY CLIN IMMUN, V61, P216	29	51	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	6					486	494		10.1016/0091-6749(80)90010-X	http://dx.doi.org/10.1016/0091-6749(80)90010-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KV363	7000872	Bronze			2022-12-18	WOS:A1980KV36300009
J	SOLOMON, WR; BURGE, HA; BOISE, JR				SOLOMON, WR; BURGE, HA; BOISE, JR			EXCLUSION OF PARTICULATE ALLERGENS BY WINDOW AIR CONDITIONERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SOLOMON, WR (corresponding author), UNIV MICHIGAN HOSP,SCH MED,DEPT INTERNAL MED,ALLERGY SECT,ANN ARBOR,MI 48109, USA.							BENAIM C, 1973, ANN ALLERGY, V31, P618; DINGLE A N, 1957, Fed Proc, V16, P615; FEINBERG SM, 1966, AM J NURS, V66, P1333, DOI 10.2307/3419793; HARRINGTON JB, 1959, J ALLERGY, V30, P357, DOI 10.1016/0021-8707(59)90044-9; HIRSCH DJ, 1978, J ALLERGY CLIN IMMUN, V62, P22, DOI 10.1016/0091-6749(78)90067-2; MANSMANN HC, 1978, ALLERGY PRINCIPLES P, pCH51; OGDEN EC, 1960, J ALLERGY, V31, P307, DOI 10.1016/0021-8707(60)90067-8; SOLOMON WR, 1978, J ALLERGY CLIN IMMUN, V61, P185, DOI 10.1016/0091-6749(78)90428-1	8	51	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	4					305	308		10.1016/0091-6749(80)90160-8	http://dx.doi.org/10.1016/0091-6749(80)90160-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	JN548	7358946				2022-12-18	WOS:A1980JN54800011
J	STEPHAN, WC; CHICK, TW; AVNER, BP; JENNE, JW				STEPHAN, WC; CHICK, TW; AVNER, BP; JENNE, JW			TACHYPHYLAXIS TO INHALED ISOPROTERENOL AND THE EFFECT OF METHYLPREDNISOLONE IN DOGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM HOSP,ALBUQUERQUE,NM 87108; UNIV NEW MEXICO,DEPT MED,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,DEPT PHARMACOL,ALBUQUERQUE,NM 87131	University of New Mexico; University of New Mexico								AVNER B P, 1977, American Review of Respiratory Disease, V115, P45; AVNER BP, 1977, P W PHARMACOL SOC, V20, P25; AVNER BP, 1978, J PHARMACOL EXP THER, V207, P23; BESSE JC, 1966, J PHARMACOL EXP THER, V154, P224; CHERVINSKY P, 1969, ANN ALLERGY, V27, P611; CHO YW, 1968, J ALLERGY, V42, P36, DOI 10.1016/0021-8707(68)90130-5; Conolly ME, 1973, CHEST              S, V63, p16S; DRAZEN JM, 1976, J APPL PHYSIOL, V40, P110, DOI 10.1152/jappl.1976.40.1.110; ELLULMICALLEF R, 1975, LANCET, V2, P1269; FLOWERS NC, 1972, J AMER MED ASSOC, V219, P33, DOI 10.1001/jama.219.1.33; GEDDES BA, 1974, AM REV RESPIR DIS, V110, P420; HOLGATE ST, 1977, LANCET, V2, P375; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; KEIGHLEY JF, 1966, ANN INTERN MED, V65, P985, DOI 10.7326/0003-4819-65-5-985; KNEUSSL MP, 1978, J APPL PHYSIOL, V45, P307, DOI 10.1152/jappl.1978.45.2.307; LEIFER KN, 1975, ANN ALLERGY, V35, P69; LICHTERFELD A, 1974, EUR J CLIN PHARMACOL, V7, P347, DOI 10.1007/BF00558204; LIN CS, 1977, J PHARMACOL EXP THER, V203, P12; MENA H, 1978, P W PHARMACOL SOC, V21, P197; MINATOYA H, 1975, BRIT J PHARMACOL, V53, P333, DOI 10.1111/j.1476-5381.1975.tb07368.x; MUKHERJEE C, 1975, P NATL ACAD SCI USA, V72, P1945, DOI 10.1073/pnas.72.5.1945; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; PLUMMER AL, 1978, CHEST, V73, P949, DOI 10.1378/chest.73.6.949; REISMAN RE, 1970, J ALLERGY, V46, P162, DOI 10.1016/0021-8707(70)90095-X; ROLLERY CT, 1973, CLIN PHARMACOL THER, V15, P59; SHENFIELD GM, 1975, THORAX, V30, P430, DOI 10.1136/thx.30.4.430; SVEDMYR NLV, 1976, CHEST, V69, P479, DOI 10.1378/chest.69.4.479; WILSON AF, 1976, J ALLERGY CLIN IMMUN, V58, P204, DOI 10.1016/0091-6749(76)90156-1	28	51	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	2					105	109		10.1016/0091-6749(80)90193-1	http://dx.doi.org/10.1016/0091-6749(80)90193-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JF199	6243320				2022-12-18	WOS:A1980JF19900004
J	SNYDERMAN, R; ROGERS, E; BUCKLEY, RH				SNYDERMAN, R; ROGERS, E; BUCKLEY, RH			ABNORMALITIES OF LEUKOTAXIS IN ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DUKE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNE EFFECTOR FUNCT LAB,DURHAM,NC 27706; DUKE UNIV,SCH MED,DEPT MED,DIV RHEUMAT & GENET DIS,DURHAM,NC 27706; DUKE UNIV,SCH MED,DIV ALLERGY IMMUNOL & PULM DIS,DURHAM,NC 27706; DUKE UNIV,SCH MED,DEPT PEDIAT,DURHAM,NC 27706; DUKE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27706	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University; Duke University			Buckley, Rebecca/AAB-1578-2019					ALTMAN LC, 1974, J CLIN INVEST, V54, P486, DOI 10.1172/JCI107784; ALTMAN LC, 1973, J IMMUNOL, V110, P801; ALTMAN LC, 1976, ANNUAL REV ALLERGY; BUCKLEY RH, 1975, J CLIN INVEST, V55, P157, DOI 10.1172/JCI107906; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUCKLEY RH, 1974, BRENNEMANS PRACTICE, V2, pCH64; CHURCH JA, 1976, J PEDIATR-US, V88, P982, DOI 10.1016/S0022-3476(76)81056-6; CLARK RA, 1973, ANN INTERN MED, V78, P515, DOI 10.7326/0003-4819-78-4-515; DAHL MV, 1976, ARCH DERMATOL, V112, P1387, DOI 10.1001/archderm.112.10.1387; FULGINITI VA, 1973, IMMUNOLOGIC DISORDER, P551; HILL HR, 1974, LANCET, V2, P617; HILL HR, 1974, LANCET, V1, P183; HILL HR, 1975, PHAGOCYTIC CELL HOST, P249; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; OPPENHEIM JJ, 1976, IMMUNOBIOLOGY MACROP; PINCUS SH, 1975, J PEDIATR-US, V87, P908, DOI 10.1016/S0022-3476(75)80903-6; ROGGE JL, 1976, ARCH DERMATOL, V112, P1391, DOI 10.1001/archderm.112.10.1391; SNYDERMAN R, 1972, J IMMUNOL, V108, P857; SNYDERMAN R, 1975, J ALLERGY CLIN IMMUN, V55, P102; SNYDERMAN R, 1976, IN VITRO METHODS CEL; SNYDERMAN R, 1972, 5TH P INT S CAN SOC; TILL G, 1975, J IMMUNOL, V114, P843; VANSCOY RE, 1975, ANN INTERN MED, V82, P766, DOI 10.7326/0003-4819-82-6-766; WITEMEYER S, 1976, J PEDIATR-US, V89, P33, DOI 10.1016/S0022-3476(76)80922-5	24	51	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	2					121	126		10.1016/0091-6749(77)90037-9	http://dx.doi.org/10.1016/0091-6749(77)90037-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR448	874212				2022-12-18	WOS:A1977DR44800006
J	WILSON, AF; NOVEY, HS; CLONINGER, P; DAVIS, J; WHITE, D				WILSON, AF; NOVEY, HS; CLONINGER, P; DAVIS, J; WHITE, D			CARDIOPULMONARY EFFECTS OF LONG-TERM BRONCHODILATOR ADMINISTRATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92664	University of California System; University of California Irvine								AMSTERDAM EA, 1974, AM J CARDIOL, V33, P737, DOI 10.1016/0002-9149(74)90214-8; BOUHUYS A, 1970, J CLIN INVEST, V49, P106, DOI 10.1172/JCI106209; CADE JF, 1971, CLIN SCI, V40, P381, DOI 10.1042/cs0400381; DESPAS PJ, 1972, J CLIN INVEST, V51, P3235, DOI 10.1172/JCI107150; FLEISCH JH, 1972, J PHARMACOL EXP THER, V181, P425; FLEISCH JH, 1973, J PHARMACOL EXP THER, V186, P44; FORMGREN H, 1970, SCAND J RESPIR DIS, V51, P195; GIBSON DG, 1971, POSTGRAD MED J, V47, P40; GOODMAN LS, 1970, PHARMACOL BASIS, P507; HERXHEIMER H, 1946, BMJ-BRIT MED J, V1, P350, DOI 10.1136/bmj.1.4444.350; HOEL PG, 1960, ELEMENTARY STATISTIC; HURST A, 1973, ANN ALLERGY, V31, P460; KANAREK DJ, 1972, ACTA ALLERGOL, V27, P302, DOI 10.1111/j.1398-9995.1972.tb01429.x; KESSLER F, 1970, HOSP ST RAPHAEL B, V1, P35; KITIMURA K, 1972, J APPL PHYSIOL, V32, P516; LAL S, 1972, LANCET, V1, P853; LEEGAARD J, 1973, ARCH DIS CHILD, V48, P229, DOI 10.1136/adc.48.3.229; MACKLEM PT, 1967, J APPL PHYSIOL, V22, P395, DOI 10.1152/jappl.1967.22.3.395; MCCARTHY D, 1973, AM REV RESPIR DIS, V107, P559, DOI 10.1164/arrd.1973.107.4.559; MCFADDEN ER, 1969, J APPL PHYSIOL, V27, P452, DOI 10.1152/jappl.1969.27.4.452; MODELL W, 1972, DRUGS CHOICE 1972 19, P422; NILSSON HT, 1972, XENOBIOTICA, V2, P363; OGILVIE CM, 1975, J CLIN INVEST, V36, P1; PARKER CW, 1973, PHYSIOLOGY IMMUNOPHA; PARKER SS, 1971, BRIT MED J, V4, P139, DOI 10.1136/bmj.4.5780.139; PATERSON JW, 1968, LANCET, V2, P426; PERSSON K, 1972, XENOBIOTICA, V2, P375, DOI 10.3109/00498257209111064; REED CE, 1974, J ALLERGY CLIN IMMUN, V53, P34, DOI 10.1016/0091-6749(74)90097-9; WEITZMAN RH, 1974, AM J MED, V57, P767, DOI 10.1016/0002-9343(74)90851-1	29	51	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					204	212		10.1016/0091-6749(76)90156-1	http://dx.doi.org/10.1016/0091-6749(76)90156-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX744	956557				2022-12-18	WOS:A1976BX74400010
J	WANDERER, AA; ELLIS, EF				WANDERER, AA; ELLIS, EF			TREATMENT OF COLD URTICARIA WITH CYPROHEPTADINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note																		Anderson P C, 1967, Mo Med, V64, P916; ARBESMAN CE, 1946, J ALLERGY, V17, P275, DOI 10.1016/0021-8707(46)90074-3; BERGEN SS, 1964, AM J DIS CHILD, V108, P270, DOI 10.1001/archpedi.1964.02090010272008; CLARKE GHV, 1969, ARCH DERMATOL, V100, P121, DOI 10.1001/archderm.1969.01610250127038; DELAUS FV, 1968, ARCH DERMATOL, V98, P67, DOI 10.1001/archderm.98.1.67; Delorme P, 1967, Union Med Can, V96, P1220; DEMIS DJ, 1960, J INVEST DERMATOL, V34, P43, DOI 10.1038/jid.1960.8; ERDOS EG, 1970, HDB EXPERIMENTAL PHA, V25, P630; HARBER LC, 1965, ARCH DERMATOL, V92, P334, DOI 10.1001/archderm.92.3.334; Horton BT, 1936, J AMER MED ASSOC, V107, P1263, DOI 10.1001/jama.1936.02770420001001; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; ILLIG L, 1967, GERM MED MTH, V12, P392; ISOKANE N, CITED INDIRECTLY; ISOKANE N, 1965, OCHANOMIZU MED J, V13, P107; KELLY FJ, 1953, AM J MED, V15, P431, DOI 10.1016/0002-9343(53)90132-6; KESTEN BM, 1948, ANN ALLERGY, V6, P410; LEME GJ, 1965, BRIT J PHARMACOL, V25, P50; NOTIER VA, 1946, MAYO CLIN P, V21, P170; PERRY EL, 1947, AM J MED SCI, V214, P553, DOI 10.1097/00000441-194711000-00014; ROTHSCHILD JE, 1949, J ALLERGY, V20, P62, DOI 10.1016/0021-8707(49)90084-2; SHERMAN WB, 1950, J ALLERGY, V21, P414, DOI 10.1016/0021-8707(50)90017-7; SOLOMON LM, 1966, ARCH DERMATOL, V94, P156, DOI 10.1001/archderm.94.2.156; STEINHARDT MJ, 1953, J ALLERGY, V24, P335, DOI 10.1016/0021-8707(53)90178-6; TINDALL JP, 1969, ARCH INTERN MED, V124, P129, DOI 10.1001/archinte.124.2.129; VELOU A, 1964, J Indian Med Assoc, V43, P401; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P13, DOI 10.1016/0091-6749(71)90050-9; WITHERSPOON FG, 1948, ARCH DERMATOL SYPH, V58, P52, DOI 10.1001/archderm.1948.01520200055007	27	51	51	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	6					366	+		10.1016/0091-6749(71)90083-2	http://dx.doi.org/10.1016/0091-6749(71)90083-2			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L0384	5287036				2022-12-18	WOS:A1971L038400006
J	Juhn, Y; Liu, HF				Juhn, Young; Liu, Hongfang			Artificial intelligence approaches using natural language processing to advance EHR-based clinical research	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						EHRs; asthma; allergy; immunology; informatics; data mining; machine learning; natural language processing; algorithms; artificial intelligence	ASTHMA ASCERTAINMENT; HEALTH; IDENTIFICATION; GENERATION; ALGORITHM	The wide adoption of electronic health record systems in health care generates big real-world data that open new venues to conduct clinical research. As a large amount of valuable clinical information is locked in clinical narratives, natural language processing techniques as an artificial intelligence approach have been leveraged to extract information from clinical narratives in electronic health records. This capability of natural language processing potentially enables automated chart review for identifying patients with distinctive clinical characteristics in clinical care and reduces methodological heterogeneity in defining phenotype, obscuring biological heterogeneity in research concerning allergy, asthma, and immunology. This brief review discusses the current literature on the secondary use of electronic health record data for clinical research concerning allergy, asthma, and immunology and highlights the potential, challenges, and implications of natural language processing techniques.	[Juhn, Young] Mayo Clin, Precis Populat Sci Lab, Div Community Pediat & Adolescent Med, Dept Pediat & Adolescent Med, Rochester, MN USA; [Juhn, Young] Mayo Clin, Dept Med, Div Allergy, Rochester, MN USA; [Liu, Hongfang] Mayo Clin, Dept Hlth Sci Res, Div Digital Hlth, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Juhn, Y (corresponding author), Mayo Clin, Precis Populat Sci Lab, Dept Pediat & Adolescent Med Internal Med Hlth Sc, 200 First St SW, Rochester, MN 55905 USA.	juhn.young@mayo.edu			National Institute of Health [R01 HL126667]; R21 grant [R21AI116839-01]	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); R21 grant	The work was supported by grants from the National Institute of Health (grant no. R01 HL126667) and the R21 grant (grant no. R21AI116839-01).	Afzal Z, 2013, PHARMACOEPIDEM DR S, V22, P826, DOI 10.1002/pds.3438; [Anonymous], 2019, MACHINE INTELLIGENCE; Attia ZI, 2019, NAT MED, V25, P70, DOI 10.1038/s41591-018-0240-2; Bakken S, 2019, J AM MED INFORM ASSN, V26, P583, DOI 10.1093/jamia/ocz073; Blumenthal KG, 2017, J ALLER CL IMM-PRACT, V5, P737, DOI 10.1016/j.jaip.2016.12.006; Chen L, 2019, J AM MED INFORM ASSN, V26, P1218, DOI 10.1093/jamia/ocz109; Cohen J., 2019, ONC WORKING APP PRIV; Crown WH, 2015, VALUE HEALTH, V18, P137, DOI 10.1016/j.jval.2014.12.005; Department of Biomedical Informatics Harvard Medical School, 2019, NAT NLP CLIN CHALL N; Epstein RH, 2013, J AM MED INFORM ASSN, V20, P962, DOI 10.1136/amiajnl-2013-001756; Fang G, 2019, J AM MED INFORM ASSN, V26, P977, DOI 10.1093/jamia/ocz036; Fleurence RL, 2014, J AM MED INFORM ASSN, V21, P578, DOI 10.1136/amiajnl-2014-002747; Friedman C, 2013, J BIOMED INFORM, V46, P765, DOI 10.1016/j.jbi.2013.06.004; Gardner RL, 2019, J AM MED INFORM ASSN, V26, P106, DOI 10.1093/jamia/ocy145; Goss Foster R, 2014, AMIA Annu Symp Proc, V2014, P580; Gustafson E, 2017, 2017 IEEE INTERNATIONAL CONFERENCE ON HEALTHCARE INFORMATICS (ICHI), P83, DOI 10.1109/ICHI.2017.31; Himes Blanca E, 2008, AMIA Annu Symp Proc, P308; HIMSS, 2017, 21 CENT CUR ACT SUMM; Jarow JP, 2017, JAMA-J AM MED ASSOC, V318, P703, DOI 10.1001/jama.2017.9991; Juhn YWC, 2020, ANN AM AC ALL ASTHM; Kaur H, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0593-9; Kimia AA, 2015, PEDIATR EMERG CARE, V31, P536, DOI 10.1097/PEC.0000000000000484; Lai KH, 2015, J BIOMED INFORM, V55, P188, DOI 10.1016/j.jbi.2015.04.008; Lemke Amy A, 2010, Genom Soc Policy, V6, P50; Liang HY, 2019, NAT MED, V25, P433, DOI 10.1038/s41591-018-0335-9; Martin-Sanchez F, 2014, Yearb Med Inform, V9, P14, DOI 10.15265/IY-2014-0020; MedicalEconomics, 2019, EHRS SHOULD BE TOOL; Mercan E, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.8777; Meystre Stephane M, 2009, AMIA Annu Symp Proc, V2009, P442; Minnesota Community Measurement, 2017, 2017 HLTH CAR QUAL R; Nadkarni PM, 2011, J AM MED INFORM ASSN, V18, P544, DOI 10.1136/amiajnl-2011-000464; National Institutes of Health, 2011, CLIN TRANSL SCI AW C; Obermeyer Z, 2019, SCIENCE, V366, P447, DOI 10.1126/science.aax2342; Pak HS, 2019, UNSTRUCTURED DATA HL; Plasek JM, 2016, J AM MED INFORM ASSN, V23, pE79, DOI 10.1093/jamia/ocv128; Segura-Bedmar I, 2018, J BIOMED INFORM, V87, P50, DOI 10.1016/j.jbi.2018.09.012; Seol HY, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2019-000524; Seol HY, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00113; Shivade C, 2014, J AM MED INFORM ASSN, V21, P221, DOI 10.1136/amiajnl-2013-001935; Shortliffe EH, 2018, JAMA-J AM MED ASSOC, V320, P2199, DOI 10.1001/jama.2018.17163; Sohn S, 2017, J AM MED INFORM ASS; Sohn S, 2018, J ALLERGY CLIN IMMUN, V141, P2292, DOI 10.1016/j.jaci.2017.12.1003; Sohn S, 2017, STUD HEALTH TECHNOL, V245, P1170, DOI 10.3233/978-1-61499-830-3-1170; Tahir D., 2019, PROVIDER GROUPS SLOW; Topalovic M., 2019, EUR RESPIR J, V53; van Wonderen KE, 2010, EUR RESPIR J, V36, P48, DOI 10.1183/09031936.00154409; Wang YS, 2018, J BIOMED INFORM, V77, P34, DOI 10.1016/j.jbi.2017.11.011; Wi CI, 2017, AM J RESP CRIT CARE, V196, P430, DOI 10.1164/rccm.201610-2006OC; Wi CI, 2018, J ALLER CL IMM-PRACT, V6, P126, DOI 10.1016/j.jaip.2017.04.041; Wu S, 2018, J BIOMED INFORM, V83, P167, DOI 10.1016/j.jbi.2018.05.016; Wu ST, 2014, J AM MED INFORM ASSN, V21, P876, DOI 10.1136/amiajnl-2013-002463; Wu ST, 2013, ANN ALLERG ASTHMA IM, V111, P364, DOI 10.1016/j.anai.2013.07.022; Xiong Y, 2019, J AM MED INFORM ASSN, V26, P1203, DOI 10.1093/jamia/ocz099	53	50	51	9	41	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					463	469		10.1016/j.jaci.2019.12.897	http://dx.doi.org/10.1016/j.jaci.2019.12.897			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	KK6ZG	31883846	Green Accepted, Bronze			2022-12-18	WOS:000512887400003
J	Zhou, LS; Leonard, A; Pavel, AB; Malik, K; Raja, A; Glickman, J; Estrada, YD; Peng, XY; del Duca, E; Sanz-Cabanillas, J; Ruano, J; Xu, H; Zhang, N; Wen, HC; Gonzalez, J; Garcet, S; Krueger, JG; Guttman-Yassky, E				Zhou, Lisa; Leonard, Alexandra; Pavel, Ana B.; Malik, Kunal; Raja, Aishwarya; Glickman, Jacob; Estrada, Yeriel D.; Peng, Xiangyu; del Duca, Ester; Sanz-Cabanillas, Juan; Ruano, Juan; Xu, Hui; Zhang, Ning; Wen, Huei-Chi; Gonzalez, Juana; Garcet, Sandra; Krueger, James G.; Guttman-Yassky, Emma			Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; biomarker; T(H)1; T(H)2; T(H)17; T(H)22; hyperplasia; loricrin; filaggrin; aging; skin	CYTOKINE PRODUCTION; IGE SENSITIZATION; ECZEMA PREVALENCE; GENE-EXPRESSION; DENDRITIC CELLS; SKIN; INTERLEUKIN-6; CENTENARIANS; INFLAMMATION; POPULATION	Background: Atopic dermatitis (AD) shows differential clinical presentation in older compared with younger patients. Nevertheless, changes in the AD molecular profile with age are unknown. Objective: We sought to characterize age-related changes in the AD profile. Methods: We evaluated age-specific changes in lesional and nonlesional tissues and blood from patients with moderate-to severe AD (n = 246) and age-matched control subjects (n = 71) using immunohistochemistry, quantitative real-time PCR, and Singulex in a cross-sectional study. Patients were analyzed by age group (18-40, 41-60, and >= 61 years). Results: Although disease severity/SCORAD scores were similar across AD age groups (mean, approximately 60 years; P = .873), dendritic cell infiltrates (CD1b(+) and Fc epsilon RI+, P < .05) decreased with age. T(H)2 measures (IL5, IL13, CCL13, CCL18, and CCL26) significantly decreased with age in patients with AD, despite increasing with age in control subjects. Consistent with T(H)2 axis decreases, serum IgE levels and eosinophil counts negatively correlated with age in patients with AD (r = -0.24 and r = -0.23, respectively; P < .05). T(H)22-secreted IL22 expression levels also decreased with age uniquely in patients with AD (P < .05). Expression of T(H)1-related (IFNG, IL12/23p40, STAT1, and CXCL9; P < .05 for CXCL9) and T(H)17-related (IL17A and IL20; P < .05 for IL20) markers increased with age in both patients with AD and control subjects. Expression of terminal differentiation measures significantly increased in older patients with AD (loricrin [LOR] and filaggrin [FLG], P < .05), whereas expression of S100As (S100A8, P < .01) and hyperplasia markers (epidermal thickness, keratin 16, and Ki67; P < .05 for keratin 16) decreased. Serum trends in AD mimicked skin findings, with T(H)2 downregulation (CCL26; r = 0.32, P < .1) and T(H)1 upregulation (IFN-gamma; r = 0.48, P < .01) with age. Conclusion: The adult AD profile varies with age. Although T(H)1/T(H)17 skewing increases in both patients with AD and control subjects, patients with AD show unique decreases in T(H)2/T(H)22 polarization and normalization of epithelial abnormalities. Thus age-specific treatment approaches might be beneficial for AD.	[Zhou, Lisa; Leonard, Alexandra; Pavel, Ana B.; Malik, Kunal; Raja, Aishwarya; Glickman, Jacob; Estrada, Yeriel D.; Peng, Xiangyu; del Duca, Ester; Xu, Hui; Zhang, Ning; Wen, Huei-Chi; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, Lab Inflammatory Skin Dis, New York, NY 10029 USA; [Sanz-Cabanillas, Juan; Ruano, Juan] Reina Sofia Univ Hosp, Dept Dermatol, Cordoba, Spain; [Gonzalez, Juana; Garcet, Sandra; Krueger, James G.] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; Hospital Universitario Reina Sofia - Cordoba; Rockefeller University	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, Lab Inflammatory Skin Dis, 5 E 98th St, New York, NY 10029 USA.	emma.guttman@mountsinai.org	Wen, Huei-Chi/ABD-7417-2021; Del Duca, Ester/AAC-2711-2022; Ruano, Juan/T-1991-2018	Del Duca, Ester/0000-0001-7948-8536; Ruano, Juan/0000-0002-0286-4107; Garcet, Sandra/0000-0002-4465-8547; , Ana Brandusa/0000-0002-8155-8553				Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Agrawal A, 2007, J IMMUNOL, V178, P6912, DOI 10.4049/jimmunol.178.11.6912; Agrawal A, 2012, EXPERT REV CLIN IMMU, V8, P73, DOI [10.1586/ECI.11.77, 10.1586/eci.11.77]; ALRAYES H, 1992, J ALLERGY CLIN IMMUN, V90, P630, DOI 10.1016/0091-6749(92)90136-P; Amaral AFS, 2016, J ALLERGY CLIN IMMUN, V137, P1788, DOI 10.1016/j.jaci.2015.09.037; Basile G, 2012, ARCH GERONTOL GERIAT, V54, P459, DOI 10.1016/j.archger.2011.05.004; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Bouree P, 2003, PATHOL BIOL, V51, P581, DOI 10.1016/j.patbio.2003.09.004; Brandt E. B., 2011, J CLIN CELL IMMUNOL, V2; Brunner PM, 2018, ANN ALLERG ASTHMA IM, V120, P34, DOI 10.1016/j.anai.2017.09.055; Brunner PM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09207-z; Busse PJ, 2017, J ALLERGY CLIN IMMUN, V139, P1808, DOI 10.1016/j.jaci.2016.09.015; Cakman I, 1996, MECH AGEING DEV, V87, P197, DOI 10.1016/0047-6374(96)01708-3; Cossarizza A, 1996, MECH AGEING DEV, V86, P173, DOI 10.1016/0047-6374(95)01691-0; Effros RB, 2005, IMMUNOL REV, V205, P147, DOI 10.1111/j.0105-2896.2005.00259.x; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Ferrucci L, 2005, BLOOD, V105, P2294, DOI 10.1182/blood-2004-07-2599; GHADIALLY R, 1995, J CLIN INVEST, V95, P2281, DOI 10.1172/JCI117919; Gilhar A, 2004, J GERONTOL A-BIOL, V59, P411; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Giuliani N, 2001, EXP GERONTOL, V36, P547, DOI 10.1016/S0531-5565(00)00220-5; Goronzy JJ, 2012, CELL MOL LIFE SCI, V69, P1615, DOI 10.1007/s00018-012-0970-0; Gregg R, 2005, CLIN EXP IMMUNOL, V140, P540, DOI 10.1111/j.1365-2249.2005.02798.x; Guttman-Yassky E, 2018, J AM ACAD DERMATOL, V78, P872, DOI 10.1016/j.jaad.2018.01.016; Guttman-Yassky E, 2017, CURR OPIN IMMUNOL, V48, P68, DOI 10.1016/j.coi.2017.08.008; Guttman-Yassky E, 2018, EXP DERMATOL, V27, P409, DOI 10.1111/exd.13336; HAGER K, 1994, NEUROBIOL AGING, V15, P771, DOI 10.1016/0197-4580(94)90066-3; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; HARVELL JD, 1994, J AM ACAD DERMATOL, V31, P1015, DOI 10.1016/S0190-9622(94)70273-X; Izuhara K., 2002, Current Drug Targets - Inflammation and Allergy, V1, P263, DOI 10.2174/1568010023344661; Jarvis D, 2005, J ALLERGY CLIN IMMUN, V116, P675, DOI 10.1016/j.jaci.2005.05.009; Kawashima T, 1989, Nihon Hifuka Gakkai Zasshi, V99, P1095; Khattri S, 2017, EXP DERMATOL, V26, P28, DOI 10.1111/exd.13112; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kleinewietfeld M, 2013, SEMIN IMMUNOL, V25, P305, DOI 10.1016/j.smim.2013.10.009; Lages CS, 2008, J IMMUNOL, V181, P1835, DOI 10.4049/jimmunol.181.3.1835; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Li Q, 2017, AM J TRANSL RES, V9, P5160; Linton PJ, 2004, NAT IMMUNOL, V5, P133, DOI 10.1038/ni1033; Listi F, 2006, ANN NY ACAD SCI, V1089, P487, DOI 10.1196/annals.1386.013; Lynch HE, 2009, TRENDS IMMUNOL, V30, P366, DOI 10.1016/j.it.2009.04.003; Margolis JS, 2014, JAMA DERMATOL, V150, P593, DOI 10.1001/jamadermatol.2013.10271; Mediaty Anja, 2005, Immun Ageing, V2, P9, DOI 10.1186/1742-4933-2-9; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Oriss TB, 1997, J IMMUNOL, V158, P3666; Pelletier M, 2010, BLOOD, V115, P335, DOI 10.1182/blood-2009-04-216085; Pereira BI, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00445; Pinti M, 2010, CURR PHARM DESIGN, V16, P597, DOI 10.2174/138161210790883705; Reed CE, 2006, J ALLERGY CLIN IMMUN, V118, P543, DOI 10.1016/j.jaci.2006.06.020; Rink L, 1998, MECH AGEING DEV, V102, P199, DOI 10.1016/S0047-6374(97)00153-X; Roubenoff R, 1998, J GERONTOL A-BIOL, V53, pM20, DOI 10.1093/gerona/53A.1.M20; Sandmand M, 2002, CLIN EXP IMMUNOL, V127, P107, DOI 10.1046/j.1365-2249.2002.01736.x; Sansoni P, 2008, EXP GERONTOL, V43, P61, DOI 10.1016/j.exger.2007.06.008; Sehra S, 2010, J IMMUNOL, V184, P3186, DOI 10.4049/jimmunol.0901860; Silverberg JI, 2013, J ALLERGY CLIN IMMUN, V132, P1132, DOI 10.1016/j.jaci.2013.08.031; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Tanei R, 2016, GERIATR GERONTOL INT, V16, P75, DOI 10.1111/ggi.12771; Thome JJC, 2015, TRENDS IMMUNOL, V36, P428, DOI 10.1016/j.it.2015.05.003; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; Ventura Maria Teresa, 2017, Clin Mol Allergy, V15, P21, DOI 10.1186/s12948-017-0077-0; Vukmanovic-Stejic M, 2015, J INVEST DERMATOL, V135, P1752, DOI 10.1038/jid.2015.63; Vukmanovic-Stejic M, 2011, CURR OPIN IMMUNOL, V23, P525, DOI 10.1016/j.coi.2011.05.008; Waller JM, 2005, SKIN RES TECHNOL, V11, P221, DOI 10.1111/j.0909-725X.2005.00151.x; Weksler ME, 2000, J CLIN IMMUNOL, V20, P240, DOI 10.1023/A:1006659401385; Zanni F, 2003, EXP GERONTOL, V38, P981, DOI 10.1016/S0531-5565(03)00160-8	73	50	54	4	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					144	156		10.1016/j.jaci.2019.01.015	http://dx.doi.org/10.1016/j.jaci.2019.01.015			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30685456	Bronze			2022-12-18	WOS:000473432800018
J	Jung, CR; Chen, WT; Tang, YH; Hwang, BF				Jung, Chau-Ren; Chen, Wei-Ting; Tang, Yu-Hsin; Hwang, Bing-Fang			Fine particulate matter exposure during pregnancy and infancy and incident asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; air pollution; birth cohort; particulate matter with an aerodynamic diameter less than 2.5 mu m; prenatal; postnatal vulnerable time windows	OUTDOOR AIR-POLLUTION; CHILDHOOD ASTHMA; BIRTH; PARTICLES; DIAGNOSIS; HEALTH; AGE	Background: Lung development is a multistage process from conception to the postnatal period, disruption of which by air pollutants can trigger later respiratory morbidity. Objective: We sought to evaluate the effects of weekly average fine particulate matter (particulate matter with an aerodynamic diameter less than 2.5 mu m [PM2.5]) exposure during pregnancy and infancy on asthma and identify vulnerable times to help elucidate possible mechanisms of the effects of PM2.5 on asthma symptoms. Methods: A birth cohort study including 184,604 children born during 2004-2011 in Taichung City was retrieved from the Taiwan Maternal and Child Health Database and followed until 2014. A daily satellite-based hybrid model was applied to estimate PM2.5 exposure for each subject. A Cox proportional hazard model combined with a distributed lag nonlinear model was used to evaluate the associations of asthma with PM2.5 exposure during pregnancy and infancy. Results: The birth cohort contained 34,336 asthmatic patients, and the mean age of children given a diagnosis of asthma was 3.39 +/- 1.78 years. Increased exposure to PM2.5 during gestational weeks 6 to 22 and 9 to 46 weeks after birth were significantly associated with an increased incidence of asthma. The exposure-response relationship indicated that the hazard ratio (HR) of asthma increased steeply at PM2.5 exposure of greater than 93 mu g/m(3) during pregnancy. Additionally, the HRs remained significant with postnatal exposure to PM2.5 between 26 and 72 mu g/m(3) (range, 1.01-1.07 mu g/m(3)), followed by a sharp increase in HRs at PM2.5 exposure of greater than 73 mu g/m(3). Conclusion: Both prenatal and postnatal exposures to PM2.5 were associated with later development of asthma. The vulnerable time windows might be within early gestation and midgestation and infancy.	[Jung, Chau-Ren; Tang, Yu-Hsin; Hwang, Bing-Fang] China Med Univ, Coll Publ Hlth, Dept Occupat Safety & Hlth, Taichung, Taiwan; [Jung, Chau-Ren] Natl Inst Environm Studies, Japan Environm & Childrens Study Programme Off, Tsukuba, Ibaraki, Japan; [Chen, Wei-Ting] Natl Taiwan Univ, Dept Atmospher Sci, Taipei, Taiwan; [Hwang, Bing-Fang] Asia Univ, Coll Med & Hlth Sci, Dept Occupat Therapy, Taichung, Taiwan	China Medical University Taiwan; National Institute for Environmental Studies - Japan; National Taiwan University; Asia University Taiwan	Hwang, BF (corresponding author), China Med Univ, Dept Occupat Safety & Hlth, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.	bfhwang@mail.cmu.edu.tw	Jung, Chau-Ren/I-7618-2019; Hwang, Bing-Fang/O-2709-2015; Chen, Wei-Ting/A-4476-2012	Jung, Chau-Ren/0000-0003-0673-9968; Hwang, Bing-Fang/0000-0002-5951-9662; Chen, Wei-Ting/0000-0002-9292-0933	China Medical University, Taichung, Taiwan [CMU107-Z-04]; Ministry of Science and Technology, Taipei, Taiwan [MOST 105-2119-M-039-002, MOST 106-2119-M-039-001, MOST 107-2119-M-039-001, MOST 106-2811-M-039-002]	China Medical University, Taichung, Taiwan(China Medical University); Ministry of Science and Technology, Taipei, Taiwan	Supported by China Medical University (CMU107-Z-04), Taichung, Taiwan, and the Ministry of Science and Technology (MOST 105-2119-M-039-002, MOST 106-2119-M-039-001, MOST 107-2119-M-039-001, and MOST 106-2811-M-039-002), Taipei, Taiwan.	Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Clark NA, 2010, ENVIRON HEALTH PERSP, V118, P284, DOI 10.1289/ehp.0900916; Deng QH, 2016, ENVIRON RES, V150, P119, DOI 10.1016/j.envres.2016.05.050; Fanucchi MV, 2015, LUNG DEV AGING ENV; Fedulov AV, 2008, AM J RESP CELL MOL, V38, P57, DOI 10.1165/rcmb.2007-0124OC; Gasparrini A, 2014, STAT MED, V33, P881, DOI 10.1002/sim.5963; Gasparrini A, 2011, J STAT SOFTW, V43, P1, DOI 10.18637/jss.v043.i08; Gehring U, 2015, LANCET RESP MED, V3, P933, DOI 10.1016/S2213-2600(15)00426-9; Gowers AM, 2012, RESPIROLOGY, V17, P887, DOI 10.1111/j.1440-1843.2012.02195.x; Gruzieva O, 2013, EPIDEMIOLOGY, V24, P54, DOI 10.1097/EDE.0b013e318276c1ea; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Hislop AA, 2002, J ANAT, V201, P325, DOI 10.1046/j.1469-7580.2002.00097.x; Holgate S., 2004, WHO MONOGRAPH; Hsu HHL, 2015, AM J RESP CRIT CARE, V192, P1052, DOI 10.1164/rccm.201504-0658OC; Jung CR, 2018, ENVIRON POLLUT, V237, P1000, DOI 10.1016/j.envpol.2017.11.016; Jung CR, 2017, ENVIRON POLLUT, V231, P1085, DOI 10.1016/j.envpol.2017.08.102; Kajekar R, 2007, PHARMACOL THERAPEUT, V114, P129, DOI 10.1016/j.pharmthera.2007.01.011; Kelly FJ, 2003, OCCUP ENVIRON MED, V60, P612, DOI 10.1136/oem.60.8.612; Korten I, 2017, PAEDIATR RESPIR REV, V21, P38, DOI 10.1016/j.prrv.2016.08.008; Li C.-Y., 2016, TAIWAN GONG GONG WEI, V35, P209; Manners S, 2014, J ALLERGY CLIN IMMUN, V134, P63, DOI 10.1016/j.jaci.2013.10.047; Martens DS, 2017, JAMA PEDIATR, V171, P1160, DOI 10.1001/jamapediatrics.2017.3024; Mauad T, 2008, AM J RESP CRIT CARE, V178, P721, DOI 10.1164/rccm.200803-436OC; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Lopes TDM, 2018, ENVIRON POLLUT, V241, P511, DOI 10.1016/j.envpol.2018.05.055; Mintz M, 2004, AM FAM PHYSICIAN, V70, P893; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Postma DS, 2007, GENDER MED, V4, pS133, DOI 10.1016/S1550-8579(07)80054-4; Radhakrishnan DK, 2014, J ALLERGY CLIN IMMUN, V134, P1057, DOI 10.1016/j.jaci.2014.05.012; Sbihi H, 2016, EUR RESPIR J, V47, P1062, DOI 10.1183/13993003.00746-2015; Schittny JC, 2017, CELL TISSUE RES, V367, P427, DOI 10.1007/s00441-016-2545-0; Smith LJ, 2010, PAEDIATR RESPIR REV, V11, P135, DOI 10.1016/j.prrv.2009.12.006; Su VYF, 2018, J ALLER CL IMM-PRACT, V6, P1927, DOI 10.1016/j.jaip.2018.01.035; Suttorp MM, 2015, NEPHROL DIAL TRANSPL, V30, P1418, DOI 10.1093/ndt/gfu325; Therneau T, USING TIME DEPENDENT; Townsend EA, 2012, ENDOCR REV, V33, P1, DOI 10.1210/er.2010-0031; Tzivian L, 2011, J ASTHMA, V48, P470, DOI 10.3109/02770903.2011.570407; Wu S, 2017, RESP OUTCOMES PRETER; Xiao QY, 2017, REMOTE SENS ENVIRON, V199, P437, DOI 10.1016/j.rse.2017.07.023; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18	41	50	52	5	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2254	+		10.1016/j.jaci.2019.03.024	http://dx.doi.org/10.1016/j.jaci.2019.03.024			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30959062	Bronze			2022-12-18	WOS:000470113200028
J	Mehlich, J; Fischer, J; Hilger, C; Swiontek, K; Morisset, M; Codreanu-Morel, F; Schiener, M; Blank, S; Ollert, M; Darsow, U; Biedermann, T; Eberlein, B				Mehlich, Jana; Fischer, Joerg; Hilger, Christiane; Swiontek, Kyra; Morisset, Martine; Codreanu-Morel, Francoise; Schiener, Maximilian; Blank, Simon; Ollert, Markus; Darsow, Ulf; Biedermann, Tilo; Eberlein, Bernadette			The basophil activation test differentiates between patients with alpha-gal syndrome and asymptomatic alpha-gal sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basophil activation test; alpha-gal syndrome; galactose-alpha-1,3-galactose; red meat allergy; CD63; CCR3; basophil allergen threshold sensitivity (CD-sens); asymptomatic alpha-gal sensitization	ALLERGEN THRESHOLD-SENSITIVITY; IGE ANTIBODIES; PORK-KIDNEY; MAMMALIAN MEAT; TICK BITES; COWS MILK; CD-SENS; REACTIVITY; DIAGNOSIS; SEVERITY	Background: Galactose-alpha-1,3-galactose (alpha-gal) syndrome is characterized by the presence of serum specific IgE antibodies to alpha-gal and delayed type I allergic reactions to the carbohydrate alpha-gal after consumption of mammalian (red) meat products and drugs of mammalian origin. Diagnostics currently rely on patient history, skin tests, determination of serum specific IgE antibodies, and oral food or drug challenges. Objective: We sought to assess the utility of different basophil parameters (basophil reactivity and sensitivity, the ratio of the percentage of CD63(+) basophils induced by the alpha-gal-containing allergen to the percentage of CD63(+) basophils after stimulation with anti-Fc epsilon RI antibody [%CD63(+)/anti-Fc epsilon RI], and area under the dose-response curve [AUC]) as biomarkers for the clinical outcome of patients with alpha-gal syndrome compared with subjects with asymptomatic alpha-gal sensitization. Methods: In addition to routine diagnostics, a basophil activation test (Flow CAST) with different concentrations of alpha-gal-containing allergens (eg, commercially available alpha-gal-carrying proteins and pork kidney extracts) was performed in 21 patients with alpha-gal syndrome, 12 alphagal-sensitized subjects, and 18 control subjects. Results: Alpha-gal-containing allergens induced strong basophil activation in a dose-dependent manner in patients. Basophil reactivity at distinct allergen concentrations, the % CD63(+)/anti-FceRI ratio across most allergen concentrations, the AUC of dose-response curves, and basophil allergen threshold sensitivity (CD-sens) with pork kidney extract were significantly higher in patients with alpha-gal syndrome compared with those in sensitized subjects. All parameters were negative in control subjects. Conclusion: The basophil activation test should be considered as an additional diagnostic test before performing time-consuming and potentially risky oral provocation tests. The % CD63(+)/anti-Fc epsilon RI ratio for all allergens and AUCs for pork kidney were the best parameters for distinguishing patients with alpha-gal syndrome from subjects with asymptomatic alpha-gal sensitization.	[Mehlich, Jana; Darsow, Ulf; Biedermann, Tilo; Eberlein, Bernadette] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Munich, Germany; [Fischer, Joerg] Eberhard Karls Univ Tuebingen, Dept Dermatol, Fac Med, Tubingen, Germany; [Hilger, Christiane; Swiontek, Kyra; Ollert, Markus] Luxembourg Inst Hlth, Dept Infect & Immun, Esch Sur Alzette, Luxembourg; [Morisset, Martine; Codreanu-Morel, Francoise] Luxembourg Hosp, Immunol Allergol Dept, Luxembourg, Luxembourg; [Schiener, Maximilian; Blank, Simon] Tech Univ Munich, Ctr Allergy & Environm ZAUM, Munich, Germany; [Schiener, Maximilian; Blank, Simon] Helmholtz Ctr Munich, Munich, Germany	Technical University of Munich; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Luxembourg Institute of Health; Luxembourg Hospital Center; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Eberlein, B (corresponding author), Tech Univ Munich, Klin & Poliklin Dermatol & Allergol Biederstein, Biedersteiner Str 29, D-80802 Munich, Germany.	bernadette.eberlein@tum.de	Blank, Simon/M-7708-2013; Morisset, Martine/A-3084-2017	Ollert, Markus W./0000-0002-8055-0103; Morisset, Martine/0000-0002-4028-703X; Biedermann, Tilo/0000-0002-5352-5105	Ministry of Higher Education and Research of Luxembourg	Ministry of Higher Education and Research of Luxembourg	Supported in part by the Ministry of Higher Education and Research of Luxembourg.	Atanaskovic-Markovic M, 2002, ALLERGY, V57, P960, DOI 10.1034/j.1398-9995.2002.23832_5.x; Biedermann T, 1999, DEUT MED WOCHENSCHR, V124, P456, DOI 10.1055/s-2007-1024334; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Commins SP, 2014, J ALLERGY CLIN IMMUN, V134, P108, DOI 10.1016/j.jaci.2014.01.024; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Eberlein B, 2012, J ALLERGY CLIN IMMUN, V130, P155, DOI 10.1016/j.jaci.2012.02.008; Fischer J, 2017, ALLERGY, V72, P1540, DOI 10.1111/all.13156; Fischer J, 2017, ALLERGY, V72, P764, DOI 10.1111/all.13073; Fischer J, 2016, ALLERGO J, V25, P35, DOI 10.1007/s15007-016-1028-7; Fischer J, 2014, J ALLERGY CLIN IMMUN, V134, P755, DOI 10.1016/j.jaci.2014.05.051; Glaumann S, 2012, ALLERGY, V67, P242, DOI 10.1111/j.1398-9995.2011.02754.x; Gonzalez-Quintela A, 2014, CLIN EXP ALLERGY, V44, P1061, DOI 10.1111/cea.12326; Hilger C, 2016, ALLERGY, V71, P711, DOI 10.1111/all.12835; Hoffmann HJ, 2015, ALLERGY, V70, P1393, DOI 10.1111/all.12698; Lee JH, 2013, J DERMATOL, V40, P578, DOI 10.1111/1346-8138.12140; Llatser R, 1998, CLIN EXP ALLERGY, V28, P1021, DOI 10.1046/j.1365-2222.1998.00362.x; Lotzsch B, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0134-7; Morisset M, 2012, ALLERGY, V67, P609, DOI 10.1111/j.1398-9995.2012.02799.x; Nilsson N, 2013, INT ARCH ALLERGY IMM, V162, P50, DOI 10.1159/000350923; Nopp A, 2006, ALLERGY, V61, P298, DOI 10.1111/j.1398-9995.2006.00987.x; Patil SU, 2012, CLIN EXP IMMUNOL, V167, P59, DOI 10.1111/j.1365-2249.2011.04503.x; Patil SU, 2018, CYTOM PART B-CLIN CY, V94, P667, DOI 10.1002/cyto.b.21537; Restani P, 2009, CURR OPIN ALLERGY CL, V9, P265, DOI 10.1097/ACI.0b013e32832aef3d; RING J, 1977, LANCET, V1, P466; Roenneberg S, 2016, J ALLER CL IMM-PRACT, V4, P531, DOI 10.1016/j.jaip.2015.11.027; Rubio A, 2011, ALLERGY, V66, P92, DOI 10.1111/j.1398-9995.2010.02432.x; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P179, DOI 10.1016/j.jaci.2014.09.001; Schmid JM, 2014, J ALLERGY CLIN IMMUN, V134, P741, DOI 10.1016/j.jaci.2014.04.029; Smodis NC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094762; Steinke JW, 2015, J ALLERGY CLIN IMMUN, V135, P589, DOI 10.1016/j.jaci.2014.12.1947; Theler B, 2009, SWISS MED WKLY, V139, P264, DOI smw-12603; van Nunen S., 2014, CURR TREAT OPTION AL, V1, P262, DOI [10.1007/s40521-014-0022-0, DOI 10.1007/S40521-014-0022-0]; Van Nunen SA, 2009, MED J AUSTRALIA, V190, P510, DOI 10.5694/j.1326-5377.2009.tb02533.x	34	50	50	3	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					182	189		10.1016/j.jaci.2018.06.049	http://dx.doi.org/10.1016/j.jaci.2018.06.049			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30125663	Bronze			2022-12-18	WOS:000454918300024
J	Jensen, ET; Kuhl, JT; Martin, LJ; Langefeld, CD; Dellon, ES; Rothenberg, ME				Jensen, Elizabeth T.; Kuhl, Jonathan T.; Martin, Lisa J.; Langefeld, Carl D.; Dellon, Evan S.; Rothenberg, Marc E.			Early-life environmental exposures interact with genetic susceptibility variants in pediatric patients with eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Early-life factors; eosinophilic esophagitis; gene-environment interaction; exposures	GENOME-WIDE ASSOCIATION; GUT MICROBIOTA; PROVIDES INSIGHT; PRETERM INFANTS; ATOPY; RECOMMENDATIONS; COLONIZATION; CHILDREN; DELIVERY; DISEASE	Background: Although eosinophilic esophagitis (EoE) is associated with certain gene variants, the rapidly increasing incidence of EoE suggests that environmental factors contribute to disease development. Objective: We tested for gene-environment interaction between EoE-predisposing polymorphisms (within TSLP, LOC283710/KLF13, CAPN14, CCL26, and TGFB) and implicated early-life factors (antibiotic use in infancy, cesarean delivery, breast-feeding, neonatal intensive care unit [NICU] admission, and absence of pets in the home). Methods: We conducted a case-control study using hospital-based cases (n = 127) and control subjects representative of the hospital catchment area (n = 121). We computed case-only interaction tests and in secondary analyses evaluated the combined and independent effects of genotype and environmental factors on the risk of EoE. Results: Case-only analyses identified interactions between rs6736278 (CAPN14) and breast-feeding (P=.02) and rs17815905 (LOC283710/KLF13) and NICU admission (P=.02) but not with any of the factors examined. Case-control analyses suggested that disease risk might be modifiable in subjects with certain gene variants. In particular, breast-feeding in those with the susceptibility gene variant at rs6736278 (CAPN14) reduced the risk of EoE (adjusted odds ratio, 0.08; 95% CI, 0.01-0.59). Admission to the NICU in those without the susceptibility gene variant at rs17815905 (LOC283710/ KLF13) significantly increased the risk of having disease (adjusted odds ratio, 4.83; 95% CI, 1.49-15.66). Conclusions: The interplay of gene (CAPN14 and LOC283710/KLF13) and early-life environment factors (breast-feeding and NICU admission) might contribute to EoE susceptibility.	[Jensen, Elizabeth T.] Wake Forest Univ Publ Hlth Sci, Dept Epidemiol & Prevent, Winston Salem, NC USA; [Langefeld, Carl D.] Wake Forest Univ Publ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA; [Jensen, Elizabeth T.; Dellon, Evan S.] Univ N Carolina, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Chapel Hill, NC USA; [Dellon, Evan S.] Univ N Carolina, Sch Med, Ctr Esophageal Dis & Swallowing, Chapel Hill, NC USA; [Kuhl, Jonathan T.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA; [Martin, Lisa J.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA; [Martin, Lisa J.; Rothenberg, Marc E.] Univ Cincinnati, Dept Pediat, Sch Med, Cincinnati, OH USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Jensen, ET (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Div Publ Hlth Sci, Dept Epidemiol & Prevent, Med Ctr Blvd, Winston Salem, NC 27157 USA.; Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Cincinnati Ctr Eosinophil Disorders, Div Allergy & Immunol, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA.	ejensen@wakehealth.edu; Rothenberg@cchmc.org	Martin, Lisa/E-2425-2016	Martin, Lisa/0000-0001-8702-9946	American College of Gastroenterology Clinical Research Award; National Institutes of Health [R01 DK101856, R37 AI045898, R01 AI124355]; Campaign Urging Research for Eosinophilic Disease (CURED); Buckeye Foundation; Sunshine Charitable Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI124355, U19AI070235, R37AI045898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392, R01DK101856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER	American College of Gastroenterology Clinical Research Award; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Campaign Urging Research for Eosinophilic Disease (CURED); Buckeye Foundation; Sunshine Charitable Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the American College of Gastroenterology Clinical Research Award. This work was also supported by National Institutes of Health grants R01 DK101856 (to E.S.D.), R37 AI045898, and R01 AI124355; the Campaign Urging Research for Eosinophilic Disease (CURED); the Buckeye Foundation; and the Sunshine Charitable Foundation and its supporters, Denise A. Bunning and David G. Bunning (to M.E.R.).	Alexander ES, 2014, J ALLERGY CLIN IMMUN, V134, P1084, DOI 10.1016/j.jaci.2014.07.021; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112; Collins MH, 2008, CLIN GASTROENTEROL H, V6, P621, DOI 10.1016/j.cgh.2008.01.004; Davis BP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86355; Dellon ES, 2015, ALIMENT PHARM THER, V41, P662, DOI 10.1111/apt.13129; Dellon ES, 2013, AM J GASTROENTEROL, V108, P679, DOI 10.1038/ajg.2013.71; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Harris JK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128346; Hruz P, 2011, GASTROENTEROLOGY, V140, pS238; Huurre A, 2008, NEONATOLOGY, V93, P236, DOI 10.1159/000111102; Jensen ET, 2013, J PEDIATR GASTR NUTR, V57, P67, DOI 10.1097/MPG.0b013e318290d15a; Jensen ET, 2017, J ALLERGY CLIN IMMUN; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Knol MJ, 2012, INT J EPIDEMIOL, V41, P514, DOI 10.1093/ije/dyr218; Knol MJ, 2011, EUR J EPIDEMIOL, V26, P433, DOI 10.1007/s10654-011-9554-9; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Lee SY, 2013, ALLERGY ASTHMA IMMUN, V5, P239, DOI 10.4168/aair.2013.5.4.239; Lexmond WS, 2014, AM J GASTROENTEROL, V109, P646, DOI 10.1038/ajg.2014.12; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Litosh VA, 2017, J ALLERGY CLIN IMMUN, V139, P1762, DOI 10.1016/j.jaci.2016.09.027; Mulder IE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028279; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Patel AL, 2016, J PEDIATR GASTR NUTR, V62, P292, DOI 10.1097/MPG.0000000000000913; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Radano MC, 2014, J ALLER CL IMM-PRACT, V2, P475, DOI 10.1016/j.jaip.2014.02.018; Rieder F, 2014, GASTROENTEROLOGY, V146, P1266, DOI 10.1053/j.gastro.2014.01.051; Rochman M, 2017, J ALLERGY CLIN IMMUN; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P23, DOI 10.1016/j.jaci.2011.03.046; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Slae M, 2015, DIGEST DIS SCI, V60, P3364, DOI 10.1007/s10620-015-3740-7; Taft DH, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-36; Tormo-Badia N, 2014, SCAND J IMMUNOL, V80, P250, DOI 10.1111/sji.12205; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; Walker A, 2014, J CLIN GASTROENTEROL, V48, pS8, DOI 10.1097/MCG.0000000000000230; Walker WA, 2015, PEDIATR RES, V77, P220, DOI 10.1038/pr.2014.160; Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917; Westerbeek EAM, 2006, CLIN NUTR, V25, P361, DOI 10.1016/j.clnu.2006.03.002	41	50	50	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					632	+		10.1016/j.jaci.2017.07.010	http://dx.doi.org/10.1016/j.jaci.2017.07.010			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	29029802	Bronze, Green Accepted			2022-12-18	WOS:000424410800020
J	Wang, Y; Zhu, JH; Zhang, L; Zhang, ZJ; He, L; Mou, Y; Deng, YH; Cao, Y; Yang, P; Su, YC; Zhao, JP; Zhang, S; Yu, QL; Hu, JF; Chen, ZS; Ning, Q; Xiang, XD; Xu, YJ; Wang, CY; Xiong, WN				Wang, Yi; Zhu, Jianghui; Zhang, Lei; Zhang, Zhijun; He, Long; Mou, Yong; Deng, Yanhan; Cao, Yong; Yang, Ping; Su, Yunchao; Zhao, Jianping; Zhang, Shu; Yu, Qilin; Hu, Jifa; Chen, Zhishui; Ning, Qin; Xiang, Xudong; Xu, Yongjian; Wang, Cong-Yi; Xiong, Weining			Role of C/EBP homologous protein and endoplasmic reticulum stress in asthma exacerbation by regulating the IL-4/signal transducer and activator of transcription 6/transcription factor EC/IL-4 receptor alpha positive feedback loop in M2 macrophages	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						C/EBP homologous protein; asthma; macrophage; endoplasmic reticulum stress	LUNG INFLAMMATION; MICE; POLARIZATION; DIFFERENTIATION; PATHOGENESIS; HOMEOSTASIS; DEFICIENCY; RESISTANCE; EXPRESSION; FIBROSIS	Background: C/EBP homologous protein (Chop), a marker of endoplasmic reticulum (ER) stress, exhibits aberrant expression patterns during asthma development. However, its exact role in asthma pathogenesis is not fully understood. Objectives: We aimed to determine the function and mechanism of Chop in the pathogenesis of allergic asthma in patients and animals. Methods: Studies were conducted in asthmatic patients and Chop 2/2 mice to dissect the role of Chop and ER stress in asthma pathogenesis. An ovalbumin (OVA)-induced allergic airway inflammation model was used to address the effect of Chop deficiency on asthma development. Next, the effect of Chop deficiency on macrophage polarization and related signaling pathways was investigated to demonstrate the underlying mechanisms. Results: Asthmatic patients and mice after OVA induction exhibited aberrant Chop expression along with ER stress. Specifically, Chop was noted to be specifically overexpressed in macrophages, and mice deficient in Chop were protected from OVA-induced allergic airway inflammation, as manifested by attenuated airway inflammation, remodeling, and hyperresponsiveness. Chop was found to exacerbate allergic airway inflammation by enhancing M2 programming in macrophages. Mechanistic studies characterized an IL-4/signal transducer and activator of transcription 6/transcription factor EC (Tfec)/IL-4 receptor a positive feedback regulatory loop, in which IL-4 induces Chop expression, which then promotes signal transducer and activator of transcription 6 signaling to transcribe Tfec expression. Finally, Tfec transcribes IL-4 receptor a expression to promote M2 programming in macrophages. Conclusions: Chop and ER stress are implicated in asthma pathogenesis, which involves regulation of M2 programming in macrophages.	[Wang, Yi; Zhu, Jianghui; Zhang, Lei; Zhang, Zhijun; He, Long; Mou, Yong; Deng, Yanhan; Cao, Yong; Yang, Ping; Zhang, Shu; Yu, Qilin; Chen, Zhishui; Xu, Yongjian; Wang, Cong-Yi; Xiong, Weining] Minist Hlth, Key Lab Organ Transplantat, Minist Educ, Ctr Biomed Res, Wuhan, Hubei, Peoples R China; [Wang, Yi; Zhang, Lei; Mou, Yong; Deng, Yanhan; Cao, Yong; Zhao, Jianping; Xu, Yongjian; Xiong, Weining] Huazhong Univ Sci & Technol, Dept Resp & Crit Care Med, Key Lab Pulm Dis,Hlth Minist,Tongji Med Coll, Key Cite Natl Clin Res Ctr Resp Dis,Tongji Hosp, Wuhan, Hubei, Peoples R China; [Su, Yunchao] Georgia Regents Univ, Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA USA; [Hu, Jifa; Chen, Zhishui; Wang, Cong-Yi] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Sponsored Program Adm, Wuhan, Hubei, Peoples R China; [Ning, Qin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Infect Dis, Wuhan, Hubei, Peoples R China; [Xiang, Xudong] Cent S Univ, Dept Emergency Med, Xiangya Hosp 2, Inst Emergency Med & Rare Dis, Changsha, Hunan, Peoples R China	Huazhong University of Science & Technology; University System of Georgia; Augusta University; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Central South University	Wang, CY; Xiong, WN (corresponding author), Tongji Hosp, Ctr Biomed Res, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.	wangcy@tjh.tjmu.edu.cn; xiongweining@tjh.tjmu.edu.cn	deng, yanhan/HHD-0477-2022	Zhao, Jianping/0000-0003-3057-5617; /0000-0002-2486-6517; Wang, Cong-Yi/0000-0001-7914-168X	National Natural Science Foundation of China [81130014, 81530024, 81428001, 81470226, 81570024]; Program Project for Chronic Diseases from the Ministry of Science and Technology [2016YFC1305002]; Funding for Generation of Experimental Animals from the Hubei State Technology Department [2015BCE100]; Program for Changjiang Scholars and Innovative Research Team in University [IRT_14R20]; Multi-interdisciplinary Creative Team for Diabetes Research from Tongji Medical College, Huazhong University of Science Technology [2017-4]; Veterans Affairs [I01BX002035] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program Project for Chronic Diseases from the Ministry of Science and Technology; Funding for Generation of Experimental Animals from the Hubei State Technology Department; Program for Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); Multi-interdisciplinary Creative Team for Diabetes Research from Tongji Medical College, Huazhong University of Science Technology; Veterans Affairs(US Department of Veterans Affairs)	All of the authors declare that their institutions received the National Natural Science Foundation of China (81130014, 81530024, 81428001, 81470226, and 81570024), the Program Project for Chronic Diseases from the Ministry of Science and Technology (2016YFC1305002), the Funding for Generation of Experimental Animals from the Hubei State Technology Department (2015BCE100), the Program for Changjiang Scholars and Innovative Research Team in University (IRT_14R20), and the Multi-interdisciplinary Creative Team for Diabetes Research (2017-4) from Tongji Medical College, Huazhong University of Science & Technology.	BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Byers DE, 2011, CHEST, V140, P768, DOI 10.1378/chest.10-2132; Chen HL, 2016, EXP THER MED, V11, P1865, DOI 10.3892/etm.2016.3141; Chen HL, 2015, INT J CLIN EXP MED, V8, P10640; Chen HL, 2015, INT J CLIN EXP PATHO, V8, P6700; Chen W, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4628502; Cheng J, 2016, DIABETES, V65, P3384, DOI 10.2337/db16-0151; Cheng S, 2014, INT J CLIN EXP MED, V7, P3202; Chung S, 2016, ONCOTARGET, V7, P17532, DOI 10.18632/oncotarget.8162; Doherty TA, 2012, J IMMUNOL, V188, P2622, DOI 10.4049/jimmunol.1101632; Gong S, 2013, FEBS J, V280, P6262, DOI 10.1111/febs.12549; Gu J, 2015, J CONTROL RELEASE, V213, pE102, DOI 10.1016/j.jconrel.2015.05.170; Guo QY, 2017, J ASTHMA, V54, P125, DOI 10.1080/02770903.2016.1205085; Haque R, 2013, J ALLERGY CLIN IMMUN, V132, P1166, DOI 10.1016/j.jaci.2013.07.038; Hoffman SM, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-141; Kim SR, 2015, ALLERGY ASTHMA IMMUN, V7, P106, DOI 10.4168/aair.2015.7.2.106; Kim SR, 2013, J ALLERGY CLIN IMMUN, V132, P1397, DOI 10.1016/j.jaci.2013.08.041; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Lee KS, 2016, THORAX, V71, P52, DOI 10.1136/thoraxjnl-2015-207096; Mauer J, 2014, NAT IMMUNOL, V15, P423, DOI 10.1038/ni.2865; Melgert BN, 2011, J ALLERGY CLIN IMMUN, V127, P831, DOI 10.1016/j.jaci.2010.10.045; Moreira AP, 2010, J ALLERGY CLIN IMMUN, V126, P712, DOI 10.1016/j.jaci.2010.06.010; Moshkovits I, 2015, P NATL ACAD SCI USA, V112, P8708, DOI 10.1073/pnas.1507625112; Oh J, 2012, J BIOL CHEM, V287, P11629, DOI 10.1074/jbc.M111.338673; Park SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143526; Ran L, 2015, DIS MODEL MECH, V8, P691, DOI 10.1242/dmm.018242; Rao XQ, 2011, CIRCULATION, V123, P2964, DOI 10.1161/CIRCULATIONAHA.110.966408; Rehli M, 2005, J IMMUNOL, V174, P7111, DOI 10.4049/jimmunol.174.11.7111; Song CW, 2008, J IMMUNOL, V181, P6117, DOI 10.4049/jimmunol.181.9.6117; Staples KJ, 2012, J ALLERGY CLIN IMMUN, V130, P1404, DOI 10.1016/j.jaci.2012.07.023; Wang AL, 2015, INT ARCH ALLERGY IMM, V166, P52, DOI 10.1159/000371764; Weinstein AG, 2016, J ALLERGY CLIN IMMUN, V137, P1916, DOI 10.1016/j.jaci.2015.12.1345; Williams Seymour G, 2003, MMWR Recomm Rep, V52, P1; Yang P, 2013, AM J PATHOL, V183, P617, DOI 10.1016/j.ajpath.2013.04.007; Yao YY, 2016, MOL THER, V24, P915, DOI 10.1038/mt.2016.36; Zhang S, 2012, AM J PATHOL, V181, P937, DOI 10.1016/j.ajpath.2012.05.035; Zhang ZJ, 2015, AM J TRANSL RES, V7, P1812; Zhong JX, 2014, J AUTOIMMUN, V53, P95, DOI 10.1016/j.jaut.2014.05.006; Zhou AX, 2015, CIRC RES, V116, P1736, DOI 10.1161/CIRCRESAHA.116.305602; Zou R, 2014, AM J TRANSL RES, V6, P517	40	50	53	2	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1550	+		10.1016/j.jaci.2017.01.024	http://dx.doi.org/10.1016/j.jaci.2017.01.024			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28238747	Bronze			2022-12-18	WOS:000417206000009
J	Durham, SR; Creticos, PS; Nelson, HS; Li, ZL; Kaur, A; Meltzer, EO; Nolte, H				Durham, Stephen R.; Creticos, Peter S.; Nelson, Harold S.; Li, Ziliang; Kaur, Amarjot; Meltzer, Eli O.; Nolte, Hendrik			Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen immunotherapy; allergic rhinoconjunctivitis; ragweed; grass; house dust mite; sublingual immunotherapy tablet; intranasal corticosteroid; antihistamine; leukotriene receptor antagonists; meta-analysis	RANDOMIZED CONTROLLED-TRIAL; FUROATE NASAL SPRAY; DOUBLE-BLIND; MOMETASONE FUROATE; NORTH-AMERICAN; RECEPTOR ANTAGONISTS; EFFICACY; SAFETY; MONTELUKAST; ASTHMA	Background: Data comparing the treatment effect of allergy immunotherapy and pharmacotherapy are lacking. Objective: We sought to indirectly compare the treatment effect of sublingual immunotherapy (SLIT)-tablets with pharmacotherapy for seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). Methods: Pooled data from randomized, double-blind, placebo-controlled trials for the clinical development programs of selected allergic rhinitis treatments were evaluated. Total nasal symptom scores (TNSSs) relative to placebo were compared. Subjects scored symptoms daily during entire pollen seasons in 6 timothy grass SLIT-tablet trials (n = 3094) and 2 ragweed SLIT-tablet trials (n = 658) and during the last 8 weeks of treatment in 2 house dust mite (HDM) SLIT-tablet trials (n = 1768). Subjects scored symptoms daily in 7 montelukast (10 mg, n = 6799), 9 desloratadine (5 mg, n = 4455), and 8 mometasone furoate nasal spray (MFNS; 200 mu g daily, n = 2140) SAR or PAR trials. SLIT-tablet trials allowed rescue medication use, whereas most pharmacotherapy trials did not. A fixed-effect meta-analysis method estimated differences in on treatment average TNSSs. Results: In grass and ragweed SLIT-tablet trials, overall improvement in TNSSs relative to placebo was 16.3% and 17.1%, respectively. In HDM SLIT-tablet trials, TNSS overall improvement relative to placebo was 16.1%. In the montelukast, desloratadine, and MFNS trials, TNSS overall improvement relative to placebo was 5.4%, 8.5%, and 22.2%, respectively, for SAR trials, and 3.7%, 4.8%, and 11.2%, respectively, for PAR trials. Conclusions: Although comparisons were limited by study design heterogeneity and use of rescue medications in SLIT-tablet trials, effects on nasal symptoms with timothy grass and ragweed SLIT-tablets were nearly as great as with MFNS and numerically greater than with montelukast and desloratadine for SAR. HDM SLIT-tablet effects were numerically greater than all pharmacotherapies for PAR. SLIT-tablets offer the additional benefit of long-term efficacy.	[Durham, Stephen R.] Royal Brompton & Harefield Hosp Natl Hlth Serv Tr, London, England; [Durham, Stephen R.] Imperial Coll, London, England; [Creticos, Peter S.] Johns Hopkins Univ, Sch Med, Creticos Res Grp, Baltimore, MD USA; [Creticos, Peter S.] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Nelson, Harold S.] Natl Jewish Hlth, Denver, CO USA; [Li, Ziliang; Kaur, Amarjot; Nolte, Hendrik] Merck & Co Inc, Kenilworth, NJ USA; [Meltzer, Eli O.] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA	Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Imperial College London; Johns Hopkins University; Johns Hopkins University; National Jewish Health; Merck & Company	Nolte, H (corresponding author), Merck Res Labs, RY34-A468,126 E Lincoln Ave,POB 2000, Rahway, NJ 07065 USA.	hendrik.nolte@merck.com			Merck & Co, Kenilworth, NJ	Merck & Co, Kenilworth, NJ	Supported by Merck & Co, Kenilworth, NJ.	Anolik R, 2008, ANN ALLERG ASTHMA IM, V100, P264, DOI 10.1016/S1081-1206(10)60452-8; [Anonymous], 2014, SHORT RAGW POLL ALL; [Anonymous], 2014, SWEET VERN ORCH PER; Baena-Cagnani CE, 2003, INT ARCH ALLERGY IMM, V130, P307, DOI 10.1159/000070218; Bergmann KC, 2014, J ALLERGY CLIN IMMUN, V133, P1608, DOI 10.1016/j.jaci.2013.11.012; Berkowitz RB, 1999, ALLERGY, V54, P64, DOI 10.1034/j.1398-9995.1999.00713.x; Bielory L, 2014, ALLERGY ASTHMA PROC, V35, P211, DOI 10.2500/aap.2014.35.3750; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Calderon MA, 2007, ALLERGY, V62, P958, DOI 10.1111/j.1398-9995.2007.01416.x; Calderon MA, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-255; Chervinsky P, 2004, ANN ALLERG ASTHMA IM, V92, P367, DOI 10.1016/S1081-1206(10)61576-1; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Creticos PS, 2013, J ALLERGY CLIN IMMUN, V131, P1342, DOI 10.1016/j.jaci.2013.03.019; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Demoly P, 2016, J ALLERGY CLIN IMMUN, V137, P444, DOI 10.1016/j.jaci.2015.06.036; Devillier P, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-71; Di Bona D, 2015, JAMA INTERN MED, V175, P1301, DOI 10.1001/jamainternmed.2015.2840; Drouin M, 1996, ANN ALLERG ASTHMA IM, V77, P153, DOI 10.1016/S1081-1206(10)63502-8; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Eifan AO, 2011, CURR OPIN ALLERGY CL, V11, P586, DOI 10.1097/ACI.0b013e32834cb994; Food and Drug Administration (FDA), 2019, PRESCR INF GRAST TIM; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Kaszuba SM, 2001, ARCH INTERN MED, V161, P2581, DOI 10.1001/archinte.161.21.2581; Kim K, 2006, ANN ALLERG ASTHMA IM, V96, P460, DOI 10.1016/S1081-1206(10)60914-3; Leger D, 2006, ARCH INTERN MED, V166, P1744, DOI 10.1001/archinte.166.16.1744; Lin SY, 2013, JAMA-J AM MED ASSOC, V309, P1278, DOI 10.1001/jama.2013.2049; Maloney J, 2014, ANN ALLERG ASTHMA IM, V112, P146, DOI 10.1016/j.anai.2013.11.018; Mandl M, 1997, ANN ALLERG ASTHMA IM, V79, P237; Matricardi PM, 2011, J ALLERGY CLIN IMMUN, V128, P791, DOI 10.1016/j.jaci.2011.03.049; Meadows A, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17270; Meltzer Eli O, 2012, Allergy Asthma Proc, V33 Suppl 1, pS113, DOI 10.2500/aap.2012.33.3603; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Murphy K, 2013, J NEGAT RESULTS BIOM, V12, DOI 10.1186/1477-5751-12-10; Nayak AS, 2002, ANN ALLERG ASTHMA IM, V88, P592, DOI 10.1016/S1081-1206(10)61891-1; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Nolte H, 2016, J ALLERGY C IN PRESS; Nolte H, 2015, J ALLERGY CLIN IMMUN, V135, P1494, DOI 10.1016/j.jaci.2014.12.1911; Nolte H, 2013, ANN ALLERG ASTHMA IM, V110, P450, DOI 10.1016/j.anai.2013.03.013; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Patel P, 2005, ANN ALLERG ASTHMA IM, V95, P551, DOI 10.1016/S1081-1206(10)61018-6; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; Philip G, 2007, ALLERGY ASTHMA PROC, V28, P296, DOI 10.2500/aap.2007.28.3000; Pullerits T, 2002, J ALLERGY CLIN IMMUN, V109, P949, DOI 10.1067/mai.2002.124467; Rak S, 2001, J ALLERGY CLIN IMMUN, V108, P921, DOI 10.1067/mai.2001.119743; Salmun Luis M, 2002, BMC Fam Pract, V3, P14, DOI 10.1186/1471-2296-3-14; Simons FER, 2003, J ALLERGY CLIN IMMUN, V111, P617, DOI 10.1067/mai.2003.168; Tao LQ, 2014, CLIN RESPIR J, V8, P192, DOI 10.1111/crj.12058; van Adelsberg J, 2003, ALLERGY, V58, P1268, DOI 10.1046/j.1398-9995.2003.00261.x; van Adelsberg J, 2003, ANN ALLERG ASTHMA IM, V90, P214, DOI 10.1016/S1081-1206(10)62144-8; Wallace DV, DIAGNOSIS MANAGEMENT; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; Wilson AM, 2004, AM J MED, V116, P338, DOI 10.1016/j.amjmed.2003.10.030	55	50	50	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1081	+		10.1016/j.jaci.2016.04.061	http://dx.doi.org/10.1016/j.jaci.2016.04.061			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27527264	Bronze, Green Submitted			2022-12-18	WOS:000385499400013
J	Weisser, M; Demel, UM; Stein, S; Chen-Wichmann, L; Touzot, F; Santilli, G; Sujer, S; Brendel, C; Siler, U; Cavazzana, M; Thrasher, AJ; Reichenbach, J; Essers, MAG; Schwable, J; Grez, M				Weisser, Maren; Demel, Uta M.; Stein, Stefan; Chen-Wichmann, Linping; Touzot, Fabien; Santilli, Giorgia; Sujer, Stefanie; Brendel, Christian; Siler, Ulrich; Cavazzana, Marina; Thrasher, Adrian J.; Reichenbach, Janine; Essers, Marieke A. G.; Schwaeble, Joachim; Grez, Manuel			Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic granulomatous disease; hyperinflammation; hematopoietic stem cell; dysfunctional hematopoiesis; competitive repopulation assay; engraftment defect; cell cycle; IL-1 beta; anakinra; gene therapy	GENE-THERAPY; NADPH OXIDASE; INFLAMMATORY MANIFESTATIONS; STERILE INFLAMMATION; NLRP3 INFLAMMASOME; ACTIVATION; IL-1; INTERLEUKIN-1; EXPRESSION; MICE	Background: Defects in phagocytic nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) function cause chronic granulomatous disease (CGD), a primary immunodeficiency characterized by dysfunctional microbicidal activity and chronic inflammation. Objective: We sought to study the effect of chronic inflammation on the hematopoietic compartment in patients and mice with X-linked chronic granulomatous disease (X-CGD). Methods: We used immunostaining and functional analyses to study the hematopoietic compartment in patients with CGD. Results: An analysis of bone marrow cells from patients and mice with X-CGD revealed a dysregulated hematopoiesis characterized by increased numbers of hematopoietic progenitor cells (HPCs) at the expense of repopulating hematopoietic stem cells (HSCs). In patients with X-CGD, there was a clear reduction in the proportion of HSCs in bone marrow and peripheral blood, and they were also more rapidly exhausted after in vitro culture. In mice with X-CGD, increased cycling of HSCs, expansion of HPCs, and impaired long-term engraftment capacity were found to be associated with high concentrations of proinflammatory cytokines, including IL-1 beta. Treatment of wild-type mice with IL-1 beta induced enhanced cell-cycle entry of HSCs, expansion of HPCs, and defects in long-term engraftment, mimicking the effects observed in mice with X-CGD. Inhibition of cytokine signaling in mice with X-CGD reduced HPC numbers but had only minor effects on the repopulating ability of HSCs. Conclusions: Persistent chronic inflammation in patients with CGD is associated with hematopoietic proliferative stress, leading to a decrease in the functional activity of HSCs. Our observations have clinical implications for the development of successful autologous cell therapy approaches.	[Weisser, Maren; Stein, Stefan; Chen-Wichmann, Linping; Brendel, Christian; Schwaeble, Joachim; Grez, Manuel] Georg Speyer Haus, Inst Tumor Biol & Expt Therapy, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany; [Demel, Uta M.; Sujer, Stefanie; Essers, Marieke A. G.] German Canc Res Ctr, Jr Res Grp Hematopoiet Stem Cells & Stress, INF280, Heidelberg, Germany; [Demel, Uta M.; Essers, Marieke A. G.] Heidelberg Inst Stem Cell Technol & Expt Med HI S, INF280, Heidelberg, Germany; [Touzot, Fabien; Cavazzana, Marina] Necker Childrens Hosp, AP HP, Biotherapy Dept, Paris, France; [Touzot, Fabien; Cavazzana, Marina] Paris Descartes Sorbonne Paris Cite Univ, Imagine Inst, Paris, France; [Santilli, Giorgia; Thrasher, Adrian J.] UCL Inst Child Hlth, Sect Mol & Cellular Immunol, London, England; [Siler, Ulrich; Reichenbach, Janine] Univ Childrens Hosp, Div Immunol, Zurich, Switzerland; [Siler, Ulrich; Reichenbach, Janine] Childrens Res Ctr Zurich, Zurich, Switzerland; [Schwaeble, Joachim] Goethe Univ Frankfurt, Dept Med Hematol Oncol, Frankfurt, Germany	Octapharma; Helmholtz Association; German Cancer Research Center (DKFZ); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; University Children's Hospital Zurich; Goethe University Frankfurt	Grez, M (corresponding author), Georg Speyer Haus, Inst Tumor Biol & Expt Therapy, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.	grez@gsh.uni-frankfurt.de	Essers, Marieke A.G./B-7758-2017; Reichenbach, Janine/U-2171-2018; Brendel, Christian/HDN-6077-2022; Touzot, Fabien/T-7797-2018	Essers, Marieke A.G./0000-0003-3117-1809; Reichenbach, Janine/0000-0002-9008-1312; Touzot, Fabien/0000-0002-0889-4905; Thrasher, Adrian/0000-0002-6097-6115; Siler, Ulrich/0000-0002-2458-2629; Cavazzana, Marina/0000-0002-0264-0891; Brendel, Christian/0000-0003-4081-4351; Stein, Stefan/0000-0003-1473-9706; Demel, Uta Margareta/0000-0002-6480-4185	Deutsche Forschungsgemeinschaft [SFB815]; European Union (FP7 integrated project NET4CGD) [305011, HEALTH.2012.2.4.4-1]; Wellcome Trust [104807/Z/14/Z]; LOEWE Center for Cell and Gene Therapy Frankfurt - Hessische Ministerium fur Wissenschaft und Kunst (HMWK) [III L 4-518/17.004, III L 5-518/17.004]; Deutsche Forschungsgemeinschaft (DFG) [SFB873]; Dietmar Hopp Foundation; Gebert Ruf Stiftung, programme "Rare Diseases-New approaches'' [GRS-046/10]; Zurich Centre for Integrative Human Physiology (ZIHP); Ettore e Valeria Rossi Foundation; German Federal Ministry of Health (BMG); Hessische Ministerium fur Wissenschaft und Kunst	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Union (FP7 integrated project NET4CGD); Wellcome Trust(Wellcome TrustEuropean Commission); LOEWE Center for Cell and Gene Therapy Frankfurt - Hessische Ministerium fur Wissenschaft und Kunst (HMWK); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Dietmar Hopp Foundation; Gebert Ruf Stiftung, programme "Rare Diseases-New approaches''; Zurich Centre for Integrative Human Physiology (ZIHP); Ettore e Valeria Rossi Foundation; German Federal Ministry of Health (BMG); Hessische Ministerium fur Wissenschaft und Kunst	Supported by grants from the Deutsche Forschungsgemeinschaft (SFB815), the European Union (FP7 integrated project NET4CGD HEALTH.2012.2.4.4-1, grant no. 305011), the Wellcome Trust (grant no. 104807/Z/14/Z), and the LOEWE Center for Cell and Gene Therapy Frankfurt funded by the Hessische Ministerium fur Wissenschaft und Kunst (HMWK; funding reference numbers: III L 4-518/17.004 (2010) and III L 5-518/17.004 [2013]). U. M. Demel, S. Suher, and M. A. G. Essers are supported by SFB873, funded by the Deutsche Forschungsgemeinschaft (DFG) and the Dietmar Hopp Foundation. J. Reichenbach and U. Siler were funded by the Gebert Ruf Stiftung, programme "Rare Diseases-New approaches'' (grant no. GRS-046/10, JR), the Zurich Centre for Integrative Human Physiology (ZIHP, JR), and by the Ettore e Valeria Rossi Foundation. The Georg-Speyer-Haus is funded jointly by the German Federal Ministry of Health (BMG) and the Hessische Ministerium fur Wissenschaft und Kunst.	Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Ahlin A, 2015, CURR OPIN HEMATOL, V22, P41, DOI 10.1097/MOH.0000000000000097; Baldridge MT, 2011, TRENDS IMMUNOL, V32, P57, DOI 10.1016/j.it.2010.12.003; Baroja-Mazo A, 2014, NAT IMMUNOL, V15, P738, DOI 10.1038/ni.2919; Bianchi M, 2011, J ALLERGY CLIN IMMUN, V127, P1243, DOI 10.1016/j.jaci.2011.01.021; Bianchi M, 2009, BLOOD, V114, P2619, DOI 10.1182/blood-2009-05-221606; Brendel C, 2013, HUM GENE THER METHOD, V24, P151, DOI 10.1089/hgtb.2012.157; Brown JR, 2003, J LEUKOCYTE BIOL, V73, P591, DOI 10.1189/jlb.1202599; Brown KL, 2008, CLIN IMMUNOL, V129, P90, DOI 10.1016/j.clim.2008.06.005; Challen GA, 2009, CYTOM PART A, V75A, P14, DOI 10.1002/cyto.a.20674; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Cole T, 2013, J ALLERGY CLIN IMMUN, V132, P1150, DOI 10.1016/j.jaci.2013.05.031; de Luca A, 2014, P NATL ACAD SCI USA, V111, P3526, DOI 10.1073/pnas.1322831111; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Dinauer Mary C, 2005, Hematology Am Soc Hematol Educ Program, P89; Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815; Essers MAG, 2010, MOL ONCOL, V4, P443, DOI 10.1016/j.molonc.2010.06.001; Feldman N, 2015, AGEING RES REV, V24, P29, DOI 10.1016/j.arr.2015.01.003; FIBBE WE, 1992, J IMMUNOL, V148, P417; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Geering B, 2013, TRENDS IMMUNOL, V34, P398, DOI 10.1016/j.it.2013.04.002; Geiger H, 2014, CURR OPIN IMMUNOL, V29, P86, DOI 10.1016/j.coi.2014.05.002; Grez M, 2011, MOL THER, V19, P28, DOI 10.1038/mt.2010.232; Griseri T, 2012, IMMUNITY, V37, P1116, DOI 10.1016/j.immuni.2012.08.025; Gungor T, 2014, LANCET, V383, P436, DOI [10.1016/s0140-6736(13)62069-3, 10.1016/S0140-6736(13)62069-3]; Hahn KJ, 2015, AM J GASTROENTEROL, V110, P938, DOI 10.1038/ajg.2015.135; Henao-Mejia J, 2012, NAT IMMUNOL, V13, P321, DOI 10.1038/ni.2257; Kang EM, 2010, BLOOD, V115, P783, DOI 10.1182/blood-2009-05-222760; Kang HJ, 2011, MOL THER, V19, P2092, DOI 10.1038/mt.2011.166; Magnani A, 2014, J ALLERGY CLIN IMMUN, V134, P655, DOI 10.1016/j.jaci.2014.04.014; Makipour S, 2008, SEMIN HEMATOL, V45, P250, DOI 10.1053/j.seminhematol.2008.06.003; McKinstry WJ, 1997, BLOOD, V89, P65, DOI 10.1182/blood.V89.1.65.65_65_71; Meissner F, 2010, BLOOD, V116, P1570, DOI 10.1182/blood-2010-01-264218; Morgenstern DE, 1997, J EXP MED, V185, P207, DOI 10.1084/jem.185.2.207; Nagamachi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087425; Oshrine B, 2015, PEDIATR BLOOD CANCER, V62, P359, DOI 10.1002/pbc.25225; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Panch SR, 2015, TRANSFUSION, V55, P265, DOI 10.1111/trf.12830; Petersen JE, 2002, J INVEST DERMATOL, V118, P424, DOI 10.1046/j.0022-202x.2001.01691.x; Rodriguez S, 2009, BLOOD, V114, P4064, DOI 10.1182/blood-2009-04-214916; Roos D., IMMUNOL, V138, P121; Rosenzweig SD, 2008, J CLIN IMMUNOL, V28, pS67, DOI 10.1007/s10875-007-9160-5; Rubartelli A, 2012, J LEUKOCYTE BIOL, V92, P951, DOI 10.1189/jlb.0512265; Santilli G, 2011, MOL THER, V19, P122, DOI 10.1038/mt.2010.226; Sauce D, 2011, BLOOD, V117, P5142, DOI 10.1182/blood-2011-01-331306; Schappi MG, 2008, SEMIN IMMUNOPATHOL, V30, P255, DOI 10.1007/s00281-008-0119-2; Segal AW, 1996, MOL MED TODAY, V2, P129, DOI 10.1016/1357-4310(96)88723-5; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Segal BH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009631; Seger RA, 2010, NETH J MED, V68, P334; Seger RA, 2008, BRIT J HAEMATOL, V140, P255, DOI 10.1111/j.1365-2141.2007.06880.x; Singh P, 2008, STEM CELLS, V26, P1009, DOI 10.1634/stemcells.2007-0461; Stein S, 2010, NAT MED, V16, P198, DOI 10.1038/nm.2088; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; van de Veerdonk FL, 2010, P NATL ACAD SCI USA, V107, P3030, DOI 10.1073/pnas.0914795107; Yang J, 2013, INT J CANCER, V133, P1967, DOI 10.1002/ijc.28198; Yonemura Y, 1996, P NATL ACAD SCI USA, V93, P4040, DOI 10.1073/pnas.93.9.4040; Zeng MY, 2013, BLOOD, V121, P3473, DOI 10.1182/blood-2012-10-461913; Zhang P, 2008, STEM CELLS, V26, P1778, DOI 10.1634/stemcells.2007-1027	59	50	50	2	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					219	+		10.1016/j.jaci.2015.11.028	http://dx.doi.org/10.1016/j.jaci.2015.11.028			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26853280	Green Submitted, Bronze			2022-12-18	WOS:000379659100024
J	Carter, MC; Clayton, ST; Komarow, HD; Brittain, EH; Scott, LM; Cantave, D; Gaskins, DM; Maric, I; Metcalfe, DD				Carter, Melody C.; Clayton, Sarah T.; Komarow, Hirsh D.; Brittain, Erica H.; Scott, Linda M.; Cantave, Daly; Gaskins, Donna M.; Maric, Irina; Metcalfe, Dean D.			Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; tryptase; urticaria pigmentosa; cutaneous mastocytosis; diffuse cutaneous mastocytosis; mastocytosis; bone marrow examination	CUTANEOUS MASTOCYTOSIS; SYSTEMIC MASTOCYTOSIS; FOLLOW-UP; CHILDREN; INVOLVEMENT; DIAGNOSIS; ADULTS; ONSET	Background: The management of children with pediatric mastocytosis poses a challenge. This is because there is limited information as to the application of clinical and laboratory findings and bone marrow histopathology as they relate to medical intervention and communication. Objective: We sought to examine clinical aspects of pediatric mastocytosis in relationship to serum tryptase levels and bone marrow pathology to provide practical guidance for management. Methods: Between 1986 and 2012, 105 children were evaluated at the National Institutes of Health. Organomegaly was confirmed by means of ultrasound. Baseline tryptase levels and at least 1 subsequent tryptase measurement was available in 84 and 37 of these children, respectively. Fifty-three children underwent a bone marrow examination. These data were used to examine relationships between clinical findings, tryptase levels, and marrow histopathology. Results: In patients with high tryptase levels and severe mediator symptoms, all with organomegaly had systemic disease, and none without organomegaly had systemic disease. Serum tryptase levels differed significantly between patients with urticaria pigmentosa and those with diffuse cutaneous (P < .0001) and systemic mastocytosis (P < .0001) and in all 3 categories versus control subjects (P < .0001). Tryptase levels and symptoms decreased over time in most patients, and tryptase levels correlated with bone marrow mast cell burden in patients with systemic mastocytosis (P < .0001). There was a significant relationship between clinical resolution and the percentage decrease in tryptase levels (P = .0014). Conclusions: The majority of children experienced major or complete disease resolution (57%), whereas the remainder exhibited partial improvement. Organomegaly was a strong indicator of systemic disease. Serum tryptase levels furthered classification and reflected clinicopathologic findings, while sequential tryptase measurements were useful in supplementing clinical judgment as to disease course.	[Carter, Melody C.; Clayton, Sarah T.; Komarow, Hirsh D.; Scott, Linda M.; Gaskins, Donna M.; Metcalfe, Dean D.] NIAID, Lab Allerg Dis, Bethesda, MD 20892 USA; [Brittain, Erica H.] NIAID, Biostat Res Branch, Bethesda, MD 20892 USA; [Cantave, Daly] NIH, Dept Nursing, Clin Ctr, Bethesda, MD 20892 USA; [Maric, Irina] NIH, Hematol Sect, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Carter, MC (corresponding author), Bldg 10-11C207,10 Ctr Dr,MSC 1881, Bethesda, MD 20892 USA.	mcarter@niaid.nih.gov			Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000249] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL080005] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	Supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.	Akoglu G, 2006, J EUR ACAD DERMATOL, V20, P969, DOI 10.1111/j.1468-3083.2006.01696.x; Alvarez-Twose I, 2012, ALLERGY, V67, P813, DOI 10.1111/j.1398-9995.2012.02812.x; Amon U, 2010, J DTSCH DERMATOL GES, V8, P695, DOI 10.1111/j.1610-0387.2010.07482.x; Ben-Amitai D, 2005, ISR MED ASSOC J, V7, P320; Bloom Barbara, 2011, Vital Health Stat 10, P1; Bodemer C, 2010, J INVEST DERMATOL, V130, P804, DOI 10.1038/jid.2009.281; Brockow K, 2003, J AM ACAD DERMATOL, V48, P508, DOI 10.1067/mjd.2003.98; CAPLAN RM, 1963, ARCH DERMATOL, V87, P146, DOI 10.1001/archderm.1963.01590140008002; Castells M, 2011, AM J CLIN DERMATOL, V12, P259, DOI 10.2165/11588890-000000000-00000; de Olano DG, 2007, CLIN EXP ALLERGY, V37, P1547, DOI 10.1111/j.1365-2222.2007.02804.x; Horny HP AC, 2008, WHO CLASSIFICATION T, P54; Hup MMA, 2002, J EUR ACAD DERMATOL, V16, P115, DOI 10.1046/j.1468-3083.2002.00370.x; Kiszewski AE, 2004, J EUR ACAD DERMATOL, V18, P285, DOI 10.1111/j.1468-3083.2004.00830.x; Komarow HD, 2009, J ALLERGY CLIN IMMUN, V124, P845, DOI 10.1016/j.jaci.2009.06.040; Lange M, 2013, J EUR ACAD DERMATOL, V27, P97, DOI 10.1111/j.1468-3083.2011.04365.x; Lanternier F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001906; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; Maric I, 2007, J ALLERGY CLIN IMMUN, V120, P680, DOI 10.1016/j.jaci.2007.05.024; MULLER U, 1990, ALLERGY, V45, P597, DOI 10.1111/j.1398-9995.1990.tb00945.x; ROSENBERG HK, 1991, AM J ROENTGENOL, V157, P119, DOI 10.2214/ajr.157.1.2048509; Sperr WR, 2002, INT ARCH ALLERGY IMM, V128, P136, DOI 10.1159/000059404; Uzzaman A, 2009, PEDIATR BLOOD CANCER, V53, P629, DOI 10.1002/pbc.22125; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2004, J ALLERGY CLIN IMMUN, V114, P3, DOI 10.1016/j.jaci.2004.02.045; Verzijl A, 2007, DERMATOLOGY, V214, P15, DOI 10.1159/000096907	25	50	52	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1673	U378		10.1016/j.jaci.2015.04.024	http://dx.doi.org/10.1016/j.jaci.2015.04.024			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26044856	Bronze, Green Accepted			2022-12-18	WOS:000366044300030
J	Chesne, J; Braza, F; Chadeuf, G; Mahay, G; Cheminat, MA; Loy, J; Brouard, S; Sauzeau, V; Loirand, G; Magnan, A				Chesne, Julie; Braza, Faouzi; Chadeuf, Gilliane; Mahay, Guillaume; Cheminat, Marie-Aude; Loy, Jennifer; Brouard, Sophie; Sauzeau, Vincent; Loirand, Gervaise; Magnan, Antoine			Prime role of IL-17A in neutrophilia and airway smooth muscle contraction in a house dust mite-induced allergic asthma model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Chesne, Julie; Braza, Faouzi; Chadeuf, Gilliane; Cheminat, Marie-Aude; Loy, Jennifer; Sauzeau, Vincent; Loirand, Gervaise; Magnan, Antoine] INSERM, U1087, Inst Thorax, Nantes, France; [Chesne, Julie; Braza, Faouzi; Chadeuf, Gilliane; Cheminat, Marie-Aude; Loy, Jennifer; Sauzeau, Vincent; Loirand, Gervaise; Magnan, Antoine] CNRS, U6291, Nantes, France; [Chesne, Julie; Braza, Faouzi; Chadeuf, Gilliane; Cheminat, Marie-Aude; Loy, Jennifer; Brouard, Sophie; Sauzeau, Vincent; Loirand, Gervaise; Magnan, Antoine] Univ Nantes, F-44035 Nantes, France; [Braza, Faouzi; Loy, Jennifer; Brouard, Sophie] INSERM, Nantes, France; [Braza, Faouzi; Loy, Jennifer; Brouard, Sophie] CHU Nantes, Inst Transplantat Urol Nephrol, F-44035 Nantes 01, France; [Mahay, Guillaume] CHU Rouen, Serv Pneumol, Rouen, France; [Sauzeau, Vincent] CHU Nantes, Serv Explorat Fonct, F-44035 Nantes 01, France; [Loirand, Gervaise] CHU Nantes, Serv Med Interne, F-44035 Nantes 01, France; [Magnan, Antoine] CHU Nantes, Inst Thorax, Serv Pneumol, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Centre National de la Recherche Scientifique (CNRS); Nantes Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; CHU de Rouen; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Chesne, J (corresponding author), INSERM, U1087, Inst Thorax, Nantes, France.	Antoine.Magnan@univ-nantes.fr	brouard, sophie c/Q-1285-2016; Sauzeau, Vincent/D-3548-2015; MAGNAN, ANTOINE/GVT-4308-2022; Loirand, Gervaise/K-1834-2014	Loirand, Gervaise/0000-0002-2306-3931; Braza, Faouzi/0000-0003-1182-1413; Sauzeau, Vincent/0000-0002-6187-0312; Chesne, Julie/0000-0001-8831-4386				Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Chesne J, 2014, AM J RESP CRIT CARE, V190, P1094, DOI 10.1164/rccm.201405-0859PP; De Boever EH, 2014, J ALLERGY CLIN IMMUN, V133, P989, DOI 10.1016/j.jaci.2014.01.002; Erle DJ, 2014, J CELL BIOL, V205, P621, DOI 10.1083/jcb.201401050; Fanta CH, 2009, NEW ENGL J MED, V360, P1002, DOI 10.1056/NEJMra0804579; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Loirand G, 2013, PHYSIOL REV, V93, P1659, DOI 10.1152/physrev.00021.2012; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC	9	50	54	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1643	1645		10.1016/j.jaci.2014.12.1872	http://dx.doi.org/10.1016/j.jaci.2014.12.1872			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25649077				2022-12-18	WOS:000355933400030
J	Seidel, MG; Hirschmugl, T; Gamez-Diaz, L; Schwinger, W; Serwas, N; Deutschmann, A; Gorkiewicz, G; Zenz, W; Windpassinger, C; Grimbacher, B; Urban, C; Boztug, K				Seidel, Markus G.; Hirschmugl, Tatjana; Gamez-Diaz, Laura; Schwinger, Wolfgang; Serwas, Nina; Deutschmann, Andrea; Gorkiewicz, Gregor; Zenz, Werner; Windpassinger, Christian; Grimbacher, Bodo; Urban, Christian; Boztug, Kaan			Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; PRIMARY BILIARY-CIRRHOSIS; COMBINED IMMUNODEFICIENCY; IMMUNE-DEFICIENCY; DISEASE; GENE; BLOOD; MANIFESTATIONS; EXPRESSION; TOLERANCE		[Seidel, Markus G.; Schwinger, Wolfgang; Urban, Christian] Med Univ Graz, Dept Pediat & Adolescent Med, Div Pediat Hematol Oncol, Graz, Austria; [Deutschmann, Andrea; Zenz, Werner] Med Univ Graz, Dept Pediat & Adolescent Med, Div Gen Pediat, Graz, Austria; [Gorkiewicz, Gregor] Med Univ Graz, Inst Pathol, Graz, Austria; [Windpassinger, Christian] Med Univ Graz, Inst Human Genet, Graz, Austria; [Hirschmugl, Tatjana; Serwas, Nina; Boztug, Kaan] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1010 Vienna, Austria; [Gamez-Diaz, Laura; Grimbacher, Bodo] Univ Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany; [Boztug, Kaan] Med Univ Vienna, Dept Pediat & Adolescent Med, Vienna, Austria	Medical University of Graz; Medical University of Graz; Medical University of Graz; Medical University of Graz; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; University of Freiburg; Medical University of Vienna	Seidel, MG (corresponding author), Med Univ Graz, Dept Pediat & Adolescent Med, Div Pediat Hematol Oncol, Graz, Austria.	markus.seidel@medunigraz.at; kboztug@cemm.oeaw.ac.at	Zenz, Werner/AAZ-3375-2021; Gorkiewicz, Gregor/ABF-1602-2021; Boztug, Kaan/AAM-4161-2021; Seidel, Markus G/N-9951-2017	Gorkiewicz, Gregor/0000-0003-1149-4782; Boztug, Kaan/0000-0001-8387-9185; Zenz, Werner/0000-0002-6218-3143; Serwas, Nina/0000-0003-2243-5446; Seidel, Markus G/0000-0003-0981-8661	Austrian Science Fund (FWF) [P 24999] Funding Source: researchfish; Austrian Science Fund FWF [P 24999] Funding Source: Medline	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Austrian Science Fund FWF(Austrian Science Fund (FWF))		Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Alangari A, 2012, J ALLERGY CLIN IMMUN, V130, P481, DOI 10.1016/j.jaci.2012.05.043; Arkwright PD, 2011, ANN NY ACAD SCI, V1238, P7, DOI 10.1111/j.1749-6632.2011.06206.x; Atkins HL, 2012, BIOL BLOOD MARROW TR, V18, pS177, DOI 10.1016/j.bbmt.2011.11.020; Burns SO, 2012, J ALLERGY CLIN IMMUN, V130, P1428, DOI 10.1016/j.jaci.2012.07.035; CANALE VC, 1967, J PEDIATR-US, V70, P891, DOI 10.1016/S0022-3476(67)80262-2; Carbone M, 2014, EUR J IMMUNOL, V44, P945, DOI 10.1002/eji.201344270; Cunningham-Rundles C, 2008, J CLIN IMMUNOL, V28, pS42, DOI 10.1007/s10875-008-9182-7; Durandy A, 2006, CURR OPIN RHEUMATOL, V18, P369, DOI 10.1097/01.bor.0000231905.12172.b5; Farmand S, 2011, KLIN PADIATR, V223, P378, DOI 10.1055/s-0031-1287835; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Gambineri Eleonora, 2008, J Allergy Clin Immunol, V122, P1105, DOI 10.1016/j.jaci.2008.09.027; Gebauer D, 2004, BIOCHEMISTRY-US, V43, P14873, DOI 10.1021/bi049498y; Gordon JR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00007; Gratwohl A., 2012, EBMT HDB PARIS, P302; Gratwohl A, 2008, AUTOIMMUNITY, V41, P673, DOI 10.1080/08916930802197677; Hirschfield GM, 2009, NEW ENGL J MED, V360, P2544, DOI 10.1056/NEJMoa0810440; Krauss AC, 2009, BONE MARROW TRANSPL, V44, P137, DOI 10.1038/bmt.2009.147; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Meffre E, 2011, ANN NY ACAD SCI, V1246, P1, DOI 10.1111/j.1749-6632.2011.06347.x; Ochs HD, 2005, IMMUNOL REV, V203, P156, DOI 10.1111/j.0105-2896.2005.00231.x; Pasquini MC, 2012, BIOL BLOOD MARROW TR, V18, P1471, DOI 10.1016/j.bbmt.2012.06.003; Passweg JR, 2004, BRIT J HAEMATOL, V125, P749, DOI 10.1111/j.1365-2141.2004.04978.x; Price S, 2014, BLOOD, V123, P1989, DOI 10.1182/blood-2013-10-535393; Rensing-Ehl A, 2010, CLIN IMMUNOL, V137, P357, DOI 10.1016/j.clim.2010.08.008; Rieber N, 2013, CLIN EXP IMMUNOL, V174, P45, DOI 10.1111/cei.12143; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Salzer E, 2013, HAEMATOLOGICA, V98, P473, DOI 10.3324/haematol.2012.068791; Schmetterer KG, 2010, INT ARCH ALLERGY IMM, V152, P390, DOI 10.1159/000288292; Schwinger W, 2006, BRIT J HAEMATOL, V135, P76, DOI 10.1111/j.1365-2141.2006.06244.x; Seelow D, 2009, NUCLEIC ACIDS RES, V37, pW593, DOI 10.1093/nar/gkp369; Seidel MG, 2012, EUR J ENDOCRINOL, V167, P131, DOI 10.1530/EJE-12-0197; Seidel MG, 2014, BRIT J HAEMATOL, V165, P419, DOI 10.1111/bjh.12766; Selmi C, 2004, GASTROENTEROLOGY, V127, P485, DOI 10.1053/j.gastro.2004.05.005; Snowden JA, 2012, EBMT HDB HAEMATOPOIE, P458; Swart JF, 2012, CURR OPIN RHEUMATOL, V24, P267, DOI 10.1097/BOR.0b013e32835264f4; van Montfrans JM, 2012, J ALLERGY CLIN IMMUN, V129, P787, DOI 10.1016/j.jaci.2011.11.013; von Boehmer H, 2010, NAT IMMUNOL, V11, P14, DOI 10.1038/ni.1794; Wang JW, 2004, ONCOGENE, V23, P4089, DOI 10.1038/sj.onc.1207567; Wang JW, 2001, J IMMUNOL, V166, P4586, DOI 10.4049/jimmunol.166.7.4586; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Yong PFK, 2011, ADV IMMUNOL, V111, P47, DOI 10.1016/B978-0-12-385991-4.00002-7	43	50	52	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1384	+		10.1016/j.jaci.2014.10.048	http://dx.doi.org/10.1016/j.jaci.2014.10.048			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25539626	Green Published, hybrid			2022-12-18	WOS:000353980700035
J	de Groot, JC; van Roon, ENH; Storm, H; Veeger, NJGM; Zwinderman, AH; Hiemstra, PS; Bel, EHD; ten Brinke, A				de Groot, Jantina C.; van Roon, Eric N. H.; Storm, Huib; Veeger, Nic J. G. M.; Zwinderman, Aeilko H.; Hiemstra, Pieter S.; Bel, Elisabeth H. D.; ten Brinke, Anneke			Vitamin D reduces eosinophilic airway inflammation in nonatopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; vitamin D; airway inflammation; eosinophils; neutrophils; nonatopic	RESPIRATORY-TRACT INFECTION; D SUPPLEMENTATION; D INSUFFICIENCY; LUNG-FUNCTION; ADULTS; EXACERBATIONS; INDUCTION; SEVERITY; CHILDREN; CELLS	Background: Low levels of vitamin D are associated with asthma severity, airway remodeling, and exacerbation rate increase, especially in nonatopic asthma. Reduced steroid responsiveness or impaired antimicrobial defense might be underlying mechanisms. Objective: We sought to evaluate the effect of vitamin D supplementation on eosinophilic and neutrophilic airway inflammation in patients with nonatopic asthma. Methods: In a double-blind, randomized, placebo-controlled trial, we investigated the effect of long-acting vitamin D-3 (400,000 IU) on sputum neutrophils and eosinophils in 44 patients with nonatopic asthma with neutrophilic (>= 53%) and/or eosinophilic (>= 3%) airway inflammation. Sputum induction was performed at baseline and after 9 weeks. Other measurements included questionnaires, blood samples, and pulmonary function. Results: Treatment with vitamin D did not significantly affect sputum neutrophils or eosinophils compared with treatment with placebo in the total group. Regarding sputum eosinophils, the effect of vitamin D appeared to be dependent on baseline sputum eosinophil levels (interaction P = .015). In patients with eosinophil levels of 26.2% or more (median in patients with sputum eosinophilia, > 3%), eosinophils decreased from a median of 41.0% to 11.8% after vitamin D treatment as compared with an increase from 51.8% to 63.3% in patients receiving placebo (P = .034). Vitamin D treatment also resulted in slightly better Asthma Control Questionnaire scores (P = .08). Conclusions: Vitamin D supplementation reduced eosinophilic airway inflammation in patients with nonatopic asthma with severe eosinophilic airway inflammation, but did not affect sputum neutrophils. Also, a small effect on asthma control was observed. These findings suggest that vitamin D might have potential as an add-on treatment option in eosinophilic asthma.	[de Groot, Jantina C.; ten Brinke, Anneke] Med Ctr Leeuwarden, Dept Resp Med, Leeuwarden, Netherlands; [van Roon, Eric N. H.] Univ Groningen, Dept Pharmacotherapy & Pharmaceut Care, Groningen, Netherlands; [van Roon, Eric N. H.] Med Ctr Leeuwarden, Dept Hosp Pharm, Leeuwarden, Netherlands; [Storm, Huib] Med Ctr Leeuwarden, Dept Clin Chem, Leeuwarden, Netherlands; [Veeger, Nic J. G. M.] Med Ctr Leeuwarden, Dept Clin Epidemiol, Leeuwarden, Netherlands; [Zwinderman, Aeilko H.] Amsterdam Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam, Netherlands; [Hiemstra, Pieter S.] Leiden Univ, Med Ctr, Dept Pulmonol, Leiden, Netherlands; [Bel, Elisabeth H. D.] Amsterdam Med Ctr, Dept Resp Med, Amsterdam, Netherlands	Medical Center Leeuwarden; University of Groningen; Medical Center Leeuwarden; Medical Center Leeuwarden; Medical Center Leeuwarden; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam	de Groot, JC (corresponding author), Henri Dunantweg 2, NL-8934 AD Leeuwarden, Netherlands.	christa_de_groot@yahoo.com	/V-8478-2019; Hiemstra, Pieter S/K-8587-2018; van Roon, Eric N/O-2112-2013; Veeger, Nic JGM/F-2966-2013	Hiemstra, Pieter S/0000-0002-0238-5982; Veeger, Nic JGM/0000-0002-1492-7937	GlaxoSmithKline; Medical Centre Leeuwarden research fund; Frysian Pulmonologists	GlaxoSmithKline(GlaxoSmithKline); Medical Centre Leeuwarden research fund; Frysian Pulmonologists	This study was supported by unrestricted grants from GlaxoSmithKline, Medical Centre Leeuwarden research fund, and Frysian Pulmonologists.	Accordini S, 2008, ALLERGY, V63, P116, DOI 10.1111/j.1398-9995.2007.01523.x; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Anto JM, 2010, ALLERGY, V65, P1021, DOI 10.1111/j.1398-9995.2009.02301.x; Barnes PJ, 2009, CLIN EXP ALLERGY, V39, P1145, DOI 10.1111/j.1365-2222.2009.03298.x; Barnes Peter J, 2009, Lancet, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Brehm JM, 2012, AM J RESP CRIT CARE, V186, P140, DOI 10.1164/rccm.201203-0431OC; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Castro M, 2014, JAMA-J AM MED ASSOC, V311, P2083, DOI 10.1001/jama.2014.5052; Ginde AA, 2009, ARCH INTERN MED, V169, P384, DOI 10.1001/archinternmed.2008.560; Goleva E, 2012, J ALLERGY CLIN IMMUN, V129, P1243, DOI 10.1016/j.jaci.2012.01.044; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Gupta A, 2011, AM J RESP CRIT CARE, V184, P1342, DOI 10.1164/rccm.201107-1239OC; Hansdottir S, 2008, J IMMUNOL, V181, P7090, DOI 10.4049/jimmunol.181.10.7090; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper Elizabeth F, 2005, Health Qual Life Outcomes, V3, P58, DOI 10.1186/1477-7525-3-58; Knudsen TB, 2009, J ASTHMA, V46, P91, DOI 10.1080/02770900802524657; Korn S, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-25; Laaksi I, 2010, J INFECT DIS, V202, P809, DOI 10.1086/654881; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Leynaert B, 2012, THORAX, V67, P625, DOI 10.1136/thoraxjnl-2011-201249; Li-Ng M, 2009, EPIDEMIOL INFECT, V137, P1396, DOI 10.1017/S0950268809002404; Mai XM, 2012, AM J EPIDEMIOL, V176, P1169, DOI 10.1093/aje/kws235; Majak P, 2011, J ALLERGY CLIN IMMUN, V127, P1294, DOI 10.1016/j.jaci.2010.12.016; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Murdoch DR, 2012, JAMA-J AM MED ASSOC, V308, P1333, DOI 10.1001/jama.2012.12505; National Institutes of Health National Heart Lung and Blood Institute Global Initiative for Asthma. Global strategy for asthma management and prevention, 2006, NAT HEART LUNG BLOOD; Piccirillo JF, 2002, OTOLARYNG HEAD NECK, V126, P41, DOI 10.1067/mhn.2002.121022; Rossini M, 2004, AGING CLIN EXP RES, V16, P432, DOI 10.1007/BF03327397; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; Spanevello A, 2000, AM J RESP CRIT CARE, V162, P1172, DOI 10.1164/ajrccm.162.3.9908057; Sutherland ER, 2007, CHEST, V132, P1962, DOI 10.1378/chest.06-2415; Sutherland ER, 2010, AM J RESP CRIT CARE, V181, P699, DOI 10.1164/rccm.200911-1710OC; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P749, DOI 10.1164/ajrccm.164.5.2009035; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Wu AC, 2012, AM J RESP CRIT CARE, V186, P508, DOI 10.1164/rccm.201202-0351OC; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759	40	50	53	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					670	U133		10.1016/j.jaci.2014.11.033	http://dx.doi.org/10.1016/j.jaci.2014.11.033			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25617224	Bronze, Green Submitted			2022-12-18	WOS:000351065000010
J	Honkoop, PJ; Loijmans, RJB; Termeer, EH; Snoeck-Stroband, JB; van den Hout, WB; Bakker, MJ; Assendelft, WJJ; ter Riet, G; Sterk, PJ; Schermer, TRJ; Sont, JK				Honkoop, Persijn J.; Loijmans, Rik J. B.; Termeer, Evelien H.; Snoeck-Stroband, Jiska B.; van den Hout, Wilbert B.; Bakker, Moira J.; Assendelft, Willem J. J.; ter Riet, Gerben; Sterk, Peter J.; Schermer, Tjard R. J.; Sont, Jacob K.		Asthma Control Cost-Utility	Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: A cluster-randomized trial in primary care	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Quality of life; fraction of exhaled nitric oxide; asthma exacerbations; asthma control; cost-effectiveness; online decision support	QUALITY-OF-LIFE; INHALED CORTICOSTEROIDS; ECONOMIC-EVALUATION; SAMPLE-SIZE; MANAGEMENT; VALIDATION; COST; STANDARDIZATION; EXACERBATIONS; QUESTIONNAIRE	Background: Aiming at partly controlled asthma (PCa) instead of controlled asthma (Ca) might decrease asthma medication use. Biomarkers, such as the fraction of exhaled nitric oxide (FENO), allow further tailoring of treatment. Objective: We sought to assess the cost-effectiveness and clinical effectiveness of pursuing PCa, Ca, or FENO-driven controlled asthma (FCa). Methods: In a nonblind, pragmatic, cluster-randomized trial in primary care, adults (18-50 years of age) with a doctor's diagnosis of asthma who were prescribed inhaled corticosteroids were allocated to one of 3 treatment strategies: (1) aiming at PCa (Asthma Control Questionnaire [ACQ] score < 1.50); (2) aiming at Ca (ACQ score < 0.75); and (3) aiming at FCa (ACQ score < 0.75 and FENO value < 25 ppb). During 12 months' follow-up, treatment was adjusted every 3 months by using an online decision support tool. Outcomes were incremental cost per quality-adjusted life year gained, asthma control (ACQ score), quality of life (Asthma Quality of Life Questionnaire score), asthma medication use, and severe exacerbation rate. Results: Six hundred eleven participants were allocated to the PCa (n = 219), Ca (n = 203), or FCa (n = 189) strategies. The FCa strategy improved asthma control compared with the PCa strategy (P <.02). There were no differences in quality of life (P >=.36). Asthma medication use was significantly lower for the PCa and FCa strategies compared with the Ca strategy (medication costs: PCa, $452; Ca, $551; and FCa, $456; P <=.04). The FCa strategy had the highest probability of cost-effectiveness at a willingness to pay of $50,000/quality-adjusted life year (86%; PCa, 2%; Ca, 12%). There were no differences in severe exacerbation rate. Conclusion: A symptom-plus FENO-driven strategy reduces asthma medication use while sustaining asthma control and quality of life and is the preferred strategy for adult asthmatic patients in primary care.	[Honkoop, Persijn J.; Snoeck-Stroband, Jiska B.; van den Hout, Wilbert B.; Bakker, Moira J.; Sont, Jacob K.] Leiden Univ, Med Ctr, Dept Med Decis Making, NL-2300 RC Leiden, Netherlands; [Honkoop, Persijn J.; Assendelft, Willem J. J.] Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, NL-2300 RC Leiden, Netherlands; [Loijmans, Rik J. B.; ter Riet, Gerben] Univ Amsterdam, Acad Med Ctr, Dept Gen Practice, NL-1105 AZ Amsterdam, Netherlands; [Sterk, Peter J.] Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, NL-1105 AZ Amsterdam, Netherlands; [Termeer, Evelien H.; Assendelft, Willem J. J.; Schermer, Tjard R. J.] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, Nijmegen, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Radboud University Nijmegen	Honkoop, PJ (corresponding author), Leiden Univ, Med Ctr, Postzone J-10s,Albinusdreef 2, NL-2300 RC Leiden, Netherlands.	P.J.Honkoop@lumc.nl	assendelft, willem/AAW-1854-2021; Sterk, P.J./AAK-8175-2020; Sont, Jacob K/J-8071-2015; Schermer, Tjard RJ/A-8511-2011; Assendelft, W.J.J./H-8008-2014; Riet, Gerben ter/A-6943-2011	assendelft, willem/0000-0002-2966-3778; Sont, Jacob K/0000-0002-5840-0651; Schermer, Tjard RJ/0000-0002-1391-2995; Assendelft, W.J.J./0000-0002-2966-3778; Riet, Gerben ter/0000-0002-2231-7637; van den Hout, Wilbert B./0000-0002-6425-0135; Honkoop, Persijn/0000-0003-2051-4183	Netherlands Organisation for Health Research and Development (ZON-MW) [80-82310-98-8627]; Netherlands Asthma Foundation (NAF) Aerocrine (Solna, Sweden) [3.4.07.044]	Netherlands Organisation for Health Research and Development (ZON-MW)(Netherlands Organization for Health Research and Development); Netherlands Asthma Foundation (NAF) Aerocrine (Solna, Sweden)	Supported by the Netherlands Organisation for Health Research and Development (ZON-MW, sub-programme Effects & Costs 80-82310-98-8627), and by the Netherlands Asthma Foundation (NAF 3.4.07.044). Aerocrine (Solna, Sweden) provided 20 of a total of 40 fraction of exhaled nitric oxide meters for free.	Aaron SD, 2008, THORAX, V63, P122, DOI 10.1136/thx.2007.082636; Accordini S, 2013, INT ARCH ALLERGY IMM, V160, P93, DOI 10.1159/000338998; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Asthma UK, 2013, ANN REP ACC 2013; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; British Thoracic Society and Scottish Intercollegiate Guidelines Network, 2008, BRIT GUID MAN ASTHM; Calhoun WJ, 2012, JAMA-J AM MED ASSOC, V308, P987, DOI 10.1001/2012.jama.10893; Campbell JD, 2008, ANN ALLERG ASTHMA IM, V101, P474, DOI 10.1016/S1081-1206(10)60285-2; Campbell MK, 2004, COMPUT BIOL MED, V34, P113, DOI 10.1016/S0010-4825(03)00039-8; Chapman KR, 2008, EUR RESPIR J, V31, P320, DOI 10.1183/09031936.00039707; Chen H, 2007, J ALLERGY CLIN IMMUN, V120, P396, DOI 10.1016/j.jaci.2007.04.040; de Jongste JC, 2009, AM J RESP CRIT CARE, V179, P93, DOI 10.1164/rccm.200807-1010OC; Dressel H, 2008, RESP MED, V102, P962, DOI 10.1016/j.rmed.2008.02.012; Fialko L, 2008, SCHIZOPHR RES, V100, P53, DOI 10.1016/j.schres.2007.10.029; Gibson PG, 2009, CLIN EXP ALLERGY, V39, P478, DOI 10.1111/j.1365-2222.2009.03226.x; Gold LS, 2012, ANN ALLERG ASTHMA IM, V109, P260, DOI 10.1016/j.anai.2012.07.024; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hewitt Richard S, 2009, Prim Care Respir J, V18, P320, DOI 10.4104/pcrj.2009.00060; Honkoop PJ, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-53; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Lamers LM, 2006, HEALTH ECON, V15, P1121, DOI 10.1002/hec.1124; Lapi F, 2013, EUR RESPIR J, V42, P79, DOI 10.1183/09031936.00080912; Lucas AE, 2012, RESP MED, V106, P1158, DOI 10.1016/j.rmed.2012.03.002; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Mortimer KJ, 2006, THORAX, V61, P405, DOI 10.1136/thx.2005.052456; National Heart Lung and Blood Institute. National Asthma Education and Prevention Program (NAEPP), 2007, 3 NAEPP NAT HEART LU; Oostenbrink JB, 2002, PHARMACOECONOMICS, V20, P443, DOI 10.2165/00019053-200220070-00002; Pavord ID, 2008, J ASTHMA, V45, P523, DOI 10.1080/02770900801978557; Petsky HL, 2012, THORAX, V67, P199, DOI 10.1136/thx.2010.135574; Powell H, 2003, MED J AUSTRALIA, V178, P223, DOI 10.5694/j.1326-5377.2003.tb05167.x; Powell H, 2011, LANCET, V378, P983, DOI 10.1016/S0140-6736(11)60971-9; Price D, 2009, ALLERGY, V64, P431, DOI 10.1111/j.1398-9995.2008.01855.x; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Rubin DB, 2004, MULTIPLE IMPUTATION; Schermer TR, 2002, AM J RESP CRIT CARE, V166, P1062, DOI 10.1164/rccm.2105116; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-1427OC; Siroux V, 2008, ALLERGY, V63, P547, DOI 10.1111/j.1398-9995.2008.01638.x; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Stinnett AA, 1998, MED DECIS MAKING, V18, pS68, DOI 10.1177/0272989X98018002S09; Sullivan PW, 2013, J ASTHMA, V50, P891, DOI 10.3109/02770903.2013.813035; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; The Dutch General Practice Society (NHG), 2007, DUTCH GEN PRACT SOC; van den Nieuwenhof L, 2006, FAM PRACT, V23, P674, DOI 10.1093/fampra/cml041; Walters SJ, 2005, QUAL LIFE RES, V14, P1523, DOI 10.1007/s11136-004-7713-0; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Willan AR, 2001, CONTROL CLIN TRIALS, V22, P228, DOI 10.1016/S0197-2456(01)00110-6	50	50	51	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					682	U158		10.1016/j.jaci.2014.07.016	http://dx.doi.org/10.1016/j.jaci.2014.07.016			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	CD4PF	25174865				2022-12-18	WOS:000351065000012
J	Speletas, M; Szilagyi, A; Psarros, F; Moldovan, D; Magerl, M; Kompoti, M; Gramoustianou, E; Bors, A; Mihaly, E; Tordai, A; Avramouli, A; Varga, L; Maurer, M; Farkas, H; Germenis, AE				Speletas, Matthaios; Szilagyi, Agnes; Psarros, Fotis; Moldovan, Dimitru; Magerl, Markus; Kompoti, Maria; Gramoustianou, Evangelia; Bors, Andras; Mihaly, Eniko; Tordai, Attila; Avramouli, Antigoni; Varga, Lilian; Maurer, Marcus; Farkas, Henriette; Germenis, Anastasios E.			Hereditary angioedema: Molecular and clinical differences among European populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MUTATIONS; GENE; DYSFUNCTION; PROTEIN		[Speletas, Matthaios; Kompoti, Maria; Gramoustianou, Evangelia; Avramouli, Antigoni; Germenis, Anastasios E.] Univ Thessaly, Sch Hlth Sci, Fac Med, Dept Immunol & Histocompatibil, Larisa, Greece; [Szilagyi, Agnes; Varga, Lilian; Farkas, Henriette] Semmelweis Univ, Hungarian Angioedema Ctr, Dept Internal Med 3, H-1085 Budapest, Hungary; [Psarros, Fotis] Navy Hosp, Dept Allergol, Athens, Greece; [Moldovan, Dimitru; Mihaly, Eniko] Univ Med & Pharm, Allergy & Lung Funct Off, Targu Mures, Romania; [Magerl, Markus; Maurer, Marcus] Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany; [Bors, Andras; Tordai, Attila] Hungarian Natl Blood Transfus Serv, Lab Mol Diagnost, Budapest, Hungary	University of Thessaly; Semmelweis University; George Emil Palade University of Medicine, Pharmacy, Science, & Technology of Targu Mures; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Speletas, M (corresponding author), Univ Thessaly, Sch Hlth Sci, Fac Med, Dept Immunol & Histocompatibil, Larisa, Greece.	agermen@med.uth.gr	Kompoti, Maria G./H-8257-2019; Szilagyi, Agnes/F-2337-2010; Germenis, Anastasios/H-5269-2019; Magerl, Markus/ABI-5335-2020; Maurer, Marcus/ABG-2174-2020	Kompoti, Maria G./0000-0003-4746-8375; Szilagyi, Agnes/0000-0002-9769-3215; Germenis, Anastasios/0000-0002-3315-6947; Magerl, Markus/0000-0001-9218-5468; Maurer, Marcus/0000-0002-4121-481X; Farkas, Henriette/0000-0003-2929-1721; Varga, Lilian/0000-0002-5484-364X; Psarros, Fotis/0000-0002-2928-150X				Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064; Bors A, 2013, J ALLERGY CLIN IMMUN, V131, P1708, DOI 10.1016/j.jaci.2012.11.015; Bowen Tom, 2010, Allergy Asthma Clin Immunol, V6, P24, DOI 10.1186/1710-1492-6-24; Cicardi M, 2012, ALLERGY, V67, P147, DOI 10.1111/j.1398-9995.2011.02751.x; DAVIS AE, 1992, NAT GENET, V1, P354, DOI 10.1038/ng0892-354; Farkas Henriette, 2010, Allergy Asthma Clin Immunol, V6, P18, DOI 10.1186/1710-1492-6-18; Kalmar L, 2005, HUM MUTAT, V25, P1, DOI 10.1002/humu.20112; Kalmar L, 2003, HUM MUTAT, V22, P498; Ng PC, 2006, ANNU REV GENOM HUM G, V7, P61, DOI 10.1146/annurev.genom.7.080505.115630; Pappalardo E, 2000, J ALLERGY CLIN IMMUN, V106, P1147, DOI 10.1067/mai.2000.110471; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Speletas M, 2009, HUM IMMUNOL, V70, P925, DOI 10.1016/j.humimm.2009.08.010; ZAHEDI R, 1995, J CLIN INVEST, V95, P1299, DOI 10.1172/JCI117780; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977	16	50	51	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					570	+		10.1016/j.jaci.2014.08.007	http://dx.doi.org/10.1016/j.jaci.2014.08.007			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25258140				2022-12-18	WOS:000349372300037
J	Ferstl, R; Frei, R; Schiavi, E; Konieczna, P; Barcik, W; Ziegler, M; Lauener, RP; Chassard, C; Lacroix, C; Akdis, CA; O'Mahony, L				Ferstl, Ruth; Frei, Remo; Schiavi, Elisa; Konieczna, Patrycja; Barcik, Weronika; Ziegler, Mario; Lauener, Roger P.; Chassard, Christophe; Lacroix, Christophe; Akdis, Cezmi A.; O'Mahony, Liam			Histamine receptor 2 is a key influence in immune responses to intestinal histamine-secreting microbes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOTHERAPY; ALLERGY		[Ferstl, Ruth; Frei, Remo; Schiavi, Elisa; Konieczna, Patrycja; Barcik, Weronika; Ziegler, Mario; Akdis, Cezmi A.; O'Mahony, Liam] Univ Zurich, Swiss Inst Allergy & Asthma Res, Davos, Switzerland; [Frei, Remo; Lauener, Roger P.; Akdis, Cezmi A.] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Lauener, Roger P.] Kantonsspital St Gallen, St Gallen, Switzerland; [Chassard, Christophe; Lacroix, Christophe] ETH, Inst Food Nutr & Hlth, Lab Food Biotechnol, Zurich, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Ferstl, R (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res, Davos, Switzerland.	liam.omahony@siaf.uzh.ch	Barcik, Weronika/L-5094-2019; O'Mahony, Liam/AAG-5838-2019; Lacroix, Christophe/B-5139-2016; Frei, Remo/AAI-9180-2020; Akdis, Cezmi/AAV-4844-2020; Ferstl, Ruth/ABB-9679-2021; Lauener, Roger P/O-8612-2016	O'Mahony, Liam/0000-0003-4705-3583; Lacroix, Christophe/0000-0003-4360-2020; Akdis, Cezmi/0000-0001-8020-019X; Lauener, Roger P/0000-0002-8412-606X; Barcik, Weronika/0000-0001-8580-9690				Bian ZX, 2011, ANN INTERN MED, V154, P290, DOI 10.7326/0003-4819-154-4-201102150-00016; Calderon MA, 2007, ALLERGY, V62, P958, DOI 10.1111/j.1398-9995.2007.01416.x; Cox L, 2010, CURR MED RES OPIN, V26, P2723, DOI 10.1185/03007995.2010.528647; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Ebo DG, 2007, CYTOM PART B-CLIN CY, V72B, P196, DOI 10.1002/cyto.b.20142; Frei R, 2012, ALLERGY, V67, P451, DOI 10.1111/j.1398-9995.2011.02783.x; Frei R, 2013, J ALLERGY CLIN IMMUN, V132, P194, DOI 10.1016/j.jaci.2013.01.013; Konieczna P, 2012, GUT MICROBES, V3, P261, DOI 10.4161/gmic.20358; Lalek N, 2010, CLIN EXP ALLERGY, V40, P1186, DOI 10.1111/j.1365-2222.2010.03524.x; Mudde GC, 1996, IMMUNOL CELL BIOL, V74, P167, DOI 10.1038/icb.1996.23; Nopp A, 2009, ALLERGY, V64, P811, DOI 10.1111/j.1398-9995.2008.01900.x; O'Mahony L, 2011, J ALLERGY CLIN IMMUN, V128, P1153, DOI 10.1016/j.jaci.2011.06.051; Pfefferle PI, 2013, J ALLERGY CLIN IMMUN, V131, P1453, DOI 10.1016/j.jaci.2013.03.020; Romano A., 2013, GENOME ANNOUNC, V1, pe00097, DOI [10.1128/genomeA.00097-12, DOI 10.1128/GENOMEA.00097-12]; Smolinska S, 2014, ALLERGY, V69, P273, DOI 10.1111/all.12330; Thomas CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031951; Til HP, 1997, FOOD CHEM TOXICOL, V35, P337, DOI 10.1016/S0278-6915(97)00121-X; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; Wurtzen PA, 2008, CLIN EXP ALLERGY, V38, P1290, DOI 10.1111/j.1365-2222.2008.03020.x	19	50	52	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					744	746		10.1016/j.jaci.2014.04.034	http://dx.doi.org/10.1016/j.jaci.2014.04.034			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24954261				2022-12-18	WOS:000341372400035
J	Mizrahi, S; Gibbs, BF; Karra, L; Ben-Zimra, M; Levi-Schaffer, F				Mizrahi, Sa'ar; Gibbs, Bernhard F.; Karra, Laila; Ben-Zimra, Micha; Levi-Schaffer, Francesca			Siglec-7 is an inhibitory receptor on human mast cells and basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NATURAL-KILLER-CELLS; IDENTIFICATION; BINDING; SOCS3		[Mizrahi, Sa'ar; Karra, Laila; Ben-Zimra, Micha; Levi-Schaffer, Francesca] Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Inst Drug Res, IL-91120 Jerusalem, Israel; [Gibbs, Bernhard F.] Univ Kent, Medway Sch Pharm, Chatham, Kent, England	Hebrew University of Jerusalem; University of Greenwich; University of Kent	Mizrahi, S (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Inst Drug Res, IL-91120 Jerusalem, Israel.	francescal@ekmd.huji.ac.il	Karra, Laila/AAX-5794-2020; Sumbayev, Vadim/HCH-7696-2022	Levi-Schaffer, Francesca/0000-0003-0620-2810				Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Gibbs BF, 2012, EXP DERMATOL, V21, P884, DOI 10.1111/exd.12018; Karra L, 2011, ADV EXP MED BIOL, V716, P143, DOI 10.1007/978-1-4419-9533-9_9; Kubo M, 2006, CURR ALLERGY ASTHM R, V6, P32, DOI 10.1007/s11882-006-0007-6; Munitz A, 2006, BLOOD, V107, P1996, DOI 10.1182/blood-2005-07-2926; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Orr SJ, 2007, J BIOL CHEM, V282, P3418, DOI 10.1074/jbc.C600216200; Yamaji T, 2002, J BIOL CHEM, V277, P6324, DOI 10.1074/jbc.M110146200; Yokoi H, 2006, ALLERGY, V61, P769, DOI 10.1111/j.1398-9995.2006.01133.x; Yokoi H, 2008, J ALLERGY CLIN IMMUN, V121, P499, DOI 10.1016/j.jaci.2007.10.004	10	50	52	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					230	233		10.1016/j.jaci.2014.03.031	http://dx.doi.org/10.1016/j.jaci.2014.03.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24810846				2022-12-18	WOS:000338930300033
J	Lougaris, V; Baronio, M; Vitali, M; Tampella, G; Cattalini, M; Tassone, L; Soresina, A; Badolato, R; Plebani, A				Lougaris, Vassilios; Baronio, Manuela; Vitali, Massimiliano; Tampella, Giacomo; Cattalini, Marco; Tassone, Laura; Soresina, Annarosa; Badolato, Raffaele; Plebani, Alessandro			Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BTK; dendritic cells; TLR9; STAT1; STAT3	X-LINKED AGAMMAGLOBULINEMIA; TEC FAMILY KINASES; CHRONIC LYMPHOCYTIC-LEUKEMIA; MYELOID CELLS; PCI-32765; INHIBITOR; BTK; MALIGNANCIES; STIMULATION; IBRUTINIB	Background: Bruton tyrosine kinase (BTK) plays an essential role in various biologic functions of different cell types. Mutations in BTK lead to X-linked agammaglobulinemia (XLA) in humans. BTK was recently linked to the innate immune system, in particular, the Toll-like receptor (TLR) pathway; however, the TLR9 pathway has never been studied in dendritic cells (DCs) of patients with XLA. Objective: The aim of this study was to investigate the role of BTK in human DC activation upon TLR9 stimulation. Methods: DCs of patients with XLA and healthy donors were stimulated via TLR4/9 and evaluated for cell activation and cytokine production. Results: We showed that BTK plays an essential role in DC responses to unmethylated CpG oligodeoxynucleotide: although responses to lipopolysaccaride/TLR4 induce normal DC activation in terms of upregulation of specific markers (CD86, CD83, CD80, HLA-DR), the CpG/TLR9 pathway is completely impaired in patients with XLA. Furthermore, cytokine production upon TLR9 activation in patients with XLA is radically impaired in terms of IL-6, IL-12, TNF-alpha, and IL-10 production. Interestingly, BTK mediated STAT1/3 upregulation in a TLR9-dependent manner. The important role of BTK in human DC activation was confirmed after incubation of healthy DCs with ibrutinib, the specific BTK inhibitor, which resulted in impairment of TLR9 responses as seen in patients with XLA. Conclusion: Analysis of these data suggests that BTK regulates human DC responses upon TLR9 engagement in terms of activation, cytokine production, and STAT1/3 upregulation. These findings may be of important significance for better understanding and managing different clinical conditions, such as agammaglobulinemia and lymphoid malignancies.	[Lougaris, Vassilios] Univ Brescia, Pediat Clin, I-25123 Brescia, Italy; Univ Brescia, Inst Mol Med A Nocivelli, Dept Clin & Expt Sci, I-25123 Brescia, Italy	University of Brescia; University of Brescia	Lougaris, V (corresponding author), Univ Brescia, Pediat Clin, Piazzale Spedali Civili 1, I-25123 Brescia, Italy.	vlougarisbs@yahoo.com	Cattalini, Marco/AFK-4529-2022; Badolato, Raffaele/A-8081-2010	Cattalini, Marco/0000-0002-7500-8838; Badolato, Raffaele/0000-0001-7375-5410	European Community [201549 (EURO-PADnet HEALTH-F2-2008-201549)]; Fondazione C. Golgi, Brescia	European Community(European Commission); Fondazione C. Golgi, Brescia	The research leading to these results has received funding from the European Community's Seventh Framework Programme FP7/2007-2013 under grant agreement no 201549 (EURO-PADnet HEALTH-F2-2008-201549). The research that led to these results also received funding from the "Fondazione C. Golgi," Brescia.	Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Bao Y, 2012, J BIOL CHEM, V287, P23769, DOI 10.1074/jbc.M112.372425; Brown JR, 2014, LEUKEMIA LYMPHOMA, V55, P263, DOI 10.3109/10428194.2013.803226; Dalpke AH, 2005, IMMUNOLOGY, V116, P203, DOI 10.1111/j.1365-2567.2005.02211.x; de Rooij MFM, 2012, BLOOD, V119, P2590, DOI 10.1182/blood-2011-11-390989; Doyle SL, 2007, J BIOL CHEM, V282, P36953, DOI 10.1074/jbc.M707682200; Gonzalez-Serrano ME, 2012, J CLIN IMMUNOL, V32, P967, DOI 10.1007/s10875-012-9706-z; Fiedler K, 2011, BLOOD, V117, P1329, DOI 10.1182/blood-2010-04-281170; Gomez-Rodriguez J, 2007, IMMUNOL REV, V218, P45, DOI 10.1111/j.1600-065X.2007.00534.x; Honda F, 2012, NAT IMMUNOL, V13, P369, DOI 10.1038/ni.2234; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Horwood NJ, 2012, INT REV IMMUNOL, V31, P87, DOI 10.3109/08830185.2012.670334; Hussain A, 2011, FEBS J, V278, P2001, DOI 10.1111/j.1742-4658.2011.08134.x; Khare A, 2011, APOPTOSIS, V16, P334, DOI 10.1007/s10495-010-0569-6; Koprulu AD, 2009, CRIT REV IMMUNOL, V29, P317, DOI 10.1615/CritRevImmunol.v29.i4.30; Marron TU, 2012, J ALLERGY CLIN IMMUN, V129, P184, DOI 10.1016/j.jaci.2011.10.009; Marron TU, 2010, CLIN IMMUNOL, V137, P74, DOI 10.1016/j.clim.2010.06.011; Mohamed AJ, 2009, IMMUNOL REV, V228, P58, DOI 10.1111/j.1600-065X.2008.00741.x; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Schmidt U, 2004, INT ARCH ALLERGY IMM, V134, P65, DOI 10.1159/000078339; Sochorova K, 2007, BLOOD, V109, P2553, DOI 10.1182/blood-2006-07-037960; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Winer ES, 2012, EXPERT OPIN INV DRUG, V21, P355, DOI 10.1517/13543784.2012.656199	24	50	51	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1644	+		10.1016/j.jaci.2013.12.1085	http://dx.doi.org/10.1016/j.jaci.2013.12.1085			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24612681	Bronze			2022-12-18	WOS:000336672500017
J	Lee, PPW; Mao, HW; Yang, WL; Chan, KW; Ho, MHK; Lee, TL; Chan, JFW; Woo, PCY; Tu, WW; Lau, YL				Lee, Pamela P. W.; Mao, Huawei; Yang, Wanling; Chan, Koon-Wing; Ho, Marco H. K.; Lee, Tsz-Leung; Chan, Jasper F. W.; Woo, Patrick C. Y.; Tu, Wenwei; Lau, Yu-Lung			Penicillium marneffei infection and impaired IFN-gamma immunity in humans with autosomal-dominant gain-of-phosphorylation STAT1 mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC MUCOCUTANEOUS CANDIDIASIS; INTERFERON		[Lee, Pamela P. W.; Mao, Huawei; Yang, Wanling; Chan, Koon-Wing; Ho, Marco H. K.; Lee, Tsz-Leung; Tu, Wenwei; Lau, Yu-Lung] Univ Hong Kong, Dept Paediat & Adolescent Med, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China; [Chan, Jasper F. W.; Woo, Patrick C. Y.] Univ Hong Kong, Dept Microbiol, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Lee, PPW (corresponding author), Univ Hong Kong, Dept Paediat & Adolescent Med, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China.	lauylung@hku.hk	Woo, Patrick Chiu Yat/AAJ-6112-2020; Chan, Jasper F. W./D-8007-2013; Lau, Yu Lung/C-4322-2009	Woo, Patrick Chiu Yat/0000-0001-9401-1832; Chan, Jasper F. W./0000-0001-6336-6657; Lau, Yu Lung/0000-0002-4780-0289; Ho, Marco/0000-0003-1802-2120				de Jager W, 2005, J IMMUNOL METHODS, V300, P124, DOI 10.1016/j.jim.2005.03.009; Lee PPW, 2012, CLIN INFECT DIS, V54, pe8, DOI 10.1093/cid/cir754; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Sisto F, 2003, INFECT IMMUN, V71, P465, DOI 10.1128/IAI.71.1.465-473.2003; Smeekens SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029248; Soltesz B, 2013, J MED GENET, V50, P567, DOI 10.1136/jmedgenet-2013-101570; SUPPARATPINYO K, 1994, LANCET, V344, P110, DOI 10.1016/S0140-6736(94)91287-4; Takezaki S, 2012, J IMMUNOL, V189, P1521, DOI 10.4049/jimmunol.1200926; Tang BSF, 2010, CLIN VACCINE IMMUNOL, V17, P1132, DOI 10.1128/CVI.00053-10; Toth B, 2012, LANCET, V379, P2500, DOI 10.1016/S0140-6736(12)60365-1; Uzel G, 2013, J ALLERGY CLIN IMMUN, V131, P1611, DOI 10.1016/j.jaci.2012.11.054; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Wang XW, 2013, J ALLERGY CLIN IMMUN, V131, P1242, DOI 10.1016/j.jaci.2012.11.005	13	50	55	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					894	+		10.1016/j.jaci.2013.08.051	http://dx.doi.org/10.1016/j.jaci.2013.08.051			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24188975	Green Submitted			2022-12-18	WOS:000332397600038
J	Solensky, R				Solensky, Roland			Penicillin allergy as a public health measure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Penicillin allergy; penicillin skin testing; Clostridium difficile; vancomycin-resistant enterococcus	BETA-LACTAM ALLERGY; CLOSTRIDIUM-DIFFICILE; VANCOMYCIN USE; HISTORY		Corvallis Clin, Corvallis, OR 97330 USA		Solensky, R (corresponding author), Corvallis Clin, 3680 NW Samaritan Dr, Corvallis, OR 97330 USA.	roland.solensky@corvallisclinic.com						del Real GA, 2007, ANN ALLERG ASTHMA IM, V98, P355, DOI 10.1016/S1081-1206(10)60882-4; Kwan T, 1999, CLIN INVEST MED, V22, P256; Lee CE, 2000, ARCH INTERN MED, V160, P2819, DOI 10.1001/archinte.160.18.2819; Loo VG, 2005, NEW ENGL J MED, V353, P2442, DOI 10.1056/NEJMoa051639; MacLaughlin EJ, 2000, ARCH FAM MED, V9, P722, DOI 10.1001/archfami.9.8.722; Macy E, 2014, J ALLERGY CLIN IMMUN, V133, P790, DOI 10.1016/j.jaci.2013.09.021; Martinez JA, 2003, ARCH INTERN MED, V163, P1905, DOI 10.1001/archinte.163.16.1905; Nadarajah K, 2005, ANN ALLERG ASTHMA IM, V95, P541, DOI 10.1016/S1081-1206(10)61016-2; Park M, 2006, ANN ALLERG ASTHMA IM, V97, P681, DOI 10.1016/S1081-1206(10)61100-3; Park MA, 2011, INT ARCH ALLERGY IMM, V154, P57, DOI 10.1159/000319209; Picard M, 2013, J ALLER CL IMM-PRACT, V1, P252, DOI 10.1016/j.jaip.2013.01.006; Sade K, 2003, CLIN EXP ALLERGY, V33, P501, DOI 10.1046/j.1365-2222.2003.01638.x; Solensky R, 2000, ANN ALLERG ASTHMA IM, V84, P329, DOI 10.1016/S1081-1206(10)62782-2; Weiss K, 2009, INT J ANTIMICROB AG, V33, pS29, DOI 10.1016/S0924-8579(09)70013-5	14	50	51	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					797	798		10.1016/j.jaci.2013.10.032	http://dx.doi.org/10.1016/j.jaci.2013.10.032			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24332220				2022-12-18	WOS:000332397600023
J	Gaudenzio, N; Laurent, C; Valitutti, S; Espinosa, E				Gaudenzio, Nicolas; Laurent, Camille; Valitutti, Salvatore; Espinosa, Eric			Human mast cells drive memory CD4(+) T cells toward an inflammatory IL-22(+) phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; T-H cells; IL-22; immunologic synapse; inflammation; psoriasis	PSORIATIC SKIN; INTERLEUKIN 22; PLASTICITY; DISTINCT; RESPONSES; CYTOKINE; EFFECTOR	Background: Mast cells are key components of the skin microenvironment in psoriasis, yet their functional role in this T-cell-mediated inflammatory disorder remains to be elucidated. Objective: To define the impact of T-cell/mast-cell cognate interactions on the cytokines produced by T-H cells. Methods: We used human primary mast cells and effector/memory CD4(+) T cells for in vitro coculture experiments, and we analyzed TH cells responses by using cytometry. CD4(+) T-cell/mast-cell conjugates in skin lesions from patients with psoriasis were analyzed by using 3-color immunohistochemistry and confocal microscopy. Results: We show that IFN-gamma-primed human mast cells formed productive immunologic synapses with antigen-experienced CD4(+) T cells. These interactions promoted the generation of T(H)22 and IL-22/IFN-gamma-producing T-H cells from the circulating memory CD4(+) T-cell pool via a TNF-alpha/IL-6-dependent mechanism. An analysis of human psoriatic skin biopsies showed a rich infiltrate of IL-22(+)CD4(+) T cells frequently found in contact with mast cells. Moreover, most of these mast-cell-conjugated lymphocytes coexpressed IFN-gamma, suggesting that IL-22(+)IFN-gamma(+) CD4(+) T cells are generated in vivo on interaction with mast cells. Conclusions: Our findings identify human mast cells as functional partners of TH cells, shaping their responses toward IL-22 production.	[Gaudenzio, Nicolas; Valitutti, Salvatore; Espinosa, Eric] INSERM, F-31300 Toulouse, France; [Gaudenzio, Nicolas; Valitutti, Salvatore; Espinosa, Eric] Univ Toulouse, CPTP, Toulouse, France; [Laurent, Camille] Ctr Hosp Univ CHU Purpan, Serv Anat & Cytol Pathol, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Espinosa, E (corresponding author), INSERM, U1043, F-31300 Toulouse, France.	eric.espinosa@inserm.fr	Valitutti, Salvatore/M-2999-2014; Laurent, Camille/G-2797-2017; espinosa, eric/E-4872-2013	Valitutti, Salvatore/0000-0002-6432-4421; espinosa, eric/0000-0002-3512-0921; Gaudenzio, Nicolas/0000-0002-5648-509X; laurent, camille/0000-0002-5375-7512	Association pour la Recherche sur le Cancer [SL220100601347]; Institut National de la Sante et de la Recherche Medicale; Association pour la Recherche sur le Cancer; INSERM	Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	This study was supported by grants from the Association pour la Recherche sur le Cancer (grant no. SL220100601347) and from Institut National de la Sante et de la Recherche Medicale.; Disclosure of potential conflict of interest: All authors have received research support from Association pour la Recherche sur le Cancer and INSERM.	Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Ackermann L, 1999, BRIT J DERMATOL, V140, P624; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Ahmadzadeh M, 2002, P NATL ACAD SCI USA, V99, P11802, DOI 10.1073/pnas.192263099; Boniface K, 2007, CLIN EXP IMMUNOL, V150, P407, DOI 10.1111/j.1365-2249.2007.03511.x; Clark RA, 2010, J INVEST DERMATOL, V130, P362, DOI 10.1038/jid.2009.247; Depoil D, 2005, IMMUNITY, V22, P185, DOI 10.1016/j.immuni.2004.12.010; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Egawa G, 2011, J INVEST DERMATOL, V131, P2178, DOI 10.1038/jid.2011.198; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Fujita H, 2009, P NATL ACAD SCI USA, V106, P21795, DOI 10.1073/pnas.0911472106; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Galli SJ, 2010, EUR J IMMUNOL, V40, P1843, DOI 10.1002/eji.201040559; Gaudenzio N, 2009, BLOOD, V114, P4979, DOI 10.1182/blood-2009-02-202648; Harvima IT, 2008, ARCH DERMATOL RES, V300, P461, DOI 10.1007/s00403-008-0874-x; Janssens AS, 2005, J CLIN PATHOL, V58, P285, DOI 10.1136/jcp.2004.017210; Kagami S, 2010, J INVEST DERMATOL, V130, P1373, DOI 10.1038/jid.2009.399; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; Laurent C, 2011, BLOOD, V118, P5371, DOI 10.1182/blood-2011-04-345777; Lin TJ, 2003, INFECT IMMUN, V71, P365, DOI 10.1128/IAI.71.1.365-373.2003; Locksley RM, 2009, J EXP MED, V206, P1643, DOI 10.1084/jem.20091442; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Mekori YA, 2004, J ALLERGY CLIN IMMUN, V114, P52, DOI 10.1016/j.jaci.2004.04.015; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Murphy KM, 2010, NAT IMMUNOL, V11, P674, DOI 10.1038/ni.1899; O'Shea JJ, 2010, SCIENCE, V327, P1098, DOI 10.1126/science.1178334; Ramirez JM, 2010, EUR J IMMUNOL, V40, P2450, DOI 10.1002/eji.201040461; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; THARP MD, 1985, J HISTOCHEM CYTOCHEM, V33, P27, DOI 10.1177/33.1.2578142; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; Van Belle AB, 2012, J IMMUNOL, V188, P462, DOI 10.4049/jimmunol.1102224; Wakim LM, 2008, J IMMUNOL, V181, P5837, DOI 10.4049/jimmunol.181.9.5837; Wang XS, 2006, J IMMUNOL METHODS, V309, P69, DOI 10.1016/j.jim.2005.11.012; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001	37	50	51	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1400	U240		10.1016/j.jaci.2013.01.029	http://dx.doi.org/10.1016/j.jaci.2013.01.029			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23518141				2022-12-18	WOS:000318912200018
J	Davies, JM; Platts-Mills, TA; Aalberse, RC				Davies, Janet M.; Platts-Mills, Thomas A.; Aalberse, Rob C.			The enigma of IgE(+) B-cell memory in human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; B cells; IgE(+) B cells; memory B cells; plasma cells; allergy; germinal center	GRASS-POLLEN IMMUNOTHERAPY; FC-EPSILON-RI; IMMUNOGLOBULIN-E; NASAL-MUCOSA; SWITCH CIRCLES; BINDING; TRANSCRIPTS; RESPONSES; LYMPHOCYTES; ANTIBODIES	Our understanding of the origin and fate of the IgE-switched B cell has been markedly improved by studies in mouse models. The immediate precursor of the IgE-switched B cell is either a relatively naive nonswitched B cell or a mature IgG-switched B cell. These 2 routes are referred to as the direct and indirect pathways, respectively. IgE responses derived from each pathway differ significantly, largely reflecting the difference in time spent in a germinal center and thus time for clonal expansion, somatic hypermutation, affinity maturation, and acquisition of a memory phenotype. The clinical and therapeutic implications for IgE responses in human subjects are still a matter of debate, largely because the immunization procedures used in the animal models are significantly different from classical atopic sensitization to allergens from pollen and mites. On the basis of the limited information available, it seems likely that these atopic IgE responses are characterized by a relatively low IgG/IgE ratio, low B-cell memory, and modest affinity maturation, which fits well with the direct switching pathway. It is still unresolved how the IgE response evolves to cover a wide epitope repertoire involving many epitopes per allergen, as well as many different allergens from a single allergen source. (J Allergy Clin Immunol 2013; 131: 972-6.)	[Davies, Janet M.] Univ Queensland, Sch Med, Lung & Allergy Res Ctr, Woolloongabba, Qld, Australia; [Davies, Janet M.] Translat Res Inst, Woolloongabba, Qld, Australia; [Platts-Mills, Thomas A.] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Aalberse, Rob C.] Sanquin Blood Supply Fdn, NL-1066 CX Amsterdam, Netherlands; [Aalberse, Rob C.] Univ Amsterdam, Acad Med Ctr, Karl Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands	University of Queensland; University of Virginia; University of Amsterdam; Academic Medical Center Amsterdam	Aalberse, RC (corresponding author), Sanquin Blood Supply Fdn, Dept Immunopathol, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	r.aalberse@sanquin.nl	Davies, Janet/C-7989-2009	Davies, Janet/0000-0002-6378-4119; Platts-Mills, Thomas/0000-0002-1263-329X	Stallergenes Pty Ltd; Australian National Health and Medical Research Council; Asthma Foundation of Queensland; University of Queensland; National Health Medical Research Council of Australia; Australian Society for Clinical Immunology and Allergy; National Institutes of Health/National Institute of Allergy and Infectious Diseases	Stallergenes Pty Ltd; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Asthma Foundation of Queensland; University of Queensland(University of Queensland); National Health Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Society for Clinical Immunology and Allergy; National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	J.M.D. has received honoraria payments for education presentations and contracted research funds from Stallergenes Pty Ltd and is supported by funds from the Australian National Health and Medical Research Council, the Asthma Foundation of Queensland, and the University of Queensland.; Disclosure of potential conflict of interest: J.M. Davies has consultancy arrangements with Stallergenes Pty Ltd, France; is employed by the University of Queensland; has received one or more grants from or has one or more grants pending with the National Health Medical Research Council of Australia, the Asthma Foundation of Queensland, the University of Queensland, and the Australian Society for Clinical Immunology and Allergy; has received one or more payments for lecturing from or is on the speakers' bureau for Stallergenes Pty Ltd; and has received one or more payments for travel/accommodations/meeting expenses from Stallergenes for delivery of research presentations. T. A. Platts-Mills has received one or more grants from or has one or more grants pending with the National Institutes of Health/National Institute of Allergy and Infectious Diseases. R. C. Aalberse declares that he has no relevant conflicts of interest.	Aalberse RC, 2011, ALLERGY, V66, P1261, DOI 10.1111/j.1398-9995.2011.02656.x; AALBERSE RC, 1993, ALLERGY, V48, P559, DOI 10.1111/j.1398-9995.1993.tb00749.x; Aalberse RC, 2004, J ALLERGY CLIN IMMUN, V113, P983, DOI 10.1016/j.jaci.2004.02.046; Anand S, 1997, MOL IMMUNOL, V34, P175, DOI 10.1016/S0161-5890(96)00110-1; Batista FD, 1996, J EXP MED, V184, P2197, DOI 10.1084/jem.184.6.2197; Brightbill HD, 2010, J CLIN INVEST, V120, P2218, DOI 10.1172/JCI40141; Burton OT, 2011, IMMUNOL REV, V242, P128, DOI 10.1111/j.1600-065X.2011.01024.x; Cameron L, 2000, J ALLERGY CLIN IMMUN, V106, P46; Cameron L, 2003, J IMMUNOL, V171, P3816, DOI 10.4049/jimmunol.171.7.3816; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; Christensen LH, 2010, J IMMUNOL, V184, P4966, DOI 10.4049/jimmunol.0904038; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; Coker HA, 2003, J IMMUNOL, V171, P5602, DOI 10.4049/jimmunol.171.10.5602; Dahlke I, 2006, J ALLERGY CLIN IMMUN, V117, P1477, DOI 10.1016/j.jaci.2005.12.1359; Davies JM, 2008, CLIN EXP ALLERGY, V38, P566, DOI 10.1111/j.1365-2222.2008.02941.x; Davies JM, 2011, CLIN EXP ALLERGY, V41, P281, DOI 10.1111/j.1365-2222.2010.03670.x; Davies JM, 2004, CLIN EXP ALLERGY, V34, P429, DOI 10.1111/j.1365-2222.2004.01900.x; Erazo A, 2007, IMMUNITY, V26, P191, DOI 10.1016/j.immuni.2006.12.006; Feichtner S, 2008, J IMMUNOL, V180, P5499, DOI 10.4049/jimmunol.180.8.5499; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Holt PG, 2011, CHEST, V139, P1165, DOI 10.1378/chest.10-2397; IRSCH J, 1995, IMMUNOTECHNOLOGY, V1, P115, DOI 10.1016/1380-2933(95)00012-7; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Karnowski A, 2006, EUR J IMMUNOL, V36, P1917, DOI 10.1002/eji.200535495; Kelly KA, 2007, IMMUNOLOGY, V120, P345, DOI 10.1111/j.1365-2567.2006.02509.x; Kerzel S, 2010, J IMMUNOL, V185, P2253, DOI 10.4049/jimmunol.0902942; KING CL, 1991, J IMMUNOL, V146, P1478; Kitagaki K, 2006, J IMMUNOL, V177, P1628, DOI 10.4049/jimmunol.177.3.1628; Lafaille JJ, 2012, NAT IMMUNOL, V13, P624; Lafaille JJ, 2012, NAT IMMUNOL, V13, P623, DOI 10.1038/ni.2313; LeGros G, 1996, EUR J IMMUNOL, V26, P3042, DOI 10.1002/eji.1830261233; Mitre E, 2005, INFECT IMMUN, V73, P4106, DOI 10.1128/IAI.73.7.4106-4111.2005; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; Rajakulasingam K, 1997, J ALLERGY CLIN IMMUN, V100, P78, DOI 10.1016/S0091-6749(97)70198-2; Schroeder JT, 2010, J ALLERGY CLIN IMMUN, V125, P896, DOI 10.1016/j.jaci.2009.10.021; Snow RE, 1998, EUR J IMMUNOL, V28, P3354, DOI 10.1002/(SICI)1521-4141(199810)28:10<3354::AID-IMMU3354>3.0.CO;2-Z; Talay O, 2012, NAT IMMUNOL, V13, P396, DOI 10.1038/ni.2256; Wang Y, 2011, SCAND J IMMUNOL, V73, P496, DOI 10.1111/j.1365-3083.2011.02525.x; Wurtzen PA, 2008, CLIN EXP ALLERGY, V38, P1290, DOI 10.1111/j.1365-2222.2008.03020.x; Xiong HZ, 2012, ADV IMMUNOL, V116, P113, DOI 10.1016/B978-0-12-394300-2.00004-1; Xiong HZ, 2012, J EXP MED, V209, P353, DOI 10.1084/jem.20111941; Yang ZY, 2012, IMMUNITY, V36, P857, DOI 10.1016/j.immuni.2012.02.009; Zemlin C, 2010, ADV GENET RES, V1, P127; ZHANG K, 1994, J IMMUNOL, V152, P3427; Zuidscherwoude M, 2012, CELL MOL IMMUNOL, V9, P373, DOI 10.1038/cmi.2012.21	49	50	50	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					972	976		10.1016/j.jaci.2012.12.1569	http://dx.doi.org/10.1016/j.jaci.2012.12.1569			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23398655	Bronze			2022-12-18	WOS:000317187200003
J	Su, WR; Fan, HM; Chen, MG; Wang, J; Brand, D; He, XS; Quesniaux, V; Ryffel, B; Zhu, L; Liang, D; Zheng, SG				Su, Wenru; Fan, Huimin; Chen, Maogen; Wang, Julie; Brand, David; He, Xiaoshun; Quesniaux, Valerie; Ryffel, Bernhard; Zhu, Ling; Liang, Dan; Zheng, Song Guo			Induced CD4(+) forkhead box protein-positive T cells inhibit mast cell function and established contact hypersensitivity through TGF-beta 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; allergic; induced regulatory T cells; contact hypersensitivity; TGF-beta	TUMOR-NECROSIS-FACTOR; FACTOR-KAPPA-B; TGF-BETA; TRANSCRIPTION FACTOR; CUTTING EDGE; EX-VIVO; ACTIVATION; SUPPRESS; EFFECTOR; RESPONSES	Background: Induced CD4(+) forkhead box protein 3-positve regulatory T (iTreg) cells are a promising source for cell-based therapies of established inflammatory and autoimmune diseases. However, their relationship to mast cell (MC) function and MC-driven diseases remains unknown. Objective: We sought to explore the roles of iTreg cells on MC function and the established MC-driven disease contact hypersensitivity (CHS). Methods: In vitro coculture studies were carried out to investigate the interaction between iTreg cells in murine or human MCs by using both direct cell-cell contact and transwell systems to separate cell-cell contact. In vivo mice iTreg cells were administered to mice with established CHS, and innate immunologic responses, such as MC infiltration and inflammatory cytokine expression at contact sites, were evaluated. Results: In vitro coculture under direct cell-cell contact resulted in indirect suppression of IgE-independent activation of MCs by murine or human iTreg cells. Mechanistically, iTreg cells suppressed proinflammatory cytokine levels by modulating nuclear factor kappa B p65 activation in MCs through T cell-derived TGF-beta 1. Injection of iTreg cells but not natural CD4(+) CD25(+) regulatory T cells into animals with established CHS resulted in the suppression of infiltration and functions of MCs and also led to decreased production of inflammatory cytokines at allergic contact areas. iTreg cell-mediated immunosuppressive effects were abrogated when iTreg cells were pretreated with TGF-beta 1 small interfering RNA. Conclusions: Our study demonstrates that iTreg cells suppress MC function and attenuate established MC-driven CHS through TGF-beta 1-dependent mechanisms. (J Allergy Clin Immunol 2012;130:444-52.)	[Su, Wenru; Chen, Maogen; Wang, Julie; Zhu, Ling; Zheng, Song Guo] Univ So Calif, Dept Med, Div Rheumatol & Immunol, Keck Sch Med, Los Angeles, CA 90033 USA; [Su, Wenru; Liang, Dan] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Fan, Huimin; Zheng, Song Guo] Tongji Univ, Inst Immunol, Shanghai E Hosp, Shanghai 200092, Peoples R China; [Chen, Maogen; He, Xiaoshun] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Brand, David] VA Med Ctr, Memphis, TN USA; [Quesniaux, Valerie; Ryffel, Bernhard] Univ Orleans, Orleans, France; [Zhu, Ling] Fujian Med Univ, Ctr Neurosci, Fuzhou 350004, Fujian, Peoples R China; [Zhu, Ling] Fujian Med Univ, Dept Immunol, Fuzhou 350004, Fujian, Peoples R China	University of Southern California; Sun Yat Sen University; Tongji University; Sun Yat Sen University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Universite de Orleans; Fujian Medical University; Fujian Medical University	Zheng, SG (corresponding author), Univ So Calif, Dept Med, Div Rheumatol & Immunol, Keck Sch Med, 2011 Zonal Ave, Los Angeles, CA 90033 USA.	zhling62@pub6.fz.fj.cn; liangd2@mail.sysu.edu.cn; szheng@usc.edu	Maogen, Chen/AAN-1551-2021	Maogen, Chen/0000-0001-9319-5334; Su, Wenru/0000-0002-0506-6362; Brand, David/0000-0002-9260-7963	National Institutes of Health [AR059103, AI084359]; ACR Within Our Reach Fund; Arthritis Foundation; Wright Foundation; Guangdong Provincial Department University Industry Cooperation [2010B090400415]; International Collaborative Projects of Shanghai Municipal Science and Technology Commission [11410702000]; Fujian Science and Technique Foundation [2009I0008]; Department of Veterans Affairs; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI084359] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059103] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACR Within Our Reach Fund; Arthritis Foundation; Wright Foundation; Guangdong Provincial Department University Industry Cooperation; International Collaborative Projects of Shanghai Municipal Science and Technology Commission; Fujian Science and Technique Foundation; Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported in part by grants from National Institutes of Health (AR059103 and AI084359), the ACR Within Our Reach Fund, the Arthritis Foundation, the Wright Foundation, the Guangdong Provincial Department University Industry Cooperation Project (2010B090400415), the International Collaborative Projects of Shanghai Municipal Science and Technology Commission (11410702000), the Fujian Science and Technique Foundation (2009I0008), and the Department of Veterans Affairs.	Azzolina A, 2003, BBA-MOL CELL RES, V1643, P75, DOI 10.1016/j.bbamcr.2003.09.003; Bardos T, 2003, ARTHRITIS RES THER, V5, pR106, DOI 10.1186/ar624; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Bopp T, 2007, J EXP MED, V204, P1303, DOI 10.1084/jem.20062129; Bryce P. J, 2005, NOVART FDN S, V271, P15, DOI [10.1002/9780470033449.ch3, DOI 10.1002/9780470033449.CH3]; Bryce Paul J, 2005, Novartis Found Symp, V271, P15; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Chadjichristos CE, 2008, CIRC RES, V102, P653, DOI 10.1161/CIRCRESAHA.107.170472; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Fonacier LS, 2010, J ALLERGY CLIN IMMUN, V125, pS138, DOI 10.1016/j.jaci.2009.05.039; Forward NA, 2009, J IMMUNOL, V183, P3014, DOI 10.4049/jimmunol.0802509; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Ghiringhelli F, 2005, J EXP MED, V202, P1075, DOI 10.1084/jem.20051511; Gri G, 2008, IMMUNITY, V29, P771, DOI 10.1016/j.immuni.2008.08.018; He B, 2009, CLIN CANCER RES, V15, P5803, DOI 10.1158/1078-0432.CCR-09-0811; Jensen Bettina M, 2006, Curr Protoc Immunol, VChapter 3, DOI 10.1002/0471142735.im0323s74; Kakurai M, 2006, AM J PATHOL, V169, P1713, DOI 10.2353/ajpath.2006.060602; Karsak M, 2007, SCIENCE, V316, P1494, DOI 10.1126/science.1142265; KERDEL FA, 1987, J INVEST DERMATOL, V88, P686, DOI 10.1111/1523-1747.ep12470344; Kim SJ, 2005, J PHARMACOL EXP THER, V314, P27, DOI 10.1124/JPET.104.082792; Kobayashi M, 2010, J INVEST DERMATOL, V130, P725, DOI 10.1038/jid.2009.289; Lan Q, 2012, J MOL CELL BIOL, V4, P22, DOI 10.1093/jmcb/mjr039; Li MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Lu LF, 2006, NATURE, V442, P997, DOI 10.1038/nature05010; Lu L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015150; Lu L, 2010, J IMMUNOL, V184, P4295, DOI 10.4049/jimmunol.0903418; Lushniak BD, 2003, INT ARCH OCC ENV HEA, V76, P325, DOI 10.1007/s00420-002-0417-2; Matsubara T, 2011, HEPATOLOGY, V53, P1282, DOI 10.1002/hep.24193; Morgan ME, 2005, ARTHRITIS RHEUM-US, V52, P2212, DOI 10.1002/art.21195; Nakae S, 2005, P NATL ACAD SCI USA, V102, P6467, DOI 10.1073/pnas.0501912102; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834; Nishida K, 2009, J EXP MED, V206, P1351, DOI 10.1084/jem.20082533; Norman MU, 2008, AM J PATHOL, V172, P1638, DOI 10.2353/ajpath.2008.070559; O'Connor RA, 2010, J IMMUNOL, V185, P7235, DOI 10.4049/jimmunol.1001551; Otsuka A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025538; Piconese S, 2009, BLOOD, V114, P2639, DOI 10.1182/blood-2009-05-220004; Rasheed Z, 2010, J PHARMACOL EXP THER, V333, P354, DOI 10.1124/jpet.109.165209; Ring S, 2006, EUR J IMMUNOL, V36, P2981, DOI 10.1002/eji.200636207; Ring S, 2010, J ALLERGY CLIN IMMUN, V125, P237, DOI 10.1016/j.jaci.2009.10.025; Ring S, 2009, J ALLERGY CLIN IMMUN, V123, P1287, DOI 10.1016/j.jaci.2009.03.022; ROBERTS LK, 1985, J IMMUNOL, V135, P2929; Sayed BA, 2008, ANNU REV IMMUNOL, V26, P705, DOI 10.1146/annurev.immunol.26.021607.090320; Sayed BA, 2007, IMMUNOL REV, V217, P53, DOI 10.1111/j.1600-065X.2007.00524.x; Suto H, 2006, J IMMUNOL, V176, P4102, DOI 10.4049/jimmunol.176.7.4102; Vocanson M, 2009, ALLERGY, V64, P1699, DOI 10.1111/j.1398-9995.2009.02082.x; Wang HW, 1998, J CLIN INVEST, V102, P1617, DOI 10.1172/JCI3704; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Zheng SG, 2004, J IMMUNOL, V172, P1531, DOI 10.4049/jimmunol.172.3.1531; Zheng SG, 2002, J IMMUNOL, V169, P4183, DOI 10.4049/jimmunol.169.8.4183; Zheng SG, 2008, J IMMUNOL, V180, P7112, DOI 10.4049/jimmunol.180.11.7112; Zheng SG, 2007, J IMMUNOL, V178, P2018, DOI 10.4049/jimmunol.178.4.2018; Zhou XH, 2010, J IMMUNOL, V185, P2675, DOI 10.4049/jimmunol.1000598; Zhou XH, 2010, J MOL CELL BIOL, V2, P164, DOI 10.1093/jmcb/mjq007	60	50	51	2	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					444	+		10.1016/j.jaci.2012.05.011	http://dx.doi.org/10.1016/j.jaci.2012.05.011			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22738679				2022-12-18	WOS:000307002200026
